A few notes about viewing Plunkett Research books in PDF format… • • • • •
When in Adobe Acrobat Reader, press the [F5] key on your keyboard to display a list of "bookmarks," which are a very thorough table of contents with links to pages within the PDF. Click a bookmark to jump to a particular chapter, table or section. For easiest viewing, increase or decrease the zoom percentage (lower left corner of the page window) as necessary. Press the [F5] key again to hide the list of bookmarks as necessary. In order to use this PDF, you must agree to the terms of the End User License Agreement that follows on page 9 of this PDF.
A few notes about the following pages… • • • • •
The pages immediately following tell you more about our book titles and how to purchase them. We suggest you print out the Customer Support form on the next page and fax it to us at 713.932.7080. You will receive a free CD-ROM version of this book's database of companies. To order other books, print the order form on page 7 of this PDF and fax it to 713.932.7080 or visit our website at www.plunkettresearch.com. The book in its entirety begins on or about page 8 of this PDF. Thank you for interest.
Plunkett’s 2003-2004 Books / CD-ROMS / eBooks in PDF / Online Subscriptions Trends, Statistics Market Research and Industry Analysis in:
Your key to Business & Looking for a job? Industry Research Doing market research?
• Advertising & Branding - NEW
• Apparel & Textiles - NEW Looking for business prospects? • Consulting Industry - NEW • Nanotechnology - NEW Writing a business plan? • Real Estate &
Planning a business strategy?
Plunkett Research, Ltd. When You Need Accurate, Timely, Innovative Information
www.plunkettresearch.com 713.932.0000
•
Construction - NEW Transportation & Logistics - NEW
• Airline, Hotel & Travel • Automobile • Computers & Internet • Energy • Consulting Industry • Engineering & Research • Entertainment & Media • Food • Health Care & Biotech • Job Seekers & Careers • Retail • Telecommunications
• Looking for a job? • Doing market research? • Looking for business
prospects? • Writing a business plan? • Planning a business strategy? Get Market Research, Industry Analysis and Corporate Profiles in One Resource! Each exciting industry title contains all of the information you need to fully understand the trends, technologies, finances and leading companies of a specific industry. Whatever field you are researching, from InfoTech to Energy to Retailing, you’ll find all of the answers you need in one value-packed, industry-specific resource.
Get Reference Titles Packed with 400 to 700 Pages of Valuable Information! Here’s what you’ll find inside each industry book: • Glossary • Industry Overview and Trends • Segment by Segment Analysis • Statistics, Charts, Tables • Technology and Research Trends • Industry Contacts and Associations • Finances • Profiles of Hundreds of Leading Companies • Thorough Indexes and Cross-Indexes
More Industry Reference Books Coming Soon! Now accepting pre-publications order for: Plunkett’s Consulting Industry Almanac 1-593920-02-4 $249.99 APPROX. PUBLICATION DATE: NOV. 2003 INCLUDES CD-ROM
Covers the prestigious consulting industry from one end to the other. Statistics, trends, mergers, finances. Includes profiles of the Consulting Industry 300 Firms, the leading companies providing consulting in marketing, information technology, management, manufacturing, health care and more.
Plunkett’s Real Estate & Construction Industry Almanac 1-593920-03-2 $249.99 APPROX. PUBLICATION DATE: JAN. 2004 INCLUDES CD-ROM
Provides detailed analysis and statistics of all facets of this industry, including architecture, engineering, property management, finance, operations, mortgages, REITs, brokerage, construction and development. Profiles of the leading 300 firms.
Plunkett’s Nanotechnology & MEMS Industry Almanac 1-593920-04-0 $249.99 APPROX. PUBLICATION DATE: MAR. 2004 INCLUDES CD-ROM
This exciting new industry will enhance technologies of all types. Nanotech has applications within biotechnology, manufacturing, aerospace and information systems. This book covers micro-electro-mechanical (MEMS), microengineering, microsystems, microsensors, carbon tubes and much more. Trends, finances and profiles of the 300 leading firms.
Plunkett’s Advertising & Branding Industry Almanac 1-593920-05-9 $249.99 APPROX. PUBLICATION DATE: JUN. 2004 INCLUDES CD-ROM
Vital to businesses of all types, advertising and branding are covered in-depth in this important volume, from media to direct mail, from online advertising to branding and image. Analysis of trends, globalization, technologies, finances and more. Profiles of the 300 leading companies.
Plunkett’s Apparel & Textiles Industry Almanac
Get Detailed Profiles and Useable Information on Hundreds of Leading Firms: • Leading Companies Profiled and Ranked by Sales and Profits • Thorough Business Descriptions • Up to 24 Executive Contacts per Company • Address, Phone, Fax, Web Sites • Growth Plans • Competitive Advantage Statements • Salaries, Benefits and Hiring Plans • Divisions and Subsidiaries
1-593920-06-7 $249.99 APPROX. PUBLICATION DATE: JUL. 2004 INCLUDES CD-ROM
An exciting, global industry, apparel and textiles are covered indepth in this book, from clothing, shoes and accessories to designers, retail stores and manufacturers. Statistics, trends and market analysis. Profiles of the 300 leading firms.
Plunkett’s Transportation & Logistics Industry Almanac 1-593920-07-5 $249.99 APPROX. PUBLICATION DATE: SEP. 2004 INCLUDES CD-ROM
This immense, global sector is vital to all businesses. This book covers exciting trends in supply chain and logistics management, transportation, intermodal shipment systems and advanced technologies. Market analysis, statistics and trends. Profiles of the 300 leading firms.
www.plunkettresearch.com
713.932.0000
TRAVEL & AIRLINES
ENGINEERING & RESEARCH
FINANCE & INVESTMENTS
Plunkett’s Airline, Hotel & Travel Industry Almanac
Plunkett’s Engineering & Research Industry Almanac 2003-2004
Plunkett’s Financial Services Industry Almanac 2002-2003
1-891775-74-X $249.99 NOVEMBER 2002 INCLUDES CD-ROM
450 pg. The only complete reference to the global travel industry, including airlines, hotels, tour operators; travel agencies; e-commerce firms, cruise lines and car rentals. Includes a trends analysis, glossary, statistics, industry contacts, thorough indexes and in-depth profiles of the 300 leading companies in the industry.
AUTOMOBILE Plunkett’s Automobile Industry Almanac 1-891775-76-6 $249.99 MARCH 2003 INCLUDES CD-ROM
412 pg. A key reference tool. Provides industry analysis, statistical tables, an automobile industry glossary, industry contacts, thorough indexes and in-depth profiles of the 300 leading automotive industry firms.
1-891775-24-3 $249.99 JULY 2003 INCLUDES CD-ROM
680 pg. Profiles of 500 leading corporations in research, engineering and development in biotech, electronics, aerospace, medicine. "...The convenience for a typical user makes this volume very attractive for the support of job-seekers and investors." – American Reference Books Annual
RETAIL Plunkett’s Retail Industry Almanac 2003 1-891775-55-3 $229.99 ANNUAL EDITION DEC 2002 INCLUDES CD-ROM
540 pg. Thorough analysis of trends, careers, suppliers, finances, shopping centers and Internet-based retailing. Profiles of 400 leading, fast-growing retailers of all types. “Consider this reference essential...covering everything from malls and superstores to mail order business.” – Midwest Book Review
FOOD & BEVERAGE
COMPUTERS & INTERNET
Plunkett’s Food industry Almanac
Plunkett’s E-Commerce & Internet Business Almanac 2003-2004
1-891775-75-8 $249.99 MAY 2003 INCLUDES CD-ROM
450 pg. Covers the entire food and beverage industry, including food producers, retailers, technologies and distributors. Provides a thorough market analysis, dozens of statistical tables, glossary, contacts, and profiles of the 340 leading companies in the global food industry.
HEALTH CARE & BIOTECH Plunkett’s Health Care Industry Almanac 2003 1-891775-54-5 $229.99 ANNUAL EDITION SEPT 2002 INCLUDES CD-ROM
716 pg. The only complete reference to the American health care industry. Profiles of the Health Care 500 firms. Academic Book of the Year Award Winner.
1-891775-58-8 $249.99 JUNE 2003 INCLUDES CD-ROM
500 pg. Complete access to the exploding Internet business. Profiles of leading corporations in e-commerce, equipment, Internet services and more.
713 pg. Profiles of 500 leading corporations in banking, insurance, mortgages, online finance, credit cards, investments, stocks. “Well researched and presented...excellent value in terms of information versus cost.” – American Reference Book Annual
Plunkett’s Online Trading, Finance & Investment Web Sites Almanac 1-891775-08-1 $149.99 JAN 2000 INCLUDES DISKETTE
547 pg. Save countless hours in your research for data on investments, stocks, bonds, commodities, banking, mortgages, economics, trends and more. Complete profiles of the 211 most vital web sites for investors and financial professionals. "Contains an abundance of useful information." – Journal of Business & Finance Librarianship
ENTERTAINMENT & MEDIA Plunkett’s Entertainment & Media Industry Almanac 2002-2003 1-891775-27-8 $229.99 MAY 2002 INCLUDES CD-ROM
515 pg. Profiles of 350 leading firms in film, radio, TV, cable, multimedia, magazines, books, newspapers and online publishing.
“Unique, well-researched.” – CHOICE Magazine
“A critically important reference.” – Midwest Book Review
Plunkett’s InfoTech Industry Almanac 2003
ENERGY
1-891775-57-X $229.99 ANNUAL EDITION APRIL 2003 INCLUDES CD-ROM
640 pg. In-depth analysis of the InfoTech Revolution. Profiles of the InfoTech 500 firms in computers, software, online, systems integration, networking and more. "Intriguing reference...interesting articles on the industry's trends." – Library Journal
"Highly recommended..." – CHOICE Magazine
TELECOMMUNICATIONS
Plunkett’s Biotech & Genetics Industry Almanac 2003-2004
Plunkett’s Telecommunications Industry Almanac 2003-2004
1-891775-28-6 $249.99 FEB 2003 INCLUDES CD-ROM
1-891775-22-7 $249.99 JULY 2002 INCLUDES CD-ROM
522 pg. Your guide to the technologies revolutionizing health care. Research, growth companies, proteomics, genomics. Vital details on the Biotech 400 firms.
533 pg. Complete guide to the rapidly evolving telecommunications industry. Profiles of leading firms in wireless, long-distance, networks, local service.
“For business researchers and job seekers, this almanac provides an overview of leading biotechnology firms and descriptions of emerging technology.” – CHOICE Magazine
1-891775-23-5 $229.99 MAR 2002 INCLUDES CD-ROM
“Essential for long-term business analysis and industry trends.” – Midwest Book Review
Plunkett’s Energy Industry Almanac 2002-2003 1-891775-20-0 $199.99 JULY 2001 INCLUDES CD-ROM
570 pg. Covers everything from major oil companies to electric and gas utilities, plus pipelines, refiners/retailers, oil field services and alternative energy. Profiles of Plunkett’s Energy 400 firms. “This impressive reference compendium covers all facets of the American energy industry...exhaustively researched...” – Midwest Book Review
Order Today! 713.932.0000 www.plunkettresearch.com
JOB SEEKERS & CAREERS Plunkett’s Employers’ Internet Sites with Careers Information 2002-2003
Each book comes with a complete database on CD-ROM...FREE.
1-891775-19-7 $199.99 JAN 2002 INCLUDES CD-ROM
• The CD-ROM database
696 pg. Profiles 500 Internet sites operated by major employers. Locate web sites with job openings and the ability to apply online. Saves countless hours of research. Indexes include international posts, internships, physically challenged and type of career.
will enable you to search by company, industry, sales, location and keywords • Create and print your own mailing lists addressed to the CEO, Humans Resources V.P. or 24 other executives by title • Build your own spread sheets and databases • Find each company’s website
“(It) will become a core addition to career centers and libraries everywhere...” – Joyce Lain Kennedy, columnist
The Almanac of American Employers 2003 1-891775-56-1 $199.99 ANNUAL EDITION DEC 2002 INCLUDES CD-ROM
718 pg. Fully updated for the job seeker and researcher. Includes salaries, benefits, corporate culture, special hiring/training programs, women and minorities in top posts, contacts. Profiles The American Employers 500. “Recommended for all libraries.” – CHOICE Magazine
Plunkett’s Companion to The Almanac of American Employers: Mid-Size Firms 2002-2003 1-891775-26-X $179.99 DEC 2001 INCLUDES CD-ROM
sample screens
684 pg. Profiles of 500 rapidly growing mid-size firms, from 200 to 2,300 employees. “The best places to work.” – USA Today
Check us out! See sample chapters at www.plunkettresearch.com
Ordering from Plunkett Research is easy. • Use the order form on the back of this brochure • Place your order online at www.plunkettresearch.com • Order by phone at 713.932.0000 • Order by fax at 713.932.7080 • Order by mail at P.O. Drawer 541737 Houston, TX 77254
Plunkett Research Online is your key to Market Research
New Plunkett’s online subscription plans
are available at value-packed prices.
Plunkett’s business, Internet and careers data is available online through subscription plans tailored to fit your organization. Access our online service by IP address, user name or other popular methods. Search and view our industry analysis, statistics and company profiles online.
Accessing our data online has many outstanding advantages. • You access the service via our server, which means that we do all of the maintenance and updating.
• All employees of a corporation, all students of a business school or even an entire university can have access to our online service’s unique data.
• Information on our online service is updated weekly. • Our newest editions and updates will be posted automatically – before they are available in print!
• Thousands of company profiles can easily be searched using a wide array of criteria.
• All profiles are easily printable, and you also have several options for exporting vital data.
• You have instant access to our updated databases of statistics, glossaries of key industry terms and contact lists of industry associations.
• Our online service is fully searchable by keyword so that users can quickly find the subject area and data they are seeking.
Online Pricing and Access Options By User Name and Password Includes online access to all of our publications and every industry covered by Plunkett Research. 1 to 5 seats . . . . . . . . .$1,995 6-20 seats . . . . . . . . . .$2,995
By IP Address Recognition, Organization-wide access Includes online access to all of our publications and every industry covered by Plunkett Research. University or School . . .$2,995 (one campus) Government or . . . . . .$2,995 Non-Profit (one agency) Public Library . . . . . . .$2,995 (one location) Corporation . . . . . . . . .$3,495 Access to Only One Industry Sector $950 You should purchase this subscription if you want access to only one of our main industry sectors, for example health care only or retail only. This subscription will provide you with organization-wide access, by your choice of user name or IP address recognition.
Order Today!
Plunkett Research, Ltd. • P. O. Drawer 541737 • Houston, Texas 77254 USA Phone: 713.932.0000 • FAX: 713.932.7080 • Online: www.plunkettresearch.com Quantity
Airline, Hotel & Travel Plunkett’s Airline, Hotel & Travel Industry Almanac ISBN 1-891775-74-X with CD-ROM
____ @ 249.99
Automobile Plunkett’s Automobile Industry Almanac ISBN 1-891775-76-6 with CD-ROM
____ @ 249.99
Computers & Internet Plunkett’s E-Commerce & Internet Business Almanac 2003-2004 ISBN 1-891775-58-8 with CD-ROM Plunkett’s InfoTech Industry Almanac 2003 ISBN 1-891775-57-X with CD-ROM Energy Plunkett’s Energy Industry Almanac 2002-2003 ISBN 1-891775-20-0 with CD-ROM Engineering & Research Plunkett’s Engineering & Research Industry Almanac 2003-2004 ISBN 1-891775-24-3 with CD-ROM Entertainment & Media Plunkett’s Entertainment & Media Industry Almanac 2002-2003 ISBN 1-891775-27-8 with CD-ROM Finance & Investments Plunkett’s Financial Services Industry Almanac 2002-2003 ISBN 1-891775-23-5 with CD-ROM Plunkett’s Online Trading, Finance & Investment Web Sites Almanac ISBN 1-891775-08-1 with Diskette Food Plunkett’s Food Industry Almanac ISBN 1-891775-75-8 with CD-ROM Health Care & Biotech Plunkett’s Health Care Industry Almanac 2003 ISBN 1-891775-54-5 with CD-ROM Plunkett’s Biotech & Genetics Industry Almanac 2003-2004 ISBN 1-891775-28-6 with CD-ROM Job Seekers & Careers The Almanac of American Employers 2003 ISBN 1-891775-56-1 with CD-ROM Plunkett’s Companion to The Almanac of American Employers: Mid-Size Firms 2002-2003 ISBN 1-891775-26-X with CD-ROM Plunkett’s Employers’ Internet Sites with Careers Information 2002-2003 ISBN 1-891775-19-7 with CD-ROM Retail Plunkett’s Retail Industry Almanac 2003 ISBN 1-891775-55-3 with CD-ROM Telecommunications Plunkett’s Telecommunications Industry Almanac 2003-2004 ISBN 1-891775-22-7 with CD-ROM
Also, we’re accepting pre-publication orders for these upcoming titles: Plunkett’s Consulting Industry Almanac 1-593920-02-4 with CD-ROM Approx. Publication Date: Nov. 2003
____ @ 249.99
____ @ 249.99 Plunkett’s Real Estate & Construction Industry Almanac ____ @ 229.99
____ @ 199.99
____ @ 249.99
____ @ 229.99
1-593920-03-2 with CD-ROM Approx. Publication Date: Jan. 2004
____ @ 249.99
Plunkett’s Nanotechnology & MEMS Industry Almanac 1-593920-04-0 with CD-ROM Approx. Publication Date: Mar. 2004
____ @ 249.99
Plunkett’s Advertising & Branding Industry Almanac 1-593920-05-9 with CD-ROM Approx. Publication Date: Jun. 2004
____ @ 249.99
____ @ 229.99 Plunkett’s Apparel & Textiles Industry Almanac ____ @ 149.99
____ @ 249.99
____ @ 229.99
1-593920-06-7 with CD-ROM Approx. Publication Date: Jul. 2004
____ @ 249.99
Plunkett’s Transportation & Logistics Industry Almanac 1-593920-07-5 with CD-ROM Approx. Publication Date: Sep. 2004
____ @ 249.99
____ @ 249.99
____ @ 199.99
Subtotal
$
Shipping/ Handling add $9.50 per book or
$
____ @ 179.99
Next day air in the US, add $23.50 per book or
$
____ @ 199.99
Airmail outside USA, add $50.00 per book.
$
FedEx outside USA, add $90.00 per book.
$
In Texas add 8.25% sales tax if you are not tax exempt.
$
TOTAL
$
____ @ 229.99
____ @ 249.99
STANDING ORDER l Check here for a standing order and receive a 10% discount on future editions of the book(s) you have ordered, which will be shipped to you automatically. You may cancel your standing order at any time.
METHOD OF PAYMENT (Our Federal ID number is 74-2440918) Purchase order number (if any): l Check enclosed l Bill me l Credit card (check one) l VISA l MasterCard l American Express Credit Card No.
Expiration Date:
SHIP TO: Name Title/Department Organization Address City Telephone E-mail
State Fax
Zip
Plunkett Research, Ltd. P. O. Drawer 541737 Houston, Texas 77254 USA 713.932.0000
PRSRT STD AUTO US POSTAGE PAID DALLAS TX PERMIT NO 6803
Customer Support Information Plunkett’s Engineering & Research Industry Almanac 2003-2004 Please register your book immediately… if you did not purchase it directly from Plunkett Research, Ltd. This will enable us to fulfill your replacement request if you have a damaged product, or your requests for assistance. Also it will enable us to notify you of future editions, so that you may purchase them from the source of your choice.
If you are an actual, original purchaser but did not receive a FREE CD-ROM version with your book…* you may request it by returning this form. ____ YES, please register me as a purchaser of the book. I did not buy it directly from Plunkett Research, Ltd. ____ YES, please send me a free CD-ROM version of the book. I am an actual purchaser, but I did not receive one with my book. (Proof of purchase may be required.) Customer Name ____________________________________________________ Title ______________________________________________________________ Organization _______________________________________________________ Address ___________________________________________________________ City_______________________________State________Zip_________________ Country (if other than USA) ___________________________________________ Phone_________________________Fax ________________________________ E-mail ____________________________________________________________
Mail or Fax to:
Plunkett Research, Ltd.
Attn: FREE CD-ROM and/or Registration P.O. Drawer 541737, Houston, TX 77254-1737 USA 713.932.0000 Fax 713.932.7080 http://www.plunkettresearch.com/ * Purchasers of used books are not eligible to register. Use of CD-ROMs is subject to the terms of their end user license agreements.
PLUNKETT’S ENGINEERING AND RESEARCH INDUSTRY ALMANAC 2003-2004 The Only Comprehensive Guide to the Engineering and Research Industry
Jack W. Plunkett Published by: Plunkett Research, Ltd., Houston, Texas http://www.plunkettresearch.com/
PLUNKETT’S ENGINEERING AND RESEARCH INDUSTRY ALMANAC 2003-2004 Editor and Publisher: Jack W. Plunkett Executive Editor and Database Manager: Martha Burgher Plunkett
E-Commerce Manager: Kevin Hinrichs
Senior Editors and Researchers: Elisa Gabbert Ghazal Siddiqi
Cover Design: Kim Paxson, Just Graphics Junction, TX
Editors, Researchers and Assistants: Elizabeth Lockett Christie Manck Ray Marumahoko Mariya Paterwic Daniel Shirley Jonathan Timms Suzanne Zarosky
Special Thanks to: National Science Foundation, Division of Science Resources Studies, Arlington, VA U.S. Patent and Trademark Office, Division of Technology, Assessment and Forecast, Alexandria, VA
Information Technology Director: Alex Preskovsky Plunkett Research, Ltd. P. O. Drawer 541737, Houston, Texas 77254 Phone: 713.932.0000 Fax: 713.932.7080 http://www.plunkettresearch.com/
Copyright 2003 by Plunkett Research, Ltd.
Published by: Plunkett Research, Ltd. P. O. Drawer 541737 Houston, Texas 77254-1737 USA Phone: 713.932.0000 Fax: 713.932.7080 Internet: www.plunkettresearch.com ISBN # 1-891775-33-2 End-User License Agreement, Limited Warranty & Limitation of Liability--Effective January 2003, Plunkett Research, Ltd. Important, read carefully: This agreement is a legal agreement between you (whether as an individual or an organization) and Plunkett Research, Ltd. By installing, copying, downloading, accessing or otherwise using the Plunkett Data, you agree to be bound by the terms of this Agreement. If you do not agree to the terms of this Agreement, do not install or use the Plunkett Data. The information (the "Data" or the "Plunkett Data") contained in this printed version or electronic file is the property of Plunkett Research, Ltd. Copyright laws and international copyright treaties, as well as other intellectual property laws and treaties, protect the Plunkett Data. LIMITED RIGHTS TO INSTALL DATA ON ELECTRONIC DEVICES: Plunkett Research, Ltd. grants you, as an individual or an organization, a non-exclusive license to use and and/or install this Data, including installation of electronic files on one individual desktop computer AND on one laptop computer AND one personal digital assistant or dedicated portable eBook reader (such as a Palm or iPaq). This is a limited license, which applies to a single user. Organizations desiring multi-user licenses may purchase additional rights at reasonable cost by contacting Plunkett Research, Ltd., 713.932.0000, http://www.plunkettresearch.com/, email:
[email protected]. LIMITED RIGHTS TO EXPORT OR COPY DATA, SUBJECT TO CONTINUED COPYRIGHT NOTICE: Limited exporting or copying of certain limited amounts of Data for creation of mailing lists, summaries and contact lists is allowed, PROVIDED THAT: 1) The exported Data is for use by one organization, company or individual only. 2) The exported Data will not be re-sold, posted to an Internet-based file, commercially published, or broadly distributed outside of the organization/corporation that has purchased the Plunkett Data. 3) Broad use, multi-premises use, or sharing outside of the organization that purchased the Plunkett Data is not allowed. 4) Violators will be subject to all penalties allowed by law. Rights under this license may not be sold or transferred. Data which may be exported or copied under the rights conferred through this paragraph may consist of any of the following: i. Up to 400 words of text; ii. Company names, addresses, telephone numbers,and executives with job titles; iii. Up to 2 tables or charts, PROVIDED THAT
said Data is immediately followed by this information in a font size that is clearly legible and of no less than 9 points in size: Copyright © Plunkett Research, Ltd., www.plunkettresearch.com, all rights reserved.
LIMITED WARRANTY: While Plunkett Research, Ltd. has made an effort to obtain the Data from sources deemed reliable, Plunkett Research, Ltd. makes no warranties, expressed or implied, regarding the accuracy, the installation or usability of an electronic file, or any aspect of the Data contained herein whether in print or electronic version. The Data is provided to the End-User “AS IS” without warranty of any kind. No oral or written information or advice given by Plunkett Research, Ltd. or its employees, distributors or representatives will create a warranty or in any way increase the scope of this Limited Warranty, and the Customer or End-User may not rely on any such information or advice. Among other things, this Limited Warranty applies to your ability to install an electronic file or software or such an installation's effects on your computer or other electronic devices. Plunkett Research, Ltd. assumes no liability and does not guarantee that this Data will install or function correctly on your computer or other electronic devices and further does not guarantee or accept any liability for the results of your attempt to install this Data, including any fault or dysfunction (including, but not limited to: computer viruses and/or alterations to computer files, registries or setups) to your computer or electronic devices that may be caused by installation or use. Customer Remedies: Plunkett Research, Ltd. and its suppliers' entire liability and your exclusive remedy shall be, at Plunkett Research Ltd.'s sole discretion, either (a) return of the price paid, if any, or (b) repair or replacement of the product that does not meet Plunkett Research, Ltd.'s Limited Warranty and that is returned to Plunkett Research, Ltd. with sufficient evidence of or receipt for your original purchase. NO OTHER WARRANTIES: TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, PLUNKETT RESEARCH, LTD. AND ITS SUPPLIERS AND DISTRIBUTORS DISCLAIM ALL OTHER WARRANTIES AND CONDITIONS, EITHER EXPRESSED OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES OR CONDITIONS OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE AND NON-INFRINGEMENT WITH REGARD TO THE PRODUCT, AND THE PROVISION OF OR FAILURE TO PROVIDE SUPPORT SERVICES. THIS LIMITED WARRANTY GIVES YOU SPECIFIC LEGAL RIGHTS. YOU MAY HAVE OTHERS, WHICH VARY FROM STATE/JURISDICTION TO STATE/JURISDICTION.
LIMITATION OF LIABILITY: TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, IN NO EVENT SHALL PLUNKETT RESEARCH, LTD. BE LIABLE FOR ANY SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES WHATSOEVER (INCLUDING, WITHOUT LIMITATION, DAMAGES FOR LOSS OF BUSINESS PROFITS, BUSINESS INTERRUPTION, LOSS OF BUSINESS INFORMATION, ABILITY TO OBTAIN OR RETAIN EMPLOYMENT OR REMUNERATION, ABILITY TO PROFITABLY MAKE AN INVESTMENT, OR ANY OTHER PECUNIARY LOSS) ARISING OUT OF THE INSTALLATION OF, USE OF, OR RELIANCE UPON THIS DATA, OR THE INABILITY TO USE THIS DATA (WHETHER IN ELECTRONIC OR PRINTED FORM) OR THE FAILURE OF PLUNKETT RESEARCH, LTD. TO PROVIDE SUPPORT SERVICES, EVEN IF PLUNKETT RESEARCH, LTD. HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. IN ANY CASE, PLUNKETT RESEARCH, LTD.’S ENTIRE LIABILITY UNDER ANY PROVISION OF THIS END-USER LICENSE AGREEMENT SHALL BE LIMITED TO THE AMOUNT ACTUALLY PAID BY YOU FOR THE PRODUCT. BECAUSE SOME STATES/JURISDICTIONS DO NOT ALLOW THE EXCLUSION OR LIMITATION OF LIABILITY, THE ABOVE LIMITATION MAY NOT APPLY TO YOU.
PLUNKETT'S ENGINEERING AND RESEARCH INDUSTRY ALMANAC 2003-2004 CONTENTS A Short Engineering and Research Industry Glossary Introduction How To Use This Book Chapter 1: Major Trends in the Engineering and Research Industry Company R&D Spotlights: IBM Lucent/Bell Labs Intel Microsoft Xerox Genentech Pfizer DuPont General Electric Chapter 2: Engineering and Research Industry Statistics Chapter 3: Engineering and Research Industry Contacts Addresses, Telephone Numbers and World Wide Web Sites Chapter 4: THE ENGINEERING 500: Who They Are and How They Were Chosen Industry List, With Codes Index of Rankings Within Industry Groups (The ENGINEERING 500 grouped by industry and ranked for sales and profits) Alphabetical Index Index of Headquarters Location by State Index of Headquarters Location by Country Index by Regions of the U.S. Where the ENGINEERING 500 Have Locations Index by Firms With International Operations Individual Profiles on each of THE ENGINEERING 500 Additional Indexes Index of Hot Spots for Advancement for Women/Minorities Index of Subsidiaries, Brand Names and Selected Affiliations List of Major Tables and Charts I. U.S. Research and Development Comparative Measures of Growth for Gross Domestic Product and R&D Federally Funded Research and Development Centers' R&D Expenditures: 2001 National Expenditures for Applied Research, by Performing Sector and Source of Funding: 1993-2002 National Expenditures for Applied Research, from Funding Sectors to Performing Sectors: 1993-2002 Continued on the next page
i 1 3 7 17 17 17 18 18 18 19 19 19 21 61 87 88 90 102 107 112 113 128 133 604 606
p. 23 p. 24 p. 25 p. 27 p. 28
Continued from the previous page
National Expenditures for Basic Research, by Performing Sector and Source of Funding: 1993-2002 National Expenditures for Basic Research, from Funding Sectors to Performing Sectors: 1993-2002 National Expenditures for Development, by Performing Sector and Source of Funding: 1993-2002 National Expenditures for Development, from Funding Sectors to Performing Sectors: 1993-2002 National Expenditures for R&D, by Performing Sector and Source of Funding: 1993-2002 National Expenditures for R&D, from Funding Sectors to Performing Sectors: 1993-2002 Trends in Federal and Non-Federal R&D Expenditures as a Percentage of Total R&D: 1953-2002 Trends in U.S. Research & Development (R&D) and Federal Outlays: 1970, 1980, 1990, 2000 and 2002 U.S. Federal Basic Research Budget Authority, by Budget Function: Fiscal Years 1995–2001 U.S. Federal R&D Budget Authority, by Budget Function: FY 1980–2001
II. Research and Development by States-U.S. California Research & Development (R&D) Profile, 1999-2000 Illinois Research & Development (R&D) Profile, 1999-2000 Maryland Research & Development (R&D) Profile, 1999-2000 Massachusetts Research & Development (R&D) Profile, 1999-2000 Michigan Research & Development (R&D) Profile, 1999-2000 New Jersey Research & Development (R&D) Profile, 1999-2000 New York Research & Development (R&D) Profile, 1999-2000 Pennsylvania Research & Development (R&D) Profile, 1999-2000 Texas Research & Development (R&D) Profile, 1999-2000 Washington Research & Development (R&D) Profile, 1999-2000 State Distribution of Expenditures for R&D, by Performing Sector and Source of Funding: 2000 Top 10 U.S. States in Total R&D Performance, Size of R&D by Performer and R&D as a Percentage of Gross State Product: 2000 III. International Research and Patents International R&D Expenditures in Constant Dollars and as a Percentage of GDP: 1981–2001 Top 20 Global Patenting Organizations, Calendar Year 2001 Top 20 Patenting Countries, 2001
p. 29 p. 30 p. 31 p. 32 p. 33 p. 34 p. 35 p. 37 p. 38 p. 39
p. 41 p. 42 p. 43 p. 44 p. 45 p. 46 p. 47 p. 48 p. 49 p. 50 p. 51 p. 52 p. 54
p. 55 p. 56 p. 58 p. 59
Plunkett Research, Ltd.
A Short Engineering & Research Industry Glossary 510 K: The application filed with the FDA for a new medical device to show that the apparatus is “substantially equivalent” to one that is already marketed. 802.11a: A faster wireless network standard than 802.11b, 802.11a operates in the 5-GHz band at speeds of 50 Mbps or more. This standard may be affected by weather and is not as suitable for outdoor use. This standard may be of little importance if 802.11g becomes popular. 802.16: This very fast wireless network standard includes 802.16 and its extension of 802.16a. 802.16a operates in the 2 to 66 GHz band with speeds as high as 166 Mbps. This standard may eventually enable wireless to compete with T1 lines. Access Network: The network that connects a user's telephone equipment to the telephone exchange. Active Server Page (ASP): A specification for a web page with an ASP extension containing Java Script or Visual Basic code. (See "Java" below.) Active X: A set of technologies developed by Microsoft Corporation for sharing information across different applications. ADME: Absorption, Distribution, Metabolism and Excretion. In clinical trials, the bodily processes studied to determine the extent and duration of systemic exposure to a drug. ADN (Advanced Digital Network): See "IDN (Integrated Digital Network)" below. ADSL (Asymmetrical Digital Subscriber Line): High-speed technology that enables the transfer of data over existing copper phone lines, allowing more bandwidth downstream than upstream. AE (Adverse Event): In clinical trials, a condition not observed at baseline or worsened if present at baseline. Sometimes called Treatment Emergent Signs and Symptoms (TESS). Ambient: Any unconfined portion of the air. Also refers to open air.
www.plunkettresearch.com
Analog: A form of transmitting information characterized by continuously variable quantities. Digital transmission, on the other hand, is characterized by discrete bits of information in numerical steps. An analog signal responds to changes in light, sound, heat and pressure. Analog IC (Integrated Circuit): A semiconductor that processes a continuous wave of electrical signals based on real-world analog quantities such as speed, pressure, temperature, light, sound and voltage. ANDA (Abbreviated New Drug Application): An application filed with the FDA for a drug showing that the substance is the same as an existing, previously approved drug (i.e., a generic version). ANSI: American National Standards Institute. Applied Research: The application of compounds, processes, materials or other items discovered during “basic research” to practical uses. The goal is to move discoveries along to the final development phase. ARPANet: Advanced Research Projects Agency Network. The forefather of the Internet, ARPANet was developed during the latter part of the 1960s by the United States Department of Defense. ASCII: American Standard Code for Information Exchange. 128 standard ASCII codes exist that represent all Latin letters, numbers and punctuation. Each ASCII code is represented by a seven-digit binary number, such as 0000000 or 0000111. This code is accepted as a standard throughout the world. ASP (Application Service Provider): A web site that enables utilization of software and databases that reside permanently on the web site rather than having to be downloaded to the user's computer. Advantages include the fact that multiple remote users may access the same tools over the Internet and that the ASP provider is responsible for developing and maintaining the software. (ASP also refers to Active Server Page. See "Active Server Page" above.) Assay: A laboratory test to identify and/or measure the amount of a particular substance in a sample. Types of assays include endpoint assay, in which a single measurement is made at a fixed time; kinetic assay, in which increasing amounts of a product are formed with time and are monitored at multiple
Plunkett Research, Ltd.
points; microbiological assay, a measurement of the concentration of antimicrobials in biological material; and immunological assay, in which analysis or measurement is based on antigen-antibody reactions. Asynchronous Communications: A stream of data routed through a network as generated instead of in organized message blocks. Most personal computers use this format to send data. ATM (Asynchronous Transfer Mode): A digital switching and transmission technology based on high speed. ATM allows voice, video and data signals to be sent over a single telephone line at speeds from 25 million to 1 billion bits per second (bps). This digital ATM speed is much faster than traditional analog phone lines, which allow no more than 2 million bps. (See "Broadband" below.) Backbone: Traditionally, the part of a communications network that carries the heaviest traffic; the high-speed line or series of connections that forms a large pathway within a network or within a region. The combined networks of AT&T, Worldcom and other large telecommunications companies make up the backbone of the Internet. Bandwidth: The data transmission capacity of a network, measured in the amount of data (in bits and bauds) it can transport in one second. A full page of text is about 15,000 to 20,000 bits. Full-motion, fullscreen video requires about 10,000,000 bits per second, depending on compression. Baseline: A set of data used in clinical studies for control or comparison. Basic Research: Attempts to discover compounds, materials, processes or other items that may be largely or entirely new and/or unique. Basic research may start with a theoretical concept that has yet to be proven. The goal is to create discoveries that can be moved along to "applied research." Basic research is sometimes referred to as “blue sky” research. Baud: Refers to how many times the carrier signal in a modem switches value per second or how many bits a modem can send and receive in a second. Beams: The coverage and geographic service area offered by a satellite transponder. A global beam effectively covers one-third of the earth’s surface. A spot beam provides a very specific high-powered
www.plunkettresearch.com
downlink pattern that is limited to a particular geographical area to which it may be steered or pointed. Binhex: A means of changing non-ASCII (or nontext) files into text/ASCII files so that they can be used, for example, as e-mail. Bioavailability: In pharmaceuticals, the rate and extent to which a drug is absorbed or is otherwise available to the treatment site in the body. Bioequivalence: In pharmaceuticals, the demonstration that a drug’s rate and extent of absorption are not significantly different from those of an existing drug that is already approved by the FDA. Bioinformatics: Computer-simulated generation and testing of new chemical compounds for possible drug use. This method is much faster and more costeffective than manual methods. Biologic: Any virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic or analogous product or arsphenamine or one of its derivatives (or any other trivalent organic arsenic compound) applicable to the prevention, treatment or cure of disease or injury. Biotechnology: A set of powerful tools that employ living organisms (or parts of organisms) to make or modify products, improve plants or animals (including humans) or develop microorganisms for specific uses. Early uses of biotechnology included traditional animal and plant breeding techniques and the use of yeast in making bread, beer, wine and cheese. Today, biotechnology is most commonly thought of to include the development of human medical therapies and processes using recombinant DNA, cell fusion, other genetic techniques and bioremediation. Bit: A single digit number, either a one or a zero, which is the smallest unit of computerized data. Bluetooth: An industry standard for a technology that enables wireless, short-distance infrared connections between devices such as PCs, Palm Pilots or PDAs, laptops, cell phones and Internet appliances. It competes with 802.11b.
Plunkett Research, Ltd.
BPS (Bits Per Second): An indicator of the speed of data movement. Branding: A marketing strategy that takes a wellknown brand and utilizes brand capital in order to increase the brand's market share, sales and availability; establish credibility; improve satisfaction; raise the profile of the firm; and increase profits. Bridge: A device that links two local area networks together so they can share files and e-mail. Broadband: The high-speed transmission range for telecommunications and computer data. Broadband refers to any transmission at 2 million bps (bits per second) or higher (much higher than analog speed). A broadband network can carry voice, video and data all at the same time. Internet users enjoying broadband access typically connect to the Internet via DSL line, cable modem or T1 line. Browse: A term referring to the viewing of computerized data. Several Internet browsers support a browse mode that allows users to sort through data quickly. (See "Browser" below.) Browser: A program that allows a user to read Internet text or graphics and to navigate from one page to another. The most popular browsers are Microsoft Internet Explorer and Netscape Navigator. B-to-B, or B2B: See "Business-to-Business" below. B-to-C, or B2C: See "Business-to-Consumer" below.
www.plunkettresearch.com
Business-to-Government: An organization focused on selling products, services or data to government units, rather than commercial businesses or consumers. Byte: There are eight bits in a byte. This set stands for a single character. Cable Modem: An interface between a cable television system and a computer or router. Most cable modems are external devices that connect to the PC through a standard 10Base-T Ethernet card and twisted-pair wiring. External Universal Serial Bus (USB) modems and internal PCI modem cards are also available. The cable modem enables a computer to access the Internet via the TV cable. Cable modem access can be very high-speed and is much faster than traditional "dial-up" access via a standard telephone line. Cable modem speeds vary, depending on the cable modem system and current traffic load. From the Internet to the computer the modem may connect at speeds as high as 1 to 3 Mbps. From the computer to network, speeds typically run between 500 Kbps and 2.5 Mbps. Cable modem access competes with DSL access. Caching: Storing data in a temporary location closer to the user so that it can be retrieved quickly when requested. CAD (Computer-Aided Design): CAD software, which generally runs on workstations, is a tool used to provide three-dimensional, on-screen design for everything from buildings to automobiles to clothing. (See "CAM" and "CAE" below.) CAE: Computer-aided engineering.
B-to-G, or B2G: See "Business-to-Government" below. Buffer: A location for temporarily storing data being sent or received. Usually located between two devices that have different data transmission rates. Business-to-Business: An organization focused on selling products, services or data to commercial customers rather than individual consumers. Business-to-Consumer: An organization focused on selling products, services or data to individual consumers rather than commercial customers.
Call Automation: Part of the telephone equipment revolution, including voice mail, automated sending and receiving of faxes and the ability for customers to place orders and gather information using a touchtone telephone to access sophisticated databases. (See "Voice Mail" below.) CAM: Computer-aided manufacturing. CANDA (Computer-Assisted New Drug Application): An electronic submission of a new drug application (NDA) to the FDA. Capacitor: An electronic circuit device for temporary storage of electrical energy.
Plunkett Research, Ltd.
www.plunkettresearch.com
CAPLA (Computer-Assisted Product License Application): An electronic submission of a biological product license application (PLA) to the FDA.
CDMA (Code Division Multiple Access): A multiple-access scheme where stations use spreadspectrum modulations and orthogonal codes to avoid interfering with one another.
Cardiac Catheterization Laboratory: Facilities offering special diagnostic procedures for cardiac patients, including the introduction of a catheter into the interior of the heart by way of a vein or artery or by direct needle puncture. Procedures must be performed in a laboratory or a special procedure room.
CDRH (Center for Devices and Radiological Health): The branch of the FDA responsible for the regulation of medical devices. www.fda.gov/cdrh
Carrier: In communications, the basic radio, television or telephony center of transmit signal. The carrier in an analog signal is modulated by varying volume or shifting frequency up or down in relation to the incoming signal. Satellite carriers operating in the analog mode are usually frequency modulated. CASE (Computer Assisted Software Engineering): The application of computer technology to systems development activities, techniques and methodologies. Sometimes referred to as Computer Aided Systems Engineering. Catheter: A tubular instrument used to add or withdraw fluids. Heart or cardiac catheterization involves the passage of flexible catheters into the great vessels and chambers of the heart. IV catheters add intravenous fluids to the veins. Foley catheters withdraw fluid from the bladder. Significant recent advances in technology allow administration of powerful drug and diagnostic therapies via catheters. CATV: Cable television. CBER (Center for Biologics Evaluation and Research): The branch of the FDA responsible for the regulation of biological products, including blood, vaccines, therapeutics and related drugs and devices to ensure purity, potency, safety, availability and effectiveness. www.fda.gov/cber CDER (Center for Drug Evaluation and Research): The branch of the FDA responsible for the regulation of drug products. www.fda.gov/cder CDF (Channel Definition Format): Used in Internet-based broadcasting. With this format, a channel serves as a web site that also sends an information file about that specific site. Users subscribe to a channel by downloading the file.
CFR (Code of Federal Regulations): The CFR is a codification of the general and permanent rules published in the Federal Register by the executive departments and agencies of the federal government. The code is divided into 50 titles that represent broad areas subject to federal regulation. Title 21 of the CFR covers FDA regulations. CGI (Common Gateway Interface): A set of guidelines that determines the manner in which a web server receives and sends information to and from software on the same machine. CGI-BIN: The frequently used name of a directory on a web server where CGI programs exist. Class I Device: An FDA classification of medical devices. General controls are sufficient to ensure safety and efficacy. Class II Device: An FDA classification of medical devices. Performance standards and special controls are sufficient to ensure safety and efficacy. Class III Device: An FDA classification of medical devices. Pre-market approval is required to ensure safety and efficacy, unless the device is substantially equivalent to a currently marketed device. (See “510 K” above.) CLEC (Competitive Local Exchange Carrier): A newer company providing local telephone service that competes against larger, traditional firms known as ILECs (Incumbent Local Exchange Carriers). Client/Server: In networking, a way of running a large computer setup. The server is the host computer that acts as the central holding ground for files, databases and application software. The clients are all of the PCs connected to the network that share data with the server. This represents a vast change from past networks, which were connected to expensive, complicated “mainframe” computers.
Plunkett Research, Ltd.
Cloning (Reproductive): A method of reproducing an exact copy of an animal or, potentially, an exact copy of a human being. A scientist removes the nucleus from a donor's unfertilized egg, inserts a nucleus from the animal to be copied and then stimulates the nucleus to begin dividing to form an embryo. In the case of a mammal, such as a human, the embryo would then be implanted in the uterus of a host female. Also see "Cloning (Therapeutic)." Cloning (Therapeutic): A method of reproducing exact copies of cells needed for research or for the development of replacement tissue or organs. A scientist removes the nucleus from a donor's unfertilized egg, inserts a nucleus from the animal whose cells are to be copied and then stimulates the nucleus to begin dividing to form an embryo. However, the embryo is never allowed to grow to any significant stage of development. Instead, it is allowed to grow for a few hours or days and stem cells are then removed from it for use in regenerating tissue. Also see "Cloning (Reproductive)." CMOS (Complementary Metal-Oxide Semiconductor): Integrated-circuit technology used for processors and memory. Coaxial Cable: A type of cable widely used to transmit telephone and broadcast traffic. The distinguishing feature is an inner strand of wires surrounded by an insulator that is in turn surrounded by another conductor, which serves as the ground. Cable TV wiring is typically coaxial. Codec: Hardware or software that converts analog to digital and digital to analog (in both audio and video formats). Codecs can be found in digital telephones, set-top boxes, computers and videoconferencing equipment. The term is also used to refer to the compression of digital information into a smaller format. Co-Location: Refers to the hosting of computer servers at locations operated by service organizations. Co-location is offered by firms that operate specially designed co-location centers with high-levels of security, extremely high-speed telecommunication lines for Internet connectivity and reliable backup electrical power systems in case of power failure, as well as a temperature controlled environment for optimum operation of computer systems.
www.plunkettresearch.com
Commerce Chain Management (CCM): In ecommerce, this refers to Internet-based tools to facilitate sales, distribution, inventory management and content personalization. (See also "Supply Chain.") Compression: A technology in which a communications signal is squeezed so that it uses less bandwidth (or capacity) than it normally would. This saves storage space and shortens transfer time. The original data is decompressed when read back into memory. COMSAT: The Communications Satellite Corporation. COMSAT serves as the U.S. Signatory to INTELSAT and INMARSAT. Coordinator: In clinical trials, the person at an investigative site who handles the administrative responsibilities of a clinical trial, acts as a liaison between the investigative site and the sponsor and reviews data and records during a monitoring visit. COSTART: In medical and drug product development, a dictionary of adverse events and body systems used for coding and classifying adverse events. CPMP (Committee on Proprietary Medicinal Products): A committee, composed of two people from each EU Member State (see “EU” below), that is responsible for the scientific evaluation and assessment of marketing applications for medicinal products in the EU. The CPMP is the major body involved in the harmonization of pharmaceutical regulations within the EU and receives administrative support from the European Medicines Evaluation Agency. (See “EMEA” below.) CPU (Central Processing Unit): The part of a computer that interprets and executes instructions. It is composed of an arithmetic logic unit, a control unit and a small amount of memory. CRA (Clinical Research Associate): An individual responsible for monitoring clinical trial data to ensure compliance with study protocol and FDA GCP regulations. CRF (Case Report Form): In clinical trials, a standard document used by clinicians to record and report subject data pertinent to the study protocol.
Plunkett Research, Ltd.
CRO (Contract Research Organization): An independent organization that contracts with a sponsor of a clinical investigation to conduct part of the work on a clinical study. Drug makers and medical device makers frequently outsource work to CROs. CRT (Case Report Tabulation): In clinical trials, a tabular listing of all data collected on study case report forms. CT Scanner: In medicine, a computed tomographic scanner used for head or whole body scans. CVMP (Committee for Veterinary Medicinal Products): A committee that is a veterinary equivalent of the CPMP (see above) in the EU (see below). Cyberspace: Refers to the entire realm of information available through computer networks. Datanets: Private networks of land-based telephone lines, satellites or wireless networks that allow corporate users to send data at high speeds to remote locations while bypassing the speed and cost constraints of traditional telephone lines. Defibrillator: In medicine, an instrument used externally (as electrodes on the chest) or implanted (as a small device similar in size to a pacemaker) that delivers an electric shock to return the heart to its normal rhythm. Development: The phase of research and development in which researchers attempt to create new products from the results of discoveries and applications created during basic and applied research. Device: In medical product development, according to the FDA, an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent or other similar or related article, including any component, part or accessory, that 1) is recognized in the official National Formulary or United States Pharmacopoeia or any supplement to them, 2) is intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment or prevention of disease, in man or animals or 3) is intended to affect the structure of the body of man or animals and does not achieve any of its principal intended purposes through chemical action within or
www.plunkettresearch.com
on the body of man or animals and is not dependent upon being metabolized for the achievement of any of its principal intended purposes. Diagnostic Radioisotope Facility: In medicine, the use of radioactive isotopes (radiopharmaceuticals) as tracers or indicators to detect an abnormal condition or disease in the body. Dial-Up Access: The connection of a computer or other device to a network through a modem and a public telephone network. The only difference between dial-up access and a telephone connection is that computers are at each end of the connection rather than people. Dial-up access is slower than DSL, ISDN and other advanced connections. Digital: Transmission of a signal reducing all of its information to ones and zeros and then regrouping them at the reception end. Digital transmission vastly improves the carrying capacity of the spectrum while reducing noise and distortion of the transmission. Digital Local Telephone Switch: A computer that interprets signals (dialed numbers) from a telephone caller and routes calls to their proper destinations. A digital switch also provides a variety of calling features not available in older analog switches, such as call waiting. Digital Signal Processor: A chip that converts analog signals such as sound and light into digital signals. Disaster Recovery: A set of rules and procedures that allow a computer site to be put back in operation after a disaster has occurred. Moving backups off-site constitutes the minimum basic precaution for disaster recovery. The remote copy is used to recover data if the local storage is inaccessible after a disaster. Discrete Semiconductor: A chip with one diode or transistor. Disk Mirroring: A data redundancy technique in which data is recorded identically on multiple separate disk drives at the same time. When the primary disk is off-line, the alternate takes over, providing continuous access to data. Disk mirroring is sometimes referred to as RAID. Distributor: Distributors do not manufacture but may be involved in sales, marketing, warehousing or
Plunkett Research, Ltd.
www.plunkettresearch.com
shipping of drugs and/or medical devices. In medicine, distributors are subject to medical device incident reporting, record keeping, tracking and registration and certification requirements under the Safe Medical Devices Act (see “SMDA” below).
EDI (Electronic Data Interchange): An accepted standard format for the exchange of data between various companies’ networks. EDI allows for the transfer of e-mail as well as orders, invoices and other files from one company to another.
DMB (Data Monitoring Board): A committee that monitors the progress of a clinical trial and carefully observes the safety data.
EFGCP (European Forum for Good Clinical Practices): The organization dedicated to finding common ground in Europe on the implementation of Good Clinical Practices. (See “GCP” below.) www.efgcp.org
DOCSIS (Data over Cable Service Interface Specification): Standards for transferring data over cable television. Domain: A domain name that has server records associated with it. (See "Domain Name" below.) Domain (Top-Level): Either an ISO country code or a common domain name such as .com, .org or .net. DRM (Digital Rights Management): Enables control and maintenance of publishers’ rights by delivering encrypted information and, instead of providing the key (or using the recipient’s public key for encryption), in effect permitting the recipient to borrow the decryption key in a highly controlled fashion. Drug Utilization Review: A quantitative assessment of patient drug use and physicians’ patterns of prescribing drugs in an effort to determine the usefulness of drug therapy. DS-1: A digital transmission format that transmits and receives information at a rate of 1,544,000 bits per second. DSL (Digital Subscriber Line): See "Digital Subscriber Line" above. DSMB (Data and Safety Monitoring Board): See “DMB” above. Duplicate Host: A single host name that maps to duplicate IP addresses. Dynamic HTML: Web content that changes with each individual viewing. For example, the same site could appear differently depending on geographic location of the reader, time of day, previous pages viewed or the user’s profile. EC (European Community): See “EU” below.
EFT (Electronic Funds Transfer): A method of moving money from one account to another via computer. Withdrawing funds from an account using an ATM is a good example, as is paying bills using Quicken software on a PC. ELA (Establishment License Application): An ELA is required for the approval of a biologic (see "Biologic" above). It permits a specific facility to manufacture a biological product for commercial purposes. (Compare to “PLA” below.) E-Mail: The use of software that allows the posting of messages (text, audio or video) over a network. Email can be used on a LAN, a WAN or the Internet, as well as via online services such as America Online. It can be used to send a message to a single recipient or may be broadcast to a large group of people at once. EMEA (European Medicines Evaluation Agency): The European agency responsible for supervising and coordinating applications for marketing medicinal products in the European Union (see “EU” below and “CPMP” above). The EMEA is headquartered in the U.K. www.eudraportal.eudra.org Emission: The release or discharge of a substance into the environment; generally refers to the release of gases or particulates into the air. Endpoint: A clinical or laboratory measurement used to assess safety, efficacy or other trial objectives of a test article in a clinical trial. Environmental Audit: An independent assessment of a facility's compliance procedures, policies and controls. Many pollution prevention initiatives require an audit to determine where wastes may be reduced or eliminated or energy conserved.
Plunkett Research, Ltd.
ESWL (Extracorporeal Shock Wave Lithotripter): A medical device used for treating stones in the kidney or urethra. The device disintegrates kidney stones non-invasively through the transmission of acoustic shock waves directed at the stones. Ethernet: The standard format on which local area network equipment works. Abiding by Ethernet standards allows equipment from various manufacturers to work together. EU (European Union): Previously known as the European Community (EC), the EU is a consolidation of different European countries (Member States) functioning as one body to facilitate trade. There are currently 15 member states: Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, The Netherlands, Portugal, Spain, Sweden and the United Kingdom. http://erupa.eu.int EU Competence: The jurisdiction in which the EU can taken legal action. Expert Systems: A practical development of AI (see "AI") that requires creation of a knowledge base of facts and rules furnished by human experts and uses a defined set of rules to access this information in order to suggest solutions to problems. Extensible Markup Language: See "XML" below. Extranet: A computer network that is accessible in part to authorized outside persons, as opposed to an intranet, which uses a firewall to limit accessibility.
www.plunkettresearch.com
commerce. The FDA’s mission is to protect the public from harm and encourage technological advances that hold the promise of benefiting society. www.fda.gov FDDI (Fiber Distributed Data Interface): A token ring passing scheme that operates at 100 Mbps over fiber-optic lines with a built in geographic limitation of 100 kilometers. This type of connection is faster than both Ethernet and T-3 connections. (See "Token Ring" below.) Fiber Optics: A type of telephone cable, made from glass, that can handle vast amounts of voice, data and video at once by carrying them along on beams of light. File Server: A computer that is modified to store and transfer large amounts of data to other computers. File servers often receive data from mainframes and store it for transfer to other micros, or from other micros to mainframes. Firewall: Hardware or software that keeps unauthorized users from accessing a server or network. Firewalls are designed to prevent data theft and unauthorized web site manipulation by "hackers." Frame Relay: An accepted standard for sending large amounts of data over phone lines and private datanets. Frame Relay refers to the fact that data is broken down into standard size "frames" prior to transmission.
FAQ: An acronym for "frequently asked questions," this kind of document answers inquiries about a given topic. Generally, FAQs come in the form of a help file or a hypertext document.
Frequency: The number of times that an alternating current goes through its complete cycle in one second. One cycle per second is referred to as one hertz; 1,000 cycles per second, one kilohertz; 1 million cycles per second, one megahertz; and 1 billion cycles per second, one gigahertz.
FCC (Federal Communications Commission): See "Federal Communications Commission" below.
Frequency Band: A term for designating a range of frequencies in the electromagnetic spectrum.
FD&C Act (Food, Drug and Cosmetic Act): The federal body of law that governs the manufacture, sale and distribution of food, drugs and cosmetics.
FTP (File Transfer Protocol): A widely used method of transferring data and files between two Internet sites.
FDA (Food and Drug Administration): The U.S. government agency responsible for the enforcement of the FD&C Act (see above), ensuring industry compliance with laws regulating products in
Fuel Cell: The fuel cell, in basic terms, consists of quantities of hydrogen and oxygen which are separated by a catalyst. Inside the cell, a chemical reaction within the catalyst generates electricity.
Plunkett Research, Ltd.
Byproducts of this reaction may include heat, carbon dioxide and water. Most fuel cells are based on hydrogen extracted from such sources as gasoline or methanol. Each source has its advantages and disadvantages. Eventually, stationary fuel cells may consume hydrogen extracted from biomass, natural gas or even water. Fuzzy Logic: Used in artificial intelligence, fuzzy logic recognizes that statements are not just "true" or "false," but also "more or less certain" or "very unlikely." Gateway: A device connecting two or more networks that may use different protocols and media. Gateways translate between the different networks and can connect locally or over wide area networks. GCP (Good Clinical Practices): FDA regulations and guidelines that define the responsibilities of the key figures involved in a clinical trial, including the sponsor, the investigator, the monitor and the Institutional Review Board. (See “IRB” below.) Gene Chips: See “DNA Chip” above. Genetically Modified (GM): Bioengineered food that is designed to resist herbicides and pests, has higher nutritional value than non-engineered food and/or lasts longer on the shelf. An example of GM food is a soybean that has been specially modified to be impervious to the application of a specific pesticide. Genomics: The study of genes, their role in diseases and our ability to manipulate them. Geostationary: A geosynchronous satellite angle with zero inclination, making a satellite appear to hover over one spot on the earth's equator. GIF (Graphic Interchange Format): A widely used format for image files. Gigabyte: A group of bytes generally defined as either 1,000 or 1,024 megabytes. Gigahertz (GHz): One billion cycles per second. See "Frequency" above. Global System for Mobile Communications (GSM): The standard cellular format used throughout Europe, making one type of cellular
www.plunkettresearch.com
phone usable in every nation on the continent and in the U.K. Globalization: The increased mobility of goods, services, labor, technology and capital throughout the world. Although globalization is not a new development, its pace has increased with the advent of new technologies, especially in the areas of telecommunications, finance and shipping. GLP (Good Laboratory Practices): A collection of regulations and guidelines to be used in laboratories where research is conducted on drugs, biologics or devices that are intended for submission to the FDA. GMP (Good Manufacturing Practices): A collection of regulations and guidelines to be used in manufacturing drugs, biologics and medical devices. Gopher: A way of making menus of material available over the Internet. This is a client/server form of program, meaning that the user must have a gopher client program in order to utilize it. HDML (Handheld Devices Markup Language): A text-based markup language designed for display on a smaller screen (e.g., cellular phone, PDA, pager). Enables the mobile user to send, receive and redirect e-mail as well as access the Internet (HDML-enabled web sites only). HDSL: High data rate digital subscriber line, delivering up to T1 or E1 speeds. Hertz: A measure of frequency equal to one cycle per second. Most radio signals operate in ranges of megahertz or gigahertz. Hit: A single request from a web browser for something from a web server, e.g., a request for text or graphics. Home Page: The main page of a web site. Usually, the home page features links to other pages within the site. Host: A host computer is any machine on a network that is responsible for services received by other machines on that network. Host Name: The first portion of a host's domain name. Also known as a firstname.
Plunkett Research, Ltd.
HotJava: This set of products, developed by Sun Microsystems, utilizes Java technology. A set of libraries intended for building applications and a Java-enabled web browser are among existing HotJava products. HTML (Hypertext Markup Language): A language for coding text for viewing on the World Wide Web. HTML is unique because it enables the use of hyperlinks from one site to another, creating a web. HTTP (Hypertext Transfer Protocol): The protocol used most frequently on the World Wide Web to move hypertext files between clients and servers on the Internet. Hub: In networking, a centralized switch box, or a common connection point, for devices in a network. Hubs contain multiple ports that can intertransmit information in order to maximize the viewing of data. Several types of hubs exist, including passive hubs (data conduits), intelligent or manageable hubs (with additional traffic-monitoring features) and switching hubs. Switching hubs read the destination address of each packet of information and then forward the packet to the correct location.
www.plunkettresearch.com
companies (CLECs, or Competitive Local Exchange Carriers) were enabled to compete against the ILECS and were granted access to their system wiring. Imaging: In medicine, the viewing of the body’s organs through external, high-tech means. This reduces the need for broad exploratory surgery. These advances, along with new types of surgical instruments, have made minimally invasive surgery possible. Imaging includes MRI (Magnetic Resonance Imaging), CT (Computed Tomography or “CAT scan”) and MEG (magnetoencephalography), improved x-ray technology, mammography, ultrasound and angiography. Immunoassay: An immunological assay. Types include agglutination, complement-fixation, precipitation, immunodiffusion and electrophoretic assays. Each type of assay utilizes either a particular type of antibody or a specific support medium (such as a gel) to determine the amount of antigen present. In Vitro: Laboratory experiments conducted in the test tube or otherwise, without using live animals and/or humans. In Vivo: Laboratory experiments conducted with live animals and/or humans.
Hyperlink: An element in an electronic document that links to another document or to another place in the same document. Generally, the user clicks on the hyperlink in order to follow it.
IND (Investigational New Drug Exemption): An IND must be filed with the FDA prior to initiating clinical trials of drugs or biologics.
ICANN: The Internet Corporation for Assigned Names and Numbers. It acts as the central coordinator for the Internet’s technical operations.
Inert Ingredients: Substances that are not active, such as water, petroleum distillates, talc, corn meal or soaps.
ICD9: International Classification of Diseases Version 9. A government coding system used for classifying diseases and diagnoses.
Informed Consent: Must be obtained in writing from people who agree to be clinical trial subjects prior to their enrollment in the study. The document must explain the risks associated with the study and treatment and describe alternative therapy available to the patient. A copy of the document must also be provided to the patient.
IDE (Investigational New Device Exemption): An IDE must be filed with the FDA prior to initiating clinical trials of medical devices considered to pose a significant risk to human subjects. IEEE (Institute of Electrical and Electronic Engineers): A standards body. ILEC (Incumbent Local Exchange Carrier): A traditional telephone company that was providing local service prior to the establishment of the Telecommunications Act of 1996, when upstart
Infrastructure: The telecommunications infrastructure is comprised of all of the cable and equipment installed in the worldwide telecommunications market. Most of today’s telecommunications infrastructure is connected by copper and fiber-optic cable, which represents a huge capital investment that telephone companies would
Plunkett Research, Ltd.
www.plunkettresearch.com
like to continue to utilize in as many ways as possible.
many types of Internet appliances will be of common use in homes in the near future.
INMARSAT: The International Maritime Satellite Organization operates a network of satellites used in international transmissions for all types of international mobile services, including maritime, aeronautical and land mobile.
Internet Telephony: This category of hardware and software enables users to utilize the Internet to make telephone calls, both local and long-distance. Also known as "voice over IP" or VoIP. Internet telephony is growing very rapidly, especially in such Asia Pacific nations as Japan and China.
Integrated Circuit (IC): Another name for a semiconductor, an IC is a piece of silicon on which thousands (or millions) of transistors have been combined. INTELSAT: The International Telecommunications Satellite Organization operates a network of 20 satellites, primarily for international transmissions, and provides domestic services to some 40 countries. Interactive TV: Allows two-way data flow between a viewer and the cable TV system. A user can exchange information with the cable system—for example, by ordering a product related to a show he/she is watching, or by voting in an interactive survey. Interexchange Carrier (IXC or IEC): Any company providing long-distance phone service between LECs and LATAs. (See "LEC" and "LATAs" below.) Interface: Refers to (1) a common boundary between two or more items of equipment or between a terminal and a communication channel, (2) the electronic device that interconnects two or more devices or items of equipment having similar or dissimilar characteristics or (3) the electronic device placed between a terminal and a communication channel to protect the network from the hazard of excess voltage levels. Internet: A global computer network that provides an easily accessible way for hundreds of millions of users to send and receive data electronically when appropriately connected via computers or wireless devices. Access is generally through HTML-enabled sites on the World Wide Web. Also known as "the Net." Internet Appliance: A non-PC device that connects users to the Internet for specific or general purposes. A good example is an electronic game machine with a screen and Internet capabilities. It is anticipated that
Intranet: A network protected by a firewall for sharing data and e-mail within an organization or company. Usually, intranets are used by organizations for internal communication. Investigator: In clinical trials, clinicians who agree to supervise the use of an investigational drug, device or biologic in humans. Responsibilities of the investigator include administering the drug, observing and testing the patient, collecting data and monitoring the care and welfare of the patient. Responsibilities of the investigator are defined in FDA regulations. IP Number/IP Address: A number or address with four parts that are separated by dots. Each machine on the Internet has its own IP (Internet protocol) number, which serves as an identifier. IRB (Institutional Review Board): This group of individuals is found in most medical institutions. The main function of the IRB is to review protocols for ethical consideration (to ensure the rights of the patients). Secondly, the IRB evaluates the benefit-torisk ratio of a new drug to see that the risk is acceptable for patient exposure. Responsibilities of the IRB are defined in FDA regulations. ISDN (Integrated Services Digital Networks): Internet connection services offered at higher speeds than standard "dial-up" service. While ISDN was considered to be an advanced service at one time, it has been eclipsed by much faster DSL, cable modem and T1 line service. ISO 9000, 9001, 9002: Standards set by the International Organization for Standardization for quality procedures. ISO 9000, 9001 and 9002 are the quality certifications for manufacturing. ISP (Internet Service Provider): A company that sells access to the Internet to individual subscribers. Leading examples are MSN and AOL.
Plunkett Research, Ltd.
IT (Information Technology): The systems, including hardware and software, that move and store voice, video and data via computers and telecommunications. ITU (International Telecommunications Union): The international body responsible for telephone and computer communications standards describing interface techniques and practices. These standards include those that define how a nation’s telephone and data systems connect to the worldwide communications network. Java: A programming language developed by Sun Microsystems that allows web pages to display interactive graphics. Java can be read by people using any type of computer or operating system. JPEG (Joint Photographic Experts Group): A widely used format for image files. Just-in-Time Delivery: Refers to a supply chain practice where manufacturers receive components on or just before the time that they are needed on the assembly line, rather than bearing the cost of maintaining several days' or weeks' supply in a warehouse. This adds greatly to the cost-effectiveness of a manufacturing plant and puts the burden of warehousing and timely delivery on the supplier of the components. Ka-Band: The frequency range from 18 to 31 GHz. The spectrum allocated for satellite communication is 30 GHz for the up-link and 20 GHz for the downlink. Kbps: One thousand bits per second. Kilobyte: A measure for 1,000 (to be exact, 1,024) bytes. Kilohertz (kHz): A measure of frequency equal to 1,000 Hertz. LAN (Local Area Network): A computer network that is generally within one office or one building. The LAN can be very inexpensive and efficient to set up when small numbers of computers are involved. It may require a network administrator and a serious investment if hundreds of computers are hooked up to the LAN. A LAN enables all computers within the office to share files and printers, to access common databases and to send e-mail to others on the network.
www.plunkettresearch.com
LATA (Local Access and Transport Area): Operational service areas established after the breakup of AT&T to distinguish local telephone service from long-distance service. The U.S. is divided into over 160 LATAs. Leased Line: A phone line that is rented for use in continuous, long-term data connections. LEC (Local Exchange Carrier): Any local telephone company, i.e., a carrier, that provides ordinary phone service under regulation within a service area. Also see "ILEC" and "CLEC." LINUX: An open, free operating system that is shared readily with millions of users worldwide. These users continuously improve and add to the software's code. It can be used to operate computer networks and Internet appliances as well as servers and PCs. LSI (Large-Scale Integration): The placement of thousands of electronic gates on a single chip. This makes the manufacture of powerful computers possible. MAN (Metropolitan Area Network): A data and communications network that operates over metropolitan areas and recently has been expanded to nationwide and even worldwide connectivity of highspeed data networks. A MAN can carry video and data. Managed Health Care: A system of prepaid plans providing comprehensive coverage to voluntarily enrolled members. Managed health care typically covers professional fees, hospital services, diagnostic services, emergency services, limited mental services, medical treatment for drug or alcohol abuse, home health services and preventive health care. Marketing: Includes all activities and expenses associated with the promotion of an item, such as selling and advertising costs, market research, public relations, royalties or commissions and souvenirs. Mbps (Megabits per second): One million bits transmitted per second. M-Commerce: Mobile e-commerce over wireless devices. Medical Device: See “Device” above.
Plunkett Research, Ltd.
Megabytes: A measure of 1 million bytes, or 1,024 kilobytes. Megahertz (MHz): A measure of frequency equal to 1 million Hertz. Metropolitan Area Network (MAN): See "MAN." Microprocessor: A computer on a digital semiconductor chip. It performs math and logic operations and executes instructions from memory. (Also known as a Central Processing Unit or CPU.) Microwave: Line-of sight, point-to-point transmission of signals at high frequency. Microwaves are used in data, voice and all other types of information transmission. The growth of fiber-optic networks has tended to curtail the growth and use of microwave relays. MIME (Multipurpose Internet Mail Extensions): A widely used method for attaching non-text files to e-mails. Modem: A device that allows a computer to be connected to a phone line, which in turn enables the computer to receive and exchange data with other machines via the Internet. Modulator: A device that modulates a carrier. Modulators are found in broadcasting transmitters and satellite transponders. The devices are also used by cable TV companies to place a baseband video television signal onto a desired VHF or UHF channel. Home video tape recorders also have built-in modulators that enable the recorded video information to be played back using a television receiver tuned to VHF channel 3 or 4. MPEG, MPEG-1, MPEG-2, MPEG-3: The Moving Picture Experts Group digital standards for the compression of motion or still video for transmission or storage. MRI (Magnetic Resonance Imaging): The use of a uniform magnetic field and radio frequencies to study the tissue and structure of the body. This procedure enables the visualization of biochemical activity of the cell in vivo without the use of ionizing radiation, radioisotopic substances or high-frequency sound.
www.plunkettresearch.com
MSP (Managed Service Provider): An outsourcer that deploys, manages and maintains the back-end infrastructure for Internet businesses. Multipoint Distribution System (MDS): A common carrier licensed by the FCC to operate a broadcastlike omni-directional microwave transmission facility within a given city. MDS carriers often pick up satellite pay-TV programming and distribute it, via their local MDS transmitter, to specially installed antennas and receivers. Nanotechnology: The science of designing, building or utilizing unique structures that are smaller than 100 nanometers. (A nanometer is one billionth of a meter.) Nanotechnology involves microscopic structures that might be no larger than the width of some cell membranes. NDA (New Drug Application): An application requesting FDA approval, after completion of Phase III studies, to market a new drug for human use in interstate commerce. Clinical trial results generally account for approximately 80% of the NDA. Network: In computing, a network is created when two or more computers are connected. Computers may be connected by wireless methods, using such technologies as 802.11b, or by a system of cables, switches and routers. Network Numbers: The first portion of an IP address, which identifies the network to which hosts in the rest of the address are connected. NIH (National Institutes of Health): A branch of the U.S. Public Health Service that conducts experimental research. www.nih.gov Node: Any single computer connected to a network or a junction of communications paths in a network. Nonclinical Studies: In vitro (laboratory) or in vivo (animal) pharmacology, toxicology and pharmacokinetic studies that support the testing of a product in humans. Usually at least two species are evaluated prior to Phase I clinical trials. Nonclinical studies continue throughout all phases of research to evaluate long-term safety issues.
Plunkett Research, Ltd.
www.plunkettresearch.com
NS (Nanosecond): A billionth of a second, a common unit of measure of computer operating speed.
Companies that market orphan drugs are granted a period of market exclusivity in return for the limited commercial potential of the drug.
NTIA (National Telecommunications and Information Administration): A unit of the Department of Commerce that addresses U.S. government telecommunications policy, standards setting and radio spectrum allocation. www.ntia.doc.gov
OS (Operating System): The software that allows applications like word processors or web browsers to run on a computer. For example, Windows 2000 is an operating system.
Nutraceutical: Nutrient + pharmaceutical – a food or part of a food that has been isolated and sold in a medicinal form and claims to offer benefits such as the treatment or prevention of disease. Object Technology: By merging data and software into "objects," a programming system becomes object-oriented. For example, an object called "weekly inventory sold" would have the data and programming needed to construct a flow chart. Some new programming systems–including Java–contain this feature. Object technology is also featured in many Microsoft products. (See "Java" above.) OC3, up to OC192: Very high-speed data lines that run at speeds from 155 to 9,600 Mbps. Online: When a device is online, it is turned on and connected to the Internet or to another device. Someone who is browsing a network or the Internet could be said to be online. Open Source: A software program for which the source code is openly available for modification and enhancement as various users and developers see fit. Open software is typically developed as a public collaboration and grows in usefulness over time. See "LINUX" above. Optical Character Recognition (OCR): An industry-wide classification system for coding information onto merchandise. Enables retailers to record information on each SKU when it is sold and to transmit that information to a computer. This is accomplished through computerized cash registers that include bar-code scanners (called point-of-sale terminals). Orphan Drug: A drug, biologic or antibiotic designated by the FDA as providing therapeutic benefit for an indication (disease or condition) affecting less than 200,000 people in the U.S.
OTC (Over-the-Counter): OTC drug products are FDA-regulated products that do not require a physician’s prescription. Some examples are aspirin, sunscreen, nasal spray and sunglasses. Packet Switching: A higher-speed way to move data through a network, in which files are broken down into smaller "packets" that are reassembled electronically after transmission. PC (Personal Computer): An affordable, efficient computer meant to be used by one person and frequently connected to a network as a client. PCMCIA: Personal Computer Memory Card International Association. Peer Review: The process used by the scientific community, whereby review of a paper, project or report is obtained through comments of independent colleagues in the same field. Perl (Practical Extraction and Report Language): A programming language geared towards text processing. Perl was developed by Larry Wall. Pharmacodynamics: The study of reactions between drugs and living systems. It can be thought of as the study of what a drug does to the body. Pharmacoeconomics: The study of the costs and benefits associated with various treatments. Pharmacokinetics (PK): The study of the processes of bodily absorption, distribution, metabolism and excretion of compounds and medicines. It can be thought of as the study of what the body does to a drug. (See “ADME” above.) Phase I Clinical Trials: Studies in this phase include initial introduction of an investigational drug into humans. These studies are closely monitored and are usually conducted in healthy volunteers. Phase I trials are conducted after the completion of extensive non-
Plunkett Research, Ltd.
clinical or pre-clinical trials not involving humans. Phase I studies include the determination of clinical pharmacology, bioavailability, drug interactions and side effects associated with increasing doses of the drug. Phase II Clinical Trials: Phase II studies include randomized, masked, controlled clinical studies conducted to evaluate the effectiveness of a drug for a particular indication(s). During Phase II trials, the minimum effective dose and dosing intervals should be determined. Phase III Clinical Trials: These studies consist of controlled and uncontrolled trials that are performed after preliminary evidence of effectiveness of a drug has been established. They are conducted to document the safety and efficacy of the drug, as well as to determine adequate directions (labeling) for use by the physician. A specific patient population needs to be clearly identified from the results of these studies. Trials during Phase III are conducted in a large number of patients to determine the frequency of adverse events and to obtain data regarding intolerance. Phase IV Clinical Trials: These studies are conducted after approval of a drug has been obtained to gather data supporting new or revised labeling, marketing or advertising claims. Pivotal Studies: In clinical trials, a Phase III trial that is designed specifically to support approval of a product. These studies are well-controlled (usually by placebo) and are generally designed with input from the FDA so that they will provide data that is adequate to support approval of the product. Two pivotal studies are required for drug product approval, but usually only one study is required for biologics. PLA (Product License Agreement): Required for the approval of a biologic, a PLA permits a manufacturer to produce a biological product for commercial purposes. (Compare to “ELA” above). Plug-In: Any small piece of software that adds extra functions to a larger piece of software. PMA (Pre-Market Approval): PMA is required for the approval of a new medical device or a device that is to be used for life-sustaining or life-supporting
www.plunkettresearch.com
purposes, is implanted in the human body or presents potential risk of illness or injury. POP: An acronym for both "Point of Presence" and "Post Office Protocol." Point of presence refers to a location that a network can be connected to (generally used to count the potential subscriber base of a cellular phone system). Post office protocol refers to the way in which e-mail software obtains mail from a mail server. Port: An interface (or connector) between the computer and the outside world. The number of ports on a communications controller or front-end processor determines the number of communications channels that can be connected to it. The number of ports on a computer determines the number of peripheral devices that can be attached to it. Portal: A comprehensive web site that is designed to be the first site seen when a computer logs on to the web. Portal sites are aimed at broad audiences with common interests and often have links to e-mail usage, a search engine and other features. Yahoo! and MSN.com are portals. Positron Emission Tomography (PET) Scanner : Nuclear medicine imaging technology that uses computers and radioactive (positron emitting) isotopes, which are created in a cyclotron or generator, to produce composite pictures of the brain and heart at work. PET scanning produces sectional images depicting metabolic activity or blood flow rather than anatomy. Post-Marketing Surveillance: The FDA’s ongoing safety monitoring of marketed drugs. Powerline: A method of networking computers, peripherals and appliances together via the electrical wiring that is built in to a home or office. Powerline competes with 802.11b and other wireless networking methods. Preclinical Studies: See “Nonclinical Studies” above. Protocol: A set of rules for communicating between computers. The use of standard protocols allows products from different vendors to communicate on a common network.
Plunkett Research, Ltd.
PSTN (Public Switched Telephone Network): A term that refers to the traditional telephone system. QOL (Quality of Life): In medicine, an endpoint of therapeutic assessment used to adjust measures of effectiveness for clinical decision-making. Typically, QOL endpoints measure the improvement of a patient’s day-to-day living as a result of specific therapy. R&D: Research and Development. Radiation Therapy: Frequently used to destroy cancerous cells, this branch of medicine is concerned with radioactive substances and the usage of various techniques of imaging, with the diagnosis and treatment of disease using any of the various sources of radiant energy. Services can include megavoltage radiation therapy, radioactive implants, stereotactic radiosurgery, therapeutic radioisotope facility or xray radiation therapy. Radioisotope: Radioisotopes have varying properties that allow them to penetrate objects at different rates. For example, a sheet of paper can stop an alpha particle, a beta particle can penetrate tissues in the body and a gamma ray can penetrate concrete. The varying penetration capabilities allow radioisotopes to be used in different ways. (Also called radioactive isotope or radionuclide.) RAM (Random Access Memory): Computer memory used to hold programs and data temporarily. RBOC (Regional Bell Operating Company): Former Bell system telephone companies (or their successors), created as a result of the breakup of AT&T by a Federal Court decree on December 31, 1983 (e.g., Southwestern Bell, now known as SBC). Real Time: A real-time system or software is one specially designed to acquire, process, store and display large amounts of rapidly changing information almost instantaneously, with microsecond responses as changes occur. Request for Bids (RFB): A firm that requires products or outsourced services sends a proposal outlining all requirements to various bidding companies. Proposing companies are asked to place a bid based on the requested goods or services.
www.plunkettresearch.com
Request for Qualifications (RFQ): Asks companies to submit qualifications to provide goods or perform a described level of service. It is used to screen who is qualified to respond to an RFB or RFP. Return on Investment (ROI): A measure of a company's profitability, expressed in percentage as: Net Profit (After Taxes)/Total Dollar Investment Router: An electronic link that enables two different local area networks to talk to each other, even though each network may be based on a different standard. S&R: Science and Research. SACD (Super Audio Compact Disc): A technology that offers high-resolution digital audio. SAN (Storage Area Network): Links host computers to advanced data storage systems. SBIR (Small Business Innovative Research): A three-phase program developed by the U.S. Department of Defense that allocates early-stage research and development funding to small technology companies. Scalable: Refers to a network that can grow and adapt as customer needs increase and change. Scalable networks can easily manage increasing numbers of workstations, servers, user workloads and added functionality. SCSI (Small Computer System Interface): A dominant, international standard interface used by UNIX servers and many desktop computers to connect to storage devices; a physical connection between devices. Semiconductor: A generic term for a device that controls electronic signals. It specifically refers to a material (such as silicon, germanium or gallium arsenide) that can be altered either to conduct electrical current or to block its passage. Server: A computer that performs and manages specific duties for a central network. It may include storage devices. Single Nucleotide Polymorphisms (SNPs): The most common type of genetic variation. SNPs are stable mutations consisting of a change at a single base in a DNA molecule. SNPs can be detected by
Plunkett Research, Ltd.
HTP analyses, for instance with gene chips, and they are then mapped by DNA sequencing. SLIP (Serial Line Internet Protocol): The connection of a traditional telephone line, or serial line, and modem to connect a computer to an Internet site.
www.plunkettresearch.com
Stem Cells: Found in human bone marrow, the blood stream and the umbilical cord, stem cells can be replicated indefinitely and can turn into any type of mature blood cell, including platelets, white blood cells or red blood cells. Also referred to as pluripotent cells. Study Coordinator: See “Coordinator” above.
SMDA (Safe Medical Devices Act): This Act became law in 1990 and amends the Food, Drug and Cosmetic Act to impose additional regulations on medical devices. SMDS (Switched Multimegabit Data Service): A method of extremely high-speed transference of data.
Supply Chain: The complete set of suppliers of goods and services required for a company to operate its business. For example, a manufacturer's supply chain may include providers of raw materials, components, custom-made parts and packaging materials.
SMTP (Simple Mail Transfer Protocol): The primary form of protocol used in the transference of e-mail.
Switch: A network device that directs packets of data between multiple ports, often filtering the data so that it travels more quickly.
SNMP (Simple Network Management Protocol): A set of communication standards for use between computers connected to TCP/IP networks.
T1: A standard for broadband digital transmission over phone lines. Generally, it can transmit at least 24 voice channels at once over copper wires, at a high speed of 1.5 million bps.
SNP: See “Single-Nucleotide Polymorphism” above. SONET (Synchronous Optical Network Technology): A mode of high-speed transmission meant to take full advantage of the wide bandwidth in fiber-optic cables. SPECT (Single Photon Emission Computerized Tomography): A nuclear medicine imaging technology that combines existing technology of gamma camera imaging with computed tomographic imaging technology to provide a more precise and clear image. Sponsor: The individual or company that assumes responsibility for the investigation of a new drug, including compliance with the FD&C Act and regulations. The sponsor may be an individual, partnership, corporation or governmental agency and may be a manufacturer, scientific institution or investigator regularly and lawfully engaged in the investigation of new drugs. The sponsor assumes most of the legal and financial responsibility of the clinical trial. SRDF (Symmetrix Remote Data Facility): A highperformance, host-independent business solution that enables users to maintain a duplicate copy of all or some of their data at a remote site.
T3: This type of transmission over phone lines supports data rates of 45 Mbps. T3 lines consist of 672 channels, and such lines are generally used by Internet service providers. These lines are also referred to as DS3 lines. (Also see “OC3.”) Target: The proteins involved in a specific disease. Drug compounds stick to specific targets in order to have the greatest positive effect and cut down on the incidence of side effects. Taste Masking: The creation of a barrier between a drug molecule and taste receptors so the drug is easier to take. It masks bitter or unpleasant tastes. TBT: Technical Barriers to Trade. TCP/IP (Transmission Control Protocol/Internet Protocol): The combination of a network and transport protocol developed by ARPANET for internetworking IP-based networks. TDMA (Time Division Multiple Access): A digital service for relatively large users of international public-switched telephony, data, facsimile and telex. TDMA also refers to a method of multiplexing digital signals that combines a number of signals passing through a common point by transmitting them
Plunkett Research, Ltd.
sequentially, with each signal sent in bursts at different times. Telecommunications: Systems of hardware and software used to carry voice, video and/or data between locations. This includes telephone wires, satellite signals, cellular links, coaxial cable and related devices. Telnet: A terminal emulation program for TCP/IP networks like the Internet, which runs on a computer and connects to a particular network. Directions entered on a computer that is connected using Telnet will be read and followed just as if they had been entered on the server itself. Through Telnet, users are able to control a server and communicate with other servers on the same network at the same time. Telnet is commonly used to control web servers remotely. TESS: See “AE” above. Token Ring: A local area network architecture in which a token, or continuously repeating frame, is passed sequentially from station to station. Only the station possessing the token can communicate on the network. Transistor: Device used for amplification or switching of electrical current. Trial Coordinator: See “Coordinator” above. UDDI: Universal Description, Discovery and Integration (UDDI), a vital protocol used in Web services. UDDI enables businesses to create a standard description of their activities so that they can be searched for appropriately by automatic software tools. Ultrasound: The use of acoustic waves above the range of 20,000 cycles per second to visualize internal body structures. Frequently used to observe a fetus.
www.plunkettresearch.com
UNIX: A multi-user, multitasking operating system that runs on a wide variety of computer systems, from PCs to mainframes. URL (Uniform Resource Locator): The address that allows an Internet browser to locate a homepage or web site. Utilization Review (or Utilization Management): A system where utilization case managers (frequently registered nurses with several years of hospital experience behind them) are assigned to each patient who receives hospitalization or extended treatment. These case managers constantly review the amount of care being provided to the patient in question, frequently resulting in significant cost savings. UWB: See "Ultrawideband" above. Validation of Data: The procedure carried out to ensure that the data contained in a final clinical trial report match the original observations. VDSL: Very high data rate digital subscriber line, operating at data rates from 12.9 to 52.8 MBPS. Vertical Integration: A business model in which one company owns many (or all) of the means of production of the many goods that comprise its product line. For example, Ford Motor Company's early River Rogue plant was designed by founder Henry Ford so that coal, iron ore and other needed raw materials arrived at one end of the plant and were processed into steel, which was then converted onsite into finished components. At the final stage of the plant, completed automobiles were assembled. Very Small Aperture Terminal (VSAT): A small Earth station terminal, generally 0.6 to 2.4 meters in size, that is often portable and primarily designed to handle data transmission and private-line voice and video communications. VOIP (Voice over IP): See "Internet Telephony."
Ultrawideband: A means of low-power, limitedrange wireless data transmission that takes advantage of bandwidth recently set aside by the FCC. Ultrawideband, or UWB, encodes signals in a dramatically different way, sending digital pulses in a relatively secure manner that will not interfere with other wireless systems that may be operating nearby.
VSAT (Very Small Aperture Terminal): A small Earth station terminal, generally between 0.6 and 2.4 meters in size, which is often portable and primarily designed to handle data transmission and private-line voice and video communications.
Plunkett Research, Ltd.
WAN (Wide Area Network): The other office network (see "LAN"), the WAN stretches over a long distance, usually connecting several buildings or locations. WAP (Wireless Access Protocol): A technology that enables the delivery of World Wide Web pages in a smaller format readable by screens on cellular phones. Web Page: A document on the World Wide Web that is identified by a URL. Web Site: A specific domain name location on the World Wide Web. Each site, which contains a homepage, usually consists of additional documents. Webcasting: The act of using the Internet (the World Wide Web, usually) to broadcast information or entertainment. Webmaster: Any individual who runs a web site. Webmasters generally perform maintenance and upkeep. WHO: World Health Organization. Assists governments in strengthening health services, furnishing technical assistance and aid in emergencies, working on the prevention and control of epidemics and promoting cooperation among different countries to improve nutrition, housing, sanitation, recreation and other aspects of environmental hygiene. Any country that is a member of the United Nations may become a member of the WHO by accepting its constitution. The WHO currently has 191 member states. Wi-Fi: A popular phrase that means 802.11b and other 802.11 specifications. See "802.11b" above. Wi-Fi5: A popular phrase that means 802.11a. See "802.11a" above. WLAN: A wireless local area network. WLANs frequently operate on 802.11-enabled equipment. Workstation: A high-powered desktop computer, usually used by engineers. World Wide Web: A computer system that provides enhanced access to various sites on the Internet through the use of hyperlinks. Clicking on a link displayed in one document takes you to a related
www.plunkettresearch.com
document. The World Wide Web is governed by the World Wide Consortium, located at www.w3.org. Also known as "the web." WSDL: An important protocol to web services, WSDL (web services description language) describes the web service being offered. XML (Extensible Markup Language): A programming language that enables designers to add extra functionality to documents that could not otherwise be utilized with standard HTML coding. XML was developed by the World Wide Web Consortium. It can communicate to various software programs the actual meanings contained in HTML documents. For example, it can enable the gathering and use of information from a large number of databases at once and place that information into one web site window. XML is an important protocol to web services.
Plunkett Research, Ltd.
www.plunkettresearch.com
INTRODUCTION
PLUNKETT'S ENGINEERING AND RESEARCH INDUSTRY ALMANAC, the second edition of our guide to the engineering and research field, is designed as a general source for researchers of all types. The data and areas of interest covered are intentionally broad, from the various types of businesses involved in engineering and research, to advances in biotechnology, to an in-depth look at the 500 major firms (which we call “THE ENGINEERING 500”) within the many sectors that make up the engineering and research industry, including energy, infotech, transportation and much more. This reference book is designed to be a general source for researchers. It is especially intended to assist with market research, strategic planning, employment searches, contact or prospect list creation (be sure to see the export capabilities of the accompanying CD-ROM that is available to book and eBook buyers) and financial research, and as a data resource for executives and students of all types. PLUNKETT'S ENGINEERING AND RESEARCH INDUSTRY ALMANAC takes a rounded approach for the general reader. This book presents a complete overview of the engineering and research field (see “How To Use This Book”). For example, advances in
design automation are discussed, as well as changes in research and development spending and patents. THE ENGINEERING 500 (the actual count is 468 firms) is our unique grouping of the biggest, most successful corporations in all segments of the engineering and research industry. Tens of thousands of pieces of information, gathered from a wide variety of sources, have been researched and are presented in a unique form that can be easily understood. This section includes thorough indexes to THE ENGINEERING 500, by geography, industry, sales, brand names, subsidiary names and many other topics. (See Chapter 4.) Especially helpful is the way in which PLUNKETT'S ENGINEERING AND RESEARCH INDUSTRY ALMANAC enables readers who have no business background to readily compare the financial records and growth plans of engineering companies and major industry groups. You’ll see the mid-term financial record of each firm, along with the impact of earnings, sales and strategic plans on each company’s potential to fuel growth, create new technologies and provide investment and employment opportunities. No other source provides this book’s easy-tounderstand comparisons of growth, expenditures, technologies, imports/exports, corporations, research and many other items of great importance. The
Plunkett Research, Ltd.
information within is crucial to people of all types who may be studying this, one of the most important industries in the world today.
www.plunkettresearch.com
•
This volume is intended to be a general guide to a quickly growing industry. That means that researchers should look to this book for an overview and, when conducting in-depth research, should contact the specific corporations or industry associations in question for the very latest changes and data. Where possible, we have listed contact names, toll-free telephone numbers and World Wide Web site addresses for the companies, government agencies and industry associations involved so that the reader may get further details without unnecessary delay.
•
Tables of industry data and statistics used in this book include the latest numbers available at the time of printing, generally through the end of 2001 or 2002.
•
We have used exhaustive efforts to locate and fairly present accurate and complete data. However, when using this book or any other source for business and industry information, the reader should use caution and due diligence by conducting further research where it seems appropriate. We wish you success in your endeavors, and we trust that your experience with this book will be both satisfactory and productive.
By scanning the data groups and the unique indexes, you can find the best information to fit your personal research needs. The best major companies are profiled and then ranked using several different groups of specific criteria. Which firms are the biggest employers? Which companies earn the most profits? These things and much more are easy to find. In addition to individual company profiles, an overview of global and domestic research and development and its trends is provided. This book’s job is to help you sort through easy-to-understand summaries of today’s technologies and trends in a quick and effective manner. Whatever your purpose for researching the engineering and research field, you’ll find this book to be a valuable guide. Nonetheless, as is true with all resources, this volume has limitations that the reader should be aware of: •
Financial data and other corporate information can change quickly. A book of this type can be no more current than the data that was available as of the time of editing. Consequently, the financial picture, management and ownership of the firm(s) you are studying may have changed since the date of this book. For example, this almanac includes the most up-to-date sales figures and profits available to the editors as of mid 2003. That means that we have typically used corporate financial data as of mid- to late 2002.
•
Corporate mergers, acquisitions and downsizing are occurring at a very rapid rate. Such events may have created significant change, subsequent to the publishing of this book, within a company you are studying.
•
Some of the companies in THE ENGINEERING 500 are so large in scope and in variety of business endeavors conducted within a parent organization that we have been unable to completely list all subsidiaries, affiliations, divisions and activities within a firm’s corporate structure.
Jack W. Plunkett Houston, Texas July 2003
Plunkett Research, Ltd.
www.plunkettresearch.com
HOW TO USE THIS BOOK
The two primary sections of this book are devoted first to an overview of the engineering and research industry and then to the “Individual Data Listings” for THE ENGINEERING 500. If time permits, you should begin your research in the front chapters of this book. Also, you will find lengthy indexes in Chapter 4 and in the back of the book.
Chapter 3: Engineering and Research Industry Contacts – Addresses, Telephone Numbers and World Wide Web Sites. This chapter covers contacts for important government agencies and industry associations. Included are numerous web sites. THE ENGINEERING 500
THE ENGINEERING AND RESEARCH INDUSTRY Glossary: A short list of engineering and research terms. Chapter 1: Major Trends in the Engineering and Research Industry. This chapter presents an encapsulated view of the major trends that are creating rapid changes in the engineering and research industry today. These trends range from changes in venture capital to fluctuations in research and development spending to the recent emphasis on nanotechnology. Chapter 2: Engineering and Research Industry Statistics. This chapter contains charts and tables tracking the scope of the industry.
Chapter 4: THE ENGINEERING 500: Who They Are and How They Were Chosen. The companies compared in this book (the actual count is 468 firms) were carefully selected from the engineering and research industry, primarily in the United States with 64 major foreign firms also included. For a complete description, see THE ENGINEERING 500 indexes in this chapter. Individual Data Listings: Look at one of the companies in THE ENGINEERING 500’s Individual Data Listings. You’ll find the following information fields: Company Name: The company profiles are in alphabetical order by company name. If you don’t find the company you are seeking, it may be a subsidiary or division of one of the firms covered in this book. Try looking it up in
Plunkett Research, Ltd.
the Index by Subsidiaries, Brand Names and Selected Affiliations in the back of the book. Ranks: Industry Group Code: An NAIC code used to group companies within like segments. (See Chapter 4 for a list of codes.) Ranks Within This Company’s Industry Group: Ranks, within this firm’s segment only, for annual sales and annual profits, with 1 being the highest rank. Business Activities: A grid arranged into five major industry categories and several sub-categories. A “Y” indicates that the firm operates within the sub-category. A complete Index by Industry is included in the beginning of Chapter 4. Types of Business: A listing of the primary types of business specialties conducted by the firm. Brands/Divisions/Affiliations: Major brand names, operating divisions or subsidiaries of the firm, as well as major corporate affiliations – such as another firm that owns a significant portion of the company’s stock. A complete Index by Subsidiaries, Brand Names and Selected Affiliations is in the back of the book. Contacts: The names and titles up to 27 top officers of the company are listed, including human resources contacts. Address: The firm’s full headquarters address, the headquarters telephone, plus toll-free and fax numbers where available. Also provided is the World Wide Web site address. Financials: Annual Sales (2002 or the latest fiscal year available to the editors, plus up to four previous years): These are stated in thousands of dollars (add three zeros if you want the full number). This figure represents consolidated worldwide sales from all operations. 2002 figures may be estimates or may be for only part of the year—partial year figures are appropriately footnoted. Annual Profits (2002 or the latest fiscal year available to the editors, plus up to four previous years): These are stated in thousands of dollars (add three zeros if you want the full number). This figure represents consolidated, after-tax net profit from all operations. 2002 figures may be estimates or may be for only part of the year—partial year figures are appropriately footnoted.
www.plunkettresearch.com
Stock Ticker: When available, the unique stock market symbol used to identify this firm’s common stock for trading and tracking purposes is indicated. Where appropriate, this field may contain “private” or “subsidiary” rather than a ticker symbol. Total Number of Employees: The approximate total number of employees, worldwide, as of the end of 2002 (or the latest data available to the editors). Apparent Salaries/Benefits: A “Y” in appropriate fields indicates “Yes.” Due to wide variations in the manner in which corporations report benefits to the U.S. Government’s regulatory bodies, not all plans will have been uncovered during our effort to research this data. Also, the availability to employees of such plans will vary according to the qualifications that employees must meet to become eligible. For example, some benefit plans may be available only to salaried workers—others only to employees who work more than 1,000 hours yearly. Benefits that are available to employees of the main or parent company may not be available to employees of the subsidiaries. NOTE: Generally, employees covered by wealthbuilding benefit plans do not fully own (“vest in”) funds contributed on their behalf by the employer until as many as five years of service with that employer have passed. Pension Plan: The firm offers a pension plan to qualified employees. The type and generosity of these plans vary widely from firm to firm. Caution: Some employers refer to plans as “pension” or “retirement” plans when they are actually 401(k) savings plans that require a contribution by the employee. True pension plans are rarely offered. ESOP Stock Plan (Employees’ Stock Ownership Plan): This type of plan is in wide use. Typically, the plan borrows money from a bank and uses those funds to purchase a large block of the corporation’s stock. The corporation makes contributions to the plan over a period of time, and the stock purchase loan is eventually paid off. The value of the plan grows significantly as long as the market price of the stock holds up. Qualified employees are allocated a share of the plan based on their length of service and their level of salary. Savings Plan, 401(k): Under this type of plan, employees make a tax-deferred deposit into an account. In the best plans, the company makes annual matching donations to the employees’ accounts, typically in some proportion to deposits made by the employees themselves. A good plan will match onehalf of employee deposits of up to 6% of wages. For example, an employee earning $30,000 yearly might
Plunkett Research, Ltd.
deposit $1,800 (6%) into the plan. The company will match one-half of the employee’s deposit, or $900. The plan grows on a tax-deferred basis, similar to an IRA. A very generous plan will match 100% of employee deposits. However, some plans do not call for the employer to make a matching deposit at all. Other plans call for a matching contribution to be made at the discretion of the firm’s board of directors. Actual terms of these plans vary widely from firm to firm. Generally, these savings plans allow employees to deposit as much as 15% of salary into the plan on a tax-deferred basis. However, the portion that the company uses to calculate its matching deposit is generally limited to a maximum of 6%. Stock Purchase Plan: Qualified employees may purchase the company’s common stock at a price below its market value under a specific plan. Typically, the employee is limited to investing a small percentage of wages in this plan. These plans usually offer a 15% discount, but the discount may range from 5 to 15%. Some of these plans allow for deposits to be made through regular monthly payroll deductions. Profit Sharing: Qualified employees are awarded an annual amount equal to some portion of a company’s profits. In a very generous plan, the pool of money awarded to employees would be 15% of profits. Typically, this money is deposited into a long-term retirement account. Caution: Some employers refer to plans as “profit sharing” when they are actually 401(k) savings plans. True profit sharing plans are rarely offered. Highest Executive Salary: The highest executive salary paid, typically a 2002 amount (or the latest year available to the editors) and typically paid to the Chief Executive Officer. Highest Executive Bonus: The apparent bonus, if any, paid to the above person. Second Highest Executive Salary: The nexthighest executive salary paid, typically a 2002 amount (or the latest year available to the editors) and typically paid to the President or Chief Operating Officer. Second Highest Executive Bonus: The apparent bonus, if any, paid to the above person. Competitive Advantage: A brief statement regarding an outstanding feature that gives the firm an edge in the marketplace. Other Thoughts: Apparent Women Officers or Directors: It is difficult to obtain this information on an exact basis, and employers generally do not disclose the data in a
www.plunkettresearch.com
public way. However, we have indicated what our best efforts reveal to be the apparent number of women who either are in the posts of corporate officers or sit on the board of directors. There is a wide variance from company to company. Hot Spot for Advancement for Women/ Minorities: A “Y” in appropriate fields indicates “Yes.” These are firms that appear either to have posted a substantial number of women and/or minorities to high posts or that appear to have a good record of going out of their way to recruit, train, promote and retain women or minorities. (See the Index of Hot Spots For Women and Minorities in the back of the book.) This information may change frequently and can be difficult to obtain and verify. Consequently, the reader should use caution and conduct further investigation where appropriate. Growth Plans/ Special Features: Listed here are observations regarding the firm’s strategy, hiring plans, plans for growth and product development, along with general information regarding a company’s business and prospects. Locations: A “Y” in the appropriate field indicates “Yes.” Primary locations outside of the headquarters, categorized by regions of the United States and by international locations. A complete index by locations is also in the front of this chapter.
Plunkett Research, Ltd.
www.plunkettresearch.com
Chapter 1 Major Trends in the Engineering and Research Industry Major Trends to Watch 1) 2) 3) 4) 5) 6) 7) 8) 9) 10) 11)
Continued Rapid Growth in the Biotech Sector Continued Caution in Investment in New Technology Startup Companies Continued Growth in the Sharing of R&D Initiatives Among Major Corporate Partners Globalization of the Research Efforts of Major Corporations Emphasis on Research and Development in Nanotechnology Continued Growth in Research Partnerships Between Corporations and Universities Continued Growth in Research and Development Spending in the U.S., Despite the Economic Downturn Growth in Defense Research Post 9/11 Number of Patent Applications Soars Growth in the Automation of Research and Design Energy Technology Research Receives Growing Attention, Particularly in Alternative Energy
A Short History of U.S. Industrial Research & Development Corporate research efforts at an organized level began in the chemical dyes industry in Europe in the mid-1800s and soon were launched at a fairly rapid rate in America. In 1876, at the age of 29, Thomas Alva Edison opened a private laboratory in Menlo
Park, New Jersey. Edison’s efforts led to his recordsetting 1,093 U.S. patents, including those for the phonograph and the incandescent light bulb. Edison’s creativity and drive eventually enabled the birth of what would become the General Electric Company, still one of the world’s premier research and manufacturing organizations. By 1900, about 40 various corporate research facilities were operating in the U.S. Rapid acceleration was fostered by a growing middle class that created demand for new products, and later was especially fueled by the intense demands for leading-edge armaments, transport and other products created by World War II. During the war, a man named Vannevar Bush was posted as the director of the Office of Scientific Research and Development within the U.S. Government. Bush’s mandate was to spur intense innovation that would give America a technological edge in warfare. The results, over an astonishingly short period of time, ranged from advanced radar to the atomic bomb. Bush argued persuasively for a long-term federal commitment to supporting industrial research. By 1962, the Federal Government was subsidizing nearly 60% of America’s corporate research budget, for everything from medical breakthroughs to electronics to defense systems. Thereafter, corporations rapidly increased their own investments in research and development efforts, resulting in a nationwide research base of unprecedented scope and cost. By 1992, however, corporate restructuring and cost cutting led to a brief period of retrenching and corporate research budget slashing.
Plunkett Research, Ltd.
In the mid-1990s, companies creating or embracing new technologies were among the most exciting and successful firms in America. As companies were striving to compete, the floodgates of research dollars were once again cranked open. Corporate America’s investments in R&D have climbed at an impressive rate nearly every year since 1996, while Federal Government investments in research have risen at a steady rate. Today, the Federal Government provides about 30% of all research dollars spent in the U.S. As a result, a disproportionate share of America’s economic growth has been created by the technology sector, and the R&D population has blossomed, such that today there are approximately 15,000 corporate research laboratories in America. They employ about 750,000 professionals and invest about $300 billion yearly in research and development. Approximately 20,000 additional U.S. firms conduct R&D at a significant level outside of dedicated labs. Despite the massive scope and highly competitive nature of corporate research, many major companies succeed without significant research efforts. Instead, they rely on components or processes developed by others. A good example is the personal computer manufacturing industry, where leaders Dell and Gateway grew very rapidly by building and marketing computers constructed from components, like hard drives and semiconductors, that were created through the research and development efforts of their suppliers. (Dell has now grown to the point that it has many engineers on its own staff, but it still relies heavily on components developed by suppliers.) A final important thought about the development of industrial R&D: Depending on the nature of their industries, various firms enter into research with widely varying expectations. For example, while aircraft maker Boeing invests nearly $2 billion in R&D yearly, that effort may yield a completely new aircraft model only once every eight or 10 years. In contrast, semiconductor maker Intel, which invests about $4 billion yearly in R&D, introduces breakthrough chip designs on a continual basis and invests only a tiny amount of its total budget in truly long-term research. (See “Intel” below.) Pharmaceutical makers are accustomed to a research-to-market cycle of as long as 10 years in order to discover, develop and commercially launch a new drug. In short, some companies are driven to vast R&D efforts in order to compete in their own rapidly evolving industries, while others patiently invest in long-term R&D hoping it will pay off handsomely through the introduction of entirely new types of
www.plunkettresearch.com
products several years hence. In 2001, publicly held drug firms in the U.S. invested over $15 billion in research and development—double the amount invested in 1994. Nonetheless, the industry launched only 24 new drugs. Here are 11 Major Trends to Watch in Research and Engineering: 1) Continued Rapid Growth in the Biotech Sector Rapid advances in genomics, proteonics and bioinformatics will lead to the introduction of a large number of new genetically engineered drugs over the mid-term. As of mid-2003, there were already approximately 153 approved drugs and 350 drugs in clinical trials that were developed through biotechnology methods. (That is, the use of technology to identify and alter the biological state of a human patient or an organism, such as the use of a drug to change the nature of a human cell. This is a radically different approach to fighting disease from traditional antibiotic methods such as penicillin.) In the most recent economic boom, particularly during late 1999 and much of 2000, venture capitalists and investment bankers bet heavily on biotech, which they saw as a promising technology-based alternative to investing in information technologies such as the Internet. A veritable frenzy of new financing poured into biotech startup companies and initial public offerings (IPOs) in 2000, which funded very aggressive research, development and marketing plans. New investments in U.S. biotech firms totaled about $32 billion in 2000—more than had been invested during the previous six years combined. The level of funding dropped quickly thereafter, largely as a result of the technology industry crash of 2000. New U.S. biotech capital totaled only $12 billion in 2001 (including venture capital, sales of stock and other means), and about $10 to $12 billion in 2002. Future levels of new funding will depend to a large extent on the ability of young biotech firms to get their new drugs successfully through Phase III trials and into the marketplace. Much of the investment burden will be borne by mature, global drug firms that partner with or acquire smaller biotech companies. The U.S. leads the world in biotechnology R&D. While firms in European nations are making serious biotech efforts, Europe as a whole is leagues behind America in the total amount invested in this field.
Plunkett Research, Ltd.
Stem cell and cloning controversies abound in the U.S. while research in these fields flourishes overseas. During the 1980s, a biologist at Stanford University, Irving L. Weissman, was the first to isolate the stem cell that builds human blood (the mammalian hematopoietic cell). Later, Weissman isolated a stem cell in a laboratory mouse and went on to co-found SysTemix, Inc. (now part of drug giant Novartis) and StemCells, Inc. to continue this work in a commercial manner. In November 1998, two different university-based groups of researchers announced that they had accomplished the first isolation and characterization of the human embryonic stem cell (ESC). James A. Thomson at the University of Wisconsin at Madison led one group. John D. Gearhart at the Johns Hopkins University School of Medicine at Baltimore led the second. The ESC is among the most versatile basic building blocks in the human body. Embryos, when first conceived, begin creating small numbers of ESCs, and these cells eventually differentiate and develop into the 200+ cell types that make up the distinct tissues and organs of the human body, from bones to brains. If scientists can reproduce and then guide the development of these basic ESCs, they could theoretically grow replacement organs and tissues in the laboratory—even such complicated tissue as brain cells or heart cells. Ethical and regulatory difficulties have arisen from the fact that the only source for human embryonic stem cells is, logically enough, human embryos. A laboratory can obtain these cells in one of three ways: 1) By inserting a patient’s DNA into an egg and thus producing a blastocyst that is a clone of the patient— which is then destroyed after only a few days of development; 2) by harvesting stem cells from aborted fetuses; or 3) by harvesting stem cells from embryos that are left over and unused after an in vitro fertilization of a hopeful mother. (Artificial in vitro fertilization requires the creation of a large number of test tube embryos per instance, but only one of these embryos is used in the final process.) A rich source of similar but non-embryonic stem cells is bone marrow. Doctors have been performing bone marrow transplants in humans for years. This procedure essentially harnesses the healing power of stem cells, which proliferate to create healthy new blood cells in the recipient. Several other nonembryonic stem cell sources have great promise (see below). In the fall of 2001, a small biotech company called Advanced Cell Technology announced the first cloning of a human embryo. The announcement set
www.plunkettresearch.com
off yet another firestorm of rhetoric and debate on the scientific and ethical questions that cloning and related stem cell technology inspire. While medical researchers laud the seemingly infinite possibilities stem cells promise for fighting disease and the aging process, conservative theologians, policy makers and pro-life groups decry the harvest of cells from aborted fetuses and the possibility of cloning as an ethical and moral abomination. Congress, under the Bush Administration, has banned the use of federal funding for the creation of new embryonic stem cell lines. This action was taken in spite of impassioned testimony regarding the healing potential of stem cells by physicians, researchers and celebrities, such as actor Michael J. Fox on behalf of research for Parkinson's disease, actor Christopher Reeve for spinal injury study and former first lady Nancy Reagan on behalf of Alzheimer's research. Stem cell research has been underway for years at biotech companies including Stem Cells, Inc., Geron and ViaCell. One company, Osiris Therapeutics, has been at work long enough to have several clinical trial programs in progress. The potential benefits are staggering. Through stem cell therapies, neurological disorders could be reversed with the growth of healthy cells in the brain. Injured cells in the spinal column could be regenerated and function fully again. Damaged organs such as hearts, livers and kidneys could be infused with healthy cells. Stem cell (and cloning) research activity is brisk in certain nations outside the U.S. To begin with, certain institutions around the world have stem cell lines in place, and some make them available for purchase. Groups that own existing lines include the National University of Singapore, Monash University in Australia and Hadassah Medical Centre in Israel. More importantly, several Asian nations, including Singapore, South Korea, Japan and China, are investing intensely in biotech research centered on cloning and the development of stem cell therapies. The global lead in the development of stem cell therapies may eventually pass to China, where the Chinese Ministry of Science and Technology readily sees the commercial potential and is enthusiastically funding research. In addition to funding from the Chinese government, investments in labs and research are being backed by Chinese universities, private companies, venture capitalists and Hong Kong investors. Meanwhile, back in the U.S., in December 2002 Stanford University announced plans to develop a privately funded library of human stem cell lines,
Plunkett Research, Ltd.
which means it will be able to operate outside of the restrictions placed on federally funded ESC research and development. It is the first U.S. university to take this path. Potential methods of developing “post-embryonic” stem cells without the use of human embryos: • • • • •
Parthenogenesis—manipulation of unfertilized eggs. Adult Stem Cells—harvesting of stem cells from bone marrow or brain tissue. Other Cells—harvesting of stem cells from human placentas or other cells. De-Differentiation—use of the nucleus of an existing cell, such as a skin cell, that is altered by an egg that has had its own nucleus removed. Transdifferentiation—making a skin cell dedifferentiate back to its primordial state so that it can then morph into a useable organ cell, such as heart tissue.
ESCs (typically harvested from five-day-old human embryos which are destroyed during the process) are used because of their ability to evolve into any cell or tissue in the body. Their versatility is undeniable, yet the implications of the death of the embryo are at the heart of the ethical and moral concerns. Meanwhile, scientists have discovered that there are stem cells in existence in many diverse places in the adult human body, and they are thus succeeding in creating stem cells without embryos, from “postembryonic” cells. Such cells are already showing the ability to differentiate and function in animal and human recipients. Best of all, these types of stem cells are not plagued by problems found in the use of ESCs, such as the tendency to form tumors when ESCs develop into differentiated cells. For scientists, the biggest challenge at present may be to discover the exact process by which stem cells are signaled to differentiate. (Differentiation is the molecular programming that causes stem cells to grow into specific types of tissue such as heart tissue or brain tissue.) Another immense challenge lies in the fact that broad use of therapeutic cloning may require immense numbers of human eggs in which to grow blastocysts.
www.plunkettresearch.com
2) Continued Caution in Investment in New Technology Startup Companies After the crash in tech company stocks in 2000, investors have been downright skittish about putting money into new technology ventures. In 2002, only $850 million was invested by venture capital firms in 110 new and existing companies (of all types), compared to $13.1 billion invested in 750 companies during the peak year of 2000. As for firms able to go public, the start of 2003 has seen a mere four IPOs of American corporations, tech-based or not, as of the end of April. (There were 158 during the same period in 2000.) However, the dark days of tech companies appear to be waning with recent technological advances and a small rebound of the tech stock market. Slowly, investors are beginning to test the waters again. For example, venture capital firm Draper Fisher Jurvetson has invested $47.5 million in 13 firms involved in the exciting new field of nanotechnology since 2000. Over the mid-term, watch for more careful, slow investment in technology firms that are up and running and have respectable numbers with regard to sales and profits. In order to receive scarce venture capital, tech companies must prove that they understand the importance of the bottom line. This depressed climate in venture capital investment is having a seriously detrimental effect on research and development overall. In recent years, many exciting new technologies were developed thanks to basic and applied research conducted by startup companies that were financed by venture capital firms and later by IPOs. While professional venture capital investors know that only about three out of 10 companies they invest in will succeed to any significant degree, they also know that occasionally research conducted at one of those startup firms will create something truly significant and will reap immense profits. Nonetheless, the venture capital market will remain sluggish until (if ever) the stock market regains serious enthusiasm for initial public stock offerings (IPOs) from young firms. This is due to the fact that selling stock in an IPO is the prime method for reaping a cash profit from a venture capital investment. 3) Continued Growth in the Sharing of R&D Initiatives Among Major Corporate Partners In fields as diverse as telecommunications, semiconductors, alternative energy, aerospace, transportation and pharmaceuticals, major corporations are sharing the increasingly immense costs of research and development. These efforts may
Plunkett Research, Ltd.
www.plunkettresearch.com
InnoCentive, a unique, online collaborative research effort: At www.innocentive.com, drug maker Eli Lilly has created a collaborative research portal. Companies needing answers to research problems can post details regarding their projects, along with a stated fee they are willing to pay for completion of research needs. Scientists and engineers from anywhere in the world can log in to select projects to work on. Fees offered run from a few thousand dollars to $50,000. Participants who log in may choose to view the site in English, Chinese, German, Russian or Spanish. The site was launched in June 2001. By May 2003, 23,000 scientists, graduate students and researchers of various types had participated. InnoCentive’s management expects to have more than 30 corporate clients posting their research requests by the end of 2003. Many of these clients prefer to remain anonymous.
as overnight international courier services and wellestablished jet airliner service to nearly anywhere in the world, helps to spur globalization on. Meanwhile, there are legions of extremely well educated scientists and engineers in areas such as India, China and Eastern Europe who can be hired for salaries that are significantly below those of their U.S.-based peers. These factors all combine to make globalized research efforts attractive for many reasons. For example, a major automotive, pharmaceutical, software or hardware company in the U.S. can create a cost-effective, 24/7 research department by handing off research or design work from America to Russia to India to Japan—it will always be daylight in some part of the world, and collaboration software makes it possible for employees to work together on the same project from anyplace on the planet. The hottest spot for U.S. firms to open foreign research centers is the city of Bangalore in India. Initially a center for writing software code, Bangalore’s supply of highly educated, Englishspeaking residents has enabled the city to evolve into a truly world-class research and development center. The labor pool is not only high-quality but also lowcost. Well-paid software engineers earn in the $10,000 to $15,000 range yearly, with PhDs earning up to $30,000—salaries much lower than those in the U.S. Intel will have 3,000 R&D people working in Bangalore by 2005. Software maker Oracle already has about 2,500, and Microsoft is investing heavily in research within India. India isn’t the only nation enjoying growth in research and engineering jobs fostered by U.S., Japanese or Western European firms. In Eastern Europe, such nations as Hungary, Poland, the Czech Republic and Romania offer well-trained people who speak English and/or German. Russia has a growing assortment of research offices funded by foreigners, and China may become a significant development center for foreign multinationals.
4) Globalization of the Research Efforts of Major Corporations Globalization is deeply affecting the corporate world at all levels. This can be seen in everything from the flood of inexpensive consumer goods flowing into the U.S. from manufacturers in China, to the growing business that American software makers are finding overseas. The advent of extremely fast communication systems, such as the Internet, global fiber-optic lines, e-mail and instant messaging, as well
5) Emphasis on Research and Development in Nanotechnology Nanotechnology is the science of designing, building or utilizing unique structures that are smaller than 100 nanometers. (A nanometer is one-billionth of a meter.) The science involves microscopic structures that might be no larger than the width of some cell membranes. In practical terms, nanotechnology will ultimately allow scientists and engineers to piece atoms together to build all manner of objects, from miniscule semiconductors to medical treatments that
be as simple as a sharing of knowledge between labs or as complex and far-ranging as major research consortia paid for by dues from corporate members, such as the semiconductor industry’s Sematech or MIT’s famous Media Lab. (However, the tough business climate since 2001 has caused many companies to curtail their support of some of these research consortia.) A highly effective research collaboration model has been established within the aircraft industry, where component suppliers, such as manufacturers of jet engines, collaborate with systems suppliers, such as makers of navigation gear (avionics) and airframes to do the R&D necessary to create an entirely new aircraft. This is precisely how the extremely successful Airbus firm was established, with more than a little encouragement from government agencies in the U.K. and France. The automobile industry is likewise benefiting from similar collaborative research and development partnerships to create new or improved cars.
Plunkett Research, Ltd.
work on the molecular level, to the clothes we wear and the structures in which we live. The National Nanotechnology Initiative, established by the Federal Government in 2000, oversees funding for 10 separate government agencies (including the Department of Energy, the Department of Defense, NASA, the National Institutes of Health, USDA and the Food and Drug Administration). Congress passed $849 million in funding for nanotechnology research in 2003, up from the $604 million approved in 2002. U.S. federal funding is expected to exceed $1 billion in the mid-term, due to increasing competition from foreign powers. As with the space race in the 1950s and 1960s, the contest for supremacy in nanotechnology is a key global issue. All associated U.S. departments and agencies plan to focus on nanotech manufacturing processes, uses of nanotechnology for chemical-biological-radioactiveexplosive detection and protection and also on instrumentation and metrology. In the private sector, companies both large and small are investing in the tiny technology in a big way. For example, Motorola Labs, a research subsidiary of telecom company Motorola, Inc., is making strides in carbon nanotechnology for use in flat-panel displays. Concurrently, tiny Sirna Therapeutics is focused on breakthroughs in RNA interference (RNAi) technology to fight disease. Nanotechnology continues to attract a reasonable flow of new money from the venture capital community. Despite the fact that commercialization of nanotech-based products may be a long way off, professional investors see great potential in firms that may become early leaders and patent-holders in this field. Much of the future of technology in general will be based on miniaturization, and nanotechnolgy, the smallest possible level of product development, will play a key role in this miniaturization trend. 6) Continued Growth in Research Partnerships Between Corporations and Universities Corporations have long seen the benefit of tapping the intellectual powers of labs, graduate students and professors at universities that focus on technologyintense disciplines. At the same time, such universities have been anxious to receive corporate funding for their research projects. This has always been a winwin situation. Lately, however, universities have enhanced their position in such partnerships by negotiating research collaboration contracts that are potentially more lucrative than was the norm in years past. Cash-strapped universities are anxious to capitalize on commercial successes that stem from
www.plunkettresearch.com
their research. At the same time, cash-strapped corporations are happy to utilize top grad students who work in university labs at nominal pay. Pharmaceutical giant Pfizer is an excellent example of a major corporation conducting research and development with the assistance of universities. Its Discovery Technology Center, located in Cambridge, Massachusetts, regularly offers fellowships to students from nearby campuses such as Harvard, MIT and the Whitehead Institute. Pfizer is currently involved in a three-year program in computational biology with students from the latter. In addition to academic institutions, Pfizer also has close ties with other companies. BioTrove, a biotech company focusing on nanotechnology within the drug discovery arena, is involved in a two-year collaborative effort with Pfizer. It is hoped that the collaboration will produce nanoscale liquid handling tools that Pfizer will use to develop new drugs. Intel is another example of a company with major in-house R&D efforts as well as external alliances. The technology giant has delivered approximately 500 active research grants to universities, which create small labs or "lablets" that combine the efforts of students and Intel staff. Associated institutions include the University of California at Berkeley, Carnegie Mellon and the University of Washington. 7) Continued Growth in Research and Development Spending in the U.S., Despite the Economic Downturn The general economic downturn in 2001-2002, combined with the terrorist attacks of September 11th and a shift in government priorities with regard to research, had a seriously detrimental effect on total R&D dollars budgeted in the U.S. through 2002, according to widely watched annual studies conducted by the Battelle Memorial Institute and R&D Magazine. These same budgets experienced healthy annual growth previously, with increases of 10.8% in 2000 and approximately 5.4% in 2001. R&D budget growth for 2002 dropped to 3.5%. For 2003, U.S. research and development budgets were forecast by the study to grow about 3.4% to a total of $302 billion, as follows: Federal spending on R&D of $89 billion (up 10.5%); industrial spending at $194 billion (up less than 1%); and university and nonprofit spending combined at $18 billion (up about 7%). In recent months, companies scrambled to cut costs, and in many cases, R&D budgets suffered. In the short-term, many firms were successful in boosting their bottom lines. In the long-term,
Plunkett Research, Ltd.
however, most are rethinking their R&D strategies. In order to stay competitive in the domestic and most certainly in the global marketplace, significant funding for R&D is a vital expense. Tech firms appear to have been the exception to this trend through 2002, spending $100.8 billion from mid-2001 through mid-2002 (up from $86.5 billion for the same period the previous year). The concept behind this continued high investment despite falling revenues is that developing the next great idea will enable a company to grab market share and pull itself into the black. Another change is the way R&D funding is allocated. Strategies are shifting to include more alliances and joint ventures with other companies, more subsidiary spin-offs based on established technologies, more contracts and cooperative efforts with federal labs and projects and higher grants and projects of greater scope on the university level. Investment levels are slowly rising, but companies are also looking for ways to leverage their investment to get more bangs for their bucks. 8) Growth in Defense Research Post 9/11 In the aftermath of the terrorist attacks of September 11, 2001, Congress approved a defense budget of $343 billion for fiscal 2002, a 10% increase from the previous fiscal year. Of that amount, $51 billion was earmarked for research and development, a 13% increase from the previous year. More than $10 billion of those dollars were to be devoted to new technology. Most government funding traditionally goes to defense contractors such as Lockheed Martin, General Dynamics and Raytheon. Post 9/11, a larger and more diverse number of firms in the private sector are receiving more government funding and bearing more of the responsibility for developing new defense technologies. In addition to conventional defense equipment such as aircraft, weapons and enemy detection systems, R&D must now focus on biological warfare and protection from attacks via data systems and the Internet. The establishment of the new Department of Homeland Security has served to focus federal dollars on anti-terrorism defense, including the gathering of intelligence. At the same time, the successes and failures of various defense systems engaged in the wars in Afghanistan and Iraq are creating demand for new defense research initiatives. The U.S. Defense Advanced Research Projects Agency (DARPA), which began as a response to the Soviet launch of the satellite Sputnik in 1957, has a long reputation of over-the-top R&D that has been responsible for a significant number of breakthroughs
www.plunkettresearch.com
since its formation more than 40 years ago. Its projects in large part brought about the Internet, the mouse, telecommunications semiconductors used in cell phones and PCs and radar-absorbent materials that are now found in stealth aircraft. After the September 11th attacks, DARPA created the Information Awareness Office (IAO) with the specific mission of detecting terrorist activities. IAO is currently developing an experimental system that focuses on technologies for language translation; data search and pattern recognition; and collaboration and decision support. As a whole, the project is called Terrorism Information Awareness (TIA) and has a projected 2004 budget of $20 million. The project is a five-year effort, progressing along with the agency's Wargaming the Asymmetric Environment (WAE) program, which focuses on predictive technology relating to observed behaviors of known terrorists. 9) Number of Patent Applications Soars In 2001, the U.S. Patent & Trademark Office (PTO) received 345,732 patent applications, up from 315,015 in 2000 and only 177,830 in 1991. The PTO forecasts that that number will reach 500,000 by 2006. To some extent, patents tend to reflect the health of R&D budgets. The greater the funding, the more patents are filed. At the same time, however, the rapid growth in the number of patent applications reflects today’s increased focus on protection of intellectual property by corporations and universities along with the extremely high traffic from biotech firms attempting to patent gene expressions and other biological discoveries. A patent application leads either to a patent grant or to a denial. The PTO granted 183,975 patents during 2001, up by about 8,000 over the previous year. Of those patents granted, 46% were to foreign applicants. A patent typically takes 18 to 24 months after application to receive a grant. In an effort to keep up with all of this patent activity, the PTO is upgrading its information systems to the extent that it hopes to launch a fully paperless patent system by fiscal 2004. Meanwhile, the overwhelmed PTO hired 768 patent examiners in fiscal 2002, bringing the total to 3,538. The term of patent protection is currently defined as beginning on the date the patent is granted and ending 20 years from the earliest filing date of the application.
Plunkett Research, Ltd.
Internet Research Tip: For the latest official statistics from the U.S. Patent & Trademark Office, visit the website of TAF, the patent office’s Technology Assessment and Forecast branch. www.uspto.gov/web/offices/ac/ido/oeip/taf/ Globally, there are 120 different national patent systems, and recent proposals to create a unified global patent system are creating buzz. "Harmonization" is the word used to describe the effort, and it will be difficult to bring about. According to the World Intellectual Property Organization, 90% of the 7 million applications filed annually worldwide are filed in more than one country, which multiplies application fees, legal fees and hours spent exponentially (fees for multinational applications can surpass $75,000, and legal fess often reach $200,000 or more). IBM, the company that holds more patents than any other company in the world, spends more than $200 million annually on the protection of its intellectual property both at home and abroad. An aborted 1989 attempt to establish an international system bogged down when the U.S. could not agree with most other participating countries on a simple first-to-file regulation when awarding patents to filers with similar claims. In the U.S., the practice has traditionally been to award a patent to the filer who can prove to be the first to conceive an idea and develop it. Although fair, the system can prove costly as applicants spend time and money in the court systems to prove who was first with an idea. Another critical difference between the U.S. patent system and those elsewhere around the globe is the one-year waiting period, during which American filers may publish or speak at public forums about their ideas without jeopardizing their patent rights. Abroad, filers are required to keep their ideas top secret until a patent is awarded. Yet another point of argument centers on patent subject matter. In the U.S., just about anything or any idea can be patented. Business practices, for example, are commonly patented, such as Amazon.com's "oneclick" technology, as well as genetic discoveries and treatments. The latter is a particularly sticky point for developing nations such as those in Latin America and Africa. Their participation in a global patent effort may well hinge on the protection of their natural resources from exploitation by foreign companies. The debate continues, but proponents of a global patent body hope to have a treaty written by late 2004. In June 2002, the Director of the U.S. Patent & Trademark Office published a comprehensive plan,
www.plunkettresearch.com
titled “21st Century Strategic Plan,” outlining his official efforts to enhance the effectiveness of the office while making it more efficient for U.S. companies to obtain patent protection abroad. Among competing tech companies, patents are something like badges of honor. Patents protect ideas and technologies as well as exclude competitors from making strides in particular areas of research. IBM leads the pack in the total number of patents awarded each year, with 3,431 new patents granted during 2001. Patents are an immense asset to IBM, and it garners more than $1.5 billion in yearly licensing revenue from the patents it holds. IBM is followed by a short list of Japanese firms including Canon (1,937 patents in 2002), NEC (1,920 patents in 2002) and Hitachi (1,882 patents in 2002). Other top patent winners in 2002 were Micron Technology (1,851), GE (1,681) and Sony (1,601). Not only do these extraordinary numbers of patents give these companies substantial bragging rights, the revenues generated can often make the difference between red and black ink in a difficult economy. As a result, watch for continued growth in the number of patent applications. 10) Growth in the Automation of Research and Design The news in automated research tools is excellent, and many firms that manufacture such tools are enjoying booming times. Advances in CAD (computer aided design) and CAE (computer aided engineering) hybrids are revolutionizing the way in which new designs are tested and enhanced. The combination of disciplines creates virtual prototypes on computers that make R&D faster and more efficient than ever before. Finite element analysis (FEA) checks a computergenerated model for flaws. It analyzes how the model would react to extremes in heat, vibration and pressure by breaking a model down into small pieces or cells in a three-dimensional grid. The computer applies simulated stimuli to one cell in the model and then tracks the response of that cell and those that surround it. The results often keep a flawed design from progressing to production and distribution. The next big thing in automated R&D is design of experiments (DOE). This statistical technology helps researchers program FEA to concentrate on particularly vulnerable areas, rather than running thousands of scans on all parts of a model, which may not be necessary. Another stride in automation is behavioral modeling. It is a software application that takes the
Plunkett Research, Ltd.
results found by the combination of FEA and DOE into family trees of cause and effect scenarios. Major variables such as model size and power are represented by large limbs, which branch out into scenarios showing how those variables react to different situations. The process allows researchers to isolate deal-breaking problems early on and pinpoint exact circumstances in which problems will likely occur. Industries adopting this new technology include automotive manufacturing, aerospace and shipyards. Meanwhile, combinatorial chemistry, DNA chips and myriad other technology-intense tools have largely automated research in biotechnology to the extent that the field has been accelerated dramatically. 11) Energy Technology Research Receives Growing Attention, Particularly in Alternative Energy Overall, the energy sector has been running far behind other industries in terms of research and development. For example, a recent study showed that of the total number of patents granted in the U.S. during the 20-year period from 1976 through 1996, only about 100 per year were energy-specific patents. Energy-specific R&D expenditures plummeted from about $12 billion during 1980 to about $4 billion during 1996, despite the fact that 1) energy is a vital and strategic sector, and 2) energy conservation, utilization, generation and production can all benefit greatly from new technologies, and those technologies will be developed only through significant R&D efforts. Here’s the bottom line: The energy sector has barely begun to tap the potential of new technologies. It is critical that R&D efforts are accelerated and that the money to back them begins to flow in larger total amounts. Post 9/11, a focus on national security, combined with concerns about clean air, global warming, trade deficits and unstable governments in the Middle East and Africa, have put a renewed emphasis on R&D focused on energy development and conservation of all types. Suddenly, both corporate and government dollars are flooding into research on fuel cells, solaror wind-generated power and energy management. In addition, research is intensifying on methods to drill extremely deep offshore wells along with technology for enhancing the flow of oil and gas from existing fields. An interesting new nuclear technology, called pebble bed reactors, is being developed, while superconductor technology has also seen renewed interest.
www.plunkettresearch.com
As a niche, energy management has tremendous potential to create profit-generating new technologies by developing synergies between advanced electronics/communications and traditional heating, cooling and refrigeration systems. For example, Alameda, California-based Silicon Energy, www.siliconenergy.com, manufactures software solutions that interact between energy sources and major commercial/industrial energy users to reduce energy usage, lower costs and optimize the energy procurement process. Energy management professionals at Oracle’s headquarters in California wear pagers that alert them if electricity demand is nearing an overload condition. U.S.-based Echelon is working on a project with a utility company in Italy to enable residential electricity consumers to regulate their home energy usage remotely via the wireless web. Meanwhile, both gas and electric utilities are using computers and wireless technology to cut operating costs. For example, millions of wireless transmitters are now installed on electric meters around the nation, automatically sending usage data to computers for billing and tracking purposes, without the use of human meter readers. By 1999, soaring oil and gas prices created a renewed interest in all things energy-efficient. Smaller cars, high-efficiency homes and even solar power are once again part of popular culture. After all, if you’ve been enduring a rolling electricity blackout in California or New York, alternative energy sources must seem extremely interesting. At the same time, renewable energy sources and cleaner-burning fuels are of great appeal to the large number of American consumers who have developed a true interest in protecting the environment. Some surveys have shown that consumers would even be willing to pay somewhat more for electricity if they knew it was coming from non-polluting, renewable sources. Alternative energy is of growing interest to some investors. Analysts at the research firm of Clean Edge, based in Oakland, California, estimate that alternative energy firms raised $2 billion during 2000 from public stock offerings and venture capital funds. Government is once again keenly interested in promoting renewable, alternative energy sources. Many states have created rebates and other incentives to encourage investment in renewable energy systems, and 33 states have new net metering policies that require electric utility companies to pay customers for generating electricity at the same price that they charge those customers for consuming it. In other words, consumers who use solar, microturbines or
Plunkett Research, Ltd.
other methods to generate more electricity than they need from time to time could see their electric meters running backwards. This is a big step forward when you consider the fact that utilities previously purchased such power from consumers at wholesale rates, which may only be 30% or 40% of the retail price. Fuel Cells: One of the hottest alternative energy technologies is the fuel cell. The fuel cell, in basic terms, consists of quantities of hydrogen and oxygen which are separated by a catalyst. Inside the cell, a chemical reaction within the catalyst generates electricity. Byproducts of this reaction may include heat, carbon dioxide and water. In other words, fuel cells do no create the toxic emissions that we currently live with from gasoline engines. Most fuel cells are based on hydrogen as a fuel, extracted from such sources as natural gas, gasoline or methanol. Each source has its advantages and disadvantages. Unfortunately, creating a hydrogen supply from fossil fuel sources such as gasoline can create emission problems. Ideally, fuel cells would burn hydrogen that is derived by using renewable energy sources, such as solar or wind, to break down water molecules into their basic components: hydrogen and oxygen. The potential market for fuel cells encompasses diverse uses in fixed applications (such as providing an electric generating plant for a home or a neighborhood), portable systems (such as portable generators for construction sites) or completely mobile uses (including the obvious use of powering an automobile). One of the greatest potential advantages of fuel cells is the fact that they are generally clean, efficient energy sources. Fuel cells are already in wide use, even powering a U.S. Post Office in Alaska. General Motors, Ford, Honda, DaimlerChrysler and Toyota all have significant fuel-cell research initiatives. In fact, GM recently exhibited a full-size pickup truck sporting a prototype fuel-cell engine that runs on hydrogen extracted from gasoline. Automakers may have a fuel-cell-powered car, perhaps a fuel-cell/electric hybrid, on the market as early as 2010, especially if the Federal Government provides substantial sponsorship for research. Not only is the automotive industry keenly interested in fuel-cell power for automobiles and trucks, it is also betting on the use of fuel cells for many other purposes. In mid-2001, General Motors made the remarkable announcement that it is developing an affordable fuel-cell-powered electric generator for ownership by individual consumers and businesses.
www.plunkettresearch.com
Meanwhile, fuel cells remain grossly expensive due to their limited production and industry’s currently low-technology base, with the estimated price for a fuel-cell-powered car hovering around $700,000. Moreover, hydrogen is not readily available to drivers. California's South Coast Air Quality Management District plans a minimum of six hydrogen-fueling stations by early 2004. Despite these difficulties, Honda and Toyota are both testing fuel-cell-powered cars in California. Five Honda cars are leased to the city of Los Angeles, each at $500 per month, while Toyota is leasing a fuel cell version of its Highlander SUV to UC Irvine and UC Davis, for which private donations have made a lease of $10,000 per month per vehicle feasible. Fuel cells may not be in wide use in automobiles until seven to 20 years have passed. However, they are currently used with great success in many special situations. For example, fuel-cell-powered electric generators currently power many remote sites. The Japanese automakers are outpacing U.S. rivals in fuel cell advances. GM hopes to market a line of fuel-cell-powered cars by 2010. The company is planning a wide variety of car and truck bodies that will mount onto a single, radical “skateboard” chassis design. The skateboard stores fuel-cell stacks and hydrogen supplies as well as circuitry that manages the flow of electric power through the various systems necessary to stop, start and maneuver the vehicle. The chassis will include a docking port that links the body above to the electronic systems. The working name for the groundbreaking design is Autonomy. Each vehicle will be equipped with software that corresponds to the type of driving associated with the selected body style. Sporty cars and light trucks will have software that provides rapid acceleration, responsive steering and rigid suspension. The software for family cars and touring sedans will provide less pickup, easier steering and a more comfortable ride even though the underlying chassis would be the same. The electric utility industry may become a large user of fuel-cell technology over the long-term. For example, the nation of Japan plans to generate a significant portion of its electricity needs by fuel cell by the year 2010. Also, fuel-cell-powered generating plants of immense size may become practical as upgrades for aging oil-, gas- or nuclear-powered generating facilities. If the concept of distributed power catches on, fuel cells could easily be the neighborhood- or home-based generator of choice in the U.S. by 2015, especially if the electric utilities
Plunkett Research, Ltd.
become involved in the manufacture or distribution of such units.
Spotlight: IBM While IBM has had its detractors in recent years (because of its difficulties in fighting off disruptive competition in many facets of the computer business), no one could ever doubt this premier firm’s leadership in the arenas of research and development. In terms of sheer numbers, IBM rules in research. During the early 1990s, the firm refocused its research efforts and boosted R&D budgets while slashing jobs and budgets throughout the rest of the company structure. By 2001, for example, the company marked the ninth year in a row of receiving more U.S. patents than any other organization—3,411, up from 2,886 patents during 2000. (At the time, IBM was the first company ever to obtain 3,000 patents in one year.) IBM's 2002 corporate R&D budget of approximately $5 billion represents about 6% of the company's annual sales. Big Blue traces its roots to an innovative entrepreneur who used machines running on punch cards to tabulate the U.S. Census of 1890. IBM’s research division traces its beginnings to 1944, when a “Pure Science Department” was launched with a handful of people. By the early 1950s, the effort had grown to about 120 people. Today, IBM has eight major research facilities scattered around the globe, employing about 3,000 researchers, including two Nobel Prize recipients. The firm is not resting on past success. Its IBM Life Sciences division created a highly sophisticated database called Design Link, which effectively manages experimental data for drug companies that is stored on up to 13 incompatible systems. The database is part of the division's larger mission to fashion IT systems that assist biotech and pharmaceutical companies in new drug development and testing. More recently, IBM is putting cuttingedge computer technology to work scanning Internet data and making intelligent analysis of market patterns and trends. The new division, called Web Fountain, has the potential to revolutionize traditional marketing efforts. Another new concept in R&D at IBM is the depth of customer involvement. Researchers are now spending up to 25% of their time working with customers, seeking opinions and ideas.
www.plunkettresearch.com
Spotlight: Lucent/Bell Labs Lucent is the telecommunications equipment manufacturer that once was a division of AT&T. During the 1990s, the breakup of “Ma Bell” created the “Baby Bells” and led to the eventual 1996 spin-off of what is now Lucent Technologies, Inc. to operate the telecom equipment business. Lucent also received a prize asset: Bell Labs—once the world’s premier telecom research organization. Bell Labs began in the early 1900s, as a descendant of the small laboratory operated by telephone inventor Alexander Graham Bell, with a $3,500 annual budget and a handful of workers. It eventually grew to become one of the most innovative and productive research organizations the world has ever known. Today, Lucent, like IBM, is a mature organization that faces daunting, and sometimes painful, competition from upstarts. Unlike IBM, the company cut its R&D budget as part of a corporate cost-cutting program. Lucent’s annual R&D budget fell from $3.5 billion in 2001 to $2.3 billion in 2002. Despite the cut, the company's budget is still ranked 21st in a list of the largest R&D budgets among U.S. companies compiled by Schonfeld & Associates. Lucent recently received its 30,000th patent. Through the years, Bell Labs/Lucent Labs has helped to develop breakthroughs such as the transistor, the laser, the orbiting communications satellite and the molecular transistor, and 11 employees have won the Nobel Prize in Physics.
Spotlight: Intel By far the world’s leader in the semiconductor industry, Intel didn’t establish its separate, central research laboratory, named Microprocessor Research Labs (MRL), until late in the game in 1995. Instead, research and development have been continuous efforts within the many units operated by the firm. In fact, the effort to produce faster, more powerful generations of semiconductors is a major daily focus of the entire semiconductor industry. Research director David Tennenhouse, a veteran of DARPA, brought to Intel a new, broader outlook with regard to research when he joined the firm in 1999. As has traditionally been the practice at DARPA, Tennenhouse expanded the scope of Intel's research beyond a focus on semiconductors. Today, Intel employs 7,000 researchers in more than 75 labs in universities and cities around the globe. In addition to the study of semiconductors, the company's $4-billion budget covers research in networking and communications, software technology
Plunkett Research, Ltd.
and computing platforms. Intel maintains U.S. labs in California, Oregon, Arizona, Washington and Massachusetts, with international facilities in Israel, Malaysia, India, China and Russia. These labs are concerned primarily with component development and design. Additional facilities in Arizona and Malaysia study potential improvements in assembly and test processes. Intel’s unique MRL research effort is divided between facilities in Santa Clara, California and Hillsboro, Oregon. It also has efforts in Israel and China. MRL is focused on long-term, blue-sky projects that may be very speculative in nature. Intel has introduced entirely new chips every one to four years. Beginning with the “4004” chip in 1971 that ran at a snail-like pace and had a small number of transistors, the company leapt to the 386 in 1985 (275,000 transistors) to the Pentium II (7.5 million transistors) in 1997 and has introduced rapidly evolving families of chips in the early 2000s that approach 1 billion transistors per chip. As of April 2003, Intel had shipped over a billion x86 processors to customers around the world.
Spotlight: Microsoft Logically enough, the world’s leading software firm is one of the world’s leading practitioners of research and development. While Microsoft has a scientific staff of only a few hundred people, it also has thousands of highly skilled engineers. Together, these R&D employees do everything from searching for innovative ideas that may lead to future services or products to writing code in development of the next edition of MS Office. In terms of pure research, few organizations can top Microsoft’s computer science labs, which rank near those of IBM, Lucent, Carnegie Mellon and MIT. Microsoft’s internal research organization (sometimes referred to as “Bill Labs” as a play on the name of famous Bell Labs) was launched early in the company’s history in 1991. The research organization grew by 50% from 1999 to 2000, to reach a total of 600 professionals on staff. The company currently has 55 separate research projects in operation, studying everything from .NET to natural language processing to wireless technology. Microsoft has increased its R&D budget significantly in recent years (to $5.3 billion in 2002) and boasts a formidable roster of talent. At its Redmond, Washington facility, for example, the firm currently has 150 interns with Ph.D.s. Current projects include Gestures, special stylus movements when using a tablet PC that approximate using keyboard
www.plunkettresearch.com
shortcuts on a desktop PC; a spam filter for e-mail; and MyLifeBits, a technology in which a computer captures episodes in human life and stores them for later access.
Spotlight: Xerox Xerox, founder of the Palo Alto Research Center (PARC), is, at the same time, one of the most admired and least admired research organizations in the world. It is among the most admired because of PARC’s development of such ground-breaking technologies for the computer industry as the graphical user interface (GUI), the process now known as local area networking (also known as LAN or Ethernet) and the laser printer. Xerox sometimes ranks among the least admired due to management’s failure to fully capitalize on some of these groundbreaking innovations. For example, while Xerox did introduce an unpopular computer (Star) using a graphical user interface, it took the upstart Apple computer company to successfully introduce GUI to the world, creating an entire culture around the Macintosh computer. PARC is so focused on innovation in business machines and business processes that it has developed a full-time staff of anthropologists whose job is to study the way that people in offices and factories interact with the machines that are supposed to serve them. The result is logical interfaces between man and machine that are sometimes the envy of other firms. While Xerox has been assaulted by fierce competition on all sides, that competition was brought on by the attention caused by its many successes. Xerox literally enabled the masses to benefit from plain paper copying at reasonable cost. As a result, it became the first U.S. firm in business history to achieve $1 billion in yearly revenues in less than 10 years—and it reached that achievement back in 1968 when $1 billion was a lofty goal for any company. Recent successes include Xerox’s incredibly profitable Docutech system. Docutech is an entire printing plant with bindery in one easy-to-operate unit that is based on highly advanced laser copying. For most of its history, PARC was an internal business unit at Xerox, but in 2002 its status was changed to that of a wholly owned subsidiary.
Spotlight: Genentech Research at the booming drug company Genentech is a very different world than that at most major drug companies. Instead of developing new drugs that treat large numbers of people, such as Pfizer's Lipitor (which helps lower cholesterol levels)
Plunkett Research, Ltd.
and Schering-Plough's Clarinex (for allergy sufferers), Genentech targets small sets of patients with specific problems. For example, take its recent successful trials of colorectal cancer drug Avastin, which treats malignant tumors through the highly novel method of cutting off their blood supply. Another Genentech drug, Herceptin, treats specific types of breast cancer, which occur in only about 25% of breast cancer patients—patients who have a distinct genetic makeup that can be identified prior to treatment to see whether they are likely to benefit from the drug. The results of this targeted R&D are higher success rates in cancer treatment and impressive sales that topped $2.7 billion in 2002. Its Founders Research Center is an $85-million research facility that was recently expanded to a total of 500,000 square feet in South San Francisco. An additional 420,000-square-foot facility is located in Vacaville, California. A relatively small company, Genentech's R&D budget for 2002 was $623.5 million, up from $526.2 million the previous year.
Spotlight: Pfizer Drug giant Pfizer's R&D illustrates the opposite end of the spectrum from Genentech. With 10 blockbuster drugs in its extensive product line that each generate more than $1 billion in annual sales, Pfizer is focused on developing drugs that will enjoy widespread use and reap huge revenues. Pfizer's $5.3 billion R&D budget for 2003 is the largest within the pharmaceutical sector. The company pioneered robotic high-throughput chemical compound screening, and uses it along with a variety of other cutting-edge technologies to study and develop new drugs. Pfizer employs approximately 12,500 researchers and scientists around the world with locations in La Jolla, California; Ann Arbor, Michigan; New London and Groton, Connecticut; and Cambridge, Massachusetts. There are also international facilities in Canada, the U.K., France and Japan. The company has lofty goals for sales growth. In order to meet those goals, it must continue to develop blockbuster drugs at a steady pace.
Spotlight: DuPont Once highly regarded as a laboratory that regularly developed products with global impact (e.g., nylon, lycra), DuPont R&D has dropped the ball in recent years with regard to new products. The company is the victim of narrow thinking, focusing primarily on improving productivity as opposed to
www.plunkettresearch.com
developing new products. The company sold DuPont Pharmaceuticals to Bristol-Meyers Squibb in 2001, thereby divesting itself of significant R&D efforts and facilities. In 2003, the company announced its plans to restructure its R&D labs, allocating half the $1.2billion annual research budget to new products (twothirds of the budget previously went to improving productivity for existing products). Researchers are to seek customer input at all stages of product development on the 75 selected projects deemed the most promising. DuPont maintains 40 research and development labs in the U.S. and an additional 35 labs in 11 other countries. Its main facilities are in Wilmington, Delaware, split between its Experimental Station, Chestnut Run and Stine-Haskell Research Center laboratories. Together, they employ more than 1,500 researchers and scientists.
Spotlight: General Electric Innovation and a renewed emphasis on R&D have been the story at GE since Jeffrey Immelt became CEO in 2001. GE's R&D efforts historically have been groundbreaking, including work in magnetic resonance imaging (MRI), fiber optics, synthetic diamonds and the 1909 tungsten filament still in use in light bulbs today. After a brief period in the ‘90s when the conglomerate appeared to devote more funding and attention to its lucrative entertainment and financial services subsidiaries, R&D is once again a major concern for GE's plethora of manufacturing arms (which include aerospace, appliances, lighting, generators, nuclear reactors and plastics, to name a few). Its Niskayuna, New York facility received a $100million facelift in 2002. The 500-plus-acre campus now boasts new laboratories and meeting facilities. GE owns and operates other facilities as part of its Global Research arm in Bangalore, India and Shanghai, China. Moreover, GE recently broke ground on a new research center in Munich, Germany. In total, the company employs more than 2,000 researchers working in a wide variety of disciplines. Long-term research areas receiving the lion's share of funding are nanotechnology, light sources, advanced propulsion and molecular imaging. Approximately 20% of the $2.6-billion annual research budget is devoted to long-range projects.
Plunkett Research, Ltd.
www.plunkettresearch.com
Chapter 2 ENGINEERING AND RESEARCH INDUSTRY STATISTICS CONTENTS: IV. U.S. Research and Development Comparative Measures of Growth for Gross Domestic Product and R&D Federally Funded Research and Development Centers' R&D Expenditures: 2001 National Expenditures for Applied Research, by Performing Sector and Source of Funding: 1993-2002 National Expenditures for Applied Research, from Funding Sectors to Performing Sectors: 1993-2002 National Expenditures for Basic Research, by Performing Sector and Source of Funding: 1993-2002 National Expenditures for Basic Research, from Funding Sectors to Performing Sectors: 1993-2002 National Expenditures for Development, by Performing Sector and Source of Funding: 1993-2002 National Expenditures for Development, from Funding Sectors to Performing Sectors: 1993-2002 National Expenditures for R&D, by Performing Sector and Source of Funding: 1993-2002 National Expenditures for R&D, from Funding Sectors to Performing Sectors: 1993-2002 Trends in Federal and Non-Federal R&D Expenditures as a Percentage of Total R&D: 1953-2002 Trends in U.S. Research & Development (R&D) and Federal Outlays: 1970, 1980, 1990, 2000 and 2002 U.S. Federal Basic Research Budget Authority, by Budget Function: Fiscal Years 1995–2001 U.S. Federal R&D Budget Authority, by Budget Function: FY 1980–2001 V. Research and Development by States-U.S. California Research & Development (R&D) Profile, 1999-2000 Illinois Research & Development (R&D) Profile, 1999-2000 Maryland Research & Development (R&D) Profile, 1999-2000 Massachusetts Research & Development (R&D) Profile, 1999-2000 Michigan Research & Development (R&D) Profile, 1999-2000 New Jersey Research & Development (R&D) Profile, 1999-2000 New York Research & Development (R&D) Profile, 1999-2000 Pennsylvania Research & Development (R&D) Profile, 1999-2000 Texas Research & Development (R&D) Profile, 1999-2000 Washington Research & Development (R&D) Profile, 1999-2000 State Distribution of Expenditures for R&D, by Performing Sector and Source of Funding: 2000 Top 10 U.S. States in Total R&D Performance, Size of R&D by Performer and R&D as a Percentage of Gross State Product: 2000
p. 23
VI. International Research and Patents
p. 55
International R&D Expenditures in Constant Dollars and as a Percentage of GDP: 1981–2001 Top 20 Global Patenting Organizations, Calendar Year 2001 Top 20 Patenting Countries, 2001
p. 24 p. 25 p. 27 p. 28 p. 29 p. 30 p. 31 p. 32 p. 33 p. 34 p. 35 p. 37 p. 38 p. 39
p. 41 p. 42 p. 43 p. 44 p. 45 p. 46 p. 47 p. 48 p. 49 p. 50 p. 51 p. 52 p. 54 p. 56 p. 58 p. 59
Plunkett Research, Ltd.
www.plunkettresearch.com
I.
U.S. Research and Development
Plunkett Research, Ltd.
www.plunkettresearch.com
Comparative Measures of Growth for Gross Domestic Product and R&D (Federally-funded, Nonfederal and Total): 1993-2002 Gross domestic product (GDP)
GDP in billions of current dollars Calendar year
R&D
R&D as a percent of GDP Federal support Nonfederal Federal GDP in R&D in R&D in GDP for R&D support support Nonfederal billions millions for R&D in millions implicit for support in of of of price millions millions of R&D as a percent of GDP R&D as for R&D as constant constant current deflator of a percent constant a 1996 1996 (1996=1.00) constant 1996 percent of GDP dollars dollars dollars of GDP dollars 1996 dollars
1993
6,642
0.9405
7,063 165,716 176,200
64,344
111,856
2.49
0.91
1.58
1994
7,054
0.9601
7,348 169,217 176,249
63,318
112,931
2.40
0.86
1.54
1995
7,401
0.9810
7,544 183,614 187,170
64,182
122,988
2.48
0.85
1.63
1996
7,813
1.0000
7,813 197,344 197,344
63,397
133,947
2.53
0.81
1.71
1997
8,318
1.0195
8,160 212,156 208,098
63,348
144,750
2.55
0.78
1.77
1998
8,782
1.0320
8,509 226,367 219,340
64,322
155,017
2.58
0.76
1.82
1999
9,274
1.0469
8,859 243,562 232,654
64,013
168,641
2.63
0.72
1.90
2000
9,825
1.0689
9,191 264,616 247,561
61,940
185,620
2.69
0.67
2.02
2001
10,082
1.0942
9,215 281,767 257,520
66,645
190,875
2.79
0.72
2.07
2002
10,441
1.1064
9,437 291,663 263,617
73,215
190,402
2.79
0.78
2.02
Note: Data are preliminary for 2001 and 2002. See the historical database provided in Table D for the full series of historical data, arranged by the same data columns as defined in this and other tables. Source: Department of Commerce, Bureau of Economic Analysis; Office of Management and Budget, and National Science Foundation/Division of Science Resources Statistics tabulations.
Plunkett Research, Ltd.
www.plunkettresearch.com
Federally Funded Research and Development Centers' R&D Expenditures: Fiscal Year 2001 (Latest Data Available) FFRDC
Total R&D
Federal R&D
Administrator
Sponsoring agency
Thousands of dollars All FFRDCs, total
9,997,231
9,615,716
University-administered FFRDCs, total Ames Laboratory
5,944,110 22,916
5,771,399 22,916
Argonne National Laboratory
478,391
452,860
Iowa State University of Sci. and Tech. University of Chicago
Ernest Orlando Lawrence Berkeley National Laboratory
408,487
337,757
University of California
Department of Energy
Fermi National Accelerator Laboratory
310,928
310,928
Department of Energy
Jet Propulsion Laboratory
1,355,461
1,355,461
Universities Research Association, Inc. California Institute of Technology
Lawrence Livermore National Laboratory
1,090,875
1,049,675
Lincoln Laboratory Los Alamos National Laboratory
380,200 1,333,194
University of California
370,616 Massachusetts Inst. of Technology 1,312,974 University of California
Department of Energy Department of Energy
National Aeronautics and Space Administration Department of Energy DoD, Department of the Air Force Department of Energy
National Astronomy and Ionosphere Center
10,986
10,979
Cornell University
National Center for Atmospheric Research
119,846
116,553
University Corporation for National Science Foundation Atmospheric Research
National Optical Astronomy Observatory
37,364
37,364
National Radio Astronomy Observatory
34,208
34,043
Princeton Plasma Physics Laboratory
76,021
75,387
Associatiation of National Science Foundation Universities for Research in Astronomy, Inc. Associated Universities, National Science Foundation Inc. Princeton University Department of Energy
Software Engineering Institute
37,052
37,052
Stanford Linear Accel Center
145,979
145,979
Thomas Jefferson National Accelerator Facility
102,202
100,855
1,887,833
1,805,952
Idaho National Engineering and Enviornmental Laboratory
14,547
13,610
Bechtel BWXT Idaho, LLC Department of Energy
National Cancer Institute at Frederick
187,222
183,478
1,598,900
1,521,700
87,164
87,164
SAIC; Charles River Department of Health and Human Laboratories, Inc.; Data Services, National Institutes of Management Services, Inc. Health Sandia Corporation, a Department of Energy subsidiary of Lockheed Martin Corporation Westinghouse Savannah Department of Energy River Co.
Industry-administered FFRDCs, total
Sandia National Laboratory Savannah River Technology Nonprofit-administered FFRDCs, total
2,165,288
2,038,365
Aerospace FFRDC
17,600
5,600
Arroyo Center
24,317
Brookhaven National Laboratory C3I FFRDC
National Science Foundation
Carnegie Mellon University DoD, Office of the Secretary of Defense Leland Stanford, Jr. Department of Energy University Southeastern Universities Department of Energy Research Association, Inc.
Aerospace Corporation
DoD, Department of the Air Force
24,317
RAND Corporation
DoD, Department of the Army
454,500
435,400
Department of Energy
29,458
29,458
Brookhaven Science Associates, Inc. MITRE Corporation
DoD, Office of the Secretary of Defense
Plunkett Research, Ltd.
www.plunkettresearch.com
Federally Funded Research and Development Centers' R&D Expenditures: Fiscal Year 2001 (Latest Data Available) (cont.) Center for Advanced Aviation System Development
5,683
5,683
Center for Naval Analyses
69,102
66,616
The CNA Corporation
DoD, Department of the Navy
Center for Nuclear Waste Regulatory Analyses
14,977
14,135
Southwest Research Institute
Nuclear Regulatory Commission
Institute for Defense Analyses Communications and Computing
43,100
43,100
Institute for Defense Analysis
National Security Agency
Institute for Defense Analysis Studies
92,930
92,930
1,161
1,161
Institute for Defense Analysis MITRE Corporation
DoD, Office of the Secretary of Defense Department of Treasury, Internal Revenue Service
National Defense Research Institute
25,512
25,512
RAND Corporation
National Renewable Energy Laboratory
207,230
205,665
DoD, Office of the Secretary of Defense Midwest Research Institute Department of Energy
Oak Ridge National Laboratory
581,046
540,116
UT-Battelle, LLC
Pacific Northwest National Laboratory
562,000
512,000
Battelle Memorial Institute Department of Energy
Project Air Force
29,361
29,361
RAND Corporation
DoD, Department of the Air Force
7,311
7,311
RAND Corporation
National Science Foundation
Internal Revenue Service (IRS) FFRDC
The Science and Technology Policy Institute
MITRE Corporation
Department of Transportation, Federal Aviation Administration
Department of Energy
Key: FFRDC = Federally funded research and development center; DoD = Department of Defense. Note: More information about the 36 FFRDCs can be found on the National Science Foundation website (www.nsf.gov/sbe/srs/ffrdc/start.htm). Source: National Science Foundation/Division of Science Resources Stastistics, Survey of Academic Research and Development Expenditures: Fiscal Year 2001.
Plunkett Research, Ltd.
www.plunkettresearch.com
National Expenditures for Applied Research, by Performing Sector and Source of Funding: 1993-2002 Performing Total Federal sector: U.S. Govt. Industry Funding sector: Calendar year5
Industry Universities FFRDCs & colleges1
Federal Total Federal Federal U.S. Govt. Total Govt.2 Industry3 Govt.2
Total
U&C FFRDCs Federal Nonfed. Non- Federal Govt. govt. Industry U&C profits Govt.4
Millions of current dollars
1993
37,286
4,838 24,251
4,295
19,956
435
5,146
2,539
496
443 1,181
487
969
1994
36,614
4,985 22,988
3,616
19,372
503
5,387
2,640
517
464 1,256
508
981
1995
40,999
4,952 26,919
3,164
23,755
535
5,653
2,775
559
494 1,311
516
1,119
1996
43,178
4,872 29,010
3,640
25,370
231
5,878
2,859
583
524 1,390
522
1,283
1997
46,689
4,997 32,430
2,648
29,782
213
5,630
2,635
557
523 1,399
516
1,364
1998
S
5,146
S
S
S
230
5,350
2,376
533
527 1,396
519
1,326
1999
S
5,530
S
S
S
274
5,945
2,776
558
556 1,494
562
1,267
2000
S
5,938
S
S
S
198
6,855
3,425
596
581 1,639
615
1,329
2001 Prelim
S
6,483
S
S
S
223
7,555
3,852
632
601 1,807
664
1,465
2002 Prelim Calendar year5
S
7,175
S
S
S
268
8,330
4,372
654
620 1,974
711
1,586
Millions of constant 1996 dollars
1993
39,645
5,144 25,785
4,567
21,219
463
5,471
2,699
527
471 1,256
518
1,030
1994
38,136
5,192 23,943
3,766
20,177
524
5,610
2,750
539
484 1,308
530
1,022
1995
41,793
5,048 27,440
3,225
24,215
545
5,763
2,828
569
503 1,336
526
1,140
1996
43,178
4,872 29,010
3,640
25,370
231
5,878
2,859
583
524 1,390
522
1,283
1997
45,796
4,901 31,810
2,597
29,212
209
5,522
2,585
546
513 1,372
506
1,338
1998
S
4,986
S
S
S
223
5,184
2,302
516
510 1,353
503
1,285
1999
S
5,282
S
S
S
262
5,679
2,651
533
531 1,427
537
1,210
2000
S
5,556
S
S
S
185
6,413
3,204
557
543 1,533
576
1,243
2001Prelim
S
5,925
S
S
S
204
6,905
3,521
577
549 1,652
606
1,339
2002 Prelim
S
6,485
S
S
S
242
7,529
3,951
591
560 1,784
642
1,433
Adjustments have been made to university R&D for 1998 and later years to eliminate double counting of funds passed through from one academic institution to another. The character of work estimation procedure for university and college R&D also was revised for 1998 and later years; hence these data are not directly comparable with data for 1997 and earlier years. 2 Historically, expenditures of industry FFRDCs for 1953-63 were not separated from total Federal support to the industrial sector. Thus, the figure for Federal support to industry includes support to FFRDCs or those years. The same is true for expenditures of nonprofit FFRDCs, which are included in Federal support for nonprofit institutions in 1953-87. 3 Industry sources of industry R&D expenditures include all non-Federal sources of industry R&D expenditures. 4 Includes all R&D expenditures of FFRDCs administered by academic institutions. 5 Expenditure levels for academic and Federal government performers are also in reference to calendar years. These levels are approximations based on fiscal-year data. For Federal government expenditures starting in 1977, the calendar-year approximation is equal to 75 percent of the amount reported in the same fiscal year plus 25 percent of the amount reported in the subsequent fiscal year. For academic expenditures in all years and for Federal government expenditures prior to 1977 the respective percentages are 50 and 50, because those fiscal years (for most academic institutions and the Federal government before 1977) begin on July 1 instead of October 1. Key: FFRDCs=federally funded research and development centers; U&C=universities and colleges; S = Suppressed pending data quality review Source: National Science Foundation/Division of Science Resources Statistics. Data were derived from NSF/SRS, Research and Development in Industry 2000; NSF/SRS, Academic Research and Development Expenditures: Fiscal Year 2000; NSF/SRS, Federal Funds for Research and Development: Fiscal Years 2000, 2001, and 2002; and NSF/SRS Survey of R&D Funding & Performance by Nonprofit Organizations: Fiscal Years 1996 and 1997. 1
Plunkett Research, Ltd.
www.plunkettresearch.com
National Expenditures for Applied Research, from Funding Sectors to Performing Sectors: 1993-2002 Funding sector:
Total U.S.
Performing Total sector U.S. Calendar year5
Federal Government
Total
Industry
U&C
Industry U&C Non- Nonprofit NonFederal Govt. Industry FFRDCs U&C2 FFRDCs3 profits FFRDCs Total Industry4 U&C2 profits U&C2 Millions of current dollars
1993
37,286 14,078
4,838
4,295
435 2,539
969
900
103 20,547
19,956
443
148 1,181
1994
36,614 13,797
4,985
3,616
503 2,640
981
960
111 19,995
19,372
464
158 1,256
1995
40,999 13,608
4,952
3,164
535 2,775
1,119
934
129 24,418
23,755
494
170 1,311
1996
43,178 13,967
4,872
3,640
231 2,859
1,283
960
122 26,076
25,370
524
182 1,390
1997
46,689 12,996
4,997
2,648
213 2,635
1,364
1,011
128 30,510
29,782
523
205 1,399
1998
S 12,794
5,146
S
230 2,376
1,326
1,060
123
S
S
527
223 1,396
1999
S 14,717
5,530
S
274 2,776
1,267
1,301
130
S
S
556
247 1,494
2000
S 15,776
5,938
S
198 3,425
1,329
1,810
209
S
S
581
279 1,639
2001 prelim
S 17,485
6,483
S
223 3,852
1,465
2,098
302
S
S
601
294 1,807
2002 prelim Calendar year5
S 19,442
7,175
S
268 4,372
1,586
2,326
275
S
S
620
295 1,974
Millions of constant 1996 dollars
1993
39,645 14,968
5,144
4,567
463 2,699
1,030
957
109 21,847
21,219
471
157 1,256
1994
38,136 14,370
5,192
3,766
524 2,750
1,022
999
116 20,826
20,177
484
165 1,308
1995
41,793 13,871
5,048
3,225
545 2,828
1,140
952
131 24,891
24,215
503
173 1,336
1996
43,178 13,967
4,872
3,640
231 2,859
1,283
960
122 26,076
25,370
524
182 1,390
1997
45,796 12,748
4,901
2,597
209 2,585
1,338
992
126 29,926
29,212
513
201 1,372
1998
S 12,396
4,986
S
223 2,302
1,285
1,027
119
S
S
510
216 1,353
1999
S 14,058
5,282
S
262 2,651
1,210
1,243
124
S
S
531
236 1,427
2000
S 14,759
5,556
S
185 3,204
1,243
1,694
195
S
S
543
261 1,533
2001prelim
S 15,980
5,925
S
204 3,521
1,339
1,918
276
S
S
549
269 1,652
2002 prelim
S 17,573
6,485
S
242 3,951
1,433
2,102
248
S
S
560
266 1,784
Because of limitations in the survey information, data on nonfederal government funding to other performers are not available and are consequently included in other sectors' support for their own R&D performance. For example, nonfederal government support to nonprofits included in nonprofits' is support for their own R&D. 2 Adjustments have been made to university R&D for 1998 and later years to eliminate double counting of funds passed through from one academic institution to another. The character of work estimation procedure for university and college R&D also was revised for 1998 and later years; hence these data are not directly comparable with data for 1997 and earlier years. 3 Includes all R&D expenditures of FFRDCs administered by academic institutions. 4 Industry sources of industry R&D expenditures include all non-Federal sources of industry R&D expenditures. 5 Expenditure levels for academic and Federal government performers are also in reference to calendar years. These levels are approximations based on fiscalyear data. For Federal government expenditures starting in 1977, the calendar-year approximation is equal to 75 percent of the amount reported in the same fiscal year plus 25 percent of the amount reported in the subsequent fiscal year. For academic expenditures in all years and for Federal government expenditures prior to 1977 the respective percentages are 50 and 50, because those fiscal years (for most academic institutions and the Federal government before 1977) begin on July 1 instead of October 1. Key: FFRDCs=federally funded research and development centers; U&C=universities and colleges; S = Suppressed pending data quality review Sources: National Science Foundation/Division of Science Resources Statistics. Data were derived from NSF/SRS, Research and Development in Industry 2000; NSF/SRS, Academic Research and Development Expenditures: Fiscal Year 2000; NSF/SRS, Federal Funds for Research and Development: Fiscal Years 2000, 2001, and 2002; and NSF/SRS Survey of R&D Funding & Performance by Nonprofit Organizations: Fiscal Years 1996 and 1997. 1
Plunkett Research, Ltd.
www.plunkettresearch.com
National Expenditures for Basic Research, by Performing Sector and Source of Funding: 1993-2002 Industry Universities FFRDCs & colleges1
Performing Total Federal sector: U.S. Govt. Industry Funding sector: Calendar year5
Federal Total Federal Federal U.S. Govt. Total Govt. Industry2 Govt.
Total
U&C FFRDCs Non- Federal Federal Nonfed. Govt. govt.3 Industry U&C profits Govt.4
Millions of current dollars
1993
28,754
2,621
6,427
466
5,961
492
13,643
8,637
952
851 2,268
936
2,968
1994
29,580
2,547
6,514
436
6,078
503
14,393
9,135
991
889 2,405
973
2,870
1995
29,562
2,689
5,569
190
5,379
530
15,139
9,629
1,069
945 2,509
987
2,661
1996
32,816
2,680
7,498
650
6,848
708
16,033 10,087
1,148
1,032 2,738 1,028
2,632
1997
36,741
2,746
9,795
1,029
8,766
625
17,485 10,788
1,242
1,170 3,129 1,156
2,660
1998
S
3,003
S
S
S
568
19,135 11,746
1,323
1,308 3,468 1,290
2,684
1999
S
3,347
S
S
S
634
20,799 12,723
1,421
1,416 3,806 1,432
2,798
2000
S
3,683
S
S
S
459
22,909 14,093
1,531
1,493 4,211 1,581
2,927
2001prelim
S
3,978
S
S
S
516
25,300 15,821
1,617
1,539 4,626 1,699
2,997
2002 prelim Calendar year5
S
4,437
S
S
S
620
27,797 17,665
1,675
1,586 5,052 1,819
3,057
Millions of constant 1996 dollars
1993
30,573
2,787
6,834
495
6,338
523
14,506
9,183
1,012
905 2,411
995
3,156
1994
30,809
2,653
6,785
454
6,331
524
14,991
9,515
1,032
926 2,505 1,014
2,989
1995
30,134
2,741
5,677
194
5,483
540
15,432
9,815
1,090
963 2,558 1,006
2,713
1996
32,816
2,680
7,498
650
6,848
708
16,033 10,087
1,148
1,032 2,738 1,028
2,632
1997
36,038
2,693
9,608
1,009
8,598
613
17,151 10,582
1,219
1,148 3,069 1,133
2,609
1998
S
2,909
S
S
S
550
18,541 11,382
1,282
1,268 3,360 1,250
2,601
1999
S
3,197
S
S
S
606
19,868 12,154
1,357
1,353 3,636 1,368
2,672
2000
S
3,446
S
S
S
429
21,432 13,184
1,432
1,397 3,940 1,479
2,738
2001prelim
S
3,636
S
S
S
472
23,123 14,459
1,477
1,406 4,228 1,552
2,739
2002 prelim
S
4,010
S
S
S
560
25,124 15,966
1,514
1,434 4,566 1,644
2,763
Adjustments have been made to university R&D for 1998 and later years to eliminate double counting of funds passed through from one academic institution to another. The character of work estimation procedure for university and college R&D also was revised for 1998 and later years; hence these data are not directly comparable with data for 1997 and earlier years. 2 Industry sources of industry R&D expenditures include all non-Federal sources of industry R&D expenditures. 3 Because of limitations in the survey information, data on nonfederal government funding to other performers are not available and are consequently included in other sectors' support for their own R&D performance. For example, nonfederal government support to nonprofits is included in nonprofits' support for their own R&D. 4 Includes all R&D expenditures of FFRDCs administered by academic institutions. 5 Expenditure levels for academic and Federal government performers are also in reference to calendar years. These levels are approximations based on fiscal-year data. For Federal government expenditures starting in 1977, the calendar-year approximation is equal to 75 percent of the amount reported in the same fiscal year plus 25 percent of the amount reported in the subsequent fiscal year. For academic expenditures in all years and for Federal government expenditures prior to 1977 the respective percentages are 50 and 50, because those fiscal years (for most academic institutions and the Federal government before 1977) begin on July 1 instead of October 1. Key: FFRDCs=federally funded research and development centers; U&C=universities and colleges; S = Suppressed pending data quality review Sources: National Science Foundation/Division of Science Resources Statistics. Data was derived from NSF/SRS, Research and Development in Industry 2000; NSF/SRS, Academic Research and Development Expenditures: Fiscal Year 2000; NSF/SRS, Federal Funds for Research and Development: Fiscal Years 2000, 2001, and 2002; and NSF/SRS Survey of R&D Funding & Performance by Nonprofit Organizations: Fiscal Years 1996 and 1997. 1
Plunkett Research, Ltd.
www.plunkettresearch.com
National Expenditures for Basic Research, from Funding Sectors to Performing Sectors: 1993-2002 Funding sector:
Total U.S.
Performing Total sector U.S. Calendar year5
Federal Government Total
Industry
U&C
Industry U&C NonFederal Non- Nonprofit Govt. Industry FFRDCs U&C2 FFRDCs3 profits FFRDCs Total Industry4 U&C2 profits U&C2 Millions of current dollars
1993
28,754 16,412
2,621
466
492 8,637
2,968
1,157
72 7,136
5,961
851
324 2,268
1994
29,580 16,702
2,547
436
503 9,135
2,870
1,137
75 7,323
6,078
889
356 2,405
1995
29,562 16,945
2,689
190
530 9,629
2,661
1,170
75 6,714
5,379
945
390 2,509
1996
32,816 18,083
2,680
650
708 10,087
2,632
1,248
79 8,308
6,848 1,032
428 2,738
1997
36,741 19,272
2,746
1,029
625 10,788
2,660
1,317
108 10,385
8,766 1,170
449 3,129
1998
S 21,001
3,003
S
568 11,746
2,684
1,461
213
S
S 1,308
489 3,468
1999
S 23,639
3,347
S
634 12,723
2,798
1,734
397
S
S 1,416
541 3,806
2000
S 26,630
3,683
S
459 14,093
2,927
2,054
616
S
S 1,493
612 4,211
2001prelim
S 29,529
3,978
S
516 15,821
2,997
2,326
903
S
S 1,539
644 4,626
2002 prelim Calendar year5
S 32,670
4,437
S
620 17,665
3,057
2,613
921
S
S 1,586
645 5,052
Millions of constant 1996 dollars
1993
30,573 17,451
2,787
495
523 9,183
3,156
1,230
77 7,587
6,338
905
344 2,411
1994
30,809 17,396
2,653
454
524 9,515
2,989
1,184
78 7,627
6,331
926
370 2,505
1995
30,134 17,273
2,741
194
540 9,815
2,713
1,193
77 6,844
5,483
963
398 2,558
1996
32,816 18,083
2,680
650
708 10,087
2,632
1,248
79 8,308
6,848 1,032
428 2,738
1997
36,038 18,903
2,693
1,009
613 10,582
2,609
1,291
106 10,186
8,598 1,148
440 3,069
1998
S 20,349
2,909
S
550 11,382
2,601
1,415
206
S
S 1,268
473 3,360
1999
S 22,580
3,197
S
606 12,154
2,672
1,656
379
S
S 1,353
517 3,636
2000
S 24,913
3,446
S
429 13,184
2,738
1,922
576
S
S 1,397
573 3,940
2001prelim
S 26,988
3,636
S
472 14,459
2,739
2,126
825
S
S 1,406
588 4,228
2002 prelim
S 29,529
4,010
S
560 15,966
2,763
2,361
832
S
S 1,434
583 4,566
Because of limitations in the survey information, data on nonfederal government funding to other performers are not available and are consequently included in other sectors' support for their own R&D performance. For example, nonfederal government support to nonprofits is included in nonprofits' support for their own R&D. 2 Adjustments have been made to university R&D for 1998 and later years to eliminate double counting of funds passed through from one academic institution to another. The character of work estimation procedure for university and college R&D also was revised for 1998 and later years; hence these data are not directly comparable with data for 1997 and earlier years. 3 Includes all R&D expenditures of FFRDCs administered by academic institutions. 4 Industry sources of industry R&D expenditures include all non-Federal sources of industry R&D expenditures. 5 Expenditure levels for academic and Federal government performers are also in reference to calendar years. These levels are approximations based on fiscalyear data. For Federal government expenditures starting in 1977, the calendar-year approximation is equal to 75 percent of the amount reported in the same fiscal year plus 25 percent of the amount reported in the subsequent fiscal year. For academic expenditures in all years and for Federal government expenditures prior to 1977 the respective percentages are 50 and 50, because those fiscal years (for most academic institutions and the Federal government before 1977) begin on July 1 instead of October 1. Key: FFRDCs=federally funded research and development centers; U&C=universities and colleges; S = Suppressed pending data quality review Sources: National Science Foundation/Division of Science Resources Statistics. Data were derived from NSF/SRS, Research and Development in Industry 2000; NSF/SRS, Academic Research and Development Expenditures: Fiscal Year 2000; NSF/SRS, Federal Funds for Research and Development: Fiscal Years 2000, 2001, and 2002; and NSF/SRS Survey of R&D Funding & Performance by Nonprofit Organizations: Fiscal Years 1996 and 1997. 1
Plunkett Research, Ltd.
www.plunkettresearch.com
National Expenditures for Development, by Performing Sector and Source of Funding: 1993-2002 Performing Total Federal sector: U.S. Govt. Industry
Industry Universities FFRDCs & colleges1
U&C FFRDCs
Federal Funding Total Federal Federal Federal Nonfed. Non- Federal Govt. govt. Industry U&C profits Govt.3 sector: U.S. Govt. Total Govt. Industry2 Govt. Total Calendar Millions of current dollars year4 1993
99,677
9,071
84,757 16,083
68,674
1,038
1,698
1,126
109
97 259
107
1,346
1994
103,023
8,823
87,890 16,209
71,681
1,196
1,814
1,212
114
102 276
112
1,466
1995
113,053
9,262
97,342 17,824
79,518
1,208
1,810
1,178
123
108 288
113
1,592
1996
121,350
9,033 105,863 17,066
88,797
1,358
1,789
1,127
128
115 305
115
1,495
1997
128,726
9,077 113,184 18,121
95,063
1,292
1,750
1,092
122
115 307
113
1,462
1998
S
9,214
S
S
S
1,280
1,677
1,024
117
116 306
114
1,577
1999
S
8,974
S
S
S
1,412
1,412
717
122
122 328
123
1,595
2000
S
7,847
S
S
S
1,021
1,210
457
131
127 360
135
1,546
2001 prelim
S
8,670
S
S
S
1,149
1,319
506
139
132 397
146
1,479
2002 prelim
S
9,954
S
S
S
1,380
1,364
495
144
136 433
156
1,416
Calendar year4
Millions of constant 1996 dollars
1993
105,982
9,645
90,119 17,100
73,019
1,104
1,806
1,197
116
103 276
114
1,431
1994
107,305
9,190
91,543 16,883
74,660
1,246
1,890
1,262
118
106 287
116
1,526
1995
115,242
9,441
99,227 18,169
81,058
1,231
1,845
1,201
125
110 293
115
1,623
1996
121,350
9,033 105,863 17,066
88,797
1,358
1,789
1,127
128
115 305
115
1,495
1997
126,264
8,903 111,019 17,774
93,245
1,267
1,716
1,071
120
113 301
111
1,434
1998
S
8,928
S
S
S
1,240
1,625
992
113
112 297
110
1,528
1999
S
8,572
S
S
S
1,349
1,349
685
117
117 313
118
1,523
2000
S
7,341
S
S
S
956
1,132
428
122
119 337
126
1,446
2001 prelim
S
7,924
S
S
S
1,050
1,206
463
127
121 363
133
1,352
2002 prelim
S
8,997
S
S
S
1,247
1,232
447
130
123 392
141
1,280
Adjustments have been made to university R&D for 1998 and later years to eliminate double counting of funds passed through from one academic institution to another. The character of work estimation procedure for university and college R&D also was revised for 1998 and later years; hence these data are not directly comparable with data for 1997 and earlier years. 2 Industry sources of industry R&D expenditures include all non-Federal sources of industry R&D expenditures.2 3 Includes all R&D expenditures of FFRDCs administered by academic institutions. 4 Expenditure levels for academic and Federal government performers are also in reference to calendar years. These levels are approximations based on fiscalyear data. For Federal government expenditures starting in 1977, the calendar-year approximation is equal to 75 percent of the amount reported in the same fiscal year plus 25 percent of the amount reported in the subsequent fiscal year. For academic expenditures in all years and for Federal government expenditures prior to 1977 the respective percentages are 50 and 50, because those fiscal years (for most academic institutions and the Federal government before 1977) begin on July 1 instead of October 1. Key: FFRDCs=federally funded research and development centers; U&C=universities and colleges; S = Suppressed pending data quality review Sources: National Science Foundation/Division of Science Resources Statistics. Data were derived from NSF/SRS, Research and Development in Industry 2000; NSF/SRS, Academic Research and Development 'Expenditures: Fiscal Year 2000; NSF/SRS, Federal Funds for Research and Development: Fiscal Years 2000, 2001, and 2002; and NSF/SRS Survey of R&D Funding & Performance by Nonprofit Organizations: Fiscal Years 1996 and 1997. 1
Plunkett Research, Ltd.
www.plunkettresearch.com
National Expenditures for Development, from Funding Sectors to Performing Sectors: 1993-2002 Funding sector:
Total U.S.
Performing sector Calendar year5
Total U.S.
Federal Government Total
Industry
U&C
U&C Non- Nonprofit Federal Industry NonGovt. Industry FFRDCs U&C2 FFRDCs3 profits FFRDCs Total Industry4 U&C2 profits U&C2 Millions of current dollars
1993
99,677 30,026
9,071
16,083
1,038 1,126
1,346
787
574 68,866
68,674
97
95
259
1994
103,023 30,293
8,823
16,209
1,196 1,212
1,466
815
573 71,886
71,681
102
103
276
1995
113,053 32,410
9,262
17,824
1,208 1,178
1,592
744
603 79,738
79,518
108
111
288
1996
121,350 31,347
9,033
17,066
1,358 1,127
1,495
698
571 89,032
88,797
115
120
305
1997
128,726 32,315
9,077
18,121
1,292 1,092
1,462
687
585 95,332
95,063
115
155
307
1998
S 32,589
9,214
S
1,280 1,024
1,577
760
507
S
S
116
168
306
1999
S 28,658
8,974
S
1,412
717
1,595
726
467
S
S
122
187
328
2000
S 23,802
7,847
S
1,021
457
1,546
515
640
S
S
127
211
360
2001 prelim
S 25,907
8,670
S
1,149
506
1,479
580
948
S
S
132
222
397
2002 prelim Calendar year5
S 28,891
9,954
S
1,380
495
1,416
587
926
S
S
136
222
433
Millions of constant 1996 dollars
1993
105,982 31,925
9,645
17,100
1,104 1,197
1,431
836
611 73,223
73,019
103
101
276
1994
107,305 31,552
9,190
16,883
1,246 1,262
1,526
849
596 74,873
74,660
106
107
287
1995
115,242 33,038
9,441
18,169
1,231 1,201
1,623
758
615 81,282
81,058
110
113
293
1996
121,350 31,347
9,033
17,066
1,358 1,127
1,495
698
571 89,032
88,797
115
120
305
1997
126,264 31,697
8,903
17,774
1,267 1,071
1,434
673
573 93,509
93,245
113
152
301
1998
S 31,578
8,928
S
1,240
992
1,528
736
491
S
S
112
163
297
1999
S 27,375
8,572
S
1,349
685
1,523
693
446
S
S
117
178
313
2000
S 22,268
7,341
S
956
428
1,446
482
599
S
S
119
197
337
2001 prelim
S 23,678
7,924
S
1,050
463
1,352
530
866
S
S
121
203
363
2002 prelim S 26,113 8,997 S 1,247 447 1,280 530 837 S S 123 201 392 of limitations in the survey information, data on nonfederal government funding to other performers are not available and are consequently included in other sectors' support for their own R&D performance. For example, nonfederal government support to nonprofits is included in nonprofits' support for their own R&D. 2 Adjustments have been made to university R&D for 1998 and later years to eliminate double counting of funds passed through from one academic institution to another. The character of work estimation procedure for university and college R&D also was revised for 1998 and later years; hence these data are not directly comparable with data for 1997 and earlier years. 1 Because
3 Includes 4 Industry
all R&D expenditures of FFRDCs administered by academic institutions.
sources of industry R&D expenditures include all non-Federal sources of industry R&D expenditures. 5 Expenditure levels for academic and Federal government performers are also in reference to calendar years. These levels are approximations based on fiscal-year data. For Federal government expenditures starting in 1977, the calendar-year approximation is equal to 75 percent of the amount reported in the same fiscal year plus 25 percent of the amount reported in the subsequent fiscal year. For academic expenditures in all years and for Federal government expenditures prior to 1977 the respective percentages are 50 and 50, because those fiscal years (for most academic institutions and the Federal government before 1977) begin on July 1 instead of October 1. Key: FFRDCs=federally funded research and development centers; U&C=universities and colleges; S = Suppressed pending data quality review Sources: National Science Foundation/Division of Science Resources Statistics. Data were derived from NSF/SRS, Research and Development in Industry 2000; NSF/SRS, Academic Research and Development 'Expenditures: Fiscal Year 2000; NSF/SRS, Federal Funds for Research and Development: Fiscal Years 2000, 2001, and 2002; and NSF/SRS Survey of R&D Funding & Performance by Nonprofit Organizations: Fiscal Years 1996 and 1997.
Plunkett Research, Ltd.
www.plunkettresearch.com
National Expenditures for R&D, by Performing Sector and Source of Funding: 1993-2002 Performing Total Federal sector: U.S. Govt. Industry Funding sector: Calendar year4
U&C FFRDCs
Industry Universities FFRDCs & colleges1
Total Federal Federal Federal U.S. Govt. Total Govt. Industry2 Govt.
Total
Federal Nonfed. Non- Federal Govt. govt. Industry U&C profits Govt.3
Millions of current dollars
1993
165,716
16,531 115,435
20,844
94,591
1,965
20,487
12,301
1,557
1,391 3,708
1,530
5,283
1994
169,217
16,355 117,392
20,261
97,131
2,202
21,594
12,987
1,622
1,456 3,937
1,594
5,317
1995
183,614
16,904 129,830
21,178
108,652
2,273
22,602
13,582
1,750
1,547 4,108
1,616
5,372
1996
197,344
16,585 142,371
21,356
121,015
2,297
23,701
14,072
1,860
1,671 4,433
1,665
5,410
1997
212,156
16,819 155,409
21,798
133,611
2,130
24,865
14,516
1,921
1,807 4,836
1,785
5,486
1998
226,367
17,362 167,102
22,086
145,016
2,078
26,162
15,146
1,973
1,951 5,170
1,923
5,588
1999
243,562
17,851 180,390
20,214
160,176
2,321
28,157
16,215
2,101
2,094 5,628
2,118
5,660
2000
264,616
17,469 197,861
17,440
180,421
1,678
30,974
17,975
2,257
2,201 6,210
2,331
5,801
2001 prelim 281,767
19,130 208,068
18,625
189,442
1,888
34,175
20,179
2,387
2,272 6,830
2,508
5,940
2002 prelim 291,663
21,566 210,848
20,933
189,915
2,268
37,491
22,531
2,473
2,342 7,459
2,686
6,059
Calendar year4
Millions of constant 1996 dollars
1993
176,200
17,576 122,738
22,163
100,575
2,089
21,783
13,079
1,655
1,479 3,943
1,627
5,617
1994
176,249
17,035 122,271
21,103
101,168
2,294
22,491
13,527
1,689
1,516 4,100
1,660
5,538
1995
187,170
17,231 132,345
21,588
110,756
2,317
23,039
13,845
1,784
1,577 4,187
1,647
5,476
1996
197,344
16,585 142,371
21,356
121,015
2,297
23,701
14,072
1,860
1,671 4,433
1,665
5,410
1997
208,098
16,497 152,436
21,381
131,055
2,089
24,390
14,238
1,885
1,773 4,743
1,751
5,381
1998
219,340
16,823 161,915
21,400
140,514
2,013
25,350
14,676
1,911
1,890 5,010
1,863
5,414
1999
232,654
17,052 172,311
19,309
153,002
2,217
26,896
15,489
2,007
2,001 5,376
2,023
5,406
2000
247,561
16,343 185,108
16,316
168,792
1,570
28,978
16,816
2,112
2,059 5,809
2,181
5,427
2001 prelim 257,520
17,484 190,163
17,023
173,140
1,725
31,234
18,443
2,181
2,076 6,242
2,292
5,429
2002 prelim 263,617
19,493 190,573
18,920
171,653
2,050
33,886
20,365
2,235
2,117 6,741
2,428
5,476
Adjustments have been made to university R&D for 1998 and later years to eliminate double counting of funds passed through from one academic institution to another. Data for 1998 and later years are not directly comparable to data for 1997 and earlier years. For fiscal year 1998, $479 million in passthrough funds were reported. For fiscal year 2002, $881 million in passthrough funds are estimated. 2 Industry sources of industry R&D expenditures include all non-Federal sources of industry R&D expenditures. 3 Includes all R&D expenditures of FFRDCs administered by academic institutions. 4 Expenditure levels for academic and Federal government performers are also in reference to calendar years. These levels are approximations based on fiscal-year data. For Federal government expenditures starting in 1977, the calendar-year approximation is equal to 75 percent of the amount reported in the same fiscal year plus 25 percent of the amount reported in the subsequent fiscal year. For academic expenditures in all years and for Federal government expenditures prior to 1977 the respective percentages are 50 and 50, because those fiscal years (for most academic institutions and the Federal government before 1977) begin on July 1 instead of October 1. Key: FFRDCs=federally funded research and development centers; U&C=universities and colleges. Sources: National Science Foundation/Division of Science Resources Statistics. Data was derived from NSF/SRS, Research and Development in Industry 2000; NSF/SRS, Academic Research and Development Expenditures: Fiscal Year 2000; NSF/SRS, Federal Funds for Research and Development: Fiscal Years 2000, 2001, and 2002; and NSF/SRS Survey of R&D Funding & Performance by Nonprofit Organizations: Fiscal Years 1996 and 1997. 1
Plunkett Research, Ltd.
www.plunkettresearch.com
National Expenditures for R&D, from Funding Sectors to Performing Sectors: 1993-2002 Funding sector:
Total U.S.
Performing sector Calendar year4
Total U.S.
Federal Government Total
Industry
U&C Federal Industry Non- Nonprofit Govt. Industry FFRDCs U&C1 FFRDCs2 profits FFRDCs
U&C
NonTotal Industry3 U&C1 profits U&C1
Millions of current dollars
1993
165,716 60,516 16,531
20,844
1,965 12,301
5,283
2,843
749
96,549
94,591 1,391
567 3,708
1994
169,217 60,792 16,355
20,261
2,202 12,987
5,317
2,911
758
99,203
97,131 1,456
617 3,937
1995
183,614 62,963 16,904
21,178
2,273 13,582
5,372
2,847
808 110,870 108,652 1,547
671 4,108
1996
197,344 63,397 16,585
21,356
2,297 14,072
5,410
2,906
772 123,416 121,015 1,671
730 4,433
1997
212,156 64,583 16,819
21,798
2,130 14,516
5,486
3,014
821 136,227 133,611 1,807
809 4,836
1998
226,367 66,383 17,362
22,086
2,078 15,146
5,588
3,281
843 147,847 145,016 1,951
880 5,170
1999
243,562 67,014 17,851
20,214
2,321 16,215
5,660
3,761
993 163,245 160,176 2,094
975 5,628
2000
264,616 66,208 17,469
17,440
1,678 17,975
5,801
4,380
1,465 183,724 180,421 2,201
1,103 6,210
2001 prelim 281,767 72,920 19,130
18,625
1,888 20,179
5,940
5,005
2,153 192,873 189,442 2,272
1,160 6,830
2002 prelim 291,663 81,004 21,566 Calendar year4
20,933
2,268 22,531
6,059
5,525
2,121 193,420 189,915 2,342
1,163 7,459
Millions of constant 1996 dollars
1993
176,200 64,344 17,576
22,163
2,089 13,079
5,617
3,023
796 102,657 100,575 1,479
603 3,943
1994
176,249 63,318 17,035
21,103
2,294 13,527
5,538
3,032
790 103,326 101,168 1,516
642 4,100
1995
187,170 64,182 17,231
21,588
2,317 13,845
5,476
2,902
823 113,017 110,756 1,577
684 4,187
1996
197,344 63,397 16,585
21,356
2,297 14,072
5,410
2,906
772 123,416 121,015 1,671
730 4,433
1997
208,098 63,348 16,497
21,381
2,089 14,238
5,381
2,956
805 133,622 131,055 1,773
793 4,743
1998
219,340 64,322 16,823
21,400
2,013 14,676
5,414
3,179
817 143,257 140,514 1,890
853 5,010
1999
232,654 64,013 17,052
19,309
2,217 15,489
5,406
3,592
948 155,934 153,002 2,001
931 5,376
2000
247,561 61,940 16,343
16,316
1,570 16,816
5,427
4,098
1,371 171,883 168,792 2,059
1,032 5,809
2001 prelim 257,520 66,645 17,484
17,023
1,725 18,443
5,429
4,574
1,968 176,276 173,140 2,076
1,060 6,242
2002 prelim 263,617 73,215 19,493
18,920
2,050 20,365
5,476
4,994
1,917 174,821 171,653 2,117
1,051 6,741
Adjustments have been made to university R&D for 1998 and later years to eliminate double counting of funds passed through from one academic institution to another. Data for 1998 and later years are not directly comparable to data for 1997 and earlier years. For fiscal year 1998, $479 million in passthrough funds were reported. For fiscal year 2002, $881 million in passthrough funds are estimated. 2 Includes all R&D expenditures of FFRDCs administered by academic institutions. 3 Industry sources of industry R&D expenditures include all non-Federal sources of industry R&D expenditures. 4 Expenditure levels for academic and Federal government performers are also in reference to calendar years. These levels are approximations based on fiscal-year data. For Federal government expenditures starting in 1977, the calendar-year approximation is equal to 75 percent of the amount reported in the same fiscal year plus 25 percent of the amount reported in the subsequent fiscal year. For academic expenditures in all years and for Federal government expenditures prior to 1977 the respective percentages are 50 and 50, because those fiscal years (for most academic institutions and the Federal government before 1977) begin on July 1 instead of October 1. Key: FFRDCs=federally funded research and development centers; U&C=universities and colleges Sources: National Science Foundation/Division of Science Resources Statistics. Data were derived from NSF/SRS, Research and Development in Industry 2000; NSF/SRS, Academic Research and Development Expenditures: Fiscal Year 2000; NSF/SRS, Federal Funds for Research and Development: Fiscal Years 2000, 2001, and 2002; and NSF/SRS Survey of R&D Funding & Performance by Nonprofit Organizations: Fiscal Years 1996 and 1997. 1
Plunkett Research, Ltd.
www.plunkettresearch.com
Trends in Federal and Non-Federal R&D Expenditures as a Percentage of Total R&D: 1953-2002 Federal Calendar year
Total Federal
Defense related
Space related Percent
Civilian related
Nonfederal
1953
53.9
48.0
1.0
4.9
46.1
1954
55.2
49.0
1.0
5.2
44.8
1955
57.4
48.7
1.0
7.7
42.6
1955
58.6
49.7
1.0
7.9
41.4
1957
62.9
53.2
0.9
8.8
37.1
1958
63.9
53.1
1.1
9.7
36.1
1959
65.4
54.3
2.6
8.6
34.6
1960
65.0
52.6
3.2
9.3
35.0
1961
65.1
50.4
5.6
9.2
34.9
1962
64.8
49.1
6.6
9.1
35.2
1963
66.5
41.9
13.6
11.0
33.5
1964
66.8
37.0
19.0
10.9
33.2
1965
65.1
33.2
20.9
11.1
34.9
1966
64.2
32.4
19.6
12.2
35.8
1967
62.4
35.3
14.4
12.7
37.6
1968
60.7
34.7
13.6
12.4
39.3
1969
58.6
34.7
11.5
12.4
41.4
1970
57.0
33.4
10.3
13.3
43.0
1971
56.4
32.7
9.6
14.1
43.6
1972
55.8
33.0
7.9
14.9
44.2
1973
53.6
32.0
6.7
14.8
46.4
1974
51.8
29.3
6.9
15.6
48.2
1975
52.0
27.6
7.5
16.8
48.0
1976
51.5
26.9
7.7
16.9
48.5
1977
51.0
27.2
6.6
17.2
49.0
1978
50.2
25.9
6.2
18.0
49.8
1979
49.2
24.8
5.6
18.8
50.8
1980
47.5
24.3
5.3
17.9
52.5
1981
46.7
24.4
5.2
17.0
53.3
1982
46.1
26.1
4.9
15.0
53.9
1983
46.2
27.7
4.2
14.2
53.8
1984
45.5
28.7
3.0
13.8
54.5
1985
46.0
29.9
3.2
12.9
54.0
1986
45.5
31.5
3.0
10.9
54.5
1987
46.4
31.8
3.2
11.4
53.6
1988
44.9
30.5
3.4
11.0
55.1
1989
42.6
27.9
3.7
11.0
57.4
1990
40.6
25.4
4.2
11.0
59.4
1991
37.8
22.6
4.5
10.8
62.2
1992
36.8
21.6
4.3
11.0
63.2
1993
36.5
21.6
4.4
10.6
63.5
1994
35.9
19.9
4.4
11.6
64.1
1995
34.3
18.5
4.5
11.2
65.7
1996
32.1
17.6
4.1
10.5
67.9
1997
30.4
16.8
4.1
9.6
69.6
Plunkett Research, Ltd.
www.plunkettresearch.com
Trends in Federal and Non-Federal R&D Expenditures as a Percentage of Total R&D: 1953-2002 (cont.) Federal Calendar year
Total Federal
Defense related
Space related Percent
Civilian related
Nonfederal
1998
29.3
15.9
3.9
9.6
70.7
1999
27.5
14.6
3.5
9.4
72.5
2000
25.0
13.5
2.4
9.1
75.0
2001 prelim
25.9
13.6
2.3
9.9
74.1
2002 prelim 27.8 15.0 2.5 10.3 72.2 Note: Data are preliminary for 2001 and 2002. Details may not sum totals because of rounding. Source: National Science Foundation/Division of Science Resources Statistics
Plunkett Research, Ltd.
www.plunkettresearch.com
Trends in U.S. Research & Development (R&D) and Federal Outlays: 1970, 1980, 1990, 2000 and 2002 (Estimate) Composition of Federal Outlays
1970
1980
1990
2002 (estimate)
2000
Billions of Current US$ Total Federal outlays
195.6
590.9
1,253.2
1,788.8
1,960.6
1
Mandatory programs
61.0
262.1
568.2
950.8
1,080.7
Net interest
14.4
52.5
184.4
223.2
188.1
120.3
276.3
500.6
614.8
691.7
81.9
134.6
300.1
295.0
319.2
8.0
14.6
41.1
41.1
46.8
4.0
12.8
19.1
21.3
24.5
N/A
N/A
N/A
N/A
N/A
34.4
128.9
181.4
298.6
348.0
7.1
15.6
22.7
32.9
40.4
15.1
30.2
63.8
74.0
87.2
Total discretionary Defense discretionary R&D outlays International discretionary R&D outlays Domestic discretionary R&D outlays Total Federal R&D outlays
Total U.S. Federal Outlays (Percent) Total Federal outlays
100.0
100.0
100.0
100.0
100.0
1
31.2
44.4
45.3
53.2
55.1
7.4
8.9
14.7
12.5
9.6
61.5
46.8
39.9
34.4
35.3
41.9
22.8
23.9
16.5
16.3
4.1
2.5
3.3
2.3
2.4
2.0
2.2
1.5
1.2
1.2
N/A
N/A
N/A
N/A
N/A
17.6
21.8
14.5
16.7
17.7
3.6
2.6
1.8
1.8
2.1
7.7
5.1
5.1
4.1
4.4
Mandatory programs Net interest Total discretionary
Defense discretionary R&D outlays International discretionary R&D outlays Domestic discretionary R&D outlays Total Federal R&D outlays
U.S. Federal R&D Outlays as Proportion of Corresponding Discretionary Outlays (Percent) Total Federal R&D as a percent of total discretionary outlays
12.6%
10.9%
12.7%
12.0%
12.6%
Defense as a percent of defense outlays
9.8%
10.8%
13.7%
13.9%
14.7%
Domestic as a percent of domestic outlays
20.7%
12.1%
12.5%
11.0%
11.6%
N/A = not available 1
Includes Social Security, Medicare, Medicaid, and other programs.
Sources: U.S. Office of Management and Budget, Historical Tables, Budget of the United States Government: Fiscal Year 2002 (Washington, DC, U.S. Government Printing Office). Science & Engineering Indicators – 2002.
Plunkett Research, Ltd.
www.plunkettresearch.com
U.S. Federal Basic Research Budget Authority, by Budget Function: Fiscal Years 1995–2001 (latest data available) US$ Mil. Budget function
1995
1996
1997
1998
1999
2000
2001
Millions of Current US$ Total
Health General science Space research and tech. National defense Energy Agriculture Natural resources and env. Transportation Education, training, employment and social services Commerce & housing credit Vet. benefits and services Administration of justice Community and regional dev. General government International affairs Income security
13,772 6,068 2,622 1,614 1,181 930 565 187 389
14,442 6,395 2,662 1,685 1,165 1,182 547 147 456
14,961 6,852 2,753 1,653 1,090 1,288 548 153 420
15,523 7,356 4,121 1,610 1,067 34 571 145 411
17,433 8,634 4,464 1,667 1,110 36 602 142 358
18,965 9,834 4,648 1,737 1,205 37 659 155 255
20,259 10,399 5,272 1,761 1,262 46 702 162 202
153 35 16 9 3 0 0 0
140 37 13 12 0 0 2 0
142 34 14 13 0 0 2 0
133 35 23 16 0 0 1 0
99 41 263 18 0 0 0 0
106 41 268 21 0 0 0 0
112 53 268 19 0 0 0 0
Millions of Constant FY 1996 US$ Total
Health General science Space research and tech. National defense Energy Agriculture Natural resources and env. Transportation Education, training, employment and social services Commerce & housing credit Vet. benefits and services Administration of justice Community and regional dev. General government International affairs Income security
14,037 6,185 2,673 1,646 1,204 948 576 190 397
14,442 6,395 2,662 1,685 1,165 1,182 547 147 456
14,711 6,738 2,707 1,625 1,072 1,266 539 150 413
15,071 7,142 4,000 1,563 1,036 33 554 141 399
16,708 8,275 4,278 1,597 1,063 34 577 136 343
17,908 9,286 4,389 1,641 1,138 35 622 146 241
18,755 9,627 4,880 1,631 1,168 43 650 150 187
156 36 16 9 3 0 0 0
140 37 13 12 0 0 2 0
140 33 14 13 0 0 2 0
129 34 23 16 0 0 1 0
95 39 252 17 0 0 0 0
100 38 253 20 0 0 0 0
104 49 248 18 0 0 0 0
Notes: Data for 1995–99 are actual budget authority. Data for 2000 are preliminary estimates, and data for 2001 are proposed based on FY 2001 budget. See Appendix table 4-1 for fiscal year gross domestic product implicit price deflators used to convert current dollars to constant 1996 dollars. Beginning in FY 1998, a number of Department of Energy programs were reclassified from energy to general science. Beginning FY 1999, the increase in the Veterans Administration basic research totals was a result of data reclassifications. Source: National Science Foundation, Division of Science Resources Studies (NSF/SRS), Federal R&D Funding by Budget Function: Fiscal Years 1999–2001, NSF 01-316 (Arlington, VA, 2001).
Plunkett Research, Ltd.
www.plunkettresearch.com
U.S. Federal R&D Budget Authority, by Budget Function: FY 1980–2001
4,890 5,065 3,932 3,110 3,233 3,708 3,845 4,394 4,612 5,493 6,700 7,283 7,351 7,440 7,726 8,074 7,844 7,694 7,928 7,864
Millions of Constant 1996 US$ 6,435 2,202 1,784 1,584 1,045 5,700 2,182 1,727 1,415 1,073 4,583 2,068 1,468 1,204 1,054 3,757 2,189 1,388 1,277 1,086 3,628 2,356 1,354 1,462 1,071 3,251 2,534 1,441 1,402 1,138 3,037 2,489 1,411 1,218 1,083 2,655 2,641 1,465 1,174 1,063 2,662 2,705 1,453 1,122 1,104 2,917 2,861 1,513 1,283 1,094 3,168 2,801 1,611 1,214 1,104 3,303 2,947 1,770 1,377 1,177 3,437 2,898 1,840 1,660 1,259 2,850 2,865 1,918 1,813 1,226 2,994 2,826 1,944 1,967 1,243 2,901 2,850 2,028 1,870 1,218 2,521 2,846 1,802 1,795 1,176 2,327 2,888 1,850 1,751 1,180 917 4,217 1,794 1,773 1,208 1,079 4,473 1,757 1,645 1,228
General Gov't
6,598 6,303 5,887 6,264 6,718 7,372 7,394 8,478 8,861 9,373 9,655 10,320 10,960 10,944 11,456 11,635 11,867 12,428 13,130 14,834
Income security
26,421 24,946 21,371 20,160 20,983 22,029 21,689 23,170 23,800 25,865 27,723 29,720 30,864 30,485 31,854 32,218 31,248 31,449 32,636 34,650
Admin. of justice
26,694 29,979 33,582 36,345 41,168 45,854 49,065 50,630 50,212 49,035 46,397 43,991 43,692 43,915 39,354 37,948 37,801 38,834 38,514 39,395
Millions of Current US$ 1,233 999 887 585 1,340 1,061 869 659 1,359 965 791 693 1,502 952 876 745 1,676 963 1,040 762 1,862 1,059 1,030 836 1,873 1,062 917 815 2,042 1,133 908 822 2,160 1,160 896 882 2,373 1,255 1,064 907 2,410 1,386 1,045 950 2,635 1,582 1,231 1,052 2,659 1,688 1,523 1,155 2,691 1,802 1,703 1,152 2,712 1,865 1,888 1,193 2,794 1,988 1,833 1,194 2,846 1,802 1,795 1,176 2,944 1,886 1,785 1,203 4,360 1,855 1,833 1,249 4,690 1,842 1,725 1,288 4,885 1,906 1,570 1,405 5,529 1,932 1,665 1,450
Commerce & housing credit Community & reg. Development
1980 53,115 1981 54,925 1982 54,953 1983 56,505 1984 62,151 1985 67,883 1986 70,753 1987 73,799 1988 74,012 1989 74,901 1990 74,121 1991 73,711 1992 74,556 1993 74,400 1994 71,208 1995 70,166 1996 69,049 1997 70,282 1998 71,150 1999 74,046
Agriculture Educ., training, employ. & social serv.
3,603 3,501 3,012 2,578 2,581 2,389 2,286 2,053 2,126 2,419 2,726 2,953 3,153 2,677 2,873 2,844 2,521 2,372 948 1,131 1,112 1,184
Transportation
2,738 3,111 2,584 2,134 2,300 2,725 2,894 3,398 3,683 4,555 5,765 6,511 6,744 6,988 7,414 7,916 7,844 7,844 8,198 8,245 8,447 8,732
International affairs Vets benefits & services
Natural resources & environment
Energy
3,694 3,871 3,869 4,298 4,779 5,418 5,565 6,556 7,076 7,773 8,308 9,226 10,055 10,280 10,993 11,407 11,867 12,670 13,576 15,553 17,762 18,858
General science
Space research & technology
14,793 15,322 14,045 13,832 14,927 16,189 16,323 17,917 19,007 21,450 23,856 26,570 28,315 28,635 30,567 31,587 31,248 32,062 33,746 36,331 38,887 41,316
Total defense 14,946 18,413 22,070 24,936 29,287 33,698 36,926 39,152 40,099 40,665 39,925 39,328 40,083 41,249 37,764 37,204 37,801 39,591 39,823 41,306 41,846 41,414
Total
1980 29,739 1981 33,735 1982 36,115 1983 38,768 1984 44,214 1985 49,887 1986 53,249 1987 57,069 1988 59,106 1989 62,115 1990 63,781 1991 65,898 1992 68,398 1993 69,884 1994 68,331 1995 68,791 1996 69,049 1997 71,653 1998 73,569 1999 77,637 2000 80,733 2001 82,730
Year
Health
Total non-defense
(latest data available)
468 298 228 189 200 220 248 267 285 347 374 433 365 348 373 369 331 373 444 403 476 497
125 160 165 177 192 210 211 223 224 279 375 378 371 382 254 287 252 190 163 190 142 114
126 143 139 157 218 193 183 215 195 212 216 219 245 250 265 257 259 267 587 644 655 655
101 106 104 107 110 114 111 110 122 128 140 178 192 220 380 525 432 409 398 432 373 516
119 104 63 44 46 50 88 99 108 74 67 88 95 57 68 70 50 48 42 59 46 63
45 34 31 37 24 47 41 49 51 45 44 51 51 49 46 59 56 59 72 88 77 74
47 43 32 32 26 21 14 25 23 27 33 30 37 36 45 43 16 9 18 38 25 42
22 22 10 6 8 17 14 17 17 15 17 4 4 1 0 1 2 2 2 3 6 6
836 485 347 275 281 299 330 345 357 418 435 484 398 370 389 376 331 366 429 384
223 261 251 258 270 286 280 288 280 336 436 423 404 407 265 293 252 186 158 181
225 233 212 229 306 263 243 278 244 256 251 245 267 266 276 262 259 262 568 614
180 173 158 156 155 155 147 142 153 154 163 199 209 234 396 535 432 401 385 412
213 169 96 64 65 68 117 128 135 89 78 98 104 61 71 71 50 47 41 56
80 55 47 54 34 64 54 63 64 54 51 57 56 52 48 60 56 58 70 84
84 70 49 47 37 29 19 32 29 33 38 34 40 38 47 44 16 9 17 36
39 36 15 9 11 23 19 22 21 18 20 4 4 1 0 1 2 2 2 3
Plunkett Research, Ltd.
www.plunkettresearch.com
U.S. Federal R&D Budget Authority, by Budget Function: FY 1980–2001 (cont.)
2000 75,543 39,156 2001 75,823 37,956
Millions of Current US$ 36,387 16,620 7,904 1,041 4,571 1,783 1,469 1,315 37,866 17,283 8,003 1,085 5,067 1,771 1,526 1,329
445 456
133 104
613 600
349 473
43 58
72 68
23 38
General Gov't
Income security
Admin. of justice
Commerce & housing credit Community & reg. Development
International affairs Vets benefits & services
Agriculture Educ., training, employ. & social serv.
Transportation
Natural resources & environment
General science
Energy
Space research & technology
Health
Total non-defense
Total defense
Total
Year
(latest data available)
6 5
Notes: Data for 1980–99 are actual budget authority, data for 2000 are preliminary estimates, and data for 2001 are proposed based on fiscal year 2001 budget. See Appendix table 4-1 for fiscal year GDP implicit price deflators used to convert current dollars to constant 1996 dollars. Beginning in fiscal year 1998, a number of Department of Energy programs were reclassified from energy to general science. Sources: National Science Foundation, Division of Science Resources Studies (NSF/SRS), Federal R&D Funding by Budget Function: Fiscal Years 1999–2001, NSF 01–316 (Arlington, VA, 2001). Science & Engineering Indicators – 2002.
Plunkett Research, Ltd.
www.plunkettresearch.com
II. Research and Development by States-U.S.
Plunkett Research, Ltd.
www.plunkettresearch.com
California Research & Development (R&D) Profile, 1999-2000 Latest data available Characteristic Doctoral scientists, 19991 1
Doctoral engineers, 1999
1
S&E doctorates awarded, 2000
State
U.S.
Rank
66,800
518,670
1
19,980
107,100
1
3,321
25,979
1
of which, in life sciences
22%
26%
in engineering
22%
21%
17%
14%
6,009
41,548
1
43,907
435,612
1
Population, 2000 (thousands)
33,872
285,231
1
Civilian labor force, 2000 (thousands)
17,091
142,172
1
Personal income per capita, 2000
$32,225
$29,451
9
Total expenditures, 2000 (millions)
$175,751
$1,615,468
1
R&D obligations, 1999 (millions)
$15,600
$73,718
1
Total R&D performance, 1999 (millions)
$47,965
$231,832
1
Industry R&D, 1999 (millions)
$39,047
$177,171
1
Academic R&D, 1999 (millions)
$3,573
$27,038
1
of which, in life sciences
56%
57%
in engineering
15%
15%
in psychology S&E postdoctorates in doctorate-granting institutions, 2000
1
S&E graduate students in doctorate-granting institutions, 2000
1
Federal spending
in physical sciences
12%
9%
$15,707
$125,236
1
Number of SBIR awards, 1995-2000
5,510
26,424
1
Patents issued to state residents, 2000
17,492
85,068
1
Gross state product, 1999 (billions)
$1,229
$9,369
1
of which, agriculture
2%
1%
manufacturing, mining, construction
19%
22%
transportation, communication, utilities
7%
8%
wholesale and retail trade
16%
16%
finance, insurance, real estate
22%
19%
services
23%
21%
government
11%
12%
Public higher education current-fund expenditures, 1997 (millions)
S&E= Science & Engineering; SBIR=Small Business Innovation Research NOTE: Rankings and totals are based on data for the 50 States, District of Columbia, and Puerto Rico. Reliability of the estimates of industry R&D and of doctoral scientists and engineers varies by State, because the sample allocation was not based on geography. The rankings do not take into account the margin of error of estimates from sample surveys. 1 Data on graduate students, doctoral scientists and engineers, and postdoctorates include all graduate degree (except M.D.) candidates and recipients in S&E fields, including health fields. Data on S&E doctorates awarded do not include health fields. Source: National Science Foundation/Division of Science Resources Statistics.
Plunkett Research, Ltd.
www.plunkettresearch.com
Illinois Research & Development (R&D) Profile, 1999-2000 Latest data available Characteristic Doctoral scientists, 19991 1
Doctoral engineers, 1999
1
S&E doctorates awarded, 2000
State
U.S.
Rank
20,540
518,670
7
4,020
107,100
9 5
1,345
25,979
of which, in life sciences
22%
26%
in engineering
22%
21%
18%
16%
1,225
41,548
8
23,370
435,612
4
Population, 2000 (thousands)
12,419
285,231
5
Civilian labor force, 2000 (thousands)
6,419
142,172
5
$31,842
$29,451
11
Total expenditures, 2000 (millions)
$60,008
$1,615,468
7
R&D obligations, 1999 (millions)
$1,316
$73,718
16
Total R&D performance, 1999 (millions)
$9,719
$231,832
8
Industry R&D, 1999 (millions)
$7,715
$177,171
8
Academic R&D, 1999 (millions)
$1,087
$27,038
7
54%
57%
in engineering
15%
15%
in physical sciences
11%
9%
$4,713
$125,236
7
393
26,424
19
Patents issued to state residents, 2000
3,833
85,068
5
Gross state product, 1999 (billions)
$446
$9,369
4
of which, agriculture
1%
1%
manufacturing, mining, construction
21%
22%
transportation, communication, utilities
9%
8%
wholesale and retail trade
16%
16%
finance, insurance, real estate
20%
19%
services
23%
21%
government
10%
12%
in psychology S&E postdoctorates in doctorate-granting institutions, 2000
1
S&E graduate students in doctorate-granting institutions, 2000
1
Personal income per capita, 2000 Federal spending
of which, in life sciences
Public higher education current-fund expenditures, 1997 (millions) Number of SBIR awards, 1995-2000
S&E= Science & Engineering; SBIR=Small Business Innovation Research NOTE: Rankings and totals are based on data for the 50 States, District of Columbia, and Puerto Rico. Reliability of the estimates of industry R&D and of doctoral scientists and engineers varies by State, because the sample allocation was not based on geography. The rankings do not take into account the margin of error of estimates from sample surveys. 1 Data on graduate students, doctoral scientists and engineers, and postdoctorates include all graduate degree (except M.D.) candidates and recipients in S&E fields, including health fields. Data on S&E doctorates awarded do not include health fields. Source: National Science Foundation/Division of Science Resources Statistics.
Plunkett Research, Ltd.
www.plunkettresearch.com
Maryland Research & Development (R&D) Profile, 1999-2000 Latest data available Characteristic Doctoral scientists, 19991 1
Doctoral engineers, 1999
1
S&E doctorates awarded, 2000
State
U.S.
Rank
21,510
518,670
6
3,440
107,100
10 13
635
25,979
of which, in life sciences
29%
26%
in engineering
22%
21%
17%
16%
1,572
41,548
6
9,563
435,612
13
Population, 2000 (thousands)
5,296
285,231
19
Civilian labor force, 2000 (thousands)
2,805
142,172
18
$33,621
$29,451
6
Total expenditures, 2000 (millions)
$45,089
$1,615,468
10
R&D obligations, 1999 (millions)
$8,094
$73,718
2
Total R&D performance, 1999 (millions)
$8,087
$231,832
10
Industry R&D, 1999 (millions)
$1,700
$177,171
22
Academic R&D, 1999 (millions)
$1,380
$27,038
6
42%
57%
in engineering
23%
15%
in physical sciences
13%
9%
Public higher education current-fund expenditures, 1997 (millions)
$2,353
$125,236
18
Number of SBIR awards, 1995-2000
1,255
26,424
4
Patents issued to state residents, 2000
1,355
85,068
20
Gross state product, 1999 (billions)
$175
$9,369
16
of which, agriculture
1%
1%
manufacturing, mining, construction
14%
22%
transportation, communication, utilities
7%
8%
wholesale and retail trade
15%
16%
finance, insurance, real estate
21%
19%
services
24%
21%
government
17%
12%
in psychology S&E postdoctorates in doctorate-granting institutions, 2000
1
S&E graduate students in doctorate-granting institutions, 2000
1
Personal income per capita, 2000 Federal spending
of which, in life sciences
S&E= Science & Engineering; SBIR=Small Business Innovation Research NOTE: Rankings and totals are based on data for the 50 States, District of Columbia, and Puerto Rico. Reliability of the estimates of industry R&D and of doctoral scientists and engineers varies by State, because the sample allocation was not based on geography. The rankings do not take into account the margin of error of estimates from sample surveys. 1 Data on graduate students, doctoral scientists and engineers, and postdoctorates include all graduate degree (except M.D.) candidates and recipients in S&E fields, including health fields. Data on S&E doctorates awarded do not include health fields. Source: National Science Foundation/Division of Science Resources Statistics.
Plunkett Research, Ltd.
www.plunkettresearch.com
Massachusetts Research & Development (R&D) Profile, 1999-2000 Latest data available Characteristic Doctoral scientists, 19991 1
Doctoral engineers, 1999
1
S&E doctorates awarded, 2000
State
U.S.
Rank
24,880
518,670
4
4,850
107,100
4 4
1,452
25,979
of which, in life sciences
25%
26%
in engineering
22%
21%
21%
16%
5,468
41,548
2
22,530
435,612
5
Population, 2000 (thousands)
6,349
285,231
13
Civilian labor force, 2000 (thousands)
3,237
142,172
13
$37,710
$29,451
3
Total expenditures, 2000 (millions)
$40,824
$1,615,468
14
R&D obligations, 1999 (millions)
$3,129
$73,718
6
Total R&D performance, 1999 (millions)
$12,190
$231,832
5
Industry R&D, 1999 (millions)
$9,314
$177,171
6
Academic R&D, 1999 (millions)
$1,381
$27,038
5
44%
57%
in engineering
18%
15%
in physical sciences
13%
9%
Public higher education current-fund expenditures, 1997 (millions)
$1,740
$125,236
28
Number of SBIR awards, 1995-2000
3,958
26,424
2
Patents issued to state residents, 2000
3,463
85,068
8
Gross state product, 1999 (billions)
$263
$9,369
11
of which, agriculture
1%
1%
manufacturing, mining, construction
18%
22%
transportation, communication, utilities
6%
8%
wholesale and retail trade
15%
16%
finance, insurance, real estate
24%
19%
services
27%
21%
government
9%
12%
in psychology S&E postdoctorates in doctorate-granting institutions, 2000
1
S&E graduate students in doctorate-granting institutions, 2000
1
Personal income per capita, 2000 Federal spending
of which, in life sciences
S&E= Science & Engineering; SBIR=Small Business Innovation Research NOTE: Rankings and totals are based on data for the 50 States, District of Columbia, and Puerto Rico. Reliability of the estimates of industry R&D and of doctoral scientists and engineers varies by State, because the sample allocation was not based on geography. The rankings do not take into account the margin of error of estimates from sample surveys. 1 Data on graduate students, doctoral scientists and engineers, and postdoctorates include all graduate degree (except M.D.) candidates and recipients in S&E fields, including health fields. Data on S&E doctorates awarded do not include health fields. Source: National Science Foundation/Division of Science Resources Statistics.
Plunkett Research, Ltd.
www.plunkettresearch.com
Michigan Research & Development (R&D) Profile, 1999-2000 Latest data available Characteristic Doctoral scientists, 19991 1
Doctoral engineers, 1999
1
S&E doctorates awarded, 2000
State
U.S.
Rank
13,770
518,670
13
4,530
107,100
7 8
993
25,979
of which, in life sciences
27%
21%
in engineering
22%
26%
17%
16%
1,108
41,548
11
17,407
435,612
9
Population, 2000 (thousands)
9,938
285,231
8
Civilian labor force, 2000 (thousands)
5,201
142,172
8
$29,071
$29,451
19
$46,823
$1,615,468
9
$840
$73,718
22
Total R&D performance, 1999 (millions)
$18,799
$231,832
2
Industry R&D, 1999 (millions)
$17,714
$177,171
2
$914
$27,038
9
of which, in life sciences
58%
57%
in engineering
20%
15%
in physical sciences
9%
5%
$5,987
$125,236
4
525
26,424
15
Patents issued to state residents, 2000
3,724
85,068
6
Gross state product, 1999 (billions)
$308
$9,369
9
of which, agriculture
1%
1%
manufacturing, mining, construction
31%
22%
transportation, communication, utilities
7%
8%
wholesale and retail trade
17%
16%
finance, insurance, real estate
14%
19%
services
20%
21%
government
10%
12%
in psychology S&E postdoctorates in doctorate-granting institutions, 2000
1
S&E graduate students in doctorate-granting institutions, 2000
1
Personal income per capita, 2000 Federal spending Total expenditures, 2000 (millions) R&D obligations, 1999 (millions)
Academic R&D, 1999 (millions)
Public higher education current-fund expenditures, 1997 (millions) Number of SBIR awards, 1995-2000
S&E= Science & Engineering; SBIR=Small Business Innovation Research NOTE: Rankings and totals are based on data for the 50 States, District of Columbia, and Puerto Rico. Reliability of the estimates of industry R&D and of doctoral scientists and engineers varies by State, because the sample allocation was not based on geography. The rankings do not take into account the margin of error of estimates from sample surveys. 1 Data on graduate students, doctoral scientists and engineers, and postdoctorates include all graduate degree (except M.D.) candidates and recipients in S&E fields, including health fields. Data on S&E doctorates awarded do not include health fields. Source: National Science Foundation/Division of Science Resources Statistics.
Plunkett Research, Ltd.
www.plunkettresearch.com
New Jersey Research & Development (R&D) Profile, 1999-2000 Latest data available Characteristic Doctoral scientists, 19991 1
Doctoral engineers, 1999
1
S&E doctorates awarded, 2000
State
U.S.
Rank
19,740
518,670
8
4,750
107,100
6 14
597
25,979
of which, in life sciences
25%
26%
in engineering
22%
21%
18%
16%
672
41,548
18
11,110
435,612
12
Population, 2000 (thousands)
8,414
285,231
9
Civilian labor force, 2000 (thousands)
4,188
142,172
9
$37,112
$29,451
4
Total expenditures, 2000 (millions)
$43,469
$1,615,468
11
R&D obligations, 1999 (millions)
$2,661
$73,718
8
Total R&D performance, 1999 (millions)
$10,536
$231,832
7
Industry R&D, 1999 (millions)
$9,453
$177,171
5
$521
$27,038
17
47%
57%
in engineering
18%
15%
in physical sciences
11%
9%
$3,148
$125,236
11
803
26,424
10
Patents issued to state residents, 2000
3,889
85,068
4
Gross state product, 1999 (billions)
$332
$9,369
8
of which, agriculture
1%
1%
manufacturing, mining, construction
16%
22%
transportation, communication, utilities
10%
8%
wholesale and retail trade
17%
16%
finance, insurance, real estate
24%
19%
services
23%
21%
government
10%
12%
in psychology S&E postdoctorates in doctorate-granting institutions, 2000
1
S&E graduate students in doctorate-granting institutions, 2000
1
Personal income per capita, 2000 Federal spending
Academic R&D, 1999 (millions) of which, in life sciences
Public higher education current-fund expenditures, 1997 (millions) Number of SBIR awards, 1995-2000
S&E= Science & Engineering; SBIR=Small Business Innovation Research NOTE: Rankings and totals are based on data for the 50 States, District of Columbia, and Puerto Rico. Reliability of the estimates of industry R&D and of doctoral scientists and engineers varies by State, because the sample allocation was not based on geography. The rankings do not take into account the margin of error of estimates from sample surveys. 1 Data on graduate students, doctoral scientists and engineers, and postdoctorates include all graduate degree (except M.D.) candidates and recipients in S&E fields, including health fields. Data on S&E doctorates awarded do not include health fields. Source: National Science Foundation/Division of Science Resources Statistics.
Plunkett Research, Ltd.
www.plunkettresearch.com
New York Research & Development (R&D) Profile, 1999-2000 Latest data available Characteristic
State
U.S.
Rank
41,230
518,670
2
6,230
107,100
3
2,217
25,979
2
of which, in life sciences
25%
26%
in engineering
20%
16%
16%
14%
3,925
41,548
3
36,420
435,612
2
Population, 2000 (thousands)
18,976
285,231
3
Civilian labor force, 2000 (thousands)
8,941
142,172
3
$34,502
$29,451
5
$110,333
$1,615,468
2
$2,689
$73,718
7
Total R&D performance, 1999 (millions)
$14,110
$231,832
3
Industry R&D, 1999 (millions)
$11,388
$177,171
3
Academic R&D, 1999 (millions)
$2,029
$27,038
2
of which, in life sciences
66%
57%
in engineering
11%
15%
in physical sciences
10%
9%
Public higher education current-fund expenditures, 1997 (millions)
$6,872
$125,236
3
Number of SBIR awards, 1995-2000
1,112
26,424
6
Patents issued to state residents, 2000
6,083
85,068
3
Gross state product, 1999 (billions)
$755
$9,369
2
of which, agriculture
0%
1%
manufacturing, mining, construction
13%
22%
transportation, communication, utilities
7%
8%
wholesale and retail trade
13%
16%
finance, insurance, real estate
33%
19%
services
23%
21%
government
10%
12%
Doctoral scientists, 19991 1
Doctoral engineers, 1999
1
S&E doctorates awarded, 2000
in psychology S&E postdoctorates in doctorate-granting institutions, 2000
1
S&E graduate students in doctorate-granting institutions, 2000
1
Personal income per capita, 2000 Federal spending Total expenditures, 2000 (millions) R&D obligations, 1999 (millions)
S&E= Science & Engineering; SBIR=Small Business Innovation Research NOTE: Rankings and totals are based on data for the 50 States, District of Columbia, and Puerto Rico. Reliability of the estimates of industry R&D and of doctoral scientists and engineers varies by State, because the sample allocation was not based on geography. The rankings do not take into account the margin of error of estimates from sample surveys. 1 Data on graduate students, doctoral scientists and engineers, and postdoctorates include all graduate degree (except M.D.) candidates and recipients in S&E fields, including health fields. Data on S&E doctorates awarded do not include health fields. Source: National Science Foundation/Division of Science Resources Statistics.
Plunkett Research, Ltd.
www.plunkettresearch.com
Pennsylvania Research & Development (R&D) Profile, 1999-2000 Latest data available Characteristic
State
U.S.
Rank
23,820
518,670
5
4,290
107,100
8
1,240
25,979
6
of which, in life sciences
25%
21%
in engineering
23%
26%
16%
14%
2,582
41,548
5
19,609
435,612
6
12,281
285,231
6
Doctoral scientists, 19991 1
Doctoral engineers, 1999
1
S&E doctorates awarded, 2000
in psychology S&E postdoctorates in doctorate-granting institutions, 2000
1
S&E graduate students in doctorate-granting institutions, 2000
1
Population, 2000 (thousands) Civilian labor force, 2000 (thousands)
5,972
142,172
6
$29,533
$29,451
17
Total expenditures, 2000 (millions)
$73,715
$1,615,468
5
R&D obligations, 1999 (millions)
$1,907
$73,718
13
Total R&D performance, 1999 (millions)
$10,695
$231,832
6
Industry R&D, 1999 (millions)
$8,932
$177,171
7
Academic R&D, 1999 (millions)
$1,389
$27,038
4
of which, in life sciences
57%
57%
in engineering
17%
15%
in physical sciences
7%
5%
$4,941
$125,236
5
889
26,424
9
Patents issued to state residents, 2000
3,636
85,068
7
Gross state product, 1999 (billions)
$383
$9,369
6
of which, agriculture
1%
1%
Personal income per capita, 2000 Federal spending
Public higher education current-fund expenditures, 1997 (millions) Number of SBIR awards, 1995-2000
manufacturing, mining, construction
24%
22%
transportation, communication, utilities
9%
8%
wholesale and retail trade
15%
16%
finance, insurance, real estate
18%
19%
services
22%
21%
government
10%
12%
S&E= Science & Engineering; SBIR=Small Business Innovation Research NOTE: Rankings and totals are based on data for the 50 States, District of Columbia, and Puerto Rico. Reliability of the estimates of industry R&D and of doctoral scientists and engineers varies by State, because the sample allocation was not based on geography. The rankings do not take into account the margin of error of estimates from sample surveys. 1 Data on graduate students, doctoral scientists and engineers, and postdoctorates include all graduate degree (except M.D.) candidates and recipients in S&E fields, including health fields. Data on S&E doctorates awarded do not include health fields. Source: National Science Foundation/Division of Science Resources Statistics.
Plunkett Research, Ltd.
www.plunkettresearch.com
Texas Research & Development (R&D) Profile, 1999-2000 Latest data available Characteristic
State
U.S.
Rank
27,170
518,670
3
8,340
107,100
2
1,572
25,979
3
of which, in life sciences
28%
26%
in engineering
25%
21%
12%
14%
2,583
41,548
4
29,314
435,612
3
20,852
285,231
2
Civilian labor force, 2000 (thousands)
10,325
142,172
2
Personal income per capita, 2000
$27,722
$29,451
25
$106,493
$1,615,468
3
$3,853
$73,718
4
Total R&D performance, 1999 (millions)
$12,429
$231,832
4
Industry R&D, 1999 (millions)
$9,935
$177,171
4
Academic R&D, 1999 (millions)
$1,801
$27,038
28
of which, in life sciences
63%
57%
in engineering
15%
15%
in physical sciences
8%
9%
Public higher education current-fund expenditures, 1997 (millions)
$8,758
$125,236
2
Number of SBIR awards, 1995-2000
1,004
26,424
7
Patents issued to state residents, 2000
6,323
85,068
2
Gross state product, 1999 (billions)
$687
$9,369
3
1%
1%
Doctoral scientists, 19991 1
Doctoral engineers, 1999
1
S&E doctorates awarded, 2000
in psychology S&E postdoctorates in doctorate-granting institutions, 2000
1
S&E graduate students in doctorate-granting institutions, 2000
1
Population, 2000 (thousands)
Federal spending Total expenditures, 2000 (millions) R&D obligations, 1999 (millions)
of which, agriculture manufacturing, mining, construction
24%
22%
transportation, communication, utilities
11%
8%
wholesale and retail trade
18%
16%
finance, insurance, real estate
15%
19%
services
20%
21%
government
11%
12%
S&E= Science & Engineering; SBIR=Small Business Innovation Research NOTE: Rankings and totals are based on data for the 50 States, District of Columbia, and Puerto Rico. Reliability of the estimates of industry R&D and of doctoral scientists and engineers varies by State, because the sample allocation was not based on geography. The rankings do not take into account the margin of error of estimates from sample surveys. 1 Data on graduate students, doctoral scientists and engineers, and postdoctorates include all graduate degree (except M.D.) candidates and recipients in S&E fields, including health fields. Data on S&E doctorates awarded do not include health fields. Source: National Science Foundation/Division of Science Resources Statistics.
Plunkett Research, Ltd.
www.plunkettresearch.com
Washington Research & Development (R&D) Profile, 1999-2000 Latest data available Characteristic
State
U.S.
Rank
13,250
518,670
15
2,370
107,100
13
406
25,979
21
of which, in life sciences
32%
26%
in engineering
20%
21%
16%
16%
1,168
41,548
9
6,210
435,612
24
5,894
285,231
15
Doctoral scientists, 19991 1
Doctoral engineers, 1999
1
S&E doctorates awarded, 2000
in psychology S&E postdoctorates in doctorate-granting institutions, 2000
1
S&E graduate students in doctorate-granting institutions, 2000
1
Population, 2000 (thousands) Civilian labor force, 2000 (thousands)
3,045
142,172
15
$31,129
$29,451
12
Total expenditures, 2000 (millions)
$33,897
$1,615,468
16
R&D obligations, 1999 (millions)
$1,307
$73,718
17
Total R&D performance, 1999 (millions)
$8,336
$231,832
9
Industry R&D, 1999 (millions)
$7,231
$177,171
9
$580
$27,038
48
of which, in life sciences
68%
57%
in engineering
11%
6%
in physical sciences
8%
15%
$3,127
$125,236
12
661
26,424
11
Patents issued to state residents, 2000
1,821
85,068
15
Gross state product, 1999 (billions)
$209
$9,369
14
of which, agriculture
2%
1%
Personal income per capita, 2000 Federal spending
Academic R&D, 1999 (millions)
Public higher education current-fund expenditures, 1997 (millions) Number of SBIR awards, 1995-2000
manufacturing, mining, construction
18%
22%
transportation, communication, utilities
8%
8%
wholesale and retail trade
17%
16%
finance, insurance, real estate
17%
19%
services
25%
21%
government
13%
12%
S&E= Science & Engineering; SBIR=Small Business Innovation Research NOTE: Rankings and totals are based on data for the 50 States, District of Columbia, and Puerto Rico. Reliability of the estimates of industry R&D and of doctoral scientists and engineers varies by State, because the sample allocation was not based on geography. The rankings do not take into account the margin of error of estimates from sample surveys. 1 Data on graduate students, doctoral scientists and engineers, and postdoctorates include all graduate degree (except M.D.) candidates and recipients in S&E fields, including health fields. Data on S&E doctorates awarded do not include health fields. Source: National Science Foundation/Division of Science Resources Statistics.
Plunkett Research, Ltd.
www.plunkettresearch.com
State Distribution of Expenditures for R&D, by Performing Sector and Source of Funding: 2000 (Latest Available Data) Performing sector: Funding sector: State
Total R&D Total R&D
Federal Govt. Federal Govt.
Rank
U&C Universities & colleges1 FFRDCs
Industry Federal Total2 Govt.2 Industry3 Thousands of current dollars
264,616,008 17,468,589 199,539,000 19,118,000 180,421,000
United States, total
Gross state R&D product intensity6 Rank % Rank 30,973,891 5,801,2299,941,551,000 2.66 Total
Alabama
27
Alaska
47
196,448
75,446
9,000
D
D
107,417
Arizona
19
3,107,291
145,601
2,445,000
153,000
2,292,000
465,777
Arkansas
42
454,401
45,489
273,000
D
D
45,769,000 4,229,000
41,540,000
California
1,730,117
664,981
1 55,092,936 1,655,628
607,000
184,000
423,000
428,122
Federal Govt.4
0 119,921,000
31
27,747,000
460.71
45
36,409 156,303,000
231.99
19
67,724,000
340.67
47
4,053,042 2,812,1341,344,623,000
14.10
8
130,894
0
251.44
0
Colorado
17
4,229,501
241,771
3,140,000
D
D
544,204
115,510 167,918,000
212.52
15
Connecticut
14
4,888,469
19,373
4,371,000
127,000
4,244,000
468,435
0 159,288,000
223.07
12
Delaware
28
1,532,130
7,598
1,444,000
7,000
1,437,000
78,126
0
36,336,000
444.22
6
D.C.
24
2,296,233 1,722,640
112,000
46,000
67,000
245,828
0
59,397,000
363.87
10
Florida
15
4,662,727
573,140
3,212,000
498,000
2,714,000
851,932
0 472,105,000
40.99
36
Georgia
21
2,796,192
273,713
1,579,000
83,000
1,496,000
926,749
0 296,142,000
100.94
37
Hawaii
46
291,409
58,658
44,000
17,000
27,000
161,300
0
42,364,000
400.69
46
Idaho
30
1,433,567
21,722
1,338,000
D
D
73,726
0
37,031,000
423.87
9
6 12,767,496
85,344
10,661,000
37,000
10,624,000
1,170,625
759,002 467,284,000
52.73
13
Illinois Indiana
18
3,252,494
71,630
2,668,000
75,000
2,593,000
509,141
Iowa
34
1,017,300
34,586
538,000
D
D
418,263
Kansas
31
1,420,089
20,162
1,140,000
D
D
Kentucky
35
866,052
7,500
582,000
1,000
581,000
Louisiana
38
626,793
99,196
126,000
1,000
125,000
399,411
Maine
45
318,726
4,755
201,000
53,000
148,000
57,753
Maryland
10
8,633,558 4,869,668
2,032,000
428,000
1,604,000
0 192,195,000
151.69
25
301.14
33
23,281
89,600,000
258,336
0
85,063,000
311.67
26
274,238
0 118,508,000
270.73
43
0 137,700,000
240.46
49
0
35,981,000
450.89
38
1,507,549
0 186,108,000
164.64
4
Massachusetts
5 13,004,427
259,172
8,032,000
1,485,792
348,339 284,934,000
114.56
5
Michigan
2 18,892,070
239,543
17,640,000
80,000
17,559,000
995,756
0 325,384,000
95.81
1
9,863,000 1,831,000
Minnesota
16
4,298,967
32,014
3,722,000
173,000
3,550,000
416,411
0 184,766,000
172.33
17
Mississippi
39
512,789
186,799
101,000
19,000
83,000
217,064
0
350.76
42
Missouri
23
2,583,036
43,851
1,893,000
18,000
1,876,000
614,101
0 178,845,000
181.44
30
Montana
48
169,856
35,344
28,000
D
D
99,069
0
21,777,000
480.78
41
Nebraska
43
438,996
25,082
199,000
D
D
208,480
0
56,072,000
370.78
40
Nevada
44
377,412
20,696
248,000
D
D
106,340
0
74,745,000
320.50
48
New Hampshire
36
775,004
35,717
586,000
D
D
150,982
0
47,708,000
391.62
27
4 13,133,222
567,666
New Jersey
417,685
12,062,000
253,000
11,809,000
New Mexico
20
3,085,199
320,838
1,158,000
D
D
New York North Carolina North Dakota
3 13,555,586 13 5,045,250 49 145,671
176,034 262,003 25,842
10,539,000 1,773,000 3,672,000 30,000 51,000 D
8,766,000 3,641,000 D
Ohio
11
7,661,540
615,458
5,962,000
539,000
Oklahoma
37
659,684
58,619
333,000
3,000
67,315,000
65,305 363,089,000
83.62
11
54,364,000
385.68
2
2,290,812 1,040,017 67,406
0 799,202,000 0 281,741,000 0 18,283,000
21.70 121.79 510.80
24 22 39
5,423,000
918,500
0 372,640,000
72.06
18
331,000
252,419
0
290.72
44
246,258 1,333,194
91,773,000
Plunkett Research, Ltd.
www.plunkettresearch.com
State Distribution of Expenditures for R&D, by Performing Sector and Source of Funding: 2000 (Latest Available Data) (cont.) Performing sector: Funding sector: State Oregon
Total R&D
Federal Govt.
Total R&D
Federal Govt.
Rank
U&C Universities & colleges1 FFRDCs
Industry Federal Total2 Govt.2 Industry3 Thousands of current dollars
Total
Gross state R&D product intensity6 Rank % Rank
Federal Govt.4
25
2,116,232
88,618
1,651,000
7,000
1,644,000
346,149
0 118,637,000
261.78
23
Pennsylvania
9
9,841,912
151,955
7,873,000
460,000
7,412,000
1,549,050
55,955 403,985,000
62.44
16
Rhode Island
29
1,500,828
240,862
1,090,000
D
D
129,697
0
36,453,000
434.12
7
South Carolina
33
1,126,164
45,754
781,000
D
D
294,184
0 113,377,000
280.99
35
South Dakota
50
84,801
13,232
44,000
16,000
28,000
27,269
0
23,192,000
470.37
50
Tennessee
26
2,057,293
88,947
1,215,000
D
D
405,013
0 178,362,000
191.15
32
7 11,552,437
464,699
8,961,000
230,000
8,731,000
2,039,642
0 742,274,000
31.56
28
Texas Utah
32
1,360,644
69,871
979,000
D
D
308,059
0
68,549,000
331.98
20
Vermont
40
465,349
3,599
396,000
D
D
64,762
0
18,411,000
502.53
14
Virginia
12
5,069,481 1,449,209
Washington
8 10,516,331
2,718,000
800,000
1,918,000
587,718
79,342 261,355,000
131.94
21
258,718
9,265,000
D
D
642,934
0 219,937,000
144.78
3
411.08
34
West Virginia
41
457,128
102,958
235,000
D
D
73,420
Wisconsin
22
2,692,876
37,816
1,981,000
18,000
1,963,000
661,470
Wyoming Other unknown
51
60,969
7,298
7,000
0
7,000
43,094
35,536
42,271,000
0 173,478,000
201.55
29
0
490.32
51
19,294,000
NA 12,130,343 42,207 11,994,000 1,094,000 10,900,000 81,969 11,268 NA NA NA NA Adjustment NA 7,630,582 949,548 1,000 NA NA 911,520 125,954 NA NA NA NA 1Adjustments have been made to university R&D for 1998 and later years to eliminate double counting of funds passed through from one academic institution to another at the national level. State-level university R&D data have not been adjusted to correct for this double counting. 2Includes performance at industry FFRDCs. 3Industry sources of R&D expenditures include all non-Federal sources of industry R&D expenditures. 4Includes all R&D expenditures of the FFRDCs, over 95% of these expenditures are Federally funded nationally. 5R&D intensity is the ratio of total R&D performed in a state to the GSP of the state. KEY: FFDRCs = federally funded research and development centers U&C = universities and colleges NA = not available D = data withheld to avoid disclosing operations of individual companies NOTES: Industry R&D data are in reference to calendar years; other R&D data are in reference to fiscal years but may serve as approximations to calendar year data. The "other unknown" category reflects reported data that could not be assigned to a geographic location. The "adjustment" category reflects the difference in state totals (and other unknown) when reported on a fiscal year basis and the U.S. Totals that have been adjusted to calendar year estimates. SOURCE: National Science Foundation/Division of Science Resources Statistics. These data were derived from four NSF surveys: Survey of Industrial R&D; Survey of R&D Expenditures at Universities and Colleges, Survey of Federal Funds for R&D, and Survey of R&D Funding and Performance by Nonprofit Organizations. Gross State Product data are from the U.S. Bureau of Economic Analysis.
Plunkett Research, Ltd.
www.plunkettresearch.com
Top 10 U.S. States in Total R&D Performance, Size of R&D by Performer and R&D as a Percentage of Gross State Product: 2000 Rank
State
Top 10 States in Total R&D Performance1 Total R&D (Mil. of Current US$)
1
California
55,092.94
2
Michigan
18,892.07
3
New York
13,555.59
4
New Jersey
13,133.22
5
Massachusetts
13,004.43
6
Illinois
12,767.50
7
Texas
11,552.44
8
Washington
10,516.33
9
Pennsylvania
9,841.91
10
Maryland
8,633.56
Rank 1 2 3 4 5 6 7 8 9 10
Top 10 States in Size of R&D, by Type of Performing Sector Universities & Colleges3 Federal Government4 Sector Industry Sector Sector California California Maryland Michigan New York District of Columbia New Jersey Texas California Illinois Pennsylvania Virginia New York Maryland Alabama Massachusetts Massachusetts Ohio Washington Illinois Florida Texas North Carolina Texas Pennsylvania Michigan New Jersey Ohio Georgia New Mexico 2
Top 10 States in R&D Intensity (States with the Highest R&D/GSP Ratio)
Rank 1 2 3 4
Michigan New Mexico Washington Maryland
5.81 5.68 4.78 4.64
GSP (Bil. of Current US$) 325.4 54.4 219.9 186.1
5 6
Massachusetts Delaware
4.56 4.22
284.9 36.3
7 8
Rhode Island California
4.12 4.10
36.5 1,344.6
9 10
Idaho District of Columbia
3.87 3.87
37.0 59.4
State
R&D/GSP (percent)
Note: GSP = gross state product; FFRDC = federally funded research and development center. Reliability of the estimates of industry R&D varies by state because the sample allocation was not based on geography. Rankings do not take into account the margin of error of estimates from sample surveys. 1 Includes in-state total R&D performance of industry, universities, Federal agencies, FFRDCs, and federally financed nonprofit R&D. 2 Includes R&D activities of industry-administered FFRDCs located within these states. 3 Excludes R&D activities of university-administered FFRDCs located within these states. 4 Includes costs associated with the administration of intramural and extramural programs by Federal personnel as well as actual intramural performance. Sources: National Science Foundation/Division of Science Resources Statistics, National Patterns of R&D Resources, annual series; GSP data are from the U.S. Bureau of Economic Analysis.
Plunkett Research, Ltd.
www.plunkettresearch.com
III. International Research and Patents
Plunkett Research, Ltd.
www.plunkettresearch.com
International R&D Expenditures in Constant Dollars and as a Percentage of GDP: 1981–2001 (Selected Nations) Total R&D expenditures U.S.
Japan2
Year
Germany3
France
Billions of constant 1996
U.K.
Italy
Canada
dollars4
1981
115.9
40.4
28.6
17.4
19.1
7.9
6.1
1985
155.8
55.6
33.6
21.5
20.1
10.9
7.9
1986
159.8
56.6
34.7
21.8
21.1
11.2
8.3
1987
162.8
60.6
36.4
22.7
21.4
12.2
8.3
1988
167.0
65.3
37.7
23.8
22.0
12.9
8.6
1989
170.4
71.4
39.1
25.3
22.6
13.5
9.2
1990
175.8
77.2
39.6
26.9
22.7
14.4
9.6
1991
179.5
79.0
42.2
27.2
21.6
13.9
9.8
1992
180.1
78.1
41.0
27.7
21.2
13.5
10.3
1993
176.2
76.1
39.6
27.7
22.0
12.7
10.8
1994
176.2
75.3
38.9
27.6
22.5
12.1
11.7
1995
187.2
80.1
39.6
27.6
22.5
11.9
11.9
1996
197.3
85.5
39.9
27.8
22.3
12.1
11.7
1997
208.1
89.0
41.1
27.4
22.1
12.9
12.4
1998
219.3
91.3
42.3
27.6
22.7
13.3
13.5
1999
232.7
91.8
45.5
28.7
24.2
13.2
14.3
2000
247.6
95.4
47.7
29.0
24.6
NA
15.3
2001
257.5
NA
48.7 NA Percent of national GDP
NA
NA
16.2
1981
2.31
2.11
2.47
1.93
2.38
0.88
1.24
1985
2.72
2.54
2.75
2.22
2.24
1.12
1.44
1986
2.70
2.51
2.77
2.21
2.26
1.13
1.47
1987
2.66
2.57
2.87
2.24
2.20
1.19
1.42
1988
2.62
2.60
2.86
2.24
2.14
1.22
1.40
1989
2.59
2.70
2.86
2.29
2.15
1.24
1.47
1990
2.62
2.78
2.75
2.37
2.15
1.29
1.53
1991
2.69
2.75
2.53
2.37
2.07
1.23
1.59
1992
2.62
2.70
2.41
2.38
2.02
1.18
1.65
1993
2.49
2.62
2.35
2.40
2.05
1.13
1.70
1994
2.40
2.57
2.26
2.34
2.01
1.05
1.76
1995
2.48
2.69
2.26
2.31
1.95
1.00
1.73
1996
2.53
2.77
2.26
2.30
1.88
1.01
1.69
1997
2.55
2.83
2.29
2.22
1.81
1.05
1.70
1998
2.58
2.94
2.31
2.17
1.80
1.07
1.79
1999
2.63
2.94
2.44
2.19
1.88
1.04
1.80
2000
2.69
2.98
2.48
2.15
1.86
NA
1.84
2001 2.79 NA 2.52 NA NA NA 1.93 1Nondefense R&D data are estimates. Foreign nondefense R&D/GDP ratios are obtained directly from OECD reports or are estimated by NSF from OECD data for: Japan for 1995 and later years; Germany for 1990 and earlier years; United Kingdom for 1988 and earlier years (except 1985); Italy for 1986 and earlier years; and Canada for 1990 and later years. NOTE: See continued table on the next page for further footnotes.
Plunkett Research, Ltd.
www.plunkettresearch.com
International R&D Expenditures in Constant Dollars and as a Percentage of GDP: 1981–2001 (Selected Nations) (Cont.) Total non-defense R&D expenditures1 U.S.
Japan2
Germany3 France U.K. Billions of constant 1996 dollars4
Year
Italy
Canada
1981
88
40
28
14
15
8
6
1985
109
55
32
17
16
10
8
1986
109
56
33
18
17
11
8
1987
111
60
35
18
18
12
8
1988
116
65
36
19
19
13
8
1989
123
71
37
21
17
13
9
1990
131
76
38
22
18
14
9
1991
139
78
41
22
18
14
10
1992
141
77
40
23
18
13
10
1993
138
75
38
24
19
13
11
1994
141
74
38
23
19
12
12
1995
152
79
38
24
19
12
12
1996
163
85
38
24
19
12
12
1997
173
88
40
25
19
13
12
1998
185
90
41
25
19
13
13
1999
199
91
45
26
21
13
14
2000
214
95
47
NA
21
NA
NA
2001
222
NA
48 NA Percent of National GDP
NA
NA
NA
1981
1.7
2.1
2.4
1.6
1.9
0.9
1.2
1985
1.9
2.5
2.6
1.8
1.8
1.1
1.4
1986
1.9
2.5
2.6
1.8
1.8
1.1
1.4
1987
1.8
2.6
2.7
1.8
1.8
1.2
1.4
1988
1.8
2.6
2.7
1.8
1.8
1.2
1.3
1989
1.9
2.7
2.7
1.9
1.7
1.2
1.4
1990
2.0
2.8
2.6
1.9
1.7
1.3
1.5
1991
2.1
2.7
2.4
1.9
1.7
1.2
1.6
1992
2.1
2.7
2.3
2.0
1.7
1.2
1.6
1993
2.0
2.6
2.3
2.0
1.7
1.1
1.7
1994
1.9
2.5
2.2
2.0
1.7
1.0
1.7
1995
2.0
2.7
2.2
2.0
1.7
1.0
1.7
1996
2.1
2.7
2.2
2.0
1.6
1.0
1.7
1997
2.1
2.8
2.2
2.0
1.5
1.1
1.7
1998
2.2
2.9
2.3
2.0
1.5
1.1
1.8
1999
2.2
2.9
2.4
2.0
1.6
1.0
1.8
2000
2.3
3.0
2.4
NA
1.6
NA
NA
2001 2.4 NA 2.5 NA NA NA NA 2 Due to changes in methodology, data on Japanese R&D in 1996 and later years may not be consistent with data in earlier years. 3 Germany's data for 1981-90 are for West Germany. Conversions of foreign currencies to U.S. dollars are calculated with OECD purchasing power parity exchange rates. Constant 1996 dollars are based on OECD implicit GDP price indices. Key: GDP = gross domestic product; NA = not available Sources: Organisation for Economic Co-operation and Development, Main Science and Technology Indicators data base (Paris, May 2002) and National Science Foundation/ Division of Science Resources Statistics.
4
Plunkett Research, Ltd.
www.plunkettresearch.com
Top 20 Global Patenting Organizations, Calendar Year 2001 Based on Number of U.S. Utility Patents Received
Rank
Organization
Number of Patents, 2001
1
International Business Machines Corp.
3,411
2
NEC Corp.
1,953
3
Canon Kabushiki Kaisha
1,877
4
Micron Technology, Inc.
1,643
5
Samsung Electronics Co., Ltd.
1,450
6
Matsushita Electric Industrial Co., Ltd.
1,440
7
Sony Corp.
1,363
8
Hitachi, Ltd.
1,271
9
Mitsubishi Denki Kabushiki Kaisha
1,184
10
Fujitsu Limited
1,166
11
Toshiba Corp.
1,149
12
Lucent Technologies, Inc.
1,109
13
General Electric Co.
1,107
14
Advanced Micro Devices, Inc.
1,086
15
Hewlett-Packard Co.
978
16
Intel Corp.
809
17
Texas Instruments, Inc.
799
18
Siemens
793
19
Motorola, Inc.
778
20
Eastman Kodak Co.
719
Note: Patent information presented reflects patent ownership at patent grant and does not include ownership changes that occur after the patent grant. Where more than one assignee (owner) exists, patents are attributed to the first-named assignee. No attempt has been made to combine data based on subsidiary relationships. However, where possible, spelling variations and variations based on name changes have been merged into a single name. While every effort is made to accurately identify all organizational entities and to report data by a single organization name, achievement of a totally clean record is not expected, particularly in view of the many variations that occur in corporate identifications. Source: U.S. Patent and Trademark Office, Technology Assessment and Forecast.
Plunkett Research, Ltd.
www.plunkettresearch.com
Top 20 Patenting Countries, 2001 (latest data available) Based on Number of U.S. Patents Received from Country of Headquarters Location Rank
Country
Number of Patents Received, 2001
1
United States of America
87,607
2
Japan
33,223
3
Germany
11,260
4
Taiwan
5,371
5
France
4,041
6
United Kingdom
3,965
7
Canada
3,606
8
South Korea
3,538
9
Sweden
1,743
10
Italy
1,709
11
Switzerland
1,420
12
Netherlands
1,332
13
Israel
970
14
Australia
875
15
Finland
732
16
Belgium
718
17
Austria
589
18
Denmark
479
19
Singapore
296
20
Spain Total Number of Patents
269 166,039
Source: U.S. Patent and Trademark Office, Technology Assessment and Forecast.
Plunkett Research, Ltd.
www.plunkettresearch.com
Chapter 3 ENGINEERING AND RESEARCH INDUSTRY CONTACTS World Wide Web Sites, Publications and Industry Associations I. II. III. IV. V. VI. VII. VIII. IX. X. XI. XII. XIII. XIV. XV. XVI. XVII.
Automotive Associations-Consumer and Safety Automotive-Parts and Supplies Biotech Associations Biotech Careers Biotech Resources Computer/Technology Careers Corporate Information E-Commerce and Internet Industry Associations E-Commerce Education and Training Economic Data and Research Electrical Engineering Industry Associations Energy Associations Energy Education Links Engineering Associations Engineering Indices Engineering Software Film and Television Associations
XVIII. XIX. XX. XXI. XXII. XXIII. XXIV. XXV. XXVI. XXVII. XXVIII. XXIX. XXX.
First Time Jobs/New Grads Food Industry Associations Health Care Careers Industry Associations-Automotive Industry Associations-Construction Industry Research/Market Research Internet Business/Technology Internet Organizations-International Job Listings, General Job Reference Tools Laboratories/Research Microelectronics Industry Associations Satellite-Related Professional Organizations XXXI. Telecommunications Industry Associations XXXII. Telecommunications Information, General XXXIII. Testing Resources XXXIV. U.S. Government Agencies
Plunkett Research, Ltd.
I.
Automotive Associations-Consumer and Safety
American Traffic Safety Services Institute (ATSSA) 15 Riverside Pkwy., Ste. 100 Fredericksburg, VA 22406-1022 Phone: 540-368-1701 Fax: 540-368-1717 Toll Free: 800-272-8772 Web Address: http://www.atssa.com/ ATSSA members provide the majority of safety features, services and materials used on our nation's roadways.
www.plunkettresearch.com
V.
BioTech Web Address: http://biotech.icmb.utexas.edu This site offers a comprehensive dictionary of biotech terms, plus extensive research data regarding biotechnology. Biotech Rumor Mill E-Mail:
[email protected] Web Address: http://www.biofind.com/rumor An open discussion forum that attracts participants from the many biotech disciplines. VI.
II.
Biotech Associations
Biotechnology Industry Organization 1625 K St. NW, Ste. 1100 Washington, DC 20006 Phone: 202-962-9200 Web Address: http://www.bio.org/ The BIO is involved in the research and development of health care, agricultural, industrial and environmental biotechnology products. IV.
Computer/Technology Careers
Automotive-Parts and Supplies
Automotive Learning Center (Plastics Council) 1300 Wilson Blvd. Arlington, VA 22209 Phone: 800-243-5790 Web Address: http://www.plastics-car.com/ The American Plastics Council's Automotive Learning Center strives to provide the automobile designer, stylist or engineer with up-to-the-minute research and information on plastics applications in cars. III.
Biotech Resources
Biotech Careers
Chase Group (The) 7300 W. 110th St., Ste. 560 Overland Park, KS 66210 Phone: 913-663-3100 Fax: 913-663-3131 E-Mail:
[email protected] Web Address: http://www.chasegroup.com/ Executive search firm specializing in biomedical and pharmaceutical placement.
Aquent 711 Boylston St. Boston, MA 02116 Phone: 617-535-5000 Fax: 617-535-5005 Toll Free: 877-727-8637 Web Address: http://www.aquent.com/ Specializes in providing businesses with computer experts (in Macintosh and Windows), filling temporary and permanent positions around the world. Brassring.com 170 High St. Waltham, MA 02454 Phone: 781-736-1000 Fax: 781-893-2433 Toll Free: 888-999-6505 E-Mail:
[email protected] Web Address: http://www.brassring.com/ Career management and development, technology trends and future outlooks. Permits the posting of resumes. ComputerJobs.com 280 Interstate North Pkwy. SE Atlanta, GA 30339-2411 Toll Free: 800-850-0045 Web Address: http://www.computerjobs.com/ Employment web site which offers users a link to computer-related job opportunities. It is organized by skill and market. Dice.com 4101 NW Urbandale Dr. Urbandale, IA 50322 Phone: 515-280-1144
Plunkett Research, Ltd.
Fax: 515-280-1452 Toll Free: 877-386-3323 Web Address: http://www.dice.com/ Provides free employment services for IT jobs. Includes advanced job searches by geographic location and category, availability announcements and resume postings, as well as employer profiles and a recruiter’s page. Also provides career links. Information Week Online Careers 600 Community Dr. Manhasset, NY 11030 Phone: 516-562-5000 Fax: 516-562-5036 Web Address: http://www.informationweek.com/career3/ Provides career services, links and job listings, as well as salary surveys and other information. Institute for Electrical and Electronics Engineers Employment Service 3 Park Ave., 17th Fl. New York, NY 10016 Phone: 212-419-7900 Fax: 212-752-4929 Web Address: http://jobs.ieeeusa.org/jobs/services IEEE-USA provides a line of employment services for technical professionals, employers and recruiters. It offers job listings by geographic area, a resume bank and links to employment services. Pencom Systems, Inc. 40 Fulton St. New York, NY 10038-1850 Phone: 212-513-7777 Fax: 212-227-1854 Web Address: http://www.pencom.com/ Geared for software professionals, this open systems recruiting company offers an interactive salary survey, career advisor, job listings and technology resources. SearchTech Solutions 307 Orchard City Dr., Ste. 206 Campbell, CA 95008 Phone: 408-540-1800 Fax: 408-540-1815 E-Mail:
[email protected] Web Address: http://www.stecs.com/ A specialty firm that establishes direct hiring and contract hiring relationships between software engineers and software engineering companies.
www.plunkettresearch.com
Provides personal assistance to people seeking jobs in computer science and information technology. Techies.com 7580 Quattro Dr. Chanhassen, MN 55317 Phone: 952-392-2040 Fax: 952-392-2020 Toll Free: 800-829-3424 Web Address: http://www.techies.com/ Allows technical job seekers to view highly technical jobs and apply for jobs online. The site also offers online training and job advice. Technology Locator 5055 Avienda Encinas, Ste. 240 Carlsbad, CA 92008 Phone: 760-579-0302 Fax: 760-579-0312 Toll Free: 877-579-0302 Web Address: http://www.tlcsd.com/ Provides engineering and information technology consultants on a contract basis to companies throughout California. Telecom Insight, Ltd. 9457 S. University Blvd., Ste. 352 Highlands Ranch, CO 80126 Phone: 303-740-6104 Fax: 303-470-6104 Web Address: http://www.telecominsight.com/ Provides IT and management resources and jobs for start-up and established companies in the wireless, IP and fixed line telecommunications industries. TeleCom Resources 1824 NE Division, Ste. 1 Bend, OR 97708 Phone: 541-388-6911 Fax: 541-388-1663 Toll Free: 800-800-6577 Web Address: http://www.telecomresources.com/ Offers search and placement services for the telecommunications industry. Webmonkey Terra Lycos Calle Nicaragua, 54 Barcelona, Spain Phone: 34-91452-3000 Web Address: http://www.hotwired.lycos.com/webmonkey/frontdoo r
Plunkett Research, Ltd.
This publication serves as a how-to guide for web developers, in addition to offering tips on what kind of web jobs are out there. VII.
Corporate Information
bizjournals.com 120 W. Morehead St., Ste. 200 Charlotte, NC 28202 Phone: 704-973-1000 Fax: 704-973-1001 E-Mail:
[email protected] Operated by the American Business Journals firm, the publisher of dozens of leading city business journals nationwide, this site provides access to research into the latest news regarding companies small and large. Business Wire Web Address: http://www.businesswire.com/ Business Wire strives to deliver news in an innovative manner. Smart News releases, industryspecific and company-specific news, today's headlines, conference calls, IPOs on the Internet, media services, Tradeshownews.com and BW Connect On-line are all accessible through this informative and continuously updated site. CNNfn Home Page Web Address: http://money.cnn.com Provides the same in-depth financial information online that CNN's cable television financial news unit provides to television viewers. Edgar Online Web Address: http://www.edgar-online.com/ A gateway and search tool for viewing corporate documents, such as annual reports on form 10K, filed with the U.S. Securities Exchange Commission. Hoover’s Online 5800 Airport Blvd. Austin, TX 78752 Phone: 512-374-4500 Fax: 512-374-4505 Toll Free: 800-486-8666 Web Address: http://www.hoovers.com/ Hoover's provides thousands of corporate profiles online. This comprehensive site also features links to news, lists, stock quotes and other corporate and business data.
www.plunkettresearch.com
PRNewswire 810 7th Ave., 35th Fl. New York, NY 10019 Phone: 212-596-1500 Toll Free: 800-832-5522 E-Mail:
[email protected] Web Address: http://www.prnewswire.com/ PR Newswire provides comprehensive communications services for public relations and investor relations professionals ranging from information distribution and market intelligence to the creation of online multimedia content and investor relations web sites. Users can also view recent corporate press releases. Silicon Investor InfoSpace, Inc. 601 108th Ave. NE, Ste. 1200 Bellevue, WA 98004 Phone: 425-201-6100 Fax: 425-201-6150 Web Address: http://www.siliconinvestor.com/ Silicon Investor is focused on technology companies. The site serves as a financial discussion forum and offers quotes, profiles and charts. VIII. E-Commerce and Internet Industry Associations Advanced Network and Services Web Address: http://www.advanced.org/ This organization strives to advance education through the increased use of computer network applications and technology. American Registry for Internet Numbers Web Address: http://www.arin.net/ ARIN is a nonprofit organization that administers and registers Internet protocol (IP) numbers. Berkman Center for Internet and Society Web Address: http://cyber.law.harvard.edu/ This research center focuses on the exploration of the development and inner-workings of and laws pertaining to the Internet. The center offers Internet courses, conferences and more. CommerceNet Web Address: http://www.commerce.net/ An industry consortium for companies using, promoting and building electronic commerce solutions on the Internet.
Plunkett Research, Ltd.
Congressional Internet Caucus Web Address: http://www.netcaucus.org/ The Congressional Internet Caucus is a bi-partisan group of over 100 members of the House and Senate working to educate their colleagues about the promise and potential of the Internet. Cooperative Association for Internet Data Analysis Web Address: http://www.caida.org/ CAIDA works to promote an atmosphere of greater cohesion on the Internet. CyberSkills Association Web Address: http://www.cyberskills.org/ This association’s program serves to provide the skills, knowledge and training needed to compete and thrive in today’s changing Internet industry.
www.plunkettresearch.com
This site offers information concerning the Internet and its surrounding laws. Internet Assigned Numbers Authority Web Address: http://www.iana.org/ This association serves as the central coordinator for the assignment of parameter values for Internet protocols. Internet Service Providers’ Consortium 1301 Shiloh Rd., Ste. 720 Kennesaw, GA 30144-8086 Fax: 678-819-1028 Toll Free: 866-533-6990 Web Address: http://www.ispc.org/ Provides services to startups, small and mediumsized ISPs and represents the needs of small and growing businesses.
Data Interchange Standards Association 333 John Carlyle St., Ste. 600 Alexandria, VA 22314 Phone: 703-548-7005 Fax: 703-548-5738 Web Address: http://www.disa.org/ The DISA is a leading association for electronic commerce. This nonprofit organization supports the development and use of electronic business interchange standards in electronic commerce.
Internet Software Consortium Web Address: http://www.isc.org/ This nonprofit organization has extensive expertise in the development, management, maintenance and implementation of Internet technologies.
Global Business Dialogue on Electronic Commerce Web Address: http://www.gbd.org/ GBDe is a company-led response to the need for strengthened international coordination with regard to worldwide electronic commerce. Steering committee includes CEOs from 24 international companies, including IBM, AOL, Bertelsmann, Fujitsu, HP and Time Warner.
National Industrial Information Infrastructure Protocols (NIIIP) Consortium Web Address: http://www.niiip.org/ A team of organizations that has entered into a cooperative development agreement with the U.S. Government to develop open industry software protocols that will make it possible for manufacturers and their suppliers to effectively interoperate.
Information Systems Security Association Web Address: http://www.issa-intl.org/ ISSA is geared towards those in the information security industry.
NASA's Learning Technologies Project Web Address: http://learn.iw.nasa.gov/ Promotes growth of a national information infrastructure using information NASA has acquired.
NetCoalition Web Address: http://www.netcoalition.com/ Some of the most innovative Internet companies in the world belong to this organization, which serves as a discussion forum for exchanging ideas about the Internet.
Internet Alliance Web Address: http://www.internetalliance.org/ Strives to assist the Internet industry in becoming the most important mass-market medium of the 21st century.
OpenNET Coalition Web Address: http://www.opennetcoalition.org/ Strives to promote the rights of all consumers to obtain affordable, high-speed Internet access.
Internet and Computer Law Association Web Address: http://www.cla.org/
People For Internet Responsibility Web Address: http://www.pfir.org/
Plunkett Research, Ltd.
PFIR is a global, grassroots, ad hoc network of individuals who are concerned about the current and future operations, development, management and regulation of the Internet in responsible manners. RosettaNet Web Address: http://www.rosettanet.org/ A consortium of computer makers, resellers and users creating e-commerce standards for transactioncentered data exchanges using a standardized set of terms for product, partner and transaction properties. Smart Card Industry Association Web Address: http://www.scia.org/ SCIA is a global trade association that strives to stimulate the use and understanding of smart card technology in the marketplace. Voice On the Net Coalition Web Address: http://www.von.org/ The VON Coalition's mission is twofold: to actively advocate the viewpoint that the IP telephony industry should remain as free of governmental regulations as possible and to educate consumers and the media on Internet communications technologies. World Wide Web Consortium (W3C) MIT Laboratory for Computer Science 200 Technology Sq. Cambridge, MA 02139 Phone: 617-253-2613 Fax: 617-258-5999 Web Address: http://www.w3.org/ This organization, housed at the Laboratory for Computer Science on the MIT campus, develops technologies and standards to enhance the performance and utility of the World Wide Web. IX.
E-Commerce Education and Training
International Center for Electronic Commerce Web Address: http://www.icec.net/ Based in Korea, the center's objectives include development of next-generation electronic commerce technologies and management schemes and establishing an international research consortium of e-commerce-related companies. X.
Economic Data and Research
STAT-USA HCHB Room 4885
www.plunkettresearch.com
U.S. Department of Commece Washington, DC 20230 Phone: 202-482-1986 Fax: 202-482-2164 Toll Free: 800-782-8872 E-Mail:
[email protected] Web Address: http://www.stat-usa.gov/ STAT-USA is an agency in the Economics and Statistics Administration of the U.S. Department of Commerce. The site offers daily economic news, statistical releases, export and trade databases and information and domestic economic databases. XI.
Electrical Engineering Industry Associations
American Institute of Physics One Physics Ellipse College Park, MD 20740 Phone: 301-209-3100 Fax: 301-209-0843 E-Mail:
[email protected] Web Address: http://www.aip.org/ A nonprofit organization aimed at the advancement and diffusion of knowledge of the science of physics and its application to human welfare. ASEE Clearinghouse for Engineering Education 1818 North St. NW Washington, DC 20036 Phone: 202-331-3500 Fax: 202-265-8504 Web Address: http://www.asee.org/ The ASEE is dedicated to promoting and improving engineering and technology education. Institute of Electrical and Electronics Societies 3 Park Ave., 17th Fl. New York, NY 10016-5997 Phone: 212-419-7900 Fax: 212-752-4929 Web Address: http://www.ieee.org/society.html This section of the IEEE site offers a directory of technical societies. International Electrotechnical Commission 3 Rue de Varembe Geneva 20, CH-1211 Switzerland Phone: 41-22-919-02-11 Fax: 41-22-919-03-00 Web Address: http://www.iec.ch/ This is the site of the Switzerland-based IEC, which promotes international cooperation on all questions
Plunkett Research, Ltd.
of standardization and related matters in electrical and electronic engineering. International Society for Optical Engineering P.O. Box 10 Bellingham, WA 98227-0010 Phone: 360-676-3290 Fax: 360-647-1445 E-Mail:
[email protected] Web Address: http://www.spie.org/ A nonprofit technical society aimed at the advancement and dissemination of knowledge in optical and optoelectronic applied science and engineering. National Institute of Standards and Technology 100 Bureau Dr., Stop 3460 Gaithersburg, MD 20899 Phone: 301-975-6478 Fax: 301-975-8295 Web Address: http://www.nist.gov/ An agency of the U.S. Department of Commerce's Technology Administration, the NIST works with industry to develop and apply technology, measurements and standards. Professional Organizations and Government Labs for Electrical Engineers Web Address: http://www.ece.umr.edu/links/professional/orgs.html This site provides a list of professional societies and government laboratories of interest to electrical engineers. XII.
Energy Associations
Electric Power Research Institute 3412 Hillview Ave. Palo Alto, CA 94304 E-Mail:
[email protected] Web Address: http://www.epri.com/ EPRI provides solutions about science and technology of importance to its global energy customers. Uranium Institute 114 Knightsbridge Bowater House W, 12th Fl. London, England SW1X 7LJ Phone: 44-20-7225-0303 Fax: 44-20-7225-0308 E-Mail:
[email protected] Web Address: http://www.uilondon.org/
www.plunkettresearch.com
International nonprofit organization involved in all stages of the production of nuclear-generated electricity. XIII.
Energy Education Links
Uranium and Nuclear Information Centre P.O. Box 1649N Melbourne, Australia 3001 Phone: 03-9629-7744 Fax: 03-9629-7207 E-Mail:
[email protected] Web Address: http://www.uic.com.au/ Provides information about the development of the Australium uranium industry, uranium mining and nuclear electricity. XIV.
Engineering Associations
Alfred P. Sloan Foundation 630 5th Ave., Ste. 2550 New York, NY 10111 Phone: 212-649-1649 Fax: 212-757-5117 Web Address: http://www.sloan.org/ Funds science and technology, economic performance, education, national issues and civics programs. American Chemical Society 1155 16th St. NW Washington, DC 20036 Phone: 202-872-4600 Fax: 202-872-4615 Toll Free: 800-227-5558 Web Address: http://www.acs.org/ A nonprofit organization aimed at promoting the understanding of chemistry and chemical sciences, representing a wide range of disciplines including chemistry, chemical engineering and other technical fields. American Concrete Institute P.O. Box 9094 Farmington Hills, MI 48333 Phone: 248-848-3700 Web Address: http://www.aci-int.org/ A professional organization that provides information on the use of concrete for structures and facilities.
Plunkett Research, Ltd.
American Institute of Aeronautics and Astronautics 1801 Alexander Bell Dr., Ste. 500 Reston, VA 20191 Phone: 703-264-7500 Fax: 703-264-7551 Toll Free: 800-699-2422 Web Address: http://www.aiaa.org/ Nonprofit society aimed at advancing the arts, sciences and technology of aeronautics and astronautics. Represents the U.S. in the International Astronautical Federation and the International Council on the Aeronautical Sciences. American Nuclear Society 555 N. Kensington Ave. LaGrange Park, IL 60526 Phone: 708-352-6611 Fax: 708-352-0499 E-Mail:
[email protected] Web Address: http://www.ans.org/ A nonprofit organization unifying the professional activities within the nuclear science and technology fields. American Physical Society One Physics Ellipse College Park, MD 20740 Phone: 301-209-3200 Fax: 301-209-0865 Web Address: http://www.aps.org/ Develops and implements effective programs in physics education and outreach. American Society for Nondestructive Testing P.O. Box 28518 1711 Arlingate Ln. Columbus, OH 43228-0518 Phone: 614-274-6003 Fax: 614-274-6899 Toll Free: 800-222-2768 Web Address: http://www.asnt.org/ The world's largest technical society for nondestructive testing professionals. ASNT promotes the discipline of nondestructive testing as a profession and facilitates nondestructive testing research and technology applications. American Society of Agricultural Engineers 2950 Niles Rd. St. Joseph, MI 49085 Phone: 269-429-0300 Fax: 269-429-3852
www.plunkettresearch.com
E-Mail:
[email protected] Web Address: http://www.asae.org/ Nonprofit professional and technical organization of members interested in engineering knowledge and technology for food and agriculture, associated industries and related resources. American Society of Civil Engineers 1801 Alexander Bell Dr. Reston, VA 20191 Phone: 703-295-6300 Toll Free: 800-548-2723 Web Address: http://www.asce.org/ The leading professional organization serving civil engineers. Ensures safer buildings, water systems and other civil engineering works by developing technical codes and standards. American Society of Mechanical Engineers 3 Park Ave. New York, NY 10016 Phone: 212-591-7722 Fax: 212-591-7674 Toll Free: 800-849-2763 E-Mail:
[email protected] Web Address: http://www.asme.org/ Offers quality programs and activities in mechanical engineering. Also facilitates the development and application of technology in areas of interest to the mechanical engineering profession. American Society of Naval Engineers 1452 Duke St. Alexandria, VA 22314 Phone: 703-836-6727 Fax: 703-836-7491 Web Address: http://www.navalengineers.org/ Nonprofit professional organization which advances the knowledge and practice of naval engineering in public and private operations. American Society of Safety Engineers 1800 E. Oakton St. Des Plaines, IL 60018 Phone: 847-699-2929 Fax: 847-768-3434 E-Mail:
[email protected] Web Address: http://www.asse.org/ World's oldest and largest professional safety organization. Manages, supervises and consults on safety, health and environmental issues in industry, insurance, government and education.
Plunkett Research, Ltd.
American Vacuum Society 120 Wall St., 32nd Fl. New York, NY 10005 Phone: 212-248-0200 Fax: 212-248-0245 Web Address: http://www.vacuum.org/ Nonprofit organization which promotes communication, dissemination of knowledge, recommended practices, research and education in the use of vacuum and other controlled environments to develop new materials, process technology and devices. ASM International 9639 Kinsman Rd. Materials Park, OH 44073 Phone: 440-338-5151 Fax: 440-338-4634 Web Address: http://www.asm-intl.org/ Society for materials engineers, a worldwide network aimed at advancing industry, technology and applications of metals and materials. Association for Computing Machinery 1515 Broadway New York, NY 10036 Phone: 212-626-0500 Fax: 212-944-1318 Toll Free: 800-342-6626 Web Address: http://www.acm.org/ World's first education and scientific computing society. Dedicated to advancing the arts, sciences and applications of information technology. Association of Iron and Steel Engineers 3 Gateway Ctr., Ste. 1900 Pittsburgh, PA 15222 Phone: 412-281-6323 Fax: 412-281-4657 Web Address: http://www.aise.org/ Largest member-based organization for the steel industry worldwide. Aimed at advancing the technical and engineering phases of the production of iron and steel. Association of Professional Engineers of Nova Scotia P.O. Box 129 Halifax, NS B3J 2M4 Canada Phone: 902-429-2250 Fax: 902-423-9769 Toll Free: 888-802-7367 E-Mail:
[email protected] www.plunkettresearch.com
Web Address: http://www.apens.ns.ca/ British Cement Association Century House Telford Ave. Crowthorne, Berkshire RG45 6YS England Phone: 01344-762676 Fax: 01344-761214 E-Mail:
[email protected] Web Address: http://www.bca.org.uk/ A professional organization, based in the U.K., to promote the better use of concrete. Cryogenic Society of America 1033 South Blvd., Ste. 13 Oak Park, IL 60302 Phone: 708-383-6220 Fax: 708-383-9337 E-Mail:
[email protected] Web Address: http://www.csa.fnal.gov/ Nonprofit organization that brings together those in all disciplines concerned with the applications of low-temperature technology. Also increases public awareness of the usefulness of cryogenic technology. Earthquake Engineering Research Institute 199 14th St., Ste. 320 Oakland, CA 94612 Phone: 510-451-0905 Fax: 510-451-5411 E-Mail:
[email protected] Web Address: http://www.eeri.org/ National nonprofit technical organization of engineers, geoscientists, architects, planners, public officials and social scientists. Aimed at reducing earthquake risk by advancing the science and practice of earthquake engineering. Engineer's Club (The) 1737 Silverwood Dr. San Jose, CA 95124 Phone: 408-445-2902 Fax: 408-265-2410 Web Address: http://www.engineers.com/ Resources and web sites for engineers and technical professionals. IEEE Communications Society 305 E. 47th St. New York, NY 10017 Phone: 212-705-8900 Fax: 212-705-8999 Web Address: http://www.comsoc.org/
Plunkett Research, Ltd.
The IEEE Communications Society is composed of industry professionals with a common interest in advancing communications technologies. Illuminating Engineering Society of North America 120 Wall St., 17th Fl. New York, NY 10005 Phone: 212-248-5000 Fax: 212-248-5017 E-Mail:
[email protected] Web Address: http://www.iesna.org/ A recognized authority on lighting in North America, te IESNA establishes scientific lighting recommendations.. Industrial Research Institute 1550 M St. NW, Ste. 1100 Washington, DC 20005-1712 Phone: 202-296-8811 Fax: 202-776-0756 Web Address: http://www.iriinc.org/ A nonprofit organization of over 260 leading industrial companies representing fields such as aerospace, automotive, chemical, computer and electronics, which carry out over 80% of industrial research effort in the United States' manufacturing sector, employ some 500,000 scientists and engineers and account for at least 30% of the gross national product. Institute for Research in Construction National Research Council of Canada Ottawa, Ontario K1A 0R6 Canada Phone: 613-993-2607 Fax: 613-952-7673 E-Mail:
[email protected] Web Address: http://www.nrc.ca/irc Provides research, building code development and materials evaluation services. The IRC is Canada's construction technology center and a division of the National Research Council. Institute of Biological Engineering 3938 West Rd., Ste. 277 Cortland, NY 13045 Phone: 607-753-9227 Fax: 607-753-9227 Toll Free: 877-423-2255 E-Mail:
[email protected] Web Address: http://www.ibeweb.org/ Professional organization encouraging inquiry and interest in biological engineering.
www.plunkettresearch.com
Institute of Industrial Engineers 25 Technology Park Norcross, GA 30092 Phone: 770-449-0460 Fax: 770-441-3295 Toll Free: 800-494-0460 E-Mail:
[email protected] Web Address: http://www.iienet.org/ This society is dedicated to the professional needs of industrial engineers. Institute of Structural Engineers 11 Upper Belgrave St. London, England SW1X 8BH Phone: 020-7235-4535 Fax: 020-7235-4294 E-Mail:
[email protected] Web Address: http://www.istructe.org.uk/ A professional organization, headquartered in the U.K., which sets and maintains standards for professional structural engineers International Society for Measurement and Control 67 Alexander Dr. Research Triangle Park, NC 27709 Phone: 919-549-8411 Fax: 919-549-8288 E-Mail:
[email protected] Web Address: http://www.isa.org/ Serves the professional development and credential needs of control system engineers, instrument technicians and others within the field of measurement and control. International Society of Pharmaceutical Engineers 3816 W. Linebaugh Ave., Ste. 412 Tampa, FL 33624 Phone: 813-960-2105 Fax: 813-264-2816 Web Address: http://www.ispe.org/ Worldwide nonprofit society of technical professionals who apply their practical knowledge in the regulated health care manufacturing industries. Materials Research Society 506 Keystone Dr. Warrendale, PA 15086 Phone: 724-779-3003 Fax: 724-779-8313 E-Mail:
[email protected] Web Address: http://www.mrs.org/
Plunkett Research, Ltd.
Dedicated to basic and applied research on materials of technological importance. Emphasizes an interdisciplinary approach to materials science and engineering. National Academy of Engineering 2101 Constitution Ave. NW Washington, DC 20418 Web Address: http://www.nae.edu/ Nonprofit institution which conducts independent studies to examine important topics in engineering and technology. National Society of Professional Engineers 1420 King St. Alexandria, VA 22314 Phone: 703-684-2800 Fax: 703-836-4875 Web Address: http://www.nspe.org/ Represents individual engineering professionals and licensed engineers across all disciplines. Netherlands Organization for Applied Scientific Research P.O. Box 6050 JA Delft, The Netherlands NL-2600 Phone: 31-15-269-69-00 Fax: 31-15-261-24-03 E-Mail:
[email protected] Web Address: http://www.tno.nl/ Large contract research organization based in The Netherlands, provides a link between fundamental research and practical application. Optical Society of America 2010 Massachusetts Ave. NW Washington, DC 20036 Phone: 202-223-8130 Fax: 202-223-1096 Web Address: http://www.osa.org/ An interdisciplinary society offering a synergy between all components of optics, from basic research to commercial applications. Society of Automotive Engineers 400 Commonwealth Dr. Warrendale, PA 15096 Phone: 724-776-4841 Toll Free: 877-606-7323 Web Address: http://www.sae.org/ Resource for technical information and expertise used in designing, building, maintaining and
www.plunkettresearch.com
operating self-propelled vehicles for use on land or sea, in air or space. Society of Cable Telecommunications Engineers 140 Philips Rd. Exton, PA 19341 Phone: 610-363-6888 Fax: 610-363-5898 Toll Free: 800-542-5040 E-Mail:
[email protected] Web Address: http://www.scte.org/ The SCTE is a nonprofit professional association dedicated to advancing the careers and serving the industry of telecommunications professionals by providing technical training, certification and standards. Society of Hispanic Professional Engineers 5400 E. Olympic Blvd., Ste. 210 Los Angeles, CA 90022 Phone: 323-725-3970 Fax: 323-725-0316 E-Mail:
[email protected] Web Address: http://www.shpe.org/ National nonprofit organization that promotes Hispanics in science, engineering and math. Society of Manufacturing Engineers One SME Dr. Dearborn, MI 48121 Phone: 313-271-1500 Fax: 313-271-2861 Toll Free: 800-733-4763 Web Address: http://www.sme.org/ The world's leading professional organization serving the manufacturing industries. Society of Nuclear Medicine 1850 Samuel Morse Dr. Reston, VA 20190 Phone: 703-708-9000 Fax: 703-708-9015 Web Address: http://www.snm.org/ International scientific and professional organization founded to promote the science, technology and practical application of nuclear medicine. Society of Petroleum Engineers 222 Palisades Creek Dr. P.O. Box 833836 Richardson, TX 75083-3836 Phone: 972-952-9393 Fax: 972-952-9435
Plunkett Research, Ltd.
E-Mail:
[email protected] Web Address: http://www.spe.org/ The SPE helps connect the oil and gas industry with ideas, answers, resources and technological information. Society of Women Engineers 120 Wall St., 11th Fl. New York, NY 10005 Phone: 212-509-9577 E-Mail:
[email protected] Web Address: http://www.swe.org/ A nonprofit educational and service organization of graduate engineers. Serves as a center of information on women in engineering. Civil Engineering Research Foundation 1015 15th St. NW, Ste. 600 Washington, DC 20005 Phone: 202-842-0555 Fax: 202-789-2943 Web Address: http://www.cerf.org/ Independent nonprofit research organization established by the American Society of Civil Engineers. Minerals Metals & Materials Society 184 Thorn Hill Rd. Warrendale, PA 15086 Phone: 724-776-9000 Fax: 724-776-3770 E-Mail:
[email protected] Web Address: http://www.tms.org/ Professional organization that encompasses the entire range of materials and engineering, from minerals processing and primary metals production to basic research and the advanced applications of materials. United Engineering Foundation 3 Park Ave., 27th Fl. New York, NY 10016 Phone: 212-591-7836 Fax: 212-591-7441 E-Mail:
[email protected] Web Address: http://www.uefoundation.org/ A nonprofit organization chartered for the advancement of engineering arts and sciences in all branches. XV.
Engineering Indices
Internet Connections for Engineering Index Web Address: http://www.englib.cornell.edu/ice
www.plunkettresearch.com
A comprehensive catalog of engineering resources. XVI.
Engineering Software
ADAPT Corporation 1773 Woodside Rd., Ste. 220 Redwood City, CA 94061 Phone: 650-306-2400 Fax: 650-364-4678 E-Mail:
[email protected] Web Address: http://www.adaptsoft.com/ Offers structural engineering software and consulting. ALGOR, Inc. 150 Beta Dr. Pittsburgh, PA 15238 Phone: 412-967-2700 Fax: 412-967-2781 E-Mail:
[email protected] Web Address: http://www.algor.com/ Offers computer-aided engineering software, including finite element analysis software and FEAbased mechanical event simulation software. ATIR Engineering Software Development, Ltd. 3314 W. Rance Terrace Chicago, IL 60645 Phone: 847-677-1945 Fax: 847-677-3456 Toll Free: 800-644-6441 E-Mail:
[email protected] Web Address: http://www.atir.com/ Provides structural analysis and design software for use on personal computers. CAiCE Software Corporation 410 Ware Blvd., Ste. 1200 Tampa, FL 33619 Phone: 813-620-1444 Fax: 813-620-9019 E-Mail:
[email protected] Web Address: http://www.caice.com/ Designs software for applications ranging from survey data processing to final plans production. Also provides consulting, custom development, training and technical services. Computers & Structures, Inc. 1995 University Ave., Ste. 540 Berkeley, CA 94704 Phone: 510-845-2177 Fax: 510-845-4096
Plunkett Research, Ltd.
E-Mail:
[email protected] Web Address: http://www.csiberkeley.com/ Offers structural and earthquake engineering software products. Data Surge 70 Autran Ave. North Andover, MA 01845 Phone: 978-664-0258 Fax: 978-664-0269 E-Mail:
[email protected] Web Address: http://www.data-surge.com/ Develops geotechnical and hydrogeologic software products for universities, companies and government institutions worldwide. Daystar Software, Inc. 8120 NW Hillside Kansas City, MO 64152 Phone: 816-741-4310 Fax: 816-741-4607 E-Mail:
[email protected] Web Address: http://www.daystarsoftware.com/ Offers structural engineering software products, developed and tested by registered professional engineers. Daystar software products are designed specifically for Windows. GEOPAK Corporation 1190 NE 163rd St. North Miami Beach, FL 33162 Phone: 305-944-5151 Toll Free: 888-436-7251 Web Address: http://www.geopak.com/ Designs civil engineering software, developed and supported by practicing civil engineers and professional land surveyors. Widely used for transportation design and engineering in the U.S. GEO-SLOPE International 1400, 633 6th Ave. SW Calgary, Alberta T2P 2Y5 Canada Phone: 403-269-2002 Fax: 403-266-4851 E-Mail:
[email protected] Web Address: http://www.geo-slope.com/ Develops and markets CAD software for geotechnical and geo-environmental modeling. LEAP Software P.O. Box 16827 Tampa, FL 33687 Phone: 813-985-9170
www.plunkettresearch.com
Fax: 813-980-3642 Toll Free: 800-451-5327 E-Mail:
[email protected] Web Address: http://www.leapsoft.com/ Designs software for structural engineering professionals. MARC Analysis Research Corporation 500 Arguello St., Ste. 200 Redwood City, CA 94063-1526 Phone: 650-381-3300 Fax: 650-381-3400 E-Mail:
[email protected] Web Address: http://www.marc.com/ Leading supplier of finite element analysis (FEA) software and nonlinear FEA technology, used to analyze and optimize designs in the aerospace, automotive, biomedical, chemical, consumer, construction, electronics, energy and manufacturing industries. Research Engineers International 22700 Savi Ranch Pkwy. Yorba Linda, CA 92887 Phone: 714-974-2500 Fax: 714-974-4771 E-Mail:
[email protected] Web Address: http://www.reiusa.com/ Develops and distributes PC-based civil and structural engineering software products for the architectural, survey, construction, transportation and utility industries. Space Radiation Associates 1430 Willamette, Ste. 1 Eugene, OR 97401 Phone: 541-746-7504 Fax: 541-746-7504 E-Mail:
[email protected] Web Address: http://www.spacerad.com/ Develops and markets software for scientific and engineering modeling tasks. Specializes in nuclear and space radiation effects in aircraft and spacecraft electronic systems and modeling the natural radiation environment. Spectra Precision Software 5901 Peachwood-Dunwoody Rd., Ste. A-300 Atlanta, GA 30328 Phone: 770-396-0700 Fax: 770-396-4290 Toll Free: 800-235-4972 E-Mail:
[email protected] Plunkett Research, Ltd.
Web Address: http://www.plus3.com/ Provides earthwork quantity takeoff, 3-D land design and visualization solutions. Products include laser alignment instruments, machine control systems, survey instruments and software. Zentech, Inc. 8582 Katy Fwy., Ste. 205 Houston, TX 77024 Phone: 713-984-9171 Fax: 713-984-9175 E-Mail:
[email protected] Web Address: http://www.zentech-usa.com/ Provides a wide range of services, including project management, specialized consulting, custom software development and joint engineering ventures. Develops and customizes software for structural analysis and design. XVII. Film and Television Associations National Cable and Telecommunications Association 1724 Massachusetts Ave. NW Washington, DC 20036 Phone: 202-775-3550 Web Address: http://www.ncta.com/ The NCTA is the principal trade association of the cable television industry in the United States. XVIII. First Time Jobs/New Grads Black Collegian Home Page Web Address: http://www.black-collegian.com/ Listings for job and internship opportunities. Includes a list of the top 100 minority corporate employers and an assessment of job opportunities. California School-to-Career Information System Phone: 916-654-6138 Web Address: http://www.stc.cahwnet.gov/ A joint project of California’s public school systems and local business partners. Aimed at helping students move easily from school into employment. CollegeGrad.com 1629 Summit Dr., Ste. 200 Cedarburg, WI 53012-9399 Phone: 262-376-1000 Fax: 262-376-1030 Web Address: http://www.collegegrad.com/
www.plunkettresearch.com
Offers in-depth resources for new grads seeking entry-level jobs. JobWeb 62 Highland Ave. Bethlehem, PA 18017-9085 Phone: 610-868-1421 Fax: 610-868-0208 Toll Free: 800-544-5272 Web Address: http://www.jobweb.com/ Provided by the National Association of Colleges and Employers, this site includes job openings and employer descriptions. Also offers a database of career fairs, searchable by state or keyword, with contact information. MonsterTrak 5 Clock Tower Pl., Ste. 500 Maynard, MA 01754 Fax: 310-474-2537 Toll Free: 800-999-8725 Web Address: http://www.monstertrak.com/ Links to hundreds of university and college career centers across the U.S. with entry-level job listings categorized by industry. Major companies also utilize MonsterTrak. National Association of Colleges and Employers 62 Highland Ave. Bethlehem, PA 18017-9085 Phone: 610-868-1421 Fax: 610-868-0208 Toll Free: 800-544-5272 Web Address: http://www.naceweb.org/ The premier U.S. organization representing college placement offices and corporate recruiters who focus on hiring new grads. This site offers in-depth resources. XIX.
Food Industry Associations
Institute of Food Technologies Department of Career Education 221 N. LaSalle St., Ste. 300 Chicago, IL 60601 Web Address: http://www.ift.org/jobs The IFT is devoted to the advancement of the science and technology of food through the exchange of knowledge. The site provides information and resources for job seekers in the food industry.
Plunkett Research, Ltd.
XX.
Health Care Careers
HMonster Toll Free: 800-666-7837 Web Address: http://myh.monster.com Managed by Monster.com, HMonster provides listings, job searches and search agents for the medical field. XXI.
Industry Associations-Automotive
Alliance of Automobile Manufacturers 1401 H St. NW, Ste. 900 Washington, DC 20005 Phone: 202-326-5500 Fax: 202-326-5567 Web Address: http://www.autoalliance.org/ The Alliance of Automobile Manufacturers is a trade association composed of 10 car and light truck manufacturers with about 600,000 employees at more than 250 facilities in 35 states. Alliance members account for more than 90% of vehicles sold in the U.S. Association for Manufacturing Technology 7901 Westpark Dr. McLean, VA 22102-4206 Phone: 703-893-2900 Fax: 703-893-1151 Toll Free: 800-524-0475 Web Address: http://www.mfgtech.org/ Actively supports and promotes American manufacturers of machine tools and manufacturing technology. Association of International Automobile Manufacturers, Inc. 1001 19th St. N, Ste. 1200 Arlington, VA 22209 Phone: 703-525-7788 Fax: 703-525-8817 Web Address: http://www.aiam.org/ The Association of International Automobile Manufacturers is the voice of non-U.S. automobile manufacturers in Washington, D.C. Automotive Multimedia Interface Collaboration 280 Enterprise Ct. Bloomfield Hills, MI 48302-0312 Phone: 248-322-5900 Fax: 248-322-5976 Web Address: http://www.ami-c.org/
www.plunkettresearch.com
AMIC is a worldwide organization of motor vehicle manufacturers created to facilitate the development and standardization of automotive information and entertainment interfaces to motor vehicle communication networks. Canadian Vehicle Manufacturers' Association 170 Attwell Dr., Ste. 400 Toronto, ON M9W 5Z5 Canada Phone: 416-364-9333 Fax: 416-367-3221 Toll Free: 800-758-7122 Web Address: http://www.cvma.ca/ The CVMA creates a framework within which member companies work together to achieve shared industry objectives on issues such as consumer protection, the environment and vehicle safety. Coordinating Research Council 3650 Mansell Rd., Ste. 140 Alpharetta, GA 30022 Phone: 678-795-0506 Fax: 678-795-0509 Web Address: http://www.crcao.com/ A nonprofit organization that directs, through committee action, engineering and environmental studies on the interaction between automotive equipment and petroleum products. Engine Manufacturers Association 2 N. LaSalle St., Ste. 2200 Chicago, IL 60602 Phone: 312-827-8700 Fax: 312-827-8737 Web Address: http://www.engine-manufacturers.org/ The voice of the engine manufacturing industry on domestic and international public policy, as well as regulatory and technical issues that impact manufacturers of engines used in a broad array of mobile and stationary applications. International Motor Vehicle Program MIT E40-207, One Amherst St. MIT Center for Technology, Policy and Industrial Development Cambridge, MA 02139-4307 Phone: 617-253-8973 Fax: 617-253-7140 E-Mail:
[email protected] Web Address: http://web.mit.edu/afs/athena/org/c/ctpid/www/imvp/ index.html
Plunkett Research, Ltd.
Launched in 1979, IMVP is a research project, funded by leading global car makers as well as government agencies, focused on research that can enhance automotive design and manufacturing methods. Through the program, more than 50 senior scientists, management experts, social scientists and engineers have conducted interdisciplinary automotive research at more than 25 universities on six continents. One of IMVP's researchers coined the phrase "lean production." Motor and Equipment Manufacturers Association 10 Laboratory Dr. P.O. Box 13966 Research Triangle Park, NC 27709-3966 Phone: 919-549-4800 Fax: 919-549-4824 E-Mail:
[email protected] Web Address: http://www.mema.org/ MEMA exclusively represents and serves manufacturers of motor vehicle components, tools and equipment, automotive chemicals and related products used in the production, repair and maintenance of all classes of motor vehicles. National Tooling and Machining Association 9300 Livingston Rd. Ft. Washington, MD 20744 Phone: 800-248-6862 Fax: 301-248-7104 Web Address: http://www.ntma.org/ Helping members of the U.S. precision custom manufacturing industries achieve business success in a global economy through advocacy, advice, networking, information, programs and services. XXII. Industry Associations-Construction Portland Cement Association 5420 Old Orchard Rd. Skokie, IL 60077 Phone: 847-966-6200 Fax: 847-966-8389 E-Mail:
[email protected] Web Address: http://www.portcement.org/ Collaborating with several allied organizations, aims to improve and expand the uses of portland cement and concrete. Precast/Prestressed Concrete Institute 209 W. Jackson Blvd. Chicago, IL 60606 Phone: 312-786-0300
www.plunkettresearch.com
Fax: 312-786-0353 E-Mail:
[email protected] Web Address: www.pci.org XXIII. Industry Research/Market Research Debbie Flanagan’s Industry Information E-Mail:
[email protected] Web Address: http://home.sprintmail.com/~debflanagan/industry.ht ml This site provides a wealth of information about where and how to get industry-specific information. The links are useful for job seekers and researchers of all types. Forrester Research 400 Technology Square Cambridge, MA 02139 Phone: 617-613-6000 Fax: 617-613-5000 Web Address: http://www.forrester.com/ Iidentifies and analyzes emerging trends in technology and their impact on business. Among the firm's specialties are the financial services, retail, healthcare, entertainment, automotive and infotech industries. Marketresearch.com 11810 Parklawn Dr. Rockville, MD 20852 Phone: 301-468-3650 Fax: 301-468-3651 Web Address: http://www.marketresearch.com/ This firm is a leading broker for market research and industry analysis written by professionals. Users can search the company's database of market research publications. Mindbranch 160 Water St. Williamstown, MA 01267 Phone: 413-458-7600 Fax: 413-458-1706 Toll Free: 800-774-4410 Web Address: http://www.mindbranch.com/ Mindbranch is a broker for industry research prepared by market research professionals. Users can browse the research organized by different industries. The site is user-friendly and covers a broad range of industries and business topics. Customers can also receive superb telephone support and suggestions about research reports.
Plunkett Research, Ltd.
www.plunkettresearch.com
Multex Investor Web Address: http://www.multexinvestor.com/ This site is an excellent source for industry and company reports written by professional stock analysts and business analysts. It also offers news and advice on stocks, funds and personal finance, and it has a superb tool that will let you screen a database of major corporations and view pertinent financial and business data on the firms that you select.
XXVI. Job Listings, General
Plunkett Research, Ltd. P.O. Drawer 541737 Houston, TX 77254-1737 Phone: 713-932-0000 Fax: 713-932-7080 E-Mail:
[email protected] Web Address: http://www.plunkettresearch.com/ Plunkett Research, Ltd. is a leading provider of market research, industry trends analysis and business statistics. Since 1985, it has served clients worldwide, including corporations, universities, libraries, consultants and government agencies. At the firm's web site, visitors can view product information and pricing, and visitors can access a great deal of basic market information on industries such as financial services, infotech, e-commerce, health care and biotech.
Career Exposure, Inc. 805 SW Broadway, Ste. 2250 Portland, OR 97205 Phone: 503-221-7779 Fax: 503-221-7780 E-Mail:
[email protected] Web Address: http://www.careerexposure.com/ An online career center and job placement service, with features for employers, recruiters and job seekers.
XXIV. Internet Business/Technology OASIS UDDI P.O. Box 455 Billerica, MA 01821 Phone: 978-667-5115 Fax: 978-667-5114 Web Address: http://www.uddi.org/ OASIS is an international technology consortium. This web site enables readers to learn about UDDI, the Universal Description, Discovery and Integration protocol, a critical component of web services. XXV. Internet Organizations-International CORDIS (Community Research and Development Information Service) Web Address: http://www.cordis.lu/ Provides information about research and development sponsored and supported by the European Union.
America's Job Bank Toll Free: 877-872-5627 Web Address: http://www.jobsearch.org/ Developed by the U.S. Department of Labor as part of an array of web-based job tools, America's Job Bank offers an extensive list of searchable employment vacancies as well other job resources.
CareerBuilder 333 Research Ct., Ste. 200 Norcross, GA 30092 Phone: 866-438-1485 Toll Free: 800-891-8880 Web Address: http://www.careerbuilder.com/ Focuses on the needs of companies but also provides a database of job openings. Resumes are sent directly to the company, and CareerBuilder allows applicants to set up a special e-mail account for job-seeking purposes. Careers.wsj.com from the Publishers of the Wall Street Journal Fax: 609-520-4731 Toll Free: 800-369-2834 Web Address: http://www.careers.wsj.com/ The Wall Street Journal's interactive job search and career-management site posts job opportunities with employers worldwide. Provides a weekly career column and a range of articles about topics including promotion, career crisis and negotiation for higher wages. DirectEmployers E-Recruiting Association, Inc. 4040 Vincennes Cir., 4th Fl. Indianapolis, IN 46268 Phone: 317-874-9000 Fax: 317-874-9100 Toll Free: 866-268-6206 E-Mail:
[email protected] Plunkett Research, Ltd.
Web Address: http://www.directemployers.com/ Operated by the nonprofit E-Recruiting Association, this site links you directly to job opportunities posted on the sites of participating employers, thus bypassing the usual job search sites. Since employers must pay Monster.com and other listing sites for each job opportunity they want to list, it can become too expensive for a growing employer to list all available jobs on third-party sites. Consequently, using DirectEmployers.com saves the employer money and gives job seekers an opportunity to see many more jobs than they might see through other jobs sites. FlipDog.com 3210 N. Canyon Rd., Ste. 300 Provo, UT 84604 Fax: 801-818-0879 E-Mail:
[email protected] Web Address: http://www.flipdog.com/ A job search engine, free to both job seekers and employers. This unique site scours the Internet to find jobs available at over 45,000 corporate sites. HotJobs 406 W. 31st St. New York, NY 10001 Web Address: http://hotjobs.yahoo.com/ Designed for experienced professionals, this Yahoobased site provides company profiles, a resume posting service and a resume workshop. The site allows posters to block resumes from being viewed by certain companies and provides a notification service of new jobs. HRS Federal Job Search Web Address: http://www.hrsjobs.com/ Database of federal jobs available across the U.S. A profile with desired job type, salary and location will initiate numerous e-mailed applicable postings to the job seeker. Monster Board (The) Toll Free: 800-666-7837 Web Address: http://www.monster.com/ An electronic career center that hosts more than 8,000 employers and serves more than 1 million job seekers each month. Job seekers can build and store a resume online, and find job listings that match their profiles. Monster e-mails the results once a week. Recruiters OnLine Network 947 Essex Ln. Medina, OH 44256
www.plunkettresearch.com
Fax: 888-237-8686 Toll Free: 888-364-4667 E-Mail:
[email protected] Web Address: http://www.recruitersonline.com/ Provides Job postings from more than 7,000 recruiters, Careers Online Magazine and a resume database, as well as other resources. TrueCareers, Inc. 11600 Sallie Mae Dr. Reston, VA 20193 Toll Free: 800-441-4062 Web Address: http://www.truecareers.com/ In addition to offering job listings, TrueCareers provides an array of career resources. XXVII. Job Reference Tools NewspaperLinks.com E-Mail:
[email protected] Web Address: http://www.newspaperlinks.com/ A useful web site that links individuals to local, national and international newspapers. Job seekers can search through the classified sections of thousands of newspapers. The site is a service of the Newspaper Association of America. Society of Human Resource Management 1800 Duke St. Alexandria, VA 22314 Phone: 703-548-3440 Fax: 703-535-6490 Toll Free: 800-283-7476 Web Address: http://www.shrm.org/ Frequently updated information for hiring managers. Also has an online library of articles by key words and provides the latest news in employment and labor law. Vault.com 150 W. 22nd St. New York, NY 10011 Phone: 212-366-4212 Web Address: http://www.vault.com/ A comprehensive career web site for employers and employees, with job postings and valuable information on the employment industry. The site focuses on helping the user understand what it's really like to work at a particular firm. Many of the features are focused on MBAs, and the site offers a wide variety of industry guides for sale.
Plunkett Research, Ltd.
XXVIII. Laboratories/Research Alberta Research Council 250 Karl Clark Rd. Edmonton, Alberta T6N 1E4 Canada Phone: 780-450-5111 Fax: 780-450-5333 E-Mail:
[email protected] Web Address: http://www.arc.ab.ca/ Provides research and development services on a contract basis. Access to resources at facilities in western Canada and to 600 experienced scientists, researchers and business experts. Applied Research Laboratories P.O. Box 8029 Austin, TX 78713 Phone: 512-835-3200 Fax: 512-835-3259 Web Address: http://www.arlut.utexas.edu/ Applied Research Laboratories at the University of Texas provides organizational directories and electronic resources. Argonne National Laboratory, Technology Development Division 9700 S. Cass Ave. Argonne, IL 60439-4814 Web Address: http://www.td.anl.gov/ Engaged in research and development in the applied nuclear technology fields. Battelle Memorial Institute 505 King Ave. Columbus, OH 43201 Phone: 614-424-6424 Toll Free: 800-201-2011 Web Address: http://www.battelle.org/ Serves industry and government in developing new technologies and products. Inserts technology into systems and processes for manufacturers; pharmaceutical and agrochemical industries; trade associations; and government agencies supporting energy, the environment, health, national security and transportation. The company has annual revenues of approximately $1 billion. Brookhaven National Laboratory P.O. Box 5000 Upton, NY 11973-5000 Phone: 631-344-8000 E-Mail:
[email protected] Web Address: http://www.bnl.gov/
www.plunkettresearch.com
Managed by the U.S. Department of Energy. Responsible for safely cleaning up and managing the site's legacy wastes. Currently engaged in the world's largest environmental cleanup project. Canada's National Research Council 1200 Montreal Rd., Bldg. M-58 Ottawa, Ontario K1A 0R6 Canada Phone: 613-993-9084 Fax: 613-952-7656 Toll Free: 877-672-2672 E-Mail:
[email protected] Web Address: http://www.nrc.ca/ Through the NRC, 16 research institutes carry out multi-disciplinary research with partners in industries and sectors key to Canada's economic development. Commonwealth Scientific and Industrial Research Organization Bag 10 Clayton South, Australia VIC 3169 Phone: 61-3-9545-2176 Fax: 61-3-9545-2175 E-Mail:
[email protected] Web Address: http://www.csiro.au/ Performs research and development over a broad range of areas including agriculture, minerals and energy, manufacturing, communications, construction, health and the environment. Daresbury Laboratory Daresbury, Warrington Cheshire, UK WA4 4AD Phone: 44-1925-603000 Fax: 44-1925-603100 E-Mail:
[email protected] Web Address: http://www.dl.ac.uk/ Operated by the Council of the Central Laboratory of Research Councils, a strong resource in computational science and engineering. Hanford Nuclear Site Web Address: http://www.hanford.gov/ Solves critical problems related to the environment, energy production and use, U.S. economic competitiveness and national security. Idaho National Engineering and Environmental Laboratory P.O. Box 1625 Idaho Falls, IL 83415 Phone: 208-526-0111 Toll Free: 800-708-2680
Plunkett Research, Ltd.
E-Mail:
[email protected] Web Address: http://www.inel.gov/ Multidisciplinary, multiprogram laboratory which designs, develops and tests nuclear weapons. MITRE Corporation 202 Burlington Rd. Bedford, MA 01730-1420 Phone: 781-271-2000 E-Mail:
[email protected] Web Address: http://www.mitre.org/ A nonprofit engineering institution offering expertise in communications, information, space, environmental and aviation systems. Operates two federally funded research and development centers for the U.S. government. National Renewable Energy Laboratory Golden, CO 80401 Phone: 303-275-3000 Web Address: http://www.nrel.gov/ Reduces nuclear danger, transfers applied environmental technology to government and nongovernment entities and forms economic and industrial alliances. Sandia National Laboratories P.O. Box 5800 Albuquerque, NM 87185 Web Address: http://www.sandia.gov/ A national security laboratory operated for the U.S. Department of Energy by the Sandia Corporation. Designs all non-nuclear components for the nation's nuclear weapons and performs a wide variety of energy research and development projects. Savannah River Site 1617 Cole Blvd. Web Address: http://www.srs.gov/ A project meant to determine if Yucca Mountain, Nevada, is a suitable site for a spent nuclear fuel and high-level radioactive waste depository. SRI International 333 Ravenswood Ave. Menlo Park, CA 94025-3493 Phone: 650-859-2000 Fax: 650-326-5512 Toll Free: 866-451-5998 E-Mail:
[email protected] Web Address: http://www.sri.com/ A nonprofit organization offering a wide range of services, including engineering services, information
www.plunkettresearch.com
technology, pure and applied physical sciences, product development, pharmaceutical discovery, biopharmaceutical discovery and policy issues. Yucca Mountain Project Web Address: http://www.ocrwm.doe.gov/ymp/index.shtml Creates and operates major facilities available to university, industrial and government personnel for basic and applied research in physical, biomedical and environmental sciences and in selected energy technologies. Partly managed by the U.S. Department of Energy. XXIX. Microelectronics Industry Associations American Electronics Association 5201 Great America Pkwy. Santa Clara, CA 54990 Phone: 408-987-4200 Fax: 408-970-8565 Web Address: http://www.aeanet.org/ AEA represents thousands of U.S. electronics firms, including electronic systems and component manufacturers, suppliers and end users. It also publishes the annual AEA Directory with geographic and product indexes. Electronic Industries Alliance 2500 Wilson Blvd. Arlington, VA 22201-3834 Phone: 703-907-7500 Web Address: http://www.eia.org/ EIA, formerly known as the Electronics Industries Association, represents thousands of electronics firms, including electronic components and consumer electronics manufacturers. Institute for Interconnecting and Packaging Electronic Circuits (IPC) 2215 Sanders Rd. Northbrook, IL 60062 Phone: 847-509-9700 Fax: 847-509-9798 Web Address: http://www.ipc.org/ The IPC is a trade association dedicated to furthering the competitive excellence and financial success of its worldwide members, participants in the electronic interconnect industry. International Microelectronics and Packaging Society 611 2nd St. NE
Plunkett Research, Ltd.
Washington, DC 20002 Phone: 202-548-4001 Fax: 202-548-6115 Web Address: http://www.imaps.org/ IMAPS is a society dedicated to the advancement and growth of the use of microelectronics and electronic packaging through professional and public education, the dissemination of information and the promotion of its portfolio of technologies. International Semiconductor Manufacturing Technology (SEMATECH) 2706 Montopolis Dr. Austin, TX 78741 Phone: 512-356-3500 Web Address: http://www.sematech.org/public/home.htm International SEMATECH is is a consortium of 12 semiconductor manufacturing companies from seven countries. National Consortia of Manufacturing Sciences 3025 Boardwalk Ann Arbor, MI 48108-3266 Phone: 734-995-0300 Fax: 734-995-4004 Web Address: http://www.ncms.org/ A nonprofit membership organization dedicated to advancing the global competitiveness of North American industry through collaboration. National Electrical Manufacturers Association 1300 N. 17th St., Ste. 1847 Rosslyn, VA 22209 Phone: 703-841-3200 Fax: 703-841-5900 Web Address: http://www.nema.org/ NEMA develops standards for the electrical manufacturing industry and promotes safety in the manufacture and use of electrical products. Semiconductor Business Association 66 Hill Grove Huddersfield, West Yorkshire HD3 2TL UK Phone: 01484-656865 Fax: 01204-370916 E-Mail:
[email protected] Web Address: http://www.semiconductor.org/ The SBA is a national trade association with members in the semiconductor and electronics industry throughout the United Kingdom.
www.plunkettresearch.com
Semiconductor Equipment and Materials International (SEMI) 3081 Zanker Rd. San Jose, CA 95134 Phone: 408-943-6900 Fax: 408-428-9600 E-Mail:
[email protected] Web Address: http://www.semi.org/ SEMI is a trade association serving the global semiconductor equipment, materials and flat panel display industries. Semiconductor Industry Association 181 Metro Dr., Ste. 450 San Jose, CA 95110 Phone: 408-436-6600 Fax: 408-436-6646 E-Mail:
[email protected] Web Address: http://www.semichips.org/ SIA represents U.S. semiconductor manufacturers and publishes the annual Status Report and Industry Directory and World Semiconductor Trade Statistics, which tracks semiconductor shipments by regional market and by product. Surface Mount Technology Association 5200 Willson Rd., Ste. 215 Edina, MN 55424 Phone: 952-920-7682 Fax: 952-926-1819 Web Address: http://www.smta.org/ SMTA represents manufacturers of products utilizing SMT applications. It is involved in technical conferences and seminar organization. Virginia Center for Innovative Technology 2214 Rock Hill Rd., Ste. 600 Herndon, VA 20170 Phone: 703-689-3000 Fax: 703-689-3041 Web Address: http://www.cit.org/ A nonprofit organization designed to enhance the research and development capability of the state's major research universities. XXX. Satellite-Related Professional Organizations Geospatial Information and Technology Association 14456 E. Evans Ave. Aurora, CO 80014-1409 Phone: 303-337-0513 Fax: 303-337-1001
Plunkett Research, Ltd.
Web Address: http://www.gita.org/ GITA is an educational association for geospatial information and technology professionals. Society of Satellite Professionals International The New York Technology Information Center 55 Broad St., 14th Fl. New York, NY 10004 Phone: 212-809-5199 Fax: 212-825-0075 Web Address: http://www.sspi.org/ The SSPI is a nonprofit member-benefit society that serves satellite professionals throughout their careers. Washington Space Business Roundtable 2200 Wilson Blvd., Ste. 102-248 Arlington, VA 22201 Phone: 703-522-7745 Fax: 703-522-4226 E-Mail:
[email protected] Web Address: http://www.wsbr.org/ WSBR is a leadership forum for the promotion of commercial space business and education in the national capital region. XXXI. Telecommunications Industry Associations CDMA Development Group (CDG) 575 Anton Blvd., Ste. 560 Costa Mesa, CA 92626 Phone: 714-545-5211 Fax: 714-545-4601 Toll Free: 888-800-2362 E-Mail:
[email protected] Web Address: http://www.cdg.org/ The CDG is comprised of the world's leading CDMA service providers and manufacturers that have joined together to lead the adoption and evolution of CDMA wireless systems around the world. Cellular Telecommunications Industry Association 1250 Connecticut Ave. NW, Ste. 800 Washington, DC 20036 Phone: 202-785-0081 Web Address: http://www.wow-com.com/ CTIA is an international organization that represents all elements of wireless communication (cellular, personal communication services, enhanced specialized mobile radio and mobile satellite services) serving the interests of service providers, manufacturers and others.
www.plunkettresearch.com
CompTel 1900 M St. NW, Ste. 800 Washington, DC 20036 Phone: 202-296-6650 Fax: 202-296-7585 Web Address: http://www.comptel.org/ CompTel is a leading association representing competitive telecommunications companies in virtually every sector of the marketplace: incumbent local exchange carriers, competitive local exchange carriers, long-distance carriers of every size, wireless service providers, Internet service providers, equipment manufacturers and software suppliers. European Telecommunications Standards Institute 650 Rte. des Lucioles Sophia Antipolis, France 06921 Phone: 33-492-944-200 Fax: 33-493-654-716 E-Mail:
[email protected] Web Address: http://www.etsi.org/ ETSI is a nonprofit organization whose mission is to produce the telecommunications standards that will be used for decades to come throughout Europe and beyond. Global System for Mobile Communications 6-8 Old Bond St. London, UK W1S 6PH Phone: 44 20-7518-0530 Fax: 44 20-7518-0531 Web Address: http://www.gsmworld.com/ A leading wireless industry representative body. Institute for Telecommunication Sciences 325 Broadway Boulder, CO 80305-3328 Phone: 303-497-5216 E-Mail:
[email protected] Web Address: http://www.its.bldrdoc.gov/ ITS is the research and engineering branch of the National Telecommunications and Information Administration, a division of the U.S. Department of Commerce. International Telecommunication Union Place des Nations 1211 Geneva 20 Switzerland Phone: 41-22-730-5111 Fax: 41-22-733-7256 E-Mail:
[email protected] Plunkett Research, Ltd.
Web Address: http://www.itu.int/ The ITU is an international organization within the United Nations in which governments and the private sector coordinate global telecom networks and services. Personal Communications Industry Association 500 Montogmery St., Ste. 700 Alexandria, VA 22314-1561 Phone: 703-739-0300 Fax: 703-836-1608 Toll Free: 800-759-0300 Web Address: http://www.pcia.com/ PCIA is an association of companies working together to increase the reach, frequency and impact of wireless technology integration into the enterprise, business and consumer markets. Telecom Research Foundation E-Mail:
[email protected] Web Address: http://www.telecomresearch.com/ A nonprofit organization that provides a free platform for sharing information worldwide on telecom regulation changes, industry and market research, product and service offerings and technology development trends. Telecommunications Industry Association 2500 Wilson Blvd., Ste. 300 Arlington, VA 22201 Phone: 703-907-7700 Fax: 703-907-7727 Web Address: http://www.tiaonline.org/ The TIA is is the leading trade association in the communications and information technology industry, focusing on market development, trade promotion, trade shows, domestic and international advocacy, standards development and enabling ebusiness. United States Telecom Association 1401 H St. NW, Ste. 600 Washington, DC 20005-2164 Phone: 202-326-7300 Fax: 202-326-7333 Web Address: http://www.usta.org/ The leading broad-based association for the local exchange carrier industry worldwide. Wireless Application Protocol Forum 2570 W El Camino Real, Ste. 304 Mountain View, CA 94040-1313 Phone: 650-949-6760
www.plunkettresearch.com
Fax: 650-949-6765 E-Mail:
[email protected] Web Address: http://www.wapforum.org/ The WAP Forum provides Internet communications and advanced telephony services on digital mobile phones, pagers, personal digital assistants and other wireless terminals. Wireless Communications Association International 1140 Connecticut Ave. NW, Ste. 810 Washington, DC 20036 Phone: 202-452-7823 Fax: 202-452-0041 Web Address: http://www.wcai.com/ The principal nonprofit trade association representing the wireless broadband industry. XXXII. Telecommunications Information, General IMT-2000 Place des Nations 1211 Geneva 20 Switzerland Phone: 41-22-730-5111 Fax: 41-22-733-7256 E-Mail:
[email protected] Web Address: http://www.imt-2000.org/ This site offers information on IMT-2000, the term used by the International Telecommunications Union for a set of globally harmonized standards for thirdgeneration mobile telecom services and equipment. XXXIII. Testing Resources Kenexa 11 Penn Ctr. 1835 Market St., 20th Fl. Philadelphia, PA 19103 Phone: 215-546-7330 Fax: 215-546-7331 Toll Free: 800-935-6694 Web Address: http://www.proveit.com/ Provides PC- and Internet-based exams to test people’s skills in everything from Windows 95 and Microsoft Access to programming languages like C++ and COBOL. Provides a downloadable demo. TeckCheck Bookman Testing Services, Inc. 2 Park Ave., Ste. 1102
Plunkett Research, Ltd.
www.plunkettresearch.com
New York, NY 10016 Phone: 212-251-6341 Fax: 509-693-6076 Web Address: http://www.teckcheck.com/ PC-based tests in 90 competencies including C, C++, CICS, DB2, Lotus Notes, Oracle, PowerBuilder, RPG and Visual Basic. Sample questions are provided.
FCC-Wireless Bureau 445 12th St. SW Washington, DC 20554 Fax: 202-418-0232 Toll Free: 888-225-5322 Web Address: http://wireless.fcc.gov Handles nearly all FCC domestic wireless telecommunications programs and policies.
XXXIV. U.S. Government Agencies
Federal Communications Commission (FCC) 445 12th St. SW Washington, DC 20554 Fax: 202-418-0232 Toll Free: 888-225-5322 E-Mail:
[email protected] Web Address: http://www.fcc.gov/ The FCC is an independent U.S. Government agency established by the Communications Act of 1934 and charged with regulating interstate and international communications by radio, television, wire, satellite and cable.
Bureau of Economic Analysis 1441 L St. Washington, DC 20230 Phone: 202-606-9900 Web Address: http://www.bea.doc.gov/ The BEA, an agency of the U.S. Department of Commerce, is the nation's economic accountant, preparing estimates that illuminate key national, international and regional aspects of the United States economy. Bureau of Labor Statistics Division of Information Services 2 Massachussets Ave. NE Washington, DC 20212 Phone: 202-691-5200 Fax: 202-691-6325 E-Mail:
[email protected] Web Address: http://stats.bls.gov/ The BLS is the principal fact-finding agency for the Federal Government in the field of labor economics and statistics. It is an independent national statistical agency that collects, processes, analyzes and disseminates statistical data to the American public, the U.S. Congress, other Federal agencies, state and local governments, business and labor. The BLS also serves as a statistical resource to the Department of Labor. Equal Employment Opportunity Commission U.S. Equal Employment Opportunity 1801 L St. NW Washington, DC 20507 Phone: 202-663-4900 Toll Free: 800-669-4000 Web Address: http://www.eeoc.gov/ Features details about various protective laws regarding employment that help gauge how much testing job candidates can be required to go through. Also provides information on how to file a discrimination claim.
FedWorld.gov U.S. Department of Commerce Springfield, VA 22161 Phone: 703-605-6000 Web Address: http://www.fedworld.gov/jobs/jobsearch.html Annotated index of links to job-, labor- and management-related U.S. Government servers. Employment opportunities, labor statistics and pointers to other government information servers are also offered. Government Printing Office 732 N. Capitol St. NW Washington, DC 20401 Phone: 202-512-0000 E-Mail:
[email protected] Web Address: http://www.gpo.gov/ The GPO is the online source for many government books and documents. International Trade Association E-Mail:
[email protected] Web Address: http://www.trade.gov/ This U.S. Government agency provides a wealth of information regarding imports and exports. In addition, it publishes in-depth analysis and statistics on various industry sectors and provides assistance to U.S. firms that wish to increase their exports.
Plunkett Research, Ltd.
Los Alamos National Laboratory University of California Phone: 510-987-0570 Web Address: http://www.lanl.gov/external Home page of the famous national energy laboratory at Los Alamos, New Mexico. This lab was originally built as a work site for the team that designed the first atomic bomb during World War Two. Currently, it provides a continual stream of research in physics and energy matters. Much of that research is put to use in the commercial sector. National Science Foundation 4201 Wilson Blvd. Arlington, VA 22230 Phone: 703-292-5111 Toll Free: 800-877-8339 E-Mail:
[email protected] Web Address: www.nsf.gov Independent government agency responsible for promoting science and engineering. National Telecommunications and Information Administration 1401 Constitution Ave. NW Washington, DC 20230 Phone: 202-482-7002 Web Address: http://www.ntia.doc.gov/ The NTIA, an agency of the U.S. Department of Commerce, is the Executive Branch's principal voice on domestic and international telecommunications and information technology issues. Oak Ridge National Laboratory P.O. Box 2008 Oak Ridge, TN 37831 Web Address: http://www.ornl.gov/ Multiprogram science and technology laboratory managed for the U.S. Department of Energy by U.T.Battelle, LLC. Conducts basic and applied research and development to create scientific knowledge and technological solutions. Office of Telecommunications Technologies Herbert C. Hoover Bldg., Rm. 4324 14th St. and Constitution Ave. NW Washington, DC 20230 Phone: 202-482-4466 Fax: 202-482-5834 Web Address: http://infoserv2.ita.doc.gov/ot/home.nsf
www.plunkettresearch.com
The OTT in the U.S. Department of Commerce supports the growth and competitiveness of the U.S. telecommunications industry. U.S. Business Advisor Web Address: http://www.business.gov/ Offers a searchable directory of business-specific government information. Topics include taxes, regulations, international trade, financial assistance and business development. The U.S. Business Advisor was created by the Small Business Administration (SBA) and an interagency task force U.S. Census Bureau Washington, DC 20233 Web Address: http://www.census.gov/ The U.S. Census Bureau is the official collector of data about the people and economy of the U.S. It provides official social, demographic and economic information. U.S. Department of Labor Francis Perkins Bldg. 200 Constitution Ave. NW Washington, DC 20210 Toll Free: 866-487-2365 Web Address: http://www.dol.gov/ The Federal Government agency responsible for labor regulations. This site provides tools to help citizens find out whether companies are complying with family and medical-leave requirements. U.S. Nuclear Regulatory Commission One White Flint N. 11555 Rockville Pike Rockville, MD 20852 Phone: 301-415-7000 Web Address: http://www.nrc.gov/ Independent agency established by the U.S. Congress to ensure adequate protection of public health and safety, common defense and security and the environment in use of nuclear materials in the United States. U.S. Patent and Trademark Office Crystal Plaza 3, Room 2C02 P.O. Box 1450 Alexandria, VA 22313-1450 Phone: 703-308-4357 Toll Free: 800-786-9199 Web Address: http://www.uspto.gov/ This agency grants trademarks and patents for protection within the United States. For statistics
Plunkett Research, Ltd.
regarding patent applications and grants, visit http://www.uspto.gov/web/patents/stats.htm. U.S. Securities and Exchange Commission (SEC) Phone: 202-942-8088 Web Address: http://www.sec.gov/ The SEC is a nonpartisan, quasi-judicial regulatory agency responsible for administering federal securities laws. These laws are to protect investors in securities markets and ensure they have access to disclosure of all material information concerning publicly traded securities. Users can access the EDGAR database of corporate financial and business information. White House (The) 1600 Pennsylvania Ave. Washington, DC 20500 Phone: 202-456-1414 Web Address: http://www.whitehouse.gov/ This site was designed for communication between the Federal Government and the American people. It provides access to all government information and services that are available on the Internet.
www.plunkettresearch.com
Plunkett Research, Ltd.
www.plunkettresearch.com
Chapter 4 THE ENGINEERING & RESEARCH 500: WHO THEY ARE AND HOW THEY WERE CHOSEN Includes Indexes by Company Name, Industry & Location And a Complete Table of Sales, Profits and Ranks The companies chosen to be listed in PLUNKETT’S ENGINEERING & RESEARCH INDUSTRY ALMANAC are not the same as the “Fortune 500” or any other list of corporations. THE ENGINEERING & RESEARCH 500 (the actual count is 468 companies) were chosen specifically for their dominance in the many facets of engineering and research in which they operate. Complete information about each firm can be found in the “Individual Profiles,” beginning at the end of this chapter. These profiles are in alphabetical order by company name. THE ENGINEERING & RESEARCH 500 includes companies from all parts of the United States, Canada, Europe and beyond. The companies operate in all engineering and research related industry segments: design and development, technology-based research and development and manufacturing. We have included companies that are making significant investments in research and development via as many disciplines as possible, whether that research is being funded by internal investment, by fees received from clients and
customers or by fees or grants collected from government agencies. Simply stated, the list contains nearly 500 of the largest, most successful, fastest growing firms in engineering, research and related industries in the United States and abroad. To be included in our list, the firms had to meet the following criteria: 1) Generally, these are U.S.-based, private sector corporations. (We have also added 64 foreignbased companies in order to better list leading firms in certain industry sectors.) 2) Publicly-held companies where stocks or bonds issued by the firm have been sold to the public (except for a number of firms that are privatelyheld that we have added in order to round-out certain niche sets of companies). 3) Prominence, or a significant presence, in research and development, engineering and supporting fields. (See the following Industry Codes section for a complete list of types of businesses that are covered). 4) The companies in THE ENGINEERING & RESEARCH 500 do not have to be exclusively in engineering or research fields.
Plunkett Research, Ltd.
5) Financial data and vital statistics must have been available to the editors of this book, either directly from the company being written about or from outside sources deemed reliable and accurate by the editors. A small number of companies that we would like to have included are not listed because of a lack of sufficient, objective data. The companies were chosen in this manner for the following reasons: • 468 Companies so there is a broad base with which to make comparisons and from which you can study the major players in this industry. • Non-Government because information about government agencies can be obtained elsewhere, and so that researchers using PLUNKETT'S ENGINEERING & RESEARCH INDUSTRY ALMANAC can best study firms in the profitseeking private sector, where innovation and financially-motivated investors are creating dynamic changes in exciting engineering and research fields. • Companies with publicly-traded stock because publicly-held firms can be compared fairly, since they are required by law to meet federal government standards in their methods of reporting and accounting for their vital statistics. INDEXES TO THE ENGINEERING & RESEARCH 500, AS FOUND IN THIS CHAPTER AND IN THE BACK OF THE BOOK: Industry List, With Codes p. 88 Index of Rankings Within Industry Groups p. 90 Alphabetical Index p. 102 Geographic Indexes Index of Headquarters Location, by State p. 107 Index of Headquarters Location, by Country p. 112 Index by Regions of the U.S. where THE ENGINEERING & RESEARCH 500 have Locations p. 113 Index by Firms with International Operations p. 128 Index of Firms Noted as “Hot Spots for Advancement” for Women/Minorities p. 604 Index of Subsidiaries, Brand Names and Selected Affiliations p. 606
www.plunkettresearch.com
INDUSTRY LIST, WITH CODES This book refers to the following list of unique industry codes, based on the NAIC code system (NAIC is used by many analysts as a replacement for older SIC codes because NAIC is more specific to today’s industry sectors): Energy 211111 213111 325110 335929
Fuel Mining & Extraction Oil and Natural Gas Exploration and Development Petroleum--Drilling Oil and Gas Wells Support Petroleum-Refining & Manufacturing Petrochemicals Manufacturing Manufacturing, Electrical Superconducting Materials and Other Wire
Entertainment & Hospitality 513210
Broadcasting Cable TV Networks
Health Care 325412 325414 339113 421450 621511 621991
Health Products, Manufacturing Drugs, Manufacturing Biological Products Medical/Dental/Surgical Equipment and Supplies, Manufacturing Health Products, Wholesale Distribution Medical/Dental/Surgical Equipment and Supplies, Distribution Health Care-Clinics, Labs and Organizations Laboratories and Diagnostics--Medical Blood and Organ Banks
InfoTech 334110 334111 334112 334119 334310 334413 334419 334515 335921 335999
Computers & Electronics Manufacturing Computer Networking and Related Equipment, Manufacturing Computer Hardware, Manufacturing Computer Storage Equipment and Misc Parts, Manufacturing Computer Accessories, Manufacturing Audio and Video Equipment, Manufacturing Chips (Semiconductors)/Integrated Circuits/Components, Manufacturing Contract Electronics Manufacturing Test Equipment/Instruments, Manufacturing Electrical Equipment & Wire, Manufacturing Fibre Optic Cable and Electrical Wire Electrical and Electronic Equipment, Manufacturing
Plunkett Research, Ltd. 511200 514191A
541512
Software Computer Software Information & Data Processing Services Online Business-to-Business or to-Consumer Intermediary Information Services-Professional Consulting--Computer and Internet
Manufacturing 236100 325000 325411 325413 326000 331000 332210 333000 333298 333313 333314 334200 334210 335000 336111 336390 336120 336410 513340
Construction Construction, Residential Chemicals Chemicals, Manufacturing Medicinals and Botanicals, Manufacturing In Vitro Diagnostic Substances, Manufacturing Plastics & Rubber Plastics and Rubber, Manufacturing Primary Minerals Steel and Metals, Manufacturing Fabricated Metals Cutlery and Hand Tools, Manufacturing Machinery Machinery, Manufacturing Fuel Cells, Solar Cells, Other Industrial Machinery, Manufacturing Business Machines, Manufacturing Optical Instrument and Lens, Manufacturing Telecommunications Equipment Communications Equipment, Manufacturing Telecommunications Equipment, Manufacturing and Related Services Electrical Equipment, Appliances, Tools Electrical Equipment/Appliances/Tools, Manufacturing Transportation-Manufacturing of Equipment Automobiles, Manufacturing Automobile Parts Manufacturing Trucks, RVs and Misc. Automotive, Manufacturing Aerospace Aerospace Related Manufacturing Satellites, Manufacturing Satellite Equipment, Manufacturing
Services 115112 230000 541310 541320 541611 541620
Agriculture Agriculture, Crop Production Support Activities Construction Construction Services Consulting & Professional Services Engineering Services Architectural Services Consulting & Professional Services Consulting--Management and Business Consulting--Environmental
www.plunkettresearch.com 541690 541710
Consulting--Scientific and Technical Research and Development--Physical, Engineering and Life Sciences 541810A Advertising/Marketing--Online Management 551110 Management of Companies and Enterprises
Plunkett Research, Ltd.
www.plunkettresearch.com
INDEX OF RANKINGS WITHIN INDUSTRY GROUPS 2002 2002 Industry Sales Sales Profits Profits Code Rank Rank (thousands) (thousands) Advertising/Marketing--Online GOOGLE INC 541810A 100,000 2 YAHOO! INC 541810A 953,100 1 42,800 1 Aerospace Related Manufacturing AIRBUS SAS 336410 20,333,000 4 BAE SYSTEMS 336410 12,953,000 8 -1,100 7 BOEING CO 336410 54,069,000 1 492,000 3 BOMBARDIER INC 336410 14,865,500 6 268,600 5 GENERAL DYNAMICS 336410 13,829,000 7 917,000 1 GOODRICH CORPORATION 336410 3,910,200 10 117,900 6 HONEYWELL INTERNATIONAL 336410 22,274,000 3 -220,000 8 ITT INDUSTRIES INC 336410 4,985,300 9 379,900 4 LOCKHEED MARTIN CORP 336410 26,578,000 2 500,000 2 RAYTHEON CO 336410 16,760,000 5 -587,000 9 Agriculture, Crop Production Support Activities EXELIXIS PLANT SCIENCES INC 115112 Architectural Services SKIDMORE OWINGS & MERRILL 541320 STV GROUP INC 541320 Audio and Video Equipment, Manufacturing SONY CORPORATION 334310 57,117,000 1 115,000 1 Automobile Parts Manufacturing DENSO CORPORATION 336390 18,102,000 3 545,000 2 JOHNSON CONTROLS INC 336390 20,103,000 1 600,000 1 VISTEON CORPORATION 336390 18,395,000 2 -352,000 3 Automobiles, Manufacturing ADAM OPEL AG 336111 14,459,000 15 AUDI AG 336111 23,690,000 13 812,000 10 BAYERISCHE MOTOREN WERKE AG 336111 44,316,000 10 2,117,000 6 DAIMLERCHRYSLER AG 336111 156,838,000 3 4,947,000 1 FIAT SPA 336111 61,014,000 6 -4,147,000 17 FORD MOTOR CO 336111 162,586,000 2 -980,000 16 FUJI HEAVY INDUSTRIES LTD 336111 10,272,000 18 228,000 11 GENERAL MOTORS CORP 336111 186,763,000 1 1,736,000 8 HONDA MOTOR CO LTD 336111 55,253,000 8 2,722,000 4 HYUNDAI MOTOR COMPANY 336111 40,187,000 11 1,198,000 9 ISUZU MOTORS LTD 336111 12,045,000 17 -324,000 15 MAZDA MOTOR CORPORATION 336111 15,794,000 14 67,000 14 MITSUBISHI MOTORS CORP 336111 24,024,255 12 84,473 13 NISSAN MOTOR CO LTD 336111 46,588,000 9 2,799,000 3 PSA PEUGEOT CITROEN SA 336111 57,054,000 7 1,771,000 7 SUZUKI MOTOR CORP 336111 12,577,000 16 169,000 12 TOYOTA MOTOR CORP 336111 107,443,000 4 4,177,000 2
Company
Plunkett Research, Ltd.
www.plunkettresearch.com
Company
2002 Sales
2002 Profits
Industry Sales Profits Code Rank Rank (thousands) (thousands) VOLKSWAGEN AG 336111 91,130,000 5 2,708,000 5 Biological Products ANIKA THERAPEUTICS INC 325414 13,200 2 -3,000 2 GTC BIOTHERAPEUTICS INC 325414 10,400 3 -24,300 3 LIFECELL CORPORATION 325414 34,400 1 1,400 1 Blood and Organ Banks SEROLOGICALS CORP 621991 145,500 1 13,900 1 Business Machines, Manufacturing PITNEY BOWES INC 333313 4,409,800 2 475,700 1 XEROX CORP 333313 15,849,000 1 91,000 2 Cable TV Networks AOL TIME WARNER INC 513210 41,065,000 1 -98,686,000 1 Chemicals, Manufacturing AIR PRODUCTS & CHEMICALS 325000 5,401,000 6 525,000 3 ALBEMARLE CORPORATION 325000 980,200 14 74,700 8 BASF AG 325000 35,031,700 1 1,635,400 1 BAYER AG 325000 32,213,100 2 1,152,600 2 CABOT CORPORATION 325000 1,557,000 11 106,000 6 DOW CHEMICAL COMPANY 325000 27,609,000 3 -338,000 12 E I DU PONT DE NEMOURS & CO 325000 24,006,000 4 -1,103,000 13 (DUPONT) IMC GLOBAL INC 325000 2,057,400 9 -110,200 10 MONSANTO CO 325000 4,673,000 8 -1,693,000 14 PRAXAIR INC 325000 5,128,000 7 409,000 4 SCOTTS CO 325000 1,760,600 10 82,500 7 SIGMA ALDRICH CORP 325000 1,207,000 12 130,700 5 SYNGENTA AG 325000 6,197,000 5 -27,000 9 TERRA INDUSTRIES INC 325000 1,042,400 13 -258,400 11 Chips (Semiconductors)/Integrated Circuits/Components, Manufacturing ADVANCED MICRO DEVICES 334413 2,697,000 3 -1,303,000 21 AFFYMETRIX INC 334413 289,947 20 -1,630 8 ALTERA CORP 334413 711,700 15 91,300 5 AMKOR TECHNOLOGY INC 334413 1,639,707 7 -826,759 19 ANALOG DEVICES INC 334413 1,707,500 6 105,300 3 ATMEL CORP 334413 1,193,800 9 -641,800 18 BROADCOM CORP 334413 1,082,900 10 -2,236,600 22 CIRRUS LOGIC INC 334413 417,500 18 -206,100 16 CYPRESS SEMICONDUCTOR 334413 774,700 13 -37,000 10 HADCO CORP 334413 INTEL CORP 334413 26,764,000 1 3,117,000 1 INTERNATIONAL RECTIFIER 334413 720,200 14 48,700 6 LSI LOGIC CORP 334413 1,816,900 5 -42,200 11 MAXIM INTEGRATED PRODUCTS INC 334413 1,025,100 11 259,200 2 MEMC ELECTRONIC MATERIALS 334413 687,200 16 -5,100 9 MICROCHIP TECHNOLOGY INC 334413 571,300 17 94,800 4 MICRON TECHNOLOGY INC 334413 2,589,000 4 -907,000 20
Plunkett Research, Ltd.
www.plunkettresearch.com
NATIONAL SEMICONDUCTOR
Company
334413
1,494,800 2002 Sales
8
-121,900 15 2002 Profits Profits Rank (thousands) -65,000 13 5,900 7 -43,500 12 -344,000 17 -113,600 14
Industry Sales Code Rank (thousands) PMC-SIERRA INC 334413 218,100 21 STANDARD MICROSYSTEMS 334413 159,300 22 TECHNITROL INC 334413 406,400 19 TEXAS INSTRUMENTS INC 334413 8,383,000 2 XILINX INC 334413 1,015,600 12 Communications Equipment, Manufacturing GLENAYRE TECHNOLOGIES 334200 67,400 2 -7,700 L3 COMMUNICATIONS HOLDINGS INC 334200 4,011,200 1 178,000 Computer Accessories, Manufacturing INFOCUS CORP 334119 653,098 3 -63,971 LEXMARK INT'L GROUP INC 334119 4,356,400 1 366,700 SYMBOL TECHNOLOGIES INC 334119 1,320,100 2 10,500 Computer Hardware, Manufacturing APPLE COMPUTER INC 334111 5,742,000 5 65,000 COGNEX CORP 334111 114,100 12 -6,000 DELL COMPUTER CORP 334111 31,168,000 3 1,246,000 DIEBOLD INC 334111 1,940,200 7 99,200 GERBER SCIENTIFIC INC 334111 502,700 10 -119,700 HEWLETT-PACKARD CO 334111 56,588,000 2 -903,000 INTERNATIONAL BUSINESS MACHINES (IBM) 334111 81,186,000 1 3,579,000 MILTOPE GROUP INC 334111 48,470 13 4,663 NCR CORPORATION 334111 5,585,000 6 -220,000 PALM INC 334111 1,030,800 9 -82,200 RADISYS CORP 334111 200,100 11 -3,300 SILICON GRAPHICS INC 334111 1,341,400 8 -46,300 SUN MICROSYSTEMS INC 334111 12,496,000 4 -587,000 Computer Networking and Related Equipment, Manufacturing 3COM CORP 334110 1,477,900 2 -596,000 ADAPTEC INC 334110 418,700 5 -196,200 CISCO SYSTEMS INC 334110 18,915,000 1 1,893,000 ELECTRONICS FOR IMAGING 334110 350,200 6 16,000 ENTERASYS NETWORKS INC 334110 484,797 4 -153,514 JUNIPER NETWORKS INC 334110 546,500 3 -119,700 NETWORK EQUIPMENT TECHNOLOGIES INC 334110 101,500 8 -37,400 TERAYON COMMUNICATION SYSTEMS 334110 129,400 7 -44,200 INC Computer Software ADOBE SYSTEMS INC 511200 1,164,800 18 191,400 AMDOCS LTD 511200 1,613,600 11 249,000 ASCENTIAL SOFTWARE 511200 113,000 37 -63,600 ASPECT COMMUNICATIONS 511200 396,100 34 -108,300 AUTODESK INC 511200 947,500 22 90,300 AVAYA INC 511200 4,956,000 4 -666,000 BEA SYSTEMS INC 511200 975,900 21 -35,700
2 1 3 1 2 4 7 2 3 10 13 1 5 11 9 6 8 12 8 7 1 2 6 5 3 4 7 6 26 30 12 35 24
Plunkett Research, Ltd.
www.plunkettresearch.com
BMC SOFTWARE INC
Company
511200 Industry Code 511200 511200 511200
1,288,900 2002 Sales (thousands)
14
-184,100 31 2002 Sales Profits Profits Rank Rank (thousands) 13 71,900 14 27 48,000 16 30 93,900 11
CADENCE DESIGN SYSTEMS 1,293,100 CERNER CORP 751,900 CITRIX SYSTEMS INC 527,400 COMPUTER ASSOCIATES INTERNATIONAL INC 511200 2,964,000 5 -1,102,000 COMPUWARE CORP 511200 1,728,500 8 -245,300 COMVERSE TECHNOLOGY INC 511200 1,270,200 15 54,600 ELECTRONIC ARTS INC 511200 1,724,700 9 101,500 ERESEARCH TECHNOLOGY 511200 41,500 39 6,200 FILENET CORP 511200 347,000 35 8,300 I2 TECHNOLOGIES INC 511200 522,500 31 -1,003,700 IDX SYSTEMS CORP 511200 460,100 33 10,000 INTERGRAPH CORP 511200 501,200 32 377,800 INTUIT INC 511200 1,358,300 12 140,200 MENTOR GRAPHICS CORP 511200 596,200 29 -14,300 MICROSOFT CORP 511200 28,365,000 1 7,829,000 MSC.SOFTWARE CORP 511200 344,200 36 -51,300 NETWORK ASSOCIATES INC 511200 941,900 23 90,200 NOVELL INC 511200 1,134,300 19 -246,800 ORACLE CORP 511200 9,673,000 2 2,224,000 PARAMETRIC TECHNOLOGY 511200 753,900 26 -75,000 PEOPLESOFT INC 511200 1,948,900 7 182,600 RATIONAL SOFTWARE CORP 511200 689,800 28 -75,900 SAP AKTIENGESELLSCHAFT 511200 7,786,000 3 534,000 SAS INSTITUTE 511200 1,180,000 17 SIEBEL SYSTEMS INC 511200 1,635,300 10 -35,700 SUNGARD DATA SYSTEMS INC 511200 2,530,300 6 325,600 SYBASE INC 511200 829,900 25 -94,700 SYMANTEC CORP 511200 1,071,400 20 -28,200 SYNOPSYS INC 511200 906,500 24 -200,000 TRIPOS INC 511200 51,100 38 900 VERISIGN INC 511200 1,221,700 16 -4,961,300 Computer Storage Equipment and Misc Parts, Manufacturing EMC CORP 334112 5,438,000 2 -119,000 HUTCHINSON TECHNOLOGY 334112 390,700 9 15,000 IOMEGA CORP 334112 614,400 8 34,700 KOMAG INC 334112 174,700 11 -41,900 MAXTOR CORP 334112 3,779,514 3 -334,067 NETWORK APPLIANCE INC 334112 798,400 7 3,000 QUANTUM CORP 334112 1,087,800 6 42,500 READ-RITE CORP 334112 262,800 10 -234,700 SEAGATE TECHNOLOGY INC 334112 6,087,000 1 153,000 STORAGE TECHNOLOGY 334112 2,039,600 5 110,000 WESTERN DIGITAL CORP 334112 2,151,200 4 65,400 Construction Services
37 33 15 10 19 18 36 17 4 9 21 1 25 13 34 2 27 8 28 3 23 5 29 22 32 20 38 9 6 5 8 11 7 4 10 1 2 3
Plunkett Research, Ltd.
www.plunkettresearch.com
DUALSTAR TECHNOLOGIES FOSTER WHEELER LTD
Company
230000 230000
81,200 3,519,200 2002 Sales
-9,600 3 -525,200 4 2002 Sales Profits Profits Rank Rank (thousands) 2 9,600 2 3 15,500 1
Industry Code (thousands) MICHAEL BAKER CORPORATION 230000 405,300 TRC COMPANIES INC 230000 180,100 Construction, Residential FLUOR CORP 236100 9,959,000 Consulting--Computer and Internet AMERICAN MANAGEMENT SYSTEMS INC 541512 986,700 CACI INTERNATIONAL INC 541512 681,900 COMPUTER SCIENCES CORP 541512 11,426,000 ELECTRONIC DATA SYSTEMS 541512 21,502,000 GETRONICS NV 541512 3,796,300 PERFICIENT INC 541512 20,500 PEROT SYSTEMS CORP 541512 1,332,100 TITAN CORP (THE) 541512 1,392,200 UNISYS CORP 541512 5,607,000 Consulting--Environmental OYO CORPORATION 541620 417,537 Consulting--Management and Business ACCENTURE 541611 13,105,000 Consulting--Scientific and Technical ONSITE ENERGY CORP 541690 12,100 US LABORATORIES 541690 Contract Electronics Manufacturing JABIL CIRCUIT INC 334419 3,545,500 Cutlery and Hand Tools, Manufacturing MEDTRONIC AVE INC 332210 Drugs, Manufacturing ABBOTT LABORATORIES 325412 17,685,000 ABGENIX INC 325412 39,438 ABLE LABORATORIES 325412 52,930 AKORN INC 325412 51,419 ALCON LABORATORIES INC 325412 3,009,100 ALLERGAN INC 325412 1,425,300 ALLIANCE PHARMACEUTICAL 325412 10,300 ALPHARMA INC 325412 1,238,000 ALZA CORP 325412 AMGEN INC 325412 5,523,000 AMYLIN PHARMACEUTICALS 325412 13,400 ANDRX CORP 325412 771,000 ASCENT PEDIATRICS INC 325412 ASTRAZENECA PLC 325412 17,841,000 AVENTIS SA 325412 21,659,000 BARR LABORATORIES INC 325412 1,189,000 BENTLEY PHARMACEUTICALS 325412 39,100 BIO TECHNOLOGY GENERAL 325412 103,000
4 1
1
164,000
1
7 8 2 1 4 9 6 5 3
28,200 30,400 344,000 1,116,000 -431,900 -2,400 78,300 -271,400 223,000
6 5 2 1 9 7 4 8 3
1
3,500
1
1
244,900
1
1
300
1
1
34,700
1
9 73 62 64 14 18 103 20
2,794,000 -208,898 23,446 -12,952 466,900 75,200 -34,200 -98,800
8 97 36 58 13 26 73 86
13 -1,392,000 99 -109,800 29 -91,800
102 89 83
8 6 23 74 53
2,836,000 2,285,000 212,200 1,600 9,700
7 10 17 49 41
Plunkett Research, Ltd.
www.plunkettresearch.com
BIOGEN INC BIOMARIN PHARMACEUTICAL
Company
325412 325412
Industry Code BRADLEY PHARMACEUTICALS 325412 BRISTOL MYERS SQUIBB CO 325412 CAMBREX CORP 325412 CARRINGTON LABORATORIES 325412 CELGENE CORP 325412 CELL GENESYS INC 325412 CELL THERAPEUTICS INC 325412 CENTOCOR INC 325412 CEPHALON INC 325412 CHIRON CORP 325412 CHRONIMED INC 325412 CIMA LABS INC 325412 COLLAGENEX PHARMACEUTICAL 325412 COLLATERAL THERAPEUTICS 325412 CONNETICS CORPORATION 325412 CORIXA CORPORATION 325412 CUBIST PHARMACEUTICALS 325412 CYTOGEN CORPORATION 325412 CYTYC CORP 325412 DEL LABORATORIES INC 325412 ELAN CORP PLC 325412 ELI LILLY & CO 325412 ENDO PHARMACEUTICALS HOLDINGS INC 325412 ENZON INC 325412 FIRST HORIZON PHARMACEUTICALS 325412 FOREST LABORATORIES INC 325412 GELTEX PHARMACEUTICALS 325412 GENENTECH INC 325412 GENZYME CORP 325412 GILEAD SCIENCES INC 325412 GLAXOSMITHKLINE PLC 325412 GUILFORD PHARMACEUTICALS 325412 HESKA CORP 325412 HI TECH PHARMACAL CO INC 325412 HYBRIDON INC 325412 ICN PHARMACEUTICALS INC 325412 ICOS CORPORATION 325412 IDEC PHARMACEUTICALS 325412 ILEX ONCOLOGY INC 325412 IMCLONE SYSTEMS INC 325412 IMMUNEX CORP 325412 IMPAX LABORATORIES INC 325412 ISIS PHARMACEUTICALS INC 325412 IVAX CORPORATION 325412
1,148,400 13,900 2002 Sales
25 98
39,700 18,119,000 526,900 18,041 135,700 39,100 16,900
Sales Rank 71 7 31 90 49 75 93
506,897 972,900 397,400 46,600 44,600
32 27 37 67 69
(thousands)
52,800 48,700 11,500 12,900 236,500 350,700 1,470,100 11,078,000 399,000 75,800 115,200 1,566,600
199,100 18 -77,500 80 2002 Profits Profits Rank (thousands) 7,600 42 2,066,000 11 36,200 33 -3,378 51 -100,000 87 -26,600 70 -49,900 77 171,528 180,800 3,700 18,600 900
21 19 45 38 50
63 -16,600 66 -207,400 101 -82,400 100 -15,700 42 47,900 40 19,500 17 -2,394,800 11 2,708,000 36 30,800 56 45,800 51 6,100 16 338,000
62 96 81 61 30 37 103 9 35 31 44 14
2,252,300 1,329,500 466,800 31,819,000 14,700 51,300 33,300 30,256 737,100 92,900 404,200 30,900 60,005
15 19 33 4 97 65 79 81 30 55 35 80 58
63,800 -13,100 72,100 5,903,000 -59,300 -8,700 3,500 16,472 -134,900 -161,600 148,100 -46,200 -157,949
28 59 27 4 79 53 46 39 91 95 22 75 94
24,500 58,320 1,197,200
86 59 22
-20,000 -56,413 122,800
64 78 24
Plunkett Research, Ltd.
www.plunkettresearch.com
JOHNSON & JOHNSON K V PHARMACEUTICAL CO KING PHARMACEUTICALS INC
Company KOS PHARMACEUTICALS INC LIGAND PHARMACEUTICALS MATRIX PHARMACEUTICAL MEDAREX INC MEDICIS PHARMACEUTICAL MEDIMMUNE INC MERCK & CO INC MGI PHARMA INC MILLENNIUM PHARMACEUTICALS MYLAN LABORATORIES INC NABI BIOPHARMACEUTICALS NAPRO BIOTHERAPEUTICS NEORX CORPORATION NEUROCRINE BIOSCIENCES NEUROGEN CORP NOVARTIS AG NOVEN PHARMACEUTICALS ORPHAN MEDICAL INC OSI PHARMACEUTICALS INC PENWEST PHARMACEUTICALS PFIZER INC PHARMACEUTICAL FORMULATIONS PHARMACEUTICAL RESOURCES PROTEIN DESIGN LABS INC REGENERON PHARMACEUTICALS SANGSTAT MEDICAL CORP SCHERING-PLOUGH CORP SCICLONE PHARMACEUTICALS SCIOS INC SEPRACOR INC SHIRE-BIOCHEM INC SICOR INC SUPERGEN INC SYNCOR INTERNATIONAL TARGETED GENETICS CORP TARO PHARMACEUTICAL INDUSTRIES TRANSKARYOTIC THERAPIES TRIANGLE PHARMACEUTICALS TULARIK INC UNITED THERAPEUTICS CORP VERTEX PHARMACEUTICALS VIRBAC INC WATSON PHARMACEUTICALS WYETH
325412 325412 325412 Industry Code 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412
36,298,000 204,100 1,179,500 2002 Sales (thousands)
172,700 96,600 39,500 212,800 847,700 51,790,000 28,200 353,000 1,104,100 196,000 34,200 11,100 18,000 15,700 23,151,000 55,400 16,100 21,800 42,000 32,373,000 53,600 381,600 46,400 22,000 120,100 10,180,000 17,800 107,300 239,000
2 45 24
6,597,000 3 31,500 34 255,100 16 2002 Sales Profits Profits Rank Rank (thousands) 47 -20,800 65 54 -32,600 71 72 -157,500 43 50,000 28 -1,098,000 1 7,150,000 84 -36,100 39 -590,200 26 260,300 46 2,100 78 -8,700 102 -23,100 91 -94,500 95 -23,700 5 3,546,000 60 13,900 94 -11,400 88 -218,500 70 -17,100 3 9,126,000 61 -6,900 38 79,500 68 -14,600 87 -124,400 50 6,300 12 1,974,000 92 -10,000 52 -88,100 41 -276,500
93 29 101 2 74 100 15 48 54 66 85 68 6 40 56 98 63 1 52 25 60 90 43 12 55 82 99
456,000 15,300
34 96
128,300 -49,500
23 76
19,300 211,600 36,500
89 44 76
-23,800 44,600 -139,800
69 32 92
25,300 30,100 161,100 63,800 1,223,200 14,584,000
85 82 48 57 21 10
-93,800 -23,700 -108,600 3,400 175,800 4,447,200
84 67 88 47 20 5
Plunkett Research, Ltd.
www.plunkettresearch.com
XOMA LTD ZILA INC
325412 325412
Company
29,900 34,900 2002 Sales
83 77
-33,200 -12,000 2002 Profits
72 57
Industry Sales Profits Code Rank Rank (thousands) (thousands) Electrical and Electronic Equipment, Manufacturing APPLIED MATERIALS INC 335999 5,062,000 5 269,000 2 CANON INC 335999 24,501,000 2 1,590,000 1 CUBIC CORP 335999 559,600 9 29,400 5 KEMET CORP 335999 508,600 10 27,300 6 LAM RESEARCH CORP 335999 943,100 7 -90,100 9 NOVELLUS SYSTEMS INC 335999 840,000 8 22,900 7 ROCKWELL AUTOMATION 335999 3,909,000 6 121,000 3 ROYAL PHILIPS ELECTRONICS 335999 33,421,000 1 -3,367,000 10 SANYO ELECTRIC COMPANY 335999 15,881,000 3 12,900 8 SHARP CORPORATION 335999 13,599,000 4 85,000 4 Electrical Equipment/Appliances/Tools, Manufacturing 3M COMPANY 335000 16,332,000 2 1,974,000 2 GENERAL ELECTRIC CO 335000 130,685,000 1 14,118,000 1 TELEFLEX INC 335000 2,076,200 3 125,300 3 Engineering Services ABB LTD 541310 18,295,000 2 -787,000 11 AMEY PLC 541310 ARCADIS NV 541310 880,661 12 41,700 3 BECHTEL GROUP INC 541310 13,300,000 3 CH2M HILL COMPANIES LTD 541310 1,999,000 7 29,700 4 CHIYODA CORPORATION 541310 1,066,800 10 900 8 EG&G INC 541310 900,000 11 ENGLOBAL CORP 541310 91,600 14 1,800 7 GEORG FISCHER LTD 541310 2,491,500 5 -14,400 9 GRUPO DRAGADOS 541310 5,377,960 4 380,494 1 KEITH COMPANIES INC (THE) 541310 91,600 15 7,800 6 PARSONS BRINCKERHOFF INC 541310 1,350,000 8 PHILIPP HOLZMANN GROUP 541310 TECHNIP-COFLEXIP 541310 TREVI-FINANZIARIA INDUSTRIALE SPA 541310 391,557 13 -17,269 10 URS CORPORATION 541310 2,427,800 6 55,200 2 VINCI 541310 18,423,000 1 WS ATKINS PLC 541310 1,149,500 9 16,800 5 Fibre Optic Cable and Electrical Wire CORNING INC 335921 3,164,000 1 -1,302,000 1 Fuel Cells, Solar Cells, Other Industrial Machinery, Manufacturing ASTROPOWER INC 333298 BALLARD POWER SYSTEMS 333298 90,900 2 -147,700 4 ENERGY CONVERSION DEVICES 333298 91,700 1 -20,900 1 FUELCELL ENERGY INC 333298 41,200 3 -48,800 3 PLUG POWER INC 333298 11,800 4 -47,200 2 In Vitro Diagnostic Substance, Manufacturing
Plunkett Research, Ltd.
www.plunkettresearch.com
BIOSITE INC BIOSOURCE INTERNATIONAL BOSTON BIOMEDICA INC
Company
325413 325413 325413
105,200 40,100 22,800 2002 Sales
2 6 8
13,400 2 -1,000 6 -1,500 8 2002 Profits Profits Rank (thousands) 22,200 1 600 5 -1,300 7 -3,700 9 5,000 3 -14,000 10 3,900 4 -14,401 11 -21,800 12
Industry Sales Code Rank (thousands) EPIX MEDICAL INC 325413 12,300 12 E-Z-EM INC 325413 122,100 1 HYCOR BIOMEDICAL INC 325413 18,600 10 IMMUNOMEDICS INC 325413 14,300 11 MERIDIAN BIOSCIENCE INC 325413 59,100 3 MYRIAD GENETICS INC 325413 53,800 4 NEOGEN CORPORATION 325413 41,100 5 SYNBIOTICS CORP 325413 21,671 9 VIROLOGIC INC 325413 25,300 7 VYSIS INC 325413 Laboratories and Diagnostics--Medical BIORELIANCE CORP 621511 82,400 3 10,800 ENZO BIOCHEM INC 621511 54,000 4 6,900 IDEXX LABORATORIES INC 621511 412,700 1 45,400 LIFE SCIENCES RESEARCH 621511 115,742 2 2,697 MEDTOX SCIENTIFIC INC 621511 52,000 5 11,700 Machinery, Manufacturing LINDE AG 333000 10,102,000 1 278,000 VALLEN CORP 333000 Management of Companies and Enterprises HLM DESIGN INC 551110 63,300 1 3 Medical/Dental/Surgical Equipment and Supplies, Distribution FISHER SCIENTIFIC INTERNATIONAL INC 421450 3,238,400 1 50,600 Medical/Dental/Surgical Equipment and Supplies, Manufacturing ABAXIS INC 339113 30,600 37 1,300 ACUSON CORPORATION 339113 ADAC LABORATORIES 339113 ALARIS MEDICAL INC 339113 460,300 25 8,200 ALKERMES INC 339113 54,100 32 -61,400 ANALOGIC CORP 339113 313,600 29 3,300 APOGENT TECHNOLOGIES INC 339113 1,074,600 16 121,100 ARROW INTERNATIONAL INC 339113 340,800 27 39,000 BAUSCH & LOMB INC 339113 1,816,700 8 72,500 BAXTER INTERNATIONAL INC 339113 8,110,000 1 778,000 BECKMAN COULTER INC 339113 2,059,400 7 135,500 BECTON DICKINSON & CO 339113 4,033,100 3 480,000 BIO RAD LABORATORIES INC 339113 892,700 17 67,900 BIOMET INC 339113 1,191,900 13 239,700 BOSTON SCIENTIFIC CORP 339113 2,919,000 6 373,000 CONMED CORP 339113 453,100 26 34,200 CR BARD INC 339113 1,273,800 12 155,000 DADE BEHRING INC 339113 1,281,500 11 DEPUY INC 339113
3 4 1 5 2 1
1 1 33
28 38 30 13 22 16 2 12 4 17 9 5 24 11
Plunkett Research, Ltd.
www.plunkettresearch.com
DIGENE CORPORATION EDWARDS LIFESCIENCES GUIDANT CORP
Company
339113 339113 339113
48,800 704,000 3,239,600 2002 Sales
33 20 4
-9,400 36 55,700 19 611,800 3 2002 Profits Profits Rank (thousands) 30,000 25 163,600 10 64,770 18 47,700 20 106,400 14 -4,700 34 -24,900 37
Industry Sales Code Rank (thousands) HAEMONETICS CORPORATION 339113 320,000 28 INSTRUMENTARIUM 339113 1,183,400 14 INVACARE CORP 339113 1,089,161 15 INVITROGEN CORPORATION 339113 648,600 21 KINETIC CONCEPTS INC 339113 579,000 22 LIFECORE BIOMEDICAL INC 339113 38,800 36 LUMINEX CORPORATION 339113 13,000 39 MALLINCKRODT INC 339113 MEDTRONIC INC 339113 6,411,000 2 984,000 NORTH AMERICAN SCIENTIFIC 339113 20,800 38 -5,200 QUIDEL CORP 339113 74,600 31 1,300 RESPIRONICS INC 339113 494,900 24 38,400 SOLA INTERNATIONAL INC 339113 529,500 23 19,100 ST JUDE MEDICAL INC 339113 1,589,900 9 276,300 STERIS CORP 339113 866,700 19 46,200 STRYKER CORP 339113 3,011,600 5 345,600 SUNRISE MEDICAL INC 339113 SYNOVIS LIFE TECHNOLOGIES 339113 39,962 35 3,041 TECHNE CORP 339113 130,900 30 27,100 THERAGENICS CORP 339113 41,900 34 5,600 VARIAN MEDICAL SYSTEMS 339113 873,100 18 93,600 ZIMMER HOLDINGS INC 339113 1,372,400 10 257,800 Medicinal and Botanicals, Manufacturing ATRIX LABORATORIES INC 325411 26,400 5 -18,200 HAUSER INC 325411 57,600 3 -5,400 IOMED INC 325411 11,800 7 -2,400 MARTEK BIOSCIENCES CORP 325411 45,500 4 -24,200 MEDPOINTE INC 325411 200,000 2 NBTY INC 325411 964,100 1 95,800 PURE WORLD INC 325411 18,100 6 -1,800 Oil and Natural Gas Exploration and Development BP PLC 211111 283,108,000 1 34,428,200 CHEVRONTEXACO CORP 211111 98,691,000 4 1,132,000 CONOCOPHILLIPS 211111 57,224,000 5 -295,000 ENI SPA 211111 EXXONMOBIL CORPORATION 211111 178,909,000 2 11,460,000 MARATHON OIL 211111 30,595,000 6 516,000 ROYAL DUTCH PETROLEUM 211111 107,659,000 3 5,651,000 SHELL OIL CO 211111 Online Business-to-Business or to-Consumer Intermediary WEBMD CORPORATION 514191A 925,900 1 -49,700 Optical Instrument and Lens, Manufacturing EASTMAN KODAK CO 333314 12,853,000 1 770,000
1 35 32 23 27 7 21 6 31 26 29 15 8 5 4 3 6 1 2 1 4 6 2 5 3
1 1
Plunkett Research, Ltd. POLAROID CORP
www.plunkettresearch.com
333314 Petrochemicals Manufacturing LYONDELL CHEMICAL 325110 3,262,000 1 -148,000 1 2002 2002 Company Industry Sales Sales Profits Profits Code Rank Rank (thousands) (thousands) Petroleum--Drilling Oil and Gas Wells Support GLOBAL INDUSTRIES LTD 213111 494,000 2 -29,400 1 HALLIBURTON COMPANY 213111 12,498,000 1 -998,000 2 Plastics and Rubber, Manufacturing COMPAGNIE MICHELIN 326000 16,398,000 1 GOODYEAR TIRE & RUBBER 326000 13,850,000 2 -1,106,000 1 Research and Development--Physical, Engineering and Life Sciences ALBANY MOLECULAR RESEARCH 541710 122,800 6 40,600 3 CELERA GENOMICS GROUP 541710 120,900 7 -211,800 20 CHESAPEAKE BIOLOGICAL LAB 541710 COVALENT GROUP INC 541710 24,700 16 2,500 5 COVANCE INC 541710 924,700 2 63,800 2 CURAGEN CORPORATION 541710 18,200 18 -90,400 17 DIVERSA CORPORATION 541710 31,700 14 -28,000 10 EXELIXIS INC 541710 44,300 11 -86,200 16 GENE LOGIC INC 541710 54,800 9 -24,100 9 GENOME THERAPEUTICS 541710 23,000 17 -34,000 12 INCYTE GENOMICS INC 541710 101,612 8 -136,885 18 KENDLE INTERNATIONAL INC 541710 214,000 4 -54,800 13 LEXICON GENETICS INC 541710 35,200 13 -59,700 14 LYNX THERAPEUTICS INC 541710 17,400 19 -15,500 7 MAXYGEN INC 541710 41,800 12 -33,900 11 ORCHID BIOSCIENCES INC 541710 50,400 10 -80,100 15 PANVERA LLC 541710 PARADIGM GENETICS INC 541710 17,200 20 -23,500 8 PAREXEL INTERNATIONAL 541710 564,900 3 13,200 4 PHARMACOPEIA INC 541710 124,400 5 -11,600 6 QUINTILES TRANSNATIONAL 541710 1,992,400 1 127,400 1 SEQUENOM INC 541710 30,900 15 -205,600 19 Satellite Equipment, Manufacturing HUGHES ELECTRONICS CORP 513340 8,934,900 1 -891,100 2 LORAL SPACE & COMMUNICATIONS LTD 513340 1,098,425 2 -1,469,211 3 ORBITAL SCIENCES CORP 513340 551,600 3 800 1 Steel and Metals, Manufacturing NKK CORPORATION 331000 12,466,000 1 -510,000 1 Superconducting Materials and Other Wire AMERICAN SUPERCONDUCTOR 335929 11,700 1 -57,000 1 Telecommunications Equipment, Manufacturing and Related Services ADC TELECOMMUNICATIONS 334210 1,047,700 12 -1,145,000 11 ADTRAN INC 334210 345,700 15 24,800 8 ADVANCED FIBRE COMMUNICATIONS 334210 344,100 16 31,800 7 ALCATEL USA INC 334210 CIENA CORP 334210 361,200 14 -1,597,500 12
Plunkett Research, Ltd. JDS UNIPHASE CORP LUCENT TECHNOLOGIES INC MOTOROLA INC
www.plunkettresearch.com 334210 334210 334210
1,098,200 12,321,000 26,679,000 2002 Sales
11 -8,738,300 16 6 -11,753,000 17 4 -2,485,000 14 2002 Company Industry Sales Profits Profits Code Rank Rank (thousands) (thousands) NOKIA CORPORATION 334210 31,526,000 3 3,351,000 2 NORTEL NETWORKS CORP 334210 10,560,000 7 -3,585,000 15 PROXIM CORPORATION 334210 144,700 17 -239,900 9 QUALCOMM INC 334210 3,039,600 8 359,700 4 SAMSUNG ELECTRONICS CO 334210 50,175,000 2 5,941,000 1 SCIENTIFIC ATLANTA INC 334210 1,671,100 9 104,400 6 SIEMENS AG 334210 82,865,000 1 2,561,000 3 TELEFON AB LM ERICSSON 334210 16,808,000 5 -2,192,000 13 TELLABS INC 334210 1,317,000 10 -313,100 10 UTSTARCOM INC 334210 981,800 13 107,900 5 Test Equipment/Instruments, Manufacturing ACTERNA CORPORATION 334515 1,132,700 6 -374,900 4 AGILENT TECHNOLOGIES INC 334515 6,010,000 1 -1,032,000 6 KLA TENCOR CORP 334515 1,637,300 3 216,200 2 PERKINELMER INC 334515 1,505,000 4 -151,900 3 TERADYNE INC 334515 1,222,200 5 -718,500 5 THERMO ELECTRON CORP 334515 2,086,400 2 309,700 1 Trucks, RVs and Misc. Automotive, Manufacturing AB VOLVO 336120 21,469,000 1 161,000 1
Plunkett Research, Ltd.
ALPHABETICAL INDEX If you are seeking a company by name and you do not find it on this list, please turn to the back of the book to the Index by Subsidiaries, Brand Names and Selected Affiliations. You might find your target firm there. 3COM CORP 3M COMPANY AB VOLVO ABAXIS INC ABB LTD ABBOTT LABORATORIES ABGENIX INC ABLE LABORATORIES ACCENTURE ACTERNA CORPORATION ACUSON CORPORATION ADAC LABORATORIES ADAM OPEL AG ADAPTEC INC ADC TELECOMMUNICATIONS INC ADOBE SYSTEMS INC ADTRAN INC ADVANCED FIBRE COMMUNICATIONS INC ADVANCED MICRO DEVICES INC AFFYMETRIX INC AGILENT TECHNOLOGIES INC AIR PRODUCTS & CHEMICALS INC AIRBUS SAS AKORN INC ALARIS MEDICAL INC ALBANY MOLECULAR RESEARCH ALBEMARLE CORPORATION ALCATEL USA INC ALCON LABORATORIES INC ALKERMES INC ALLERGAN INC ALLIANCE PHARMACEUTICAL CORP ALPHARMA INC ALTERA CORP ALZA CORP AMDOCS LTD AMERICAN MANAGEMENT SYSTEMS INC AMERICAN SUPERCONDUCTOR AMEY PLC AMGEN INC AMKOR TECHNOLOGY INC AMYLIN PHARMACEUTICALS INC ANALOG DEVICES INC
www.plunkettresearch.com
ANALOGIC CORP ANDRX CORP ANIKA THERAPEUTICS INC AOL TIME WARNER INC APOGENT TECHNOLOGIES INC APPLE COMPUTER INC APPLIED MATERIALS INC ARCADIS NV ARROW INTERNATIONAL INC ASCENT PEDIATRICS INC ASCENTIAL SOFTWARE CORPORATION ASPECT COMMUNICATIONS CORP ASTRAZENECA PLC ASTROPOWER INC ATMEL CORP ATRIX LABORATORIES INC AUDI AG AUTODESK INC AVAYA INC AVENTIS SA BAE SYSTEMS BALLARD POWER SYSTEMS BARR LABORATORIES INC BASF AG BAUSCH & LOMB INC BAXTER INTERNATIONAL INC BAYER AG BAYERISCHE MOTOREN WERKE AG BEA SYSTEMS INC BECHTEL GROUP INC BECKMAN COULTER INC BECTON DICKINSON & CO BENTLEY PHARMACEUTICALS INC BIO RAD LABORATORIES INC BIO TECHNOLOGY GENERAL CORP BIOGEN INC BIOMARIN PHARMACEUTICAL BIOMET INC BIORELIANCE CORP BIOSITE INC BIOSOURCE INTERNATIONAL INC BMC SOFTWARE INC BOEING CO BOMBARDIER INC BOSTON BIOMEDICA INC BOSTON SCIENTIFIC CORP BP PLC BRADLEY PHARMACEUTICALS BRISTOL MYERS SQUIBB CO BROADCOM CORP CABOT CORPORATION CACI INTERNATIONAL INC
Plunkett Research, Ltd.
CADENCE DESIGN SYSTEMS INC CAMBREX CORP CANON INC CARRINGTON LABORATORIES INC CELERA GENOMICS GROUP CELGENE CORP CELL GENESYS INC CELL THERAPEUTICS INC CENTOCOR INC CEPHALON INC CERNER CORP CH2M HILL COMPANIES LTD CHESAPEAKE BIOLOGICAL LAB CHEVRONTEXACO CORPORATION CHIRON CORP CHIYODA CORPORATION CHRONIMED INC CIENA CORP CIMA LABS INC CIRRUS LOGIC INC CISCO SYSTEMS INC CITRIX SYSTEMS INC COGNEX CORP COLLAGENEX PHARMACEUTICAL COLLATERAL THERAPEUTICS COMPAGNIE MICHELIN COMPUTER ASSOCIATES INTERNATIONAL INC COMPUTER SCIENCES CORP COMPUWARE CORP COMVERSE TECHNOLOGY INC CONMED CORP CONNETICS CORPORATION CONOCOPHILLIPS CORIXA CORPORATION CORNING INC COVALENT GROUP INC COVANCE INC CR BARD INC CUBIC CORP CUBIST PHARMACEUTICALS CURAGEN CORPORATION CYPRESS SEMICONDUCTOR CORP CYTOGEN CORPORATION CYTYC CORP DADE BEHRING INC DAIMLERCHRYSLER AG DEL LABORATORIES INC DELL COMPUTER CORPORATION DENSO CORPORATION DEPUY INC DIEBOLD INC DIGENE CORPORATION
www.plunkettresearch.com
DIVERSA CORPORATION DOW CHEMICAL COMPANY (THE) DUALSTAR TECHNOLOGIES CORPORATION E I DU PONT DE NEMOURS & CO (DUPONT) EASTMAN KODAK CO EDWARDS LIFESCIENCES CORP EG&G INC ELAN CORP PLC ELECTRONIC ARTS INC ELECTRONIC DATA SYSTEMS CORP ELECTRONICS FOR IMAGING INC ELI LILLY & CO EMC CORP ENDO PHARMACEUTICALS HOLDINGS INC ENERGY CONVERSION DEVICES INC ENGLOBAL CORP ENI SPA ENTERASYS NETWORKS INC ENZO BIOCHEM INC ENZON INC EPIX MEDICAL INC ERESEARCH TECHNOLOGY INC EXELIXIS INC EXELIXIS PLANT SCIENCES INC EXXONMOBIL CORPORATION E-Z-EM INC FIAT SPA FILENET CORP FIRST HORIZON PHARMACEUTICALS FISHER SCIENTIFIC INTERNATIONAL INC FLUOR CORP FORD MOTOR CO FOREST LABORATORIES INC FOSTER WHEELER LTD FUELCELL ENERGY INC FUJI HEAVY INDUSTRIES LTD GELTEX PHARMACEUTICALS GENE LOGIC INC GENENTECH INC GENERAL DYNAMICS GENERAL ELECTRIC CO GENERAL MOTORS CORP GENOME THERAPEUTICS CORP GENZYME CORP GEORG FISCHER LTD GERBER SCIENTIFIC INC GETRONICS NV GILEAD SCIENCES INC GLAXOSMITHKLINE PLC GLENAYRE TECHNOLOGIES INC GLOBAL INDUSTRIES LTD GOODRICH CORPORATION GOODYEAR TIRE & RUBBER COMPANY (THE)
Plunkett Research, Ltd.
GOOGLE INC GRUPO DRAGADOS GTC BIOTHERAPEUTICS INC GUIDANT CORP GUILFORD PHARMACEUTICALS INC HADCO CORP HAEMONETICS CORPORATION HALLIBURTON COMPANY HAUSER INC HESKA CORP HEWLETT-PACKARD CO HI TECH PHARMACAL CO INC HLM DESIGN INC HONDA MOTOR CO LTD HONEYWELL INTERNATIONAL INC HUGHES ELECTRONICS CORP HUTCHINSON TECHNOLOGY INC HYBRIDON INC HYCOR BIOMEDICAL INC HYUNDAI MOTOR COMPANY I2 TECHNOLOGIES INC ICN PHARMACEUTICALS INC ICOS CORPORATION IDEC PHARMACEUTICALS CORP IDEXX LABORATORIES INC IDX SYSTEMS CORP ILEX ONCOLOGY INC IMC GLOBAL INC IMCLONE SYSTEMS INC IMMUNEX CORP IMMUNOMEDICS INC IMPAX LABORATORIES INC INCYTE GENOMICS INC INFOCUS CORP INSTRUMENTARIUM INTEL CORP INTERGRAPH CORP INTERNATIONAL BUSINESS MACHINES (IBM) INTERNATIONAL RECTIFIER CORP INTUIT INC INVACARE CORP INVITROGEN CORPORATION IOMED INC IOMEGA CORP ISIS PHARMACEUTICALS INC ISUZU MOTORS LTD ITT INDUSTRIES INC IVAX CORPORATION JABIL CIRCUIT INC JDS UNIPHASE CORP JOHNSON & JOHNSON JOHNSON CONTROLS INC JUNIPER NETWORKS INC
www.plunkettresearch.com
K V PHARMACEUTICAL CO KEITH COMPANIES INC (THE) KEMET CORP KENDLE INTERNATIONAL INC KINETIC CONCEPTS INC KING PHARMACEUTICALS INC KLA TENCOR CORP KOMAG INC KOS PHARMACEUTICALS INC L3 COMMUNICATIONS HOLDINGS INC LAM RESEARCH CORP LEXICON GENETICS INC LEXMARK INT'L GROUP INC LIFE SCIENCES RESEARCH LIFECELL CORPORATION LIFECORE BIOMEDICAL INC LIGAND PHARMACEUTICALS INC LINDE AG LOCKHEED MARTIN CORP LORAL SPACE & COMMUNICATIONS LTD LSI LOGIC CORP LUCENT TECHNOLOGIES INC LUMINEX CORPORATION LYNX THERAPEUTICS INC LYONDELL CHEMICAL COMPANY MALLINCKRODT INC MARATHON OIL MARTEK BIOSCIENCES CORP MATRIX PHARMACEUTICAL MAXIM INTEGRATED PRODUCTS INC MAXTOR CORP MAXYGEN INC MAZDA MOTOR CORPORATION MEDAREX INC MEDICIS PHARMACEUTICAL CORP MEDIMMUNE INC MEDPOINTE INC MEDTOX SCIENTIFIC INC MEDTRONIC AVE INC MEDTRONIC INC MEMC ELECTRONIC MATERIALS INC MENTOR GRAPHICS CORP MERCK & CO INC MERIDIAN BIOSCIENCE INC MGI PHARMA INC MICHAEL BAKER CORPORATION MICROCHIP TECHNOLOGY INC MICRON TECHNOLOGY INC MICROSOFT CORP MILLENNIUM PHARMACEUTICALS INC MILTOPE GROUP INC MITSUBISHI MOTORS CORP MONSANTO CO
Plunkett Research, Ltd.
MOTOROLA INC MSC.SOFTWARE CORP MYLAN LABORATORIES INC MYRIAD GENETICS INC NABI BIOPHARMACEUTICALS NAPRO BIOTHERAPEUTICS INC NATIONAL SEMICONDUCTOR CORP NBTY INC NCR CORPORATION NEOGEN CORPORATION NEORX CORPORATION NETWORK APPLIANCE INC NETWORK ASSOCIATES INC NETWORK EQUIPMENT TECHNOLOGIES INC NEUROCRINE BIOSCIENCES INC NEUROGEN CORP NISSAN MOTOR CO LTD NKK CORPORATION NOKIA CORPORATION NORTEL NETWORKS CORP NORTH AMERICAN SCIENTIFIC NOVARTIS AG NOVELL INC NOVELLUS SYSTEMS INC NOVEN PHARMACEUTICALS ONSITE ENERGY CORPORATION ORACLE CORP ORBITAL SCIENCES CORP ORCHID BIOSCIENCES INC ORPHAN MEDICAL INC OSI PHARMACEUTICALS INC OYO CORPORATION PALM INC PANVERA LLC PARADIGM GENETICS INC PARAMETRIC TECHNOLOGY CORP PAREXEL INTERNATIONAL PARSONS BRINCKERHOFF INC PENWEST PHARMACEUTICALS CO PEOPLESOFT INC PERFICIENT INC PERKINELMER INC PEROT SYSTEMS CORP PFIZER INC PHARMACEUTICAL FORMULATIONS INC PHARMACEUTICAL RESOURCES INC PHARMACOPEIA INC PHILIPP HOLZMANN GROUP PITNEY BOWES INC PLUG POWER INC PMC-SIERRA INC POLAROID CORP PRAXAIR INC
www.plunkettresearch.com
PROTEIN DESIGN LABS INC PROXIM CORPORATION PSA PEUGEOT CITROEN SA PURE WORLD INC QUALCOMM INC QUANTUM CORP QUIDEL CORP QUINTILES TRANSNATIONAL CORP RADISYS CORP RATIONAL SOFTWARE CORP RAYTHEON CO READ-RITE CORP REGENERON PHARMACEUTICALS INC RESPIRONICS INC ROCKWELL AUTOMATION ROYAL DUTCH PETROLEUM CO ROYAL PHILIPS ELECTRONICS SAMSUNG ELECTRONICS CO LTD SANGSTAT MEDICAL CORP SANYO ELECTRIC COMPANY LTD SAP AKTIENGESELLSCHAFT SAS INSTITUTE SCHERING-PLOUGH CORP SCICLONE PHARMACEUTICALS SCIENTIFIC ATLANTA INC SCIOS INC SCOTTS CO SEAGATE TECHNOLOGY INC SEPRACOR INC SEQUENOM INC SEROLOGICALS CORP SHARP CORPORATION SHELL OIL CO SHIRE-BIOCHEM INC SICOR INC SIEBEL SYSTEMS INC SIEMENS AG SIGMA ALDRICH CORP SILICON GRAPHICS INC SKIDMORE OWINGS & MERRILL LLP SOLA INTERNATIONAL INC SONY CORPORATION ST JUDE MEDICAL INC STANDARD MICROSYSTEMS CORPORATION STERIS CORP STORAGE TECHNOLOGY CORP STRYKER CORP STV GROUP INC SUN MICROSYSTEMS INC SUNGARD DATA SYSTEMS INC SUNRISE MEDICAL INC SUPERGEN INC SUZUKI MOTOR CORPORATION
Plunkett Research, Ltd.
SYBASE INC SYMANTEC CORP SYMBOL TECHNOLOGIES INC SYNBIOTICS CORP SYNCOR INTERNATIONAL CORPORATION SYNGENTA AG SYNOPSYS INC SYNOVIS LIFE TECHNOLOGIES INC TARGETED GENETICS CORP TARO PHARMACEUTICAL INDUSTRIES TECHNE CORP TECHNIP-COFLEXIP TECHNITROL INC TELEFLEX INC TELEFON AB LM ERICSSON TELLABS INC TERADYNE INC TERAYON COMMUNICATION SYSTEMS INC TERRA INDUSTRIES INC TEXAS INSTRUMENTS INC THERAGENICS CORP THERMO ELECTRON CORP TITAN CORP (THE) TOYOTA MOTOR CORPORATION TRANSKARYOTIC THERAPIES TRC COMPANIES INC TREVI-FINANZIARIA INDUSTRIALE SPA TRIANGLE PHARMACEUTICALS TRIPOS INC TULARIK INC UNISYS CORP UNITED THERAPEUTICS CORP URS CORPORATION US LABORATORIES UTSTARCOM INC VALLEN CORP VARIAN MEDICAL SYSTEMS INC VERISIGN INC VERTEX PHARMACEUTICALS INC VINCI VIRBAC INC VIROLOGIC INC VISTEON CORPORATION VOLKSWAGEN AG VYSIS INC WATSON PHARMACEUTICALS INC WEBMD CORPORATION WESTERN DIGITAL CORP WS ATKINS PLC WYETH XEROX CORP XILINX INC XOMA LTD
www.plunkettresearch.com
YAHOO! INC ZILA INC ZIMMER HOLDINGS INC
Plunkett Research, Ltd.
GEOGRAPHICAL INDEXES 1) Company headquarters locations by state 2) Foreign company headquarters locations by country 3) Offices and subsidiaries by regions of the U.S. 4) Firms with international operations The headquarters locations of each company are in the following indexes to help you locate members of THE ENGINEERING AND RESEARCH 500 within the part of the country, or the world, of interest. However, companies are constantly opening and closing various locations. You should consider contacting companies that particularly interest you, to see whether they have locations in your area.
INDEX OF HEADQUARTERS LOCATION BY STATE To help you locate members of THE ENGINEERING & RESEARCH 500 geographically, the city and state of the headquarters of each company are indexed. ALABAMA ADTRAN INC; Huntsville INTERGRAPH CORP; Huntsville MILTOPE GROUP INC; Hope Hull ARIZONA MEDICIS PHARMACEUTICAL CORP; Scottsdale MICROCHIP TECHNOLOGY INC; Chandler ZILA INC; Phoenix CALIFORNIA 3COM CORP; Santa Clara ABAXIS INC; Union City ABGENIX INC; Fremont ACUSON CORPORATION; Mountain View ADAC LABORATORIES; Milpitas ADAPTEC INC; Milpitas ADOBE SYSTEMS INC; San Jose ADVANCED FIBRE COMMUNICATIONS INC; Petaluma ADVANCED MICRO DEVICES INC; Sunnyvale AFFYMETRIX INC; Santa Clara AGILENT TECHNOLOGIES INC; Palo Alto ALARIS MEDICAL INC; San Diego ALLERGAN INC; Irvine
www.plunkettresearch.com
ALLIANCE PHARMACEUTICAL CORP; San Diego ALTERA CORP; San Jose ALZA CORP; Mountain View AMGEN INC; Thousand Oaks AMYLIN PHARMACEUTICALS INC; San Diego APPLE COMPUTER INC; Cupertino APPLIED MATERIALS INC; Santa Clara ASPECT COMMUNICATIONS CORP; San Jose ATMEL CORP; San Jose AUTODESK INC; San Rafael BEA SYSTEMS INC; San Jose BECHTEL GROUP INC; San Francisco BECKMAN COULTER INC; Fullerton BIO RAD LABORATORIES INC; Hercules BIOMARIN PHARMACEUTICAL; Novato BIOSITE INC; San Diego BIOSOURCE INTERNATIONAL INC; Camarillo BROADCOM CORP; Irvine CADENCE DESIGN SYSTEMS INC; San Jose CELL GENESYS INC; South San Francisco CHEVRONTEXACO CORPORATION; San Ramon CHIRON CORP; Emeryville CISCO SYSTEMS INC; San Jose COLLATERAL THERAPEUTICS; San Diego COMPUTER SCIENCES CORP; El Segundo CONNETICS CORPORATION; Palo Alto CUBIC CORP; San Diego CYPRESS SEMICONDUCTOR CORP; San Jose DIVERSA CORPORATION; San Diego EDWARDS LIFESCIENCES CORP; Irvine ELECTRONIC ARTS INC; Redwood City ELECTRONICS FOR IMAGING INC; Foster City EXELIXIS INC; South San Francisco FILENET CORP; Costa Mesa FLUOR CORP; Aliso Viejo GENENTECH INC; South San Francisco GILEAD SCIENCES INC; Foster City GOOGLE INC; Mountain View HAUSER INC; Long Beach HEWLETT-PACKARD CO; Palo Alto HUGHES ELECTRONICS CORP; El Segundo HYCOR BIOMEDICAL INC; Garden Grove ICN PHARMACEUTICALS INC; Costa Mesa IDEC PHARMACEUTICALS CORP; San Diego IMMUNEX CORP; Thousand Oaks IMPAX LABORATORIES INC; Hayward INCYTE GENOMICS INC; Palo Alto INTEL CORP; Santa Clara INTERNATIONAL RECTIFIER CORP; El Segundo INTUIT INC; Mountain View INVITROGEN CORPORATION; Carlsbad IOMEGA CORP; San Diego
Plunkett Research, Ltd.
ISIS PHARMACEUTICALS INC; Carlsbad JDS UNIPHASE CORP; San Jose JUNIPER NETWORKS INC; Sunnyvale KEITH COMPANIES INC (THE); Irvine KLA TENCOR CORP; San Jose KOMAG INC; San Jose LAM RESEARCH CORP; Fremont LIGAND PHARMACEUTICALS INC; San Diego LSI LOGIC CORP; Milpitas LYNX THERAPEUTICS INC; Hayward MATRIX PHARMACEUTICAL; Fremont MAXIM INTEGRATED PRODUCTS INC; Sunnyvale MAXTOR CORP; Milpitas MAXYGEN INC; Redwood City MEDTRONIC AVE INC; Santa Rosa MSC.SOFTWARE CORP; Santa Ana NATIONAL SEMICONDUCTOR CORP; Santa Clara NETWORK APPLIANCE INC; Sunnyvale NETWORK ASSOCIATES INC; Santa Clara NETWORK EQUIPMENT TECHNOLOGIES INC; Fremont NEUROCRINE BIOSCIENCES INC; San Diego NORTH AMERICAN SCIENTIFIC; Chatsworth NOVELLUS SYSTEMS INC; San Jose ONSITE ENERGY CORPORATION; Carlsbad ORACLE CORP; Redwood City PALM INC; Santa Clara PEOPLESOFT INC; Pleasanton PMC-SIERRA INC; Santa Clara PROTEIN DESIGN LABS INC; Fremont PROXIM CORPORATION; Sunnyvale QUALCOMM INC; San Diego QUANTUM CORP; Milpitas QUIDEL CORP; San Diego RATIONAL SOFTWARE CORP; Cupertino READ-RITE CORP; Freemont SANGSTAT MEDICAL CORP; Fremont SCICLONE PHARMACEUTICALS; San Mateo SCIOS INC; Sunnyvale SEAGATE TECHNOLOGY INC; Scotts Valley SEQUENOM INC; San Diego SICOR INC; Irvine SIEBEL SYSTEMS INC; San Mateo SILICON GRAPHICS INC; Mountain View SOLA INTERNATIONAL INC; San Diego SUN MICROSYSTEMS INC; Palo Alto SUNRISE MEDICAL INC; Carlsbad SUPERGEN INC; Dublin SYBASE INC; Dublin SYMANTEC CORP; Cupertino SYNBIOTICS CORP; San Diego
www.plunkettresearch.com
SYNCOR INTERNATIONAL CORPORATION; Woodland Hills SYNOPSYS INC; Mountain View TERAYON COMMUNICATION SYSTEMS INC; Santa Clara TITAN CORP (THE); San Diego TULARIK INC; South San Francisco URS CORPORATION; San Francisco US LABORATORIES; San Diego UTSTARCOM INC; Alameda VARIAN MEDICAL SYSTEMS INC; Palo Alto VERISIGN INC; Mountain View VIROLOGIC INC; South San Francisco WATSON PHARMACEUTICALS INC; Corona WESTERN DIGITAL CORP; Lake Forest XILINX INC; San Jose XOMA LTD; Berkeley YAHOO! INC; Sunnyvale COLORADO ATRIX LABORATORIES INC; Fort Collins CH2M HILL COMPANIES LTD; Englewood HESKA CORP; Fort Collins NAPRO BIOTHERAPEUTICS INC; Boulder STORAGE TECHNOLOGY CORP; Louisville CONNECTICUT CURAGEN CORPORATION; New Haven FUELCELL ENERGY INC; Danbury GENERAL ELECTRIC CO; Fairfield GERBER SCIENTIFIC INC; South Windsor NEUROGEN CORP; Branford PENWEST PHARMACEUTICALS CO; Danbury PITNEY BOWES INC; Stamford PRAXAIR INC; Danbury TRC COMPANIES INC; Windsor XEROX CORP; Stamford DELAWARE ASTROPOWER INC; Newark E I DU PONT DE NEMOURS & CO (DUPONT); Wilmington FLORIDA ANDRX CORP; Davie CITRIX SYSTEMS INC; Fort Lauderdale IVAX CORPORATION; Miami JABIL CIRCUIT INC; St. Petersburg KOS PHARMACEUTICALS INC; Miami NABI BIOPHARMACEUTICALS; Boca Raton NOVEN PHARMACEUTICALS; Miami
Plunkett Research, Ltd.
GEORGIA FIRST HORIZON PHARMACEUTICALS; Alpharetta GLENAYRE TECHNOLOGIES INC; Duluth SCIENTIFIC ATLANTA INC; Lawrenceville SEROLOGICALS CORP; Norcross THERAGENICS CORP; Buford IDAHO MICRON TECHNOLOGY INC; Boise ILLINOIS ABBOTT LABORATORIES; Abbott Park AKORN INC; Buffalo Grove BAXTER INTERNATIONAL INC; Deerfield BOEING CO; Chicago DADE BEHRING INC; Deerfield IMC GLOBAL INC; Lake Forest MOTOROLA INC; Schaumburg TELLABS INC; Naperville VYSIS INC; Downers Grove INDIANA BIOMET INC; Warsaw DEPUY INC; Warsaw ELI LILLY & CO; Indianapolis GUIDANT CORP; Indianapolis ZIMMER HOLDINGS INC; Warsaw IOWA TERRA INDUSTRIES INC; Sioux City KENTUCKY LEXMARK INT'L GROUP INC; Lexington LOUISIANA GLOBAL INDUSTRIES LTD; Carlyss MAINE IDEXX LABORATORIES INC; Westbrook MARYLAND ACTERNA CORPORATION; Germantown BIORELIANCE CORP; Rockville CELERA GENOMICS GROUP; Rockville CHESAPEAKE BIOLOGICAL LAB; Baltimore CIENA CORP; Linthicum DIGENE CORPORATION; Gaithersburg EG&G INC; Gaithersburg GENE LOGIC INC; Gaithersburg GUILFORD PHARMACEUTICALS INC; Baltimore LOCKHEED MARTIN CORP; Bethesda MARTEK BIOSCIENCES CORP; Columbia
www.plunkettresearch.com
MEDIMMUNE INC; Gaithersburg UNITED THERAPEUTICS CORP; Silver Spring MASSACHUSETTS ABLE LABORATORIES; Needham ALKERMES INC; Cambridge AMERICAN SUPERCONDUCTOR; Westborough ANALOG DEVICES INC; Norwood ANALOGIC CORP; Peabody ANIKA THERAPEUTICS INC; Woburn ASCENT PEDIATRICS INC; Wilmington ASCENTIAL SOFTWARE CORPORATION; Westboro BIOGEN INC; Cambridge BOSTON BIOMEDICA INC; West Bridgewater BOSTON SCIENTIFIC CORP; Natick CABOT CORPORATION; Boston COGNEX CORP; Natick CUBIST PHARMACEUTICALS; Lexington CYTYC CORP; Boxborough EMC CORP; Hopkinton EPIX MEDICAL INC; Cambridge GELTEX PHARMACEUTICALS; Waltham GENOME THERAPEUTICS CORP; Waltham GENZYME CORP; Cambridge GTC BIOTHERAPEUTICS INC; Framingham HAEMONETICS CORPORATION; Braintree HYBRIDON INC; Cambridge MILLENNIUM PHARMACEUTICALS INC; Cambridge PARAMETRIC TECHNOLOGY CORP; Needham PAREXEL INTERNATIONAL; Waltham PERKINELMER INC; Wellesley POLAROID CORP; Waltham RAYTHEON CO; Lexington SEPRACOR INC; Marlborough TERADYNE INC; Boston THERMO ELECTRON CORP; Waltham TRANSKARYOTIC THERAPIES; Cambridge VERTEX PHARMACEUTICALS INC; Cambridge MICHIGAN COMPUWARE CORP; Farmington Hills DOW CHEMICAL COMPANY (THE); Midland ENERGY CONVERSION DEVICES INC; Rochester Hills FORD MOTOR CO; Dearborn GENERAL MOTORS CORP; Detroit NEOGEN CORPORATION; Lansing STRYKER CORP; Kalamazoo VISTEON CORPORATION; Dearborn
Plunkett Research, Ltd.
www.plunkettresearch.com
MINNESOTA 3M COMPANY; St. Paul ADC TELECOMMUNICATIONS INC; Eden Prarie CHRONIMED INC; Minnetonka CIMA LABS INC; Eden Prairie HUTCHINSON TECHNOLOGY INC; Hutchinson LIFECORE BIOMEDICAL INC; Chaska MEDTOX SCIENTIFIC INC; St. Paul MEDTRONIC INC; Minneapolis MGI PHARMA INC; Bloomington ORPHAN MEDICAL INC; Minnetonka ST JUDE MEDICAL INC; St. Paul SYNOVIS LIFE TECHNOLOGIES INC; St. Paul TECHNE CORP; Minneapolis
LIFE SCIENCES RESEARCH; East Millstone LIFECELL CORPORATION; Branchburg LUCENT TECHNOLOGIES INC; Murray Hill MEDAREX INC; Princeton MEDPOINTE INC; Somerset MERCK & CO INC; Whitehouse Station ORCHID BIOSCIENCES INC; Princeton PHARMACEUTICAL FORMULATIONS INC; Edison PHARMACOPEIA INC; Cranbury PURE WORLD INC; Bedminster SCHERING-PLOUGH CORP; Kenilworth WEBMD CORPORATION; Elmwood Park WYETH; Madison
MISSOURI AMDOCS LTD; Chesterfield CERNER CORP; Kansas City K V PHARMACEUTICAL CO; St. Louis MALLINCKRODT INC; Hazelwood MEMC ELECTRONIC MATERIALS INC; St. Peters MONSANTO CO; St. Louis SIGMA ALDRICH CORP; St. Louis TRIPOS INC; St. Louis
NEW YORK ALBANY MOLECULAR RESEARCH; Albany AOL TIME WARNER INC; New York BARR LABORATORIES INC; Pomona BAUSCH & LOMB INC; Rochester BRISTOL MYERS SQUIBB CO; New York COMPUTER ASSOCIATES INTERNATIONAL INC; Islandia COMVERSE TECHNOLOGY INC; Woodbury CONMED CORP; Utica CORNING INC; Corning DEL LABORATORIES INC; Uniondale DUALSTAR TECHNOLOGIES CORPORATION; Long Island City EASTMAN KODAK CO; Rochester ENZO BIOCHEM INC; Farmingdale E-Z-EM INC; Westbury FOREST LABORATORIES INC; New York HI TECH PHARMACAL CO INC; Amityville IMCLONE SYSTEMS INC; New York INTERNATIONAL BUSINESS MACHINES (IBM); Armonk ITT INDUSTRIES INC; White Plains L3 COMMUNICATIONS HOLDINGS INC; New York LORAL SPACE & COMMUNICATIONS LTD; New York NBTY INC; Bohemia OSI PHARMACEUTICALS INC; Melville PARSONS BRINCKERHOFF INC; New York PFIZER INC; New York PHARMACEUTICAL RESOURCES INC; Spring Valley PLUG POWER INC; Latham REGENERON PHARMACEUTICALS INC; Tarrytown SKIDMORE OWINGS & MERRILL LLP; New York
NEW HAMPSHIRE APOGENT TECHNOLOGIES INC; Portsmouth BENTLEY PHARMACEUTICALS INC; North Hampton ENTERASYS NETWORKS INC; Rochester FISHER SCIENTIFIC INTERNATIONAL INC; Hampton HADCO CORP; Salem NEW JERSEY ALPHARMA INC; Fort Lee AVAYA INC; Basking Ridge BECTON DICKINSON & CO; Franklin Lakes BIO TECHNOLOGY GENERAL CORP; East Brunswick BRADLEY PHARMACEUTICALS; Fairfield CAMBREX CORP; East Rutherford CELGENE CORP; Warren COVANCE INC; Princeton CR BARD INC; Murray Hill CYTOGEN CORPORATION; Princeton ENZON INC; Bridgewater FOSTER WHEELER LTD; Clinton HONEYWELL INTERNATIONAL INC; Morristown IMMUNOMEDICS INC; Morris Plains JOHNSON & JOHNSON; New Brunswick
Plunkett Research, Ltd.
STANDARD MICROSYSTEMS CORPORATION; Hauppauge SYMBOL TECHNOLOGIES INC; Holtsville NORTH CAROLINA GOODRICH CORPORATION; Charlotte HLM DESIGN INC; Charlotte PARADIGM GENETICS INC; Research Triangle Park QUINTILES TRANSNATIONAL CORP; Durham SAS INSTITUTE; Cary TRIANGLE PHARMACEUTICALS; Durham OHIO DIEBOLD INC; North Canton GOODYEAR TIRE & RUBBER COMPANY (THE); Akron INVACARE CORP; Elyria KENDLE INTERNATIONAL INC; Cincinnati MERIDIAN BIOSCIENCE INC; Cincinnati NCR CORPORATION; Dayton SCOTTS CO; Marysville STERIS CORP; Mentor OREGON EXELIXIS PLANT SCIENCES INC; Portland INFOCUS CORP; Wilsonville MENTOR GRAPHICS CORP; Wilsonville RADISYS CORP; Hillsboro PENNSYLVANIA AIR PRODUCTS & CHEMICALS INC; Allentown AMKOR TECHNOLOGY INC; West Chester ARROW INTERNATIONAL INC; Reading CENTOCOR INC; Malvern CEPHALON INC; West Chester COLLAGENEX PHARMACEUTICAL; Newton COVALENT GROUP INC; Wayne ENDO PHARMACEUTICALS HOLDINGS INC; Chadds Ford ERESEARCH TECHNOLOGY INC; Philadelphia MICHAEL BAKER CORPORATION; Moon Township MYLAN LABORATORIES INC; Canonsburg RESPIRONICS INC; Murrysville STV GROUP INC; Douglassville SUNGARD DATA SYSTEMS INC; Wayne TECHNITROL INC; Trevose TELEFLEX INC; Plymouth Meeting UNISYS CORP; Blue Bell SOUTH CAROLINA KEMET CORP; Simpsonville
www.plunkettresearch.com
TENNESSEE KING PHARMACEUTICALS INC; Bristol TEXAS ALCATEL USA INC; Plano ALCON LABORATORIES INC; Ft. Worth BMC SOFTWARE INC; Houston CARRINGTON LABORATORIES INC; Irving CIRRUS LOGIC INC; Austin CONOCOPHILLIPS; Houston DELL COMPUTER CORPORATION; Round Rock ELECTRONIC DATA SYSTEMS CORP; Plano ENGLOBAL CORP; Houston EXXONMOBIL CORPORATION; Irving HALLIBURTON COMPANY; Houston I2 TECHNOLOGIES INC; Dallas ILEX ONCOLOGY INC; San Antonio KINETIC CONCEPTS INC; San Antonio LEXICON GENETICS INC; The Woodlands LUMINEX CORPORATION; Austin LYONDELL CHEMICAL COMPANY; Houston MARATHON OIL; Houston PERFICIENT INC; Austin PEROT SYSTEMS CORP; Plano SHELL OIL CO; Houston TEXAS INSTRUMENTS INC; Dallas VALLEN CORP; Houston VIRBAC INC; Fort Worth UTAH IOMED INC; Salt Lake City MYRIAD GENETICS INC; Salt Lake City NOVELL INC; Provo VERMONT IDX SYSTEMS CORP; Burlington VIRGINIA ALBEMARLE CORPORATION; Richmond AMERICAN MANAGEMENT SYSTEMS INC; Fairfax CACI INTERNATIONAL INC; Arlington GENERAL DYNAMICS; Falls Church ORBITAL SCIENCES CORP; Dulles WASHINGTON CELL THERAPEUTICS INC; Seattle CORIXA CORPORATION; Seattle ICOS CORPORATION; Bothell MICROSOFT CORP; Redmond NEORX CORPORATION; Seattle TARGETED GENETICS CORP; Seattle
Plunkett Research, Ltd.
WISCONSIN JOHNSON CONTROLS INC; Milwaukee PANVERA LLC; Madison ROCKWELL AUTOMATION; Milwaukee
www.plunkettresearch.com
INDEX OF HEADQUARTERS LOCATION BY COUNTRY To help you locate members of THE ENGINEERING & RESEARCH 500 that have nonU.S. headquarters, the city and country of the headquarters of such companies are included in the following index. BERMUDA ACCENTURE; Hamilton CANADA BALLARD POWER SYSTEMS; Burnaby BOMBARDIER INC; Montreal NORTEL NETWORKS CORP; Brampton SHIRE-BIOCHEM INC; Laval FINLAND INSTRUMENTARIUM; Helsinki NOKIA CORPORATION; Espoo FRANCE AIRBUS SAS; Blagnac Cedex AVENTIS SA; Schiltingheim COMPAGNIE MICHELIN; Clermont-Ferrand PSA PEUGEOT CITROEN SA; Paris TECHNIP-COFLEXIP; Paris La Defense Cedex VINCI; Rueil-Malmaison Cedex GERMANY ADAM OPEL AG; Rüsselsheim AUDI AG; Ingolstadt BASF AG; Ludwigshafen BAYER AG; Leverkusen BAYERISCHE MOTOREN WERKE AG; Munich DAIMLERCHRYSLER AG; Stuttgart LINDE AG; Wiesbaden PHILIPP HOLZMANN GROUP; Frankfurt SAP AKTIENGESELLSCHAFT; Walldorf SIEMENS AG; Munich VOLKSWAGEN AG; Wolfsburg IRELAND ELAN CORP PLC; Dublin ISRAEL TARO PHARMACEUTICAL INDUSTRIES; Haifa Bay ITALY ENI SPA; Rome FIAT SPA; Turin
Plunkett Research, Ltd.
TREVI-FINANZIARIA INDUSTRIALE SPA; Cesena JAPAN CANON INC; Tokyo CHIYODA CORPORATION; Yokohama DENSO CORPORATION; Aichi FUJI HEAVY INDUSTRIES LTD; Tokyo HONDA MOTOR CO LTD; Tokyo ISUZU MOTORS LTD; Tokyo MAZDA MOTOR CORPORATION; Hiroshima MITSUBISHI MOTORS CORP; Tokyo NISSAN MOTOR CO LTD; Tokyo NKK CORPORATION; Tokyo OYO CORPORATION; Tokyo SANYO ELECTRIC COMPANY LTD; Moriguchi City, Osaka SHARP CORPORATION; Osaka SONY CORPORATION; Tokyo SUZUKI MOTOR CORPORATION; Shizuoka TOYOTA MOTOR CORPORATION; Toyota SOUTH KOREA HYUNDAI MOTOR COMPANY; Seoul SAMSUNG ELECTRONICS CO LTD; Seoul SPAIN GRUPO DRAGADOS; Madrid SWEDEN AB VOLVO; Gothenburg TELEFON AB LM ERICSSON; Stockholm SWITZERLAND ABB LTD; Zurich GEORG FISCHER LTD; Schaffhausen NOVARTIS AG; Basel SYNGENTA AG; Basel THE NETHERLANDS ARCADIS NV; Arnhem GETRONICS NV; Amsterdam ROYAL DUTCH PETROLEUM CO; The Hague ROYAL PHILIPS ELECTRONICS; Amsterdam UNITED KINGDOM AMEY PLC; Abingdon ASTRAZENECA PLC; London BAE SYSTEMS; Farnborough BP PLC; London GLAXOSMITHKLINE PLC; Brentford WS ATKINS PLC; Epsom
www.plunkettresearch.com
INDEX BY REGIONS OF THE U.S. WHERE THE ENGINEERING & RESEARCH 500 FIRMS HAVE LOCATIONS WEST 3COM CORP 3M COMPANY AB VOLVO ABAXIS INC ABBOTT LABORATORIES ABGENIX INC ACCENTURE ACTERNA CORPORATION ACUSON CORPORATION ADAC LABORATORIES ADAPTEC INC ADC TELECOMMUNICATIONS INC ADOBE SYSTEMS INC ADTRAN INC ADVANCED FIBRE COMMUNICATIONS INC ADVANCED MICRO DEVICES INC AFFYMETRIX INC AGILENT TECHNOLOGIES INC AIR PRODUCTS & CHEMICALS INC AKORN INC ALARIS MEDICAL INC ALCATEL USA INC ALCON LABORATORIES INC ALLERGAN INC ALLIANCE PHARMACEUTICAL CORP ALPHARMA INC ALTERA CORP ALZA CORP AMDOCS LTD AMERICAN MANAGEMENT SYSTEMS INC AMGEN INC AMKOR TECHNOLOGY INC AMYLIN PHARMACEUTICALS INC ANALOG DEVICES INC AOL TIME WARNER INC APOGENT TECHNOLOGIES INC APPLE COMPUTER INC APPLIED MATERIALS INC ARCADIS NV ARROW INTERNATIONAL INC ASPECT COMMUNICATIONS CORP ASTRAZENECA PLC ASTROPOWER INC ATMEL CORP ATRIX LABORATORIES INC
Plunkett Research, Ltd.
AUDI AG AUTODESK INC AVAYA INC AVENTIS SA BAE SYSTEMS BASF AG BAUSCH & LOMB INC BAXTER INTERNATIONAL INC BAYER AG BAYERISCHE MOTOREN WERKE AG BEA SYSTEMS INC BECHTEL GROUP INC BECKMAN COULTER INC BECTON DICKINSON & CO BIO RAD LABORATORIES INC BIO TECHNOLOGY GENERAL CORP BIOMARIN PHARMACEUTICAL BIOMET INC BIOSITE INC BIOSOURCE INTERNATIONAL INC BMC SOFTWARE INC BOEING CO BOMBARDIER INC BOSTON BIOMEDICA INC BOSTON SCIENTIFIC CORP BP PLC BRISTOL MYERS SQUIBB CO BROADCOM CORP CACI INTERNATIONAL INC CADENCE DESIGN SYSTEMS INC CANON INC CELL GENESYS INC CELL THERAPEUTICS INC CEPHALON INC CERNER CORP CH2M HILL COMPANIES LTD CHEVRONTEXACO CORPORATION CHIRON CORP CHRONIMED INC CIENA CORP CIRRUS LOGIC INC CISCO SYSTEMS INC CITRIX SYSTEMS INC COGNEX CORP COLLATERAL THERAPEUTICS COMPAGNIE MICHELIN COMPUTER ASSOCIATES INTERNATIONAL INC COMPUTER SCIENCES CORP COMPUWARE CORP COMVERSE TECHNOLOGY INC CONMED CORP CONNETICS CORPORATION
www.plunkettresearch.com
CONOCOPHILLIPS CORIXA CORPORATION CORNING INC COVANCE INC CR BARD INC CUBIC CORP CYPRESS SEMICONDUCTOR CORP DADE BEHRING INC DAIMLERCHRYSLER AG DELL COMPUTER CORPORATION DENSO CORPORATION DEPUY INC DIEBOLD INC DIVERSA CORPORATION DOW CHEMICAL COMPANY (THE) E I DU PONT DE NEMOURS & CO (DUPONT) EASTMAN KODAK CO EDWARDS LIFESCIENCES CORP EG&G INC ELAN CORP PLC ELECTRONIC ARTS INC ELECTRONIC DATA SYSTEMS CORP ELECTRONICS FOR IMAGING INC ELI LILLY & CO EMC CORP ENERGY CONVERSION DEVICES INC ENTERASYS NETWORKS INC EXELIXIS INC EXELIXIS PLANT SCIENCES INC EXXONMOBIL CORPORATION FILENET CORP FISHER SCIENTIFIC INTERNATIONAL INC FLUOR CORP FORD MOTOR CO FOSTER WHEELER LTD FUELCELL ENERGY INC FUJI HEAVY INDUSTRIES LTD GENE LOGIC INC GENENTECH INC GENERAL DYNAMICS GENERAL ELECTRIC CO GENERAL MOTORS CORP GENZYME CORP GEORG FISCHER LTD GILEAD SCIENCES INC GLAXOSMITHKLINE PLC GLENAYRE TECHNOLOGIES INC GOODRICH CORPORATION GOODYEAR TIRE & RUBBER COMPANY (THE) GOOGLE INC GUIDANT CORP HADCO CORP HALLIBURTON COMPANY
Plunkett Research, Ltd.
HAUSER INC HESKA CORP HEWLETT-PACKARD CO HLM DESIGN INC HONDA MOTOR CO LTD HONEYWELL INTERNATIONAL INC HUGHES ELECTRONICS CORP HYCOR BIOMEDICAL INC HYUNDAI MOTOR COMPANY I2 TECHNOLOGIES INC ICN PHARMACEUTICALS INC ICOS CORPORATION IDEC PHARMACEUTICALS CORP IDEXX LABORATORIES INC IDX SYSTEMS CORP IMMUNEX CORP IMPAX LABORATORIES INC INCYTE GENOMICS INC INFOCUS CORP INTEL CORP INTERGRAPH CORP INTERNATIONAL BUSINESS MACHINES (IBM) INTERNATIONAL RECTIFIER CORP INTUIT INC INVACARE CORP INVITROGEN CORPORATION IOMED INC IOMEGA CORP ISIS PHARMACEUTICALS INC ISUZU MOTORS LTD ITT INDUSTRIES INC IVAX CORPORATION JABIL CIRCUIT INC JDS UNIPHASE CORP JOHNSON & JOHNSON JOHNSON CONTROLS INC JUNIPER NETWORKS INC KEITH COMPANIES INC (THE) KENDLE INTERNATIONAL INC KLA TENCOR CORP KOMAG INC L3 COMMUNICATIONS HOLDINGS INC LAM RESEARCH CORP LEXMARK INT'L GROUP INC LIGAND PHARMACEUTICALS INC LOCKHEED MARTIN CORP LORAL SPACE & COMMUNICATIONS LTD LSI LOGIC CORP LUCENT TECHNOLOGIES INC LYNX THERAPEUTICS INC MALLINCKRODT INC MARATHON OIL MARTEK BIOSCIENCES CORP
www.plunkettresearch.com
MATRIX PHARMACEUTICAL MAXIM INTEGRATED PRODUCTS INC MAXTOR CORP MAXYGEN INC MEDAREX INC MEDIMMUNE INC MEDTRONIC AVE INC MEDTRONIC INC MEMC ELECTRONIC MATERIALS INC MENTOR GRAPHICS CORP MERCK & CO INC MICHAEL BAKER CORPORATION MICROCHIP TECHNOLOGY INC MICRON TECHNOLOGY INC MICROSOFT CORP MILLENNIUM PHARMACEUTICALS INC MILTOPE GROUP INC MITSUBISHI MOTORS CORP MONSANTO CO MOTOROLA INC MSC.SOFTWARE CORP MYRIAD GENETICS INC NABI BIOPHARMACEUTICALS NAPRO BIOTHERAPEUTICS INC NATIONAL SEMICONDUCTOR CORP NBTY INC NEORX CORPORATION NETWORK APPLIANCE INC NETWORK ASSOCIATES INC NETWORK EQUIPMENT TECHNOLOGIES INC NEUROCRINE BIOSCIENCES INC NISSAN MOTOR CO LTD NOKIA CORPORATION NORTEL NETWORKS CORP NORTH AMERICAN SCIENTIFIC NOVELL INC NOVELLUS SYSTEMS INC ONSITE ENERGY CORPORATION ORACLE CORP ORBITAL SCIENCES CORP OSI PHARMACEUTICALS INC OYO CORPORATION PALM INC PARAMETRIC TECHNOLOGY CORP PAREXEL INTERNATIONAL PARSONS BRINCKERHOFF INC PEOPLESOFT INC PERKINELMER INC PEROT SYSTEMS CORP PFIZER INC PHARMACOPEIA INC PITNEY BOWES INC PMC-SIERRA INC
Plunkett Research, Ltd.
POLAROID CORP PRAXAIR INC PROTEIN DESIGN LABS INC PROXIM CORPORATION QUALCOMM INC QUANTUM CORP QUIDEL CORP QUINTILES TRANSNATIONAL CORP RADISYS CORP RATIONAL SOFTWARE CORP RAYTHEON CO READ-RITE CORP RESPIRONICS INC ROCKWELL AUTOMATION ROYAL DUTCH PETROLEUM CO ROYAL PHILIPS ELECTRONICS SAMSUNG ELECTRONICS CO LTD SANGSTAT MEDICAL CORP SANYO ELECTRIC COMPANY LTD SAP AKTIENGESELLSCHAFT SAS INSTITUTE SCHERING-PLOUGH CORP SCICLONE PHARMACEUTICALS SCIENTIFIC ATLANTA INC SCIOS INC SCOTTS CO SEAGATE TECHNOLOGY INC SEQUENOM INC SEROLOGICALS CORP SHELL OIL CO SICOR INC SIEBEL SYSTEMS INC SIEMENS AG SIGMA ALDRICH CORP SILICON GRAPHICS INC SKIDMORE OWINGS & MERRILL LLP SOLA INTERNATIONAL INC SONY CORPORATION ST JUDE MEDICAL INC STANDARD MICROSYSTEMS CORPORATION STERIS CORP STORAGE TECHNOLOGY CORP STRYKER CORP STV GROUP INC SUN MICROSYSTEMS INC SUNGARD DATA SYSTEMS INC SUNRISE MEDICAL INC SUPERGEN INC SUZUKI MOTOR CORPORATION SYBASE INC SYMANTEC CORP SYMBOL TECHNOLOGIES INC SYNBIOTICS CORP
www.plunkettresearch.com
SYNCOR INTERNATIONAL CORPORATION SYNGENTA AG SYNOPSYS INC TARGETED GENETICS CORP TECHNIP-COFLEXIP TECHNITROL INC TELEFLEX INC TELEFON AB LM ERICSSON TELLABS INC TERADYNE INC TERAYON COMMUNICATION SYSTEMS INC TEXAS INSTRUMENTS INC THERMO ELECTRON CORP TITAN CORP (THE) TOYOTA MOTOR CORPORATION TRC COMPANIES INC TRIPOS INC TULARIK INC UNISYS CORP URS CORPORATION US LABORATORIES UTSTARCOM INC VALLEN CORP VARIAN MEDICAL SYSTEMS INC VERISIGN INC VERTEX PHARMACEUTICALS INC VIROLOGIC INC WATSON PHARMACEUTICALS INC WESTERN DIGITAL CORP WS ATKINS PLC WYETH XEROX CORP XILINX INC XOMA LTD YAHOO! INC ZIMMER HOLDINGS INC
SOUTHWEST 3COM CORP 3M COMPANY ABBOTT LABORATORIES ACCENTURE ACUSON CORPORATION ADAC LABORATORIES ADC TELECOMMUNICATIONS INC ADTRAN INC ADVANCED FIBRE COMMUNICATIONS INC ADVANCED MICRO DEVICES INC AFFYMETRIX INC AGILENT TECHNOLOGIES INC AIR PRODUCTS & CHEMICALS INC AIRBUS SAS ALARIS MEDICAL INC
Plunkett Research, Ltd.
ALBEMARLE CORPORATION ALCATEL USA INC ALCON LABORATORIES INC ALLERGAN INC ALPHARMA INC ALTERA CORP AMDOCS LTD AMERICAN MANAGEMENT SYSTEMS INC AMYLIN PHARMACEUTICALS INC ANALOG DEVICES INC AOL TIME WARNER INC APOGENT TECHNOLOGIES INC APPLE COMPUTER INC APPLIED MATERIALS INC ARCADIS NV ASPECT COMMUNICATIONS CORP ASTRAZENECA PLC ATMEL CORP AUDI AG AVAYA INC AVENTIS SA BAUSCH & LOMB INC BAXTER INTERNATIONAL INC BAYERISCHE MOTOREN WERKE AG BEA SYSTEMS INC BECHTEL GROUP INC BECKMAN COULTER INC BECTON DICKINSON & CO BIO RAD LABORATORIES INC BIO TECHNOLOGY GENERAL CORP BIOMET INC BMC SOFTWARE INC BOEING CO BOMBARDIER INC BOSTON SCIENTIFIC CORP BP PLC BRISTOL MYERS SQUIBB CO BROADCOM CORP CABOT CORPORATION CACI INTERNATIONAL INC CADENCE DESIGN SYSTEMS INC CANON INC CARRINGTON LABORATORIES INC CERNER CORP CH2M HILL COMPANIES LTD CHEVRONTEXACO CORPORATION CHIRON CORP CHRONIMED INC CIENA CORP CIRRUS LOGIC INC CISCO SYSTEMS INC CITRIX SYSTEMS INC
www.plunkettresearch.com
COMPUTER ASSOCIATES INTERNATIONAL INC COMPUTER SCIENCES CORP COMPUWARE CORP COMVERSE TECHNOLOGY INC CONMED CORP CONNETICS CORPORATION CONOCOPHILLIPS CORNING INC CR BARD INC CYPRESS SEMICONDUCTOR CORP DADE BEHRING INC DAIMLERCHRYSLER AG DELL COMPUTER CORPORATION DENSO CORPORATION DEPUY INC DIEBOLD INC DOW CHEMICAL COMPANY (THE) E I DU PONT DE NEMOURS & CO (DUPONT) EASTMAN KODAK CO EG&G INC ELAN CORP PLC ELECTRONIC ARTS INC ELECTRONIC DATA SYSTEMS CORP ELI LILLY & CO EMC CORP ENGLOBAL CORP ENI SPA ENTERASYS NETWORKS INC EXXONMOBIL CORPORATION FILENET CORP FISHER SCIENTIFIC INTERNATIONAL INC FLUOR CORP FORD MOTOR CO FOSTER WHEELER LTD FUELCELL ENERGY INC GENENTECH INC GENERAL DYNAMICS GENERAL ELECTRIC CO GENERAL MOTORS CORP GENZYME CORP GERBER SCIENTIFIC INC GLAXOSMITHKLINE PLC GLENAYRE TECHNOLOGIES INC GLOBAL INDUSTRIES LTD GOODRICH CORPORATION GOODYEAR TIRE & RUBBER COMPANY (THE) GOOGLE INC GUIDANT CORP HADCO CORP HALLIBURTON COMPANY HEWLETT-PACKARD CO HLM DESIGN INC
Plunkett Research, Ltd.
HONDA MOTOR CO LTD HONEYWELL INTERNATIONAL INC HUGHES ELECTRONICS CORP I2 TECHNOLOGIES INC IDEXX LABORATORIES INC IDX SYSTEMS CORP ILEX ONCOLOGY INC IMC GLOBAL INC IMMUNEX CORP INTEL CORP INTERGRAPH CORP INTERNATIONAL BUSINESS MACHINES (IBM) INTUIT INC INVACARE CORP IOMEGA CORP ISUZU MOTORS LTD ITT INDUSTRIES INC IVAX CORPORATION JABIL CIRCUIT INC JDS UNIPHASE CORP JOHNSON & JOHNSON JOHNSON CONTROLS INC KEITH COMPANIES INC (THE) KINETIC CONCEPTS INC LAM RESEARCH CORP LEXICON GENETICS INC LEXMARK INT'L GROUP INC LINDE AG LOCKHEED MARTIN CORP LORAL SPACE & COMMUNICATIONS LTD LSI LOGIC CORP LUCENT TECHNOLOGIES INC LUMINEX CORPORATION LYONDELL CHEMICAL COMPANY MALLINCKRODT INC MARATHON OIL MAXIM INTEGRATED PRODUCTS INC MEDICIS PHARMACEUTICAL CORP MEDTRONIC INC MEMC ELECTRONIC MATERIALS INC MENTOR GRAPHICS CORP MERCK & CO INC MICHAEL BAKER CORPORATION MICROCHIP TECHNOLOGY INC MICRON TECHNOLOGY INC MICROSOFT CORP MITSUBISHI MOTORS CORP MONSANTO CO MOTOROLA INC MSC.SOFTWARE CORP NABI BIOPHARMACEUTICALS NATIONAL SEMICONDUCTOR CORP NBTY INC
www.plunkettresearch.com
NEORX CORPORATION NETWORK ASSOCIATES INC NETWORK EQUIPMENT TECHNOLOGIES INC NISSAN MOTOR CO LTD NOKIA CORPORATION NORTEL NETWORKS CORP NOVELL INC NOVELLUS SYSTEMS INC ORACLE CORP ORBITAL SCIENCES CORP ORCHID BIOSCIENCES INC OYO CORPORATION PARAMETRIC TECHNOLOGY CORP PARSONS BRINCKERHOFF INC PEOPLESOFT INC PERFICIENT INC PERKINELMER INC PEROT SYSTEMS CORP PFIZER INC PITNEY BOWES INC PMC-SIERRA INC POLAROID CORP PRAXAIR INC QUALCOMM INC QUANTUM CORP QUINTILES TRANSNATIONAL CORP RADISYS CORP RATIONAL SOFTWARE CORP RAYTHEON CO RESPIRONICS INC ROCKWELL AUTOMATION ROYAL DUTCH PETROLEUM CO ROYAL PHILIPS ELECTRONICS SAMSUNG ELECTRONICS CO LTD SAP AKTIENGESELLSCHAFT SAS INSTITUTE SCHERING-PLOUGH CORP SCOTTS CO SEAGATE TECHNOLOGY INC SHELL OIL CO SIEBEL SYSTEMS INC SIEMENS AG SIGMA ALDRICH CORP SILICON GRAPHICS INC SONY CORPORATION ST JUDE MEDICAL INC STANDARD MICROSYSTEMS CORPORATION STERIS CORP STORAGE TECHNOLOGY CORP STV GROUP INC SUN MICROSYSTEMS INC SUNGARD DATA SYSTEMS INC SYBASE INC
Plunkett Research, Ltd.
SYMBOL TECHNOLOGIES INC SYNCOR INTERNATIONAL CORPORATION SYNOPSYS INC TECHNIP-COFLEXIP TELEFLEX INC TELEFON AB LM ERICSSON TELLABS INC TERADYNE INC TERRA INDUSTRIES INC TEXAS INSTRUMENTS INC THERMO ELECTRON CORP TITAN CORP (THE) TOYOTA MOTOR CORPORATION TRC COMPANIES INC UNISYS CORP URS CORPORATION US LABORATORIES VALLEN CORP VIRBAC INC VISTEON CORPORATION WESTERN DIGITAL CORP WS ATKINS PLC WYETH XEROX CORP XILINX INC YAHOO! INC ZILA INC ZIMMER HOLDINGS INC
MIDWEST 3COM CORP 3M COMPANY ABBOTT LABORATORIES ACCENTURE ACTERNA CORPORATION ACUSON CORPORATION ADAC LABORATORIES ADAPTEC INC ADC TELECOMMUNICATIONS INC ADTRAN INC ADVANCED FIBRE COMMUNICATIONS INC ADVANCED MICRO DEVICES INC AFFYMETRIX INC AGILENT TECHNOLOGIES INC AIR PRODUCTS & CHEMICALS INC AIRBUS SAS AKORN INC ALARIS MEDICAL INC ALBANY MOLECULAR RESEARCH ALBEMARLE CORPORATION ALCATEL USA INC ALKERMES INC ALLERGAN INC
www.plunkettresearch.com
ALPHARMA INC ALTERA CORP AMDOCS LTD AMERICAN MANAGEMENT SYSTEMS INC AMERICAN SUPERCONDUCTOR AMGEN INC AMKOR TECHNOLOGY INC AMYLIN PHARMACEUTICALS INC ANALOG DEVICES INC ANALOGIC CORP AOL TIME WARNER INC APOGENT TECHNOLOGIES INC APPLE COMPUTER INC ARCADIS NV ASPECT COMMUNICATIONS CORP ASTRAZENECA PLC ATMEL CORP AUDI AG AVAYA INC AVENTIS SA BAE SYSTEMS BARR LABORATORIES INC BASF AG BAUSCH & LOMB INC BAXTER INTERNATIONAL INC BAYER AG BAYERISCHE MOTOREN WERKE AG BEA SYSTEMS INC BECHTEL GROUP INC BECKMAN COULTER INC BECTON DICKINSON & CO BIO RAD LABORATORIES INC BIOMET INC BMC SOFTWARE INC BOEING CO BOMBARDIER INC BOSTON SCIENTIFIC CORP BP PLC BRISTOL MYERS SQUIBB CO BROADCOM CORP CABOT CORPORATION CACI INTERNATIONAL INC CADENCE DESIGN SYSTEMS INC CAMBREX CORP CANON INC CERNER CORP CH2M HILL COMPANIES LTD CHEVRONTEXACO CORPORATION CHIRON CORP CHRONIMED INC CIENA CORP CIMA LABS INC CIRRUS LOGIC INC
Plunkett Research, Ltd.
CISCO SYSTEMS INC CITRIX SYSTEMS INC COGNEX CORP COMPAGNIE MICHELIN COMPUTER ASSOCIATES INTERNATIONAL INC COMPUTER SCIENCES CORP COMPUWARE CORP COMVERSE TECHNOLOGY INC CONOCOPHILLIPS CORNING INC COVANCE INC CR BARD INC CUBIC CORP CYPRESS SEMICONDUCTOR CORP DADE BEHRING INC DAIMLERCHRYSLER AG DELL COMPUTER CORPORATION DENSO CORPORATION DEPUY INC DIEBOLD INC DOW CHEMICAL COMPANY (THE) E I DU PONT DE NEMOURS & CO (DUPONT) EASTMAN KODAK CO EG&G INC ELAN CORP PLC ELECTRONIC ARTS INC ELECTRONIC DATA SYSTEMS CORP ELECTRONICS FOR IMAGING INC ELI LILLY & CO EMC CORP ENERGY CONVERSION DEVICES INC ENTERASYS NETWORKS INC EXXONMOBIL CORPORATION FILENET CORP FISHER SCIENTIFIC INTERNATIONAL INC FLUOR CORP FORD MOTOR CO FOREST LABORATORIES INC FOSTER WHEELER LTD FUELCELL ENERGY INC FUJI HEAVY INDUSTRIES LTD GENENTECH INC GENERAL DYNAMICS GENERAL ELECTRIC CO GENERAL MOTORS CORP GENZYME CORP GEORG FISCHER LTD GLAXOSMITHKLINE PLC GLENAYRE TECHNOLOGIES INC GOODRICH CORPORATION GOODYEAR TIRE & RUBBER COMPANY (THE) GOOGLE INC
www.plunkettresearch.com
GUIDANT CORP HADCO CORP HALLIBURTON COMPANY HESKA CORP HEWLETT-PACKARD CO HLM DESIGN INC HONDA MOTOR CO LTD HONEYWELL INTERNATIONAL INC HUGHES ELECTRONICS CORP HUTCHINSON TECHNOLOGY INC HYUNDAI MOTOR COMPANY I2 TECHNOLOGIES INC ICN PHARMACEUTICALS INC IDEXX LABORATORIES INC IDX SYSTEMS CORP IMC GLOBAL INC IMMUNEX CORP INCYTE GENOMICS INC INSTRUMENTARIUM INTEL CORP INTERGRAPH CORP INTERNATIONAL BUSINESS MACHINES (IBM) INTUIT INC INVACARE CORP ISUZU MOTORS LTD ITT INDUSTRIES INC IVAX CORPORATION JABIL CIRCUIT INC JDS UNIPHASE CORP JOHNSON & JOHNSON JOHNSON CONTROLS INC JUNIPER NETWORKS INC K V PHARMACEUTICAL CO KEITH COMPANIES INC (THE) KENDLE INTERNATIONAL INC KING PHARMACEUTICALS INC L3 COMMUNICATIONS HOLDINGS INC LAM RESEARCH CORP LEXMARK INT'L GROUP INC LIFECORE BIOMEDICAL INC LINDE AG LOCKHEED MARTIN CORP LORAL SPACE & COMMUNICATIONS LTD LSI LOGIC CORP LUCENT TECHNOLOGIES INC LYONDELL CHEMICAL COMPANY MALLINCKRODT INC MARATHON OIL MAXIM INTEGRATED PRODUCTS INC MAZDA MOTOR CORPORATION MEDPOINTE INC MEDTOX SCIENTIFIC INC MEDTRONIC INC
Plunkett Research, Ltd.
MEMC ELECTRONIC MATERIALS INC MENTOR GRAPHICS CORP MERCK & CO INC MERIDIAN BIOSCIENCE INC MGI PHARMA INC MICHAEL BAKER CORPORATION MICROCHIP TECHNOLOGY INC MICRON TECHNOLOGY INC MICROSOFT CORP MITSUBISHI MOTORS CORP MONSANTO CO MOTOROLA INC MSC.SOFTWARE CORP MYLAN LABORATORIES INC NABI BIOPHARMACEUTICALS NATIONAL SEMICONDUCTOR CORP NBTY INC NCR CORPORATION NEOGEN CORPORATION NETWORK ASSOCIATES INC NISSAN MOTOR CO LTD NOKIA CORPORATION NORTEL NETWORKS CORP NOVARTIS AG NOVELL INC NOVELLUS SYSTEMS INC ORACLE CORP ORPHAN MEDICAL INC PALM INC PANVERA LLC PARAMETRIC TECHNOLOGY CORP PAREXEL INTERNATIONAL PARSONS BRINCKERHOFF INC PEOPLESOFT INC PERFICIENT INC PERKINELMER INC PEROT SYSTEMS CORP PFIZER INC PITNEY BOWES INC PMC-SIERRA INC POLAROID CORP PRAXAIR INC PROTEIN DESIGN LABS INC QUALCOMM INC QUANTUM CORP QUINTILES TRANSNATIONAL CORP RADISYS CORP RATIONAL SOFTWARE CORP RAYTHEON CO RESPIRONICS INC ROCKWELL AUTOMATION ROYAL DUTCH PETROLEUM CO ROYAL PHILIPS ELECTRONICS
www.plunkettresearch.com
SAP AKTIENGESELLSCHAFT SAS INSTITUTE SCHERING-PLOUGH CORP SCOTTS CO SEAGATE TECHNOLOGY INC SEROLOGICALS CORP SHARP CORPORATION SHELL OIL CO SIEBEL SYSTEMS INC SIEMENS AG SIGMA ALDRICH CORP SILICON GRAPHICS INC SKIDMORE OWINGS & MERRILL LLP SONY CORPORATION ST JUDE MEDICAL INC STANDARD MICROSYSTEMS CORPORATION STERIS CORP STORAGE TECHNOLOGY CORP STRYKER CORP STV GROUP INC SUN MICROSYSTEMS INC SUNGARD DATA SYSTEMS INC SUNRISE MEDICAL INC SYBASE INC SYMANTEC CORP SYMBOL TECHNOLOGIES INC SYNCOR INTERNATIONAL CORPORATION SYNGENTA AG SYNOPSYS INC SYNOVIS LIFE TECHNOLOGIES INC TECHNE CORP TELEFLEX INC TELLABS INC TERADYNE INC TERRA INDUSTRIES INC TEXAS INSTRUMENTS INC THERMO ELECTRON CORP TITAN CORP (THE) TOYOTA MOTOR CORPORATION TRC COMPANIES INC TRIPOS INC UNISYS CORP UNITED THERAPEUTICS CORP URS CORPORATION US LABORATORIES VALLEN CORP VERISIGN INC VISTEON CORPORATION VYSIS INC WATSON PHARMACEUTICALS INC WESTERN DIGITAL CORP WS ATKINS PLC WYETH
Plunkett Research, Ltd.
XEROX CORP XILINX INC YAHOO! INC ZILA INC ZIMMER HOLDINGS INC
SOUTHEAST 3COM CORP 3M COMPANY AB VOLVO ABBOTT LABORATORIES ACCENTURE ACTERNA CORPORATION ACUSON CORPORATION ADAC LABORATORIES ADAPTEC INC ADC TELECOMMUNICATIONS INC ADTRAN INC ADVANCED FIBRE COMMUNICATIONS INC ADVANCED MICRO DEVICES INC AFFYMETRIX INC AGILENT TECHNOLOGIES INC AIR PRODUCTS & CHEMICALS INC ALARIS MEDICAL INC ALBEMARLE CORPORATION ALCATEL USA INC ALCON LABORATORIES INC ALLERGAN INC ALPHARMA INC ALTERA CORP AMDOCS LTD AMERICAN MANAGEMENT SYSTEMS INC AMKOR TECHNOLOGY INC AMYLIN PHARMACEUTICALS INC ANALOG DEVICES INC ANDRX CORP AOL TIME WARNER INC APOGENT TECHNOLOGIES INC APPLE COMPUTER INC APPLIED MATERIALS INC ARCADIS NV ASPECT COMMUNICATIONS CORP ASTRAZENECA PLC ASTROPOWER INC AUDI AG AUTODESK INC AVAYA INC AVENTIS SA BAE SYSTEMS BASF AG BAUSCH & LOMB INC BAXTER INTERNATIONAL INC BAYER AG
www.plunkettresearch.com
BAYERISCHE MOTOREN WERKE AG BEA SYSTEMS INC BECHTEL GROUP INC BECKMAN COULTER INC BECTON DICKINSON & CO BIO RAD LABORATORIES INC BIO TECHNOLOGY GENERAL CORP BIOMET INC BMC SOFTWARE INC BOEING CO BOMBARDIER INC BOSTON SCIENTIFIC CORP BP PLC BRISTOL MYERS SQUIBB CO BROADCOM CORP CABOT CORPORATION CACI INTERNATIONAL INC CADENCE DESIGN SYSTEMS INC CERNER CORP CH2M HILL COMPANIES LTD CHEVRONTEXACO CORPORATION CHIRON CORP CHRONIMED INC CIENA CORP CIRRUS LOGIC INC CISCO SYSTEMS INC CITRIX SYSTEMS INC COGNEX CORP COMPAGNIE MICHELIN COMPUTER ASSOCIATES INTERNATIONAL INC COMPUTER SCIENCES CORP COMPUWARE CORP COMVERSE TECHNOLOGY INC CONMED CORP CONOCOPHILLIPS CORNING INC CR BARD INC CUBIC CORP CYPRESS SEMICONDUCTOR CORP DADE BEHRING INC DAIMLERCHRYSLER AG DELL COMPUTER CORPORATION DENSO CORPORATION DEPUY INC DIEBOLD INC DOW CHEMICAL COMPANY (THE) E I DU PONT DE NEMOURS & CO (DUPONT) EASTMAN KODAK CO EDWARDS LIFESCIENCES CORP EG&G INC ELAN CORP PLC ELECTRONIC ARTS INC
Plunkett Research, Ltd.
ELECTRONIC DATA SYSTEMS CORP ELI LILLY & CO EMC CORP ENTERASYS NETWORKS INC EXXONMOBIL CORPORATION FILENET CORP FIRST HORIZON PHARMACEUTICALS FISHER SCIENTIFIC INTERNATIONAL INC FLUOR CORP FORD MOTOR CO FOSTER WHEELER LTD FUELCELL ENERGY INC GENENTECH INC GENERAL DYNAMICS GENERAL ELECTRIC CO GENERAL MOTORS CORP GENZYME CORP GEORG FISCHER LTD GLAXOSMITHKLINE PLC GLENAYRE TECHNOLOGIES INC GLOBAL INDUSTRIES LTD GOODRICH CORPORATION GOODYEAR TIRE & RUBBER COMPANY (THE) GOOGLE INC HADCO CORP HAEMONETICS CORPORATION HALLIBURTON COMPANY HEWLETT-PACKARD CO HLM DESIGN INC HONDA MOTOR CO LTD HONEYWELL INTERNATIONAL INC HUGHES ELECTRONICS CORP HYUNDAI MOTOR COMPANY I2 TECHNOLOGIES INC IDEXX LABORATORIES INC IDX SYSTEMS CORP IMC GLOBAL INC IMMUNEX CORP INTEL CORP INTERGRAPH CORP INTERNATIONAL BUSINESS MACHINES (IBM) INTUIT INC INVACARE CORP ISUZU MOTORS LTD ITT INDUSTRIES INC IVAX CORPORATION JABIL CIRCUIT INC JDS UNIPHASE CORP JOHNSON & JOHNSON JOHNSON CONTROLS INC KEMET CORP KING PHARMACEUTICALS INC KOS PHARMACEUTICALS INC
www.plunkettresearch.com
L3 COMMUNICATIONS HOLDINGS INC LAM RESEARCH CORP LEXMARK INT'L GROUP INC LINDE AG LOCKHEED MARTIN CORP LORAL SPACE & COMMUNICATIONS LTD LSI LOGIC CORP LUCENT TECHNOLOGIES INC LYONDELL CHEMICAL COMPANY MALLINCKRODT INC MARATHON OIL MARTEK BIOSCIENCES CORP MAXIM INTEGRATED PRODUCTS INC MAZDA MOTOR CORPORATION MEDTRONIC INC MENTOR GRAPHICS CORP MERCK & CO INC MERIDIAN BIOSCIENCE INC MICHAEL BAKER CORPORATION MICROCHIP TECHNOLOGY INC MICRON TECHNOLOGY INC MICROSOFT CORP MILTOPE GROUP INC MITSUBISHI MOTORS CORP MONSANTO CO MOTOROLA INC MSC.SOFTWARE CORP MYLAN LABORATORIES INC NABI BIOPHARMACEUTICALS NATIONAL SEMICONDUCTOR CORP NBTY INC NEOGEN CORPORATION NETWORK ASSOCIATES INC NISSAN MOTOR CO LTD NOKIA CORPORATION NORTEL NETWORKS CORP NOVARTIS AG NOVELL INC NOVELLUS SYSTEMS INC NOVEN PHARMACEUTICALS ORACLE CORP ORBITAL SCIENCES CORP PARADIGM GENETICS INC PARAMETRIC TECHNOLOGY CORP PAREXEL INTERNATIONAL PARSONS BRINCKERHOFF INC PEOPLESOFT INC PERKINELMER INC PEROT SYSTEMS CORP PFIZER INC PITNEY BOWES INC PMC-SIERRA INC POLAROID CORP
Plunkett Research, Ltd.
PRAXAIR INC PROXIM CORPORATION QUALCOMM INC QUANTUM CORP QUINTILES TRANSNATIONAL CORP RADISYS CORP RATIONAL SOFTWARE CORP RAYTHEON CO RESPIRONICS INC ROCKWELL AUTOMATION ROYAL DUTCH PETROLEUM CO ROYAL PHILIPS ELECTRONICS SAP AKTIENGESELLSCHAFT SAS INSTITUTE SCHERING-PLOUGH CORP SCIENTIFIC ATLANTA INC SCOTTS CO SEROLOGICALS CORP SHELL OIL CO SIEBEL SYSTEMS INC SIEMENS AG SIGMA ALDRICH CORP SILICON GRAPHICS INC SOLA INTERNATIONAL INC SONY CORPORATION ST JUDE MEDICAL INC STERIS CORP STORAGE TECHNOLOGY CORP STRYKER CORP STV GROUP INC SUN MICROSYSTEMS INC SUNGARD DATA SYSTEMS INC SUNRISE MEDICAL INC SYBASE INC SYMANTEC CORP SYMBOL TECHNOLOGIES INC SYNCOR INTERNATIONAL CORPORATION SYNGENTA AG SYNOPSYS INC TECHNIP-COFLEXIP TELEFLEX INC TELLABS INC TERRA INDUSTRIES INC TEXAS INSTRUMENTS INC THERAGENICS CORP THERMO ELECTRON CORP TITAN CORP (THE) TOYOTA MOTOR CORPORATION TRC COMPANIES INC UNISYS CORP URS CORPORATION US LABORATORIES VALLEN CORP
www.plunkettresearch.com
VERISIGN INC VISTEON CORPORATION WATSON PHARMACEUTICALS INC WESTERN DIGITAL CORP WS ATKINS PLC WYETH XEROX CORP XILINX INC YAHOO! INC ZIMMER HOLDINGS INC
NORTHEAST 3COM CORP 3M COMPANY AB VOLVO ABB LTD ABBOTT LABORATORIES ABLE LABORATORIES ACCENTURE ACTERNA CORPORATION ACUSON CORPORATION ADAC LABORATORIES ADAPTEC INC ADC TELECOMMUNICATIONS INC ADTRAN INC ADVANCED FIBRE COMMUNICATIONS INC ADVANCED MICRO DEVICES INC AFFYMETRIX INC AGILENT TECHNOLOGIES INC AIR PRODUCTS & CHEMICALS INC AIRBUS SAS AKORN INC ALARIS MEDICAL INC ALBANY MOLECULAR RESEARCH ALBEMARLE CORPORATION ALCATEL USA INC ALCON LABORATORIES INC ALKERMES INC ALLERGAN INC ALPHARMA INC ALTERA CORP AMDOCS LTD AMERICAN MANAGEMENT SYSTEMS INC AMERICAN SUPERCONDUCTOR AMGEN INC AMKOR TECHNOLOGY INC AMYLIN PHARMACEUTICALS INC ANALOG DEVICES INC ANALOGIC CORP ANIKA THERAPEUTICS INC AOL TIME WARNER INC APOGENT TECHNOLOGIES INC APPLE COMPUTER INC
Plunkett Research, Ltd.
APPLIED MATERIALS INC ARCADIS NV ARROW INTERNATIONAL INC ASCENT PEDIATRICS INC ASCENTIAL SOFTWARE CORPORATION ASPECT COMMUNICATIONS CORP ASTRAZENECA PLC ASTROPOWER INC ATMEL CORP AUDI AG AVAYA INC AVENTIS SA BAE SYSTEMS BARR LABORATORIES INC BASF AG BAUSCH & LOMB INC BAXTER INTERNATIONAL INC BAYER AG BAYERISCHE MOTOREN WERKE AG BEA SYSTEMS INC BECHTEL GROUP INC BECKMAN COULTER INC BECTON DICKINSON & CO BENTLEY PHARMACEUTICALS INC BIO RAD LABORATORIES INC BIO TECHNOLOGY GENERAL CORP BIOGEN INC BIOMET INC BIORELIANCE CORP BIOSOURCE INTERNATIONAL INC BMC SOFTWARE INC BOEING CO BOMBARDIER INC BOSTON BIOMEDICA INC BOSTON SCIENTIFIC CORP BP PLC BRADLEY PHARMACEUTICALS BRISTOL MYERS SQUIBB CO BROADCOM CORP CABOT CORPORATION CACI INTERNATIONAL INC CADENCE DESIGN SYSTEMS INC CAMBREX CORP CANON INC CELERA GENOMICS GROUP CELGENE CORP CENTOCOR INC CEPHALON INC CERNER CORP CH2M HILL COMPANIES LTD CHESAPEAKE BIOLOGICAL LAB CHEVRONTEXACO CORPORATION CHIRON CORP
www.plunkettresearch.com
CHRONIMED INC CIENA CORP CIRRUS LOGIC INC CISCO SYSTEMS INC CITRIX SYSTEMS INC COGNEX CORP COLLAGENEX PHARMACEUTICAL COMPAGNIE MICHELIN COMPUTER ASSOCIATES INTERNATIONAL INC COMPUTER SCIENCES CORP COMPUWARE CORP COMVERSE TECHNOLOGY INC CONMED CORP CONOCOPHILLIPS CORNING INC COVALENT GROUP INC COVANCE INC CR BARD INC CUBIC CORP CUBIST PHARMACEUTICALS CURAGEN CORPORATION CYTOGEN CORPORATION CYTYC CORP DADE BEHRING INC DAIMLERCHRYSLER AG DEL LABORATORIES INC DELL COMPUTER CORPORATION DENSO CORPORATION DEPUY INC DIEBOLD INC DIGENE CORPORATION DOW CHEMICAL COMPANY (THE) DUALSTAR TECHNOLOGIES CORPORATION E I DU PONT DE NEMOURS & CO (DUPONT) EASTMAN KODAK CO EG&G INC ELAN CORP PLC ELECTRONIC ARTS INC ELECTRONIC DATA SYSTEMS CORP ELECTRONICS FOR IMAGING INC ELI LILLY & CO EMC CORP ENDO PHARMACEUTICALS HOLDINGS INC ENI SPA ENTERASYS NETWORKS INC ENZO BIOCHEM INC ENZON INC EPIX MEDICAL INC ERESEARCH TECHNOLOGY INC EXXONMOBIL CORPORATION E-Z-EM INC FILENET CORP
Plunkett Research, Ltd.
FISHER SCIENTIFIC INTERNATIONAL INC FLUOR CORP FORD MOTOR CO FOREST LABORATORIES INC FOSTER WHEELER LTD FUELCELL ENERGY INC FUJI HEAVY INDUSTRIES LTD GELTEX PHARMACEUTICALS GENE LOGIC INC GENENTECH INC GENERAL DYNAMICS GENERAL ELECTRIC CO GENERAL MOTORS CORP GENOME THERAPEUTICS CORP GENZYME CORP GEORG FISCHER LTD GERBER SCIENTIFIC INC GETRONICS NV GILEAD SCIENCES INC GLAXOSMITHKLINE PLC GLENAYRE TECHNOLOGIES INC GOODRICH CORPORATION GOODYEAR TIRE & RUBBER COMPANY (THE) GOOGLE INC GTC BIOTHERAPEUTICS INC GUILFORD PHARMACEUTICALS INC HADCO CORP HAEMONETICS CORPORATION HALLIBURTON COMPANY HAUSER INC HESKA CORP HEWLETT-PACKARD CO HI TECH PHARMACAL CO INC HLM DESIGN INC HONDA MOTOR CO LTD HONEYWELL INTERNATIONAL INC HUGHES ELECTRONICS CORP HYBRIDON INC HYUNDAI MOTOR COMPANY I2 TECHNOLOGIES INC ICN PHARMACEUTICALS INC IDEXX LABORATORIES INC IDX SYSTEMS CORP ILEX ONCOLOGY INC IMC GLOBAL INC IMCLONE SYSTEMS INC IMMUNEX CORP IMMUNOMEDICS INC IMPAX LABORATORIES INC INCYTE GENOMICS INC INTEL CORP INTERGRAPH CORP INTERNATIONAL BUSINESS MACHINES (IBM)
www.plunkettresearch.com
INTERNATIONAL RECTIFIER CORP INTUIT INC INVACARE CORP ITT INDUSTRIES INC IVAX CORPORATION JABIL CIRCUIT INC JDS UNIPHASE CORP JOHNSON & JOHNSON JOHNSON CONTROLS INC JUNIPER NETWORKS INC KENDLE INTERNATIONAL INC KLA TENCOR CORP KOS PHARMACEUTICALS INC L3 COMMUNICATIONS HOLDINGS INC LAM RESEARCH CORP LEXICON GENETICS INC LEXMARK INT'L GROUP INC LIFE SCIENCES RESEARCH LIFECELL CORPORATION LINDE AG LOCKHEED MARTIN CORP LORAL SPACE & COMMUNICATIONS LTD LSI LOGIC CORP LUCENT TECHNOLOGIES INC LYONDELL CHEMICAL COMPANY MALLINCKRODT INC MARTEK BIOSCIENCES CORP MAXIM INTEGRATED PRODUCTS INC MAXTOR CORP MEDAREX INC MEDIMMUNE INC MEDPOINTE INC MEDTOX SCIENTIFIC INC MEDTRONIC INC MENTOR GRAPHICS CORP MERCK & CO INC MERIDIAN BIOSCIENCE INC MICHAEL BAKER CORPORATION MICROCHIP TECHNOLOGY INC MICRON TECHNOLOGY INC MICROSOFT CORP MILLENNIUM PHARMACEUTICALS INC MILTOPE GROUP INC MITSUBISHI MOTORS CORP MONSANTO CO MOTOROLA INC MSC.SOFTWARE CORP MYLAN LABORATORIES INC NABI BIOPHARMACEUTICALS NATIONAL SEMICONDUCTOR CORP NBTY INC NEOGEN CORPORATION NETWORK APPLIANCE INC
Plunkett Research, Ltd.
NETWORK ASSOCIATES INC NETWORK EQUIPMENT TECHNOLOGIES INC NEUROGEN CORP NISSAN MOTOR CO LTD NOKIA CORPORATION NORTEL NETWORKS CORP NORTH AMERICAN SCIENTIFIC NOVARTIS AG NOVELL INC NOVELLUS SYSTEMS INC ONSITE ENERGY CORPORATION ORACLE CORP ORBITAL SCIENCES CORP ORCHID BIOSCIENCES INC OSI PHARMACEUTICALS INC OYO CORPORATION PARAMETRIC TECHNOLOGY CORP PAREXEL INTERNATIONAL PARSONS BRINCKERHOFF INC PENWEST PHARMACEUTICALS CO PEOPLESOFT INC PERKINELMER INC PEROT SYSTEMS CORP PFIZER INC PHARMACEUTICAL FORMULATIONS INC PHARMACEUTICAL RESOURCES INC PHARMACOPEIA INC PITNEY BOWES INC PLUG POWER INC PMC-SIERRA INC POLAROID CORP PRAXAIR INC PROTEIN DESIGN LABS INC PROXIM CORPORATION PSA PEUGEOT CITROEN SA PURE WORLD INC QUALCOMM INC QUANTUM CORP QUINTILES TRANSNATIONAL CORP RADISYS CORP RATIONAL SOFTWARE CORP RAYTHEON CO REGENERON PHARMACEUTICALS INC RESPIRONICS INC ROCKWELL AUTOMATION ROYAL DUTCH PETROLEUM CO ROYAL PHILIPS ELECTRONICS SAMSUNG ELECTRONICS CO LTD SANGSTAT MEDICAL CORP SAP AKTIENGESELLSCHAFT SAS INSTITUTE SCHERING-PLOUGH CORP SCIENTIFIC ATLANTA INC
www.plunkettresearch.com
SCOTTS CO SEAGATE TECHNOLOGY INC SEPRACOR INC SEQUENOM INC SEROLOGICALS CORP SHELL OIL CO SHIRE-BIOCHEM INC SIEBEL SYSTEMS INC SIEMENS AG SIGMA ALDRICH CORP SILICON GRAPHICS INC SKIDMORE OWINGS & MERRILL LLP SOLA INTERNATIONAL INC SONY CORPORATION ST JUDE MEDICAL INC STANDARD MICROSYSTEMS CORPORATION STERIS CORP STORAGE TECHNOLOGY CORP STRYKER CORP STV GROUP INC SUN MICROSYSTEMS INC SUNGARD DATA SYSTEMS INC SUNRISE MEDICAL INC SYBASE INC SYMANTEC CORP SYMBOL TECHNOLOGIES INC SYNCOR INTERNATIONAL CORPORATION SYNGENTA AG SYNOPSYS INC TARO PHARMACEUTICAL INDUSTRIES TECHNITROL INC TELEFLEX INC TELEFON AB LM ERICSSON TELLABS INC TERADYNE INC TEXAS INSTRUMENTS INC THERMO ELECTRON CORP TITAN CORP (THE) TOYOTA MOTOR CORPORATION TRANSKARYOTIC THERAPIES TRC COMPANIES INC TREVI-FINANZIARIA INDUSTRIALE SPA TRIANGLE PHARMACEUTICALS TRIPOS INC TULARIK INC UNISYS CORP UNITED THERAPEUTICS CORP URS CORPORATION US LABORATORIES UTSTARCOM INC VALLEN CORP VERISIGN INC VERTEX PHARMACEUTICALS INC
Plunkett Research, Ltd.
VISTEON CORPORATION WATSON PHARMACEUTICALS INC WEBMD CORPORATION WESTERN DIGITAL CORP WS ATKINS PLC WYETH XEROX CORP XILINX INC YAHOO! INC ZIMMER HOLDINGS INC
www.plunkettresearch.com
INDEX OF FIRMS WITH INTERNATIONAL OPERATIONS 3COM CORP 3M COMPANY AB VOLVO ABAXIS INC ABB LTD ABBOTT LABORATORIES ACCENTURE ACTERNA CORPORATION ACUSON CORPORATION ADAC LABORATORIES ADAM OPEL AG ADAPTEC INC ADC TELECOMMUNICATIONS INC ADOBE SYSTEMS INC ADTRAN INC ADVANCED FIBRE COMMUNICATIONS INC ADVANCED MICRO DEVICES INC AFFYMETRIX INC AGILENT TECHNOLOGIES INC AIR PRODUCTS & CHEMICALS INC AIRBUS SAS ALARIS MEDICAL INC ALBEMARLE CORPORATION ALCATEL USA INC ALCON LABORATORIES INC ALKERMES INC ALLERGAN INC ALPHARMA INC ALTERA CORP ALZA CORP AMDOCS LTD AMERICAN MANAGEMENT SYSTEMS INC AMERICAN SUPERCONDUCTOR AMEY PLC AMGEN INC AMKOR TECHNOLOGY INC AMYLIN PHARMACEUTICALS INC ANALOG DEVICES INC ANALOGIC CORP AOL TIME WARNER INC APOGENT TECHNOLOGIES INC APPLE COMPUTER INC APPLIED MATERIALS INC ARCADIS NV ARROW INTERNATIONAL INC ASCENTIAL SOFTWARE CORPORATION ASPECT COMMUNICATIONS CORP ASTRAZENECA PLC ASTROPOWER INC
Plunkett Research, Ltd.
ATMEL CORP AUDI AG AUTODESK INC AVAYA INC AVENTIS SA BAE SYSTEMS BALLARD POWER SYSTEMS BASF AG BAUSCH & LOMB INC BAXTER INTERNATIONAL INC BAYER AG BAYERISCHE MOTOREN WERKE AG BEA SYSTEMS INC BECHTEL GROUP INC BECKMAN COULTER INC BECTON DICKINSON & CO BENTLEY PHARMACEUTICALS INC BIO RAD LABORATORIES INC BIO TECHNOLOGY GENERAL CORP BIOGEN INC BIOMARIN PHARMACEUTICAL BIOMET INC BIORELIANCE CORP BIOSOURCE INTERNATIONAL INC BMC SOFTWARE INC BOEING CO BOMBARDIER INC BOSTON SCIENTIFIC CORP BP PLC BRISTOL MYERS SQUIBB CO BROADCOM CORP CABOT CORPORATION CACI INTERNATIONAL INC CADENCE DESIGN SYSTEMS INC CAMBREX CORP CANON INC CARRINGTON LABORATORIES INC CENTOCOR INC CEPHALON INC CERNER CORP CH2M HILL COMPANIES LTD CHEVRONTEXACO CORPORATION CHIRON CORP CHIYODA CORPORATION CIENA CORP CIRRUS LOGIC INC CISCO SYSTEMS INC CITRIX SYSTEMS INC COGNEX CORP COMPAGNIE MICHELIN COMPUTER ASSOCIATES INTERNATIONAL INC COMPUTER SCIENCES CORP
www.plunkettresearch.com
COMPUWARE CORP COMVERSE TECHNOLOGY INC CONMED CORP CONNETICS CORPORATION CONOCOPHILLIPS CORNING INC COVALENT GROUP INC COVANCE INC CR BARD INC CUBIST PHARMACEUTICALS CYPRESS SEMICONDUCTOR CORP DADE BEHRING INC DAIMLERCHRYSLER AG DEL LABORATORIES INC DELL COMPUTER CORPORATION DENSO CORPORATION DEPUY INC DIEBOLD INC DIGENE CORPORATION DOW CHEMICAL COMPANY (THE) E I DU PONT DE NEMOURS & CO (DUPONT) EASTMAN KODAK CO EDWARDS LIFESCIENCES CORP EG&G INC ELAN CORP PLC ELECTRONIC ARTS INC ELECTRONIC DATA SYSTEMS CORP ELECTRONICS FOR IMAGING INC ELI LILLY & CO EMC CORP ENERGY CONVERSION DEVICES INC ENI SPA ENTERASYS NETWORKS INC ERESEARCH TECHNOLOGY INC EXELIXIS INC EXXONMOBIL CORPORATION E-Z-EM INC FIAT SPA FILENET CORP FISHER SCIENTIFIC INTERNATIONAL INC FLUOR CORP FORD MOTOR CO FOREST LABORATORIES INC FOSTER WHEELER LTD FUELCELL ENERGY INC FUJI HEAVY INDUSTRIES LTD GELTEX PHARMACEUTICALS GENERAL DYNAMICS GENERAL ELECTRIC CO GENERAL MOTORS CORP GENZYME CORP GEORG FISCHER LTD GERBER SCIENTIFIC INC
Plunkett Research, Ltd.
GETRONICS NV GILEAD SCIENCES INC GLAXOSMITHKLINE PLC GLENAYRE TECHNOLOGIES INC GLOBAL INDUSTRIES LTD GOODRICH CORPORATION GOODYEAR TIRE & RUBBER COMPANY (THE) GOOGLE INC GRUPO DRAGADOS GUIDANT CORP HADCO CORP HAEMONETICS CORPORATION HALLIBURTON COMPANY HAUSER INC HESKA CORP HEWLETT-PACKARD CO HLM DESIGN INC HONDA MOTOR CO LTD HONEYWELL INTERNATIONAL INC HUGHES ELECTRONICS CORP HUTCHINSON TECHNOLOGY INC HYCOR BIOMEDICAL INC HYUNDAI MOTOR COMPANY I2 TECHNOLOGIES INC ICN PHARMACEUTICALS INC IDEXX LABORATORIES INC ILEX ONCOLOGY INC IMC GLOBAL INC IMMUNOMEDICS INC INCYTE GENOMICS INC INFOCUS CORP INSTRUMENTARIUM INTEL CORP INTERGRAPH CORP INTERNATIONAL BUSINESS MACHINES (IBM) INTERNATIONAL RECTIFIER CORP INTUIT INC INVACARE CORP INVITROGEN CORPORATION IOMEGA CORP ISUZU MOTORS LTD ITT INDUSTRIES INC IVAX CORPORATION JABIL CIRCUIT INC JDS UNIPHASE CORP JOHNSON & JOHNSON JOHNSON CONTROLS INC JUNIPER NETWORKS INC KEITH COMPANIES INC (THE) KEMET CORP KENDLE INTERNATIONAL INC KINETIC CONCEPTS INC KLA TENCOR CORP
www.plunkettresearch.com
KOMAG INC L3 COMMUNICATIONS HOLDINGS INC LAM RESEARCH CORP LEXMARK INT'L GROUP INC LIFE SCIENCES RESEARCH LIFECORE BIOMEDICAL INC LINDE AG LOCKHEED MARTIN CORP LORAL SPACE & COMMUNICATIONS LTD LSI LOGIC CORP LUCENT TECHNOLOGIES INC LYNX THERAPEUTICS INC LYONDELL CHEMICAL COMPANY MALLINCKRODT INC MARATHON OIL MAXIM INTEGRATED PRODUCTS INC MAXTOR CORP MAXYGEN INC MAZDA MOTOR CORPORATION MEDAREX INC MEDIMMUNE INC MEDTRONIC INC MEMC ELECTRONIC MATERIALS INC MENTOR GRAPHICS CORP MERCK & CO INC MERIDIAN BIOSCIENCE INC MICHAEL BAKER CORPORATION MICROCHIP TECHNOLOGY INC MICRON TECHNOLOGY INC MICROSOFT CORP MILLENNIUM PHARMACEUTICALS INC MILTOPE GROUP INC MITSUBISHI MOTORS CORP MONSANTO CO MOTOROLA INC MSC.SOFTWARE CORP NABI BIOPHARMACEUTICALS NAPRO BIOTHERAPEUTICS INC NATIONAL SEMICONDUCTOR CORP NBTY INC NEOGEN CORPORATION NETWORK APPLIANCE INC NETWORK EQUIPMENT TECHNOLOGIES INC NISSAN MOTOR CO LTD NKK CORPORATION NOKIA CORPORATION NORTEL NETWORKS CORP NOVARTIS AG NOVELL INC NOVELLUS SYSTEMS INC ONSITE ENERGY CORPORATION ORACLE CORP ORCHID BIOSCIENCES INC
Plunkett Research, Ltd.
OSI PHARMACEUTICALS INC OYO CORPORATION PANVERA LLC PARAMETRIC TECHNOLOGY CORP PAREXEL INTERNATIONAL PARSONS BRINCKERHOFF INC PENWEST PHARMACEUTICALS CO PEOPLESOFT INC PERFICIENT INC PERKINELMER INC PEROT SYSTEMS CORP PFIZER INC PHARMACEUTICAL RESOURCES INC PHARMACOPEIA INC PHILIPP HOLZMANN GROUP PITNEY BOWES INC PLUG POWER INC PMC-SIERRA INC POLAROID CORP PRAXAIR INC PROTEIN DESIGN LABS INC PROXIM CORPORATION PSA PEUGEOT CITROEN SA QUALCOMM INC QUANTUM CORP QUIDEL CORP QUINTILES TRANSNATIONAL CORP RADISYS CORP RATIONAL SOFTWARE CORP RAYTHEON CO READ-RITE CORP RESPIRONICS INC ROCKWELL AUTOMATION ROYAL DUTCH PETROLEUM CO ROYAL PHILIPS ELECTRONICS SAMSUNG ELECTRONICS CO LTD SANGSTAT MEDICAL CORP SANYO ELECTRIC COMPANY LTD SAP AKTIENGESELLSCHAFT SAS INSTITUTE SCHERING-PLOUGH CORP SCICLONE PHARMACEUTICALS SCIENTIFIC ATLANTA INC SCOTTS CO SEPRACOR INC SEQUENOM INC SEROLOGICALS CORP SHARP CORPORATION SHELL OIL CO SHIRE-BIOCHEM INC SICOR INC SIEBEL SYSTEMS INC SIEMENS AG
www.plunkettresearch.com
SIGMA ALDRICH CORP SILICON GRAPHICS INC SKIDMORE OWINGS & MERRILL LLP SOLA INTERNATIONAL INC SONY CORPORATION ST JUDE MEDICAL INC STANDARD MICROSYSTEMS CORPORATION STERIS CORP STORAGE TECHNOLOGY CORP STRYKER CORP SUN MICROSYSTEMS INC SUNGARD DATA SYSTEMS INC SUNRISE MEDICAL INC SUZUKI MOTOR CORPORATION SYBASE INC SYMANTEC CORP SYMBOL TECHNOLOGIES INC SYNBIOTICS CORP SYNCOR INTERNATIONAL CORPORATION SYNGENTA AG SYNOPSYS INC TARO PHARMACEUTICAL INDUSTRIES TECHNE CORP TECHNIP-COFLEXIP TECHNITROL INC TELEFLEX INC TELEFON AB LM ERICSSON TELLABS INC TERADYNE INC TERAYON COMMUNICATION SYSTEMS INC TERRA INDUSTRIES INC TEXAS INSTRUMENTS INC THERMO ELECTRON CORP TITAN CORP (THE) TOYOTA MOTOR CORPORATION TRANSKARYOTIC THERAPIES TRC COMPANIES INC TREVI-FINANZIARIA INDUSTRIALE SPA TRIPOS INC TULARIK INC UNISYS CORP URS CORPORATION US LABORATORIES UTSTARCOM INC VALLEN CORP VERISIGN INC VERTEX PHARMACEUTICALS INC VINCI VIRBAC INC VISTEON CORPORATION VOLKSWAGEN AG VYSIS INC WATSON PHARMACEUTICALS INC
Plunkett Research, Ltd.
WESTERN DIGITAL CORP WS ATKINS PLC WYETH XEROX CORP XILINX INC YAHOO! INC ZIMMER HOLDINGS INC
www.plunkettresearch.com
Plunkett Research, Ltd.
www.plunkettresearch.com
Individual Data Profiles On Each Of THE ENGINEERING & RESEARCH 500
Plunkett Research, Ltd.
www.plunkettresearch.com
3COM CORP
www.3com.com
Industry Group Code: 334110 Ranks within this company's industry group: Sales:2 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:8
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Networking Equipment-Diversified Modems
3Com is one of the leading industry providers of Ethernet, Fast Ethernet and Gigabit Ethernet connectivity. The company targets sectors of the enterprise and service provider markets and has recently restructured its operations. To improve the competitiveness of Business Connectivity Company (BCC) and Business Networks Company (BNC), 3Com merged BCC into BNC to drive further efficiencies in each business while leveraging growth opportunities. The company has structured its operations around these two businesses. BNC focuses on the enterprise market and now consists of three divisions: the local area network (LAN) infrastructure division, the personal systems division and the connectivity division. The connectivity division focuses on basic client connectivity products and solutions. The Network Jack product is now managed under the personal systems division; other offerings formerly managed under BCC are now managed under the LAN infrastructure division of BNC. CommWorks Corporation continues to focus on the telecommunications service provider market in which it provides Internet protocol-based access and infrastructure and services platforms. In recent news, 3Com entered into a patent right agreement with Infineon Technologies AG regarding Ethernet over DSL. Beyond salary, 3Com offers performance-based incentives, including a special bonus program, Kadoos. After four years of continuous service, employees are offered a paid sabbatical. Employees can schedule their own hours as long as they meet the needs of a position and respond to the advice of managers. 3Com's benefits package includes dental and vision coverage, semi-annual bonuses, flexible maternity, on-site fitness facilities and no enforced dress code.
BRANDS/DIVISIONS/AFFILIATES: Business Networks Company CommWorks Corporation Business Connectivity Company
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Bruce L. Claflin, CEO Bruce L. Claflin, Pres. Mark A. Slaven, CFO/VP-Finance Mark D. Michael, Corp. Sec. Mark D. Michael, General Counsel Mark A. Slaven, Sr. VP-Planning Jeanne Cox, VP-Corp. Branding and Comm. Irfan Ali, Pres., CommWorks Corp. Dennis Connors, Pres., Bus. Connectivity John McClelland, Pres., Bus. Networks Gwen McDonald, Sr. VP-Corp. Services Eric A. Benhamou, Chmn.
Phone: 408-326-5000 Fax: 408-326-5001 Toll-Free: 800-638-3266 Address: 5400 Bayfront Plaza, Santa Clara, CA 95052 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,477,900 (12 months) 2002 Profits: $-596,000 (12 months) Stock Ticker: COMS 2001 Sales: $2,820,900 2001 Profits: $-965,400 Employees: 4,615 2000 Sales: $4,333,942 2000 Profits: $674,303 Fiscal Year Ends: 5/31 1999 Sales: $5,202,253 1999 Profits: $403,874 1998 Sales: $5,156,016 1998 Profits: $30,214
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $781,250 Bonus: $210,375 Stock Purch. Plan: Y Second Exec. Salary: $508,653 Bonus: $122,458 ADVANTAGE: Maker of the first Ethernet interface/ Superior quality of network adapters that are competitive on an international level.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
3M COMPANY
www.mmm.com
Industry Group Code: 335000 Ranks within this company's industry group: Sales:2 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:2
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Y Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Diversified Manufacturing Health Care Products Consumer and Office Markets Electro and Communications Products Transportation and Safety Products Security and Protection Service Products
3M Company, originally known as Minnesota Mining and Manufacturing Company, is an integrated enterprise involved in the research, manufacture and marketing of a variety of products. 3M operates in more than 60 countries, and its products are sold in nearly 200 countries. The firm controls 40 business units organized into seven segments: health care, industrial, consumer and office, display and graphics, electro and communications, transportation and safety and security and protection services. 3M additionally produces apparel, drink ware, bags and travel equipment, golf products and business products. 3M develops technologies in fuel cell components, light management, film solutions and light fiber. Among the company’s most popular products are Post-it products and Scotch Tape. Because of the company’s dedication to environmental safety, one out of every eight 3M scientists works with processes and chemicals aimed at minimizing impact on the environment. Via its technical collaboration with Nitto Denko, 3M has developed a two-in-one product that combines polarizing film with polarization conversion film for liquid crystal displays. Recently, 3M unveiled its newest concrete protection product, 3M Scotch-Clad TC deck coatings, which is the industry’s first two-coat concrete protection system. In other news, 3M acquired GuardiaNet Systems, Inc., a software company serving the public library market. Also, the 3M Telecom Enterprise Department joined Extreme, Inc.’s Go Purple Extreme Solution Partners Program, thus expanding the market for 3M’s complete LAN/campus network solution. Employees enjoy a gym, reduced price concert and sporting event tickets, merchandise discounts and flexible scheduling options.
BRANDS/DIVISIONS/AFFILIATES: Minnesota Mining and Manufacturing Company Nitto Denko GuardiaNet Systems, Inc. Extreme, Inc. 3M Telecom Enterprise Department Post-it Products Scotch Tape 3M Scotch-Clad TC Deck Coatings
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. W. James McNerney, Jr., CEO Patrick D. Campbell, Sr. VP/CFO David W. Powell, Sr. VP-Mktg. M. Kay Grenz, VP-Human Resources Jay V. Ihlenfeld, VP-Research & Dev. Ronald G. Nelson, Controller Ronald R. Belschner, Sr. VP-Eng. Ronald R. Belschner, Sr. VP-Mfg. & Logistics Gregg M. Larson, Sec. Robert F. Ziegler, Sr. VP-Legal Affairs & General Counsel Robert J. Burgstahler, Sr. VP-Bus. Dev. and Corp. Services J. Mark Borseth, Treas. Steven J. Landwehr, Exec. VP-Transportation Bus. Charles Reich, Exec. VP-Health Care Bus. Moe S. Nozari, Exec. VP-Consumer and Office Bus. Harold J. Wiens, Exec. VP-Industrial Bus. W. James McNerney, Jr., Chmn. Joseph A. Giordano, Exec. VP-Intl. Oper.
Phone: 651-733-1110 Fax: 651-736-2133 Toll-Free: 800-364-3577 Address: 3M Center, Bldg. 220-11W-02, St. Paul, MN 551441000 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $16,332,000 (12 months) 2002 Profits: $1,974,000 (12 months) Stock Ticker: MMM 2001 Sales: $16,079,000 2001 Profits: $1,430,000 Employees: 68,774 2000 Sales: $16,724,000 2000 Profits: $1,782,000 Fiscal Year Ends: 12/31 1999 Sales: $15,748,000 1999 Profits: $1,763,000 1998 Sales: $15,094,000 1998 Profits: $1,213,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $1,400,000 Stock Purch. Plan: Y Second Exec. Salary: $595,402 Significant research capabilities/ Lengthy history of product innovation. ADVANTAGE:
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $3,310,830 Bonus: $512,514
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
AB VOLVO
www.volvo.com
Industry Group Code: 336120 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Profits:1
Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Truck Manufacturer Marine Engines Construction Equipment
Volvo AB is one of the world's largest producers of trucks, buses and construction equipment. Having sold its automotive unit to Ford Motors, the company (which is also known as the Volvo Group) operates six divisions: Trucks, Volvo Bus Corporation, Volvo Construction Equipment, Volvo Penta, Volvo Aero and Volvo Financial Services. The Trucks division consists of Volvo Trucks, Renault Trucks and Mack Trucks. Volvo Bus Corporation is the second largest manufacturer of heavy buses and coaches in the world. Volvo Construction Equipment operates in the U.S., Canada, Mexico, Ireland, the U.K., Brazil, China and Korea, and offers a wide variety of heavy equipment including backhoes, compact wheel loaders and articulated haulers. Volvo Penta manufactures engines for use in shipping, leisure boating, power plants and heavy equipment. Volvo Aero is located exclusively in Sweden and constructs military engines, commercial engines, space propulsion components and land and marine gas turbines in addition to providing engine and aviation services. Volvo Financial Services covers customer financing, insurance, treasury, real estate and related services operations. In recent news, the Mack Truck division launched the new Granite, a truck with construction applications, while Renault Trucks introduced the Magnum and Midlum trucks. Volvo Bus Corporation was awarded the Bus Builder of the Year 2002. Volvo Construction Equipment announced the development of a backhoe loader and the acquisition of a range of skid steer loaders. Volvo Penta introduced a marine leisure diesel engine, KAD300, the D2-55 diesel engine for sailboats and a 16-liter engine for commercial marine use. Volvo Aero signed a new agreement for the manufacture of 23 Vulcain engines for the Ariane 5 rocket.
BRANDS/DIVISIONS/AFFILIATES: Volvo Aero Mack Trucks, Inc. Volvo Trucks North America, Inc. Volvo Construction Equipment Renault Trucks Volvo Financial Services Volvo Penta Volvo Bus Corporation
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Leif Johansson, CEO Volvo Group Leif Johansson, Pres. Jan Engstrom, Pres.-Volvo Bus Corporation Jorma Halonen, Pres./CEO-Volvo Truck Corporation Michel Gigou, Pres.-Volvo Trucks North America Lennart Jeansson, Exec. VP Lars Ramqvist, Chmn.
Phone: 46-31-59-66-00 Fax: 46-31-54-57-72 Toll-Free: Address: , Gothenburg, S-40508 Sweden
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $21,469,000 (12 months) 2002 Profits: $161,000 (12 months) Stock Ticker: VOLVY 2001 Sales: $18,057,000 2001 Profits: $-140,000 Employees: 71,160 2000 Sales: $13,800,000 2000 Profits: $500,000 Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Owns some of the world's leading truck, engine and equipment brands.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ABAXIS INC
www.abaxis.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:37 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:33
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Equipment-Point-of-Care Blood Analyzer Systems Veterinary Products
Abaxis, Inc. develops, manufactures and markets a portable blood analysis system for use in any patient-care setting to provide clinicians with rapid blood constituent measurements. The system is marketed as the VetScan Chemistry System in the veterinary market and as the Piccolo Point-of-Care Analyzer in the human medical market. The system consists of a compact 6.9-kilogram analyzer and a series of single-use plastic discs, called reagent discs, containing all the chemicals required to perform a panel of up to 12 tests. The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma using either venous or fingerstick samples. In addition to the blood analysis system, Abaxis sells the VetScan HMT Hematology Analyzer, which provides a complete blood count including a three-part white blood cell differential in less than two minutes, with results for eight selectable species, plus two user-configurable programs. Abaxis also produces a bi-monthly electronic newsletter entitled VetCom for the veterinary community. Abaxis markets its products in the U.S., Europe, Latin America and Asia and has offices located in California and Germany. In recent news, Abaxis signed distribution agreements with T. Chatani and Co., Ltd. and Milburn Distributions, Inc. to expand Abaxis’s distribution market to Japan and increase distribution in the United States. Abaxis offers its employees comprehensive medical benefits, as well as flexible time off and a flexible spending account plan.
BRANDS/DIVISIONS/AFFILIATES: Piccolo Point-of-Care Analyzer VetScan Chemistry System VetScan HMT Hematology Analyzer VetCom Newsletter
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Clinton H. Severson, CEO Robert B. Milder, COO Clinton H.Severson, Pres. Alberto R. Santa Ines, VP-Finance/CFO Robert Schoen, VP-Mktg. and Sales Kenneth Aron, VP-Research and Dev. Vladimir E. Ostioch, VP-Eng. Kenneth Aron, VP-Dev. Ron Blasig, U.S. Dir.-Mktg., Piccolo and Human Diagnostics Pam Conboy, U.S. Dir.-Mktg., Veterinary Products Achim Henkel, European Dir.-Sales and Mktg. Clinton H. Severson, Chmn.
Phone: 510-675-6500 Fax: 510-441-6150 Toll-Free: 800-822-2947 Address: 3240 Whipple Rd., Union City, CA 94587 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $30,600 (12 months) 2002 Profits: $1,300 (12 months) Stock Ticker: ABAX 2001 Sales: $29,501 2001 Profits: $ 188 Employees: 124 2000 Sales: $23,200 2000 Profits: $- 600 Fiscal Year Ends: 3/31 1999 Sales: $13,300 1999 Profits: $-4,200 1998 Sales: $12,200 1998 Profits: $-4,400
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $265,000 Stock Purch. Plan: Second Exec. Salary: $165,000 ADVANTAGE: Sophisticated portable systems that can perform up to 12 different blood tests.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $82,500 Bonus: $66,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ABB LTD
www.abb.com
Industry Group Code: 541310 Ranks within this company's industry group: Sales:2 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Y Y Y Y
Profits:11
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Y Gases: Other: Y
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Diversified Engineering Services Transmission and Distribution Systems
ABB, Ltd. is a global technology company that serves the manufacturing, process and consumer industries and the utilities, oil and gas markets. The company is a leading global supplier of distribution systems, medium-voltage equipment and distribution transformers, which decrease voltage to levels needed by end-users. ABB’s core businesses are the power technologies and automation technologies divisions. Its oil, gas and petrochemicals division is scheduled for divestment. The power technologies division develops products, systems and services for power transmission, distribution and automation, including energy trading management software, natural gas and electricity retailing and customer billing systems. The automation technologies division develops solutions for control, motion, protection and plant integration for the process and utility industries. ABB anticipates a compound average annual revenue growth of approximately 4% from 2002 through 2005. In recent news, ABB signed a rail consortium agreement with Mowlem Railways and Network Rail to upgrade power supply systems on commuter routes in southeast England. The company also formed an alliance with Accenture, Intel Corporation and Microsoft Corporation to provide computing diagnostics, solution design, development and integration services for manufacturers. The alliance will utilize ABB’s Industrial IT, the comprehensive, standardsbased architecture that links products and services with the information needed to install, operate and maintain them. In mid-2002, the firm agreed to sell most of the assets of its structured-finance unit to GE, a move that will greatly reduce ABB's debt. The sale is part of the firm's strategy to refocus on its core business, after generally disappointing financial results and a failed bid to acquire Honeywell International. Also, the company will merge its power technologies and automation technologies units. Unfortunately, it is facing large potential losses from asbestos liability suits in the U.S.
BRANDS/DIVISIONS/AFFILIATES: Industrial IT
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jürgen Dormann, CEO Peter Voser, CFO Gary Steel, VP-Human Resources Markus Bayegan, Chief Tech. Officer Haider Rashid, CIO John Scriven, General Counsel/VP-Legal Affairs and Compliance Bjorn Edlund, VP-Corp. Comm. Michel Gerber, VP-Investor Rel. Dinesh Paliwal, Div. Head-Automation Tech. Erik Fougner, Div. Head-Oli, Gas and Petrochemicals Peter Smits, Div. Head-Power Tech. Donald P. Aiken, U.S. Mgr. Jurgen Dormann, Chmn.
Phone: 41-1-317-7111 Fax: 41-1-317-4420 Toll-Free: Address: Affolternstrasse 44, Zurich, CH-8050 Switzerland
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $18,295,000 (12 months) 2002 Profits: $-787,000 (12 months) Stock Ticker: ABB 2001 Sales: $23,726,000 2001 Profits: $-691,000 Employees: 156,865 2000 Sales: $22,967,000 2000 Profits: $1,443,000 Fiscal Year Ends: 12/31 1999 Sales: $24,681,000 1999 Profits: $1,614,000 1998 Sales: $30,872,000 1998 Profits: $1,305,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Global company with large client base/ Currently dealing with financial difficulties.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ABBOTT LABORATORIES
www.abbott.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:9 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:8
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Antibiotics and Synthetic Hormones Nutritional Products Hospital Products Specialty Products
Abbott Laboratories is a global, broad-based health care company that specializes in the discovery, development, manufacture and sale of a diversified line of health care products and services. Abbott’s products are sold in 130 countries. The company operates through five major business segments: pharmaceutical products, diagnostic products, hospital products, specialty products and nutritional products (through its Ross products division). Principal pharmaceutical products include Depakote, Flomax, Prevacid and a broad line of cardiovascular products. The diagnostics segment markets the product AxSym and systems for blood banks, hospitals and commercial laboratories. Hospital products include drugs and drug delivery systems, perioperative and intensive care products, cardiovascular products and renal and oncology products. The specialty products division produces generic injectables as well as other pharmaceutical compounds, such as IsFlo, PropoFlo and SevoFlo, for perioperative health care for the veterinary market. Ross products include a broad line of adult and pediatric nutritionals, specialty pharmaceuticals and consumer products. Some popular Ross brands are Similac and Isomil infant formulas, Ensure, Pedialyte, Selsun Blue and the Fact Plus line of pregnancy tests. Abbott also conducts its own research and development. Among Abbott’s developments is Norvir, an AIDS drug that, when taken with another protease inhibitor or other anti-viral drugs, can reduce HIV in the blood to undetectable levels. Through a joint venture called TAP Pharmaceutical Products, Abbott makes the best-selling prostate cancer drug, Lupron. The company offers employees adoption assistance, legal assistance, flexible hours, telecommuting, an onsite childcare center, sports programs and wellness programs. It also offers 12-week summer internships to college students in such areas as engineering, research and marketing. Abbott has been recognized as one of the top 50 best companies for minorities in Fortune Magazine and has been ranked among the top 10 best companies for working mothers by Working Mother magazine.
BRANDS/DIVISIONS/AFFILIATES: Ross AxSym Depakote Ensure Flomax Isomil Similac IsFlo
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Miles D. White, CEO Thomas C. Freyman, Sr. VP-Finance/CFO Thomas M. Wascoe, Sr. VP-Human Resources Jeffrey M. Leiden, Exec. VP/Chief Scientific Officer Karen L. Miller, VP-IT Gary L. Flynn, Controller John C. Landgraf, VP-Corp. Eng. Jose M. de Lasa, Corp. Sec. Jose M. de Lasa, General Counsel John C. Landgraf, VP-Oper., Diagnostics Steven J. Weger, Jr., VP-Corp. Planning and Dev. Catherine V. Babington, VP-Public Affairs Catherine V. Babington, VP-Investor Rel. Terrence C. Kearney, Treas. Richard A. Gonzalez, Pres./COO-Medical Products Joy A. Amundson, Sr. VP-Ross Products Christopher B. Begley, Sr. VP-Hospital Products Jeffrey M. Leiden, Pres./COO-Pharmaceutical Products Miles D. White, Chmn. William G. Dempsey, Sr. VP-Int'l Oper.
Phone: 847-937-6100 Fax: 847-937-1511 Toll-Free: Address: 100 Abbott Park Rd., Abbott Park, IL 60064-6400 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $17,685,000 (12 months) 2002 Profits: $2,794,000 (12 months) Stock Ticker: ABT 2001 Sales: $16,285,000 2001 Profits: $1,550,000 Employees: 71,819 2000 Sales: $13,745,900 2000 Profits: $2,786,000 Fiscal Year Ends: 12/31 1999 Sales: $13,177,600 1999 Profits: $2,445,800 1998 Sales: $12,512,700 1998 Profits: $2,334,400
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $1,497,388 Stock Purch. Plan: Second Exec. Salary: $807,408 ADVANTAGE: Heavily involved in research/ Worldwide recognition.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $1,250,000 Bonus: $680,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ABGENIX INC
www.abgenix.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:73 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:97
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Diversified Antibody Research
Abgenix, a leading biopharmaceutical company, develops and intends to commercialize several products for a variety of diseases. The company specializes in developing treatments for inflammatory and autoimmune disorders and cancer, as well as cardiovascular diseases, transplant-related and infectious diseases. Abgenix has developed a proprietary technology known as XenoMouse to help rapidly generate highly specific, fully human antibody product candidates. Under the XenoMouse model, the antibody gene of a genetically engineered mouse is suppressed and replaced with human antibody gene expression. The rest of the mouse’s immune system is left intact. The firm generates revenues by licensing XenoMouse technology to pharmaceutical and biotechnology companies interested in developing antibody-based products. The company also owns SLAM technology, which enables the rapid identification of antibodies with desired functions and characteristics. In its XenoMax technology, Abgenix uses SLAM technology to select and isolate antibodies with particular functions and characteristics from antibody-producing cells generated by XenoMouse animals. Client customers Pfizer, Inc. and Amgen, Inc. have recently initiated clinical trials with fully human antibodies generated from XenoMouse animals. In addition, under a joint development and commercialization agreement Abgenix is co-developing ABX-EGF, its leading proprietary antibody product candidate, with Amgen and Immunex Corporation. The company provides a comprehensive program of employee compensation and benefits, including medical, dental, vision, EAP, a flexible spending program and stock options.
BRANDS/DIVISIONS/AFFILIATES: XenoMouse ABX-EGF XenoMax SLAM
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Raymond M. Withy, CEO Raymond M. Withy, Pres. Kurt W. Leutzinger, CFO John C. Meyer, Dir.-Human Resources C. Geoffery Davis, Chief Scientific Officer H. David Miller, VP-IT Gisela M. Schwab, Chief Medical Officer Patrick M. Murphy, VP-Mfg. Susan L. Thorner, Corp. Sec. Susan L. Thorner, VP/General Counsel Gregory M. Bell, VP-Oper. Gayle M. Mills, VP-Bus. Dev. Gregory M. Bell, VP-Clinical Dev., Inflammation Steve M. Chamow, VP-Process Sciences Bruce A. Keyt, VP-Preclinical Dev. Gregory M. Landes, VP-Product Discovery R. Scott Greer, Chmn.
Phone: 510-608-6500 Fax: 510-608-6511 Toll-Free: Address: 6701 Kaiser Dr., Fremont, CA 94555 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $39,438 (12 months) 2002 Profits: $-208,898 (12 months) Stock Ticker: ABGX 2001 Sales: $63,606 2001 Profits: $-60,856 Employees: 387 2000 Sales: $59,449 2000 Profits: $-8,793 Fiscal Year Ends: 12/31 1999 Sales: $15,330 1999 Profits: $-19,499 1998 Sales: $4,803 1998 Profits: $-16,827
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $366,667 Stock Purch. Plan: Y Second Exec. Salary: $273,000 ADVANTAGE: Collaboration with major firms/ Proprietary XenoMouse technology.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $158,000 Bonus: $157,500
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
ABLE LABORATORIES
www.ablelabs.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:62 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:36
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Generic
Able Laboratories, Inc., which recently merged with DynaGen, Inc., develops, manufactures and sells prescription generic medications. These generic drugs are the chemical and therapeutic equivalents of brandname drugs. Its manufacturing facility produces the medications in tablet, capsule and suppository dosage form. Some of these generic drugs deal with the treatment of health issues involving tension headaches, attention disorder, anxiety disorder, obesity and rheumatoid arthritis. The company has received 16 abbreviated new drug application (ANDA) approvals and one new drug application approval from the FDA. There are several drug applications pending. Recently, Able Labs announced that it entered into an ANDA transfer and marketing agreement with IVAX Pharmaceuticals, Inc., a subsidiary of IVAX Corporation, for Able Labs' Tramadol Hydrochloride Tablets. Able Labs will manufacture and supply Tramadol exclusively to IVAX under their label, and IVAX will exclusively sell Able Labs' manufactured product. In other news, Able Labs received FDA approval for its ANDAs for hydrocodone bitartrate and acetaminophen tablets and its acetaminophen and codeine phosphate tablets.
BRANDS/DIVISIONS/AFFILIATES: Superior Pharmaceutical Co. Able Labs DynaGen, Inc. Tramadol
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Dhananjay G. Wadekar, CEO Dhananjay G. Wadekar, Pres. Dhananjay G. Wadekar, CFO Loken Patel, VP-Mktg. and Sales George H. Sager, Jr., Controller Dhananjay G. Wadekar, Corp. Sec. Kamlesh Haribhakti, Dir.-Product Dev. Dhananjay G. Wadekar, Treas. Shailesh Daftari, Exec. VP Shashikant Shah, VP-Quality/Regulatory Dwight Nix, VP-Nat'l Accounts Iva Klemick, Dir.-Regulatory Affairs Dhananjay G. Wadekar, Chmn.
Phone: 781-449-4926 Fax: 781-890-0118 Toll-Free: Address: 200 Highland Ave., Ste. 301, Needham, MA 02494 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $52,930 (12 months) 2002 Profits: $23,446 (12 months) Stock Ticker: ABLA 2001 Sales: $19,600 2001 Profits: $-4,500 Employees: 288 2000 Sales: $31,500 2000 Profits: $-8,500 Fiscal Year Ends: 12/31 1999 Sales: $29,100 1999 Profits: $-8,200 1998 Sales: $25,000 1998 Profits: $-12,600
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Merger with DynaGen.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
Top Exec. Salary: $145,000 Second Exec. Salary: $
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
ACCENTURE
www.accenture.com
Industry Group Code: 541611 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y Y Y Y
GROWTH PLANS/SPECIAL FEATURES:
Consulting Services Outsourcing Performance Management Technology Research Solutions Engineering Solutions Operations
Accenture (formerly Andersen Consulting) is a leading provider of management and technology consulting services and solutions. The company has more than 110 offices in 46 countries, providing customers with a wide range of consulting, technology and outsourcing services. Accenture serves 84 of the Fortune Global 100 and more than half of the Global 500. Clients of the company include AT&T, Microsoft, Sony, Sprint, Bank of America, London Stock Exchange, Visa, DaimlerChrysler, the City of Boston, the U.S. Postal Service and the U.S. Department of Commerce. The firm delivers services and solutions through five global market units: communications and high tech, financial services, products, resources and government. Together these comprise 18 industry groups. Accenture offers its customers eight primary service lines, including strategy and business architecture, customer relationship management, supply chain management, human performance, finance and performance management, technology research and innovation, solutions engineering and solutions operations. Moreover, the company has over 150 alliances with leading technology-related solutions providers around the world. Through its strategic alliances, Accenture is able to offer an unparalleled array of technology solutions to meet its clients’ diverse business needs. In recent news, the firm signed a seven-year deal with Telecom Italia Group, under which it will provide outsourced payroll processing and administration services. Accenture also announced an agreement with global transportation and logistics company Neptune Orient Lines for the outsourcing of the group’s transaction-based finance functions. In other news, the company was awarded a five-year outsourcing contract to provide Borden Chemical, Inc. with human resource administrative services, claims processing, payroll processing and information technology management. Accenture provides employee training for a full range of learning and places an emphasis on hiring recent college graduates.
BRANDS/DIVISIONS/AFFILIATES: Andersen Consulting Accenture Technology Ventures
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Joe W. Forehand, CEO Stephan A. James, COO-Capabilities Harry L. You, CFO Joellin Comerford, Group Dir.-Sales Dev. Arnaud Andre, Managing Partner-People Mgmt. Douglas G. Scrivner, Corp. Sec. Douglas G. Scrivner, General Counsel William Copacino, Group Chief Exec.-Bus. Consulting Capability Group James E. Murphy, Managing Dir.-Comm. Michael G. McGrath, Treas. Pamela J. Craig, Managing Partner-Bus. Oper. William D. Green, COO-Client Services Jackson L. Wilsom, Chief Exec.-Bus.-Process Outsourcing Diego Visconti, Group Chief Exec.-Comm. and High-Tech Oper. Joe W. Forehand, Chmn.
Phone: 441-296-8262 Fax: 441-296-4245 Toll-Free: Address: 41 Cedar House, Hamilton, HM12 Bermuda
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $13,105,000 (12 months) 2002 Profits: $244,900 (12 months) Stock Ticker: ACN 2001 Sales: $13,348,000 2001 Profits: $377,000 Employees: 75,000 2000 Sales: $9,752,100 2000 Profits: $2,463,900 Fiscal Year Ends: 8/31 1999 Sales: $9,549,900 1999 Profits: $2,022,700 1998 Sales: $8,214,800 1998 Profits: $1,685,300
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $2,112,000 Stock Purch. Plan: Second Exec. Salary: $1,848,000 ADVANTAGE: One of the world's largest consulting firms/ First-class client base worldwide.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $40,624 Bonus: $35,546
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ACTERNA CORPORATION
www.acterna.com
Industry Group Code: 334515 Ranks within this company's industry group: Sales:6 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:4
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Network Testing Equipment Manufacturer Computer Products and Systems
Acterna Corporation, formerly Dynatech, is a leading developer and manufacturer of communications equipment in three categories: communications testing equipment, industrial computing and communications and visual communications. The company’s TTC division, formerly known as Telecommunications Techniques Co., provides telecommunications testing equipment that enables service providers (such as long-distance and competitive access providers), large service users (such as large corporate and government network operators) and equipment manufacturers to test and analyze systems from a central location. Acterna's industrial computer source division produces and markets durable computer equipment for companies that require such that withstands excessive stresses, such as those found in production facilities and field technician environments. The company’s visual communications division is focused on two market niches: the production of passenger cabin video information systems for the aviation market (through its Airshow, Inc. subsidiary) and digital color enhancement technologies (through subsidiary da Vinci Systems, Inc.) Acterna recently sold its status and performance monitoring product line to Tollgrade Communications in order to further concentrate resources on its communications testing capabilities. The firm continues to search for growth in the cable market through the development of its test tools, as well as the integration of workforce management solutions through its TechSync portfolio. In other news, Marconi selected the company as its advanced network tester at its optical network research and development labs in Genoa, Italy. Additionally, Acterna was selected to provide performance-enhancing testing solutions tools for Powercor Australia, one of the country's largest electricity distributors. The firm offers its employees dental and vision insurance, credit union membership, flextime, tuition reimbursement and a referral program. Additionally, the company provides its workers with discounts on auto and homeowners' insurance, cell phones and financial planning assistance.
BRANDS/DIVISIONS/AFFILIATES: Dynatech DataViews Airshow, Inc. da Vinci Systems ComCoTec Parallax Graphics TechSync Telecommunications Techniques Co.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John R. Peeler, CEO John R. Peeler, Pres. John Ratliff, CFO John D’Anna, Sr. VP-Americas Sales Carol Cristiano, VP-Human Resources S. David Bent, CIO Richard H. Goshorn, Corp. Sec. Richard H. Goshorn, General Counsel Douglas J. Halbert, Jr., Sr. VP-Oper. Wolfgang Schuster, Pres.-Transport, Fiber Optics and Wireless Helmut Berg, Pres.-Data Network Services Roger Friedli, Sr. VP-Europe, Middle East and Africa Sales Jim Platner, VP-Asia Pacific Sales Ned C. Lautenbach, Chmn.
Phone: 301-353-1550 Fax: 301-353-1536 Toll-Free: 800-638-2049 Address: 20400 Observation Dr., Germantown, MD 20876-4023 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,132,700 (12 months) 2002 Profits: $-374,900 (12 months) Stock Ticker: ACTR 2001 Sales: $1,167,800 2001 Profits: $-171,800 Employees: 4,973 2000 Sales: $453,200 2000 Profits: $6,000 Fiscal Year Ends: 3/31 1999 Sales: $522,900 1999 Profits: $6,400 1998 Sales: $472,948 1998 Profits: $41,776
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $440,600 Bonus: $150,000 Stock Purch. Plan: Second Exec. Salary: $306,269 Bonus: $150,000 ADVANTAGE: Unique network provides entertainment for airline passengers/ Strategic acquisitions.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ACUSON CORPORATION
www.acuson.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales: Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Equipment-Diagnostic Ultrasound Systems
Acuson is a leading manufacturer of upgradeable diagnostic medical ultrasound systems that generate and display ultrasound images. The firm is a part of the ultrasound division of Siemens Medical Solutions, a subsidiary of Siemens USA. Siemens USA is owned by the giant German firm Siemens AG. Acuson develops general imaging products for various medical fields, including radiology, obstetrics, gynecology and urology. Acuson also offers digital lab solutions, which enable users to access, review and manage medical images taken in a digital format. The firm also produces transducers for various applications, including breast, pediatric, neonatal head, cardiac and intraoperative uses. Acuson’s main focus is on echocardiographic products that specialize in the heart. Its revolutionary products include the Sequoia Echo, Sequoia GI, CV70, Aspen Echo, Aspen GI and Cypress. In addition, the company has developed the AcuNav diagnostic ultrasound catheter that aids in the diagnosis and the treatment management of heart disease sufferers by enabling doctors to see through the blood into cardiac chambers. The AcuNav catheter is compatible with Acuson’s echocardiographic products. The firm provides educational services and training seminars regarding its products. The firm’s corporate culture seeks to foster innovation, technology, diversity and teamwork, as evidenced by the fact that two-thirds of Siemens medical products are less than three years old. Benefits offered to employees include business-casual dress, vision and hearing coverage, dental and prescription coverage, an employee assistance program, mental health/substance abuse coverage and flexible work schedules. Additionally, employees are entitled to receive tuition assistance, scholarship programs for children, adoption assistance and career training and development programs.
BRANDS/DIVISIONS/AFFILIATES: Siemens Ecton, Inc. Sequoia Aspen 128XP CV70 Cypress AcuNav
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John Pavlidis, CEO Lars Becker, VP/COO John Pavlidis, Pres. Karl Blaim, Sr. VP/CFO Rick E. Smith, Sr. VP-Worldwide Sales and Mktg. Charles H. Dearborn, VP-Human Resources and Legal Affairs Jin Kim, Sr. VP/Chief Tech. Officer L. Thomas Morse, Corp. Controller Edward P. Cornell, Sr. VP-Eng. Bradford C. Anker, VP-Mfg. Corinne Z. Augustine, VP-Strategic Programs Robert J. Gallagher, Sr. VP Lourens B. Steger, VP-Worldwide Services Bus. Organization John Allison, VP-Product Creation Bill Carrano, VP-Worldwide Mktg.
Phone: 650-969-9112 Fax: 650-943-7006 Toll-Free: 800-422-8766 Address: 1230 Shorebird Way, Mountain View, CA 94043-1344 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $ 2001 Profits: $ Employees: 1,932 2000 Sales: $ 2000 Profits: $ Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Bonus: $ Stock Purch. Plan: Second Exec. Salary: $ Bonus: $ ADVANTAGE: Highly regarded medical diagnostic ultrasound systems and image management products.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ADAC LABORATORIES
www.adaclabs.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales: Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Equipment-Medical Imaging Systems Health Care Information Systems Radiation Therapy Systems PET Systems CT Systems
ADAC Laboratories, a Philips Medical Systems company, is a world leader in the development of nuclear medicine imaging, positron emission tomograpy (PET) and radiation therapy planning systems and a leading supplier of radiology and cardiology information and image management systems. The parent company is Netherlands-based Koninklijke (Royal) Philips Electronics N.V. ADAC produces a wide variety of nuclear medicine products, including leading-edge single-, dual- and triplehead gamma cameras. The company's SKYLight nuclear medicine camera allows dual-detector total body spots, standing body imaging and full-brain single photon emission computed tomography imaging. ADAC offers a full line of PET products including MCD/AC, CPET Plus and the GSO-based PET system, ADAC-Allegro. The firm develops turnkey systems to assist hospitals in planning patient radiation treatments. The Pinnacle radiation oncology system's computers deliver three-dimensional volumetric image processing and dose computation capabilities, allowing physicians to precisely estimate the amount of high-energy radiation needed to target a specific area for the treatment of cancer. ADAC provides health care providers with computer software applications that process and archive patient and clinical information, including ENVOI (which focuses on radiology) and the CorCAAT (which focuses on cardiology). ADAC provides its employees with insurance, an employee assistance program, up to $3500 per year in tuition reimbursement, flexible spending accounts and membership in a credit union. In addition, the company sponsors family picnics, rallies, parties, car pool services, a series of awards, a basketball court, shower and locker facilities, sports teams and discounts at local health clubs.
BRANDS/DIVISIONS/AFFILIATES: Koninklijke (Royal) Philips Electronics N.V. Philips Medical Systems SKYLight CPET ENVOI CorCAAT Pinnacle SmartSim
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Gerhard F. Burbach, CEO Gerhard F. Burbach, Pres. Arno Kolen, CFO Larry McAlister, VP-Human Resources
Phone: 408-321-9100 Fax: 408-321-9536 Toll-Free: 800-538-8531 Address: 540 Alder Dr., Milpitas, CA 95035 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $ 2001 Profits: $ Employees: 900 2000 Sales: $324,000 2000 Profits: $-1,000 Fiscal Year Ends: 9/30 1999 Sales: $342,131 1999 Profits: $-33,620 1998 Sales: $300,528 1998 Profits: $7,386
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Y Second Exec. Salary: $ ADVANTAGE: Significant global market share in nuclear medicine.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ADAM OPEL AG
www.opel.com
Industry Group Code: 336111 Ranks within this company's industry group: Sales:15 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Profits:
Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Automobile Manufacturing
Adam Opel AG, a subsidiary of General Motors, is a manufacturer of cars and trucks including the Astra, Corsa, Speedster, Vectra and Frontera. In addition, Opel builds commercial vehicles, the Arena and Vivaro, as well as automotive components. The company is GM's largest non-U.S. subsidiary. Opel operates 10 plants in 7 countries in Europe, and 26 manufacturing and assembly plants on 5 continents, including a newly opened plant in Rüsselsheim, Germany. In recent news, the firm's alternative fuel vehicle, the Opel Zafira 1.6 CNG, which runs alternatively on gas and diesel engines, was honored as the best car of the year for 2002 in the Alternative Propulsion category by the German automotive industry magazine Autoflotte. The company plans to launch The Signum, Opel/Vauxhall’s Business Class vehicle in early 2003. Also planned are the Vectra station wagon and the Vectra GTS. Opel’s other initiatives include: ECOTEC 4and 6-cylinder engines, the G90 concept car and a new fuel cell propulsion system.
BRANDS/DIVISIONS/AFFILIATES: General Motors Agila Corsa Astra Zafira Vectra Omega Frontera
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jan Jozef Brems, Managing Dir. Walter G. Borst, Financial Dir. Martin Smith, Dir.-Design Ditmar W. Porth, Dir. Production Alain Uyttenhoven, Dir.-Brand Kris Vilhelmsson, Brand Communication Dir. Hans H. Demant, Exec. Dir.-Opel ITDC Carl-Peter Forster, Chmn.
Phone: 49-6142-660 Fax: 49-6142-664-859 Toll-Free: Address: Postfach 1710, Rüsselsheim, 65423 Germany
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $14,459,000 (12 months) 2002 Profits: $ (12 months) Stock Ticker: Subsidiary 2001 Sales: $14,173,000 2001 Profits: $ Employees: 36,000 2000 Sales: $ 2000 Profits: $ Fiscal Year Ends: 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: This firm is GM's major operation in Europe.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ADAPTEC INC
www.adaptec.com
Industry Group Code: 334110 Ranks within this company's industry group: Sales:5 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:7
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Networking Equipment-Adapters & Controllers Input/Output Software Products Single Chip SCSI Host Adapters Storage Systems Technology Storage Networking
Adaptec develops storage solutions for e-business and Internet applications that move, manage and protect data and critical content. Its storage solutions are used in highperformance networks, servers, network attached storage devices, workstations and desktop personal computers, from the world's leading manufacturers of computer, storage and networking products. The company’s solutions are sold through original equipment manufacturers (OEMs) and distribution channels to a wide variety of end users, ranging from large-scale enterprises to retail consumers. Adaptec currently operates in three business segments: the storage solutions group (SSG), the desktop solutions group (DSG) and the storage networking group (SNG). SSG's interface products enable the movement, storage and protection of data across a range of server platforms, direct attached storage, servers, storage area networks, based servers, network attached storage, devices and storage subsystems. DSG provides high-performance I/O connectivity solutions for personal computing platforms, including notebook and desktop PCs and consumer electronic devices. SNG provides storage connectivity solutions for servers, storage devices, fabric switches and network attached storage devices. Recently, the company acquired the outstanding technology of Tricord Systems, Inc., a company that develops technology for managing network attached storage systems.
BRANDS/DIVISIONS/AFFILIATES: Tricord Systems, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Robert N. Stephens, CEO Robert N. Stephens, Pres. David A. Young, CFO Thomas M. Flageollet, VP-Worldwide Sales Shirley Olerich, VP-Human Resources Mark Delsman, VP-Chief Tech. Officer Joan Konsdorf, CIO John Lazlo, VP-Bus. Dev. John Lazlo, VP-Investor Rel. Ahmet Houssein, VP/Mgr.-Host I/O Products Group Steve Cochran, VP/Mgr.-RAID Products Group Carl J. Conti, Chmn.
Phone: 408-945-8600 Fax: 408-262-2533 Toll-Free: Address: 691 S. Milpitas Blvd., Milpitas, CA 95035 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $418,700 (12 months) 2002 Profits: $-196,200 (12 months) Stock Ticker: ADPT 2001 Sales: $582,000 2001 Profits: $39,700 Employees: 1,713 2000 Sales: $811,200 2000 Profits: $170,800 Fiscal Year Ends: 3/31 1999 Sales: $692,400 1999 Profits: $-13,300 1998 Sales: $1,007,300 1998 Profits: $172,900
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $616,751 Stock Purch. Plan: Y Second Exec. Salary: $379,539 Strong market penetration/Strong brand image. ADVANTAGE:
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $1,200,000 Bonus: $350,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ADC TELECOMMUNICATIONS INC
www.adc.com
Industry Group Code: 334210 Ranks within this company's industry group: Sales:12 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:11
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Telecommunications Equipment-Voice, Data & Video Signal Transmission Transmission and Networking Systems Integrated Equipment Solutions Software Consulting Systems Integration Internet Protocol Based Offerings
ADC Telecommunications provides a broad range of network equipment, software and integration services for broadband, multi-service networks that deliver Internet/data, video and voice communications over telephone, cable television, Internet, broadcast, wireless and enterprise networks. The company’s broadband, multi-service network solutions enable local access, highspeed transmission and software management of communication services from service providers to consumers and businesses over fiber-optic, copper, coaxial and wireless media. ADC serves its customers through two main business units: broadband infrastructure and access and integrated solutions. The broadband infrastructure and access unit focuses on Internet Protocol (IP)-based offerings for the cable industry, digital subscriber line (DSL) offerings for the telecommunications industry and broadband connectivity products for wireline, cable and wireless communications network applications. The integrated solutions division focuses on operations support system (OSS) software and system integration services for broadband, multiservice communications over wireline and wireless networks. Systems integration services are used to design, equip and build communications networks that deliver Internet, data, video and voice services to consumers and businesses. OSS software includes communications billing, customer management, network performance and service-level assurance software used by service providers to operate communications networks. ADC customers include local and long-distance telephone companies, cable television operators, wireless service providers, new competitive service providers, broadcasters, governments, businesses, system integrators and communications equipment manufacturers and distributors. Recently, the company announced an extension of its supply agreement with SBC Services, Inc., in which the company is a preferred supplier to SBC of connectivity products. ADC offers employees child care and elder care referrals, as well as tax-advantaged reimbursement programs for day care and health care expenses.
BRANDS/DIVISIONS/AFFILIATES:
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Richard R. Roscitt, CEO Richard R. Roscitt, Pres. Robert E. Switz, Exec. VP/CFO William F. O'Brien, VP/Chief Mktg. Officer Laura N. Owen, VP-Human Resources Charles T. Roehrick, VP/Controller Jeffrey D. Pflaum, Corp. Sec. Jeffrey D. Pflaum, Chief Legal Officer Mary E. Quay, VP-Worldwide Oper. Barclay W. Firzpatrick, VP-Bus. Dev. Gokul Hemmady, VP/Treas. Jo Anne M. Anderson, VP/Pres.-Systems Integration Lawrence S. Barker, VP/Pres.-Software Systems Michael K. Pratt, VP/Pres.-Wireline Patrick D. O'Brien, VP/Pres.-Connectivity Richard R. Roscitt, Chmn.
Phone: 952-938-8080 Fax: 952-917-1717 Toll-Free: 800-366-3889 Address: 13625 Technology Dr., Eden Prarie, MN 55343 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,047,700 (12 months) 2002 Profits: $-1,145,000 (12 months) Stock Ticker: ADCT 2001 Sales: $2,402,800 2001 Profits: $-1,287,700 Employees: 7,600 2000 Sales: $3,287,900 2000 Profits: $868,100 Fiscal Year Ends: 10/31 1999 Sales: $1,926,900 1999 Profits: $87,600 1998 Sales: $1,379,700 1998 Profits: $146,700
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $924,000 Stock Purch. Plan: Second Exec. Salary: $386,000 ADVANTAGE: Capable of providing turn-key consulting, software and systems integration.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $1,994,258 Bonus: $1,500,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ADOBE SYSTEMS INC
www.adobe.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:18 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:7
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Software-Desktop & Publishing
Adobe Systems, Inc. develops graphic design, publishing and imaging software using web, print, video, wireless and broadband applications. The company’s most widely used products include Adobe Acrobat, which enables users to transmit and read PDF (portable document format) files; Adobe Pagemaker, which allows users to create business documents and web pages with layout tools, templates and stock arts; and Adobe Photoshop, which enables users to edit graphic images. The company’s products are used by a variety of customers, including web and graphic designers, professional publishers, business users and individual consumers. In addition, Adobe develops software solutions for the nascent e-book industry. Through Adobe Ventures, a joint venture formed with Granite Ventures, LLC, Adobe invests in firms that develop authoring, publishing or distributing information products that will prove beneficial to the firm. In recent news, Adobe signed an agreement with ACCESS Co., Ltd., a Japan-based mobile content delivery and access technologies provider, to integrate Adobe Reader software into a future version of ACCESS’s NetFront web browser. This will allow consumers to utilize Adobe Reader on consumer electronics and mobile platforms. Adobe takes part in several community relations programs. The company offers support such as cash grants, software donations, software training and volunteers to underserved populations living in areas where Adobe employees live and work. Recipients are often schools and nonprofit organizations. Adobe offers its employees a full range of medical benefits, as well as group legal services, long-term care, educational assistance, adoption benefits, a matching gift program and a cafeteria and on-site fitness center at the corporate headquarters.
BRANDS/DIVISIONS/AFFILIATES: Adobe Acrobat Adobe Pagemaker Adobe Photoshop Adobe Ventures
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Bruce Chizen, CEO Bruce R. Chizen, Pres. Murray Demo, Sr. VP/CFO Melissa Dyrdahl, Sr. VP-Corp. Mktg. Theresa Townsley, Sr. VP-Human Resources Karen Cottle, Sr. VP/Corp. Sec. Karen Cottle, General Counsel Jim Stephens, Sr. VP-Worldwide Sales and Field Oper. Kyle Mashima, Sr. VP-Strategic Dev. Kevin Burr, VP-Corp. Comm. Shantanu Narayen, Exec. VP-Worldwide Products James Heeger, Sr. VP-Digitial Imaging and Video Products John E. Warnock, Chmn. Pierre Van Beneden, VP-Europe, Middle East and Africa
Phone: 408-536-6000 Fax: 408-537-6000 Toll-Free: 800-833-6687 Address: 345 Park Ave., San Jose, CA 95110-2704 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,164,800 (12 months) 2002 Profits: $191,400 (12 months) Stock Ticker: ADBE 2001 Sales: $1,229,700 2001 Profits: $205,600 Employees: 3,341 2000 Sales: $1,266,000 2000 Profits: $288,000 Fiscal Year Ends: 11/30 1999 Sales: $1,015,434 1999 Profits: $237,751 1998 Sales: $894,791 1998 Profits: $105,144
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $874,999 Bonus: $233,113 Stock Purch. Plan: Y Second Exec. Salary: $467,500 Bonus: $108,675 ADVANTAGE: Owns a well-known line of graphics software/Growing popularity of Acrobat product.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ADTRAN INC
www.adtran.com
Industry Group Code: 334210 Ranks within this company's industry group: Sales:15 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:8
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Telecommunications Equipment-High Speed Digital Transmission Service and Installation
ADTRAN, Inc. designs, develops and manufactures digital transmission products, particularly digital subscriber line (DSL) products, providing high-speed communications over existing telephone networks for telephone companies and corporate end users. Products are marketed globally through direct sales forces, resellers and distributors. The company's product lines, which are comprised of over 500 principal products, are built around core technologies developed to address the local loop and central office digital communications marketplace. These products include a comprehensive line of transmission, repeater, extension and termination products. The company is divided into two operating segments: carrier networks (CN) and enterprise networks (EN). CN customers include all of the major domestic incumbent local exchange carriers, large independent carriers and competitive service providers. Its global markets include China, Europe, Canada, Latin America and Australia. The company’s EN customers include private and public enterprises worldwide in numerous vertical industries. The main product lines for the CN division include the Total Access System and HDSL/HDSL2/HDSL4 transport technologies. The Total Access System is a distributed access solution that includes broadband and narrowband access platforms, outside plant access terminals, voice concentrators and system management and professional services. The EN division provides product line solutions for wide area connectivity across today's diverse communications networks and technologies. Key product lines include the ATLAS series of integrated access devices, the NetVanta Series of VPN networking devices, the TSU series of T1 services units, the IQ series of frame relay performance monitoring devices, the ISU series of ISDN service units, the TRACER series of wireless products and the DSU series of DDS service units. Recently, the company introduced the newest access router, the NetVanta 3305. ADTRAN offers employees a full range of benefits including tuition reimbursement, a technical development program and other training.
BRANDS/DIVISIONS/AFFILIATES: ATLAS Series NetVanta Series Total Access System HDSL/HDSL2/HDSL4 TRACER Series DSU Series TSU Series IQ Series
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Mark C. Smith, CEO Howard A. Thrailkill, COO Howard A. Thrailkill, Pres. James E. Matthews, Sr. VP-Finance/CFO Pete Ritch, Dir.-Human Resources Kevin W. Schneider, VP-Tech. Tom Elkins, VP-IT Lonnie S. McMillian, Sr. VP-Eng. Lonnie S. McMillian, Corp. Sec. James L. North, General Counsel Peter E. Voetsch, Sr. VP-Oper. John R. Cooper, VP-Finance Thomas R. Stanton, VP/General Mgr.-Carrier Networks Danny J. Windham, Sr. VP/General Mgr.-Enterprise Networks M. Melvin Bruce, VP-Carrier Networks Eng. Robert A. Fredrickson, VP-Carrier Networks Sales Mark C. Smith, Chmn.
Phone: 256-963-8000 Fax: 256-963-8699 Toll-Free: 800-923-8726 Address: 901 Explorer Blvd., Huntsville, AL 35814 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $345,700 (12 months) 2002 Profits: $24,800 (12 months) Stock Ticker: ADTN 2001 Sales: $387,100 2001 Profits: $17,300 Employees: 1,549 2000 Sales: $462,900 2000 Profits: $120,800 Fiscal Year Ends: 12/31 1999 Sales: $367,200 1999 Profits: $50,900 1998 Sales: $286,600 1998 Profits: $40,300
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $308,288 Stock Purch. Plan: Y Second Exec. Salary: $303,519 ADVANTAGE: Over 500 principal products and 24-hour, 7-days-a-week telephone support.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $97,500 Bonus: $95,875
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ADVANCED FIBRE COMMUNICATIONS INC Industry Group Code: 334210 Ranks within this company's industry group: Sales:16 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
www.afc.com
Profits:7 Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Telecommunications Equipment-Voice, Video & Data Signal Transmission Loop Carrier Systems
Advanced Fibre Communications, Inc. designs and manufactures end-to-end distributed multi-service access solutions for the portion of the telecommunications network between the carrier's central office and its subscribers. The company's OmniMAX product family is a multiservice broadband solution for providing voice and data services to the telecommunications industry. The OmniMAX portfolio consists of integrated multiservice access platforms, integrated access devices, optical network access concentrators, network services, network element management systems, environmentally hardened outside plant cabinets, indoor cabinets and related service and transmission technologies. The OmniMAX product family provides narrowband, wideband and broadband services to customers and consists of AccessMAX, PremMAX, TransMAX, ATLAS and Panorama. AccessMAX is the product family of IMAPs and environmentally hardened cabinets and technology for last-mile voice, data and broadband DSL solutions. Its products include the UMC1000, DMAX, AccessMAX System 8, EMAX and EMAXplus. The PremMAX IAD aggregates voice and data traffic at the customer premise onto the access loop. TransMAX is a family of optical network access platforms and includes a multiservice access concentrator allowing voice and data integration over packet-aware optical networks, enhancing data handling efficiencies over traditional non-packet-aware optical networks, saving bandwidth and money. ATLAS is a professional service organization made up of teams of professionals, regionally located, who provide consulting and complete end-to-end installation and operations, maintenance and provisioning services for voice, data and video networks. The Panorama element management system is a software application product providing a centralized graphic user interface for point and click management of the OmniMAX network. Recently, Advanced Fibre Communications introduced TransMAX 1500, the first-ever environmentally hardened optical add/drop multiplexer.
BRANDS/DIVISIONS/AFFILIATES: OmniMAX AccessMAX PremMAX TransMAX ATLAS Panorama EMAXplus UMC1000
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John A. Schofield, CEO John A. Schofield, Pres. Keith Pratt, CFO/Sr. VP-Finance and Admin. Charles C. Geiger, VP-Mktg. E. James Sackman, VP/Chief Tech. Officer Leon Blackburn, VP/Corp. Controller Jorge Valdes, VP-Eng. Amy M. Paul, Corp. Sec. Amy M. Paul, VP/General Counsel Jeffrey Rosen, VP-Oper. Victoria L. Perrault, VP-Admin. Services Jack Ermey, VP-Global Sales Doak K. Smailer, VP-Quality and IT Charles C. Geiger, VP-Project Mgmt. John A. Schofield, Chmn.
Phone: 707-794-7700 Fax: 707-794-7777 Toll-Free: Address: 1465 N. McDowell Blvd., Petaluma, CA 94954 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $344,100 (12 months) 2002 Profits: $31,800 (12 months) Stock Ticker: AFCI 2001 Sales: $327,600 2001 Profits: $167,800 Employees: 843 2000 Sales: $416,800 2000 Profits: $77,600 Fiscal Year Ends: 12/31 1999 Sales: $296,600 1999 Profits: $249,100 1998 Sales: $312,700 1998 Profits: $27,200
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $403,846 Stock Purch. Plan: Y Second Exec. Salary: $254,086 ADVANTAGE: Expertise in complex telecommunication systems and services.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $341,402 Bonus: $188,281
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ADVANCED MICRO DEVICES INC
www.amd.com
Industry Group Code: 334413 Ranks within this company's industry group: Sales:3 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:21
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Microprocessors Semiconductors
Advanced Micro Devices, Inc. (AMD) designs, develops, manufactures and markets complex monolithic integrated circuits for use by manufacturers of a broad range of electronic equipment and systems, particularly for personal computers, workstations, servers, telecommunications equipment, data and network communications equipment and consumer electronics. AMD has manufacturing operations in the United States, Europe and Asia, and is a major competitor to Intel, the industry leader. The company makes mid-priced microprocessors such as the K6 chip, as well as network and voice/data communication chipsets, erasable programmable read-only memories, flash memories and programmable flash devices. AMD's Alchemy Semiconductor, Inc. designs, develops and markets lowpower, high-performance microprocessors for personal connectivity devices such as personal digital assistants, web tablets and portable and wired Internet access devices and gateways. The company recently introduced the AMD Athlon MP Processor 2600, used to run missioncritical applications. The advanced Hammer 64 bit chip was scheduled to be introduced by the end of 2002, but was later moved back to April 2003. Staff members have the option to telecommute, are given maternity benefits and are offered a discount on public transportation. There is no dress code at Advanced Micro Devices, and the company offers gym memberships, a sabbatical program and elder care referral.
BRANDS/DIVISIONS/AFFILIATES: Am486 AMD-K6 NexGen, Inc. Duron Athlon Hammer Alchemy Semiconductor, Inc. Barton
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Hector Ruiz, CEO Hector Ruiz, Pres. Bob Rivet, Sr. VP/CFO Rob Herb, Exec. VP/Chief Sales and Mktg. Officer William T. Siegle, Sr. VP-Tech./Chief Scientist Thomas M. McCoy, Sr. VP/General Counsel Michael Haase, Dir.-Investor Rel. Bertrand Cambou, VP-Memory Group Billy Edwards, VP-Personal Connectivity Solutions Dirk Meyer, Sr. VP-Computation Products W. J. Sanders, III, Chmn.
Phone: 408-732-2400 Fax: 408-894-0547 Toll-Free: 800-538-8450 Address: One AMD Pl., Sunnyvale, CA 94086 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $2,697,000 (12 months) 2002 Profits: $-1,303,000 (12 months) Stock Ticker: AMD 2001 Sales: $3,891,800 2001 Profits: $-60,600 Employees: 12,146 2000 Sales: $4,664,200 2000 Profits: $983,000 Fiscal Year Ends: 12/31 1999 Sales: $2,857,600 1999 Profits: $-88,900 1998 Sales: $2,542,100 1998 Profits: $-104,000
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Stock Purch. Plan: Y ADVANTAGE: Award winning high-speed chips.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $1,000,000 Second Exec. Salary: $775,962
Bonus: $1,217,412 Bonus: $19,337
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
AFFYMETRIX INC
www.affymetrix.com
Industry Group Code: 334413 Ranks within this company's industry group: Sales:20 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:8
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Chips-Genetics Genetic Testing Instruments
Affymetrix develops technology for examining and managing complex genetic information for use in biomedical research, genomics and clinical diagnostics. The cornerstone of the company is its GeneChip technology, used for sequence analysis, genotyping and gene expression monitoring. Its integrated GeneChip platform includes disposable DNA probe arrays (chips) consisting of gene sequences set out in an ordered, highdensity pattern, certain reagents for use with the probe arrays, a scanner and other instruments to process the probe arrays and software to analyze and manage genomic information from the probe arrays. The firm maintains three primary focuses as part of its business strategy: gene expression monitoring, DNA analysis and clinical applications. Markets for its products include all aspects of molecular biology research in the life sciences, including basic human disease research, genetic analysis, pharmaceutical drug discovery and development, pharmacogenomics, toxicogenomics and agricultural research. Affymetrix currently sells its products directly to pharmaceutical, biotechnology, agrichemical, diagnostics and consumer products companies as well as academic research centers, government research laboratories, private foundation laboratories and clinical reference laboratories in North America, Europe and Japan. In recent news, the company entered into a supply agreement with Perlegen Sciences, Inc. for Perlegen's core SNP discovery and genotying research. A license to new single nucleotide polymorphism content and broader surveying methods and access to whole genome technologies will be made available through the CustomSeq product line. In other news, Affymetrix announced an agreement with ParAllele BioScience, Inc. With this supply agreement, the company provides certain instrumentation and arrays to be used by ParAllele in combination with its proprietary typing technology for research and third-party genotyping services. The company offers its workers an employee discount program, legal and financial services, health fitness discounts, a tuition assistance plan and a lunch program.
BRANDS/DIVISIONS/AFFILIATES: GeneChip CustomSeq Spotted Array Systems GeneChip CustomExpress GenFlex Tag Array
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Stephen P. A. Fodor, CEO Susan E. Siegel, Pres. Gregory T. Schiffman, Sr. VP/CFO Barbara A. Caulfield, Exec. VP/General Counsel Trevor J. Nicholls, Global Oper. Trevor J. Nicholls, Chief Commercial Officer Stephen P. A. Fodor, Chmn.
Phone: 408-731-5000 Fax: 408-731-5441 Toll-Free: 888-362-2447 Address: 3380 Central Expy., Santa Clara, CA 95051 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $289,947 (12 months) 2002 Profits: $-1,630 (12 months) Stock Ticker: AFFX 2001 Sales: $224,900 2001 Profits: $-33,121 Employees: 877 2000 Sales: $200,830 2000 Profits: $-53,990 Fiscal Year Ends: 12/31 1999 Sales: $109,074 1999 Profits: $-25,504 1998 Sales: $52,413 1998 Profits: $-26,800
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $470,194 Stock Purch. Plan: Second Exec. Salary: $420,196 ADVANTAGE: Owns leading gene analysis technology/Growth through acquisitions.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $500,000 Bonus: $300,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
AGILENT TECHNOLOGIES INC
www.agilent.com
Industry Group Code: 334515 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:6
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Test Equipment Fiber Optic Communication Devices Image Sensors Patient Monitoring Equipment Ultrasound Imaging Equipment Bioinstrumentation
Agilent Technologies, Inc. is an international diversified technology company that manufactures instruments, test equipment and other solutions to markets within the communications, electronics, life sciences and chemical analysis industries. The company separated from Hewlett-Packard as part of a corporate realignment. Agilent operates through three main businesses: test and measurement, semiconductor products and life sciences and chemical analysis. Its test and measurement business provides standard and customized solutions that are used in the design, development, manufacture, installation, deployment and operation of electronic equipment and systems and communications networks and services. These solutions include test and measurement instruments and systems, automated test equipment, communications network monitoring, management, optimization tools, software design tools and associated services. The company’s semiconductor products business is a leading supplier of semiconductor components, modules and assemblies for highperformance communications systems. It designs, develops and manufactures products for the networking and personal systems markets. Agilent’s life sciences and chemical analysis business provides application-focused solutions that include instruments, software, consumables and services that enable customers to identify, quantify and analyze the physical and biological properties of substances and products. The seven key product categories include: microarrays, microfluidics, gas chromatography, liquid chromatography, mass spectrometry, informatics and related consumables and services. Agilent recently introduced the HFBR-1506AM transmitter and HFBR-2506AM receiver to be used in industrial networks. The company offers employees retirement savings, profit sharing, educational reimbursement, flexible work hours, flexible time off, sports teams and health and fitness facilities. Agilent also provides flexible maternity benefits and telecommuting. Dress code is business casual.
BRANDS/DIVISIONS/AFFILIATES: Agilent 1100 Series Hewlett-Packard Co. HFBR-1506AM HFBR-2506AM
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Edward W. Barnholt, CEO William P. Sullivan, Exec. VP/COO Edward W. Barnholt, Pres. Adrian T. Dillon, CFO Larry C. Holmberg, Sr. VP-Sales, Mktg. and Customer Support Jean M. Halloran, VP-Human Resources Thomas A. Saponas, Chief Tech. Officer Marty Chuck, CIO Dorothy D. Hayes, Controller G. Craig Nordlund, Corp. Sec. G. Craig Nordlund, General Counsel William R. Hahn, Sr. VP-Strategic Programs William R. Hahn, Sr. VP-Corp. Rel. William P. Sullivan, Sr. VP-Semiconductor Products Jack P. Trautman, Sr. VP/General Mgr.-Automated Test Group Chris van Ingen, Sr. VP/General Mgr.-Life Sciences Thomas White, Sr. VP/General Mgr.-Comm. Solutions Edward W. Barnholt, Chmn.
Phone: 650-752-5000 Fax: 650-752-5633 Toll-Free: Address: 395 Page Mill Rd., Palo Alto, CA 94306 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $6,010,000 (12 months) 2002 Profits: $-1,032,000 (12 months) Stock Ticker: A 2001 Sales: $8,396,000 2001 Profits: $168,000 Employees: 36,000 2000 Sales: $10,773,000 2000 Profits: $757,000 Fiscal Year Ends: 10/31 1999 Sales: $8,331,000 1999 Profits: $512,000 1998 Sales: $7,952,000 1998 Profits: $257,000
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $925,000 Stock Purch. Plan: Second Exec. Salary: $552,493 ADVANTAGE: Operates worldwide/One of the world's leaders in testing products.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $474,684 Bonus: $650,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
AIR PRODUCTS & CHEMICALS INC
www.airproducts.com
Industry Group Code: 325000 Ranks within this company's industry group: Sales:6 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:3
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Y Oil/Chem. Svcs.: Gases: Y Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Industrial Gases & Chemicals Manufacturer Air Pollution Control Equipment
Air Products and Chemicals is a leader in the United States industrial gases market. It produces argon, helium, hydrogen, nitrogen, oxygen and other gases. The company serves corporations in the steel and petroleum industries, the chemical processing business and electronics manufacturing. The company also produces chemicals, air pollution control equipment and hydrogen purification systems. Air Products continues to grow its wide-scale distribution of industrial gases through the establishment of on-site plants. The company recently acquired Sanwa Chemical Industry Co., Ltd., a leading Japanese producer of specialty polyamide resins and epoxy curing agents with operations in Tokyo, Japan and in Singapore. The acquisition marks Air Products' first performance products operations in Asia and will enhance existing performance materials division businesses currently operating in the region. Air Products entered into a 10-year agreement with Boeing for the supply of highpressure helium and a proprietary pumping system, to be used by Boeing's Delta IV rocket program in California. The rocket system is part of an ongoing U.S. Air Force initiative to reduce space launch costs through use of evolved expendable launch vehicles. The firm also signed an exclusive multi-year agreement to supply Shanghai LanBao Photoelectric Materials Co., Ltd of China with its ultra-high purity White Ammonia product, as well as other electronic specialty gases. In other news, Air Products agreed to build, own and operate a 34-million standardcubic-feet-per-day hydrogen facility for Catlettsburg Refining, a subsidiary of Marathon Ashland Petroleum. To encourage, recognize and reward outstanding environmental, health and safety achievements, Air Products recently created the EH&S Leadership Awards Program. The company strives to demonstrate integrity and ethical conduct in its business and professional relationships. The company is also focused on employee and product safety and respect for the environment. In fact, Air Products now enjoys one of the safest workplaces of any company in its industry.
BRANDS/DIVISIONS/AFFILIATES: Sanwa Chemical Industry Co. BOC Group
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John P. Jones, III, CEO John P. Jones, III, Pres. John R. Owings, CFO Leonard V. Broese van Groenou, VP-Human Resources Miles P. Drake, Chief Tech. Officer Joseph H. McMakin, VP-Global IT Paul E. Huck, Controller Nirmal Chatterjee, VP-Corp. Eng. W. Douglas Brown, Corp. Sec. W. Douglas Brown, General Counsel Hermann Ortega, VP-Oper. Michael Parsell, VP-Bus. Dev. Alexander W. Masetti, VP-Investor Rel. Marshall L. Sullivan, Treas. Mark L. Bye, Pres.-Air Products Asia Jeffry L. Byrne, VP-Chemical and Process Industries William J. Cantwell, VP-Process Mgmt. Cecil C. Chappelow, VP-Gases and Equipment Tech. John P. Jones, III, Chmn.
Phone: 610-481-4911 Fax: 610-481-5900 Toll-Free: Address: 7201 Hamilton Blvd., Allentown, PA 18195 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $5,401,000 (12 months) 2002 Profits: $525,000 (12 months) Stock Ticker: APD 2001 Sales: $5,717,200 2001 Profits: $560,200 Employees: 17,200 2000 Sales: $5,467,100 2000 Profits: $124,200 Fiscal Year Ends: 9/30 1999 Sales: $5,039,800 1999 Profits: $450,500 1998 Sales: $4,934,500 1998 Profits: $546,800
SALARIES/BENEFITS: Pension Plan: Y Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $900,000 Stock Purch. Plan: Second Exec. Salary: $620,000 ADVANTAGE: Worldwide operations/Large market share.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
AIRBUS SAS
www.airbus.com
Industry Group Code: 336410 Ranks within this company's industry group: Sales:4 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Profits: Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Aircraft Manufacturer
Airbus SAS, a joint venture formed by the European Aeronautic Defense and Space Company and U.K.-based BAE Systems, is the world’s second-largest commercial aircraft manufacturer behind Boeing. The company currently has more than 2,700 aircraft in operation. Airbus’s single-aisle and wide-body jets have capacities ranging from 110 to 400 passengers. The firm’s A380 model, due in 2006, will carry 555 passengers. The company also produces A300, A310, A318, A319, A320, A330, A340 and 600ST aircraft as well as corporate jetliners and freighters. Airbus has operations in nearly 200 locations around the globe that are overseen by its divisions: Airbus North America, Airbus China, Airbus Japan and Airbus Transport International. Engineering operations are organized around five main design offices, which manufacture cockpit systems and avionics; fuselage, fin, cabin interior and pressurization and air conditioning systems; wings, fuel systems and landing gear; flap and slat systems and cargo holds and handling systems; and horizontal and other tail plane systems. In recent news, Airbus signed an agreement with U.S. Airways, following its emergence from bankruptcy protection, to replace a prior order of aircraft and more than double the size of U.S. Airways’ fleet of Airbus widebody aircraft. China Aviation Supplies and JetBlue Airways signed agreements with Airbus for aircraft to be delivered beginning in 2004. Also, Airbus recently delivered aircraft to Thomas Cook Airlines and PrivatAir, a German business aviation specialist. There are at least 50 different nationalities and over 20 languages spoken among Airbus's 45,000 employees. English is the company's working language.
BRANDS/DIVISIONS/AFFILIATES: European Aeronautic Defence and Space Co. BAE Systems Airbus North America Airbus Transport International Airbus China Airbus Japan A380
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Noel Forgeard, CEO Gustav Humbert, COO Noel Forgeard, Pres. Andreas Sperl, CFO Erik Pillet, Exec. VP-Human Resources Alain Garcia, Exec. VP/Pres.-Eng. Karl-Heinz Hartmann, Exec. VP-Mfg. Philippe Delmas, Exec. VP-Gov't Rel., Comm. and External Affairs Bill Black, Exec. VP-Quality and Integration Ray Wilson, Exec. VP-Procurement Francisco Fernandez Sainz, Exec. VP/Pres.-Airbus Military SAS John Leahy, Chief Commercial Officer Manfred Bischoff, Chmn.
Phone: 33-5-61-93-33-87 Fax: 33-5-61-93-49-55 Toll-Free: Address: One Rond Point Maurice Bellonte, Blagnac Cedex, 31707 France
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $20,333,000 (12 months) 2002 Profits: $ (12 months) Stock Ticker: Foreign 2001 Sales: $18,159,000 2001 Profits: $ Employees: 46,000 2000 Sales: $ 2000 Profits: $ Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Growing market share worldwide.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $ Second Exec. Salary: $
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West:
Southwest: Y
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
AKORN INC
www.akorn.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:64 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:58
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Ophthalmic and Injectable Surgical Products
Akorn, Inc. manufactures and markets diagnostic and therapeutic pharmaceuticals in specialty areas such as ophthalmology, rheumatology, anesthesia and antidotes. Through its ophthalmics division, the company markets an extensive line of diagnostic and therapeutic ophthalmic pharmaceutical products as well as surgical instruments and related supplies. Diagnostic products, primarily used in the office setting, include mydriatics, cycloplegics, anesthetics, topical stains, gonioscopic solutions and angiography dyes. Therapeutic products, sold primarily to wholesalers and other national account customers, include antibiotics, anti-infectives, steroids, steroid combinations, glaucoma medications, decongestants/antihistamines and anti-edema medications. Akorn also markets surgical products such as surgical instruments, balanced salt solution, post-operative kits, surgical tapes, eye shields, anti-ultraviolet goggles, facial drape supports and other supplies. Non-pharmaceutical products include various artificial tear solutions, preservative-free lubricating ointments, lid cleansers, vitamin supplements and contact lens accessories. Additionally, Akorn markets a line of specialty injectable pharmaceutical products, including anesthesia products used in the treatment of rheumatoid arthritis and pain management. Contract services and injectable pharmaceutical products are marketed under the name Taylor Pharmaceuticals, a former subsidiary that has been absorbed into the company. The Taylor name is used because of its recognizability. In recent news, the company received approval from the U.S. Food and Drug Administration for Lidocaine Jelly 2%, which is used as a topical anesthetic by urologists and hospitals. The company provides its employees with tuition reimbursement and a comprehensive health benefits plan.
BRANDS/DIVISIONS/AFFILIATES: Taylor Pharmaceuticals, Inc. Lidocaine Jelly
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Arthur S. Przybyl, CEO Arthur S. Przybyl, COO Arthur S. Przybyl, Pres. Ben J. Pothast, VP/CFO Abu Alam, VP-Research and Dev. Ben J. Pothast, Corp. Sec. Ben J. Pothast, Treas. John N. Kooper, Chmn.
Phone: 847-279-6100 Fax: 847-279-6123 Toll-Free: 800-535-7155 Address: 2500 Millbrook Dr., Buffalo Grove, IL 60089-4694 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $51,419 (12 months) 2002 Profits: $-12,952 (12 months) Stock Ticker: AKRN 2001 Sales: $42,200 2001 Profits: $-19,600 Employees: 326 2000 Sales: $66,927 2000 Profits: $2,187 Fiscal Year Ends: 12/31 1999 Sales: $64,632 1999 Profits: $6,670 1998 Sales: $56,667 1998 Profits: $4,647
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $148,263 Stock Purch. Plan: Y Second Exec. Salary: $145,186 ADVANTAGE: Merger with Pasadena Research Laboratories, Inc.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $137,116 Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
ALARIS MEDICAL INC
www.alarismed.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:25 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:28
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Equipment-Infusion Systems Intravenous Infusion Pumps Pacemaker Recorders
Alaris Medical, Inc. is a leading provider of infusion systems and related technologies to the United States hospital and international infusion systems markets. The company’s intravenous infusion systems are used to deliver one or more fluids, primarily pharmaceuticals or nutritionals, to patients. The systems consist of medication safety systems, single- and multi-channel large volume infusion pumps, syringe pumps and dedicated and non-dedicated disposable administration sets. In addition, Alaris Medical is a leading provider of patient monitoring products that measure and monitor temperature, pulse, pulse oximetry and blood pressure. The company’s Medley Medication Safety System permits integration of administration, monitoring and clinical best practice guidelines from a single platform. The infusion pumps include large-volume infusion pumps such as the Gemini series, Signature Edition Family, MedSystem III and Asena GW and syringe infusion pumps such as P1000, P3000, PCAM, P6000, P7000 and Asena GS, GH and CC, which are sold primarily in Western Europe. Alaris Medical also manufactures and markets hospital thermometry instruments, related disposable probe covers and stand-alone, non-invasive, multi-parameter instruments, which measure and monitor a combination of temperature, pulse and blood pressure and other vital signs. The Alaris Center for Medication Safety and Clinical Improvement informs health care professionals of the risks associated with critical drug delivery errors. Alaris Medical’s wholly-owned subsidiary, Alaris Medical Systems, Inc., develops solutions for medication safety. Recently, the subsidiary was granted a patent license relating to needle-free valve products from Filtertek, Inc.
BRANDS/DIVISIONS/AFFILIATES: Alaris Medical Systems, Inc. Signature Edition Family Medley Medication Safety System MedSystem III P1000 Asena Gemini PCAM
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. David L. Schlotterbeck, CEO David L. Schlotterbeck, Pres. William C. Bopp, Sr. VP/CFO Kevin Whitely, VP-Mktg. James Runchey, VP-Human Resources Stuart Rickerson, Corp. Sec. Stuart Rickerson, VP/General Counsel Sally M. Grigoriev, VP-Oper. Anthony B. Semedo, VP-Corp. Dev. Bill Murphy, VP-Quality and Regulatory Affairs Jake St. Philip, VP/Mgr.-North America Robert F. Mathews, VP-Finance Frederic Denerolle, VP/Mgr.-Int'l Bus. Unit
Phone: 858-458-7000 Fax: 858-458-7760 Toll-Free: 800-854-7128 Address: 10221 Wateridge Cir., San Diego, CA 92121-2772 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $460,300 (12 months) 2002 Profits: $8,200 (12 months) Stock Ticker: AMI 2001 Sales: $412,800 2001 Profits: $-9,800 Employees: 2,899 2000 Sales: $378,948 2000 Profits: $-11,558 Fiscal Year Ends: 12/31 1999 Sales: $389,927 1999 Profits: $-28,400 1998 Sales: $373,795 1998 Profits: $-24,400
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $493,275 Stock Purch. Plan: Y Second Exec. Salary: $283,165 ADVANTAGE: A global leader in infusion systems and proprietary disposable products.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $712,001 Bonus: $181,371
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ALBANY MOLECULAR RESEARCH
www.albmolecular.com
Industry Group Code: 541710 Ranks within this company's industry group: Sales:6 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:3
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Research and Development Services Drug Discovery and Development
Albany Molecular Research, Inc. (Albany) is a leading, fully integrated provider of drug discovery and development, chemistry research and manufacturing services to companies in the pharmaceutical, genomic and biotechnology industries. Albany also provides contract chemistry services to customers across the entire product development cycle, from lead discovery to commercial manufacturing. These services include drug discovery, medicinal chemistry, chemical development, analytical chemistry services and small-scale and pilot-plant manufacturing. The company has also expanded its service offerings to include commercial manufacturing through its strategic relationship with Organichem Corporation. Albany’s services permit its customers to reduce overall drug development time and cost and to simultaneously pursue a greater number of drug discovery and development opportunities. Albany’s proprietary research and development activities led to the development, patenting and manufacturing of a substantially pure form of the active ingredient in the nonsedating antihistamine marketed by Aventis as Allegra. The company’s key research facilities include Albany Research Center, Bothell Research Center, Bruno Biotechnology Development Center and Syracuse Research Center. Recently, Albany added drug metabolism assay and metabolite production capabilities to its drug discovery and development technologies, which will provide information concerning the metabolic properties and enzyme interactions of compounds. In other news, the company signed a three-year drug discovery research agreement with Merck & Co., Inc. Under this agreement, Albany will perform chemistry research and lead optimization using computer-assisted chemical design and synthesis technologies. Albany also announced a drug discovery collaboration with Genzyme Corp., in which it will provide libraries of natural product extracts for biological screening.
BRANDS/DIVISIONS/AFFILIATES: Allegra Organichem Corp. Flourous Technologies, Inc. EnzyMed Bothell Research Center Syracuse Research Center Bruno Biotechnology Development Center Albany Research Center
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Thomas E. D'Ambra, CEO Donald E. Kuhla, COO Donald E. Kuhla, Pres. David P. Waldek, CFO Harold Meckler, VP-Science and Tech. David P. Waldek, Corp. Sec. James J. Grates, VP-Oper. Lawrence D. Jones, Sr. VP-Bus. Dev. David P. Waldek, Treas. Barry A. Berkowitz, Corp. VP Michael P. Trova, Sr. VP-Medicinal Chemistry Thomas E. D'Ambra, Chmn.
Phone: 518-464-0279 Fax: 518-464-0289 Toll-Free: Address: 21 Corporate Circle, Albany, NY 12203 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $122,800 (12 months) 2002 Profits: $40,600 (12 months) Stock Ticker: AMRI 2001 Sales: $56,800 2001 Profits: $34,400 Employees: 860 2000 Sales: $66,603 2000 Profits: $23,593 Fiscal Year Ends: 12/31 1999 Sales: $43,471 1999 Profits: $13,800 1998 Sales: $33,294 1998 Profits: $10,497
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $279,231 Stock Purch. Plan: Second Exec. Salary: $250,000 ADVANTAGE: Highly diversified research and development.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $108,750 Bonus: $36,000
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
ALBEMARLE CORPORATION
www.albemarle.com
Industry Group Code: 325000 Ranks within this company's industry group: Sales:14 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:8
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Y Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Polymer and Fine Chemicals Manufacturer
Albemarle Corporation is a producer of polymer and fine chemicals, including additives to or intermediates for plastics, elastomers, cleaning products, agricultural compounds, pharmaceuticals, photographic chemicals, drilling compounds and biocides. The majority of the firm’s sales are made directly to cleaning product manufacturers and chemical, pharmaceutical, drilling and water treatment companies. The company’s Polymer Chemicals division manufactures flame retardants that enable polymer materials to meet fire-safety requirements. Additionally, the division is a leading producer of aluminum alkyls, which are used as co-catalysts in the production of polyolefins. The firm’s Fine Chemicals division produces agrichemicals and alkyl and inorganic bromides. The division’s bromine-based chemicals are often utilized during chemical synthesis, oil and gas well drilling, water purification and glass production. Albemarle has entered into a joint venture with Arab Potash Company, Ltd. in order to expand its bromine production capabilities. The Fine Chemicals division is also a leading manufacturer of ibuprofen. Moreover, the division’s pilot plant in Dayton, Ohio produces pharmaceutical intermediaries for a wide array of drugs under clinical trial. In recent news, Albemarle has acquired Ethyl Corporation’s fuel and lubricant antioxidants working capital, patents and intellectual property for $27 million.
BRANDS/DIVISIONS/AFFILIATES: Polymer Chemicals Division Fine Chemicals Division Arab Potash Company, Ltd.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Mark C. Rohr, CEO Mark C. Rohr, Pres. Paul F. Rocheleau, CFO John M. Steitz, VP-Bus. Oper. E. Whitehead Elmore, Exec. VP William M. Gottwald, Chmn.
Phone: 804-788-6000 Fax: 804-788-6020 Toll-Free: 800-535-3030 Address: 330 S. Fourth St., PO Box 1335, Richmond, VA 23219 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $980,200 (12 months) 2002 Profits: $74,700 (12 months) Stock Ticker: ALB 2001 Sales: $916,900 2001 Profits: $68,200 Employees: 3,000 2000 Sales: $917,500 2000 Profits: $101,800 Fiscal Year Ends: 12/31 1999 Sales: $845,900 1999 Profits: $88,800 1998 Sales: $820,900 1998 Profits: $84,700
SALARIES/BENEFITS: Pension Plan: Y Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: High profit margins.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $528,850 Second Exec. Salary: $500,000
Bonus: $170,000 Bonus: $175,000
LOCATIONS: ("Y" = Yes) West:
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ALCATEL USA INC
www.usa.alcatel.com
Industry Group Code: 334210 Ranks within this company's industry group: Sales: Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Transmission Equipment-Data, Video and Voice Network System Products
Alcatel USA, Inc. designs, develops, manufactures and markets digital switching, transmission, access and private network system products for the worldwide telecommunications marketplace. Alcatel USA was formed when the Plano, Texas-based company DSC Communications was purchased by Paris-based Alcatel, Inc. Products offered by the company allow telecommunications service providers to build and upgrade their networks to support a wide range of voice, data and video services. The company supplies products to a domestic and international customer base, including local exchange telephone companies, long-distance carriers, cellular telephone companies, international telephone companies, various Fortune 1000 companies and utility companies. Alcatel's domestic customers include the RHCs and most major domestic independent telephone and long-distance companies, including WorldCom, U.S. Sprint Communications Company and GTE Communications Systems. In recent news, the company sold the majority of its assets to Sanmina.
BRANDS/DIVISIONS/AFFILIATES: Litespan-2000 Starspan Metrospan Airspan NKT Elektronic A/S Alcatel DSC/Celcore, Inc. Sanmina
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Serge Tchuruk, CEO Andre Navarri, COO Andre Navarri, Pres. Jean-Pascal Beaufret, CFO Thomas Edig, Sr. VP-Corp. Human Resources Niel Ransom, Chief Tech. Officer Pascal Durand-Barthez, General Counsel Olivier Baujard, VP-Corp. Strategy Olivier Houssin, Pres.-e-Bus. Group Caroline Mille, Sr. VP-Corp. Comm. Claire Pedini, VP-Investor Rel. Etienne Fouques, Exec. VP/Pres.-Mobile Comm. Group Christian Reinaudo, Exec. VP Jacques Dunoque, Pres.-Europe and South America Mike Quigley, Sr. Exec. VP/Pres.-North America Serge Tchuruk, Chmn. Ron Spithill, Exec. VP/Pres.-Asia Pacific
Phone: 972-477-2555 Fax: 972-519-3999 Toll-Free: Address: 1000 Coit Rd., Plano, TX 75075 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Private 2001 Sales: $ 2001 Profits: $ Employees: 2000 Sales: $ 2000 Profits: $ Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Y Second Exec. Salary: $ ADVANTAGE: A leader in proprietary architecture for digital switching, with offices worldwide.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ALCON LABORATORIES INC
www.alconlabs.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:14 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:13
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Manufacturer Ophthalmic Equipment Manufacturer
Founded in 1945, Alcon Laboratories is the largest eye care company in the world. It specializes in the development, manufacture and marketing of ophthalmic products and instrumentation. The firm was a subsidiary of Swiss food giant Nestlé, S.A. until it was spun off in March 2002. Nestlé currently owns about 75% of the company. Alcon maintains manufacturing plants, laboratories and offices in 50 countries. Its products are sold in over 75 countries. The company makes more than 10,000 unique products including prescription and over the counter drugs, contact lens solutions, surgical instruments, intraocular lenses and office systems for ophthalmologists. Brand names such as the Acrysof foldable lens, Patanol solution for eye allergies, AcrySof intraocular lenses, Betoptic for glaucoma and the Opti-Free system for contact lens care are known throughout the world. Alcon has a history of heavy investment in research and development. Housed at the company's headquarters in Fort Worth is the 400,000 square-foot William C. Conner Research Center, the largest eye research center in the world. From 2002 through 2005, Alcon plans to spend more than $1 billion on eye-related research, more than any entity outside of the National Eye Institute. Alcon's subsidiaries include Alcon Summit Autonomous, Alcon Surgical, Inc. and Falcon Pharmaceuticals, Ltd. Alcon offers employee education programs, wellness programs, a dependent care plan and an employee credit union. Some locations offer onsite fitness centers, cafeterias and company stores. Alcon also offers discounts on laser eye surgery.
BRANDS/DIVISIONS/AFFILIATES: Opti-Free Patanol Vexol AcrySof Alcon Summit Autonomous Nestlé, S.A. LADARVision Falcon Pharmaceuticals
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Tim Sear, CEO Allen Baker, Exec. VP/COO Tim Sear, Pres. Charles Miller, Sr. VP-Finance/CFO Jack Walters, VP-Human Resources Gerald D. Cagle, Sr. VP-Research and Dev. Andre Bens, Sr. VP-Global Mfg. Cary Rayment, Sr. VP-U.S. Oper. Mary Dulle, Dir.-Corp. Comm. Andre Bens, Tech. Support Fred Pettinato, Sr. VP-Int'l Oper.
Phone: 817-551-6878 Fax: 817-568-7201 Toll-Free: Address: 6201 South Fwy., Ft. Worth, TX 76134 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $3,009,100 (12 months) 2002 Profits: $466,900 (12 months) Stock Ticker: ACL 2001 Sales: $2,747,700 2001 Profits: $315,600 Employees: 11,000 2000 Sales: $2,553,600 2000 Profits: $331,700 Fiscal Year Ends: 12/31 1999 Sales: $2,401,000 1999 Profits: $346,900 1998 Sales: $2,174,000 1998 Profits: $335,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Stock Purch. Plan: ADVANTAGE: A global leader in eye care.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $ Second Exec. Salary: $
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest:
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ALKERMES INC
www.alkermes.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:32 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:38
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Sustained-Release Injection Systems
Alkermes specializes in the development of sophisticated drug delivery technologies. Two of the company's main areas of focus, ProLease and Medisorb technologies, release injectable drugs in controlled amounts over a specified short period of time. Significant concentration is also placed on Alkermes’ Advanced Inhalation Research (AIR) technology, a major innovation among pulmonary delivery systems, which maximizes drug delivery to the lungs. Aside from patenting new products, the company’s expansion is concentrated toward forming partnerships to license its products. Alkermes first product, Nutropin Depot, developed in collaboration with Genetech, Inc., is based on ProLease technology. Risperdal Consta, an anti-psychotic drug developed in collaboration with Janssen Pharmaceutica, is based on Medisorb technology and is expected to be the firm’s second product to reach the U.S. market. Recently, the company announced its partner, Johnson & Johnson Pharmaceutical Research and Development, received approval to market Risperdal Consta in Germany. Alkermes also entered an alliance with Eli Lilly and Company to develop an inhaled form of insulin for the treatment of diabetes based on the Alkermes AIR pulmonary drug delivery system. The company has proprietary projects in development stages including Albuterol for the treatment of asthma and Vivitrex for the treatment of alcohol abuse. Employee benefits at Alkermes include tuition reimbursement, a comprehensive health plan and transportation subsidies. Notably, every employee starts with an allowance of three weeks of vacation time per year.
BRANDS/DIVISIONS/AFFILIATES: ProLease Medisorb Nutropin Depot Albuterol Vivitrex Albulast Risperdal Consta AIR
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Richard F. Pops, CEO David Broecker, COO David Broecker, Pres. James M. Frates, VP/CFO J. Duncan Higgons, Sr. VP-Mktg. Raymond T. Bartus, Sr. VP-Life Sciences Research and Dev. Elliot W. Ehrich, VP-Medical Affairs Gordon Pugh, VP-Oper. J. Duncan Higgons, Sr. VP-Bus. Dev. James M. Frates, Treas. Michael J. Landine, VP-Corp. Dev. Paul F. Hebert, VP-Process Dev. Stephen E. Zale, VP-Formulations
Phone: 617-494-0171 Fax: 617-494-9263 Toll-Free: Address: 88 Sidney St., Cambridge, MA 02139-4234 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $54,100 (12 months) 2002 Profits: $-61,400 (12 months) Stock Ticker: ALKS 2001 Sales: $56,000 2001 Profits: $-16,900 Employees: 415 2000 Sales: $22,900 2000 Profits: $-68,000 Fiscal Year Ends: 3/31 1999 Sales: $33,900 1999 Profits: $-41,100 1998 Sales: $25,500 1998 Profits: $-12,600
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $406,462 Stock Purch. Plan: Y Second Exec. Salary: $294,685 ADVANTAGE: Focus on new drug delivery technologies.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $175,000 Bonus: $100,000
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ALLERGAN INC
www.allergan.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:18 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:26
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Supplies-Eye Care Niche Pharmaceuticals
Allergan is a technology-driven global health care company that develops and commercializes specialty pharmaceutical products for the ophthalmic, neurological, dermatological and other specialty markets. The company focuses on products for the treatment of a wide range of disease areas, including glaucoma and retinal disease, cataracts, dry eye, psoriasis, acne, photodamage, movement disorders, metabolic disease and various cancers. The company recently completed the spin-off of its optical medical device business. The spin-off was effected by contributing the company’s optical medical device business to a newly formed subsidiary, Advanced Medical Optics, Inc. The company produces Alphagan and Lumigan ophthalmic solutions, which are used for the treatment of open-angle glaucoma and ocular hypertension. Botox is used therapeutically in the treatment of certain neuromuscular disorders which are characterized by involuntary muscle contractions or spasms. The FDA recently granted approval for the use of Botox in smoothing wrinkles. This innovative application of the muscle relaxant has become one of the fastest growing cosmetic treatments performed by surgeons in the United States. Allergan’s skin care product line is comprised of tazarotene products in cream and gel formulations marketed under the names Tazorac, Zorac and Avage; Azelex, an acne product; and M.D. Forte, a line of alpha hydroxy acid products for ultraviolet sunscreen protection. Other products introduced by Allergan include Array multifocal lens for cataract patients and Refresh Tears for dry eyes. In recent news, the company announced that the FDA approved its antiinfective ZYMAR product. ZYMAR was developed to treat ocular infection due to susceptible bacteria.
BRANDS/DIVISIONS/AFFILIATES: Alphagan Lumigan Azelex Tazorac Botox Refresh Tears ZYMAR Advanced Medical Optics, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. David E.I. Pyott, CEO David E.I. Pyott, Pres. Eric Brandt, VP/CFO Lester J. Kaplan, VP/Pres.-Research and Dev. Douglas S. Ingram, VP/Corp. Sec. Douglas S. Ingram, General Counsel Jacqueline J. Schiavo, VP-Oper. Jeffrey L. Edwards, VP-Corp. Dev. Jeffrey L. Edwards, VP-Investor Rel. Jeffrey L. Edwards, Treas. David A. Fellows, VP/Pres.-Europe, Africa and Asia Pacific Region Nelson R. A. Marques, VP/Pres.-Latin American Region F. Michael Ball, VP/Pres.-North American Region David E.I. Pyott, Chmn.
Phone: 714-246-4500 Fax: 714-246-4971 Toll-Free: 800-347-4500 Address: 2525 Dupont Dr., Irvine, CA 92612-9534 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,425,300 (12 months) 2002 Profits: $75,200 (12 months) Stock Ticker: AGN 2001 Sales: $1,745,500 2001 Profits: $224,900 Employees: 4,900 2000 Sales: $1,625,500 2000 Profits: $215,100 Fiscal Year Ends: 12/31 1999 Sales: $1,452,400 1999 Profits: $188,200 1998 Sales: $1,296,100 1998 Profits: $-90,200
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Technology-based growth strategy.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $870,384 Second Exec. Salary: $367,538
Bonus: $875,000 Bonus: $223,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ALLIANCE PHARMACEUTICAL CORP Industry Group Code: 325412 Ranks within this company's industry group: Sales:103 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
www.allp.com Profits:73
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Cardiovascular and Respiratory Diagnostic Products
Alliance Pharmaceutical Corp. uses perfluorochemical and surfactant technologies to develop therapeutic and diagnostic products. The firm’s products are primarily intended for use during acute care situations, including cardiology and surgical applications. The company’s leading product candidate, Oxygent, is an intravascular oxygen carrier designed to augment oxygen delivery in surgical patients at risk of acute tissue oxygen deficit. Oxygent is primarily intended to provide oxygen to tissues during elective surgeries in which a blood transfusion is anticipated. The blood substitute is universally compatible with all blood types and has a shelf-life of approximately two years. A single unit of Oxygent is expected to deliver as much oxygen as one to two units of red blood cells. The company and Baxter Healthcare Corporation have formed a joint venture to further develop and market Oxygent in the United States, Canada and Europe. Additionally, Alliance manufactures Imagent, an intravenous contrast agent designed to enhance ultrasound images of the heart. Recently, the company agreed to sell its Imagent assets to Photogen Technologies. The company’s Molecular Biosystems subsidiary manufactures Optison, an intravenous ultrasound contrast agent that is marketed by Amersham in the United States and Europe.
BRANDS/DIVISIONS/AFFILIATES: Oxygent Molecular Biosystems Optison
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Duane J. Roth, CEO Tim Hart, CFO B. Jack DeFranco, VP-Mktg. Dev. Carole McWilson, Dir.-Human Resources David H. Klein, Sr. VP-Pharmaceutical Dev. N. Simon Faithfull, VP-Medical Affairs Joni Harvey, VP-Oper. Gwen Rosenberg, VP-Corp. Comm. Tim Hart, Treas. H. Joerg Limmer, VP-Clinical Dev. Christiane O. Rockwell, VP-Quality Assurance Duane J. Roth, Chmn.
Phone: 858-410-5200 Fax: 858-410-5201 Toll-Free: Address: 6175 Lusk Blvd., San Diego, CA 92121 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $10,300 (12 months) 2002 Profits: $-34,200 (12 months) Stock Ticker: ALLP.OB 2001 Sales: $1,900 2001 Profits: $-60,700 Employees: 92 2000 Sales: $16,000 2000 Profits: $-46,467 Fiscal Year Ends: 6/30 1999 Sales: $8,251 1999 Profits: $-62,473 1998 Sales: $21,209 1998 Profits: $-33,003
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $472,850 Bonus: $200,000 Stock Purch. Plan: Second Exec. Salary: $351,260 Bonus: $110,000 Has several collaborative relationships with multinational pharmaceutical companies. ADVANTAGE:
OTHER THOUGHTS: Apparent Women Officers or Directors: 4 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
ALPHARMA INC
www.alpharma.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:20 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:86
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Animal Health Human Pharmaceuticals
Alpharma, Inc. is a multinational pharmaceutical company that develops, manufactures and markets specialty generic and proprietary human pharmaceutical and animal health products. The company is one of the largest manufacturers of generic liquid and topical pharmaceuticals in the United States and has an established and growing market position in finished pharmaceuticals in Europe and the Far East. Alpharma offers a comprehensive range of over 800 tablet, capsule, liquid and topical generic human phrmaceutical products and over 100 animal health products. It is one of the world's leading producers of important specialty antibiotics. The company is also known as a leading provider of animal feed additives for poultry and livestock and vaccines for farmed fish. Alpharma is continuing to strengthen its international market presence and is accelerating research and development for new products. The company's human pharmaceuticals business is comprised of the U.S. and international businesses. The U.S. human pharmaceuticals business is comprised of the generic and branded pharmaceuticals businesses. The human pharmaceuticals international business is comprised of the international generics and active pharmaceutical ingredients businesses. In recent news, the international generics segment divested its vitamin business to Nopal AS, a subsidiary of Industrier, the company's controlling stockholder. In connection with this sale, the unit entered into a supply agreement with Nopal to supply certain vitamin products and two distribution agreements, through which Nopal will continue to sell the company's medical plaster and tape products to the grocery sector, and the company will sell Nopal's acquired vitamin products to the pharmacy and health care sector.
BRANDS/DIVISIONS/AFFILIATES:
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Ingrid Wiik, CEO Ingrid Wiik, Pres. Matthew T. Farrell, Exec. VP/CFO Robert F. Wrobel, Exec. VP/Corp. Sec. Robert F. Wrobel, Chief Legal Officer Michael J. Nestor, Exec. VP/Pres.-U.S. Human Pharmaceuticals Carol A. Wrenn, Exec. VP/Pres.-Animal Health Div. Einar W. Sissener, Chmn.
Phone: 201-947-7774 Fax: 201-947-4879 Toll-Free: 800-645-4216 Address: One Executive Dr., Fort Lee, NJ 07024 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,238,000 (12 months) 2002 Profits: $-98,800 (12 months) Stock Ticker: ALO 2001 Sales: $975,000 2001 Profits: $-37,900 Employees: 4,700 2000 Sales: $919,523 2000 Profits: $61,143 Fiscal Year Ends: 12/31 1999 Sales: $732,443 1999 Profits: $36,972 1998 Sales: $604,584 1998 Profits: $24,211
SALARIES/BENEFITS: Pension Plan: Y Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $705,000 Stock Purch. Plan: Second Exec. Salary: $475,000 ADVANTAGE: The largest manufacturer of generic liquid and topical pharmaceuticals in the U.S.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $290,000 Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ALTERA CORP
www.altera.com
Industry Group Code: 334413 Ranks within this company's industry group: Sales:15 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:5
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Circuits-CMOS Programmable Logic Devices Development System Software
Altera Corporation designs, manufactures and markets high-performance, high-density programmable logic devices (PLDs); intellectual property cores, also known as megafunctions; and associated development tools. Founded in 1983, Altera was the first supplier of complementary metal oxide semiconductor (CMOS) PLDs and is currently a global leader in this market. Altera offers a broad range of general-purpose PLDs that present unique features as well as differing densities and performance specifications for implementing particular applications. Programmable logic's primary advantage is that it allows for quicker design cycles, meeting customers' needs for quick time-to-market. Programmable logic allows customers to experiment and iterate their designs in a relatively short amount of time and with minimum cost. In most instances, this is quicker and easier than achieving a design in a deterministic fashion. The firm offers a broad line of CMOS programmable logic devices that address high-speed, high-density and low-power applications. Its products serve a wide range of markets, including telecommunications, data communication, electronic data processing, computer peripheral and industrial applications. Altera’s proprietary development tools consists of the Quartus II and MAX+PLUS II software. These tools enable customers to design and program PLDs. Recently, Altera entered into a distribution agreement with Pioneer Standard Electronics, Inc. Pioneer will provide technical support and distribution to customers in North America. Altera offers its employees 85-100% paid dental and vision coverage, bonuses, maternity benefits, limited telecommuting allowances and gym membership benefits. There is no dress code.
BRANDS/DIVISIONS/AFFILIATES: APEX MAX+PLUS II MAX 7000 FLEX 8000 MAX 9000 Quartus II FLASHlogic Multi-Chip Module
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John Daane, CEO Denis M. Berlan, Exec. VP/COO John Daane, Pres. Nathan Sarkisian, Sr. VP/CFO Erik Cleage, Sr. VP-Mktg. John R. Finzhenry, VP-Human Resources Martin Langhammer, VP-Science John E. Turner, VP-Design Eng. Katherine Schuelke, Corp. Sec. Katherine Schuelke, General Counsel Thomas B. Murchie, VP-Oper. Lance Lissner, Sr. VP-Bus. Dev. Scott Wylie, VP-Investor Rel. George A. Papa, Sr. VP-Worldwide Sales Jordan Plofsky, Sr. VP-Vertical Markets John P. Daane, Chmn.
Phone: 408-544-7000 Fax: 408-544-8303 Toll-Free: Address: 101 Innovation Dr., San Jose, CA 95134-2020 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $711,700 (12 months) 2002 Profits: $91,300 (12 months) Stock Ticker: ALTR 2001 Sales: $839,400 2001 Profits: $-39,800 Employees: 1,882 2000 Sales: $1,376,800 2000 Profits: $496,900 Fiscal Year Ends: 12/31 1999 Sales: $836,600 1999 Profits: $224,000 1998 Sales: $654,300 1998 Profits: $154,400
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $614,815 Bonus: $450,000 Stock Purch. Plan: Y Second Exec. Salary: $472,935 Bonus: $1,116,150 Continual expansion of Altera's product lines, including the acquisition of the Intel programmable logic ADVANTAGE: business.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ALZA CORP
www.alza.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Drug Delivery Technologies Drug Therapies and Systems
ALZA Corporation, a wholly owned subsidiary of Johnson & Johnson, develops and markets innovative pharmaceutical products by using advanced drug delivery technologies to add medical and economic value to drug therapies. ALZA markets over 30 commercialized products and holds over 3,000 issued or pending patents worldwide. The company focuses on several therapeutic areas, including oncology, AIDS, pain management, endocrinology and urology. ALZA selects and develops new human pharmaceutical products, combining the company's proprietary drug delivery systems with various drug compounds. Some of the company’s more commonly known drugs are Ditropan XL for the treatment of urge urinary incontinence, DUROS for the palliative treatment of advanced prostate cancer, OROS for the treatment of attention deficit/hyperactivity disorder, ETRANS (fentanyl) for chronic pain, E-TRANS (LHRH) for infertility, E-TRANS Macroflux for Type II diabetes, Caelyx for the treatment of advanced ovarian cancer and NicoDerm CQ, which is a smoking-cessation aid. ALZA recently announced an expanded collaboration agreement with Pfizer, Inc. for Pfizer’s use of ALZA’s push-pull oral drug delivery technology. ALZA offers employees an extensive benefits package including 85% paid dental coverage, stock options, bonuses, adoption assistance, maternity leave, telecommuting and transit. In addition, the company also matches gifts to charities and has a holiday shutdown period and a sabbatical program.
BRANDS/DIVISIONS/AFFILIATES: Johnson & Johnson Pfizer, Inc. NicoDerm CQ Ditropan XL Caelyx DUROS OROS E-TRANS
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Howard B. Rosen, Pres. B. Michael Silber, VP-Research and Tech. Dev. Ellen Rose, Dir.-Corp. Comm. Kathy Kim, Corp. Comm. Specialist
Phone: 650-564-5000 Fax: 650-564-7070 Toll-Free: 800-233-5222 Address: 1900 Charleston Rd., Mountain View, CA 94039 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $ 2001 Profits: $ Employees: 2,442 2000 Sales: $988,500 2000 Profits: $223,300 Fiscal Year Ends: 12/31 1999 Sales: $795,900 1999 Profits: $91,000 1998 Sales: $646,900 1998 Profits: $108,300
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Advanced drug delivery technologies.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Top Exec. Salary: $ Second Exec. Salary: $
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
AMDOCS LTD
www.amdocs.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:11 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:6
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Computer Software-Customer Services & Business Operations Outsourcing Operations Customer Relationship Management
Amdocs, Ltd. is a holding company that provides information system solutions and software products and services to major communications companies in North America, Europe and other countries around the world. Its subsidiaries include Amdocs, Ltd. and Amdocs Management, Ltd. in the U.K.; Amdocs Development, Ltd. in Cyprus; Amdocs, Ltd. in Israel; Amdocs Software Systems, Ltd. in Ireland; Amdocs Canada, Inc.; and Amdocs, Inc., Amdocs Champaign, Inc. and Amdocs Stamford, Inc. in the United States. Amdocs provides products and services to leading communications and Internet protocol (IP) companies worldwide; these offerings include customer relationship management (CRM), billing and order management systems for communications providers and business support systems (BSS) for directory publishing companies. The firm's delivery options include stand-alone applications modules, pre-integrated products, product-based customized solutions and a range of outsourcing operations. Amdocs' BSS products are software products designed to support the business operations of communications companies, including order management, call rating, invoice calculation, bill formatting, fraud management and collections. Its systems support a range of communications services, including wireline, wireless, broadband and electronic and mobile commerce. The firm's customers include Verizon, BellSouth, Deutsche Telekom, Sprint PCS and SBC Internet Services. In 2001, the company formed Certen, Inc. with Bell Canada to provide customer care and billing solutions to Bell Canada and its affiliated companies. Certen is 10%-owned by Amdocs. Recently Amdocs was chosen by Cable and Wireless, a global telecommunications group, to provide end-to-end billing and customer care for its mobile operations in the West Indies and Macau.
BRANDS/DIVISIONS/AFFILIATES: Amdocs Management, Ltd. Amdocs Development, Ltd. Amdocs, Inc. Amdocs Software Systems, Ltd. Amdocs Champaign, Inc. Amdocs Stamford, Inc. Bell Canada Certen, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Bruce K. Anderson, CEO Ron Moskovitz, CFO Paul Joseph, Dir.-Human Resources Thomas G. O'Brien, Corp. Sec. Thomas G. O'Brien, Dir.-Investor Rel. Thomas G. O'Brien, Treas. Dov Baharav, CEO/Pres., Amdocs Management Shlomo Baleli, Sr. VP, Amdocs Management Yigal Bar-Yossef, Sr. VP-UK Mario Segal, Sr. VP/COO, Amdocs Management
Phone: 314-212-7000 Fax: 314-212-7500 Toll-Free: 888-727-8508 Address: 1390 Timberlake Manor Pkwy., Chesterfield, MO 63017 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,613,600 (12 months) 2002 Profits: $249,000 (12 months) Stock Ticker: DOX 2001 Sales: $1,533,900 2001 Profits: $66,400 Employees: 9,000 2000 Sales: $1,118,300 2000 Profits: $6,000 Fiscal Year Ends: 9/30 1999 Sales: $626,900 1999 Profits: $98,500 1998 Sales: $403,800 1998 Profits: $30,400
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Y Second Exec. Salary: $ ADVANTAGE: A leading provider of customer service solutions for the Internet.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
AMERICAN MANAGEMENT SYSTEMS INC Industry Group Code: 541512 Ranks within this company's industry group: Sales:7 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
www.amsinc.com
Profits:6 Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Consulting-Computer System Integration & Design E-Commerce Programming Business & Technology Consulting E-Business & E-Government Soultions Homeland Security & Training Learning Solutions
American Management Systems (AMS) is an international information-technology consulting firm. The firm’s primary services include business and technology consulting, systems integration, e-business and e-government solutions, customer relationship management, information security, homeland security and training and learning solutions. The company’s focus industries include new media and communications firms, financial services institutions, state and local governments and education, federal government agencies and other corporate clients. AMS is a business partner for many of the largest and most respected organizations in its specialty markets, including eight out of 10 of the world’s largest communication firms; many of the top U.S. banks; most federal agencies; 43 state and local governments; some of the largest energy companies in the U.S., Canada and Europe; and hundreds of companies in the Fortune 500. Approximately 85% of the company’s revenues come from clients it has worked with in previous years. AMS has formed a cross-target market practice to focus on delivering high-value, customer-facing web solutions, including eBill, eCare and eMarketing - tailored to clients in the financial services, telecommunications, government and utilities sectors. These solutions help firms achieve greater cost savings, deliver improved customer service and leverage cross-sell and up-sell opportunities. The firm’s new eCustomer practice builds upon the company's existing e-commerce client base. Recently, AMS selected Marketswitch Corporation as a partner to deliver advanced decision management solutions. AMSprovides leading edge e-business services and solutions to transform both private and public businesses into organizations that fully utilize emerging technologies to succeed in the digital economy. AMS was spotlighted in Working Mother magazine's 100 Best Companies for Working Mothers. The firm hires a balanced mix of recent university graduates and experienced professionals.
BRANDS/DIVISIONS/AFFILIATES: AMS Management Systems Deutschland Nordic Business Management Systems AMS Management Systems Netherlands AMS Management Systems Australia AMS Management Systems Mexico
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Alfred T. Mockett, CEO William M. Purdy, COO William M. Purdy, Pres. John S. Brittain, Jr., CFO/Exec. VP Tim Matlack, Chief Human Resources Officer Paul Turner, Chief Tech. Officer/Exec. VP Frank A. Nicolai, Corp. Sec./Exec. VP Frank A. Nicolai, Chief Admin. Officer Greg Hero, Exec. VP-New Media and Comm. Ronald L. Schillereff, Exec. VP/Investor Relations John S. Brittain, Jr., Treasurer Ronald L. Schillereff, Exec. VP Larry R. Seidel, Exec. VP Donna Morea, Exec. VP Vernon Irvin, Exec. VP
Phone: 703-267-8000 Fax: 703-267-5073 Toll-Free: Address: 4050 Legato Rd., Fairfax, VA 22033 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $986,700 (12 months) 2002 Profits: $28,200 (12 months) Stock Ticker: AMSY 2001 Sales: $1,183,300 2001 Profits: $15,900 Employees: 6,300 2000 Sales: $1,279,300 2000 Profits: $43,800 Fiscal Year Ends: 12/31 1999 Sales: $1,240,300 1999 Profits: $56,900 1998 Sales: $1,057,800 1998 Profits: $51,800
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $400,000 Stock Purch. Plan: Y Second Exec. Salary: $66,667 ADVANTAGE: Expansion in Europe to answer a growing overseas need.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $150,000 Bonus: $1,046,666
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
AMERICAN SUPERCONDUCTOR
www.amsuper.com
Industry Group Code: 335929 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Superconductivity Products Power Electronic Switches Superconductivity Technology Electric Transmission Cables
American Superconductor Corp. is engaged in developing products using the company’s two core technologies, superconducting materials and power electronic switches. The firm produces high-temperature superconductor (HTS) wires, which are capable of carrying more than 140 times the electrical current of conventional copper wire of the same dimension. These wires can carry electric power with zero resistance, meaning no loss of electricity as it travels through the cable. American Superconductor also develops and markets advanced power electronic switches that control, modulate and move large amounts of power efficiently and inexpensively. The company sells products based on these two technologies to electrical equipment manufacturers, industrial power users and businesses that produce and deliver power. American Superconductor also manufactures and sells superconducting magnetic energy storage (SMES) systems, which are used by customers to improve power quality and reliability and increase power transfer capacity in constrained transmission grids. In order to accelerate commercial deployment of its products, American Superconductor has formed strategic alliances with major electric power infrastructure companies including Electricite de France, one of the world’s largest electric utilities, and General Electric. The company recently secured contracts from the Tennessee Valley Authority, Dupont, Northeast Utilities and Rayburn Electric. The firm also announced its selection by the U.S. Department of Energy as prime contractor for a high-temperature superconductor power transmission cable project in the Long Island Power Authority transmission grid. The nearly half-mile power cable system will be the world’s first live grid installation of a superconductor cable at transmission voltages. In other news, the company was selected by the U.S. Navy’s Office of Naval Research as prime contractor to lead a team in designing and building a prototype 36.5-megawatt high-temperature superconductor propulsion motor for electric warships. Benefits offered to employees include vision insurance, tuition reimbursement and wholesale club memberships.
BRANDS/DIVISIONS/AFFILIATES: Integrated Electronics, LLC GE Industrial Systems PowerModule
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Gregory J. Yurek, CEO Gregory J. Yurek, Pres. Kevin Bisson, CFO Chet Lyons, VP-Corp. Strategic Mktg. Michele L. Shindelman, VP-Human Resources Alexis P. Malozemoff, Sr. VP/Chief Tech. Officer Ross S. Gibson, Corp. Sec. Ross S. Gibson, VP/Chief Admin. Officer Thomas M. Rosa, VP-Acc. and Finance David Paratore, VP-SuperMachines Eric Snitgen, VP-AMSC Wires Charles W. Stankiewicz, VP-Power Electronic Systems Gregory J. Yurek, Chmn.
Phone: 508-836-4200 Fax: 508-836-4248 Toll-Free: Address: 2 Technology Dr., Westborough, MA 01581 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $11,700 (12 months) 2002 Profits: $-57,000 (12 months) Stock Ticker: AMSC 2001 Sales: $16,800 2001 Profits: $-21,700 Employees: 340 2000 Sales: $15,100 2000 Profits: $-17,600 Fiscal Year Ends: 3/31 1999 Sales: $11,300 1999 Profits: $-15,300 1998 Sales: $15,100 1998 Profits: $-12,400
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $365,750 Stock Purch. Plan: Second Exec. Salary: $228,228 ADVANTAGE: Excellent technology/Strong government contracts.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $122,500 Bonus: $43,770
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
AMEY PLC
www.amey.co.uk
Industry Group Code: 541310 Ranks within this company's industry group: Sales: Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Y Y Y Y
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y Y
GROWTH PLANS/SPECIAL FEATURES:
Engineering Services Construction Risk Management and Implementation Environmental Services Engineering Design and Analysis Systems Engineering & Integration
Amey PLC, based in the United Kingdom, provides business support services such as facilities management, procurement, consulting and plant equipment and hire. The firm provides a broad range of support services to public and private organizations in addition to its ownership of large-scale transportation infrastructure concessions. The company also operates a construction division, Amey Construction, which provides building contracting, tunneling and civil engineering. The company also provides risk management and implementation services. This division provides other companies with information on business continuity planning and disaster recovery; financial accounting and business support services; project and program management; health, safety and environmental services; engineering design and analysis; and systems engineering and systems integration. Additionally, the firm owns Comax, a company that specializes in business outsourcing. Amey recently announced the sale of Amey Vectra, Ltd. to Volvere PLC. The decision to divest Vectra, which provides specialist technical and business consulting as well as environmental services to the nuclear, oil and gas, defense and transportation sectors, will allow Amey to refocus management resources on its core business activities. The company also recently applied for cancellation of its listing of shares on the London Stock Exchange.
BRANDS/DIVISIONS/AFFILIATES: Amey Rail Amey Construction Comax
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Brian L. Staples, Group Chief Exec. José Leo, Group Finance Dir. Alan Springett, Human Resources Carol Hui, Corp. Sec. Carol Hui, Dir.-Legal Affiars Charles M Mogg, Group Dir.-Corp. Dev. Robert Osborne, Group Dir./Managing Dir., Amey Construction Richard W. Entwhistle, Group Dir./Managing Dir., Amey Rail Richard W Entwistle, Group Dir.-Strategic Partnerships Ian Robinson, Chmn.
Phone: 44-1235-848-811 Fax: 44-1235-848-822 Toll-Free: Address: Sutton Courtenay, Abingdon, Oxfordshire OX14 4PP UK
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Foreign 2001 Sales: $1,141,200 2001 Profits: $-21,900 Employees: 6,886 2000 Sales: $1,009,300 2000 Profits: $30,000 Fiscal Year Ends: 12/31 1999 Sales: $826,200 1999 Profits: $6,900 1998 Sales: $781,900 1998 Profits: $20,500
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Bonus: $ Stock Purch. Plan: Second Exec. Salary: $ Bonus: $ Wide range of integrated services enables the firm to manage complete project needs. ADVANTAGE:
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
AMGEN INC
www.amgen.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:13 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:102
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Diversified Advanced Cellular and Molecular Biology
Amgen, Inc. is a global biotechnology company that develops, manufactures and markets human therapeutics based on advanced cellular and molecular biology. Its products are used for the treatment of nephrology, oncology, inflammation, neurology, and metabolic disorders. The company has research facilities in the United States and has clinical development staff in the United States, Europe, Canada, Australia and Japan. Amgen manufactures and markets a line of human therapeutic products: Neupogen, Epogen, Aranesp, Enbrel, Kineret and Neulasta. Neupogen and Neulasta selectively stimulate the growth of infection-fighting white blood cells (known as neutrophils). Kineret and Enbrel reduce the signs and symptoms of moderately to severely active rheumatoid arthritis. Epogen and Aranesp stimulate the production of red blood cells. The firm recently acquired Immunex Corporation, a leading biotechnology company dedicated to developing immune system science to protect human health. The acquisition enhanced Amgen’s strategic position within the biotechnology industry by strengthening and diversifying its product base and product pipeline in key therapeutic areas and discovery research capabilities in proteins and antibodies. Employee benefits include dental and vision insurance, tuition reimbursement, relocation benefits, child care assistance, a fitness program and team-building entertainment such as art shows, picnics and a children’s holiday party. Amgen’s MBA Leadership Program provides career opportunities in finance and marketing for MBA students.
BRANDS/DIVISIONS/AFFILIATES: Neupogen Epogen Aranesp Enbrel Kineret Neulasta Immunex Corp.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Kevin W. Sharer, CEO Kevin W. Sharer, Pres. Richard D. Nanula, CFO George Morrow, Sr. VP-Sales and Mktg. Brian McNamee, VP-Human Resources Roger Perlmutter, Exec. VP-Research and Dev. Hassan Dayem, Sr. VP/CIO Marc M.P. de Garidel, VP/Controller George Morstyn, Sr. VP-Dev./Chief Medical Officer Edward E. Bjurstrom, VP-Mfg. Steven M. Orde, Sr. VP/Corp. Sec. Steven M. Orde, General Counsel Dennis M. Fenton, Exec. VP-Oper. Richard D. Nanula, Exec. VP-Strategy Richard D. Nanula, Exec. VP-Corp. Comm. John J. Elginer, Treas. Beth C. Seidenberg, Sr. VP-Dev. Sarah M. Jensen, VP-Eng. and Oper. Services Kevin W. Sharer, Chmn.
Phone: 805-447-1000 Fax: 805-447-1010 Toll-Free: 800-772-6436 Address: One Amgen Center Dr., Thousand Oaks, CA 913201799 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $5,523,000 (12 months) 2002 Profits: $-1,392,000 (12 months) Stock Ticker: AMGN 2001 Sales: $3,763,000 2001 Profits: $1,119,700 Employees: 10,100 2000 Sales: $3,629,400 2000 Profits: $1,138,500 Fiscal Year Ends: 12/31 1999 Sales: $3,340,100 1999 Profits: $1,096,400 1998 Sales: $2,718,200 1998 Profits: $863,200
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $933,333 Bonus: $860,533 Stock Purch. Plan: Y Second Exec. Salary: $637,917 Bonus: $1,500,000 ADVANTAGE: A global biotechnology company with a specific market niche/One of the best-known and fastest growing biotech firms.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
AMKOR TECHNOLOGY INC
www.amkor.com
Industry Group Code: 334413 Ranks within this company's industry group: Sales:7 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:19
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Semiconductors-Packaging & Testing
Amkor is one of the world's largest independent providers of semiconductor packaging and test services and technology. The firm offers one of the industry's broadest integrated sets of packaging and test services, which are the final procedures necessary to prepare semiconductor devices for further use. The company’s customer base consists of more than 300 companies, including most of the world's largest semiconductor companies. Atmel Corporation, Intel Corporation, LSI Logic Corporation, Motorola, Inc., Philips Electronics, Sony Semiconductor Corporation, Texas Instruments, Inc. and Toshiba Corporation all utilize the company’s services. With over 1,000 different package types, Amkor offers one of the semiconductor industry's broadest lines of packaging and test services. The company provides customers with a wide array of packaging alternatives, including mature leadframe packages and newer advanced leadframe and laminate packages. Amkor also offers an extensive line of services to test digital logic, analog and mixed signal semiconductor devices. The company has designed and developed state-of-the-art thin package formats and laminate packages including PowerQuad, Super BGA, fleXBGA and ChipArray BGA packages. Recently, Amkor reached an agreement to sell its wafer fabrication services, provided by Anam Semiconductor, Inc., to Anam itself. The company also recently introduced a low-cost memory and I/O card to be used in portable applications.
BRANDS/DIVISIONS/AFFILIATES: PowerQuad SuperBGA fleXBGA ChipArray BGA Metric Quad Flat Pack ePad MicroLeadFrame Think Shrink
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. James J. Kim, CEO John N. Bourch, COO John N. Bourch, Pres. Kenneth T. Joyce, Exec. VP/CFO Bruce Freyman, Exec. VP-Worldwide Product and Mfg. Oper. Eric R. Larson, Exec. VP-Corp. Dev. James J. Kim, Chmn.
Phone: 610-431-9600 Fax: 610-431-5881 Toll-Free: Address: 1345 Enterprise Dr., West Chester, PA 19380 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,639,707 (12 months) 2002 Profits: $-826,759 (12 months) Stock Ticker: AMKR 2001 Sales: $1,517,900 2001 Profits: $-450,900 Employees: 20,276 2000 Sales: $2,387,300 2000 Profits: $154,200 Fiscal Year Ends: 12/31 1999 Sales: $1,909,972 1999 Profits: $76,719 1998 Sales: $1,567,983 1998 Profits: $75,460
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $790,000 Bonus: $79,000 Stock Purch. Plan: Second Exec. Salary: $580,000 Bonus: $58,000 ADVANTAGE: One of the largest independent providers of semiconductor packaging and test services in the world.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
AMYLIN PHARMACEUTICALS INC
www.amylin.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:99 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:89
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Diabetes Drugs for Metabolic Disorders
Amylin Pharmaceuticals, Inc. develops novel medicines for treating diabetes and related metabolic disorders. The company was founded after the discovery of amylin, a hormone that is missing in persons with type 1 diabetes and deficient in those with type 2 diabetes. Amylin Pharmaceuticals, Inc. is currently developing and testing four products. SYMLIN, a drug intended to treat diabetics who use insulin, is in phase III clinical studies. This drug is a synthetic version of the human hormone (amylin) that demonstrates activity in blood glucose regulation. Marketing authorization applications for SYMLIN have been accepted for filing by the EMEA and Swiss Regulatory Authorities. AC2993 is currently in phase III evaluation for the treatment of type 2 diabetes. It is an amino acid peptide that exhibits several anti-diabetic, or glucose lowering, actions. AC2993 LAR, an injectable long-acting formulation of AC2993, is currently in phase II evaluation also. AC3056, an in-licensed drug from Aventis Pharma, is being evaluated as a treatment to prevent restenosis after vascular repair procedures and for diseases resulting from atherosclerosis. AC3056 is currently in phase I studies. Recently, Amylin signed a global agreement with Eli Lilly to collaborate on the development and commercialization of its AC2993, receiving $325 million from Lilly, which greatly improved Amylin's financial condition..
BRANDS/DIVISIONS/AFFILIATES: Amylin Europe, Ltd. Pramlintide SYMLIN AC2993 LAR AC2993 AC3056
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Joseph C. Cook, Jr., CEO Mark G. Foletta, CFO/VP-Finance Cathy Jackson, Human Resources Admin. Andrew A. Young, VP/Sr. Research Fellow Nancy K. Dahl, VP/Corp. Sec. Nancy K. Dahl, General Counsel Martin R. Brown, Sr. VP-Oper. Michael Step, Sr. VP-Corp. Dev. Alain D. Baron, Sr. VP-Clinical Research Daniel M. Bradbury, Exec. VP Julia R. Brown, Exec. VP Joann L. Data, Sr. VP-Regulatory Affairs and Quality Assurance Joseph C. Cook, Jr., Chmn.
Phone: 858-552-2200 Fax: 858-552-2212 Toll-Free: Address: 9373 Towne Centre Dr., San Diego, CA 92121 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $13,400 (12 months) 2002 Profits: $-109,800 (12 months) Stock Ticker: AMLN 2001 Sales: $ 2001 Profits: $-72,000 Employees: 350 2000 Sales: $ 100 2000 Profits: $-44,000 Fiscal Year Ends: 12/31 1999 Sales: $ 100 1999 Profits: $-30,600 1998 Sales: $16,200 1998 Profits: $-51,098
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $475,000 Stock Purch. Plan: Second Exec. Salary: $300,000 ADVANTAGE: Has developed a synthetic hormone with excellent potential to treat diabetes.
OTHER THOUGHTS: Apparent Women Officers or Directors: 4 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $250,000 Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ANALOG DEVICES INC
www.analog.com
Industry Group Code: 334413 Ranks within this company's industry group: Sales:6 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:3
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Integrated Circuits-Analog & Digital
Analog Devices, Inc. designs, manufactures and markets a broad line of high-performance analog, mixed-signal and digital signal processing (DSP) integrated circuits (ICs) that address a wide range of real-world signal-processing applications. The company’s principal products are used in a wide array of electronic equipment ranging from industrial process control, factory automation systems equipment, smart munitions, base stations, central office equipment, wireless telephones, computers, cars, CAT scanners, digital cameras and DVD players. Its products are sold primarily to original equipment manufacturers (OEMs) that incorporate them into a wide variety of equipment and systems for use in communications, computer, industrial, scientific instrumentation, military/aerospace, automotive and high-performance consumer electronics products. Analog operates manufacturing facilities in Massachusetts, California, North Carolina, Ireland, the United Kingdom, the Philippines and Taiwan. The company recently introduced the AD7655, which is an analog-to-digital converter used in complex applications.
BRANDS/DIVISIONS/AFFILIATES: SHARC 32-Bit Floating-Point DSP ADSP-21171 AD899 Complete Read Channel AD8001 AD7655 AD20msp815 Personal Soundcomm Chipset ADM663/666 Voltage Regulators AD835 Multiplier
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jerald G. Fishman, CEO Jerald G. Fishman, Pres. Joseph E. McDonough, VP-Finance/CFO Vincent Roche, VP-Worldwide Sales Ross Brown, VP-Human Resources Samuel H. Fuller, VP-Research and Dev. Robert R. Marshall, VP-Worldwide Mfg. Russell K. Johnsen, VP-Corp. Bus. Dev. William A. Martin, Treas. Brian McAloon, Group VP-DSP and System Products Group William N. Giudice, VP/General Mgr.-Micromachined Products Robert McAdam, VP/General Mgr.-Analog Semiconductor Components
Phone: 781-329-4700 Fax: 781-461-3638 Toll-Free: 800-262-5643 Address: One Technology Way, Norwood, MA 02062-9106 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,707,500 (12 months) 2002 Profits: $105,300 (12 months) Stock Ticker: ADI 2001 Sales: $2,276,900 2001 Profits: $356,400 Employees: 9,000 2000 Sales: $2,577,500 2000 Profits: $607,100 Fiscal Year Ends: 10/31 1999 Sales: $1,450,400 1999 Profits: $196,800 1998 Sales: $1,230,600 1998 Profits: $82,400
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $860,146 Stock Purch. Plan: Y Second Exec. Salary: $398,977 Expanding core technology through extensive research and development. ADVANTAGE:
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $317,630 Bonus: $105,585
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ANALOGIC CORP
www.analogic.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:29 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:30
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Equipment-Medical Image Processing Signal Processing Equipment Portable, Multi-Functional Patient Monitors Explosive Detection Security Systems
Analogic Corporation designs, manufactures and sells advanced health and security systems and subsystems to be utilized in medical, industrial and scientific applications. Analogic’s divisions specialize in computed tomography, digital radiography systems, life care systems, medical imaging components, test and measurement, ultrasound systems and customer service. Its subsidiaries include BK Medical A/S, Camtronics Medical Systems, International Security Systems, SKY Computers, Sound Technology and Peabody Marriott Hotel. The company is a leader in precision analog-to-digital and digital-to-analog signals, such as those representing temperature, pressure, voltage, weight, velocity, ultrasound and X-ray intensity into and from the numeric form required by data processing equipment. Analogic's medical imaging data acquisition systems and related computing equipment are incorporated into computer assisted tomography scanners that generate images of the internal anatomy to diagnose medical conditions. The company also manufactures a lightweight, portable, multi-functional, custom patient monitor instrument, used in a variety of hospital settings, that acquires, calculates and displays combinations of the five most common vital sign parameters: ECG, respiration, temperature, NIBP and SpO2. Analogic also manufactures the EXACT system, an advanced computed tomography imaging system capable of providing data for full 3-D images of every object in a package, parcel or bag. The company also entered into an agreement with Sanders Design International to develop, manufacture and deploy an aircraft infrared countermeasures system for commercial airlines. Additionally, Analogic announced the formulation of a strategic marketing agreement with Lockheed Martin Corporation to market threat detection products. Employee benefits include medical and dental insurance and tuition reimbursement. The Boston Globe recently named Analogic Boston's Company of the Year.
BRANDS/DIVISIONS/AFFILIATES: Sound Technology EXACT System B-K Medical A/S Camtronics Medical Systems International Security Systems SKY Computers Sanders Design International Lockheed Martin Corporation
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Bernard M. Gordon, CEO John W. Wood, Jr., Pres. John J. Millerick, Sr. VP/CFO John W. Kirby, VP-Human Resources Thor T. Wallace, VP-Info. Tech. Thor T. Wallace, CIO Julian Soshnick, VP/General Counsel Michael Magnifico, VP-Corp. Oper. Paul M. Roberts, Dir.-Corp. Comm. John J. Millerick, Treas. Lothar Koob, Exec. VP Bernard M. Gordon, Chmn.
Phone: 978-977-3000 Fax: 978-977-6809 Toll-Free: Address: 8 Centennial Dr., Peabody, MA 01960 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $313,600 (12 months) 2002 Profits: $3,300 (12 months) Stock Ticker: ALOG 2001 Sales: $360,600 2001 Profits: $15,200 Employees: 1,860 2000 Sales: $297,619 2000 Profits: $14,108 Fiscal Year Ends: 7/31 1999 Sales: $279,694 1999 Profits: $19,513 1998 Sales: $294,472 1998 Profits: $23,888
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $366,300 Bonus: $50,000 Stock Purch. Plan: Second Exec. Salary: $215,100 Bonus: $25,000 ADVANTAGE: Expertise in several important technologies enables the firm to obtain very desirable contracts under which it supplies electronics systems to other firms.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ANDRX CORP
www.andrx.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:29 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:83
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Controlled Release Drug Delivery Technologies
Andrx Corporation formulates and commercializes controlled-release oral pharmaceuticals using proprietary drug delivery technologies. To date, the company has developed 10 different drug delivery technologies that have been patented or for which patent applications have been filed. Andrx believes that its technologies are flexible and can be modified to apply to a variety of pharmaceutical products. Through Andrx Pharmaceuticals and Andrx Laboratories, the company is applying proprietary drug delivery technologies and formulation skills, either directly or through collaborative arrangements, to the development of generic versions of select brand-name pharmaceuticals. Andrx also markets and distributes generic drugs manufactured by third parties. Andrx currently manufactures and sells bioequivalent versions of Cardizem CD, Dilacor XR, Ventolin, Glucophage, K-Dur and Naprelan. The company also manufactures and sells a bioequivalent version of Oruvail, which was developed through Andrx's ANCIRC Pharmaceuticals joint venture with Watson and is used for the treatment of patients with rheumatoid arthritis and osteoarthritis. In its brand program, Andrx sells and markets internally developed products including Altocor, Metformin XT and Valproate. Anda, a unit of the company, purchases products directly from manufactures and wholesalers and markets them through its telemarketing staff and sales representatives. In recent news, the company signed a multi-year agreement with L. Perrigo Company, whereby Andrx will manufacture and supply Perrigo bioequivalent versions of Claritin-D 12 Hour, Claritin Reditabs and Claritin-D 24 Hour, which Perrigo will market as over-the-counter products.
BRANDS/DIVISIONS/AFFILIATES: Andrx Laboratories Andrx Pharmaceuticals Anda, Inc. Cartia XT Diltia XT Metformin IR Ketroprofen ANCIRC Pharmaceuticals
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Richard J. Lane, CEO Elliot F. Hahn, Pres. Angelo C. Malahias, Sr. VP/CFO Scott Lodin, Exec. VP/Corp. Sec. Scott Lodin, General Counsel Daniel H. Movens, Exec. VP-Oper., Anda, Inc. Lawrence J. Rosenthal, Exec. VP-Sales and Mktg., Andrx Pharmaceuticals Elliot F. Hahn, Chmn.
Phone: 954-584-0300 Fax: 954-217-4327 Toll-Free: Address: 4955 Orange Dr., Davie, FL 33314 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $771,000 (12 months) 2002 Profits: $-91,800 (12 months) Stock Ticker: ADRX 2001 Sales: $749,000 2001 Profits: $37,500 Employees: 2,100 2000 Sales: $520,000 2000 Profits: $58,500 Fiscal Year Ends: 12/31 1999 Sales: $476,000 1999 Profits: $94,100 1998 Sales: $247,100 1998 Profits: $8,400
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $348,400 Bonus: $175,000 Stock Purch. Plan: Y Second Exec. Salary: $323,600 Bonus: $150,000 ADVANTAGE: Applies proprietary drug delivery technologies and formulation skills to the development of generic versions of brand name drugs.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
ANIKA THERAPEUTICS INC
www.anikatherapeutics.com
Industry Group Code: 325414 Ranks within this company's industry group: Sales:2 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:2
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Bone, Cartilage and Soft Tissue Tissue Repair Technology
Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products and devices intended to promote the protection and healing of bone, cartilage and soft tissue. These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. Due to its unique biophysical and biochemical properties, HA plays an important role in a number of physiological functions, such as the protection and lubrication of soft tissues and joints, the maintenance of the structural integrity of tissues and the transport of molecules to and within cells. The company's currently marketed products consist of ORTHOVISC, an HA product used in the treatment of some forms of osteoarthritis in humans, and HYVISC, an HA product used in the treatment of equine osteoarthritis. ORTHOVISC is approved for sale and marketed in Canada, Europe, Turkey, Israel and Iceland. The company also manufactures AMVISC and AMVISC Plus, used as viscoelastic supplements in ophthalmic surgery, for Bausch & Lomb Surgical, a subsidiary of Bausch & Lomb. STAARVISC II, an injectable ophthalmic viscoelastic, is produced for STAAR Surgical Company, and ShellGel, also an injectable ophthalmic viscoelastic, is produced for Cytosol Ophthalmics, Inc. Anika is currently developing INCERT, an HA-based product designed for use in the prevention of post-surgical adhesions. Anika holds exclusive rights to manufacture OSSIGEL for Orquest, Inc. Recently, Anika announced a three-year supply agreement with a unit of Allergan, Inc. Allergan will market Anika's CoEase, a product used during opthalamic surgery, including cataract and intraocular lens implantation. In other news, the company signed an exclusive distribution agreement for ORTHOVISC in Canada with Rivex Pharma, Inc. and in the U.K. with Surgicraft, Ltd., a manufacturer and distributor of medical devices.
BRANDS/DIVISIONS/AFFILIATES: ORTHOVISC HYVISC INCERT AMVISC STAARVISC II ShellGel CoEase
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Charles H. Sherwood, CEO Charles H. Sherwood, Pres. William J. Knight, VP-Finance/CFO Bob Tellis, Sr. VP-Sales and Mktg. Scott P. Bruder, VP-Research and Dev. Frank Luppino, Exec. Dir.-Oper. Ed Gaj, Jr., Exec. Dir.-New Bus. Dev. William J. Knight, Treas. Ed Gaj, Jr., Exec. Dir.-Mktg.
Phone: 781-932-6616 Fax: 781-935-4120 Toll-Free: Address: 236 W. Cummings Park, Woburn, MA 01801 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $13,200 (12 months) 2002 Profits: $-3,000 (12 months) Stock Ticker: ANIK 2001 Sales: $11,300 2001 Profits: $-6,800 Employees: 60 2000 Sales: $16,335 2000 Profits: $ 174 Fiscal Year Ends: 12/31 1999 Sales: $13,500 1999 Profits: $-2,500 1998 Sales: $13,273 1998 Profits: $3,752
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $205,750 Stock Purch. Plan: Second Exec. Salary: $203,696 ADVANTAGE: Focus on unique technologies based on hyaluronic acid.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $54,500 Bonus: $54,500
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
AOL TIME WARNER INC
www.aoltimewarner.com
Industry Group Code: 513210 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Internet Access Service Television Production Music Production Film Production E-Commerce Entertainment Investments
AOL Time Warner, Inc., the result of the merger of America Online and Time Warner, is the world’s leading media and entertainment company. Its principal business objective is to create and distribute branded information and entertainment throughout the world. AOL Time Warner’s business classifications are entertainment, including interests in recorded music and music publishing, filmed entertainment, television production and television broadcasting; cable networks, including interests in cable television programming and sports franchises; publishing, including interests in magazine publishing, book publishing and direct marketing; and cable systems. With 12.7 million cable subscribers, AOL Time Warner is the second-largest cable television provider in the nation, and through its cable systems, it is a major provider of cable modem-based Internet access service. Time and EMI Music intend to combine their recorded music businesses in a joint venture that will approximately equal Universal Music Group in size. The company also operates New Line Cinema, Warner Bros., Home Box Office, Cinemax, the Time, Inc. family of over 200 magazines, CompuServe, MapQuest, Netscape, ISP Road Runner, Turner Broadcasting, the Atlanta Braves, CNN, the Cartoon Network, Looney Tunes, DC Comics and Elektra Entertainment Group, among others. Since its merger, AOL Time Warner has struggled to achieve the media synergy it sought. AOL has launched an interface for broadband customers that features enhanced multimedia and access by multiple users at once. The unit will launch many value-added features during 2003-2004 in an effort to boost subscriber income. At the same time, it forecasts large drops in online advertising revenues over previous years.
BRANDS/DIVISIONS/AFFILIATES: Time, Inc. Warner Bros. America Online (AOL) Home Box Office Turner Broadcasting System Cable News Network EMI Music Netscape
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Richard D. Parsons, CEO Wayne H. Pace, Exec. VP/CFO William J. Raduchel, Exec. VP/Chief Tech. Officer James W. Barge, Sr. VP/Controller Paul T. Cappuccio, Exec. VP/Corp. Sec. Paul T. Cappuccio, General Counsel Patricia Fili-Krushel, Exec. VP-Admin. Adolf R. DiBiasio, Exec. VP-Strategy and Investments Edward I. Adler, Sr. VP-Corp. Comm. John K. Martin, Jr., VP-Investor Rel. Robert M. Kimmitt, Exec. VP-Global and Strategic Policy Jonathan F. Miller, CEO, America Online Don Logan, Chmn.-Media and Comm. Michael Kelly, Pres.-Global Mktg. Solutions Stephen M. Case, Chmn. Michael Lynton, Pres.-Int'l
Phone: 212-484-8000 Fax: 212-489-6183 Toll-Free: Address: 75 Rockefeller Plaza, New York, NY 10019 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $41,065,000 (12 months) 2002 Profits: $-98,686,000 (12 months) Stock Ticker: AOL 2001 Sales: $38,234,000 2001 Profits: $-4,921,000 Employees: 91,250 2000 Sales: $7,703,000 2000 Profits: $1,152,000 Fiscal Year Ends: 12/31 1999 Sales: $4,804,000 1999 Profits: $754,000 1998 Sales: $3,114,000 1998 Profits: $-80,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $1,000,000 Bonus: $10,000,000 Stock Purch. Plan: Second Exec. Salary: $1,000,000 Bonus: $6,000,000 Owner of leading names in Internet access, e-mail, publishing and programming/Major cable and Internet ADVANTAGE: assets/34 million AOL subscribers.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
APOGENT TECHNOLOGIES INC
www.apogent.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:16 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:13
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Equipment-Laboratory Diagnostic Products
Apogent Technologies, Inc. designs, manufactures and markets laboratory, diagnostic and life science products for health care diagnostics and scientific research. The company operates through subsidiaries that are categorized in three business segments: clinical diagnostics, labware and life sciences and laboratory equipment. The firm markets its products to distributors, pharmaceutical and biotechnology companies, original equipment manufacturers and clinical, research and industrial laboratories mostly in the U.S., Europe and Japan. The clinical diagnostics segment offers products geared towards diagnostic testing and screening services such as specimen collection, drug testing and pregnancy testing. Products include microscope slides, cover glass, glass tubes, diagnostic test kits, stains and reagents, culture media and other products used in detecting causes of various diseases and conditions. Apogent’s labware and life sciences unit produces reusable labware, consumables and high-end instrumentation for life science and research applications. The segment’s products are used in areas such as combinatorial chemistry, chromatography, laboratory safety and packaging applications. Products include reusable and disposable plastic and glass products, products for critical packaging applications, environmental and safety containers and instruments used in drug discovery. Through its laboratory equipment division, Apogent offers a broad range of equipment for research, industrial, clinical and general laboratory applications. Products include hot plates, stirrers and shakers, systems for producing ultra pure water, bottle top dispensers, furnaces and fluorometers and solvent evaporation technology. The company recently initiated a modified Dutch Auction tender offer to repurchase shares of its outstanding common stock, because management believed that the stock was undervalued. Apogent has also realigned several of its lines of business.
BRANDS/DIVISIONS/AFFILIATES: Advanced Biotechnologies, Ltd. Forefront Diagnostics Capitol Vial, Inc. Marsh Bio Products Genevac, Ltd. Chromacol, Ltd. Separation Technology, Inc. Lab-Line Instruments, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Frank H. Jellinek, Jr., CEO Frank H. Jellinek, Jr., Pres. Dennis Brown, CFO Gary J. Marmontello, VP-Human Resources Peter Scheu, Group Pres.-Clinical Diagnostics Michael K. Bresson, Exec. VP/Corp. Sec. Michael K. Bresson, General Counsel Dennis Brown, Treas. Robert Ahlgren, Group Pres.-Labware and Life Sciences Robert Griffin, VP-Regulatory Affairs Mark F. Stuppy, Group Pres.-Clinical Consumables Companies Stephen K. Wiatt, Group Pres.-Industrial Glass Companies Kenneth F. Yontz, Chmn.
Phone: 603-433-6131 Fax: 603-431-0860 Toll-Free: 800-327-9970 Address: 30 Penhallow St., Portsmouth, NH 03801 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,074,600 (12 months) 2002 Profits: $121,100 (12 months) Stock Ticker: AOT 2001 Sales: $984,500 2001 Profits: $96,000 Employees: 6,900 2000 Sales: $863,600 2000 Profits: $128,300 Fiscal Year Ends: 9/30 1999 Sales: $715,000 1999 Profits: $142,500 1998 Sales: $557,800 1998 Profits: $76,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $751,384 Stock Purch. Plan: Y Second Exec. Salary: $348,010 ADVANTAGE: Subsidiaries manufacture over 5,000 products.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $126,042 Bonus: $800,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
APPLE COMPUTER INC
www.apple.com
Industry Group Code: 334111 Ranks within this company's industry group: Sales:5 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:4
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y Y
GROWTH PLANS/SPECIAL FEATURES:
Computer Hardware-PCs Software Printers Computer Accessories Retail Stores Operating Systems
Apple Computer, Inc. is a world leader in the design and manufacture of microprocessor-based personal computers, hardware and software. As one of the originators of graphical user interface (GUI) technology, the company has made a major impact in the world of computing, operating throughout the Americas, Europe and Asia. Apple products include basic iMac PCs, Power Mac G4 Cube processors, powerful Power Mac G4 PCs, sleek iBook notebook computers and PowerBook notebook PCs that feature G4 processors. The G4 Cube is less than one-fourth the size of most PCs yet houses a 450 MHz Power PC G4 processor with a VelocityEngine that reaches supercomputer speeds of over 3 billion calculations per second. In addition, Apple offers the QuickTime 6 suite of multimedia applications, the Mac OS X operating system and a host of software and accessories all designed to run on Apple hardware. The QuickTime TV network now features more than 50 premium channels of video, music and news from leading international content providers such as ABCNEWS.com, Disney.com and HBO. The common thread among all Apple products are eye-catching designs and colors coupled with ease of use. The Macintosh-type computer has a devoted following that believes the Mac has significant advantages over the PC, especially for graphics and artistic endeavors. In recent news, Apple introduced its new line of iMacs, which includes a 1GHz PowerPC G4 processor, the firm's fastest ever, and a 17-inch viewable flat screen monitor. In early 2003, Apple launched an innovative new online music sales service called iTunes Music Store, www.applemusic.com, enabling customers to download and permanently store over 200,000 songs for only 99 cents each. Apple Computer offers extensive employee benefits, including insurance coverage, fitness plans, health education and preventive care.
BRANDS/DIVISIONS/AFFILIATES: MacIntosh QuickTime Mac OS X Power Mac G4 Cube iBook iMac iTunes Music Store QuickTime TV Network
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Steve P. Jobs, CEO Fred D. Anderson, CFO Peter Oppenheimer, Sr. VP-Finance/Controller Jonathan Rubinstein, Sr. VP-Hardware Eng. Nancy R. Heinen, Corp. Sec. Nancy R. Heinen, General Counsel Timothy D. Cook, Sr. VP-Worldwide Oper. Ronald B. Johnson, Sr. VP-Retail Phil Schiller, VP-Worldwide Product Mktg. Avadis Tevanian, Jr., Sr. VP-Software Eng. Sina Tamaddon, Sr. VP-Applications
Phone: 408-996-1010 Fax: 408-974-2113 Toll-Free: 800-692-7753 Address: One Infinite Loop, Cupertino, CA 95014 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $5,742,000 (12 months) 2002 Profits: $65,000 (12 months) Stock Ticker: AAPL 2001 Sales: $5,363,000 2001 Profits: $-25,000 Employees: 10,211 2000 Sales: $7,983,000 2000 Profits: $786,000 Fiscal Year Ends: 9/30 1999 Sales: $6,134,000 1999 Profits: $601,000 1998 Sales: $5,941,000 1998 Profits: $309,000
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $2,268,698 Stock Purch. Plan: Y Second Exec. Salary: $656,631 ADVANTAGE: Custom loyalty/Innovative advertising.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
APPLIED MATERIALS INC
www.appliedmaterials.com
Industry Group Code: 335999 Ranks within this company's industry group: Sales:5 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:2
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Electronic Equipment-Semiconductor Manufacturing Related Wafer and Integrated Circuit Manufacturing
Applied Materials, Inc. (AMI) is a global leader in the semiconductor industry that develops, manufactures, markets and services semiconductor wafer fabrication equipment. The company markets its products to companies that specialize in semiconductor wafer and semiconductor integrated circuit manufacturing. AMI designs systems that perform most of the primary steps in the fabrication of semiconductor chips. The company’s customers include Advanced Micro Devices, Intel, Lucent and Motorola. The current semiconductor industry standard for wafer size is 200 millimeters, or eight inches, of which AMI is one of the leading manufacturers. The industry, however, has begun using 300-millimeter wafers, and AMI has responded by creating an entire new line of systems for 300-millimeter wafer processing for all its core technologies. The firm markets and sells its products worldwide through a direct sales force. North America (primarily the United States), representing 26% of sales, is the company's largest market. AMI's manufacturing activities consist primarily of assembling various components into finished systems at its manufacturing site in Austin, Texas. In March 2003, the firm announced a 14% staff reduction. The Applied Global University for employees extends educational opportunities tailored to specific job requirements. College training programs are designed to give recent graduates experience with relevant technologies. In addition, Applied Materials provides mentor/career counseling and on-site classes. Over 45% of all new hires are minorities. Applied Materials also provides life and health insurance and, in most locations, has wellness centers which include nutrition and weight control programs, a fitness center and stress management services.
BRANDS/DIVISIONS/AFFILIATES: Parker Technologies, Inc. AKT, Inc. Obsidian, Inc. Etec Systems, Inc. Display Products Group, Inc. Global Knowledge Services, Inc. Electron Vision Corporation AM Japan, LLC
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Michael R. Splinter, CEO Dan Maydan, Pres. Emeritus Joseph R. Bronson, Sr. VP/CFO Kye Hwan Oh, VP/Chief Mktg. Officer Julio A. Aranovich, VP-Global Human Resources Nancy H. Handel, Controller Ray Leubner, VP-Mfg. Joseph J. Sweeney, VP-Legal Affairs and Intellectual Property Menachem Erad, VP-Oper. and Planning Glen O. Toney, VP-Corp. Affairs Michael K. O'Farrell, VP-Comm. and University Rel. George Davis, Treas. Sasson Somekh, Exec. VP David N. K. Wang, Exec. VP Tetsuo Iwasaki, Sr. VP James C. Morgan, Chmn.
Phone: 408-727-5555 Fax: 408-496-6421 Toll-Free: 800-882-0373 Address: 3050 Bowers Ave., Santa Clara, CA 95054-3299 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $5,062,000 (12 months) 2002 Profits: $269,000 (12 months) Stock Ticker: AMAT 2001 Sales: $7,343,000 2001 Profits: $775,200 Employees: 17,365 2000 Sales: $9,564,400 2000 Profits: $2,063,600 Fiscal Year Ends: 10/31 1999 Sales: $4,859,100 1999 Profits: $746,700 1998 Sales: $4,041,700 1998 Profits: $230,900
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Y Top Exec. Salary: $809,558 Bonus: $1,268,000 Stock Purch. Plan: Y Second Exec. Salary: $682,212 Bonus: $1,029,770 Largest producer of wafer fabrication systems and services for the worldwide semiconductor industry. ADVANTAGE:
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest:
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ARCADIS NV
www.arcadis.nl
Industry Group Code: 541310 Ranks within this company's industry group: Sales:12 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Y Y Y Y
Profits:3
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y Y Y
GROWTH PLANS/SPECIAL FEATURES:
Engineering Services Consulting Services
Arcadis N.V is an international engineering company involved in environmental, communications, buildings and infrastructure projects. The company's projects are related to public utilities, real estate, rural and urban development, plant construction and telecommunications network development. The firm also engages in environmental services such as soil, air and water pollution monitoring and prevention. Arcadis has operations in Africa, Asia, Europe and North and South America. Some of the company’s projects include the renovation of the Olympic Stadium in Berlin and the design and construction of the Amsterdam Arena, as well as its involvement in the improvement of the Feyenoord Stadium in Rotterdam. Arcadis owns the Brazilian engineering firm Logos Engenharia, which specializes in project management. In recent news, the company acquired German based HOMOLA Projectmanagement AG, a project management firm with businesses in Germany and the Czech Republic and annual revenues of over $10 million. Additionally, Arcadis recently announced the sale of 60% of its shares in Dynamicon BV, a temporary staffing agency, to HQ Group BV. The remaining 40% of the shares will be sold to HQ within the next three years.
BRANDS/DIVISIONS/AFFILIATES: ARCADIS Geraghty & Miller, Inc. HOMOLA Projectmanagement AG Dynamicon BV Logos Engenharia
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Harrie L. J. Noy, Exec. Chmn. Henk W. M. W. ten Cate, Dir.-Finance Wim G.M. Rupert, Dir.-Human Resources Anja M. van Bergen-van Kruijsbergen, Corp. Sec. Hans van Dord, Dir.-Bus. Dev. Joost Slooten, Corp. Comm. Joost Slooten, Investor Rel. Craig Eisen, Mergers and Acquisitions Luck M. van Leeuwen, Chmn.
Phone: 31-26-377-8911 Fax: 31-26-351-5235 Toll-Free: Address: Utrechseweg 68, Arnhem, 6812 AH The Netherlands
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $880,661 (12 months) 2002 Profits: $41,700 (12 months) Stock Ticker: Foreign 2001 Sales: $502,200 2001 Profits: $22,400 Employees: 8,503 2000 Sales: $518,900 2000 Profits: $19,500 Fiscal Year Ends: 12/31 1999 Sales: $488,900 1999 Profits: $18,600 1998 Sales: $457,300 1998 Profits: $15,300
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Y Second Exec. Salary: $ ADVANTAGE: Stable revenues/Extensive niche experience.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ARROW INTERNATIONAL INC
www.arrowintl.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:27 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:22
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Equipment-Catheters and Related Products Cardiac Assistance Devices
Arrow International, Inc. develops, manufactures and markets a broad range of clinically advanced disposable catheters and related products for critical care medicine and interventional cardiology and radiology. The company's critical care catheterization products are used to access the central vascular system for administration of fluids, drugs and blood products. Arrow's cardiac care products are used for the diagnosis and treatment of patients with heart and vascular disease. Anesthesiologists, critical care specialists, surgeons, cardiologists, nephrologists, emergency and trauma physicians and other health care providers use the company’s products. Arrow’s critical care products include the Arrow-Howes multi-lumen catheter, a catheter equipped with three or four channels that enables the simultaneous administration of multiple critical care therapies through a single puncture site; FlexTip Plus epidural catheters, which are designed to minimize indwelling complications associated with conventional epidural catheters; and percutaneous thrombolytic devices, which are designed for clearance of thrombosed hemodialysis grafts in chronic hemodialysis patients. Cardiac care products include intra-aortic balloon (IAB) pumps and catheters, used primarily to augment temporarily the pumping capability of the heart following cardiac surgery, serious heart attack or balloon angioplasty; AutoCAT, an advanced automatic IAB pump continuously monitors and selects the best signal from multiple electrocardiogram and arterial pressure sources to automatically adjust balloon inflation; the Berman angiographic catheter, used for pediatric cardiac angiographic procedures; and the Super Arrow-Flex, a sheath that provides a kink-resistant passageway for the introduction of catheters into the vascular system. In recent news, the company began development of the Magnaflow, a new technology for magnetically guiding and facilitating the placement of enteral nutrition catheters in patients. The firm offers its employees a continuing education program, matching gift donations and a fitness center.
BRANDS/DIVISIONS/AFFILIATES: Arrow-Howes ARROWguard FlexTip Plus AutoCAT Berman Arrow LionHeart Super Arrow-Flex Magnaflow
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Marlin Miller, Jr., CEO Philip B. Fleck, COO Philip B. Fleck, Pres. Frederick J. Hirt, CFO/VP-Finance Christopher Mennone, VP-Int'l Sales and Mktg. Philip Jacobelli, Dir.-Human Resources Carl N. Botterbusch, VP-Research and Eng. Scott W. Hurley, Controller T. Jerome Holleran, Corp. Sec. Paul Frankhouser, Exec. VP-Bus. Dev. John C. Long, VP/Treas. Carl Anderson, Mgr.-Critical Care Bus. Carl N. Botterbusch, VP-Cardiac Assist Div. Tom Nickel, VP-Regulatory Affairs and Quality Assurance Marlin Miller, Jr., Chmn.
Phone: 610-378-0131 Fax: 610-374-5360 Toll-Free: 800-233-3187 Address: 2400 Bernville Rd., Reading, PA 19605 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $340,800 (12 months) 2002 Profits: $39,000 (12 months) Stock Ticker: ARRO 2001 Sales: $334,000 2001 Profits: $46,500 Employees: 3,005 2000 Sales: $320,300 2000 Profits: $46,200 Fiscal Year Ends: 8/31 1999 Sales: $259,900 1999 Profits: $35,700 1998 Sales: $260,900 1998 Profits: $8,600
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $450,000 Bonus: $75,668 Stock Purch. Plan: Second Exec. Salary: $286,198 Bonus: $62,770 ADVANTAGE: A leading supplier of central vascular access catheterization/Excellent new product development.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ASCENT PEDIATRICS INC
www.ascentpediatrics.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Reformulated Pediatric Drugs
Ascent Pedriatics, a of subsidiary Medicis, is engaged in the development and marketing of pharmaceuticals for use in the treatment of common pediatric illnesses. Ascent seeks to develop a broad line of products that are based on commonly-prescribed off-patent pharmaceuticals, attempting to improve the products by reducing their dosing frequency, improving their taste, making them easier to administer or developing them as substitutes for products with considerable side effects. Ascent also specializes in taste masking, which involves the removal or masking of an objectionable or unpleasant taste of various common ingredients used in pediatric pharmaceuticals. The company believes that a drug's taste is a critical factor in pediatric patient compliance, particularly when frequent dosing is required. The firm is focusing on obtaining regulatory approval of Primsol and Orapred and currently is preparing for the commercial launch of these products.
BRANDS/DIVISIONS/AFFILIATES: Feverall Alpharma Primsol Orapred
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Alan R. Fox, CEO Alan R. Fox, Pres. Eliot Lurier, VP/CFO Gregory A. Vannatter, VP-Mktg. And Business Diane Worrick, VP-Human Resources Mumtaz Ahmed, VP-Medical Affairs Bobby R. Owen, VP-Oper. William E. Brochu, VP-Regulatory and Quality Affairs Steve Evans, National Sales Dir.
Phone: 978-658-2500 Fax: 978-658-3939 Toll-Free: Address: 187 Ballardvale St., Ste. B125, Wilmington, MA 01887 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $ 2001 Profits: $ Employees: 63 2000 Sales: $4,464 2000 Profits: $-14,339 Fiscal Year Ends: 12/31 1999 Sales: $7,048 1999 Profits: $-15,653 1998 Sales: $4,476 1998 Profits: $-18,231
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Unique strategy to improve existing drugs for use by children.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
ASCENTIAL SOFTWARE CORPORATION www.ascentialsoftware.com Industry Group Code: 511200 Ranks within this company's industry group: Sales:37 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:26
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Software-Database Management Enterprise Integration Solutions
Ascential Software Corporation is a leading provider of enterprise integration solutions to customers in such industries as financial services, telecommunications, health care, life sciences, manufacturing, consumer goods and retail. The company was formed in July 2001, when Informix Corporation completed the sale of its database business to IBM. Ascential Enterprise Integration Suite, the firm's principle software product, allows business to gather vast amounts of unorganized, disparate data into coherent, usable information all the while reducing cost and increasing profitability. The suite includes MetaRecon data profiling and source system analysis software; INTEGRITY, software that identifies, corrects and reconciles inaccurate or redundant data; and DataStage data transformation software. Combined, this software is built on a platform of services that offers end-to-end data management, complete connectivity and unlimited scalability. Ascential has offices worldwide and supports more than 2,200 customers including American Express, AT&T, Exxon Mobile, Ferrari, General Motors and PepsiCO. In recent news, Ascential expanded its worldwide customer base to include Canon, headquartered in Tokyo, which will use DataStage technology to ensure the quality of its product line. Ascential offers employees medical, dental and vision insurance plans.
BRANDS/DIVISIONS/AFFILIATES: Torrent Systems Ardent Software Prism Solutions Dovetail Software INTEGRITY MetaRecon DataStage IBM
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Peter Gyenes, CEO Pete Fiore, Pres. Robert McBride, CFO Michael Cassettari, VP-Mktg. Eileen Bergquist, VP-Human Resources Lee Scheffler, Chief Tech. Officer Jim Welch, VP-Eng. Scott Semel, Corp. Sec. Scott Semel, General Counsel David Roy, VP-Investor Rel. Jason Silvia, VP-Worldwide Client Services Jim Vedda, VP-Worldwide Sales Bob Zurek, VP-Advanced Tech. Peter Gyenes, Chmn.
Phone: 508-366-3888 Fax: 508-366-3669 Toll-Free: 800-966-9875 Address: 50 Washington St., Westboro, MA 01581 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $113,000 (12 months) 2002 Profits: $-63,600 (12 months) Stock Ticker: ASCL 2001 Sales: $481,300 2001 Profits: $624,900 Employees: 639 2000 Sales: $929,300 2000 Profits: $-98,300 Fiscal Year Ends: 12/31 1999 Sales: $871,536 1999 Profits: $-11,164 1998 Sales: $735,506 1998 Profits: $50,184
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $600,000 Stock Purch. Plan: Second Exec. Salary: $591,667 ADVANTAGE: Strategic partnerships with successful solution providers/Large customer base.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ASPECT COMMUNICATIONS CORP
www.aspect.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:34 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:30
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Computer Software-Customer Service Request Processing Call Transaction Processing Solutions
Aspect Communications Corp. is the leading provider of customer relationship portals, which are contact servers for managing dynamic customer contact transactions across wired and wireless communication channels. The firm has led this industry for over 16 years, beginning in call centers and now extending to multi-channel contact centers. Aspect’s portal allows businesses to manage customer contacts dynamically to achieve relationships, opportunities and customer loyalty. It achieves this by synchronizing all customer contact points, including live and self-service, with demonstrated customer return on investment. Other products include Aspect eBusiness Architect, a drag-and-drop development environment designed to ease electronic customer relations management (eCRM); Aspect Adapters, which offer outof-box integration to third-party applications ensuring investment protection; and Aspect Customer DataMart, which consolidates information from enterprise resources for single- and multi-channel contact centers. Aspect's client list inlcudes Sears, British Airways, Blockbuster, American Express and Sprint, as well as many other business in a wide range of industries. The company offers its employees smoking-cessation and weight-loss program reimbursement, as well as education reimbursement of up to $5,000 per year.
BRANDS/DIVISIONS/AFFILIATES: Aspect Telecommunications Corp. eBusiness Architect Aspect Adapters Customer DataMart
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Beatriz V. Infante, CEO Gary L. Smith, COO Beatriz V. Infante, Pres. Gary A. Wetsel, Exec. VP-Finance/CFO David B. Puglia, Sr. VP-Global Mktg. John R. Viera, Sr. VP-Human Resources Gary E. Barnett, Chief Tech. Officer/Exec. VP-Products Mark J. Meltzer, General Counsel Betsy Rafael, Chief Admin. Officer Robert A. Blatt, VP-Corp. Dev. Carol Broadbent, VP-Corp. Comm. Chris T. Purpura, Sr. VP-Market Dev. and Worldwide Alliances James Patrice, Sr. VP-Customer Support and Education Michael G. DeMatteis, Sr. VP-Sales, Americas Beatriz V. Infante, Chmn.
Phone: 408-325-2200 Fax: 408-325-2260 Toll-Free: 800-226-8441 Address: 1310 Ridder Park Dr., San Jose, CA 95131-2313 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $396,100 (12 months) 2002 Profits: $-108,300 (12 months) Stock Ticker: ASPT 2001 Sales: $449,400 2001 Profits: $-151,800 Employees: 1,391 2000 Sales: $590,500 2000 Profits: $-35,300 Fiscal Year Ends: 12/31 1999 Sales: $489,100 1999 Profits: $-28,900 1998 Sales: $512,300 1998 Profits: $32,500
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $450,483 Stock Purch. Plan: Y Second Exec. Salary: $367,915 ADVANTAGE: Provides software tailored for customer service needs.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $174,688 Bonus: $150,833
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ASTRAZENECA PLC
www.astrazeneca.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:8 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:7
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Diversified Pharmaceutical Manufacturing
AstraZeneca is a leading pharmaceutical company that provides innovative, effective products to fight disease in areas of medical necessity. Formed in 1999, the company is the result of the merger of the Zeneca Group with Astra. The firm invests an average of $3.1 billion on annual research and development, and enjoys sales in over 100 countries. It also operates manufacturing sites in 20 countries and major research centers in five countries. The company focuses on therapeutic interventions in cardiovascular, central nervous system, gastrointestinal, infection, oncology, pain control and anesthesia and respiratory areas. The firm’s product lines include Accolate, Atacand, Casodex, Diprivan, EMLA, Nolvadex, Prilosec, Rhinocort and Zomig, to name a few. The United Kingdom-based company conducts business in Sweden, the U.K. and the United States. AstraZeneca’s research facilities are the Bioinformatics Centre, the AstraZeneca Transgenic Centre and the AstraZeneca Biotech Laboratory. The company has U.S. patent rights for Nolvadex, a drug developed for the treatment of breast cancer. Additionally, the company has FDA approval for Faslodex, another treatment for breast cancer, and Atacand HCT, a therapeutic drug for hypertension. The FDA approved Symbicort Turbuhaler is used for the treatment of asthma and Pulmicort Respules, a breakthrough in the treatment of asthma in children and infants. The company recently opened a new $145 million drug manufacturing facility in Bristol, U.K. This new facility will house the processes for synthesis, purification, drying and milling of rosuvastatin, the active ingredient in Crestor, a newly developed treatment for dyslipidaemia.
BRANDS/DIVISIONS/AFFILIATES: Bioinformatics Centre Novartis Agribusiness Pulmicort Respules Accolate Faslodex Diprivan Prilosec Zeneca Group
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Tom McKillop, CEO Jonathan Symonds, CFO Tony Bloxham, Human Resources Jan Lundberg, Discovery Research Barrie Thorpe, Exec. VP-Oper. Martin Nicklasson, VP-Dev. David Brennan, VP-North America Bruno Angelici, VP-Europe and Row John Patterson, VP-Product Strategy and Licensing Percy N. Barnevik, Chmn.
Phone: 44-20-7304-5000 Fax: 44-20-7304-5183 Toll-Free: Address: 15 Stanhope Gate, London, W1 Y1LN UK
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $17,841,000 (12 months) 2002 Profits: $2,836,000 (12 months) Stock Ticker: AZN 2001 Sales: $16,480,000 2001 Profits: $1,097,000 Employees: 54,600 2000 Sales: $18,103,000 2000 Profits: $865,000 Fiscal Year Ends: 12/31 1999 Sales: $18,445,000 1999 Profits: $-3,539,000 1998 Sales: $15,402,000 1998 Profits: $1,036,000
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $1,191,000 Stock Purch. Plan: Second Exec. Salary: $732,000 ADVANTAGE: One of the world's leading diversified drug companies.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $588,000 Bonus: $347,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ASTROPOWER INC
www.astropower.com
Industry Group Code: 333298 Ranks within this company's industry group: Sales: Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Solar Energy Technology
AstroPower produces the world's largest solar electric (photovoltaic) cells along with a full line of solar modules for off-grid and on-grid applications. Specifically, the firm develops, manufactures, markets and sells a range of solar electric power generation products, including solar cells, modules, panels and its SunChoice pre-packaged systems for the global marketplace. Solar cells are the core component inside every solar electric power system and provide a renewable source of alternative electric power. Modules are assemblies of solar cells connected together and encapsulated in a weatherproof package. Panels are typically used to reduce field assembly cost in systems where hundreds or thousands of individual modules are required. In addition to its products, AstroPower sells wholesale solar electric power under long-term purchase agreements through a joint venture with GPU International, Inc. Through subsidiary Atersa, the firm operates manufacturing plants in the U.S. and Europe, as well as regional sales offices around the world. AstroPower recently introduced a new line of residential solar electric power systems, featuring solar power arrays that fully integrate into a home’s roof. The new systems have a faster installation time, reduced installation cost and enhanced aesthetics compared to traditional rooftopmounted solar power systems. The firm was also awarded a contract by the Sacramento Municipal Utility District to complete a project for the development of an integrated solar electric power system tailored to the California residential market. In other news, Atersa was selected to supply solar electric power systems to power 227 rural villages in Senegal. AstroPower offers its employees tuition reimbursement, dental insurance and direct deposit. Additionally, employees are eligible to receive a University of Delaware ID card, which entitles them to use of the library, fitness facilities and local discounts. The company was also recently named one of the 200 best small companies by Forbes, based on sales, market value and profits.
BRANDS/DIVISIONS/AFFILIATES: GPU International Atersa Silicon-Film SunChoice APex SunUPS SunLine
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. George W. Roland, Acting CEO Gilbert H. Steinberg, Acting CFO Tracey Pierce, Dir.-Human Resources James A. Rand, VP-Advanced Eng. Richard K. McDowell, Sr. VP-Mfg. Gilbert H. Steinberg, Chmn.
Phone: 302-366-0400 Fax: 302-368-6474 Toll-Free: Address: 300 Executive Dr., Newark, DE 19702-3316 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $61,400 ( 9 months) 2002 Profits: $2,900 ( 9 months) Stock Ticker: APWR 2001 Sales: $69,500 2001 Profits: $3,500 Employees: 682 2000 Sales: $49,800 2000 Profits: $3,500 Fiscal Year Ends: 12/31 1999 Sales: $34,600 1999 Profits: $2,300 1998 Sales: $23,200 1998 Profits: $2,400
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $278,228 Stock Purch. Plan: Second Exec. Salary: $174,504 ADVANTAGE: Produces the largest photovoltaic cells in the world.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $45,064 Bonus: $32,532
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ATMEL CORP
www.atmel.com
Industry Group Code: 334413 Ranks within this company's industry group: Sales:9 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:18
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Circuits-Non-Volatile Memory & Logic Integrated Flash Memories
Atmel Corporation designs, manufactures and markets semiconductors, including advanced logic, nonvolatile memory, mixed signal and RF integrated circuits (ICs). Using the most advanced wafer processes, Atmel distinguishes itself from the competition with its ability to integrate dense nonvolatile memory, logic and analog functions on a single chip. The company produces a full range of chips including application-specific ICs, memory, microcontrollers and programmable logic. Atmel’s semiconductors are used in applications in a variety of markets, including security, automotive and industrial, multimedia and imaging and military and aerospace. The company’s strategy is to offer products that provide the enabling technology and features that allow Atmel's customers to develop and bring to market new, valueadded systems and products. Atmel devotes substantial resources, including management time, to research and development in order to increase the performance of its existing product lines, to develop new product lines and to develop new processes and design technologies. The company does business in Asia, North America and Europe. Current customers include Motorola, Cisco, Polaroid, Lucent and Sony. Atmel provides employees with health, dental and vision insurance, as well as a prescription drug plan, life insurance and disability plans. Tuition reimbursement is also available.
BRANDS/DIVISIONS/AFFILIATES: Atmel Finance, Inc. Atmel Semiconductor Corp. Atmel Asia, Ltd. Atmel FSC, Inc. Atmel Korea, Ltd. Atmel U.K., Ltd. Temic
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. George Perlegos, CEO George Perlegos, Pres. Donald Colvin, CFO/VP-Finance B. Jeffrey Katz, VP-Mktg. Joann Morano, Mgr.-Human Resources Mikes N. Sisois, VP-IT Ralph Bohannon, Sr. VP-Mfg. Mark Bertelsen, Corp. Sec. Mike Ross, VP/General Counsel Mikes N. Sisois, VP-Planning John Bryant, VP-Flash Mktg. James Hu, VP-Process Dev. Graham Turner, VP-Microcontroller Unit George Perlegos, Chmn.
Phone: 408-441-0311 Fax: 408-436-4200 Toll-Free: Address: 2325 Orchard Pkwy., San Jose, CA 95131 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,193,800 (12 months) 2002 Profits: $-641,800 (12 months) Stock Ticker: ATML 2001 Sales: $1,472,300 2001 Profits: $-418,300 Employees: 7,550 2000 Sales: $2,012,700 2000 Profits: $266,000 Fiscal Year Ends: 12/31 1999 Sales: $1,330,200 1999 Profits: $53,300 1998 Sales: $1,111,100 1998 Profits: $-50,000
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Global customer base.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $356,980 Second Exec. Salary: $311,324
Bonus: $175,183 Bonus: $152,778
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ATRIX LABORATORIES INC
www.atrixlabs.com
Industry Group Code: 325411 Ranks within this company's industry group: Sales:5 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:5
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Equipment-Dental/Periodontol Drug Delivery Systems Oncology Products
Atrix Laboratories is engaged in the research, development and commercialization of a broad range of medical, dental and veterinary products based on its proprietary drug delivery systems. Its five patented drug delivery technologies involve proprietary oncology, pain management, growth hormone releasing peptide-1, oral interferon and dermatology products. Atrigel is a release implant for local or systemic delivery of drugs, proteins and peptides from minutes to months. Bema is used in the delivery of drugs from minutes to hours. SMP is a topical gel providing two-stage dermal delivery of water insoluble drugs. MCA is a water-resistant topical gel providing sustained drug delivery. BCP is a non-cytotoxic gel/liquid for topical delivery. Atrix has significant strategic alliances with companies including Pfizer, Inc., SanofiSynthelabo, Inc., MediGene AG, Fujisawa Healthcare, Inc., Elan International Services, Ltd., Geneva Pharmaceuticals, Inc. and CollaGenex Pharmaceuticals, Inc. Atrix executed a non-exclusive comprehensive research and worldwide licensing agreement with Pfizer to provide broad-based access to its proprietary drug delivery systems in the development of new products. Recently, Pfizer submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) for a novel bone growth product which uses Atrix's proprietary Atrigel drug delivery technology. Atrix also formed a joint venture with Elan Corporation to develop and commercialize oncology and pain management products. The joint venture will utilize Atrix’s Bema and Atrigel systems to control side effects caused by chemotherapy, radiation therapy, breakthrough cancer pain and tumor-directed cytotoxic agents. In other news, Atrix entered into an exclusive North American marketing agreement with EmerGen, Inc. for a leuprolide product for the treatment of endometriosis. The company also launched Eligard 22.5mg, a new product for the treatment of advanced prostate cancer. Atrix Laboratories provide its employees with health and dental benefits and tuition assistance.
BRANDS/DIVISIONS/AFFILIATES: Atridox Atrisorb Gtr Atrigel Elan Corp. Eligard Bema ViroTex SMP
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. David R. Bethune, CEO Brian G. Richmond, CFO Stephen L. Warren, VP-Research and Dev. Michael R. Duncan, VP-Technical Oper. Michael R. Duncan, VP-Mfg. Brian G. Richmond, Corp. Sec. Charles P. Cox, Sr. VP-Corp. Dev. Brian G. Richmond, Treas. Richard L. Dunn, Principle Research Scientist Mark D. Sweeney, VP-Quality Assurance David W. Osborne, VP-Dermatology Div. J. Steven Garrett, VP-Dental Div. David R. Bethune, Chmn.
Phone: 970-482-5868 Fax: 970-482-9735 Toll-Free: Address: 2579 Midpoint Dr., Fort Collins, CO 80525 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $26,400 (12 months) 2002 Profits: $-18,200 (12 months) Stock Ticker: ATRX 2001 Sales: $15,800 2001 Profits: $-25,500 Employees: 167 2000 Sales: $10,043 2000 Profits: $-47,411 Fiscal Year Ends: 12/31 1999 Sales: $5,600 1999 Profits: $-13,200 1998 Sales: $21,100 1998 Profits: $1,700
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $271,667 Stock Purch. Plan: Y Second Exec. Salary: $260,000 ADVANTAGE: Holds several patents relating to drug delivery technology..
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
AUDI AG
www.audi.com
Industry Group Code: 336111 Ranks within this company's industry group: Sales:13 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Profits:10
Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Automobile Manufacturing Sports Car Engines
Audi Ag, a subsidiary of Volkswagen, manufactures highend luxury cars. The company has production facilities in Germany, Hungary, Brazil, China, Italy, Malaysia, Great Britain and Thailand. The Audi brand consists of Audi, SEAT and Lamborghini. The firm has six business segments: Audi AG; Audi Hungaria Motor Kft., where most Audi engines are manufactured; Cosworth Technology Limited, which builds engines for passenger cars and Lamborghini engines for sports cars; Lamborghini Automobili, which produces extremely high-end sports cars; Autogerma S.p.a., which initially marketed the VW Beetle in Italy and is the general importer for the Audi, Seat, Skoda, Volkswagen and Volkswagen Commercial Vehicles brands in Italy; and Audi Do Brasil E Cia, with facilities for body manufacturing, final assembly and painting. The paint shop in Brazil is considered to be most advanced and environment-friendly in the world. Audi models include A4 sedans (Avant and Cabriolet), A6 sedans (A6 3.0, S6 Avant and RS 6), A8 sedans (A8, A8 L and S8 sedan), TT sports cars (Coupe and Roadster) and the all road Quattro SUV. J.D. Power and Associates awarded the most appealing Premium Sports Car to Audi TT for the both the years 2002 and 2001.
BRANDS/DIVISIONS/AFFILIATES: Volkswagen Audi AG Audi Hungaria Motor Kft. Lamborghini Automobili Cosworth Technology Limited Autogerma TT Roadster Audi A8
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Martin Winterkorn, CEO Peter Abele, CFO Martin Winterkorn, Chmn.
Phone: 49-841-89-40300 Fax: 49-841-89-30900 Toll-Free: Address: Finanzanalytik und Publizität, I/FF-12, Ingolstadt, D85045 Germany
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $23,690,000 (12 months) 2002 Profits: $812,000 (12 months) Stock Ticker: Foreign 2001 Sales: $19,516,000 2001 Profits: $681,000 Employees: 51,198 2000 Sales: $18,786,200 2000 Profits: $328,800 Fiscal Year Ends: 12/31 1999 Sales: $15,253,200 1999 Profits: $212,100 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Owns the respected Audi and Volkswagen brands.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
AUTODESK INC
www.autodesk.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:22 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:12
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Software-Design & Drafting Multimedia Software
Autodesk, Inc. is a leader in the development and marketing of design and drafting software and multimedia tools, primarily for the business and professional environment. The company’s flagship product, AutoCAD, is one of the world’s leading computer-aided design tools. The firm also produced AutoCAD LT, AutoSketch and AutoCAD Designer, which is available in almost 20 languages. Autodesk also develops software for multimedia, home improvement, visual effects and editing. To keep pace with the rapid technological change in computer hardware, the company maintains an aggressive program of new product development. Autodesk actively collaborates with and supports independent software developers that offer items that enhance and complement AutoCAD software and other products. Autodesk’s Discreet division is a leader in digital content creation tools for visual effects, 3D animation, editing and production for films, video, HDTV, Internet, broadcast graphics and interactive games. Discreet recently launched Character Studio 4 for the latest version of the 3D Studio Max software. Some of the new features it showcases are motion property analysis and visualization, quaternionbased function curves and a non-linear animation mixer. In 2003, Discreet clients, for the eighth year in a row, swept the visual effects category of the Academy Awards. In other recent news, Autodesk has added the Tulane University Architecture School and Washington Department of Transportation to its list of clients. The company has a casual dress work environment, and at some locations, employees may bring their pets to work. The headquarters has on-site fitness facilities. As a bonus, the company offers a paid six-week sabbatical every four years. Autodesk is considered a top company for working mothers.
BRANDS/DIVISIONS/AFFILIATES: AutoCAD CAiCE Lightscape Discreet AutoSketch AutoCAD Designer Character Studio 4 Studio Max
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Carol A Bartz, CEO Carol A. Bartz, Pres. Steve Cakebread, CFO Jan Becker, VP-Human Resources Marcia K. Sterling, Corp. Sec. Michael E. Sutton, VP-Oper. Joseph H. Astroth, VP-Location Services Div. Carl Bass, VP-Design Solutions Div. Paul Lypaczewski, VP-Discreet Div. John G. Sanders, VP-Platform Tech. Carol A. Bartz, Chmn.
Phone: 415-507-5000 Fax: 415-507-5100 Toll-Free: Address: 111 McInnis Pkwy., San Rafael, CA 94903 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $947,500 (12 months) 2002 Profits: $90,300 (12 months) Stock Ticker: ADSK 2001 Sales: $936,300 2001 Profits: $93,200 Employees: 3,646 2000 Sales: $820,182 2000 Profits: $9,808 Fiscal Year Ends: 1/31 1999 Sales: $871,879 1999 Profits: $97,132 1998 Sales: $768,684 1998 Profits: $56,215
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $841,667 Bonus: $550,000 Stock Purch. Plan: Y Second Exec. Salary: $376,667 Bonus: $150,000 ADVANTAGE: Strong demand for products/Leader in the design-automation and multimedia markets.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
AVAYA INC
www.avaya.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:4 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:35
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Software-Voice & Data Integration Interactive Voice Response Systems Support Services Networking Systems and Software Remote Diagnostics Testing Customer Self-Service Software
Avaya, Inc. is a leading provider of communications systems and software for businesses, government agencies and other organizations in the United States and worldwide. Avaya offers voice, converged voice and data, consumer relationship management (CRM), messaging, multi-service networking and structured cabling products and services. Multi-service networking products support infrastructures that carry voice, video and data traffic over any protocols supported by the Internet on local area and wide area data networks. Structured cabling systems are flexible networks designed to connect phones, workstations, personal computers, local area networks and other devices through a building or across one or more campuses. The company supports its customers with comprehensive global service offerings, including remote diagnostics testing, installation, on-site repair and maintenance. Notably, Avaya successfully designed, developed and implemented the communications technology for the 2002 FIFA World Cup in Korea and Japan, an operation in size and complexity that had not been seen before at a major sporting event. Avaya leads all other companies in its industry, encompassing 36.6% of the interaction CRM marketshare. Avaya is committed to promoting diversity in the workplace and offers a variety of programs that address the needs of different ethnic and social groups. In addition to a benefits package and several education programs, workers at Avaya receive remote access to the company network, onsite credit unions, employee discounts and a matching gift program.
BRANDS/DIVISIONS/AFFILIATES: ECLIPS Alchemy DEFINITY INDeX Merlin Magix Quintus Corp. Cyber IQ Systems VPNet Technologies
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Donald K. Peterson, CEO Donald K. Peterson, Pres. Garry K. McGuire, CFO Maryanne DiMarzo, VP-Human Resources Karyn Machima, Sr. VP-Strategy and Tech. Michael C. Crowley, CIO Pamela F. Craven, Sr. VP/Corp. Sec. Pamela F. Craven, General Counsel Garry K. McGuire, Sr. VP-Oper. Stephan Clark, VP-Connectivity Solutions Lou D'Ambrosio, VP-Worldwide Services David Johnson, VP-Small and Medium Bus. Solutions Ravi Sethi, Pres., Avaya Labs Donald K. Peterson, Chmn.
Phone: 908-953-6000 Fax: 908-953-7609 Toll-Free: 866-462-8292 Address: 211 Mt. Airy Rd., Basking Ridge, NJ 07920 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $4,956,000 (12 months) 2002 Profits: $-666,000 (12 months) Stock Ticker: AV 2001 Sales: $6,793,000 2001 Profits: $-352,000 Employees: 18,800 2000 Sales: $7,680,000 2000 Profits: $-375,000 Fiscal Year Ends: 9/30 1999 Sales: $8,268,000 1999 Profits: $282,000 1998 Sales: $7,754,000 1998 Profits: $43,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $940,000 Stock Purch. Plan: Y Second Exec. Salary: $450,000 ADVANTAGE: Expertise in interactive voice response systems/Broad customer base.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $947,969 Bonus: $287,333
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
AVENTIS SA
www.aventis.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:6 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:10
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Diversified Pharmaceutical Manufacturing Vaccines and Proteins Skin Care Treatments
Aventis SA, a global leader in the pharmaceutical industry, offers a wide assortment of patented prescription drugs to treat patients with serious diseases through its many subsidiaries, including Aventis Pharma, which accounts for approximately 85% of revenues. Aventis has leading positions in several therapeutic areas, including cardiology, oncology, diabetes and respiratory. The firm’s core business is in prescription drugs, human vaccines through Aventis Pasteur and animal health through Merial, its joint venture with Merck & Co. The company’s primary products are Allegra and Telfast for the treatment of seasonal allergies, Lovenox and Clexane for the treatment of deep vein thrombosis and heart attacks, Taxotere for the treatment of breast cancer, Delix and Tritace for the treatment of hypertension, Actonel for the treatment of osteoporosis and Lantus for the treatment of diabetes. Its primary markets are the United States, France, Germany and Japan. The U.S. accounts for the majority of sales of Aventis’s strategic brands. In addition, Aventis is continually developing therapeutic innovations, including compounds for the treatment of diabetes, cancer, cardiovascular diseases and respiratory problems. Other research and development efforts include progress in AIDS vaccines, Alzheimer’s treatments and Parkinson’s care. In recent news, the U.S. FDA approved Aventis’s basal insulin drug, Lantus, for flexible administration. Also, the company donated samples of its proprietary cell line for SARS vaccine research. Additionally, Aventis signed an agreement with Vivalis to combine the ALVAC canarypox virus platform of Aventis Pasteur and Vivalis’s proprietary avian stem cell platform to research vaccines for HIV and cancer. The company's annual incentive opportunities are among the most lucrative in the pharmaceutical industry.
BRANDS/DIVISIONS/AFFILIATES: Aventis Pharma Allegra Lovenox Merial Aventis Pasteur Aventis Behring Taxotere Lantus
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Igor Landau, Chmn.-Mgmt. Board Richard J. Markham, COO Patrick Langlois, CFO Heinz-Werner Meier, Exec. VP-Human Resources Dirk Oldenburg, Exec. VP/General Counsel Thierry Soursac, Exec. VP-Commercial Oper. Giles Brisson, Head-Comm. and Public Affairs Arvind K. Sood, Head-Investor Rel. Carston Tilger, Head-Media Rel. Frank L. Douglas, Exec. VP-Drug Innovation and Approval Jurgen Dormann, Chmn.-Supervisory Board
Phone: 33-3-88-99-1100 Fax: 33-3-88-99-1101 Toll-Free: Address: 16 Ave. de l'Europe, Schiltingheim, 67300 France
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $21,659,000 (12 months) 2002 Profits: $2,285,000 (12 months) Stock Ticker: AVE 2001 Sales: $20,447,000 2001 Profits: $1,455,000 Employees: 91,729 2000 Sales: $21,006,000 2000 Profits: $-27,000 Fiscal Year Ends: 12/31 1999 Sales: $12,714,000 1999 Profits: $-859,000 1998 Sales: $15,501,900 1998 Profits: $921,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: One of the world's largest pharmaceutical firms.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
BAE SYSTEMS
www.baesystems.com
Industry Group Code: 336410 Ranks within this company's industry group: Sales:8 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Profits:7 Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Aircraft Manufacturer Electronic Systems
BAE Systems, formed by the merger of British Aerospace and Marconi Electronic Systems, is involved in a wide variety of operations in the aerospace and defense industries. The company owns 20% of Airbus, a commercial airline producer that provides passenger planes to many of the major airline companies. The company and Lockheed Martin have partnered to form the Joint Strike Fighter program, the world’s largest-ever military aircraft development and production competition. Additionally, the company is currently involved in the production of the Eurofighter Typhoon. BAE Systems, along with Saab, have locked in deals for the Gripen combat aircraft. It is also the prime contractor for the U.K. Type 45 Destroyers, the Astute class nuclear-powered submarine and two new Royal Navy aircraft carriers. The company also has a presence in the production of satellites and various ground technologies. In addition, the company performs research and development in a variety of related fields including radar, avionics, guided weapons and electronic systems. BAE Systems has business relations in 129 countries and is present in 5 continents. The company expects an increase in its defense-related activity in the future and continued steady performance in the civil sector. BAE was recently awarded a five-year, $141-million contract to supply explosives to the U.S. Army Joint Munitions Command. BAE Systems offers a variety of career benefits in a manner that enables employees to personalize their options. Employees choose from medical, dental and vision coverage, short- and long-term disability, life insurance and business travel accident coverage, among others.
BRANDS/DIVISIONS/AFFILIATES: Airbus SAS Joint Strike Fighter Eurofighter Typhoon British Aerospace Harrier Nimrod Hawk Marconi Electronic Systems
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Mike Turner, CEO Chris Geoghegan, COO George Rose, Financial Dir. Mike Rouse, Mktg. Dir. Alastair Imrie, Human Resources Dir. Michael Lester, Group Legal Dir. Alison Wood, Strategy Dir. Hugh Colver, Comm. Dir. Steve Mogford, COO-BAE Systems Programs Grenville Hodge, Group Internal Audit Mark Ronald, Pres., BAE Systems North America Richard Evans, Chmn.
Phone: 44-1252-373232 Fax: 44-1252-383000 Toll-Free: Address: Warwick House, Farnborough Aerospace Ctr., Farnborough, GU146YU UK
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $12,953,000 (12 months) 2002 Profits: $-1,100 (12 months) Stock Ticker: Foreign 2001 Sales: $19,069,800 2001 Profits: $-185,800 Employees: 68,100 2000 Sales: $18,198,300 2000 Profits: $-28,400 Fiscal Year Ends: 12/31 1999 Sales: $14,442,800 1999 Profits: $530,500 1998 Sales: $14,290,000 1998 Profits: $1,150,000
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: One of the world’s leading aerospace firms/Merger with Marconi.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
BALLARD POWER SYSTEMS
www.ballard.com
Industry Group Code: 333298 Ranks within this company's industry group: Sales:2 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:4
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Fuel Cells Manufacturing
Ballard Power Systems is a world leader in the development, manufacturing and marketing of zeroemission proton exchange membrane fuel cells. The company’s fuel cells are primarily used in transportation, electricity generation and portable power products, enabling these products with environmentally clean and safe technology. The fuel cell combines hydrogen, which is obtained from methanol, natural gas, petroleum or renewable sources, and oxygen from the air to generate electricity without combustion. The only emission as a result of this reaction is pure water. Ballard is currently partnering with global giants, including DaimlerChrysler, Ford, GPU International, ALSTOM and EBARA, to commercialize its fuel cell technology. The company has supplied fuel cell products to Honda, Nissan, Volkswagen, Yamaha, Cinergy and Coleman Powermate. Ballard, in partnership with DaimlerChrysler, recently delivered the first zero-emission Mercedes-Benz Citaro Bus powered with a Ballard fuel cell engine to public transport authorities in Spain. This represents the first step in the company’s European Fuel Cell Bus Project, which will eventually include the shipment of 30 Citaro buses equipped with 205 kW Ballard fuel cell engines to Amsterdam, Barcelona, Hamburg, London, Luxembourg, Madrid, Porto, Rekjavik, Stockholm and Stuttgart.
BRANDS/DIVISIONS/AFFILIATES: Ballard Generation Systems Ballard Material Products XCELLSIS Ecostar Ballard Automotive
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Dennis Campbell, CEO Dennis Campbell, COO Dennis Campbell, Pres. David Smith, CFO Ross Witschonke, VP-Mktg. and Sales Peter Stickler, VP-Human Resources Fred Vasconcelos, Chief Tech. Officer Lee Craft, VP-Oper. Noordin Nanji, VP-Corp. Strategy and Dev. Firoz Rasul, Chmn.
Phone: 604-454-0900 Fax: 604-412-4700 Toll-Free: Address: 4343 N. Fraser Way, Burnaby, BC V5J 5J9 Canada
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $90,900 (12 months) 2002 Profits: $-147,700 (12 months) Stock Ticker: BLDP 2001 Sales: $36,200 2001 Profits: $-96,200 Employees: 1,300 2000 Sales: $27,400 2000 Profits: $-57,200 Fiscal Year Ends: 12/31 1999 Sales: $22,900 1999 Profits: $-51,300 1998 Sales: $16,200 1998 Profits: $ 500
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: World leader in proton exchange membrane fuel cells.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
BARR LABORATORIES INC
www.barrlabs.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:23 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:17
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Breast Cancer Female Health Care Psychotherapeutics Generic Pharmaceuticals
Barr Laboratories, Inc. is an established pharmaceutical company engaged in the development, manufacture and marketing of generic and proprietary prescription pharmaceuticals. The company currently markets more than 80 generic and five proprietary products, representing various dosage strengths and product forms of 32 chemical entities. The firm’s product line is concentrated primarily on six core therapeutic categories: oncology, female health care, cardiovascular, anti-infectives, pain management and psychotherapeutics. Barr’s business strategy has three core components, including the development and marketing of generic pharmaceuticals that have one or more barriers to entry, developing the generic version and then challenging patents protecting select brand pharmaceuticals where the company believes that such patents are either invalid, unenforceable or not infringed by the company's product. The third business focus is centered on the development and introduction of proprietary pharmaceuticals. The company's largest selling product, Tamoxifen Citrate (Tamoxifen), the generic equivalent of Nolvadex, is used to treat advanced breast cancer, as well as impede the recurrence of tumors following surgery. The company has FDA approval for many of its generic medicines, including Flutamide capsules, a generic form of Eulexin that treats metastatic carcinoma of the prostate; Fluoxetine Hydrochloride, a generic form of Eli Lilly's Prozac, an anti-depressant; Norethindrone Acetate, the generic equivalent to Aygestin, which is utilized in women's health care; Nortel, which substitutes for Ortho-McNeil's Modicon and Ortho-Novum tablets; and Trexal, an antimetabolite used to treat certain neoplastic diseases. Barr recently received FDA approval for the manufacture of a generic version of Roche Pharmaceutical’s Accutane Capsules. Barr Laboratories provides employees with a full benefits package and tuition reimbursement programs.
BRANDS/DIVISIONS/AFFILIATES: Tamoxifen Barr Research, Inc. Fluoxetine Hydrochloride Trexal Nortel Norethindrone Acetate Flutamide
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Bruce L. Downey, CEO Paul M. Bisaro, COO Paul M. Bisaro, Pres. William T. McKee, VP/CFO Timothy P. Catlett, VP-Sales and Mktg. Catherine F. Higgins, VP-Human Resources Salah Ahmed, VP-Research and Dev. Suzanne Donaghy, VP/CIO Michael J. Bogda, VP-Eng. Michael J. Bogda, VP-Mfg. William T. McKee, Corp. Sec. Fredrick J. Killion, General Counsel Lance J. Bronnenkant, Pres.-Research and Dev. Oper. Martin Zeiger, Sr. VP-Strategic Bus. Dev. Jake Hansen, VP-Gov't Affairs Carol A. Cox, VP-Investor Rel. William T. McKee, Treas. Carole S. Ben-Maimon, Pres./CEO, Barr Research, Inc. Christine Mundkur, VP-Quality and Regulatory Counsel Amy Niemann, VP-Proprietary Mktg. Bruce L. Downey, Chmn.
Phone: 845-362-1100 Fax: 845-362-2774 Toll-Free: 800-227-7522 Address: 2 Quaker Rd., Pomona, NY 10970-0519 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,189,000 (12 months) 2002 Profits: $212,200 (12 months) Stock Ticker: BRL 2001 Sales: $509,700 2001 Profits: $62,500 Employees: 1,075 2000 Sales: $482,278 2000 Profits: $42,342 Fiscal Year Ends: 6/30 1999 Sales: $444,033 1999 Profits: $49,250 1998 Sales: $377,304 1998 Profits: $32,720
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Aggressive generic drug strategy.
OTHER THOUGHTS: Apparent Women Officers or Directors: 6 Hot Spot for Advancement for Women/Minorities: Y
Top Exec. Salary: $746,154 Second Exec. Salary: $397,115
Bonus: $500,000 Bonus: $250,000
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
BASF AG
www.basf.com
Industry Group Code: 325000 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Y Chemicals: Y Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Chemicals-Manufacturing Agricultural Products
BASF is the world's largest chemical company. Its product line comprises chemicals, plastics, colorants and pigments, dispersions, automotive and industrial coatings, crop-protection agents, fine chemicals and oil and gas. BASF has production facilities in 38 countries and serves customers in more than 170 countries around the world. It serves as a parent company to 164 wholly-owned subsidiaries and a number of joint ventures. The firm's agricultural products division produces and markets herbicides, fungicides and insecticides. Wintershall AG, BASF's oil and gas subsidiary, is Germany's largest mineral oil and natural gas producer. Its performance chemicals division produces pigments, inks, printing supplies, coatings and polymers for a variety of industries including printing, automobiles, textiles and leathers. The company's chemicals division produces a broad spectrum of petrochemicals, inorganic chemicals and intermediates. The plastics and fibers division produces foams, styrenics, engineering plastics and polyurethanes. In recent news, BASF purchased the rights to a liquid insecticide called fipronil from Bayer CropScience AG. The chemical will be marketed in a portfolio of insecticides sold under the trade name Regent. Employees receive medical, dental and life insurance, disability, reimbursement accounts and relocation benefits. The company also provides tuition reimbursement, matching gifts and a scholarship program.
BRANDS/DIVISIONS/AFFILIATES: Wintershall AG Regent
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Dr. Jürgen F. Strube, CEO Max Dietrich Kley, CFO Jurgen F. Strube, Chmn.
Phone: 49-621-60-0 Fax: 49-621-60-42525 Toll-Free: Address: Carl-Bosch St. 38, Ludwigshafen, 67056 Germany
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $35,031,700 (12 months) 2002 Profits: $1,635,400 (12 months) Stock Ticker: BF 2001 Sales: $29,206,000 2001 Profits: $5,221,000 Employees: 92,545 2000 Sales: $33,989,000 2000 Profits: $1,163,900 Fiscal Year Ends: 12/31 1999 Sales: $31,539,000 1999 Profits: $1,245,500 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: World's largest chemical company.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $ Second Exec. Salary: $
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
BAUSCH & LOMB INC
www.bausch.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:8 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:16
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Supplies-Eye Care Generic and Prescription Pharmaceuticals
Bausch and Lomb, Inc. is a world leader in the development, manufacture and marketing of health care products for the eye. Its products are marketed in over 100 countries. Bausch and Lomb operates in three segments: vision care, pharmaceuticals and surgical products. The company’s vision care division includes contact lenses, lens care products and the vision accessories business. Vision care products are marketed to licensed eye care professionals, health products retailers, independent pharmacies, drug stores, food stores and mass merchandisers by the company's sales force and distributors. The pharmaceutical division manufactures and sells generic and proprietary prescription pharmaceuticals with a strategic emphasis in the ophthalmic field and over-the-counter ophthalmic medications. The surgical sector manufactures and sells products and equipment for cataract, refractive and retinal surgery. Some of Bausch and Lomb’s significant consumer and eye care professional recognition products include ReNu, ReNu MultiPlus Solution, Boston RPG Lenses, SofLens Multi-Focal Contact Lenses, Optima FW Contact Lenses, Sensitive Eyes Saline Solution, Ocuvite Vitamins, Alrex and Opcon Eye Drops. Bausch & Lomb offers its customers the LENSender Direct Lens Delivery service in which the company ships the contact lenses directly to the customers’ homes or offices. Recently, Bausch and Lomb unveiled the pioneering intraocular lens (IOL) insertion system, SofPort System. The SofPort System is the first and only IOL insertion system that is an integrated, single-use, single-handed planar delivery system. This system will allow cataract surgeons to perform less invasive surgery, thus reducing eye trauma and potentially improving patient recovery time. Bausch and Lomb offers employment around the world, with positions ranging from customer service to research and development. It offers comprehensive benefits.
BRANDS/DIVISIONS/AFFILIATES: SofPort System ReNu Boston RPG Lenses SofLens Multi-Focal Contact Lenses Sensitive Eyes Saline Solution Ocuvite Vitamins Alrex Opcon Eye Drops
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Ronald L. Zarrella, CEO Stephen C. McCluski, CFO David R. Nachbar, Sr. VP-Human Resources Gary M. Aron, Sr. VP-Research and Dev. Marie L. Smith, CIO Jurij Z. Kushner, Controller Gary M. Aron, Sr. VP-Eng. Jean F. Geisel, Sec. Robert B. Stiles, General Counsel Barbara M. Kelley, VP-Corp. Comm. Barbara M. Kelley, VP-Investor Rel. Alan H. Resnick, VP-Treas. Alan H. Farnsworth, Sr. VP/Pres., Europe, Middle East and Africa John M. Loughlin, Sr. VP/Pres., Asia Region Angela J. Panzarella, VP, Global Vision Care Efrain Rivera, VP/Pres., Latin American and Canada Ronald L. Zarrella, Chmn.
Phone: 585-338-6000 Fax: 585-338-6007 Toll-Free: 800-344-8815 Address: 1 Bausch & Lomb Pl., Rochester, NY 14604-2701 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,816,700 (12 months) 2002 Profits: $72,500 (12 months) Stock Ticker: BOL 2001 Sales: $1,711,900 2001 Profits: $21,500 Employees: 11,500 2000 Sales: $1,772,400 2000 Profits: $83,400 Fiscal Year Ends: 12/31 1999 Sales: $1,764,300 1999 Profits: $444,800 1998 Sales: $1,604,500 1998 Profits: $25,200
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $1,100,000 Stock Purch. Plan: Second Exec. Salary: $399,337 ADVANTAGE: Strategic positioning in eye care products/Increasing international market share.
OTHER THOUGHTS: Apparent Women Officers or Directors: 4 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $231,780 Bonus: $219,635
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
BAXTER INTERNATIONAL INC
www.baxter.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:2
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Supplies-Intravenous and Renal Dialysis Systems Tissue Heart Valves Biosurgery Products Vaccines
Baxter International, Inc. develops, manufactures and distributes its medical products in 29 countries and sells them in over 100 countries. Its products are used by hospitals, clinical and medical research labs, blood and blood dialysis centers, rehab facilities, nursing homes, doctor’s offices and patients undergoing supervised home care. The company operates in three segments: medication delivery, which provides a range of intravenous solutions and specialty products that are used in combination for fluid replenishment, nutrition therapy, pain management, antibiotic therapy and chemotherapy; BioScience, which develops biopharmaceuticals, biosurgery products, vaccines and blood collection, processing and storage products and technologies; and renal, which develops products and provides services to treat end-stage kidney disease. The medication delivery segment includes ASTA Medica Oncology, a Germanbased manufacturer of chemotherapy drugs. The BioScience division is known as a leading producer of both plasma-based and recombinant clotting factors for hemophilia, as well as biopharmaceuticals used to treat immune deficiencies, cancer and other disorders. The company has a European licensure for Ceprotin, a new protein C concentrate used to treat congenital protein C deficiency. Baxter has been growing its presence in renal care by addressing the needs of kidney-disease patients from initial diagnosis through dialysis and organ replacement. Baxter's international business has recently increased with the approval by the Japanese Ministry of Health, Labor and Welfare of the company’s peritoneal dialysis solution, EXTRANEAL. This solution offers the potential for increased removal of fluid from the bloodstream during dialysis. Baxter is commited to maintaining a highly diverse workforce. The company offers employees a relaxed work environment with business casual dress.
BRANDS/DIVISIONS/AFFILIATES: Immuno International AG Research Medical, Inc. EXTRANEAL Baxter Healthcare Corp. Cook Pharmaceutical Solutions ASTA Medica Oncology Ceprotin Fusion Medical Technologies, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Harry M. Jansen Kraemer, Jr., CEO Brian P. Anderson, CFO Karen J. May, VP-Human Resources Norbert G. Riedel, Chief Scientific Officer John Moon, CIO J. Michael Gatling, VP-Global Mfg. Oper. Jan Stern Reed, Corp. Sec. Thomas J. Sabatino, Jr., General Counsel Neville J. Jeharajah, VP-Investor Rel. and Financial Planning Steven J. Meyer, Treas. David F. Drohan, VP/Pres.-Medication Delivery Thomas H. Glanzmann, VP/Pres.-BioScience Alan Heller, VP/Pres.-Rental James R. Hurley, VP-Integration and Alliance Mgmt. Harry M. Jansen Kraemer, Jr., Chmn. John L. Quick, VP-Quality and Regulatory
Phone: 847-948-2000 Fax: 847-948-3948 Toll-Free: 800-422-9837 Address: One Baxter Pkwy., Deerfield, IL 60015-4633 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $8,110,000 (12 months) 2002 Profits: $778,000 (12 months) Stock Ticker: BAX 2001 Sales: $7,663,000 2001 Profits: $612,000 Employees: 54,600 2000 Sales: $6,896,000 2000 Profits: $740,000 Fiscal Year Ends: 12/31 1999 Sales: $6,380,000 1999 Profits: $797,000 1998 Sales: $5,706,000 1998 Profits: $315,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $916,346 Stock Purch. Plan: Y Second Exec. Salary: $620,192 ADVANTAGE: A leader in manufacturing heart valves/Worldwide marketing.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $403,000 Bonus: $164,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
BAYER AG
www.bayer-ag.de
Industry Group Code: 325000 Ranks within this company's industry group: Sales:2 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:2
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Y Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Chemicals-Manufacturing AgriBio Products Coatings and Colorants Detergents and Cleaning Products Pharmaceuticals Diagnostics
Bayer AG is one of the world's largest manufacturers of chemicals. The company, also known as The Bayer Group, serves as the parent entity for four divisions: Bayer HealthCare, Bayer CropScience, Bayer Polymers and Bayer Chemicals. Bayer HealthCare oversees the efforts of the Pharmaceuticals, Consumer Care, Biological Products, Diagnostics and Animal Health divisions. Products produced include Advantage flea control, AlkaSeltzer, Aspirin (Bayer created aspirin in 1899), Ciprobay to fight infectious diseases, Glucobay to treat diabetes and Polyglobin for immune therapy. Bayer CropScience, which recently became a legally independent entity, was formed by the merger of Bayer's Crop Protection Business Group with the newly acquired $6.6 billion Aventis CropScience company. The division is the second largest supplier of agri-bio products in the world. Bayer Polymers was formed by the combination of Bayer's Plastics, Rubber, Polyurethanes and Coatings and Colorants business groups along with subsidiary Bayer Faser GmbH. The division focuses on engineering thermoplastics, isocyanates and polycarbonates for use in CDs and DVDs. Bayer Chemicals is comprised of Bayer's Basic and Fine Chemicals and Specialty Products. It also includes organic colorants and inorganic pigments formerly under the Coatings and Colorants business group. This division is a leader in the global chemical market with representation in all major consumer countries and regions. The most important products produced by Bayer Chemicals are Bayferrox, pigments for the construction industry; Baypure, detergents and cleaning products; and Preventol, material protection agents. In addition, Bayer operates three service companies: Bayer Business Services, which performs business and administrative tasks; Bayer Technology Services, which provides technological expertise and utilities procurement for Bayer divisions; and Bayer Industry Services, which provides infrastructure services for the company's German production sites. Bayer HealthCare is the first company to receive approval for an assay measuring viral loads in hepatitis C patients.
BRANDS/DIVISIONS/AFFILIATES: Bayer Group (The) Advantage Alka-Seltzer Ciprobay Glucobay Bayferrox Baypure Preventol
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Werner Wenning, Chmn.-Mgmt. Board Klaus Kuehn, CFO Richard Pott, Labor Dir. Udo Oels, Innovation, Tech. and Environment Manfred Schneider, Chmn.-Supervisory Board
Phone: 49-214-30-58992 Fax: 49-214-307-1986 Toll-Free: Address: Werk Leverkusen, Leverkusen, 51368 Germany
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $32,213,100 (12 months) 2002 Profits: $1,152,600 (12 months) Stock Ticker: BAY 2001 Sales: $25,792,000 2001 Profits: $860,000 Employees: 116,900 2000 Sales: $27,764,000 2000 Profits: $3,563,000 Fiscal Year Ends: 12/31 1999 Sales: $27,511,200 1999 Profits: $3,380,500 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $ Stock Purch. Plan: Y Second Exec. Salary: $ ADVANTAGE: One of the largest manufacturers of chemicals in the world/Created aspirin.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
BAYERISCHE MOTOREN WERKE AG Industry Group Code: 336111 Ranks within this company's industry group: Sales:10 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
www.bmw.com Profits:6
Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Automobile Manufacturing Financial Services Consulting Services Fleet Management IT Solutions Engines
Bayerische Motoren Werke (BMW), based in Munich, Germany, is one of the leading vehicle manufacturers in Europe, with brands including the BMW line. BMW models include the 325 series coupe, sedan and convertible; the 525 series coupe and sport wagon; the M3 coupe and convertible; the X5 sport utility vehicle; and the Z4 roadster. In addition, the company produces the MINI brand of cars and a line of motorcycles and related accessories. Other operations include software, through Softlab; BMW Financial Services, which provides leasing, financing and other services internationally; Bavaria Wirtschaftsagentur, which provides insurance and other services to the BMW Group; BMW M, which develops high-performance sports cars; and BMW Car IT, a think tank for IT development and software. Through BMW Motoren, the group also manufactures engines. Recently, the firm announced record-breaking annual sales of more than 1 million BMW and MINI-brand vehicles in 2002.
BRANDS/DIVISIONS/AFFILIATES: BMW of North America, LLC BMW Softlab GmbH MINI Bavaria Wirtschaftsagentur Nexolab BMW Car IT Alphabet Fuhrpark Management
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Helmut Panke, CEO Stefan Krause, Dir.-Finance Michael Ganal, Dir.-Sales and Mktg. Ernst Baumann, Dir.-Human Resources and Industrial Rel. Burkhard Goschel, Dir.-Dev. Norbert Reithofer, Dir.-Production Helmut Panke, Chmn.-Mgmt. Board
Phone: 49-89-382-0 Fax: 49-89-382-2-44-18 Toll-Free: Address: Petuelring 130, Munich, D-80788 Germany
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $44,316,000 (12 months) 2002 Profits: $2,117,000 (12 months) Stock Ticker: Foreign 2001 Sales: $34,071,000 2001 Profits: $1,653,000 Employees: 101,395 2000 Sales: $33,291,200 2000 Profits: $966,100 Fiscal Year Ends: 12/31 1999 Sales: $34,642,800 1999 Profits: $-2,504,400 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Owns the respected BMW brand.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $ Second Exec. Salary: $
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
BEA SYSTEMS INC
www.beasys.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:21 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:24
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Software-Transaction Processing Java-Based Software
BEA Systems, Inc. is one of the world’s leading application infrastructure software providers, with over 13,000 customers worldwide. Customers look to BEA to improve or build e-commerce systems that will improve efficiency and response time in today’s rapidly moving business environment. Prior to the introduction of BEA’s WebLogic Enterprise Platform, companies had to rely on a variety of separate technologies to create their e-business commerce systems. With WebLogic, BEA has created a system that encompasses every aspect of infrastructure development. This system, which reduces the cost of ebusiness, combines server, portal and integration technologies to allow companies to satisfy their web needs without the chore of individually piecing them together. These products allow companies to create platforms for a variety of applications, including billing, transaction processing and customer service. BEA provides application software to 100% of Fortune 500’s financial securities companies, network communications companies and computer and office equipment manufacturers. In recent news, BEA’s focus on growth has been evident with the signing of 60 new customers who adopted WebLogic systems. BEA Systems offers its employees tuition reimbursement, credit union membership, company performance awards, financial planning assistance and flexible spending accounts.
BRANDS/DIVISIONS/AFFILIATES: WebLogic Enterprise Platform eLink WebLogic Server Java Jbuilder
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Alfred S. Chuang, CEO Alfred S. Chuang, Pres. William M. Klein, CFO Charlie Ill, VP-Sales Jeanne Wu, VP-Human Resources Scott Dietzen, Chief Tech. Officer Rhonda L. Hocker, CIO Dave Logan, VP-Corp. Dev. William T. Coleman, III, Chief Customer Advocate Tod Nielsen, Chief Mktg. Officer Oliver Helleboid, Pres.-Products Organization Thomas Ashburn, Pres.-BEA Worldwide Services William T. Coleman, III, Chmn.
Phone: 408-570-8000 Fax: 408-570-8901 Toll-Free: 800-817-4232 Address: 2315 N. 1st St., San Jose, CA 95131 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $975,900 (12 months) 2002 Profits: $-35,700 (12 months) Stock Ticker: BEAS 2001 Sales: $819,800 2001 Profits: $17,100 Employees: 3,116 2000 Sales: $464,410 2000 Profits: $-19,574 Fiscal Year Ends: 1/31 1999 Sales: $289,042 1999 Profits: $-51,582 1998 Sales: $166,447 1998 Profits: $-22,912
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $437,500 Bonus: $246,890 Stock Purch. Plan: Y Second Exec. Salary: $412,500 Bonus: $764,109 ADVANTAGE: A leading provider of e-commerce software that enables clients of all types to build online offerings
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
BECHTEL GROUP INC
www.bechtel.com
Industry Group Code: 541310 Ranks within this company's industry group: Sales:3 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Y Y Y Y
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y Y
GROWTH PLANS/SPECIAL FEATURES:
Engineering, Construction and Project Management Services
Bechtel Group, Inc. is one of the world’s largest engineering companies. The company offers construction, engineering, procurement, management, safety, technological and financial services. The firm has participated in such notable projects as the construction of the Hoover Dam, the creation of the Bay Area Rapid Transit system in San Francisco and the quelling of the oil field fires in Kuwait following the Gulf War. Recently, the U.S. Agency for International Development awarded a multi-million dollar capital construction contract to Bechtel that calls for the repair and reconstruction of vital elements of Iraq’s infrastructure. Moreover, the firm has been awarded a program management contract for Cingular Wireless’ expansion to a GSM/GPRS network. Bechtel’s role in this 16,000-site project will include procurement and construction and materials management. In the fall of 2002, the company and ConocoPhillips renewed their collaborative pursuit of liquefied natural gas (LNG) projects. The collaboration will build upon the recent success of ConocoPhillips as a participant in the LNG industry as well as Bechtel’s engineering and construction of major LNG projects in Trinidad and Egypt. Additionally, the firm is currently providing engineering and construction services for the first major power plant to be built in New York in 10 years.
BRANDS/DIVISIONS/AFFILIATES: BCN Data Systems International Water InterGen Global Supply Group Bechtel Bettis, Inc. Bechtel COSAPI
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Riley P. Bechtel, CEO Adrian Zaccaria, COO Adrian Zaccaria, Pres. Peter Dawson, CFO Jim Illich, Human Resources Geir Ramleth, Information Sys. & Tech. Rick Burt, Legal & Risk Mgmt. Susan Kubanis, Sustainable Dev. Kevin Berg, Environmental, Safety & Health Services Jock Covey, Corp. & External Affairs George Nutwell, Bus. Services Andy Greig, Pres., Mining & Metals Div. Riley P. Bechtel, Chmn.
Phone: 415-768-1234 Fax: 415-768-9038 Toll-Free: Address: 50 Beale St., San Francisco, CA 94105 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $13,300,000 (12 months) 2002 Profits: $ (12 months) Stock Ticker: Private 2001 Sales: $13,400,000 2001 Profits: $ Employees: 44,473 2000 Sales: $14,300,000 2000 Profits: $ Fiscal Year Ends: 12/31 1999 Sales: $12,600,000 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: One of the best known and most respected names in engineering.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
BECKMAN COULTER INC
www.beckmancoulter.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:7 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:12
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Equipment-Laboratory Instruments Test Kits for Laboratories
Beckman Coulter designs, manufactures and markets systems that consist of instruments, chemistries, software and supplies to meet a variety of laboratory needs. Its products have a range of applications, from instruments used for pioneering medical research and drug discovery to diagnostic tools found in hospitals and physicians' offices. Beckman’s product lines include virtually all blood tests routinely performed in hospital laboratories and a range of systems for medical and pharmaceutical research. The organization has approximately 200,000 systems operating in laboratories around the world, with more than half of its annual revenues coming from aftermarket customer purchases of operating supplies, chemistry kits and services. Beckman markets its products in approximately 130 countries, with nearly half its revenues coming from outside the U.S. The firm’s customers include hospital clinical laboratories, physicians' offices, group practices, commercial reference laboratories, universities, medical research laboratories, pharmaceutical companies and biotechnology firms. Beckman operations are organized into three divisions: clinical diagnostics, life science research and specialty testing. The company recently entered into a distribution agreement with Cell Signaling Technologies, Inc. under the terms of this agreement, Beckman will distribute existing CST products as well as work together in the development of antibodies used to explore, define and monitor major regulatory circuits controlling cell growth. Additionally, Beckman has signed a contract with HealthTrust Purchasing Group whereby Beckman will provide the healthcare purchasing organization with medical laboratory chemistry systems and tests. The company offers jobs in all aspects of its worldwide operations including customer service, communications, administration and legal divisions. The company offers tuition reimbursement to qualified employees.
BRANDS/DIVISIONS/AFFILIATES: Beckman Coulter Primary Care Diagnostics Beckman Coulter/Centrifuge Division Hybritech Incorporated Coulter Corporation Immunotech S.A.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John P. Wareham, CEO John P. Wareham, Pres. Amin Khalifa, CFO Fidencio M. Mares, VP-Human Resources James T. Glover, Controller William H. May, Sec. William H. May, General Counsel Edgar E. Vivanco, VP-Oper. Fidencio M. Mares, VP-Corp. Comm. Paul Glyer, Treas. Elias Caro, Pres., Biomedical Research Div. Geroge E. Bers, VP Edgar E. Vivanco, Pres., Specialty Testing Div. Scott Garrett, Pres., Clinical Diagnostics Div. John P. Wareham, Chmn.
Phone: 714-871-4848 Fax: 714-773-8283 Toll-Free: 800-233-4685 Address: 4300 N. Harbor Blvd., Fullerton, CA 92834 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $2,059,400 (12 months) 2002 Profits: $135,500 (12 months) Stock Ticker: BEC 2001 Sales: $1,984,000 2001 Profits: $138,400 Employees: 10,000 2000 Sales: $1,886,900 2000 Profits: $125,500 Fiscal Year Ends: 12/31 1999 Sales: $1,808,700 1999 Profits: $106,000 1998 Sales: $1,718,200 1998 Profits: $33,500
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $752,097 Stock Purch. Plan: Second Exec. Salary: $290,720 ADVANTAGE: A key player in clinical protein analysis/Vast, worldwide customer base.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $118,800 Bonus: $22,100
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
BECTON DICKINSON & CO
www.bd.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:3 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:4
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Equipment-Injection/Infusion Prefillable Drug Delivery Systems Disposable Scrubs
Becton, Dickinson & Company (BD) manufactures and sells a broad line of medical supplies, devices and diagnostic systems used by health care professionals, medical research institutions and the general public. The company operates in three segments: medical systems, biosciences and clinical laboratory solutions. The medical systems segment offers hypodermic products, specially designed devices for diabetes care, prefillable drug delivery systems and infusion therapy products. It also offers anesthesia and surgical products, ophthalmic surgery devices; critical care systems, elastic support products and thermometers. The biosciences segment offers industrial microbiology products, cellular analysis systems, research and clinical reagents for cellular and nucleic acid analysis, cell culture lab ware and growth media, hematology instruments and other diagnostic systems, including immunodiagnostic test kits. Products and services that the clinical laboratory solutions segment offers are specimen collection products and services, consulting services and customized, automated bar-code systems for patient identification and point-of-care data capture. Two of BD’s most popular products are Hypak prefillable syringes and Vacutainer blood-collection products. Outside of the U.S., BD’s products are manufactured and sold in Europe, Japan, Mexico, Asia Pacific, Canada and Brazil. BD Biosciences and NuGenesis Technologies are currently working to provide a productivity solution that creates an easy-to-use data management and archival system for flow cytometry data. The company recently announced the discontinuation of sales of many conventional needles across a range of product categories. This discontinuation is reflective of the industry’s focus on creating safer alternatives that will protect healthcare workers from injuries. The firm offers employees fitness centers, health centers and adoption assistance as well as stock options and scholarship programs. In addition, the company offers LifeWorks, a family resource program designed to provide all employees and families with information on topics ranging from retirement to adoption.
BRANDS/DIVISIONS/AFFILIATES: Med-Safe Systems, Inc. Vacutainer Hypak Clontech Laboratories, Inc. BD Autoguard
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Edward J. Ludwig, CEO Edward J. Ludwig, Pres. John R. Considine, CFO Jean-Marc Dageville, VP-Human Resources Vincent A. Forlenza, Sr. VP-Tech. Bridget M. Healy, Corp. Sec. Bridget M. Healy, General Counsel William A. Kozy, Sr. VP-Oper. Vincent A. Forlenza, Sr. VP-Strategy & Dev. Deborah J. Neff, Pres., Becton Dickinson Biosciences Gary M. Cohen, Pres., Worldwide Medical Systems Edward J. Ludwig, Chmn.
Phone: 201-847-6800 Fax: 201-847-6475 Toll-Free: 800-284-6845 Address: 1 Becton Dr., Franklin Lakes, NJ 07417-1880 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $4,033,100 (12 months) 2002 Profits: $480,000 (12 months) Stock Ticker: BDX 2001 Sales: $3,754,300 2001 Profits: $401,600 Employees: 25,249 2000 Sales: $3,618,300 2000 Profits: $392,900 Fiscal Year Ends: 9/30 1999 Sales: $3,418,400 1999 Profits: $275,700 1998 Sales: $3,116,900 1998 Profits: $236,600
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $850,000 Stock Purch. Plan: Second Exec. Salary: $535,000 ADVANTAGE: Widely known for quality products and technology/International presence.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $750,000 Bonus: $410,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
BENTLEY PHARMACEUTICALS INC www.bentleypharm.com Industry Group Code: 325412 Ranks within this company's industry group: Sales:74 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:49
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Diversified Drug Delivery Technologies
Bentley Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on advanced drug delivery technologies and pharmaceutical products. The company has U.S. and international patent and other proprietary rights to technologies that enhance or facilitate the absorption of drugs across membranes of the skin, mouth, nose, vagina and eye. Bentley is developing products incorporating these technologies and seeks to form alliances with major biotechnology companies to facilitate the development and commercialization of its products. Currently, the company has strategic alliances with Pfizer, Inc., Auxilium A2, Inc. and Teva Pharmaceutical Industries. The firm has a significant commercial presence in Spain, where it manufactures and markets more than 100 pharmaceutical products. The company's product line consists of generic and branded products within four primary areas: cardiovascular, gastrointestinal, infectious and neurological diseases. Bentley's CPE-215 technology enhances the absorption of drugs across skin membranes and can be incorporated into a variety of formats and products, including creams, ointments, gels, solutions, lotions, sprays or patches. The technology has a record of safety in humans as a food additive and fragrance. Bentley has a number of products in various stages of development, including a topical testosterone gel for the treatment of hypogonadism; an improved acetaminophen for pain relief; an antifungal nail lacquer; an androgenic steroid therapy for chronic fatigue syndrome; and intranasal insulin for diabetes. The company's branded products include Belmazol, sold by others as Prilosec; Senioral, sold by others as Denoral; and Enalapril Belmac, sold by others as Vasotec. In recent news, the firm received approval to market Paroxetine, the generic equivalent of Paxil, in Spain. Bentley also recently extended its research and development relationship with Pfizer, giving Pfizer access to the company's drug delivery platform.
BRANDS/DIVISIONS/AFFILIATES: Belmac Corp. Laboratorios Belmac Laboratorios Davur Belmazol Mio Relax Enalapril Belmac Senioral Codeisan
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. James R. Murphy, CEO James R. Murphy, Pres. Michael D. Price, VP/CFO Robert M. Stote, Sr. VP/Chief Science Officer Robert J. Gyurik, VP-Pharmaceutical Dev. Michael D. Price, Corp. Sec. Jordan A. Hovrath, VP/General Counsel Michael D. Price, Treas. James R. Murphy, Chmn.
Phone: 603-964-8006 Fax: 603-964-6889 Toll-Free: Address: 65 Lafayette Rd., 3rd Fl., North Hampton, NH 038622403 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $39,100 (12 months) 2002 Profits: $1,600 (12 months) Stock Ticker: BNT 2001 Sales: $26,400 2001 Profits: $1,400 Employees: 287 2000 Sales: $18,617 2000 Profits: $- 745 Fiscal Year Ends: 12/31 1999 Sales: $20,200 1999 Profits: $-1,100 1998 Sales: $15,200 1998 Profits: $-2,900
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Has a large international market.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $390,000 Second Exec. Salary: $304,500
Bonus: $100,000 Bonus: $30,000
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
BIO RAD LABORATORIES INC
www.bio-rad.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:17 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:17
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Equipment-Life Sciences Research Clinical Diagnostics
Bio-Rad Laboratories manufactures and supplies the life science research, health care and analytical chemistry markets with a broad range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The firm’s life science division develops laboratory devices, biomaterials, imaging products and microscopy systems. The division uses electrophoresis, image analysis and microplate readers, chromatography, gene transfer and sample preparation and amplification as its primary technological applications. Bio-Rad Laboratories provides its services to universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers and biotechnology researchers. The company’s clinical diagnostics division encompasses a broad array of technologies incorporated into a variety of tests used to detect, identify and quantify substances in blood or other bodily fluids and tissues. The test results are used as aids for medical diagnosis, detection, evaluation, monitoring and treatment of diseases and other medical conditions. Recently, Bio-Rad Laboratories introduced KnowItAll ADME/Tox, the latest addition to its KnowItAll Informatics System. KnowItAll ADME/Tox helps drug developers avoid millions of dollars of unnecessary research and development costs by enabling them to predict, evaluate and eliminate unsuitable drug candidates early in the drug discovery process. Specifically, KnowItAll ADME/Tox includes applications that allow researchers to identify compounds with potentially poor absorption profiles, predict a compound’s metabolic fate and assess its potential toxicity. Additionally, the firm recently acquired Quantase, Ltd., a provider of newborn screening diagnostic products. Bio-Rad offers its employees tuition reimbursement and dental and vision insurance.
BRANDS/DIVISIONS/AFFILIATES: KnowItAll Informatics System KnowItAll ADME/Tox Quantase, Ltd.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Norman Schwartz, CEO James J. Bennett, COO Norman Schwartz, Pres. Christine Tsingos, CFO Richard Anderson, VP-Human Resources Sanford S. Wadler, Corp. Sec. Sanford S. Wadler, General Counsel Ronald Hutton, Treas. John Goetz, Group Mgr. David Schwartz, Chmn.
Phone: 510-724-7000 Fax: 510-741-5817 Toll-Free: 800-224-6723 Address: 1000 Alfred Nobel Dr., Hercules, CA 94547 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $892,700 (12 months) 2002 Profits: $67,900 (12 months) Stock Ticker: BIO 2001 Sales: $817,500 2001 Profits: $44,200 Employees: 4,600 2000 Sales: $725,884 2000 Profits: $31,100 Fiscal Year Ends: 12/31 1999 Sales: $555,399 1999 Profits: $11,721 1998 Sales: $447,863 1998 Profits: $24,302
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $531,495 Stock Purch. Plan: Y Second Exec. Salary: $494,000 ADVANTAGE: Diverse group of customers/ Excellent proprietary technologies.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $317,526 Bonus: $311,220
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
BIO TECHNOLOGY GENERAL CORP Industry Group Code: 325412 Ranks within this company's industry group: Sales:53 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
www.btgc.com Profits:41
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Weight Loss Endocrine and Metabolic Disorder Products
Bio-Technology General (BTG) is engaged in the research, development, production and marketing of biopharmaceutical products. Through a combination of internal research and development, acquisitions, collaborative relationships and licensing arrangements, BTG has developed a number of therapeutic products, including nine products that have received regulatory approval for sale. The company’s approved products include OXANDRIN, an oral anabolic agent primarily used to treat patients suffering from AIDS-related weight loss, and DELATESTRYL, which is used to treat testosterone deficiency and delayed puberty. Additionally, the firm is currently conducting clinical studies of several products. Products under development include Fibrimage, a diagnostic agent used to detect deep vein thrombosis, and Puricase, an enzyme that eliminates excess uric acid in individuals with symptomatic gout. Recently, the firm acquired Rosemont Pharmaceuticals, Ltd., which develops, manufactures and markets prescription drugs in oral liquid form. Rosemont Pharmaceuticals’ product line includes a number of central nervous system and cardiovascular drugs, as well as Soltamox, an oral liquid formulation of tamoxifen used to treat breast cancer. BTG has also acquired Myelos Corp., a biopharmaceutical company focused on the development of novel therapeutics to treat diseases of the nervous system. The acquisition has added the drug Prosaptide, a compound used to treat neuropathic pain associated with diabetic peripheral neuropathy, to the company’s lineup. Bio-Technology General offers its employees dental and vision insurance and referral bonuses.
BRANDS/DIVISIONS/AFFILIATES: OXANDRIN DELATESTRYL Fibrimage Puricase Rosemont Pharmaceuticals, Ltd. Soltamox Myelos Corp. Prosaptide
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Sim Fass, CEO Christopher G. Clement, COO Christopher G. Clement, Pres. Whitney K. Stearns, Jr., CFO Steven Vorrius, VP-Mktg. Leah Berkovits, VP-Human Resources Zeb Horowitz, Chief Medical Officer Ronald J. Simko, VP-Mfg. Robert M. Shaw, Corp. Sec. Robert M. Shaw, General Counsel Robert M. Shaw, Chief Admin. Officer Lawrence B. Brown, VP-Bus. Dev. Leah Berkovits, VP-Corp. Comm. Whitney K. Stearns, Jr., Treas. Yehuda Sternlicht, Chief Acc. Officer Dana B. Shinbaum, VP-Strategic Planning Ernest L. Kelly, Sr. VP-Quality Assurance Tom Fogarty, VP-Nat'l Sales Sim Fass, Chmn.
Phone: 732-418-9300 Fax: 732-418-0766 Toll-Free: Address: One Tower Ctr., 14th Fl., East Brunswick, NJ 08830 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $103,000 (12 months) 2002 Profits: $9,700 (12 months) Stock Ticker: BTGC 2001 Sales: $102,000 2001 Profits: $-30,300 Employees: 490 2000 Sales: $84,900 2000 Profits: $7,700 Fiscal Year Ends: 12/31 1999 Sales: $85,300 1999 Profits: $13,900 1998 Sales: $76,900 1998 Profits: $17,700
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $445,552 Stock Purch. Plan: Y Second Exec. Salary: $300,827 ADVANTAGE: Innovative products for niche diseases.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $115,000 Bonus: $85,711
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest:
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
BIOGEN INC
www.biogen.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:25 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:18
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Multiple Sclerosis Psoriasis Treatments
Biogen, Inc. is a biopharmaceutical company that develops, manufactures and markets novel therapeutic products. The company’s products include AVONEX, used to decrease the frequency of neurological attacks in patients with relapsing forms of multiple sclerosis (MS), and AMEVIVE, a biologic therapy designed to treat adults with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. Biogen is also conducting clinical studies of a number of drugs, including ANTEGREN, which the company developed in collaboration with Elan Corporation. ANTEGREN is a humanized monoclonal antibody that has the potential to treat MS and Crohn’s disease. Additionally, the firm is currently developing a lymphotoxin-beta receptor blocking agent as a potential treatment for several autoimmune diseases and an interferon beta gene delivery product for the treatment of glioma. Biogen also generates revenue by licensing drugs it has developed to other companies, including Schering-Plough, Merck and Abbott Labs. The company’s licensed products include alpha interferon and hepatitis B vaccines. Biogen recently launched PsoriasisSupport.com, a web site that provides content and community support for people with psoriasis. In June 2003 Biogen announced that it intends to acquire IDEC Pharmaceuticals. After the merger, Biogen will change its name to Biogen IDEC. The newly merged company will rank near the top of all biotech firms, with annual revenues of more than $1.5 billion and a research budget of more than $500 million. Biogen offers its employees dental insurance, tuition reimbursement, referral bonuses and matching gifts to educational institutions.
BRANDS/DIVISIONS/AFFILIATES: AVONEX AMEVIVE ANTEGREN PsoriasisSupport.com IDEC Biogen IDEC
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. James C. Mullen, CEO James C. Mullen, Pres. Peter N. Kellogg, CFO/Exec. VP-Finance Craig Schneier, Exec. VP-Human Resources Burt A. Adelman, Exec. VP-Research and Dev. Patrick J. Purcell, CIO Whaijen Soo, Sr. VP-Medical Research Thomas J. Bucknum, General Counsel John W. Palmer, Sr. VP-Corp. Dev. Sylvie L. Gregoire, Exec. VP-Tech. Oper. Hans Peter Hasler, Exec. VP-Commercial Oper. Nadine Cohen, Sr. VP-Regulatory Affairs Cornelis Been, Sr. VP-Oncology James C. Mullen, Chmn.
Phone: 617-679-2000 Fax: 617-679-2617 Toll-Free: Address: 14 Cambridge Ctr., Cambridge, MA 02142-1481 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,148,400 (12 months) 2002 Profits: $199,100 (12 months) Stock Ticker: BGEN 2001 Sales: $1,043,400 2001 Profits: $272,700 Employees: 2,633 2000 Sales: $926,452 2000 Profits: $333,577 Fiscal Year Ends: 12/31 1999 Sales: $794,435 1999 Profits: $220,450 1998 Sales: $557,587 1998 Profits: $138,697
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $810,000 Bonus: $800,000 Stock Purch. Plan: Y Second Exec. Salary: $598,748 Bonus: $218,800 ADVANTAGE: Marketer of AVONEX, a treatment for relapsing forms of multiple sclerosis/Expertise in molecular biology.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
BIOMARIN PHARMACEUTICAL
www.biomarinpharm.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:98 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:80
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Mucopolysaccharidosis-I Carbohydrate Enzyme Therapies
BioMarin Pharmaceutical, Inc. is a developer of carbohydrate enzyme therapies for debilitating, lifethreatening, chronic genetic disorders and other diseases and conditions. Its lead drug product, Aldurazyme, is being developed for the treatment of mucopolysaccharidosis-I, or MPS-I. MPS-I is a lifethreatening genetic disorder caused by the lack of a sufficient quantity of the enzyme (alpha)-L-iduronidase. Patients with MPS-I have multiple debilitating symptoms resulting from the buildup of carbohydrate residues in all tissues in the body. These symptoms include delayed physical and mental growth, enlarged liver and spleen, skeletal and joint deformities, airway obstruction, heart disease, reduced endurance and pulmonary function and impaired hearing and vision. BioMarin has a joint venture with Genzyme for the worldwide development and commercialization of Aldurazyme. The company recently completed regulatory filings seeking approval to market Aldurazyme in the U.S. and Europe. Neutralase is also being developed for reversal of anticoagulation by heparin in patients undergoing coronary artery bypass graft (CABG), surgery and angioplasty. Other products that BioMarin is developing include Aryplase for the treatment of MPS VI and Vibrilase for the treatment of acute burn injuries. In recent news, BioMarin completed the acquisition of Glyko Biomedical, Ltd., a Canadian company. The firm offers numerous benefits to eligible part time and full time employees, such as an educational assistance program, a business casual environment, an employee development program and generous amounts of paid vacation. Additionally, BioMarin offers its employees medical, dental and vision insurance, as well as access to a number of social events that include a holiday gala, summer picnic and monthly birthday parties.
BRANDS/DIVISIONS/AFFILIATES: Aldurazyme Glyko Biomedical Genzyme Neutralase Aryplase Vibrilase
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Fredric D. Price, CEO John C. Klock, Pres. Louis Drapeau, CFO/VP-Finance Christopher M. Starr, Sr. VP-Scientific Oper. Kim R. Tsuchimoto, VP/Controller John L. Jost, VP-Mfg. and Process Dev. Louis Drapeau, Corp. Sec. Jeffrey I. Landau, VP-Admin. Emil D. Kakkis, Sr. VP-Bus. Oper. Robert A. Baffi, VP-Quality Assurance and Control Brian K. Brandley, VP-Pharmacology and Toxicology Robert A. Heft, VP-Product Dev. and Program Mgmt. Stuart J. Swiedler, VP-Clinical Affairs Fredric D. Price, Chmn.
Phone: 415-884-6700 Fax: 415-382-7427 Toll-Free: Address: 371 Bel Marin Keys Blvd., Ste. 210, Novato, CA 94949 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $13,900 (12 months) 2002 Profits: $-77,500 (12 months) Stock Ticker: BMRN 2001 Sales: $11,700 2001 Profits: $-67,600 Employees: 219 2000 Sales: $12,326 2000 Profits: $-37,364 Fiscal Year Ends: 12/31 1999 Sales: $7,000 1999 Profits: $-28,100 1998 Sales: $1,200 1998 Profits: $-12,300
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Joint venture with Genzyme.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $408,269 Second Exec. Salary: $250,000
Bonus: $278,500 Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
BIOMET INC
www.biomet.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:13 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:9
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Supplies-Orthopedic Electrical Bone Growth Stimulators Powered Surgical Instruments Arthroscopy Products Imaging Equipment Human Bone Joint Replacement Systems
Biomet, Inc. designs, manufactures and markets products used primarily by musculoskeletal medical specialists in both surgical and non-surgical therapies. Products include reconstructive and fixation devices, electrical bone growth stimulators, orthopedic support devices, operating room supplies, general surgical instruments, arthroscopy products, spinal products, bone cements and accessories, bone substitute materials, craniomaxillofacial implants and instruments and dental reconstructive implants and associated instrumentation. Biomet manufactures numerous knee systems, including the Maxim Total Knee System, the Finn Knee Replacement System and the AGC Total Knee System. The firm also manufactures several hip and shoulder replacement systems. Biomet’s subsidiary, Arthrotek, Inc., manufactures surgical systems, pumps, shavers, cameras, arthroscopic imagers and bone cement removal systems, while its Walter Lorenz Surgical, Inc. subsidiary manufactures orthopedic equipment. The firm’s other subsidiaries are Biomet Merck Group, EBI, L.P. formerly Electro-Biology, Inc. and 3i formerly Implant Innovations, Inc. Biomet invests in the communities where it conducts business and encourages employees to participate in nonprofit, charitable, educational, civic, cultural and service organizations.
BRANDS/DIVISIONS/AFFILIATES: Anthrotek, Inc. Walter Lorenz Surgical, Inc. EBI, L.P. Biomet Merck Group 3i Maxim Total Knee System Finn Knee Replacement System AGC Total Knee System
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Dane A. Miller, CEO Dane A. Miller, Pres. Gregory D. Hartman, Sr. VP-Finance/CFO William C. Kolter, VP-Mktg. Darlene K. Whaley, VP-Human Resources Anthony L. Flemming, VP-Research and Dev. James W. Haller, Controller Richard J. Borror, Jr., VP-Mfg. Daniel P. Hann, Sr. VP/Sec. Daniel P. Hann, General Counsel Thomas R. Allen, VP-Oper., The Americas and Asia Pacific Greg W. Sasso, VP-Corp. Dev. Greg W. Sasso, VP-Corp. Comm. Gregory D. Hartman, Treas. Garry L. England, Sr. VP-Warsaw Oper. Craig Blaschke, VP-Biomaterials Tech. David L. Montgomery, VP-Sales, Biomet Orthopedics, Inc. James W. Haller, VP-Finance, Biomet Orthopedics, Inc. Niles L. Noblitt, Chmn. Charles E. Niemier, Sr. VP-Intl. Oper.
Phone: 574-267-6639 Fax: 574-267-8137 Toll-Free: 800-348-9500 Address: 56 East Bell Dr., Warsaw, IN 46581-0587 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,191,900 (12 months) 2002 Profits: $239,700 (12 months) Stock Ticker: BMET 2001 Sales: $1,030,700 2001 Profits: $197,500 Employees: 3,240 2000 Sales: $923,600 2000 Profits: $173,771 Fiscal Year Ends: 5/31 1999 Sales: $830,800 1999 Profits: $125,026 1998 Sales: $706,150 1998 Profits: $127,859
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $279,700 Stock Purch. Plan: Second Exec. Salary: $273,800 Expertise in orthopedics/Steady growth. ADVANTAGE:
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $230,000 Bonus: $209,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
BIORELIANCE CORP
www.bioreliance.com
Industry Group Code: 621511 Ranks within this company's industry group: Sales:3 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y Y Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:3
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Research-Nonclinical Product Testing Contract Drug Manufacturing
BioReliance Corporation is a leading contract service organization that provides testing, development and manufacturing services for biologics and for other biomedical products. Its clients include biotechnology and pharmaceutical companies worldwide. BioReliance provides its services throughout the product cycle, starting from early preclinical development through licensed production. Through its testing and development business, the firm evaluates products to ensure that they are free of disease-causing agents and do not cause adverse effects; characterizes products' chemical structures; develops formulations for long-term stability; and validates purification processes under regulatory guidelines. In its manufacturing business, BioReliance develops unique production processes and manufactures biologics on behalf of clients both for use in clinical trials and for the worldwide commercial market. BioReliance's testing services include assessments of the cell banks used to manufacture biologics, validation of purification processes for clearance of adventitious agents such as viruses and testing of in-process and final products. Recently, BioReliance entered into a laboratory agreement with MedImmune, Inc., in which it will perform a range of tests for MedImmune’s developed products. In other news, the company entered into a multi-year manufacturing agreement with Celltech Group, one of Europe’s largest biotechnology companies. Under this agreement, BioReliance will manufacture and supply clinical-grade, antibody fragment-based drugs to Celltech. BioReliance provides its employees with health benefits, tuition reimbursement and bonuses.
BRANDS/DIVISIONS/AFFILIATES:
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Capers W. McDonald, CEO Capers W. McDonald, Pres. John L. Coker, VP-Finance/CFO Ronald R. Baker, VP-Mktg. and Sales John J. Gilly, VP-U.S. Mfg. John L. Coker, Corp. Sec. John L. Coker, VP-Admin. John L. Coker, Treas. Raymond F. Cosgrove, VP-European Testing and Dev. David Jacobson-Kram, VP-Toxicology and Laboratory Animal Health
Phone: 301-738-1000 Fax: 301-738-1036 Toll-Free: Address: 14920 Broschart Rd., Rockville, MD 20850 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $82,400 (12 months) 2002 Profits: $10,800 (12 months) Stock Ticker: BREL 2001 Sales: $69,700 2001 Profits: $5,900 Employees: 638 2000 Sales: $55,900 2000 Profits: $1,200 Fiscal Year Ends: 12/31 1999 Sales: $47,200 1999 Profits: $-1,000 1998 Sales: $49,800 1998 Profits: $3,700
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Experts in biologies manufacturing.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $381,253 Second Exec. Salary: $213,473
Bonus: $173,750 Bonus: $94,825
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
BIOSITE INC
www.biosite.com
Industry Group Code: 325413 Ranks within this company's industry group: Sales:2 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:2
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Diagnostics Rapid Immunoassays
Biosite, Inc. is a research-based diagnostics company dedicated to the discovery and development of novel protein-based tests that improve physicians' ability to diagnose diseases. The firm combines separate yet integrated discovery and diagnostics businesses to access proteomics research, identify proteins with high diagnostics value, develop and commercialize products and educate the medical community on new approaches to diagnosis. Biosite is a leading provider of rapid immunoassays, or antibody-based diagnostic tests, sold primarily for use in hospitals worldwide. The company's products include the Triage Drugs of Abuse Panel, the Triage Cardiac Panel and the Triage BNP Test. Triage Drugs of Abuse Panel and Triage TOX Drug Screen are rapid, qualitative urine screens that analyze a single test sample for up to eight different illicit and prescription drugs or drug classes and provide results in approximately 10 to 15 minutes. The Triage BNP Test is the first and only blood test currently approved in the U.S. for the diagnosis of congestive heart failure. The firm's Biosite Discovery business is dedicated to the identification of new protein markers of acute diseases that lack effective diagnostic tests. Additionally, with Biosite Discovery, the company has the capacity to offer antibody development services to pharmaceutical and biotechnology companies seeking high-affinity antibodies for use in their drug research. In return, Bosite seeks diagnostic licenses. In recent news, the company announced it has signed a distribution agreement with Biosyn Diagnostics UK, Ltd. With this agreement, Biosyn will distribute Biosite’s products within England, Scotland and Wales.
BRANDS/DIVISIONS/AFFILIATES: Triage Drugs of Abuse Panel Triage Meter Triage Cardiac Panel Triage TOX Drug Screen Triage BNP Test Biosite Discovery
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Kim D. Blickenstaff, CEO Kim D. Blickenstaff, Pres. Christopher J. Twomey, VP-Finance/CFO James E. Douglas, VP-Mktg. and Sales Laura Weatherford, Human Resources Kenneth F. Buechler, VP-Research and Dev. Thomas M. Watlington, Sr. VP-Commercial Oper. Christopher R. Hibberd, VP-Strategic Planning and Bus. Dev. Nadine Padilla, VP-Corp. and Investor Rel. Peter Witerzens, VP-Oper. Gunars E. Valkirs, VP-Discovery Gary A. King, VP-Worldwide Mktg.
Phone: 858-455-4808 Fax: 858-455-4815 Toll-Free: Address: 11030 Roselle St., San Diego, CA 92121 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $105,200 (12 months) 2002 Profits: $13,400 (12 months) Stock Ticker: BSTE 2001 Sales: $65,600 2001 Profits: $6,700 Employees: 513 2000 Sales: $55,000 2000 Profits: $6,163 Fiscal Year Ends: 12/31 1999 Sales: $43,700 1999 Profits: $1,100 1998 Sales: $37,100 1998 Profits: $-1,100
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $311,250 Bonus: $100,567 Stock Purch. Plan: Second Exec. Salary: $246,000 Bonus: $176,581 Biosite's Triage rapid diagnostic tests are used in nearly 50% of U.S. hospitals and in approximately 40 ADVANTAGE: international markets
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
BIOSOURCE INTERNATIONAL INC
www.biosource.com
Industry Group Code: 325413 Ranks within this company's industry group: Sales:6 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:6
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Supplies-Enzyme-Linked Immunosorbent Assay Test Kits (ELISA) Clinical Diagnostics
BioSource International, Inc. develops, manufactures and distributes products used worldwide in disease-related biomedical research and clinical diagnostics. Its products enable scientists and biomedical researchers to better understand the biochemistry, immunology and cell biology of the human body, as well as disease processes. The company offers over 3,650 products, including assays, antibodies, bioactive proteins and peptides, serum and buffers. The firm’s bioactive protein products include Interleukin 4, a protein that suppresses the growth of a variety of malignancies, and Tumor Necrosis Factor, a protein that plays a vital role in the regulation of the immune system. BioSource International also produces oligonucleotides, which are synthesized polymers made from the same building blocks that form DNA. The firm recently launched the industry’s first p38 MAPK ELISA assay. The protein p38 MAPK is important in drug discovery research focused on mitogen activated protein kinases. Companies are studying p38 MAPK modifiers as drug candidates in a wide variety of diseases including several types of cancer, Parkinson’s disease, diabetes and cardiovascular disease. BioSource International’s p38 MAPK ELISA kit is directly targeted at applications for these areas of research.
BRANDS/DIVISIONS/AFFILIATES: p38 MAPK ELISA
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Leonard M. Hendrickson, CEO Leonard M. Hendrickson, Pres. Charles C. Best, CFO/Exec. VP-Finance David S. Thrower, Sr. VP-Mktg. & Sales Cy Cabradilla, Jr., VP-Molecular Biology Jean-Pierre L. Conte, Chmn.
Phone: 805-987-0086 Fax: 805-987-3385 Toll-Free: 800-242-0607 Address: 542 Flynn Rd., Camarillo, CA 93012 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $40,100 (12 months) 2002 Profits: $-1,000 (12 months) Stock Ticker: BIOI 2001 Sales: $35,200 2001 Profits: $ 700 Employees: 296 2000 Sales: $32,210 2000 Profits: $- 166 Fiscal Year Ends: 12/31 1999 Sales: $29,257 1999 Profits: $3,577 1998 Sales: $21,859 1998 Profits: $-5,136
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Focus on molecular biology.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $250,000 Second Exec. Salary: $166,400
Bonus: $99,650 Bonus: $59,023
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
BMC SOFTWARE INC
www.bmc.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:14 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:31
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y Y
GROWTH PLANS/SPECIAL FEATURES:
Computer Software-Mainframe Related Maintenance, Enhancement and Support Services Training
BMC Software is one of the largest independent systems software developers. The company provides software solutions that enhance the availability, performance and recoverability of its customers’ applications. These solutions fall into categories including enterprise server management, business integrated scheduling, application and database performance management, recovery and storage management and other software solutions. The firm's integrated software solutions address the numerous technology layers within the information technology (IT) enterprise, including operating systems, databases, middleware, storage and network devices, web application servers, transaction servers and the applications themselves. Business-to-business and business-toconsumer e-business adds additional complexity to client environments; BMC serves these groups by providing tools that monitor, manage, control and optimize all components in an e-business transaction. The company's portfolio of more than 450 systems management solutions allows its customers to manage these components and technologies within their IT systems from end-to-end, from legacy databases and applications on large mainframes to customer-facing web portals and exchanges. In addition, BMC's professional services organization provides a comprehensive suite of consulting services and education. With its growing professional services business, the firm has moved from being a provider of software products to becoming a complete solutions provider. Continuing its aggressive acquisition strategy, BMC recently acquired IT Masters International, an enterprise management solutions firm. The acquisition further strengthens the company’s service level management solutions by adding adaptive service management capabilities to its product portfolio. BMC also acquired Remedy Corp, marking a major step in its transition from a tools and utilities vendor to a leader in the enterprise management space. The company's enclosed corporate campus features an on-site car wash, a health club, laundry service, a hair salon and two restaurants.
BRANDS/DIVISIONS/AFFILIATES: PATROL Optimizer Remedy Corp IT Masters International Recovery Manager Boole & Babbage, Inc. New Dimension Software, Ltd. Project Golden Gate
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Robert E. Beauchamp, CEO Robert E. Beauchamp, Pres. John W. Cox, CFO Darroll Buytenhuys, Sr. VP-Global Sales, Services and Mktg. Roy J. Wilson, Sr. VP-Human Resources Dan Barnea, Sr. VP-Research and Dev. Robert H. Whilden, Jr., Sr. VP/Corp. Sec. Robert H. Whilden, Jr., General Counsel Jerome Adams, Sr. VP-Admin. Neil Yekell, Dir.-Investor Rel. Stephen B. Solcher, VP/Treas. Jeff Hawn, Sr. VP-Oper. Pam Austin, Dir.-Worldwide Public Rel. Garland Cupp, Chmn.
Phone: 713-918-8800 Fax: 713-918-8000 Toll-Free: 800-841-2031 Address: 2101 CityWest Blvd., Houston, TX 77042-2827 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,288,900 (12 months) 2002 Profits: $-184,100 (12 months) Stock Ticker: BMC 2001 Sales: $1,504,000 2001 Profits: $42,400 Employees: 6,335 2000 Sales: $1,719,200 2000 Profits: $242,500 Fiscal Year Ends: 3/31 1999 Sales: $1,303,900 1999 Profits: $362,600 1998 Sales: $985,200 1998 Profits: $188,500
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $600,000 Bonus: $1,019,836 Stock Purch. Plan: Y Second Exec. Salary: $425,004 Bonus: $601,985 ADVANTAGE: Large R&D investment/Addressing broad-based computer needs/Aggressive acquisition strategy.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
BOEING CO
www.boeing.com
Industry Group Code: 336410 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Profits:3 Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Commercial Aircraft Manufacturing Aerospace Technology and Manufacturing Satellite Manufacturing Air Traffic Management Technology Airborne Internet Access Services Aerospace Product Finance
The Boeing Company is one of the world's largest aerospace companies, developing leading-edge technologies for the manufacture of commercial jetliners and military aircraft. The company is the largest exporter in the U.S. and is the nation’s largest NASA contractor. Outside of its domestic operations, Boeing’s customers span 145 countries and employees work in 60 different nations. The corporation is organized into four main units: Commercial Airplanes, Space and Communications, Military Aircraft and Missiles and Customer and Commercial Financing. Boeing’s main commercial products include the 717, 737, 747, 757, 767 and 777 families of jetliners as well as the MD-80, MD-90, MD-11 and Boeing Business Jets. Some of Boeing's main military aircraft products include the F-15 Eagle fighter-bomber, the AH-64D Apache helicopter, the F/A-18E/F Super Hornet and Air Force One. The company recently developed a system that allows airline passengers the ability to access the Internet in flight under its Connexion by Boeing unit. The company has an aggressive acquisition policy, with purchases of SBS International, a developer of airline flight operations software; the space and communications businesses of Hughes Corporation as well as Hughes Electron Dynamics; and Jeppesen Sanderson, Inc., a provider of flight information services. Due to the slowdown in the airline industry Boeing's production was approximately 380 new aircraft in 2002 and will reduce to 275 in 2003. The company recently introduced the Boeing Business Express, the newest variant of the Boeing 717-200. This aircraft, equipped with workstations, meeting spaces and videoconferencing, can be configured to hold 40 to 80 passengers. In mid 2003, Boeing announced the development of a radical new aircraft dubbed 7E7, to be constructed largely of carbon fiber rather than traditional aluminum. If successful, the 7E7 will offer great fuel economy and will be built in both long-haul and short-haul models. Boeing employees enjoy a full benefits package including health care, disability and life insurance.
BRANDS/DIVISIONS/AFFILIATES: Connexion by Boeing Hughes Corporation SBS International, Inc. Jeppesen Sanderson, Inc. SSG-Shared Services Group Boeing Commercial Airplane Group Boeing Space & Communications Group Boeing Precision Gear, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Philip M. Condit, CEO Harry C. Stonecipher, Pres. Michael Sears, CFO/Sr.VP Laurette T. Koellner, Chief People Officer David O. Swain, Chief Tech. Officer James A. Bell, Controller Allen Mulally, CEO-Commercial Aircraft James C. Johnson, Corp. Sec., Asst. General Counsel Douglas G. Bain, General Counsel Laurette T. Koellner, Chief Admin. Officer Walter E. Skowronski, Treas. James Albaugh, Pres./CEO, Integrated Defense Systems Bonnie W. Soodik, Sr.VP/Pres., Shared Services Group Gale C. Andrews, VP-Ethics and Bus. Conduct Rudy De Leon, Sr. VP-Washington, D.C. Oper. Philip M. Condit, Chmn.
Phone: 312-544-2000 Fax: 312-544-2082 Toll-Free: Address: 100 N. Riverside Plaza, Chicago, IL 60606 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $54,069,000 (12 months) 2002 Profits: $492,000 (12 months) Stock Ticker: BA 2001 Sales: $58,198,000 2001 Profits: $2,827,000 Employees: 166,000 2000 Sales: $51,321,000 2000 Profits: $2,128,000 Fiscal Year Ends: 12/31 1999 Sales: $57,993,000 1999 Profits: $2,309,000 1998 Sales: $56,154,000 1998 Profits: $1,120,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: World's leading aircraft manufacturer.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
Top Exec. Salary: $1,547,308 Second Exec. Salary: $749,424
Bonus: $982,800 Bonus: $440,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
BOMBARDIER INC
www.bombardier.com
Industry Group Code: 336410 Ranks within this company's industry group: Sales:6 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Profits:5 Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y Y
GROWTH PLANS/SPECIAL FEATURES:
Aircraft Manufacturer Defense Services Financial Services Fleet Management Train and Railway Equipment Watercraft
Bombardier, Inc., a diversified manufacturing company, has operations in transportation, aerospace, recreational products and financial services. Through its aerospace division, the firm is the largest producer of regional aircraft, the third-largest producer of civil aircraft and one of the two largest makers of business jets in the world. Its business aircraft include Learjet and Challenger models. In addition, this division provides defense services including fleet management and aviation training management. The company also makes multi-role amphibious aircraft, suitable for such tasks as forest-fire fighting, maritime surveillance, search and rescue and utility transport. Bombardier’s transportation division is now the world’s largest producer of railway vehicles and equipment, following its recent acquisition of the Adtranz rail systems division of DaimlerChrysler for $725 million. This unit also produces monorail systems, light rail transit systems, rapid transit systems and propulsion and controls technology, among other products. The company’s recreational products division creates snowmobiles (such as Ski-Doo), all-terrain vehicles, boats and other watercraft, outboard engines (including Evinrude and Johnson), rotax engines and utility vehicles. Bombardier Capital offers services including inventory finance and ski industry finance. In recent news, the firm received an additional $227-million order for regional trains from Deutsche Bahn in Germany. Moreover, U.S. Airways has put in an order for 85 Bombardier aircrafts, totaling $2.2 billion, with a reconfirmable order of an additional 90. In early 2003, the firm announced restructuring plans to include the possible sale of the snowmobile division, writedowns and a new stock issue.
BRANDS/DIVISIONS/AFFILIATES: Adtranz Learjet Challenger Aircraft Sea-Doo Ski-Doo Outboard Marine Corp. Metronet Consortium London Underground
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Paul Tellier, CEO Paul Tellier, Pres. Pierre Alary, Sr. VP/Interim CFO Roger Carle, Corp. Sec. Michael Denham, Sr. VP-Strategy Yvon Turcot, Sr. VP-Public Affairs Michel Lord, VP-Investor Rel. Robert Greenhill, Pres./COO, Bombardier International Pierre Lortie, Pres./COO, Bombardier Transportation Brian Peters, Pres./COO, Bombardier Capital Pierre Beaudoin, Pres./COO, Bombardier Aerospace Laurent Beaudoin, Chmn.
Phone: 514-861-9481 Fax: 514-861-7053 Toll-Free: Address: 800 Rene-Levesque Blvd. W., Montreal, Quebec H3B 1Y8 Canada
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $14,865,500 (12 months) 2002 Profits: $268,600 (12 months) Stock Ticker: Foreign 2001 Sales: $11,063,400 2001 Profits: $246,000 Employees: 74,879 2000 Sales: $10,705,300 2000 Profits: $648,500 Fiscal Year Ends: 1/31 1999 Sales: $9,418,600 1999 Profits: $497,100 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Y Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $1,250,000 Bonus: $950,000 Stock Purch. Plan: Y Second Exec. Salary: $460,000 Bonus: $300,000 ADVANTAGE: Manufacturer of highly regarded corporate and commuter aircraft/Acquisition of Adtranz.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
BOSTON BIOMEDICA INC
www.bbii.com
Industry Group Code: 325413 Ranks within this company's industry group: Sales:8 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y Y Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:8
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Diagnostics Laboratory Services Pressure Cycling Technology Clinical Trials After-Sales Services
Boston Biomedica, Inc. and its subsidiaries provide products and services for the detection and treatment of infectious diseases such as AIDS and viral hepatitis. The firm's business units are BBI Diagnostics, a manufacturer of quality control and other diagnostic products used to increase the accuracy of in vitro diagnostic tests; BBI Biotech Research Laboratories, the research and development arm of the company; BBI Source Scientific (BBISS), a developer and manufacturer of laboratory and medical instruments; and the pressure cycling technology (PCT) research and development segment. The PCT segment develops solutions for health care problems including extraction of nucleic acids, inactivation of pathogens in human plasma, food safety and genomics. This division is currently manufacturing prototypes of the Barocycler instrument and disposable PULSE tubes utilizing PCT technology. Formerly, Boston Biomedica was also engaged in clinical laboratory activities, but the firm exited this segment of business in late 2000. BBI Diagnostics' products include quality control panels, diagnostic components and Accurun run controls, all used in connection with infectious disease testing. BBISS manufactures lab instruments including readers, washers and other small medical devices used in hospital and clinics and in research, environmental and food testing labs. Products include MicroChem and MicroChemII photometers, ChemStat automated photometers, EXECWASH washing systems and Verif-EYE reflectance readers. Boston Biomedica's other services include clinical trials, laboratory instrumentation services and after-sales services, including third-party maintenance. In recent news, the company announced that it has released for sale the first product based on its PCT technology, the PCT Sample Preparation System, which consists of the Barocycler instrument and single-use PULSE tubes. The product will be sold for use in the fields of genomics and proteomics.
BRANDS/DIVISIONS/AFFILIATES: BBI Source Scientific BBI Biotech Research Laboratories BBI Diagnostics PULSE Barocycler Accurun MicroChem ChemStat
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Richard T. Schumacher, CEO Kevin W. Quinlan, COO Kevin W. Quinlan, Pres. Kathleen W. Benjamin, VP-Human Resources Patricia E. Garrett, Sr. VP-Science and Tech. Richard J. D'Allesandro, VP-IT Patricia E. Garrett, Sr. VP-Strategic Programs Kevin W. Quinlan, Treas. Mark M. Manak, Sr. VP/Mgr., BBI Biotech Research Laboratories David F. Petersen, Sr. VP/Mgr., BBI Source Scientific Richard T. Schumacher, Chmn.
Phone: 508-580-1900 Fax: 508-580-1110 Toll-Free: 800-676-1881 Address: 375 West St., West Bridgewater, MA 02379 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $22,800 (12 months) 2002 Profits: $-1,500 (12 months) Stock Ticker: BBII 2001 Sales: $21,800 2001 Profits: $3,400 Employees: 197 2000 Sales: $19,470 2000 Profits: $-8,001 Fiscal Year Ends: 12/31 1999 Sales: $19,798 1999 Profits: $- 800 1998 Sales: $19,265 1998 Profits: $-4,400
SALARIES/BENEFITS: Pension Plan: Y Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: New focus on drug development.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Top Exec. Salary: $237,500 Second Exec. Salary: $185,000
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
BOSTON SCIENTIFIC CORP
www.bostonscientific.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:6 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:5
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Supplies-Surgery Interventional Medical Products
Boston Scientific Corporation is a developer, manufacturer and marketer of minimally invasive medical devices. The company’s products are used in a wide range of interventional medical specialties, including cardiology, electrophysiology, gastroenterology, neuro-endovascular therapy, pulmonary medicine, radiology, urology and vascular surgery. The firm’s products include steerable catheters, micro-guidewires, polypectomy snares and stents. Stents, which are flexible metal tubes that are used to open arteries, account for 20% of sales. The company sells its products to over 10,000 hospitals, clinics, outpatient facilities and medical offices. Boston Scientifc’s electrophysiology division is currently investigating advanced modalities for arrhythmia diagnosis and treatment of atrial flutter and atrial fibrillation. Additionally, the firm’s oncology division is studying technologies intended to treat kidney disease and symptomatic uterine fibroids. Recently, Boston Scientific received U.S. Food and Drug Administration approval of its Enteryx technology for the treatment of symptoms of gastroesophageal reflux disease. The Enteryx procedure involves injecting a patented liquid polymer into the lower esophageal sphincter, which helps to prevent or reduce reflux of gastric acid into the esophagus. In the spring of 2003, the company entered into an alliance with Osiris Therapeutics, Inc. to develop and commercialize a new therapy to treat cardiovascular disease. The companies will initially focus on applying mesenchymal stem cell technology to help patients who have suffered a heart attack. Boston Scientific offers its employees dental and vision insurance, tuition reimbursement and adoption assistance.
BRANDS/DIVISIONS/AFFILIATES: Enteryx
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. James R. Tobin, CEO James R. Tobin, Pres. Lawrence C. Best, CFO/Sr. VP-Finance Robert G. MacLean, Sr. VP-Human Resources Fred A. Colen, Chief Tech. Officer Paul W. Sandman, Corp. Sec. Paul W. Sandman, General Counsel James H. Taylor, Jr., Sr. VP-Oper. Paul Donovan, VP-Corp. Comm. Lawrence C. Best, Sr. VP-Admin. Paul A. LaViolette, Group Pres.-Cardiovascular Stephen F. Moreci, Group Pres.-Endosurgery Peter M. Nicholas, Chmn.
Phone: 508-650-8000 Fax: 508-647-2393 Toll-Free: Address: One Boston Scientific Pl., Natick, MA 01760-1537 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $2,919,000 (12 months) 2002 Profits: $373,000 (12 months) Stock Ticker: BSX 2001 Sales: $2,673,000 2001 Profits: $-54,000 Employees: 13,900 2000 Sales: $2,664,000 2000 Profits: $373,000 Fiscal Year Ends: 12/31 1999 Sales: $2,842,000 1999 Profits: $371,000 1998 Sales: $2,234,000 1998 Profits: $-264,400
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $763,069 Bonus: $610,000 Stock Purch. Plan: Second Exec. Salary: $435,011 Bonus: $369,096 ADVANTAGE: Products used in a broad range of interventional medical specialties/Continues to grow through acquisitions/Sells to 10,000 organizations.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
BP PLC
www.bp.com
Industry Group Code: 211111 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Y Chemicals: Y Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Oil & Gas, Exploration and Production Petrochemicals Manufacturing Lubricants
BP, PLC is the world’s second-largest integrated oil company and the largest producer of hydrocarbons in the United States. The company’s main activities are the exploration and production of crude oil and natural gas, the manufacturing of petrochemicals, refining, marketing and supply and transportation. The firm has acquired Atlantic Richfield Company (ARCO) in an effort to increase its proved reserves and is now the leading gasoline marketer in the western U.S. One of the company’s notable discoveries came in Spring 2001, when BP announced the discovery of 1 trillion cubic feet of gas in reservoirs off the east coast of Trinidad. The firm currently operates roughly 29,000 gas stations under the BP, Amoco and ARCO brand names. Additionally, BP owns Burmah Castrol, a business that increases BP’s worldwide lubricant activities. BP supplies lubricants to major shipping companies, small fishing vessel operators, automotive manufacturers and consumers under the highly recognizable Castrol brand. The company’s BP Solar subsidiary is one of the world’s largest manufacturers of photovoltaic modules and systems. BP Solar and the Spanish and Philippine governments have an agreement that brings solar power to 150 isolated villages in the Philippines. BP Solar anticipates that it will continue to receive similar contracts because of the prohibitive cost of extending power lines and the difficulty of transporting generator fuel to remote, developing areas. The company recently increased its interests in both its Taiwanese and Korean PTA joint ventures with the announcement of 59.02% ownership of China American Petrochemical Company in Taiwan and 47.41% ownership of Samsung Petrochemical Company in Korea. These represent a 14% increase in BP’s equity capacity in Asia. BP offers its employees tuition reimbursement, adoption assistance, service and retirement awards and health insurance.
BRANDS/DIVISIONS/AFFILIATES: Atlantic Richfield Co. Amoco Burmah Castrol BP Solar Air BP BP Exploration BP Bitumen BP Pipelines North America
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John Browne, Group Chief Exec. Byron E. Grote, CFO Doug Ford, Chief Exec.-Mktg. Richard L. Olver, Human Resources Judith Hanratty, Corp. Sec. Rodney F. Chase, Deputy Group Chief Exec. Doug Ford, Chief Exec.-Refining Byron E. Grote, Chief Exec.-Chemicals Dick Olver, Chief Exec.-Exploration and Production
Phone: 44-20-7496-4000 Fax: 44-20-7496-4630 Toll-Free: Address: Britannic House, One Finsbury Circus, London, EC2M 7BA UK
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $283,108,000 (12 months) 2002 Profits: $34,428,200 (12 months) Stock Ticker: BP 2001 Sales: $174,218,000 2001 Profits: $8,010,000 Employees: 110,150 2000 Sales: $148,062,000 2000 Profits: $10,183,000 Fiscal Year Ends: 12/31 1999 Sales: $83,566,000 1999 Profits: $4,596,000 1998 Sales: $68,304,000 1998 Profits: $2,826,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $2,762,000 Stock Purch. Plan: Second Exec. Salary: $2,035,000 ADVANTAGE: A focus on diversified energy sources including renewables.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
BRADLEY PHARMACEUTICALS
www.bradpharm.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:71 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:42
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Respiratory Drugs-Dermatology
Bradley Pharmaceuticals markets over-the-counter and prescription pharmaceutical and health-related products. The firm’s product line currently includes dermatological brands marketed by its Doak Dermatologics subsidiary and nutritional, respiratory and internal medicine brands marketed by its Kenwood Therapeutics division. Bradley’s growth strategy is to make acquisitions, including through co-marketing and licensing agreements, of established products from major pharmaceutical organizations that the company believes require intensified marketing and promotional attention. The company’s dermatology products include Acidmantle HC, Lidamantle HC, Carmol HC, Carmol Scalp Treatment Kit and Rosula. GlutofacMX is the company’s prescription-only nutritional multivitamin product. Glutofac-MX aids in the maintenance of proper mineral levels and is especially useful for the elderly and patients with special nutritional needs, an inadequate diet, illness, infection, trauma or recent surgery. Respiratory products include Brontex, Deconamine and Tyzine. Pamine and Anamantle are the company’s two gastroenterology products. In recent news, the company announced the extension of a longterm contract with Difa Cooper SpA for the distribution rights of Trans-Ver-Sal in Italy. Trans-Ver-Sal is a unique dermal patch delivery system for wart removal.
BRANDS/DIVISIONS/AFFILIATES: Kenwood Laboratories Doak Dermatologics Carmol 40 Glutofac-MX Deconamine Pamine Acidmantle Trans-Ver-Sal
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Daniel Glassman, CEO Daniel Glassman, Pres. R. Brent Lenczycki, VP/CFO Robert S. Dubin, Sr. VP-Sales Dileep Bhagwat, VP/Chief Scientific Officer Bruce W. Simpson, Corp. Sec. Gene L. Goldberg, Sr. VP-Bus. Planning Iris S. Glassman, Treas. Bradley Glassman, VP-Global Mktg., Kenwood Therapeutics Robert Corbo, VP-Quality Control and Assurance Gene L. Goldberg, Sr. VP-Mktg. Daniel Glassman, Chmn.
Phone: 973-882-1505 Fax: 973-575-5366 Toll-Free: Address: 383 Rte. 46 W., Fairfield, NJ 07004 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $39,700 (12 months) 2002 Profits: $7,600 (12 months) Stock Ticker: BPRX 2001 Sales: $25,700 2001 Profits: $3,600 Employees: 181 2000 Sales: $18,557 2000 Profits: $-2,063 Fiscal Year Ends: 12/31 1999 Sales: $18,850 1999 Profits: $ 561 1998 Sales: $15,900 1998 Profits: $ 900
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $285,300 Stock Purch. Plan: Second Exec. Salary: $172,000 Successful growth strategy/Broad product line. ADVANTAGE:
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $218,800 Bonus: $79,500
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
BRISTOL MYERS SQUIBB CO
www.bms.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:7 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:11
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Cardiovascular Medical Devices Personal Care Products
The Bristol-Myers Squibb Company is one of the largest health and personal care companies in the world. Highly diversified, Bristol Myers produces and distributes pharmaceutical products, medical devices, nonprescription health products and nutritional and beauty aids. BristolMyers is a producer of many important medicines and a leader in providing drugs for anti-cancer therapies and treatments for heart disease, high blood pressure, stroke, type-2 diabetes, HIV/AIDS, depression, anxiety and pain. Some leading and well-known products include Pravachol, a cholesterol-reduction drug; TAXOL, a cancer treatment drug; and Excedrin, a headache and migraine drug. Its Clairol group, the number one hair products company in the U.S., produces hair care, skin care and hair color items, with such products as Nice n’ Easy, Infusium 23, Loving Care and Herbal Essences. Mead Johnson Nutritionals, a subsidiary of the company, offers nutritional products for infants and adults, including energy drinks, energy bars, beverages, infant formula and vitamins such as Boost, Enfamil and Poly-Vi-Sol. Another subsidiary, ConvaTec, offers ostomy care and modern wound care products such as Active Life, a one-piece ostomy system; DuiDERM, a hydroactive gel; and SAF-Clens, a chronic wound cleanser. The company’s acquisition of DuPont Pharmaceuticals Company has strengthened its virology and cardiovascular franchises, as well as its research and development and discovery efforts. In recent news, Bristol announced it has signed an agreement with Xenogen Corporation, a leader in the field of real-time in vivo imaging, whereby the two firms will work to provide a nonexclusive license for Xenogen’s patented technology. Additionally, a separate agreement between the two companies will allow Xenogen rights to use Bristol’s Cre Lox Technology, a solution that allows the streamlining of medical research systems. Bristol-Myers’ employees enjoy high pay, above-average benefits and two weeks or more of vacation each year. Some facilities offer child-care services, and the firm sends baby formula to an employee's home for a newborn's first year.
BRANDS/DIVISIONS/AFFILIATES: ConvaTec Clairol, Inc. Mead Johnson Nutritionals Excedrin Nice n' Easy Boost DuPont Pharmaceuticals Erbitux
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Peter R. Dolan, CEO Peter R. Dolan, Pres. Andrew R. J. Bonfield, Sr. VP/CFO Wendy L. Dixon, Chief Mktg. Officer Stephen E. Bear, Sr. VP-Human Resources James B. D. Palmer, Chief Scientific Officer Curtis L. Tomlin, VP/Controller Andrew G. Bodnar, Sr. VP-Medical Sandra Leung, Corp. Sec. John L. McGoldrick, Exec. VP/General Counsel Tamar D. Howson, Sr. VP-Corp. Dev. John L. Skule, Sr. VP-Corp. Affairs Harrison M. Bains, Treas. Elliott Sigal, Sr. VP-Drug Discovery and Exploratory Dev. Dean J. Mitchell, Pres., U.S. Primary Care Donald J. Hayden, Jr., EXP/VP-Americas Andrew G. Bodnar, Sr. VP-Stratey and External Affairs Lamberto Andreotti, VP-Intl.
Phone: 212-546-4000 Fax: 212-546-4020 Toll-Free: Address: 345 Park Ave., New York, NY 10154-0037 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $18,119,000 (12 months) 2002 Profits: $2,066,000 (12 months) Stock Ticker: BMY 2001 Sales: $19,423,000 2001 Profits: $5,245,000 Employees: 44,000 2000 Sales: $18,216,000 2000 Profits: $4,711,000 Fiscal Year Ends: 12/31 1999 Sales: $16,878,000 1999 Profits: $4,167,000 1998 Sales: $15,061,000 1998 Profits: $3,141,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $1,100,000 Bonus: $1,314,922 Stock Purch. Plan: Second Exec. Salary: $712,000 Bonus: $521,626 ADVANTAGE: Large research and development budget/Continues to launch new products rapidly.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
BROADCOM CORP
www.broadcom.com
Industry Group Code: 334413 Ranks within this company's industry group: Sales:10 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:22
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Integrated Circuits-Broadband Transmission Circuits for Cable Modems
Broadcom Corporation provides highly integrated silicon solutions that enable broadband digital transmission of voice, data and video content to and throughout the home and within the business enterprise. The firm's products enable digital data to be transmitted at high speeds over existing communications infrastructures that were not necessarily made to support this kind of transmission. The company also designs, develops and supplies integrated circuits for communications markets, including cable set-top boxes, cable modems, high-speed office networks, direct broadcast satellite and terrestrial digital broadcast, home networking and DSL. Broadcom's CablexChange is a software solution for voice-over Internet protocol applications. Through its acquisitions, Broadcom has expanded its product offerings as well as enabled the convergence of technology into advanced system-on-a-chip solutions for the delivery of voice, video and data in a variety of applications. Its customers include Dell, Cisco Systems, IBM, Motorola and EchoStar. Broadcom recently implemented a restructuring program that resulted in a 16% reduction of its worldwide workforce. The program also included a reorganization of the company’s broadband communications, networking, carrier access and home networking business units. In other news, Broadcom extended its supply agreement with cable modem maker Motorola and is now the primary supplier of chips for Motorola’s DOCSIS 1.0-, 1.1- and 2.0based SURFboard cable modems. The firm also recently entered the storage controller market, commencing sample shipments of its new line of Serial Advanced Technology Attachment host controllers.
BRANDS/DIVISIONS/AFFILIATES: ServerWorks CablexChange
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Alan E. Ross, CEO Henry T. Nicholas, III, Pres. William J. Ruehle, CFO Laura Brandlin, Dir.-Mktg. Nancy Tullos, VP-Human Resources Henry Samueli, Chief Tech. Officer Ken Venner, CIO Scott J. Poteracki, Controller Vahid Manian, VP-Mfg. David A. Dull, General Counsel David A. Dull, VP-Bus. Affairs Bill Blanning, VP-Corp. Comm. Nick Kormeluk, Dir.-Investor Rel. Robert A. Rango, VP-Network Infrastructure Ford G. Tamer, VP-Switch and Security Jeff L. Thermond, VP-Home and Wireless Networking Raju Vegesna, Pres., ServerWorks Henry T. Nicholas, Chmn.
Phone: 949-450-8700 Fax: 949-450-8710 Toll-Free: Address: 16251 Alton Pkwy., Irvine, CA 92619-7013 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,082,900 (12 months) 2002 Profits: $-2,236,600 (12 months) Stock Ticker: BRCM 2001 Sales: $961,800 2001 Profits: $-2,742,000 Employees: 2,589 2000 Sales: $1,096,200 2000 Profits: $-687,800 Fiscal Year Ends: 12/31 1999 Sales: $521,200 1999 Profits: $72,500 1998 Sales: $216,700 1998 Profits: $21,400
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $155,000 Stock Purch. Plan: Y Second Exec. Salary: $110,500 ADVANTAGE: Chip designs that enable state-of-the-art broadband communications.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $97,747 Bonus: $29,936
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
CABOT CORPORATION
www.cabot-corp.com
Industry Group Code: 325000 Ranks within this company's industry group: Sales:11 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:6
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Y Chemicals: Y Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Chemicals Specialty Fluids
Cabot Corporation is engaged in specialty chemicals, performance materials and specialty fluids. The company and its affiliates have manufacturing facilities in the United States and more than 20 other countries. It manufactures and sells carbon black, fumed oxides, inkjet colorants, aerogels and specialty fluids. The company’s carbon black products are used in tires, industrial products and high-performance applications. The performance products business group (PPB) manufactures specialized grades of carbon black which are used as pigments, to enhance conductivity and static charge control, to provide UV protection, to enhance mechanical properties and to provide chemical flexibility through surface treatment. These products are used in industries such as inks, coatings, cables, pipes, toners and electronics. The PPB group also markets carbon black and produces and markets black and white thermoplastic concentrates and specialty compounds to the plastics industry. Fumed metal oxides that the company manufactures and sells include fumed silica and fumed alumina. Cabot’s aerogels, which are marketed under the Nanogel trademark, are hydrophobic silica particles with potential uses in a variety of thermal and sound insulation applications. The company’s specialty fluids business produces and markets cesium formate as a drilling and completion fluid for use primarily in high-pressure and high-temperature oil and gas well operations. In recent news, the company announced it is restructuring its European businesses. The restructuring involves the closure of Cabot’s manufacturing facility in Spain, the consolidation of all European businesses in one shared service center and the implementation of a staffing model.
BRANDS/DIVISIONS/AFFILIATES: Nanogel
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Kennett F. Burnes, CEO Kennett F. Burnes, Pres. John A. Shaw, Exec. VP/CFO Robby D. Sisco, VP-Human Resources David C. Bonner, VP-Research and Dev./Chief Tech. Officer Craig A. Bickel, VP-IT Eduardo E. Cordeiro, VP/Controller Helmut Lorat, VP-Eng. Jane A. Bell, Corp. Sec. Brian A. Berube, VP/General Counsel Paul J. Gormisky, VP-Corp. Planning Janis O. Studer, VP/Treas. William J. Brady, Exec. VP/Mgr.-Fumed Metal Oxides William P. Noglows, Exec. VP/Mgr.-Carbon Black Charles A. Gray, VP-Tech. Ho-il Kim, VP-Strategic Dev. Kennett F. Burnes, Chmn.
Phone: 617-345-0100 Fax: 617-342-6103 Toll-Free: Address: 2 Seaport Ln., Ste. 1300, Boston, MA 02210 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,557,000 (12 months) 2002 Profits: $106,000 (12 months) Stock Ticker: CBT 2001 Sales: $ 2001 Profits: $ Employees: 4,500 2000 Sales: $ 2000 Profits: $ Fiscal Year Ends: 9/30 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $725,000 Stock Purch. Plan: Second Exec. Salary: $450,000 ADVANTAGE: Highly profitable performace products/Focus on carbon black.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $600,000 Bonus: $140,000
LOCATIONS: ("Y" = Yes) West:
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
CACI INTERNATIONAL INC
www.caci.com
Industry Group Code: 541512 Ranks within this company's industry group: Sales:8 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:5
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y Y
GROWTH PLANS/SPECIAL FEATURES:
Consulting-InfoTech Related Engineering Simulation Software Information Management Tools Marketing Systems Software
CACI International, Inc. is an information technology (IT) products and services provider that specializes in developing and integrating systems, software and simulation products in support of government agencies and commercial enterprises worldwide. During its 35 years in business, the company has grown to 70 offices in the United States and Europe. Additionally, CACI provides managed network services, including the planning and building of voice, video and data networks, managing network communications infrastructures and protecting networks from security breaches. The company also offers a range of information management tools, such as workflow management systems and software, which enable users to automate all aspects of document administration. The firm offers marketing systems software and database products targeted to clients that need systems and analysis for retail sales of consumer products, direct marketing campaigns, franchise or branch site location projects and similar requirements. In its simulation technology business, CACI offers simulation languages, software products and services that enable clients to visualize the impact of proposed changes or new technologies before implementation. CACI’s simulation offerings include solutions for military training and wargaming exercises; manufacturing; wide area communications networks, including satellites, land lines and metro area networks; local area computer networks; the study of business processes; and the design of distributed computer systems architectures. CACI’s primary markets are agencies of national governments, major corporations, state and local governments and other business organizations. The company was recently awarded a five-year blanket purchase agreement to provide IT support for the Department of Defense national security network and computer infrastructures. The contract is worth $450 million. The company offers its employees training programs, tuition reimbursement and employee discounts on merchandise and services.
BRANDS/DIVISIONS/AFFILIATES: Urban Warfare Simulation AFNET FedSelect SIMPROCESS Impass ACORN Quickbid FINDER
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. J.P. London, CEO J.P. London, Pres. Stephen L. Waechter, Exec. VP/CFO Gregory R. Bradford, Mgr.-Mktg. Systems Group Patrick G. Stefl, VP-Human Resources J.P Elefante, Corp. Sec. J.P Elefante, General Counsel J.P Elefante, Exec. VP-Contract and Admin. Services William J. Curry, VP-e-Commerce Div. Jody A. Brown, VP-Public Rel. David Dragics, Dir.-Investor Rel. Stephen L. Waechter, Treas. L.Kenneth Johnson, Pres.-U.S. Oper. J.P. London, Chmn.
Phone: 703-841-7800 Fax: 703-841-7882 Toll-Free: Address: 1100 N. Glebe Rd., Arlington, VA 22201 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $681,900 (12 months) 2002 Profits: $30,400 (12 months) Stock Ticker: CAI 2001 Sales: $563,800 2001 Profits: $22,300 Employees: 5,524 2000 Sales: $490,473 2000 Profits: $38,412 Fiscal Year Ends: 6/30 1999 Sales: $433,449 1999 Profits: $14,170 1998 Sales: $316,864 1998 Profits: $11,715
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $400,000 Bonus: $1,252,242 Stock Purch. Plan: Y Second Exec. Salary: $307,000 Bonus: $843,911 ADVANTAGE: Large company with clients in major segments of government and commercial markets.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
CADENCE DESIGN SYSTEMS INC
www.cadence.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:13 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:14
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Software-Electronic Design Automation Design Realization Solutions
Cadence Design Systems, Inc. provides comprehensive software services and offers design and methodology services for the product development requirements of the world’s leading electronics companies. The firm licenses its leading-edge electronics design automation software and hardware technology and provides a range of professional services to companies throughout the world to help optimize its customers’ product development processes. Cadence has design centers located in the U.S., the U.K., Canada and Japan. One-half of its revenues are produced outside of the U.S. The company is also a supplier of design realization solutions, which are used by companies to design and develop integrated circuits and systems, including semiconductors, computer systems and peripherals, telecommunications and networking equipment, mobile and wireless devices, automotive electronics, consumer products and other advanced electronics. Cadence is involved in strategic partnerships with companies including Agilent, HP and Xilinx. In recent news, the company and IBM announced an agreement to develop and market electronic design solutions using IBM’s Linux-based technology. The company has established a community affairs program in order to enhance and ensure the diversity and strength of its community through various long-term assistance programs. Cadence offers its workforce an extensive benefits package that includes 85%-paid dental coverage, vision coverage, stock options, bonuses, maternity, telecommuting options, gym membership, dry cleaning, holiday parties, a concierge service and matching gifts to charities.
BRANDS/DIVISIONS/AFFILIATES: Cadence Berkeley Laboratories
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. H. Raymond Bingham, CEO H. Raymond Bingham, Pres. William Porter, Sr. VP/CFO Penny Herscher, Exec. VP/Chief Mktg. Officer Joe Murphy, Corp. VP-Worldwide Human Resources Steve Teig, Sr. VP/Chief Scientist/Chief Tech. Officer R.L. Smith McKeithen, Sr. VP/Sec. R.L. Smith McKeithen, General Counsel Kevin Bushby, Sr. VP-Worldwide Field Oper. Ping Chao, Sr. VP/Mgr.-Digital IC Solutions Dave DeMaria, Exec. VP-Systems Solutions Ted Vucurevich, Sr. VP-Office of the Chief Tech. Officer Glen S. Fukushima, Sr. VP-Cadence Design Systems, Inc. Donald L. Lucas, Chmn. Matthew Chan, Sr. VP-Asia Pacific
Phone: 408-943-1234 Fax: 408-943-0513 Toll-Free: Address: 2655 Seely Ave., Bldg. 5, San Jose, CA 95134 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,293,100 (12 months) 2002 Profits: $71,900 (12 months) Stock Ticker: CDN 2001 Sales: $1,430,400 2001 Profits: $141,300 Employees: 5,600 2000 Sales: $1,279,600 2000 Profits: $50,000 Fiscal Year Ends: 12/31 1999 Sales: $1,093,303 1999 Profits: $-14,075 1998 Sales: $1,320,180 1998 Profits: $25,124
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $850,032 Stock Purch. Plan: Y Second Exec. Salary: $448,107 ADVANTAGE: A large customer base that relies on Cadence for daily needs.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $1,466,250 Bonus: $797,702
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
CAMBREX CORP
www.cambrex.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:31 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:33
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Y Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drug Ingredients for Over the Counter and Prescription Drugs Chemical Processes Animal Health Products
Cambrex Corporation primarily provides products and services to the worldwide life sciences industry, operating in three segments: human health, biosciences and Rutherford Chemicals, Inc.. Recently, the company combined its specialty and fine chemicals and animal health and agriculture products operating units under the new Rutherford Chemicals business unit. Currently, the company's overall strategy for these segments is to focus on niche markets that have global opportunities, build on strong customer relations to enhance its new products pipeline and support state-of-the-art technology. The human health division manufactures active pharmaceutical ingredients used in prescription and over-the-counter drugs that treat gastro-intestinal, cardiovascular, endocrine, central nervous system, respiratory, antiinfective and various other problems. This segment constitutes the largest portion of the company's revenue. The biosciences division consists of cell culture products, endotoxin detection products, electrophoresis and chromatography products and contract biopharmaceutical manufacturing services at clinical and commercial scales for the biotechnology and pharmaceutical industries. Services include media optimization, cell banking and purification. The company manufactures more than 1,800 products which are sold to more than 14,000 customers worldwide. The Rutherford Chemicals segment includes operations in animal health, agriculture and specialty and fine chemicals. These products are used in feed additive, agriculture, photography, pigments, polymers, fuel/oil addition, catalysts, telecommunications, coatings, electronics, specialty plastics and other specialty additives. In recent news, the company announced the release of an e-commerce software solution that includes a product catalog, order placement and self service inquiry. Employee benefits at Cambrex include awards, tuition reimbursement plans, scholarship programs and a health plan, all of which begin on the first day of employment.
BRANDS/DIVISIONS/AFFILIATES: Marathon Biopharmaceuticals Cambrex Profarmaco Milano Rutherford Chemicals, Inc. Cambrex Karlskoga AB Cambrex Bio Science Baltimore, Inc. Cambrex Bio Science Rockland, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. James A. Mack, CEO James A. Mack, Pres. James A. Mack, COO Luke M. Beshar, Sr. VP/CFO Ron D. Carroll, VP/Chief Tech. Officer Robert J. Congiusti, VP-Info. Services Peter E. Thauer, Corp. Sec. Peter E. Thauer, Sr. VP-Law/General Counsel Steven M. Klosk, Exec. VP-Admin. Salvatore J. Guccione, Exec. VP-Corp. Strategy and Dev. Thomas N. Bird, VP-Bus. Dev., Life Sciences Keith Henderson, Pres., Rutherford Chemicals, Inc. N. David Eansor, Pres.-Bioproducts Monika Lekander, Pres., Cambrex Pharma James A. Mack, Chmn.
Phone: 201-804-3000 Fax: 201-804-9852 Toll-Free: Address: One Meadowlands Plaza, East Rutherford, NJ 07073 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $526,900 (12 months) 2002 Profits: $36,200 (12 months) Stock Ticker: CBM 2001 Sales: $498,900 2001 Profits: $26,600 Employees: 2,216 2000 Sales: $484,246 2000 Profits: $49,605 Fiscal Year Ends: 12/31 1999 Sales: $481,388 1999 Profits: $38,132 1998 Sales: $457,241 1998 Profits: $39,102
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $537,500 Stock Purch. Plan: Second Exec. Salary: $364,845 ADVANTAGE: Has technical expertise in a wide range of chemical processes.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $114,000 Bonus: $48,000
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
CANON INC
www.canon.com
Industry Group Code: 335999 Ranks within this company's industry group: Sales:2 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Business Machines-Copiers Printers and Scanners Television Lenses X-Ray Equipment Fax Machines Photovoltaic Cells
Canon, Inc. ranks number one worldwide in sales of copying machines and laser printers. The firm is actively working toward its goal of becoming the top worldwide manufacturer in all of its core business areas, including computer peripherals such as printers and scanners, facsimile machines, digital and film cameras and semiconductor production equipment, by 2005. Other Canon products include x-ray equipment, medical image recording equipment, photovoltaic cells and television lenses. The company’s best-known proprietary technology is Bubble Jet. This technology, which involves distributing ink via heat pressure, has allowed Canon to develop cheaper printers of higher quality than its competitors. The company is aggressively developing its photo imaging technology. The firm recently unveiled a line of digital cameras that connect directly to a printer without using a PC. Canon, together with five other companies, recently proposed an industry standard, tentatively named DPS, which, if adopted, would enable all compliant digital cameras and printers to communicate directly. The firm has seen decreased demand for its printers and other IT-related equipment, which corresponds with shrinking global demand for PCs and peripheral equipment. However, Canon has seen increases in demand for its digital cameras and digital video camcorders, as well as steady growth in demand for copying machines. The company actively pursues ways to minimize its environmental impact. Since 1999, the firm has released an annual environmental report, outlining its environmental impact, future goals and results of environmental management. For example, Canon has reduced the electric energy consumption of its main products.
BRANDS/DIVISIONS/AFFILIATES: Canon USA, Inc. Bubble Jet
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Fujio Mitarai, CEO Fujio Mitarai, Pres. Toshizo Tanaka, CFO Yukio Yamashita, VP-Human Resources Kinya Uchida, Pres., Canon USA, Inc. Fujio Mitarai, Chmn.
Phone: 81-3-3758-2111 Fax: 81-3-5482-5135 Toll-Free: Address: 30-2, Shimomaruko 3-chome, Ohta-ku, Tokyo, 1468501 Japan
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $24,501,000 (12 months) 2002 Profits: $1,590,000 (12 months) Stock Ticker: Foreign 2001 Sales: $22,027,100 2001 Profits: $1,269,400 Employees: 93,620 2000 Sales: $24,272,000 2000 Profits: $1,170,000 Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: One of the world's leading names in cameras and digital imaging.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
CARRINGTON LABORATORIES INC www.carringtonlabs.com Industry Group Code: 325412 Ranks within this company's industry group: Sales:90 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:51
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Carbohydrate-Based Alginates Injectable Human Anti-Cancer Vaccines Poultry Vaccines Topical Dressings Veterinary Anti-Cancer Vaccines
Carrington Laboratories, Inc. is a world-class biopharmaceutical and consumer products operation. The company is engaged in the development, manufacturing and marketing of naturally-derived complex carbohydrates and other natural product therapeutics for the treatment of major illnesses, the dressing and management of wounds and nutritional supplements. The company formulates aloe vera into a variety of products. The firm grows its aloe vera on a plantation in Costa Rica. Carloe, Inc., a subsidiary of the Carrington Laboratories, markets raw materials and finished products from aloe vera utilizing patented complex carbohydrate technology. In addition, the company’s Mom’s Aloe Store subsidiary is the exclusive online retailer of Carrington and AloeCeuticals products. Mom’s Aloe Store also features health care articles and product specials. Carrington also markets its SaliCept Oral Patch. This product is intended for use in tooth extraction sites and to help manage alveolar osteitis and is dispensed by licensed oral surgeons and dental professionals. The oral patch will continue to be marketed for general oral pain applications in non-prescription form. Carrington has granted exclusive Japanese distribution rights for the Oral Patch to Sunstar, Inc., a leading manufacturer of oral care products in Japan. The company’s DelSite Biotechnologies, Inc. subsidiary is in charge of overseeing new product development. The company’s latest acquisition, the business of the Custom Division of Creative Beauty Innovations, Inc., designs and manufactures bath, body, skin and hair products for companies who market these products under their own private labels. This acquisition is expected to increase the company’s annual revenue by $6 to $7 million.
BRANDS/DIVISIONS/AFFILIATES: WoundCare.com SaliCept Oral Patch Mom's Aloe Store Creative Beauty Innovations, Inc. Carloe, Inc. Sabila Industrial, S.A. DelSite Biotechnologies, Inc. RadiaCare Gel
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Carlton E. Turner, CEO Carlton E. Turner, Pres. Robert W. Schnitzius, CFO Carol Kitchell, Dir.-Human Resources Kenneth M. Yates, VP-Research & Dev. Robert W. Schnitzius, Corp. Sec. Walt Jones, VP-Bus. Dev. Maria Eaton, VP-Investor Rel. Robert W. Schnitzius, Treas. Robert A. Fildes, Interim Exec. VP-Research & Dev. George DeMott, Chmn.
Phone: 972-518-1300 Fax: 972-518-1020 Toll-Free: 800-527-5216 Address: 2001 Walnut Hill Ln., Irving, TX 75038 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $18,041 (12 months) 2002 Profits: $-3,378 (12 months) Stock Ticker: CARN 2001 Sales: $17,600 2001 Profits: $ 400 Employees: 252 2000 Sales: $23,103 2000 Profits: $-3,476 Fiscal Year Ends: 12/31 1999 Sales: $28,100 1999 Profits: $-2,000 1998 Sales: $23,600 1998 Profits: $-1,600
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $314,780 Bonus: $21,262 Stock Purch. Plan: Second Exec. Salary: $181,166 Bonus: $18,401 ADVANTAGE: Product portfolio based primarily on complex carbohydrate technology derived from the aloe vera plant.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West:
Southwest: Y
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
CELERA GENOMICS GROUP
www.celera.com
Industry Group Code: 541710 Ranks within this company's industry group: Sales:7 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:20
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Research-Human Genome Mapping Information Management and Analysis Software
Celera Genomics Group, a division of Applera Corporation, is engaged principally in the generation, compilation, sale and support of genomic information as well as related information management and analysis software. The company also provides discovery, validation and licensing of proprietary gene products, genetic markers and information concerning genetic variability and related consulting, contract research and development services. Specifically, it assists pharmaceutical, biotechnology and life science research entities in areas of research, including new drugs and improved drug development processes; novel genes and factors that regulate and control gene expression; and interrelationships between genetic variability, disease and drug response. Notably, Celera completed mapping the human genome well ahead of the government-sponsored Human Genome Project and ahead of its own expectations. The underlying human genetic sequence is the basis for Celera’s development of a value-added, integrated information and discovery system. The system includes increasing layers of functional information such as gene expression data, comparative data from other model organisms (such as the Drosophila fruit fly and mouse), genetic variation and ultimately gene function. Users of the information and discovery system will have the ability to browse, view and analyze the data in an integrated way that should assist scientists and commercial enterprises in accelerating their understanding of the human genetic code. The company is involved in drug discovery and development collaborations with Aventis Pharma, Merck, Maxim Pharmaceuticals, Isis Pharmaceuticals and SomaLogic. In recent news, Celera Genomics and Applied Biosystems entered into a marketing and distribution agreement pursuant to which Applied Biosystems has become the exclusive marketer of the Celera Discovery System and related information assets, as part of Applied Biosystems' new knowledge business.
BRANDS/DIVISIONS/AFFILIATES: Celera Discovery System Applera Corp. Celera Diagnostics
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Kathy Ordonez, Pres. Peter Chambre, COO/VP-Applera Ugo DeBlasi, VP-Finance Bridgette Robinson, VP-Human Resources Robert Booth, Chief Scientific Officer John Reynders, VP-Info. Systems Samuel Broder, Chief Medical Officer Lothar Krinke, VP-Bus. Dev. and Strategic Planning Jason Molle, Sr. VP-Online Bus. David Block, Exec. VP/COO-Therapeutics Mark Adams, VP-Bioinformatics Michael Venuti, Sr. VP-Research James P. Yee, Head of Dev.
Phone: 240-453-3000 Fax: 240-453-4000 Toll-Free: 877-235-3721 Address: 45 W. Gude Dr., Rockville, MD 20850 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $120,900 (12 months) 2002 Profits: $-211,800 (12 months) Stock Ticker: CRA 2001 Sales: $89,400 2001 Profits: $-186,200 Employees: 820 2000 Sales: $42,700 2000 Profits: $-92,700 Fiscal Year Ends: 6/30 1999 Sales: $12,500 1999 Profits: $-44,900 1998 Sales: $4,200 1998 Profits: $-8,300
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $889,227 Stock Purch. Plan: Second Exec. Salary: $484,069 ADVANTAGE: Aggressive strategy/Rapid development of gene-mapping data.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $646,834 Bonus: $258,851
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
CELGENE CORP
www.celgene.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:49 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:87
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Immunotherapy Agricultural Products
Celgene Corp. is a commercial-stage biopharmaceutical company primarily engaged in the discovery, development and commercialization of small molecule drugs designed to treat cancer and immunological diseases through gene and protein regulation. Celgene's drugs are designed to modulate multiple disease-related genes, including cytokines, growth factor genes and apoptosis genes. Because these drugs can be administered orally, they have the potential to advance the standard of care beyond current injectible protein drugs. The FDA approved the firm's first commercialized product, THALOMID, for sale in the U.S. in 1998. THALOMID is used for the treatment of acute cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL), a complication of leprosy, and as a maintenance therapy to prevent and suppress cutaneous manifestation recurrences. The FDA has also approved Focalin, Celgene's chirally pure version of Ritalin, a treatment for attention deficit disorder. Currently, the company has two immunomodulatory drugs, or IMIDs, in development: REVIMID and ACTIMID. REVIMID is being evaluated for multiple myeloma and metastatic malignant melanoma therapy. ACTIMID is also being evaluated for the treatment of multiple myeloma. In addition, the company has developed the S.T.E.P.S. program, an educational program to instruct in the safe and appropriate use of THALOMID. Other products in development include SelCIDs, small molecule drugs that modulate disease-causing cytokines, and SERMs, which overcome many of the risks associated with hormone replacement therapy. In recent news, Celgene advanced its leading JNK inhibitor into clinical testing. In addition, a study in Blood, the journal of the American Society of Hematology, showed that REVIMID has anti-tumor activity in patients with relapsed and refractory multiple myeloma.
BRANDS/DIVISIONS/AFFILIATES: Celgro, Inc. THALOMID S.T.E.P.S. Focalin REVIMID ACTIMID SelCIDs SERM
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John W. Jackson, CEO Sol J. Barer, COO Sol J. Barer, Pres. Robert J. Hugin, Sr. VP/CFO George W.J. Matcham, Sr. VP-Research and Dev. David I. Stirling, Exec. VP-Pharmaceutical Research and Dev. Joseph J. Day, Sr. VP-Planning and Bus. Dev. David I. Stirling, Chief Scientific Officer Steven D. Thomas, VP-Regulatory Affairs and Project Mgmt. Jerome B. Zeldis, Chief Medical Officer/VP-Medical Affairs John W. Jackson, Chmn.
Phone: 732-271-1001 Fax: 732-271-4184 Toll-Free: Address: 7 Powder Horn Dr., Warren, NJ 07059 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $135,700 (12 months) 2002 Profits: $-100,000 (12 months) Stock Ticker: CELG 2001 Sales: $114,200 2001 Profits: $-1,900 Employees: 560 2000 Sales: $84,200 2000 Profits: $-16,300 Fiscal Year Ends: 12/31 1999 Sales: $38,000 1999 Profits: $-29,600 1998 Sales: $19,200 1998 Profits: $-29,400
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Successful growth strategy.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $506,250 Second Exec. Salary: $405,000
Bonus: $230,344 Bonus: $131,625
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
CELL GENESYS INC
www.cellgenesys.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:75 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:70
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Viral Infections and Cancer Gene Delivery Technologies
Cell Genesys, Inc. is a biotechnology company that focuses its research and product development efforts on human disease therapies that are based on innovative gene modification technologies. The company’s strategic objective is to develop and commercialize biological therapies, including cancer vaccines, oncolytic virus therapies and cancer gene therapies, to treat multiple types of cancer. Cell Genesys's clinical programs include GVAX cancer vaccines in Phase II studies for prostate, lung and pancreatic cancer and Phase I/II studies for multiple myeloma. Ongoing clinical programs evaluating the company's oncolytic virus therapies include CG7870, an intratumorally administered therapy for early-stage prostate cancer. In addition, Cell Genesys has preclinical oncolytic virus therapy programs evaluating potential therapies for bladder cancer, liver cancer and colon cancer, as well as preclinical cancer gene therapy programs evaluating potential therapies for multiple types of cancer. Cell Genesys has a majority-owned subsidiary, Ceregene, Inc., which is focused on gene therapies for neurological disorders, and the company continues to hold equity ownership of its former subsidiary, Abgenix, Inc., which is focused on the development and commercialization of antibody therapies. In recent news, the company plans to initiate two Phase II clinical trials of GVAX lung cancer vaccine, one which is expected to be sponsored and partially funded by the Southwest Oncology Group, a cooperative clinical trials group of the National Cancer Institute, and another to be sponsored by Cell Genesys. The company offers its employees educational assistance, pre-paid legal services and day care services for mildly ill children.
BRANDS/DIVISIONS/AFFILIATES: GVAX Cancer Vaccine Abgenix, Inc. Somatix Therapy Corp. Ceregene, Inc. Calydon, Inc. Neurologic Gene Therapeutics
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Stephen A. Sherwin, CEO Joseph J. Vallner, COO Joseph J. Vallner, Pres. Matthew J. Pfeffer, VP/CFO Christine McKinley, VP-Human Resources Dale G. Ando, VP-Clinical Research Michael W. Ramsay, Sr. VP-Mfg. Robert H. Tidwell, Sr. VP-Corp. Dev. Peter K. Working, Sr. VP-Research and Dev. Dale G. Ando, VP-Regulatory Affairs Stephen A. Sherwin, Chmn.
Phone: 650-266-3000 Fax: 650-266-3010 Toll-Free: Address: 500 Forbes Blvd., South San Francisco, CA 94080 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $39,100 (12 months) 2002 Profits: $-26,600 (12 months) Stock Ticker: CEGE 2001 Sales: $28,300 2001 Profits: $-28,700 Employees: 336 2000 Sales: $24,209 2000 Profits: $168,920 Fiscal Year Ends: 12/31 1999 Sales: $33,600 1999 Profits: $-12,000 1998 Sales: $24,100 1998 Profits: $-12,100
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $445,000 Stock Purch. Plan: Y Second Exec. Salary: $315,000 ADVANTAGE: Strong acquisitions and licensing agreements.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $200,000 Bonus: $100,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
CELL THERAPEUTICS INC
www.cticseattle.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:93 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:77
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Cancer, Inflammatory Disease and Immune Disease
Cell Therapeutics focuses on developing, acquiring and commercializing treatments for cancer. The company’s goal is to build a leading, vertically integrated biopharmaceutical company with a diversified portfolio of oncology drugs and drug candidates. Cell Therapeutics’ research and in-licensing activities are concentrated on identifying new, less toxic and more effective ways to treat cancer. The company has one marketed product, TRISENOX, an arsenic trioxide injection. This lead product is designed to treat leukemia, lymphomas and other cancers. Products that the company is researching include XYOTAX, CT-2106 and CT-2584. XYOTAX is linked to paclitaxel, the active ingredient in Taxol, the world’s best-selling cancer drug. It is currently in Phase II trials in the U.S. and Europe. CT-2106 appears to be capable of delivering more chemotherapy directly to tumors and is in development for the treatment of advanced colon, lung and ovarian cancer. Recently, Cell Therapeutics announced it would partner with Hope Heart Institute to collaborate on the research of new cancer targets. PanGenex, Inc., a majority-owned subsidiary of Cell Therapeutics, will be involved in this two-year agreement through the use of its double gene technology. Cell Therapeutics offers its workforce medical benefits, annual incentives, stock options and an employee assistance program.
BRANDS/DIVISIONS/AFFILIATES: TRISENOX XYOTAX CT-2106 CT-2584 PanGenex, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. James A. Bianco, CEO Edward F. Kenney, COO/Exec. VP James A. Bianco, Pres. Louis A. Bianco, Exec. VP-Finance Carolyn M. Paradise, Chief Medical Officer Louis A. Bianco, Exec. VP-Admin. Susan O. Moore, Exec. VP-Corp. Resource Dev. Jack W. Singer, Exec. VP Michael B. Mumford, Exec. VP-Dev. and Tech. Oper. James Canfield, Exec. VP/Chief Admin. Officer
Phone: 206-282-7100 Fax: 206-284-6206 Toll-Free: 800-215-2355 Address: 201 Elliott Ave. W, Ste. 400, Seattle, WA 98119-4230 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $16,900 (12 months) 2002 Profits: $-49,900 (12 months) Stock Ticker: CTIC 2001 Sales: $6,200 2001 Profits: $-80,300 Employees: 286 2000 Sales: $ 502 2000 Profits: $-51,929 Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $-36,280 1998 Sales: $13,200 1998 Profits: $-24,972
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Focus on drugs for cancer patients.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Top Exec. Salary: $433,008 Second Exec. Salary: $300,120
Bonus: $222,013 Bonus: $48,874
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
CENTOCOR INC
www.centocor.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Autoimmune Disease Monoclonal Antibodies
Centocor, Inc., a subsidiary of Johnson & Johnson, is a biotechnology company that develops and commercializes novel therapeutic and diagnostic products and services that solve critical needs in human health care. The company concentrates on research and development, manufacturing and market development with a primary technological focus on monoclonal antibodies and DNAbased products. Centocor manufactures the drug REMICADE for autoimmune conditions such as Crohn’s disease and rheumatoid arthritis. The company also manufactures ReoPro, which prevents blood clots during angioplasty; FRAGMIN, which treats angina and prevents complications during a heart attack; Retavase, which is administered for the treatment of heart attacks; and Panorex, a treatment marketed only in Germany for colorectal cancer. The firm’s business partners include Eli Lilly, which has granted it marketing rights to ReoPro. Centocor also has marketing agreements with Fujisawa Pharmaceutical Co., Tanabe Seiyaku Co., Ortho-McNeil Pharmaceutical and Schering-Plough Corp. In recent news, the FDA granted approval for the marketing of REMICADE for use in the treatment of Crohn’s disease using 8-week maintenance dosing. The drug has previously been approved for use in inducing and maintaining clinical remission in patients with moderate to sever Crohn’s disease. The firm offers its employees external tuition reimbursement, as well as in-house courses on subjects such as management, business and science.
BRANDS/DIVISIONS/AFFILIATES: ReoPro Panorex cA2 Johnson & Johnson REMICADE FRAGMIN RETAVASE
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Joseph C. Scodari, CEO W. Anthony Vernon, Pres. Richard A. Bierly, CFO Lawrence Cunningham, VP-Human Resources Harlan Weisman, Clinical Research and Dev. James Macquire, VP-IT Richard McCloskey, Chief Medical Officer Christopher D. Allman, Dir.-Corp. Comm. Martin R. Page, VP-Worldwide Regulatory Affairs and Quality Bruce Carroll, Mgr.-Gov't Rel. David P. Holveck, Sr. VP-Research and Dev. David P. Holveck, Chmn.
Phone: 610-651-6000 Fax: 610-651-6100 Toll-Free: Address: 200 Great Valley Pkwy., Malvern, PA 19355-1307 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $1,100,000 2001 Profits: $ Employees: 3,000 2000 Sales: $693,000 2000 Profits: $ Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Continual development of new, advanced drugs.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
CEPHALON INC
www.cephalon.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:32 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:21
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Sleep-Related Disorders Neurological Disorder Treatments
Cephalon is a biopharmaceutical company that is engaged in the discovery, development and marketing of products to treat sleep disorders, neurological and psychiatric disorders, cancer and pain. The company is focused on creating treatments for diseases such as Lou Gehrig’s disease, narcolepsy, Alzheimer’s disease, cancer and multiple sclerosis. In addition to conducting an active research and development program, Cephalon markets three products in the United States (Provigil, Actiq and Gabitril) and a number of products in various countries throughout Europe. Provigil significantly increases wakefulness in patients that suffer from abnormal daytime sleepiness due to obstructive sleep apnea. The drug is designed as a wake-promoting agent for sleep disorders related to narcolepsy. Actiq is a treatment breakthrough for cancer pain and Gabitril is used for the treatment of epilepsy. In recent news, the company signed a license agreement with Tanabe Seiyaku Co., Ltd. Under this agreement, Tanabe will commercialize the Actiq product in Japan. Employees at Cephalon receive a full benefits package that includes flexible spending accounts.
BRANDS/DIVISIONS/AFFILIATES: Myotrophin Provigil Anesta Actiq Group Lafon Gabitril Modafinil Apokinin
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Frank Baldino, Jr., CEO J. Kevin Buchi, Sr. VP/CFO Carl A. Savini, Sr. VP-Human Resources Jeffry L. Vaught, Sr. VP-Research and Dev. John E. Osborn, Sr. VP/Corp. Sec. John E. Osborn, General Counsel Robert P. Roche, Jr., Sr. VP-Pharmaceutical Oper. Peter E. Grebow, Sr. VP-Worldwide Bus. Dev. Paul Blake, Sr. VP-Clinical Research and Regulatory Affairs Frank Baldino, Jr., Chmn.
Phone: 610-344-0200 Fax: 610-738-6590 Toll-Free: Address: 145 Brandywine Pkwy., West Chester, PA 19380 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $506,897 (12 months) 2002 Profits: $171,528 (12 months) Stock Ticker: CEPH 2001 Sales: $226,100 2001 Profits: $-55,500 Employees: 1,271 2000 Sales: $111,790 2000 Profits: $-101,200 Fiscal Year Ends: 12/31 1999 Sales: $51,434 1999 Profits: $-79,400 1998 Sales: $16,330 1998 Profits: $-71,100
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $649,500 Stock Purch. Plan: Second Exec. Salary: $309,446 ADVANTAGE: Multidisciplinary technology approach.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $1,800,900 Bonus: $245,237
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
CERNER CORP
www.cerner.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:27 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:16
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Software-Clinical Medical Information Systems Access Management Consulting Services
Cerner designs, develops, installs and supports information technology and content solutions for health care organizations, as well as consumers, physicians and health care providers via the Internet. Cerner's solutions are designed to provide appropriate health information and knowledge to care givers, clinicians and consumers as well as appropriate management information to health care administrations on a real-time basis. It allows secure access to data by clinical and administrative users in organized care settings and by general consumers from their homes. The Cerner Millennium platform of applications is a single-architecture health care information system capable of both retrieving and disseminating clinical and financial information across an entire health system. Cerner also markets more than 200 solutions options that complement its major information systems. In addition, Cerner offers comprehensive consulting services including learning services, readiness assessments, planning and change management and process redesign and also sells third-party computers and related hardware to its software licensees. The company currently has more than 1,500 clients worldwide. In recent news, the company released a new health care intelligence solution, PowerInsight, which provides health care organizations with a single data warehouse of resources and information regarding data collection, decision-making and scientific content. The company offers employees a fitness center as well as immunizations and health screenings for them and their dependents. Employees also enjoy flexible work schedules and an onsite Montessori school.
BRANDS/DIVISIONS/AFFILIATES: Cerner Millennium Platform PowerInsight PathNet Laboratory Information Systems MedNet Internal Medicine Information System RadNet Radiology Information System HNA Millennium Health Network Architecture Dynamic Healthcare Technologies, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Neal L. Patterson, CEO Glenn P. Tobin, Exec. VP/COO Earl H. Devanny, III, Pres. Marc G. Naughton, Sr. VP/CFO Alan D. Dietrich, Sr. VP/Chief Mktg. Officer Stan Sword, Sr. VP-Human Resources David P. McCalle, Jr., VP/Chief Scientist Jeffrey A. Townsend, Sr. VP/Chief Eng. Officer Randy Sims, Corp. Sec. Randy Sims, General Counsel Vicki L. Carlew, VP-Corp. Comm. Jack A. Newman, Jr., Exec. VP Robert M. Smith, Exec. VP Douglas M. Krebs, Pres.-Global Organization Jeffrey S. Rose, Chief Medical Officer Neal L. Patterson, Chmn.
Phone: 816-221-1024 Fax: 816-474-1742 Toll-Free: Address: 2800 Rockcreek Pkwy., Ste. 601, Kansas City, MO 64117 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $751,900 (12 months) 2002 Profits: $48,000 (12 months) Stock Ticker: CERN 2001 Sales: $542,600 2001 Profits: $-42,400 Employees: 4,791 2000 Sales: $404,504 2000 Profits: $105,300 Fiscal Year Ends: 12/31 1999 Sales: $340,197 1999 Profits: $-1,200 1998 Sales: $330,902 1998 Profits: $20,600
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $492,307 Bonus: $377,704 Stock Purch. Plan: Second Exec. Salary: $397,692 Bonus: $354,713 ADVANTAGE: The company's Health Network Architecture is one of the industry's most comprehensive sets of applications designed to manage health and automate processes across the continuum of care.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
CH2M HILL COMPANIES LTD
www.ch2m.com
Industry Group Code: 541310 Ranks within this company's industry group: Sales:7 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Y Y Y Y
Profits:4
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Engineering Services-Consultation Nuclear Management Services
CH2M HILL Companies, Ltd. is an employee-owned firm that provides engineering, consulting, design, construction, procurement, operations, maintenance and program and project management services to clients in the public and private sectors. The company’s Environmental Services division offers ecological and natural resource damage assessments, environmental consulting for remediation projects and treatment systems for properties that have been contaminated by toxic or radioactive waste. The firm’s Nuclear Services segment manages the decontamination and demolition of weapons production facilities and designs nuclear waste treatment and handling facilities. CH2M HILL’s Operations Management International subsidiary provides water, wastewater and electrical utility services to private and public clients. Additionally, the firm’s Wright, Williams & Kelly subsidiary provides productivity measurement and enhancement software and consulting services. Recently, the company formed an alliance with Bizcom U.S.A., Inc. in order to increase its ability to respond to clients’ growing concern about the security of highways, airports, seaports and bridges. Under the terms of the alliance, Bizcom’s EM2000 emergency management software will be used in conjunction with CH2M HILL’s existing line of security products, including its GeoProtect software. GeoProtect is a geospatial-based mapping tool, designed to help cities and businesses plan for and respond to terrorist attacks and other emergencies. CH2M HILL offers its employees dental insurance and tuition reimbursement. Employees may elect to work all or part of their scheduled hours away from the office via telecommuting.
BRANDS/DIVISIONS/AFFILIATES: Operations Management International Wright, Williams & Kelly GeoProtect
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Ralph R. Peterson, CEO Ralph R. Peterson, Pres. Samuel H. Iapalucci, CFO Peter Hannan, Human Resources Samuel H. Iapalucci, Corp. Sec. Ralph R. Peterson, Chmn.
Phone: 303-771-0900 Fax: 720-286-9250 Toll-Free: Address: 9191 S. Jamaica St., Englewood, CO 80112 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,999,000 (12 months) 2002 Profits: $29,700 (12 months) Stock Ticker: Private 2001 Sales: $ 2001 Profits: $ Employees: 10,600 2000 Sales: $ 2000 Profits: $ Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Significant environmental expertise.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $639,267 Second Exec. Salary: $369,646
Bonus: $525,000 Bonus: $285,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
CHESAPEAKE BIOLOGICAL LAB
www.cblinc.com
Industry Group Code: 541710 Ranks within this company's industry group: Sales: Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Research and Development Commercial Drug Production
Chesapeake Biological Laboratories, Inc. is an established contract service provider of pharmaceutical and biopharmaceutical product development and production services for parenteral (injectable) and other sterile products. The company is a subsidiary of Canadian plasma manufacturer Cangene. It serves a broad range of customers, from major international pharmaceutical firms to emerging biotechnology companies. Chesapeake has provided services on a contract basis to more than 150 pharmaceutical and biotechnology companies and has contributed to the development and production of more than 175 therapeutic products. Customers contract with Chesapeake to produce development-stage products for use in FDA-required toxicology studies and clinical trials and to provide manufacturing services for FDA-approved products for commercial sale. The specialized development services provided by the company include research and development on sterile product formulations; test method development and validation; process design and manufacturing validations; regulatory and compliance consulting; preparation of clinical trial and toxicology materials; container-closure system design; and accelerated and ongoing stability studies. Recently, Chesapeake and its partners were awarded a federal contract for the production of a smallpox vaccine.
BRANDS/DIVISIONS/AFFILIATES: Cangene
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Thomas P. Rice, CEO John T. Botek, COO John T. Botek, Pres. John T. Jannsen, CFO Charles Proby, VP-Mktg. and Sales Narlin Beaty, Chief Tech. Officer Joseph G. Wendel, Controller Joseph G. Wendel, Treas. Vicki Wolff-Long, VP-Project Mgmt. and Laboratory Services Elizabeth Troll, Dir.-Quality Assurance and Regulatory Affairs
Phone: 410-843-5000 Fax: 410-843-4414 Toll-Free: Address: 1111 S. Paca St., Baltimore, MD 21230-2591 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Private 2001 Sales: $ 2001 Profits: $ Employees: 130 2000 Sales: $ 2000 Profits: $ Fiscal Year Ends: 3/31 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Client base of over 150 firms.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Top Exec. Salary: $ Second Exec. Salary: $
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
CHEVRONTEXACO CORPORATION www.chevrontexaco.com Industry Group Code: 211111 Ranks within this company's industry group: Sales:4 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:4
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Y Chemicals: Y Oil/Chem. Svcs.: Y Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Oil & Gas, Exploration and Production Natural Gas Coal Mining Chemicals
ChevronTexaco Corporation, formed by the merger of Chevron and Texaco, and its subsidiary companies represent a vertically integrated enterprise principally engaged in worldwide petroleum operations, chemicals operations, coal mining, power and energy services. Petroleum operations consist of exploring for, developing, producing, refining, marketing and transporting crude oil, natural gas and petroleum products. Chemicals operations include the manufacture and marketing of commodity petrochemicals and plastics for industrial uses and the manufacture and marketing of fuel and lubricating oil additives. The company operates in the United States and approximately 180 other countries. Currently, the firm is focusing on exploring deepwater sites in Australia, Brazil, the Gulf of Mexico and West Africa. ChevronTexaco and Nigerian partner Famfa Oil announced a large discovery in waters off the coast of Nigeria. Research reveals that the well will yield several hundred million barrels of usable oil. The company has also joined forces with Energy Conservation Devices, Inc. to develop the Texaco Ovonic Fuel Cell Company, which is focused on the development and advancement of ovonic regenerative fuel cell commercialization. Chevron’s acquisition of Texaco created a global enterprise with reserves of 11.2 billion barrels of oil equivalent (BOE), daily production of 2.7 million BOE, assets of $77 billion and operations throughout the world. In the United States, ChevronTexaco is the nation's second-largest producer of oil and gas. The company recently introduced a new business segment, ChevronTexaco Global Gas, which will play a key role in ChevronTexaco’s strategic plans to commercialize its existing natural gas resource base as well as enable the development of new opportunities worldwide. The company offers its employees tuition assistance, matching gifts for higher education, a scholarship program for employees' dependents and company sports teams.
BRANDS/DIVISIONS/AFFILIATES: Texaco Chevron Corp. Texaco Ovonic Fuel Cell Co. Caltex Corp. Monterey Resources, Inc. Dynegy, Inc. ChevronTexaco Global Gas
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. David J. O'Reilly, CEO John Watson, CFO John E. Bethancourt, Human Resources Charles James, General Counsel Sam Laidlaw, VP-Bus. Dev. Darald Callahan, Exec. VP-Power, Chemicals and Tech. Patricia Woertz, Exec. VP-Downstream David J. O'Reilly, Chmn.
Phone: 925-842-1000 Fax: 925-842-3530 Toll-Free: Address: 6001 Bollinger Canyon Rd., San Ramon, CA 94583 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $98,691,000 (12 months) 2002 Profits: $1,132,000 (12 months) Stock Ticker: CVX 2001 Sales: $104,409,000 2001 Profits: $3,288,000 Employees: 53,014 2000 Sales: $117,095,000 2000 Profits: $7,727,000 Fiscal Year Ends: 12/31 1999 Sales: $85,168,000 1999 Profits: $3,247,000 1998 Sales: $72,694,000 1998 Profits: $1,917,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Global resources.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $1,075,000 Second Exec. Salary: $615,000
Bonus: $700,000 Bonus: $425,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
CHIRON CORP
www.chiron.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:27 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:19
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Cancer Biopharmaceuticals
Chiron is a biotechnology company that participates in three global health care businesses: biopharmaceuticals, vaccines and blood testing. The company applies a broad and integrated scientific approach to the development of innovative products for preventing and treating cancer, infectious diseases and cardiovascular disease. Chiron Biopharmaceuticals discovers, develops, manufactures and markets a range of therapeutic products, including TOBI for pseudomonal lung infections in cystic fibrosis patients, Betaseron for multiple sclerosis and Proleukin for cancer. Chiron Vaccines, the fifth-largest vaccines business in the world, currently offers more than 30 vaccines including meningococcal, flu, travel and pediatric vaccines. Its vaccines include Menjugate for meningococcal meningitis, Fluad for influenza, Encepur for tick-borne encephalitis and Rabipur/RabAvert for rabies. Chiron Blood Testing provides products used by the blood banking industry. With its collaborator, Gen-Probe, it is developing and commercializing nucleic acid testing blood screening assays, including the Procleix HIV-1/HCV Assay. Through the company’s joint business with OrthoClinical Diagnostics, Inc., a Johnson & Johnson company, it develops and markets a line of immunodiagnostic screening and supplemental tests for infectious diseases. In recent news, the company acquired development and distribution rights for aerosolized cyclosporine from Novartis. Aerosolized cyclosporine is currently being tested for the treatment of lung transplant acute rejection. The company offers its employees educational assitance, credit union membership and acess to prepaid legal services, as well as discounted auto and home insurance. The firm also has a LifeCare service that povides information and support on topics such as adoption, prenatal planning and child care.
BRANDS/DIVISIONS/AFFILIATES: TOBI Proleukin Betaseron Fluad Chiron Vaccines Chiron Blood Testing Chiron Biopharmaceuticals Ortho-Clinical Diagnostics, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Howard Pien, CEO Howard Pien, Pres. James R. Sulat, VP/CFO Lewis T. Williams, Chief Scientific Officer William G. Green, Corp. Sec. William G. Green, General Counsel Craig A. Wheeler, Pres., Chiron Biopharmaceuticals Linda W. Short, VP-Corp. Resources Jack Goldstein, Pres., Chiron Vaccines Seán P. Lance, Chmn.
Phone: 510-655-8730 Fax: 510-655-9910 Toll-Free: Address: 4560 Horton St., Emeryville, CA 94608-2916 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $972,900 (12 months) 2002 Profits: $180,800 (12 months) Stock Ticker: CHIR 2001 Sales: $1,140,700 2001 Profits: $180,100 Employees: 4,044 2000 Sales: $972,119 2000 Profits: $8,500 Fiscal Year Ends: 12/31 1999 Sales: $762,646 1999 Profits: $160,600 1998 Sales: $736,673 1998 Profits: $524,100
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $742,308 Stock Purch. Plan: Y Second Exec. Salary: $433,077 ADVANTAGE: Facilities on four continents/ Strong line of vaccines.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $1,250,000 Bonus: $345,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
CHIYODA CORPORATION
www.chiyoda-corp.com
Industry Group Code: 541310 Ranks within this company's industry group: Sales:10
Profits:8
Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Y Y Y Y
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y Y
GROWTH PLANS/SPECIAL FEATURES:
Engineering & Construction Services Consulting Services
Chiyoda Corporation is a Japanese engineering firm operating in hydrocarbon/chemical, engineering, environmental preservation, metal and mining, architecture, automotive and other industries. Chiyoda has offices in countries throughout the world, including Indonesia, the U.K., the U.S., the Philippines, China, Germany, Malaysia, the Netherlands, Nigeria, Poland, Saudi Arabia, Singapore, Thailand, India and Iran. The company provides comprehensive engineering services that range from feasibility studies of design to maintenance, engineering, procurement, construction and start-up assistance. The company’s Eureka process provides an ideal process of producing clean fuel from heavy residual materials. The first Eureka unit was installed in Japan over 20 years ago and still produces a quality product without any deterioration in performance. Chiyoda has also developed many environmental preservation and pollution prevention systems, such as Biofiner, the CTG Engineering Method, the Pack Drain Method and the Thoroughbred 121 FGD Process. Chiyoda offers petroleum-refining companies the ability to procure construction materials, equipment and spare parts through its Internet procurement service, called I-MOR. Chiyoda is an extremely successful and well-known company and is awarded contracts for large projects numerous times per month. The company has won nine Earth Environment Awards from the Nihon Kogyo Shimbun division, in cooperation with the Ministry of International Trade and Industry, the Environment Agency and the Federation of Economic Organizations. The firm recently announced it had been awarded a contract for the Al-Khaleej Gas Project in Qatar. This project will provide a reliable gas supply to significant projects within Qatar from reserves in the country’s North Field.
BRANDS/DIVISIONS/AFFILIATES: C&E Corp. Eureka Biofiner CTG Engineering Method Pack Drain Method Thoroughbred 121 FGD Process Chiyoda-Dames & Moore I-MOR
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Nobuo Seki, CEO Nobuo Seki, Pres. Hiizu Ichikawa, Sr. Dir.-Mgmt. and Finance Yoshihiro Shirasaki, VP-Tech. Support Akira Kadoyama, VP-Domestic Product Oper. Hideo Nakatani, VP-Domestic Bus. Dev. Hiroshi Shibata, Sr. Exec. Officer-Finance and Corp. Admin. Takashi Yamamoto, Exec. Officer-Chemicals and Pharmaceuticals Div. Junichi Sakaguchi, Exec. Officer-Tech. Support Wataru Shimono, Exec. Officer-Int'l Project Oper.
Phone: 81-45-521-1231 Fax: 81-45-503-0200 Toll-Free: Address: 2-12-1, Tsurumichuo, Tsurumi-ku, Yokohama, 2308601 Japan
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,066,800 (12 months) 2002 Profits: $ 900 (12 months) Stock Ticker: Foreign 2001 Sales: $1,018,500 2001 Profits: $-36,500 Employees: 2,535 2000 Sales: $8,056,300 2000 Profits: $14,700 Fiscal Year Ends: 3/31 1999 Sales: $2,774,400 1999 Profits: $-97,600 1998 Sales: $2,280,600 1998 Profits: $-389,200
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Comprehensive services and proprietary technologies.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
CHRONIMED INC
www.chronimed.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:37 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:45
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Chronic Conditions Diagnostic Products Disease Management Services
Chronimed, Inc. is an integrated health care company specializing in diagnostic products, specialty pharmacy services and disease management for people with chronic health conditions. The company develops, manufactures, markets and distributes pharmaceuticals, medical diagnostic products and educational materials by mail and retail pharmacy. It also provides specialized disease management services to specific populations of patients with selected chronic conditions. Chronimed mainly services customers who require a high-cost regimen of maintenance prescription drugs or medical products over the course of their lives, require treatment by specialists and/or require a significant amount of self-management and ongoing education. Chronimed provides patients with a convenient, competitively priced source of prescription drugs, medical products, counseling support and a variety of educational materials to help patients achieve maximum control over their chronic conditions. The firm’s StatScript Management Services subsidiary provides pharmacy services to HIV and AIDS patients. Chronimed recently agreed to acquire SangStat's Transplant Pharmacy, which facilitates mail-order distribution of prescriptions and transplant patient management services. The company expects that the purchase will allow an increased volume of mail orders. The company also purchased a pharmacy in Los Angeles known as one of the largest providers of specialty pharmaceutical products for people with HIV/AIDS and other chronic conditions. The company offers its employees tuition reimbursement and access to two credit unions.
BRANDS/DIVISIONS/AFFILIATES: Home Direct Medical Services, Inc. Chronimed Holdings, Inc. Clinical Partners, Inc. StatScript Management Services Transplant Pharmacy
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Henry F. Blissenbach, CEO Gregory H. Keane, CFO Michelle R. Jahn, VP-Mktg. and Sales Shawn L. Featherston, VP-Human Resources Patrick L. Taffe, VP/CIO Kenneth S. Guenthner, General Counsel Anthony Zappa, VP-Oper. Brian Reagan, VP-Corp. Dev. Gregory H. Keane, Treas. Henry F. Blissenbach, Chmn.
Phone: 952-979-3600 Fax: 952-979-3969 Toll-Free: 800-444-5951 Address: 10900 Red Circle Dr., Minnetonka, MN 55343 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $397,400 (12 months) 2002 Profits: $3,700 (12 months) Stock Ticker: CHMD 2001 Sales: $297,900 2001 Profits: $10,800 Employees: 372 2000 Sales: $222,500 2000 Profits: $-4,100 Fiscal Year Ends: 6/30 1999 Sales: $168,600 1999 Profits: $4,100 1998 Sales: $115,600 1998 Profits: $7,200
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $295,200 Stock Purch. Plan: Y Second Exec. Salary: $180,000 ADVANTAGE: Focus on serving patients with chronic disease.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $60,000 Bonus: $17,280
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
CIENA CORP
www.ciena.com
Industry Group Code: 334210 Ranks within this company's industry group: Sales:14 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:12
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Telecommunications Equipment-Multiplexing Systems for Fiber Optic Telecommunications Networks
CIENA Corporation is a global provider of intelligent optical networking systems that change the fundamental economics of service-provider networks by simplifying them and reducing operating costs. The company’s customers include long-distance carriers, local exchange carriers, Internet service providers, wireless and wholesale carriers, systems integrators, governments, large businesses and non-profit institutions. CIENA recently acquired by merger ONI Systems Corp., which offered optical transport and access products for metropolitan networks and enterprises. The addition of ONI’s products to CIENA’s product portfolio allows CIENA to offer its customers a broader and more comprehensive set of solutions for addressing the bandwidth and service requirements of their networks. The company also recently opened an office in Beijing, China. This representative office complements the earlier launch of the company’s Asia Pacific headquarters in Hong Kong. CIENA offers its employees discounted homeowner’s and automobile insurance, tuition and health club fee reimbursement and medical, dental, vision and life insurance.
BRANDS/DIVISIONS/AFFILIATES: CoreDirector Sentry LightWorks MultiWave Metro One ONI Systems Corp.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Gary B. Smith, CEO Gary B. Smith, Pres. Joseph R. Chinnici, CFO/Sr. VP-Finance Steve W. Chaddick, Sr. VP-Mktg. Jennifer Sharp, Sr. VP-Human Resource Dev. Stephen B. Alexander, Sr. VP/Chief Tech. Officer Andrew C. Petrik, Controller Russell B. Stevenson, Jr., Sr. VP/Corp. Sec. Russell B. Stevenson, Jr., General Counsel Mark Cummings, Sr. VP-Oper. Steve W. Chaddick, Sr. VP/Corp. Strategy Officer Andrew C. Petrik, Treas. Jesús León, Sr. VP/Chief Dev. Officer Patrick H. Nettles, Chmn.
Phone: 410-865-8500 Fax: 410-694-5750 Toll-Free: 800-921-1144 Address: 1201 Winterson Rd., Linthicum, MD 21090-2205 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $361,200 (12 months) 2002 Profits: $-1,597,500 (12 months) Stock Ticker: CIEN 2001 Sales: $1,603,200 2001 Profits: $-1,794,100 Employees: 2,118 2000 Sales: $858,750 2000 Profits: $81,387 Fiscal Year Ends: 10/31 1999 Sales: $482,085 1999 Profits: $-3,924 1998 Sales: $508,087 1998 Profits: $45,700
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Global customer base.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $650,000 Second Exec. Salary: $561,538
Bonus: $700,000 Bonus: $575,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
CIMA LABS INC
www.cimalabs.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:67 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:38
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Reformulated Drug Delivery Systems
Cima Labs develops and manufactures fast-dissolve and enhanced-absorption oral drug delivery systems. OraSolv and DuraSolv, the firm's proprietary fast-dissolve technologies, are oral dosage forms that dissolve quickly in the mouth without chewing or the need for water. The company manufactures five pharmaceutical brands utilizing these technologies, including Triaminic Softchews for Novartis, Tempra FirsTabs for Bristol-Myers Squibb and Zomig-ZMT for AstraZeneca. Cima's technologies enable consumers in certain age groups or with limited ability to swallow conventional tablets to receive medication in an oral dosage form that is more convenient than traditional tablet-based dosage forms. Both OraSolv and DuraSolv are capable of incorporating taste-masked active drug ingredients into tablets with the benefits of ease of administrations, improved dosing compliance and increased accuracy compared to liquid formulations. The company is also developing several new drug delivery technologies, including sustained release technology and new OraVescent technologies, such as OraVescent SL, for delivery under the tongue, and OraVescent BL, for delivery between the gum and cheek. Cima is also developing OraVescent SS, designed for site-specific administration, which would allow an active drug to be transported to a specific part of the gastrointestinal tract to be released for absorption. PakSolv is the firm's proprietary packaging system for soft, brittle tablets and is used for all of its OraSolv products. In addition, Cima is evaluating applications for its microemulsions technology, designed to improve the bioavailability of a range of active drug ingredients. In recent news, Cima formed a collaborative agreement with Aventis to develop a fastdissolve version of Allegra, a leading antihistamine. In addition, the company commenced clinical trials of its OraVescent fentanyl product for treating cancer pain.
BRANDS/DIVISIONS/AFFILIATES: DuraSolv OraSolv OraVescent PakSolv Triaminic Softchews Tempra FirsTabs Zomig-ZMT
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John M. Siebert, CEO John Hontz, COO John M. Siebert, Pres. David A. Feste, VP-Finance/CFO Ronald Gay, Dir.-Human Resources David A. Feste, Corp. Sec.
Phone: 952-947-8700 Fax: 952-947-8770 Toll-Free: Address: 10000 Valley View Rd., Eden Prairie, MN 55344-9631 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $46,600 (12 months) 2002 Profits: $18,600 (12 months) Stock Ticker: CIMA 2001 Sales: $32,000 2001 Profits: $15,000 Employees: 219 2000 Sales: $23,900 2000 Profits: $4,000 Fiscal Year Ends: 12/31 1999 Sales: $13,400 1999 Profits: $-1,300 1998 Sales: $7,600 1998 Profits: $-3,200
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $292,398 Stock Purch. Plan: Second Exec. Salary: $209,877 ADVANTAGE: Successful introduction of new drug delivery techniques.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
CIRRUS LOGIC INC
www.cirrus.com
Industry Group Code: 334413 Ranks within this company's industry group: Sales:18 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:16
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Integrated Circuits-Analog & Digital Highly Integrated Chips Manufacturing Kits Subsystem Modules
Cirrus Logic, Inc. is a leading supplier of high-performance analog and DSP chips for Internet entertainment and electronics. The company also produces audio integrated circuits and targets high-volume audio, storage and communications applications providers as potential customers. Cirrus Logic offers a broad line of products under the Cirrus Logic name as well as the Crystal, Maverick and 3Ci brand names, which enable systemlevel applications in mass storage (magnetic and optical), audio (professional, consumer and PC) and precision data conversion (16 bits and higher). The firm is strongly positioned for continued growth in the DVD market, as explosive growth in DVD-based home entertainment systems drive sales of its multi-channel digital A/V receivers. With the goal of establishing early market leadership, the company recently introduced the semiconductor industry's most comprehensive, featurerich and cost-effective DVD+RW recording platform solution. This fully functional reference platform (based upon its flagship DVD processor) is designed to help consumer electronics manufacturers accelerate widespread adoption of DVD+RW recording products. In a related development, ADS Technologies plans to incorporate Cirrus’s USB-DVR 2.0 reference design into the latest version of its Instant DVD line of consumer digital video recording products. In other news, Cirrus’s CS7410 music processor will power a new portable, CDbased MP3 player to be manufactured by Hong Kongbased Starlight Electronics. The product is slated to be marketed and distributed as a house label brand by two major U.S. consumer electronics retail chains. Cirrus offers its employees a casual work environment and full health benefits, including a vision plan and dental coverage, as well as tuition reimbursement and a computer purchase plan.
BRANDS/DIVISIONS/AFFILIATES: Crystal PCSI CS7410 Maverick 3Ci Starlight Electronics ADS Technologies PicoPower Technology, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. David D. French, CEO David D. French, Pres. Steven D. Overly, CFO Terry M. Leeder, Sr. VP-Sales Steven Overly, Sr. Human Resources Officer Craig H. Ensley, Sr. VP-Eng. Steven D. Overly, Corp. Sec. Steven D. Overly, General Counsel Gerald R. Gray, VP-Global Oper.
Phone: 512-445-7222 Fax: 512-445-7581 Toll-Free: 800-888-5016 Address: 4210 S. Industrial Dr., Austin, TX 78744 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $417,500 (12 months) 2002 Profits: $-206,100 (12 months) Stock Ticker: CRUS 2001 Sales: $778,700 2001 Profits: $143,200 Employees: 1,203 2000 Sales: $564,400 2000 Profits: $-47,100 Fiscal Year Ends: 3/31 1999 Sales: $628,105 1999 Profits: $-427,403 1998 Sales: $954,270 1998 Profits: $36,493
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $449,039 Stock Purch. Plan: Y Second Exec. Salary: $285,766 ADVANTAGE: A leading supplier of high-performance analog and DSP chips.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $361,250 Bonus: $165,383
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
CISCO SYSTEMS INC
www.cisco.com
Industry Group Code: 334110 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Networking Equipment-Diversified Backbone Routers Adapters and Hubs Router Management Software
Cisco Systems, Inc., a global leader in Internet networking, provides end-to-end solutions that customers use to build unified information infrastructures of their own or to connect to other networks. The company’s multiservice broadband solutions enable service providers to rapidly deploy a breadth of revenue-generating services such as corporate Internet/intranet access, secure virtual private networks (VPN), residential and business voiceover IP services, digital video and streaming media. The firm also provides Gigabit Ethernet network products that run on copper wires to those clients that cannot obtain access to optical services. Furthermore, Cisco has launched a new network storage router product line. The company's pre-engineered solutions are intended to be consistent with customer requirements and are expected to reduce service providers' time to market and the cost of deploying the optical network. In order to boost its security offerings, the firm recently acquired Okena, a developer of innovative behavior-based security technology. Okena’s products surpass conventional desktop and server security solutions that guard against threats such as viruses, worms, Trojan horses and buffer overload attacks, because they do not necessarily need to recognize a signature before launching a defense. Thus, its technology is able to prevent known and unknown attacks before they can occur. Cisco’s future strategy seeks to focus its IPbased networking expertise on several promising new growth markets across the service provider, enterprise and commercial customer spaces. The company will create solutions for converged packet networks, metropolitan networks, VPNs, packet voice and cable infrastructures. For business clients in enterprise and commercial spaces, Cisco seeks to provide solutions for security, wireless LANs and IP telephony. The firm announced in March 2003 that it will acquire Linksys, a leading maker of networking gear for PCs. Cisco Systems offers its employees commuting vouchers, a matching gift program, dental and vision insurance, an on-site fitness center and stationery store and corporate discounts for travel, tires and amusement parks.
BRANDS/DIVISIONS/AFFILIATES: Okena Linksys
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John T. Chambers, CEO John T. Chambers, Pres. Dennis Powell, CFO James Richardson, Chief Mktg. Officer Kate Dcamp, Sr. VP-Human Resources Peter Solvik, Sr. VP-IT Carl Redfield, Sr. VP-Mfg. Oper. Richard J. Justice, Sr. VP-Worldwide Field Oper. Mario Mazzola, Chief Dev. Officer Larry R. Carter, Sr. VP-Admin. Howard Charney, Sr. VP Susan L. Bostrom, Sr. VP-Internet Bus. Solutions Mike Volpi, Sr. VP-Routing Tech.
Phone: 408-526-4000 Fax: 408-526-4100 Toll-Free: 800-326-1941 Address: 170 W. Tasman Dr., San Jose, CA 95134 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $18,915,000 (12 months) 2002 Profits: $1,893,000 (12 months) Stock Ticker: CSCO 2001 Sales: $22,293,000 2001 Profits: $-1,014,000 Employees: 36,000 2000 Sales: $18,928,000 2000 Profits: $2,668,000 Fiscal Year Ends: 7/31 1999 Sales: $12,173,000 1999 Profits: $2,023,000 1998 Sales: $8,489,000 1998 Profits: $1,331,000
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $447,120 Bonus: $556,289 Stock Purch. Plan: Y Second Exec. Salary: $425,700 Bonus: $529,639 ADVANTAGE: Focus on expertise in Internet Protocol (IP) switches/Industry leader/Growth through multiple acquisitions.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
CITRIX SYSTEMS INC
www.citrix.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:30 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:11
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Software-Application Server
Citrix Systems, Inc. is an application-server software and services company. The firm's Windows Application Servers and Management Services Products permit organizations to deploy and manage Windows applications without regard to location or type of client hardware platforms. These products operate by executing the Windows applications on a multi-user Windows NT server and provide endusers access to the server from a variety of client platforms. The Windows Application Servers product line consists primarily of MetaFrame and WinFrame products. MetaFrame software is an enhancement to Microsoft Windows NT Server 4.0, Terminal Server Edition and Windows 2000 server products, which Microsoft launched in February 2000. The products are designed to minimize the memory and processing requirements of client systems, resulting in a highly scalable, bandwidth-efficient solution for deployment and management of applications. Citrix Systems’ MetaFrame and WinFrame application server software, when used in conjunction with a web server, provides Internet and intranet access to standard and custom developed Windows applications as well. For example, using the company's products, an organization could add secure interactive access to an application directly from a webpage without developing any new programs or changing its existing application program or database. Citrix has more than 100,000 customers worldwide, including 99 of the Fortune 100 firms. Citrix Systems was recently included in the Standard & Poor's 500 Index. Citrix's achievements include financial success, rapid growth and a strong product line.
BRANDS/DIVISIONS/AFFILIATES: Digital Independence MetaFrame Independent Computing Architecture Innovex
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Mark B. Templeton, CEO Mark B. Templeton, Pres. John P. Cunningham, CFO/VP-Finance and Admin. Douglas Wheeler, Sr. VP-Mktg. Leslie Pendergrast, VP-Human Resources Edward E. Iacobucci, Chief Tech. Off./VP-Strategy & Tech. Jeanne M. Moreno, CIO Marc-Andre Boisseau, Controller/Principal Acct Officer Bruce C. Chittenden, VP-Engineering Daniel P. Roy, General Counsel David Weiss, VP-Product Strategy Chris Phoenix, VP-Citrix iBusiness Unit Barry Davis, VP-Corp. Alliances Robert Bartolotta, Mgr., Public Relations John P. Cunningham, Treas. Michael Wendl, Managing Dir.-Europe, Middle East, Africa Linda Haury, Dir., Americas Mktg.
Phone: 954-267-3000 Fax: 954-267-9319 Toll-Free: Address: 6400 NW 6th Way, Fort Lauderdale, FL 33309 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $527,400 (12 months) 2002 Profits: $93,900 (12 months) Stock Ticker: CTXS 2001 Sales: $551,800 2001 Profits: $105,300 Employees: 1,670 2000 Sales: $470,400 2000 Profits: $94,500 Fiscal Year Ends: 12/31 1999 Sales: $403,300 1999 Profits: $116,900 1998 Sales: $248,600 1998 Profits: $61,100
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $307,500 Stock Purch. Plan: Second Exec. Salary: $232,500 ADVANTAGE: Focus on products that serve Internet firms.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $176,396 Bonus: $83,298
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
COGNEX CORP
www.cognex.com
Industry Group Code: 334111 Ranks within this company's industry group: Sales:12 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:7
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Hardware-Human Vision Replacement Hardware for Industrial Machine Vision
Cognex designs, develops, manufactures and markets machine vision systems that are used to automate a wide range of manufacturing processes where vision is required. Cognex machine vision systems consist of two primary elements: a computer, which serves as a machine vision engine; and software that processes and analyzes images. When connected to a video camera, the machine vision system captures images and extracts information, which determines appropriate action for other equipment in the manufacturing process. Machine vision systems are used in a variety of industries including the semiconductor, electronics, automotive, consumer products, metals, plastics and paper industries. Machine vision is important for applications in which human vision is inadequate due to fatigue, visual acuity or speed, or in instances where substantial cost savings are obtained through the reduction of direct labor and improved product quality. Cognex’s line of systems covers the entire spectrum of vision needs. Its In-Sight vision sensors are low-cost, general-purpose systems. The PC-based vision systems combine software and hardware products and incorporate PatMax, a powerful, high accuracy object location software package. SmartView Web/Surface Inspection systems detect, identify and visualize defects on the surfaces of products that are manufactured in a continuous fashion. Cognex recently announced that they had expanded the data access capabilities of the SmartView system, which is the industry’s leading web inspection system. In addition, Cognex offers customized systems that will create solutions to a company’s specific needs. In recent news, Samsung announced they would integrate Cognex’s In-Sight 1700 wafer reader in all its chip manufacturing plants in Korea. Cognex has numerous gatherings for employees' families annually including a circus and winter carnival. Every day at noon employees are invited out to participate in a game of Ultimate Frisbee. In addition, there are a variety of after work socials and team building sessions. At the company headquarters in Massachusetts there is a state-of-the-art fitness and cafeteria facility.
BRANDS/DIVISIONS/AFFILIATES: SmartView Web Inspection PatMax In-Sight 1700
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Robert J. Shillman, CEO Robert J. Shillman, Pres. Richard A. Morin, VP-Finance/CFO William Silver, CTO Marilyn Matz, VP-Eng. Richard A. Morin, Treas. Patrick Alias, Exec. VP Justin Testa, VP-Mktg. Robert J. Shillman, Chmn.
Phone: 508-650-3000 Fax: 508-650-3333 Toll-Free: Address: 1 Vision Dr., Natick, MA 01760 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $114,100 (12 months) 2002 Profits: $-6,000 (12 months) Stock Ticker: CGNX 2001 Sales: $140,700 2001 Profits: $-11,100 Employees: 622 2000 Sales: $250,700 2000 Profits: $68,100 Fiscal Year Ends: 12/31 1999 Sales: $152,100 1999 Profits: $30,400 1998 Sales: $121,800 1998 Profits: $20,200
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $236,896 Stock Purch. Plan: Y Second Exec. Salary: $176,058 ADVANTAGE: Specialization in artificial vision systems.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $504,000 Bonus: $310,500
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
COLLAGENEX PHARMACEUTICAL
www.collagenex.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:69 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:50
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Dental Disease Dermatology Products
CollaGenex Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on providing innovative medical therapies to the dental and dermatology markets. Dental products that CollaGenex markets include Periostat, its own development; Atridox, Atrisorb-Freeflow and Atrisorb-D Freeflow, products of Atrix Laboratories; and Vioxx, developed by Merck. Periostat is the first and only pharmaceutical to treat adult periodontitis by inhibiting the enzymes that destroy periodontal support tissues. Adult periodontitis, a chronic disease characterized by the progressive loss of attachment between the tooth root and the surrounding periodontal structures, may result in tooth loss if untreated. Vioxx is a prescription non-steroidal antiinflammatory drug. Products for the dermatology market include Pandel, used for the treatment of dermatitis and psoriasis, and PR-Q, developed for the treatment of dry skin. CollaGenex’s development products are based on its core technologies, IMPACS and Restoraderm. IMPACS compounds have the potential to treat diseases that cause inflammation and destruction of the connective tissues. Restoraderm delivers ingredients to the dermal layers underlying the skin. Recently, CollaGenex and Medtronic, Inc. entered into a license agreement involving IMPACS; Medtronic will use IMPACS to treat aortic aneurysms and other forms of vascular disease with medical devices. In other news, the company and Discovery Laboratories, Inc. announced a research collaboration to develop a treatment for respiratory diseases.
BRANDS/DIVISIONS/AFFILIATES: Periostat Atridox Vioxx Atrisorb-Freeflow PR-Q Pandel IMPACS Restoraderm
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Brian M. Gallagher, CEO Brian M. Gallagher, Pres. Nancy C. Broadbent, CFO David P. Pfeiffer, VP-Mktg. and Sales Nancy C. Broadbent, Sec. Nancy C. Broadbent, Treas. Robert A. Ashley, Sr. VP-Commercial Dev. Jeffrey S. Day, VP-Dermatology Douglas C. Gehrig, VP-Sales Michael Romanowicz, VP-Professional Affairs and Managed Care Brian M. Gallagher, Chmn.
Phone: 215-579-7388 Fax: 215-579-8577 Toll-Free: Address: 41 University Dr., Ste. 200, Newton, PA 18940 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $44,600 (12 months) 2002 Profits: $ 900 (12 months) Stock Ticker: CGPI 2001 Sales: $35,200 2001 Profits: $-8,100 Employees: 148 2000 Sales: $24,300 2000 Profits: $-8,830 Fiscal Year Ends: 12/31 1999 Sales: $16,100 1999 Profits: $-14,600 1998 Sales: $3,500 1998 Profits: $-11,600
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $315,000 Stock Purch. Plan: Second Exec. Salary: $225,000 ADVANTAGE: Focus on drugs for dental care/Unique therapy for periodontitis.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $131,615 Bonus: $93,908
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
COLLATERAL THERAPEUTICS
www.collateralthx.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Cardiovascular Disease
Collateral Therapeutics is focused on the discovery and development of non-surgical gene therapy products for the treatment of cardiovascular diseases, including coronary artery disease, peripheral vascular disease, congestive heart failure and heart attack. The firm believes that its products under development hold the potential to revolutionize the treatment of cardiovascular diseases. These products could provide a new standard of care by offering patients simpler, more cost-effective and lowerrisk alternatives to currently available treatments such as coronary artery bypass surgery and angioplasty. Collateral’s initial gene therapy products are designed to promote and enhance angiogenesis, a natural biological process that results in the growth of additional blood vessels to increase levels of blood flow to oxygendeprived tissues. The company’s lead product, GENERX, is being developed as a treatment for chest pain due to coronary artery disease. GENERX is undergoing two Phase 2b/3 trials, one in the U.S and one in Europe. GENVASCOR, a second product designed for the treatment of patients with peripheral vascular disease, is beginning Phase 1/2 trials in Europe. Preclinical research is underway for GENEVX, for ischemic heart disease, and CORGENIC, for congestive heart failure. Collateral has several research and license agreements with academic institutions, including the Regents of the University of California, New York University, University of Texas Southwestern Medical Center and the Veterans Medical Research Foundation in San Diego. Recently, Collateral Therapeutics was acquired by Schering AG.
BRANDS/DIVISIONS/AFFILIATES: CORGENIC GENERX GENVASCOR GENEVX Schering AG
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jack W. Reich, CEO Christopher J. Reinhard, COO Christopher J. Reinhard, Pres. Christopher J. Reinhard, CFO John F. Warner, VP-Research and Tech. Tyler M. Dylan, Corp. Sec. Tyler M. Dylan, General Counsel Jeffrey Friedman, VP-Dev. Patricia L. Novak, Sr. Dir.-Program Mgmt. Juliet Singh, VP-Regulatory Affairs and Quality Assurance
Phone: 858-794-3400 Fax: 858-794-3440 Toll-Free: Address: 11622 El Camino Real, San Diego, CA 92130 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 3 months. 2002 Sales: $12,000 ( 3 months) 2002 Profits: $5,600 ( 3 months) Stock Ticker: Private 2001 Sales: $5,200 2001 Profits: $-14,600 Employees: 70 2000 Sales: $2,000 2000 Profits: $-14,600 Fiscal Year Ends: 12/31 1999 Sales: $6,400 1999 Profits: $-7,700 1998 Sales: $5,400 1998 Profits: $-4,900
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Bonus: $ Stock Purch. Plan: Second Exec. Salary: $ Bonus: $ ADVANTAGE: Successful trials of new products for non-invasive treatment of cardiovascular diseases.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
COMPAGNIE MICHELIN
www.michelin.com
Industry Group Code: 326000 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Profits:
Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Plastics and Rubber, Manufacturing Tire Production Road Maps and Atlases
Compagnie Michelin, based in France, is a worldwide corporation best known for its production of tires for cars, trucks, aircraft, earthmovers and motorcycles, to name a few. Michelin is the world’s second leading tire producer, behind Bridgestone. In addition to tires, Michelin has a tourism division, called ViaMichelin, which produces road maps and atlases, city maps, travel guidebooks and hotel and restaurant guidebooks. ViaMichelin, the digital travel division, boasts the Internet’s largest online road map database. Michelin’s sports division sponsors and outfits a wide variety of racing categories including Formula One, Motorcycle Grand Prix, Superbike and American LeMans Series. The company has 20 production plants in the U.S. that specialize in the manufacture of tires for cars and light trucks, heavy-duty trucks and other products. In addition, the U.S. is home to one of three Michelin Technology Centers, the others being in Europe and Japan. These technology centers are responsible for the creation of, for example, the Michelin PAX System. This tire system, which was born from their PAV concept, his highlighted by its ability to provide safety and mobility when driving with zero air pressure. It is the standard system on the Renault Scenic and in January 2003, Michelin signed a deal with Rolls Royce to have the PAX system become standard on their new line of cars. Michelin is listed with the Paris stock exchange. Michelin offers employees healthcare which includes major medical, dental and percription drug plans. Insurance offers include supplemental term life, accidental death and dismemberment, dependant life and business travel accident insurance. For those employess who are in school, Michelin provides reimbursement for education costs to those who qualify. Many of Michelin's locations provide on-site fitness centers.
BRANDS/DIVISIONS/AFFILIATES: Uniroyal Kleber BFGoodrich ViaMichelin Michelin PAX System P&A Brands Siamtyre Kormoran
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Edouard Michelin, CEO Michel Rollier, CFO Francois Michelin, Managing Partner Rene Zingraff, Managing Partner Eric Bourdais de Charbonniere, Chmn.
Phone: 33-4-73-98-59-00 Fax: 33-4-73-98-59-04 Toll-Free: 800-000222 Address: 12, cours Sablon, Clermont-Ferrand, 63000 France
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $16,398,000 (12 months) 2002 Profits: $ (12 months) Stock Ticker: ML 2001 Sales: $14,427,000 2001 Profits: $262,000 Employees: 126,285 2000 Sales: $14,887,100 2000 Profits: $375,700 Fiscal Year Ends: 12/31 1999 Sales: $13,859,300 1999 Profits: $155,100 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: The world’s largest tire producer.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $ Second Exec. Salary: $
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
COMPUTER ASSOCIATES INTERNATIONAL INC www.cai.com Industry Group Code: 511200 Ranks within this company's industry group: Sales:5 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:37
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Software-Diversified Network Management Tools
Computer Associates International, Inc. (CAI) designs, develops, markets and supports standardized computer software products for use with a broad range of desktop, midrange and mainframe computers. The company offers a wide array of products under its seven brand names in three strategic categories and six focus areas. The strategic categories are process management, information management and infrastructure management. The six focus areas are enterprise management, security, storage, portal and business intelligence, application life cycle management and data management and application development. CAI’s brand names include Unicenter for enterprise management, eTrust for security, BrightStor for storage, CleverPath for portal and business intelligence, AllFusion for application life cycle management and Advantage and Jasmine for data management and application development. CAI serves organizations in more than 100 countries, including more than 95% of the Fortune 500 companies. Recently, the company acquired Netreon, Inc., a developer of storage network software. With the acquisition, CAI gains Netreon’s SANexec Designer solutions. These solutions will be incorporated into the company’s BrightStor family, which will enable the company to offer solutions that manage every stage of the storage life cycle. The company offers free courses in English as a second language to its New York-area employees. Additionally, CAI offers tuition reimbursement, on-site fitness centers, adoption assistance programs and free continental breakfasts. Under the management of TaiwaneseAmerican Charles Wang, CAI has become one of the top five companies for Asians, providing free minority community infrastructure and self-enrichment classes.
BRANDS/DIVISIONS/AFFILIATES: Unicenter eTrust BrightStor CleverPath AllFusion Advantage Jasmine Netreon, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Sanjay Kumar, CEO Sanjay Kumar, Pres. Ira Zar, CFO/Exec. VP-Finance Nancy Bhagat, Sr. VP-Mktg. Andy Goodman, Sr. VP-Human Resources Yogesh Gupta, Chief Tech. Officer Steven M. Woghin, Sr. VP/General Counsel Charles Holleran, Sr. VP-Corp. Comm. Russell M. Artzt, Exec. VP-Alliances and eTrust Solutions Mark Combs, Sr. VP-Advantage and Mainframe Solutions Stephen Richards, Exec. VP-Sales and Field Oper. Frank Yang, Sr. VP-BrightStor Solutions Charles B. Wang, Chmn.
Phone: 631-342-5224 Fax: 631-342-5329 Toll-Free: 800-225-5224 Address: One Computer Associates Plaza, Islandia, NY 11749 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $2,964,000 (12 months) 2002 Profits: $-1,102,000 (12 months) Stock Ticker: CA 2001 Sales: $4,198,000 2001 Profits: $-591,000 Employees: 16,600 2000 Sales: $6,103,000 2000 Profits: $696,000 Fiscal Year Ends: 3/31 1999 Sales: $4,666,000 1999 Profits: $626,000 1998 Sales: $4,206,000 1998 Profits: $1,169,000
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $1,000,000 Stock Purch. Plan: Y Second Exec. Salary: $750,000 ADVANTAGE: Very aggressive marketing/Growth through acquisitions.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $4,783,000 Bonus: $3,156,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
COMPUTER SCIENCES CORP
www.csc.com
Industry Group Code: 541512 Ranks within this company's industry group: Sales:2 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:2
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y Y
GROWTH PLANS/SPECIAL FEATURES:
Consulting-InfoTech Related Systems Integration Credit Services
Computer Sciences Corp. is a major provider of information technology (IT) and business process outsourcing, systems integration and consulting and professional services. In the global commercial market sector, the company's service offerings are marketed to clients in a wide array of industries, including aerospace and defense; automotive; chemical and energy; consumer goods; financial services; health care; manufacturing; media; public sector; retail and distribution; telecommunications; traffic and transportation; travel and hospitality; and utilities. Its outsourcing services involve operating all or a portion of a customer's technology infrastructure, including systems analysis, applications development, network operations, desktop computing and data center management. The company also provides business process outsourcing, which is the management of a client's non-core business functions, such as claims processing, credit checking, logistics or customer call centers. Computer Sciences' systems integration segment encompasses designing, developing, implementing and integrating complete information systems. The consulting and professional services segment includes advising clients on the strategic acquisition and utilization of IT and on business strategy, security, modeling, simulation, engineering, operations, change management and business process reengineering. The company also licenses sophisticated software systems for the health care and financial services markets and provides a broad array of end-to-end ebusiness solutions that meet the needs of large commercial and government clients. Recently, the company signed an agreement to provide outsourcing services to TDC, the second largest company in Denmark. Computer Sciences was also chosen to provide technology services to FirstCaribbean International Bank. Computer Sciences Corp. offers employees special career-planning programs, a tuition reimbursement plan and in-house college-level courses.
BRANDS/DIVISIONS/AFFILIATES: CSC Healthcare Corp. CSC Financial Services Group CSC Pinnacle Alliance CSC Credit Services
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Van B. Honeycutt, CEO Edward P. Boykin, COO Edward P. Boykin, Pres. Leon J. Level, VP/CFO Donald DeBuck, VP/Controller Hayward D. Fisk, Corp. Sec. Hayward D. Fisk, General Counsel Paul T. Tucker, VP-Corp. Dev. Michael W. Laphen, Pres.-European Group Paul M. Cofoni, Pres.-Federal Sector Van B. Honeycutt, Chmn.
Phone: 310-615-0311 Fax: 310-3229768 Toll-Free: Address: 2100 E. Grand Ave., El Segundo, CA 90245 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $11,426,000 (12 months) 2002 Profits: $344,000 (12 months) Stock Ticker: CSC 2001 Sales: $10,524,000 2001 Profits: $233,200 Employees: 67,000 2000 Sales: $9,370,694 2000 Profits: $402,872 Fiscal Year Ends: 3/31 1999 Sales: $8,111,405 1999 Profits: $355,502 1998 Sales: $7,027,881 1998 Profits: $274,567
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $1,164,123 Stock Purch. Plan: Second Exec. Salary: $624,591 ADVANTAGE: Offers a broad base of computer services/Continues to grow.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $1,041,186 Bonus: $522,994
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
COMPUWARE CORP
www.compuware.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:8 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:33
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Software-Mainframes Network Software Product Application Management and Development Software for UNIX Systems
Compuware provides software products and professional services designed to increase the productivity of the information systems departments of its target market, the 20,000 largest enterprises worldwide. Compuware initially focused on the testing and implementation environment in the mainframe market, where it gained extensive experience and established long-term customer relationships. Currently, the company has expanded its presence into the distributed and web systems markets, offering products and professional services in the application development, integration, testing and performance management areas. The company also focuses on developing, marketing and supporting highquality software tools to support both traditional uses of the mainframe and to enhance the efforts of IT staff that work to web-enable their legacy applications portfolio. In addition, Compuware is actively pursuing product integration to enhance the synergy among the functional groups working on key application projects to make the entire process more streamlined, automated and repeatable. Some of Compuware’s most notable customers are BANK ONE, Kelly Services and Microsoft. The firm also has strategic partnerships with companies such as IBM, Hewlett-Packard, SAP, Compaq and many others. The firm recently released its Vantage Release 8.5 product, featuring an increased level of information accessibility and instant reporting. Furthermore, its new web-based user interface provides the ability to conveniently manage an entire enterprise from a single console. In other news, Compuware entered into a technology agreement with AMD to add x86-64 support to Compuware SoftICE64 .The agreement enables developers to more rapidly build software targeted for upcoming AMD Opteron and AMD Athlon processors. Benefits for hourly employees include health insurance, a referral bonus and recreational discounts on attractions such as travel, movie tickets and amusement parks. In addition to the above, full-time employees enjoy benefits such as vision and group legal coverage, as well as education assistance.
BRANDS/DIVISIONS/AFFILIATES: UnderWare, Inc. NuMega Technologies, Inc. CACI Products Group Nomex, Inc. Data Processing Resources Corp. High Plains Solutions SoftICE64 Vantage Release 8.5
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Peter Karmanos, Jr., CEO Tommi A. White, COO Joseph A. Nathan, Pres. Laura L. Fournier, CFO Denise A. Knobblock, VP-Human Resources Lisa Elkin, VP-Comm. Lisa Elkin, VP-Investor Rel. Laura L. Fournier, Treas. Hank Jallos, Exec. VP-Global Account Mgmt. W. Alan Canrell, Sr. VP-Professional Services Peter Karmanos, Jr., Chmn.
Phone: 248-737-7300 Fax: 248-737-7108 Toll-Free: 800-521-9353 Address: 31440 Northwestern Hwy., Farmington Hills, MI 483342564 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,728,500 (12 months) 2002 Profits: $-245,300 (12 months) Stock Ticker: CPWR 2001 Sales: $2,010,100 2001 Profits: $119,100 Employees: 10,164 2000 Sales: $2,230,600 2000 Profits: $352,000 Fiscal Year Ends: 4/30 1999 Sales: $1,638,400 1999 Profits: $349,900 1998 Sales: $1,139,318 1998 Profits: $193,944
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $950,000 Stock Purch. Plan: Y Second Exec. Salary: $750,000 ADVANTAGE: Aggressive growth through acquisitions.
OTHER THOUGHTS: Apparent Women Officers or Directors: 4 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $700,000 Bonus: $600,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
COMVERSE TECHNOLOGY INC
www.cmvt.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:15 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:15
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Software-Telecommunications Voice Messaging Systems Mobile Messaging and Data Value-Added Services Wireless Communications Systems
Comverse Technology, Inc. designs, develops, manufactures, markets and supports computer and telecommunications systems and software for multimedia communications and information processing applications. The company’s products are used in a broad range of applications by wireless and wireline telecommunications network operators, call centers and other public and commercial organizations worldwide. Comverse’s lines of enhanced services and platform products enable telecommunications network operators to offer a variety of revenue-generating services that are accessible to large numbers of simultaneous users, including a broad range of integrated messaging, information distribution and personal assistant services. These include call answering, voice mail, fax mail, unified messaging, pre-paid services, short-text messaging, wireless Internet access and a wide range of interactive voice response services. More than 390 wireless and wireline telecommunications service providers in more than 100 countries, including the majority of the 20 largest telecom companies in the world, use the company's platforms. Through subsidiary Verint Systems, Inc., formerly known as Comverse Infosys, Inc., the company provides analytic solutions for communications interception, digital video security and surveillance and enterprise business intelligence. Through Ulticom, Inc., the company provides service enabling signaling software for wireline, wireless and Internet communications. Recently, Comverse and Avaya announced an agreement to develop a new managed service providing communications solutions and services for telecommnications service providers. These managed services will involve reduced company expenses in messaging services such as voice mail.
BRANDS/DIVISIONS/AFFILIATES: TRILOGUE ULTRA Ulticom, Inc. Verint Systems Wydeband Startel Starhome Loronix
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Zeev Bregman, CEO Itsik Danziger, Pres. David Kreinberg, Exec. VP-Finance/CFO William F. Sorin, Corp. Sec. Kobi Alexander, Chmn.
Phone: 516-677-7200 Fax: 516-677-7355 Toll-Free: Address: 170 Crossways Park Dr., Woodbury, NY 11797 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,270,200 (12 months) 2002 Profits: $54,600 (12 months) Stock Ticker: CMVT 2001 Sales: $1,225,100 2001 Profits: $249,100 Employees: 4,789 2000 Sales: $909,700 2000 Profits: $173,100 Fiscal Year Ends: 1/31 1999 Sales: $708,800 1999 Profits: $109,400 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Stock Purch. Plan: Y ADVANTAGE: Global customer base.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $403,000 Second Exec. Salary: $385,008
Bonus: $7,458,915 Bonus: $125,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
CONMED CORP
www.conmed.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:26 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:24
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Equipment-Surgical and Medical Procedure Instruments for IV Therapy
Conmed Corporation is a leading developer, manufacturer and supplier of a broad range of medical instruments and systems used in surgical and other medical procedures. The company’s product offerings include electrosurgical systems, electrocardiogram electrodes and accessories; surgical suction instruments, intravenous therapy accessories and wound care products. The firm specializes in instruments and implants for arthroscopic sports medicine and powered surgical instruments for orthopedic surgery and neurosurgery. In addition, Conmed has broadened its product offerings to include arthroscopic surgery devices and products and imaging products for minimally invasive surgery. The company’s product breadth has enhanced its ability to market to hospitals, surgery centers, GPOs (Group Purchasing Organizations) and other customers, particularly as institutions seek to reduce costs and minimize the number of suppliers. Linvatec, a subsidiary of Conmed, specializes in the production of arthroscopy surgical hardware and imaging equipment. It also hosts Web Partners, an Internet service for customers that offers operating room solutions. Conmed acquisitions include the minimal access surgery product portfolio from Imagyn Medical Technologies, a move that strengthens its position in the laparoscopic instrument market. Conmed has significantly expanded its sports medicine product offerings with the recent acquisition of Bionx Implants, Inc., a manufacturer and seller of bio-absorbable implants for sports medicine surgical procedures. Additionally, the company has acquired CORE Dynamics, Inc., a developer and manufacturer of minimally invasive laparoscopic surgical devices with annual sales of $7.5 million. The company offers employees medical and dental plans, travel and accident insurance and tuition reimbursement.
BRANDS/DIVISIONS/AFFILIATES: Aspen Laboratories, Inc. CONMED Andover Medical, Inc. Birtcher Medical Systems, Inc. Bionx Implants, Inc. New Dimensions in Medicine, Inc. Linvatec Corporation CORE Dynamics, Inc. Imagyn Medical Technologies
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Eugene R. Corasanti, CEO Joseph J. Corasanti, COO Joseph J. Corasanti, Pres. Robert D. Shallish, Jr., CFO/VP-Finance John J. Stotts, VP-Patient Care Elizabeth Bowers, VP-Human Resources Daniel S. Jonas, VP-Legal Affairs/General Counsel Thomas M. Acey, Treas. William W. Abraham, Sr. VP Gerald G. Woodard, Pres., Linvatec Eugene T. Star, Pres., Conmed Electrosurgery Frank Williams, VP-Endoscopy Eugene R. Corasanti, Chmn.
Phone: 315-797-8375 Fax: 315-797-0321 Toll-Free: Address: 525 French Rd., Utica, NY 13502 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $453,100 (12 months) 2002 Profits: $34,200 (12 months) Stock Ticker: CNMD 2001 Sales: $428,700 2001 Profits: $24,400 Employees: 2,541 2000 Sales: $392,200 2000 Profits: $19,300 Fiscal Year Ends: 12/31 1999 Sales: $372,600 1999 Profits: $27,200 1998 Sales: $336,442 1998 Profits: $19,400
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $361,928 Bonus: $52,502 Stock Purch. Plan: Second Exec. Salary: $222,590 Bonus: $34,655 ADVANTAGE: CONMED is a leading provider of advanced electrosurgical systems and ECG electrodes and accessories.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest:
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
CONNETICS CORPORATION
www.connetics.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:63 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:62
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Dermatology Topical Steroids
Connetics Corp. is a specialty pharmaceutical company focusing exclusively on the treatment of dermatological conditions. The firm currently markets two products, Luxiq Foam and OLUX Foam, which compete in the topical steroids market and have clinically proven therapeutic advantages for the treatment of scalp dermatoses in a novel formulation. Luxiq is a foam preparation of a mildpotency topical steroid for mild to moderate conditions such as psoriasis, eczema and dermatitis. OLUX is one of the most widely prescribed super high-potency topical steroids. Recently, OLUX received FDA approval for nonscalp indications. The company's Connetics Center for Skin Biology brings together dermatologists and pharmacologists from across the country to explore how topical drugs interact with and penetrate the skin. The Center's goal is to learn how to optimize drug penetration, distribution and efficiency at the targeted treatment site on the skin and to evaluate new chemical entities for the development of innovative dermatological products. In 2001, the company acquired the Soltec Research division of Australia-based F. H. Faulding, establishing Connetics as the only independent company serving the dermatology segment that has integrated product innovation, development and commercialization abilities. The acquisition also enabled Connetics to control its delivery technologies worldwide. In recent news, the firm and DPT Laboratories completed a state-of-the-art aerosol manufacturing facility in San Antonio, Texas. Connetics offers its employees health insurance and disability coverage, pre-tax spending accounts and education assistance.
BRANDS/DIVISIONS/AFFILIATES: Luqix OLUX Soltec Research Connetics Center for Skin Biology
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Thomas G. Wiggans, CEO C. Gregory Vontz, Exec. VP/COO Thomas G. Wiggans, Pres. John L. Higgins, CFO/Exec. VP-Finance Joseph Finster, Sr. VP-Mktg. Rebecca Gardiner, Sr. VP-Human Resources Katrina J. Church, Corp. Sec. Katrina J. Church, Exec. VP-Legal Affairs/General Counsel John L. Higgins, Exec. VP-Admin. John L. Higgins, Exec. VP-Corp. Dev. Rebecca Gardiner, Sr. VP-Organizational Dynamics Robert G. Lederer, Sr. VP-Commercial Oper. Charles J. Democko, VP-Regulatory Affairs Linda J. Fenney, Sr. VP-Product Dev. G. Kirk Raab, Chmn.
Phone: 650-843-2800 Fax: 650-843-2899 Toll-Free: Address: 3400 W. Bayshore Rd., Palo Alto, CA 94303 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $52,800 (12 months) 2002 Profits: $-16,600 (12 months) Stock Ticker: CNCT 2001 Sales: $34,100 2001 Profits: $-16,700 Employees: 190 2000 Sales: $40,800 2000 Profits: $27,000 Fiscal Year Ends: 12/31 1999 Sales: $26,900 1999 Profits: $-27,300 1998 Sales: $9,100 1998 Profits: $-26,600
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $420,000 Bonus: $210,000 Stock Purch. Plan: Y Second Exec. Salary: $277,880 Bonus: $110,000 ADVANTAGE: Successful clinical trials/Drugs in development with indications for multiple disease therapies.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
CONOCOPHILLIPS
www.conocophillips.com
Industry Group Code: 211111 Ranks within this company's industry group: Sales:5 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:6
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Y Chemicals: Y Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Oil & Gas, Exploration and Production Natural Gas Distribution Gasoline Retailing Pipelines Energy Trading Power Plant Development
Houston-based ConocoPhillips is a major integrated global energy company that resulted from the merger between Conoco, Inc. and Phillips Petroleum Company. ConocoPhillips' business is organized into five operating segments: exploration and production, midstream, refining and marketing, chemicals and emerging businesses. The exploration and production segment explores for and produces crude oil, natural gas and natural gas liquids worldwide and mines oil sands to extract bitumen and upgrade it into synthetic crude oil. The midstream division gathers and processes natural gas produced by ConocoPhillips and others and fractionates and markets natural gas liquids, primarily in the United States, Canada and Trinidad. The company’s refining and marketing segment refines, markets and transports crude oil and petroleum products, primarily in the United States, Europe and Asia. The chemicals group manufactures and markets petrochemicals and plastics on a worldwide basis. The emerging businesses segment encompasses the development of new businesses beyond the company's traditional operations, including new technologies related to carbon fibers, natural gas conversion into clean fuels and related products (gas-to-liquids), fuels technology and power generation. ConocoPhillips' worldwide crude oil production, including its share of equity affiliates' production, currently average 682,000 barrels per day. In recent news, ConocoPhillips announced a license agreement with El Behera Natural Gas Liquefaction Company S.A.E. The license agreement allows El Behera the use of the company’s proprietary liquefaction technology at a liquefied natural gas facility to be located in Egypt. The firm offers employees health and retirement benefits as well as tuition refund plans.
BRANDS/DIVISIONS/AFFILIATES: Jet Seca Turkpetrol Conoco Global Power Du Pont Conoco, Inc. Phillips Petroleum
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. James J. Mulva, CEO James J. Mulva, Pres. John A. Carrig, CFO/Sr. VP-Finance Jim W. Nokes, Exec. VP-Mktg. Thomas C. Knudson, VP-Human Resources John R. Hopkins, VP-Exploration and Production Tech. Gene L. Batchelder, CIO Stephen F. Gates, Sr. VP-Legal/General Counsel John E. Lowe, Exec. VP-Planning and Strategic Transactions Thomas C. Knudson, Sr. VP-Gov't Affairs and Comm. W.B. Berry, Exec. VP-Exploration and Production Philip L. Frederickson, Exec. VP-Commercial Rick A. Harrington, Sr. VP Joseph C. High, VP Archie W. Dunham, Chmn. Jim W. Nokes, Exec. VP-Supply
Phone: 281-293-1000 Fax: 212-207-1068 Toll-Free: Address: 600 N. Dairy Ashford, Houston, TX 77079 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $57,224,000 (12 months) 2002 Profits: $-295,000 (12 months) Stock Ticker: COP 2001 Sales: $24,050,000 2001 Profits: $1,661,000 Employees: 57,000 2000 Sales: $38,737,000 2000 Profits: $1,902,000 Fiscal Year Ends: 12/31 1999 Sales: $27,039,000 1999 Profits: $744,000 1998 Sales: $16,995,000 1998 Profits: $450,000
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $1,375,000 Stock Purch. Plan: Y Second Exec. Salary: $1,358,336 Diversified, worldwide energy business/Merger with Phillips Petroleum Co. ADVANTAGE:
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $1,612,000 Bonus: $26,640,502
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
CORIXA CORPORATION
www.corixa.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:66 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:96
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Cancer and Infectious Disease Drugs-Autoimmune Diseases
Corixa Corporation is a research and development-based biotechnology company committed to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. The company is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of separate proprietary vaccine components. Specifically, its product development revolves around five platforms: antigens, antibody therapeutics, adjuvants, targeted oncologics and autoimmune disease therapeutics. Consequently, the firm uses its expertise in immunology and its proprietary technology platforms to discover and develop vaccines, antigen-based products (including monoclonal antibody-based products) and novel adjuvants. Currently, the company has 16 compounds undergoing clinical trials and 22 preclinical programs, as well as 32 collaborated studies. The company’s partners include GlaxoSmithKline, Medicis, Organon, ScheringPlough and Zambon Group. Corixa’s main product, Melacine, entered the market and is designed to treat Stage IV melanoma, an aggressive malignancy that has a very high rate of mortality. The company also has several drugs in clinical trials that are being tested to treat rheumatoid arthritis, multiple sclerosis and infectious diseases such as hepatitis B, herpes virus, human papilloma virus and malaria. Recently, Corixa announced a collaboration with Genesis Research and Development Corporation, Ltd. for the development of PVAC, a treatment for psoriasis.
BRANDS/DIVISIONS/AFFILIATES: Melacine PVAC Detox Coulter Pharmaceutical
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Steven Gillis, CEO David Fanning, COO/Sr. VP Michelle Burris, Sr. VP/CFO Bernie Paul, VP-Human Resources Steven Reed, Exec. VP/Chief Scientific Officer William Derrick, VP/CIO Kathleen McKereghan, Sr. VP/Corp. Sec. Kathleen McKereghan, General Counsel Cindy Jacobs, Sr. VP-Clinical Research Gary Christianson, VP-Tech. Oper. Kenneth Grabstein, Exec. VP/Dir.-Immunology Monica Krieger, VP-Regulatory Affairs Steven Gillis, Chmn.
Phone: 206-754-5711 Fax: 206-754-5715 Toll-Free: Address: 1124 Columbia St., Ste. 200, Seattle, WA 98104 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $48,700 (12 months) 2002 Profits: $-207,400 (12 months) Stock Ticker: CRXA 2001 Sales: $58,100 2001 Profits: $148,000 Employees: 366 2000 Sales: $37,000 2000 Profits: $-667,100 Fiscal Year Ends: 12/31 1999 Sales: $26,500 1999 Profits: $-54,800 1998 Sales: $18,300 1998 Profits: $-21,300
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $435,600 Bonus: $72,600 Stock Purch. Plan: Second Exec. Salary: $290,000 Bonus: $60,000 ADVANTAGE: Rapidly growing product line/Drugs in development that are targeted to treat a wide variety of diseases.
OTHER THOUGHTS: Apparent Women Officers or Directors: 4 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
CORNING INC
www.corning.com
Industry Group Code: 335921 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Cable-Fiber Optic Optical Switching Products Networking Devices Cathode Ray Products Semiconductor Materials LCD Products
Corning, Inc. is a global, technology-based corporation that operates in two broadly based business segments: telecommunications and technologies. The telecommunications segment produces optical fiber and cable, optical hardware and equipment, photonic modules and components and optical networking devices for the worldwide telecommunications industry. The technologies segment manufactures specialized products with unique properties for customer applications utilizing glass, glass ceramic and polymer technologies. Products include liquid crystal display (LCD) glass for flat panel displays, environmental products, life science products, glass panels and funnels for televisions and cathode ray products, semiconductor materials, optical and technical products. Corning and its subsidiaries manufacture products at approximately 96 plants in 18 countries. Longdistance providers worldwide, such as MCI and Sprint, use the company’s LEAF optical fiber to help meet the everincreasing demand for voice and data transmission. Because of high demand for this fiber, Corning recently made public plans to invest $750 million in its fiber production capacity to up output by 50%. While LEAF takes care of long-haul networks, the company uses an advanced optical fiber, MetroCor, in metropolitan telecommunications networks. The company recently announced that it expects its display technologies business to see revenue growth of 20 to 40% over the next three years, due to a dramatic increase in market penetration of LCD desktop monitors, continuing growth of laptop computers and the growing popularity of LCD televisions. The company offers its employees a retirement plan, flexible spending accounts, educational assistance, corporate-sponsored childcare and elder care assistance. A company-sponsored training program helps keep employees abreast of the market.
BRANDS/DIVISIONS/AFFILIATES: LEAF Optical Fiber Oak Industries, Inc. Quanterra, Inc. Samco Scientific Corp. IntelliSense Corp. U.S. Precision Lens, Inc. Pyrex MetroCor
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. James Houghton, CEO Wendell P. Weeks, COO James B. Flaws, CFO Pamela C. Schneider, VP-Human Resources/Diversity Officer Joseph A. Miller, Chief Tech. Officer Katherine A. Asbeck, Sr. VP/Controller A. John Peck, Jr., Sr. VP/Corp. Sec. William D. Eggers, General Counsel Kirk P. Gregg, Chief Admin. Officer Robert L. Ecklin, Exec. VP-Strategic Growth Mark S. Rogus, VP/Treas. Larry Aiello, Jr., Pres.-Int'l/CEO-Cable Systems Wendell P. Weeks, Pres.-Optical Comm. Peter Volkanis, Pres.-Tech. James Houghton, Chmn.
Phone: 607-974-9000 Fax: 607-974-8091 Toll-Free: Address: One Riverfront Plaza, Corning, NY 14831-0001 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $3,164,000 (12 months) 2002 Profits: $-1,302,000 (12 months) Stock Ticker: GLW 2001 Sales: $6,272,000 2001 Profits: $-5,498,000 Employees: 23,200 2000 Sales: $7,127,000 2000 Profits: $422,000 Fiscal Year Ends: 12/31 1999 Sales: $4,741,000 1999 Profits: $518,100 1998 Sales: $3,831,900 1998 Profits: $435,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: The leading name in optical fibers.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Top Exec. Salary: $850,000 Second Exec. Salary: $575,000
Bonus: $1,598,255 Bonus: $1,027,195
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
COVALENT GROUP INC
www.covalentgroup.com
Industry Group Code: 541710 Ranks within this company's industry group: Sales:16 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:5
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Management-Drug and Medical Device Clinical Trials Trial Management Software
Covalent Group, Inc. is a total research management organization that designs and manages clinical trials in the drug and medical device development process. It also designs and manages associated cost containment and quality-of-care components. The company specializes in Phase I through IV clinical trials, cost effectiveness studies and outcomes studies for major customer groups such as pharmaceutical companies, managed care organizations, insurers and employers. It offers a full array of integrated services, including study design, clinical trial monitoring and management, data management, biostatistical analysis and regulatory affairs services. Covalent is structured to deliver customized high-quality solutions to its Fortune 500 and other clients. To aid its pharmaceutical and managed care customers in clinical trials and outcomes research projects, Covalent has also developed several proprietary products utilizing interactive speech recognition technology. They include TeleTrial, a clinical trial management system, and Virtual HouseCall, a disease assessment system. Covalent recently signed several clinical consulting contracts with top pharmaceutical companies. The contracts cover a wide range of therapeutic areas including oncology, neurology, gastroenterology, cardiovascular diseases, vaccines and infectious diseases. These agreements reflect Covalent's ongoing strategy of leveraging its consultative services to further research management and development programs. By partnering early in the development process with pharmaceutical companies, the company is able to proactively optimize the design and conduct of clinical trials. Covalent's consultative approach to clinical development benefits its clients by focusing on innovative results-oriented solutions and integrating these solutions with operational expertise and experience.
BRANDS/DIVISIONS/AFFILIATES: TeleTrial Virtual HouseCall
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Kenneth M. Borrow, CEO Brian Dickson, COO Jorge A. Leon, CFO Mary Ann Flafinski, VP-Human Resources David Weitz, VP/CIO Brian Dickson, Chief Medical Officer David Weitz, Corp. Sec. David Weitz, Treas.
Phone: 610-975-9533 Fax: 610-975-9556 Toll-Free: Address: 1275 Drummers Ln., Ste. 100, Wayne, PA 19087 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $24,700 (12 months) 2002 Profits: $2,500 (12 months) Stock Ticker: CVGR 2001 Sales: $18,400 2001 Profits: $2,000 Employees: 158 2000 Sales: $12,027 2000 Profits: $1,000 Fiscal Year Ends: 12/31 1999 Sales: $14,700 1999 Profits: $1,400 1998 Sales: $9,400 1998 Profits: $- 900
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $261,458 Stock Purch. Plan: Second Exec. Salary: $199,000 ADVANTAGE: Significant new contracts for research services.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $55,000 Bonus: $15,000
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
COVANCE INC
www.covance.com
Industry Group Code: 541710 Ranks within this company's industry group: Sales:2 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y Y Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:2
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Research and Development-Drug Preclinical/Clinical Trials Laboratory Testing and Analysis
Covance, Inc. is a leading drug development services company providing a wide range of product development services to pharmaceutical, biotechnology and medical device industries. The company also offers health economics and outcomes services for managed care organizations, hospitals and other health care providers and laboratory testing services to the chemical, agrochemical and food industries. Covance's early development services include preclinical and Phase I clinical service capabilities, and late-stage development services include clinical development, clinical support and commercialization services. Covance has also introduced several Internet-based products. Study Tracker is an Internet-based client access product which permits customers of toxicology services to review study data and schedules on a near real-time basis. LabLink is a client access program that allows customers of central laboratory services to review and query lab data on a near real-time basis. Trial Tracker is a web-enabled clinical trial project management and tracking tool intended to allow both employees and customers of its late-stage clinical business to review and manage all aspects of clinical trial projects. Digitography in the company’s central diagnostics business allows on-screen digital ECG waveform measurement with resolution unmatched in the industry. In recent news, Covance announced it will include flow cytometry services within its North American safety assessment services. The addition of flow cytometry will enhance the evaluation of a new drug’s immunotoxic potential. Covance offers its employees medical, dental and vision coverage, tuition reimbursement and alternative work schedules. The dress code is business-casual.
BRANDS/DIVISIONS/AFFILIATES: Study Tracker LabLink Trial Tracker Covance Clinical Research Unit, Inc. Covance Pharmaceutical Packaging Services, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Christopher A. Kuebler, CEO Christopher A. Kuebler, Pres. William Klitgaard, Sr. VP/CFO Raul Valentine, Dir.-Human Resources Jeffrey S. Hurwitz, Corp. Sec. Jeffrey S. Hurwitz, General Counsel Beth Leahy, VP-Comm. Beth Leahy, VP-Investor Rel. Joseph L. Herring, Pres.-Early Dev. Services F. John Mills, Pres.-Clinical Support Services Alan Horgan, Pres.-Clinical Dev. Services Christopher A. Kuebler, Chmn.
Phone: 609-452-4440 Fax: 609-452-9375 Toll-Free: 800-773-0011 Address: 210 Carnegie Ctr., Princeton, NJ 08540-6233 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $924,700 (12 months) 2002 Profits: $63,800 (12 months) Stock Ticker: CVD 2001 Sales: $855,900 2001 Profits: $47,900 Employees: 6,900 2000 Sales: $868,087 2000 Profits: $15,236 Fiscal Year Ends: 12/31 1999 Sales: $829,980 1999 Profits: $45,818 1998 Sales: $731,574 1998 Profits: $48,608
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $528,091 Bonus: $447,738 Stock Purch. Plan: Y Second Exec. Salary: $327,992 Bonus: $356,657 ADVANTAGE: Provides turnkey services that assist drug companies in bringing new drugs to market/Offices in 17 countries.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
CR BARD INC
www.crbard.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:12 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:11
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Equipment-Urological Catheters Diagnostic and Interventional Products
C.R. Bard, Inc. is engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The company holds strong market positions in vascular, urological, oncological and surgical diagnostic and interventional products. C.R. Bard’s line of minimally invasive vascular products includes peripheral angioplasty stents, catheters, guidewires, introducers and accessories, vena cava filters and biopsy devices; electrophysiology products including cardiac mapping and electrophysiology laboratory systems and diagnostic and temporary pacing electrode catheters; fabrics and meshes and implantable blood vessel replacements. Its surgical specialties products include meshes for vessel and hernia repair; irrigation devices for orthopaedic, laparoscopic and gynecological procedures; and products for topical hemostasis. These products include the PerFix plug, Composix sheet, HydroFlex MultiApplication Irrigation Pump System, Avitene and Avifoam. The company also offers account management, supply chain and business enhancement services. C.R. Bard markets its products through 22 subsidiaries and a joint venture in 92 countries outside the United States. Principal markets are Japan, Canada, the United Kingdom and continental Europe. In recent news, the company acquired the assets of Genyx Medical, Inc., a privately held medical device company that develops, manufactures and markets Uryxr, a proprietary injectable bulking agent for the treatment of stress urinary incontinence. C.R. Bard offers employment with an emphasis on engineering and research, with a recent move into Internet technologies. The company offers its employees health and retirement plans, along with international youth exchanges and scholarships for children of employees.
BRANDS/DIVISIONS/AFFILIATES: Bard Access Systems Bard Devices, Inc. Bard Medical Systems PerFix Composix HydroFlex Uryxr Genyx Medical, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Timothy M. Ring, CEO John H. Weiland, Group Pres. Todd C. Schermerhorn, CFO/Sr. VP Bronwen K. Kelly, VP-Human Resources Vincent J. Gurnari, Jr., VP-IT Charles P. Grom, VP/Controller James R. Adwers, VP-Medical Affairs Nadia J. Bernstein, Corp. Sec. Nadia J. Bernstein, General Counsel Joseph A. Cherry, VP-Oper. Robert L. Mellen, VP-Strategic Planning and Bus. Dev. Eric J. Shick, VP-Investor Rel. Todd C. Schermerhorn, VP/Treas. Timothy M. Ring, Group Pres. Christopher D. Gasner, VP-Quality Assurance Susan Alpert, VP-Regulatory Sciences Timothy M. Ring, Chmn.
Phone: 908-277-8000 Fax: 908-277-8240 Toll-Free: 800-367-2273 Address: 730 Central Ave., Murray Hill, NJ 07974 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,273,800 (12 months) 2002 Profits: $155,000 (12 months) Stock Ticker: BCR 2001 Sales: $1,181,300 2001 Profits: $143,200 Employees: 7,700 2000 Sales: $1,098,800 2000 Profits: $106,900 Fiscal Year Ends: 12/31 1999 Sales: $1,036,500 1999 Profits: $118,100 1998 Sales: $1,164,700 1998 Profits: $252,300
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $925,000 Bonus: $1,179,029 Stock Purch. Plan: Second Exec. Salary: $412,500 Bonus: $353,769 ADVANTAGE: Holds strong positions in vascular, urological and oncological diagnosis and intervention products.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
CUBIC CORP
www.cubic.com
Industry Group Code: 335999 Ranks within this company's industry group: Sales:9 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:5
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
Y
GROWTH PLANS/SPECIAL FEATURES:
Automated Ticketing Systems Manufacturing Instrumented Training Systems for National Defense Packaging and Shipping Containers
Cubic Corp. and its subsidiaries and divisions design, develop, manufacture and install products utilized within the military defense and mass transit networks. The company operates through its two major divisions: transportation systems and the defense group. Military defense products include equipment for use in customized military range instrumentation, training and applications systems, communications and surveillance systems, HF and VHF/UHF surveillance receivers, transceivers and avionics systems. Services provided by the defense segment include computer simulation training, distributed interactive simulation, development of military training doctrine and field operations and maintenance. The transportation systems segment designs, produces, installs and services electronic revenue collection systems for mass transit projects, including railways and buses, and is the leader in this industry worldwide. Transit products include contactless smart cards, passenger gates, central computer systems and ticket vending machines. The cities of New York, Washington, D.C., San Francisco, Chicago, London, Singapore, Los Angeles, San Diego, Shanghai and Guangzhou, China and Sydney, Australia have implemented the company’s revenue collection systems. Cubic Corp. also manufactures replacement parts for its products. In addition, it operates a corrugated paper converting facility through its Consolidated Converting Company subsidiary. In recent news, the company introduced the Cubic Driver Control Unit to the European market. This processing platform creates an interface for driver log-on, smart card collection and management of bus equipment.
BRANDS/DIVISIONS/AFFILIATES: Cubic Transportation Systems, Inc. Cubic Defense Systems, Inc. Consolidated Converting Co. Cubic Applications, Inc. Scanpoint Technology Nextfare Web Services Cubic Driver Control Unit
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Walter J. Zable, CEO Walter J. Zable, Pres. William W. Boyle, CFO/VP-Finance Bernard A. Kulchin, VP-Human Resources Thomas A. Baz, VP/Corp. Controller Kenneth A. Kopf, VP/General Counsel John D. Thomas, VP/Treas. Walter C. Zable, Pres., Cubic Transportation Systems Richard M. Lober, CEO/Pres., Cubic Communications, Inc. Jack A. Walter, CEO/Pres., Cubic Applications Walter J. Zable, Chmn.
Phone: 858-277-6780 Fax: 858-277-1878 Toll-Free: Address: 9333 Balboa Ave., San Diego, CA 92123 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $559,600 (12 months) 2002 Profits: $29,400 (12 months) Stock Ticker: CUB 2001 Sales: $501,700 2001 Profits: $20,800 Employees: 4,500 2000 Sales: $531,516 2000 Profits: $674,000 Fiscal Year Ends: 9/30 1999 Sales: $510,800 1999 Profits: $14,000 1998 Sales: $414,100 1998 Profits: $ 900
SALARIES/BENEFITS: Pension Plan: Y Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $550,000 Stock Purch. Plan: Second Exec. Salary: $365,000 ADVANTAGE: Excellent proprietary technology in smart cards and ticketing systems.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $202,244 Bonus: $115,043
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
CUBIST PHARMACEUTICALS
www.cubist.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:101 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:81
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Infectious Disease
Cubist Pharmaceuticals, Inc. is focused on the research, development and commercialization of novel antimicrobial drugs to combat serious and life-threatening bacterial and fungal infections. The firm is currently conducting multiple Phase III trials for Cidecin, its lead product candidate and the first in a new class of antimicrobial drugs called lipopeptides. Because Cidecin attacks bacteria through a novel mechanism and has demonstrated the unique ability in vitro to rapidly kill virtually all clinically significant grampositive bacteria, it may be particularly effective in treating infections caused by drug-resistant bacteria that cannot be eradicated by existing antibiotics. In addition, its oncedaily dosing regimen is optimally safe and effective, as well as more convenient and cost-effective than multiple daily doses. Cubist is also developing an oral formulation of the antibiotic ceftriaxone, which has only been available in intravenous form, marketed under the brand name Rocephin. The company is also developing, through a research agreement with Emisphere Technologies, an oral formulation of daptomycin, a member of the lipopeptide class. Cubist also generates revenues through the licensing of its VITA functional genomics technology. Other patented assets and technologies include the NatChem family of compound extracts from a collection of rare fungi; NatGen technologies, a set of advanced genetic tools that enable the cloning of large fragments of DNA; and Directed Biosynthesis, a tool for the genetic modification of metabolic pathways. In recent news, the company announced that it received a patent for oncedaily Cidecin. In addition, Cubist and Gilead Sciences announced the termination of their European marketing agreement for Cidecin. Cubist reacquired all rights to the product. Cubist offers its employees benefits including medical plans, tuition reimbursement, flexible spending accounts, on-site massage therapy and subsidized parking and public transportation.
BRANDS/DIVISIONS/AFFILIATES: Cidecin Rocephin TerraGen Discovery, Inc. VITA Technology NatGen NatChem Directed Biosynthesis
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Scott M. Rocklage, CEO Michael W. Bonney, COO Michael W. Bonney, Pres. Thomas A. Shea, VP-Finance/CFO Francis P. Tally, Exec. VP-Scientific Affairs Robert J. McCormack, Sr. VP-Drug Dev. Robert J. Janosky, VP-Mfg. Christopher D.T. Guiffre, Corp. Sec. Christopher D.T. Guiffre, General Counsel Thomas A. Shea, VP-Admin. Oliver S. Fetzer, Sr. VP-Bus. Dev. David W.J. McGirr, Treas. Thomas J. Slater, VP-Commercial Dev. Dennis D. Keith, VP-Chemistry Dev. Frederick B. Oleson, Jr., VP-Pre-Clinical Dev. Julian E. Davies, Exec. VP-Tech. Dev.
Phone: 781-860-8660 Fax: 781-861-0566 Toll-Free: Address: 65 Hayden Ave., Lexington, MA 02421 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $11,500 (12 months) 2002 Profits: $-82,400 (12 months) Stock Ticker: CBST 2001 Sales: $14,400 2001 Profits: $-69,900 Employees: 204 2000 Sales: $5,200 2000 Profits: $-44,300 Fiscal Year Ends: 12/31 1999 Sales: $6,800 1999 Profits: $-24,100 1998 Sales: $1,700 1998 Profits: $-14,400
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Focus on lipopeptides.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $375,000 Second Exec. Salary: $263,000
Bonus: $245,313 Bonus: $40,502
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
CURAGEN CORPORATION
www.curagen.com
Industry Group Code: 541710 Ranks within this company's industry group: Sales:18 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:17
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Bio-Pharmaceuticals Genomics Technology Genetic Coding and Expressions Bioinformatics
CuraGen is a genomics-based drug discovery and development company that researches, develops and uses technologies based on the discovery of genes and an understanding of their functions and relationships. The company works independently to accelerate the discovery and development of products to improve human and animal health and the vitality of agriculture. It has established internal programs to develop products to treat metabolic diseases, cancer, inflammatory diseases and central nervous system (CNS) disorders. Specifically, its genomics technology and information systems platform, known as GeneScape, has four primary systems: SeqCalling, for gene sequencing and discovery of variations in gene sequences; GeneCalling, a patented technology for gene discovery; PathCalling, for analyzing the function and relationship among genes; and SNPCalling, to identify and characterize human genetic variations. CuraGen markets such genomic technologies and information to pharmaceutical, biotechnology, agricultural and animal health companies through research collaborations. The firm currently has strategic alliances with Abgenix, Inc., Biogen, Inc., COR Therapeutics, Inc., Genentech, Inc., GlaxoSmithKline, Inc., Sequenom, Inc., Roche Vitamins, Inc. and Pioneer HiBred International, Inc. In recent news, CuraGen’s product CG53135 has been clinically shown to stimulate cell growth, reduce tissue inflammation and degeneration and minimize the severity of damage associated with intestinal inflammation. Benefit plans for qualified employees consist of extensive insurance (including pet insurance) plans and perks designed to lure well-educated high-tech employees. Employees also enjoy wireless cell phone, day care and Avis corporate discounts.
BRANDS/DIVISIONS/AFFILIATES: GeneScape GeneCalling PathCalling SeqCalling SNPCalling CG53135 HSB Group, Inc. Women's Health U.S.A., Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Johnathan M. Rothberg, CEO Johnathan M. Rothberg, Pres. David M. Wurzer, Exec. VP/CFO Donna Starzecki, Dir.-Human Resources Timothy Shannon, Sr. VP-Research and Dev./Chief Medical Officer John E. Murphy, CIO/VP Bruce E. Taillon, Group Leader-Eng. Elizabeth A. Whayland, Corp. Sec. Thomas F. McCaffery, III, General Counsel/VP Steven Henck, Dir.-Oper. Hovan Asdourian, Sr. VP-Bus. Dev. Mark R. Vincent, Dir.-Corp. Comm. Mark R. Vincent, Dir.-Investor Rel. David M. Wurzer, Treas. Richard H. Booth, CEO, HSB Group, Inc. Robert E. Patricelli, CEO/Pres., Women's Health U.S.A., Inc. Michael P. McKenna, VP-Collaborative Research Elizabeth A. Whayland, Dir.-Financial Mgmt. Johnathan M. Rothberg, Chmn.
Phone: 203-401-3330 Fax: 203-401-3333 Toll-Free: Address: 555 Long Wharf Dr., 11th Fl., New Haven, CT 06511 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $18,200 (12 months) 2002 Profits: $-90,400 (12 months) Stock Ticker: CRGN 2001 Sales: $23,500 2001 Profits: $42,900 Employees: 403 2000 Sales: $20,838 2000 Profits: $-26,978 Fiscal Year Ends: 12/31 1999 Sales: $15,104 1999 Profits: $-25,763 1998 Sales: $9,257 1998 Profits: $-18,937
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $334,387 Stock Purch. Plan: Second Exec. Salary: $235,594 ADVANTAGE: Excellent genomics technology/Strong research alliances.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $112,500 Bonus: $75,000
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
CYPRESS SEMICONDUCTOR CORP
www.cypress.com
Industry Group Code: 334413 Ranks within this company's industry group: Sales:13 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Profits:10
Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Integrated Circuits-Non-Memory Microelectromechanical Systems Technology
Cypress Semiconductor Corporation provides highperformance integrated circuit solutions to rapidly growing markets such as data communications, telecommunications, computation, consumer products and industrial control. The company aims to become the preferred silicon supplier for Internet switching systems. The firm has an agreement with Eureka Technology that allows access to Eureka intellectual property in support of the Cypress Delta39K family of complex programmable logic devices (CPLDs). The Eureka intellectual property cores targeted to Cypress CPLDs are optimized for use in the company’s Warp design tool. Warp is a design solution that integrates graphic captures, simulation, synthesis and management, replacing the traditional multivendor, multi-tool approach to programmable logic device design. Moreover, the firm licenses and implements LaserLink Technology’s innovative Make-Link process in order to increase manufacturing yields and lower production costs. Unlike deletive techniques, Make-Link’s additive connections can reduce the number of operations required to implement logic circuits, and the links can be made to carry greater currents with no resistance penalty. Silicon Light Machines, a subsidiary of the firm, is a private supplier of microelectromechanical systems technology applicable to fiber-optic networks and other applications. The Silicon Light Machines acquisition was part of a series of moves by Cypress to provide comprehensive solutions for next-generation WAN applications, including highspeed switches and routers and storage and backplane solutions. In recent news, Cypress and Honeywell International, a technology and manufacturing leader, have signed an agreement to jointly develop new technology for integrated circuits used in satellites, strategic missiles and other space vehicles. The new circuits will process information faster and at higher capacities while withstanding the adverse radiation environment in space. Cypress offers its employees credit union membership, tuition reimbursement, a prepaid legal plan and a computer purchase plan.
BRANDS/DIVISIONS/AFFILIATES: Silicon Light Machines Warp Delta39K Silicon Magnetic Systems Cypress MicroSystems
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. T.J. Rodgers, CEO T.J. Rodgers, Pres. Emmanuel T. Hernandez, CFO/Exec. VP-Finance Ralph Schmitt, VP-Mktg. and Sales Ilhan Refioglu, VP-Timing Tech. Mark Ross, Chief Tech. Officer Steve Whelan, VP-Wireless Infrastructure/Terminal Div. Chris Seams, VP-Worldwide Wafer Mfg. Emmanuel T. Hernandez, Exec. VP-Admin. Paul Keswick, VP-New Product Dev. Antonio R. Alvarez, Sr. VP-Memory Products Wayne Cantu, VP-Quality Systems Dan Morris, VP-WAN and Storage Network Div. Jeff Kaszubinski, CEO, Silicon Magnetic Systems Eric A. Benhamou, Chmn.
Phone: 408-943-2600 Fax: 408-943-6841 Toll-Free: Address: 3901 N. 1st St., San Jose, CA 95134-1599 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $774,700 (12 months) 2002 Profits: $-37,000 (12 months) Stock Ticker: CY 2001 Sales: $819,200 2001 Profits: $-407,500 Employees: 4,101 2000 Sales: $1,287,800 2000 Profits: $277,300 Fiscal Year Ends: 12/31 1999 Sales: $705,487 1999 Profits: $91,054 1998 Sales: $554,891 1998 Profits: $-104,918
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Provides integrated circuit solutions.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $364,000 Second Exec. Salary: $371,785
Bonus: $42,293 Bonus: $25,882
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
CYTOGEN CORPORATION
www.cytogen.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:100 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:61
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Cancer Protein Pathway Database
Cytogen Corp. is a biopharmaceutical company with a mission to set new standards in cancer care. Its principal lines of business focus on prostate cancer and oncology. Both are built upon the company's expertise in antibodies and molecular recognition, which are directed to the development of novel products for the diagnosis, imaging, staging and treatment of cancer. The firm has established a pipeline of product candidates based on its proprietary antibody and prostate specific membrane antigen (PSMA) technologies. FDA-approved products include ProstaScint, a monoclonal antibody-based imaging agent used to image the extent and spread of prostate cancer; BrachySeed, a uniquely designed, next-generation radioactive seed implant for the treatment of localized prostate cancer; Quadramet, a therapeutic agent marketed for the relief of bone pain in prostate and other types of cancer; and OncoScint CR/OV, a diagnostic imaging agent for colorectal and ovarian cancer. Cytogen is involved in strategic alliances with Progenics Pharmaceuticals, Inc., The Dow Company, Memorial Sloan-Kettering Cancer Center, Molecular Staging, Inc., Elan Corp. and Draxis Health, Inc. Recently, Cytogen and Advanced Magnetics, Inc. announced studies in the use of Combidex in detecting lymph node disease in breast cancer patients. In other news, the company announced it has entered into a five-year agreement with Matritech, Inc. Under this agreement, Cytogen will be the sole U.S. distributor for Matritech’s NMP2 BladderCheck test. Cytogen offers its employees tuition assistance, flexible spending accounts and stock options.
BRANDS/DIVISIONS/AFFILIATES: ProstaScint BrachySeed Quadramet OncoScint PSMA Technology
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. H. Joseph Reiser, CEO H. Joseph Reiser, Pres. Lawrence R. Hoffman, CFO/VP Deborah A. Kaminsky, VP-Sales and Mktg. William F. Goeckeler, VP-Research and Dev. Michael D. Becker, VP-Investor Rel. James A. Grigsby, Chmn.
Phone: 609-750-8200 Fax: 609-750-8124 Toll-Free: Address: 600 College Rd. E, Princeton, NJ 08540 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $12,900 (12 months) 2002 Profits: $-15,700 (12 months) Stock Ticker: CYTOD 2001 Sales: $11,700 2001 Profits: $-12,100 Employees: 49 2000 Sales: $10,500 2000 Profits: $-27,300 Fiscal Year Ends: 12/31 1999 Sales: $11,200 1999 Profits: $ 700 1998 Sales: $19,900 1998 Profits: $-13,200
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $314,423 Stock Purch. Plan: Second Exec. Salary: $219,423 ADVANTAGE: Expertise in antibodies and molecular recognition.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $100,000 Bonus: $45,311
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
CYTYC CORP
www.cytyc.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:42 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:30
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Diagnostics Sample Preparation Systems for Medical Testing
Cytyc Corporation designs, develops, manufactures and markets sample preparation systems for medical diagnostic applications, primarily focused on women’s health. The company’s ThinPrep System is an innovative method for the automated preparation of cervical cell specimens on microscopic slides for use in cervical cancer screening, as well as non-gynecological testing applications. The ThinPrep System includes the ThinPrep 2000 Processor; the ThinPrep 3000 Processor, which is the firm’s advanced automated sample processor; and the ThinPrep Pap Test, which aims to replace the conventional Pap smear for cervical cancer screening. The company believes that the ThinPrep System improves accuracy in the detection of cervical cancer and precancerous lesions by making the slide more representative of the patient’s clinical condition, improving preservations of the sample, standardizing the presentation of cells on the slide and reducing the presence of obstructing debris. Cytyc Health Corporation, a subsidiary of the firm, is primarily focusing on the launch of FirstCyte Ductal Lavage, the company’s proprietary technology to aid in breast cancer risk assessment. FirstCyte Ductal Lavage, which Cytyc intends to market as the ThinPrep Breast Test, was a product of Pro Duct Health, Inc., a company that Cytyc acquired and merged with Cytyc Health Corporation. In recent news, Cytyc and Digene Corporation have terminated their merger agreement. The company offers its employees several benefits, including health, dental, vision and life coverage plans; tuition reimbursements; flexible spending accounts; and employee assistance programs.
BRANDS/DIVISIONS/AFFILIATES: ThinPrep System Cytyc Health Corporation FirstCyte Ductal Lavage ThinPrep Pap Test ThinPrep 2000 Processor ThinPrep 3000 Processor ThinPrep Imaging System Pro Duct Health, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Patrick J. Sullivan, CEO Patrick J. Sullivan, Pres. Robert L. Bowen, CFO/VP A. Suzanne Meszner-Eltrich, VP-Human Resources James Linder, Chief Medical Officer A. Suzanne Meszner-Eltrich, Sec. A. Suzanne Meszner-Eltrich, General Counsel Christopher A. Bleck, VP-Commercial Oper. Robert L. Bowen, Treas. Daniel J. Levangie, Pres./CEO, Cytyc Health Corporation Ellen E. Sheets, VP-Clinical Affairs
Phone: 978-263-8000 Fax: 978-635-1033 Toll-Free: 800-442-9892 Address: 85 Swanson Rd., Boxborough, MA 01719 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $236,500 (12 months) 2002 Profits: $47,900 (12 months) Stock Ticker: CYTC 2001 Sales: $221,000 2001 Profits: $12,600 Employees: 626 2000 Sales: $142,100 2000 Profits: $38,200 Fiscal Year Ends: 12/31 1999 Sales: $81,100 1999 Profits: $5,600 1998 Sales: $44,300 1998 Profits: $-11,700
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $375,000 Stock Purch. Plan: Y Second Exec. Salary: $250,000 ADVANTAGE: Can extend its technology into additional markets.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $599,989 Bonus: $350,005
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
DADE BEHRING INC
www.dadebehring.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:11 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Equipment/Supplies-Diagnostic and Testing Instruments Clinical Chemistry Instrument Systems Hemostasis Instrument Systems Cardiac Diagnostic Systems Drug Testing Therapeutic Drug Monitoring
Dade Behring, Inc. is one of the largest suppliers of in-vitro diagnostics (IVD) products and services to clinical laboratories in the United States and the third-largest IVD supplier to clinical laboratories in the world. Of the total estimated $21-billion global IVD market, the company serves two-thirds of the industry, including IVD instruments, reagents, consumables, service and data management systems targeted primarily at clinical laboratories and near-patient testing. Within the firm’s served markets, Dade has leadership positions in six of the seven core product markets, including routine chemistry/immunoassay, cardiac, hemostasis, plasma protein, microbiology, infectious disease diagnostics and drugs of abuse testing/therapeutic drug monitoring (DAT/TDM). IVD tests are conducted primarily in clinical laboratories, which include primarily hospital-based laboratories and reference laboratories. Dade’s customer base consists of approximately 25,000 customers worldwide and provides products and services to over 90% of U.S. hospital-based clinical laboratories as well as the majority of reference laboratories worldwide. The company manufactures and markets a broad offering of IVD products and services, including instruments (approximately 13% of sales), reagents and consumables (approximately 83% of sales) and services (approximately 4% of sales). Dade's business within the U.S. represents more than half of the company’s total sales. Dade recently announced an agreement with Shriners Hospitals for Children that makes the company the exclusive provider of chemistry, hemostasis and microbiology medical diagnostics for Shriners’ 22 pediatric hospitals. Additionally, the company introduced the Protis software solution. Protis is designed to handle the interpretation and consolidation of multiple test results in laboratories, streamlining the flow of data.
BRANDS/DIVISIONS/AFFILIATES: Behring Diagnostics Dade MicroScan, Inc. Dade Diagnostics Dade Finance, Inc. Aventis Bain Capital Goldman Sachs Protis Software
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. James Reid-Anderson, CEO Stephen W. Barnes, COO James Reid-Anderson, Pres. John Duffey, CFO Robert Maple, Sr. VP-Human Resources Susan A. Evans, VP-Research Robert A. Boghosian, CIO Nelson Chai, VP-Bus. Dev. Robert W. Brightfelt, Pres.-Global Products Hiroshi Uchida, Pres.-Asia Donal M. Quinn, Pres.-Europe, Middle East and Africa Marc N. Casper, Pres.-Americas James Reid-Anderson, Chmn.
Phone: 847-267-5300 Fax: 847-267-1066 Toll-Free: Address: 1717 Deerfield Rd., Deerfield, IL 60015-0778 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,281,500 (12 months) 2002 Profits: $ (12 months) Stock Ticker: Private 2001 Sales: $1,235,000 2001 Profits: $ Employees: 6,000 2000 Sales: $1,184,000 2000 Profits: $ Fiscal Year Ends: 12/31 1999 Sales: $1,309,200 1999 Profits: $ 1998 Sales: $1,285,200 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $749,260 Stock Purch. Plan: Second Exec. Salary: $412,224 ADVANTAGE: A global leader in IVD products and services.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $1,567,559 Bonus: $662,133
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
DAIMLERCHRYSLER AG
www.daimlerchrysler.com
Industry Group Code: 336111 Ranks within this company's industry group: Sales:3 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Profits:1
Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Automobile Manufacturer Financial Services Commercial Vehicles, Trucks and Buses Insurance Brokerage Real Estate Management Telecommunications
DaimlerChrysler designs, manufactures, assembles and sells passenger cars and commercial vehicles under multiple brand names, including Chrysler, Mercedes Benz, Dodge, Eagle, Jeep and Plymouth. It also provides financial and other services relating to the automotive value-added chain. The company also owns a 10% interest in Hyundai and a 37% stake in Mitsubishi Motors Corp. DaimlerChrysler is parent to The DaimlerChrysler Group, which has five business segments: Mercedes Benz passenger cars and Smart; the Chrysler group; commercial vehicles; services; and other activities. The DaimlerChrysler Group is active primarily in Europe, the United States, Canada and Mexico. Through its alliances with Mitsubishi Motors Corp. and Hyundai Motor Company, it expects to increase its presence in the Asian market. It is also a leading commercial vehicle manufacturer in South America. Mercedes Benz passenger cars are world-renowned for their innovative technology, highest levels of comfort, quality and safety and pioneering design. The Smart is a micro-compact passenger car designed to respond to the challenges of urban mobility and optimum use of resources. DaimlerChrysler is developing a high-end luxury limousine under the brand name Maybach. The firm has also introduced a new micro-compact car, the Smart City Coupe, a diesel version of the Smart. DaimlerChrysler plans to expand the Smart product line by adding a twoseat roadster model and a coupe derivative in 2003 and, beginning in 2004, a four-door model. Mitsubishi Motors plans to offer a vehicle under its own brand name using the same platform and major components of the Smart.
BRANDS/DIVISIONS/AFFILIATES: Dodge Eagle Jeep Plymouth Chrysler Mercedes Benz Hyundai Mitsubishi Motors Corp.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Wolfgang Bernhard, COO, Chrysler Corp. Dieter Zetsche, CEO-Chrysler Manfred Gentz, Finance Joe Eberhardt, Exec. VP-Global Mktg., Chrysler Günther Fleig, Human Resources Thomas Weber, Research and Tech. Manfred Gentz, Controlling Manfred Bischoff, Aerospace and Industrial Non-Automotive Rüdiger Grube, Corp. Dev. Michael Muehlbayer, Treas. Juergen Hubbert, Mercedes Car Group Dieter Zetsche, Chrysler Group Thomas W. Sidlik, Procurement and Supply, Chrysler Group Kim Schroer, Group Exec. VP-Global Mktg. Juergen E. Schrempp, Chmn. Gary C. Valade, Global Procurement and Supply
Phone: 49-711-17-95277 Fax: 49-711-17-94075 Toll-Free: Address: Epplestrasse 225, Stuttgart, 70546 Germany
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $156,838,000 (12 months) 2002 Profits: $4,947,000 (12 months) Stock Ticker: DCX 2001 Sales: $136,256,000 2001 Profits: $-590,000 Employees: 365,571 2000 Sales: $152,446,000 2000 Profits: $7,411,000 Fiscal Year Ends: 12/31 1999 Sales: $151,035,000 1999 Profits: $5,785,000 1998 Sales: $154,615,000 1998 Profits: $5,656,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Bonus: $ Stock Purch. Plan: Second Exec. Salary: $ Bonus: $ Merger of Daimler Benz and Chrysler created an automobile industry giant with global brands. ADVANTAGE:
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
DEL LABORATORIES INC
www.dellabs.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:40 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:37
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Over-the-Counter Drugs Cosmetics
Del Laboratories, Inc. manufactures, markets and distributes cosmetics and proprietary over-the-counter pharmaceuticals. The company’s principal cosmetics products are nail care, nail color, color cosmetics, beauty implements, bleaches and depilatories, personal care and other related cosmetic items. The firm’s cosmetics products are marketed under brand names such as Sally Hansen Hard as Nails and Sally Hansen Professional Nail (nail care and nail color products); CornSilk (face makeup); Naturistics (color cosmetics and bath and body care); LaCross (beauty implements); and New York Color (color cosmetics). The company’s pharmaceutical products include oral analgesics, acne treatment products, first aid products and eye/ear medications. Its pharmaceutical products are marketed under such brand names as Orajel and Tanac (oral analgesics); Propa pH (acne treatment); Pronto (pediculicides); Arthricare (topical arthritis treatment); Stye (ophthalmic ointment); and Auro-Dri (ear remedy). Del Laboratories’ products are sold principally in the United States and Canada to wholesalers, independent and chain drug stores, mass merchandisers and food stores. The company seeks to increase sales by aggressively marketing its products under established brand names. The firm’s customers include Walgreens, Rite Aid, CVS and Eckerd, major drug store chains; WalMart and Target, major national chain mass merchandisers; and numerous regional chain drug stores and mass merchandisers. Del Laboratories distributes its pharmaceutical products to drug wholesalers, including McKesson Drug and Bergen Brunswig, and national food chains, including Kroger and Safeway. Wal-Mart accounts for approximately 25% of sales. The company’s products are sold in a limited number of foreign countries. Del Laboratories encourages employee advancement through company-paid professional and technical skills seminars. The company also offers a tuition reimbursement program.
BRANDS/DIVISIONS/AFFILIATES: Sally Hansen Orajel Hard as Nails Naturistics Auto-Dri Pronto Propa pH Del Pharmaceuticals, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Dan K. Wassong, CEO Dan K. Wassong, Pres. Enzo J. Vialardi, CFO/Exec. VP Harvey P. Alstodt, Exec. VP-Sales, Cosmetics Div., North America Patrick Lloyd, Human Resources Thomas Redder, CIO Timothy A. Hogan Jr., VP-Oper. Charles J. Hinkaty, VP/Pres., Del Pharmaceuticals, Inc. William McMenemy, Exec. VP-Mktg., Cosmetics Div., North America Dan K. Wassong, Chmn.
Phone: 516-844-2020 Fax: 631-293-1515 Toll-Free: Address: 178 EAB Plaza, Uniondale, NY 11556 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $350,700 (12 months) 2002 Profits: $19,500 (12 months) Stock Ticker: DLI 2001 Sales: $332,700 2001 Profits: $9,800 Employees: 1,800 2000 Sales: $294,883 2000 Profits: $4,717 Fiscal Year Ends: 12/31 1999 Sales: $265,056 1999 Profits: $-4,000 1998 Sales: $273,511 1998 Profits: $11,100
SALARIES/BENEFITS: Pension Plan: Y Savings Plan:
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $805,478 Stock Purch. Plan: Second Exec. Salary: $376,250 ADVANTAGE: The company is significantly expanding distribution efforts.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $1,932,000 Bonus: $450,000
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
DELL COMPUTER CORPORATION
www.dell.com
Industry Group Code: 334111 Ranks within this company's industry group: Sales:3 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:2
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Computer Hardware-PCs, Manufacturing Printers Server Host Retail Computer Kiosks Network Switches Storage Devices
Dell Computer Corporation, the number one computer systems supplier worldwide, supplies personal computers (PCs) to companies, government agencies, educational institutions and individual consumers. The company provides telephone and Internet sales, customized computer systems, system installation and management, guided technology transitions, online and phone technical support, and next-day on-site product service. Dell offers extensive lines of network switches, retail computer kiosks, storage devices, printers and server hosting. The Dell line of high-performance computer systems includes Dimension and OptiPlex desktop computers, Latitude and Inspiron notebook computers, PowerEdge servers, PowerApp server appliances, Dell Precision workstation products and PowerVault storage products. DellHost is Dell's integrated Web hosting service. The company’s innovative online selling strategy makes it one of the most successful e-commerce firms. Its inventory management system is legendary. Dell recently released the OptiPlex GX270 and SX270 desktops, the company’s first computer systems to include the U.S. Environmental Protection Agency’s ENERGY STAR designation in the default configuration. Dell also released a single-processor workstation, the Dell Precision Workstation 360, that offers improved front-side bus and memory bandwidth, an Intel 875P chipset featuring Performance Acceleration Technology and the option of a mini-tower chassis or new desktop chassis with high-end graphics support and added expandability. In other news, Dell and Good Technology, Inc. have formed a strategic alliance to collaborate on handheld devices and services that are both wireless e-mail and data accessible and affordable. Dell provides employees with dental and vision insurance, family and medical leave, an employee referral program, adoption assistance and a fitness center.
BRANDS/DIVISIONS/AFFILIATES: OptiPlex SX270 OptiPlex GX270 Inspiron PowerApp DellHost Good Technology, Inc. Dimension Dell Precision Workstation 360
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Michael S. Dell, CEO Kevin B. Rollins, COO Kevin B. Rollins, Pres. James M. Schneider, Sr. VP/CFO Michael A. George, Chief Mktg. Officer Paul D. McKinnon, VP-Human Resources Randall D. Mott, Sr. VP/CIO Thomas B. Green, Sr. VP-Sec. Thomas B. Green, Sr. VP-Law Thomas P. Green, Sr. VP-Admin. Michael A. George, VP-eBusiness Elizabeth Heller Allen, VP-Corp. Comm. Lynn A.Tyson, VP-Investor Rel. Thurmond B. Woodard, VP-Global Diversity Lawrence A. Pentland, VP-Americas Int'l William J. Amelio, Sr. VP/Pres., Asia-Pacific/Japan Paul D. Bell, Sr. VP/Pres., Europe, Middle East and Africa Michael S. Dell, Chmn. Charles H. Saunders, Sr. VP-Dell Intl. Services Martin J. Garvin, Sr. VP-Worldwide Procurement
Phone: 512-338-4400 Fax: 512-728-3653 Toll-Free: 800-289-3355 Address: One Dell Way, Round Rock, TX 78682 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $31,168,000 (12 months) 2002 Profits: $1,246,000 (12 months) Stock Ticker: DELL 2001 Sales: $31,188,000 2001 Profits: $2,177,000 Employees: 34,600 2000 Sales: $25,265,000 2000 Profits: $1,666,000 Fiscal Year Ends: 1/31 1999 Sales: $18,243,000 1999 Profits: $1,460,000 1998 Sales: $12,327,000 1998 Profits: $944,000
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $925,962 Bonus: $347,236 Stock Purch. Plan: Y Second Exec. Salary: $721,154 Bonus: $243,389 The number one PC maker in the world/Custom-tailored web sites enable large customers to configure ADVANTAGE: and order new computers and obtain negotiated discount pricing while online.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
DENSO CORPORATION
www.globaldenso.com
Industry Group Code: 336390 Ranks within this company's industry group: Sales:3 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Profits:2
Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Automobile Parts Manufacturer Air Conditioning and Heating Systems Radiators Antilock Brake System Electronics Fuel Systems
DENSO Corp., based in Japan, is a leading global automotive parts manufacturer, producing components for most of the world's major carmakers. The firm's subsidiaries are located in the United States, Canada, Mexico, Brazil, Argentina, the Netherlands, the United Kingdom, Germany, Spain, Italy, France, Hungary, Sweden, Belgium, Poland, Portugal, Turkey, Australia, Singapore, Thailand, Indonesia, India and China, among others. Products include air conditioning and heating systems, starters and alternators, spark plugs, radiators, antilock brake systems, electronics, filters and fuel systems. Toyota Motor, the firm's former parent company, now owns about 25% of DENSO. In recent news, DENSO invested in a new sales and manufacturing company in Turkey, DENSO Automotive Parts Industry, Inc., to sell starters and alternator products, as well as produce thermal products. The company also recently announced that it developed, with Toyota, the world's first air conditioner using natural refrigerant, carbon dioxide, to be launched in Toyota's fuel cell hybrid vehicle. In addition, DENSO acquired a minority share in Doowon Climate Control Co., Ltd. of Korea, enabling the firm to establish a climate control business in the country.
BRANDS/DIVISIONS/AFFILIATES: DENSO International America, Inc. Techma U.S.A., Inc. ASMO Manufacturing, Inc. Actis Manufacturing, Ltd. DENSO Wireless Systems America, Inc. Michigan Automotive Compressor, Inc. DENSO Sales California, Inc. Toyota Motor
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Hiromu Okabe, CEO Hiromu Okabe, Pres. Akira Takahashi, Chmn.
Phone: 81-566-25-5594 Fax: 81-566-25-4509 Toll-Free: Address: 1-1 Showa-cho, Kariya, Aichi, 448-8661 Japan
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $18,102,000 (12 months) 2002 Profits: $545,000 (12 months) Stock Ticker: Foreign 2001 Sales: $15,950,600 2001 Profits: $481,300 Employees: 86,600 2000 Sales: $17,850,900 2000 Profits: $586,800 Fiscal Year Ends: 3/31 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Bonus: $ Stock Purch. Plan: Second Exec. Salary: $ Bonus: $ ADVANTAGE: One of the world's largest automotive components makers/Relationship with Toyota.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
DEPUY INC
www.depuy.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales: Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Equipment/Supplies-Orthopedic Devices Fixative Products
DePuy, Inc., a subsidiary of Johnson & Johnson, is a leading designer, manufacturer and distributor of orthopedic devices and supplies. Its products are used primarily by orthopedic medical specialists and, in the case of the company's spinal implants, spinal specialists and neurosurgeons. The products are used in both surgical and non-surgical therapies to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, trauma and sports-related injuries. The company operates through five subsidiaries. DePuy Orthopaedics develops products for hip and extremity implants, knee implants, environmental protection products and other surgical equipment. It recently launched AllAboutArthritis.com, an Internet source for educational information on arthritis and its treatment. The DePuy ACE subsidiary produces orthopedic trauma products. DePuy AcroMed develops spinal products, including the MOSS Miami System, ISOLA Rod, Screw and Hook System, VSP plates and screws and Bremer Air-Flo Halo External Stabilization System. Codman and Shurtleff, Inc. treats central nervous system disorders through its hydrocephalic shunt valve systems, neuro endoscopes and spinal fixation implant products. DePuy Casting manufactures and distributes products to manage bone fractures. DePuy International is based in England and represents the company’s interests abroad. In recent news, DePuy AcroMed acquired Link Spine Group, Inc., a privately owned corporation located in Branford, Connecticut. The acquisition provides the subsidiary with exclusive worldwide rights to the SB Charite Artificial Disc, the principal product of Link Spine Group. The artificial disc is approved and marketed in over 30 countries outside the U.S. DePuy AcroMed plans to submit a premarket approval application to the FDA for the product.
BRANDS/DIVISIONS/AFFILIATES: Johnson & Johnson DePuy ACE DePuy Casting DePuy AcroMed Codman and Shurtleff, Inc. DePuy Orthopaedics DePuy International Link Spine Group, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Kevin K. Sidow, Worldwide Pres. Michael J. Dormer, Chmn.
Phone: 574-267-8143 Fax: 574-267-7196 Toll-Free: 800-473-3789 Address: 700 Orthopaedic Dr., Warsaw, IN 46581-0988 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $ 2001 Profits: $ Employees: 2000 Sales: $ 2000 Profits: $ Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Y Second Exec. Salary: $ ADVANTAGE: Broad product selection/Merger with Johnson & Johnson.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
DIEBOLD INC
www.diebold.com
Industry Group Code: 334111 Ranks within this company's industry group: Sales:7 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:3
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Hardware-Automated Teller Machines Self-Service Terminals
Diebold, Inc. is engaged in the manufacture, sale, installation and service of automated self-service transaction systems, electronic and physical security products, software and integrated systems. The firm's North America segment sells financial and retail systems and services financial, retail and medical systems in the United States and Canada. The international segment sells and services financial and retail systems worldwide. Diebold is one of the largest providers of ATMs and ATM software. The company also designs card-based systems for colleges and universities around the world, used to provide identification, pay fees, purchase books and meals, withdraw money and access buildings and events. Professional and technical services include strategic analysis and planning of new systems, system integration, architectural engineering, consulting, remote monitoring and troubleshooting. The firm is also involved in maintenance and repair, with over 400 service centers in North America alone. Diebold's security systems include drive-up pharmacy solutions, alarm and monitoring systems, vaults, doors, safes, deposit boxes, locks, bulletresistant barriers and modular counter equipment. The company also offers electronic security products, including digital surveillance systems. The company has acquired Sersi Italia, a company specializing in multivendor customer service and closed-circuit television monitoring of automated teller machines (ATMs) for banks and post offices throughout Italy, and Global Election Systems, Inc. (GES), now known as Diebold Election Systems, Inc. (DESI), a manufacturer and supplier of electronic voting terminals and solutions. In recent news, the company introduced a new automated teller machine, Opteva. Opteva provides enhanced software solutions, services and technology to financial institutions. Diebold offers its employees continuous development and education programs.
BRANDS/DIVISIONS/AFFILIATES: AccuVote Express Delivery XT Diebold Election Systems, Inc. RemoteTeller Agilis Power MicroBranch Mosler, Inc. Sersi Italia Opteva
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Walden W. O'Dell, CEO Walden W. O'Dell, Pres. Gregory T. Geswein, Sr. VP/CFO Thomas W. Swidarski, VP-Global Mktg. Charles B. Scheurer, VP-Corp. Human Resources Kevin J. Krakora, VP/Controller Charee Francis-Vogelsang, VP/Corp. Sec. Warren W. Dettinger, VP/General Counsel Thomas W. Swidarski, VP-Strategic Dev. Donald E. Eagon, Jr., VP-Global Comm. Donald E. Eagon, Jr., VP-Investor Rel. Robert J. Warren, VP/Treas. Anthony J. Rusciano, VP-Nat'l Accounts Dennis B. Moriarty, VP-Customer Bus. Solutions David Bucci, Sr. VP-Customer Solutions Walden W. O'Dell, Chmn. Michael J. Hillock, Pres.-Diebold Int'l Larry D. Ingram, VP-Procurement and Services
Phone: 330-490-4000 Fax: 330-490-3794 Toll-Free: 800-999-3600 Address: 5995 Mayfair Rd., North Canton, OH 44720-8077 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,940,200 (12 months) 2002 Profits: $99,200 (12 months) Stock Ticker: DBD 2001 Sales: $1,760,300 2001 Profits: $66,900 Employees: 13,072 2000 Sales: $1,743,608 2000 Profits: $136,919 Fiscal Year Ends: 12/31 1999 Sales: $1,259,200 1999 Profits: $128,900 1998 Sales: $1,185,707 1998 Profits: $76,148
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $500,000 Stock Purch. Plan: Second Exec. Salary: $370,000 ADVANTAGE: World leader in self-service financial transaction systems.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $260,000 Bonus: $148,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
DIGENE CORPORATION
www.digene.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:33 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:36
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Supplies-DNA/RNA Tests Human Papillomavirus
Digene Corp. develops, manufactures and markets its proprietary DNA and RNA testing systems for the screening, monitoring and diagnosis of human diseases. The company uses its patented Hybrid Capture Gene Analysis System to focus on women’s cancer and infectious diseases. The firm’s lead product is the only FDA-approved test for human papillomavirus (HPV), the cause of more than 99% of cervical cancer cases. Digene is currently working to establish its HPV test as the standard for cervical cancer screening instead of the current Pap smear. Digene also developed its Hybrid Capture technology to include DNA tests for the detection of chlamydia, gonorrhea and other sexually transmitted infections. In addition, the firm operates in genomics research with the goal of applying its technology platform to develop gene expression DNA microarray products and services, expand its clinical testing services for use in the pharmaceutical market and correlate proprietary genebased information with clinical diseases. The company markets its product through a direct sales force in the U.S. and through distributors in other countries. Abott Laboratories markets and distributes all of the company’s women’s cancer and infectious diseases products and certain blood virus products in Europe, Africa and the Middle East. The FDA recently approved Digene’s PreMarket Approval Supplement application for its hc2 HighRisk HPV DNA Test, which is used with a Pap test to adjunctively screen women age 30 and older to assess the presence or absence of high-risk HPV types. The favorable decision allows the firm to market its HPV Test with the Pap test for this screening indication. In other news, the firm established new subsidiaries in Germany and Switzerland bringing the total number of European countries in which Digene now has a direct sales and marketing operational presence to 18. Digene offers its employees a health care plan; dental, vision and prescription drug coverage; life insurance; short and long-term disability insurance and tuition reimbursement.
BRANDS/DIVISIONS/AFFILIATES: Hybrid Capture Gene Analysis System Digene Europe hc2 High-Risk HPV DNA Test
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Evan Jones, CEO Charles M. Fleischman, COO Evan Jones, Pres. Charles M. Fleischman, CFO Robert McG. Lilley, Sr. VP-Global Sales and Mktg. Larry Welman, VP-Human Resources Attila T. Lorincz, Chief Scientific Officer Joseph P. Slattery, Sr. VP-Info. Systems. Joseph P. Slattery, Controller Jay Payne, VP-Eng. Belinda O. Patrick, Sr. VP-Mfg. Oper. Donna M. Seyfried, VP-Bus. Dev. Susan M. Keese, VP-Global Product Oper. Linda Alexander, VP-Women's Health
Phone: 301-944-7000 Fax: 301-944-7121 Toll-Free: 800-344-3631 Address: 1201 Clopper Rd., Gaithersburg, MD 20878 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $48,800 (12 months) 2002 Profits: $-9,400 (12 months) Stock Ticker: DIGE 2001 Sales: $34,200 2001 Profits: $-6,500 Employees: 243 2000 Sales: $23,000 2000 Profits: $-6,800 Fiscal Year Ends: 6/30 1999 Sales: $17,500 1999 Profits: $-9,300 1998 Sales: $12,000 1998 Profits: $-14,100
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $273,910 Stock Purch. Plan: Second Exec. Salary: $271,410 ADVANTAGE: Manufactures the only FDA approved test for human papillomavirus.
OTHER THOUGHTS: Apparent Women Officers or Directors: 5 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $150,000 Bonus: $60,000
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
DIVERSA CORPORATION
www.diversa.com
Industry Group Code: 541710 Ranks within this company's industry group: Sales:14 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:10
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Research-Enzyme and Biological Compound Discovery Gene Expression Libraries
Diversa Corp. is a leader in applying proprietary genomic technologies for the rapid discovery and optimization of novel products from genes and gene pathways. The firm is directing its integrated portfolio of technologies to the discovery, evolution and production of commercially valuable molecules with pharmaceutical applications, such as monoclonal antibodies and orally active drugs, as well as enzymes and small molecules with agricultural, chemical and industrial applications. The company has formed joint ventures with The Down Chemical Company (Innovase) and Syngenta Seeds (Zymetrics, Inc.). Innovase and Zymetrics are focused on the near-term commercialization of products for industrial and agricultural markets, respectively. Diversa's Gene Site Saturation Mutagenesis (GSSM) technology is a powerful mutagenesis system designed to optimize enzyme stability and binding affinity while minimizing immunogenicity. The company's complementary technology, Tunable GeneReassembly, synthesizes DNA fragments to create novel genes. Diversa uses the large collection of genetic material captured in its PathwayLibrary to accelerate the discovery of small-molecule pharmaceuticals. The firm's protein therapeutics and antibody program focuses on the application of its DirectEvolution technologies, as well as the GigaMatrix screening platform, to improve protein therapeutics and to generate novel antibodies. The company's products include Pyrolase 160 and Pyrolase 200 enzymes for oil and gas well fracturing operations and ThermalAce, a thermostable DNA polymerase. Recently launched products include feed and food additives, enzymes for baking and malting, flavor and fragrance ingredients and enzymes for peptide synthesis. In other news, Diversa licensed a product for improved enzymatic synthesis of key pharmaceutical intermediates to the pharmaceutical division of Dow. Diversa offers its employees health, dental and vision insurance, stock options, health club reimbursement and flexible spending accounts.
BRANDS/DIVISIONS/AFFILIATES: Innovase ThermalAce Zymetrics, Inc Pyrolase 160 Enzyme Pyrolase 200 Enzyme Replicase Gene Site Saturation Mutagenesis Tunable GeneReassembly
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jay M. Short, CEO Jay M. Short, Pres. Karin Eastham, CFO/Sr. VP-Finance Janice Delperdang, Dir.-Human Resources Jay M. Short, Chief Tech. Officer R. Patrick Simms, Sr. VP-Oper. William H. Baum, Exec. VP-Bus. Dev. Carolyn A. Erickson, VP-Intellectual Property
Phone: 858-526-5000 Fax: 858-526-5551 Toll-Free: Address: 4955 Directors Pl., San Diego, CA 92121-1609 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $31,700 (12 months) 2002 Profits: $-28,000 (12 months) Stock Ticker: DVSA 2001 Sales: $36,000 2001 Profits: $-15,700 Employees: 279 2000 Sales: $24,301 2000 Profits: $-8,064 Fiscal Year Ends: 12/31 1999 Sales: $10,300 1999 Profits: $-9,000 1998 Sales: $1,300 1998 Profits: $-13,500
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $320,000 Stock Purch. Plan: Second Exec. Salary: $260,000 ADVANTAGE: Innovative enzyme and gene evolution/Royalty-based research agreements.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $256,000 Bonus: $130,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
DOW CHEMICAL COMPANY (THE)
www.dow.com
Industry Group Code: 325000 Ranks within this company's industry group: Sales:3 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:12
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Y Oil/Chem. Svcs.: Gases: Other: Y
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Chemicals Manufacturer Reinsurance Plastics Olefin and Styrene Silicon
The Dow Chemical Co. is engaged in the manufacture and sale of chemicals, plastic materials, agricultural and consumer products and other specialized products and services. The company, which was the largest U.S. producer of chemicals and plastics in fiscal 2002, serves customers in 175 countries and a wide range of markets including food, transportation, health and medicine, personal and home care and building and construction, among others. Dow currently operates 191 manufacturing plants in 38 countries and supplies more than 3,400 products. The company’s agricultural science business, Dow AgroSciences LLC, is a global leader in providing pest management, agricultural and crop biotechnology products. It develops products for crop production, weed, insect and plant management and industrial and commercial pest management. The division is currently involved in building a leading plant genetics and biotechnology business in crop seeds and traits for seeds. The company recently announced it has reached a deal with General Motors Corp, the world’s largest automobile manufacturer, which will culminate in the world’s largest ever fuel cell transaction. The intent is to commercialize GM’s hydrogen fuel cell technology to generate electricity from hydrogen created as a co-product of Dow’s operations. The two companies will begin testing in late 2003 and run through 2005. If the tests are successful, Dow, whose annual research and development budget exceeds $1 billion, could use the power generated by the fuel cells for future commercial use. These first tests will be conducted at Dow’s facilities in Freeport, Texas, with similar processes to take place in other locations, pending the initial results. Dow's compensation package is regularly benchmarked against packages offered by compaines in the same geography and are consistantly ranked at the top of all employers within the same region.
BRANDS/DIVISIONS/AFFILIATES: Dow Europe Union Carbide Dow AgroSciences Dow Corning
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. William Stavropolous, CEO William Stavropolous, Pres. J. Pedro Reinhard, CFO Lawrence J. Washington, Jr., Corp. VP-Human Resources Richard M. Gross, VP-Research & Dev. David E. Kepler, CIO Frank H. Brod, Controller Tina S. Van Dam, Corp. Sec. Richard L. Manetta, General Counsel A. A. Allemang, Exec. VP-Oper. David E. Kepler, VP-Electronic Bus. and Commerce Lawrence J. Washington, Jr., VP-Public Affairs Fernando Ruiz, Treas. Lawrence J. Washington, Jr., Corp. VP-Environment/Health & Safety Kathleen M. Bader, Corp. VP-Quality and Bus. Excellence A. Charles Fischer, Pres./CEO-Dow AgroSciences L. Respini, Pres.-Dow Europe
Phone: 989-636-1000 Fax: 989-636-1830 Toll-Free: 800-422-8193 Address: 2030 Dow Center, Midland, MI 48674 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $27,609,000 (12 months) 2002 Profits: $-338,000 (12 months) Stock Ticker: DOW 2001 Sales: $27,805,000 2001 Profits: $-385,000 Employees: 49,959 2000 Sales: $23,008,000 2000 Profits: $1,513,000 Fiscal Year Ends: 12/31 1999 Sales: $19,989,000 1999 Profits: $1,326,000 1998 Sales: $19,442,000 1998 Profits: $1,304,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan:
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $1,839,996 Stock Purch. Plan: Y Second Exec. Salary: $1,014,200 ADVANTAGE: Significant financial resources/Massive R&D budget.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $930,000 Bonus: $650,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
DUALSTAR TECHNOLOGIES CORPORATION www.dualstar.com Industry Group Code: 230000 Ranks within this company's industry group: Sales:4 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Y Y Y
Profits:3
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y Y
GROWTH PLANS/SPECIAL FEATURES:
Building and Energy Management Direct Broadcast Satellite Services Electrical Systems Supply and Installation Heating, Ventillation and Air-Conditioning Systems Information Technology Infastructure
Through its subsidiaries, DualStar Technologies Corp. designs and installs infrastructure systems and provides services that control and enhance building environments. The firm operates through the two business areas of communications and construction. The company’s communications subsidiary, DualStar Communications, Inc., provides enhanced local, regional and long-distance telephony, direct broadcast satellite, cable television and high-speed Internet access. On the construction side, subsidiary High-Rise designs and installs electrical systems for newly constructed commercial and residential buildings. Centrifugal/Mechanical Associates conducts mechanical contracting services such as heating, ventilation and air conditioning. Integrated Controls Enterprises supplies, installs and services energy management, commercial temperature control systems, facility management and building automation systems. Another subsidiary, BMS Electric, installs and maintains low-voltage electrical systems in the areas of building management systems and control, as well as fire and security systems. Property Control, Inc. manages DualStar’s fixed asset and peripheral office needs. DualStar’s production facilities fabricate and manufacture mechanical and electrical systems and subsystems, and, where necessary, purchase components, assemblies and services from outside manufacturers and distributors. As part of a restructuring plan, the firm recently sold its cable television subsidiary ParaComm, Inc. to Madeleine, LLC. The firm also discontinued its telephone business in New York City and sold certain communication assets in the Los Angeles area.
BRANDS/DIVISIONS/AFFILIATES: Integrated Controls Enterprises, Inc. Centrifugal/Mechanical Associates, Inc. DualStar Communications, Inc. Property Control, Inc. High-Rise Electric, Inc. HR Electrical Systems, Inc. BMS Electric
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Gregory Cuneo, CEO Gregory Cuneo, Pres. Robert J. Birnbach, CFO Linda Rillotta, VP-Human Resources Robert J. Birnbach, Corp. Sec. Ronald Fregara, Pres., Centrifugal/Mechanical Associates Vincent D'Onofrio, Pres., OnTera Barry Halpern, Pres., High-Rise
Phone: 718-340-6655 Fax: 718-340-6695 Toll-Free: Address: 11-30 47th Ave., Long Island City, NY 11101 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $81,200 (12 months) 2002 Profits: $-9,600 (12 months) Stock Ticker: DSTR 2001 Sales: $83,218 2001 Profits: $-15,713 Employees: 316 2000 Sales: $87,285 2000 Profits: $-8,651 Fiscal Year Ends: 6/30 1999 Sales: $92,650 1999 Profits: $1,322 1998 Sales: $94,280 1998 Profits: $ 556
SALARIES/BENEFITS: Pension Plan: Y Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $275,000 Stock Purch. Plan: Second Exec. Salary: $260,000 ADVANTAGE: A focused provider of building services/ New focus on telecommunications.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $251,065 Bonus: $33,333
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
E I DU PONT DE NEMOURS & CO (DUPONT) www.dupont.com Industry Group Code: 325000 Ranks within this company's industry group: Sales:4 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:13
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Y Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Chemical Manufacturing Textiles Nutrition and Health Products Electronics Agricultural Seeds Including Genetically-Modified Seeds Fuel Cell Technology
E. I. du Pont de Nemours and Company (DuPont) is the second largest chemical manufacturer in the United States, with operations in approximately 75 countries. Dupont produces chemicals and treatments for an extensive number of industries including aerospace, agriculture, electronics, polymers, textiles, nutrition and transportation, with products such as Teflon, Lycra, Stainmaster, Antron, Dacron, Kevlar, Corian, Mylar and its newest line, Sorona. The company is segmented into five business platforms: Agriculture and Nutrition; Electronic and Communication Technologies; Performance Materials; Coatings and Color Technologies; and Safety and Protection. In recent news, the company announced plans to form a new subsidiary, DuPont Textiles and Interiors. More recently, the firm expanded its agriculture and nutrition businesses through an alliance with Bunge Limited. The resulting joint venture, called Solae LLC, will focus on the global production and distribution of food ingredients such as soy proteins and lecithins. The firm also has major efforts in fuel cell technology. DuPont invests more than $1.5 billion yearly in research and development. DuPont offers its employees family leave options, counseling on topics including parenting, continuing education and career planning, dependent care spending accounts and flexible work schedules.
BRANDS/DIVISIONS/AFFILIATES: Teflon Lycra Stainmaster Sorona Dacron Kevlar Corian Mylar
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Charles Holliday, CEO Richard R. Goodmanson, Exec. VP/COO Gary M. Pfeiffer, Sr. VP/CFO Dennis Zeleny, Sr. VP-Global Human Resources Thomas M. Connelly, Sr. VP-Science and Tech. Stacey J. Mobley, Sr. VP/General Counsel W. Donald Johnson, Group VP-Oper. and Svcs. John W. Himes, Sr. VP-Corp. Strategy Edward J. Donnelly, Group VP-DuPont Coatings Diane H. Gulyas, Group VP-DuPont Electronic and Comm. Tech. John C. Hodgson, Exec. VP Ellen J. Kullman, Group VP-DuPont Safety & Protection Charles Holliday, Chmn.
Phone: 302-774-1000 Fax: 302-774-7321 Toll-Free: Address: 1007 Market St., Wilmington, DE 19898 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $24,006,000 (12 months) 2002 Profits: $-1,103,000 (12 months) Stock Ticker: DD 2001 Sales: $24,726,000 2001 Profits: $4,339,000 Employees: 79,000 2000 Sales: $28,268,000 2000 Profits: $2,314,000 Fiscal Year Ends: 12/31 1999 Sales: $26,918,000 1999 Profits: $7,690,000 1998 Sales: $24,767,000 1998 Profits: $4,480,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $1,085,000 Bonus: $ Stock Purch. Plan: Second Exec. Salary: $640,000 Bonus: $ ADVANTAGE: The second largest chemical manufacturer in the U.S./One of the top 20 U.S. firms in research and development.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
EASTMAN KODAK CO
www.kodak.com
Industry Group Code: 333314 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Y Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Photography Equipment-Professional Films and Photographic Papers Cameras Digital Imaging Products Infoimaging Medical Imaging Products
Eastman Kodak Company (Kodak) is engaged primarily in developing, manufacturing and marketing traditional and digital imaging products, services and solutions for consumers, professionals, health care providers, the entertainment industry and other commercial customers. Kodak is a major participant in infoimaging, a $225-billion industry composed of devices (digital cameras and PDAs), infrastructure (online networks and delivery systems) and services and media (software, film and paper). The company harnesses technology, market reach and a host of industry partnerships to provide innovative products and services for customers who need the information-rich content that images contain. The firm's photography segment includes traditional and digital product offerings for consumer, advanced amateur and professional markets, including films, photographic papers, processing services, chemicals and cameras. In 2001, this division acquired Ofoto, Inc., accelerating its growth in the online photography market. The health imaging segment offers products used to capture, store, process, print and display images and information in a variety of forms for customers in the health care industry, for both primary and referral diagnoses. These products include medical films, chemicals, processing equipment and digital medical imaging systems and solutions. The commercial imaging segment provides imaging solutions for markets such as banking and insurance and state, local and federal government applications. Products include industrial films, micrographics peripherals, large-format printers and electro-optical systems. Other operations of the company include the components group, the imaging sensor solutions business and an optics business. Recently, Kodak completed its acquisition of Burrell Colour, Inc. and its affiliates, including Burrell Professional Labs. The company offers its employees health care benefits including a health care reimbursement account, life insurance, financial planning, flexible scheduling, a cash balance retirement plan and domestic partner benefits.
BRANDS/DIVISIONS/AFFILIATES: Eastman Gelatine Corp. Ofoto, Inc. NexPress Burrell Colour, Inc. Burrell Professional Labs Advantix EasyShare KODAK GOLD
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Daniel A. Carp, CEO Antonio M. Perez, COO/Pres. Robert H. Brust, Exec. VP/CFO Larry Morgan, VP/Dir.-Worldwide Mktg. Robert L. Berman, VP-Human Resources James C. Stoffel, Chief Tech. Officer/Sr. VP-Research and Dev. Mark V. Gulling, VP/CIO Robert P. Rozek, Controller Yosuke Kojima, VP-Digital Cameras Dan Kerpelman, Pres.-Health Imaging Alain Popelard, VP-Global Mfg. and Logistics Gary P. Van Graafeiland, Sr. VP/General Counsel Philip V. Tatusko, VP-Global Oper. and Commercial Imaging David G. Monderer, VP-Corp. Bus. Dev. Robert L. LaPerle, VP-Kodak.com Sandra E. Taylor, VP/Dir.-Public Rel. Essie L. Calhoun, VP-Comm. Rel. and Corp. Contributions William G. Love, Treas. Karen A. Smith-Pilkington, Pres.-Kodak Professional Services Michael P. Morley, Exec. VP/Chief Admin. Officer Richard S. Morabito, Chief Purchasing Officer
Phone: 716-724-4000 Fax: 716-724-0663 Toll-Free: Address: 343 State St., Rochester, NY 14650 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $12,853,000 (12 months) 2002 Profits: $770,000 (12 months) Stock Ticker: EK 2001 Sales: $13,234,000 2001 Profits: $76,000 Employees: 70,000 2000 Sales: $13,994,000 2000 Profits: $1,407,000 Fiscal Year Ends: 12/31 1999 Sales: $14,089,000 1999 Profits: $1,392,000 1998 Sales: $13,406,000 1998 Profits: $1,390,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $1,000,000 Stock Purch. Plan: Second Exec. Salary: $667,984 ADVANTAGE: A worldwide provider of imaging products.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $507,500 Bonus: $176,400
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
EDWARDS LIFESCIENCES CORP
www.edwards.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:20 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:19
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Supplies-Cardiovascular Disease Related Cardiac Surgery Products
Edwards Lifesciences is an international leader in providing products and services for patients with cardiovascular disease. The firm designs products for four main cardiovascular diseases: heart valve disease, coronary artery disease, peripheral vascular disease and congestive heart failure. Its products and technologies are categorized into four main areas: cardiac surgery, critical care, vascular and perfusion. Products in the cardiac surgery category include tissue heart valves and repair products manufactured under several private labels, including Carpentier-Edwards and Cosgrove-Edwards. The company’s critical care line of products includes hemodynamic monitoring devices, which are used for measuring heart pressure and output during surgery, under the Swan-Ganz brand name. Edwards additionally markets a range of products required to perform hemofiltration, such as access catheters, filters and solutions. The critical care line also consists of central venous catheters, including the firm’s Advanced Venous Access, AVA HF and AVA 3Xi devices. Vascular products include balloon-tipped, catheter-based products, surgical clips and inserts. Edwards developed the Lifepath AAA endovascular graft system to treat potentially lifethreatening abdominal aortic aneurysms. The company has sold its U.S. perfusion services operation to Fresenuis Medical Care A.G., although it still maintains a small perfusion services operation in Europe. The firm’s products and services are supplied throughout the world via direct sales and distributor relationships with several companies, including Baxter International. In recent news, Edwards has acquired various assets of Embol-X, a medical technology company. This acquisition includes Embol’s surgically placed, intra-aortic embolic management system, designed to prevent blood clots or tissue fragments from traveling through the blood stream during cardiac surgery. The company offers its employees medical, dental, life and vision insurance; health care reimbursement plans; dependent care reimbursement plans; and employee assistance programs. Benefits vary by country location.
BRANDS/DIVISIONS/AFFILIATES: Carpentier-Edwards Cosgrove-Edwards Swan-Ganz Lifepath AAA Fogarty XenoLogiX Advanced Venous Access AVA 3Xi
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Michael A. Mussaliem, CEO Bruce Bentcover, CFO/Corp. VP Rob Reindl, Human Resources Stuart L. Foster, VP-Tech. and Discovery Randel W. Woodgrift, VP-Mfg. Bruce P. Garren, Sec./VP Bruce P. Garren, General Counsel John H. Kehl, Jr., VP-Corp. Strategy and Bus. Dev. Huimin Wang, VP/Pres.-Japan J. Randall Nelson, VP/Pres.-North America Andrè-Michel Ballester, VP/Pres., Europe and Intercontinental Michael A. Mussaliem, Chmn.
Phone: 949-250-2500 Fax: 949-250-2525 Toll-Free: Address: One Edwards Way, Irvine, CA 92614 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $704,000 (12 months) 2002 Profits: $55,700 (12 months) Stock Ticker: EW 2001 Sales: $692,000 2001 Profits: $-11,000 Employees: 5,000 2000 Sales: $804,000 2000 Profits: $-272,000 Fiscal Year Ends: 12/31 1999 Sales: $905,000 1999 Profits: $82,000 1998 Sales: $865,000 1998 Profits: $62,000
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $636,538 Bonus: $481,000 Stock Purch. Plan: Y Second Exec. Salary: $339,231 Bonus: $166,500 ADVANTAGE: A global leader in products and services for late stage cardiovascular disease/Worldwide distribution.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
EG&G INC
www.egginc.com
Industry Group Code: 541310 Ranks within this company's industry group: Sales:11 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:
Transportation: Aerospace: Automotive: Y Y
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y Y
GROWTH PLANS/SPECIAL FEATURES:
Engineering Services Consulting Services Facilities Operations Warehousing Services Distribution Services
EG&G, a business segment of URS Corporation, provides management and operations and maintenance capabilities in support of large military installations and operations. The company operates through two divisions, aerospace technical services and engineering and technology services. The firm is a leading provider of services in the areas of asset management, systems engineering, facilities operations and maintenance, management services, environmental and civil engineering, warehousing and distribution services, information technology and environmental and safety compliance. EG&G’s services include the management of complex government installations and ranges, including oversight of all construction, testing and operation of base systems and processes, operation and maintenance of chemical agent disposal systems, management of base logistics and transportation and support of high security environments. In recent news, the company announced it was awarded a multiyear Army Forces Command operations, planning, training and resource support services contract. EG&G will provide support services for operations planning, training services for weapon systems, troop mobilization planning and execution, antiterrorist assessment and force protection training for Army installations. The company offers its employees comprehensive benefits including educational assistance, a savings plan and an employee assistance program.
BRANDS/DIVISIONS/AFFILIATES: URS Corp.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. George R. Melton, Pres. William F. Neeb, Jr., VP-Finance David W. Wallace, VP-Mktg. Robert Rudisin, VP-Human Resources Stuart I. Young, VP/General Counsel Edward A. Katkic, VP-Plans and Programs Randall A. Wotring, VP/Mgr.-Eng. and Tech. Services Frank A. Visted, VP/Deputy General Mgr.-Eng. and Tech. Services Lex N. Allen, VP/Mgr.-Aerospace Tech. Services Michael J. Donnelly, VP/Deputy General Mgr.-Aerospace Tech. Services
Phone: 301-258-6554 Fax: 301-721-2202 Toll-Free: Address: 200 Orchard Ridge Dr., Ste. 100, Gaithersburg, MD 20878 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $900,000 (12 months) 2002 Profits: $ (12 months) Stock Ticker: Subsidiary 2001 Sales: $ 2001 Profits: $ Employees: 10,000 2000 Sales: $ 2000 Profits: $ Fiscal Year Ends: 10/31 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Diversified service offerings.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $ Second Exec. Salary: $
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ELAN CORP PLC
www.elan.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:17 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:103
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Neurology Drugs-Acute Care Drugs-Delivery
Elan Corporation, a leading global specialty pharmaceutical company, focuses on the discovery, development and marketing of therapeutic products and services in neurology, acute care and pain management. The firm also deals with the development and commercialization of products through the use of its extensive range of proprietary drug delivery technologies. The Irish company conducts its worldwide business through wholly owned subsidiaries incorporated in Ireland, the United States, the United Kingdom and other countries. Elan is focusing its research and development in Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, pain management and autoimmune diseases. The company uses its proprietary technologies and multidisciplinary expertise to develop, market and license drug delivery products to its pharmaceutical clients. Elan scientists discovered of the use of the compound AN1792, also known as AIP-001, an immunotherapeutic agent that is under development in collaboration with Wyeth for the treatment of Alzheimer's disease. The firm also collaborates with Pharmacia to develop beta secratese inhibitors for the treatment of Alzheimer's disease. In addition, the firm, in collaboration with Biogen, Inc., has under development certain neurologic, autoimmune and pain products including a humanized monoclonal antibody, Antegren (natalizumab), for use in multiple sclerosis and Crohn’s disease. Its core pipeline is comprised of four products: Antegren (for acute and chronic multiple sclerosis and Crohn’s disease) in Phase III, Prialt (for severe chronic pain) in Phase III, Zonegran (for migraine and mania) in Phase II and ELN-154088 (for pain) to begin Phase II trials soon. In August 2002, the company was under scrutiny for its accounting practices and debt load. In response, it announced plans to cut its workforce by 20% and take other steps to cut costs and improve its outlook. As part of this effort, it recently completed the sale of its United States, Canadian and any Japanese rights to Abelcet (injectible amphotericin B lipid formulation), and certain related assets to Enzon, Inc.
BRANDS/DIVISIONS/AFFILIATES: AN-1792 AIP-001 Antegren Biogen, Inc. Prialt Wyeth Pharmacia Zonegran
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Donal J. Geaney, CEO Shane Cooke, CFO/Exec. VP. Campbell Fitch, VP-Human Resources Ivan Leiberburg, Chief Scientific and Medical Officer William Daniel, Controller Lisabeth F. Murphy, Exec. VP-Legal Affairs, Intellectual Property Paul Breen, VP-Oper. Seamus C. Mulligan, Exec. VP-Bus. and Corp. Dev. Arthur Falk, VP-Corp. Compliance Lars Ekman, Pres. Research & Dev. Mary Pendergast, Executive VP, Govt. Affairs Garo Armen, Chmn.
Phone: 353-1-709-4000 Fax: 353-1-662-4949 Toll-Free: 866-347-3185 Address: Lincoln House, Lincoln Place, Dublin, 2 Ireland
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,470,100 (12 months) 2002 Profits: $-2,394,800 (12 months) Stock Ticker: ELN 2001 Sales: $1,512,900 2001 Profits: $-887,200 Employees: 4,500 2000 Sales: $1,302,000 2000 Profits: $-294,500 Fiscal Year Ends: 12/31 1999 Sales: $1,007,800 1999 Profits: $303,400 1998 Sales: $676,700 1998 Profits: $-1,190,700
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Extensive list of important partnerships and marketing or research agreements.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ELECTRONIC ARTS INC
www.ea.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:9 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:10
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Software-Video Games Online Interactive Games
Electronic Arts (EA) operates globally in two principal business segments. Its core business segment is the creation, marketing and distribution of entertainment software. This software has been developed for 42 different hardware platforms to date, including Sony PlayStation and PlayStation 2; Nintendo 64, Nintendo GameCube and Nintendo Game Boy; and Microsoft Xbox. The firm distributes more than 90 proprietary titles in North America as well as localized versions of these titles around the world. EA also distributes a number of copublished titles and titles developed by affiliated labels. In 2002, 16 of the company's titles sold over 1 million units. The company's designers regularly work with celebrities and organizations in sports, entertainment and other areas to develop realistic, interactive gaming products. EA has contracts with FIFA, NASCAR, PGA TOUR, Tiger Woods, Warner Bros. and the NFL, among others. The firm's second business segment is EA.com, its online and ecommerce division. EA.com develops, publishes and distributes online interactive games, with operations including subscription revenues collected for play on its web sites, web site advertising, sales of packaged goods for Internet-only games and sales of EA games sold through the firm's web store. Online games include Ultima Online and Motor City Online. The division also generates revenues through the AOL Games Channel. EA recently consolidated the assets and operations of EA.com into its core operations, in an attempt to increase efficiency and directly integrate EA's online activities into the company's core console and PC business. The firm also restructured its operations by consolidating its Los Angeles, Irvine and Las Vegas studios into a major game development studio in Los Angeles. EA now has major centralized studio operations in Canada, California, Orlando, Florida, Tokyo, Japan and the U.K. Electronic Arts provides employees with benefits including dental and vision coverage, on-site fitness facilities and no enforced dress code. In addition, the company offers adoption assistance, video game certificates, service awards and a company store.
BRANDS/DIVISIONS/AFFILIATES: EA.com Pogo Corp. Kesmai Corp. Ultima Online Ultima Renaissance Motor City Online Sim City Medal of Honor
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Lawrence F. Probst, CEO John S. Riccitiello, COO John S. Riccitiello, Pres. Warren Jenson, CFO J. Russell Rueff, Jr., Sr. VP-Human Resources Ruth A. Kennedy, Sr. VP/Corp. Sec. Ruth A. Kennedy, General Counsel Warren Jenson, Chief Admin. Officer Erick Hachenburg, Mgr.-EA.com Don A. Mattrick, Pres.-Worldwide Studios Paul Lee, COO-EA Worldwide Studios Nancy L. Smith, Exec. VP-North American Publishing David L. Carbone, Sr. VP-Finance Lawrence F. Probst, Chmn.
Phone: 650-628-1500 Fax: 650-628-1414 Toll-Free: Address: 209 Redwood Shores Pkwy., Redwood City, CA 94065 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,724,700 (12 months) 2002 Profits: $101,500 (12 months) Stock Ticker: ERTS 2001 Sales: $1,322,300 2001 Profits: $-11,100 Employees: 3,500 2000 Sales: $1,420,011 2000 Profits: $116,751 Fiscal Year Ends: 3/31 1999 Sales: $1,221,863 1999 Profits: $72,872 1998 Sales: $908,852 1998 Profits: $72,562
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $611,023 Stock Purch. Plan: Second Exec. Salary: $510,728 ADVANTAGE: Growing list of entertainment titles for game platforms/Strong commitment to R&D.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $985,000 Bonus: $590,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ELECTRONIC DATA SYSTEMS CORP Industry Group Code: 541512 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
www.eds.com Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y Y
GROWTH PLANS/SPECIAL FEATURES:
Consulting-Independent Systems Systems Development Process Management Outsourcing Systems Integration
Electronic Data Systems Corporation (EDS) is a world leader in applying information technology. EDS offers its clients a range of services, including the management of computers, networks, information systems, information processing facilities, business operations and related personnel, providing advantages in cost-effectiveness, speed of implementation and state-of-the-art technology. EDS generally performs one or more of five basic functions: management consulting services, creation of information technology systems, assembly of information technology platforms, management of information technology operations and management of business operations. A.T. Kearney, one of the largest high-value consulting firms in the world, is the firm’s management consulting unit. The subsidiary has expertise in all major industries and offers a full spectrum of services, including strategy and organization, operations, technology solutions and executive search. EDS also offers a full range of Internet-related services to assist clients with participation in electronic markets. It serves more than 9,000 accounts in 55 countries, in addition to managing over 46,000 servers worldwide. In addition, the firm introduced the Intelligent Network Foundation, a nextgeneration network that provides management and infrastructure support to wireless and conventional platforms. This enables the convergence of voice, video and data systems into a single transparent network. EDS recently announced a seven-year contract with Aon Corporation’s human resources outsourcing group. Under the agreement, EDS will engineer and implement systems architecture to provide a world-class human computing environment and other information technology support for Aon. EDS believes in promotion from within. The company, which has its own employee wellness division called Lifekey, offers flexible scheduling. Job sharing and fourday work weeks are also available. Additional benefits include tuition assistance and adoption assistance.
BRANDS/DIVISIONS/AFFILIATES: eBreviate Intelligent Network Foundation A.T. Kearney PLM Solutions
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Michael H. Jordan, CEO Jeffrey M. Heller, COO Jeffrey M. Heller, Pres. James E. Daley, Exec. VP/CFO Donald R. Uzzi, Sr. VP-Mktg., Comm. and Advertising Troy W. Todd, Exec. VP-Human Resources Terry Milholland, Chief Tech. Officer Douglas L. Frederick, VP-Info. Solutions Richard O. King, VP-Mfg. D. Gilbert Friedlander, Corp. Sec. D. Gilbert Friedlander, General Counsel Bob Segert, VP-Strategy John W. McCain, Pres.-e-Solutions Reza Jafari, VP-Corp. Comm. Myrna B. Vance, VP-Investor Rel. Scott Krenz, Treas. Kim McMann, Pres.-Bus. Process Mgmt. Tina M. Sivinski, Pres.-Energy Global Industries
Phone: 972-604-6000 Fax: 972-605-6033 Toll-Free: 800-566-9337 Address: 5400 Legacy Dr., Plano, TX 75024 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $21,502,000 (12 months) 2002 Profits: $1,116,000 (12 months) Stock Ticker: EDS 2001 Sales: $21,543,000 2001 Profits: $1,363,000 Employees: 137,000 2000 Sales: $19,226,800 2000 Profits: $1,143,300 Fiscal Year Ends: 12/31 1999 Sales: $18,731,300 1999 Profits: $420,900 1998 Sales: $16,891,000 1998 Profits: $743,400
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Excellent customer base.
OTHER THOUGHTS: Apparent Women Officers or Directors: 4 Hot Spot for Advancement for Women/Minorities: Y
Top Exec. Salary: $1,500,000 Second Exec. Salary: $737,036
Bonus: $7,000,000 Bonus: $1,621,185
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ELECTRONICS FOR IMAGING INC
www.efi.com
Industry Group Code: 334110 Ranks within this company's industry group: Sales:6 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:2
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Networking Equipment-Print Quality Applications and System Software
Electronics for Imaging, Inc. (EFI) develops color servers that enable low-volume, or short production run, color printing in an office environment and applications and system software that facilitates color correction and device-independent color management. The company continues to focus on its Fiery and Splash color servers and the development of new models designed to expand the market that these products serve. These servers are sophisticated computers that enable digital color copier machines to accept, process and print digital color images from personal computers and computer networks. The company’s efforts are expanding to include the development of new Fiery products to support printing on a wide range of devices, including additional digital color copiers, desktop color laser printers, wide-format color inkjet printers and digital black-and-white copiers. In addition to its servers, EFI has developed innovative technologies like eBeam, which can capture handwritten notes and images from any standard whiteboard and display them on a PC or Mac computer, and PrintMe, which gives customers the ability to print their e-mail messages from any printer or fax machine. EFI recently introduced PrintMe Enterprises, a corporate solution that lets any employee of a company print to any printer in their organization using a laptop or e-mail capable mobile device. In addition, EFI acquired Best GmbH, a global software company that provides proofing products for the print and publishing markets. This acquisition strengthens EFI's position in the graphic arts and workflow software markets. EFI has an on-site fitness facility at its California offices and offers gym membership reimbursement for employees at other locations. In addition, the company hosts a lunch every Friday, open to all employees, where awards are given to outstanding employees, new hires are introduced and executives discuss product development.
BRANDS/DIVISIONS/AFFILIATES: Fiery EfiColor ColorWise eBeam PowerBand PrintMe Best GmbH Splash
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Guy Gecht, CEO Fred Rosenzweig, COO Fred Rosenzweig, Pres. Joseph Cutts, CFO Maureen Dunphy, Dir.-Mktg., Europe Joseph Cutts, Corp. Sec. Mimi Sells, Dir.-Corp. Comm. Guy Gecht, Chmn.
Phone: 650-357-3500 Fax: 650-357-3231 Toll-Free: 800-568-1917 Address: 303 Velocity Way, Foster City, CA 94404 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $350,200 (12 months) 2002 Profits: $16,000 (12 months) Stock Ticker: EFII 2001 Sales: $517,600 2001 Profits: $38,900 Employees: 927 2000 Sales: $588,400 2000 Profits: $54,400 Fiscal Year Ends: 12/31 1999 Sales: $570,752 1999 Profits: $95,283 1998 Sales: $446,999 1998 Profits: $47,821
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: A market leader in color servers.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Top Exec. Salary: $476,667 Second Exec. Salary: $458,333
Bonus: $395,271 Bonus: $344,119
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ELI LILLY & CO
www.lilly.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:11 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:9
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Depression Computer-Based Prescription Drug Claims Processing Disease-Management Services Animal Health Products Vitamins Medical Communication Networks
Eli Lilly and Company develops, manufactures and sells pharmaceutical products. Through PCS Health Systems, the company provides prescription benefit management services in the U.S., employing more than 35,000 people worldwide. The company markets its medicines in 159 countries, and additionally has major research and development facilities in nine countries. Eli Lilly, which conducts clinical trials in more than 30 countries, has annual research and development expenses of over $2 billion. The firm owns Integrated Medical Systems, Inc., which develops and operates physician-focused medical communication networks. Eli Lily's Prozac is the most widely prescribed branded antidepressant worldwide. The company's products include central-nervous system agents, anti-infectives, endocrine products, an anti-ulcer agent, oncolytic agents, cardiovascular therapy products, sedatives and vitamins. Eli Lilly’s separate e-business venture, InnoCentive LLC, is a wholly owned enterprise that uses the power of the Internet to create and enhance open-source scientific research and development. Eli Lilly is building a $100 million research facility at its corporate headquarters in Indianapolis. The building, scheduled for completion in 2003, will provide laboratories for approximately 370 scientists and support personnel engaged in drug discovery. Over the next decade, the company plans to invest $1 billion in its Indianapolis operations, creating an estimated 7,500 new jobs. The company has recently been named to Fortune Magazine’s \"100 Best Companies\" list as well as Money Magazine’s \"Corporate America’s Best Benefits\" list. Additionally, according to Forbes, Eli Lilly ranks among the nation’s most admired companies both within the pharmaceutical industry and among industries in general. The company offers employees one week of vacation when they get married, as well as up to 10 weeks of paid maternity leave. The firm also has as an on-site fitness center, flexible hours or telecommuting, parenting and dependant care leaves, adoption assistance and tuition reimbursement.
BRANDS/DIVISIONS/AFFILIATES: Axid Ceclor Prozac Integrated Medical Systems, Inc. Tazidime Singapore Economic Development Board InnoCentive LLC. PCS Health Systems
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Sidney Taurel, CEO Sidney Taurel, Pres. Charles E. Golden, Exec. VP/CFO James Harper, VP-Mktg. & Sales Pedro P. Granadillo, VP-Human Resources Steven Paul, Exec. VP-Science & Tech. W. Roy Dunbar, CIO Scott Canute, VP-Mfg. Robert A. Armitage, General Counsel Gerhard Mayr, VP-Pharmaceutical Oper. John C. Lechleiter, Ph.D., VP-Pharmaceutical Products & Corp. Dev. Newton Crenshaw, VP-Comm. & Public Affairs Albertus van den Bergh, Pres., Neuroscience Products Deborah Steelman, VP-Global Affairs Lori Queisser, VP-Chief Compliance Officer Elizabeth Klimes, Pres., Diabetes & Growth Disorder Products Sidney Taurel, Chmn.
Phone: 317-276-2000 Fax: 317-277-6579 Toll-Free: 800-545-5979 Address: Lilly Corporate Center, Indianapolis, IN 46285-0001 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $11,078,000 (12 months) 2002 Profits: $2,708,000 (12 months) Stock Ticker: LLY 2001 Sales: $11,542,000 2001 Profits: $2,780,000 Employees: 43,700 2000 Sales: $10,862,200 2000 Profits: $3,057,800 Fiscal Year Ends: 12/31 1999 Sales: $10,002,900 1999 Profits: $2,720,900 1998 Sales: $9,236,800 1998 Profits: $2,097,900
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $1,391,100 Stock Purch. Plan: Second Exec. Salary: $820,080 ADVANTAGE: Well-known worldwide for its pharmaceutical products.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $474,366 Bonus: $190,669
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
EMC CORP
www.emc.com
Industry Group Code: 334112 Ranks within this company's industry group: Sales:2 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:9
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Storage Equipment-Mainframe Disk Memory Solid-State Disk Drives Network Storage Systems
EMC Corporation, along with its subsidiaries, designs, manufactures, markets and supports a wide range of hardware and software products and provides services for the storage, management protection and sharing of electronic information. To address the difficulties in effective management, sharing, protection and availability of critical information that result from growing size and scope of computer systems, the company operates the Enterprise Storage Network (ESN). ESN is a dedicated network connecting EMC storage systems and software to all major computing platforms via various network protocols. EMC’s Data General division designs, manufactures, markets and supports the company’s line of AViiON open systems servers. The Symmetrix Enterprise Storage system, the company’s flagship product, offers a high level of functionality, performance and availability in data centers. The EMC Connectrix Enterprise Storage Network System is the industry’s first fully integrated fiber channel network connectivity solution. The company’s objective is to extend its position as the enterprise storage solutions leader in the information technology industry and to strengthen the EMC e-infostructure as the standard for network storage. EMC markets its products through multiple distribution channels, including its direct sales force and selected distributors, systems integrators, resellers and OEMs. It has a direct sales presence throughout North America, Latin America, Europe and the Middle East. EMC recently announced a partnership with Eastman Kodak to equip health care facilities with the Kodak DirectView PACS solution. This system combines Kodak’s picture archiving and communication solutions with EMC’s flexible storage platforms. In July 2003, the company announced that it intends to acquire Legato Systems for $1.3 billion. The company offers employees basic dental, medical and life insurance, as well as health and dependent care spending accounts. It also provides credit union convenience, discounted personal property insurance, direct deposit, onsite day care and employee discount programs.
BRANDS/DIVISIONS/AFFILIATES: Enterprise Storage Network CLARiiON Data General AViiON Symmetrix Enterprise Storage System Connectrix Enterprise Storage Network
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Joseph M. Tucci, CEO Joseph M. Tucci, Pres. William J. Teuber, Jr, CFO David Goulden, VP-Mktg. Mark S. Lewis, Chief Tech. Officer Paul T. Dacier, General Counsel Frank M. Hauck, Exec. VP-Customer Oper. David Goulden, VP-Bus. Dev. Irina Simmons, Treas. David A. Donatelli, Exec. VP-Storage Platforms Oper. Donald S. Swatik, VP-Global Solutions Group Erez Ofer, Exec. VP-Open Software Oper. Bill Scannell, Sr. VP-Sales Michael C. Ruettgers, Chmn. Joseph F. Walton, Sr. VP-Global Services
Phone: 508-435-1000 Fax: 508-497-6961 Toll-Free: 877-362-6973 Address: 35 Parkwood Dr., Hopkinton, MA 01748-9103 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $5,438,000 (12 months) 2002 Profits: $-119,000 (12 months) Stock Ticker: EMC 2001 Sales: $7,091,000 2001 Profits: $-508,000 Employees: 17,400 2000 Sales: $8,872,816 2000 Profits: $1,782,075 Fiscal Year Ends: 12/31 1999 Sales: $6,715,610 1999 Profits: $1,010,570 1998 Sales: $5,436,158 1998 Profits: $653,978
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $1,000,000 Stock Purch. Plan: Y Second Exec. Salary: $1,000,000 ADVANTAGE: Producer of the first fully integrated fibre channel connectivity system.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $700,000 Bonus: $700,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ENDO PHARMACEUTICALS HOLDINGS INC Industry Group Code: 325412 Ranks within this company's industry group: Sales:36 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
www.endo.com
Profits:35 Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Pain Management
Endo Pharmaceuticals Holdings, Inc. is a fully integrated specialty pharmaceutical company with market leadership in pain management. The company discovers, produces and markets pharmaceutical products under both generic and brand names. The principal use of these products is for the treatment of pain. The branded products, Percodan, Zydone, Lidoderm and Percocet, are sold to health care professionals throughout the U.S. Percocet and Zydone are used to treat moderate to severe pain, Lidoderm is used to treat post-herpetic neuralgia and Percodan is used to treat severe pain. Endo’s primary generic product is morphine sulfate extended-release tablets. It also offers a generic version of Sinemet (carbidopa/levodopa) for the treatment of the symptoms of idiopathic Parkinson’s disease. Recently, Endo codeveloped an oral extended-release (ER) version of oxymorphone with Penwest Pharmaceuticals and developed an oral immediate-release (IR) version of oxymorphone. The new drug applications for oxymorphone ER and IR were filed with the U.S. FDA. The company is also developing a patented prescription oral rinse (0.1% triclosan) for the management of oral mucositis, painful mouth sores that often occur in patients undergoing cancer treatment.
BRANDS/DIVISIONS/AFFILIATES: Percodan Lidoderm Percocet Zydone Oxymorphone BML Pharmaceuticals, Inc. Endo Pharmaceuticals, Inc. Immunol
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Carol A. Ammon, CEO Peter A. Lankau, COO Peter A. Lankau, Pres. Jeffrey R. Black, CFO/Sr. VP David Bass, VP-Human Resources David A. Lee, Sr. VP-Research and Dev. Caroline B. Manogue, Sr. VP/Corp. Sec. Caroline B. Manogue, General Counsel Mariann T. MacDonald, Exec. VP-Oper. Jeffrey R. Black, Treas. Peter A. Lankau, Sr. VP-U.S. Bus. Carol A. Ammon, Chmn.
Phone: 610-558-9800 Fax: 610-558-8979 Toll-Free: Address: 100 Painters Dr., Chadds Ford, PA 19317 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $399,000 (12 months) 2002 Profits: $30,800 (12 months) Stock Ticker: ENDP 2001 Sales: $252,000 2001 Profits: $-36,500 Employees: 277 2000 Sales: $197,429 2000 Profits: $-156,840 Fiscal Year Ends: 12/31 1999 Sales: $138,500 1999 Profits: $3,260 1998 Sales: $108,370 1998 Profits: $ 201
SALARIES/BENEFITS: Pension Plan: Y Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Expertise in pain management drugs.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
Top Exec. Salary: $460,000 Second Exec. Salary: $368,333
Bonus: $480,000 Bonus: $346,500
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
ENERGY CONVERSION DEVICES INC Industry Group Code: 333298 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
www.ovonic.com Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Solar Energy Technology Ovonic Battery Technology
Energy Conversion Devices, Inc. (ECD) is a technology and manufacturing company engaged in the invention, engineering, development and commercialization of proprietary materials, products and production technology. ChevronTexaco owns 20% of the company. Through ECD’s ownership of more than 350 U.S. patents, over 700 foreign patents and more than 40 years of experience, the company has established a leadership role in the development of proprietary materials, products and production technology based on its amorphous materials that are engineered to have chemical and structural disorder at the atomic level. The firm manufactures and sells its products through joint venture companies and licensing arrangements with major companies throughout the world. ECD's Ovonic Battery Company, Inc. subsidiary developed the proprietary NiMh battery technology, which has achieved recognition by major battery manufacturers worldwide and has been utilized in joint ventures with General Motors and Texaco. Through its joint venture company, Ovonyx, Inc., ECD works with Intel, STMicroelectronics and BAE Systems on the Ovonic information solutions side of the business and with General Electric on the Ovonic media solutions side. Another joint venture, United Solar Systems Corp. (UniSolar), makes thin-film amorphous silicon solar technology for telecommunications, lighting and other uses. Antiglare screens and solar-controlled windows are produced by the company’s thin-film materials, which include optical and vapor barrier films. Recently, the joint venture and Independent Energy Solutions unveiled the solar energy product SolarQuilt. Additionally, ECD acquired all of N.V. Belaert SA’s interests in Uni-Solar and another joint venture, Bekaert ECD Solar Systems, LLC. The company offers comprehensive medical, vision and dental plans as well as life insurance, disability benefits and vacation and holiday pay. Stan Ovshinsky, the founder, president and CEO of the company, has been honored as one of Time Magazine’s Heroes of the Planet. Several of the top executives are women.
BRANDS/DIVISIONS/AFFILIATES: NiMh Battery Technology SolarQuilt ChevronTexaco United Solar Systems Corp. Bekaert ECD Solar Systems, LLC
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Stanford R. Ovshinsky, CEO James Metzger, COO Stanford R. Ovshinsky, Pres. Nancy M. Bacon, Sr. VP-Finance Marilyn Roper, Dir.-Human Resources Nancy M. Bacon, Treas. Hellmut Fritzsche, VP Iris M. Ovshinsky, VP/Co-Founder Robert Stempel, Chmn.
Phone: 248-293-0440 Fax: 248-844-1214 Toll-Free: 800-528-0617 Address: 2956 Waterview Dr., Rochester Hills, MI 48309 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $91,700 (12 months) 2002 Profits: $-20,900 (12 months) Stock Ticker: ENER 2001 Sales: $71,400 2001 Profits: $-5,100 Employees: 519 2000 Sales: $30,000 2000 Profits: $-16,700 Fiscal Year Ends: 6/30 1999 Sales: $29,300 1999 Profits: $-13,800 1998 Sales: $31,600 1998 Profits: $-16,700
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $349,713 Stock Purch. Plan: Second Exec. Salary: $299,730 ADVANTAGE: Successful development of unique technologies.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $24,076 Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ENGLOBAL CORP
www.englobal.com
Industry Group Code: 541310 Ranks within this company's industry group: Sales:14 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Y
Profits:7
Transportation: Aerospace: Automotive:
Y Y
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Engineering Services Microcomputer Systems Consulting Services
ENGlobal, formerly Industrial Data Systems, is a fully integrated engineering firm that also offers related products and services. The company’s main focus is the manufacturing of specialized microcomputer systems for industrial applications, such as manufacturing, process control, discrete manufacturing, data acquisition, telecommunications and man-machine interfaces. Through its ENGlobal Engineering subsidiary, the firm offers engineering consulting services to various corporations. Services include conceptual studies, project definition, cost estimation, engineering design and material procurement. The Thermal Corporation subsidiary manufactures air-handling equipment such as cooling, heating and ventilation systems. Furthermore, the ENGlobal Constant Power division designs and manufactures standard and custom products for power ranges including battery chargers, battery monitoring systems, DC power supplies, DC/AC inverters, uninterruptible power systems, power conditioners, power distribution systems and solar voltaic systems. ENGlobal Technologies, Inc., a wholly-owned subsidiary that was non-operational prior to 2003, provides products and services supporting the advanced automation and environmental technology fields. This subsidiary supports a wide range of continuous processes, serving the oil and gas industry, pulp and paper industry, pharmaceutical industry and petrochemical and chemical industries. In recent news, the company announced that ENGlobal Engineering signed a contract with Sasol North America, Inc. With this contract, ENGlobal will supply professionals to work in Sasol’s chemical plant in Louisiana along with providing office engineering support.
BRANDS/DIVISIONS/AFFILIATES: ENGlobal Engineering, Inc. Industrial Data Systems, Inc. IDS Engineering, Inc. Constant Power Manufacturing, Inc. Thermal Corp. SafeCase
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Michael L. Burrow, CEO William A. Coskey, COO William A. Coskey, Pres. Robert W. Raiford, CFO John Vidrine, VP-IT Ken J. Hendrick, Corp. Controller Hulda L. Coskey, Corp. Sec./Chief Governance Officer Michael M. Patton, Sr. VP-Bus. Dev. Robert W. Raiford, Treas. Robert W. Raiford, Exec. VP-ENGlobal Engineering, Inc. Michael L. Burrow, Chmn.
Phone: 281-821-3200 Fax: 281-821-5488 Toll-Free: 800-411-6040 Address: 600 Century Plaza Dr., Ste. 140, Houston, TX 77073 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $91,600 (12 months) 2002 Profits: $1,800 (12 months) Stock Ticker: ENG 2001 Sales: $22,100 2001 Profits: $1,000 Employees: 910 2000 Sales: $17,000 2000 Profits: $ 400 Fiscal Year Ends: 12/31 1999 Sales: $12,200 1999 Profits: $- 300 1998 Sales: $12,700 1998 Profits: $ 400
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $239,941 Stock Purch. Plan: Second Exec. Salary: $185,007 ADVANTAGE: Comprehensive turnkey engineering services.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $9,490 Bonus: $7,315
LOCATIONS: ("Y" = Yes) West:
Southwest: Y
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
ENI SPA
www.eni.it
Industry Group Code: 211111 Ranks within this company's industry group: Sales: Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Y Y
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Y Chemicals: Oil/Chem. Svcs.: Y Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Oil and Natural Gas Exploration, Production, Sale and Distribution Engineering and Construction Services
Eni S.p.A. is an integrated energy company with operations in the oil, natural gas, electricity generation, engineering, oilfield services and petrochemicals industries. The firm conducts business in more than 70 countries and produces over 1.5 million barrels of oil equivalent a day. The company operates in the exploration and production of oil and natural gas in Italy, North Africa, West Africa, the Middle East, the North Sea and the Gulf of Mexico, as well as in Latin America, Australia, the Far East and the Caspian Sea. Eni also operates in the supply, transmission, distribution and sale of natural gas. Its refining and refined products operations are primarily in Italy, Europe and Latin America. The company is the leading transporter of petroleum products in Italy. Eni is comprised of five controlled subsidiaries: Snam Rete Gas S.p.A., Italgas S.p.A., EniPower S.p.A., Snamprogetti S.p.A. and Salpem S.p.A. Through Saipem and Snamprogetti, Eni operates in oilfield services, engineering and contracting. Other Eni companies include Sofid, Padana Assicurazioni, EniTechnologie, Stogit, Eni Corporate University and Sieco. A number of other Eni companies, including Agip USA and AmericanAgip, carry out procurement services and trade in crude oils and petroleum products, including MTBE and methanol. Recently, the company acquired the Norwegian company Fortum Petroleum AS, which subsequently changed its name to Eni Norge AS. In addition, Atriplex, an Eni wholesale company, changed its name to Agip Fuel. In other news, Eni subsidiary Saipem acquired India-based Company International Development Process and Engineering.
BRANDS/DIVISIONS/AFFILIATES: Snam Rete Gas S.p.A. Snamprogetti S.p.A. Italgas S.p.A. EniPower S.p.A. Saipem S.p.A. Agip Fuel Eni Norge AS Agip USA
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Vittorio Mincato, CEO Marco Mangiagalli, CFO Renato Roffi, Sr. VP-Personnel and Organization Group Luigi Patron, Chief Tech. Officer Carlo Grande, Sr. VP-Legal Affairs Group Roberto Jaquinto, Sr. VP-Admin. Group Leonardo Maugeri, Sr. VP-Strategies Eugenio Palmieri, Sr. VP-Public Affairs and Comm. Group Jadran Trevisan, Mgr.-Investor Rel. Stefano Cao, COO-Exploration and Production Div. Luciano Sgubini, COO-Gas and Power Div. Gilberto Callera, COO-Refining and Mktg. Div. Fabrizio d'Adda, Sr. VP-Safety and Environmental Group Roberto Poli, Chmn. Leonardo Maugeri, Sr. VP-Int'l Rel. Vittorio Giacomelli, Sr. VP-Procurement Group
Phone: 39-065-9821 Fax: 39-065-982-2141 Toll-Free: Address: Piazzale Mattei, 1, Rome, 00144 Italy
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: E 2001 Sales: $43,607,000 2001 Profits: $6,908,000 Employees: 70,948 2000 Sales: $42,609,300 2000 Profits: $ Fiscal Year Ends: 12/31 1999 Sales: $27,881,000 1999 Profits: $ 1998 Sales: $49,724,357 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Highly diversified services and global operations.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West:
Southwest: Y
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ENTERASYS NETWORKS INC
www.cabletron.com
Industry Group Code: 334110 Ranks within this company's industry group: Sales:4 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:6
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Computer Networking Equipment-LAN Connectivity WAN Connectivity Hardware and Software Layer 3 Switches Routers Wireless Networking Equipment Support Services
Enterasys Networks, Inc., formerly Cabletron Systems, Inc., delivers flexible and scalable network access and communications equipment and software to Global 2000 enterprises, service providers and small businesses worldwide. The company’s networking solutions focus on the network security, availability and mobility needs of enterprises. Its significant installed base of customers consists of commercial enterprises, governmental entities and health care, educational and non-profit institutions. The company’s products are classified into five principal categories: switching, routing, wireless networking, security and support services. Its Matrix and Vertical Horizon switches address the broad market for secure, high-speed connectivity to individual users and departments within the enterprise network. Enterasys’s routers are typically deployed in the center of the enterprise network, where security and traffic control are most important to enterprises. When linked to its multilayer Matrix switches, the firm's X-Pedition routers provide a complete network solution, where both switches and routers share similar, complementary security and management features. The wireless networking RoamAbout product family allows easy, secure, authorized and economical access to the network from enterprise buildings or campuses located within 25 miles of each other. Enterasys also offers dedicated security devices and products, which include the Dragon, Netsight Atlas and Aurorean product lines. Baylor University recently selected Enterasys to provide UPN service for its 11 residence halls. The firm provides employees with an internal training program and tuition reimbursement.
BRANDS/DIVISIONS/AFFILIATES: Matrix Switches Vertical Horizon Switches X-Pedition Routers RoamAbout Dragon Netsight Atlas Aurorean Cabletron Systems, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. William O'Brien, CEO William O'Brien, Pres. Richard Haak, CFO Mads Lillelund, Exec. VP-Worldwide Sales Kim Buxton, VP-Human Resources John Roese, Chief Tech. Officer Len Couture, Chief IT Officer Tom Bunce, VP-Eng. Gerry Haines, Chief Legal Officer Laura Howard, Exec. VP-Corp. Mktg. Gil Arbel, Exec. VP-Product Mgmt. Ray Hunt, Exec. VP-Supply Chain Mgmt.
Phone: 603-332-9400 Fax: 603-332-8007 Toll-Free: Address: 35 Industrial Way, Rochester, NH 03866-5005 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $484,797 (12 months) 2002 Profits: $-153,514 (12 months) Stock Ticker: ETS 2001 Sales: $394,545 2001 Profits: $-531,290 Employees: 2,300 2000 Sales: $1,350,697 2000 Profits: $54,558 Fiscal Year Ends: 12/31 1999 Sales: $1,378,733 1999 Profits: $-61,775 1998 Sales: $1,377,330 1998 Profits: $-34,961
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $467,077 Stock Purch. Plan: Y Second Exec. Salary: $253,847 Reorganization into four companies/Substantial government contracts. ADVANTAGE:
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $600,000 Bonus: $200,500
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ENZO BIOCHEM INC
www.enzo.com
Industry Group Code: 621511 Ranks within this company's industry group: Sales:4 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y Y Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:4
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Services-Clinical Reference Labs and Diagnostic Testing Medical Diagnostic Products
Enzo Biochem, Inc. is engaged in the research, development and production of innovative health care products based on molecular biology and genetic engineering techniques. The firm’s proprietary labeling and detection products for gene sequences and genetic analysis have garnered approximately 200 patents. The company’s Enzo Therapeutics, Inc. subsidiary is currently conducting clinical trials of its gene medication for HIV-1 infection as well as its immune regulation medicines for hepatitis B, hepatitis C and Crohn’s disease. Recently, Enzo Therapeutics also began clinical studies of the effectiveness of its immune regulation technology in treating graft versus host disease, a major complication of bone marrow and stem cell transplantation. Additionally, the firm’s Enzo Clinical Labs subsidiary provides a number of services to physicians and clinical laboratories, including blood tests, cytology studies, tissue pathology, hormone studies and screening for cancer and infectious diseases. The subsidiary also offers an Alpha Fetoprotein Quad test, which determines the likelihood of fetal defects. Enzo Diagnostics, another subsidiary, offers several diagnostic products, including a line of non-radioactive nucleic acid probes that have been chemically labeled to allow for detection of infectious agents. Enzo Diagnostics also offers MaxSense, a line of membrane kits that include all of the reagents and buffers necessary to perform a gene analysis on a membrane.
BRANDS/DIVISIONS/AFFILIATES: Enzo Therapeutics, Inc. Enzo Diagnostics, Inc. Enzo Clinical Labs, Inc. MaxSense
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Elazar Rabbani, CEO Shahram K. Rabbani, COO Barry W. Weiner, Pres. Herbert B. Bass, VP-Finance Debbie Sohmer, Human Resources Shahram K. Rabbani, Corp. Sec. Barbara E. Thalenfeld, VP-Corp. Dev. Shahram K. Rabbani, Treas. Dean Engelhardt, Exec. VP Norman E. Kelker, Sr. VP David C. Goldberg, VP-Bus. Dev. Elazar Rabbani, Chmn.
Phone: 631-755-5500 Fax: 631-755-5561 Toll-Free: Address: 60 Executive Blvd., Farmingdale, NY 11735 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $54,000 (12 months) 2002 Profits: $6,900 (12 months) Stock Ticker: ENZ 2001 Sales: $58,400 2001 Profits: $6,800 Employees: 231 2000 Sales: $50,000 2000 Profits: $6,600 Fiscal Year Ends: 7/31 1999 Sales: $44,300 1999 Profits: $6,500 1998 Sales: $40,400 1998 Profits: $3,400
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $367,656 Bonus: $245,000 Stock Purch. Plan: Second Exec. Salary: $332,526 Bonus: $230,000 Has proprietary technologies and expertise in manipulating and modifying genetic material and other ADVANTAGE: biological molecules.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
ENZON INC
www.enzon.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:56 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:31
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Polyethylene Glycol Technology Single-Chain Antibody Technology
Enzon, Inc. is a biopharmaceutical company that develops and commercializes products for life-threatening diseases. The firm is focused on the advancement of its product pipeline through continued research and development of its proprietary PEG and SCA technologies. Enzon's PEG (polyethylene glycol) technology is used to improve the delivery, safety and efficacy of proteins and small molecules with known therapeutic efficacy. SCA (singlechain antibody) technology is used to discover and produce antibody-like molecules that can offer the therapeutic benefits of monoclonal antibodies while addressing some of their limitations. The company has developed four products that use PEG technology, with several more in development. PEG-INTRON, is a PEGenhanced version of Schering-Plough's INTRON product. The PEG version allows for more frequent dosing and yields greater efficacy. The drug has approval for use as a monotherapy and in combination with REBETOL. In addition, it may have further applications for treating HIV, hepatitis B and multiple sclerosis. PROTHECAN is a PEG-enhanced version of camptothecin, a compound shown to be potent against certain types of tumors. ADAGEN is a PEG treatment for severe combined immunodeficiency disease, or SCID. ONCASPAR is used for the treatment of acute lymphoblastic leukemia. The firm has also initiated Phase I trials of a PEG version of paclitaxel. Enzon has licensed its SCA technology to several firms that are developing pharmaceuticals based on the genetically engineered proteins. Recently, the company acquired the North American and Japanese rights to Abelcet, Elan Corp.'s injectible amphotericin B lipid formulation.
BRANDS/DIVISIONS/AFFILIATES: ONCASPAR ADAGEN PEG-INTRON PROTHECAN SCA Ventures Abelcet
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Arthur J. Higgins, CEO Arthur J. Higgins, Pres. Kenneth J. Zuerblis, VP-Finance/CFO Ulrich M. Grau, Chief Scientific Officer Kenneth J. Zuerblis, Corp. Sec.
Phone: 908-541-8600 Fax: 908-575-9457 Toll-Free: Address: 685 Rte. 202/206, Bridgewater, NJ 08807 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $75,800 (12 months) 2002 Profits: $45,800 (12 months) Stock Ticker: ENZN 2001 Sales: $31,587 2001 Profits: $11,525 Employees: 127 2000 Sales: $17,000 2000 Profits: $-6,300 Fiscal Year Ends: 6/30 1999 Sales: $13,200 1999 Profits: $-4,900 1998 Sales: $14,600 1998 Profits: $-3,600
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $500,000 Stock Purch. Plan: Second Exec. Salary: $280,615 ADVANTAGE: PEG (polyethylene glycol) technology.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $750,000 Bonus: $136,000
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
EPIX MEDICAL INC
www.epixmed.com
Industry Group Code: 325413 Ranks within this company's industry group: Sales:12 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Vascular Disease Diagnosis Products MRI Contrast Agents
EPIX Medical, Inc. is a specialty pharmaceutical company engaged in the development of targeted contrast agents to improve the capability and expand the use of magnetic resonance imaging (MRI) as a tool for diagnosing human disease. The firm's lead product, MS-325, is an injectable intravascular contrast agent designed for multiple cardiovascular imaging applications, including peripheral vascular disease and coronary artery disease. EPIX believes that MS-325 will significantly enhance the quality of MRI images and provide physicians with a non-invasive and cost-effective diagnostic method. MS-325 has the potential to replace highly invasive and costly conventional x-ray angiography, over which it has a number of advantages. MS-325 is safer, involving only low-energy radio waves rather than ionizing radiation; allows arterial and venous imaging in a single exam; and enables wholebody and three-dimensional data. Additional applications for the product include breast cancer, myocardial perfusion and arthritis imaging. The product is currently in Phase III clinical trials. EPIX's business strategy includes maximizing the value of its strategic relationships, which include collaborations with Schering AG, General Electric Medical Systems, Siemens Medical Systems and Pfizer. Recently, EPIX completed patient enrollment in a second Phase III study of MS-325. The firm offers a competitive compensation package that includes stock options; health, dental, life and disability insurance; tuition reimbursement; health club reimbursement; and transportation.
BRANDS/DIVISIONS/AFFILIATES: MS-325
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Michael D. Webb, CEO Stephen C. Knight, COO Stephen C. Knight, Pres. Pamela E. Carey, VP-Finance/CFO Gregg Mayer, VP-Strategic Mktg. Alan P. Carpenter, Exec. VP-Research and Dev. Gregory Sorensen, Dir.-Medical/VP-Clinical Dev. Pamela E. Carey, VP-Admin. Robert Weisskoff, VP-Bus. Dev. and Imaging Gregg Mayer, VP-Corp. Comm. Randall B. Lauffer, Chief Scientific Officer Susan M. Flint, VP-Regulatory Affairs and Clinical Oper. Christopher F. Gabrieli, Chmn.
Phone: 617-250-6000 Fax: 617-250-6031 Toll-Free: Address: 71 Rogers St., Cambridge, MA 02142-1118 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $12,300 (12 months) 2002 Profits: $22,200 (12 months) Stock Ticker: EPIX 2001 Sales: $9,600 2001 Profits: $-19,200 Employees: 93 2000 Sales: $6,900 2000 Profits: $-27,320 Fiscal Year Ends: 12/31 1999 Sales: $1,100 1999 Profits: $-17,000 1998 Sales: $1,800 1998 Profits: $-14,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $282,832 Stock Purch. Plan: Y Second Exec. Salary: $265,887 ADVANTAGE: Producer of drugs to enhance MRI testing.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $106,062 Bonus: $83,090
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
ERESEARCH TECHNOLOGY INC
www.ert.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:39 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:19
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Software-Clinical Trials Integrated Software Applications Distance Learning
eResearch Technology, Inc. (ERT) is a provider of technology and services that improve the accuracy, timeliness and efficiency of trial set-up, data collection and interpretation and new drug, biologic and device application submission. Its products and services are provided globally through two business segments: cardiac safety, which includes centralized cardiac safety services; and clinical research technology and services, which includes the development, marketing and support of clinical research technology. Clinical trial sponsors and clinical research organizations utilize the cardiac safety services during clinical trials. The clinical research technology and services segment includes the licensing of its proprietary software products and the provision of maintenance and consulting services in support of its proprietary software products. The eResearch Network (eResNet) technology provides an integrated end-to-end clinical research solution that includes trials, data and safety management modules. eResCom is a central command and control web portal that provides real-time information related to monitoring clinical trial activities, data quality and safety. The recently launched EXPeRT Cardiac Safety Intelligent Data Management System provides for workflow-enabled cardiac safety data collection, interpretation and distribution of electrocardiographic (ECG) data and images.
BRANDS/DIVISIONS/AFFILIATES: EXPeRT eResearch Network eData Entry eResCom Accelerator eRT Operating Company eHealth Education
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Joseph A. Esposito, CEO Joseph A. Esposito, Pres. Bruce Johnson, Sr. VP/CFO Scott Grisanti, Chief Mktg. Officer Joel Morganroth, Chief Scientist Jeffrey S. Litwin, Sr. VP/Chief Medical Officer Anna Marie Pagliaccetti, VP/Corp. Sec. Anna Marie Pagliaccetti, General Counsel Scott Grisanti, Sr. VP-Bus. Dev. Robert S. Brown, Sr. VP-Outsourcing Partnerships Vincent Renz, Sr. VP-Tech. and Consulting/Chief Tech. Officer Thomas P. Devine, Sr. VP/Chief Dev. Officer Joel Morganroth, Chmn.
Phone: 215-972-0420 Fax: 215-972-0414 Toll-Free: Address: 30 S. 17th St., Philadelphia, PA 19103-4001 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $41,500 (12 months) 2002 Profits: $6,200 (12 months) Stock Ticker: ERES 2001 Sales: $28,000 2001 Profits: $-3,800 Employees: 224 2000 Sales: $28,100 2000 Profits: $ 100 Fiscal Year Ends: 12/31 1999 Sales: $42,800 1999 Profits: $5,300 1998 Sales: $31,800 1998 Profits: $ 700
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $270,000 Stock Purch. Plan: Second Exec. Salary: $175,000 ADVANTAGE: Focus on streamlining the data collection process.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $271,389 Bonus: $111,385
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
EXELIXIS INC
www.exelixis.com
Industry Group Code: 541710 Ranks within this company's industry group: Sales:11 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:16
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Research-Genetic Data Model System Genetics Drugs-Agriculture
Exelixis, Inc. is a leading biotechnology company focused on the life sciences industries through its expertise in comparative genomics and model system genetics. These technologies provide a rapid, efficient and costeffective way to move from DNA sequence data to knowledge about the function of genes and the proteins that they encode. The firm’s technology is broadly applicable to all life science industries including pharmaceutical, diagnostic, agricultural biotechnology and animal health. Exelixis believes that the proprietary technology created through Genoptera will provide unique insecticide targets that would be difficult to generate using alternative technology. The firm, in collaboration with IMCB, has identified a gene that mediates the immune response. Recently, Exelixis and Bristol-Myers Squibb got into a licensing agreement to create a new generation of potential cancer drugs and received an exclusive worldwide license to develop and commercialize the Bristol-Myers Squibb anticancer compound, Rebeccamycin. Phase I and early Phase II clinical trials are underway at the National Cancer Institute. The firm also announced its broad alliance with GlaxoSmithKline plc to discover, develop and commercialize novel therapeutics in the areas of vascular biology, inflammatory disease and oncology. Exelixis has two subsidiaries, Artemis Pharmaceuticals GmbH headquartered in Cologne, Germany and Exelixis Plant Sciences in Portland, Oregon. The firm has a portfolio of 41 issued U.S. patents and 169 pending U.S. patent applications. In addition to these, 13 U.S. and corresponding international patent applications were filed with Aventis Cropsciences as part of its Agrinomics joint venture. Another 11 U.S. or international patent applications were filed with Bayer Corporation as part of the Genoptera joint venture. In addition to basic benefits, the company offers tuition reimbursement, a corporate fitness program and the opportunity to participate in a variety of entertainment events such as concerts, movies, happy hour gatherings, picnics and movies.
BRANDS/DIVISIONS/AFFILIATES: Artemis Pharmaceuticals GmbH IMCB Bayer AG Bristol-Myers Squibb Company GlaxoSmithKline plc Aventis Cropsciences Exelixis Plant Sciences, Inc. Rebeccamycin
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. George A. Scangos, CEO George A. Scangos, Pres. Glen Y. Sato, CFO Geoffrey Duyk, Exec. VP/Chief Scientific Officer Pamela A. Simonton, VP-Corp. Tech. Dev. Gregory D. Plowman, VP-Pharmaceutical Research Kimberly J. Manhard, VP-Regulatory Affairs Lloyd M. Kunimoto, Sr. VP-Bus. Dev. Jane Green, VP-Corp. Comm. Michael Morrissey, VP-Discovery Research Glen Y. Sato, VP-Legal Affairs Robert M. Myers, Exec. VP-Pharmaceuticals Jeffrey R. Latts, Sr. VP/Chief Medical Officer
Phone: 650-837-7000 Fax: 650-837-8300 Toll-Free: Address: 170 Harbor Way, South San Francisco, CA 94083 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $44,300 (12 months) 2002 Profits: $-86,200 (12 months) Stock Ticker: EXEL 2001 Sales: $41,000 2001 Profits: $-71,200 Employees: 550 2000 Sales: $24,800 2000 Profits: $-75,300 Fiscal Year Ends: 12/31 1999 Sales: $10,500 1999 Profits: $-18,700 1998 Sales: $2,300 1998 Profits: $-15,700
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $420,000 Stock Purch. Plan: Y Second Exec. Salary: $300,000 ADVANTAGE: Innovative biotech research/Genoptera joint venture.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $252,000 Bonus: $107,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
EXELIXIS PLANT SCIENCES INC
www.exelixis.com
Industry Group Code: 115112 Ranks within this company's industry group: Sales: Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Agriculture-Produce Spoilage Reduction Products Biotech Products For Agriculture
Exelisis Plant Sciences, Inc. (EPS), formerly Agritope, Inc., is a wholly owned subsidiary of Exelisis, Inc. EPS is an agricultural biotechnology company that develops improved plant products and provides technology to the agricultural industry. The firm conducts plant research activities in Portland, Oregon and plant genomics in South San Francisco, California. EPS investigates plant biotechnology ranging from disease resistance and environmental stress to human nutrition. The company is working to produce biochemical compounds from plants which have value in human and animal nutrition and that are known to reduce the risk of disease and or certain types of cancer. EPS has developed assays by which it can determine the genetic mechanisms of plants and how these compound productions are controlled in them. EPS and Aventis CropScience formed a joint venture company called Agrinomics LLC. This venture focuses on finding and determining the function of plant genes. Recently, Aventis CropScience was acquired by Bayer, and the collaboration was transferred to Bayer CropScience.
BRANDS/DIVISIONS/AFFILIATES: Aventis CropScience Agrinomics LLC Exelixis, Inc. Bayer CropScience Agritope, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Bruce C. Galton, CEO Bruce C. Galton, Pres. D. Ry Wagner, VP-Research Gilbert N. Miller, Exec. VP/Sec. Matthew G. Kramer, VP-Product Dev. Matthew G. Kramer, GM and VP-Agricultural Trait Development
Phone: 503-670-7702 Fax: 503-403-5790 Toll-Free: Address: 16160 SE Upper Boones Ferry Rd., Portland, OR 97224-7744 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $ 2001 Profits: $ Employees: 44 2000 Sales: $ 2000 Profits: $ Fiscal Year Ends: 9/30 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Y Second Exec. Salary: $ ADVANTAGE: Partnerships with Aventis/Unique agricultural focus.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
EXXONMOBIL CORPORATION
www.exxonmobil.com
Industry Group Code: 211111 Ranks within this company's industry group: Sales:2 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:2
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Y Chemicals: Y Oil/Chem. Svcs.: Gases: Other: Y
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Oil & Gas, Exploration and Production Gas Refining and Supply Coal and Mineral Exploration Chemicals
In 1999, Exxon Corporation and Mobil Corporation merged, forming Exxon Mobil Corporation (ExxonMobil). Coincident with the merger, ExxonMobil announced a new organizational structure built on a concept of 11 separate global businesses. Each is designed to allow the company to compete more effectively in a changing worldwide energy industry. The five global upstream businesses are exploration, development, production, gas marketing and upstream research. The four global downstream businesses are refining and supply, fuels marketing, lubricants and petroleum specialties and technology, plus a chemical company and a coal and minerals company. Divisions and affiliated companies operate or market products in the United States and about 200 other countries. The firm's principal business is energy, involving exploration for and production of crude oil and natural gas, manufacturing of petroleum products and transportation and sale of crude oil, natural gas and petroleum products. ExxonMobil is a major manufacturer and marketer of basic petrochemicals, including olefins, aromatics, polyethylene and polypropylene plastics and a wide variety of specialty products. The company is also engaged in the exploration, mining and sale of coal, copper and other minerals. In addition, the firm has interests in electric power generation facilities. In recent news, Qatar Petroleum and ExxonMobil signed an agreement enabling it to supply Liquefied Natural Gas from Qatar to the United Kingdom. Additionally, ExxonMobil Chemical recently acquired Advanced Elastomer Systems, significantly expanding its global Ethylene Elastomers portfolio. More recently, ExxonMobil announced plans to invest $100 million in the Global Climate and Energy Project, led by Stanford University. The company offers adaptable work arrangements depending on employee needs. The firm also offers superior job training, tuition reimbursement and relocation assistance to its workforce, as well as adoption assistance, product discounts and military leaves of absence.
BRANDS/DIVISIONS/AFFILIATES: Mobil Oil Corp. Exxon Company International Exxon Coal and Minerals Company Exxon Chemical Company Exxon Exploration Company Exxon China, Inc. Exxon Research and Engineering Company Exxon Ventures (CIS), Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Lee R. Raymond, CEO Lee R. Raymond, Pres. Lucille J. Cavanaugh, VP-Human Resources Donald D. Humphreys, VP/Controller Charles W. Matthews, Jr., VP/General Counsel Kenneth P. Cohen, VP-Public Affairs T. Peter Townsend, VP-Investor Rel. Frank A. Risch, VP/Treas. K. T. Koonce, Pres.-Production Rex W. Tillerson, Sr. VP Harry J. Longwell, Sr. VP Eugene A. Renna, Sr. VP
Phone: 972-444-1000 Fax: 972-444-1350 Toll-Free: Address: 5959 Las Colinas Blvd., Irving, TX 75039-2298 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $178,909,000 (12 months) 2002 Profits: $11,460,000 (12 months) Stock Ticker: XOM 2001 Sales: $187,510,000 2001 Profits: $15,320,000 Employees: 92,500 2000 Sales: $232,748,000 2000 Profits: $17,720,000 Fiscal Year Ends: 12/31 1999 Sales: $185,527,000 1999 Profits: $7,910,000 1998 Sales: $169,642,000 1998 Profits: $8,074,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Stock Purch. Plan: ADVANTAGE: The world's largest oil company.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $2,850,000 Second Exec. Salary: $1,250,000
Bonus: $2,700,000 Bonus: $863,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
E-Z-EM INC
www.ezem.com
Industry Group Code: 325413 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:5
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Equipment-Diagnostic Imaging Therapeutic Devices Custom Pharmaceuticals Gastrointestinal Products Immunoassay Tests X-Ray Protection Equipment
E-Z-EM, Inc. is primarily engaged in developing, manufacturing and marketing diagnostic products used by physicians during image-assisted procedures to detect anatomic abnormalities and diseases. Its products and services are designed for use in the radiology, gastroenterology, speech pathology and virtual colonoscopy industries. The company operates through its diagnostic products segment, which includes the imaging products division and subsidiaries Enteric Products, Inc. and AngioDynamics, Inc. The imaging products division handles the core of the business, gastrointestinal and interventional radiology, as well as diagnostic imaging specialties such as CT, MRI and ultrasound. Enteric Products, Inc. primarily develops technology for detecting Helicobacter pylori bacteria, the primary cause of peptic ulcer disease and gastric cancer. Through AngioDynamics, Inc., the company manufactures and markets a variety of therapeutic and diagnostic products used to diagnose and treat vascular disease. Products include stents, diagnostic catheters and angiographic, thrombolytic and image-guided vascular access products. E-Z-EM contrast systems consist of specially developed powdered and liquid barium sulfate formulations and consumable medical devices, which function together as a system for examination of the various parts of the gastrointestinal tract. The company also produces non-contrast systems that include diagnostic radiology devices, custom contract pharmaceuticals, gastrointestinal cleansing laxatives, Xray protection equipment and immunoassay tests. Recently, E-Z-EM formed a strategic alliance with 3CPM to market 3CPM’s Electrogastrogram Analyzer, which aids in the diagnosis of dysrhythmias. Additionally, the company’s reactive skin decontamination lotion received 510(k) clearance from the FDA. The lotion neutralizes and destroys chemical warfare agents. The company offers its employees a comprehensive health plan, along with discounts at optical retail stores, employee training, development programs, tuition reimbursement and various recreational events.
BRANDS/DIVISIONS/AFFILIATES: AngioDynamics, Inc. Enteric Products, Inc. E-Z-EM Canada, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Anthony A. Lombardo, CEO Anthony A. Lombardo, Pres. Dennis J. Curtin, Sr. VP/CFO Joseph J. Palma, Sr. VP-Global Sales Sandra D. Baron, VP-Global Human Resources Jeffrey S. Peacock, Sr. VP-Global Scientific and Tech. Oper. Joseph A. Cacchioli, VP/Controller Archie B. Williams, VP-Clinical Affairs and Medical Comm. Craig A. Burk, VP-Mfg. Peter J. Graham, VP/Corp. Sec. Peter J. Graham, General Counsel Brad S. Schreck, Sr. VP-Global Mktg. Arthur L. Zimmet, Sr. VP-Special Projects Robert M. Bloomfield, VP-Market Research Earmonn P. Hobbs, VP-AngioDynamics Howard S. Stern, Chmn.
Phone: 516-333-8230 Fax: 516-997-9534 Toll-Free: Address: 717 Main St., Westbury, NY 11590 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $122,100 (12 months) 2002 Profits: $ 600 (12 months) Stock Ticker: EZM 2001 Sales: $113,300 2001 Profits: $3,300 Employees: 932 2000 Sales: $112,100 2000 Profits: $6,000 Fiscal Year Ends: 5/31 1999 Sales: $107,200 1999 Profits: $4,800 1998 Sales: $102,900 1998 Profits: $-6,000
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Y Top Exec. Salary: $320,000 Bonus: $71,088 Stock Purch. Plan: Second Exec. Salary: $218,820 Bonus: $114,880 ADVANTAGE: A world leader in developing and manufacturing contrast agents for gastrointestinal radiology.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
FIAT SPA
www.fiat.com
Industry Group Code: 336111 Ranks within this company's industry group: Sales:6 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Profits:17 Y Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Automobile Manufacturer Agricultural and Construction Equipment Insurance Aviation Products Components Production Systems
Based in Turin, Italy, Fiat is primarily engaged in the manufacture and sale of automobiles, commercial vehicles and agricultural and construction equipment. Through various subsidiaries, the company is also engaged in other businesses, including metallurgic products, components, production systems, aviation, publishing and communications, insurance and business solutions. Fiat Auto sells Fiat, Lancia and Alfa Romeo cars, as well as light commercial vehicles under the Fiat brand. The division also provides an integrated system of mobility and insurance services through Targa Service and its joint ventures, as well as financial services through Fidis. In addition, Fiat owns a majority stake in Ferrari and Maserati. Through CNH Global, 71%-owned by the company, Fiat manufactures agricultural and construction equipment under the New Holland and Case brands. Products include the TM line of tractors, the C Series wheel loader line and a high-lift telescopic handler. Through Iveco, Fiat offers products including light commercial vehicles and heavy-load vehicles for on- or off-road applications, as well as buses, special-purpose vehicles for defense applications and diesel engines for industrial and vehicle applications. The company's Teskid specializes in metallurgic components for the automotive industry. Magneti Marelli also designs, develops and manufactures automotive components, systems and modules, sold under brands including Carello, Jaeger, Solex and Weber. Comau is a global supplier of industrial automation systems to automotive manufacturers, with services including logistics and management, maintenance and process engineering. FiatAvio develops and produces components and systems for aviation and marine applications. In addition, Fiat has operations in publishing and communications (Itedi), insurance (Toro Assicurazioni) and business solutions. Recently, the firm sold its truck rental unit to French investment company Eurazeo. In other news, Fiat is considering a spin-off of its auto unit to revitalize the loss-making division.
BRANDS/DIVISIONS/AFFILIATES: Fiat Auto CNH Global Ferrari Maserati Magneti Marelli Comau Itedi Alfa Romeo
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Umberto Agnelli, Chmn. Ferruccio Luppi, CFO Pier L. Fattori, Corp. Sr. VP-Human Resources Carlo Gatto, Pres.-Bus. Solutions Paolo Annibaldi, Corp. Sr. VP-External Rel. and Comm. Alessandro Barberis, Co-CEO Luca C. Di Montezemolo, CEO, Ferrari Paolo Monferino, Pres./CEO, CNH Umberto Quadrino, Exec. VP-Components and Industrial Sectors Umberto Agnelli, Chmn.
Phone: 39-011-686-1111 Fax: 39-011-686-3798 Toll-Free: Address: 250 Via Nizza, Turin, 10126 Italy
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $61,014,000 (12 months) 2002 Profits: $-4,147,000 (12 months) Stock Ticker: FIA 2001 Sales: $54,661,000 2001 Profits: $-397,000 Employees: 198,764 2000 Sales: $57,679,000 2000 Profits: $625,000 Fiscal Year Ends: 12/31 1999 Sales: $48,741,000 1999 Profits: $356,000 1998 Sales: $46,910,300 1998 Profits: $396,600
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Owns a majority stake in Ferrari and Maserati.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
FILENET CORP
www.filenet.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:35 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:18
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Software-Document Management Optical Storage and Retrieval Libraries
FileNET Corporation pioneered the document-imaging and workflow markets in response to the needs of paperintensive organizations. Many companies in turn have integrated the information produced by FileNET to improve productivity, decision-making and customer service, while saving money. The company develops, markets and services web-based content management and e-business applications. These applications help corporations and government organizations build Intranets, business-tobusiness and business-to-consumer portals to manage their business information and work processes more productively. FileNET developed the innovative Panagon family product line and, through a partnership with Microsoft, implemented a major series of new global marketing, development and support programs. The Panagon products allow users to create, access, edit, process, organize, secure, store and archive digital content of all types for web-based applications, as well as for client/server environments. FileNET also offers professional services related to the implementation of their software products, as well as customer support. Additionally, the firm manufactures and sells a line of 12inch optical storage and retrieval libraries. The company recently introduced its new FileNET P8 architecture, the largest product launch in the company’s history, which allows each FileNet solution to integrate all FileNET ECM capabilities as needed. In recent news, the city of Helsinki, Finland, has implemented a FileNET ECM solution that will manage all of the city’s critical documents, optimize business processes and provide citizens with 24-hour Internet access to city government records for the first time.
BRANDS/DIVISIONS/AFFILIATES: COLD OSAR Panagon FileNET P8
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Lee D. Roberts, CEO Ron L. Ercanbrack, Pres. Sam M. Auriemma, CFO Martyn Christian, VP-Mktg. Audrey Schaeffer, VP-Human Resources Dan Whelan, Chief Tech. Officer Andy Stameson, CIO Sam M. Auriemma, Corp. Sec. Katharina M. Mueller, General Counsel Chas Kunkelmann, Sr. VP-Worldwide Channel Oper. Michael Harris, VP-Strategy Michael Harris, VP-Corp. Comm. David Despard, Sr. VP-Global Professional Services Bill Kreidler, Sr. VP-Customer Technical Oper. and Services Franz Zihlmann, Sr. VP-Dev. Karl Doyle, VP-Bus. Dev. Lee D. Roberts, Chmn. Hugh Sutherland, VP-Asia Pacific Oper.
Phone: 714-327-3400 Fax: 714-327-3233 Toll-Free: 800-345-3638 Address: 3565 Harbor Blvd., Costa Mesa, CA 92626-1420 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $347,000 (12 months) 2002 Profits: $8,300 (12 months) Stock Ticker: FILE 2001 Sales: $332,500 2001 Profits: $-16,600 Employees: 1,705 2000 Sales: $398,600 2000 Profits: $38,500 Fiscal Year Ends: 12/31 1999 Sales: $347,100 1999 Profits: $19,700 1998 Sales: $310,200 1998 Profits: $1,000
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $525,000 Bonus: $ Stock Purch. Plan: Y Second Exec. Salary: $375,000 Bonus: $ ADVANTAGE: Marketing relationships with Microsoft Corp., Hewlett-Packard and Sun Microsystems.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
FIRST HORIZON PHARMACEUTICALSwww.horizonpharm.com Industry Group Code: 325412 Ranks within this company's industry group: Sales:51 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:44
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Acquisition and Licensing Prescription Drug Sales
As a specialty pharmaceutical company, First Horizon Pharmaceutical Corp. (FHP) markets and sells brandname prescription products. The firm focuses on the treatment of cardiovascular, obstetrical, gynecological, pediatric and gastroenterological conditions and disorders. FHP acquires or licenses pharmaceutical products that are not actively marketed but that have high sales growth potential, are promotion-sensitive and complement FHP’s existing products. FHP enlists third-party manufacturers to manufacture its products. The company promotes its portfolio of 17 branded prescription products through a nationwide sales and marketing force, targeting highprescribing physicians in cardiology, obstetrics and gynecology, pediatrics and gastroenterology. Products include Sular tablets for hypertension, Prenate GT tablets for prenatal care, Robinul adjunctive therapy for peptic ulcer and Tanafed for nasal congestion and pressure relief due to colds, sinuses and allergies or hay fever. The company has recently undergone several managerial changes and is implementing a reengineering plan and new operating budget to improve the product selling process, expand its costumer base and streamline expenses. The firm offers its employees medical, dental and vision insurance, a company car and equity participation.
BRANDS/DIVISIONS/AFFILIATES: Prenate GT Robinul Cognex Protuss Aventis Sular Tanafed Zoto-HC
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Patrick Fourteau, COO Patrick Fourteau, Pres. Darrell Borne, CFO Robert D. Godfrey, Jr., VP-Sales and Sales Oper. Nrupal Shah, Human Resources William G. Campbell, Controller William G. Campbell, VP-Admin. William G. Campbell, Treas. Christopher D. Offen, Exec. VP/Chief Commercial Officer John N. Kapoor, Chmn.
Phone: 770-442-9707 Fax: 770-442-9594 Toll-Free: Address: 6195 Shiloh Rd., Alpharetta, GA 30005 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $115,200 (12 months) 2002 Profits: $6,100 (12 months) Stock Ticker: FHRX 2001 Sales: $69,300 2001 Profits: $10,700 Employees: 249 2000 Sales: $36,649 2000 Profits: $2,507 Fiscal Year Ends: 12/31 1999 Sales: $18,600 1999 Profits: $ 800 1998 Sales: $9,300 1998 Profits: $ 100
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $278,750 Stock Purch. Plan: Second Exec. Salary: $183,542 ADVANTAGE: Capitalizes on drugs initially produced by other pharmaceutical companies.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $42,000 Bonus: $28,000
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
FISHER SCIENTIFIC INTERNATIONAL INC www.fisherscientific.com Industry Group Code: 421450 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Equipment/Supplies Distributor Contract Manufacturing
Fisher Scientific International, Inc. is a world leader in servicing the needs of the scientific community. The company provides more than 600,000 products and services to research, health care, industrial, educational and government customers in 145 countries. The firm’s products and services enable scientific discovery and clinical laboratory testing for more than 350,000 customers. Fisher strives to serve as a one-stop source for the scientific and laboratory needs of its customers. Products include scientific instruments and equipment, clinical consumables, diagnostic reagents, safety and clean room supplies, laboratory equipment and workstations. Over 80% of the firm’s revenue comes from the sales of consumable products. Services include pharmaceutical services for Phase III and Phase IV clinical trials, laboratory instrument calibration and repair, contract manufacturing and custom chemical synthesis. The domestic distribution segment manufactures, sells and distributes products to three primary customer markets: scientific research (pharmaceutical, biotechnology, industrial customers and colleges and universities), clinical laboratory (group purchasing organizations, reference laboratories and independent hospital and physician office laboratories) and industrial safety (industrial companies, public safety organizations and controlled environments). The international distribution segment consists of distribution businesses located in Europe, Canada, Asia and Latin America that sell and distribute products primarily to the scientific research market. The laboratory workstations segment engages in the manufacture and sale of laboratory furniture and fume hoods to the scientific research laboratory market and the manufacture and sale of consoles and enclosures to the technology, communication and financial markets.
BRANDS/DIVISIONS/AFFILIATES: Fisher Research Fisher Science Education Fisher HealthCare Medical Analysis Systems, Inc. VecTest Fisher Hamilton Fisher Clinical Services, Inc. Cole-Parmer Instrument Company
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Paul M. Montrone, CEO David T. Della Penta, COO David T. Della Penta, Pres. Kevin P. Clark, VP/CFO Todd M. DuChene, Corp. Sec. Todd M. DuChene, General Counsel Gregory J. Heinlein, Treas. Patrick J. Balthrop, Pres., Fisher HealthCare Paul M. Montrone, Chmn.
Phone: 603-926-5911 Fax: 603-926-0222 Toll-Free: 800-395-5442 Address: One Liberty Ln., Hampton, NH 03842 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $3,238,400 (12 months) 2002 Profits: $50,600 (12 months) Stock Ticker: FSH 2001 Sales: $2,880,000 2001 Profits: $16,400 Employees: 9,100 2000 Sales: $2,622,300 2000 Profits: $22,700 Fiscal Year Ends: 12/31 1999 Sales: $2,515,000 1999 Profits: $23,400 1998 Sales: $2,294,000 1998 Profits: $-49,500
SALARIES/BENEFITS: Pension Plan: Y Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $815,000 Bonus: $1,100,000 Stock Purch. Plan: Y Second Exec. Salary: $300,000 Bonus: $810,000 ADVANTAGE: Provides the industry's broadest range of products, systems and services for research and testing centers around the globe.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
FLUOR CORP
www.fluor.com
Industry Group Code: 236100 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Y Y Y Y
Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Construction Services Engineering Services Consulting Services Project Management Asset Management Staffing Services
Fluor Corp., one of the largest engineering and construction companies in the world, operates in five principal business segments. The energy and chemicals segment is an integrated service supplier providing a full range of design, engineering, procurement, construction and project management services in the energy and chemical industries, including upstream oil and gas production, refining petrochemical and specialty and fine chemicals. Typical projects include upgrades, fire and explosion rebuilds, pipeline installations and oil sands projects. The industrial and infrastructure segment provides the engineering, procurement and construction services necessary for the development of manufacturing and life sciences facilities, commercial and institutional buildings, mining, telecommunication and transportation projects. This segment provides resources including industrial design and architecture. The power segment designs, engineers and constructs power generation facilities primarily in the fossil fuel power industry through Duke/Fluor Daniel, a partnership with Duke Energy Corp. The global services segment brings together a variety of customized services, broadening its participation in the outsourcing market. Services include facilities management, maintenance and asset management for oil and gas, chemicals, power and manufacturing industries. The firm is also a leading industrial equipment supplier through American Equipment Company. In addition, Fluor provides staffing solutions and procurement services. The company's fifth segment is government services, which provides project management primarily to the Departments of Energy and Defense. Recently, Fluor announced its plans to construct one of the world’s largest cell culture manufacturing facilities for the world’s oldest biotechnology company, Biogen. Additionally, Fluor formed a joint venture with AMEC plc, a leading British construction and engineering company, to strengthen its ability to undertake contracts to rebuild Iraq’s oil industry The company offers employees health, life and retirement plans as well as education and family assistance programs.
BRANDS/DIVISIONS/AFFILIATES: Duke/Fluor Daniel American Equipment Company Biogen Department of Energy Department of Defense Fluor/AMEC Fluor Federal Services Fluor Global Sourcing
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Alan L. Boeckmann, CEO D. Michael Steuert, Sr. VP/CFO John A. Hopkins, Group Exec.-Sales and Mktg. H. Steven Gilbert, Sr. Exec.-Human Resources Victor L. Prechtl, VP/Controller Lawrence N. Fisher, Corp. Sec. Lawrence N. Fisher, Sr. VP-Law Ronald W. Oakley, Group Exec.-Strategic Oper. John L. Hopkins, Group Exec.-Strategic Planning Lee Tashjian, VP-Corp. Comm. Lila J. Churney, VP-Investor Rel. Stephen F. Hull, Treas. J. Robert Fluor II, VP-Corp. & Public Affairs Robert A. McNamara, Group Exec.-Industrial & Infrastructure Kirk D. Grimes, Group Exec.-Energy and Chemicals Ronald W. Oakley, Group Exec.-Gov. Alan L. Boeckmann, Chmn. Mark A. Stevens, Group Exec.-Global Services
Phone: 949-349-2000 Fax: 949-349-2585 Toll-Free: Address: One Enterprise Dr., Aliso Viejo, CA 92656-2606 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $9,959,000 (12 months) 2002 Profits: $164,000 (12 months) Stock Ticker: FLR 2001 Sales: $8,972,000 2001 Profits: $19,000 Employees: 44,809 2000 Sales: $9,970,200 2000 Profits: $123,900 Fiscal Year Ends: 12/31 1999 Sales: $12,417,400 1999 Profits: $104,200 1998 Sales: $13,504,800 1998 Profits: $235,300
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $828,689 Bonus: $1,421,500 Stock Purch. Plan: Second Exec. Salary: $540,000 Bonus: $667,400 ADVANTAGE: One of the world's leading engineering firms/Contracts with the U.S. Department of Energy.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
FORD MOTOR CO
www.ford.com
Industry Group Code: 336111 Ranks within this company's industry group: Sales:2 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Profits:16
Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Automobile Manufacturer Automobile Financing
Ford Motor Company is the world's second-largest producer of cars and trucks. The firm's business is divided into three operating segments: automotive, financial services and The Hertz Corporation. The automotive segment is engaged in the design, manufacture, sale and service of cars and trucks. Ford sold approximately 7 million vehicles throughout the world in 2002, under brands including Ford, Mercury, Lincoln, Volvo, Jaguar, Land Rover, Aston Martin and TH!NK. In addition, the company's customer service division supports owners of its vehicles through a network of franchised dealers, providing service parts, tools, technology and support to facilitate customer satisfaction and owner loyalty. The financial services segment is engaged in vehicle-related financing, leasing and insurance. Ford's motor credit company is the world's largest automotive finance company, providing services in 36 countries for more than 11 million customers. The Hertz Corporation rents and leases cars, trucks, and other industrial vehicles. The firm operates from approximately 7,000 locations throughout the U.S. and in over 140 foreign countries. The firm's goal is for its luxury brands to provide a combined total of one-third of yearly profits by 2005. The international brands are focusing on cutting costs through such methods as component sharing and synergies in purchasing and logistics. After discontinuing its electric vehicle program, Ford is focused on approaches with more market appeal, including gasolineelectric hybrids and fuel-cell systems. To this end, Ford has recently announced support of the Clear Act legislation which will, among other things, provide consumer-based tax incentives for the purchase of vehicles that use alternative fuels and advanced technologies. Minorities acccount for 15.1% of all officers and managers, as well as 35% of new hires. Senior executives at Ford meet periodically with minority groups to discuss diversity efforts. The firm has also been named to Working Mother magazine's 100 Best Firms for Working Mothers.
BRANDS/DIVISIONS/AFFILIATES: Lincoln Mercury Land Rover Hertz Jaguar Mazda Motor Corp. TH!NK Aston Martin Volvo
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. William C. Ford, Jr., CEO Nicholas V. Scheele, COO Nicholas V. Scheele, Pres. Don Leclair, CFO Joseph Greenwell, VP-Mktg. Joe W. Laymon, VP-Human Resources Richard Parry-Jones, Chief Tech. Officer Marvin W. Adams, VP/CIO Don R. Leclair, Controller William W. Boddie, VP-Global Core Eng. Roman J. Krygier, Group VP-Mfg. Dennis E. Ross, VP/General Counsel Joseph Greenwell, VP-Oper. David W. Thursfield, Group VP-Global Purchasing Martin B. Zimmerman, VP-Corp. Affairs Richard N. Beattie, VP-Investor Rel. Malcolm S. MacDonald, Treas./VP-Finance Louise K. Goeser, VP-Quality Darryl B. Hazel, Pres., Lincoln Mercury Janet E. Valentic, VP-Global Mktg. William Clay Ford, Jr., Chmn.
Phone: 313-322-3000 Fax: 313-845-6073 Toll-Free: 800-555-5259 Address: One American Rd., Dearborn, MI 48126-2798 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $162,586,000 (12 months) 2002 Profits: $-980,000 (12 months) Stock Ticker: F 2001 Sales: $162,412,000 2001 Profits: $-5,453,000 Employees: 350,321 2000 Sales: $170,064,000 2000 Profits: $3,467,000 Fiscal Year Ends: 12/31 1999 Sales: $162,558,000 1999 Profits: $7,222,000 1998 Sales: $144,416,000 1998 Profits: $22,071,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $1,750,000 Stock Purch. Plan: Second Exec. Salary: $900,000 ADVANTAGE: One of the world's top multi-national corporations.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $7,700,000 Bonus: $2,000,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
FOREST LABORATORIES INC
www.frx.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:16 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:14
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Asthma Over-the-Counter Pharmaceuticals
Forest Laboratories, Inc. develops, manufactures and sells branded and generic prescription and over-the-counter pharmaceuticals that are used to treat a wide range of illnesses. In order to broaden the company's product base and support its strong growth rate, Forest Laboratories acquired the products Climara (treatment for hypertension and angina) and Tiazac (treatment of high blood pressure). These products represent markets with current sales totaling $7 billion and as much as $500 million in potential sales for Forest. The company is in a strategic alliance with H. Lundbeck A/S, which covers the U.S. marketing rights to central nervous system products developed by Lundbeck. Three new products already licensed to Forest are Celexa, also known as Citalopram (treatment for depression), Lu25-109 (treatment for Alzheimer’s disease) and Lu28-179 (anxiolytic compound). The firm has continued to pursue licensing agreements and strategic alliances with various companies and their products. Forest is involved in a license agreement for the development and marketing in the U.S. of Neramexane, a patented novel NMDA receptor antagonist developed by Merz & Co. of Germany. Forest also has a distribution, marketing, trademark license and supply agreement for the U.S. rights to acamprosate (Campral). This agreement was reached with Lipha S.A., a subsidiary of Merck KgaA, and is for the treatment of alcohol addiction. The company’s FDA-approved Flunisolide HFA is used to treat asthma. The drug uses a new non-CFC propellant and a built-in spacer. Forest recently submitted a supplemental new drug application to the FDA to expand the labeling of its Lexapro drug, already approved for treatment of depression, to include the treatment of panic disorders. Forest Labs offers its employees competitive salaries, benefits and incentives.
BRANDS/DIVISIONS/AFFILIATES: Climara Neramexane Campral Flunisolide HFA Tosara Group Celexa Aerobid Tiazac
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Howard Solomon, CEO Kenneth E. Goodman, COO Kenneth E. Goodman, Pres. John E. Eggers, CFO Elaine Hochberg, Sr. VP-Mktg. Bernard J. McGovern, VP-Human Resources Lawrence S. Olanoff, Exec. VP-Scientific Affairs John A. DiBella, Controller Terrill J. Howell, VP-Oper., Forest Pharmaceuticals William J. Candee, III, Sec. Richard Overton, VP-Oper. and Facilities Mary E. Prehn, VP-Licensing and Corp. Dev. Charles E. Triano, VP-Investor Rel. Shankar Hariharan, VP-Pharmaceutical Research and Dev. William B. Sparks, Exec. VP-Forest Pharmaceuticals Raymond Stafford, CEO-Forest Europe Ivan Gergel, Sr. VP-Research, Clinical Dev. and Medical Affairs Howard Solomon, Chmn.
Phone: 212-421-7850 Fax: 212-750-9152 Toll-Free: 800-947-5227 Address: 909 3rd Ave., New York, NY 10022 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,566,600 (12 months) 2002 Profits: $338,000 (12 months) Stock Ticker: FRX 2001 Sales: $1,205,200 2001 Profits: $215,100 Employees: 3,731 2000 Sales: $899,300 2000 Profits: $112,688 Fiscal Year Ends: 3/31 1999 Sales: $624,000 1999 Profits: $77,173 1998 Sales: $474,700 1998 Profits: $36,697
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $880,000 Stock Purch. Plan: Y Second Exec. Salary: $588,000 ADVANTAGE: Large product base/Excellent distribution channels.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $425,000 Bonus: $275,000
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
FOSTER WHEELER LTD
www.fwc.com
Industry Group Code: 230000 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Y Y Y Y
Profits:4
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Chemical, Petroleum and Industrial Plants-Design and Development Engineering and Construction
Foster Wheeler Ltd. provides services in the petroleum and gas, petrochemical, pharmaceutical, biotechnology, health care, chemical processing, engineering and construction, energy equipment and power systems industries. The company operates through its numerous subsidiaries, some of which are Foster Wheeler Power Machinery Co. Ltd., Foster Wheeler Intl. Corp., Foster Wheeler Energy Corp., Foster Wheeler Constructors and Steril S.p.A. The company’s engineering services include industrial plant construction, water treatment plant engineering and petroleum, chemical and alternative fuel facilities construction. Other services include manufacturing energy equipment, pollution control equipment and steam generation services. Foster Wheeler operates under two business groups: the Engineering and Construction Group and the Energy Equipment Group. The company has engineered and built process, power and industrial facilities in over 125 countries. Also, Foster Wheeler produces technical papers and a quarterly newsletter, Foster Wheeler Review, concerning the company’s global project developments. In recent news, Foster Wheeler sold its wholly owned subsidiary, Foster Wheeler Environmental Corporation, to Tetra Tech, Inc. for approximately $80 million. Foster Wheeler Europe Limited announced an agreement with Shell Global Solutions International B.V. to collaborate in the marketing and licensing of Shell hydroconversion and fluid catalytic cracking technologies outside the U.S. Additionally, Foster Wheeler Energy Limited announced a long term agreement with ExxonMobil to upgrade facilities, ensuring that the facilities are in compliance with evolving legislation.
BRANDS/DIVISIONS/AFFILIATES: Engineering and Construction Group Energy Equipment Group Foster Wheeler Energy Limited Foster Wheeler Europe Limited Foster Wheeler Power Machinery Co. Limited Steril S.p.A.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Raymond J. Milchovich, CEO Raymond J. Milchovich, Pres. Kenneth A. Hiltz, Sr. VP/CFO James E. Schessler, VP-Human Resources Brian K. Ferraioli, VP/Controller Lisa F. Gardner, VP/Sec. Thomas R. O'Brien, Sr. VP/General Counsel James E. Schessler, VP-Admin. Maureen Bingert, Corp. Comm. Ryan J. Esko, Treas. Bernard H. Cherry, Pres./CEO, Foster Wheeler Power Group, Inc. William K. Comerford, Dir.-Health, Safety and Environment Compliance Steven I. Weinstein, VP/Deputy General Counsel Raymond J. Milchovich, Chmn.
Phone: 908-730-4000 Fax: 908-730-5313 Toll-Free: Address: Perryville Corp. Park, 53 Frontage Rd., Clinton, NJ 08809 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $3,519,200 (12 months) 2002 Profits: $-525,200 (12 months) Stock Ticker: FWC 2001 Sales: $3,315,300 2001 Profits: $-327,100 Employees: 8,945 2000 Sales: $3,891,400 2000 Profits: $39,500 Fiscal Year Ends: 12/31 1999 Sales: $3,867,000 1999 Profits: $-174,500 1998 Sales: $4,536,800 1998 Profits: $-31,500
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $848,400 Stock Purch. Plan: Second Exec. Salary: $338,000 Multiple military and government contracts. ADVANTAGE:
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $500,000 Bonus: $160,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
FUELCELL ENERGY INC
www.fuelcellenergy.com
Industry Group Code: 333298 Ranks within this company's industry group: Sales:3 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:3
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Fuel Cell Technology
FuelCell Energy, Inc. is a developer of carbonate fuel cell technology for stationary power generation and has developed a proprietary patented carbonate fuel cell utilized for stationary power generation. Significant funding for the organization comes from the United States Department of Energy and the United States Department of Defense, as well as other outside sources. FuelCell Energy’s patented fuel cell technology is known as the Direct FuelCell, because it introduces hydrocarbon fuel, such as pipeline natural gas, directly into the fuel cell without requiring external reforming for producing hydrogen. This one-step operation results in a more efficient, simpler and more cost-effective energy conversion system compared with most other fuel cells, which utilize complex external reforming equipment to convert fuel to hydrogen. Products are designed to meet the power requirements of a wide range of customers, such as utilities, industrial facilities, data centers, shopping centers, wastewater treatment plants, office buildings, hospitals, universities and hotels. In recent news, FuelCell Energy signed an agreement with Alliance Power, Inc. to integrate the Direct FuelCell power plants into Alliance’s portfolio of distributed generation solutions. FuelCell Energy provides its employees with life, medical and dental insurance.
BRANDS/DIVISIONS/AFFILIATES: Evercel Direct FuelCell
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jerry D. Leitman, CEO Christopher R. Bentley, Exec. VP/COO Jerry D. Leitman, Pres. Joseph G. Mahler, Sr. VP/CFO Herbert T. Nock, Sr. VP-Mktg. and Sales Hansraj C. Maru, Exec. VP/Chief Tech. Officer Jerry D. Leitman, Chmn.
Phone: 203-825-6000 Fax: 203-825-6100 Toll-Free: Address: 3 Great Pasture Rd., Danbury, CT 06813 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $41,200 (12 months) 2002 Profits: $-48,800 (12 months) Stock Ticker: FCEL 2001 Sales: $26,200 2001 Profits: $-15,400 Employees: 425 2000 Sales: $20,700 2000 Profits: $-4,500 Fiscal Year Ends: 10/31 1999 Sales: $20,000 1999 Profits: $-1,000 1998 Sales: $24,300 1998 Profits: $- 400
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Patented fuel cell technology.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $373,888 Second Exec. Salary: $261,908
Bonus: $180,000 Bonus: $76,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
FUJI HEAVY INDUSTRIES LTD
www.fhi.co.jp
Industry Group Code: 336111 Ranks within this company's industry group: Sales:18 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Profits:11
Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Automobiles, Manufacturing Engines Railcars Specialty Vehicles
Fuji Heavy Industries (FHI), based in Japan, is a manufacturer of cars, buses, railcars, engines, aircraft components and specialty vehicles. The firm is bestknown for its Subaru make of cars, including all-wheeldrive vehicles such as the Outback and Forester models. These vehicles are unique in that they are built on smallcar platforms but have a sport utility vehicle (SUV) look and feel. The company has operations throughout Asia as well as in the U.S., Canada and Europe, through subsidiaries including Subaru of America, Subaru Research and Development, Fuji Heavy Industries U.S.A, Robin Europe Industrial Engine and Equipment and Robin Manufacturing U.S.A. FHI's general-purpose engines are sold under the Robin trademark. In 2002, the firm formed a joint venture to develop a rechargeable battery for automobiles. FHI has also partnered with General Motors to increase international sales. In recent news, the company established a joint venture with JATCO to develop and produce continuously variable transmissions. In addition, FHI announced it would begin supplying the Forester SUV to General Motors India.
BRANDS/DIVISIONS/AFFILIATES: Subaru Subaru of America Robin Outback Forester Subaru Research and Development, Inc. Subaru of Indiana Automotive, Inc. Subaru Vehicle Distribution
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Takeshi Tanaka, CEO Kyoji Takenaka, COO Kyoji Takenaka, Pres. Hideo Wada, Exec. VP-Sales and Mktg. Masaru Katsurada, Sr. VP-Tech. Research Toshifumi Terao, VP-IT Shunsuke Takagi, Sr. VP-Finance and Acc. Takao Tsuchiya, Sr. VP-Eng. Hiroyuki Oikawa, VP-Mfg. Yoji Ishimaru, VP-Legal Hideshige Gomi, Exec. VP-Product and Portfolio Planning Teruo Hanada, Sr. Exec. VP-Compliance and Industrial Products Koichi Arasawa, Exec. VP-Quality Assurance Hiroyuki Nakatsubo, Pres.-Aerospace Takeo Tsumuji, Sr. VP-Transportation Div. Takeshi Tanaka, Chmn. Takao Saito, Sr. VP/Pres., Subaru of America Kunitaka Nakahara, Sr. VP-Purchasing
Phone: 81-3-3347-2111 Fax: 81-3-3347-2338 Toll-Free: Address: Subaru Bldg., 7-2 Nishi-Shinjuku 1-chome, Shinjuku, Tokyo, 160-8316 Japan
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $10,272,000 (12 months) 2002 Profits: $228,000 (12 months) Stock Ticker: Foreign 2001 Sales: $10,384,900 2001 Profits: $179,100 Employees: 26,483 2000 Sales: $12,606,900 2000 Profits: $297,100 Fiscal Year Ends: 3/31 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Excellent technology base.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $ Second Exec. Salary: $
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
GELTEX PHARMACEUTICALS
www.geltex.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Kidney Failure Polymer-based Pharmaceuticals
GelTex Pharmaceuticals, Inc., a wholly owned subsidiary of Genzyme Corporation, is focused on the development of non-absorbed, polymer-based pharmaceuticals that selectively bind to and eliminate target substances from the intestinal tract. The company acquired SunPharm Corporation, and as a result, it gained additional expertise in two chemically related classes of molecules, polyamines and iron chelators. GelTex's first product, Renagel, treats end-stage renal disease and has FDA approval for marketing in the U.S. The firm is in agreement with Chugai Pharmaceutical Co., Ltd. to market and sell Renagel in Japan where the product is in Phase III clinical trials. GelTex is also involved in a collaborative agreement with Sankyo Pharma, Inc. regarding Welchol, an FDA approved lipid-lowering agent. Other products in the company's pipeline include: C. difficile (for infectious diseases) in Phase II trials; Polyamines (for cancer) in Phase II trials; Iron Chelators (for iron overload) in the research and development stage; Anti-obesity (for weight management) in the research and development stage; and Oral Mucositis (for ulcers of the mouth) in the research and development stage.
BRANDS/DIVISIONS/AFFILIATES: SunPharm Corporation Renagel Tablets Welchol Genzyme Corporation Chugai Pharmaceutical Co. Sankyo Pharma, Inc. Polyamines Iron Chelators
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Timothy Noyes, Pres. Edmund J. Sybertz, Sr. VP-Research & Dev. Mukund Chorghade, VP-Chemical Dev. Sciences Steven K. Burke, VP-Clinical Research Cynthia Arbeeny, VP-Metabolic Diseases Research Judith Marquis, VP-Preclinical Development Joann Nestor, VP-Administration/Sr. Corp. Counsel Thomas Neenan, VP-New Ventures Scott De'Aeth, VP-Quality Affairs Jeffrey Klinger, VP-Infectious Diseases W. Harry Mandeville, VP-Chemical Tech. Randy Holmes-Farley, VP-Chemical Research
Phone: 781-290-5888 Fax: 781-290-5890 Toll-Free: 800-510-5059 Address: 153 2nd Ave., Waltham, MA 02451 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $ 2001 Profits: $ Employees: 2000 Sales: $ 2000 Profits: $ Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Y Second Exec. Salary: $ ADVANTAGE: Award winning staff/Expansion into Japanese market.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
GENE LOGIC INC
www.genelogic.com
Industry Group Code: 541710 Ranks within this company's industry group: Sales:9 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:9
Transportation: Aerospace: Automotive:
Y
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Research-Gene Expression Data (Drug Discovery) Bioinformatics
Gene Logic is a leading provider of integrated genomicsbased information products, services and bioinformatics related to gene activity in human disease and toxicity, which enable global pharmaceutical and biotechnology companies. The company is building and commercializing a comprehensive survey of gene expression in human and animal tissues. The firm markets gene expression database products to global pharmaceutical, health care and life science industries. Its GeneExpress reference database includes BioExpress, ToxExpress and Genesis: The GeneExpress Enterprise System. BioExpress is a broad and in-depth survey of gene expression in a wide range of normal and diseased human tissues, tissues from experimental animals and human and animal cell lines. DataSuites are disease/indication-specific subsets derived from BioExpress, which provides comprehensive gene expression, genetic and clinical information from a focused range of normal and diseased tissue samples. CustomSuites, which combine proprietary information from BioExpress and customers’ proprietary information generated either in-house or by Gene Logic, are customized DataSuites tailored to the specific research interests of its customers. ToxExpress is a collection of predictive models based on gene expression profiles and predictive modeling capabilities. Genesis Enterprise System is a proprietary bioinformatics system that allows customers to combine and analyze detailed clinical histories and full genomic information. In addition, the company provides custom database services to clients who wish to discover drug targets using previously gathered information. Recently, Gene Logic introduced ToxSuites and ToxScreen Reports, expanding the information products within its ToxExpress database. ToxSuites will be comprised of liver and kidney organ data sets, and ToxScreen Reports will provide summaries of liver toxicity of individual compounds. Gene Logic provides dental insurance, flexible spending accounts and life insurance to its employees, pays 100% of qualified college tuition and provides an annual bonus.
BRANDS/DIVISIONS/AFFILIATES: GeneExpress BioExpress ToxExpress Genesis: The GeneExpress Enterprise System DataSuites CustomSuites ToxSuites ToxScreen Reports
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Mark D. Gessler, CEO Mark D. Gessler, Pres. Philip L. Rohrer, Jr., CFO David S. Murray, Sr. VP-Mktg. and Sales Victor M. Markowitz, Sr. VP/Chief Info. Officer F. Dudley Staples, Jr., Sr. VP/Corp. Sec. F. Dudley Staples, Jr., General Counsel Douglas Dolginow, Sr. VP-Pharmacogenomics Mark D. Gessler, Chmn.
Phone: 301-987-1700 Fax: 301-987-1701 Toll-Free: 800-436-3564 Address: 708 Quince Orchard Rd., Gaithersburg, MD 20878 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $54,800 (12 months) 2002 Profits: $-24,100 (12 months) Stock Ticker: GLGC 2001 Sales: $43,300 2001 Profits: $-33,200 Employees: 264 2000 Sales: $26,883 2000 Profits: $-24,017 Fiscal Year Ends: 12/31 1999 Sales: $19,200 1999 Profits: $-20,600 1998 Sales: $13,200 1998 Profits: $-44,900
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $400,000 Bonus: $249,986 Stock Purch. Plan: Y Second Exec. Salary: $292,320 Bonus: $129,255 ADVANTAGE: Strong alliances with other biotech companies/Excellent bioinformatics technologies.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
GENENTECH INC
www.gene.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:15 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:28
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Biotechnology Genetically Engineered Drugs
Genentech, Inc. is a biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. Genentech is responsible for producing technology that has spawned 15 approved biotechnology products. The company’s products consist of a variety of cardio-centric medications, as well as cancer, GHD and cystic fibrosis treatments. Biotechnology products offered by Genentech include Herceptin, which is used in treatments of certain metastatic breast cancers; Nutropin, a sustained-release formulation of growth hormone for the treatment of growth hormone deficiency (GHD) in children; TNKase singlebolus thrombolytic agent for the treatment of acute myocardial infarction; and Pulmozyme Inhalation Solution for the treatment of cystic fibrosis. The company also produces the Rituxan antibody, which it markets together with IDEC Pharmaceuticals, for the treatment of patients with relapsed or refractory low-grade or follicular, CD20positive B-cell non-Hodgkin's lymphoma. Through its long-standing Patient Assistance Program, Genentech assures that everyone who needs these important medicines can get them. The firm also supports the continuing improvement of patient care through its postmarketing studies, which collect data on the health progress of patients who use Genentech medicines nationwide. Scientists of the company publish around 250 scientific papers per year and are highly regarded as among the most prolific in the scientific industry. The firm’s scientists focus mainly in the areas of cardiovascular disease and cancer, the number one and number two fatal diseases in the U.S. In recent news, the company announced its Phase III study of Avastin and chemotherapy resulted in extended survival rates in metastatic colorectal cancer patients. Avastin is an antibody developed to inhibit angiogenesis (the formation of new blood vessels) as a potential treatment for solidtumor cancers. The drug is expected to launch in 2004. Company perks include on-campus bicycles, an on-site hair salon and free espresso.
BRANDS/DIVISIONS/AFFILIATES: Avastin TNKase Herceptin Rituxan Activase Pulmozyme Nutropin Depot Nutropin AQ
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Arthur D. Levinson, CEO Myrtle S. Potter, COO Arthur D. Levinson, Pres. Louis J. Lavigne, Jr., Exec. VP/CFO Richard H. Scheller, Sr. VP-Research Susan Desmond-Hellmann, Chief Medical Officer Stephen G. Juelsgaard, Exec. VP/Corp. Sec. Stephen G. Juelsgaard, General Counsel Myrtle S. Potter, Exec. VP-Commercial Oper. Susan Desmond-Hellmann, Exec. VP-Dev. Susan Desmond-Hellmann, Exec. VP-Product Oper. Arthur D. Levinson, Chmn.
Phone: 650-225-1000 Fax: 650-225-6000 Toll-Free: 800-488-6519 Address: One DNA Way, South San Francisco, CA 94080-4990 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $2,252,300 (12 months) 2002 Profits: $63,800 (12 months) Stock Ticker: DNA 2001 Sales: $2,081,700 2001 Profits: $150,300 Employees: 5,252 2000 Sales: $1,736,400 2000 Profits: $-74,200 Fiscal Year Ends: 12/31 1999 Sales: $1,401,000 1999 Profits: $-1,157,500 1998 Sales: $1,150,900 1998 Profits: $181,900
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $811,200 Bonus: $1,135,000 Stock Purch. Plan: Y Second Exec. Salary: $543,656 Bonus: $450,000 ADVANTAGE: Strong strategic alliance strategy/High new product potential/Excellent record of successful development.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
GENERAL DYNAMICS
www.generaldynamics.com
Industry Group Code: 336410 Ranks within this company's industry group: Sales:7 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
Profits:1 Y
Y
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y Y
GROWTH PLANS/SPECIAL FEATURES:
Aerospace Products and Services Military Combat Vehicles Shipbuilding Information Systems and Technology Defense Systems and Services Business Jet Manufacturing
General Dynamics Corp. (GDC) engages in businesses including information and communications technology, land and amphibious combat systems, naval and commercial shipbuilding and business aviation. The firm's operations are divided into four segments: information systems and technology (IST), marine systems, combat systems and aerospace. GDC's customers include the U.S. military, other government organizations, the armed forces of allied nations and a diverse based of corporate and industrial buyers. The IST group provides defense and commercial customers with infrastructure and systems integration skills required to process, communicate and manage information effectively. The group has market-leading positions in the design, deployment and maintenance of wireline and wireless voice and data networks, telecommunications system security, encryption and fiber optics. The combat systems group provides systems integration, design, development, production and support for armored vehicles, armaments, munitions and components, with products lines including unmanned systems, medium-caliber guns, space propulsion systems, reactive armor and suspensions, engines and transmissions. The marine systems division provides the U.S. Navy with combat vessels, including nuclear submarines, surface combatants and auxiliary ships. The segment also provides ship management services for the U.S. government and builds commercial ships. The aerospace group designs, develops, manufactures and provides services for technologically advanced business jet aircraft. Gulfstream Aerospace has delivered more than 1,300 aircraft for customers around the world. The firm recently acquired GM Defense for $1.1 billion, making it the nation's leading builder of armored vehicles. In other news, subsidiary General Dynamics Network Systems acquired Creative Technology. The Virginia-based information technology and consulting firm primarily serves the Department of Defense and the intelligence community.
BRANDS/DIVISIONS/AFFILIATES: Freeman Energy Corp. Gulfstream Aerospace Santa Barbara Sistemas Material Service Corp. American Overseas Marine GM Defense Electric Boat Company Creative Technology
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Nicholas D. Chabraja, CEO Joseph T. Lombardo, COO Nicholas D. Chabraja, Pres. Walter M. Oliver, Sr. VP-Human Resources Kenneth A. Hill, VP-IT John W. Schwartz, Controller David A. Savner, Corp. Sec. David A. Savner, General Counsel David K. Heebner, Sr. VP-Planning Kendell Pease, VP-Corp. Comm. David H. Fogg, Treas. Michael W. Toner, Exec. VP-Marine Systems Arthur J. Veitch, Exec. VP-Combat Systems and Resources David D. Baier, VP-Taxes Michael E. Chandler, VP-Network Systems Nicholas D. Chabraja, Chmn.
Phone: 703-876-3000 Fax: 703-876-3125 Toll-Free: Address: 3190 Fairview Park Dr., Falls Church, VA 22042-4523 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $13,829,000 (12 months) 2002 Profits: $917,000 (12 months) Stock Ticker: GD 2001 Sales: $12,163,000 2001 Profits: $943,000 Employees: 54,000 2000 Sales: $10,356,000 2000 Profits: $901,000 Fiscal Year Ends: 12/31 1999 Sales: $8,959,000 1999 Profits: $880,000 1998 Sales: $7,398,000 1998 Profits: $589,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $1,050,000 Stock Purch. Plan: Second Exec. Salary: $450,000 ADVANTAGE: High profit margin/Excellent record of profitable growth.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $2,300,000 Bonus: $550,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
GENERAL ELECTRIC CO
www.ge.com
Industry Group Code: 335000 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Electrical Equipment and Appliances Energy Systems Broadcast Television Lighting Medical Equipment Aircraft Engines and Components
General Electric Company (GE) is one of the largest and most diversified industrial corporations in the world, with divisions dealing in electricity, appliances, transportation, computer-related information, financial services and network and cable television. GE's products include major appliances; lighting products; industrial automation products; medical diagnostic imaging equipment; motors; electrical distribution and control equipment; locomotives; power generation and delivery products; nuclear power support services and fuel assemblies; commercial and military aircraft jet engines; and engineered materials, such as plastics, silicones and superabrasive industrial diamonds; and chemicals for treatment of water and process systems. GE Medical Systems develops diagnostic and therapy equipment including magnetic resonance (MR) scanners, computed tomography (CT) scanners, X-ray, nuclear imaging and ultrasound equipment. GE Aircraft Engines has grown to be the world’s leading producer of aircraft engines for commercial and military use. GE Plastics contributes heavily to the world’s supply of high-performance polymers for varied applications. General Electric also manages a successful financing subsidiary, GE Capital Corporation, offering services for business or personal financing around the globe. The corporation also maintains its traditional businesses in the area of energy and appliances: GE Power Systems and GE Appliances. Through its affiliate, the National Broadcasting Company, Inc., GE delivers network television services, operates television stations, and provides cable, Internet and multimedia programming and distribution services. Through another affiliate, General Electric Capital Services, Inc., GE offers a broad array of financial and other services including consumer financing, commercial and industrial financing, real estate financing, asset management and leasing, mortgage services, consumer savings and insurance services, and specialty insurance and reinsurance. The company offers employees on-the-job training programs, generous benefits, bonuses and the opportunity to work overseas.
BRANDS/DIVISIONS/AFFILIATES: General Electric Capital Corporation General Electric Aircraft Engines General Electric Appliances General Electric Lighting General Electric Medical Systems NBC Television Columbia/HCA Specialty Underwriters
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jeffrey R. Immelt, CEO Keith S. Sherin, Sr. VP-Finance/CFO William J. Conaty, Sr. VP-Human Resources Scott C. Donnelly, Sr. VP-Research & Dev. Gary M. Reiner, Sr. VP/CIO Benjamin W. Heineman, Jr., Sr. VP/Corp. Sec. Benjamin W. Heineman, Jr., Sr. VP/General Counsel Robert A. Jeffe, Sr. VP-Corp. Bus. Dev. Robert C. Wright, CEO, National Broadcasting Company, Inc. John Krenicki, Jr., Pres./CEO, GE Plastics John G. Rice, Pres./CEO, GE Power Systems Charlene Begley, Pres./CEO, GE Transportation Systems Jeffrey R. Immelt, Chmn. Ferdinando Beccalli, Pres./CEO, GE Europe
Phone: 203-373-2211 Fax: 203-373-3131 Toll-Free: 800-626-2004 Address: 3135 Easton Tpke., Fairfield, CT 06828-0001 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $130,685,000 (12 months) 2002 Profits: $14,118,000 (12 months) Stock Ticker: GE 2001 Sales: $125,679,000 2001 Profits: $13,684,000 Employees: 315,000 2000 Sales: $129,853,000 2000 Profits: $12,735,000 Fiscal Year Ends: 12/31 1999 Sales: $111,630,000 1999 Profits: $10,717,000 1998 Sales: $100,469,000 1998 Profits: $9,296,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan:
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $3,000,000 Stock Purch. Plan: Second Exec. Salary: $2,229,167 ADVANTAGE: Superior management and product lines/Leading player in a number of industries.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $3,900,000 Bonus: $4,300,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
GENERAL MOTORS CORP
www.gm.com
Industry Group Code: 336111 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Profits:8
Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Automobile, Truck and Engine Manufacturing Information Technologies Financing and Insurance
General Motors Corporation (GM) makes and sells cars, trucks, automotive systems and locomotives worldwide. The firm sells automobiles under brands including Chevrolet, Pontiac, Buick, Cadillac, GMC, Saturn, Hummer, Saab, Opel, Vauxhall and Holden. GM parts and accessories are marketed under the GM, GM Goodwrench and ACDelco brands through GM's service and parts operations division. Subsidiary General Motors Acceptance Corporation and its subsidiaries provide financing and insurance options worldwide. GM’s OnStar subsidiary is an industry leader in in-vehicle safety, security and information services. It provides more than 2 million subscribers with a variety of services, including automatic notification of air-bag deployment, stolen vehicle location, remote door unlocking, emergency services dispatch, roadside aid, remote diagnostics, route support and concierge services. Subsidiary GM Locomotives designs, manufactures and markets diesel-electric locomotives, medium-speed diesel engines, locomotive components, light armored vehicles, turret systems and locomotive maintenance services to a global customer base. Subsidiary Allison Transmission operates in the design, manufacture and sale of medium- and heavy-duty automatic transmissions. Additionally, GM owns 49% of Isuzu Motors and 20% of Fuji Heavy Industries (manufacturers of Subaru), Suzuki Motor and Fiat Auto. GM recently announced plans to sell its stake in subsidiary Hughes Electronics to News Corp, in order to focus on its core global automotive operations. GM plans to continue its strategy of increasing worldwide market share by leveraging its global development and manufacturing operations. Of the company's officers and managers, 14.7% are minorities; 21.6% of the entire work force are minorities. One-fourth of the company's suppliers are owned by minorities. General Motors provides certain employees with a new company car every three months. The firm also offers international job opportunities, vehicle discounts, a tuition assistance plan, flexible scheduling and outstanding family leave and child care options.
BRANDS/DIVISIONS/AFFILIATES: Isuzu Motors OnStar Fuji Heavy Industries Allison Transmission Fiat Auto Cadillac Pontiac Chevrolet
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. G. Richard Wagoner, Jr., CEO G. Richard Wagoner, Jr., Pres. John M. Devine, CFO John F. Smith, VP-US Mktg. Kathleen S. Barclay, VP-Human Resources Ralph J. Szygenda, CIO Hans-Heinrich Demant, VP-Eng. Troy A. ClarkGuy D. Briggs, VP-Mfg. Nancy E. Polis, Corp. Sec. Thomas A. Gottschalk, General Counsel Robert A. Lutz, VP-Product Dev. Walter G. Borst, Treas. Robert A. Lutz, Chmn.-Product Dev. Michael J. Burns, Pres.-GM Europe Peter H. Hanenberger, Managing Dir.-Holden Ltd. Peter Augustsson, VP-Saab Automobile G. Richard Wagoner, Jr., Chmn. Bo I. Andersson, VP-Global Purchasing
Phone: 313-556-5000 Fax: 313-556-5108 Toll-Free: Address: 300 Renaissance Center, Detroit, MI 48265 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $186,763,000 (12 months) 2002 Profits: $1,736,000 (12 months) Stock Ticker: GM 2001 Sales: $177,260,000 2001 Profits: $601,000 Employees: 350,000 2000 Sales: $184,632,000 2000 Profits: $4,452,000 Fiscal Year Ends: 12/31 1999 Sales: $176,558,000 1999 Profits: $6,002,000 1998 Sales: $161,315,000 1998 Profits: $2,956,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $2,000,000 Stock Purch. Plan: Second Exec. Salary: $1,452,000 ADVANTAGE: Diversified holdings in major European and Asian car manufacturers.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $500,000 Bonus: $784,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
GENOME THERAPEUTICS CORP
www.genomecorp.com
Industry Group Code: 541710 Ranks within this company's industry group: Sales:17 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:12
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drug Target Discovery Genomics Database
Genome Therapeutics Corporation is a leader in the field of genomics-based drug target discovery, defined as the identification and functional characterization of genes associated with infectious and human diseases. The company’s two business segments are the biopharmaceutical division and GenomeVision Services. The company has over 10 years of experience in the field of genomic research and has been sponsored by the United States government. Genome Therapeutics has developed numerous technologies and tools that are widely used in the genomic field. The company’s lead product, Ramoplanin, is in Phase III clinical trials for the prevention of bloodstream infections. Six other products are being developed in collaboration with companies including Schering-Plough, Wyeth, AstraZeneca and bioMerieux for the treatment of asthma, osteoporosis and ulcers. The firm developed the PathoGenome Database, a commercial source of microbial genomic information that provides customers with genomic information about microbial organisms and fungi. The database was introduced on the Internet for worldwide access through a partnership with Compugen via that company's LabOnWeb.com. Its GenomeVision Services includes library construction and customized sequencing services to pharmaceutical companies, biotechnology companies and research institutions on a contract basis. Recently, the company, the University of Southampton and ScheringPlough Corporation introduced the discovery of a gene linked to asthma, known as ADAM33. This finding will aid in the development of prevention and treatment of asthma. Genome Therapeutics offers a wide range of benefits to its employees, including health and dental insurance, life insurance and disability benefits. In addition, the firm reimburses qualified tuition expenses. Genome Therapeutics also offers flexible work schedules, confidential counseling services, fitness center access, a bonus for employee referral and stock options.
BRANDS/DIVISIONS/AFFILIATES: Ramoplanin GenomeVision Services LabOnWeb.com PathoGenome Database Compugen ICAgen
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Steven M. Rauscher, CEO Steven M. Rauscher, Pres. Stephen Cohen, Sr. VP/CFO Martin Williams, Sr. VP-Mktg. Joseph A. Pane, VP-Human Resources Richard Labaudiniere, Sr. VP-Research and Dev. Timothy S. Leach, VP-Clinical and Medical Affairs Martin Williams, Sr. VP-Corp. Dev. Christopher Taylor, Investor Rel. and Corp. Mktg. Robert J. Hennessey, Chmn.
Phone: 781-398-2300 Fax: 781-893-9535 Toll-Free: Address: 100 Beaver St., Waltham, MA 02453 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $23,000 (12 months) 2002 Profits: $-34,000 (12 months) Stock Ticker: GENE 2001 Sales: $35,700 2001 Profits: $-10,100 Employees: 152 2000 Sales: $26,400 2000 Profits: $-2,800 Fiscal Year Ends: 8/31 1999 Sales: $24,000 1999 Profits: $-6,300 1998 Sales: $19,200 1998 Profits: $-15,800
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: A leader in genomics technology.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $360,000 Second Exec. Salary: $230,000
Bonus: $121,500 Bonus: $75,134
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
GENZYME CORP
www.genzyme.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:19 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:59
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs Surgical Products Genetic Testing Services Oncology Drugs
Genzyme Corporation develops, manufactures and markets innovative products and services for major unmet medical needs. The company operates worldwide in 26 countries, primarily in North America and Europe. The firm conducts operations through three divisions: Genzyme Biosurgery, Genzyme General and Genzyme Molecular Oncology. Genzyme Biosurgery develops and markets a portfolio of devices, advanced biomaterials and biotherapeutics, primarily for the cardiothoracic, orthopaedic and general surgery markets. Genzyme General primarily develops and markets drugs and services for the treatment of genetic disorders and their chronic debilitating diseases. This division’s major products include Cerezyme and Ceredase (for the treatment of Gaucher’s disease), Fabrazyme, GT 56-252, Thyrogen, Aldurazyme and Myozyme. Moreover, Genzyme General has a strong pipeline of therapeutic products under development. The division also manufactures and markets diagnostic products, genetic testing services and pharmaceutical intermediates. Genzyme Molecular Oncology is developing a new generation of cancer products, focusing primarily on cancer vaccines and angiogenesis inhibitors. This division draws from a broad array of medical expertise in the gene discovery, gene therapy, small-molecule drug discovery, protein therapeutic and genetic diagnostic fields. In recent news, the company announced that Aldurazyme was approved by the FDA and is available in the U.S. for patients with the genetic disease mucopolysaccharidosis 1 (MPS 1). Aldurazyme was created through a collaboration between Genzyme and BioMarin. Genzyme offers its employees several family-oriented employee benefits such as day care, elder care and adoption resource and referral services.
BRANDS/DIVISIONS/AFFILIATES: Renagel Thyrogen Cerezyme Aldurazyme Myozyme Genzyme General Genzyme Molecular Oncology Genzyme Biosurgery
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Henri A. Termeer, CEO Henri A. Termeer, Pres. Michael S. Wyzga, Sr. VP-Finance/CFO Zoltan Csimma, Sr. VP-Human Resources Alan E. Smith, Sr. VP-Research/Chief Scientific Officer Peter Traynor, Corp. Controller Richard A. Moscicki, Sr. VP/Chief Medical Officer Thomas J. DesRosier, Sr. VP/General Counsel Mark Bamforth, Sr. VP-Corp. Oper. Richard H. Douglas, Sr. VP-Corp. Dev. Elliott D. Hillback, Jr., Sr. VP-Corp. Affairs Evan M. Lebson, VP/Treas. Earl M. Collier, Exec. VP/Pres.-Biosurgery Roger W. Louis, Chief Compliance Officer Mara Aspinall, Pres.-Genetics and Pharmaceuticals Alison Lawton, Sr. VP-Regulatory Affairs Henri A. Termeer, Chmn. Jim Geraghty, Sr. VP-Int'l Dev.
Phone: 617-252-7500 Fax: 617-252-7600 Toll-Free: Address: One Kendall Sq., Cambridge, MA 02139-1562 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,329,500 (12 months) 2002 Profits: $-13,100 (12 months) Stock Ticker: GENZ 2001 Sales: $1,223,600 2001 Profits: $-112,100 Employees: 5,600 2000 Sales: $752,483 2000 Profits: $85,956 Fiscal Year Ends: 12/31 1999 Sales: $635,366 1999 Profits: $142,077 1998 Sales: $569,319 1998 Profits: $133,052
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $1,162,202 Bonus: $312,000 Stock Purch. Plan: Y Second Exec. Salary: $565,000 Bonus: $83,100 ADVANTAGE: Genzyme Corp. owns one of the largest recombinant protein manufacturing operations in the world.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
GEORG FISCHER LTD
www.georgfischer.com
Industry Group Code: 541310 Ranks within this company's industry group: Sales:5 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Y
Transportation: Aerospace: Automotive:
Profits:9
Y
Y
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Engineering Services Automotive Products
Georg Fischer operates in various industrial sectors, including the engineering, production, marketing and sale of technologically demanding processes, plants, systems and related components. International corporate operations are divided into four groups with a high degree of entrepreneurial responsibility: automotive products, piping systems, manufacturing technology and plant engineering. The plant engineering group offers comprehensive and customized services, operation units and plants for a wide variety of complex industrial applications on a worldwide basis. The piping systems group was recently recognized for its dedication and commitment in supplying products and services according to the standards set by Texas Instruments. The division also won Intel’s Preferred Quality Supplier Award for excellence in performance. The firm’s automotive products group has supplied parts for projects of Renault S.A., France’s leading car manufacturer. Under the terms of contract, the company supplied highly stressed axle components, steering knuckles and hubs, which is noteworthy since the French market tends to be dominated by state-owned foundries. In addition, the automotive products group has a joint venture with the Brazilian company Fundicao Tupy, the largest Latin American supplier of castings for the private and commercial vehicle industry, in order to supply products made by Georg to customers in Latin America. As the automotive industry becomes increasingly global, the firm’s commitment to Brazil is an important and necessary strategic step towards the expansion of production and supply activities.
BRANDS/DIVISIONS/AFFILIATES: Agie, Ltd. Buss, Inc. Charmilles Technologies SA Waeschle Maschinenfabrik GmbH
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Kurt Stirnemann, CEO Martin Huber, Pres. Friedrich Rufer, Head-Corp. Finance Sabina Schmid, Human Resources Ernst Willi, Head-Corp. Dev. Jurg Krebser, Head-Piping Systems Group Ferdinand Stutz, Head-Automotive Products Group Kurt E. Stirnemann, Head-Mfg. Tech. Group Martin Huber, Chmn.
Phone: 41-52-631-1111 Fax: 41-52-631-2837 Toll-Free: Address: Amsler-Laffon-Strasse 9, Schaffhausen, CH-8201 Switzerland
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $2,491,500 (12 months) 2002 Profits: $-14,400 (12 months) Stock Ticker: Foreign 2001 Sales: $2,329,800 2001 Profits: $38,900 Employees: 13,737 2000 Sales: $2,421,800 2000 Profits: $93,700 Fiscal Year Ends: 12/31 1999 Sales: $2,035,700 1999 Profits: $82,300 1998 Sales: $2,209,000 1998 Profits: $104,700
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Highly diversified company/Global presence.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
GERBER SCIENTIFIC INC
www.gerberscientific.com
Industry Group Code: 334111 Ranks within this company's industry group: Sales:10 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:10
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Hardware-Automated Manufacturing Systems Automation Software Products
Gerber Scientific, Inc. is a holding company providing corporate management services and financial resources to its subsidiaries. The company designs, manufactures and sells sophisticated automation hardware and software products for use in the optical, signmaking and specialty graphics, apparel and flexible goods, automotive and aerospace industries. The firm also markets computeraided design and computer-aided manufacturing systems to automate the design and production processes in a broad range of industries. The company has six principal subsidiaries: Gerber Scientific Products and Spandex PLC, which comprise the firm's signmaking and specialty graphics business; Gerber Garment Technology, Inc., a leader in computer-based design and manufacture of systems for producing sewn goods; Gerber Coburn Optical, Inc., which creates ophthalmic lens processing systems; Gerber Innovations, which specializes in rotary machining die tool production systems; and SignStorey, creators of in-store marketing communication systems. In a strategic move to increase market penetration of its optical lens processing technologies, Gerber Coburn Optical created the Premier Lab, a compact ophthalmic lab system geared to lower volume wholesale or retail prescription lens processing. The company recently unveiled its newest imaging system, the Gerber Jetseter. The Jetseter is a new wide-format piezoelectric drop-ondemand inkjet printer that will give professionals the most comprehensive range of image applications available. Gerber offers its workers full tuition reimbursement and life, business, travel and medical insurance. The firm actively supports employee volunteerism and participates in community education programs.
BRANDS/DIVISIONS/AFFILIATES: Gerber Garment Technology, Inc. Gerber Scientific Products, Inc. Gerber Systems Corporation Gerber Coburn Optical, Inc. Gerber Innovations Spandex PLC Premier Lab SignStorey
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Marc T. Giles, CEO Bernard J. Demko, COO Marc T. Giles, Pres. Shawn M. Harrington, CFO/Exec. VP Anthony L. Mattacchione, VP/Controller Richard F. Treacy, Jr., Corp. Sec. Richard F. Treacy, Jr., General Counsel James S. Arthurs, Pres., Gerber Garment Tech. John R. Hancock, Pres., Gerber Coburn Elaine A. Pullen, Pres., Gerber Scientific Products Doris W. Skoch, Pres., Spandex PLC
Phone: 860-644-1551 Fax: 860-643-7039 Toll-Free: Address: 83 Gerber Rd. W., South Windsor, CT 06074 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $502,700 (12 months) 2002 Profits: $-119,700 (12 months) Stock Ticker: GRB 2001 Sales: $553,000 2001 Profits: $-23,600 Employees: 2,207 2000 Sales: $610,700 2000 Profits: $25,900 Fiscal Year Ends: 4/30 1999 Sales: $594,600 1999 Profits: $29,600 1998 Sales: $430,500 1998 Profits: $7,400
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Stock Purch. Plan: ADVANTAGE: Diverse products and applications.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Top Exec. Salary: $317,836 Second Exec. Salary: $303,239
Bonus: $171,875 Bonus: $212,823
LOCATIONS: ("Y" = Yes) West:
Southwest: Y
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
GETRONICS NV
www.getronics.com
Industry Group Code: 541512 Ranks within this company's industry group: Sales:4 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:9
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y Y
GROWTH PLANS/SPECIAL FEATURES:
Consulting-InfoTech Related Systems Integration
Getronics NV is a leading provider of information and communication technology (ICT) solutions and services to e-business companies. The firm consults with clients to determine their ICT needs and develops strategies to meet those needs. The Netherlands-based company has a presence in over 30 countries, as well as service partner agreements in 70 more. Getronics also designs, builds and manages ICT infrastructures for its clients. The company’s major U.S. clients include Merrill Lynch, Shell Oil, the U.S. Mint and Road Runner. The firm also maintains strategic partnerships with over 20 premier hardware and software suppliers around the world, which enables it to offer a comprehensive array of solutions to clients’ needs. Getronics operates in three distinct segments. CustomerPlace focuses on improving clients' use of ICT in order to develop stronger relationships with customers. KnowledgePlace focuses on streamlining ICT processes. NetWorkPlace develops the framework for building, maintaining and managing clients' ICT infrastructure. Getronics offers a number of internships yearly for college students.
BRANDS/DIVISIONS/AFFILIATES: Wang Global CustomerPlace KnowledgePlace Connect Systems Integrator NetWorkPlace G2E
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Cees G. van Lujik, CEO Cees G. van Lujik, Pres. Harry Vreedenburgh, VP-Finance Mattijs Kropholler, Mgr.-Human Resources Steven van Maasakker, VP-Legal Services Barry Sykes, VP-Global Bus. Dev. Stuart Appleton, VP-Corp. Comm. Axel Ruckert, Chmn.
Phone: 31-20-586-1412 Fax: 31-20-586-1568 Toll-Free: Address: Donauweg 10, Amsterdam, 1043 AJ The Netherlands
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $3,796,300 (12 months) 2002 Profits: $-431,900 (12 months) Stock Ticker: Foreign 2001 Sales: $3,675,200 2001 Profits: $-921,200 Employees: 23,000 2000 Sales: $3,834,635 2000 Profits: $55,749 Fiscal Year Ends: 12/31 1999 Sales: $3,407,222 1999 Profits: $109,641 1998 Sales: $1,420,655 1998 Profits: $98,663
SALARIES/BENEFITS: Pension Plan: Y Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: A leading provider of e-commerce communication technology and services.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
GILEAD SCIENCES INC
www.gilead.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:33 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:27
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Infectious Disease and Cancer Biopharmaceutical Products
Gilead Sciences, Inc. biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases worldwide such as viral and bacterial infections and cancer. Gilead maintains research, development, manufacturing or sales and marketing facilities in the United States, Europe and Australia. Gilead has six products that it currently markets within the U.S.: Hepsera for the treatment of chronic hepatitis B, AmBisome for the prevention of fungal infections, Tamiflu for the treatment of influenza and Vistide, Viread and DaunoXome, of which are used in the treatment of AIDS. Viread is the first nucleotide analogue reverse inhibitor approved for the treatment of HIV, and remains in cells for longer periods of time than many other antiretroviral drugs, allowing for once-daily dosing. The company recently completed the acquisition of Triangle Pharmaceuticals, Inc. Triangle develops drug candidates in the antiviral area, with a particular focus on potential therapies for HIV, including AIDS, and the hepatitis B virus. Triangle's portfolio consists of several drug candidates in clinical trials, including emtricitabine for the treatment of HIV infection, emtricitabine for the treatment of hepatitis B, amdoxovir for the treatment of HIV infection and clevudine for the treatment of hepatitis B. Triangle has filed marketing applications for emtricitabine for the treatment of HIV in the United States and the European Union. The company has an assistance program for its employees and offers tuition reimbursement for job-related courses. The firm also offers a subsidized café, free health club membership, on-site massages, vacation discounts and a variety of sports teams and family events. The company's dress code is casual.
BRANDS/DIVISIONS/AFFILIATES: Hepsera AmBisome Vistide Tamiflu DaunoXome Viread Triangle Pharmaceuticals, Inc. NeXstar Pharmaceuticals, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John C. Martin, CEO John C. Martin, Pres. John F. Milligan, Sr. VP-CFO Michael K. Inouye, Sr. VP-Commercial Oper. Marsha Roberts, VP-Human Resources Norbert W. Bischofberger, Exec. VP-Research and Dev. Nicole Onetto, Sr. VP-Medical Affairs Anthony D. Caracciolo, VP-Mfg. Mark L. Perry, Corp. Sec. Mark L. Perry, Exec. VP-Oper. John F. Milligan, VP-Corp. Dev. Crispin G.S. Eley, Sr. VP-Pharmaceutical Oper. Choung U. Kim, VP-Medicinal Chemistry Max D. Hensley, VP-Intellectual Property William A. Lee, Ph.D., Sr. VP-Research James M. Denny, Chmn.
Phone: 650-574-3000 Fax: 650-578-9264 Toll-Free: 800-445-3235 Address: 333 Lakeside Dr., Foster City, CA 94404 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $466,800 (12 months) 2002 Profits: $72,100 (12 months) Stock Ticker: GILD 2001 Sales: $233,800 2001 Profits: $52,300 Employees: 1,250 2000 Sales: $195,600 2000 Profits: $-56,800 Fiscal Year Ends: 12/31 1999 Sales: $169,000 1999 Profits: $-66,500 1998 Sales: $151,100 1998 Profits: $-44,800
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $653,334 Bonus: $616,000 Stock Purch. Plan: Y Second Exec. Salary: $429,750 Bonus: $315,000 Strong research, development and commercialization capabilities in antiviral and cancer therapies. ADVANTAGE:
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
GLAXOSMITHKLINE PLC
www.gsk.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:4 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:4
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Prescription Asthma Drugs Antivirals Dermatalogicals Neurologicals Oral Care Products
GlaxoSmithKline (GSK), formed from the merger of Glaxo Wellcome and SmithKline Beecham, and its subsidiaries constitute a major global drug and health products company engaged in the creation, discovery, development, manufacture and marketing of pharmaceutical and consumer health-related products. GSK’s headquarters are located in Middlesex, England, with operation headquarters in Philadelphia, Pennsylvania and Triangle Park, North Carolina, in addition to operating companies in approximately 102 countries. The firm’s major markets are the U.S., Japan, the U.K., Berlin and Italy. GSK operates in two industry segments: pharmaceuticals (prescription drugs and vaccines) and consumer health care (over-the-counter medicines, oral care and nutritional health care). Pharmaceutical product offerings include treatments for central nervous system disorders, such as Paxil for depression and anxiety and Lamictal for epilepsy; respiratory treatments, such as Flovent for asthma and Ventolin for bronchitis; antibacterials such as Augmentin and Amoxil; anti-virals such as Valtrex for genital herpes and Zeffix for hepatitis B; gastro-intestinal treatments such as Zantac for ulcer, reflux and dyspepsia; cardiovascular treatments such as Lanoxin for congestive heart failure; and arthritis treatments such as Relafen for osteoarthritis. Consumer health care products include over-the-counter medicines such as Tums, Citrucel and Nicorette; oral care products such as Aquafresh and Polident; and nutritional health care products. In recent news, the company announced it signed a licensing agreement with The Medivir Group for a nucleoside analogue reverse transcriptase inhibitor, MIV210. MIV-210 is in clinical development for the treatment of HIV.
BRANDS/DIVISIONS/AFFILIATES: Lanoxin Flovent Paxil Augmentin Zantac Relafen Tums Citrucel
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jean-Pierre Garnier, CEO Robert Ingram, COO John Coombe, CFO Daniel Phelan, Sr. VP-Human Resources Tachi Yamada, Pres.-Research and Dev. Ford Calhoun, Sr. VP-IT David Pulman, Pres.-Global Mfg. and Supply Rupert Bondy, Sr. VP/General Counsel David Stout, Pres./COO-Pharmaceutical Oper. Jennie Younger, Sr. VP-Corp. Comm. and Partnerships Marc Dunoyer, Pres.-Japan Chris Viehbacher, Pres.-US Pharmaceuticals John Ziegler, Pres.-Consumer Health Care Andrew Witty, Pres.-Europe Christopher A. Hogg, Chmn. Russell Greig, Pres.-Int'l
Phone: 44-20-8047-5000 Fax: 44-20-8047-7807 Toll-Free: 888-825-5249 Address: 980 Great West Rd., Brentford, Middlesex TW8 9GS UK
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $31,819,000 (12 months) 2002 Profits: $5,903,000 (12 months) Stock Ticker: GSK 2001 Sales: $29,858,600 2001 Profits: $-158,800 Employees: 100,000 2000 Sales: $26,346,500 2000 Profits: $-7,537,200 Fiscal Year Ends: 12/31 1999 Sales: $24,476,800 1999 Profits: $1,401,900 1998 Sales: $23,319,700 1998 Profits: $1,544,700
SALARIES/BENEFITS: Pension Plan: Y Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $ Bonus: $ Stock Purch. Plan: Second Exec. Salary: $ Bonus: $ ADVANTAGE: One of the world's leading health care companies/The largest health care company in the U.K.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
GLENAYRE TECHNOLOGIES INC
www.glenayre.com
Industry Group Code: 334200 Ranks within this company's industry group: Sales:2 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:2
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Communications Equipment-Switches, Transmitters & Controllers
Glenayre Technologies, Inc. provides communications messaging systems consisting of enhanced services and unified communications solutions and products for communications service providers (CSPs), including wireless, traditional and broadband carriers. The company's enhanced services and communications platforms include a broad range of integrated messaging and personal communications applications, such as call answering, voice messaging, fax messaging and unified communications. Its unified communications platform allows CSPs to provide their subscribers with access to voice, fax and e-mail messages in a single mailbox which can be accessed with a web browser, a wireless personal digital assistant or any mobile, wireless or wireline telephone. Glenayre’s products and applications are packaged and delivered in product portfolios under the Versera brand name. The company has installed its products in over 100 countries. The firm has employees in offices worldwide, including the Philippines, India, Japan, England, the Netherlands and Mexico. Major service providers using Glenayre's systems include Nextel, Voice Stream, Verizon, Alltel, US Cellular, Cricket, KPN, Cosmote, Smart and Starhub. Recently, the company introduced Vistanta, a presence and availability platform, and iConnect, a suite of intelligent mobile communication applications (products acquired from Teltier Technologies, Inc.) to its Versera solutions. Glenayre offers its employees health, dental, vision, life, accident and disability insurance. The company also provides educational opportunities. Its employees may attend seminars, trade shows and conferences as well as receive tuition reimbursement and in-house training. Glenayre also offers extracurricular activities such as picnics, parties and sports tournaments.
BRANDS/DIVISIONS/AFFILIATES: iConnect Versera Enhanced Services Versera Unified Communications Suite Versera Voice Services Suite Versera Multimedia Messaging Suite Vistanta
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Eric L. Doggett, CEO Eric L. Doggett, Pres. Debra Ziola, Sr. VP/Interim CFO Bill Edwards, Sr. VP-Mktg. and Sales Debra Ziola, Chief Acc. Officer Debra Ziola, Corp. Sec. Rolf Madson, Sr. VP-Products Clarke H. Bailey, Chmn.
Phone: 770-283-1000 Fax: 770-497-3990 Toll-Free: Address: 11360 Lakefield Dr., Duluth, GA 30097 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $67,400 (12 months) 2002 Profits: $-7,700 (12 months) Stock Ticker: GEMS 2001 Sales: $97,500 2001 Profits: $-270,500 Employees: 456 2000 Sales: $251,600 2000 Profits: $14,100 Fiscal Year Ends: 12/31 1999 Sales: $238,089 1999 Profits: $-128,528 1998 Sales: $367,039 1998 Profits: $-39,770
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Stock Purch. Plan: Y ADVANTAGE: Product installations worldwide.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $385,849 Second Exec. Salary: $333,115
Bonus: $387,905 Bonus: $60,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
GLOBAL INDUSTRIES LTD
www.globalind.com
Industry Group Code: 213111 Ranks within this company's industry group: Sales:2 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:1
Transportation: Aerospace: Automotive: Y
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Marine Construction and Support Services Oil Field Support Diving Services
Global Industries, Ltd. is a leading offshore construction company that offers a comprehensive and integrated range of marine construction and support services. These services include pipeline construction, platform installation and removal, subsea construction, diving services and deepwater remote intervention. The firm’s fleet of 17 dive support vessels and 22 liftboats provide efficient work platforms for virtually every phase of offshore oil and gas exploration, development and production. Clients use the company’s diving services for exploration support, pipeline installation, periodic inspection, repair and maintenance of fixed platforms and pipelines and, ultimately, salvage and site clearance. Global’s ROV Technologies subsidiary provides clients with specialized services such as intervention planning, system integration testing, tooling hardware design and fabrication. Moreover, the company’s Pelican Transportation subsidiary transports general commodities, oilfield equipment, pipeline and supplies for energy and construction companies.
BRANDS/DIVISIONS/AFFILIATES: Global Divers ROV Technologies Pelican Transportation Red Adair Company (The) Global Offshore Mexico
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. William J. Dore, CEO J. Michael Pearson, COO Peter Atkinson, Pres. Tim Miciotto, CFO Mike Buckley, VP-Human Resources William Dore, Jr., Corp. Dir.-Investor Rel. Robert E. Fulton, Treas. James J. Dore, Pres., Global Divers and Marine Contractors
Phone: 337-583-5000 Fax: 337-583-5100 Toll-Free: Address: 8000 Global Dr., Carlyss, LA 70665 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $494,000 (12 months) 2002 Profits: $-29,400 (12 months) Stock Ticker: GLBL 2001 Sales: $406,100 2001 Profits: $6,200 Employees: 1,911 2000 Sales: $298,700 2000 Profits: $-16,700 Fiscal Year Ends: 12/31 1999 Sales: $387,500 1999 Profits: $-1,100 1998 Sales: $342,200 1998 Profits: $39,000
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Stock Purch. Plan: Y ADVANTAGE: Expansion of deepwater capabilities.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $377,083 Second Exec. Salary: $199,583
Bonus: $ Bonus: $10,000
LOCATIONS: ("Y" = Yes) West:
Southwest: Y
Midwest:
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
GOODRICH CORPORATION
www.goodrich.com
Industry Group Code: 336410 Ranks within this company's industry group: Sales:10 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Profits:6 Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Y Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Aerospace Systems Manufacturer Specialty Plastics
Goodrich Corporation, formerly known as BFGoodrich Company, is one of the largest worldwide suppliers of components, systems and services to the commercial, regional, business and general aviation markets. The company is also a leading supplier of aircraft and satellite systems products to the global military and space markets. Its business is conducted on a global basis with manufacturing, service and sales undertaken in various locations throughout the world. The products and services are principally sold to customers in North America and Europe. Goodrich operates through three business segments: airframe systems, engine systems and electronic systems. Goodrich has completed the acquisition of Aeronautical Systems from TRW, Inc. The acquired businesses design and manufacture commercial and military aerospace systems and equipment, including engine controls, flight controls, power systems, cargo systems, hoists and winches and actuation systems. The company recently announced that it had entered into a definitive agreement to sell its avionics business to L-3 Communications. In other news, the company announced it has entered into an agreement with easyJet Airlines, a low-cost scheduled airline service in Europe. Through the agreement, the company will supply the wheels and brakes for more than 200 A320 aircraft.
BRANDS/DIVISIONS/AFFILIATES: Aeronautical Systems Godfrey Engineering, Inc. Goodron Reality, Inc. Rosemount Aerospace, Inc. Simmonds Precision Products, Inc. Tramco, Inc. BFGoodrich Company
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Marshall O. Larsen, CEO Marshall O. Larsen, Pres. Ulrich R. Schmidt, Exec. VP/CFO Terrence G. Linnert, VP-Human Resources Jerry S. Lee, Sr. VP-Tech. and Innovation Robert D. Koney, Jr., VP/Controller Terrence G. Linnert, General Counsel Terrence G. Linnert, VP-Admin. Joseph F. Andolino, VP-Bus. Dev. and Tax Scott E. Kuechle, VP/Treas. Cynthia M. Egnotovich, Segment Pres.-Electronic Systems John J. Carmola, Segment Pres.-Engine Systems John J. Grisik, Segment Pres.-Airframe Systems David L. Burner, Chmn.
Phone: 704-423-7000 Fax: 704-423-7100 Toll-Free: Address: 4 Coliseum Ctr., 2730 W. Tyvola Rd., Charlotte, NC 28217-4578 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $3,910,200 (12 months) 2002 Profits: $117,900 (12 months) Stock Ticker: GR 2001 Sales: $4,184,500 2001 Profits: $289,200 Employees: 22,900 2000 Sales: $4,363,800 2000 Profits: $286,300 Fiscal Year Ends: 12/31 1999 Sales: $4,319,800 1999 Profits: $138,700 1998 Sales: $3,950,800 1998 Profits: $226,500
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $950,000 Stock Purch. Plan: Second Exec. Salary: $600,000 ADVANTAGE: Successful repositioning from tires to aerospace.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $41,800 Bonus: $202,500
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
GOODYEAR TIRE & RUBBER COMPANY (THE) www.goodyear.com Industry Group Code: 326000 Ranks within this company's industry group: Sales:2 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Profits:1
Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Y Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Tires Manufacturing Automotive Service Shops Industrial Chemicals Belts Hoses Blimps
The Goodyear Tire and Rubber Company is one of the world's leading manufacturers of tires and rubber products. Goodyear invests heavily in the research and development of new tires designed to meet special needs. Aside from tires, Goodyear manufactures and markets several lines of rubber and reinforced plastic products for the transportation industry and numerous rubber-related chemicals for various applications. The firm also provides automotive repair and other services. It is a leading producer of industrial hoses, chemicals and belts for automobiles. Many of the company's products are bought by airlines and farmers. Goodyear maintains a major presence on the global stage with divisions scattered all over the world, including rubber plantations in Indonesia and over 900 retail stores in the U.S. The Goodyear replacement products division manufactures belts, hoses and air springs for applications in machines from heavyduty trucks to lawn mowers. The chemical division specializes in synthetic polymers, resins and latex. Goodyear's industrial products segment manufactures airsprings, industrial hoses, conveyer belt products, power transmission products and molded transportation products. Goodyear recently christened its newest blimp, the Spirit of America. Benefits for qualified employees include a chance to ride on the famed Goodyear Blimp, a new set of tires each year at store cost and access to a local private family park.
BRANDS/DIVISIONS/AFFILIATES: Kelly Springfield Tire Co. Cosmoflex, Inc. Belt Concepts of America, Inc. Celeron Corp. North American Tires Dunlop Kelly Tires Sumitomo Rubber Industries
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Samir G. Gibara, CEO Robert J. Keegan, COO Robert J. Keegan, Pres. Robert W. Tieken, CFO Cathryn M. Fischer, Chief Mktg. Officer Donald D. Harper, Sr. VP-Global Human Resources Joseph M. Gingo, Sr. VP-Tech. Eric A. Berg, CIO C. Thomas Harvie, General Counsel Clark E. Sprang, Sr. VP-Bus. Dev. and Bus. Integration Eric A. Berg, VP-e-Commerce Isabel H. Jasinowski, VP-Gov't Rel. Stephanie W. Bergeron, Sr. VP-Corp. Financial Oper. Vernon L. Dunckel, Sr. VP-Global Product Supply Jarro F. Kaplan, Pres., Eastern Europe, Africa and Middle East
Phone: 330-796-2121 Fax: 330-796-2222 Toll-Free: Address: 1144 E. Market St., Akron, OH 44316 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $13,850,000 (12 months) 2002 Profits: $-1,106,000 (12 months) Stock Ticker: GT 2001 Sales: $14,147,000 2001 Profits: $-204,000 Employees: 92,742 2000 Sales: $14,417,100 2000 Profits: $40,300 Fiscal Year Ends: 12/31 1999 Sales: $13,355,400 1999 Profits: $243,200 1998 Sales: $13,081,600 1998 Profits: $637,500
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $1,250,000 Bonus: $930,675 Stock Purch. Plan: Second Exec. Salary: $826,667 Bonus: $566,724 ADVANTAGE: Sells products throughout the world/The firm is suffering from a high debt load and large pension liabilities.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
GOOGLE INC
www.google.com
Industry Group Code: 541810A Ranks within this company's industry group: Sales:2 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Search Engine Paid Search Listing Advertising Services Shopping Site Weblog Tool
Google is the world's largest World Wide Web search engine and through its partnerships with Yahoo!, Netscape and others, answers more questions than any other service online. While Google searches are free of charge to consumers, the firm has many revenue streams from its business clients. It is very successful at charging fees to other sites that use its search technology. Also, it has a lucrative program that enables business clients to bid for placement of advertising that is presented to browsers based on the relevancy of a business's keywords. The firm's business model is working so well that revenues may reach as high as $750 million for 2003. The Google system receives more than 200 million searches daily from consumers worldwide, and Google provides unique web formats in 88 different languages to accommodate the world's diverse web surfers. More than 50% of its searches come from consumers outside the U.S. The system indexes the content of 3 billion pages on the World Wide Web. Google's staff includes more than 60 people with PhD-level educations. The company's technology is based on a unique, distributed-computing system that utilizes about 10,000 low-end servers rather than a small number of high-powered computers. Perks for employees may include massages, free snacks, free gourmet lunches and stock options. Benefits include 100% employer paid health care, vision and dental coverage; 15 days vacation the first year, 20 days the 4th year and 25 days the 6th year; 10 paid holidays and a 401(k) savings plan with matching deposits of up to $2,200 yearly. The Googleplex campus includes a gym and a sauna and a grand piano in the lobby. There are also weekly roller hockey games and organized bike rides for employees. The atmosphere is packed with energy and achievement while maintaining a casual look and feel.
BRANDS/DIVISIONS/AFFILIATES: Froogle Blooger Kleiner Perkins Sequoia Capital Applied Semantics CIRCA Technology AdSense AdWords
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Eric E. Schmidt, CEO George Reyes, CFO Omid Kordestani, Sr. VP Worldwide Sales Craig Silverstein, Director of Technology Sergey Brin, Pres.-Technology Jonathan Rosenberg, VP-Product Dev. Wayne Rosing, VP-Eng. Larry Page, Pres.-Products David C. Drummond, VP-Corp. Dev. Joan Braddi, VP-Licensing Sales Cindy McCaffrey, VP-Corp. Marketing Susan Wojcicki, Dir.-Product Management
Phone: 650-330-0100 Fax: 650-618-1499 Toll-Free: Address: 2400 Bayshore Pkwy., Mountain View, CA 94043 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $100,000 (12 months) 2002 Profits: $ (12 months) Stock Ticker: Private 2001 Sales: $ 2001 Profits: $ Employees: 500 2000 Sales: $ 2000 Profits: $ Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Bonus: $ Stock Purch. Plan: Second Exec. Salary: $ Bonus: $ ADVANTAGE: Widely perceived as providing the most relevant search returns/ Paid positioning service generates very healthy revenues.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
GRUPO DRAGADOS
www.dragados.com
Industry Group Code: 541310 Ranks within this company's industry group: Sales:4 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Y Y
Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Engineering Services Construction Services
Grupo Dragados, S.A. is a leading Spanish construction and engineering firm that services a wide variety of sectors, including transportation infrastructure, real estate, offshore activities, energy, hydraulics, environment, industrial equipment, concessions and maintenance. The company has worked in more than 60 countries, operating under four major divisions: Dragados Industrial International, Dragados Concessions International, Dragados Servicios and Dragados Obras Y Poryectos. Dragados Servicios handles the service division and Dragados Obras Y Poryectos handles the construction division of the company. Grupo Dragados has built more than 130 dams worldwide, over 2,500 kilometers of motorways and toll roads, 1,500 bridges and 500,000 dwellings. The company also provides consulting services for engineering design on various projects. Obralia, Grupo Dragados’ Internet construction portal made up of E-difica and Build2Build, allows construction companies to request offers, buy and sell by catalog, manage and document projects and other specialized services. Recently, Grupo Dragados purchased Cartera Grupo Logistico in order to become the major shareholder of Autoterminal, the leading Spanish company specializing in steeving and handling cars, thereby increasing its presence in the automobile logistics industry.
BRANDS/DIVISIONS/AFFILIATES: Cartera Grupo Logistico Autoterminal Dragados Industrial International Dragados Concessions International Dragados Servicios Dragados Obras Y Poryectos Obralia E-difica
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Antonio García Ferrer, Exec. Chmn. Demetrio Ullastres Llorente, COO-Construction and Concessions Jose Zornoza Soto, Sr. VP-Financial Dept. Antonio Gonzalez Suarez, Sr. VP-Human Resources Lorenzo Diaz Revenga, COO-Industrial Jesus Ruiz-Beato Bravo, Sr. VP-Legal Dept. Jose Luis Lopez Molinillo, Sr. VP-Admin. Juan Galvan Morante, Sr. VP-Planning and Systems Jaime Sanmartin Jordana, VP-Investor Rel. Jose Azpilicueta Ferrer, Sr. VP-Institutional Relations Jose Maria Osorio Sanchez, Sr. VP-Quality and Environment Alberto Laveron Simavilla, Sr. VP-Auditing Luis Janini Tatay, COO-Services
Phone: 34-91-583-30-00 Fax: 34-91-583-21-22 Toll-Free: Address: Avenida Tenerife, 4-6 San Sebastian De Los Reyes, Madrid, 28700 Spain
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $5,377,960 (12 months) 2002 Profits: $380,494 (12 months) Stock Ticker: Foreign 2001 Sales: $4,812,900 2001 Profits: $213,100 Employees: 59,000 2000 Sales: $4,232,500 2000 Profits: $190,400 Fiscal Year Ends: 12/31 1999 Sales: $3,491,800 1999 Profits: $116,100 1998 Sales: $4,046,100 1998 Profits: $102,800
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Bonus: $ Stock Purch. Plan: Second Exec. Salary: $ Bonus: $ ADVANTAGE: Well known company with many lucrative Spanish contracts/New focus on Internet operations.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
GTC BIOTHERAPEUTICS INC
www.gtc-bio.com
Industry Group Code: 325414 Ranks within this company's industry group: Sales:3 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:3
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Anticoagulants Genetically Engineered Therapeutic Products Transgenic Animals
GTC Biotherapeutics, Inc. (GTC), formerly Genzyme Transgenics Corp., applies transgenic technology to the development of recombinant proteins for therapeutic uses. Currently, GTC is using its technology platform to work toward commercialization in 15 therapeutic protein drug programs. Twelve of the programs focus on proteins that are proprietary to its partners, and three focus on proteins that the firm began developing internally. The company’s technology platform includes the ability to generate transgenic animals that express specific recombinant proteins in their milk and provide for animal husbandry, breeding and milking, as well as the ability to purify the milk to a clarified intermediate bulk material that may undergo manufacturing to obtain a clinical grade product. The firm generates transgenic animals through microinjection and nuclear transfer, and it expects to rely primarily on nuclear transfer techniques in new program development work. GTC uses goats in most of its commercial development programs due to relatively short generation times and relatively high milk production volume. The company’s products include Remicade, a monoclonal antibody marketed for rheumatoid arthritis, and Antegren, which is intended to treat neurological disorders. Recently, the company and Fresenius AG formed a joint venture to expand the commercial development opportunities of GTC’s recombinant human serum albumin program. GTC offers its employees dental insurance, tuition reimbursement and fitness club membership rebates.
BRANDS/DIVISIONS/AFFILIATES: Genzyme Transgenics Corp. Remicade Antegren D2E7 Antithrombin III
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Geoffrey F. Cox, CEO Geoffrey F. Cox, Pres. John B. Green, CFO/Sr. VP-Finance Jim Kimble, Human Resources Harry M. Meade, Sr. VP-Research and Dev. Daniel S. Woloshen, General Counsel Gregory Liposky, Sr. VP-Oper. Paul Horan, Sr. VP-Corp. Dev. Thomas E. Newberry, VP-Corp. Comm. Thomas E. Newberry, VP-Investor Rel. John B. Green, Treas. Carol A. Ziomek, VP-Dev. Suzanne Groet, VP-Therapeutic Protein Dev. Mark Adams, VP-Commercial Dev. Richard A. Scotland, VP-Regulatory Affairs Geoffrey F. Cox, Chmn.
Phone: 508-620-9700 Fax: 508-370-3797 Toll-Free: Address: 175 Crossing Blvd., Ste. 410, Framingham, MA 017029322 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $10,400 (12 months) 2002 Profits: $-24,300 (12 months) Stock Ticker: GTCB 2001 Sales: $13,700 2001 Profits: $-16,600 Employees: 182 2000 Sales: $16,200 2000 Profits: $-14,100 Fiscal Year Ends: 12/31 1999 Sales: $13,800 1999 Profits: $-18,800 1998 Sales: $11,600 1998 Profits: $-19,600
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $420,055 Bonus: $112,420 Stock Purch. Plan: Y Second Exec. Salary: $257,005 Bonus: $50,321 ADVANTAGE: A leader in the application of transgenic technology to the development of genetically engineered proteins.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
GUIDANT CORP
www.guidant.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:4 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:3
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Equipment-Cardiovascular Therapeutic Devices Implantable Cardioverter Defibrillator Systems Catheters Pacemakers Stents
Guidant Corporation designs, develops, manufactures and markets a broad range of products for use in cardiac rhythm management, vascular intervention and cardiac surgery. The company offers a number of implantable devices that can monitor the heart and deliver electricity to treat coronary abnormalities such as tachycardia, bradycardia and heart failure. Recently, the company received U.S. Food and Drug Administration approval of its VITALITY AVT implantable cardioverter defibrillator (ICD) system. This system combines complete ventricular and atrial therapies in the world’s smallest (30 cubic centimeters) and thinnest (11 millimeters) dual chamber ICD. The firm also manufactures a number of pacemakers that feature blended sensor technology designed to measure patient workload through respiration and motion, providing rate response based on the patient’s activity. Guidant’s emerging therapies division produces surgical devices that allow physicians to perform a coronary artery bypass while a patient’s heart remains beating. Additionally, this division develops devices used to treat abdominal aortic aneurysms (AAA). The company’s ANCURE System for endovascular repair of AAA allows many patients to forgo a highly invasive surgical procedure and enjoy shorter hospital stays. The firm’s diverse product line also includes biliary stent systems, coronary dilation catheters, coronary guide wires and postoperative atrial fibrillation management devices. In the spring of 2003, Guidant acquired X Technologies, Inc., which manufactures FX miniRAIL, a coronary device used in the treatment of de novo lesions and in-stent restenosis. Guidant offers its employees tuition reimbursement, dental and vision insurance and matching gifts to charity. The company’s offices in Santa Clara, Temecula and St. Paul feature on-site fitness centers, and employees at other locations receive reimbursement for a portion of their health club membership fees.
BRANDS/DIVISIONS/AFFILIATES: VITALITY AVT ANCURE System X Technologies, Inc. FX miniRAIL EASYTRAK MEGALINK VasoView PULSAR
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Ronald W. Dollens, CEO Ronald W. Dollens, Pres. Keith E. Brauer, CFO/VP-Finance Mark C. Bartell, Pres., U.S. Sales Oper. Roger Marchetti, VP-Human Resources William F. McConnell, Jr., CIO Debra Minott, Corp. Sec. Debra Minott, General Counsel A. Jay Graf, Group Chmn. Beverly Huss, Pres., Endovascular Solutions Maria Degois-Sainz, Pres., Cardiac Surgery Dana G. Mead, Jr., Pres., Vascular Intervention Guido J. Neels, Group Chmn.
Phone: 317-971-2000 Fax: 317-971-2040 Toll-Free: Address: 111 Monument Circle, 29th Fl., Indianapolis, IN 46204 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $3,239,600 (12 months) 2002 Profits: $611,800 (12 months) Stock Ticker: GDT 2001 Sales: $2,707,600 2001 Profits: $484,000 Employees: 11,000 2000 Sales: $2,548,700 2000 Profits: $374,300 Fiscal Year Ends: 12/31 1999 Sales: $2,352,300 1999 Profits: $341,200 1998 Sales: $1,913,100 1998 Profits: $-24,800
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $618,000 Bonus: $1,050,000 Stock Purch. Plan: Y Second Exec. Salary: $406,860 Bonus: $437,500 ADVANTAGE: Provides innovative, cost-effective products and services to the global cardiology and minimally invasive surgery marketplace.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
GUILFORD PHARMACEUTICALS INC www.guilfordpharm.com Industry Group Code: 325412 Ranks within this company's industry group: Sales:97 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:79
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Neurological Diagnostic Products
Guilford Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the research, development and marketing of products that target the neurological, surgical and critical care markets. Its proprietary drug, GLIADEL Wafer, is used to treat a type of brain cancer. Guilford is marketing the product in the U.S. and parts of Europe. Its neurological products program is engaged in the research and development of small molecules that regenerate damaged nerves or protect nerves from damage for potential treatment of a range of neurodegenerative diseases and conditions, such as Parkinson’s disease, Alzheimer’s disease, stroke, amyotrophic lateral sclerosis, multiple sclerosis, spinal cord injury and peripheral neuropathies. AQUAVAN Injection is a water-soluble prodrug of propofol, which is the most widely used general anesthetic in the world. Guilford’s scientists are developing novel compounds to protect brain cells from ischemia. These compounds, known as NAALADase inhibitor compounds, target neuropathic pain and disease modification of diabetic neuropathy. In animal models, it has been demonstrated that treatment with NAALADase inhibitors can normalize pain sensitivity, improve nerve conduction velocity and promote re-myelination of peripheral nerves. Neuro-immunophilin ligands are a novel class of drugs developed by Guilford that may have the ability to cause nerve growth as well as repair. Its neuro-immunophilin ligand drug GPI 1485 recently began Phase II clinical trials. In other news, Guilford began a Phase II trial of AQUAVAN Injection in Europe. Guilford offers its employees discretionary bonuses, dental and vision plans, education reimbursement, a fitness center and on-site chair masssages. The company has a policy of business casual attire and offers residency sponsorship for employees who are foreign nationals.
BRANDS/DIVISIONS/AFFILIATES: GLIADEL Wafer AQUAVAN Injection NAALADase Inhibitors GPI 1485
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Craig R. Smith, CEO David P. Wright, Pres./Chief Bus. Officer Andrew R. Jordan, CFO Michael Kelly, VP-Mktg. and Sales Margaret M. Contessa, Sr. VP-Human Resources Barbara S. Slusher, Sr. VP-Research Valerie Riddle, VP-Medical Affairs Nancy J. Linck, Sr. VP/Corp. Sec. Nancy J. Linck, General Counsel John P. Brennan, Sr. VP-Oper. Thomas C. Seoh, Sr. VP-Corp. Dev. Gregory M. Hockel, VP-Regulatory Affairs Andrew R. Jordan, Treas. Denise Battles, VP-Corp. Quality Jean-Marie Vallet, VP-Bus. Dev. William C. Vincek, VP-Pharmaceutical Dev. Craig R. Smith, Chmn.
Phone: 410-631-6300 Fax: 410-631-6338 Toll-Free: Address: 6611 Tributary St., Baltimore, MD 21224 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $14,700 (12 months) 2002 Profits: $-59,300 (12 months) Stock Ticker: GLFD 2001 Sales: $20,500 2001 Profits: $-60,300 Employees: 235 2000 Sales: $18,100 2000 Profits: $-47,100 Fiscal Year Ends: 12/31 1999 Sales: $21,600 1999 Profits: $-26,900 1998 Sales: $12,500 1998 Profits: $-29,700
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $483,333 Stock Purch. Plan: Second Exec. Salary: $320,000 ADVANTAGE: Alliance with Amgen/Novel treatments for brain cancer.
OTHER THOUGHTS: Apparent Women Officers or Directors: 6 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $210,000 Bonus: $90,000
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
HADCO CORP
www.hadco.com
Industry Group Code: 334413 Ranks within this company's industry group: Sales: Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Profits:
Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Electronic Interconnect Solutions
HADCO Corporation, a subsidiary of Sanmina, is a leading developer and supplier of advanced electronic interconnect products and services. It manufactures highdensity double-sided and complex multilayer printed circuits and backplane assemblies used in the computer, telecommunications and industrial automation industries. The company’s customers include large, medium and small original equipment manufacturers of electronic systems, as well as independent sub-contract manufacturers. HADCO has operations and sales offices throughout the U.S. and in Canada. HADCO relies on a technology strategy that takes full advantage of its industry strength, talent and resources. The company is represented by independent manufacturers' representatives located in North America, South America, Europe, Mexico, South Africa, Asia, Australia, New Zealand and the Middle East. Regional direct sales offices are located throughout North America and in Ireland and Singapore. The company offers a Service Award Program to reward top employees.
BRANDS/DIVISIONS/AFFILIATES: Sanmina Corp. HVRFlex
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Andrew E. Lietz, CEO Andrew E. Lietz, Pres. F. Gordon Bitter, CFO William M. Beckenbaugh, Chief Tech. Officer John D. Caruso, Sr. VP-VAM Mfg. F. Gordon Bitter, Treas. Timothy P. Losik, Sr. VP-Tech. Center Mfg. Christopher T. Mastrogiacomo, Sr. VP-Volume Mfg.
Phone: 603-898-8000 Fax: 603-896-2100 Toll-Free: Address: 12A Manor Pkwy., Salem, NH 03079 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $ 2001 Profits: $ Employees: 7,850 2000 Sales: $ 2000 Profits: $ Fiscal Year Ends: 10/31 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ Excellent technology base/Acquired by Sanmina Corporation. ADVANTAGE:
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
HAEMONETICS CORPORATION
www.haemonetics.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:28
Profits:25
Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Equipment-Blood-Recovery Systems Surgical Blood Salvage Equipment
Haemonetics Corporation is a global medical devices company engaged in the manufacture of automated systems for the collection, processing and surgical salvage of blood. Haemonetics markets its products to hospitals, commercial plasma fractionators and national health organizations in over 50 countries. Haemonetics' equipment incorporates various processes and devices such as centrifugal drives, ultrasonic sensors, optical systems, pneumatics and various electromechanical assemblies. The equipment is designed to regulate the blood processing procedure while ensuring patient and donor safety. Different optical systems used by the firm monitor and control the blood processing procedure through various combinations of light emitting diodes, lensing arrays, fiber optics and charge coupled devices, all in conjunction with the system's microprocessor. A revolutionary component of the firm’s equipment range was its introduction and use of disposable parts, which, in conjunction with specialized programming, maximizes donor-patient safety. Currently, about one-third of the company's business is in the U.S., one-third in Europe and one-third in Asia. Haemonetics and the U.S. Military have implemented the deployment of a new frozen blood storage program that utilizes the firm’s technology. The U.S. Military will use the firm’s systems to freeze red blood cells for up to 10 years and, when needed, thaw those cells. Haemonetics technology automates the blood freezing process in a closed system that allows for 14-day storage of thawed cells. In recent news, the American Red Cross and Fifth Dimension Information Systems (5D), a subsidiary of Haemonetics, have announced plans to implement 5D’s LOGIC Software system to automate and manage retrieval and inventory logistics. U.S. workers are offered on-site child-care, a business casual environment, tuition reimbursement, an on-site cafeteria, a referral bonus program, service awards and a wellness program, as well as basic life insurance and travel accident insurance, a dental plan and an on-site child care center.
BRANDS/DIVISIONS/AFFILIATES: Cell Saver HaemoLite Collectfirst PCS PCS2 LOGIC Software Fifth Dimension Information Systems Intercept Platelet System
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Brad Nutter, CEO Brad Nutter, Pres. Ronald J. Ryan, Sr. VP/CFO Stephen Swenson, Exec. VP-Mktg. and Sales Debra Canner, Human Resources Tom Headley, Exec. VP-Research and Dev. Mark Popovsky, Corp. Medical Dir. Robert Ebbelling, Sr. VP-Mfg. Lisa Lopez, Sr. VP/General Counsel Marci Sindell, Corp. VP-Bus. Design Timothy Surgenor, Exec. VP-Corp. Stuart Burgess, Chmn.
Phone: 781-848-7100 Fax: 781-356-3558 Toll-Free: Address: 400 Wood Rd., Braintree, MA 02184-9114 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $320,000 (12 months) 2002 Profits: $30,000 (12 months) Stock Ticker: HAE 2001 Sales: $293,900 2001 Profits: $7,200 Employees: 1,498 2000 Sales: $280,600 2000 Profits: $15,400 Fiscal Year Ends: 3/31 1999 Sales: $284,500 1999 Profits: $21,100 1998 Sales: $285,800 1998 Profits: $-24,800
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $487,306 Stock Purch. Plan: Y Second Exec. Salary: $287,717 ADVANTAGE: Haemonetics is the world leader in automated blood processing equipment.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $421,348 Bonus: $184,114
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
HALLIBURTON COMPANY
www.halliburton.com
Industry Group Code: 213111 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Y Y
Profits:2
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Y Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Oil & Gas Drilling Support Services Software Development
Halliburton Co. is one of the world’s largest providers of products and services to the oil and gas industries. The company operates in two business segments: energy services and engineering and construction. The energy services group consists of Halliburton Energy Services, Landmark Graphics Corporation and operations through various project service lines. The segment provides a wide range of services and products as well as integrated solutions for the exploration, development and production of oil and gas. Services include pressure pumping, cementing, production enhancement, logging and perforation, drilling systems and services, completion products and reservoir description. Products include the firm's Magnetic Resonance Imaging Logging (MRIL), hightemperature logging and traditional open-hole and casedhole logging tools. Landmark Graphics is the leading supplier of integrated exploration and production software information systems and professional data management services for the upstream oil and gas industry. Halliburton's engineering and construction group, Halliburton KBR, provides a range of services to energy and industrial customers and government entities worldwide, including onshore engineering and construction, offshore deepwater capabilities, maintenance and logistics for government facilities and installations, maintenance for private sector customers and civil engineering and consulting services in the Asia/Pacific region. Recently, the firm reached a group settlement agreement totaling $4 billion for asbestosrelated cases. Additionally, through Landmark Graphics Corporation and Halliburton Energy Services, the company released the products DecisionSpace DMS, an advanced software for risk assessment and integration, and MRILab, a logging tool that analyzes fluid reservoir properties. Halliburton Energy Services also performed the world’s first automatic internally oriented downhole tubing conveyed perforation job.
BRANDS/DIVISIONS/AFFILIATES: Halliburton KBR Halliburton Energy Services Landmark Graphics Corp. Halliburton Deepwater MRILab DecisionSpace DMS
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. David J. Lesar, CEO David J. Lesar, Pres. C. Christopher Gaut, Exec. VP/CFO Weldon J. Mire, VP-Human Resources Robert F. Heinemann, Sr. VP/Chief Tech. Officer Arthur D. Huffman, VP/CIO R. Charles Muchmore, Jr., VP/Controller Margaret E. Carriere, VP/Corp. Sec. Bert Cornelison, Exec. VP/General Counsel Cedric W. Burgher, VP-Investor Rel. Jerry H. Blurton, VP/Treas. Charles E. Dominy, VP-Gov't Affairs David R. Smith, VP-Tax John W. Gibson, Jr., Pres./CEO-Energy Services Group Robert R. Harl, Pres./CEO-Eng. and Construction Group David J. Lesar, Chmn.
Phone: 713-676-3011 Fax: 713-676-7070 Toll-Free: Address: 1401 McKinney, Ste. 2400, Houston, TX 77010 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $12,498,000 (12 months) 2002 Profits: $-998,000 (12 months) Stock Ticker: HAL 2001 Sales: $12,939,000 2001 Profits: $809,000 Employees: 83,000 2000 Sales: $11,944,000 2000 Profits: $501,000 Fiscal Year Ends: 12/31 1999 Sales: $12,313,000 1999 Profits: $438,000 1998 Sales: $14,504,000 1998 Profits: $-15,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $1,100,000 Stock Purch. Plan: Y Second Exec. Salary: $550,000 ADVANTAGE: Largest supplier of drilling support services in the world.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $1,719,972 Bonus: $406,773
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
HAUSER INC
www.hauser.com
Industry Group Code: 325411 Ranks within this company's industry group: Sales:3 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:4
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Y Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Vitamins/Nutrition Manufacturing Color Enhancers Chemical Engineering Services Contract Research and Development Bulk Fine Chemicals Laboratory Testing Services
Hauser, Inc. is a supplier of natural product extracts, botanical raw materials and related products to the dietary supplement market in the United States. Hauser manufactures extracts from raw botanical materials using its proprietary technologies in extraction and purification. The firm and its subsidiaries source, process and distribute products for sale to customers including branded product sellers. The company, through its subsidiary Hauser Technical Services, Inc., also provides interdisciplinary laboratory testing services, chemical engineering services and contract research and development. These services are principally marketed to the pharmaceutical, dietary supplement and food ingredient industries. Recent acquisitions include Wilcox Drug Company, Inc., a distributor of raw botanical materials, and ZetaPharm, Inc., a distributor of bulk fine chemicals, excipients and generic active ingredients. Hauser’s natural products include RoseOx and RoseEssential Plus antioxidants and TT550, a gingerbased anti-nausea product. The firm has reached an agreement to license certain intellectual property and provide consulting services to Tisorex, a New Jersey company formed to produce bulk paclitaxel using raw material harvested from taxus bacata trees. In the spring of 2003, Hauser filed for Chapter 11 bankruptcy protection.
BRANDS/DIVISIONS/AFFILIATES: Hauser Chemical Research, Inc. Hauser Technical Services, Inc. Hauser Laboratories Wilcox Drug Company ZetaPharm, Inc. RoseOx RoseEssential Plus TT550
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Kenneth C. Cleveland, CEO Kenneth C. Cleveland, Pres. Thomas W. Hanlon, CFO Peter Hafermann, VP-Mktg. & Sales Thomas W. Hanlon, Corp. Sec. Thomas W. Hanlon, Treas. Dieter W. Luelsdorf, CEO/Pres., ZetaPharm, Inc.
Phone: 310-669-2164 Fax: 310-637-3644 Toll-Free: Address: 20710 S. Alameda St., Long Beach, CA 90810 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $57,600 (12 months) 2002 Profits: $-5,400 (12 months) Stock Ticker: HAUS 2001 Sales: $66,700 2001 Profits: $-33,300 Employees: 228 2000 Sales: $81,200 2000 Profits: $-28,400 Fiscal Year Ends: 3/31 1999 Sales: $36,300 1999 Profits: $-29,700 1998 Sales: $32,000 1998 Profits: $-3,100
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $291,000 Stock Purch. Plan: Y Second Exec. Salary: $188,000 ADVANTAGE: Products come from natural sources such as tree extracts/ Diversified services.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $70,000 Bonus: $50,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
HESKA CORP
www.heska.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:65 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:53
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Animal Health & Pet Care Veterinary Diagnostics Products and Services
Heska Corp. focuses on the discovery, development and marketing of animal health care products. The company makes a concerted effort to use biotechnology to create a broad range of diagnostic, therapeutic and vaccine products to animals, primarily dogs, cats and horses. The business is comprised of two segments, Companion Animal Health and Diamond Animal Health. Its Diamond Animal Health subsidiary manufactures food animal vaccines as well as other food animal products that are marketed and distributed by other animal health companies. In addition, Diamond manufactures certain companion animal health products for marketing and sale by Heska. The Companion Animal Health segment includes diagnostic and monitoring instruments and supplies as well as single use diagnostic tests, vaccines and pharmaceuticals, primarily for canine and feline use. Its line of veterinary diagnostic instruments includes the iSTAT Portable Clinical Analyzer, the HESKA Vet ABC-Diff Hematology Analyzer and the SPOTCHEM EZ Chemistry Analyzer. The company’s veterinary monitoring instruments are the VET/IV 2.2 and the VET/OX 4404. The E.R.D.-SCREEN Urine Test can identify dogs at risk for kidney disease before the majority of kidney function is lost. The company is also developing an E.R.D.HEALTHSCREEN Feline Urine Test. It also sells the HESKA Trivalent Intranasal/Intraocular Vaccine, a threeway modified live vaccine to prevent disease caused by the three most common respiratory viruses of cats: calicivirus, rhinotracheitis virus and panleukopenia virus. In collaboration with Dolphin Medical, Inc., the company recently announced the launch of HESKA Vet/Ox G2 Digital Monitor. The portable product monitors heart rate, body temperature, oxygen saturation and respiratory rate.
BRANDS/DIVISIONS/AFFILIATES: Diamond Animal Health Companion Animal Health E.R.D.-Screen Urine Test HESKA Vet ABC-Diff Hematology Analyzer i-STAT Portable Clinical Analyzer VET/OX 4404 HESKA Vet/Ox G2 Digital Monitor
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Robert B. Grieve, CEO James H. Fuller, COO James H. Fuller, Pres. Jason Napolitano, CFO Mark Cicotello, VP-Human Resources Dan T. Stinchcomb, Exec. VP-Research and Dev. Carol T. Verser, Exec. VP-Bus. Dev. Carol T. Verser, Exec. VP-Intellectual Property Robert B. Grieve, Chmn.
Phone: 970-493-7272 Fax: 970-493-9505 Toll-Free: 800-464-3752 Address: 1613 Prospect Pkwy., Fort Collins, CO 80525 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $51,300 (12 months) 2002 Profits: $-8,700 (12 months) Stock Ticker: HSKA 2001 Sales: $48,300 2001 Profits: $-18,700 Employees: 270 2000 Sales: $52,700 2000 Profits: $-21,900 Fiscal Year Ends: 12/31 1999 Sales: $51,200 1999 Profits: $-35,800 1998 Sales: $39,800 1998 Profits: $-44,300
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $297,499 Stock Purch. Plan: Y Second Exec. Salary: $255,149 ADVANTAGE: Successful product development/Veterinary focus.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $23,174 Bonus: $18,540
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
HEWLETT-PACKARD CO
www.hp.com
Industry Group Code: 334111 Ranks within this company's industry group: Sales:2 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:13
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y Y Y
GROWTH PLANS/SPECIAL FEATURES:
Computer Hardware-PCs Computer Software Plotters Fax Machines Consulting Outsourcing
Hewlett-Packard (HP) is one of the world’s largest international providers of imaging and printing systems, computing systems and information technology services. Its ScanJet family of scanners features machines for consumers with simple scanning needs as well as machines designed as communications tools for networked offices. Products include the PhotoSmart C500 digital camera, for wireless image printing; the OfficeJet R 80 Series of all-in-one products, combining printing, scanning, copying and faxing in a flatbed design; and the Jetdirect Autoswitch, which allows more than one PC to share printers in a non-networked environment. In 2000, HP split in two, spinning off Agilent Technologies, a maker of electronics focused on instruments. Current servicerelated revenue is about $12 billion yearly, which leaves the firm behind IBM in this area. HP and Compaq Corp. merged in mid-2002, creating one of the largest global technology companies. The new HP plans to offer the industry's most complete set of information technology products and services for businesses and consumers and has pledged a commitment to serve customers with open systems and architectures. The combined company will have leading worldwide revenue positions in servers, access devices (such as PCs and PDAs) and imaging and printing, as well as leading revenue positions in information technology services, storage and management software. The firm anticipates generating cost synergies of about $2.5 billion annually as a result of the merger and will initially maintain the two separate brand identities. HP continues to retain a significant presence in Houston, which is a key strategic center of engineering and product development. The new company will be structured around four operating units: imaging and printing, access devices, IT infrastructure and services. The company offers its employees flexible work hours and strives to maintain a no-layoff policy. Other benefits include maternity leave, telecommuting and a businesscasual dress code. HP offers free lunches twice weekly, as well as access to sports club facilities.
BRANDS/DIVISIONS/AFFILIATES: Compaq Corp. ScanJet Laserjet Inkjet Apollo Consumer Products, Inc. Jetdirect Autoswitch Eliptica
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Carleton S. Fiorina, CEO Robert P. Wayman, Exec. VP-Finance/CFO Michael J. Winkler, Chief Mktg. Officer Susan D. Bowick, Exec. VP-Human Resources Shane V. Robison, Chief Tech. Officer Robert V. Napier, CIO Ann O. Baskins, Corp. Sec. Ann O. Baskins, General Counsel Allison Johnson, Global Brand and Comm. Peter Blackmore, Exec. VP-Enterprise Systems Group Jeff Clark, Exec. VP-Supply Chain/Customer Oper. Duane E. Zitzner, Exec. VP-Personal Systems Group Vyomesh Joshi, Exec. VP-Imaging and Printing Group Carleton S. Fiorina, Chmn.
Phone: 650-857-1501 Fax: 650-857-5518 Toll-Free: Address: 3000 Hanover St., Palo Alto, CA 94304 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $56,588,000 (12 months) 2002 Profits: $-903,000 (12 months) Stock Ticker: HPQ 2001 Sales: $45,226,000 2001 Profits: $408,000 Employees: 141,000 2000 Sales: $48,782,000 2000 Profits: $3,697,000 Fiscal Year Ends: 10/31 1999 Sales: $42,370,000 1999 Profits: $3,491,000 1998 Sales: $39,419,000 1998 Profits: $2,945,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $1,000,000 Stock Purch. Plan: Second Exec. Salary: $925,000 ADVANTAGE: Merger with Compaq/Industry-leading printers.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $1,766,250 Bonus: $402,633
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
HI TECH PHARMACAL CO INC
www.hitechpharm.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:79 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:46
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Generic Nutritional Products Manufacturing Contract Services Inhalation Products Diabetes Products
Hi-Tech Pharmacal Co., Inc. is a manufacturer and marketer of prescription, over-the-counter and nutritional products that are sold in liquid and semi-solid forms. The company is also a leading manufacturer of ophthalmic, optic and inhalation products and provides sterile manufacturing contract services. Hi-Tech Pharmacal currently markets in excess of 70 generic products to approximately 100 customers consisting of generic distributors, drug wholesalers, chain drug stores, mass merchandise chains and mail order companies. The firm also markets a line of branded products primarily for people with diabetes, including Diabetic Tussin, a leading sugar-free over-the-counter cough medication, and DiabetiSweet, an aspartame-free sugar substitute. HiTech Pharmacal has acquired SweetThoughts.com, a web site dedicated to providing health education, support and products for people with diabetes. Additionally, Hi-Tech markets a number of niche brands to the general health care marketplace, including Nasal Ease, a nasal moisturizer, and Kosher Care, a line of over-the-counter products certified as Kosher. Recently, the firm received U.S. Food and Drug Administration approval of its Fluoxetine Oral Solution, a generic equivalent of Eli Lilly’s Prozac medication.
BRANDS/DIVISIONS/AFFILIATES: Diabetic Tussin DiabetiSweet SweetThoughts.com Nasal Ease Kosher Care Fluoxetine Oral Solution
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. David S. Seltzer, CEO David S. Seltzer, Pres. Arthur S. Goldberg, CFO/VP-Finance Carole Wood, Human Resources David S. Seltzer, Corp. Sec. Elan Bar-Giora, Exec. VP-Oper. David S. Seltzer, Treas. Bernard Seltzer, Chmn.
Phone: 631-789-8228 Fax: 631-789-8429 Toll-Free: Address: 369 Bayview Ave., Amityville, NY 11701-2802 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $33,300 (12 months) 2002 Profits: $3,500 (12 months) Stock Ticker: HITK 2001 Sales: $29,600 2001 Profits: $2,400 Employees: 164 2000 Sales: $26,400 2000 Profits: $1,700 Fiscal Year Ends: 4/30 1999 Sales: $23,300 1999 Profits: $1,900 1998 Sales: $22,400 1998 Profits: $1,700
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $347,000 Bonus: $154,000 Stock Purch. Plan: Second Exec. Salary: $241,500 Bonus: $30,000 With a long list of prescription and over-the-counter generic and branded products, Hi-Tech Pharmacal ADVANTAGE: Co., Inc. continues to grow as one of the few niche generic manufacturers.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
HLM DESIGN INC
www.hlmdesign.com
Industry Group Code: 551110 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:1
Transportation: Aerospace: Automotive: Y
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y Y
GROWTH PLANS/SPECIAL FEATURES:
Management-Architectural, Engineering and Planning Firms
HLM Design, Inc. provides management services to architectural, engineering and planning (AEP) firms that design complex projects for customers in the healthcare, justice, education, defense and hospitality industries. The company provides financial planning, equipment and supplies management, administrative and bookkeeping services and marketing support to its AEP clients. The firm also assists its clients in recruiting architects and engineers. As part of its expansion strategy, HLM Design frequently attempts to establish service agreements with large AEP firms that have extensive operating histories in previously untapped large metropolitan and high-growth suburban markets. The company strives to provide these firms with economies of scale and increased purchasing power. Moreover, the firm’s geographically dispersed composition enables smaller customers to accommodate future clients with national operations that might otherwise have sought larger firms to service their needs. HLM Design believes that demand for its management services will increase as the complexity of architectural projects increases.
BRANDS/DIVISIONS/AFFILIATES: HLM Design of North America, Inc. HLM Design USA, Inc. HLM Design Architecture, Engineering and Planning JPJ Architects, Inc. G.A. Design International Holdings, Ltd.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Joseph M. Harris, CEO Vernon B. Brannon, COO Joseph M. Harris, Pres. Vernon B. Brannon, CFO Lynn Kitchin, Human Resources Joseph M. Harris, Chmn.
Phone: 704-358-0779 Fax: 704-358-0229 Toll-Free: Address: 121 W. Trade St., Ste. 2950, Charlotte, NC 28202 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $63,300 (12 months) 2002 Profits: $ 3 (12 months) Stock Ticker: HMD 2001 Sales: $64,300 2001 Profits: $ 700 Employees: 434 2000 Sales: $53,100 2000 Profits: $ 800 Fiscal Year Ends: 4/30 1999 Sales: $37,800 1999 Profits: $ 800 1998 Sales: $29,300 1998 Profits: $ 800
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $300,000 Stock Purch. Plan: Y Second Exec. Salary: $250,000 ADVANTAGE: Expanding company/Targets previously untapped urban markets.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $30,000 Bonus: $25,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
HONDA MOTOR CO LTD
www.honda.com
Industry Group Code: 336111 Ranks within this company's industry group: Sales:8 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Profits:4
Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Automobiles, Manufacturing Motorcycles Marine Engines Lawn and Garden Equipment
Honda Motor Co., Ltd. designs and manufactures a range of products, from specialty sports cars to small engines, which incorporate its highly efficient internal combustion engine technology. In 2001, over 12.5 million Honda engines were sold around the globe. The firm operates a worldwide network made up of nearly 440 subsidiaries and affiliates. Honda has more than 109 production facilities in 29 foreign countries, supplying Honda parts to most of the world's industrialized countries. Honda operates through three segments: motorcycles, automobiles and other businesses. Through the motorcycle unit, Honda produces sports, business and commuter models to meet a range of demands. These motorcycles utilize air- or water-cooled gasoline engines with single, two, four or six cylinders, manufactured by the company. The firm produces more than 6.2 million motorcycles and ATVs (allterrain vehicles) per year. In addition, the firm manufactures automobiles under the Acura and Honda trademarks. Honda models include the Civic, a subcompact car; the Accord, an intermediate passenger car; the NSX, a specialty sports car; the Prelude, a compact car; the Integra, a compact passenger car; the Odyssey, a minivan; the Orthia, a sub-compact station wagon; the Partner, a sub-compact wagon for commercial utility; and the CR-V, an SUV, among others. Honda's other operations consist primarily of sales of power products and related parts. These products include power tillers, portable generators, outboard engines, water pumps, lawn mowers and lawn tractors. Recently, Honda announced it would add 200 jobs as part of its $30-million plant expansion in Greensboro, North Carolina. This will boost U.S. engine production capacity by 50%. In other news, the company began leasing its newly developed fuel-cell passenger car models to government offices in Japan in late 2002. Honda offers employees benefits including health, life and disability plans.
BRANDS/DIVISIONS/AFFILIATES: Honda of America Manufacturing Honda R&D Americas, Inc. Honda Marine Acura Civic Accord CR-V Prelude
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Takeo Fukui, CEO Koichi Amemiya, Exec. VP Satoshi Aoki, Sr. Managing Dir. Michiyoshi Hagino, Sr. Managing Dir. Yoshihide Munekuni, Chmn.
Phone: 033-423-1111 Fax: 212-541-9855 Toll-Free: Address: 1-1, 2-chome Minami-Aoyama, Minato-ku, Tokyo, 1078556 Japan
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $55,253,000 (12 months) 2002 Profits: $2,722,000 (12 months) Stock Ticker: HMC 2001 Sales: $52,169,700 2001 Profits: $1,874,400 Employees: 120,600 2000 Sales: $57,454,900 2000 Profits: $2,472,100 Fiscal Year Ends: 3/31 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Y Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Bonus: $ Stock Purch. Plan: Second Exec. Salary: $ Bonus: $ ADVANTAGE: Recognized by consumers worldwide for high quality, superior design and reasonable prices.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
HONEYWELL INTERNATIONAL INC
www.honeywell.com
Industry Group Code: 336410 Ranks within this company's industry group: Sales:3 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Profits:8 Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Y Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Aerospace/Defense Products Manufacturer Automation and Control Systems Specialty Chemicals
Honeywell International, Inc. is a leading producer of hightech control systems, including turboprop engines for airplanes, specialty chemicals for heavy equipment, polymers for electronics and thermostat controls for heating and cooling homes. The company is divided into four sectors: aerospace solutions, automation and control solutions, specialty materials and transportation and power systems. The aerospace unit is associated with engines, electronic systems, landing systems and federal manufacturing and technologies services. The automation and control solutions division deals with control products such as heating and air conditioning for homes and buildings, water controls and electronic systems for burners, broilers and furnaces along with security and fire products and services. The specialty materials segment involves nylon products and services, flurocarbons, nuclear services and life sciences. The transportation and power systems division includes charge air systems and thermal systems. Honeywell is engaged in manufacturing, sales and research and development mainly in the United States, Europe, Canada, Asia and Latin America. In recent news, the company announced it has introduced the HB3000, a 30-inch, wide-screen liquid crystal display monitor for the business jet cabin. The company is also developing an APEX/R avionics system for the light turbine-powered aircraft. The APEX/R system will display information such as traffic and weather and provide lifelike graphics to aid in the instrumental navigating of the aircraft. The firm offers employees relocation assistance and tuition reimbursement. Additionally, employees receive discounts on computers, automobiles, cell phones and other products.
BRANDS/DIVISIONS/AFFILIATES: ASI Specialty Chemicals AlliedSignal International Finance Corp. Honeywell Aerospace Solutions Honeywell Software Solutions HB3000 APEX/R
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. David M. Cote, CEO Giannantonio Ferrari, COO Richard F. Wallman, Sr. VP/CFO Tom Weidenkopf, Sr. VP-Human Resources Barry C. Johnson, Chief Tech. Officer Larry Kittelberger, Sr. VP/CIO Richard J. Diemer, Jr., Controller Peter M. Kreindler, Sr. VP/General Counsel Larry Kittelberger, Sr. VP-Admin. Tom Weidenkopf, Sr. VP-Corp. Comm. James V. Gelly, Treas. Nance K. Dicciani, Pres./CEO-Specialty Materials Robert D. Johnson, Pres./CEO-Aerospace Rob Gillette, Pres./CEO-Power Systems and Transportation Kevin Gilligan, Pres./CEO-Control Solutions and Automation David M. Cote, Chmn.
Phone: 973-455-2000 Fax: 973-455-4807 Toll-Free: 800-707-4555 Address: 101 Columbia Rd., Morristown, NJ 07962-2497 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $22,274,000 (12 months) 2002 Profits: $-220,000 (12 months) Stock Ticker: HON 2001 Sales: $23,652,000 2001 Profits: $-99,000 Employees: 108,000 2000 Sales: $25,023,000 2000 Profits: $1,659,000 Fiscal Year Ends: 12/31 1999 Sales: $23,735,000 1999 Profits: $1,541,000 1998 Sales: $15,128,000 1998 Profits: $1,331,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $992,308 Stock Purch. Plan: Second Exec. Salary: $761,538 A leading name in the controls industry. ADVANTAGE:
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $1,000,000 Bonus: $571,154
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
HUGHES ELECTRONICS CORP
www.hughes.com
Industry Group Code: 513340 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:2
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Satellite Broadcasting Satellite-Based Television Distribution
Hughes Electronics Corporation is one of the world’s top providers of digital television entertainment and wireless systems. Hughes has developed a wide range of entertainment, information and communications services for home and business use, including video, data, voice, multimedia and Internet services. The company’s DIRECTV subsidiary offers over 11 million subscribers access to more than 200 television channels broadcast in a digital format, providing sharper pictures and clearer sound. The firm’s PanAmSat subsidiary is the owner and operator of one of the largest commercial satellite fleets in the world, which provides satellite services to longdistance telecommunications carriers, corporations and Internet service providers. The Hughes Network Systems (HNS) segment is one of the largest manufacturers of DIRECTV subscriber equipment, shipping over 8 million units. HNS is also leading the development of SPACEWAY, a $1.8-billion next-generation, satellitebased broadband communications platform that is expected to provide business customers with high-speed, two-way data communications on a more cost-efficient basis than systems that are currently available. SPACEWAY will be launched in 2004. HNS offers DirecPC Turbo Internet service throughout the U.S. Hughes also recently purchased Telocity Delaware, Inc., making it the only company with the ability to offer, on a national basis, a portfolio of consumer entertainment and information services that includes digital multichannel television and high-speed wired and satellite broadband Internet access. As part of the company’s focus on broadband entertainment and communications, Hughes sold its satellite manufacturing operations to the Boeing Company. In April 2003, the company announced that a majority stake will be acquired by News Corporation for about $6.6 billion.
BRANDS/DIVISIONS/AFFILIATES: DIRECTV PanAmSat SPACEWAY Hughes Network Systems DIRECWAY Telocity Delaware, Inc. DirecPC News Corporation
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jack A. Shaw, CEO Jack A. Shaw, Pres. Michael J. Gaines, Corp. VP/CFO Sandra Harrison, Corp. Sr. VP-Human Resources Patrick T. Doyle, Corp. VP/Controller Larry D. Hunter, Corp. Sr. VP/General Counsel Sandra Harrison, Corp. Sr. VP-Admin. Robert A. Marsocci, VP-Corp. Comm. Eddy W. Hartenstein, Corp. Sr. Exec. VP/CEO, DIRECTV, Inc. Roxanne S. Austin, Corp. Exec. VP/Pres./COO, DIRECTV, Inc. Pradman P. Kaul, Corp. Sr. VP/CEO, Hughes Network Systems Patrick T. Doyle, Chief Acc. Officer Harry J. Pearce, Chmn.
Phone: 310-364-6000 Fax: 310-322-6174 Toll-Free: Address: 200 N. Sepulveda Blvd., El Segundo, CA 90245-0956 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $8,934,900 (12 months) 2002 Profits: $-891,100 (12 months) Stock Ticker: GMH 2001 Sales: $8,262,000 2001 Profits: $-621,600 Employees: 11,600 2000 Sales: $7,287,600 2000 Profits: $813,000 Fiscal Year Ends: 12/31 1999 Sales: $5,560,300 1999 Profits: $-291,300 1998 Sales: $3,480,600 1998 Profits: $250,700
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Millions of subscribers for Direct TV service.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
HUTCHINSON TECHNOLOGY INC
www.htch.com
Industry Group Code: 334112 Ranks within this company's industry group: Sales:9 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:6
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Hardware-Disk Drive Suspension Assemblies Tissue Spectrometers
Hutchinson Technology designs and manufactures suspension assemblies for disk drives. Suspension assemblies are precise metal springs that hold a disk drive’s recording head at microscopic distances above the drive’s disks. The firm’s products include conventional assemblies, trace suspension assemblies, base plates and flexures. Trace suspension assemblies incorporate thin electrical conductors that connect the recording head to the drive’s electronic circuitry. This eliminates the need for wires that can interfere with the head’s performance. Trace suspension assemblies also enable customers to eliminate manufacturing steps and adopt automated assembly processes. By contrast, conventional assemblies require customers to add an electrical circuit to the suspension. Consequently, the company anticipates that demand for conventional assemblies will continue to decrease as demand for trace suspension assemblies increases. Hutchinson Technology’s customers include TDK, Seagate, IBM, Read-Rite and Alps Electric. The company’s BioMeasurement division has developed InSpectra, a tissue spectrometer that uses Near Infrared Spectroscopy to measure local, rather than systemic, oxygen saturation of hemoglobin in tissue. The device, which recently received U.S. Food and Drug Administration approval, painlessly measures tissue oxygenation at various depths and is not affected by motion. Hutchinson Technology offers its employees dental insurance, tuition reimbursement and relocation assistance.
BRANDS/DIVISIONS/AFFILIATES: InSpectra
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Wayne M. Fortun, CEO Beatrice A. Graczyk, COO Wayne M. Fortun, Pres. John A. Ingleman, CFO Richard J. Penn, VP-Mktg. and Sales Rebecca A. Albrecht, VP-Human Resources R. Scott Schaefer, Chief Tech. Officer John A. Ingleman, Corp. Sec. Richard C. Myers, VP-Bus. Dev. Darlene Polzin, Dir.-Investor Rel. Peggy J. Lietzau, Dir.-Corp. Planning Dale M. Ruzicka, Dir.-Asian Oper. Christina M. Temperante, Pres.-BioMeasurement Div. Jeffrey W. Green, Chmn.
Phone: 763-587-3797 Fax: 763-587-1645 Toll-Free: Address: 40 W. Highland Park, Hutchinson, MN 55350 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $390,700 (12 months) 2002 Profits: $15,000 (12 months) Stock Ticker: HTCH 2001 Sales: $401,200 2001 Profits: $-56,300 Employees: 3,336 2000 Sales: $459,600 2000 Profits: $-73,600 Fiscal Year Ends: 9/30 1999 Sales: $580,300 1999 Profits: $17,600 1998 Sales: $407,600 1998 Profits: $-48,400
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Stock Purch. Plan: Y ADVANTAGE: Very large market share.
OTHER THOUGHTS: Apparent Women Officers or Directors: 5 Hot Spot for Advancement for Women/Minorities: Y
Top Exec. Salary: $546,168 Second Exec. Salary: $261,934
Bonus: $935,000 Bonus: $202,735
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
HYBRIDON INC
www.hybridon.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:81 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:39
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-AIDS, Cancer and Hepatitis Antisense Technology
Hybridon, Inc. is a leading company engaged in the discovery and development of novel therapeutics and diagnostics using synthetic DNA. Its activities are based on four technologies: proprietary immunomodulatory oligonucleotide (IMO) technology, which uses synthetic DNA to modulate responses of the immune system; antisense technology, which uses synthetic DNA to inhibit the production of disease-associated proteins at the cellular level; cancer therapy potentiation, which uses synthetic DNA to enhance the anti-tumor activity of certain marketed anticancer drugs; and Cyclicon technology, which uses novel synthetic DNA structures in drug target validation and drug discovery. The firm's advanced antisense chemistries have several advantages over earlier antisense drug candidates, including fewer side effects, greater stability in the body, greater potency and greater potential for multiple routes of administration, including oral delivery. Hybridon's IMO compounds can be used as monotherapies in the treatment of conditions such as cancer, asthma, allergies and infectious diseases, as well as in combination therapies with antibodies, vaccines and chemotherapies. Currently, the firm is developing GEM 231, a second-generation antisense drug used to potentiate the anti-tumor activity of irinotecan. The company is also bringing its lead IMO preclinical candidate, HYB 2055, into trials. In mid-2001, Hybridon formed a licensing agreement with Isis Pharmaceuticals, allowing Isis to use the patents for its antisense chemistry and delivery applications. The company has also collaborated with EpiGenesis Pharmaceuticals to develop up to five antisense drugs for the treatment of respiratory diseases. Notably, the firm was recently ranked among the Top 50 Most Innovative Small Companies by Inc. Magazine.
BRANDS/DIVISIONS/AFFILIATES: Cyclicons GEM 231 IMO Technology Camptosar HYB 2055
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Stephen R. Seiler, CEO Sudhir Agrawal, Pres. Robert G. Andersen, CFO Sudir Agrawal, Chief Scientific Officer Robert G. Andersen, VP-Oper. Felice A. de Jong, Dir.-Bus. Dev. Jin-yan Tang, VP-Chemistry Timothy M. Sullivan, VP-Preclinical Drug Dev. R. Russell Martin, Sr. VP-Drug Dev.
Phone: 617-679-5500 Fax: 617-679-5592 Toll-Free: Address: 345 Vassar St., Cambridge, MA 02139 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $30,256 (12 months) 2002 Profits: $16,472 (12 months) Stock Ticker: HYBN 2001 Sales: $1,600 2001 Profits: $-5,300 Employees: 27 2000 Sales: $ 573 2000 Profits: $-2,923 Fiscal Year Ends: 12/31 1999 Sales: $1,180 1999 Profits: $-10,500 1998 Sales: $1,623 1998 Profits: $-19,793
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $345,000 Stock Purch. Plan: Y Second Exec. Salary: $251,000 ADVANTAGE: Holds many U.S. and European patents relating to antisense technology.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $300,000 Bonus: $172,500
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
HYCOR BIOMEDICAL INC
www.hycorbiomedical.com
Industry Group Code: 325413 Ranks within this company's industry group: Sales:10 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:7
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Diagnostics Autoimmune Diagnostics
Hycor Biomedical researches, develops and manufactures medical diagnostic products for clinical laboratories and specialty physicians, with a particular focus on allergy and autoimmune testing and urinalysis products. It operates two wholly-owned subsidiaries, Hycor Biomedical GmbH and Hycor Biomedical, Ltd. The company’s main product is its leading KOVA Microscopic Urinalysis product, which examines human urine for specific signs of disease. Hycor’s allergy diagnostic product line, which includes HYTEC 480 and 288, features radioimmunoassays and enzymatic immunoassays that test for reactions to more than 900 allergens. Furthermore, the company’s smallest division, which is devoted to autoimmune diagnostics, manufactures devices that test for systemic lupus erythematosus and rheumatoid arthritis. HY-TEC 288, the world’s first blood-based automated allergy and autoimmune disease testing system, permits eight autoimmune factors and hundreds of allergies in a single run. The firm also received FDA marketing approval for its rheumatoid factor IgA ELISA autoimmune test, which will help diagnose rheumatoid arthritis. In recent news, Hycor Biomedical announced the renewal of a three-year supply agreement with Laboratory Corporation of America Holdings. Under this agreement, Hycor will continue to serve as the primary supplier of in vitro allergy testing reagents to Laboratory Corp.
BRANDS/DIVISIONS/AFFILIATES: Cogent Diagnostics, Ltd. KOVA HY-TEC 288 HY-TEC 480 ELISA Hycor Biomedical, Ltd. Hycor Biomedical GmbH
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. J. David Tholen, Pres. J. David Tholen, CEO Reginald P. Jones, Sr. VP/CFO Mary Jo Deal, Sr. VP-Mktg. and Sales Thomas M. Li, VP-Research and Dev. Nelson F. Thune, Sr. VP-Oper. and Planning Reginald P. Jones, Treas.
Phone: 714-933-3000 Fax: 714-933-3222 Toll-Free: 800-382-2527 Address: 7272 Chapman Ave., Garden Grove, CA 92841 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $18,600 (12 months) 2002 Profits: $-1,300 (12 months) Stock Ticker: HYBD 2001 Sales: $17,300 2001 Profits: $ Employees: 148 2000 Sales: $17,072 2000 Profits: $ 981 Fiscal Year Ends: 12/31 1999 Sales: $18,400 1999 Profits: $ 200 1998 Sales: $18,400 1998 Profits: $-6,600
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $235,955 Bonus: $27,612 Stock Purch. Plan: Y Second Exec. Salary: $219,253 Bonus: $25,657 ADVANTAGE: Maker of the world's first blood-based automated allergy and autoimmune disease testing system.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
HYUNDAI MOTOR COMPANY
www.hyundai-motor.com
Industry Group Code: 336111 Ranks within this company's industry group: Sales:11 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Profits:9
Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Automobiles, Manufacturing Trucks
Hyundai Motor is the number-one automobile manufacturer in South Korea. The company makes cars and minivans as well as trucks, buses and other commercial vehicles. Export models include the Accent, a sub-compact; the Sonata, a mid-size sedan; compact sedan Elantra; and Tiburon, a sport coupe; as well as such newer models as the Santa Fe sport utility vehicle (SUV) and the XG350, a luxury sedan and the company's new flagship vehicle. The company's Korean models include the Atos sub-compact. In addition, Hyundai owns approximately 46% of Kia Motors. Subsidiary Hyundai Motor America (HMA) has facilities throughout the U.S., including locations in New Jersey, Illinois, Georgia and California. The subsidiary distributes Hyundai vehicles throughout the U.S. to be sold and serviced by more than 600 dealerships. Hyundai also makes machine tools for factory automation and material handling. Recently, the firm debuted its latest concept vehicle, the OLV (Outdoor Lifestyle Vehicle). The low-cost SUV is designed to be economical in both operation and price.
BRANDS/DIVISIONS/AFFILIATES: Kia Motors Accent Sonata Atos Excel Hyundai Motor America Hyundai America Technical Center Elantra
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Chung Mong-Koo, CEO Kim Dong-Jin, Pres. Chung Mong-Koo, Chmn.
Phone: 82-2-3464-2545 Fax: 82-2-3463-3484 Toll-Free: Address: 231 Yangjae-Dong, Seocho-Gu, Seoul, 137-938 South Korea
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $40,187,000 (12 months) 2002 Profits: $1,198,000 (12 months) Stock Ticker: Foreign 2001 Sales: $17,002,600 2001 Profits: $880,500 Employees: 49,855 2000 Sales: $14,389,700 2000 Profits: $527,200 Fiscal Year Ends: 12/31 1999 Sales: $12,468,200 1999 Profits: $362,700 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: The number-one automobile manufacturer in South Korea.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
I2 TECHNOLOGIES INC
www.i2.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:31 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:36
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Software-Supply Chain Management Customer Relationship Management Solutions
i2 Technologies, Inc. is a leading provider of enterprise software applications and solutions for dynamic value chain management, a business approach to manage variability and increase efficiency in the value chain by reducing complexity, increasing visibility and increasing transaction velocity. The firm's product suites are designed to help enterprises improve operating efficiencies, collaborate with suppliers and customers, respond to market demands and engage in business interactions over the Internet. These products include solutions for supply chain management (SCM), supplier relationship management (SRM) and customer relationship management (CRM). In addition, i2 provides content and content management solutions, as well as integration services to enable its products to work with other applications. The company also provides consulting, training and maintenance services and support for these offerings. Globally, i2 has over 1,400 customers in a range of industries, including high-tech manufacturing, telecommunications, consumer products, retail, pharmaceuticals and health care, metals, chemicals, oil and gas, automotive and industrial, utilities, logistics and transportation and aerospace and defense. The company's key products include the i2 SCM, i2 SRM and i2 CRM suites, i2 Content and TradeMatrix Open Commerce Network (OCN). In recent news, the firm formed a partnership with DCM Solutions, Inc. The agreement will allow each company to recommend and generate qualified sales leads for their products in the retail industry. The company offers its employees a range of benefits including medical, dental and vision plans and health and dependent care spending accounts.
BRANDS/DIVISIONS/AFFILIATES: Trade Service Corp. ec-Content, Inc. RightWorks Corp. i2 SCM i2 SRM i2 CRM i2 Content TradeMatrix Open Commerce Network
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Sanjiv Sidhu, CEO Sam Nakane, COO Bill Beecher, Exec. VP/CFO Janet Eden-Harris, Chief Mktg. Officer Pallab Chatterjee, Pres.-Solutions Oper. Rob Bearden, Exec. VP/Pres.-Americas Region Raymond Teh, Pres.-APAC Region Jim Contardi, Pres.-i2 EMEA Hiten D. Varia, Exec. VP/Chief Delivery Officer Sanjiv Sidhu, Chmn. Yoichi Yokomizo, Pres./CEO-i2 Japan
Phone: 469-357-1000 Fax: 214-860-6060 Toll-Free: 800-800-3288 Address: One i2 Pl., 11701 Luna Rd., Dallas, TX 75234 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $522,500 (12 months) 2002 Profits: $-1,003,700 (12 months) Stock Ticker: ITWO 2001 Sales: $985,600 2001 Profits: $-7,751,200 Employees: 4,800 2000 Sales: $1,126,300 2000 Profits: $-1,752,000 Fiscal Year Ends: 12/31 1999 Sales: $571,110 1999 Profits: $23,515 1998 Sales: $369,157 1998 Profits: $5,219
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $225,000 Bonus: $586,800 Stock Purch. Plan: Y Second Exec. Salary: $179,798 Bonus: $174,758 ADVANTAGE: Excellent supply chain software technology/Aggressive marketing on a global scale.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ICN PHARMACEUTICALS INC
www.icnpharm.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:30 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:91
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Viral Disease Oncology Drugs Pain Management Drugs Over-the-Counter Drugs Nutritional Products HIV Treatments
ICN Pharmaceuticals is a global, research-based pharmaceutical company that primarily develops, manufactures and markets a broad spectrum of pharmaceutical, over-the-counter and nutritional products under the ICN brand name. The firm operates primarily in North and Latin America, Europe and the Pacific Rim. The company’s pharmaceutical products treat viral and bacterial infections, diseases of the skin, neuromuscular disorders, cancer, cardiovascular disease, diabetes and psychiatric disorders. ICN’s research and new product development, conducted primarily through its majorityowned subsidiary Ribapharm, Inc., focuses on innovative treatments for dermatology, infectious diseases and cancer. The company’s antiviral drug, ribavirin, is sold under the trade name Virazole in North America and most European countries, as Vilona and Virazide in Latin America and as Virazide in Spain. Ribavirin is used for the treatment of several different human viral diseases, including RSV, hepatitis, herpes, influenza, measles and chicken pox. Major products in the antibacterial group include Ancobon/Ancotil, Anapenil and Yectamicina. Ancobon/Ancotil is a systemic anti-fungal product that is used in the treatment of serious infections. Anapenil is an antibiotic product that is used in the treatment of susceptible infections. Yectamicina is a bactericidal aminoglycoside antibiotic that is used in the treatment of respiratory, urinary, gastrointestinal tract infections, sepsis, meningitis and bone infections due to Gramnegative and Gram-positive bacteria. Dermatological products include Efudex/Efudix, Oxsoralen-Ultra, Kinerase, Glyquin and Solaquin Forte, which are principally used for actinic keratosis, psoriasis, reducing wrinkles and other signs of aging and pigmentation disorders. In recent news, the company has made the decision to divest its Russian pharmaceuticals segment, biomedicals segment, photonics business, raw materials businesses and manufacturing capability in Hungary and the Czech Republic and Circe unit.
BRANDS/DIVISIONS/AFFILIATES: Virazide Virazole Ancobon/Ancotil Anapenil Yectamicina Efudex/Efudix Oxsoralen-Ultra Ribapharm, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Robert W. O'Leary, CEO Timothy C. Tyson, COO Timothy C. Tyson, Pres. Barry G. Bailey, Exec. VP/CFO John I. Cooper, Exec. VP-Global Mfg. Gregory Keever, Exec. VP/Corp. Sec. Gregory Keever, General Counsel Bill A. MacDonald, Exec. VP-Strategic Planning Wesley P. Wheeler, Pres.-North America Robert W. O'Leary, Chmn. Michael J. Kays, Sr. VP-Global Procurement
Phone: 714-545-0100 Fax: 714-641-7223 Toll-Free: 800-548-5100 Address: 3300 Hyland Ave., Costa Mesa, CA 92626 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $737,100 (12 months) 2002 Profits: $-134,900 (12 months) Stock Ticker: ICN 2001 Sales: $858,100 2001 Profits: $64,100 Employees: 11,625 2000 Sales: $800,300 2000 Profits: $90,200 Fiscal Year Ends: 12/31 1999 Sales: $747,400 1999 Profits: $118,600 1998 Sales: $838,100 1998 Profits: $-352,100
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $400,000 Bonus: $2,308,051 Stock Purch. Plan: Second Exec. Salary: $283,135 Bonus: $287,200 ADVANTAGE: Continues to grow internationally through acquisitions including an expanding market share in Europe.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ICOS CORPORATION
www.icos.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:55 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:95
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Blood Flow Biopharmaceutical Products
ICOS Corporation researches and develops new pharmaceuticals, determining points of intervention within various diseases so as to create specific and efficacious drugs. The company combines its capabilities in molecular, cellular and structural biology, high-throughput drug screening, medicinal chemistry and gene expression profiling to develop innovative products with significant commercial potential. This integrated approach has been applied to erectile dysfunction and other urologic disorders, sepsis, pulmonary arterial hypertension and other cardiovascular diseases and inflammatory diseases. The company has established collaborations with pharmaceutical and biotechnology companies, including Eli Lilly and Company and Biogen, Inc. The product candidates in development include IC747 for the treatment of psoriasis, RTX for the treatment of interstitial cystitis, IC14 for the treatment of sepsis and IC485 for the treatment of chronic obstructive pulmonary disease. ICOS and Biogen are working to develop and commercialize the orally active, small-molecule LFA-1 antagonists as oral therapeutics for the treatment of inflammatory conditions. The companies will cross-license LFA-1 antagonist technology and patents, including IC747. Lilly ICOS, LLC, a joint venture established with Eli Lilly, received approval from the European Commission to market Cialis for the treatment of erectile dysfunction. Lilly ICOS began shipping Cialis to European wholesalers, and Cialis is now available by prescription in pharmacies across Europe. In recent news, the company received an approvable letter from the U.S. FDA regarding Cialis. As a result, a U.S. regulatory decision for Cialis is projected, with product launch anticipated to occur shortly after approval. Employees are offered tuition reimbursement, an on-site child care facility and credit union membership. Additionally, the firm offers organized team sports, company picnics, an annual golf tournament and company mixers.
BRANDS/DIVISIONS/AFFILIATES: Cialis Pafase Sitaxsentan LeukArrest Lilly ICOS, LLC LFA-1 IC747
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Paul N. Clark, CEO Paul N. Clark, Pres. Michael A. Stein, VP/CFO Leonard M. Blum, VP-Mktg. and Sales Michelle Yetman, Dir.-Human Resources W. Michael Gallatin, VP/Dir.-Science David A. Goodkin, Chief Medical Officer/VP-Dev. Gary L. Wilcox, Corp. Sec. Gary L. Wilcox, Exec. VP-Oper. Clifford J. Stocks, VP-Bus. Dev. Thomas P. St. John, VP-Therapeutic Dev. Paul N. Clark, Chmn.
Phone: 425-485-1900 Fax: 425-489-0356 Toll-Free: Address: 22021 20th Ave. SE, Bothell, WA 98021 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $92,900 (12 months) 2002 Profits: $-161,600 (12 months) Stock Ticker: ICOS 2001 Sales: $93,400 2001 Profits: $-80,200 Employees: 525 2000 Sales: $90,700 2000 Profits: $-97,900 Fiscal Year Ends: 12/31 1999 Sales: $79,600 1999 Profits: $-33,200 1998 Sales: $110,800 1998 Profits: $31,300
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $650,000 Stock Purch. Plan: Y Second Exec. Salary: $462,000 ADVANTAGE: Expansion through the development of strategic alliances.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $149,520 Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
IDEC PHARMACEUTICALS CORP
www.idecpharm.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:35 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:22
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Cancer, Autoimmune Disease and Inflammatory Disease Biopharmaceuticals Contract Manufacturing
IDEC Pharmaceuticals researches, develops and manufactures drug therapies for the treatment of cancer, autoimmune and inflammatory diseases. The firm’s products focus on acting through the immune system's mechanisms by binding to specific, readily targeted immune cells in the patient's blood or lymphatic system. IDEC also provides contract manufacturing services in which it supports other companies’ manufacturing needs, including quality assurance and control, engineering, regulatory affairs, legal services and validation services. The company manufactures Rituxan, a treatment for nonHodgkin’s lymphoma (immune system tumors). Rituxan was the first monoclonal antibody approved by the FDA to treat cancer and has achieved sales revenues of over $400 million annually. IDEC has received FDA approval for ZEVALIN, a radioimmunotherapy that it hopes will supplement Rituxan as another drug targeting cancer. The company is also developing products for the treatment of cancer and various autoimmune and inflammatory diseases, such as rheumatoid arthritis, allergic asthma and allergic rhinitis. The firm has a number of drugs under various stages of development, including Humanized Anti-CD40L (IDEC-131) for the treatment of autoimmune diseases, PRIMATIZED AntiCD4 (IDEC-151) for a treatment for rheumatoid arthritis and PRIMATIZED Anti-CD23 (IDEC-152) as a treatment for allergic asthma and allergic rhinitis as well as chronic lymphocytic leukemia. In recent news, IDEC entered into a collaboration agreement with Biogen, Inc., under which it in-licensed three products, including IDEC-201. IDEC will complete an ongoing Phase I/II study in patients with glial tumors that was begun by its licensor, Biogen. In June 2003, IDEC announced that it intends to be acquired by Biogen. The newly merged company will be called Biogen IDEC. The firm offers its employees vision care benefits as well as financial assistance for continuing education. Credit union membership and recreation discounts to attractions and events are also offered.
BRANDS/DIVISIONS/AFFILIATES: Rituxan ZEVALIN IDEC-151 PROVAX IDEC-131 PAGE-4 IDEC-201 Biogen
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. William H. Rastetter, CEO William R. Rohn, COO William R. Rohn, Pres. Phillip M. Schneider, CFO Chuck Howe, VP-Sales Nabil Hanna, Chief Scientific Officer Edward M. Rodriguez, VP/Controller John E. Leonard, VP-Product Dev. Paul Grint, Chief Medical Officer David Broad, VP-Biological Bulk Mfg. John Dunn, Sr. VP/General Counsel Connie L. Matsui, VP-Planning and Resource Dev. Wolfgang Berthold, Sr. VP-Biopharmaceutical Sciences Michael E. Wiebe, VP-Quality Bertrand C. Liang, VP-Clinical Oncology and Hematology Mark C. Wiggins, VP-Bus. Dev. and Mktg. William H. Rastetter, Chmn.
Phone: 858-431-8500 Fax: 858-431-8750 Toll-Free: Address: 3030 Callan Rd., San Diego, CA 92121 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $404,200 (12 months) 2002 Profits: $148,100 (12 months) Stock Ticker: IDPH 2001 Sales: $272,700 2001 Profits: $101,700 Employees: 995 2000 Sales: $154,700 2000 Profits: $48,100 Fiscal Year Ends: 12/31 1999 Sales: $118,000 1999 Profits: $43,200 1998 Sales: $87,000 1998 Profits: $21,500
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $575,000 Bonus: $383,812 Stock Purch. Plan: Y Second Exec. Salary: $422,650 Bonus: $225,695 ADVANTAGE: Focused on developing targeted therapies for the treatment of cancer and autoimmune diseases.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
IDEXX LABORATORIES INC
www.idexx.com
Industry Group Code: 621511 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y Y Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Veterinary Laboratory Testing and Consulting Point-of-Care Diagnostic Products Contaminant Test Products
IDEXX Laboratories is a worldwide leader in providing diagnostic, detection and information products for various industries. The company operates in two primary business areas: products and services for the veterinary market, referred to as the companion animal group, and products and services for food and environmental markets, referred to as the food and environmental group. Products and services include point-of-care veterinary diagnostic products, laboratory and consulting services, veterinary pharmaceutical products, veterinary practice information management software systems and Internet portal and application service providers, products that test water for certain microbiological contaminants and products that test milk for antibiotic residues. It provides a broad range of single-use, hand-held test kits that allow quick, accurate and convenient testing for a variety of companion animal diseases and health conditions. The principal single-use tests, sold under the SNAP name, include a feline combination test, the SNAP Combo FIV antibody/FeLV antigen test, which enables veterinarians to test simultaneously for feline leukemia virus and feline immunodeficiency virus; a canine combination test, the SNAP 3Dx, which tests simultaneously for Lyme disease, Ehrlichia canis and heartworm; and a canine heartwormonly test. The company currently offers commercial veterinary laboratory and consulting services in the U.S. through facilities located in Arizona, California, Colorado, Illinois, Maryland, Massachusetts, New Jersey, Oregon and Texas. IDEXX also sells products that detect microbial contaminants in water and antibiotic residues in milk. Its Colilert-18 and Colisure tests simultaneously detect total coliforms and E. coli in water. The company’s two principal products for use in testing for antibiotic residue in milk are the SNAP Beta-lactam test and the Parallux system. IDEXX offers its workers performance bonuses, a tuition assistance program, an employee referral program and personal growth leave.
BRANDS/DIVISIONS/AFFILIATES: Colilert-18 SNAP Parallux Colisure
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jonathan W. Ayers, CEO Jonathan W. Ayers, Pres. Merilee Raines, VP-Finance Erwin F. Workman, Jr., Exec. VP/Chief Scientific Officer Conan R. Deady, VP/Corp. Sec. Conan R. Deady, General Counsel Merilee Raines, Treas. Roland H. Johnson, VP Louis W. Pollock, Sr. VP Robert S. Hulsy, VP Salvator S. Fratoni, VP Jonathan W. Ayers, Chmn.
Phone: 207-856-0300 Fax: 207-856-0346 Toll-Free: Address: One IDEXX Dr., Westbrook, ME 04092-2041 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $412,700 (12 months) 2002 Profits: $45,400 (12 months) Stock Ticker: IDXX 2001 Sales: $386,100 2001 Profits: $37,600 Employees: 2,181 2000 Sales: $367,400 2000 Profits: $36,600 Fiscal Year Ends: 12/31 1999 Sales: $358,400 1999 Profits: $32,600 1998 Sales: $321,700 1998 Profits: $-15,200
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $471,000 Stock Purch. Plan: Y Second Exec. Salary: $305,135 ADVANTAGE: Vast line of products and services/Worldwide distribution.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $525,000 Bonus: $255,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
IDX SYSTEMS CORP
www.idx.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:33 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:17
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Software-Health Care Practice Management Software Transcription Services e-Commerce Services
IDX Systems provides information technology (IT) services to various health care organizations, including leading integrated delivery networks (IDNs), physician group practices, management service organizations (MSOs) and academic medical services. The firm’s IDXtendR system has a variety of features, which include the ability to schedule patients, providers and resources; store patient information, registration and visits; detail inpatient and outpatient admission and discharge information; and manage billing and accounts receivable information. IDX products and services improve health care administrative, financial and clinical providers' effectiveness by providing reliable contributions to clinical knowledge, enhancements to the revenue cycle and improvements to administrative efficiency. Through its EDiX Corp. subsidiary, the company offers Internet-based services for patients and physicians, including online services such as clinical documentation and transcription, as well as e-commerce services for efficient health care delivery. IDX Systems provides management solutions for dealing with large group practices and efforts to improve patient conditions at failing hospitals. The company recently launched a new web site to introduce its range of product offerings. IDX also formed agreements with several health care systems for the implementation of its Imagecast Radiology Information System. IDX offers its employees a child care resource center and tuition assistance. New hires start with three weeks of vacation.
BRANDS/DIVISIONS/AFFILIATES: EDiX Corp. IDXtendR Carecast Imagecast Flowcast
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. James H. Crook, Jr., CEO James H. Crook, Jr., Pres. John A. Kane, Sr. VP-Finance/CFO Robert F. Galin, VP-Sales Cynthia B. Limoges, VP-Human Resources Michael J. Whalen, VP/CIO Robert W. Baker, Jr., Sr. VP/Corp. Sec. Robert W. Baker, Jr., General Counsel John A. Kane, Sr. VP-Admin John A. Kane, Treas. Michael J. Whalen, VP-Info. Systems Support and Planning Trevor D. Stanley, Managing Dir.-IDX Europe Thomas W. Butts, Pres./Mgr.-Flowcast Div. Lawrence A. Krassner, Pres./Mgr.-Carecast Div. Richard E. Tarrant, Chmn.
Phone: 802-862-1022 Fax: 802-862-6848 Toll-Free: Address: 40 IDX Dr., Burlington, VT 05402-1070 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $460,100 (12 months) 2002 Profits: $10,000 (12 months) Stock Ticker: IDXC 2001 Sales: $379,900 2001 Profits: $-8,600 Employees: 4,971 2000 Sales: $341,893 2000 Profits: $-35,968 Fiscal Year Ends: 12/31 1999 Sales: $340,999 1999 Profits: $-7,944 1998 Sales: $350,187 1998 Profits: $16,834
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $372,984 Bonus: $24,850 Stock Purch. Plan: Y Second Exec. Salary: $355,000 Bonus: $20,000 ADVANTAGE: Well-designed products focused on the health care industry/Excellent solutions for imaging systems.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
ILEX ONCOLOGY INC
www.ilexoncology.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:80
Profits:75
Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y Y
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Cancer Anticancer Drug Development Clinical Trials Monitoring Clinical Results Submission Services
ILEX Oncology manufactures drugs and offers services aimed at the prevention and treatment of cancer. Through its ILEX Products division, the company researches and develops a line of therapeutic drugs, which include CAMPATH for the treatment of chronic lymphocyctic leukemia and multiple sclerosis, CLOFAREX for acute/pediatric leukemias and Apomine for solid tumors. The firm’s ILEX Oncology Services subsidiary provides pharmaceutical and biotechnology companies with contract research drug development services, including chemistry and toxicology services, small-scale manufacturing for clinical trials, clinical protocol organization design, monitoring clinical trials and preparation of regulatory submissions. ILEX also conducts drug development research, targeted medicinal chemistry and preclinical studies in the fields of angiogenesis inhibition and apoptosis. The firm is developing a pipeline of compounds to treat both advanced-stage cancers and early-stage cancers or premalignant conditions. The diversification of its products is one of its key strategies, as is maintaining one of the most experienced drug development organizations for anticancer drugs in the industry. Another strategic advantage is that ILEX office locations in both the U.S. and Europe enable the company to conduct global clinical trials and process regulatory applications simultaneously in both markets. Recently, ILEX Oncology signed a sublicensing agreement with Ventana Medical Systems to commercialize CAMPATH. The company also launched a Phase I/II trial to evaluate the effects of Apomine in postmenopausal women with osteoporosis.
BRANDS/DIVISIONS/AFFILIATES: CAMPATH ILEX Oncology Services, Inc. OXYPRIM ILX-295501 CLOFAREX ILX23-7553 Apomine Symphar S.A.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jeffrey H. Buchalter, CEO Ze'ev Shaked, Exec. VP/COO Jeffrey H. Buchalter, Pres. Mark P. Mellin, Sr. VP/CFO John Barnes, Sr. Dir.-Human Resources Glenn C. Rice, VP-Research, ILEX Products Don York, Sr. Dir.-IT Terrence A. Rugg, VP-Medical Affairs, ILEX Oncology Services Ronald G. Tefteller, VP/General Counsel Michael T. Dwyer, Sr. VP-Admin. Ian W.D. Clements, VP-Corp. Dev. and Commercial Oper. Corey H. Levenson, Sr. Dir-Tech. Assessment Craig A. Tooman, Sr. VP-Corp. Comm. Timothy M. Ruane, Sr. VP-Bus. Mgmt. Al Jecminek, VP-Licensing and Intellectual Property William D. Mikrut, VP-Clinical Oper. Kathleen Heck, Pres., ILEX Oncology Services Craig L. Bentzen, VP-Research, Europe
Phone: 210-949-8200 Fax: 210-949-8210 Toll-Free: Address: 4545 Horizon Hill Blvd., San Antonio, TX 78229 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $30,900 (12 months) 2002 Profits: $-46,200 (12 months) Stock Ticker: ILXO 2001 Sales: $24,600 2001 Profits: $-121,000 Employees: 277 2000 Sales: $27,600 2000 Profits: $-39,000 Fiscal Year Ends: 12/31 1999 Sales: $18,100 1999 Profits: $-46,100 1998 Sales: $14,300 1998 Profits: $-21,200
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $3,250,000 Bonus: $90,000 Stock Purch. Plan: Y Second Exec. Salary: $245,000 Bonus: $76,037 ADVANTAGE: Promising company with several landmark drugs waiting for FDA approval/Multiple revenue streams.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West:
Southwest: Y
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
IMC GLOBAL INC
www.imcglobal.com
Industry Group Code: 325000 Ranks within this company's industry group: Sales:9 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:10
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Y Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Agricultural Chemicals Manufacturer Phosphate Production
IMC Global, Inc. is the world’s largest producer and marketer of concentrated phosphates and potash crop nutrients, which are used to create fertilizers. The firm’s principle products include diammonium phosphate, triple superphosphate, potassium magnesium sulphate and potassium sulphate. IMC Global has an annual capacity of 8 million short tons of concentrated phosphates, representing 9 percent of global capacity. Moreover, the firm has an annual capacity of 11.1 million short tons of potash, representing 17 percent of global capacity. The company is also a leading provider of feed ingredients for the animal nutrition industry. IMC Global’s PhosFeed subsidiary offers a number of branded mineral nutrient products, including Biofos, Dynafos, Multifos, Monofos and Dyna-K. Additionally, the subsidiary recently introduced Animate, an anionic mineral supplement for transition dairy cows, and Conserve-N, a manure treatment product that reduces the ammonia and odor in livestock and poultry operations. Recently, the company sold its White River Nahcolite Minerals sodium bicarbonate mine and plant to AmerAlia, Inc. for $20.7 million. In order to reduce to cost of storing and delivering sulphur, the firm’s IMC Phosphates subsidiary has partnered with Savage Industries to create Gulf Sulphur Services, Ltd., a joint venture that specializes in sulphur supply services. IMC Global offers its employees dental and vision insurance, tuition reimbursement and matching gifts to charities.
BRANDS/DIVISIONS/AFFILIATES: IMC Phosphates IMC Potash PhosFeed Gulf Sulphur Services, Ltd. Animate Conserve-N Biofos Dynafos
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Douglas A. Pertz, CEO John J. Ferguson, COO John J. Ferguson, Pres. J. Reid Porter, CFO Stephen P. Malia, Sr. VP-Human Resources Robert M. Qualls, Controller Mary Ann Hynes, General Counsel E. Paul Dunn, Jr., Treas. C. Steven Hoffman, Pres., IMC Sales & Marketing Douglas A. Pertz, Chmn.
Phone: 847-739-1200 Fax: 847-739-1617 Toll-Free: Address: 100 S. Saunders Rd., Ste. 300, Lake Forest, IL 60045 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $2,057,400 (12 months) 2002 Profits: $-110,200 (12 months) Stock Ticker: IGL 2001 Sales: $1,958,700 2001 Profits: $-66,500 Employees: 5,276 2000 Sales: $2,095,900 2000 Profits: $-345,000 Fiscal Year Ends: 12/31 1999 Sales: $2,369,300 1999 Profits: $-773,300 1998 Sales: $2,696,200 1998 Profits: $-9,000
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $862,500 Stock Purch. Plan: Second Exec. Salary: $405,000 Focus on agricultural products and commodities. ADVANTAGE:
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $640,220 Bonus: $233,401
LOCATIONS: ("Y" = Yes) West:
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
IMCLONE SYSTEMS INC
www.imclone.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:58 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:94
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Cancer Diagnostic Products
ImClone Systems, Inc. is a biopharmaceutical company engaged in the research and development of novel cancer treatments. The company focuses on three strategies for treating cancer: growth factor inhibitors, therapeutic cancer vaccines and angiogenesis inhibitors. The firm’s lead product candidate is IMC-C225, which is currently in pivotal trials for treating head and neck cancer. Upon approval, ImClone intends to market IMC-C225 in the United Sates and Canada. The company will rely on its development and marketing partner, Merck KGaA, to market the drug outside North America. The next most advanced product candidate is BEC2, a cancer vaccine. In partnership with Merck KGaA, the firm is testing the vaccine for preventing recurrence or progression of smallcell lung cancer. The company is also developing inhibitors of angiogenesis, which could be used to treat various kinds of cancer and other diseases. Its lead clinical candidate for angiogenesis inhibition is IMC-1C11. In addition to the development of its lead product candidates, ImClone continues to conduct new product research, both independently and in collaboration with academic and corporate partners. These partners include CombiChem and Memorial Sloan-Kettering Cancer Center. The company also develops diagnostic products and vaccines for certain infectious diseases. ImClone has also entered into an agreement with Bristol-Myers Squibb to co-develop and co-promote IMC-C225, an investigational cancer drug, in the U.S., Canada and Japan. ImClone recently underwent a restructuring that included new top management, due in part to a series of stock scandals and the problems some of its products have had with the FDA. The company offers its employees comprehensive health insurance as well as tuition reimbursement.
BRANDS/DIVISIONS/AFFILIATES: IMC-C225 BEC2 IMC-1C11 Merck KGaA
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Daniel S. Lynch, Acting CEO Daniel S. Lynch, VP-Finance/CFO Ronald A. Martell, VP-Mktg. and Sales Lisa Cammy, Dir.-Human Resources Peter Bohlen, Sr. VP-Research Charles Dunne, VP-MIS and Facilities Gary Paulter, VP-Eng. and Facilities Richard P. Crowley, VP-Mfg. Daniel S. Lynch, Corp. Sec. John B. Landes, General Counsel Paul A. Goldstein, VP-Financial Oper. Michael Howerton, VP-Bus. Dev. Andrea F. Rabney, VP-Corp. Comm. Peter R. Borzilleri, VP-Internal Audit Michael N. Needle, VP-Clinical Affairs Larry Witte, VP-Research Lily Waiyee Lee, VP-Regulatory and Biostatistics
Phone: 212-645-1405 Fax: 212-645-2054 Toll-Free: Address: 180 Varick St., New York, NY 10014 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $60,005 (12 months) 2002 Profits: $-157,949 (12 months) Stock Ticker: IMCL 2001 Sales: $50,237 2001 Profits: $-127,607 Employees: 501 2000 Sales: $6,253 2000 Profits: $-70,400 Fiscal Year Ends: 12/31 1999 Sales: $2,100 1999 Profits: $-34,600 1998 Sales: $4,200 1998 Profits: $-21,400
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $550,000 Stock Purch. Plan: Second Exec. Salary: $451,404 ADVANTAGE: Innovative cancer treatments/Partnership with Merck KGaA.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $545,000 Bonus: $450,000
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
IMMUNEX CORP
www.immunex.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Cancer, Autoimmune Disease and Infectious Disease Biopharmaceuticals
Immunex, a subsidiary of Amgen, is a biopharmaceutical company that develops drugs based on immune system science for the treatment of inflammatory, infectious and cardiovascular diseases, cancer, asthma and rheumatoid arthritis. Immunex draws from a vast array of scientific expertise in the fields of immunology, cytokine biology, vascular biology, antibody-based therapeutics and smallmolecule research. Many of the firm’s current and potential biotechnology products are recombinant analogs of cytokines and cytokine receptors. Cytokines are protein messengers that coordinate the functions of immune cells as well as other types of cells and tissues. The company’s recombinant cytokine products primarily expand and activate immune cell populations, providing a normal immune response. The firm’s approved products include ENBREL (a TNF receptor that reduces inflammatory activity in rheumatoid arthritis), LEUKINE (a yeast-derived colony that fights infections following bone marrow transplants and chemotherapy for acute myelogenous leukemia) and NOVANTRONE (a line of drugs for the treatment of various cancers, including prostate cancer). In addition, Immunex has a number of drugs that are currently under development, including IL-4 for asthma, AVREND for kidney cancer and MOBISTA for various cancers. The company has concentrated its expansion toward exploring new opportunities through research and development collaborations. In recent news, Immunex entered into an agreement with Genentech, Inc. to produce ENBREL at Genentech’s manufacturing facility in South San Francisco, California. The manufacturing facility is subject to FDA approval, which the parties hope to obtain in 2004. Upon approval, the Genentech facility will become a licensed manufacturing site for commercial supply of ENBREL The company provides comprehensive training for employees to develop personal, computer, managerial and organizational skills. Immunex’s headquarters in Seattle, Washington houses a fully equipped fitness center.
BRANDS/DIVISIONS/AFFILIATES: LEUKINE NOVANTRONE THIOPLEX AMICAR ENBREL NUVANCE Amgen
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Edward V. Fritzky, CEO Peggy V. Phillips, COO Edward V. Fritzky, Pres. David A. Mann, CFO Philip Laub, VP-Human Resources Douglas E. Williams, Chief Tech. Officer Barry G. Pea, Corp. Sec. Barry G. Pea, General Counsel Efi Cohen-Arazi, Sr. VP-Supply Oper. Deborah Helleson, VP-Bus. Dev. David A. Mann, Treas. Michael Aguir, VP-Finance Daniel Burge, VP-Clinical Dev. Kendall Mohler, VP-Biological Sciences Thomas O. Daniel, Sr. VP-Discovery Research
Phone: 805 447 1000 Fax: 805 447 1010 Toll-Free: Address: One Amgen Center Dr., Thousand Oaks, CA 913201799 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $986,800 2001 Profits: $170,000 Employees: 1,618 2000 Sales: $861,800 2000 Profits: $154,400 Fiscal Year Ends: 12/31 1999 Sales: $541,700 1999 Profits: $44,300 1998 Sales: $243,500 1998 Profits: $1,000
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Acquired by Amgen.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Top Exec. Salary: $680,016 Second Exec. Salary: $407,004
Bonus: $1,445,000 Bonus: $393,750
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
IMMUNOMEDICS INC
www.immunomedics.com
Industry Group Code: 325413 Ranks within this company's industry group: Sales:11 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:9
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Diagnostics
Immunomedics develops, manufactures and markets diagnostic imaging and therapeutic products for the detection of cancer and various other diseases. The company’s products are created from monoclonal antibodies and fragments to deliver radioisotopes, chemotherapeutic agents and toxins to tumors. Diagnostic imaging products manufactured by Immunomedics include CEA-Scan, for the detection of colorectal, lung and breast cancers, and LeukoScan, for the detection of infections and inflammatory bowel disease. CEA-Scan has been approved in the U.S., Canada and Europe, and LeukoScan has been approved in Europe. Products under development include LymphoScan (epratuzumab), for the detection of nonHodgkin’s lymphoma, and AFP-Scan, for the diagnosis of primary liver and germ-cell cancers. Immunomedics granted a license to Amgen, Inc. to further develop and commercialize the unlabeled form of epratuzumab in North America and Australia. Amgen is currently evaluating this compound in Phase II and Phase III clinical trials for the treatment of patients with non-Hodgkin's lymphoma. Recently, Immunomedics announced the CEA patent portfolio has been licensed to Medix Biochemica and to Beckman-Coulter, Daiichi Pure Chemicals and Dako. Immunomedics provides comprehensive benefits to its employees, including tuition reimbursement and time-off benefits.
BRANDS/DIVISIONS/AFFILIATES: IMG Technologies CEA-Scan LeukoScan LymphoCide CEA-Cide LymphoScan AFP-Scan
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Cynthia L. Sullivan, CEO Cynthia L. Sullivan, Pres. Gerard G. Gorman, VP/CFO David M. Goldenberg, Chief Scientific Officer Ivan D. Horak, Exec. VP-Research and Dev. David M. Goldenberg, Chmn.
Phone: 973-605-8200 Fax: 973-605-8282 Toll-Free: Address: 300 American Rd., Morris Plains, NJ 07950 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $14,300 (12 months) 2002 Profits: $-3,700 (12 months) Stock Ticker: IMMU 2001 Sales: $11,229 2001 Profits: $-4,750 Employees: 94 2000 Sales: $3,200 2000 Profits: $-9,600 Fiscal Year Ends: 6/30 1999 Sales: $6,000 1999 Profits: $-11,300 1998 Sales: $7,600 1998 Profits: $-11,800
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Innovative imaging technology.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $300,000 Second Exec. Salary: $228,301
Bonus: $125,000 Bonus: $137,500
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
IMPAX LABORATORIES INC
www.impaxlabs.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:86 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:64
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Generic Drug Delivery Technologies
IMPAX Laboratories, Inc., formed by the merger of Impax Pharmaceuticals and Global Pharmaceutical Corp., is a technology-based, specialty pharmaceutical company focused on the development and commercialization of generic and brand-name pharmaceuticals, utilizing its controlled-release and other in-house development and formulation expertise. In the generic market, the firm is primarily focusing on selected controlled-release versions of brand-name drugs. In the brand-name drugs market, the company is developing products for the treatment of central nervous system disorders. Its product portfolio consists of development-stage projects to which IMPAX is applying its formulation and development expertise to produce modified versions of currently marketed drugs. The company plans to market branded products through the IMPAX Pharmaceuticals division and generic products through the Global Pharmaceuticals division. IMPAX has developed several proprietary controlled-release delivery technologies that can be utilized with a variety of oral dosage forms and drug release rates. These include the concentric multiple-particulate delivery system, the timed multiple-action delivery system and the dividable multipleaction delivery system. The firm markets approximately 20 generic pharmaceuticals. Generic products include controlled-release versions of Prilosec, Claritin, Allegra, Tricor and Wellbutrin. The company also has three branded projects under development. Recently, IMPAX received final approval for Omeprazole delayed-release capsules, a generic version of Prilosec. The company also received approval for a generic version of Flumadine flu treatment.
BRANDS/DIVISIONS/AFFILIATES: Global Pharmaceutical Corp. Impax Pharmaceuticals Bupropion Fenofibrate Omeprazole Loratadine Oxycodone
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Charles Hsaio, Co-CEO Larry Hsu, COO Larry Hsu, Pres. Cornel C. Spiegler, CFO David S. Doll, Sr. VP-Sales and Mktg. Joseph A. Storella, VP-Oper. Barry R. Edwards, Co-CEO May Chu, VP-Quality Affairs
Phone: 510-476-2000 Fax: 510-471-3200 Toll-Free: Address: 30831 Huntwood Ave., Hayward, CA 94544 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $24,500 (12 months) 2002 Profits: $-20,000 (12 months) Stock Ticker: IPXL 2001 Sales: $6,600 2001 Profits: $-25,100 Employees: 273 2000 Sales: $10,200 2000 Profits: $-25,000 Fiscal Year Ends: 12/31 1999 Sales: $1,200 1999 Profits: $-8,900 1998 Sales: $4,400 1998 Profits: $-5,200
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $195,000 Stock Purch. Plan: Second Exec. Salary: $195,000 ADVANTAGE: Innovative drug delivery technology/Niche multi-source pharmaceuticals.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $102,395 Bonus: $102,395
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
INCYTE GENOMICS INC
www.incyte.com
Industry Group Code: 541710 Ranks within this company's industry group: Sales:8 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:18
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Research-Genetic Information (Drug Discovery) Genomic Databases
Incyte Genomics owns the largest commercial portfolio of issued U.S. patents covering human, full-length genes, the proteins they encode and the antibodies directed against them. The firm intends to use its intellectual property and genomic information to become a leader in therapeutic small molecule, secreted protein and antibody discoveries. By January 2003, the company had launched three new full-scale small molecule drug discovery programs, one in inflammation and two in cancer. Current products include information databases, intellectual property licensing and full-length clones. Incyte has developed a leading integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. These technologies primarily consist of genomic databases and pharmaceutically relevant intellectual property licenses, which help pharmaceutical and biotechnology researchers in their therapeutic discovery and development efforts. These efforts include gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. The company operates three sequence databases of gene information: LifeSeq Gold for humans, ZooSeq for animals and LifeExpress, a gene and protein expression database. The firm maintains research services that enable life science researchers to query and analyze these databases online, utilizing features such as Workbench that let users keep track of their research. Furthermore, the company offers technology for the analysis of single nucleotide polymorphisms, which are genetic variations that could potentially lead to specific diseases or conditions. The company recently acquired Maxia Pharmaceuticals, a privately held small molecule drug discovery and development company. This acquisition dramatically expands the company’s drug discovery and development programs.
BRANDS/DIVISIONS/AFFILIATES: Proteome LifeSeq Gold PathoSeq ZooSeq LifeExpress LifeTools LifeProt Maxia Pharmaceuticals
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Paul A. Friedman, CEO Michael D. Lack, COO Robert Stein, Pres. John Vuko, CFO James R. Neal, Exec. VP-Sales and Mktg. Paula J. Swain, VP-Human Resources Robert Stein, Chief Scientific Officer Ken Jacobsen, Sr. VP-Info. Sciences Tim Henn, Corp. Controller E. Lee Bendekgey, Exec. VP/General Counsel Jim Merryweather, Exec. VP-Bus. Dev. Robert Venema, Treas. Randy Harris, Sr. VP-Sales Brian W. Metcalf, Chief Drug Discovery Scientist Ingrid Akerblom, VP-Informatics Cate Sabatini, VP-Customer Support Roy A. Whitfield, Chmn.
Phone: 650-855-0555 Fax: 650-855-0572 Toll-Free: Address: 3160 Porter Dr., Palo Alto, CA 94304 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $101,612 (12 months) 2002 Profits: $-136,885 (12 months) Stock Ticker: INCY 2001 Sales: $219,300 2001 Profits: $-183,200 Employees: 491 2000 Sales: $194,200 2000 Profits: $-29,700 Fiscal Year Ends: 12/31 1999 Sales: $157,000 1999 Profits: $-26,800 1998 Sales: $134,800 1998 Profits: $3,500
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $600,084 Bonus: $290,631 Stock Purch. Plan: Second Exec. Salary: $500,000 Bonus: $242,192 ADVANTAGE: Operates sequence databases of gene information for humans, animals and bacterial and fungal genomes.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
INFOCUS CORP
www.infocus.com
Industry Group Code: 334119 Ranks within this company's industry group: Sales:3 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:3
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Hardware-Data and Video Projectors Portable Projection Equipment
InFocus Corporation is a leader in presentation technology, manufacturing a wide variety of data and video projectors. The firm produces business projectors, home projectors such as the InFocus ScreenPlay series for entertainment purposes, software such as ProjectorNet technology for managing multiple projectors within a corporation and accessories such as portable screens, stands, carrying cases and projector lamps. Additionally, InFocus offers personal projectors for mobile presenters, conference room projectors for corporate and campus meetings and fixed-auditorium projectors for large-scale audiences. The projectors feature LCD and digital light processing (DLP) technologies and can project from sources such as personal computers, workstations, VCRs and laser disc players. The projectors have a wide range of applications, including training sessions, meetings, sales presentations, technical seminars and group collaborations. Through its partnership with Texas Instruments, InFocus manufactures Texas Instruments’ DLP-based microdisplay technology. InFocus markets its products under its own name and the names of its subsidiaries, Proxima and ASK. Recently, InFocus unveiled the industry’s first wireless digital projection system, LiteShow. Moreover, the InFocus ScreenPlay 7200 home cinema projector and InFocus X1 multi-use projector received the Innovations 2003 Design and Engineering Showcase Honors at the International CES Expo. InFocus offers employees on-site dry cleaning pickup and delivery services, as well as an on-site massage therapist. The company also donates projection technology to schools participating in the Intel Model School Program.
BRANDS/DIVISIONS/AFFILIATES: LiteShow Proxima ASK ScreenPlay ProjectorNet X1
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John V. Harker, CEO John V. Harker, Pres. Michael D. Yonker, Exec. VP-Finance/CFO Kyle Ranson, Exec. VP-Worldwide Sales and Mktg. Lucinda K. Rockwell, VP-Human Resources David. F. Glaess, VP-Worldwide Research and Dev. Gary R. Pehrson, Exec. VP-Dev. and Oper. Scott P. Hix, VP/General Mgr.-Bus. Dev. Amar Samra, Sr. VP/Mgr.-EMEA Candace Peterson, VP-Corp. Mktg. and Strategy Thomson Chan, VP/Mgr.-Asia Pacific Raymond D. Stapleton, Sr., VP/Mgr.-Global Services and Solutions John V. Harker, Chmn.
Phone: 503-685-8888 Fax: 503-685-8887 Toll-Free: 800-294-6400 Address: 27700B SW Parkway Ave., Wilsonville, OR 97070 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $653,098 (12 months) 2002 Profits: $-63,971 (12 months) Stock Ticker: INFS 2001 Sales: $760,600 2001 Profits: $20,200 Employees: 1,020 2000 Sales: $886,700 2000 Profits: $51,900 Fiscal Year Ends: 12/31 1999 Sales: $390,700 1999 Profits: $26,900 1998 Sales: $306,700 1998 Profits: $- 700
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $569,462 Stock Purch. Plan: Second Exec. Salary: $321,232 ADVANTAGE: A leader in electronic projection products.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $157,003 Bonus: $12,300
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
INSTRUMENTARIUM
www.instrumentarium.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:14 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:10
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Equipment-Patient Monitoring Devices Anesthesia Systems Diagnostic Imaging Equipment Infant Care Equipment
Instrumentarium, a global leader in medical technology, provides health care products, technologies and solutions. The company operates under two segments: anesthesia and critical care and medical equipment. The anesthesia and critical care segment, which accounts for 80% of sales, is comprised of the Datex-Ohmeda, Spacelabs Medical, Deio and Instrumed divisions. The DatexOhmeda division supplies systems and solutions for operating rooms and critical care areas of the hospital, including anesthesia systems, equipment and services, patient monitors, ventilators and workstations, such as the System 5 Integrated Anesthesia Workstation. The Spacelabs Medical division oversees critical care patient monitoring, anesthesia delivery, diagnostic cardiology and clinical information systems, and provides patient monitors and clinical information systems. Among its products are the Ultraview Anesthesia Delivery System and the Ultraview Web Source. The Deio division provides clinical information management solutions. The Instrumed division provides installation, information system integration, training and technical support to customers in Finland. The medical equipment segment is comprised of the medical equipment, Soredex, Ohmeda Medical and Medko Medical divisions. The medical equipment division develops, manufactures and markets diagnostic X-ray, mammography, dental and surgical imaging. The Soredex division also provides diagnostic imaging equipment but additionally manufactures dental imaging products. The Ohmeda Medical division manufactures infant care equipment such as infant incubators, warmers, jaundice management systems and vital signs monitors. The Medko Medical division provides customers with consulting, planning, delivery, installation, training and warranty. General Electric plans to acquire Instrumentarium.
BRANDS/DIVISIONS/AFFILIATES: Datex-Ohmeda Spacelabs Medical, Inc. Deio Soredex Medko Instrumed Ultraview General Electric
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Olli Rikkala, CEO Olli Rikkala, Pres. Juhani Lassila, VP-Finance Peter Tchernych, VP-Project Sales Timo Koskinen, VP-Human Resources Dev. Ritva Sotamaa, General Counsel Hannu Ahjopalo, VP-Corp. Dev. and New Strategic Ventures Juhani Lassila, VP-Investor Rel. Juhani Lassila, Treas. Peter Tchernych, VP-Trade Financing Matti Salmivuori, VP-Group Admin. Richard Atkin, VP-North American Sales and Service, Datex-Ohmda Arto Kontturi, VP-Asia-Pacific Sales and Service, Datex-Ohmda Timo Peltola, Chmn.
Phone: 358-10-394-11 Fax: 359-9-146-4172 Toll-Free: Address: Kuortaneenkatu 2, Helsinki, 00031 Finland
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,183,400 (12 months) 2002 Profits: $163,600 (12 months) Stock Ticker: Foreign 2001 Sales: $242,100 2001 Profits: $-2,100 Employees: 1,177 2000 Sales: $249,000 2000 Profits: $-4,700 Fiscal Year Ends: 12/31 1999 Sales: $301,200 1999 Profits: $9,800 1998 Sales: $275,200 1998 Profits: $2,700
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $440,000 Stock Purch. Plan: Second Exec. Salary: $200,000 ADVANTAGE: Advanced patient monitoring technology.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
INTEL CORP
www.intel.com
Industry Group Code: 334413 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Microprocessors Telecommunications Equipment Semiconductors Home Network Equipment Digital Imaging Products Software Development
Intel Corporation is the world's largest semiconductor maker and a leading manufacturer of computer products. Along with Microsoft, IBM and their peers, Intel is among the most important and successful firms in the technology industry. Intel supplies the chips, boards, systems and software that are necessary for computer architecture. The company's major products include microprocessors, chipsets, flash memory products, networking and communications products; embedded processors and microcontrollers; and digital imaging and other PCperipheral products. Intel is organized into five operating segments according to the firm's various product lines: the Intel architecture business group; the wireless communications and computing group; the network communications group (enhanced by the acquisition of Shiva Corporation); the communications products group; and the new business group. In addition, Intel Capital is Intel's strategic investment group. Intel recently acquired Xircom, Inc., which will enable Intel to provide new products for notebook and mobile computing uses. The company has also acquired VxTel, Inc., a semiconductor company that has developed unique Voice over Packet (VoP) products, which help deliver high-quality voice and data communications over next-generation optical networks. Intel’s new Centrino technology consists of a processor, chipset and integrated wireless LAN capability. Centrino was designed to be a faster, lighter chip for use in portable wireless equipment. All salaried employees receive three weeks of vacation. The entire workforce, including the CEO, works in cubicles, and there are no reserved parking spaces. In addition, the company offers telecommuting, a businesscasual dress code, free PCs and unlimited Internet access at home.
BRANDS/DIVISIONS/AFFILIATES: Centrino Pentium Softcom Microsystems, Inc. Xircom, Inc. VxTel, Inc. Shiva Corporation Level One Communications Itanium
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Craig R. Barrett, CEO Paul Otellini, COO Andy D. Bryant, Exec. VP/CFO Chun Shen Chen, VP & Co-Director Sales/Mkt. Group Patricia Murray, VP-Human Resources Robert J. Baker, Sr. VP-Tech. Douglas F. Busch, VP/CIO Jon A. Olson, VP-Finance/Controller Patrick P. Gelsinger, Chief Tech. Officer Robert J. Baker, Sr. VP-Mfg. F. Thomas Dunlap, Jr., Corp. Sec. F. Thomas Dunlap, Jr., General Counsel Stephen P. Natchsheim, Dir.-Oper./Intel Capital Kirby A. Dyess, Sr. VP/Dir.-New Bus. Dev. Sandra K. Morris, Dir.-e-Bus. Ronald J. Smith, Sr. VP-Wireless Comm./Computing Sean M. Maloney, Exec. VP-Intel Comm. Group Pamela L. Pollace, VP-Worldwide Mktg. Oper. Louis J. Burns, General Mgr.-Desktop Platforms Group Andrew S. Grove, Chmn.
Phone: 408-765-8080 Fax: 408-765-9904 Toll-Free: 800-547-8806 Address: 2200 Mission College Blvd., Santa Clara, CA 95052 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $26,764,000 (12 months) 2002 Profits: $3,117,000 (12 months) Stock Ticker: INTC 2001 Sales: $26,539,000 2001 Profits: $1,291,000 Employees: 78,700 2000 Sales: $33,726,000 2000 Profits: $10,535,000 Fiscal Year Ends: 12/31 1999 Sales: $29,389,000 1999 Profits: $7,314,000 1998 Sales: $26,273,000 1998 Profits: $6,068,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $575,000 Bonus: $1,075,300 Stock Purch. Plan: Y Second Exec. Salary: $525,000 Bonus: $981,800 Intel's semiconductors are used in about 80% of PCs/Unique new 64-bit Itanium chips, capable of running ADVANTAGE: 20 operations simultaneously, the first major chip redesign in years.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
INTERGRAPH CORP
www.intergraph.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:32 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:4
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y Y
GROWTH PLANS/SPECIAL FEATURES:
Computer Software-Mapping & Design Geospatial Products Management Consulting Mapping and Location Solutions Imaging Software
Intergraph Corporation is a worldwide provider of end-toend technical solutions and systems integration services. The company’s products enable customers in local and federal governments, transportation, process and building, mapping, utilities, communications and public safety industries to acquire, share and reuse design and mapping data over the Internet. The Government Solutions subsidiary provides management consulting, technology and integrated solutions in the commercial and government sectors. The Intergraph Mapping and GIS Solutions (IMGS) subsidiary serves government agencies and commercial enterprises with end-to-end geospatial solutions for cartography and map production and enterprise-wide mapping and GIS. IMGS include the GeoMedia, Modula GIS Environment and Digital Cartographic Studio platforms. IntelliWhere, a division of IMGS, addresses the emerging technologies of wireless Internet and location-based services (LBS). This division's products leverage GeoMedia technology to provide LBS solutions that are device and data independent. IntelliWhere focuses on mobile workforces in transportation, state and local government, telecommunications, utilities, the military and emergency response. Intergraph Process, Power and Offshore supplies software and services to the process, power and offshore petroleum industries. The company’s Public Safety subsidiary develops software solutions for law enforcement organizations, fire and emergency medical services, airports, military and commercial security forces and automobile clubs for roadside assistance. Intergraph’s Z/I Imaging, Inc. solutions include aerial cameras; photogrammetric scanners; stereo workstations; and image management, processing and distribution software. The imaging software includes enterprise solutions that combine the power of a client/server image management and distribution system with a highperformance imaging engine to quickly provide the information needed. The company recently formed a partnership with Trimble to offer solutions for mobile resource management.
BRANDS/DIVISIONS/AFFILIATES: Intergraph Government Solutions Intergraph Public Safety Intergraph Mapping and GIS Solutions Intergraph Process, Power and Offshore GeoMedia Z/I Imaging IntelliWhere
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. James F. Taylor, Jr., CEO Larry J. Laster, CFO John R. Wynn, Corp. Sec. David Vance Lucas, VP/General Counsel Jack C. Ickes, VP-Corp. Services Eugene H. Wrobel, VP/Treas. William E. Salter, Pres.-Gov't Solutions Roger O. Coupland, Pres.-Public Safety Graeme J. Farrell, Exec. VP-Asia Pacific Oper. James F. Taylor, Jr., Chmn.
Phone: 256-730-2000 Fax: 256-730-2040 Toll-Free: 800-345-4856 Address: 288 Dunlop Blvd., Huntsville, AL 35894-0001 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $501,200 (12 months) 2002 Profits: $377,800 (12 months) Stock Ticker: INGR 2001 Sales: $532,100 2001 Profits: $19,900 Employees: 3,800 2000 Sales: $690,500 2000 Profits: $10,100 Fiscal Year Ends: 12/31 1999 Sales: $914,880 1999 Profits: $-71,577 1998 Sales: $1,005,007 1998 Profits: $-19,634
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Stock Purch. Plan: Y ADVANTAGE: Expertise in imaging and mapping.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $300,000 Second Exec. Salary: $260,000
Bonus: $85,266 Bonus: $195,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
INTERNATIONAL BUSINESS MACHINES (IBM) www.ibm.com Industry Group Code: 334111 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y Y
GROWTH PLANS/SPECIAL FEATURES:
Computer Hardware-PCs, Notebooks & Mainframes Supercomputers Networking Systems IT-Related Services E-Commerce Solutions and Support IT Consulting and Outsourcing
International Business Machines Corp. (also known as IBM or Big Blue) is the world’s top producer of computer hardware and is second only to Microsoft as a leading producer of software. While the company maintains a significant product line in the home-computing market, it remains committed to focusing on the production of large mainframe computers for enterprise-level needs. Perhaps more than any other company, IBM has gone to great pains to change its image and structure to continually adjust to the dynamic computer industry. The company has positioned itself as a major player in e-commerce and Internet software, infrastructure and services. IBM is also one of the world’s largest consulting and outsourcing firms, possessing significant long-term contracts for staffing and managing computer departments at major corporate and institutional client locations. In addition, at $5.3 billion yearly, IBM's research budget is one of the largest in the world. Recently, IBM and AXA Group announced a $1-billion on-demand technology services agreement, which will enhance the performance and efficiency of AXA's global computing infrastructure. IBM plans to integrate AXA's server, mainframe and storage systems into an on-demand computing structure. This will result in AXA shifting from a traditional fixed-cost approach to one in which important technology is accessed as a flexible, variable-cost service. This agreement is an example of a recent internal business transformation at IBM to an on-demand business that will take advantage of its current IT infrastructure offerings, to produce an end-toend view incorporating customers, suppliers, employees and stakeholders. In a related development, the firm acquired Rational Software Corp., which develops business software products. Rational’s open software development platform will be an important part of IBM’s ebusiness on-demand program. AMD and IBM entered into an agreement to develop chip-making technologies for use in future high-performance products. IBM has an outstanding reputation for taking care of its employees. It offers educational reimbursement, flexible work schedules, social activities and child care.
BRANDS/DIVISIONS/AFFILIATES: Lotus Development Corp. Mylex Corp. Data Beam Corp. Tivoli Systems, Inc. PwC Consulting Blueprint Worldwide Rational Software Corp. IBM
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Samuel J. Palmisano, CEO Samuel J. Palmisano, Pres. John R. Joyce, Sr. VP/CFO Abby F. Kohnstamm, Sr. VP-Mktg. J. Randall MacDonald, Sr. VP-Human Resources Nicholas M. Donofrio, Sr. VP-Tech. Nicholas M. Donofrio, Sr. VP-Mfg. Harriet P. Pearson, Chief Privacy Officer J. Bruce Harreld, Sr. VP-Strategy Doug T. Elix, Sr. VP-IBM Global Services Paul M. Horn, Sr. VP-Research Linda S. Sanford, Sr. VP-Enterprise On Demand Steven A. Mills, Sr. VP-Software Group Samuel J. Palmisano, Chmn. Robert Moffat, Jr., Sr. VP-Integrated Supply Chain
Phone: 914-499-1900 Fax: 914-765-7382 Toll-Free: 800-426-4968 Address: New Orchard Rd., Armonk, NY 10504 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $81,186,000 (12 months) 2002 Profits: $3,579,000 (12 months) Stock Ticker: IBM 2001 Sales: $85,866,000 2001 Profits: $7,723,000 Employees: 355,421 2000 Sales: $88,396,000 2000 Profits: $8,093,000 Fiscal Year Ends: 12/31 1999 Sales: $87,548,000 1999 Profits: $7,712,000 1998 Sales: $81,667,000 1998 Profits: $6,328,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $2,000,000 Bonus: $1,500,000 Stock Purch. Plan: Y Second Exec. Salary: $1,100,000 Bonus: $3,000,000 ADVANTAGE: The world's largest information technology company/Continued focus on e-commerce, consulting and outsourced services.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
INTERNATIONAL RECTIFIER CORP
www.irf.com
Industry Group Code: 334413 Ranks within this company's industry group: Sales:14 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:6
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Semiconductors-Power MOSFETS Thrysistors
International Rectifier (IR) is a leading manufacturer of power semiconductors, which refine electricity from wall outlets to convert it to a more usable form. Major products sold by the company include MOSFETs (metal oxide semiconductor field effect transistors), high-voltage integrated circuits and IGBTs (insulated gate bipolar transistors). IR also sells rectifiers, diodes and thrysistors, which condition electrical power to make it safer. The company’s technology has a broad range of commercial and industrial applications, including extension of battery life, automotive electronic systems and motor controls. Corporate clients include Boeing, Bosch, Chrysler, Delphi, Emerson, Fujitsu, IBM, Matsushita, Philips, Sanken, Sanyo, Siemens and Sony. IR has been working on developing new technology to increase power and minimize costs for its products. The company recently developed a series of four new 12-volt MOSFETs, which deliver up to 15% higher current handling capability when compared to industry-standard 30-volt devices. The firm has also developed a new line of standard-recovery diodes. The diodes are mounted in a plastic-cap case, which improves surge current capability up to 40% over standard diodes. These devices are used to convert alternating current into direct current. The company offers employees scholarship programs and courses for individual development, vocational and skill development and management education for its employees.
BRANDS/DIVISIONS/AFFILIATES: FlipFET
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Alexander Lidow, CEO Michael P. McGee, Exec. VP/CFO Robert M. Grant, Exec. VP-Global Sales and Mktg. Dennis Taylor, Dir.-Human Resources Donald R. Dancer, Corp. Sec. Donald R. Dancer, General Counsel Walter T. Lifsey, Exec. VP-Oper. Robert J. Mueller, Exec. VP-External Affairs Eric Lidow, Chmn.
Phone: 310-726-8000 Fax: 310-322-3332 Toll-Free: Address: 233 Kansas St., El Segundo, CA 90245 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $720,200 (12 months) 2002 Profits: $48,700 (12 months) Stock Ticker: IRF 2001 Sales: $978,600 2001 Profits: $87,600 Employees: 5,900 2000 Sales: $753,300 2000 Profits: $68,400 Fiscal Year Ends: 6/30 1999 Sales: $545,400 1999 Profits: $-5,800 1998 Sales: $551,900 1998 Profits: $16,500
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $700,000 Stock Purch. Plan: Second Exec. Salary: $677,650 ADVANTAGE: A leader in field effect transistors/New power-saving technologies.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $500,000 Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
INTUIT INC
www.intuit.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:12 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:9
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Computer Software-Financial Management Small Business Accounting Software Financial Services Online Home Loans Online Insurance Online
Intuit, Inc. is a leading provider of financial software and web-based services for consumers, small businesses and accounting professionals. The company’s Quicken product line simplifies personal finance, small business management, payroll processing, tax preparation and filing and online home loans. The QuickBooks product line brings extensive bookkeeping capabilities to small business users in an easy-to-use design that does not require customers to be familiar with debit/credit accounting. Moreover, the QuickBooks Internet Gateway platform gives QuickBooks customers direct access to a broad range of online services that address the specific needs of small businesses. For example, the QuickBooks Merchant Account service enables small businesses to accept credit card payments from their customers. QuickBooks also features the Site Builder web site creation tool, a subscription service that enables small businesses to set up and maintain professional-looking web sites quickly and inexpensively. The company’s Quicken.com web site enables customers to automate financial management tasks and make better financial decisions by giving them software tools, resources and objective information about a variety of personal finance topics such as investment and retirement. Intuit’s Quicken TurboTax line of products makes it easy for individuals and small business owners to prepare their own federal and state income tax returns. The firm sells software solutions developed specifically for several industries, including construction, real estate and retailing. In recent news, Intuit and IBM announced a marketing and technology alliance to help small and medium sized business customers better manage critical business components, including order processing, inventory control, accounting, purchasing and customer service. The agreement with Intuit Eclipse covers the U.S., Canada and Mexico regions. Intuit offers its employees a range of child and elder care referral services, on-site dental care, yoga classes, home loan assistance and tuition reimbursement.
BRANDS/DIVISIONS/AFFILIATES: Quicken QuickBooks Quicken TurboTax QuickBooks Pro QuickenMortgage QuickTax Intuit Master Builder Solution Provider Site Builder
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Stephen M. Bennett, CEO Stephen M. Bennett, Pres. Brad Henske, CFO Caroline Donahue, VP-Sales Jim Grenier, VP-Human Resources Shan Chinnasamy, Chief Tech. Officer Jennifer Hall, CIO Dotty Hayes, Controller Dennis Adsit, Sr. VP-Oper. Raymond Stern, Sr. VP-Corp. Dev. Lisa Lang, VP-Corp. Comm. Linda Fellows, VP-Investor Rel. Linda Fellows, Treas. Mark S. Bercow, VP-Intuit Developer Network Melanie Singer, VP-Software Eng. Ginny Lee, VP-Bus. Oper. Dan Manack, Sr. VP-Accountant Bus. Bill Campbell, Chmn. Scott Beth, VP-Procurement
Phone: 650-944-6000 Fax: 650-944-3699 Toll-Free: 800-446-8848 Address: 2535 Garcia Ave., Mountain View, CA 94043 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,358,300 (12 months) 2002 Profits: $140,200 (12 months) Stock Ticker: INTU 2001 Sales: $1,261,500 2001 Profits: $-82,800 Employees: 6,500 2000 Sales: $1,093,825 2000 Profits: $305,661 Fiscal Year Ends: 7/31 1999 Sales: $940,435 1999 Profits: $386,564 1998 Sales: $689,282 1998 Profits: $6,182
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $825,000 Bonus: $1,860,375 Stock Purch. Plan: Y Second Exec. Salary: $412,000 Bonus: $289,140 ADVANTAGE: Broad customer base for product upgrades and line extensions/Excellent web-based marketing strategy.
OTHER THOUGHTS: Apparent Women Officers or Directors: 6 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
INVACARE CORP
www.invacare.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:15 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:18
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Supplies-Wheelchairs Home Health Care Equipment
Invacare is a leading manufacturer and distributor of health care products for the non-acute care environment, including the home health care and retail care markets. The firm sells its products to over 25,000 home health care and retail locations in the U.S., Australia, Canada, Europe and New Zealand. The company’s product line includes wheelchairs, motorized scooters, home care beds, mattress overlays and patient aids. In addition, through Invacare Continuing Care Group, the firm is a manufacturer and distributor of beds and furnishings for the non-acute care markets. The company also manufactures, markets and distributes many accessory products, including spare parts, wheelchair cushions, arm rests, wheels and respiratory parts. New product development has been given a strong emphasis as part of Invacare's strategy to gain market share and maintain competitive advantage. As a result, the company introduced 45 new products including the Pronto, the Platinum 5 Concentrator, the Infinity FloGel and ViscoFoam Cushions, the HomeFill II Convenience Pack and IVC Manual Wheelchairs. Recently, the company introduced the IVC Home Care Bed, which is more durable, easier to clean and set up and costs less to repair.
BRANDS/DIVISIONS/AFFILIATES: Pronto Platinum 5 Concentrator Infinity FloGel HomeFill II Convenience Pack IVC Manual Wheelchair IVC Home Care Bed ViscoFoam
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. A. Malachi Mixon, III, CEO Gerald B. Blouch, COO Gerald B. Blouch, Pres. Gregory C. Thompson, Sr. VP/CFO Louis F.J. Slangen, Sr. VP-Sales and Mktg. Diane J. Davie, Sr. VP-Human Resources Joseph B. Richey, II, Pres.-Tech. Div. Russ Lenahan, VP-IT Joseph B. Richey, II, Sr. VP-Electronic and Design Eng. Thomas R. Miklich, Corp. Sec. Bridget A. Miller, General Counsel David A. Johnson, VP-Oper. and Logistics Neal J. Curran, VP-Eng. and Product Dev. Stephen D. Neese, VP-e-Commerce Judy Kovacs, VP/General Mgr.-Service and Parts Ken Sparrow, Pres.-Invacare Europe W. Darrel Lowery, VP-North American Logistics Hugh L. Martyn, Regional Managing Dir.-Australasia A. Malachi Mixon, III, Chmn. Michael A. Perry, VP-Supply Group
Phone: 440-329-6000 Fax: 440-366-9008 Toll-Free: 800-333-6900 Address: One Invacare Way, Elyria, OH 44036 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,089,161 (12 months) 2002 Profits: $64,770 (12 months) Stock Ticker: IVC 2001 Sales: $1,053,600 2001 Profits: $35,200 Employees: 5,300 2000 Sales: $1,013,200 2000 Profits: $59,900 Fiscal Year Ends: 12/31 1999 Sales: $882,800 1999 Profits: $41,500 1998 Sales: $801,200 1998 Profits: $45,800
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $860,000 Bonus: $760,958 Stock Purch. Plan: Second Exec. Salary: $532,000 Bonus: $451,250 Invacare is the leading home medical equipment manufacturer in the world based upon its distribution ADVANTAGE: channels and the breadth of its product lines and sales.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
INVITROGEN CORPORATION
www.invitrogen.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:21 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:20
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Diagnostics-Gene Cloning Kits
Invitrogen develops, manufactures and markets research tools in kit form and provides other research products to customers engaged in life sciences research and the commercial manufacture of genetically engineered products. The company is a leading supplier of over 700 research kits and reagents that simplify and improve gene cloning, gene expression and gene analysis techniques. The company’s TOPO TA Cloning Kits reduce the time required for a key step in the gene cloning process (ligation reaction) from 12 hours to five minutes while increasing the success rate from 50% to over 90%. Other cloning kits manufactured by the company include the FastTrack 2.0 Kit (isolation of pure, full-length mRNA directly from cells or tissues), Discovery Line (RNA and DNA libraries created from hard-to-obtain human tissue sources) and Echo Cloning System (usage of recombination for rapid DNA cloning into multiple expression vectors). Additionally, it supplies sera, cell and tissue culture media and reagents used in life sciences research, as well as in processes to grow cells in the laboratory and produce pharmaceuticals and other materials. Invitrogen has been involved in a number of acquisitions and mergers. The company recently announced it has completed the acquisition of InforMax, Inc., a provider of bioinformatics software.
BRANDS/DIVISIONS/AFFILIATES: TOPO TA Cloning Kit FastTrack 2.0 Kit Novex Electrophoresis GmbH Life Technologies, Inc. Discovery Line Zero Blunt PCR Cloning Kit InforMax, Inc. Ethrog Biotechnologies
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Gregory T. Lucier, CEO/Pres. Lewis J. Shuster, COO Lyle C. Turner, Pres. C. Eric Winzer, CFO Alison Rowland, VP-Mktg. L. James Runchey, VP-Human Resources John Carrino, VP-Research and Dev. William Needles, VP/CIO Ann M. McCormick, VP-Mfg. Oper. John A. Cottingham, VP/Corp. Sec. John A. Cottingham, VP/General Counsel John D. Thompson, VP-Corp. Dev. Paul Goodson, VP-Investor Rel. Daryl J. Faulkner, VP-Europe James R. Glynn, Exec. VP August Sick, VP-Bus. Dev. Albie Neal, VP-Asia Pacific Lyle C. Turner, Chmn. Daryl J. Faulkner, Sr. VP-Intl. Oper.
Phone: 760-603-7200 Fax: 760-603-7201 Toll-Free: Address: 1600 Faraday Ave., Carlsbad, CA 92008 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $648,600 (12 months) 2002 Profits: $47,700 (12 months) Stock Ticker: IVGN 2001 Sales: $629,300 2001 Profits: $-147,700 Employees: 2,744 2000 Sales: $246,200 2000 Profits: $-54,300 Fiscal Year Ends: 12/31 1999 Sales: $92,900 1999 Profits: $9,200 1998 Sales: $70,600 1998 Profits: $5,000
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Merger with Life Technologies.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
Top Exec. Salary: $465,234 Second Exec. Salary: $342,708
Bonus: $20,820 Bonus: $19,688
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
IOMED INC
www.iomed.com
Industry Group Code: 325411 Ranks within this company's industry group: Sales:7 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:3
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drug Delivery Systems Local Inflammation Therapies
IOMED, Inc. is a leader in the development, manufacture and sale of active drug transport systems primarily used to treat acute local inflammation in the sports and occupational medicine and physical therapy markets. The firm seeks opportunities to market or develop new products, as well as collaborative agreements to develop its non-invasive drug technology. Its proprietary technologies are in various stages of research and product development for the treatment of inflammation and ophthalmic diseases. These products are used in the sitespecific, non-invasive administration of soluble salts or other drugs into the body as an alternative to hypodermic injection, to avoid the pain of needle insertion, to minimize the infiltration of carrier fluids and to avoid damage caused by needles in traumatized tissue. IOMED markets two iontophoretic system products used to deliver corticosteroids for local inflammation conditions and to deliver Iontocaine, the firm's topical solution for local dermal anesthesia. The firm's patented Phoresor System is designed for clinical use and is comprised of a reusable dose controller and single-use, disposable transdermal patch kits. Patch kits include IOGEL, TransQ and Anestrode. In addition, the company markets Numby Stuff, an Iontocaine product primarily for use in the pediatrics market. Products in development include IontoDex, designed for patient in-home use in the treatment of local inflammation. IOMED has also developed the OcuPhor platform for safe and effective administration of therapeutics to the back of the eye. In recent news, the firm began distributing Liquid Ice in North America. The product, manufactured by Americool, is a reusable, self-contained cooling and compression wrap. IOMED offers its employees health care coverage, life insurance, educational assistance and other benefits.
BRANDS/DIVISIONS/AFFILIATES: Phoresor System Iontocaine IOGEL Numby Stuff TransQ IontoDex GelSponge OcuPhor
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. James R. Weersing, CEO Robert J. Lollini, COO Robert J. Lollini, CFO Timothy B. Lucas, Dir.-Nat'l Sales Mary A. Crowther, VP-Human Resources Greg A. Fischer, Exec. VP-Mfg. and Product Dev. Mary A. Crowther, VP-Admin. Services Jessica Barrett, Dir.-Product Mktg. Peter J. Wardle, Chmn.
Phone: 801-975-1191 Fax: 801-972-9072 Toll-Free: 800-621-3347 Address: 2441 S. 3850 West, Ste. A, Salt Lake City, UT 84120 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $11,800 (12 months) 2002 Profits: $-2,400 (12 months) Stock Ticker: IOX 2001 Sales: $11,395 2001 Profits: $-7,876 Employees: 54 2000 Sales: $10,800 2000 Profits: $-1,200 Fiscal Year Ends: 6/30 1999 Sales: $10,500 1999 Profits: $ 100 1998 Sales: $10,300 1998 Profits: $-1,100
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $200,000 Stock Purch. Plan: Second Exec. Salary: $160,000 ADVANTAGE: Expertise in the use of electrical currents for drug delivery.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
IOMEGA CORP
www.iomega.com
Industry Group Code: 334112 Ranks within this company's industry group: Sales:8 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:5
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Storage Equipment-Zip Disk Drives Magnetic Disk Drives Network Attached Storage Servers Data Storage Software
Iomega Corp. designs, manufactures and markets innovative data management solutions based on removable media technology for home and office computers. The firm's principal data management solutions include magnetic drives and disks marketed under the trademark Zip; a high-performance, portable, external drive device incorporating hard disk technology marketed under the Peerless trademark; and optical drives marketed under the Iomega CD-RW and Predator trademarks. Iomega also markets network attached storage (NAS) servers that organize, share and protect critical business data. The firm's products can be purchased as aftermarket products for personal computers (PCs) or as built-in features of PCs and other OEM products. Its data management solutions install easily and add a versatile source of additional storage capacity. Zip drives use reliable, high-capacity removable magnetic disks to protect and secure digital valuables on desktop and laptop computers used in home and office settings. Iomega CD-RW products allow users to capture and share digital valuables using industry-standard CD formats such as CD-recordable (CD-R) and CD-rewritable (CD-RW) discs. The Peerless disk, which incorporates hard drive technology in 10GB and 20 GB capacities, offers high capacity in a compact, portable form. Since its founding in 1995, more than 46 million Zip drives and 280 million Zip disks have been shipped. In 2001, the company discontinued its Jaz and PocketZip products. Other products include QuikSync software and HotBurn CD Writer software. Recently, Iomega launched the new iStorage Online storage choice, a fast, flexible solution that provides users with convenient access to files from any Internet connection, making web-based storage easy, scalable and secure. Employee benefits at Iomega include medical, dental and vision plans, flexible spending accounts, income protection, tuition assistance, adoption assistance and an employee assistance program.
BRANDS/DIVISIONS/AFFILIATES: Zip Drive Peerless Predator Iomega CD-RW HotBurn CD Writer QuikSync iStorage Online
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Werner Heid, CEO Werner Heid, Pres. Barry Zwarenstein, VP/CFO Susan Huberman, VP-Corp. Mktg. Anna Aguirre, VP-Human Resources and Facilities Mahmoud Mostafa, Exec. VP-Research Thomas Kampfer, VP/Corp. Sec. Thomas Kampfer, General Counsel Mahmoud Mostafa, Exec. VP-Dev. and Oper. Scott Sheehan, VP-Bus. Dev. Sean Burke, General Mgr.-Mobile and Desktop Solutions Ulrike Tegmeier, VP/Dir.-Europe Greg Rhine, VP/Mgr.-Americas James Payne, VP/Dir.-Asia Pacific
Phone: 858-795-7000 Fax: 858-795-7001 Toll-Free: Address: 4435 Eastgate Mall, 3rd. Fl., San Diego, CA 92121 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $614,400 (12 months) 2002 Profits: $34,700 (12 months) Stock Ticker: IOM 2001 Sales: $834,300 2001 Profits: $-93,300 Employees: 850 2000 Sales: $1,300,200 2000 Profits: $169,600 Fiscal Year Ends: 12/31 1999 Sales: $1,525,129 1999 Profits: $-103,489 1998 Sales: $1,694,385 1998 Profits: $-54,222
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $890,530 Stock Purch. Plan: Y Second Exec. Salary: $349,821 ADVANTAGE: Committed to R & D/Products respond to growing market needs.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $5,937 Bonus: $145,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ISIS PHARMACEUTICALS INC
www.isip.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:59 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:78
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Cytomegalovirus Retinitis Antisense Technology
Isis Pharmaceuticals, Inc. is a pioneer of antisense technology, which is based on the direct application of gene sequence information to combat various diseases. The company developed Vitravene, the first antisense drug to achieve marketing clearance, to treat cytomegalovirus retinitis in people with AIDS. Isis has 13 additional antisense compounds in its pipeline, eight of which are being tested in human clinical trials, including ISIS 3521, ISIS 5132 and ISIS 2503 for the treatment of solid tumors, ISIS 2302 for inflammatory diseases and ISIS 14803 for the hepatitis C virus. The company’s second-generation drugs represent approximately half of the drugs in development. The GeneTrove division uses antisense technology to provide information for various pharmaceutical companies about human genes, including their functions, behaviors and effectiveness in fighting diseases. The Ibis Therapeutics division focuses on the discovery of small molecular drugs that function by binding to RNA. Isis Pharmaceuticals engages in numerous partnerships in the areas of GeneTrove antisense-based functional genomics, antisense drug discovery and development, Ibis Therapeutics antisense-based small molecule drug therapy and intellectual property licensing, including partnerships with Eli Lilly & Company, Merck & Co., Inc. and Antisense Therapeutics Limited. Recently, Eli Lilly & Company selected the second-generation antisense agent, ISIS 23722, for clinical development. Also, Isis Pharmaceuticals announced the start of a multiyear collaboration with Ercole Biotech, Inc., the purpose of which is to discover and develop antisense drugs that regulate alternative RNA splicing.
BRANDS/DIVISIONS/AFFILIATES: Vitravene ISIS 23722 Ibis Therapeutics Division GeneTrove Division Antisense Therpeutics Limited Merck & Co., Inc. Ercole Biotech, Inc. Eli Lilly & Company
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Stanley T. Crooke, CEO B. Lynne Parshall, CFO Patricia Lowenstam, VP-Human Resources C. Frank Bennett, VP-Antisense Research John McNeil, VP-Informatics B. Lynne Parshall, Exec. VP/Sec. Jon T. Holmlund, VP-Dev. Richard K. Brown, VP-Bus. Dev. Karen Lundstedt, VP-Corp. Comm. Karen Lundstedt, VP-Investor Rel. Douglas L. Cole, VP-Tech. Dev. Arthur A. Levin, VP-Dev. Aron Stein, VP-Regulatory Affairs and Quality Assurance David J. Ecker, VP/Pres., Ibis Therapeutics Stanley T. Crooke, Chmn.
Phone: 760-931-9200 Fax: 760-931-9639 Toll-Free: Address: 2292 Faraday Ave., Carlsbad, CA 92008 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $58,320 (12 months) 2002 Profits: $-56,413 (12 months) Stock Ticker: ISIS 2001 Sales: $53,300 2001 Profits: $-73,800 Employees: 523 2000 Sales: $37,300 2000 Profits: $-53,500 Fiscal Year Ends: 12/31 1999 Sales: $33,900 1999 Profits: $-59,200 1998 Sales: $39,200 1998 Profits: $-43,000
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $486,000 Stock Purch. Plan: Y Second Exec. Salary: $385,799 ADVANTAGE: Combination of work in molecular biology and antisense technology.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $205,286 Bonus: $136,650
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
ISUZU MOTORS LTD
www.isuzu.co.jp
Industry Group Code: 336111 Ranks within this company's industry group: Sales:17 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Profits:15
Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Automobiles, Manufacturing/ Relationship with GM Trucks and Buses
Isuzu Motors, Ltd. manufactures and sells sport utility vehicles, trucks, pickups, diesel engines and buses. The sport utility vehicle line up includes the Trooper, Rodeo (U.S. model), Rodeo Sport (U.S. model), VshiCROSS (U.S. model), Axiom (U.S. model), Isuzu D-Max (Thai model) and Panther (Indonesian model). General Motors owns 49% interest in the firm. Its light, medium and heavy truck models include the CXZ, FTR, FSS, NKR and NHR trucks and EXR tractor. Gala, Erga and Erga Mio comprise Isuzu’s branded line of buses. Isuzu has placed major efforts in its diesel engine innovations throughout the years. The company is in the process of developing fuel-efficient and low-emissions diesel engines. It currently produces 60 types of diesel engine models. DMAX, Ltd. and Isuzu Motors America, Inc., subsidiaries of the company, are the U.S. production and sales facilities for Isuzu diesel engines. In recent news, the company and General Motors established a new joint venture, known as GMI Diesel Engineering, Ltd., to produce diesel engines in Fujisawa City.
BRANDS/DIVISIONS/AFFILIATES: Trooper Rodeo Axiom Panther Gala DMAX, Ltd. Isuzu Motors America, Inc. General Motors
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Yoshinori Ida, Pres. Shigeki Toma, CFO/Div. Exec.-Corp. Finance Kozo Sakaino, Sr. Div. Exec.-Sales Basil N. Drossos, Sr. Div. Exec.-Corp. Admin. Shigeki Toma, Div. Exec.-Corp. Planning Kazuhira Seki, Sr. Counselor Randall J. Schwarz, Sr. Div. Exec.-Oper. and Mgmt. Takeshi Inoh, Chmn.
Phone: 81-3-5471-1141 Fax: 81-3-5471-1043 Toll-Free: Address: 26-1 Minami-oi 6-chome, Shinagawa-ku, Tokyo, 1408722 Japan
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $12,045,000 (12 months) 2002 Profits: $-324,000 (12 months) Stock Ticker: Foreign 2001 Sales: $12,421,800 2001 Profits: $-528,700 Employees: 26,234 2000 Sales: $14,280,000 2000 Profits: $-528,700 Fiscal Year Ends: 3/31 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Y Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Excellent diesel engine technology.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $ Second Exec. Salary: $
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ITT INDUSTRIES INC
www.ittind.com
Industry Group Code: 336410 Ranks within this company's industry group: Sales:9 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Profits:4 Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Aerospace/Defense Products Manufacturer Fluid Technology Products Switch Applications
ITT Industries, Inc. is an industrial world power in engineering and manufacturing, providing a wide range of equipment for defense systems and services, fluid technology products, electrical connectors and switches. The company is divided into four main segments: fluid technology, defense electronics and services, motion and flow control and electronic products. The fluid technology division is engaged in the design, development, production, sale and support of products, systems and services used to move, measure and manage fluids. It is a worldwide supplier of a range of pumps, mixers, heat exchangers, valves and systems for industrial, residential, agricultural and commercial applications. The defense electronics and services division develops, manufactures and supports high-technology electronic systems and components for worldwide defense and commercial markets, as well as communications systems, engineering and applied research. The motion and flow control division produces fluid handling materials, specialty shock absorbers and brake friction materials, marine products and switch applications for industrials and aerospace. The division also develops solutions through its engineered process solutions group. The electronic components division consists of all products marketed under the Cannon brand, including connectors, network services, telecommunications switches, cabling and computing, aerospace and industrial applications. ITT Industries has operations in North America, Europe and the Middle East. In recent news, ITT Industries acquired Italy-based Uniservice Wellpoint, which produces dewatering systems for rental and sale. In addition, ITT Industries has been chosen to build the aeration, pumping and mixing systems at the Sylaibiya Wastewater Treatment and Reclamation plant in Kuwait. The company has also been awarded a contract with a potential value of up to $31 million to upgrade Boeing Integrated Defense Systems’ 12 Global Positioning System Block IIF satellites.
BRANDS/DIVISIONS/AFFILIATES: Uniservice Wellpoint ITT Fluid Technology Corp. ITT Defense and Electronics, Inc. Cannon
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Louis J. Giuliano, CEO Louis J. Giuliano, Pres. David J. Anderson, Sr. VP/CFO Scott A. Crum, Sr. VP/Dir.-Human Resources Robert L. Ayers, Pres.-Fluid Tech. Steven A. Fass, VP/CIO Edward W. Williams, Sr. VP/Corp. Controller Kathleen S. Stolar, VP/Sec. Vincent A. Maffeo, Sr. VP/General Counsel Martin Kamber, Sr. VP/Dir.-Corp. Dev. Thomas R. Martin, Sr. VP/Dir.-Corp. Rel. Ralph D. Allen, VP-Investor Rel. Donald E. Foley, Sr. VP/Treas./Dir.-Taxes Steven F. Gaffney, VP-Value-Based Six Sigma Henry J. Driesse, Sr. VP/Pres.-Defense Brenda Reichelderfer, Sr. VP/Pres.-Motion and Control Gerard Gendron, Pres.-Cannon Louis J. Giuliano, Chmn. Mark Steele, Pres.-ITT Industries China
Phone: 914-641-2000 Fax: 914-696-2950 Toll-Free: Address: 4 W. Red Oak Ln., White Plains, NY 10604 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $4,985,300 (12 months) 2002 Profits: $379,900 (12 months) Stock Ticker: ITT 2001 Sales: $4,675,700 2001 Profits: $276,700 Employees: 38,000 2000 Sales: $4,829,400 2000 Profits: $264,500 Fiscal Year Ends: 12/31 1999 Sales: $4,632,000 1999 Profits: $232,900 1998 Sales: $4,492,700 1998 Profits: $1,532,500
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $921,912 Bonus: $1,850,000 Stock Purch. Plan: Second Exec. Salary: $512,173 Bonus: $615,000 ADVANTAGE: The company has successfully repositioned itself from being a very diverse conglomerate to a new focus on industrial product niches.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
IVAX CORPORATION
www.ivax.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:22 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:24
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Generic Nutraceuticals Respiratory Drugs Over-the-Counter Drugs
IVAX Corporation is a holding company whose subsidiaries are among the leading manufacturers of generic and proprietary drug products in the world. IVAX has operations in over 20 countries across the globe. New compounds in earlier stages of development are being designed to treat cystic fibrosis, HIV infection and neurological disorders such as Parkinson's disease. In its proprietary drugs division, the company has an especially strong focus on respiratory and oncology drugs. At the core of the company’s respiratory franchise are advanced delivery systems, which include a patented breathactivated metered-dose inhaler called Easi-Breathe and a patented dry powder inhaler called Airmax, as well as conventional metered-dose inhalers. Oncology drugs include Paxene, an injectable anticancer drug, and TP-38, a treatment for malignant brain tumors. New drugs under development include an oral form of Paxene called Paxoral, a product for the treatment of multiple sclerosis, a patented drug for allergic disorders, a product for the treatment of severe epilepsy and a compound for the treatment of brain cancer. Other research and development areas are focused on formulating compounds for the treatment of diseases including asthma, cystic fibrosis and Alzheimer’s disease. IVAX Pharmaceuticals, Inc., a subsidiary of the company, manufactures and markets approximately 58 brandequivalent prescription drugs in capsule or tablet forms. In recent news, IVAX acquired ChemSource Corporation, which is based in Puerto Rico. ChemSource develops, manufactures and sells active pharmaceutical ingredients for various pharmaceuticals products, including many products which the company currently sells or has under development. The company also recently entered into a license agreement with Novartis Pharma AG to utilize the patented multi-dose dry powder inhaler, Airmax, for Novartis's trademarked medicines Foradil and Miflonide in the European Union and certain other countries. The company offers its employees dental, medical and vision plans, as well as educational assistance and employee assistance programs.
BRANDS/DIVISIONS/AFFILIATES: Airmax Easi-Breathe Paxene Paxoral TP-38 ChemSource Corp. IVAX Pharmaceuticals, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Phillip Frost, CEO Neil Flanzraich, Pres. Thomas E. Beier, Sr. VP-Finance/CFO Richard Denness, VP-Mktg. and Sales J. Michael Lopez, VP-Human Resources Jane Hsiao, Chief Tech. Officer Jimmy Wang, VP/CIO Steven Rubin, Sr. VP/Corp. Sec. Steven Rubin, General Counsel Subbarao V. Uppaluri, Sr. VP-Strategic Planning Subbarao V. Uppaluri, Treas. Isaac Kaye, Deputy CEO Robert Prego, Sr., VP-Latin American Oper. Rafick G. Henein, Sr. VP Bruce J. Wendel, VP-Bus. Dev. and Licensing Phillip Frost, Chmn.
Phone: 305-575-6000 Fax: 305-575-6055 Toll-Free: 800-980-4829 Address: 4400 Biscayne Blvd., Miami, FL 33137 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,197,200 (12 months) 2002 Profits: $122,800 (12 months) Stock Ticker: IVX 2001 Sales: $1,215,400 2001 Profits: $243,200 Employees: 8,360 2000 Sales: $793,400 2000 Profits: $131,000 Fiscal Year Ends: 12/31 1999 Sales: $656,500 1999 Profits: $70,700 1998 Sales: $625,700 1998 Profits: $71,600
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $735,000 Stock Purch. Plan: Y Second Exec. Salary: $692,003 ADVANTAGE: Focus on respiratory and oncology drugs.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $487,500 Bonus: $402,750
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
JABIL CIRCUIT INC
www.jabil.com
Industry Group Code: 334419 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Contract Electronics-Printed Circuit Boards Maintenance and Support Services
Jabil Circuit is a leading producer of electronic manufacturing services (EMS). The firm designs and manufactures circuit board assemblies and systems for major original equipment manufacturers in the networking, telecommunications, computing and storage, instrumentation and medical, computer, peripherals, automotive and consumer products industries. In addition, the company offers warranty and repair services, end-user distribution and design and implementation of product testing. Customers include Cisco Systems, Dell Computer, Hewlett-Packard, Johnson Controls, Intel Corporation, Valeo, Lucent Technologies, Nokia Corporation, Marconi Communications and Royal Philips Electronics. Despite the recent economic climate, Jabil has continued to experience growth as technology companies have turned increasingly to outsourcing in order to reduce product cost, achieve accelerated time-tomarket and time-to-volume production, access advanced design and manufacturing technologies, improve inventory management and purchasing power, reduce capital investment in manufacturing facilities and achieve parallel manufacturing of the same product throughout the world. The firm believes further growth opportunities exist for EMS providers to penetrate the worldwide electronics market. Jabil currently operates facilities in 15 countries in the Americas, Europe and Asia. The company offers fitness facilities and educational assistance to its employees.
BRANDS/DIVISIONS/AFFILIATES: GET Manufacturing, Inc. General Electronics, Ltd. Digitek Electronics, Ltd. Link Win, Ltd. Skytop International, Ltd. CGE International, Ltd. Bull Information Telenor Technology Services
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Timothy L. Main, CEO Mark T. Mondello, COO Timothy L. Main, Pres. Chris A. Lewis, CFO Jeffrey J. Lumetta, VP-Tech. Services J. Patrick Redmond, Controller Robert L. Paver, Corp. Sec. Robert L. Paver, General Counsel Wesley B. Edwards, Sr. VP-Strategic Oper. John P. Lovato, Sr. VP-Bus. Dev. Beth A. Walters, VP-Comm. Beth A. Walters, VP-Investor Rel. Forbes I.J. Alexander, Treas. Michel Charriau, COO-Europe William E. Peters, Sr. VP-Oper. Steve Borges, VP-Bus. Dev. Joseph A McGee, VP-Global Bus. Units William D. Morean, Chmn.
Phone: 727-577-9749 Fax: 727-579-8529 Toll-Free: Address: 10560 9th St. N., St. Petersburg, FL 33716 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $3,545,500 (12 months) 2002 Profits: $34,700 (12 months) Stock Ticker: JBL 2001 Sales: $4,330,700 2001 Profits: $118,500 Employees: 20,000 2000 Sales: $3,558,321 2000 Profits: $145,648 Fiscal Year Ends: 8/31 1999 Sales: $2,238,391 1999 Profits: $84,819 1998 Sales: $1,484,245 1998 Profits: $57,469
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $700,000 Stock Purch. Plan: Y Second Exec. Salary: $280,000 ADVANTAGE: Ability to offer turn-key design and manufacturing.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $210,000 Bonus: $112,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
JDS UNIPHASE CORP
www.jdsu.com
Industry Group Code: 334210 Ranks within this company's industry group: Sales:11 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:16
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Telecommunications Equipment-Laser Subsystems Optoelectronics Transmitters Amplifiers Multiplexers Testing Instruments
JDS Uniphase Corporation, the result of a merger between Uniphase Corporation and JDS FITEL, is a leading provider of advanced fiber-optic components and modules. These products are sold to the world's leading telecommunications and cable television system and subsystem providers, commonly referred to as OEMs, and include established system providers, such as Alcatel, Ciena, Cisco, Corning, Lucent, Marconi, Motorola, Nortel, Scientific Atlanta, Siemens and Tyco, along with emerging system providers, such as Corvis, ONI Systems, Juniper Networks and Sycamore. These telecommunication system and subsystem providers use JDS components and modules as the building blocks for the systems that they ultimately supply to telecommunications carriers. In addition to its communications products, the firm has a growing optical technology business. End-market applications include flat-panel monitors, projection systems, photocopiers, facsimile machines, scanners, security products and decorative surface treatments. The company also produces semiconductor lasers, high-speed external modulators, transmitters, amplifiers, couplers, multiplexers, circulators, tunable filters, optical switches and isolators for fiber-optic applications, in addition to supplying its OEM customers with test instruments for both system production applications and network installation. In addition, the firm designs, manufactures and markets laser subsystems for a broad range of OEM applications; optical display and projection products used in computer displays and other similar applications; and light interference pigments used in security products and decorative surface treatments. JDS recently acquired Optical Coating Laboratory, Inc, E-TEK Dynamics, Inc., SDL, Inc. and IBM’s optical transceiver business. The firm also recently initiated its global realignment program. Elements of this restructuring plan include the elimination of over 15,400 jobs, consolidation of manufacturing, research and development, sales and administrative facilities and elimination of a number of product development programs. Further reductions are likely.
BRANDS/DIVISIONS/AFFILIATES: Optical Coating Laboratory, Inc. EPITAXX, Inc. IOT Limited Fujian Casix Lasers, Inc. Ramar Corp. E-TEK Dynamics, Inc. JDS FITEL Uniphase, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jozef Straus, CEO Syrus Madavi, COO Syrus Madavi, Pres. Ronald C. Foster, CFO Mark Sobey, VP-Global Sales and Mktg. Frederick L. Leonberger, Sr. VP/Chief Tech. Officer Christopher S. Dewees, General Counsel Donald E Bossi, Pres.-Transmission Group Stan Lumish, Pres.-Optical Layer Group Joseph C. Zils, Pres.-Thin Film Products Group Martin A. Kaplan, Chmn.
Phone: 408-546-5000 Fax: 408-546-4300 Toll-Free: 800-498-5378 Address: 1768 Automation Pkwy., San Jose, CA 95131 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,098,200 (12 months) 2002 Profits: $-8,738,300 (12 months) Stock Ticker: JDSU 2001 Sales: $3,232,800 2001 Profits: $-56,121,900 Employees: 9,222 2000 Sales: $1,430,400 2000 Profits: $-904,700 Fiscal Year Ends: 6/30 1999 Sales: $282,828 1999 Profits: $-171,057 1998 Sales: $185,200 1998 Profits: $-19,600
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $505,763 Stock Purch. Plan: Second Exec. Salary: $299,999 ADVANTAGE: Offices worldwide/Leading technology and product lines.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $278,208 Bonus: $142,161
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
JOHNSON & JOHNSON
www.jnj.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:2 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:3
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Personal Health Care and Hygiene Products Manufacturer Sterilization Products Skin Care Products Self Diagnostic Products Drug Research and Development Medical Equipment
Johnson & Johnson is one of the world’s largest, most comprehensive and broadly based manufacturers of health care products. The company has more than 200 companies in 54 countries and markets its products in almost every country in the world. Johnson & Johnson’s worldwide operations are divided into three segments: consumer, pharmaceutical and medical devices and diagnostics. The company’s principal consumer goods are personal care and hygiene products, including nonprescription drug, adult skin and hair care, baby care, oral care, first aid and sanitary protection products. Major brands in this segment include Mylanta, Band-Aid, Tylenol, Aveeno and Monistat. The pharmaceutical segment covers a wide spectrum of health fields, including antifungal, anti-infective, cardiovascular, dermatology, hematology, immunology, pain management, psychotropic and women’s health. Among Johnson & Johnson’s pharmaceutical products are Risperdal, an antipsychotic used to treat schizophrenia, and Remicade for the treatment of Crohn’s Disease and rheumatoid arthritis. In the medical devices and diagnostics segment, Johnson & Johnson makes a number of professional products including suture and mechanical wound closure products, surgical instruments, disposable contact lenses, joint replacement products, intravenous catheters and medical equipment. Recently, the women’s health division of Ethicon, Inc., a Johnson & Johnson subsidiary, announced that the new GYNECARE THERMACHOICE III Uterine Balloon Therapy System has received pre-market approval from the U.S. Food and Drug Administration (FDA). The division, Gynecare, contends that the uterine balloon therapy system will provide pre-menopausal women greater comfort during menstrual periods. Johnson & Johnson offers its employees on-site childcare at many locations, a hotline with childcare advice and reimbursement for adoption fees. Major sites also offer on-site fitness centers. Working Mother Magazine recently ranked the firm among the Best Companies for Working Mothers for the 16th consecutive year.
BRANDS/DIVISIONS/AFFILIATES: Ethicon, Inc. Gynecare DePuy AcroMed, Inc. Link Spine Group, Inc. Band-Aid Tylenol GYNECARE THERMACHOICE III SB Clarite Artificial Disc
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. William C. Weldon, CEO James T. Lenehan, Pres. Robert J. Darretta, VP-Finance & CFO Michael J. Carey, VP-Human Resources Raymond W. Ruddon, VP-Science & Tech. JoAnn H. Heisen, CIO Stephen J. Cosgrove, Corp. Controller Michael H. Ullmann, Corp. Sec. Roger S. Fine, General Counsel Russell Deyo, VP-Admin. Larry G. Pickering, VP-Corp. Dev. Helen E. Short, VP-Investor Rel. John A. Papa, Treas. Willard D. Nielsen, VP-Public Affairs Thomas M. Gorrie, VP-Gov. Affairs and Policy Per A. Peterson, Chmn.-Research & Dev., Pharmaceuticals Group J. Andrea Alstrup, VP-Advertising William C. Weldon, Chmn.
Phone: 732-524-0400 Fax: 732-524-3300 Toll-Free: 800-328-9033 Address: One Johnson & Johnson Plaza, New Brunswick, NJ 08933 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $36,298,000 (12 months) 2002 Profits: $6,597,000 (12 months) Stock Ticker: JNJ 2001 Sales: $33,004,000 2001 Profits: $5,668,000 Employees: 108,300 2000 Sales: $30,129,000 2000 Profits: $5,023,000 Fiscal Year Ends: 12/29 1999 Sales: $28,267,000 1999 Profits: $4,258,000 1998 Sales: $24,642,000 1998 Profits: $3,111,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $1,097,115 Bonus: $1,207,500 Stock Purch. Plan: Y Second Exec. Salary: $1,050,000 Bonus: $897,750 ADVANTAGE: Johnson & Johnson is the world's largest and most comprehensive manufacturer of health care products serving the consumer, pharmaceutical and professional markets.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
JOHNSON CONTROLS INC
www.johnsoncontrols.com
Industry Group Code: 336390 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Profits:1
Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Automobile Parts and Controls Manufacturer Batteries Energy Management Services Building Controls Automotive Interior Components Automotive Seating
Johnson Controls, Inc. was founded by Professor Warren Johnson in 1885 to manufacture his invention, the electric room thermostat. The company is now a multi-billion dollar corporation working in automotive systems and building controls. The automotive segment is engaged in the design and manufacture of complete seat systems, seating components and interior trim systems for manufacturers of cars and light trucks. The controls segment is a major worldwide supplier of control systems, services and products providing energy management, temperature and ventilation control, security and fire safety for nonresidential buildings. The plastics segment is one of the world’s largest producers of polyethylene terephthalate plastic containers. Products using this plastic include soft drink bottles and containers for other beverage, food, household and personal care items. The company’s customers include BMW, Daimler-Chrysler, Ford, Toyota, Volkswagen, AutoZone, Interstate Battery System of America, Bank of America, IBM and Wal-Mart. The Department of Defense selected Johnson Controls to provide the energy management and environmental control system for the Pentagon, one of the largest control system projects in the company's history. Johnson Controls recently agreed to acquire Varta’s automotive battery division, a major European automotive battery manufacturer. This acquisition will augment the firm’s leadership in the European market. Johnson Controls has formulated detailed plans for developing its business in Europe. These plans include aligning its facilities management and building systems and service operations into a single unit, which will focus on the needs of its customers around the world. Johnson Controls offers diversity awareness workshops for its employees, as well as the Inroads program, which focuses on identifying and training young minority talent.
BRANDS/DIVISIONS/AFFILIATES: C&D Technologies, Inc. Uniloy Milacron, Inc. VISTA Network Integration Services, Inc. Alliance Sagem Hoppecke Automotive Homelink Metasys
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John M. Barth, CEO John M. Barth, Pres. Stephen A. Roell, CFO Susan F. Davis, VP-Human Resources Steven J. Bomba, VP-Corp. Tech. Subbash Valanju, VP/CIO R. Bruce McDonald, Controller John P. Kennedy, General Counsel Darlene Rose, VP-Corp. Dev. and Strategy Denise M. Zutz, VP-Corp. Comm. Ben Bastianen, Treas. Rande Somma, Pres.-Automotive Systems Keith Wandell, Pres.-Battery Giovanni Fiori, Pres.-Europe/Africa/Latin America/Asia-Pacific Brian J. Stark, Pres.-Controls Group
Phone: 414-524-1200 Fax: 414-524-2077 Toll-Free: Address: 5757 N. Green Bay Ave., Milwaukee, WI 53201 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $20,103,000 (12 months) 2002 Profits: $600,000 (12 months) Stock Ticker: JCI 2001 Sales: $18,427,000 2001 Profits: $478,000 Employees: 112,000 2000 Sales: $17,154,600 2000 Profits: $472,400 Fiscal Year Ends: 9/30 1999 Sales: $16,139,400 1999 Profits: $419,600 1998 Sales: $12,586,800 1998 Profits: $337,700
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $1,175,001 Stock Purch. Plan: Second Exec. Salary: $775,005 ADVANTAGE: Major global market share in automotive products and in plastics.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $978,000 Bonus: $579,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
JUNIPER NETWORKS INC
www.juniper.net
Industry Group Code: 334110 Ranks within this company's industry group: Sales:3 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:5
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Networking Equipment-Internet Routers IP Network Systems
Juniper Networks provides high-performance IP networking systems that enable service providers to meet the demands of the rapidly growing Internet. To help its customers remain competitive and grow with the new IP infrastructure, Juniper Networks developed a family of router platforms that deliver wire-rate performance, solutions that easily scale, market-leading port density, flexible and manageable control over traffic and optimal bandwidth efficiency. This family consists of the M5, M10, M20, M40 and M160 Internet backbone routers with JUNOS Internet software. The flagship product of the company, M40, combines the features of JUNOS software, high-performance ASIC-based (applicationspecific integrated circuit) packet forwarding technology and Internet optimized architecture into a purpose-built solution for service providers. The company sells its Internet backbone routers primarily through a direct sales force and original equipment manufacturers. JUNOS Internet software offers a full suite of Internet-scale, Internet-tested routing protocols and provides new levels of traffic engineering capabilities. Recently, Juniper Networks announced that NTT Communications, a global service provider and subsidiary of the NTT Group, has deployed Juniper Networks' T-series platform in its IP network. This global network covers Asia, Japan, North America and Europe.
BRANDS/DIVISIONS/AFFILIATES: JUNOS Internet Software M2O Router M4O Router M5 Router M10 Router M160 Router
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Scott Kriens, CEO Lloyd Carney, COO Scott Kriens, Pres. Marcel Gani, CFO Pradeep Sindhu, Chief Tech. Officer Peter L. Wexler, VP-Eng. Lisa Berry, VP/General Counsel Jim Dolce, Exec. VP-Worldwide Field Oper. Scott Kriens, Chmn.
Phone: 408-745-2000 Fax: 408-745-2100 Toll-Free: 888-586-4737 Address: 1194 N. Mathilda Ave., Sunnyvale, CA 94089 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $546,500 (12 months) 2002 Profits: $-119,700 (12 months) Stock Ticker: JNPR 2001 Sales: $887,000 2001 Profits: $-13,400 Employees: 1,542 2000 Sales: $673,501 2000 Profits: $147,916 Fiscal Year Ends: 12/31 1999 Sales: $102,606 1999 Profits: $-9,034 1998 Sales: $3,807 1998 Profits: $-30,971
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $275,000 Stock Purch. Plan: Second Exec. Salary: $185,000 ADVANTAGE: Blue-ribbon backers/Great proprietary technology.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $157,960 Bonus: $90,806
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
K V PHARMACEUTICAL CO
www.kvpharma.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:45 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:34
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Generic Drug Delivery Processes and Systems Raw Materials for the Drug Industry
KV Pharmaceuticals develops a wide variety of drug delivery systems, including oral and topic site-specific treatments, tablets and controlled-released and tastemasking systems. The company’s site-specific treatments and tablets isolate drugs to a specific area of the body to increase their effectiveness. The controlled-release systems, which include Meter Release and Micro Release, release drugs at specific time intervals. The tastemasking systems are aimed at improving the taste of otherwise unpleasant-tasting drugs. These systems include Liquette, FlavorTech and Micromask. KV operates through its three subsidiary businesses: Ther-Rx Corporation, ETHEX Corporation and Particle Dynamics, Inc. The company established Ther-RX to market brand name pharmaceutical products that KV develops internally using its proprietary technologies. ETHEX manufactures generic products and markets them to national drug store chains and distributors across the country. ETHEX’s current product line consists of more than 70 products and focuses on four main therapeutic areas: women’s health, cardiovascular, pain management and respiratory. Particle Dynamics develops, manufactures and markets technologically enhanced raw material products for the pharmaceutical, nutritional, food and personal care industries. Recently, KV acquired the Niferex product lines from Schwarz Pharma and the Chromagen and StrongStart product lines from Altana, Inc. The company was among those included in the Investor’s Business Daily’s list of The Stable Seventy.
BRANDS/DIVISIONS/AFFILIATES: ETHEX Corporation Ther-RX Corporation Particle Dynamics, Inc. Liquette Meter Release Niferex Chromagen StrongStart
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Marc S. Hermelin, CEO Gerald R. Mitchell, CFO Alan G. Johnson, Corp. Sec. Alan G. Johnson, Sr. VP-Strategic Planning and Corp. Growth Catherine Biffignani, VP-Corp. Comm. Catherine Biffignani, VP-Investor Rel. Gerald R. Mitchell, Treas. Raymond F. Chiostri, VP/Group Pres./CEO, Particle Dynamics, Inc. Victor M. Hermelin, Chmn.
Phone: 314-645-6600 Fax: 314-644-2419 Toll-Free: Address: 2503 S. Hanley Rd., St. Louis, MO 63144 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $204,100 (12 months) 2002 Profits: $31,500 (12 months) Stock Ticker: KVA 2001 Sales: $182,900 2001 Profits: $23,600 Employees: 860 2000 Sales: $146,000 2000 Profits: $24,300 Fiscal Year Ends: 3/31 1999 Sales: $114,900 1999 Profits: $23,300 1998 Sales: $98,486 1998 Profits: $11,304
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Stock Purch. Plan: ADVANTAGE: Acquisition of existing drugs.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $894,060 Second Exec. Salary: $350,600
Bonus: $1,416,500 Bonus: $50,000
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
KEITH COMPANIES INC (THE)
www.keithco.com
Industry Group Code: 541310 Ranks within this company's industry group: Sales:15 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Y
Profits:6
Transportation: Aerospace: Automotive:
Y Y
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Engineering Services-Environmental Civil Engineering Services
The Keith Companies, Inc. is an engineering and consulting firm that offers such services as land planning, site acquisition, surveying, mapping, permit processing and civil, environmental and industrial engineering. The company’s civil engineering services include project feasibility analysis, development cost projections, infrastructure design, pro forma cost studies and preparation of construction documents. The firm’s surveying and mapping services include establishing boundaries for preliminary engineering and identifying potentially problematic areas of construction sites. Additionally, the company’s site acquisition services consist of selecting prospective properties, identifying and overcoming restrictions against the intended use of properties and negotiating acquisition agreements. The Keith Companies’ diverse client base includes real estate developers, residential and commercial builders, architects, state and federal agencies, retailers and energy providers. The firm’s Tettemer & Associates subsidiary provides a number of environmental engineering services, including detention and sedimentation basin design, surface water management, water quality analysis, wetland restoration and flood control engineering. The company’s Crosby Mead Benton & Associates subsidiary provides landscape architecture, civil engineering and surveying services to residential, commercial and industrial development companies and government agencies. The Keith Companies recently acquired ALNM Group, Inc., an engineering and consulting company that provides environmental, civil, mechanical and electrical engineering services primarily to public utilities, municipalities and hospitals.
BRANDS/DIVISIONS/AFFILIATES: Tettemer & Associates Crosby Mead Benton & Associates ALNM Group, Inc. Thompson-Hysell Engineers Pacific Engineering Corporation Universal Energy, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Aram H. Keith, CEO Eric C. Nielsen, COO Eric C. Nielsen, Pres. Gary C. Campanaro, CFO Gary C. Campanaro, Corp. Sec. Aram H. Keith, Chmn.
Phone: 949-923-6000 Fax: 949-923-6121 Toll-Free: Address: 19 Technology Dr., Irvine, CA 92618 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $91,600 (12 months) 2002 Profits: $7,800 (12 months) Stock Ticker: TKCI 2001 Sales: $69,500 2001 Profits: $5,800 Employees: 850 2000 Sales: $53,400 2000 Profits: $4,700 Fiscal Year Ends: 12/31 1999 Sales: $39,600 1999 Profits: $2,200 1998 Sales: $29,200 1998 Profits: $1,700
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $382,100 Stock Purch. Plan: Second Exec. Salary: $212,663 ADVANTAGE: Diverse client base/Expanding international presence.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
KEMET CORP
www.kemet.com
Industry Group Code: 335999 Ranks within this company's industry group: Sales:10 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:6
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Electronic Equipment-Surface-Mount Ceramic Capacitors
KEMET Corporation is one of the world's largest manufacturers of high-performance capacitors, including the world’s most complete line of surface-mount tantalum, ceramic and aluminum capacitors. During fiscal year 2002, the company shipped approximately 12.9 billion capacitors, comprised of approximately 35,000 different varieties. Capacitors are one of the essential passive components used on circuit boards, which are contained in virtually all electronic applications and products. Capacitors alter the relationship of currents and voltages in a given electrical system, filter or smooth out electrical signals where required and retard signals of low frequencies while permitting signals of higher frequencies to pass with minimal attenuation. Different types of capacitors are distinguished based on dielectric material, configuration, capacitance level and tolerance, performance characteristics, marking and packaging. KEMET’s capacitors are used in communication systems, data processing equipment, personal computers, cellular phones, automotive electronic systems and military and aerospace systems. The firm utilizes a direct sales force to market its capacitors to a diverse and growing number of OEMs, electronic manufacturing service providers and electronics distributors. KEMET's largest customers include Alcatel, Arrow Electronics, Dell, HP, IBM, Intel, Lucent Technologies, Motorola, Nokia, Pioneer, Qualcomm, Sanmina/SCI, Siemens, Solectron, TTI and Visteon. The company recently announced plans to begin manufacturing operations in China, to better serve its Asian markets.
BRANDS/DIVISIONS/AFFILIATES: KEMET Electronics Corp.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. David E. Maguire, CEO Jeffrey Graves, COO Jeffrey Graves, Pres. D. Ray Cash, CFO D. Ray Cash, Corp. Sec. Harris L. Crowley, Jr., Exec. VP David E. Maguire, Chmn.
Phone: 864-963-6300 Fax: 864-963-6322 Toll-Free: Address: 2835 KEMET Way, Simpsonville, SC 29681 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $508,600 (12 months) 2002 Profits: $27,300 (12 months) Stock Ticker: KEM 2001 Sales: $1,406,100 2001 Profits: $352,300 Employees: 6,900 2000 Sales: $822,095 2000 Profits: $70,119 Fiscal Year Ends: 12/31 1999 Sales: $565,569 1999 Profits: $6,150 1998 Sales: $667,721 1998 Profits: $49,190
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $587,500 Stock Purch. Plan: Second Exec. Salary: $333,000 ADVANTAGE: One of the world's largest manufacturers of tantalum capacitors.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $1,116,000 Bonus: $509,000
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
KENDLE INTERNATIONAL INC
www.kendle.com
Industry Group Code: 541710 Ranks within this company's industry group: Sales:4 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:13
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y Y
GROWTH PLANS/SPECIAL FEATURES:
Research & Development-Clinical Trials Statistical Analysis e-Learning Clinical Trial Software
Kendle International is a contract research organization providing drug research and development services in the pharmaceutical and biotechnology industries. Services offered by the company include clinical trial management, clinical data management, statistical analysis, medical technical writing, regulatory/validation consulting and representation and medical communications services. Kendle runs a state-of-the-art clinical pharmacology unit in The Netherlands, where it offers services for drugs undergoing Phase I and IIA clinical trials. Through its health care communications division, the firm provides organizational, meeting management and publication services to various professional associations and pharmaceutical companies. The firm’s proprietary software, TrialWare, enables clinical trial data to be processed faster through automated workflow, parallel processing and standardization. The TrialWare product line includes a database management system, TrialBase; an interactive voice response patient randomization system, TriaLine; an online case report forms review system, TrialView; and a coding enhancement feature, TriAlert. The company also operates eKendleCollege, an online e-learning division that runs seminars and training programs, focusing on the organization of clinical trials. Kendle has been working to expand its overseas operations with strategic acquisitions of foreign contract research organizations. Kendle offers its employees stock options, flexible work schedules, business-casual dress and continuing education through its corporate university and tuition reimbursement program, as well as the option to telecommute. Additionally, senior personnel are eligible for a management bonus. Full- or part-time associates who work at least 24 hours a week are eligible for benefits.
BRANDS/DIVISIONS/AFFILIATES: eKendleCollege TriAlert TrialWare TrialWeb TrialBase TrialView TriaLine
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Candace K. Kendle, CEO Christopher C. Bergen, COO Christopher C. Bergen, Pres. Karl Brenkert, III, Sr. VP/CFO Thomas Stilgenbauer, Exec. VP/Chief Mktg. Officer Anthony L. Forcellini, Sr. VP-Oper. Karl Brenkert, III, Treas. Keith A. Cheesman, Dir.-Admin. Malcolm Summers, Dir.-European Regulatory Consulting Melanie A. Bruno, VP-Global Regulatory Affairs Candace K. Kendle, Chmn.
Phone: 513-381-5550 Fax: 513-381-5870 Toll-Free: 800-733-1572 Address: 1200 Carew Tower, 441 Vine St., Cincinnati, OH 45202 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $214,000 (12 months) 2002 Profits: $-54,800 (12 months) Stock Ticker: KNDL 2001 Sales: $154,300 2001 Profits: $4,200 Employees: 1,650 2000 Sales: $120,500 2000 Profits: $-2,100 Fiscal Year Ends: 12/31 1999 Sales: $117,200 1999 Profits: $7,700 1998 Sales: $89,500 1998 Profits: $7,200
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $290,338 Bonus: $33,518 Stock Purch. Plan: Y Second Exec. Salary: $251,815 Bonus: $22,669 ADVANTAGE: Developing web-enabled technologies to aid drug development research/Steady growth.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
KINETIC CONCEPTS INC
www.kci1.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:22 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:14
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Equipment-Specialized Mattresses and Beds Kinetic Therapy Products Circulatory Devices
Kinetic Concepts, Inc. (KCI) is a leading developer and manufacturer of therapeutic healing systems that alleviate complications of immobility due to disease, trauma, obesity and surgery. KCI is comprised of three business units: KCI USA, KCI International and KCI Corporate. KCI USA, the company’s largest business unit, markets products and services in the United States. KCI International provides healing therapies worldwide with direct operations in 15 countries, contracted distributors in select markets and manufacturing and engineering capabilities in the U.K. and Ireland. The corporate division provides engineering, manufacturing and administrative support to the other business units. The company’s products specifically address pressure relief, pulmonary care, bariatric care, circulatory improvement and wound closure. KCI’s primary products are specialty beds and mattress overlays, including the KinAir and TheraPulse lines, which target pressure sores through improved airflow and pulsating, massaging actions. Kinetic therapy products, including TriaDyne and PediDyne, promote pulmonary care by preventing or treating pneumonia and other complications. The company produces therapeutic support surfaces and aids for obese patients, including the BariAir Therapy System, which can serve as both a bed and an examination table. Through its NuPulse subsidiary, KCI manufactures circulatory medical devices aimed at improving blood circulation and reducing edemas. Furthermore, the company manufactures the Vacuum Assisted Closure (V.A.C.) device, a wound closure therapy using sub-atmospheric pressure. Recently, the company unveiled two additions to the V.A.C. System, the V.A.C. round foam and thin foam dressings, which facilitate the appropriate sizing of dressings for wounds.
BRANDS/DIVISIONS/AFFILIATES: KCI USA, Inc. KCI International, Inc. KinAir NuPulse V.A.C. System TheraPulse TriaDyne PediDyne
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Dennert O. Ware, CEO Dennert O. Ware, Pres. Martin J. Landon, CFO/VP-Finance Rush E. Cone, VP-Human Resources Daniel C. Wadsworth, Jr., VP-Global Research and Dev. Martin J. Landon, Controller Michael J. Burke, VP-Mfg. Dennis E. Noll, Sr. VP/Corp. Sec. Dennis E. Noll, General Counsel G. Frederick Rush, VP-Corp. Dev. Lulu Olson, VP-Tax Acc./Treas. Christopher M. Fashek, Pres., KCI USA Jorg W. Menten, Pres., KCI Int'l Steven J. Hartpence, VP-Bus. Systems Robert Jaunich, II, Chmn.
Phone: 210-524-9000 Fax: 210-255-6998 Toll-Free: 888-275-4524 Address: 8023 Vantage Dr., San Antonio, TX 78230 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $579,000 (12 months) 2002 Profits: $106,400 (12 months) Stock Ticker: Private 2001 Sales: $455,947 2001 Profits: $23,901 Employees: 2,900 2000 Sales: $352,032 2000 Profits: $9,129 Fiscal Year Ends: 12/31 1999 Sales: $320,232 1999 Profits: $- 314 1998 Sales: $329,945 1998 Profits: $11,776
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $495,000 Stock Purch. Plan: Second Exec. Salary: $260,303 ADVANTAGE: Recognized worldwide for its hospital bed technology.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $860,000 Bonus: $323,716
LOCATIONS: ("Y" = Yes) West:
Southwest: Y
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
KING PHARMACEUTICALS INC
www.kingpharm.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:24 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:16
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Diversified Vaccines Biologicals
King Pharmaceuticals, Inc. manufactures branded pharmaceutical products that cover therapeutic areas such as cardiology, antibiotics, anti-infectives, critical care, urinary, respiratory, ophthalmic and women’s health. The company acquires branded products from larger pharmaceutical companies. Key products include Altace, an angiotensin converting enzyme inhibitor that serves as a drug treatment for hypertension, Levoxyl, a thyroid hormone replacement or supplemental therapy for hypothyroidism, and Thrombin-JMI, a non-injectable aid to hemostasis whenever bleeding from capillaries and small venules is accessible. The firm produces the laborinducing drug, Pitocin, and the hemorrhoid treatment, Anusol-HC. King has an exclusive license from Novavax, Inc. to promote, market, distribute and sell Estrasorb, used in transdermal estrogen replacement therapy. Additionally, King and Novavax co-market King’s oral contraceptive product Nordette in the U.S. and Puerto Rico. The subsidiary, King Pharmaceuticals International, markets products in territories other than the continental United States, Alaska and Hawaii. King’s other subsidiaries are King Pharmaceuticals Research and Development, Jones Pharma, Inc. and Meridian Medical Technologies, Inc. The company is in the process of acquiring the U.S. and Puerto Rico primary care business of Elan Corporation, plc.
BRANDS/DIVISIONS/AFFILIATES: Altace Jones Pharma, Inc. Meridian Medical Technologies, Inc. King Pharmaceuticals Reseach and Development King Pharmaceuticals International Elan Corporation, plc Levoxyl Novavax, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jefferson J. Gregory, CEO Kyle P. Macione, Pres. James R. Lattanzi, CFO John A. A. Bellamy, Exec. VP-Legal Affairs/General Counsel Jefferson J. Gregory, Chmn. Ernest C. Bourne, Pres.-Intl. Div.
Phone: 423-989-8000 Fax: 423-274-8677 Toll-Free: 800-776-3637 Address: 501 5th St., Bristol, TN 37620 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,179,500 (12 months) 2002 Profits: $255,100 (12 months) Stock Ticker: KG 2001 Sales: $872,300 2001 Profits: $218,000 Employees: 1,843 2000 Sales: $620,200 2000 Profits: $64,509 Fiscal Year Ends: 12/31 1999 Sales: $512,500 1999 Profits: $99,937 1998 Sales: $294,400 1998 Profits: $83,900
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $450,000 Bonus: $100,000 Stock Purch. Plan: Second Exec. Salary: $384,374 Bonus: $75,000 ADVANTAGE: Great success at acquiring and promoting existing drug products/Acquisition of Jones Pharma.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
KLA TENCOR CORP
www.kla-tencor.com
Industry Group Code: 334515 Ranks within this company's industry group: Sales:3 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:2
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Test Equipment-Silicon Wafer Production Support Services Software Analysis Services
KLA-Tencor Corporation is one of the world's leading suppliers of process control and yield management solutions for the semiconductor and related microelectronics industries. The firm’s comprehensive portfolio of products, software, analysis, services and expertise is designed to help integrated circuit manufacturers manage yield throughout the entire wafer fabrication process, from research and development to final mass production yield analysis. The company offers products and services that are used by most major semiconductor manufacturers in the world. KLA-Tencor provides in-line wafer defect monitoring, reticle and photomask defect inspection, critical dimension scanning electron microscope (CD SEM) metrology, wafer overlay, film and surface measurement and overall yield and fabwide data analysis. Its products can be categorized into five groups: defect inspection, metrology, yield management software solutions, customer service and support and data storage. KLA-Tencor’s inspection tools are used to detect, count, classify and characterize particles and pattern defects in off-line engineering applications, as well as in-line at various stages during the wafer, semiconductor and reticle manufacturing processes. Recently, the company announced the opening of its first online customer support center in Taiwan to serve customers in China, Taiwan and Southeast Asia. The firm actively recruits employees from colleges and offers flexible schedules to college students.
BRANDS/DIVISIONS/AFFILIATES:
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Kenneth L. Schroeder, CEO Gary E. Dickerson, COO Gary E. Dickerson, Pres. John H. Kispert, Exec. VP/CFO Dennis J. Fortino, Exec. VP-Lithography and Parametic Solutions Richard P. Wallace, Exec. VP-Wafer Inspection, Review and Analysis Kenneth Levy, Chmn.
Phone: 408-875-3000 Fax: 408-875-4266 Toll-Free: Address: 160 Rio Robles, San Jose, CA 95134 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,637,300 (12 months) 2002 Profits: $216,200 (12 months) Stock Ticker: KLAC 2001 Sales: $2,103,800 2001 Profits: $66,700 Employees: 5,700 2000 Sales: $1,498,812 2000 Profits: $253,798 Fiscal Year Ends: 6/30 1999 Sales: $843,181 1999 Profits: $39,212 1998 Sales: $1,166,325 1998 Profits: $134,096
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $492,649 Stock Purch. Plan: Second Exec. Salary: $378,268 ADVANTAGE: A world leader in process control and yield management solutions.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $218,040 Bonus: $159,046
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
KOMAG INC
www.komag.com
Industry Group Code: 334112 Ranks within this company's industry group: Sales:11 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:8
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Storage Equipment-Thin-Film Disks
Komag, Inc. produces thin-film media disks, the primary storage medium for digital data used in computer disk drives. The company’s disks can be found in computers, enterprise storage systems, digital video recorders, video game systems such as Microsoft’s X-Box and consumer electronic storage systems. Komag, which develops its products in the U.S. and manufactures them in Southeast Asia, does over 80% of its business with Western Digital Corporation, Seagate and Maxtor, all major suppliers of hard drives. The company has been working to develop its technology and release new thin-film disks with faster performance and higher storage capacity at lower costs. Today’s areal densities allow for approximately 80 GB of storage per 3.5-inch disk platter. The firm recently emerged from Chapter 11 bankruptcy protection and was listed on the NASDAQ exchange. The company offers a work life program to its employees, through which trained counselors assist employees with child care issues and referrals, elder care, adoption and school selection for elementary and secondary schools and colleges.
BRANDS/DIVISIONS/AFFILIATES: Komag Material Technology, Inc. HMT Technology
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Thien Hoo Tan, CEO Thien Hoo Tan, Pres. Kathleen A. Bayless, VP/CFO Ray L. Martin, Sr. VP-Customer Sales and Service Michael A. Russak, Chief Tech. Officer Kathleen A. Bayless, Corp. Sec. Christopher H. Bajorek, Exec. VP-Advanced Tech. Thien Hoo Tan, Chmn.
Phone: 408-576-2000 Fax: 408-944-9255 Toll-Free: Address: 1710 Automation Pkwy., San Jose, CA 95131 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $174,700 (12 months) 2002 Profits: $-41,900 (12 months) Stock Ticker: KOMG 2001 Sales: $282,600 2001 Profits: $-296,400 Employees: 4,353 2000 Sales: $358,500 2000 Profits: $-68,100 Fiscal Year Ends: 12/31 1999 Sales: $331,946 1999 Profits: $-283,049 1998 Sales: $328,883 1998 Profits: $-366,336
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $423,077 Stock Purch. Plan: Second Exec. Salary: $374,999 ADVANTAGE: Recently emerged from Chapter 11 bankruptcy.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $43,269 Bonus: $36,058
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
KOS PHARMACEUTICALS INC
www.kospharm.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:47 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:65
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Cardiovascular Drugs-Respiratory Diseases
Kos Pharmaceuticals, Inc. (Kos) develops and produces proprietary prescription products for the treatment of chronic cardiovascular and respiratory diseases. The company markets Niaspan, for the treatment of cholesterol disorders, as well as Mavik and Tarka (through a joint effort with Knoll Pharmaceutical), used in the treatment of hypertension. In addition, the firm has a number of products under development, including a device utilizing aerosolized inhalation formulations, Nicostation (a drug to complement Niaspan by treating mixed lipid disorders), isosorbide-5-mononitrate (a treatment for angina pectoritis) and a solid-dose drug delivery system that will formulate compounds. Kos has concentrated its expansion on improving its position in the $14-billion cardiovascular pharmaceuticals market. The firm is currently looking into new applications for its solid-dose technology of gastric retention delivery systems designed for pharmaceutical products. Kos continues to develop new inhalation delivery technologies for the treatment of diabetes and respiratory diseases. The company anticipates developing biotherapeutic compounds in order to complement in vitro and in vivo data demonstrating the performance and efficacy of delivering proteins via the lungs. Kos is also working on a line of inhalation devices including a breath-coordinated inhaler, a breath-actuated inhaler and a spacerless MDI device that generates low plume force. These products will offer a variety of benefits. In recent news, the company was granted a third U.S. patent for the unique pharmacokinetic features of its Niaspan and Advicor cholesterol drugs. The company also recently entered into an alliance with the American Heart Association to provide personalized treatment information via the Internet to patients with cholesterol disorders. The company provides its employees with tuition reimbursement, vision and dental care and an employee assistance program.
BRANDS/DIVISIONS/AFFILIATES: Tarka Advicor Nicostation Niaspan Mavik
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Adrian Adams, CEO Adrian Adams, Pres. Christopher Kiritsy, CFO Robert E. Baldini, Chief Sales and Mktg. Officer Susan Taylor, VP-Human Resources David J. Bova, Sr. VP-Research and Dev. Christopher Rieder, VP-IT Juan Rodriguez, VP/Controller Mark McGovern, VP-Medical Affairs Richard King, Sr. VP-Commercial Oper. Christopher Kiritsy, VP-Bus. Dev. Frederick Sexton, Sr. VP-Product Dev. Marvin Blanford, VP-Compliance Eugenio Cefali, VP-Clinical Dev. David Heatherman, VP-Managed Care
Phone: 305-577-3464 Fax: 305-577-4596 Toll-Free: Address: 1001 Brickell Bay Dr., 25th Fl., Miami, FL 33131 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $172,700 (12 months) 2002 Profits: $-20,800 (12 months) Stock Ticker: KOSP 2001 Sales: $91,400 2001 Profits: $2,400 Employees: 726 2000 Sales: $60,200 2000 Profits: $-35,300 Fiscal Year Ends: 12/31 1999 Sales: $36,300 1999 Profits: $-54,600 1998 Sales: $13,000 1998 Profits: $-79,200
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $395,600 Bonus: $400,000 Stock Purch. Plan: Y Second Exec. Salary: $250,000 Bonus: $175,000 ADVANTAGE: Concentrated expansion within the cardiovascular market/Expertise in inhalation delivery technologies.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
L3 COMMUNICATIONS HOLDINGS INC Industry Group Code: 334200 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
www.l3comm.com
Profits:1 Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Electronic Equipment-Specialized Communications Intelligence, Surveillance and Reconnaissance Systems Instrumentation Products Microwave Components Airborne Systems
L-3 Communications is a supplier of sophisticated secure communications and intelligence, surveillance and reconnaissance (ISR) systems, training, simulation and support services, aviation products and aircraft modernization, as well as specialized products. The firm produces high-data-rate communication systems, microwave components, avionics, ocean systems, telemetry products, instrumentation products and space products. The systems and equipment produced by L-3 communications are essential to nearly all major communication, command and control, intelligencegathering and space systems. The U.S. Department of Defense, U.S. government intelligence agencies, major aerospace and defense contractors, foreign governments and commercial customers all utilize the company’s systems. L-3’s products are used in a variety of airborne, space, ground and sea-based communication systems, as well as in transmission, processing, recording, monitoring and dissemination functions. The company recently announced that its display systems division has been awarded a contract to provide cockpit displays for the F15K Eagle fighter aircraft for Boeing. In other news, the security and detection system unit will supply Poland's airports with automatic baggage inspection systems.
BRANDS/DIVISIONS/AFFILIATES:
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Frank C. Lanza, CEO Robert V. LaPenta, Pres. Robert V. LaPenta, CFO Kenneth W. Manne, VP-Human Resources Joseph Paresi, VP-Product Dev. Vincent T. Taylor, VP/CIO Ralph G. D'Ambrosio, VP/Controller Christopher Cambria, Sr. VP/Corp. Sec. Christopher Cambria, General Counsel Charles J. Schafer, VP-Bus. Oper. David T. Butler, VP-Planning Cynthia Swain, VP-Corp. Comm. Stepehen M. Souza, VP/Treas. Michael T. Strianese, Sr. VP-Finance Jill Wittels, VP-Bus. Dev. Joseph S. Paresi, VP-Product Dev. Gregory B. Roberts, Corp. VP Frank C. Lanza, Chmn. Ralph Denino, VP-Procurement
Phone: 212-697-1111 Fax: 212-867-5249 Toll-Free: Address: 600 3rd Ave., New York, NY 10016 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $4,011,200 (12 months) 2002 Profits: $178,000 (12 months) Stock Ticker: LLL 2001 Sales: $2,347,400 2001 Profits: $115,500 Employees: 27,000 2000 Sales: $1,910,100 2000 Profits: $82,700 Fiscal Year Ends: 12/31 1999 Sales: $1,405,500 1999 Profits: $58,700 1998 Sales: $1,037,000 1998 Profits: $32,600
SALARIES/BENEFITS: Pension Plan: Y Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $750,000 Bonus: $750,000 Stock Purch. Plan: Y Second Exec. Salary: $545,577 Bonus: $650,000 ADVANTAGE: Serves several aircraft manufacturers, commercial airline operators and the United States Government.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
LAM RESEARCH CORP
www.lamrc.com
Industry Group Code: 335999 Ranks within this company's industry group: Sales:7 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:9
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Electronic Equipment-Semiconductor Manufacturing Related Etch Processing Systems
Founded in 1980, Lam Research Corporation is a leading supplier of processing equipment and services for the global semiconductor industry. Lam designs, manufactures, markets and services semiconductor processing equipment used in semiconductor device fabrication. The company’s etch products are used to deposit special films on silicon wafers and to selectively etch away portions of various films, creating an integrated circuit. With the acquisition of OnTrak Systems in the late '90s, Lam entered the chemical mechanical planarization (CMP) product and applications sector. CMP cleaning tools remove particles from the surface of the semiconductor wafer. The firm also offers wafer cleaning services and equipment, needed to maximize results and maintain accuracy and high yield. In addition, Lam provides technical support, training, spares and service and has enjoyed many top honors as an equipment supplier and innovator. Headquartered in Fremont, California, the company maintains more than 40 customer support centers throughout the United States, Japan, Europe and the Asia Pacific region to meet the needs of its global customer base. In recent news, Lam introduced the 2300 Versys Star silicon etch system for 200 and 300 millimeter applications. Additionally, the 2300 Etch Series was recently selected by Advanced Micro Devices, Inc. to develop next-generation logic and flash processes. In addition to medical, dental and insurance benefits, Lam offers its employees on-site training, education assistance, wellness programs (including health club discounts) and adoption aid. Other benefits include affordable legal services and flexible spending accounts for health and dependent care.
BRANDS/DIVISIONS/AFFILIATES: OnTrak Systems, Inc. Exelan Dielectric 2300 Versys Silicon 2300 Versys Metal 2300 Teres CMP Synergy Integra CMP 2300 Versys Star
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. James W. Bagley, CEO Stephen G. Newberry, COO Stephen G. Newberry, Pres. Mercedes Johnson, VP-Finance/CFO Steven A. Lindsey, VP-Corp. Mktg. Terry Bean, Dir.-Human Resources Nicolas J. Bright, VP-Science Alexander M. Voshchenkov, VP/Chief Tech. Officer Richard H. Lovgren, General Counsel Scott J. Landstrom, VP-Oper. Ernest Maddock, VP-Bus. Dev. Craig Garber, Treas/VP-Corp. Finance Kevin Crofton, Mgr.-CMP/Clean Products Group Thierry Fried, VP-Europe Regional Oper. Ferdinand Seemann, VP-North America Sales and Field Oper. David Hemker, VP-New Product Dev.
Phone: 510-572-0200 Fax: 510-572-6454 Toll-Free: Address: 4650 Cushing Pkwy., Fremont, CA 94538-6470 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $943,100 (12 months) 2002 Profits: $-90,100 (12 months) Stock Ticker: LRCX 2001 Sales: $1,519,800 2001 Profits: $52,100 Employees: 2,500 2000 Sales: $1,230,767 2000 Profits: $204,756 Fiscal Year Ends: 6/30 1999 Sales: $647,955 1999 Profits: $-112,913 1998 Sales: $1,052,586 1998 Profits: $-144,599
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $487,696 Stock Purch. Plan: Y Second Exec. Salary: $472,500 Worldwide network of offices/Advanced technology. ADVANTAGE:
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $300,000 Bonus: $202,500
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
LEXICON GENETICS INC
www.lexgen.com
Industry Group Code: 541710 Ranks within this company's industry group: Sales:13 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:14
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Research & Development-Genetics Genetic Databases
Genomics firm Lexicon Genetics is devoted to determining gene functions for drug discovery through the use of knockout mouse technology. The technology alters the DNA of various genes in mouse cells to determine the function of the disrupted gene. The company maintains the OmniBank database and mouse clone library where tens of thousands of embryonic cell clones are catalogued and stored. Through its Internet exchange, Lexgen.com, Lexicon allows researchers to view the DNA sequence of each cell clone online. Companies using the OmniBank online database include German pharmaceutical firm Boehringer Ingelheim, The R.W. Johnson Pharmaceutical Research Institute and American Home Products. The firm also operates the Human Gene Trap database, which documents the DNA sequences of over 50,000 human genes. LexVision is a program under which the company is determining the functions of human genes that could serve as possible targets for pharmaceuticals. Lexicon recently issued a non-exclusive license to Biogen, Inc. for the use of its patented isogenic DNA gene targeting technologies in Biogen's internal research programs. The firm also granted a non-exclusive license to Millennium Pharmaceuticals, Inc. covering the use of Lexicon's isogenic DNA technology. Millennium will use the technology in its drug discovery and target validation programs. In other news, the company was issued a sixth U.S. patent in the field of gene trapping. Lexicon was also awarded two patents covering the full-length sequences of potential drug targets discovered through its gene discovery programs. The firm offers its employees relocation assistance, an educational assistance plan and reimbursement accounts for child care and vision coverage.
BRANDS/DIVISIONS/AFFILIATES: OmniBank LexVision Lexgen.com Seek Target Validation (S-T-V) Program Lexicon Pharmaceuticals Human Gene Trap
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Arthur T. Sands, CEO Arthur T. Sands, Pres. Julia P. Gregory, CFO Walter F. Colbert, Sr. VP-Human Resources Brian P. Zambrowicz, Exec. VP-Research David Kimball, VP-Medicinal Chemistry Jeffrey L. Wade, Exec. VP/General Counsel Ray B. Webb, VP-Finance and Admin. Randall B. Riggs, Sr. VP-Bus. Dev. Carol L. Hensley, VP-Corp. Comm. Alan J. Main, Sr. VP-Lexicon Pharmaceuticals James R. Piggott, Sr. VP-Pharmaceutical Biology Lance K. Ishimoto, VP-Intellectual Property Christophe Person, VP-Informatics
Phone: 281-863-3000 Fax: 281-863-8088 Toll-Free: Address: 8800 Technology Forest Pl., The Woodlands, TX 77381-1160 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $35,200 (12 months) 2002 Profits: $-59,700 (12 months) Stock Ticker: LEXG 2001 Sales: $30,600 2001 Profits: $-35,200 Employees: 579 2000 Sales: $14,500 2000 Profits: $-26,000 Fiscal Year Ends: 12/31 1999 Sales: $4,700 1999 Profits: $-12,500 1998 Sales: $2,200 1998 Profits: $-7,500
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $400,000 Stock Purch. Plan: Second Exec. Salary: $260,000 Provides Internet access to major databases of cell clones for genomic study. ADVANTAGE:
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $250,000 Bonus: $125,000
LOCATIONS: ("Y" = Yes) West:
Southwest: Y
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
LEXMARK INT'L GROUP INC
www.lexmark.com
Industry Group Code: 334119 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Accessories-Laser & Inkjet Printers Connectivity Products
Lexmark International Group, Inc., a former subsidiary of IBM, is a global developer, manufacturer and supplier of laser and inkjet printers and associated consumable supplies for the office and home markets. Lexmark also sells dot matrix printers for printing single and multi-part forms by business users. The company’s installed base of printers supports a large and profitable printer supplies business. Because consumable supplies must be replaced on average one to three times a year, depending on type of printer and usage, demand for laser and inkjet print cartridges is increasing at a higher rate than their associated printer shipments. In addition to its core printer business, Lexmark develops, manufactures and markets a broad line of other office imaging products, which include supplies for IBM-branded printers, after-market supplies for original equipment manufacturer products and typewriters and typewriter supplies that are sold under the IBM trademark. The company’s research and development activity for the past four years has focused on laser and inkjet printers, associated supplies and network connectivity products. The company is committed to being a technology leader in its targeted areas and is actively engaged in the design and development of additional products and enhancements to its existing products. Its engineering effort focuses on laser, inkjet and connectivity technologies, as well as design features that will increase efficiency and lower production costs. In line with this effort, the company recently announced new software offerings that enhance employee productivity and reduce document costs. The Lexmark Document Solutions Suite is designed to minimize the expense of manual and paper-based processes. Lexmark is committed to fostering a healthy corporate atmosphere. The company offers its employees protection against major health care expenses and temporary loss of income due to sickness and accident and provides retirement income, capital accumulation, disability income, survivor benefits, paid vacation and 12 paid holidays.
BRANDS/DIVISIONS/AFFILIATES: Document Solutions Suite
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Paul J. Curlander, CEO Gary E. Morin, Exec. VP/CFO Jeri Stromquist, VP-Human Resources Gary Stromquist, VP/Controller Vincent J. Cole, VP/Corp. Sec. Vincent J. Cole, General Counsel Roger P. Rydell, VP-Corp. Comm. Kurt M. Braun, Treas. Daniel P. Bork, VP-Tax Najib Bahous, VP-Customer Services Timothy P. Craig, Pres.-Consumer Printer Div. David Goodnight, VP-Asia Pacific and Latin America Paul J. Curlander, Chmn.
Phone: 606-232-2000 Fax: 606-232-2403 Toll-Free: 800-232-2403 Address: 740 New Circle Rd. NW, Lexington, KY 40550 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $4,356,400 (12 months) 2002 Profits: $366,700 (12 months) Stock Ticker: LXK 2001 Sales: $4,142,800 2001 Profits: $273,600 Employees: 12,100 2000 Sales: $3,807,000 2000 Profits: $285,400 Fiscal Year Ends: 12/31 1999 Sales: $3,452,300 1999 Profits: $318,500 1998 Sales: $3,020,600 1998 Profits: $243,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan:
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $846,438 Stock Purch. Plan: Second Exec. Salary: $386,438 ADVANTAGE: Acquired the IBM line of printers and related technology.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $1,250,000 Bonus: $419,225
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
LIFE SCIENCES RESEARCH
www.lsrinc.net
Industry Group Code: 621511 Ranks within this company's industry group: Sales:2 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:5
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Services-Labs/Testing Drug Development Services
Life Sciences Research, Inc., formerly Huntingdon Life Sciences Group, is a global contract research organization offering worldwide preclinical and nonclinical testing for biological safety evaluation research services. It provides these product development services to pharmaceutical, biotechnology, agrochemical and industrial chemical companies. The company serves the rapidly evolving regulatory and commercial requirements to perform safety evaluations on new pharmaceutical compounds and chemical compounds contained within the products. In addition, it tests the effect of such compounds and performs tests assessing the safety and efficacy of veterinary products. Life Sciences Research's services address safety concerns surrounding a diverse range of products, spanning such areas as agricultural herbicides and other pesticides, medical devices, veterinary medicines and specialty chemicals used in the manufacture of pharmaceutical intermediates and manufactured foodstuffs and products. The company offers drug development services for many therapeutic areas, including anti-cancer, anti-inflammatory, cardiovascular, central nervous system, hormones and fertility.
BRANDS/DIVISIONS/AFFILIATES: Huntingdon Life Sciences Group
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Andrew H. Baker, CEO Brian Cass, COO Richard Michaelson, CFO Richard Michaelson, Corp. Sec. Andrew H. Baker, Chmn.
Phone: 732-649-9961 Fax: 732-649-0021 Toll-Free: Address: P.O. Box 2360 Mettlers Rd., East Millstone, NJ 08875 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $115,742 (12 months) 2002 Profits: $2,697 (12 months) Stock Ticker: LSRI.OB 2001 Sales: $99,200 2001 Profits: $-8,400 Employees: 1,439 2000 Sales: $88,600 2000 Profits: $-9,800 Fiscal Year Ends: 12/31 1999 Sales: $81,500 1999 Profits: $-5,700 1998 Sales: $73,700 1998 Profits: $-34,200
SALARIES/BENEFITS: Pension Plan: Y Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $300,780 Stock Purch. Plan: Second Exec. Salary: $221,073 ADVANTAGE: One of the world's leading contract research organizations.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
LIFECELL CORPORATION
www.lifecell.com
Industry Group Code: 325414 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Tissue Grafting Skin Replacement Technology
LifeCell Corporation specializes in regenerative medicine, developing and manufacturing products geared toward the repair, replacement and preservation of human tissues. The company has developed and patented several proprietary technologies, including a method for producing an extracellular tissue matrix, a method for cell preservation through signal transduction and a method for freeze-drying biological cells and tissues without damage. LifeCell markets four major products based on these tissue matrix technologies: Alloderm and Cymetra for burns and plastic reconstructive surgery, Repliform for the urogynecology market (treatment of urinary incontinence) and Graft Jacket, an acellular periosteum replacement graft. Alloderm is a human tissue product that supports the regeneration of normal human soft tissue. The company also distributes cryopreserved allograft skin for use as a temporary wound dressing in the treatment of burns. It is the exclusive marketing agent for the SmartPReP Platelet Concentration System in the United States to ENT (ear, nose and throat), plastic reconstructive surgeons and general surgeons in hospitals. In addition, the firm has a number of products currently under development, including Thrombosol, a formulation for extended storage of platelets and technologies to enhance the storage of red blood cells for transfusion.
BRANDS/DIVISIONS/AFFILIATES: Alloderm Cymetra Repliform Thrombosol Graft Jacket SmartPReP
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Paul G. Thomas, CEO Paul G. Thomas, Pres. Steven T. Sobieski, VP/CFO Lisa N. Colleran, VP-Mktg. Judy Colyn, Mgr.-Human Resources Stephen A. Livesey, Exec. VP/Chief Science Officer William E. Barnhart, Sr. VP-Oper. Lisa N. Colleran, VP-Bus. Dev.
Phone: 908-947-1100 Fax: 908-947-1200 Toll-Free: Address: One Millennium Way, Branchburg, NJ 08876-3876 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $34,400 (12 months) 2002 Profits: $1,400 (12 months) Stock Ticker: LIFC 2001 Sales: $27,800 2001 Profits: $-2,100 Employees: 168 2000 Sales: $22,772 2000 Profits: $-7,138 Fiscal Year Ends: 12/31 1999 Sales: $12,700 1999 Profits: $-9,200 1998 Sales: $8,000 1998 Profits: $-7,300
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $288,750 Stock Purch. Plan: Second Exec. Salary: $220,584 Expertise in human tissue regeneration. ADVANTAGE:
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $129,938 Bonus: $56,249
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
LIFECORE BIOMEDICAL INC
www.lifecore.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:36 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:34
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Dental Implants Tissue Regeneration Products
Lifecore Biomedical, Inc. develops and manufactures medical and surgical devices that are used in fields such as dentistry, general surgery, ophthalmology, drug delivery, veterinary medicine and wound care management. The company’s Hyaluronan division develops products utilizing hyaluronan, a naturally occurring polysaccharide that lubricates soft tissues in the body. The division’s INTERGEL solution reduces the incidence of tissue adhesions commonly formed as part of the body’s natural healing process when tissues are subjected to accidental or surgical trauma. Ethicon’s GYNECARE subsidiary markets INTERGEL in Europe and the United States. The division also uses hyaluronan as a component in ophthalmic, orthopedic and veterinary medical devices. Lifecore’s oral restorative division develops and markets precision surgical and prosthetic devices for the restoration of damaged or deteriorating dentition systems. The division offers a number of titanium-based dental implant systems, including RESTORE, SUSTAIN and STAGE-1. Additionally, Lifecore manufactures tissue regeneration products that restore soft tissue that has deteriorated as the result of periodontal disease. The company’s customers include Musculoskeletal Transplant Foundation and Alcon, Inc. The firm also manufactures Bexco Pharma’s HY-50 product, an aseptically packaged hyaluronan solution that is used as a veterinary orthopedic drug. Lifecore Biomedical offers its employees dental insurance and an on-site fitness center.
BRANDS/DIVISIONS/AFFILIATES: INTERGEL RESTORE SUSTAIN STAGE-1
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. James W. Bracke, CEO James W. Bracke, Pres. Dennis J. Allingham, CFO Andre P. Decarie, VP-Mktg. and Sales Kristen Weiss-Todd, Human Resources James W. Bracke, Corp. Sec. Colleen M. Olson, VP-Corp. Admin. Oper. Brian J. Kane, VP-New Bus. Dev.
Phone: 952-368-4300 Fax: 952-368-3411 Toll-Free: Address: 3515 Lyman Blvd., Chaska, MN 55318 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $38,800 (12 months) 2002 Profits: $-4,700 (12 months) Stock Ticker: LCBM 2001 Sales: $34,100 2001 Profits: $-3,700 Employees: 199 2000 Sales: $32,800 2000 Profits: $-1,600 Fiscal Year Ends: 6/30 1999 Sales: $27,300 1999 Profits: $1,600 1998 Sales: $25,600 1998 Profits: $ 200
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: International expansion.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Top Exec. Salary: $302,156 Second Exec. Salary: $194,967
Bonus: $30,000 Bonus: $19,287
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
LIGAND PHARMACEUTICALS INC
www.ligand.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:54 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:71
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Cancer Small-Molecule Drugs
Ligand Pharmaceuticals develops new drugs that address a wide variety of medical needs, including cancer, skin diseases, hormone-related diseases, osteoporosis, metabolic disorders and cardiovascular and inflammatory diseases. The company’s products include Panretin gel, a topical treatment used to treat lesions stemming from AIDS-related Kaposi’s sarcoma, and Ontak and Targretin, prescribed for patients with cutaneous T-cell lymphoma. The newest product, AVINZA, is a treatment for chronic moderate to severe pain. Ligand has formed research and development collaborations with numerous global pharmaceutical companies, including Abbott Laboratories, Allergan, Bristol-Myers Squibb, GlaxoSmithKline, Organon, Pfizer, TAP Pharmaceutical Products and Wyeth. These corporate partner products are being studied for the treatment of large market indications such as osteoporosis, diabetes, contraception and cardiovascular disease. Recently, Organon, a business unit of Akzo Nobel, and Ligand announced that the companies will co-promote AVINZA with more than 800 sales representatives in the United States. Organon brings strong relationships in primary care, anesthesiology, hospitals and managed care to support AVINZA.
BRANDS/DIVISIONS/AFFILIATES: AVINZA Morphelan Panretin Targretin ONTAK
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. David E. Robinson, CEO Thomas H. Silberg, Exec. VP/COO David E. Robinson, Pres. Paul V. Maier, Sr. VP/CFO William A. Pettit, Sr. VP-Human Resources and Admin. Andres Negro-Vilar, Chief Scientific Officer/Sr. VP-Research Gian Aliprandi, VP/Sr. Corp. Controller Warner R. Broaddus, VP/Corp. Sec. Warner R. Broaddus, General Counsel Phillip A. Duffy, VP-Tech. Oper. Russell L. Allen, VP-Corp. Dev. and Strategic Planning Steven D. Reich, Sr. VP-Clinical Research Eric S. Groves, VP-Project Mgmt. James L'Italien, Sr. VP-Regulatory Affairs and Compliance David E. Robinson, Chmn.
Phone: 858-550-7500 Fax: 858-550-7506 Toll-Free: Address: 10275 Science Center Dr., San Diego, CA 92121-1117 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $96,600 (12 months) 2002 Profits: $-32,600 (12 months) Stock Ticker: LGND 2001 Sales: $76,300 2001 Profits: $-43,000 Employees: 402 2000 Sales: $48,110 2000 Profits: $-72,376 Fiscal Year Ends: 12/31 1999 Sales: $38,285 1999 Profits: $-74,719 1998 Sales: $17,673 1998 Profits: $-117,886
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $573,945 Stock Purch. Plan: Second Exec. Salary: $369,550 ADVANTAGE: A leader in the discovery and development of small-molecule drugs.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $100,000 Bonus: $88,700
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
LINDE AG
www.linde.de
Industry Group Code: 333000 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Y Y
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Profits:1
Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Y Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Machinery-Materials Handling Equipment Industrial Gases Warehouse Equipment Refrigeration and Cooling Systems Project Development
German-based Linde AG is a highly diversified engineering group comprised of more than 120 companies throughout the world. The company is active in the gas and engineering, material handling and refrigeration industries through its six divisions: Linde Gas, Linde Engineering, Linde Material Handling, OM Carrelli Elecatori S.p.A., STILL GmbH and Linde Refrigeration. Linde Gas supplies industrial and medical gases throughout Europe, particularly targeting on-site and health care businesses. The subsidiary is also involved in the helium and environmentally friendly fuel markets. Products include medical gases, rare gases, hydrogen, carbon dioxide and other gases. Linde Engineering is a plant construction company with extensive process engineering knowledge and experience in planning, project development and construction of turnkey industrial plants. The subsidiary constructs chemical and petrochemical plants and hydrogen plants, among others, and manufactures plant components and modules, liquefied gas tanks, catalysts, vacuum-brazed plate-type heat exchangers and coil-wound heat exchangers and reactors. Linde Material Handling is comprised of subsidiaries Linde Forklift and Linde Hydraulics, allowing the company to produce both hydraulics and industrial trucks. The company markets its trucks and warehouse equipment under the Linde, STILL and FIAT OM brands. Linde Refrigeration manufactures refrigeration systems and equipment and processes cooling systems for industrial applications. Through the subsidiary, Linde AG is the only company in the market that offers turnkey competence in Eastern Europe, Asia and South America. Recently, Wiesbaden, a subsidiary of Linde Engineering, created the world’s first hydrogen filling station using 700bar technology.
BRANDS/DIVISIONS/AFFILIATES: Linde Gas Linde Engineering Linde Material Handling OM Carrelli Alecatori S.p.A. STILL GmbH Linde Hydraulics Linde Forklift Linde Refrigeration
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Wolfgang Reitzle, CEO Wolfgang Reitzle, Pres. Hero Brahms, Group Dir.-Accounts and Taxes Hubertus Krossa, Head-Sales and Mktg. Hero Brahms, Labor Dir. Hero Brahms, Group Dir.-Controlling Aldo Belloni, Head-Gas and Eng. Bus. Segment Hans-Georg Haeseler, Head-Legal Hero Brahms, Group Dir.-Bus. Admin. Hero Brahms, Group Dir.-Treas. Aldo Belloni, Group Dir.-Patents Hubertus Krossa, Head-Refrigeration Bus. Segment Hans-Peter Schmohl, Head-Material Handling Bus. Segment Manfred Schneider, Chmn.
Phone: 49-611-770-0 Fax: 49-611-770-269 Toll-Free: Address: Abraham-Lincoln-Strasse 21, Wiesbaden, 65189 Germany
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $10,102,000 (12 months) 2002 Profits: $278,000 (12 months) Stock Ticker: Foreign 2001 Sales: $8,040,000 2001 Profits: $253,000 Employees: 46,521 2000 Sales: $7,956,000 2000 Profits: $258,400 Fiscal Year Ends: 12/31 1999 Sales: $6,303,400 1999 Profits: $262,500 1998 Sales: $6,406,500 1998 Profits: $302,500
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Multifaceted international with many areas of expertise.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West:
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
LOCKHEED MARTIN CORP
www.lockheedmartin.com
Industry Group Code: 336410 Ranks within this company's industry group: Sales:2 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Y
Transportation: Aerospace: Automotive:
Profits:2 Y
Y Y
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Aerospace & Defense-Diversified Systems Integration and Technology Services
Lockheed Martin is one of the country’s premier high-tech companies, specializing in advanced technological systems. The company serves both domestic and international customers, with U.S. government agencies accounting for 80% of all sales. The firm is divided into four major business areas: aeronautics, space, systems integration and technology services. The company also has a large telecommunications sector, which provides space-related technological support such as radio and television satellites. Its commercial satellite business successfully launched five satellites for customers worldwide, including EchoStar VII for EchoStar Communications; NStar-C for NTT DoCoMo, Inc.; NSS-6 and NSS-7 satellites for New Skies Satellites, N.V.; and most recently Nimiq 2 for Telesat. Its aeronautics division is the prime contractor on the F-16 tactical fighter aircraft and continues to provide upgrades for the U.S. Air Force and its international customers. Lockheed Martin’s energy business manages two large laboratory facilities in the U.S. and participates in the management of a large facility in the U.K. The Knolls Atomic Power Laboratory designs nuclear reactors for the U.S. Navy. It also supports the existing fleet of nuclear-powered ships and trains the Navy personnel who operate those ships. Recently, Lockheed Martin was selected by the Royal Mail to develop, operate and support an online postage service in the U.K. It was also chosen to provide systems integration services in support of the London Metropolitan Police’s new command, control, communications and information system, intended to improve the delivery of police services throughout metropolitan London. In addition, Poland announced its intent to purchase 48 F-16 aircraft, subject to completion of definitive contract negotiations. The company offers its employees a variety of benefits, including health and vision insurance.
BRANDS/DIVISIONS/AFFILIATES: Joint Strike Fighter Lockheed Martin Missiles and Fire Control Lockheed Martin Global Telecommunications Lockheed Martin Air Traffic Management Lockheed Martin Aeronautics Co. EchoStar VII F-22 Raptor F-16
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Vance D. Coffman, CEO Robert J. Stevens, COO Robert J. Stevens, Pres. Christopher E. Kubasik, Sr. VP/CFO Michael F. Camardo, Exec. VP-Tech. Services Rajeev Bhalla, VP/Controller Frank H. Menaker, Jr, Sr. VP/General Counsel Anthony G. Van Schaick, VP/Treas. Dain M. Hancock, Exec. VP-Lockheed Martin Aeronautics Robert B. Coutts, Exec. VP-Systems Integration Albert E. Smith, Exec. VP-Space Systems Vance D. Coffman, Chmn.
Phone: 301-897-6000 Fax: 301-897-6704 Toll-Free: Address: 6801 Rockledge Dr., Bethesda, MD 20817-1877 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $26,578,000 (12 months) 2002 Profits: $500,000 (12 months) Stock Ticker: LMT 2001 Sales: $23,990,000 2001 Profits: $249,000 Employees: 125,000 2000 Sales: $25,329,000 2000 Profits: $-1,046,000 Fiscal Year Ends: 12/31 1999 Sales: $25,530,000 1999 Profits: $382,000 1998 Sales: $26,266,000 1998 Profits: $1,001,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $1,553,846 Bonus: $2,600,000 Stock Purch. Plan: Second Exec. Salary: $835,000 Bonus: $1,330,000 ADVANTAGE: One of the world's largest defense contractors/Will receive immense revenues from the Joint Strike Fighter supersonic aircraft project.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
LORAL SPACE & COMMUNICATIONS LTD Industry Group Code: 513340 Ranks within this company's industry group: Sales:2 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
www.loral.com
Profits:3 Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Satellite Equipment-Communications & Weather Satellite Systems Fixed Satellite and Network Services Managed Communications Networks
Loral Space and Communications, Ltd. is a leader in satellite communications. Loral is organized into two operating segments: satellite manufacturing and technology; and satellite services, including fixed satellite services and network services. The company designs and manufactures satellites and space systems and develops satellite technology for a broad variety of customers and applications through its space systems segment. Through Loral Skynet, Loral leases transponder capacity to customers for various applications, including television and cable broadcasting, news gathering, Internet access and transmission, private voice and data networks, business television, distance learning and direct-to-home television, and provides satellite telemetry, tracking and control services. Loral also provides network services such as managed communications networks, Internet and intranet services, business television and business media services to its customers. It provides satellite capacity to support distribution of U.S. television network programming. The ABC, CBS and Fox television networks are its major customers. The company's satellites also provide capacity for video distribution, satellite newsgathering and other satellite services to international broadcasters, news organizations, telecommunications service providers and Internet service providers. Through the Loral Global Alliance, Loral seeks to offer its customers an integrated portfolio of satellite capacity that provides one-stop shopping for local, regional and global GEO satellite services. This Loral Skynet-led alliance, with 10 satellites currently in orbit and 15 planned, further enhances the geographic reach, market presence and offerings of its members. In recent news, the company announced that it has signed an agreement with Andrita Studios, Inc. to develop a digital cable distribution platform on the company’s Telstar 7 satellite. In July 2003, the firm filed for bankruptcy protection, partly due to very slow orders for new satellites in the manufacturing sector. As part of a proposed reorganization, Loral plans to sell its fleet of six communications satellites to Intelsat for about $1 billion.
BRANDS/DIVISIONS/AFFILIATES: Loral Skynet Loral CyberStar Loral Global Alliance Globalstar CyberStar, LP Telstar
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Bernard L. Schwartz, CEO Eric J. Zahler, COO Eric J. Zahler, Pres. Richard J. Townsend, Exec. VP/CFO Joel Schindall, VP/Chief Tech. Officer Harvey B. Rein, VP/Controller Avi Katz, Corp. Sec. Avi Katz, General Counsel Stephen L. Jackson, VP-Admin. Russell R. Mack, VP-Bus. Ventures Jeanette H. Clonan, VP-Comm. Jeanette H. Clonan, VP-Investor Rel. Richard P. Mastoloni, VP/Treas. Terry J. Hart, VP/Pres., Loral Skynet C. Patrick DeWitt, VP/Pres.-Space Systems Laurence D. Atlas, VP-Gov't Rel. and Telecommunications Donald Kutyna, VP-Space Tech. Bernard L. Schwartz, Chmn.
Phone: 212-697-1105 Fax: 212-338-5662 Toll-Free: Address: 600 3rd Ave., New York, NY 10016 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,098,425 (12 months) 2002 Profits: $-1,469,211 (12 months) Stock Ticker: LOR 2001 Sales: $1,069,600 2001 Profits: $-196,400 Employees: 2,800 2000 Sales: $1,224,111 2000 Profits: $-1,469,678 Fiscal Year Ends: 12/31 1999 Sales: $1,457,720 1999 Profits: $-201,916 1998 Sales: $1,301,702 1998 Profits: $-138,798
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $1,744,576 Stock Purch. Plan: Second Exec. Salary: $1,000,000 ADVANTAGE: Filed for bankruptcy protection in July 2003.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $600,000 Bonus: $225,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
LSI LOGIC CORP
www.lsilogic.com
Industry Group Code: 334413 Ranks within this company's industry group: Sales:5 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:11
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Chips & Integrated Circuits Application-Specific Integrated Circuits
LSI Logic is a leader in the design, development, manufacture and marketing of complex, high-performance integrated circuits and storage systems. The company is focused on the four markets of consumer products, communications, storage components and storage area network systems. Its integrated circuits are used in a wide range of communication devices, including devices used for wireless, broadband, data networking and set-top box applications. LSI also provides integrated circuit products and board-level products for use in consumer applications, high-performance storage controllers and systems for storage area networks. The company’s semiconductor segment develops application-specific integrated circuits (ASICs) and standard products, which include microprocessors for wireless handsets, Ethernet products for local area networks, silicon solutions for broadband infrastructures and encoders and decoders for video games and digital television systems. The firm’s storage area network (SAN) systems segment offers a broad line of products and solutions, including controller modules, drive modules and storage systems. The SAN systems segment is anchored by LSI Logic’s MetaStor product line. The MetaStor E-Series storage systems for storage area networks combine fibre channel performance with proprietary Multi-Pathing Architecture to deliver high performance for a wide variety of applications. LSI has a sabbatical plan, allowing employees to take four weeks of paid time off, as well as regular vacation time, after 10 years of continuous service. LSI is involved in community affairs and runs a community contributions program. The company also features an on-site fitness center.
BRANDS/DIVISIONS/AFFILIATES: MetaStor CoreWare HyperPHY GigaBlaze ATMizer OakDSPCore DataPath Systems IntraServer Technology
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Wilfred J. Corrigan, CEO Byron Look, Exec. VP/CFO Frank A. Tornaghi, Exec. VP-Worldwide Sales Jon R. Gibson, VP-Human Resources Christopher L. Hamlin, Sr. VP/Chief Tech. Officer David Pursel, Corp. Sec. David Pursel, General Counsel Joseph M. Zelayeta, Exec. VP-Worldwide Oper. Diana L. Matley, VP-Investor Rel. Bryon Look, Treas. W. Richard Marz, Exec. VP-Comm. and ASIC Tech. Giuseppe Staffaroni, Exec. VP-Consumer Products John D'Errico, Exec. VP-LSI Storage Components Wilfred J. Corrigan, Chmn.
Phone: 408-433-8000 Fax: 408-433-3220 Toll-Free: 866-574-5741 Address: 1621 Barber Ln., Milpitas, CA 95035 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,816,900 (12 months) 2002 Profits: $-42,200 (12 months) Stock Ticker: LSI 2001 Sales: $1,784,900 2001 Profits: $-992,000 Employees: 5,281 2000 Sales: $2,737,700 2000 Profits: $236,600 Fiscal Year Ends: 12/31 1999 Sales: $2,089,444 1999 Profits: $67,174 1998 Sales: $1,516,891 1998 Profits: $-139,478
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $793,858 Bonus: $1,400,000 Stock Purch. Plan: Second Exec. Salary: $383,082 Bonus: $500,000 ADVANTAGE: Develops customized products in collaboration with customers/Developer of system-on-a-chip CoreWare solutions.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
LUCENT TECHNOLOGIES INC
www.lucent.com
Industry Group Code: 334210 Ranks within this company's industry group: Sales:6 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:17
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Telecommunications Equipment-Broadband Networking Communications Software Products
Lucent Technologies, Inc. designs, develops and manufactures communications systems, software products and supply systems for most of the world's largest communications network operators and service providers. The company's research and development activities are conducted through Bell Laboratories, a leading technology development laboratory in the communications sector. The company has been downsizing significantly in recent years in response to a slowing market for telecommunications equipment and tough competition from smaller companies that make leading-edge products. Lucent is organized around two distinct customer segments: integrated network solutions (INS), focusing on the needs of wireline service providers, and mobility solutions, focusing on the needs of wireless service providers. INS offers a broad range of circuit switching, packet switching, access and optical networking products, as well as network management software. The mobility solutions group focuses on providers with end-to-end solutions and products that support their needs for radio access, core networks, network management and application and service delivery systems. Recently, Lucent introduced the MiLife Intelligent Services Gateway Software Developers Kit, which enables mobile operators to introduce services to market quickly. In other news, Cingular Wireless chose Lucent’s PacketStar Multiservice Media Gateway to provide an inexpensive alternative for moving voice and data traffic on its mobile network. The company has suffered deep declines in revenues, along with large losses, due to the telecommunications industry slump. Currently, it is focusing on offering a wider range of services to customers in an effort to return to profitability during 2004. Lucent offers its employees a relocation program, as well as tuition reimbursement of $7,000 to $9,000 a year for college or graduate courses. The company made Fortune Magazine's list of The 50 Best Companies for Minorities. Roughly one-half of all management-track employees are minorities.
BRANDS/DIVISIONS/AFFILIATES: Bell Laboratories MiLife Intelligent Services Gateway PacketStar Multiservice Media Gateway
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Patricia F. Russo, CEO Robert C. Holder, COO Patricia F. Russo, Pres. Frank D'Amelio, Exec. VP/CFO William T. O'Shea, Exec. VP-Mktg. Ruth E. Bruch, Sr. VP/CIO John Kritzmacher, Sr. VP/Controller Richard J. Rawson, Sr. VP/Corp. Sec. Richard J. Rawson, General Counsel William T. O'Shea, Exec. VP-Corp. Strategy Kathleen M. Fitzgerald, Sr. VP-Public Rel. and Advertising MaryAnn Niebojeski, VP-Investor Rel. William T. O'Shea, Pres., Bell Labs John G. Heindel, Pres.-Lucent Worldwide Services James K. Brewington, Pres.-Mobility Solutions Janet G. Davidson, Pres.-Integrated Network Solutions Patricia F. Russo, Chmn. Jose Mejia, Pres.-Supply Chain Networks
Phone: 908-582-8500 Fax: 908-508-2576 Toll-Free: 888-458-2368 Address: 600 Mountain Ave., Murray Hill, NJ 07974 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $12,321,000 (12 months) 2002 Profits: $-11,753,000 (12 months) Stock Ticker: LU 2001 Sales: $21,294,000 2001 Profits: $-16,198,000 Employees: 47,000 2000 Sales: $33,813,000 2000 Profits: $1,219,000 Fiscal Year Ends: 9/30 1999 Sales: $30,617,000 1999 Profits: $4,789,000 1998 Sales: $24,367,000 1998 Profits: $1,065,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $1,100,000 Bonus: $5,129,636 Stock Purch. Plan: Y Second Exec. Salary: $900,000 Bonus: $3,069,334 ADVANTAGE: Provides products and services to most of the world's largest telecom companies and service providers.
OTHER THOUGHTS: Apparent Women Officers or Directors: 5 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
LUMINEX CORPORATION
www.luminexcorp.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:39 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:37
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Bioassay Devices Microspheres
Luminex manufactures and markets a technology platform based on bioassays, which are used in the life sciences industry to detect biochemicals, proteins and genes in samples for the purpose of drug discovery, genetic analysis, pharmacogenomics and clinical diagnostics. The company’s LabMAP system performs up to 100 bioassays on a single drop of fluid through Luminex 100, an instrument combining diode lasers, digital signal processors and other software. The firm also manufactures development microspheres (used to discover and optimize characteristics of individual biomolecular interactions), calibration microspheres (used to assure consistency in measurements) and multi-analyte microspheres (which enable reactions and controls to be mixed and measured after they are optimized). Luminex has concentrated its expansion toward exploring new ventures through alliances and collaborations. The firm recently entered into three agreements with Bayer Diagnostics, a division of Bayer Corporation. The contracts cover a license harmony and related supply agreement for Luminex's xMAP technology, as well as a multi-year agreement relating to the development of a new cellular analyzer. Part of the license agreement grants Bayer Diagnostics the right to develop and distribute invitro diagnostic products based on Luminex technology. Bayer will also design and market a new cellular analyzer based on in-house and Luminex technology and software. Luminex will manufacture the instrument platform and receive royalties from the commercialization of Bayer's product based on the cellular analyzer, as well as revenue from the sale of the instruments. In other news, Luminex was recently named the highest-ranking life sciences company on the 2002 Deloitte & Touche Technology Fast 500, a ranking of the fastest growing technology companies in North America.
BRANDS/DIVISIONS/AFFILIATES: Luminex 100 Luminex XYP LumAvidin LabMAP xMAP Bayer Diagnostics
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Thomas W. Erickson, CEO Thomas W. Erickson, COO Mark B. Chandler, Pres. James L. Persky, VP/CFO James E. Schepp, VP-Mktg. and Sales Eddie Chien, Human Resources Ralph L. McDade, VP-Scientific Affairs Harriss T. Currie, Controller Michael D. Spain, Chief Medical Officer Oliver H. Meek, VP-Mfg. Randel S. Marfin, VP-Bus. Dev. James L. Persky, Treas. James W. Jacobson, VP-Tech. Oper.
Phone: 512-219-8020 Fax: 512-219-5195 Toll-Free: 888-219-8020 Address: 12212 Technology Blvd., Austin, TX 78727 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $13,000 (12 months) 2002 Profits: $-24,900 (12 months) Stock Ticker: LMNX 2001 Sales: $20,900 2001 Profits: $-15,700 Employees: 117 2000 Sales: $8,600 2000 Profits: $-12,500 Fiscal Year Ends: 12/31 1999 Sales: $3,100 1999 Profits: $-9,200 1998 Sales: $ 400 1998 Profits: $-5,600
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Advanced bioassay technology.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $350,000 Second Exec. Salary: $260,000
Bonus: $35,000 Bonus: $20,000
LOCATIONS: ("Y" = Yes) West:
Southwest: Y
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
LYNX THERAPEUTICS INC
www.lynxgen.com
Industry Group Code: 541710 Ranks within this company's industry group: Sales:19 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:7
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
DNA Cloning and Analysis Technology Proteomics Technology
Lynx Therapeutics, Inc. is a leader in the development and application of novel technologies for the discovery of gene expression patterns and genomic variations important to the pharmaceutical, biotechnology and agricultural industries. The firm's proprietary cloning procedure, Megaclone, forms the foundation of these technologies. Megaclone transforms a sample containing millions of DNA molecules into one made up of millions of microbeads, each of which carries approximately 100,000 copies of one of the DNA molecules in the sample. The procedure enables the DNA molecules to be analyzed simultaneously in various applications. In addition, it eliminates the need to store and handle millions of individual DNA clones. Applications based on Megaclone include Massively Parallel Signature Sequencing (MPSS), which generates gene sequence information from microbeads; Megasort, which enables researchers to focus on potential target genes by permitting the direct physical isolation of nearly all the genes differentially expressed between samples; and Megatype, which enables a single experiment to yield the disease- or trait-associated single nucleotide polymorphisms (SNPs) that differentiate large populations of genomes. Lynx is also developing a proteomics technology, Protein ProFiler, which is expected to provide high-resolution analysis of complex mixtures of proteins from cells or tissues. The company formed Axaron Bioscience as a joint venture with BASF to employ Lynx's technology in neuroscience, toxicology and microbiology research programs. In recent news, Lynx formed a two-year collaborative research agreement with the University of California at Davis to study gene expression in the Arabidopsis plant. Lynx offers its employees a benefits package including educational assistance, stock options, a casual dress code, an employee referral plan, health club membership, flexible spending accounts, flu shots and medical, dental and vision plans. Additional benefits include free snacks, subsidized lunches, sports teams and weekly massages.
BRANDS/DIVISIONS/AFFILIATES: Megasort Megatype Megaclone Lynx Therapeutics GmbH Axaron Bioscience AG Protein ProFiler Massively Parallel Signature Sequencing (MPSS)
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Kevin P. Corcoran, CEO Kevin P. Corcoran, Pres. Edward C. Albini, CFO Kathy A. San Roman, VP-Human Resources John E. Wiktorowicz, Dir.-Proteomics Edward C. Albini, Corp. Sec. Kathy A. San Roman, VP-Admin. Elizabeth S. Song, Dir.-Bus. Dev. and Alliances Mgmt. Thomas J. Vasicek, VP-Bus. Dev. Jen-i Mao, VP-Genetic Analysis Daixing Zhou, Dir.-Bioinformatics Sarah McCurdy, Mgr.-Bus. Dev. and Commercialization
Phone: 510-670-9300 Fax: 510-670-9302 Toll-Free: Address: 25861 Industrial Blvd., Hayward, CA 94545 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $17,400 (12 months) 2002 Profits: $-15,500 (12 months) Stock Ticker: LYNX 2001 Sales: $19,300 2001 Profits: $-16,700 Employees: 128 2000 Sales: $12,600 2000 Profits: $-13,300 Fiscal Year Ends: 12/31 1999 Sales: $12,900 1999 Profits: $-6,700 1998 Sales: $7,000 1998 Profits: $-4,300
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $290,192 Stock Purch. Plan: Y Second Exec. Salary: $209,796 ADVANTAGE: Unique cloning technology/High-profile partnerships for drug development.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
LYONDELL CHEMICAL COMPANY
www.lyondell.com
Industry Group Code: 325110 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Y Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Polymers and Petrochemicals Manufacturer Intermediate and Performance Chemical Marketer
Lyondell Chemical Co. is a leading producer of intermediate and performance chemicals and polymers that are used for a wide variety of applications, including food packaging, automobile parts, clothing and grooming aids, home building materials and household products. The company, a global firm with billions of dollars in assets and operations in close to 20 countries, is one of the top producers of propylene oxide, an important chemical used in consumer and industrial applications. Through its LYONDELL-CITGO Refining LP subsidiary, Lyondell has become one of the largest refiners in the U.S. Through its Equistar Chemicals, L.P. subsidiary, Lyondell produces polymer resins, which are used to make plastic films, and petrochemicals, which are used as the basis for many synthetic materials. Lyondell, through Equistar, has become one of the largest North American producers of ethylene, propylene and polyethylene. Equistar’s e-business tool, CustomerXPRESS, enables customers to place, change and verify orders online. Recently, Lyondell completed the development of its product, ACRYFLOW Resins. The company also completed the Formulation Tool Kit. Additionally, Lyondell announced that Equistar has agreed to supply Sunoco, Inc. with propylene for the next fifteen years and to also sell its Pasadena, Texas-based Bayport polypropylene manufacturing unit to Sunoco. The firm provides employees with educational assistance, and offers matching gifts and volunteer grants for charitable activities. Lyondell and Equistar received the American Chemistry Council's Performance Improvement Award for employee safety performance for the second year in a row. Lyondell is also ranked number one in corporate governance policies and procedures by Institutional Shareholder Services, Inc.
BRANDS/DIVISIONS/AFFILIATES: Equistar Chemicals, L.P. LYONDELL-CITGO Refining LP CustomerXPRESS ACRYFLOW Resins Formulation Tool Kit
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Dan F. Smith, CEO Morris Gelb, Exec. VP/COO Dan F. Smith, Pres. T. Kevin DeNicola, Sr. VP/CFO John A. Hollinshead, VP-Human Resources J. Rick Fontenot, VP-Research & Dev. Eric A. Silva, VP-IT Charles L. Hall, VP/Controller James W. Bayer, Sr. VP-Mfg. Kerry A. Galvin, Corp. Sec. Kerry A. Galvin, Sr. VP-General Counsel Bart de Jong, VP-Corp. Dev. Karen A. Twitchell, VP/Treas. John R. Beard, Sr. VP/Pres., Lyondell Chemical Europe Edward J. Dineen, Sr. VP-Chemicals and Polymers W. Norman Phillips, Jr., Sr. VP-Fuels and Raw Materials Charles Yang, Pres., Lyondell Asia Pacific
Phone: 713-652-7200 Fax: 713-309-2074 Toll-Free: Address: 1221 McKinney St., Houston, TX 77010 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $3,262,000 (12 months) 2002 Profits: $-148,000 (12 months) Stock Ticker: LYO 2001 Sales: $3,226,000 2001 Profits: $150,000 Employees: 3,350 2000 Sales: $4,036,000 2000 Profits: $437,000 Fiscal Year Ends: 12/31 1999 Sales: $3,693,000 1999 Profits: $-115,000 1998 Sales: $1,447,000 1998 Profits: $52,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $1,018,004 Stock Purch. Plan: Second Exec. Salary: $511,036 ADVANTAGE: Diversified refining assets and partnerships.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $509,226 Bonus: $210,772
LOCATIONS: ("Y" = Yes) West:
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
MALLINCKRODT INC
www.mallinckrodt.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales: Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs Imaging Agents Respiratory Products Diagnostics Anesthesia Devices
Mallinckrodt develops and manufactures a wide range of medical products and devices, primarily used by hospitals for diagnostic and treatment purposes. The company’s imaging group produces a full line of imaging agents and radiopharmaceuticals, including ultrasound and MRI contrast agents, catheters for diagnosis and therapy and x-ray contrast media. Through its respiratory segment, the firm offers a variety of products, including anesthesia devices, medical gases, oxygen therapy and asthma management products, sleep diagnostics and therapy devices and blood analysis products. Mallinckrodt’s pharmaceuticals division is focused on providing pain relief and addiction therapy, with a product line that includes codeine, phosphate, morphine sulfate, naltrexone (for alcohol addiction) and methylphenidate (for attention deficit hyperactivity disorder). Mallinckrodt has been working toward the development and release of new products. The company is the developer of the OxiFirst Fetal Oxygen Monitoring System, widely hailed to be the first major breakthrough in obstetrical monitoring since the 1960s. This new technology enables obstetricians to monitor fetus oxygenation during labor and delivery. The firm’s imaging division has developed OptiMARK, the first and only MRI contrast agent FDA approved for administration by power injection. Mallinckrodt is a subsidiary of Tyco International, Ltd.
BRANDS/DIVISIONS/AFFILIATES: Nellcor Puritan Bennett OptiMARK Tyco International Mallinckrodt Pharmaceuticals Mallinckordt Respiratory Mallinckordt Imaging OxiFirst Fetal Oxygen Monitoring System
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. C. Ray Holman, CEO Douglas A. McKinney, CFO Lenita Maljan, VP-Human Resources Kathy Schaefer, Controller Michael J. Collins, Pres.-Pharmaceuticals Div. Forrest Whittaker, Pres.-Respiratory Div. Mark Thom, Pres.-Imaging Div. Douglas A. McKinney, VP-Shared Services C. Ray Holman, Chmn.
Phone: 314-654-2000 Fax: 314-654-5380 Toll-Free: Address: 675 McDonnell Blvd., Hazelwood, MO 63042 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $ 2001 Profits: $ Employees: 12,265 2000 Sales: $ 2000 Profits: $ Fiscal Year Ends: 6/30 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Expertise in diagnostic equipment.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Top Exec. Salary: $732,840 Second Exec. Salary: $322,793
Bonus: $4,072,400 Bonus: $1,095,600
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
MARATHON OIL
www.marathon.com
Industry Group Code: 211111 Ranks within this company's industry group: Sales:6 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:5
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Y Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Oil & Gas, Exploration and Production Petroleum Marketing
Marathon Oil Company, formerly a business of the USX Corporation, is engaged in the worldwide exploration of crude oil and natural gas. Marathon currently has crude oil and natural gas production operations in 10 countries and produces an average of 412,000 barrels of oil equivalent per day. Primary exploration activities are in the U.S., U.K., Angola, Canada, Equatorial Guinea and Norway. Marathon Petroleum Norge A/S, a subsidiary, recently made two separate, significant oil discoveries off the coast of Norway. Through Marathon Ashland Petroleum, LLC (MAP), the company operates in the domestic refining, marketing and transportation of petroleum products. MAP, based in Findlay, Ohio, is 62%owned by Marathon Oil and 38%-owned by Ashland, Inc. With more than $8 billion in assets, MAP currently ranks as the nations’ sixth-largest petroleum refiner, with major operations in the Midwest, Great Plains and Southeast. MAP’s retail operations include 3,800 Marathon- and Ashland-branded stations and another 2,000 stations operated by Speedway SuperAmerica, LLC, a whollyowned subsidiary of MAP. Marathon recently completed its acquisition of Khanty Mansiysk Oil Corporation for approximately $280 million. This acquisition will add an estimated 250 million barrels of proved and probable oil reserves and an estimated 900 million barrels of total potential oil resource located in the Khanty Mansiysk region of Western Siberia. MAP, through Speedway SuperAmerica, recently announced the sale of all 193 of its convenience stores located in Florida, South Carolina, North Carolina and Georgia to Sunoco for $140 million in cash plus store inventories.
BRANDS/DIVISIONS/AFFILIATES: Pennaco Energy, Inc. Marathon Group Marathon Ashland Petroleum, LLC Speedway SuperAmerica, LLC Marathon Petroleum Norge A/S Khanty Mansiysk Oil Corp.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Clarence P. Cazalot, Jr., CEO Clarence P. Cazalot, Jr., Pres. John T. Mills, CFO Eileen Campbell, Human Resources William F. Schwind, Jr., Corp. Sec. William F. Schwind, Jr., General Counsel Steven B. Hinchman, VP-Product Oper. Steven J. Lowden, VP-Bus. Dev. Jerry Howard, VP-Corp. Affairs Philip G. Behrman, Sr. VP-Worldwide Exploration G. David Golder, Sr. VP-Commercialization and Dev. Thomas J. Usher, Chmn.
Phone: 713-629-6600 Fax: 713296-2952 Toll-Free: Address: 5555 San Felipe Ave., Houston, TX 77056 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $30,595,000 (12 months) 2002 Profits: $516,000 (12 months) Stock Ticker: MRO 2001 Sales: $33,066,000 2001 Profits: $157,000 Employees: 28,166 2000 Sales: $39,914,000 2000 Profits: $411,000 Fiscal Year Ends: 12/31 1999 Sales: $29,534,000 1999 Profits: $698,000 1998 Sales: $27,887,000 1998 Profits: $674,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Highly diversified business.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $783,333 Second Exec. Salary: $325,833
Bonus: $1,100,000 Bonus: $325,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
MARTEK BIOSCIENCES CORP
www.martekbio.com
Industry Group Code: 325411 Ranks within this company's industry group: Sales:4 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:6
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Nutritional Oils Pharmaceutical Products
Martek Biosciences Corp. has pioneered the commercial development of microalgae into a portfolio of high-value products and product candidates consisting of nutritional products and advanced detection systems, among others. The company has developed production methods and intellectual property for two important fatty acids, DHA and ARA, which may help develop the eyes and central nervous systems of newborns and promote adult mental and cardiovascular health. Martek is investigating the potential benefit of DHA supplementation on cardiovascular health and breast cancer, as well as on cystic fibrosis and visual and neurological disorders. Currently, the firm is targeting the infant formula market and the adult nutritional market for its nutritional oils. Martek has licensed its DHASCO and ARASCO oil blends to a number of companies in the infant formula market, including Abbott Laboratories and Mead Johnson Nutritionals. Martek also produces Neuromins, a DHA dietary supplement, and Neuromins PL, a DHA supplement specifically designed for pregnant and lactating women. These products are distributed through marketing agreements with firms including Natrol, Inc., Source Naturals, Inc., Nature's Way and Neutraceutical Corp. The products are sold at outlets such as Safeway, Vitamin World, Eckerd's and Savon. Martek also sells bulk DHA oil and powder for applications such as children's chewables and nutritional drinks. In addition, the firm develops fluorescent marker products from microalgae with potential applications in automated biological screening. The markers bring greater speed, sensitivity and simplicity to existing tests and applications. These dye products include SureLight, CryptoLight and SensiLight. In addition, Martek's genomics group is developing technologies that may allow the firm to transfer DHA-producing genetic material of microalgae into agricultural products such as corn. Recently, Abbott launched the first soy-based infant formula in the U.S. to contain DHA and ARA.
BRANDS/DIVISIONS/AFFILIATES: DHASCO OmegaTech, Inc. ARASCO Neuromins Formulaid CryptoLight SensiLight SureLight
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Henry Linsert, Jr., CEO Richard J. Radmer, Pres. Peter L. Buzy, CFO Jerome C. Keller, Sr. VP-Sales and Mktg. Richard J. Radmer, Chief Scientific Officer George P. Barker, Sr. VP/Corp. Sec. George P. Barker, General Counsel Thomas C. Fisher, Sr. VP-Oper. Peter L. Buzy, Treas.
Phone: 410-740-0081 Fax: 410-740-2985 Toll-Free: Address: 6480 Dobbin Rd., Columbia, MD 21045 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $45,500 (12 months) 2002 Profits: $-24,200 (12 months) Stock Ticker: MATK 2001 Sales: $18,800 2001 Profits: $-13,700 Employees: 198 2000 Sales: $9,700 2000 Profits: $-15,700 Fiscal Year Ends: 10/31 1999 Sales: $6,100 1999 Profits: $-14,800 1998 Sales: $6,900 1998 Profits: $-13,500
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $286,167 Stock Purch. Plan: Second Exec. Salary: $182,400 ADVANTAGE: Microalgae expertise/Partnership with Abbott Labs.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $82,700 Bonus: $52,360
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
MATRIX PHARMACEUTICAL
www.matx.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Cancer Aqueous-Based Protein Gel Systems
Matrix Pharmaceuticals develops drug candidates for cancer in the form of aqueous-based protein gel systems that deliver water-soluble chemotherapeutic agents. The company covers a wide variety of fields, including tumor biology and physiology, advanced imaging techniques, pharmaceutical chemistry, polymer chemistry, analytical chemistry and biochemistry. One of the company’s main products, IntraDose, is currently under development as an injectable gel for solid tumors in the head and the neck. Another product under development, FMdC, is part of the anticancer class of nucleoside analogs that target solid tumors and cancers of blood cell origin. Matrix's MPI 5020 Radiopotentiator utilizes aqueous protein gel technology to enhance the effects of radiation treatment for solid tumors. In a major development, Chiron Corporation acquired Matrix in early 2002. California-based Chiron is a global pharmaceutical company that develops and commercializes high-value products, with a strategic focus on cancer and infectious disease. The firm commercializes its products through three business units: biopharmaceuticals, vaccines and blood testing.
BRANDS/DIVISIONS/AFFILIATES: IntraDose MPI 5020 Radiopotentiator FMdC Chiron Corporation
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Michael D. Casey, CEO Michael D. Casey, Pres. Jeanette Fritzsky, VP-Sales and Mktg. Lori Gillespie, Human Resources Coordinator Richard E. Jones, VP-Research and Dev. Ronald P. Lucas, VP-Oper. Harry D. Pedersen, VP-Corp. Dev. Richard D. Leavitt, Sr. VP-Medical and Regulatory Affairs Dennis M. Brown, VP-Discovery Research
Phone: 510-742-9900 Fax: 510-742-8510 Toll-Free: Address: 34700 Campus Dr., Fremont, CA 94555 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $ 2001 Profits: $ Employees: 106 2000 Sales: $ 2000 Profits: $ Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Focus on the use of advanced technologies to create cancer therapies.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
MAXIM INTEGRATED PRODUCTS INC Industry Group Code: 334413 Ranks within this company's industry group: Sales:11 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
www.maxim-ic.com Profits:2
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Integrated Circuits-Analog & Mixed Signal High-Frequency Design Processes
Maxim Integrated Products, Inc. designs, develops, manufactures and markets a broad range of linear and mixed-signal integrated circuits, commonly referred to as analog circuits. In the United States and Canada, the firm sells its products through a direct sales and applications organization in eight regional sales offices and through its own and other unaffiliated distribution channels. Maxim's products include data converters, interface circuits, microprocessor supervisors, operational amplifiers, power supplies, multiplexers, switches, battery chargers and voltage references. The company also provides a range of high-frequency design processes and capabilities that can be used in custom design. The company focuses on the quality of its products, which are individually tested using specialized test equipment. In addition, long-term operating life and mechanical stress tests are routinely performed on samples to assure continued, long-term product performance. Maxim’s research and development programs emphasize development of technically innovative proprietary products. The firm also develops second source products used for industry-standard parts. Maxim’s total product introductions exceed 2,100. The company sells products directly to original equipment manufacturers and has a long-term supply arrangement with Tektronix, Inc. The firm’s recent expansion activities include the completion of a new test facility in Samutprakarn Province, Thailand. This facility, along with the existing site in Cavite, the Philippines, has the manufacturing capability and shipping space to accommodate the company’s future growth plans.
BRANDS/DIVISIONS/AFFILIATES:
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John F. Gifford, CEO John F. Gifford, Pres. Carl Jasper, CFO Sharon E. Smith-Lenox, Controller Jennifer E. Gilbert, VP Alan Hale, VP Pirooz Parvarandeh, VP Vijay Ullal, VP John F. Gifford, Chmn.
Phone: 408-737-7600 Fax: 408-737-7194 Toll-Free: 800-998-8000 Address: 120 San Gabriel Dr., Sunnyvale, CA 94086 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,025,100 (12 months) 2002 Profits: $259,200 (12 months) Stock Ticker: MXIM 2001 Sales: $1,576,600 2001 Profits: $334,900 Employees: 6,067 2000 Sales: $864,924 2000 Profits: $280,619 Fiscal Year Ends: 6/30 1999 Sales: $606,965 1999 Profits: $196,122 1998 Sales: $560,220 1998 Profits: $178,144
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $300,000 Bonus: $2,893,117 Stock Purch. Plan: Second Exec. Salary: $200,000 Bonus: $757,240 ADVANTAGE: Products are gaining international acceptance/Acquired Tektronix integrated circuits operations.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
MAXTOR CORP
www.maxtor.com
Industry Group Code: 334112 Ranks within this company's industry group: Sales:3 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:11
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Storage Equipment-Hard Disk Drives Server Appliances
Maxtor Corporation is one of the world’s leading suppliers of hard disk drives for desktop computer systems, selling billions of dollars' worth of its products annually. The company’s current product line is dominated by its DiamondMax, Diamond Max Plus and Fireball products, which are drives designed for both mainstream desktop personal computers and higher-performance desktop systems. These 3.5-inch disk drives have storage capacities that range from 10 to 160 gigabytes. The firm also offers MaxAttach server appliances that provide storage systems for networks, with special features such as data protection, data management and storage capacities ranging from 20 to 80 gigabytes. The company’s MaxAttach NAS 4000 system can hold 240 gigabytes in 1.75 inches of rack mount space. Furthermore, the data transfer rates of the company’s Ultra ATA/100 DiamondMax hard drive can exceed 100 megabytes a second. Maxtor’s anticipated future growth and increased international presence are evident in its plans to begin building a new manufacturing facility in China. The new 800,000-square-foot building, scheduled for completion in the second half of 2004, will focus primarily on desktop hard drive production. The firm distributes hard drive products to major technology companies including Dell, Sony, DirecTV, Apple, IBM, Hewlett-Packard, Panasonic and TiVo. The company’s products are also sold at major retail stores including Best Buy, CompUSA and Staples. Maxtor offers employees comprehensive insurance plans, short- and long-term disability coverage, tuition reimbursement, discount programs and employee awards programs.
BRANDS/DIVISIONS/AFFILIATES: Maxtor Network Systems Group Fireball MaxAttach DiamondMax No Quibble Reflect-It Formula 4 MaxFax
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Paul J. Tufano, CEO Paul J. Tufano, Pres. Michael Cordano, VP-Mktg. and Sales Phil Duncan, VP-Human Resources and Real Estate Pantelis Alexopoulos, Chief Tech. Officer Glenn H. Stevens, Corp. Sec. Glenn H. Stevens, General Counsel Pantelis Alexopoulos, Exec. VP-Desktop Product Dev. Misha Rozenberg, Chief Quality Officer Michael Wingert, Exec. VP/Mgr.-Server Products Group Chong Sup Park, Chmn. David Beaver, Chief Procurement Officer
Phone: 408-894-5000 Fax: 408-952-3600 Toll-Free: 800-262-9867 Address: 500 McCarthy Blvd., Milpitas, CA 95035 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $3,779,514 (12 months) 2002 Profits: $-334,067 (12 months) Stock Ticker: MXO 2001 Sales: $3,797,000 2001 Profits: $-646,400 Employees: 12,449 2000 Sales: $2,704,900 2000 Profits: $32,400 Fiscal Year Ends: 12/31 1999 Sales: $2,486,100 1999 Profits: $-50,100 1998 Sales: $2,408,500 1998 Profits: $31,200
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: A world leader in hard disk drives.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $838,942 Second Exec. Salary: $535,096
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
MAXYGEN INC
www.maxygen.com
Industry Group Code: 541710 Ranks within this company's industry group: Sales:12 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:11
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Research & Development-Molecular Evolution DNA Sequences
Maxygen is a leading supplier of directed evolution technology for optimization of genes and their use in the development of products in protein pharmaceuticals, vaccines, agriculture and chemicals. The company’s proprietary technologies combine advanced molecular biology techniques with those of classical breeding to develop protein pharmaceuticals, preventative and therapeutic vaccines, chemicals and agriculture. Components include DNAShuffling, a proprietary process for recombining genes into a library of novel DNA sequences, and MaxyScan, a series of screening capabilities for the identification of desired properties from the library. Maxygen believes its technology provides distinctive advantages over traditional biotechnology by shortening time required to generate lead product candidates, lowering costs associated with research and expanding the potential for discovery. The firm is looking to evaluate opportunities in other fields, including antibody engineering, nutraceuticals, natural products, gene therapy and liquid fuels. The firm has alliances with companies that are market leaders in their respective industries, including Lundbeck, the International AIDS Vaccine Initiative (IAVI), Novozymes, DuPont, Chevron, Pfizer, Syngenta and Hercules. Maxygen is focused on developing products for a number of applications, including the treatment of multiple forms of cancer, infectious diseased such as HIV and hepatitis, allergies and antoimmune diseases. Codexis, Inc., the company’s chemical sector, is focused on improving existing chemical processes and creating novel processes for the manufacturing of specialty and fine chemical products. The company believes its MolecularBreeding directed evolutions technologies have the potential to provide a significant number of high-value chiral intermediates, bulk actives and natural products. Maxygen benefits include employee service awards, concierge service, credit union, annual Costco memberships and tuition reimbursment. The company pays 75% of employee mass transit costs as well as provides on-site bike lockers.
BRANDS/DIVISIONS/AFFILIATES: MolecularBreeding DNAShuffling MaxyScan Codexis, Inc. Verdia
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Russell J. Howard, CEO Simba Gill, Pres. Lawrence Briscoe, CFO Howard A. Simon, VP-Human Resources Paul Spence, VP-Research and Dev. Michael Rabson, General Counsel Elliot Goldstein, VP-Clinical Dev. and Denmark Oper. John Bedbrook, Pres/CEO, Verdia Alan Shaw, Pres/CEO, Codexis Isaac Stein, Chmn.
Phone: 650-298-5300 Fax: 650-364-2715 Toll-Free: Address: 200 Penobscot Dr., Redwood City, CA 94063 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $41,800 (12 months) 2002 Profits: $-33,900 (12 months) Stock Ticker: MAXY 2001 Sales: $30,500 2001 Profits: $-45,000 Employees: 280 2000 Sales: $24,500 2000 Profits: $-59,600 Fiscal Year Ends: 12/31 1999 Sales: $14,000 1999 Profits: $-11,300 1998 Sales: $2,700 1998 Profits: $-8,800
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: MolecularBreeding technology.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $396,550 Second Exec. Salary: $339,900
Bonus: $59,483 Bonus: $50,985
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
MAZDA MOTOR CORPORATION
www.mazda.com
Industry Group Code: 336111 Ranks within this company's industry group: Sales:14 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Profits:14
Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Automobiles, Manufacturing
Mazda Motor Corp. is the number-five manufacturer of automobiles in Japan, following such competitors as Toyota, Honda and Nissan. The company produces cars, trucks, minivans and commercial vehicles. Models sold in the United States include the Miata and RX-7 sports cars; B-series pick-up trucks; Millennia, Protégé and 626 sedans; and the MPV minivan. Mazda is also developing the ASV (Advanced Safety Vehicle), a concept car with safety features that include a collision-avoidance system to detect the presence of oncoming cars and pedestrians. The firm operates approximately 20 manufacturing plants located around the world, including two in Japan. Ford Motor Company owns about one-third of the firm's stock. Recently, the company introduced its new Washu concept vehicle, a next-generation design that combines sports car and family car features. Mazda also recently debuted its new RX-8 model. Mazda employees receive comprehensive medical, dental, vision and life insurance, educational assistance and access to new and used vehicle purchase, parts purchase and rental car programs. Mazda also offers a casual attire policy.
BRANDS/DIVISIONS/AFFILIATES: Miata Millenia 626 RX-7 MPV Protégé Mazda North American Operations Ford Motor Co.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Lewis Booth, CEO Robert Shanks, Sr. Managing Dir./CFO James O'Sullivan, Pres./CEO Mazda North America Kazuhide Watanabe, Chmn.
Phone: 81-82-282-1111 Fax: 81-82-287-5190 Toll-Free: Address: 3-1 Shinchi, Fuchu-cho, Aki-gun, Hiroshima, 730-8670 Japan
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $15,794,000 (12 months) 2002 Profits: $67,000 (12 months) Stock Ticker: Foreign 2001 Sales: $15,957,200 2001 Profits: $-1,228,900 Employees: 19,948 2000 Sales: $20,487,400 2000 Profits: $247,900 Fiscal Year Ends: 3/31 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Relationship with Ford.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $ Second Exec. Salary: $
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
MEDAREX INC
www.medarex.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:72 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:93
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Human Monoclonal Antibodies
Medarex is a leading biopharmaceutical company devoted to the production of human monoclonal antibody-based therapeutics to fight various diseases. The firm’s UltiMab Human Antibody Development System uses transgenic mice in which mouse-derived antibody gene expression is suppressed and effectively replaced with human antibody gene expression. With UltiMab, the company can create all types of antibodies that are fully human, with no mouse protein sequences embedded in the genetic code. Consequently, UltiMab antibodies are less likely to be rejected by a human patient. In addition, the antibodies are more likely to have favorable safety profiles and be eliminated less rapidly from the human body, potentially reducing the frequency and amount of dosing required to effect disease targets. The company has a variety of product candidates, developed by the company or through collaborations, that are currently in clinical testing stages, including MDX-33 for idiopathic thrombocytopenia purpura (ITP); MDX-010 for prostate cancer, malignant melanoma and melanoma vaccines; MDX-214 for cancer; IDM-1 for ovarian cancer; and HuMax-IL15 for rheumatoid arthritis. The firm is also developing antibodies to treat antiinflammatory diseases, lymphoma, breast and other cancers. The UltiMab technology is licensed to pharmaceutical and biotechnology companies that also pay royalties on commercial sales of their products. Over 41 pharmaceutical and biotechnology companies have partnered with Medarex to jointly research and development opportunities for new antibodies and to develop and commercialize products. Some of the most recent alliances have been formed with the Massachusetts Biologic Laboratories, concerning the development of a treatment for SARS, and the Amrad Corporation, concerning the research and development of fully human therapeutic antibodies against interleukin-13 receptor alpha. The company owns a major interest in Genmab, a Danish biotechnology company.
BRANDS/DIVISIONS/AFFILIATES: UltiMab Human Antibody Development System KM-Mouse HuMax-CD4 Trans-Phage Technology Genmab MDX-33 MDX-214 IDM-1
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Donald L. Drakeman, CEO Donald L. Drakeman, Pres. Christian S. Schade, Exec. VP-Finance Nancy Dawley, Human Resources Nils Lonberg, Sr. VP-Science W. Bradford Middlekauff, Corp. Sec. W. Bradford Middlekauff, General Counsel Christian S. Schade, Exec. VP-Admin. Ronald A. Pepin, VP-Bus. Dev. Geoffrey M. Nichol, Sr. VP-Product Dev. Irwin Lerner, Chmn.
Phone: 609-430-2880 Fax: 609-430-2850 Toll-Free: Address: 707 State Rd., Ste. 206, Princeton, NJ 08540-1437 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $39,500 (12 months) 2002 Profits: $-157,500 (12 months) Stock Ticker: MEDX 2001 Sales: $42,300 2001 Profits: $-2,700 Employees: 431 2000 Sales: $22,500 2000 Profits: $3,300 Fiscal Year Ends: 12/31 1999 Sales: $9,900 1999 Profits: $-17,000 1998 Sales: $6,800 1998 Profits: $-22,500
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: UltiMab mouse technology.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $641,538 Second Exec. Salary: $380,077
Bonus: $200,000 Bonus: $120,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
MEDICIS PHARMACEUTICAL CORP
www.medicis.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:43 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:29
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Dermatological Drugs-Pediatric
Medicis Pharmaceutical Corp. is a leading developer and provider of specialty pharmaceuticals for the treatment of various dermatological, pediatric and podiatric conditions. The company markets a wide range of prescription products, which include DYNACIN and TRIAZ for acne, LUSTRA for skin dyschromia, OVIDE for head lice, NOVCACET for acne rosacea, LOPROX for seborrheic dermatitis and LIDEX and SYNALAR for inflammatory and hyperproliferative skin diseases. The firm’s primary nonprescription product is its ESOTERICA line of topical creams for minor skin discoloration conditions such as age spots, uneven skin tones, dark patches, blotches and freckles. Medicis also sells PLEXION, a prescription cleanser for treating acne rosacea. In addition, Medicis operates SunAndSkin.com, a web site devoted to promoting skin care awareness and providing information about the effects of the sun on the skin. The firm’s Ascent Pediatrics subsidiary develops child-appropriate doses of existing prescription drugs. The company’s customers are made up of some of the leading wholesale pharmaceutical distributors including Cardinal Health, Inc., MeKesson Corporation, Quality King Distributors and AmerisourceBergen Corporation. Medicis recently closed the acquisition of all outstanding shares of HA North American Sales AB from the Q-Med Group. HA holds a license for the exclusive U.S. and Canadian rights to market, distribute and commercialize the dermal filler product lines RESTYLANE and PERLANE Fine.
BRANDS/DIVISIONS/AFFILIATES: ESOTERICA PLEXION SunAndSkin.com Ascent Pediatrics DYNACIN HA North American Sales AB RESTYLANE PERLANE
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jonah Shacknai, CEO Mark A. Prygocki, CFO Richard J. Havens, Sr. VP-Sales and Mktg. Adriane Young, Dir.-Human Resources Mitchell S. Wortzman, Sr. VP-Research and Dev. Joseph P. Cooper, Sr. VP-Mfg. and Distribution Mark A. Prygocki, Corp. Sec. Jin Sun Kim, General Counsel Joseph P. Cooper, Exec. VP-Bus. Dev. Libby Retherford, Dir.-Corp. Comm. Mark A. Prygocki, Treas. Jonah Shacknai, Chmn.
Phone: 602-808-8800 Fax: 602-808-0822 Toll-Free: Address: 8125 N. Hayden Rd., Scottsdale, AZ 85258 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $212,800 (12 months) 2002 Profits: $50,000 (12 months) Stock Ticker: MRX 2001 Sales: $167,800 2001 Profits: $40,400 Employees: 279 2000 Sales: $139,100 2000 Profits: $43,000 Fiscal Year Ends: 6/30 1999 Sales: $116,900 1999 Profits: $41,400 1998 Sales: $77,600 1998 Profits: $-12,400
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Focus on dermatological drugs.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Top Exec. Salary: $687,000 Second Exec. Salary: $285,000
Bonus: $600,000 Bonus: $338,000
LOCATIONS: ("Y" = Yes) West:
Southwest: Y
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
MEDIMMUNE INC
www.medimmune.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:28 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:101
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Infectious Disease Drugs for Transplant Patients
MedImmune is a biotechnology company engaged in the development and production of pharmaceuticals for infectious diseases and transplantation operations. The company’s Synagis drug (for the treatment of respiratory syncytial virus) is the first monoclonal antibody approved for an infectious disease and has become a primary pediatric product for the prevention of RSV, a major cause of viral pneumonia and brochiolitis in infants and children. In addition, the firm markets CytoGam, a treatment for the cytomegalovirus disease arising from organ transplant complications. Other products include Ethyol for the reduction of toxicities from cancer chemotherapy and radiotherapy, NeuTrexin for the treatment of pneumonia in AIDS patients and Hexalen for the treatment of advanced forms of ovarian cancer. MedImmune has eleven other products in various stages of clinical testing. The company’s subsidiary, MedImmune Oncology, has offices in the U.S. and the Netherlands and primarily conducts the clinical development activities for cancer-focused products. The firm is currently involved in a research collaboration and worldwide exclusive licensing agreement with Genaera Corporation, a biopharmaceutical company focused on developing medicines from genomics and natural products for the treatment of serious diseases. The two companies work together on developing and commercializing antibodies that prevent symptoms of asthma and other respiratory diseases. The company recently announced that, driven by strong sales of the firm’s flagship Synagis drug, revenues from the first quarter 2003 have reached a record high at $436 million, up 32% from the first quarter of 2002. Medimmune offers employees health, dental and vision coverage, education assistance and credit union membership.
BRANDS/DIVISIONS/AFFILIATES: CytoGam RespiGam Synagis U.S. Bioscience, Inc. MedImmune Oncology, Inc. Ethyol NeuTrexin Hexalen
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. David M. Mott, CEO Melvin D. Booth, COO Melvin D. Booth, Pres. Gregory S. Patrick, CFO Armando Anido, Sr. VP-Mktg. & Sales Pamela J. Lupien, Human Resources James F. Young, Pres.-Research and Dev. Franklin H. Top, Jr., Exec. VP/Medical Dir. Gail Folena-Wasserman, Sr. VP-Corp. Dev. Edward M. Connor, Sr. VP-Clinical Dev. Wayne T. Hockmeyer, Chmn.
Phone: 301-417-0770 Fax: 301-527-4200 Toll-Free: Address: 35 W. Watkins Mill Rd., Gaithersburg, MD 20878 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $847,700 (12 months) 2002 Profits: $-1,098,000 (12 months) Stock Ticker: MEDI 2001 Sales: $618,700 2001 Profits: $149,000 Employees: 1,605 2000 Sales: $540,500 2000 Profits: $111,200 Fiscal Year Ends: 12/31 1999 Sales: $383,400 1999 Profits: $93,400 1998 Sales: $227,200 1998 Profits: $47,200
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $1,000,000 Stock Purch. Plan: Y Second Exec. Salary: $833,333 ADVANTAGE: Makes the primary pediatric product for the prevention of RSV.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $800,000 Bonus: $1,200,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
MEDPOINTE INC
www.medpointeinc.com
Industry Group Code: 325411 Ranks within this company's industry group: Sales:2
Profits:
Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Personal Care Products Cough/Cold Treatments At-Home Pregnancy Tests
MedPointe, Inc., formerly Carter-Wallace, is a specialty pharmaceutical company that manufactures and sells a diversified line of health care products. The company operates via branded product acquisitions, joint ventures, co-marketing and co-promotion of current and new products, life cycle management, targeted promotions and licensing. The firm’s target customers are allergists, ENTs, pediatricians, primary care physicians, health care organizations, hospitals and wholesalers. Its prescription pharmaceutical products division, Wallace Pharmaceuticals, produces pediatric, respiratory, cough/cold and central nervous system therapies. The company’s primary product is Astelin, a nasal spray that treats both seasonal allergic rhinitis and nonallergic vasomotor rhinitis. The product, which promises 12 hours of symptom relief, is the only marketed second-generation antihistamine that has been approved by the U.S. FDA to treat these forms of rhinitis. MedPointe recently acquired all U.S. and Canadian rights to Optivar, a prescription-only treatment for itching of the eye associated with allergic conjunctivitis. The new product complements the company’s current flagship product. MedPointe sales representatives are rewarded with a payfor-performance compensation plan with no upper limit.
BRANDS/DIVISIONS/AFFILIATES: Astelin Optivar Wallace Pharmaceuticals Carlyle Group (The) Cypress Group (The) Ferrer Freeman & Company, LLC Frazier Healthcare Ventures Carter-Wallace
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Anthony H. Wild, CEO Paul S. Herendeen, Exec. VP/CFO David Fink, VP-Mktg. Richard N. Spivey, VP-Research and Dev. Anthony Vaccarellli, VP/CIO Beth P. Hecht, Sr. VP/Corp. Sec. Beth P. Hecht, General Counsel Paul R. Edick, Exec. VP-Oper. John Hawkins, Exec. VP-Corp. Dev. and External Affairs John Hawkins, Exec. VP-Investor Rel. Michael A. Tropiano, VP/Corp. Treas. James S. Burns, Exec. VP-Planning Willie H. Robinson, Corp. VP-Quality and Environmental Affairs Paul R. Edick, Sr. VP/Pres., Wallace Pharmaceuticals Anthony H. Wild, Chmn.
Phone: 732-564-2200 Fax: Toll-Free: Address: 265 Davidson Ave., Ste. 300, Somerset, NJ 088734120 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $200,000 (12 months) 2002 Profits: $ (12 months) Stock Ticker: Private 2001 Sales: $222,700 2001 Profits: $49,300 Employees: 600 2000 Sales: $747,700 2000 Profits: $43,300 Fiscal Year Ends: 3/31 1999 Sales: $668,900 1999 Profits: $28,200 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $1,039,500 Stock Purch. Plan: Second Exec. Salary: $1,054,650 ADVANTAGE: Diverse set of products/Numerous international product lines.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $1,350,000 Bonus: $1,039,500
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
MEDTOX SCIENTIFIC INC
www.medtox.com
Industry Group Code: 621511 Ranks within this company's industry group: Sales:5 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:2
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Services-Labs Substance Abuse Testing Services Forensic Analysis On-Site Occupational Testing Products
Medtox Scientific operates in two related market segments: forensic and clinical laboratory testing services to corporations, pharmaceutical companies and health care organizations (the laboratory division), and the manufacture and distribution of diagnostic drug screening devices (the diagnostics division). The company’s laboratory division services include forensic toxicology, clinical toxicology, clinical testing for the pharmaceutical industry and analysis of heavy and trace metals. The diagnostics division manufactures 15 FDA-approved drugscreening devices for use in corporate, corrections, rehab and clinical trial programs that can detect substances in humans, food, animals and the environment. The firm’s Ez-Screen and Ez-Quant tests are used to detect toxins that contaminate corn, wheat, rye, barley and other agricultural products consumed by humans. The diagnostic division provides a wide range of services, including therapeutic drug monitoring, emergency toxicology, occupational testing, forensic analysis and onsite drug screening tests. The company’s Profile-II and Verdict-II are used for detecting cannabinoids (THC), cocaine, opiates, amphetamines and phencyclidine (PCP) in human urine. The firm also performs gas chromatography/mass spectrometry on infants’ stools to test for the presence of various drugs that may have resulted from maternal drug abuse. Medtox owns Leadtech Corp., a clinical laboratory that primarily examines lead concentrations in the blood of pediatric patients. Medtox is currently directing its efforts on testing for biological agents and toxins as is evident with its collaboration with the Department of Defense, a partnership that is focusing on the development and manufacture of test kits for the detection of several biological agents and toxins, including anthrax.
BRANDS/DIVISIONS/AFFILIATES: EDITEK, Inc. Leadtech Corp. Profile Verdict Ez-Screen Ez-Quant MEDTOX Laboratories, Inc New Brighton Business Center, LLC
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Richard J. Braun, CEO Richard J. Braun, Pres. James Schoonover, Chief Mktg. Officer Susan Puskas, VP-Human Resources Kevin J. Wiersma, COO-Laboratory Div. B. Mitchell Owens, COO-Diagnostics Div. Jennifer Collins, VP/Laboratory Dir. Susan Puskas, VP-Quality Assurance and Regulatory Affairs Richard J. Braun, Chmn.
Phone: 651-636-7466 Fax: 651-636-5351 Toll-Free: 800-832-3244 Address: 402 W. County Rd. D, St. Paul, MN 55112 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $52,000 (12 months) 2002 Profits: $11,700 (12 months) Stock Ticker: TOX 2001 Sales: $49,100 2001 Profits: $2,500 Employees: 473 2000 Sales: $42,900 2000 Profits: $-2,600 Fiscal Year Ends: 12/31 1999 Sales: $35,000 1999 Profits: $1,400 1998 Sales: $29,600 1998 Profits: $-2,300
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $265,000 Bonus: $15,000 Stock Purch. Plan: Second Exec. Salary: $150,000 Bonus: $8,000 ADVANTAGE: Able to offer a complete line of testing and analysis services, including on-site services for major employers.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
MEDTRONIC AVE INC
www.medtronicave.com
Industry Group Code: 332210 Ranks within this company's industry group: Sales: Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Medical Instruments Coronary Products
Medtronic AVE, Inc., a subsidiary of Medtronic, is a medical device company that manufactures technologies for use in coronary, peripheral and neurovascular conditions. The company develops coronary products that include stents, balloon catheters, guide catheters, diagnostic catheters and guidewires. Medtronic AVE’s peripherial technologies feature the Bridge Extra Support Renal Stent System, for use in patients with atherosclerotic disease of the renal arterties; the Bridge SE Biliary Stent System, a device indicated for palliation of malignant neoplasms in the biliary tree; and the Col-Sur P.A.D., a noninvasive approach to hemostasis. Neurovascular products include the company’s Solstice System and the QS-10 Guidewire. The company also manufactures the GuardWire Plus Temporary Occlusion and Aspiration System, the first distal protection system available in the U.S. for use in diseased saphenous vein grafts. Medtronic AVE’s AneuRx Stent Graft was developed for the treatment of abdominal aortic aneurysm. The company offers its employees a comprehensive benefits package including elder care assistance, adoption assistance benefits, rooms designated for nursing mothers and tuition reimbursement.
BRANDS/DIVISIONS/AFFILIATES: Bridge Solstice Col-Sur P.A.D. AneuRx QS-10 Guidewire GuardWire Plus
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. William A. Hawkins, Pres. Katie M. Szyman, VP-Finance/CFO Kim McEachron, VP-Human Resources Tony Semedo, VP-Research and Dev. Katie M. Szyman, VP-IT Mark Schlossberg, General Counsel Mark Schlossberg, VP-Bus. Dev. Chris Hadland, VP-Quality Assurance Sara Toyloy, VP-Regulatory Affairs Alan Milinazzo, VP-Coronary and Peripheral Bus. Pat Mackin, VP-Endovascular Bus.
Phone: 707-525-0111 Fax: Toll-Free: Address: 3576 Unocal Pl., Santa Rosa, CA 95403 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $ 2001 Profits: $ Employees: 1,265 2000 Sales: $ 2000 Profits: $ Fiscal Year Ends: 4/30 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Focus on coranary technologies
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
Top Exec. Salary: $ Second Exec. Salary: $
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
MEDTRONIC INC
www.medtronic.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:2 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Equipment-Defibrillators and Pacing Products Coronary Angioplasty Balloons Implantable Drug Delivery Systems Implantable Brain Stimulation Devices
Medtronic is a world leader in medical technology that has pioneered device-based therapies that restore and extend health and alleviate pain. The company’s primary products include those for bradycardia pacing, tachyarrhythmia management, atrial fibrillation management, heart failure management, coronary and peripheral vascular disease, heart valve replacement, extracorporeal cardiac support, minimally invasive cardiac surgery, spinal and neurosurgery and neurodegenerative disorders. Medtronic acquired Sofamor Danek Group, Inc., a developer, manufacturer and marketer of devices, instruments, computer-assisted visualization products and biomaterials used in the treatment of spinal and cranial disorders. Another subsidiary, Arterial Vascular Engineering, Inc., designs, manufactures and markets minimally invasive solutions for the treatment of coronary and peripheral vascular disease. Subsidiary Vitatron is a global specialist in cardiac rhythm disorders, and is the only Dutch company to develop and produce pacing therapies. The firm works closely with the medical and scientific community in furthering the development of pacemakers. Medtronic recently announced the first U.S. implant of the InSync III Marquis implantable cardioverterdefibrillator system, as well as the start of a new clinical trial of the company’s newest generation cardiac resynchronization therapy device for high-risk heart failure patients. Concurrently, the firm announced the start of a clinical trial for the Medtronic Attain Bipolar, over-the-wire left-heart lead. In other news, the firm began distributing a HIPAA Privacy Regulation version of the Medtronic Paceart System that incorporates several new features designed to empower clinics to protect the privacy of patient data. The information management system allows clinicians to efficiently organize historical data about a patient’s heart rhythm. Medtronic provides its workforce with benefits that include free health screenings. The company also offers awards and bonuses. In addition, the firm provides 100% tuition reimbursement and has no formal dress code.
BRANDS/DIVISIONS/AFFILIATES: Medtronic Freestyle InStent, Inc. AneuRX, Inc. Paceart System InSync III Marquis AVECOR Cardiovascular, Inc. Cardiac Rhythm Management Arterial Vascular Engineering, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Arthur D. Collins, Jr., CEO Arthur D. Collins, Jr., COO Arthur D. Collins, Jr., Pres. Robert Ryan, CFO Janet Fiola, Sr. VP-Human Resources Stephen N. Oeserle, Sr. VP-Science and Tech. Jeff Balagna, CIO David Scott, Corp. Sec. David Scott, General Counsel Stephen H. Mahle, Sr. VP/Pres.-Cardiac Rhythm Management Robert Guezuraga, Sr. VP-Cardiac Surgery William A. Hawkins, Sr. VP-Vascular Scott R. Ward, Sr. VP-Neurological and Diabetes Arthur D. Collins, Jr., Chmn.
Phone: 763-514-4000 Fax: 763-514-4879 Toll-Free: 800-328-2518 Address: 710 Medtronic Pkwy. NE, Minneapolis, MN 55432-5604 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $6,411,000 (12 months) 2002 Profits: $984,000 (12 months) Stock Ticker: MDT 2001 Sales: $5,551,800 2001 Profits: $1,046,000 Employees: 28,000 2000 Sales: $5,016,300 2000 Profits: $1,084,200 Fiscal Year Ends: 4/30 1999 Sales: $4,232,500 1999 Profits: $466,700 1998 Sales: $3,423,100 1998 Profits: $594,600
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $320,008 Bonus: $207,704 Stock Purch. Plan: Y Second Exec. Salary: $760,000 Bonus: $647,782 ADVANTAGE: World's leading company specializing in implantable therapies, such as pacemakers.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
MEMC ELECTRONIC MATERIALS INC Industry Group Code: 334413 Ranks within this company's industry group: Sales:16 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
www.memc.com Profits:9
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Silicon Wafers Manufacturer
MEMC Electronic Materials, Inc. is a leading supplier of silicon wafers to the semiconductor industry. Silicon wafers are the fundamental building block on which nearly all microelectric applications are made. The company primarily produces prime polished, epitaxial and monitor wafers. The firm’s prime polished wafers are manufactured with a sophisticated chemical-mechanical polishing process that removes surface defects and produces extremely flat, mirror-like surfaces. Prime polished wafers are used in a broad range of advanced integrated circuit applications. Epitaxial wafers consist of a thin, single-crystal silicon layer grown on the polished surface of a silicon wafer substrate. The epi layer is designed to have different compositional and electrical properties than the underlying wafer. This compositional change can be used to improve isolation between circuit elements fabricated on the epi wafer. The firm’s monitor wafers allow customers to test their semiconductor fabrication lines and processes. Although monitor wafers are essentially identical to prime polished wafers with respect to cleanliness, other specifications are generally less rigorous. This produces a cost-effective solution for non-critical wafer applications. The company markets its products to semiconductor manufacturers such as Samsung Electronics and STMicroelectronics.
BRANDS/DIVISIONS/AFFILIATES: Advanta Optia Aegis
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Nabeel Gareeb, CEO Nabeel Gareeb, Pres. James M. Stolze, CFO Thomas P. Stiffler, Sr. VP-Human Resources Chandrasekhar Sadasivam, Sr. VP-Research and Dev. David L. Fleisher, Corp. Sec. David L. Fleisher, General Counsel Jonathon P. Jansky, Sr. VP-Oper. Janine Orf, Dir.-Investor Rel. John W. Marren, Chmn.
Phone: 636-474-5000 Fax: 636-474-5158 Toll-Free: Address: 501 Pearl Dr., St. Peters, MO 63376 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $687,200 (12 months) 2002 Profits: $-5,100 (12 months) Stock Ticker: WFR 2001 Sales: $617,900 2001 Profits: $-518,400 Employees: 4,700 2000 Sales: $871,600 2000 Profits: $-43,400 Fiscal Year Ends: 12/31 1999 Sales: $693,600 1999 Profits: $-151,500 1998 Sales: $758,900 1998 Profits: $-316,300
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $402,275 Stock Purch. Plan: Second Exec. Salary: $258,583 ADVANTAGE: Several unique, patented technologies.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $677,000 Bonus: $255,200
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
MENTOR GRAPHICS CORP
www.mentor.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:29 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:21
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Computer Software-Component Design, Simulation & Testing Consulting Services
Mentor Graphics Corp. is a technology leader in electronic design automation (EDA), providing software and hardware design tools that enable companies to send better electronic products to market faster and more costeffectively. The firm manufactures, markets and supports EDA products and provides related services which are used by engineers to design, analyze, simulate, model, implement and verify the components of electronic systems. These products are marketed worldwide, primarily to large companies in the communications, computer, consumer electronics, semiconductor, aerospace, networking, multimedia and transportation industries. Products are used in the design of 3-D graphic boards, digital audio broadcast radios, smart cards, Bluetooth technology and other applications. Mentor's system design products support the printed circuit design process from schematic entry through physical layout of the printed circuit board. These include the Board Station, Expedition, ICX, DataFusion and AutoActive series. Field programmable gate array (FPGA) products for design creation, documentation and verification include ModelSlim, Precision Synthesis, Advantage and LeonardoSpectrum. Physical verification and analysis products include the Calibre line, MachTA, Eldo and ADVance MS. System-on-chip verification and test products include XRAY embedded software products, Celaro accelerated verification hardware products and the intellectual property of the firm's Inventra division. In recent news, Mentor granted a multi-year intellectual property access agreement to AMI Semiconductor, a leader in the design and manufacture of applicationspecific integrated circuits (ASICs). Under this agreement, AMI will provide its customers with Mentor's Inventra IP solutions for a range of applications. Mentor offers its employees benefits including adoption assistance, health care spending accounts and medical, dental and life insurance. The firm also offers an employee assistance program.
BRANDS/DIVISIONS/AFFILIATES: Inventra DataFusion AutoActive Board Station Expedition Advantage ModelSlim LeonardoSpectrum
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Walden C. Rhines, CEO Gregory K. Hinckley, Pres. Brian Derrick, VP-Corp. Mktg. Gary Rebello, VP-Human Resources Henry Potts, VP/Mgr.-Systems Design Rich Decker, VP-IT Tony Adrian, VP/Corp. Controller Dean Freed, VP/General Counsel Dennis Weldon, Dir.-Corp. Bus. Dev. Dennis Weldon, Treas. L. Don Maulsby, Sr. VP-World Trade Jue-Hsien Cherm, VP/Mgr.-Deep Submicron Div. Bill Martin, VP-Consulting Div. Don Cantow, VP-Global Accounts Hans Windele, VP-Europe
Phone: 503-685-7000 Fax: 503-685-7704 Toll-Free: 800-592-2210 Address: 8005 SW Boeckman Rd., Wilsonville, OR 97070-7777 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $596,200 (12 months) 2002 Profits: $-14,300 (12 months) Stock Ticker: MENT 2001 Sales: $600,400 2001 Profits: $31,100 Employees: 3,500 2000 Sales: $598,800 2000 Profits: $55,000 Fiscal Year Ends: 12/31 1999 Sales: $511,134 1999 Profits: $2,234 1998 Sales: $490,393 1998 Profits: $- 519
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $539,900 Stock Purch. Plan: Y Second Exec. Salary: $414,900 ADVANTAGE: A pioneer in electronic design automation.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $158,500 Bonus: $112,900
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
MERCK & CO INC
www.merck.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:2
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Manufacturer Human Health Products
Merck & Co., Inc. is a leading global research-driven pharmaceutical company that manufactures a broad range of products and provides pharmaceutical benefit services through subsidiary Merck-Medco. The company also operates the Merck Institute for Science Education, a program that encourages elementary students to be enthusiastic about science. Merck’s products are sold in approximately 150 countries. The products include therapeutic and preventative agents generally sold by prescription and medications used to control and alleviate disease in livestock, small animals and poultry. The company develops drugs that treat ailments associated with American eating habits, including high cholesterol, hypertension and heart failure. These products generate approximately one-third of the company’s sales. Merck’s top-selling cholesterol drugs are Zocor and Mevacor, and its primary hypertension drugs are Vasotec and Prinivil. Singulair is offered as both seasonal allergy and asthma medicine, both of which are offered in tablets that are taken once a day. The seasonal allergy Singulair is a leukotriene blocker, and the asthma Singular is a nonsteroid that controls asthma. The firm ascribes its current financial success to five key medicines: Vioxx, a once-aday medicine for both osteoarthritis and acute pain; Zocor, a prescription drug which controls cholesterol levels; Cozaar and Hyzaar, high blood pressure medicines; and Fosamax, which prevents postmenopausal osteoporosis. Every month, Merck’s web site offers quizzes and information, called InfoParks, on different diseases, such as HIV, heart disease and hepatitis. The company announced plans to spin-off Medco Health Solutions during 2003. Merck offers its employees on-site fitness facilities with personal trainers, day-care and summer camp programs and extensive training. The company also offers on-site auto maintenance and video rentals for employees at its headquarters location. Additionally, employees may receive scholarships, tuition reimbursement and financial planning assistance. Notably, over 50% of managers and supervisors are female.
BRANDS/DIVISIONS/AFFILIATES: Merck-Medco Managed Care, L.L.C. Medco Health Solutions Vioxx Zocor Cozaar Hyzaar Fosamax Singulair
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Raymond V. Gilmartin, CEO Raymond V. Gilmartin, Pres. Judy C. Lewent, Sr. VP/CFO/Pres., Human Health-Asia Marcia J. Avedon, Sr. VP-Human Resources Peter S. Kim, Pres., Merck Research Laboratories Richard C. Henriques, Jr., VP/Controller Robert H. Boisclair, Pres., Merck Mfg. Div. Kenneth C. Frazier, Sr. VP/General Counsel Linda M. Distlerath, VP-Public Affairs Bradley T. Sheares, Pres., U.S. Human Health Margaret G. McGlynn, Pres., U.S. Human Health Adel A.F. Mahmoud, Pres., Merck Vaccine Div. David W. Anstice, Pres., Human Health Raymond V. Gilmartin, Chmn. Per Wold-Olsen, Pres., Human Health-Europe, Middle East, Africa
Phone: 908-423-1000 Fax: 908-735-1253 Toll-Free: Address: One Merck Dr., Whitehouse Station, NJ 08889-0100 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $51,790,000 (12 months) 2002 Profits: $7,150,000 (12 months) Stock Ticker: MRK 2001 Sales: $47,716,000 2001 Profits: $7,282,000 Employees: 62,000 2000 Sales: $40,363,200 2000 Profits: $6,821,700 Fiscal Year Ends: 12/31 1999 Sales: $32,714,000 1999 Profits: $5,890,500 1998 Sales: $26,898,200 1998 Profits: $5,248,200
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $1,483,334 Stock Purch. Plan: Second Exec. Salary: $854,170 ADVANTAGE: World class drug firm with massive research capabilities.
OTHER THOUGHTS: Apparent Women Officers or Directors: 4 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $1,500,000 Bonus: $800,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
MERIDIAN BIOSCIENCE INC
www.meridianbioscience.com
Industry Group Code: 325413 Ranks within this company's industry group: Sales:3 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:3
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Supplies-Diagnosis Kits Contract Manufacturing
Meridian Biosciences, Inc. is a fully integrated life sciences company that develops, manufactures and markets a broad range of disposable diagnostic test kits and related diagnostic products used for the rapid diagnosis of infectious diseases such as pneumonia, valley fever, Lyme disease, stomach ulcers, urinary tract infection, chlamydia and herpes. The company also offers biopharmaceutical capabilities and serves as an original equipment manufacturer for other diagnostic companies. Meridian’s diagnostic products provide accuracy, simplicity and speed and aid in the early diagnosis and treatment of common medical conditions such as gastrointestinal, viral and respiratory infections. All of the company’s tests focus on in vitro immunodiagnostic testing. Meridian's diagnostic product development strategy is to combine existing technologies with new product designs, both through internal or joint product development and through product acquisitions, licensing and supply arrangements. Internal and joint product development activities focus on the development or enhancement of immunodiagnostic technologies and applications to simplify, accelerate or increase the accuracy of diagnoses of certain infectious diseases. Meridian’s target markets are hospital networks, clinical and hospital laboratories, physicians' offices, nursing homes, health maintenance organizations, veterinary laboratories and water treatment facilities. Recently, the company expanded its operations to include a new life science production facility located at its subsidiary, Viral Antigens, Inc. (VAI), which will optimize manufacturing processes and produce specific insect cellderived recombinant protein. Meridian also announced the launch of the life science business unit, which will better facilitate the research, development and manufacture of biopharmaceuticals and clinical diagnostics.
BRANDS/DIVISIONS/AFFILIATES: Viral Antigens, Inc. MonoSpot ImmunoCard STAT Premier HpSA Test
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. William J. Motto, CEO John A. Kraeutler, COO John A. Kraeutler, Pres. Melissa A. Lueke, VP/CFO Richard L. Eberly, VP-Sales and Mktg. Marlene Cook, Dir.-Human Resources Kenneth J. Kozak, VP-Research and Dev. Melissa A. Lueke, Corp. Sec. Lawrence J. Baldini, VP-Oper. Brenda Hughes, Head-Investor Rel. Antonio A. Interno, Sr. VP/Managing Dir.-MDE Susan D. Rolih, VP-Regulatory Affairs and Quality Assurance William J. Motto, Chmn.
Phone: 513-271-3700 Fax: 513-271-3762 Toll-Free: Address: 3471 River Hills Dr., Cincinnati, OH 45244-3091 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $59,100 (12 months) 2002 Profits: $5,000 (12 months) Stock Ticker: VIVO 2001 Sales: $56,500 2001 Profits: $-10,300 Employees: 334 2000 Sales: $57,096 2000 Profits: $7,111 Fiscal Year Ends: 9/30 1999 Sales: $53,927 1999 Profits: $2,073 1998 Sales: $33,200 1998 Profits: $5,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $387,700 Stock Purch. Plan: Y Second Exec. Salary: $280,000 ADVANTAGE: Leading supplier of parasitology diagnostics.
OTHER THOUGHTS: Apparent Women Officers or Directors: 4 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $104,344 Bonus: $75,544
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
MGI PHARMA INC
www.mgipharma.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:84 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:74
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Oncology and Rheumatology
MGI PHARMA is a pharmaceutical company concentrating on the acquisition, development and marketing of drugs for the treatment of cancer and rheumatology disorders. The company’s Salagen tablets, which account for almost all of the company's sales, are a treatment for radiationinduced xerostomia (chronic dry mouth) in patients of head and neck cancer and of Sjogren’s syndrome. Sjogren’s syndrome is an automimmune disease that damages moisture-producing glands. In addition, the firm manufactures Azulfidine EN-tabs and Riadura for rheumatoid arthritis patients, Luxiq foam for corticosteroidresponsive scalp dermatoses in psoriatic arthritis patients and Didronel I.V. Infusion for hypercalcemia of malignancy in various cancer patients. MGI PHARMA has formed several alliances aimed at research and marketing opportunities. Recently, the company was named to Deloitte & Touche's prestigious Fast 50 program, which is a ranking of the 50 fastest-growing technology companies in Minnesota. In other news, the firm and Helsinn Healthcare SA, a privately owned Swiss pharmaceutical group, announced that the FDA accepted their new drug application to market Palonosetron. The drug is used in the prevention of chemotherapy-induced nausea and vomiting. The firm provides employees with a continuing education program, credit union membership, discount off-site airport parking and discounted tickets for entertainment and cultural activities.
BRANDS/DIVISIONS/AFFILIATES: Didronel I.V. Infusion Azulfidine EN-tabs Ridaura Palonosetron Salagen Irofulven MethylGene Luxiq
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Charles N. Blitzer, CEO Leon O. Moulder, Jr., COO Leon O. Moulder, Jr., Pres. William C. Brown, CFO Alan R. Caplan, VP-Sales Edgar F. Timberlake, VP-Human Resources John R. MacDonald, Sr. VP-Research and Dev. William C. Brown, Controller Michael T. Cullen, Jr., Chief Medical Officer Robert M. Johnson, VP-Pharmaceutical Mfg. Robert M. Johnson, VP-Int'l Oper. Leon O. Moulder, Exec. VP John R. MacDonald, Dir.-Pharmacology and Toxicology
Phone: 952-346-4700 Fax: 952-346-4800 Toll-Free: Address: 5775 W. Old Shakopee Rd., Ste. 100, Bloomington, MN 55437 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $28,200 (12 months) 2002 Profits: $-36,100 (12 months) Stock Ticker: MOGN 2001 Sales: $33,000 2001 Profits: $-34,800 Employees: 161 2000 Sales: $25,200 2000 Profits: $-19,500 Fiscal Year Ends: 12/31 1999 Sales: $24,700 1999 Profits: $4,700 1998 Sales: $16,800 1998 Profits: $ 400
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Proprietary Salagen product.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $370,000 Second Exec. Salary: $236,775
Bonus: $149,850 Bonus: $65,350
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
MICHAEL BAKER CORPORATION
www.mbakercorp.com
Industry Group Code: 230000 Ranks within this company's industry group: Sales:2 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Y Y Y Y
Profits:2
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Y Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Engineering and Construction Consulting Services
Michael Baker Corporation provides engineering and energy expertise for public and private sector clients worldwide. The firm's engineering segment provides a variety of design and related consulting services. Services include design-build, construction management, planning, program management, surveying, mapping, geographic information systems, architectural and interior design, construction inspection, constructability reviews, software development, site assessment and restoration, strategic regulatory analysis, regulatory compliance, and advanced management systems. The engineering segment has designed a wide range of projects, such as highways, bridges, airports, busways, corporate headquarters, data centers, correctional facilities and educational facilities. This segment has also provided services in the water/wastewater, pipeline, emergency and consequence management, resource management and telecommunications markets. The energy segment specializes in providing a full range of total asset management services for operating energy production facilities worldwide. The segment's comprehensive services range from complete outsourcing solutions to specific services such as training, personnel recruitment, pre-operations engineering, maintenance management systems, field operations and maintenance, mechanical equipment maintenance, procurement and supply chain management. The energy segment primarily serves both major and smaller independent oil and gas producing companies. An innovative service delivery method employed by the segment is OPCO, a sophisticated operating model. In recent news, the company opened an office in the Port of Spain and is now providing services to the Trinidad and Tobago markets. Recent clients that have implemented the company’s services include Apache Corporation, the Mississippi Department of Transportation, BP America, Inc. and the Connecticut Department of Transportation. The company offers its employees free financial investment assistance, a savings bond purchase plan and 100% tuition reimbursement.
BRANDS/DIVISIONS/AFFILIATES: OPCO
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Donald P. Fusilli, Jr., CEO Donald P. Fusilli, Jr., Pres. William P. Mooney, Exec. VP/CFO H. James McKnight, Exec. VP/Corp. Sec. H. James McKnight, General Counsel James B. Richards, Jr., Exec. VP John D. Whiteford, Exec. VP Richard L. Shaw, Chmn.
Phone: 412-269-6300 Fax: 412-375-3977 Toll-Free: 800-642-2537 Address: Airside Business Park, 100 Airside Dr., Moon Township, PA 15108 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $405,300 (12 months) 2002 Profits: $9,600 (12 months) Stock Ticker: BKR 2001 Sales: $ 2001 Profits: $ Employees: 4,179 2000 Sales: $ 2000 Profits: $ Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $400,005 Stock Purch. Plan: Second Exec. Salary: $240,998 ADVANTAGE: Anility to serve a wide variety of clients on a global basis.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $259,503 Bonus: $25,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
MICROCHIP TECHNOLOGY INC
www.microchip.com
Industry Group Code: 334413 Ranks within this company's industry group: Sales:17 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:4
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Semiconductors-Specialized Microcontrollers
Microchip Technology develops and manufactures specialized semiconductor products that are used for embedded control applications. The firm provides highly cost-effective embedded control products that offer the advantages of small size, low voltage/power operation and ease of development, enabling timely and cost-effective product integration by its customers. The company’s product portfolio comprises field-programmable RISCbased microcontrollers that serve 8- and 16-bit embedded control applications, and a broad spectrum of highperformance linear and mixed-signal, power management and thermal management devices. It also offers complementary microperipheral products, including interface devices, serial EEPROMS and its patented KEELOQ security devices. Wireless companies target the firm’s popular ASSP KEELOQ security products for use in applications including automotive remote keyless entry systems, immobilizer systems for vehicles and automatic garage and gate openers. The EEPROM products are used for non-volatile program and data storage in systems where such data must be either modified frequently or retained for long periods. Microchip recently signed a definitive agreement to acquire PowerSmart, Inc., a privately held fabless semiconductor company that develops and sells high-accuracy field-programmable integrated circuits and battery sensors. Microchip offers its employees tuition reimbursement, a cash bonus plan and a health club reimbursement account.
BRANDS/DIVISIONS/AFFILIATES: KEELOQ PIC Smart Serials EEPROM PowerSmart, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Steve Sanghi, CEO Steve Sanghi, Pres. Gordon W. Parnell, VP/CFO Mitchell R. Little, VP-Worldwide Sales David S. Lambert, VP-Fab Oper. Richard J. Simoncic, VP-Analog and Interface Products Div. Steve Sanghi, Chmn.
Phone: 602-786-7200 Fax: 602-899-9210 Toll-Free: Address: 2355 W. Chandler Blvd., Chandler, AZ 85224-6199 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $571,300 (12 months) 2002 Profits: $94,800 (12 months) Stock Ticker: MCHP 2001 Sales: $715,700 2001 Profits: $142,800 Employees: 3,041 2000 Sales: $495,729 2000 Profits: $102,044 Fiscal Year Ends: 3/31 1999 Sales: $406,460 1999 Profits: $50,088 1998 Sales: $396,894 1998 Profits: $64,368
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $426,839 Stock Purch. Plan: Y Second Exec. Salary: $213,582 ADVANTAGE: Worldwide customer base/Continued R&D.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $2,134 Bonus: $110,613
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
MICRON TECHNOLOGY INC
www.micron.com
Industry Group Code: 334413 Ranks within this company's industry group: Sales:4 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:20
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Components-Semiconductor Memory PCs and Peripherals Servers
Micron Technology, Inc. and its subsidiaries principally design, develop, manufacture and market semiconductor memory products (DRAMs and SDRAMs) and personal computer systems. DRAMs (high-density, low-cost-perbit, random access memory) are the company's primary semiconductor memory product. DRAMs are the most widely used semiconductor memory component in PC systems. Synchronous DRAMs (SDRAMs) are memory components that operate faster than standard DRAMs, due in part to the addition of a clock input that synchronizes all operations and allows PC systems to transfer data at faster rates, allowing subsystems to maintain pace with high-speed CPUs and graphics engines. Other semiconductor memory products produced by the company include static random access memory (SRAM) and flash memory devices. Flash devices are used in digital cellular phones, networking applications, workstations, servers and PCs. The company's PC operations develop, market, manufacture, sell and support a wide range of desktop and notebook PC systems and network servers and sell, resell and support a variety of additional peripherals, software and services.
BRANDS/DIVISIONS/AFFILIATES: Micron Semiconductor, Inc. Micron Display Technology, Inc. Micron Electronics, Inc. Micron Investments, Inc. Micron Communications, Inc. Micron Construction, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Steven R. Appleton, CEO Steven R. Appleton, Pres. Wilbur G. Stover, Jr., VP-Finance/CFO Dean A. Klein, VP-Mktg. Dev. JoAnne S. Pfeifer, VP-Human Resources D. Mark Durcan, Chief Tech. Officer James E. Mahoney, VP-Info. Systems Roderic W. Lewis, VP/Corp. Sec. Roderic W. Lewis, General Counsel Jay L. Hawkins, VP-Oper. Kipp A. Bedard, VP-Corp. Affairs Norman L. Schlachter, Treas. Jan du Preez, VP-Networking and Comm. Group Roderic W. Lewis, VP-Legal Affairs Trung T. Doan, VP-Process Dev. Robert M. Donnely, VP-Computing and Consumer Group Steven R. Appleton, Chmn.
Phone: 208-368-4000 Fax: 208-368-4435 Toll-Free: Address: 8000 S. Federal Way, Boise, ID 83707-0006 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $2,589,000 (12 months) 2002 Profits: $-907,000 (12 months) Stock Ticker: MU 2001 Sales: $3,935,900 2001 Profits: $-625,000 Employees: 18,700 2000 Sales: $7,336,300 2000 Profits: $1,504,200 Fiscal Year Ends: 8/31 1999 Sales: $3,764,000 1999 Profits: $-68,900 1998 Sales: $3,025,300 1998 Profits: $-247,100
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $110,777 Stock Purch. Plan: Y Second Exec. Salary: $329,539 ADVANTAGE: Award-winning products/Diversified operations.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $39,137 Bonus: $19,864
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
MICROSOFT CORP
www.microsoft.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Computer Software-Diversified Internet Access Provider Entertainment and Cable TV Interests Computer Peripherals Personal Game Players Venture Capital
Microsoft Corp., the world’s leading (and largest) software firm, develops, manufactures, licenses, sells and supports a wide range of some of the most globally critical software existing today. The company offers online services; computer books and input devices, including operating systems for intelligent devices, PCs and servers; server applications for client/server environments; business and consumer productivity applications; software development tools; and Internet and intranet software and technologies. The company has also made an investment in cable operator Comcast. Windows CE software is one of the operating systems for millions of cable modems purchased by major cable television operators worldwide. Microsoft now jointly operates MSNBC news programming with the National Broadcasting Corporation (NBC). Microsoft is making a serious move into web services with its .Net initiative. Other initiatives include Passport.net, Office.net and VisualBasic.net. These programs are based on the XML language, and about 50% of the firm's $4 billion annual research budget is currently slotted for these products. XML offers several advantages for categorizing and shaping information. The company’s popular Xbox video game system, which sold 3.9 million units during fiscal 2002, represents a significant move into the computer hardware market. Microsoft’s real-time embedded Automotive v3.5 operating system can be found in the new flagship BMW 7 Series model line. This combination of telecommunications and computing will benefit the auto industry as the complexity of automotive systems continues to evolve. The firm recently announced plans to launch a comprehensive line of wireless networking products for home and office. Microsoft expects that these new products will make the conversion to wireless from a modem, cable or DSL Internet connection more consumer-friendly. Microsoft provides its workforce with relocation expenses, health club membership, tuition reimbursement and adoption assistance. Restricted stock awards are granted to qualified employees, a 2003 shift from the firm's longstanding stock option plan.
BRANDS/DIVISIONS/AFFILIATES: Windows Comcast MSNBC Passport.net Xbox .Net WebTV Hotmail
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Steve Ballmer, CEO John Connors, CFO Orlando Ayala, Group VP-Worldwide Sales and Mktg. Ken DiPietro, Sr. VP-Human Resources Eric Rudder, VP-Tech. Strategy Rick Devenuti, CIO Scott Boggs, VP/Corp. Controller Bill Neukom, Corp. Sec. Brad Smith, General Counsel Richard Emerson, Sr. VP-Corp. Dev. Strategy Bruce Leak, Pres., WebTV Networks, Inc. Blake Irving, VP-Corp. Comm. Carla Lewis, Sr. Dir.- Investor Rel. Brent Callinicos, Treas. William Gates, III, Chief Software Architect Linda Stone, VP-Corp. and Industry Initiatives William Gates, III, Chmn.
Phone: 425-882-8080 Fax: 425-936-7329 Toll-Free: 800-285-7772 Address: One Microsoft Way, Redmond, WA 98052-6399 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $28,365,000 (12 months) 2002 Profits: $7,829,000 (12 months) Stock Ticker: MSFT 2001 Sales: $25,296,000 2001 Profits: $7,346,000 Employees: 50,500 2000 Sales: $22,956,000 2000 Profits: $9,421,000 Fiscal Year Ends: 6/30 1999 Sales: $19,747,000 1999 Profits: $7,785,000 1998 Sales: $15,262,000 1998 Profits: $4,490,000
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $568,723 Bonus: $350,000 Stock Purch. Plan: Y Second Exec. Salary: $547,500 Bonus: $205,810 ADVANTAGE: Owns industry-standard PC operating systems, Internet browsers and office applications.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
MILLENNIUM PHARMACEUTICALS INC Industry Group Code: 325412 Ranks within this company's industry group: Sales:39 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
www.mlnm.com
Profits:100 Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Gene-Based Discovery Platform Pharmacogenomics
Millennium Pharmaceuticals researches small-molecule, biotherapeutic and predictive medicine products. The company integrates large-scale genetics, genomics, highthroughput screening and informatics to create a drug discovery platform that accelerates the development of therapeutic and diagnostic products. The platform identifies important genes, determines their functions, validates drug and product development targets, formulates assays based on these targets and identifies product candidates. The company’s three primary fields of emphasis are cancer, metabolic diseases (such as obesity) and inflammation. In addition, Millennium has significant programs in infectious diseases, cardiovascular diseases and diseases of the central nervous system. The firm focuses on developing small-molecule drugs, which are typically formulated into pills for oral consumption, as well as proteins and monoclonal antibodies, which are typically only available in injectable form. The company licenses its platform to various pharmaceutical and biotechnological firms in exchange for royalties from the sale of the firm’s products. Millennium recently began shipment of its newest drug used for the treatment of cancer, VELCADE, to wholesalers and medical centers around the country. The firm’s merger with COR Therapeutics, Inc. resulted in Millennium acquiring Integrilin, a drug that treats acute coronary problems. The firm also received substantial research and development capabilities in the areas of cardiovascular disease and oncology. The firm’s Millennium University offers employees a variety of in-house workshops and off-site seminars designed to enhance career development at the company. Employees are eligible for bonus opportunities depending on Millenium’s achievement of various goals as well as individual performance.
BRANDS/DIVISIONS/AFFILIATES: Millennium Predictive Medicine, Inc. LeukoSite, Inc. CAMPATH LDP-02 LDP-977 Integrilin COR Therapeutics, Inc. Cambridge Discovery Chemistry
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Mark J. Levin, CEO Kevin Starr, COO Mark J. Levin, Pres. Kenneth Bate, CFO Linda K. Pine, Sr. VP-Human Resources Robert I. Tepper, VP-Research and Dev. John B. Douglas, III, General Counsel Mark J. Levin, Chmn.
Phone: 617-679-7000 Fax: 617-374-7788 Toll-Free: Address: 75 Sidney St., Cambridge, MA 02139 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $353,000 (12 months) 2002 Profits: $-590,200 (12 months) Stock Ticker: MLNM 2001 Sales: $246,200 2001 Profits: $-192,000 Employees: 2,079 2000 Sales: $196,300 2000 Profits: $-309,600 Fiscal Year Ends: 12/31 1999 Sales: $183,700 1999 Profits: $-352,000 1998 Sales: $133,700 1998 Profits: $10,300
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $482,001 Stock Purch. Plan: Y Second Exec. Salary: $428,846 ADVANTAGE: R&D alliance with Abbott Labs and Bayer.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $365,765 Bonus: $245,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
MILTOPE GROUP INC
www.miltope.com
Industry Group Code: 334111 Ranks within this company's industry group: Sales:13 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:5
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Computer Hardware-Military & Rugged Computer Peripheral Equipment Airline Ticket Printers Internet Terminals
Miltope is engaged in the design, development, manufacture and testing of computers and computer peripheral equipment for military, rugged and other specialized applications requiring reliable operations in severe land, sea and airborne environments for both military and commercial customers. Miltope’s product lines include a broad range of computer printers, disk memory products, transportable microcomputers and electronically erasable programmable read-only memory, together with subsystems incorporating these products. The firm also delivers components for cabin management and in-flight entertainment systems, public access Internet terminals and a complete line of rugged SUN and HewlettPackard RISC workstations and related peripherals. Aside from its military-based operations, the company’s commercial segment develops, manufactures and markets products primarily for transportation, telecommunications and in-field maintenance markets. Airborne printers, airline ticket and boarding pass printers, rugged public access Internet terminals, mass storage devices and derivatives of rugged hand-held Intel-based computers and portable RISC workstations are created within the commercial operations. Miltope's customers include industry giants Boeing, British Airways, Continental Airlines, American Airlines and United Airlines. Though expanding its market breadth, Miltope continues to grow its primary military-based operations through government contracts. The company is in the midst of a five-year, $120-million contract with U.S. Army Maintenance Support Device and recently received a $6-million order from the United States Army Tank Automotive Command for the upgrade, manufacture and test of the Mortar Fire Control System Commander’s Interface computer.
BRANDS/DIVISIONS/AFFILIATES:
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Thomas R. Dickinson, CEO Thomas R. Dickinson, Pres. Tom B. Dake, VP-Finance/CFO Teddy G. Allen, Chmn.
Phone: 334-284-8665 Fax: 334-613-6302 Toll-Free: 800-645-8673 Address: 500 Richardson Rd. S, Hope Hull, AL 36043 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $48,470 (12 months) 2002 Profits: $4,663 (12 months) Stock Ticker: MILT 2001 Sales: $45,200 2001 Profits: $-2,277 Employees: 158 2000 Sales: $40,700 2000 Profits: $-1,400 Fiscal Year Ends: 12/31 1999 Sales: $30,233 1999 Profits: $-5,601 1998 Sales: $26,444 1998 Profits: $-3,021
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Focus on rugged equipment.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $212,502 Second Exec. Salary: $142,980
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
MITSUBISHI MOTORS CORP
www.mitsubishi-motors.co.jp
Industry Group Code: 336111 Ranks within this company's industry group: Sales:12 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Profits:13
Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Automobiles, Manufacturing Trucks
Mitsubishi Motors Corporation is a global manufacturer and distributor of automobiles, trucks, buses, parts and powertrains. Based in Tokyo, Japan, the company is the fourth largest automaker in its home market and recently formed a strategic alliance with DaimlerChyrsler AG, which owns a 37% stake. Mitsubishi Motor Sales of America, Inc. (MMSA) is the exclusive U.S. distributor of a full line of Mitsubishi Motors-brand passenger cars and sport utility vehicles. MMSA markets three categories of automobiles: sedans, sports cars and sport utility vehicles. The Mitsubishi brand includes the Eclipse sports coupe, Montero, the Outlander and the Galant mid-size sedan, which together account for nearly half of its passenger car sales in the U.S. The firm recently experienced a record fourth consecutive increase in annual sales. MMSA is looking forward to another period of rapid growth, with plans to launch four new products within the next several months. Approximately half of the vehicles MMSA sells in the U.S. are assembled at a facility in Bloomington/Normal, Illinois, where the firm also assembles Chrysler and Dodge brand vehicles. Mitsubishi Fuso offers a line of truck models in the U.S. and Canada. Mitsubishi Motors Credit of America, Inc. provides Mitsubishi Motors retailers with a variety of wholesale financing and retail options to assist clients in purchasing or leasing Mitsubishi brand vehicles. In recent news, Mitsubishi Motors announced plans to completely consolidate its North American sales, manufacturing, finance and research and development operations into a single organization. Elsewhere, Mitsubishi Motors plans to re-invest in its Thai plant to boost truck production and exports. Benefits offered vary by location. In the U.S., Mitsubushi Motors employees receive dental and vision insurance, a car lease or purchase plan, education reimbursement, fitness membership discounts and an employee referral program, as well as discounts for amusements and activities nationwide. The firm is also committed to the training and development of its employees through the variety of courses it offers.
BRANDS/DIVISIONS/AFFILIATES: Galant Eclipse Montero Aspire Lancer Evolution Outlander DaimlerChrysler AG Mitsubishi Motor Sales of America, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Rolf Eckrodt, CEO Takashi Usami, COO Rolf Eckrodt, Pres. Junji Midorikawa, CFO Eiji Iwakuni, Sr. VP-Domestic Sales and Mktg. Bernd Staudinger, CIO Joachim Coers, Sr. Exec./Controller Tadayoshi Juge, Exec. Officer-Bus. Affairs Takashi Sonobe, Chief Bus. Ethics Officer Steven A. Torok, Exec. VP Ulrich W. Walker, Exec. VP Masanori Tani, Sr. VP Takashi Sonobe, Chmn.
Phone: 81-3-5232-7165 Fax: 81-3-5232-7747 Toll-Free: Address: 33-8 Shiba 5-chome, Minato-ku, Tokyo, 108-8410 Japan
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $24,024,255 (12 months) 2002 Profits: $84,473 (12 months) Stock Ticker: Foreign 2001 Sales: $26,446,457 2001 Profits: $-2,244,867 Employees: 63,143 2000 Sales: $31,608,900 2000 Profits: $-221,100 Fiscal Year Ends: 3/31 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Relationship with DaimlerChrysler.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $ Second Exec. Salary: $
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
MONSANTO CO
www.monsanto.com
Industry Group Code: 325000 Ranks within this company's industry group: Sales:8 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:14
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Y Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Chemicals-Agricultural Herbicides
Monsanto Company, originally formed as a subsidiary of Pharmacia Corporation, is a global provider of technologybased solutions and agricultural products for growers and downstream customers, such as grain processors, food companies and consumers, in agricultural markets. The firm's herbicides, seeds and related biotechnology trait products can be combined to provide growers with integrated solutions to produce higher-yield crops while controlling weeds, insects and diseases more efficiently and cost-effectively. The company's principal agricultural products include Roundup herbicide for agricultural and industrial applications; Harness and Degree herbicides for control of pre-emergent annual grass and broadleaf weeds in corn; Lasso herbicides for grass and weeds in corn, soybean, peanut and sorghum crops; Maverick herbicide for control of grassy weeds in wheat; Machete herbicide for control of grass and weeds in rice, barley and wheat; Avadex and Far-Go herbicides for wheat, barley, peas and lentils; Permit, Manage and Sempra herbicides for weeds in corn, cotton and sugarcane; Posilac, which increases milk production in dairy cows; and Monsanto Choice Genetics swine genetics products. Monsanto also provides Roundup lawn and garden products for the residential market. In addition, the company offers EnviroChem engineering and construction management services. The firm's seeds and genomics products include Roundup Ready, Bollgard, YieldGard, Agroceres, Asgrow and Hartz traits and seeds. Recently, Monsanto and Dow AgroSciences reached an agreement that will provide farmers worldwide with greater access to a range of agricultural products and technologies, including Roundup Ready corn, soybeans, cotton and canola. Monsanto offers its employees health, disability and life insurance and a cash balance pension plan.
BRANDS/DIVISIONS/AFFILIATES: Pharmacia Corporation Roundup Harness Degree Lasso Maverick Machete Avadex
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Hugh Grant, CEO Terrell K. Crews, Exec. VP/CFO John M. Murabito, Sr. VP-Human Resources Robert T. Fraley, Exec. VP/Chief Tech. Officer Janet M. Holloway, CIO Richard Clark, VP/Controller Mark Leidy, VP-Mfg. Charles Burson, Exec. VP/Corp. Sec. Charles Burson, General Counsel Jerry Steiner, VP-Strategy Sarah Hull, Sr. VP-Public Affairs Carlos Popik, VP-Latin America Carl Casale, VP-North America Steven L. Engelberg, Sr. VP-Gov't Affairs Cheryl Morley, Pres.-Animal Agricultural Group Philippe Castaing, Mgr.-Europe and Africa
Phone: 314-694-1000 Fax: 314-694-8394 Toll-Free: Address: 800 N. Lindbergh Blvd., St. Louis, MO 63167 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $4,673,000 (12 months) 2002 Profits: $-1,693,000 (12 months) Stock Ticker: MON 2001 Sales: $5,462,000 2001 Profits: $295,000 Employees: 13,700 2000 Sales: $5,493,000 2000 Profits: $149,000 Fiscal Year Ends: 12/31 1999 Sales: $5,248,000 1999 Profits: $150,000 1998 Sales: $4,448,000 1998 Profits: $-125,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $867,312 Stock Purch. Plan: Y Second Exec. Salary: $561,539 Leading international agricultural products company. ADVANTAGE:
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $357,000 Bonus: $198,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
MOTOROLA INC
www.motorola.com
Industry Group Code: 334210 Ranks within this company's industry group: Sales:4 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:14
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Telecommunications Equipment-Cellular Telephones Two-Way Land Mobile Communication Systems Semiconductors Paging and Wireless Data Systems
Motorola, Inc. is a global leader in providing integrated communications solutions and embedded electronic solutions, including software-enhanced wireless telephone, two-way radio, messaging products, satellite communications products and systems and networking and Internet-access products for consumers, network operators and commercial, government and industrial customers. The company also provides embedded semiconductor solutions for customers in networking, transportation, wireless communications and imaging and entertainment markets. Furthermore, Motorola provides embedded electronic systems for automotive, communications, imaging, manufacturing systems, computer and industrial markets and digital and analog systems and set-top terminals for broadband cable television operators. The network management group (NMG), part of the firm's communications enterprise, is comprised of the network communications division and the satellite ventures division. NMG holds and manages investments in wireless operating systems in a number of international jurisdictions and in gateway companies for the Iridium satellite communications network. The internet and networking group (ING) manufactures and sells cable modems, cable access units, analog and digital transmission devices and other data communication devices, as well as wireline networking products like routers for carrying converged voice and data traffic. The company was recently selected by the Hong Kong Police Department to deliver its third-generation Command and Control Communications system, a contract that will net the company $69 million. In addition, Motorola and MTV have formed a $75-million marketing partnership, the largest marketing alliance ever for either company. The partnership will allow MTV to extend its programming and web access internationally via Motorola’s wireless devices. Through Motorola University, the company provides each employee with at least one week of training per year. The firm also offers a wellness program and near- or on-site child care.
BRANDS/DIVISIONS/AFFILIATES: Command and Control Communications
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Christopher B. Galvin, CEO Mike Zafirovski, COO David W. Devonshire, CFO Glenn Gienko, VP-Human Resources Padmasree Warrior, Chief Tech. Officer A. Peter Lawson, Corp. Sec. A. Peter Lawson, General Counsel Leif Soderberg, VP-Corp. Dev. and Strategy Dan Moloney, Pres./CEO-Broadband Comm. Kevin Loosemore, Corp. VP/Pres.-Professional Services Gene Delaney, Exec. VP/Pres.-Global Rel. and Resources Greg Brown, CEO-Comm., Gov't and Industrial Solutions Dennis Carey, CEO-Integrated Electronic Systems Fred Shlapak, Pres./CEO-Semiconductor Products Adrian Nemcek, Pres./CEO-Global Telecom Solutions Christopher B. Galvin, Chmn.
Phone: 847-576-5000 Fax: 847-576-5372 Toll-Free: 800-262-8509 Address: 1303 E. Algonquin Rd., Schaumburg, IL 60196 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $26,679,000 (12 months) 2002 Profits: $-2,485,000 (12 months) Stock Ticker: MOT 2001 Sales: $30,004,000 2001 Profits: $-3,937,000 Employees: 97,000 2000 Sales: $37,580,000 2000 Profits: $1,318,000 Fiscal Year Ends: 12/31 1999 Sales: $33,075,000 1999 Profits: $891,000 1998 Sales: $31,340,000 1998 Profits: $-907,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $1,275,000 Bonus: $1,250,000 Stock Purch. Plan: Y Second Exec. Salary: $975,000 Bonus: $875,000 ADVANTAGE: One of the most respected names in electronics/Large market share in mobile communications.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
MSC.SOFTWARE CORP
www.mscsoftware.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:36
Profits:25
Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive: Y
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Software-Computer-Aided Engineering Engineering Consulting
MSC.Software Corporation is a leader in the development, marketing and support of simulation software. The firm provides services and systems to optimize product design and quality and reduce costs and time to market. The company also provides information systems and software integration systems through its product lifecycle management software. The company’s most popular software products include MSC.Nastran, MSC.Marc, MSC.Dytran and MSC.Patran. MSC's solutions are intended to equip engineers with greater freedom to innovate design concepts, optimize complex solutions and exploit materials as a design variable. MCAE analysis is used to simulate the performance of a design before its physical manufacture, reducing the costly physical testing of prototypes and permitting a substantial increase in the number of design trade-offs and design cycles. Engineers use MSC's simulation software worldwide in several industries, including aerospace, automotive, shipbuilding, consumer products and electronic packaging. MSC also provides strategic consulting services to customers to improve the integration and performance of their MCAE technologies. MSC practices an aggressive acquisition strategy and recently purchased Mechanical Dynamics, Inc., a publicly traded company that specializes in virtual prototyping solutions. Training seminars are conducted in local languages at MSC’s offices worldwide and at actual client sites.
BRANDS/DIVISIONS/AFFILIATES: Engineering-e.com MARC Analysis Research Corp. Universal Analytics, Inc. Computerized Structural Analysis and Res. Corp. Knowledge Revolution, Inc. MSC.Fatigue MSC.SuperForge MacNeal-Schwendler Corp.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Frank Perna, Jr., CEO Louis A. Greco, CFO Richard C. Murphy, Sr. VP-Global Sales Charles Davis, Controller Louis A. Greco, Corp. Sec. John Di Lullo, General Mgr.-Engineering-e.com Div. Christopher St. John, VP-Services Nader Khoshniyati, Exec. VP-Systems Kenneth D. Blakely, Sr. VP-Software and Services Robert Ryan, Exec. VP Frank Perna, Jr., Chmn.
Phone: 714-540-8900 Fax: 714-784-4056 Toll-Free: Address: 2 MacArthur Pl., Santa Ana, CA 92707 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $344,200 (12 months) 2002 Profits: $-51,300 (12 months) Stock Ticker: MNS 2001 Sales: $236,100 2001 Profits: $10,300 Employees: 1,514 2000 Sales: $178,024 2000 Profits: $11,133 Fiscal Year Ends: 12/31 1999 Sales: $149,235 1999 Profits: $5,097 1998 Sales: $125,397 1998 Profits: $-12,979
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $353,385 Stock Purch. Plan: Second Exec. Salary: $277,820 ADVANTAGE: Enables engineers to broaden creative efforts and optimize complex solutions.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $400,000 Bonus: $160,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
MYLAN LABORATORIES INC
www.mylan.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:26 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:15
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Generic Branded Drugs for Cardiology, Dermatology and Neurology
Mylan Laboratories is a fully integrated pharmaceuticals company that develops, markets and distributes generic and branded prescription drugs. The firm markets an extensive line of generic products through two business units: Mylan Pharmaceuticals and UDL Laboratories. The company manufactures and markets approximately 111 generic pharmaceuticals in capsule or tablet forms as well as 73 generic products under supply and distribution agreements with other pharmaceutical companies. Mylan’s most profitable generic product, Nifedipine ER (Procardia XL), is used for the treatment of hypertension and angina. The company’s branded products portfolio, sold through its Bertek Pharmaceuticals subsidiary, includes Maxzide, Digitek and Nitrek for the treatment of various heart conditions and Avita, Mentax and Anticin for skin conditions. Through Mylan Technologies subsidiary, parent company Mylan develops components for drug delivery systems and dressings, including MEDIFILM (medical and wound care films), MEDIFLEX (transdermal backing materials), MEDIRELEASE (release liners) and MEDIDERM (skin contact adhesive laminates). Mylan continues to work on expanding its product line, with emphasis on its generic pharmaceutical offerings. The company recently acquired a new drug application for the sale of Tizanidine Hydrochloride tablets, the generic equivalent of Elan Corporation’s Zanaflex, which is a short-acting drug used for the management of spasticity.
BRANDS/DIVISIONS/AFFILIATES: Bertek Pharmaceuticals, Inc. Mylan Pharmaceuticals Mylan Technologies UDL Laboratories, Inc. Maxzide Digitek Nitrek Mentax
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Robert J. Coury, CEO Louis J. DeBone, COO Louis J. DeBone, Pres. Edward J. Borkowski, CFO John P. O'Donnell, Chief Scientific Officer Gary E. Sphar, Controller Roger L. Foster, Corp. Sec. Roger L. Foster, General Counsel Thomas S. Clark, VP-Corp. Affairs Patricia A. Sunseri, VP-Investor & Public Rel. James J. Mauzey, SVP, Pres./CEO-Bertek Pharmaceuticals Inc. Stuart A. Williams, Chief Legal Officer Harry A. Korman, VP, Pres., UDL Laboratories Inc. John P. O'Donnell, EVP-Mylan Pharmaceuticals Inc. Milan Puskar, Chmn.
Phone: 724-514-1800 Fax: 724-514-1870 Toll-Free: Address: 1500 Corporate Dr., Ste. 400, Canonsburg, PA 15317 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,104,100 (12 months) 2002 Profits: $260,300 (12 months) Stock Ticker: MYL 2001 Sales: $846,700 2001 Profits: $37,100 Employees: 2,200 2000 Sales: $790,100 2000 Profits: $154,200 Fiscal Year Ends: 3/31 1999 Sales: $721,100 1999 Profits: $115,400 1998 Sales: $555,400 1998 Profits: $100,777
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Stock Purch. Plan: ADVANTAGE: A fully integrated pharmaceutical firm.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $1,000,000 Second Exec. Salary: $325,000
Bonus: $1,000,000 Bonus: $500,000
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
MYRIAD GENETICS INC
www.myriad.com
Industry Group Code: 325413 Ranks within this company's industry group: Sales:4 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:10
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Diagnosis and Testing Products
Myriad Genetics, Inc. is a genomics company focused on the development of therapeutic and diagnostic products based on the discovery of major common human disease genes and their biological pathways. The company utilizes analyses of extensive family histories and genetic material, as well as a number of proprietary technologies, to identify inherited gene mutations, which increase the risk to individuals of developing these diseases. The firm developed ProNet, a proprietary high-throughput assay to identify protein-protein interactions, in a five-year, $51million collaboration with Schering AG. The discovery of disease-predisposing genes and their biochemical pathways provides Myriad with three significant commercial opportunities: the development of therapeutic products for the treatment and prevention of major diseases associated with them; the marketing of subscriptions to the ProNet database of protein interactions; and the development and marketing of molecular diagnostic and information services for the identification of individuals who are genetically predisposed to disease. Subsidiary Myriad Pharmaceuticals, Inc., formed in 1999, develops therapeutic lead compounds and markets them to pharmaceutical companies. Subsidiary Myriad Genetic Laboratories develops and markets proprietary molecular diagnostic products in the areas of predictive medicine and personalized medicine. Myriad also develops therapeutic products in conjunction with its strategic partners, including Bayer Corporation, Eli Lilly and Company, Monsanto Company, Novartis Corporation and Schering. In recent news, Myriad and Genetic Technologies, Ltd. announced a strategic alliance under which they will cross-license certain technologies related to the identification of non-coding DNA alterations and the assessment of inherited human diseases. Myriad will receive a broad, non-exclusive license to Genetic Technologies' non-coding DNA analysis and mapping patents for all applications in human therapeutics and diagnostics.
BRANDS/DIVISIONS/AFFILIATES: Myriad Genetic Laboratories Myriad Pharmaceuticals, Inc. ProNet
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Peter D. Meldrum, CEO Peter D. Meldrum, Pres. Jay M. Moyes, CFO Mark H. Skolnick, Chief Scientific Officer Richard Marsh, General Counsel S. George Simon, VP-Bus. Dev. William A. Hockett, III, VP-Corp. Comm. Gregory C. Critchfield, Pres., Myriad Genetic Laboratories Adrian N. Hobden, Pres., Myriad Pharmaceuticals, Inc. Sudhir Saharabudhe, Exec. VP-Research
Phone: 801-584-3600 Fax: 801-584-3640 Toll-Free: Address: 320 Wakara Way, Salt Lake City, UT 84108 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $53,800 (12 months) 2002 Profits: $-14,000 (12 months) Stock Ticker: MYGN 2001 Sales: $45,200 2001 Profits: $-7,200 Employees: 491 2000 Sales: $34,000 2000 Profits: $-8,700 Fiscal Year Ends: 6/30 1999 Sales: $25,300 1999 Profits: $-10,000 1998 Sales: $23,200 1998 Profits: $-9,800
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $385,518 Stock Purch. Plan: Second Exec. Salary: $286,518 ADVANTAGE: Excellent partnerships/Success in research projects.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $131,015 Bonus: $81,015
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
NABI BIOPHARMACEUTICALS
www.nabi.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:46 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:48
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Infectious Disease and Autoimmune Disorder Vaccines
Nabi Biopharmaceuticals, formerly Nabi, is a vertically integrated research and development biopharmaceutical company that focuses on serious unmet medical needs. The firm has a broad product portfolio and significant research capabilities focused on the development and commercialization of drugs that prevent and treat infectious, autoimmune and addictive diseases such as hepatitis B, hepatitis C and staphylococcus aureus infections, immune thrombocytopenia purpura and nicotine addiction. The company currently markets four biopharmaceutical products. Nabi-HB prevents hepatitis B infections. WinRho SDF treats acute, chronic and HIVrelated immune thrombocytopenia purpura, an autoimmune disease that manifests itself in abnormally low platelet levels resulting in excessive bleeding. Autoplex T is used in the treatment of hemophilia A, a blood clotting disorder. Cancer patients who develop hyperuricemia following chemotherapy use Aloprim to treat the condition, which affects more than 90,000 patients in the U.S. The company has significant clinical trials programs involving StaphVAX, Altastaph, Civacir and NicVAX. StaphVAX is being developed for the 12 million patients estimated to be at high risk of infection and who are able to respond to a vaccine by producing their own antibodies. Nabi is developing Civacir for the prevention of hepatitis C virus (HCV) re-infection of transplanted livers in patients infected with HCV. Another product under development, NicVAX, is expected to help smokers quit. NicVAX is an experimental vaccine that induces the production of high levels of nicotine-specific antibodies. Once these antibodies bind to nicotine molecules, they are unable to cross the blood/brain barrier to bind and activate the neuroreceptors, which provide the positive reinforcement from smoking. Nabi offers its employees medical, dental, vision and life insurance, as well as a discount prescription program. Employees also receive flexible spending accounts, access to one of three full-service credit unions, an employee assistance program, an employee referral program and business-casual dress.
BRANDS/DIVISIONS/AFFILIATES: Nabi-HB WinRho SDF Autoplex T Aloprim StaphVAX NicVAX Civacir Altastaph
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. David J. Gury, CEO Thomas H. McLain, COO Thomas H. McLain, Pres. Mark L. Smith, Sr. VP-Finance/CFO Gary A. Siskowski, Sr. VP-Mktg. and Sales Mark L. Smith, Chief Acc. Officer C. Thomas Johns, Sr. VP-Mfg. Oper. Daniel E. Greenleaf, Sr. VP-Oper. Mark L. Smith, Treas. Robert B. Naso, Sr. VP-Quality, Regulatory and Product Dev. Raafat Fahim, VP-Vaccine Mfg. Oper. David J. Gury, Chmn.
Phone: 561-989-5800 Fax: 561-989-5801 Toll-Free: Address: 5800 Park of Commerce Blvd. NW, Boca Raton, FL 33487 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $196,000 (12 months) 2002 Profits: $2,100 (12 months) Stock Ticker: NABI 2001 Sales: $234,800 2001 Profits: $104,700 Employees: 722 2000 Sales: $228,800 2000 Profits: $4,400 Fiscal Year Ends: 12/31 1999 Sales: $233,600 1999 Profits: $3,300 1998 Sales: $243,100 1998 Profits: $-21,800
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $483,000 Stock Purch. Plan: Y Second Exec. Salary: $274,615 ADVANTAGE: One of the world's largest suppliers of source and specialty plasma.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $384,854 Bonus: $225,494
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
NAPRO BIOTHERAPEUTICS INC
www.naprobio.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:78 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:54
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Cancer Cancer Chemotherapeutic Technology
NaPro BioTherapeutics, Inc. is a biopharmaceutical company that develops natural-product pharmaceuticals. The company focuses on the development and manufacture of cancer chemotherapeutic technology. NaPro’s frontline product is Paclitaxel, which is a natural anti-cancer compound. This product was recognized by the NCI (National Cancer Institute) for exhibiting cytotoxic activity toward harmful leukemia cells as well as slowing some tumor growth. At this time, Paclitaxel is only administered intraveniously. Pre-clinical development is currently underway to present an oral form of Paclitaxel. This breakthrough would decrease the dangers of administering the product through intravenous delivery. NaPro has joined forces with Abbott Laboratories and F.H. Faulding & Co., Ltd. to increase development and marketing of Paclitaxel in the United States and worldwide. The firm also is united with F.H. Faulding & Co., Ltd. to establish sales and manufacturing in Australia, New Zealand and Southeast Asia, with Tzamal Pharma for the development and distribution in Israel and with JCR Pharmaceuticals Co., Ltd. for the supply and distribution in Japan. The company is currently evaluating the purchase of new products and technologies in the natural products field. It is developing new anti-cancer compounds, NaPro 80239 for use in hematological cancer, NaPro 80661 and NaPro 82739 for solid tumors and NaPro 102339 for a directed drug delivery product. In recent news, NaPro introduced a new gene editing technology that will provide researchers with genes prepared for testing and evaluation.
BRANDS/DIVISIONS/AFFILIATES: Paclitaxel F.H. Faulding & Co., Ltd. Abbott Laboratories Tzamal Pharma JCR Pharmaceuticals Co., Ltd. NaPro 80239 NaPro 80661 NaPro 102339
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Leonard P. Shaykin, CEO Sterling K. Ainsworth, Pres. Gordon H. Link, VP-Finance/CFO Patricia A. Pilia, Exec. VP-Bioresearch/Tech. Brian McCudden, VP-Mfg. Patricia A. Pilia, Sec. Kai Larson, VP-General Counsel David L. Denny, VP-Oper. Patricia A. Pilia, Treas. James D. McChesney, VP-Natural Products Chemistry Sterling K. Ainsworth, Chief Scientific Officer Gordon H. Link, Pres.-Genomics Division Brenda P. Fielding, VP-Regulatory Affairs Leonard P. Shaykin, Chmn.
Phone: 303-530-3891 Fax: 303-530-1296 Toll-Free: 800-976-2776 Address: 6304 Spine Rd., Unit A, Boulder, CO 80301 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $34,200 (12 months) 2002 Profits: $-8,700 (12 months) Stock Ticker: NPRO 2001 Sales: $15,700 2001 Profits: $-25,800 Employees: 151 2000 Sales: $8,100 2000 Profits: $-16,600 Fiscal Year Ends: 12/31 1999 Sales: $7,600 1999 Profits: $-9,000 1998 Sales: $5,000 1998 Profits: $-2,600
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $259,423 Stock Purch. Plan: Second Exec. Salary: $239,331 ADVANTAGE: Clinical success/International distribution.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $100,000 Bonus: $200,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
NATIONAL SEMICONDUCTOR CORP Industry Group Code: 334413 Ranks within this company's industry group: Sales:8 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
www.national.com Profits:15
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Chips-Analog Mixed Signal Integrated Circuits
National Semiconductor Corporation designs, develops, manufactures and markets a wide array of semiconductor products, including a broad line of analog, mixed-signal and other integrated circuits. These products are used in information appliances, personal systems, wireless communications, flat panel and CRT displays, power management, local and wide area networks and consumer applications. The company is grouped into five organizational units. The analog group develops and manufactures numerous building block products such as high-performance operational amplifiers, power management products, high-efficiency audio amplifiers and thermal management products. The information appliance and wireless group consists of the company’s information appliance, wireless and advanced I/O business units, which focus on providing easier access to the Internet with the Geode product family of silicon and system solutions. The displays group manufactures products that enhance the performance of flat panel monitors, CRT monitors and notebook TFT displays. The group consists of the firm’s flat panel displays and CRT displays business units. The wired communications group consists of the enterprise networks division, which provides complete solutions for networking security and networking management, and the network interface business unit, which develops high-speed differential interconnect products. The custom solutions group supplies a range of application-specific and standard integrated circuits for targeted customers in the telecommunications, automotive and consumer electronics markets. This group engages with other internal product line business units to facilitate the exchange and acquisition of intellectual property to deliver systems-on-achip solutions for key strategic partners. National Semiconductor's employee benefits include paid dental, vision coverage, quarterly bonuses, maternity, limited telecommuting, on-site fitness facilities and a business-casual dress code. In addition, the company provides use of a 15-acre on-site private park, an accredited university, massages and a train shuttle.
BRANDS/DIVISIONS/AFFILIATES:
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Brian L. Halla, CEO Donald Macleod, Exec. VP/COO Brian L. Halla, Pres. Lewis Chew, CFO/Sr. VP-Finance Edward Sweeney, Sr. VP-Worldwide Human Resources Kamal K. Aggarwal, Exec. VP-Central Tech. Ulrich J. Seif, Sr. VP/CIO Kamal K. Aggarwal, Exec VP-Mfg. Group John M. Clark, III, Corp. Sec. John M. Clark, III, General Counsel Donald Macleod, General Mgr.-Product Lines Jean-Louis Bories, General Mgr.-Info. Appliance Group Suneil Parulekar, Sr. VP-Analog Products Group Brian L. Halla, Chmn.
Phone: 408-721-5000 Fax: 408-739-9803 Toll-Free: Address: 2900 Semiconductor Dr., Santa Clara, CA 95052-8090 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,494,800 (12 months) 2002 Profits: $-121,900 (12 months) Stock Ticker: NSM 2001 Sales: $2,112,600 2001 Profits: $245,700 Employees: 10,100 2000 Sales: $2,139,900 2000 Profits: $620,800 Fiscal Year Ends: 5/31 1999 Sales: $1,956,800 1999 Profits: $-1,009,900 1998 Sales: $2,536,700 1998 Profits: $-98,600
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $8,641,799 Stock Purch. Plan: Y Second Exec. Salary: $536,338 ADVANTAGE: Products include a number of industry firsts/Analog expertise.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $700,000 Bonus: $375,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
NBTY INC
www.nbty.com
Industry Group Code: 325411 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Nutritional Supplements Sports Nutrition Products
NBTY, Inc. is a leading manufacturer of high-quality nutritional supplements in the United States, United Kingdom and worldwide. The firm markets more than 1,000 products, including vitamins, minerals, herbs, amino acids, sports nutrition products, diet aids and other nutritional supplements. NBTY markets these products under the brands Nature’s Way, Vitamin World, Nutrition Warehouse, Puritan’s Pride and Holland and Barrett. The company distributes products through a number of channels, including catalogs, the Internet, retail stores, mass merchandisers, drug store chains, supermarkets, independent pharmacies and health food stores. Puritan's Pride offers, through mail order and e-commerce, a full line of vitamins and other nutritional supplement products as well as selected personal care items at prices which are usually lower than those of similar products sold in retail stores. The company's www.puritan.com and www.vitamins.com web sites provide a practical and convenient method for consumers to purchase products that promote healthy living. NBTY has completed three acquisitions: the mail order operations of HealthCentral.com; the Knox gelatin nutritional supplement business of Kraft Foods; and the Synergy Plus product line of nutritional supplements. The company also recently acquired Health & Diet Group, Ltd. and the FSC wholesale business from Royal Numico N.V. In other news, NBTY announced it has ceased sales of products that contain ephedra.
BRANDS/DIVISIONS/AFFILIATES: Nature's Way Nutrition Warehouse Puritan’s Pride Holland and Barrett Vitamins.com Vitamin World Puritan.com HealthCentral.com
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Scott Rudolph, CEO Harvey Kamil, Pres. Harvey Kamil, CFO James P. Flaherty, VP-Mktg. and Advertising William Shanahan, VP-IT Michael Slade, Corp. Sec. Michael Slade, Sr. VP-Strategic Planning Scott Rudolph, Chmn.
Phone: 631-567-9500 Fax: 631-567-7148 Toll-Free: Address: 90 Orville Dr., Bohemia, NY 11716 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $964,100 (12 months) 2002 Profits: $95,800 (12 months) Stock Ticker: NBTY 2001 Sales: $806,900 2001 Profits: $41,900 Employees: 8,100 2000 Sales: $720,900 2000 Profits: $51,500 Fiscal Year Ends: 9/30 1999 Sales: $630,900 1999 Profits: $27,300 1998 Sales: $572,100 1998 Profits: $38,800
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $710,197 Bonus: $600,000 Stock Purch. Plan: Second Exec. Salary: $383,656 Bonus: $250,000 After completing a $50-million infrastructure investment program, NBTY now has the ability to ADVANTAGE: manufacture approximately 95% of the tablets and two-piece capsules it sells.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
NCR CORPORATION
www.ncr.com
Industry Group Code: 334111 Ranks within this company's industry group: Sales:6 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:11
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Computer Hardware-Point-of-Sale Computer Systems Barcode Scanning Equipment Cash Registers Data Warehousing Web-Based Kiosks Consulting Services
NCR Corporation is a global solutions company with leading positions in the production of automatic teller machines (ATMs), point-of-sale terminals and scanners, high-end scalable data warehousing and web-based kiosks. NCR's products are designed to help businesses process consumer transactions. The company also offers businesses the opportunity to centralize detailed information in a data warehouse; analyze the complex relationships among all of the different data elements; and respond with programs designed to improve consumer acquisition, retention and profitability. NCR offers specific services for the retail and financial industries, while providing general services for other industries, such as telecommunications, transportation, insurance, utilities, ecommerce, consumer good manufacturers and government entities. The company operates in six primary business segments: data warehousing solutions, financial self-service solutions, retail store automation solutions, customer services, Systemedia and payment and imaging solutions. NCR provides data warehousing solutions, combining Teradata hardware, software, professional consulting services and customer support services with third-party products and services from leading technology partners. Financial self-service solutions include an extensive product line of ATMs and related software and services. NCR’s retail store automation segment delivers effective, state-of-the-art retail products, such as point-ofscale workstations, scanners, web-enabled kiosks for selfcheckout and electronic shelf labels. In addition to providing maintenance and support for the base of NCR solution customers, the customer services segment provides services from consulting to site design, to staging and implementation and maintenance for third parties, to complete systems management. Payment and imaging solutions utilize advanced recognition and workflow technologies to automate item-based transaction processing. NCR supports individual and cultural differences in the workplace through diversity councils, work/life programs and other career management programs.
BRANDS/DIVISIONS/AFFILIATES: Systemedia Teradata
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Mark V. Hurd, CEO Mark V. Hurd, Pres. Earl Shanks, CFO/Sr. VP Wilbert J. M. Buiter, VP-Human Resources Jonathan S. Hoak, Sr. VP/General Counsel Michael Koehler, Sr. VP-Teradata Div. Mark Quinlan, VP-Systemedia Div. Gerald A. Gagliardi, Sr. VP-Worldwide Customer Services Lars Nyberg, Chmn.
Phone: 937-445-5000 Fax: 937-445-1682 Toll-Free: Address: 1700 S. Patterson Blvd., Dayton, OH 45479 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $5,585,000 (12 months) 2002 Profits: $-220,000 (12 months) Stock Ticker: NCR 2001 Sales: $5,917,000 2001 Profits: $217,000 Employees: 29,700 2000 Sales: $5,959,000 2000 Profits: $178,000 Fiscal Year Ends: 12/31 1999 Sales: $6,196,000 1999 Profits: $337,000 1998 Sales: $6,505,000 1998 Profits: $122,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $1,080,000 Stock Purch. Plan: Y Second Exec. Salary: $543,270 ADVANTAGE: Long-term expertise in cash registers, point-of-sale equipment and ATMs.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $280,000 Bonus: $350,000
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
NEOGEN CORPORATION
www.neogen.com
Industry Group Code: 325413 Ranks within this company's industry group: Sales:5 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:4
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Diagnostic Test Kits Food Safety Test Kits Agricultural Test Kits
Neogen Corporation develops, manufactures and markets a diverse line of products for food and animal safety. The company provides more than 200 diagnostic test kits that detect food-borne bacteria, natural toxins, food allergens, drug residues, pesticide residues, plant diseases and sanitation concerns. Neogen’s food safety division develops and markets one-stop solutions to keep food and feed safe from contamination. The company’s Acumedia subsidiary produces culture media that is used in a variety of food safety tests, such as food-borne pathogen detection. Neogen’s animal safety division manufactures and markets pharmaceuticals, vaccines, topicals and diagnostic products to the professional animal care market. The firm’s Ideal Instruments subsidiary provides more than 200 precision instruments to the veterinary market. Ideal’s needles and syringes accurately deliver drugs to animals, reducing residues in meat and milk. Other instruments offered by the subsidiary are used in animal obstetrics and surgery, as well as in animal health administration. In recent news, the company opened a sales and distribution center in Shanghai, China. The expansions allows Neogen to better serve the expanding food safety market, as well as more closely oversee its current Chinese animal safety operations. Neogen recently acquired Adgen Ltd., a private company based in Ayr, Scotland.
BRANDS/DIVISIONS/AFFILIATES: Ideal Instruments Agdia, Inc. AmVet Pharmaceuicals ISO-GRID Gene-Trak DNA Acumedia QA Life Sciences Adgen Ltd.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. James L. Herbert, CEO Lon M. Bohannon, COO James L. Herbert, Pres. Richard R. Current, CFO Joseph M. Madden, VP-Scientific Affairs Gerald S. Traynor, VP-Mfg. Thomas H. Reed, Corp. Sec. Lon M. Bohannon, VP-Admin. Anthony E. Maltese, Mgr.-Corp. Dev. Mark A. Mozola, VP-Research and Dev. Terri A. Morrical, VP/General Mgr. Gerald S. Traynor, VP-Instrument Dev.
Phone: 517-372-9200 Fax: 517-372-9027 Toll-Free: 800-234-5333 Address: 620 Lesher Pl., Lansing, MI 48912 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $41,100 (12 months) 2002 Profits: $3,900 (12 months) Stock Ticker: NEOG 2001 Sales: $34,900 2001 Profits: $3,200 Employees: 265 2000 Sales: $23,500 2000 Profits: $3,100 Fiscal Year Ends: 5/31 1999 Sales: $22,200 1999 Profits: $2,300 1998 Sales: $18,500 1998 Profits: $2,200
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Steady, profitable growth.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $216,356 Second Exec. Salary: $128,735
Bonus: $100,000 Bonus: $35,000
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
NEORX CORPORATION
www.neorx.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:102 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:66
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Cancer and Heart Disease Drug Delivery Devices
NeoRx Corporation develops innovative therapeutic biopharmaceuticals primarily for the treatment of cancer and cardiovascular and inflammatory diseases. As part of its operating strategy, the firm seeks to form alliances for developing and commercializing its Skeletal Targeted Radiotherapy and Pretarget platforms. NeoRx also outlicenses intellectual property rights from its portfolio of over 100 U.S. patents, which includes more than 25 patents relating to its Pretarget technology platform. Its portfolio also consists of cardiovascular drug delivery devices and antibody, radiopharmaceutical, ligand-linker and targeting technologies for imaging and therapeutics. In addition, the firm seeks to acquire or in-license novel lead compounds for cancer or related disorders, especially small-molecule, antibody or peptide product candidates in preclinical or early clinical testing. As part of its cancer treatment program, NeoRx has conducted clinical trials of its Skeletal Targeted Radiation product, combined with chemotherapy, in patients with multiple myeloma. The company's goal is to improve the effectiveness and reduce toxicities of current therapeutic methods. NeoRx’s focus is on toxic agents (regarding tumors) and on catering to unmet healthcare needs related to cancer. Products that the company develops target metastatic cancer and attempt to reduce the risk that cancer has spread. The firm recently announced additional workforce reductions, as part of its previously announced program to conserve cash by focusing on clinical development of Skeletal Targeted Radiotherapy. In other news, NeoRx sold IDEC Pharmaceuticals Corporation certain intellectual property and granted it certain licenses and option rights. The intellectual property sold includes a portfolio of the firm’s U.S. and international patents and certain associated technology and know-how relating to antibody-based therapeutics and ligand-linker technology.
BRANDS/DIVISIONS/AFFILIATES: International Isotopes, Inc. Holmium-166 DOTMP Pretarget Skeletal Targeted Radiotherapy
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Douglass B. Given, CEO Wolfgang Oster, COO Douglass B. Given, Pres. Richard Anderson, CFO Linda T. Findlay, VP-Human Resources Richard Ghalie, VP-Medical Richard Anderson, Corp. Sec. Richard Ghalie, VP-Regulatory Affairs
Phone: 206-281-7001 Fax: 206-284-7112 Toll-Free: Address: 410 W. Harison St., Seattle, WA 98119-4007 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $11,100 (12 months) 2002 Profits: $-23,100 (12 months) Stock Ticker: NERX 2001 Sales: $2,900 2001 Profits: $-23,800 Employees: 36 2000 Sales: $3,500 2000 Profits: $-11,400 Fiscal Year Ends: 12/31 1999 Sales: $ 600 1999 Profits: $-12,000 1998 Sales: $9,100 1998 Profits: $-4,400
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $234,202 Stock Purch. Plan: Y Second Exec. Salary: $192,385 ADVANTAGE: Focus on therapies with lessened side effects.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $50,000 Bonus: $17,500
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
NETWORK APPLIANCE INC
www.netapp.com
Industry Group Code: 334112 Ranks within this company's industry group: Sales:7 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:7
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Storage Equipment-Network Data Clustered Data Servers
Network Appliance supplies network-attached data storage and access devices, or filers, that provide fast, simple, reliable and cost-effective file service for dataintensive network environments. The company pioneered the concept of the network appliance, an extension of the industry trend towards dedicated, specialized devices that perform a single function in the network. Network Appliance's filer products combine specialized proprietary software and state-of-the-art industry-standard hardware to provide a unique solution for NFS, Common Internet File System and HTTP server markets. As a part of the company’s ongoing development process, Network Appliance is constantly enhancing its Data ONTAP operating system. The company also features its NetApp F630, NetApp F740 and NetApp F760 filers for expandable storage, simple administration and easy file backup and recovery. In addition, Network Appliance has new network file servers under development. The company uses advanced features from Tandem Computers’ ServerNet Interconnect technology in the NetApp F6300 clustered data server. The result is an ultra-high availability data server cluster for supporting enterprise-level applications. The firm’s product line also includes two storage management software solutions: SnapManager for Microsoft Exchange, which allows customers to perform online backup and rapid data recovery, and ApplianceWatch, which allows IT professionals to centrally manage, administer and optimize their systems for superior performance. In an effort to strengthen its position in the enterprise storage and data delivery market, the company recently began working with Intel Corporation to develop innovative market standards-compliant iSCSI solutions. The firm offers its employees medical, dental and vision benefits, vacation, sick leave and life insurance packages. Network Appliance's culture is centered around the ideas of change, adaptability and organizational evolution being necessary for success.
BRANDS/DIVISIONS/AFFILIATES: Data ONTAP NetAPP F Series NetCache SnapManager ApplianceWatch
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Daniel Warmenhoven, CEO Thomas F. Mendoza, Pres. Steve Gomo, CFO/Sr. VP-Finance Ed Deenihan, Sr. VP-Sales Chris Carlton, Sr. VP-People and Places Steve Kleiman, Sr. VP-Eng./Chief Tech. Officer David Hitz, Exec. VP-Eng. Mark Jon Bluth, VP-Oper. Jeffry R. Allen, VP-Bus. Oper. James Lau, Exec. VP/Chief Strategy Officer D. Patrick Linehan, Sr. VP/Mgr.-EMEA Chris Liotta, Sr. VP/Mgr.-Content Delivery Bus. Unit Mark Santora, Sr. VP-Worldwide Mktg.
Phone: 408-822-6000 Fax: 408-822-4501 Toll-Free: Address: 495 E. Java Dr., Sunnyvale, CA 94089 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $798,400 (12 months) 2002 Profits: $3,000 (12 months) Stock Ticker: NTAP 2001 Sales: $1,006,200 2001 Profits: $74,900 Employees: 2,280 2000 Sales: $579,300 2000 Profits: $73,792 Fiscal Year Ends: 4/30 1999 Sales: $289,420 1999 Profits: $35,613 1998 Sales: $166,163 1998 Profits: $20,965
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $400,000 Stock Purch. Plan: Y Second Exec. Salary: $300,000 ADVANTAGE: A pioneer in the concept of network appliances.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $332,000 Bonus: $124,500
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
NETWORK ASSOCIATES INC
www.nai.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:23 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:13
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Software-Security Virus Protection Software
Network Associates, Inc. is a leading supplier of security and availability solutions for e-business applications. The company’s products are developed for network security and management. Top grossing products include the McAfee Anti-Virus product line and the Sniffer network fault and performance e-management product line. The company also produces a family of McAfee wireless products designed to protect mobile devices from viruses. The McAfee business section is part of a partnership with CacheFlow, Inc. for the development of new management solutions for security and Internet scanning for virus and code attacks protection. Sniffer Technologies, a whollyowned subsidiary of Network Associates, develops security systems that monitor, validate and evaluate network infrastructure operations. Sniffer management solutions are used by the majority of Fortune e-50 companies. Magic Solutions, another subsidiary of Network Associates, offers the Magic Service Desk Suite, the industry's first browser-based service desk, with capabilities to customize the internal and external support process. The McAfee Security division of Network Associates produces McAfee ThreatScan, which provides companies with a proactive technology for preventing virus attacks and stopping recurring outbreaks before they impact the corporate network. ThreatScan software is a virus vulnerability assessment tool that works in conjunction with McAfee's leading anti-virus management console, ePolicy Orchestrator, to scour the enterprise network for devices that are vulnerable to virus infection. In recent news, America West Airlines selected Network Associates to manage its IT service desk operations with the Magic Service Desk solution.
BRANDS/DIVISIONS/AFFILIATES: McAfee Anti-Virus CacheFlow, Inc. Student Survival Kit ePolicy Orchestrator Sniffer Technologies Entercept Security Technologies Magic Solutions Magic Service Desk Suite
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. George Samenuk, CEO Steven Richards, COO Gene Hodges, Pres. Steven Richards, CFO Dale Veno, CIO Kent Roberts, General Counsel Sandra England, VP-Bus. Dev. and Strategic Research Art Matin, Pres., McAfee Ray Smets, Pres., Sniffer Technologies Jeff Honeycomb, Pres., Magic Solutions George Samenuk, Chmn.
Phone: 972-963-8000 Fax: 408-970-9727 Toll-Free: Address: 3965 Freedom Cir., Santa Clara, CA 95054 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $941,900 (12 months) 2002 Profits: $90,200 (12 months) Stock Ticker: NET 2001 Sales: $834,500 2001 Profits: $-100,700 Employees: 3,803 2000 Sales: $745,700 2000 Profits: $-102,700 Fiscal Year Ends: 12/31 1999 Sales: $683,668 1999 Profits: $-159,901 1998 Sales: $990,045 1998 Profits: $36,438
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $714,922 Stock Purch. Plan: Y Second Exec. Salary: $290,000 ADVANTAGE: Excellent technology/Extensive investment in R&D.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $540,000 Bonus: $108,596
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
NETWORK EQUIPMENT TECHNOLOGIES INC Industry Group Code: 334110 Ranks within this company's industry group: Sales:8 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
www.net.com
Profits:3 Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Networking Systems-WAN Connectivity Application-Specific Integrated Circuits
Network Equipment Technologies, Inc. (NET) provides services to wide area networks (WANs). A WAN has a switching system, connected by long-distance digital transmission links, that allows users to electronically exchange information. The company provides its services to businesses, government agencies, telecommunications providers and Internet service providers (ISPs). U.S. Government agencies, the U.S. Department of Defense, NATO and agencies in Austria, China and Thailand are responsible for approximately 50% of the company’s sales and are conducted through subsidiary N.E.T. Federal, Inc.. Other customers include agencies in the financial, banking, insurance, energy, transportation, manufacturing and retail sectors. The company produces the applicationspecific integrated circuits (ASICs) Terror and Trilogy. Other products include the LAN/WAN Exchange Edge Router, the FrameXpress Switching Module, the CellXpress, Prime Switch and SONET Transmission Manager. The development of new products and improvement of existing products are required to keep the firm on the cutting edge of technology. The firm has strengthened it position internationally by supplying products capable of delivering voice over Internet protocol (VoIP) solutions throughout the Asian market. The company is using its SHOUTIP platform to provide these services. SHOUTIP is an open programmable, nextgeneration packet telephony platform designed to maximize the potential of VoIP systems. NET offers employees educational assistance, a transportation reimbursement program, employee referral awards and an onsite fitness and cafeteria center at its headquarters in Oregon.
BRANDS/DIVISIONS/AFFILIATES: SHOUTIP Terror Trilogy SONET Transmission Manager FrameXpress CellXpress Prime Switch N.E.T. Federal, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Hubert A.J. Whyte, CEO John C. Batty, COO Hubert A.J. Whyte, Pres. John F. McGrath, Jr., CFO Stephen Gleave, VP-Mktg. John C. Batty, Corp. Sec. Jeff Range, VP-Oper. Hans Kramer, VP-Bus. and Product Dev. Craig Forbes, VP-Strategic Initiatives John Guisto, VP-Global Services Gary Lau, VP-Gov't and North American Enterprise Sales Andy Sceats, VP-Global Sales Dixon Doll, Chmn.
Phone: 510-713-7300 Fax: 510-574-4000 Toll-Free: 800-828-8080 Address: 6500 Paseo Padre Pkwy., Fremont, CA 94555 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $101,500 (12 months) 2002 Profits: $-37,400 (12 months) Stock Ticker: NWK 2001 Sales: $144,300 2001 Profits: $-20,800 Employees: 498 2000 Sales: $225,686 2000 Profits: $-40,070 Fiscal Year Ends: 3/31 1999 Sales: $263,835 1999 Profits: $-6,959 1998 Sales: $308,721 1998 Profits: $14,350
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $400,000 Bonus: $4,333 Stock Purch. Plan: Y Second Exec. Salary: $280,962 Bonus: $63,345 ADVANTAGE: Strategic distribution partnerships allowed Network Equipment to extend product reach, capitalizing on current networking market trends.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
NEUROCRINE BIOSCIENCES INC
www.neurocrine.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:91 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:85
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Neurological and Immune Disorder
Neurocrine Biosciences, Inc. is a neuroimmunology company focused on the discovery and development of therapeutics to treat diseases and disorders of the central nervous and immune systems. The company's neuroscience, endocrine and immunology segments provide a unique biological understanding of the molecular interaction of the central nervous, immune and endocrine systems, which facilitates the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes. The firm’s lead drug candidate, Indiplon, is a non-benzodiazepine gamma amino-butyric acid receptor agonist that is used to treat insomnia. The company is developing an immediate-release version of the drug in order to accommodate those who have trouble falling asleep or those who cannot fall asleep after suddenly awaking in the middle of the night. Neurocrine Biosciences is also developing a modified release formulation, which provides one dose at bedtime and a second dose in the middle of the night, in order to accommodate those who have difficulty remaining asleep. Additionally, the firm is developing NBI-3301, a protein in which a blood cell-derived growth factor has been joined with a Pseudomonas exotoxin, a potent toxin that can destroy cancer cells. NBI-3301 may be used to treat malignant glioma, the most common form of malignant brain cancer. Neurocrine Biosciences offers its employees dental and vision insurance, carwash services and massage therapy sessions. Additionally, the company sponsors a number of recreational events for its employees, including summer picnics, holiday parties and an annual bowling tournament.
BRANDS/DIVISIONS/AFFILIATES: Indiplon NBI-3301
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Gary A. Lyons, CEO Gary A. Lyons, Pres. Paul W. Hawran, CFO Cynthia J. Thomas, VP-Human Resources Henry Pan, Chief Medical Officer Margaret E. Valeur-Jensen, Corp. Sec. Margaret E. Valeur-Jensen, General Counsel Kevin C. Gorman, VP-Bus. Dev. Henry Pan, Exec. VP-Clinical Dev. Paul J. Conlon, VP-Drug Discovery John Saunders, VP-Medicinal Chemistry D. Bruce Campbell, Sr. VP-Dev. Joseph A. Mollica, Chmn.
Phone: 858-658-7600 Fax: 858-658-7601 Toll-Free: Address: 10555 Science Center Dr., San Diego, CA 92121 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $18,000 (12 months) 2002 Profits: $-94,500 (12 months) Stock Ticker: NBIX 2001 Sales: $41,200 2001 Profits: $-36,900 Employees: 276 2000 Sales: $14,600 2000 Profits: $-28,800 Fiscal Year Ends: 12/31 1999 Sales: $16,800 1999 Profits: $-16,800 1998 Sales: $16,000 1998 Profits: $-20,000
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $437,000 Bonus: $200,000 Stock Purch. Plan: Y Second Exec. Salary: $315,000 Bonus: $91,000 ADVANTAGE: Neocrine utilizes advanced technologies to enhance its drug discovery capabilities.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
NEUROGEN CORP
www.neurogen.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:95 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:68
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Neurological and Psychiatric Small Molecule Drugs
Neurogen Corp. is a leading small molecule drug discovery and development company targeting new drug candidates to improve the lives of patients suffering from neurological, inflammatory, pain and metabolic disorders. The firm has generated a portfolio of new drug programs through its fully integrated, proprietary drug discovery platform. Its Accelerated Intelligent Drug Discovery (AIDD) process and its expertise in cellular function assays allow the company to rapidly and cost-effectively identify active compounds during the drug discovery process. AIDD is an integrated system of hardware, software and processes that allows scientists to improve on the trial and error approach traditionally associated with discovery and development, through iterative application of screening, computational modeling and synthesis. The system works in tandem with its focused compound library and Virtual Screening on its Virtual Library, with several hundred billion virtual compounds. Neurogen has discovered 10 small molecule candidates that the firm and its partners are leading through human clinical trials. Two of these candidates, for the treatment of Alzheimer's disease and insomnia, are being tested by Pfizer, Inc. The company is also testing products for inflammatory disorders, Parkinson's disease, anxiety and depression, pulmonary disease, stress, pain and obesity. The company has also formed a licensing and research agreement with Aventis. Recently, Neurogen announced the results from a Phase II clinical study of NGD 97-1 for the treatment of Alzheimer's disease. The company also recently reduced its workforce by approximately 10% in order to enhance efficiency.
BRANDS/DIVISIONS/AFFILIATES: Accelerated Intelligent Drug Discovery Virtual Screening Virtual Library NGD 97-1
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. William Koster, CEO William Koster, Pres. Alan Hutchison, Exec. VP-Discovery Research Kenneth R. Shaw, Sr. VP-Chemistry and Pharmaceutical Dev. Stephen R. Davis, Exec. VP/Chief Bus. Officer Edmund P. Harrigan, Exec. VP/Chief Dev. Officer James E. Krause, Sr. VP-Biology Charles J. Manly, VP-Discovery Tech. James V. Cassella, VP-Clinical Research and Dev.
Phone: 203-488-8201 Fax: 203-481-8683 Toll-Free: Address: 35 NE Industrial Rd., Branford, CT 06405 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $15,700 (12 months) 2002 Profits: $-23,700 (12 months) Stock Ticker: NRGN 2001 Sales: $11,500 2001 Profits: $-25,400 Employees: 163 2000 Sales: $20,400 2000 Profits: $-15,500 Fiscal Year Ends: 12/31 1999 Sales: $10,200 1999 Profits: $-14,600 1998 Sales: $11,100 1998 Profits: $-9,500
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $285,107 Stock Purch. Plan: Second Exec. Salary: $274,152 ADVANTAGE: Focus on small molecule research/Alliance with Pfizer.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $60,849
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
NISSAN MOTOR CO LTD
www.nissan-global.com
Industry Group Code: 336111 Ranks within this company's industry group: Sales:9
Profits:3
Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Automobiles, Manufacturing Industrial Machinery
Nissan Motor Co., Ltd. is engaged in the development, manufacturing, sales and servicing of automotive products, marine equipment and industrial machinery. The firm’s major geographical areas of operation are Japan, North America, Europe, Asia, the Middle East and Mexico. The company functions through several separate business units within each location, each of which specializes in performing a specific function. North America’s operations are as follows: Nissan North America, Inc. markets seven vehicle lines through 1,100 dealers in the continental United States through its Fleet Sales operation, while Nissan Canada markets and distributes Nissan and Infiniti vehicles to Canadian dealerships. The Nissan Technical Center North America is responsible for technology and engineering functions. Nissan Trading Corp. conducts complex international trade transactions involving automotive materials, components and vehicles among Nissan companies and their suppliers. Additionally, the center recently formed close relationships with the Big Three automakers as part of a strategic initiative. The company’s Denver Data Center is a communications hub that supports data traffic for affiliates in North America as well as internationally to Nissan's locations in Europe and Japan. Nissan Design America creates vehicles specifically for the North American market. Nissan Logistics Corporation handles logistics procurement for North American-made parts and acts as a distribution network. In addition, Renault and Nissan have formed an alliance in order to meet the challenges of the globalization of markets, competitiveness and the acceleration of technological change. Nissan-Renault ranks as one of the world's six leading automotive groups. In recent news, the group agreed to enhance the scope of joint purchasing initiatives spearheaded by Renault-Nissan Purchasing. Benefits offered to employees vary by location. In North America, the company provides dental and vision insurance, a car lease/purchase plan, tuition reimbursement, child care assistance, credit union membership and a business casual environment.
BRANDS/DIVISIONS/AFFILIATES: NISSAN 180 Nissan Logistics Corp. Nissan Design America Nissan Trading Corp. Nissan North America, Inc. Nissan-Renault Nissan Canada Infiniti
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Carlos Ghosn, CEO, Pres., Co-Chm. Carlos Ghosn, CEO, Pres., Co-Chm. Norio Matsumura, Exec. VP-Global Sales and Mktg. Kuniyuki Watanabe, Sr. VP-Human Resources Eiichi Abe, Sr. VP-Research Itaru Koeda, Exec. VP-Purchasing Shuji Yamagata, Sr. VP-Vehicle Design Eng. Tadao Takahashi, Exec. VP-Mfg. Kuniaki Sasaki, Sr. VP-Admin. Bernard Ray, Sr. VP-Purchasing Strategy Takeshi Isayama, Exec. VP-Gov't and External Affairs Hajime Kawasaki, Sr. VP-Customer Service Toshiyuki Shiga, Sr. VP-Overseas Sales Norio Matsumura, Exec. VP-Overseas Oper.
Phone: 81-3-3543-5523 Fax: 81-3-5565-2228 Toll-Free: Address: 17-1 Ginza 6-chome Chuo-ku, Tokyo, 104-8023 Japan
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $46,588,000 (12 months) 2002 Profits: $2,799,000 (12 months) Stock Ticker: Foreign 2001 Sales: $49,109,800 2001 Profits: $2,670,000 Employees: 125,099 2000 Sales: $56,387,500 2000 Profits: $-6,456,300 Fiscal Year Ends: 3/31 1999 Sales: $52,426,100 1999 Profits: $-220,800 1998 Sales: $52,303,700 1998 Profits: $-111,600
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: One of the world's leading car and truck manufacturers.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
NKK CORPORATION
www.nkk.co.jp
Industry Group Code: 331000 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y Y
Engineering: Design: Construction: Eng. Services: Consulting:
Y Y
Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y Y
GROWTH PLANS/SPECIAL FEATURES:
Steel Manufacturing Engineering Services Environmental Solutions Large-Scale Integration
JFE Holdings, Inc. was formed through a merger between Kawasaki Steel Corporation and NKK Corporation, both leading Japanese steel manufacturers. The company operates in the steel, engineering, urban development, LSI, recycling and environmental solutions industries through its subsidiaries: JFE Steel Corporation, JFE Engineering Corporation, JFE Urban Development Corporation and Kawasaki Microelectronics, Inc. All subsidiaries provide recycling and environmental solutions. JFE Urban Development focuses on the development of residential, business and commercial facilities and the operation of leisure facilities. Kawasaki Microelectronics centers on the application-specific integrated circuit (ASIC) field. Another JFE subsidiary, JFE R&D Corporation, focuses on the research and development of technologies and projects that are pertinent to all subsidiaries and that display growth potential. Technologies include the Super-OLAC for steel plate manufacturing, Ignition Burner for sintering plants, the Continuous Hot Metal Temperature Measurement System and a system for the prolongation of coke oven life. The company is affiliated with California Steel Industries, Inc., Stelco, the SK Steel Corporation, Hyundai HYSCO and the National Steel Corporation, headquartered in Indiana. Recently, JFE Steel Corporation and Kobe Steel, Ltd. announced an agreement to form a joint venture called JFE Welding Co., Ltd. that will require both companies to shift production of welding wires to the joint venture.
BRANDS/DIVISIONS/AFFILIATES: Kawasaki Steel Corp. NKK Corp. JFE Steel Corp. JFE Engineering Corp. JFE Urban Development Corp. Kawasaki Microelectronics Super-OLAC JFE Welding Co., Ltd.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Yoichi Shimogaichi, Co-CEO Yoichi Shimogaichi, Pres. Tetsuo Miyazaki, Exec. VP-Finance Tetsuo Miyazaki, Exec. VP/Controller Cho Otani, Exec. VP-Legal Div. Cho Otani, Exec. VP-Admin. Cho Otani, Exec. VP-Corp. Planning Tetsuo Miyazaki, Exec. VP-Investor Rel. Kanji Emoto, Co-CEO Mikoto Wakamatsu, Sr. VP-Environmental Center and DME Project Shigeharu Dote, Pres./CEO, JFE Engineering Corp. Fumio Sudo, Pres./CEO, JFE Steel Corp. Kanji Emoto, Chmn.
Phone: 81-3-3217-4049 Fax: 81-3-3214-6110 Toll-Free: Address: 1-1-2, Marunouchi, Chiyoda-ku, Tokyo, 100-0005 Japan
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $12,466,000 (12 months) 2002 Profits: $-510,000 (12 months) Stock Ticker: Foreign 2001 Sales: $14,464,000 2001 Profits: $794,293,130 Employees: 28,413 2000 Sales: $15,974,100 2000 Profits: $-435,300 Fiscal Year Ends: 3/31 1999 Sales: $13,816,900 1999 Profits: $-829,200 1998 Sales: $14,536,500 1998 Profits: $107,300
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Highly diversified business base.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $ Second Exec. Salary: $
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
NOKIA CORPORATION
www.nokia.com
Industry Group Code: 334210 Ranks within this company's industry group: Sales:3 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:2
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Telecommunications Equipment-Cellular Telephones Wireless Network Systems
Nokia is a leading supplier of mobile, fixed and IP networks and related products and the world’s top mobile phone manufacturer, holding a 35% share of the mobile phone market. Moreover, Nokia accounts for approximately 50% of the market value of the Helsinki stock exchange. The company is a world leader in developing innovative wireless solutions. One such advancement is FriendsTalk, a mobile chat application that allows users to participate in Internet chatting even when they are away from their computers. The application works with the Nokia 3310 mobile phone. The firm has acquired DiscoveryCom, which is involved in the manufacture of communications products for the installation and maintenance of DSL services. The firm’s Nokia NetAct Optimizer is a versatile network optimization tool that analyzes network performance and displays the results on a geographical map. Moreover, the tool proposes configuration changes to enable the operator to achieve its performance targets. By solving performance and capacity problems and allowing the operator to focus on other tasks, the Nokia NetAct Optimizer speeds the network optimization process and increases automation. Other partnerships include a pilot project with Nordea, a Finland services group, to test the use of mobile chip identification in the delivery of banking services. Furthermore, the company recently announced a collaboration with IBM to develop and deliver an assortment of enterprise wireless e-business solutions. Nokia places a high priority on diversity and personal and professional growth and development. The company continually trains its employees and offers a wide range of bonus programs, including short-term incentives to annual profit sharing programs.
BRANDS/DIVISIONS/AFFILIATES: DiscoveryCom Network Alchemy Telekol Corp. AIRCOM International Diamond Lane Communications InTalk Corp. FriendsTalk Nokia NetAct Optimizer
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jorma Ollila, CEO Pekka Ala-Pietila, Pres. Olli-Pekka Kallasvuo, Exec. VP/CFO Yrjo Neuvo, Exec. VP/Chief Tech. Officer Veli Sundback, Exec. VP-Corp. Rel. and Trade Policy Matti Alahuhta, Pres.-Mobile Phones Sari Baldauf, Pres.-Networks J.T. Bergqvist, Exec. VP-IP Mobility Networks Pertti Korhonen, Exec. VP-Mobile Software
Phone: 358-7180-08000 Fax: 358-7180-38226 Toll-Free: Address: Keilalahdentie 4, Espoo, FIN-00045 Finland
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $31,526,000 (12 months) 2002 Profits: $3,351,000 (12 months) Stock Ticker: NOK 2001 Sales: $27,801,000 2001 Profits: $1,961,000 Employees: 51,748 2000 Sales: $27,978,300 2000 Profits: $3,543,300 Fiscal Year Ends: 12/31 1999 Sales: $18,211,300 1999 Profits: $2,341,300 1998 Sales: $12,274,100 1998 Profits: $1,620,200
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $ Bonus: $ Stock Purch. Plan: Y Second Exec. Salary: $ Bonus: $ ADVANTAGE: Nokia's incredible engineering and marketing prowess have made it the leading cellular phone maker in the world.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
NORTEL NETWORKS CORP
www.nortelnetworks.com
Industry Group Code: 334210 Ranks within this company's industry group: Sales:7 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:15
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Telecommunications Equipment-Switching, Wireless & Broadband Network Systems Communications Equipment and Systems Multimedia Communications Solutions Cellular Mobile Telecommunications Switches Optical Telecommunications Equipment
Nortel Networks Corporation is the leading global manufacturer of fully digital telecommunications switching equipment. Its business consists of a full range of services, from design to installation and servicing for service provider, carrier and enterprise customers. The company provides solutions to its customers for Internet support and voice, data and video networks. Nortel is the first to offer customers a new class of customer partnerships through its services provider, eBusiness, enterprise solutions, service to small and medium businesses, at-home solutions and government networks. Part of the firm’s strategy to date has involved using acquisitions to stay technologically ahead of strong competitors. In recent years, the firm has been forced to cut its workforce by nearly half due to the depressed economic conditions within the telecommunications industry. Recently, a leading European telecom operator, Connex, deployed Nortel's Passport 20000 Multiservice Switches, which enabled convergence of its voice and data traffic into one cost-effective network. In other news, Nortel announced amendments to its existing security agreements to facilitate its future financial flexibility. Nortel has also improved its ability to provide integrated solutions for wireless operators that will seamlessly link existing and future wireless wide area networks with fast-emerging wireless hot spots (also known as wireless local area networks). This solution will also enable operators to provide consolidated billing, security and authentication without needing to restructure their existing networks.
BRANDS/DIVISIONS/AFFILIATES: NETGEAR, Inc. Entrust Technologies, Inc. Volera, Inc. Bay Networks, Inc. Arris Interactive Connex
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Frank Dunn, CEO Frank Dunn, Pres. Doug Beatty, CFO Charles Childers, Chief Mktg. Officer William J. Donovan, Sr. VP-Human Resources Greg Mumford, Chief Tech. Officer Albert Hitchcock, CIO Douglas C. Beatty, Controller Deborah J. Noble, Corp. Sec. Nicholas J. DeRoma, General Counsel Chahram Bolouri, Pres.-Global Oper. Klaus M. Buechner, Sr. VP-Bus. Dev. Andrew Lark, VP-Global Comm. Katharine B. Stevenson, Treas. Pascal Debon, Pres.-Wireless Networks Malcolm Collins, Pres.-Enterprise Networks Sue Spradley, Pres.-Wireline Networks Gary R. Donahee, Pres.-Americas
Phone: 905-863-0000 Fax: 905-863-8408 Toll-Free: 800-466-7835 Address: 8200 Dixie Rd., Ste. 100, Brampton, Ontario L6T 5P6 Canada
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $10,560,000 (12 months) 2002 Profits: $-3,585,000 (12 months) Stock Ticker: NT 2001 Sales: $17,511,000 2001 Profits: $-27,302,000 Employees: 36,960 2000 Sales: $30,275,000 2000 Profits: $-3,470,000 Fiscal Year Ends: 12/31 1999 Sales: $21,287,000 1999 Profits: $-351,000 1998 Sales: $16,857,000 1998 Profits: $-1,282,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $564,833 Stock Purch. Plan: Second Exec. Salary: $534,917 A leading manufacturer of fully digital telecommunications switching equipment. ADVANTAGE:
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $4,200,000 Bonus: $1,298,509
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
NORTH AMERICAN SCIENTIFIC
www.nasi.net
Industry Group Code: 339113 Ranks within this company's industry group: Sales:38 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:35
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Radioactive Seeds (Prostate Cancer) Radioactive Implant Therapeutics Environmental Monitoring Brachytherapy
North American Scientific, Inc. (NASI) designs, develops and produces innovative radioisotopic products, including brachytherapy seeds and radiopharmaceuticals, for the treatment and diagnosis of disease. The firm has applied its expertise in radioisotopes to develop and market products for medical, environmental, research and industrial applications. Since 1996, NASI has focused primarily on medical markets. The company's first two therapeutic products are brachytherapy seeds for the treatment of prostate cancer, marketed under the trademarks IoGold and PdGold by Mentor Corporation, the firm's distribution partner. In 2000, the company acquired Boston-based Theseus Imaging Corp., expanding NASI's products into larger markets. Theseus's primary product candidate is Apomate, an in vivo nuclear medicine imaging agent that targets cell death. The drug is in clinical trials for applications including determining response to chemotherapy, assessing the location and extend of heart attack damage and detecting heart transplant rejection. NASI's other products include radiation calibration and reference source products and Prospera, a line of high-activity brachytherapy seeds for use in the treatment of ocular melanoma and other solid tumor applications. In recent news, subsidiary Theseus Imaging announced plans to submit a new drug application to the FDA for its Hynic-Annexin V program.
BRANDS/DIVISIONS/AFFILIATES: Mentor Corporation Gold Standard Theseus Imaging Corp. Prospera Apomate IoGold PdGold Hynic-Annexin V
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. L. Michael Cutrer, CEO L. Michael Cutrer, Pres. Alan I. Edrick, Sr. VP/CFO George Jones, Exec. VP-Sales and Mktg. Allan M. Green, Chief Tech. Officer David Stiles, VP-Brachytherapy Sales and Mktg. Irwin J. Gruverman, Chmn.
Phone: 818-734-8600 Fax: 818-734-8606 Toll-Free: Address: 20200 Sunburst St., Chatsworth, CA 91311 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $20,800 (12 months) 2002 Profits: $-5,200 (12 months) Stock Ticker: NASI 2001 Sales: $19,300 2001 Profits: $-2,000 Employees: 75 2000 Sales: $17,500 2000 Profits: $-6,000 Fiscal Year Ends: 10/31 1999 Sales: $12,800 1999 Profits: $3,400 1998 Sales: $5,800 1998 Profits: $1,100
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $290,000 Stock Purch. Plan: Y Second Exec. Salary: $200,000 ADVANTAGE: Unique method for delivery of radioactive therapy.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $75,000 Bonus: $40,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
NOVARTIS AG
www.novartis.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:5 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:6
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Diversified Therapeutic Drug Discovery Branded Pharmaceuticals Over-the-Counter Drugs Nutritionals Soft Contact Lenses
Novartis is engaged in research and development and is a leader in life sciences with a strong focus on improving the well being of animals, plants, crops and humans. It operates in two principle business segments: Novartis Pharmaceuticals, comprised of the Oncology, Transplantation, Ophthalmics and Mature Products divisions, and Novartis Consumer Health, which includes generics, over the counter drugs, animal health, medical nutrition, infant and baby products and CIBA Vision. Through its pharmaceuticals division, Novartis develops, manufactures and markets prescription medicines. Its generics division competes in two segments: finished dosage forms and active pharmaceutical ingredients and their intermediates. Finished dosage forms are sold to pharmacies, hospitals and other health care outlets, while active ingredients and their intermediates for pharmaceutical and biotechnological substances are sold to industrial customers. Consumer health operates in the over-the-counter self-medication, health and functional nutrition and medical nutrition units. CIBA Vision is a world leader in the research, development and manufacturing of eye care products, namely soft contact lenses, lens care products and ophthalmic surgical products. Through its animal health division, Novartis enhances and extends the life of companion animals and improves the health and productivity of farm animals. This business unit owns Grand Laboratories, Inc. and ImmTech Biologics, Inc., both engaged in the development of vaccines for cattle and pigs. Novartis has established the Novartis Institute for Biomedical Research, Inc. in Cambridge, Massachusetts, where U.S. and Japanese research operations are held. All other worldwide research activities are performed in Europe. The firm will open a new $750 million, 1,000-employee lab in Cambridge, MA in 2004. Novartis provides medical, dental and vision insurance to employees, in addition to childcare and elderly care support, educational advancement support and family care support. Novartis also offers health and fitness programs and counseling services.
BRANDS/DIVISIONS/AFFILIATES: CIBA Vision Grand Laboratories, Inc. ImmTech Biologics, Inc. Novartis Institute for Biomedical Research, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Daniel Vasella, CEO Daniel Vasella, Pres. Raymund Breu, CFO Norman Walker, Exec. Dir.-Human Resources Max Kaufmann, Corp. Sec. Urs Barlocher, Dir.-Legal and General Affairs Thomas Ebeling, CEO Pharmaceuticals Paul Choffat, CEO Consumer Health Marc Fishman, Pres., Novartis Institutes for Biomedical Research Daniel Vasella, Chmn.
Phone: 41-61-324-1111 Fax: 41-61-324-8001 Toll-Free: Address: Lichtstrasse 35, Basel, CH-4056 Switzerland
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $23,151,000 (12 months) 2002 Profits: $3,546,000 (12 months) Stock Ticker: NVS 2001 Sales: $19,070,000 2001 Profits: $5,225,000 Employees: 72,868 2000 Sales: $21,312,500 2000 Profits: $4,291,666 Fiscal Year Ends: 12/31 1999 Sales: $19,324,404 1999 Profits: $3,963,690 1998 Sales: $18,870,238 1998 Profits: $3,577,381
SALARIES/BENEFITS: Pension Plan: Y Savings Plan:
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $ Bonus: $ Stock Purch. Plan: Second Exec. Salary: $ Bonus: $ ADVANTAGE: A combination of acquisitions and strong research have made this one of the most promising pharma companies in the world.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
NOVELL INC
www.novell.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:19 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:34
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Software-Networking & Application Distributed Infrastructure Internet Information Services E-Business Software
Novell, Inc. is a leader in Internet business solutions, services and software designed to secure and operate information networks. Novell's One Net strategy is to provide the capability for global networks, including corporate, public, intranet, extranets, the Internet, wired and wireless, to work together as one to securely connect customers, employees, suppliers and partners across organizational barriers. Net business solutions built with Novell software and services enable web-based access to multiple business applications, processes and other IT resources. Novell’s NetWare network server operating system links PCs to corporate networks and integrates directories, databases, storage systems and printers. The company’s ManageWise software manages and remotely controls a customer’s entire network, allowing clients to perform all network management tasks from one point of administration. Its capabilities include monitoring Novell Directory Services, managing NetWare and Windows servers, analyzing network traffic and tracking network inventory. In addition, early-warning alarms help prevent downtime by alerting administrators to problems before they impact network performance. Cambridge Technology Partners, the firm’s technology services and consulting subsidiary, assists customers in streamlining their network and technology operations. In addition, Novell and Accenture created Volera, a company that offers the Excelerator platform, the fastest caching and content networking platform in the industry based on third-party testing. Novell recently announced that the South Carolina Department of Health and Human Services (DHHS) selected the exteNd product suite for its web portal access needs. The software, developed by Novell, will give all DHHS employees operating across 150 different hospitals secure access to the agency’s web portal. Novell offers employees wellness programs, fitness facilities, credit union membership and a software discount purchase program.
BRANDS/DIVISIONS/AFFILIATES: Volera Cambridge Technology Partners NetWare One Net ManageWise Novell Directory Services Excelerator exteNd
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jack L. Messman, CEO Jack L. Messman, Pres. Joseph S. Tibbetts, Jr., Sr. VP/CFO Debra Bergevine, Chief Mktg. Officer Alan Friedman, VP-People Carl Ledbetter, VP-Research and Dev. Alan Nugent, Chief Tech. Officer Carl Ledbetter, VP-Eng. Joe LaSala, Corp. Sec. Joe LaSala, General Counsel Ralph Linsalata, VP-Corp. Dev. and Planning David A. Litwack, VP-Web Application Dev. Products Gary Schuster, VP-Comm. Hitoshi Yoshida, Pres.-Novell Japan Mark Hardardt, VP-Sales Carv Moore, Pres.-Novell Americas Robert Couture, VP-Worldwide Services Jack L. Messman, Chmn. Rhonda O'Donnell, Pres.-Novell Asia Pacific
Phone: 801-861-7000 Fax: 801-228-7077 Toll-Free: 800-453-1267 Address: 1800 S. Novell Pl., Provo, UT 84606 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,134,300 (12 months) 2002 Profits: $-246,800 (12 months) Stock Ticker: NOVL 2001 Sales: $1,040,100 2001 Profits: $-272,800 Employees: 6,524 2000 Sales: $1,161,735 2000 Profits: $49,470 Fiscal Year Ends: 10/31 1999 Sales: $1,272,820 1999 Profits: $190,747 1998 Sales: $1,083,887 1998 Profits: $101,976
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $523,883 Bonus: $569,780 Stock Purch. Plan: Y Second Exec. Salary: $410,481 Bonus: $404,283 ADVANTAGE: One of the best-known names in computer networking/Renewed focus on directory technology.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
NOVELLUS SYSTEMS INC
www.novellus.com
Industry Group Code: 335999 Ranks within this company's industry group: Sales:8 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:7
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Electronic Equipment-Semiconductor Production Related Chemical Mechanical Planarization Products
Novellus Systems, Inc. manufactures, markets and services advanced automated fabrication systems for the deposition of thin films within the semiconductor equipment market. The company is a leading supplier of high-productivity deposition systems used in the fabrication of integrated circuits. The company’s product offerings are centered on the advanced systems used to deposit the films of conducting and insulating material, using chemical vapor deposition (CVD), physical vapor deposition (PVD) and electroplating or Electrofill. CVD systems employ a chemical plasma to deposit all of the dielectric (insulating) layers and certain of the conductive metal layers on the surface of a semiconductor wafer. PVD systems are used to deposit conductive metal layers by sputtering metallic atoms from the surface of a target source via high DC power. Electrofill systems are used for depositing copper conductive layers in a dual damascene design architecture using an aqueous solution. VECTOR is a CVD system for depositing dielectric films on 300mm wafers. The firm's 300mm PVD product, INOVA xT with HCM technology, offers superior barrier performance leading to low via resistance and improved device reliability. Novellus Systems recently acquired SpeedFam-IPEC, Inc., a supplier of chemical mechanical planarization (CMP) products used in the fabrication of advanced copper interconnects. This acquisition has enabled the company to become one of the industry’s top suppliers of CMP products. Novellus offers its employees three weeks of vacation, 10 paid holidays per year, five weeks of paid sabbatical after every five years of service, medical, dental and vision insurance, tuition reimbursement and other benefits.
BRANDS/DIVISIONS/AFFILIATES: Nippon Novellus Electrofill VECTOR INOVA xT SpeedFam-IPEC, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Richard S. Hill, CEO Peter R. Hanley, Pres. Kevin Royal, VP/CFO John A. Chenault, Exec. VP-Worldwide Sales and Service Oper. Wilbert G. M. van den Hoek, Chief Tech. Officer Craig Stevens, VP-Eng. David Williams, VP-Mfg. Jeffrey Benzing, Exec. VP-Oper. Wilbert van den Hoek, Exec. VP-Integration and Advanced Dev. Jeffrey C. Benzing, Exec. VP-Deposition and Surface Integrity Products Richard Faubert, Exec. VP-Chemical Mechanical Planarization Group Kevin Jennings, VP-Mktg. Craig Stevens, VP-Product Dev. Richard S. Hill, Chmn.
Phone: 408-943-9700 Fax: 408-943-3422 Toll-Free: Address: 4000 N. 1st St., San Jose, CA 95134 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $840,000 (12 months) 2002 Profits: $22,900 (12 months) Stock Ticker: NVLS 2001 Sales: $1,339,300 2001 Profits: $144,500 Employees: 3,228 2000 Sales: $1,173,700 2000 Profits: $151,100 Fiscal Year Ends: 12/31 1999 Sales: $592,741 1999 Profits: $76,574 1998 Sales: $518,778 1998 Profits: $52,828
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $709,615 Stock Purch. Plan: Y Second Exec. Salary: $400,096 ADVANTAGE: A leading supplier of high-productivity deposition systems.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $449,247 Bonus: $142,585
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
NOVEN PHARMACEUTICALS
www.noven.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:60 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:40
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Transdermal Drug Delivery Systems Women's Health Products
Noven Pharmaceuticals, Inc. is a leader in the development and manufacture of advanced transdermal drug delivery products and technologies and prescription transdermal products. Its principal commercialized products are transdermal drug delivery systems, utilizing its DOT Matrix technology, for use in hormone replacement therapy. The firm's first product was an estrogen patch for the treatment of menopausal symptoms, marketed under the name Vivelle in the U.S. and Canada and under the name Menorest in Europe and other markets. The company also launched the smallest transdermal estrogen patch ever approved by the U.S. FDA, Vivelle-Dot. The product is currently marketed in several foreign countries and began marketing under the name Estradot in the U.S. in 2002. Noven also developed a combination estrogen/progestin transdermal patch for the treatment of menopausal symptoms, marketed under the name CombiPatch in the U.S. and Estalis in Europe and other markets. The firm is currently developing a range of products, including MethyPatch, a transdermal delivery system for the treatment of attention deficit hyperactivity disorder. Other areas of focus include central nervous system conditions and pain management. In addition, Noven has partial ownership of a joint venture formed in partnership with Novartis Pharmaceuticals, called Vivelle Ventures, doing business under the name Novogyne Pharmaceuticals. The company markets Vivelle, Vivelle-Dot and CombiPatch in the U.S. In recent news, the FDA accepted a new drug application for MethyPatch.
BRANDS/DIVISIONS/AFFILIATES: Vivelle Menorest Vivelle-Dot CombiPatch Estalis MethyPatch Estradot Novogyne Pharmaceuticals
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Robert C. Strauss, CEO Robert C. Strauss, Pres. James B. Messiry, VP/CFO W. Neil Jones, VP-Mktg. and Sales Juan A. Mantelle, VP/Chief Tech. Officer Jeffery P. Eisenberg, Corp. Sec. Jeffery P. Eisenberg, General Counsel Paven Handa, Exec. Dir.-Bus. Dev. Joseph C. Jones, VP-Corp. Affairs Jeffery P. Eisenberg, VP-Strategic Alliances
Phone: 305-253-5099 Fax: 305-251-1887 Toll-Free: Address: 11960 SW 144th St., Miami, FL 33186 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $55,400 (12 months) 2002 Profits: $13,900 (12 months) Stock Ticker: NOVN 2001 Sales: $45,900 2001 Profits: $12,100 Employees: 274 2000 Sales: $42,900 2000 Profits: $19,600 Fiscal Year Ends: 12/31 1999 Sales: $31,600 1999 Profits: $10,500 1998 Sales: $21,800 1998 Profits: $-4,100
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $485,100 Stock Purch. Plan: Second Exec. Salary: $220,500 ADVANTAGE: Growing line of unique therapies based on transdermal delivery.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
ONSITE ENERGY CORPORATION
www.onsitenergy.com
Industry Group Code: 541690 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:1
Transportation: Aerospace: Automotive: Y Y
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Energy Services and Environmental Consulting Energy-Efficient Products
Onsite Energy Corporation assists industrial, commercial and institutional customers in lowering energy costs through the development, engineering and installation of energy-efficient products. The company offers installation of a number of cost-effective technologies, including boiler retrofits, efficient refrigeration systems and natural gas appliances. Onsite Energy also develops and maintains distributed generation resources, including combined heat and power systems and peak shaving and base load generation. Moreover, the firm offers consulting services, including direct access planning and energy and market assessments. Recently, the company was awarded a $3.6-million contract to increase the energy efficiency of San Diego’s police department headquarters. Under the terms of the agreement, Onsite Energy will install solar photovoltaic and combined heat and power systems and upgrade the facility’s HVAC systems. The company will also attach solar control film to the building’s windows in order to minimize air conditioning power requirements and heat loss. Additionally, the U.S. Department of Energy, Los Angeles County, California State University, Johnson & Johnson and General Motors have initiated energy efficiency projects with Onsite Energy. Onsite Energy offers its employees dental insurance.
BRANDS/DIVISIONS/AFFILIATES: Onsite Energy de Panama
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Richard T. Sperberg, CEO Richard T. Sperberg, Pres. Paul E. Blevins, CFO Kimberly Boeck, Dir.-Human Resources Audrey Nelson Stubenberg, General Counsel Gregory E. Maynard, VP-Project Implementation Charles C. McGettigan, Chmn.
Phone: 760-931-2400 Fax: 760-931-2405 Toll-Free: Address: 701 Palomar Airport Rd., Ste. 200, Carlsbad, CA 92009 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $12,100 (12 months) 2002 Profits: $ 300 (12 months) Stock Ticker: ONSE 2001 Sales: $12,000 2001 Profits: $-1,700 Employees: 34 2000 Sales: $18,200 2000 Profits: $-6,600 Fiscal Year Ends: 6/30 1999 Sales: $43,600 1999 Profits: $-6,900 1998 Sales: $12,300 1998 Profits: $-2,200
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Expertise in energy efficiency
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Top Exec. Salary: $220,000 Second Exec. Salary: $161,000
Bonus: $39,873 Bonus: $48,333
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ORACLE CORP
www.oracle.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:2 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:2
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Computer Software-Database Management E-Business Applications Software
Oracle Corporation is a leading supplier of software for information management and ranks second among the world's independent software specialists behind Microsoft. The company develops, manufactures, markets and distributes software that helps corporations manage and expand their businesses. Oracle’s software products can be categorized into two broad areas: systems software and Internet business applications software. Systems software is a complete Internet platform for developing and deploying applications on the Internet and corporate intranets. The platform includes database management software and development tools that allow users to create, retrieve and modify the various types of data stored in a computer system. Internet business applications software allows users to access information or use the applications through a simple Internet browser on any client computer, automating the performance of specific business data processing functions for procurement and financial, project, human resources, supply chain and customer relationship management. Oracle’s software runs on a broad range of computers including mainframes, minicomputers, workstations, PCs, laptops and information appliances (such as hand-held devices and mobile phones), and is supported on more than 85 different operating systems. In addition to computer software products, Oracle offers a range of consulting, education and support services for its customers. The firm has made a shift to Internet-based software and development tools in order to eliminate the need for customers to install software locally. This effort is centered around Oracle-operated portals including Oracle Business Online, Oracle Sales Online and Portal.Oracle.com. Recently, Oracle China (Beijing Oracle Software Systems), a subsidiary of the company, established a strategic alliance with Flag Software, a Chinese software company focusing on the Linux operating system and applications. Oracle's employee benefits include telecommuting, gym membership and no enforced dress code. The company headquarters offers a fitness center with an outdoor pool.
BRANDS/DIVISIONS/AFFILIATES: Oracle China My.Oracle.Com Oracle9i Database Oracle9i Real Application Clusters Oracle Media Server Oracle WebDB Oracle Jdeveloper Portal.Oracle.com
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Lawrence J. Ellison, CEO Jeffrey O. Henley, CFO Mark Jarvis, Chief Mktg. Officer Joyce Westerdahl, VP-Human Resources Jennifer Minton, Controller Daniel Cooperman, Corp. Sec. Daniel Cooperman, General Counsel Charles E. Phillips, Exec. VP-Corp. Strategy and Bus. Dev. Keith Block, Exec. VP-North America Safra Catz, Exec. VP Ronald A. Wohl, Exec. VP-Applications Dev. Charles Rozwat, Exec. VP-Server Tech. Lawrence J. Ellison, Chmn.
Phone: 650-506-7000 Fax: 650-506-7200 Toll-Free: 800-672-2531 Address: 500 Oracle Pkwy., Redwood City, CA 94065 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $9,673,000 (12 months) 2002 Profits: $2,224,000 (12 months) Stock Ticker: ORCL 2001 Sales: $10,859,700 2001 Profits: $2,561,100 Employees: 42,006 2000 Sales: $10,130,128 2000 Profits: $6,296,803 Fiscal Year Ends: 5/31 1999 Sales: $8,827,252 1999 Profits: $1,289,758 1998 Sales: $7,143,866 1998 Profits: $813,695
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $825,000 Stock Purch. Plan: Y Second Exec. Salary: $500,000 ADVANTAGE: Among the world's independent software companies.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $1,571,379 Bonus: $1,244,534
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ORBITAL SCIENCES CORP
www.orbital.com
Industry Group Code: 513340 Ranks within this company's industry group: Sales:3 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Profits:1 Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Satellites-Low and Medium Earth Orbit Launch Vehicle Systems
Orbital Sciences Corporation designs, develops, manufactures and operates small space systems for U.S. government agencies and commercial and scientific customers. The company’s product offerings include suborbital rockets that are used as target and boost vehicles for missile defense systems and space launch vehicles that place satellites weighing up to 3,000 pounds into low-Earth orbit. The firm also designs and produces suborbital launch vehicles that place payloads into a variety of high-altitude trajectories but, unlike space launch vehicles, do not place payloads into orbit around the Earth. The U.S. Missile Defense Agency and various branches of the U.S. military frequently use Orbital Sciences’ suborbital launch vehicles for ballistic missile interceptor experiments. The firm has been selected by the U.S. Air Force to combine surplus government Peacekeeper ballistic missile equipment with its space launch vehicle technology to conduct space and suborbital launch missions over the next decade. Additionally, the company offers low-Earth orbit satellites, which are used for communications and scientific and military missions, and geosynchronous Earth orbit communications satellites. Orbital Sciences’ transportation management division develops and produces fleet management systems that are used primarily by metropolitan mass transit operators in the United States. Specifically, the division combines global positioning vehicle tracking technology with terrestrial wireless communications to help transit agencies manage public bus and light rail systems. Recently, Orbital Sciences was awarded a $900-million contract from Boeing to develop, build, test and support missile interceptor booster vehicles. Orbital Sciences offers its employees dental and vision insurance and tuition reimbursement.
BRANDS/DIVISIONS/AFFILIATES: Pegasus Taurus Minotaur
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. David W. Thompson, CEO James R. Thompson, COO James R. Thompson, Pres. Garrett E. Pierce, CFO Susan Rogers, Human Resources W. Jean Floyd, Sr. VP-Tech. Oper. N. Paul Brost, Sr. VP-Bus. Oper. N. Paul Brost, Sr. VP-Finance Jack Danko, General Mgr.-Space Systems Group Ronald J. Grabe, General Mgr.-Launch Systems Group David W. Thompson, Chmn.
Phone: 703-406-5000 Fax: 703-406-3502 Toll-Free: Address: 21839 Atlantic Blvd., Dulles, VA 20166 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $551,600 (12 months) 2002 Profits: $ 800 (12 months) Stock Ticker: ORB 2001 Sales: $415,200 2001 Profits: $19,000 Employees: 2,000 2000 Sales: $725,700 2000 Profits: $-278,200 Fiscal Year Ends: 12/31 1999 Sales: $874,900 1999 Profits: $-121,900 1998 Sales: $730,662 1998 Profits: $-56,552
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $430,000 Stock Purch. Plan: Y Second Exec. Salary: $420,000 ADVANTAGE: A leading maker of ground stations that receive Earth images.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $326,814 Bonus: $1,023,351
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest:
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
ORCHID BIOSCIENCES INC
www.orchid.com
Industry Group Code: 541710 Ranks within this company's industry group: Sales:10 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:15
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Research-Bioinformatics Genetic Technology Pharmacogenetic Testing Genetic Databases Genotyping Instrument Hardware Reagents
Orchid BioSciences is engaged in the development and commercialization of technologies, products and services designed to measure and analyze information related to genetic diversity, or the genetic variability that distinguishes one organism from another. The firm has established a portfolio of business units that provide products and services focusing on the analysis of genetic variability through genotyping, the measurement of genetic variability in a person, plant or animal individual. This data is used in the field of identity genomics for paternity and forensics identification testing, as well as by health care providers in organ transplantation compatibility testing. It is also used in genetic disease susceptibility testing and to help physicians manage treatment regimens. Orchid focuses on applications including SNP (single nucleotide polymorphism) genotyping and pharmacogenetics. The firm's business units include Orchid Life Sciences, which develops and markets products and services for SNP genotyping to life sciences and biomedical researchers and pharmaceutical, agricultural, diagnostic and biotechnology companies; Orchid Identity Genomics, which provides DNA testing for paternity and forensics determinations to government authorities as well as individuals and organizations (through Orchid GeneScreen and Orchid Cellmark); Orchid Diagnostics, which provides products and services for genetic testing; and Orchid GeneShield, which develops programs designed to accelerate the adoption and use of personalized medicine by patients and physicians. At the core of Orchid's technologies is its proprietary SNP-IT primer extension technology, a method of isolating the precise location of the site of a suspected SNP and utilizing the inherent accuracy of DNA polymerase to determine the presence or absence of the SNP. SNP-IT products include SNPcode and SNPstream. The company offers its employees credit union membership, reward and recognition programs and alternative work schedules for many positions, including flextime and teleworking.
BRANDS/DIVISIONS/AFFILIATES: Orchid Biocomputer Orchid Diagnostics Orchid GeneScreen Orchid Cellmark Orchid GeneShield Orchid Life Sciences SNPstream SNPware
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Dale R. Pfost, CEO Dale R. Pfost, Pres. Andrew P. Savadelis, CFO/Sr. VP-Finance Michael T. Boyce-Jacino, Chief Scientific Officer/VP-Life Sciences Donald R. Marvin, Sr. VP/Mgr.-Diagnostics Russell T. Granzow, VP-Corp. Bus. Dev. and Strategy Mark D. Stolorow, Exec. Dir.-Orchid Cellmark Keith W. Brown, Sr. VP/Mgr.-Identity Genomics Christopher S. Smith, Exec. Dir.-Orchid GeneScreen M. Lee Morse, VP/Mgr.-Orchid GeneShield
Phone: 609-750-2200 Fax: 609-750-6400 Toll-Free: Address: 4390 U.S. Rte. One, Princeton, NJ 08540 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $50,400 (12 months) 2002 Profits: $-80,100 (12 months) Stock Ticker: ORCH 2001 Sales: $31,200 2001 Profits: $-84,700 Employees: 492 2000 Sales: $18,400 2000 Profits: $-47,900 Fiscal Year Ends: 12/31 1999 Sales: $1,800 1999 Profits: $-28,200 1998 Sales: $2,800 1998 Profits: $-11,500
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $365,750 Stock Purch. Plan: Second Exec. Salary: $291,500 ADVANTAGE: Excellent potential for new uses of its diagnostics technology.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $79,233 Bonus: $96,250
LOCATIONS: ("Y" = Yes) West:
Southwest: Y
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ORPHAN MEDICAL INC
www.orphan.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:94 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:56
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Rare Disease Antidotes
Orphan Medical, Inc. acquires, develops and markets pharmaceutical products of high medical value for patients within selected therapeutic areas, currently concentrating on antidotes, oncology support and sleep disorders. The company's lead antidote and oncology support products are Antizol and Busulfex, respectively, and are available commercially in the United States and several foreign countries. Xyrem is Orphan's lead product in the sleep disorders area. The firm also manufactures and distributes Cystadane and Sucraid, which treat two rare congenital diseases. Antizol-Vet is marketed through separate channels to the veterinary community. Orphan utilizes a targeted marketing approach, focusing on areas characterized by well-defined patient populations treated by well-defined groups of specialists, which makes a large sales force unnecessary because marketing efforts can be focused on a limited number of medical specialists or patients. In recent news, the company announced the commercial launch of is Xyrem product in oral solution form. The drug is being sold through a specialty sales force to sleep centers and other physicians who treat cataplexy patients. It is the first and only approved medication for the treatment of cataplexy, a debilitating symptom of narcolepsy. Express Scripts, a pharmacy benefit management company, was named the exclusive distributor of the drug. Orphan also recently reported that Xyrem prescriptions written to date have exceeded company expectations.
BRANDS/DIVISIONS/AFFILIATES: Antizol Busulfex Xyrem Sucraid Cystadane Elliotts B Solution Antizol-Vet
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John H. Bullion, CEO William Houghton, COO Timothy G. McGrath, VP/CFO Pamela J. Stahl, VP-Commercial Oper. Dayton T. Reardan, VP-Regulatory Affairs Mark D. Perrin, Exec. VP/Chief Commercial Officer John H. Bullion, Chmn.
Phone: 612-513-6900 Fax: 612-541-9209 Toll-Free: 888-867-7426 Address: 13911 Ridgedale Dr., Ste. 250, Minnetonka, MN 55305 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $16,100 (12 months) 2002 Profits: $-11,400 (12 months) Stock Ticker: ORPH 2001 Sales: $11,300 2001 Profits: $-6,000 Employees: 113 2000 Sales: $11,200 2000 Profits: $-6,100 Fiscal Year Ends: 12/31 1999 Sales: $6,500 1999 Profits: $-5,200 1998 Sales: $5,000 1998 Profits: $-8,200
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $256,938 Bonus: $128,131 Stock Purch. Plan: Second Exec. Salary: $200,000 Bonus: $109,635 ADVANTAGE: Focus on therapies for rare diseases/Ability to capitalize on drug therapies developed by other companies.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
OSI PHARMACEUTICALS INC
www.osip.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:88 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:98
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Small Molecule Cancer Treatments
OSI Pharmaceuticals is a leading biopharmaceutical company primarily focused on the discovery, development and commercialization of innovative products for the treatment of cancer. It has built a pipeline of discovery programs and drug candidates addressing major, unmet needs in cancer and selected opportunities arising from its drug discovery research programs that represent significant commercial opportunities outside of cancer. The firm has three candidates in clinical trials and seven projects with candidates in late-stage preclinical development. In late 2001, OSI acquired the oncology assets of Gilead Sciences, Inc., providing the company with three additional oncology candidates in clinical trials, as well as a first-class oncology clinical development team and strong toxicology groups. OSI's most advanced drug candidate, Tarceva, is a small molecule inhibitor of the epidermal growth factor receptor, the protein product of which is overexpressed in many solid tumor cancers. Tarceva is an oral, once-a-day drug with utility in treating a wide range of tumor types, including lung cancer, head and neck cancer and ovarian cancer. The drug is currently in Phase III clinical trials. Other oncology products in development include GS7904L, a liposomal thymidycate; OSI-211, a liposomal lurtotecan; and OSI760 and OSIC-0961370, adenosine receptor inhibitors. OSI's other research programs include the areas of diabetes, respiratory diseases, cholesterol lowering and cosmeceuticals. Recently, the company announced several restructuring adjustments designed to refocus efforts on oncology, including staff reductions. In addition, the company recently initiated two Phase II trials of OSI211 for ovarian and small-cell lung cancer. OSI offers its employees medical, dental and life insurance, stock options, tuition reimbursement, flexible spending plans, an employee assistance program and employee functions and activities.
BRANDS/DIVISIONS/AFFILIATES: Tarceva Aston Molecules Gilead Sciences, Inc. OSI-760 OSIC-0961370 GS7904L OSI-211
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Colin Goddard, CEO Robert L. Van Nostrand, VP/CFO Linda E. Amper, VP-Human Resources Nicholas G. Bacopoulos, Pres., Research and Dev. Raymond Bendele, VP-Pharmaceutical Dev. Barbara Wood, General Counsel Linda E. Amper, VP-Bus. Admin. Geoffrey Cooper, VP-Bus. Dev. John A. Slack, VP-Dev. Neil Gibson, VP-Research Nicole Onetto, Exec. VP-Oncology Arthur M. Bruskin, VP-Strategic Planning Jim McCormack, VP-U.K. Research
Phone: 631-962-2000 Fax: 631-752-3880 Toll-Free: Address: 58 S Service Rd., Ste. 110, Melville, NY 11747 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $21,800 (12 months) 2002 Profits: $-218,500 (12 months) Stock Ticker: OSIP 2001 Sales: $26,000 2001 Profits: $-23,700 Employees: 429 2000 Sales: $28,700 2000 Profits: $-16,300 Fiscal Year Ends: 9/30 1999 Sales: $22,700 1999 Profits: $-9,800 1998 Sales: $19,500 1998 Profits: $-10,200
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $488,769 Stock Purch. Plan: Y Second Exec. Salary: $304,856 ADVANTAGE: Expertise in identifying small molecule drug candidates for further development.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $250,000 Bonus: $60,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
OYO CORPORATION
www.oyo.co.jp
Industry Group Code: 541620 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:1
Transportation: Aerospace: Automotive: Y Y
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Research-Geological Environmental Services Equipment Manufacturing Surveying
OYO Corporation is a leading Japanese provider of civil engineering consulting, geological investigations, environmental engineering and services involved in various types of problem solving. The company is focused on the creation of geoengineering, localization, globalization, specialization and integration. OYO's business is growing to include environmental services and disaster prevention. The firm is engaged in civil engineering consulting through city planning, architecture, land-use planning and civil engineering structures. The firm’s geological investigational services include aerial photographic interpretation, geophysical exploration, field measurement and fossil and rock analysis. Other services the firm provides include environmental engineering, equipment manufacturing and surveys. The company's products include seismic, geo-electric, borehole geophysics and in-suit equipment. OYO’s seismic instruments include the McSEIS-3, SonicViewer-SX, Seismic Starter and McSEIS-SX24. Borehole imaging tools include the company’s Optical Borehole Camera and the Acoustic Borehole Televiewer with data processing software. The corporation is composed of over 20 companies, domestic and overseas.
BRANDS/DIVISIONS/AFFILIATES: McSEIS-3 SonicViewer-SX Seismic Starter McSEIS-SX24 Optical Borehole Camera Acoustic Borehole Televiewer OYO Corporation U.S.A. Klein Associates, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Moriyuki Taya, Pres. Naobumi Daibo, Sr. Exec. Officer/CFO Satoru Ohya, Exec. Advisor Takeshi Okubo, Chmn.
Phone: 81-3-3234-0811 Fax: 81-3-3234-0383 Toll-Free: Address: 2-6 Kudan-kita, 4-chrome Chiyoda-ku, Tokyo, 10020073 Japan
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $417,537 (12 months) 2002 Profits: $3,500 (12 months) Stock Ticker: Foreign 2001 Sales: $395,000 2001 Profits: $-7,700 Employees: 1,198 2000 Sales: $53,500 2000 Profits: $-1,200 Fiscal Year Ends: 12/31 1999 Sales: $507,100 1999 Profits: $7,400 1998 Sales: $328,600 1998 Profits: $8,000
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Focus on geotechnical services.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $ Second Exec. Salary: $
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
PALM INC
www.palm.com
Industry Group Code: 334111 Ranks within this company's industry group: Sales:9 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:9
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Hardware-Handheld Organizers Handheld Computer Accessories
Palm, Inc. is a leading global provider of handheld computing devices, or personal digital assistants (PDAs). PDAs offer unique features that make it convenient to manage contact information, addresses, personal calendars and other everyday data in a mobile device. The company develops, designs and markets its Palmbranded handheld devices, which currently include the Palm III, Palm V and Internet-enabled Palm VII product families, as well as the m100 and m500 series. The firm’s Palm devices are small, pocket-sized computers that feature pen-based input and allow users to automatically copy and conform, or synchronize, information between the device and a personal computer. The Palm VII allows Internet content providers and users to wirelessly send and receive information via the web in a format optimized for handheld devices. The company saw its market share of the handheld hardware business drop from 50% to only 32% in the three years ending with 2002, as more and more competition gained traction. Nonetheless, there was a 30 million customer base of Palm users worldwide by mid 2003. Palm also markets a wide selection of accessories, including the Corex CardScan Executive, which scans business cards directly into the PDA, and the Palm Portable Keyboard. The Palm Solutions Group is responsible for the company’s branded handheld computers, enterprise software, peripherals and associated accessories. The group recently expanded into the Chinese market. In mid 2003 the firm announced that it will acquire competitor Handspring Inc. Also, the company split itself in two, spinning off PalmSource, its operating system software unit, as an independent company. PalmSource licenses the Palm OS platform to manufacturers of information appliances, such as Nokia, QUALCOMM, Symbol, Sony and TRG.
BRANDS/DIVISIONS/AFFILIATES: Palm Pilot Palm V Palm VII Palm OS PalmSource Solutions Group m100 Handspring
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Eric Benhamou, CEO Todd Bradley, COO Judy Bruner, CFO Gabi Schindler, Sr. VP-Mktg., PalmSource Marianne Jackson, Sr. VP-Human Resources William Maggs, Chief Tech. Officer Marina Levinson, VP/CIO Steve Sakoman, Chief Products Officer, PalmSource Dory Yochum, Chief Admin. Officer, PalmSource Albert B. Chu, VP-Bus. Dev., PalmSource David Nagel, CEO, PalmSource Todd Bradley, CEO, Solutions Group Ken Wirt, Sr. VP-Mktg. and Products, Solutions Group Doug Solomon, Chief Strategy Officer Eric Benhamou, Chmn.
Phone: 408-326-9000 Fax: 408-326-5009 Toll-Free: 800-881-7256 Address: 5470 Great America Pkwy., Santa Clara, CA 95052 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,030,800 (12 months) 2002 Profits: $-82,200 (12 months) Stock Ticker: PALM 2001 Sales: $1,559,312 2001 Profits: $-356,476 Employees: 1,171 2000 Sales: $1,057,597 2000 Profits: $45,910 Fiscal Year Ends: 5/31 1999 Sales: $563,525 1999 Profits: $29,628 1998 Sales: $272,137 1998 Profits: $4,171
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $514,596 Stock Purch. Plan: Y Second Exec. Salary: $365,000 ADVANTAGE: A leading provider of handheld computing devices.
OTHER THOUGHTS: Apparent Women Officers or Directors: 4 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $426,000 Bonus: $125,200
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
PANVERA LLC
www.panvera.com
Industry Group Code: 541710 Ranks within this company's industry group: Sales: Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Research-Drug Discovery Drug Discovery Technology and Services
PanVera, a subsidiary of Invitrogen Corporation, designs, develops and commercializes advanced drug discovery technologies, services and instrumentation to accelerate the discovery of new medicines. The company’s technology platform provides an advanced way to identify commercially useful targets, enable rapid assay development and rapidly test compounds for use as potential new medicines that act upon those targets. PanVera’s proprietary large-scale biology program identifies proteins involved in disease (targets), rapidly incorporates these targets into tests, or assays, that measure activity in targets and then rapidly screens hundreds of thousands of compounds against these assays to identify potential drugs. The company’s Neacon 2000 Fluorescence Polarization Instrument is used for research and methods development. Its CoreHTS drug screening assays have the ability to screen hundreds of thousands of potential new drugs in the relatively short time period of a few days.
BRANDS/DIVISIONS/AFFILIATES: Neacon 2000 CoreHTS Invitrogen Corp.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Thomas G. Klopack, COO Michael G. Wokasch, Pres. John R. Pashkowsky, VP-Finance Scott Beckey, VP-Strategic Sales, Software and Systems Pamela Fritz, Sr. Dir.-Human Resources Peter J. Coassin, VP-Instrumentation/Research and Dev. John D. Mendlein, General Counsel Michael J. Dunn, VP-Bus. Dev. John R. Pashkowsky, Treas. Harry Stylli, Sr. VP-Commercial Dev. Paul J. England, Sr. VP-Research John D. Mendlein, Chief Knowledge Officer
Phone: 608-204-5000 Fax: 608-204-5200 Toll-Free: 800-791-1400 Address: 501 Charmany Dr., Madison, WI 53719 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $ 2001 Profits: $ Employees: 103 2000 Sales: $ 2000 Profits: $ Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Y Second Exec. Salary: $ ADVANTAGE: Advanced technology in drug discovery research.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
PARADIGM GENETICS INC
www.paragen.com
Industry Group Code: 541710 Ranks within this company's industry group: Sales:20 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:8
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Research-Gene Function Agricultural Gene Research
Paradigm Genetics is a gene research company with an agricultural focus. The company is currently studying arabidopsis thalania (a product from the mustard family), rice and six filamentous fungi. The firm analyzes gene functions using functional genomics and bioinformatics. Paradigm's Genefunction Factory acts as a laboratory where scientists discover and modify genes, measure the consequences of the manipulated gene modification and determine gene function. The company's FunctionFinder allows integration of gene discovery, gene function determination and gene use identification. Paradigm has entered into a strategic alliance with Bayer for the development of novel herbicides. The company has also allied with Pharmacia for the development of increased crop output and nutritional and human health products. Paradigm is organized around five scientific departments and an informatics division. These departments include plant research, microbial research, DNA technologies, metabolic profiling and biochemistry. Informatics deals with the construction, storage and management of the data flow from scientific research. The firm recently underwent internal restructuring in order to better focus resources on growing its human health care and agricultural businesses. The restructuring included the establishment of distinct business units for health care and agriculture, the realignment of research groups and a reduction of its workforce by approximately 20%. Primarily administrative and research positions were affected by this move. In other news, Paradigm was awarded a five-year toxicogenomics contract by the National Institute of Environmental Health Sciences, to determine how toxicants work and cause damage at the cellular level. The research may result in better methods of risk assessment and compound optimization for both the pharmaceutical and agricultural chemical industries. Finally, due to a series of planned divestitures and expected new contracts, Paradigm is expecting to report its first profitable quarter earlier than had been expected, towards the end of 2003.
BRANDS/DIVISIONS/AFFILIATES: Genefunction Factory FunctionFinder
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Heinrich Gugger, CEO John A. Ryals, Pres. Phil Alfano, CFO Ken Hunt, VP-Mktg. James D. Bucci, VP-Human Resources John Hamer, Chief Scientific Officer Barry Buzogany, Corp. Sec. Barry Buzogany, General Sec. Ian A.W. Howes, VP-Oper. Ken Hunt, VP-Bus. Strategy Jin Sun Kim, VP-Health Care Keith Davis, VP-Agricultural Research Tom Colattsky, VP-Health Care Research
Phone: 919-425-3000 Fax: 919-544-8094 Toll-Free: Address: 108 Alexander Dr., Research Triangle Park, NC 277094528 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $17,200 (12 months) 2002 Profits: $-23,500 (12 months) Stock Ticker: PDGM 2001 Sales: $24,500 2001 Profits: $-16,000 Employees: 194 2000 Sales: $10,337 2000 Profits: $-17,724 Fiscal Year Ends: 12/31 1999 Sales: $2,197 1999 Profits: $-10,620 1998 Sales: $ 871 1998 Profits: $-4,290
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Heavy emphasis on gene research.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $325,000 Second Exec. Salary: $200,417
Bonus: $44,055 Bonus: $38,295
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
PARAMETRIC TECHNOLOGY CORP
www.ptc.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:26 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:27
Transportation: Aerospace: Automotive: Y
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Software-CAD, Engineering & Manufacturing Engineering Consulting Services
Parametric Technology Corporation develops, markets and supports product lifecycle management software solutions that help manufacturers improve the competitiveness of their products and product development processes. The firm provides its customers with software that streamlines engineering processes, improves product quality, optimizes product information management and reduces cost and time-to-market cycles. Parametric provides its services domestically and internationally. Its leading product, Pro/ENGINEER 3-D modeling software, is used by NASA, among other enterprises. Windchill Software, one of Parametric's flagship lines of solutions, enables users to enhance their businesses via the Internet. Parametric, through an agreement with Cadence Design Systems, has created a product similar to Windchill that allows customers to access and manage printed circuit board data created from Cadence's Allegro and Concept HDL products. The firm, which is on a continuous cycle of product enhancement, also offers CADDS 5i Release 11, a mechanical computer-aided design (MCAD) program. CADDS 5i and Pro/ENGINEER are used by airplane, ship and automobile manufacturing companies. Parametric has expanded its existing alliance with Computer Science Corporation to help clients collaborate with their customers by providing tools and consulting experience. Leading aerospace and aviation companies, including Embraer SA, utilize Parametric’s MCAD and online product development services to enhance competition. The company believes in promotion from within and professional growth through training.
BRANDS/DIVISIONS/AFFILIATES: Pro/ENGINEER 3-D CADDS 5i Windchill
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. C. Richard Harrison, CEO C. Richard Harrison, Pres. Thomas L. Beaudoin, CFO Thomas V. Butta, Chief Mktg. Officer James E. Heppelmann, Chief Tech. Officer Barry F. Cohen, Exec. VP-Strategic Services and Partners James E. Heppelmann, Exec. VP-Software Products Paul J. Cunningham, Exec. VP-Worldwide Sales
Phone: 781-370-5000 Fax: 781-370-6000 Toll-Free: 800-477-6435 Address: 140 Kendrick St., Needham, MA 02494 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $753,900 (12 months) 2002 Profits: $-75,000 (12 months) Stock Ticker: PMTC 2001 Sales: $934,600 2001 Profits: $-8,200 Employees: 4,533 2000 Sales: $928,414 2000 Profits: $-3,980 Fiscal Year Ends: 9/30 1999 Sales: $1,057,601 1999 Profits: $119,293 1998 Sales: $1,017,970 1998 Profits: $86,697
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $491,000 Stock Purch. Plan: Y Second Exec. Salary: $400,000 ADVANTAGE: Worldwide customer base/Extensive customer support.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $183,985 Bonus: $455,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
PAREXEL INTERNATIONAL
www.parexel.com
Industry Group Code: 541710 Ranks within this company's industry group: Sales:3 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:4
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Research & Development-Clinical Trial and Data Management, Biostatistical Analysis and Report Production Clinical Research Medical Publishing Web-Based Solutions
PAREXEL International Corporation is a leading biopharmaceutical services company that provides clinical development, medical marketing, consulting and technology products and services to the worldwide pharmaceutical, biotechnology and medical device industries. The firm's primary objective is to provide solutions for managing the biopharmaceutical product life cycle with the goal of reducing time, risk and cost associated with the development and commercialization of new therapies. Products and services include clinical trial management, data management, biostatistical analysis, study design, medical marketing, clinical pharmacology, regulatory and medical consulting, performance improvement, industry training and publishing, web-based portal solutions, interactive voice response systems, electronic data capture solutions, medical diagnostic services and other drug development consulting services. PAREXEL produces several publications through its subsidiaries Droit & Pharmacie, Barnett International and Cambridge Medical Publications, including The Journal of International Medical Research. Perceptive Informatics, its information technology subsidiary, provides a variety of technology products and services designed to improve clients' product development and commercialization processes, including interactive voice response systems and clinical trial management systems. Recently, PAREXEL acquired the software company FW Pharma Systems, Ltd. FW Pharma now functions under the operations of Perceptive Informatics.
BRANDS/DIVISIONS/AFFILIATES: FW Pharma Systems, Ltd. Perceptive Informatics, Inc. Barnett International Droit & Pharmacie Cambridge Medical Publications Journal of International Medical Research (The)
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Josef H. von Rickenbach, CEO Carl A. Spalding, COO Carl A. Spalding, Pres. James F. Winschel, Sr. VP/CFO Mark T. Beaudouin, VP/Corp. Sec. Mark T. Beaudouin, General Counsel Ulf Schneider, Sr. VP/Chief Admin. Officer Jill Baker, Sr. Dir.-Investor Rel. Peter Rietman, VP/Treas. Andrew J. Morffew, Pres.-PAREXEL Consulting Group Andrew L. Smith, Pres.-Medical Mktg. Services Mark A. Goldberg, Pres., Perceptive Informatics, Inc. Michael E. Woehler, Pres.-Clinical Research Services Josef H. von Rickenbach, Chmn. Mary Bareilles, Sr. VP-Asia/Pacific
Phone: 781-487-9900 Fax: 781-487-0525 Toll-Free: Address: 195 West St., Waltham, MA 02154-1163 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $564,900 (12 months) 2002 Profits: $13,200 (12 months) Stock Ticker: PRXL 2001 Sales: $387,560 2001 Profits: $- 825 Employees: 4,640 2000 Sales: $378,200 2000 Profits: $5,500 Fiscal Year Ends: 6/30 1999 Sales: $348,500 1999 Profits: $15,600 1998 Sales: $285,442 1998 Profits: $9,319
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $472,205 Stock Purch. Plan: Y Second Exec. Salary: $400,000 ADVANTAGE: Multifaceted company/Heavy emphasis on clinical research.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $148,500 Bonus: $138,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
PARSONS BRINCKERHOFF INC
www.pbworld.com
Industry Group Code: 541310 Ranks within this company's industry group: Sales:8 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Y Y Y Y
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Diversified Engineering Services Program Management Services
Parsons Brinckerhoff, Inc. provides planning, design and construction and program management services for construction projects around the world. The company’s design services include condition assessments, special facilities design and civil, electrical, mechanical and structural engineering. The firm primarily focuses on the design of highways, tunnels, bridges, transit systems, airports, railroads, ports and power facilities. Parsons Brinckerhoff also undertakes a number of telecommunications and environmental projects. The company’s signature projects include the design of New York City’s first subway and the reconfiguration of the Fort Washington Way interstate connector in Cincinnati. Recently, Parsons Brinckerhoff and HNTB were selected to perform project and construction management services for security modifications to Burbank Airport. The $35million project involves installation of improved baggage and passenger security screening equipment and conveyance systems. In the spring of 2003, the company was awarded a contract by the University of California to provide construction management oversight services for the expansion of facilities at Los Alamos National Laboratory. Under the terms of the agreement, the company provides design review services, project controls monitoring, cost estimation, general and specialty inspections and administrative support. Parsons Brinckerhoff offers its employees tuition reimbursement.
BRANDS/DIVISIONS/AFFILIATES: PB Facilities, Inc. PB Aviation, Inc. PB Farradyne, Inc. PB Buildings, Inc. PB Constructors, Inc. PB Telecommunications, Inc. Parsons Brinckerhoff Power, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Thomas J. O'Neill, CEO Thomas J. O'Neill, Pres. Richard A. Schrader, CFO John J. Ryan, Dir.-Human Resources
Phone: 212-465-5000 Fax: 212-465-5096 Toll-Free: Address: One Penn Plaza, New York, NY 10119 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,350,000 (12 months) 2002 Profits: $ (12 months) Stock Ticker: Private 2001 Sales: $ 2001 Profits: $ Employees: 9,294 2000 Sales: $1,160,000 2000 Profits: $ Fiscal Year Ends: 10/31 1999 Sales: $945,000 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Bonus: $ Stock Purch. Plan: Second Exec. Salary: $ Bonus: $ ADVANTAGE: Long history of engineering services/Extensive expertise in transportation engineering.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
PENWEST PHARMACEUTICALS CO
www.penw.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:70 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:63
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Active Ingredient Release
Penwest Pharmaceuticals Co. is engaged in the research, development and commercialization of novel drug delivery technologies. Penwest’s proprietary TIMERx controlled release drug delivery technology is applicable to a broad range of orally administered drugs, including soluble and insoluble drugs and those with a narrow therapeutic index. Successful drug formulations utilizing the TIMERx system include Nifedipine XL, which is used to treat hypertension and angina, and Cystrin CR, a controlled release version of oxybutynin for urge incontinence. Additionally, Penwest and Endo Pharmaceuticals are currently conducting clinical studies of EN3202, an extended-release oral form of the opioid oxymorphone. EN3202 is designed to treat the pain associated with osteoarthritis, lower back problems and certain types of cancer. The company also offers a number of drug delivery systems based on its TIMERx platform, including Geminex, which releases different active ingredients contained in one pharmaceutical product, and SyncroDose, a system that delivers drugs chronotherapeutically in the body. Penwest and Arakis are currently utilizing the SyncroDose technology to develop a product candidate for the treatment of rheumatoid arthritis. Recently, Penwest sold its excipient assets to Josef Rettenmaier Holding GmbH & Co. for $41.75 million. Penwest Pharmaceuticals offers its employees dental and vision insurance and tuition reimbursement.
BRANDS/DIVISIONS/AFFILIATES: TIMERx Cystrin CR Nifedipine XL EN3202 Geminex SyncroDose
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Tod R. Hamachek, CEO Jennifer L. Good, CFO/Sr. VP-Finance Camille Roca, Human Resources Anand R. Baichwal, Chief Scientific Officer Mehrdad Abedin, CIO/VP-IT Fred Banti, VP-Corp. Dev. Deborah A. Fox, VP-Bus. Dev. Thomas R. Sciascia, VP-Clinical Oper. Steven A. Gordziel, VP-Pharmaceutical Dev. Neal Parks, VP-Technical Oper. Tod R. Hamachek, Chmn.
Phone: 203-796-3700 Fax: 203-794-1393 Toll-Free: 877-736-9378 Address: 39 Old Ridgebury Rd., Ste. 11, Danbury, CT 068105120 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $42,000 (12 months) 2002 Profits: $-17,100 (12 months) Stock Ticker: PPCO 2001 Sales: $40,000 2001 Profits: $-16,000 Employees: 66 2000 Sales: $42,100 2000 Profits: $-8,800 Fiscal Year Ends: 12/31 1999 Sales: $37,300 1999 Profits: $-7,700 1998 Sales: $29,000 1998 Profits: $-8,800
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $380,000 Bonus: $100,000 Stock Purch. Plan: Y Second Exec. Salary: $195,000 Bonus: $40,219 ADVANTAGE: Established manufacturer and distributor of excipients to the pharmaceutical and nutritional industries.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
PEOPLESOFT INC
www.peoplesoft.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:7 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:8
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Computer Software-Human Resources Customer Relationship Management Software Consulting and Support Services
PeopleSoft, Inc. designs, develops, markets and supports a family of enterprise application software products for use throughout large and medium-sized organizations. These products include customer relationship management (CRM), human resources management (HRM), financial management and supply chain management (SCM) solutions, as well as a range of industry-specific products. Within each of its application suites the company offers world-class embedded analytics and portal applications with a high degree of flexibility, rapid implementation and scalability across multiple databases and operating systems. PeopleSoft also provides services including project planning, online analytic processing deployment, software product enhancements and support and training. The firm's first Internet-based enterprise application, PeopleSoft 8, was introduced in late 2000. PeopleSoft 8 software products are based on the company's proprietary Pure Internet Architecture. Another offering is PeopleTools, a set of integrated development and reporting tools for applications including business process and system analysis and administration of upgrades. In addition, the company offers a variety of consulting services, including technical and functional implementation, optimization, project planning and minor product modifications. Recent acquisitions include Teamscape, a learning management systems provider, and Calico Commerce, whose best-of-breed product configurator improved PeopleSoft's CRM and SCM software. Recently, the firm announced the release of four new products in its HRM suite, including ePerformance and Mobile Time Management. In mid 2003, PeopleSoft annouced plans to acquire competitor JD Edwards. Then, Oracle launched a hostile takeover bid for PeopleSoft before the JD Edwards acquisition could be completed. The outcome of Oracle's bid remains to be seen and make take several months to work out. One out of three employees at PeopleSoft was referred by another employee. Full- and part-time workers receive benefits including medical, dental and vision insurance and education reimbursement.
BRANDS/DIVISIONS/AFFILIATES: AppConnect PeopleSoft 8 Vantive Corporation (The) PeopleTools PeopleSoft Workflow PeopleSoft eCenter Teamscape Corp. Calico Commerce, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Craig A. Conway, CEO Craig A. Conway, Pres. Kevin T. Parker, Exec. VP-Finance/CFO Nanci Caldwell, Exec. VP/Chief Mktg. Officer Ram Gupta, Exec. VP-Products and Tech. Anne S. Jordan, Sr. VP/Corp. Sec. Anne S. Jordan, General Counsel Kevin T. Parker, Exec. VP-Admin. Guy Dubois, Exec. VP-Int'l David A. Duffield, Chmn. W. Phillip Wilmington, Exec. VP-Americas
Phone: 925-694-3000 Fax: 925-694-4444 Toll-Free: 800-380-7638 Address: 4460 Hacienda Dr., Pleasanton, CA 94588 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,948,900 (12 months) 2002 Profits: $182,600 (12 months) Stock Ticker: PSFT 2001 Sales: $2,073,300 2001 Profits: $191,600 Employees: 8,293 2000 Sales: $1,736,500 2000 Profits: $145,700 Fiscal Year Ends: 12/31 1999 Sales: $1,429,146 1999 Profits: $-177,765 1998 Sales: $1,474,768 1998 Profits: $139,938
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $1,000,000 Bonus: $2,325,000 Stock Purch. Plan: Y Second Exec. Salary: $350,000 Bonus: $1,057,000 ADVANTAGE: Software expertise in management of customer relations, human resources and more.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
PERFICIENT INC
www.perficient.com
Industry Group Code: 541512 Ranks within this company's industry group: Sales:9 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:7
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Consulting-On-Site Technical Services Middleware and Web Services
Perficient provides professional software services using leading and emerging technologies to web-enable complex enterprise systems. Through outsourcing partnerships with leading Internet companies, the firm develops expertise solutions around a targeted set of core technologies and products. Under these outsourcing arrangements, Perficient provides its customers and partners with teams of expert technology professionals that manage the implementation of their products for enduser customers. The company provides middleware and web services, enterprise portal applications and content management solutions. Middleware services include ebusiness architecture and development, enterprise solutions, systems integration and advanced technical training and mentoring programs. Perficient’s enterprise portal segment develops and coordinates portal communications solutions for some of the largest companies in the world. Content management solutions range from project analysis to developing content management, personalization, globalization, syndication and staging applications. The company’s business is structured around two relationship models, each based on providing teams of technology experts. The Virtual Services Organization (VSO) model encompasses a team of IT professionals dedicated to a specific software company partner, which performs the services on behalf of the partner. The direct model performs specific solutions through direct relationships with end-customers. Perficient currently has a major contract with IBM whereby Perficient‘s advanced technology services group exclusively serves IBM and its customers. The company received over $5 million in new contracts during the last quarter of 2002, adding clients such as Affiliated Computer Services, Amdocs, US Recordings, Washington University in St. Louis and Yahoo!. The firm promotes an enjoyable working atmosphere with a variety of official and unofficial social gatherings and a casual dress code.
BRANDS/DIVISIONS/AFFILIATES:
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jack McDonald, CEO Jeff Davis, COO Mark Mauldin, CFO Tim Thompson, VP-Bus. Dev. Dale Klein, VP-Corp. Dev. Jack McDonald, Chmn.
Phone: 512-531-6000 Fax: 512-531-6011 Toll-Free: Address: 7600-B N. Capital of Texas Hwy., Ste. 340, Austin, TX 78731 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $20,500 (12 months) 2002 Profits: $-2,400 (12 months) Stock Ticker: PRFT 2001 Sales: $20,400 2001 Profits: $-43,900 Employees: 141 2000 Sales: $20,000 2000 Profits: $-13,600 Fiscal Year Ends: 12/31 1999 Sales: $3,200 1999 Profits: $-1,400 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $225,000 Stock Purch. Plan: Y Second Exec. Salary: $136,667 ADVANTAGE: Growth through alliances and acquisitions.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $46,406 Bonus: $25,370
LOCATIONS: ("Y" = Yes) West:
Southwest: Y
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
PERKINELMER INC
www.perkinelmer.com
Industry Group Code: 334515 Ranks within this company's industry group: Sales:4 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Y Y Y Y
Profits:3
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y Y Y Y
GROWTH PLANS/SPECIAL FEATURES:
Medical Equipment-Assorted Instruments Mechanical Components Life Science Systems Fluid Science Components Engineering Services Testing Services
PerkinElmer, Inc. is a leading provider of scientific instruments, consumables and services to the pharmaceutical, biomedical, environmental testing and general industrial markets. The firm designs, manufactures, markets and services products and systems within three business units: life and analytical sciences, optoelectronics and fluid sciences. The life and analytical sciences unit is a provider of drug discovery, genetic screening, environmental and chemical analysis tools and instrumentation. The principal products of the segment include EnVision, the first modular multi-label plate reader designed for use in high-throughput screening laboratories; ProXPRESS, a proteomics imaging system for multiwavelength imaging, which provides highresolution and flexibility for accurate, reproducible detection of proteins; SmartStation, an integrated workstation with liquid handling and the superior detection capabilities of EnVision; and ProXCISION, an instrument for automated, high-precision excision of protein candidates from 2-D protein gels and bands from 1-D protein gels. The optoelectronics segment provides a broad range of digital imaging, sensor and specialty lighting components used in the biomedical, consumer products and other specialty end markets. New product releases by the segment include FX-4400, a high-output guided arc xenon bulb used in analytical and life sciences instrumentation applications requiring large-area illumination or simultaneous sample screening; and ColdBlue, a cooled charge-coupled device camera offering improved sensitivity and detection of very faint signals, used in applications such as protein quantification and fluorescent microscopy. The fluid sciences segment offers critical fluid control and containment systems for highly demanding environments such as turbine engines and semiconductor fabrication facilities. The segment offers its products under brand names including Belfab, Callisto, Centurion and PressureScience. In recent news, the company announced the launch of the DELFIA celiac disease hybridization assay, a test that measures susceptibility to celiac, an autoimmune disorder.
BRANDS/DIVISIONS/AFFILIATES: ProXPRESS FX-4400 EnVision Belfab ColdBlue SmartStation ProXCISION DELFIA
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Gregory L. Summe, CEO Gregory L. Summe, Pres. Robert F. Friel, Sr. VP/CFO Richard F. Walsh, Sr. VP-Human Resources Neil Cook, Chief Scientific Officer Gregory D. Perry, Controller Terrence L. Carlson, General Counsel Terrence L. Carlson, Sr. VP-New Bus. Dev. Gregory D. Perry, Treas. Peter B. Coggins, Exec. VP/Pres.-Life and Analytical Sciences Jeffrey D. Capello, VP-Finance/Chief Acc. Officer Robert A. Barrett, Sr. VP/Pres.-Fluid Sciences John D. Murphy, Sr. VP/Pres.-Optoelectronics Gregory L. Summe, Chmn.
Phone: 781-237-5100 Fax: 781-237-9386 Toll-Free: Address: 45 William St., Wellesley, MA 02481-4078 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,505,000 (12 months) 2002 Profits: $-151,900 (12 months) Stock Ticker: PKI 2001 Sales: $1,330,100 2001 Profits: $34,500 Employees: 10,700 2000 Sales: $1,695,267 2000 Profits: $90,520 Fiscal Year Ends: 12/31 1999 Sales: $1,363,129 1999 Profits: $154,316 1998 Sales: $854,382 1998 Profits: $102,002
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $860,959 Stock Purch. Plan: Second Exec. Salary: $444,321 ADVANTAGE: Global technology company with major government and industry contracts.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $529,125 Bonus: $261,450
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
PEROT SYSTEMS CORP
www.perotsystems.com
Industry Group Code: 541512 Ranks within this company's industry group: Sales:6
Profits:4
Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y Y
GROWTH PLANS/SPECIAL FEATURES:
Consulting-Technology Business Process Consulting Software Solutions Outsourcing
Perot Systems Corp. is a worldwide provider of information technology (IT) services and business solutions to a broad range of customers. The firm offers integrated solutions designed around specific business objectives, with services including technology outsourcing, business process outsourcing, development and integration of systems and applications and business and technology consulting services. In 2001, Perot Systems realigned its operating structure to focus service offerings around its key strengths. Services are now divided into two primary lines of business, IT solutions and consulting. The IT solutions business serves four vertical industry groups: health care (including providers, payors, pharmaceutical and supply chain markets), financial services (including banking, investment and insurance markets), industrial services (including automotive, engineering, construction and consumer goods markets) and strategic markets (including travel, transportation, telecommunications and energy). The IT solutions group also provides global infrastructure services. Perot's consulting business includes Solutions Consulting and the global software services group. Solutions Consulting provides strategy services and software solutions including enterprise resources planning, supply chain management, e-commerce and customer relationship management. The global software services group optimizes the application services delivery options for its IT solutions customers with delivery resources, innovative architectures, proprietary methodologies and repeatable processes. This group includes Technical Resource Connection and HCL Perot Systems, a joint venture. In recent news, Perot Systems agreed to acquire Soza and Company, Ltd., a government IT company, which will significantly expand the firm's government services unit. Perot Systems offers competitive employee benefits, including cafeteria plan options, medical, dental and vision plans and flexible spending accounts (including dependent care and health care accounts). The company also offers life insurance, accidental death insurance, tuition reimbursement and group legal services.
BRANDS/DIVISIONS/AFFILIATES: Perot Systems Government Services Perot Consulting Solutions Consulting Technical Resource Connection HCL Perot Systems Soza and Company, Ltd.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Ross Perot, Jr., CEO Brian Maloney, COO Ross Perot, Jr., Pres. Russell Freeman, VP/CFO Eddie Reeves, VP-Mktg. Darcy Anderson, VP-Human Resources and Corp. Support Richard Schroth, Chief Tech. Officer Michael McClaskey, CIO Chuck Lyles, VP-Health Care Industry Group Peter Altabef, VP/Corp. Sec. Peter Altabef, General Counsel Eddie Reeves, VP-Comm. Mark Miller, CEO, Perot Consulting Marc Barnett, Global Software Services Greg Bedner, Pres./CEO, Perot Systems Gov't Services Sharon O'Malley, VP-Gov't Services Mktg. David Cohen, European Team Leader
Phone: 972-577-0000 Fax: 972-577-6790 Toll-Free: 888-317-3768 Address: 2300 W. Plano Pkwy., Plano, TX 75075-8499 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,332,100 (12 months) 2002 Profits: $78,300 (12 months) Stock Ticker: PER 2001 Sales: $1,204,700 2001 Profits: $-2,700 Employees: 9,100 2000 Sales: $1,105,900 2000 Profits: $55,500 Fiscal Year Ends: 12/31 1999 Sales: $1,151,553 1999 Profits: $75,497 1998 Sales: $993,589 1998 Profits: $40,465
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $530,400 Stock Purch. Plan: Y Second Exec. Salary: $500,000 ADVANTAGE: A leading provider of technology consulting services.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $132,600 Bonus: $400,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
PFIZER INC
www.pfizer.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:3 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Diversified Prescription Pharmaceuticals Consumer Products
Pfizer, Inc. is a research-based, global pharmaceutical company. The firm operates in two business segments, pharmaceuticals and over-the-counter drugs. Pfizer's pharmaceutical division includes prescription pharmaceuticals for treating cardiovascular diseases, infectious diseases, central nervous system disorders, diabetes, erectile dysfunction, allergies, arthritis and other disorders. Major drugs offered by the company include Zoloft and Neurontin for the treatment of central nervous system disorders; Diflucan for the treatment of various fungal infections; Viracept for treatment of HIV infections; and Zithromax, an oral or injectable antibiotic. The pharmaceutical segment also develops products for livestock as well as companion animals. The firm’s Revolution topical liquid is the first medicine that can protect against external parasites, gastrointestinal worms and heartworms. In addition, the company’s Capsugel subsidiary is one of the world’s largest producers of twopiece capsules used in manufacturing prescription and over-the-counter pharmaceuticals and nutritional supplements. Pfizer’s consumer products segment markets many of the world’s best-known consumer health brands, including Benadryl, Rolaids, Zantac 75, Visine, Cortizone and BenGay. In a major development, Pfizer acquired Pharmacia Corporation for $60 billion, making it the largest pharmaceutical company in the U.S., Europe, Japan and Latin America. The combined entity is the largest privately funded biomedical research firm in the world, with a research and development pipeline of some 120 chemical entities, as well as over 80 additional projects for product development. Continuing operations under the Pfizer name, the company plans to file 20 new drug applications in the next five years. Pfizer offers its workforce medical, vision and dental plans, tuition reimbursement, adoption assistance, a matching gift program, child care assistance, a referral program, education loans and four-year college scholarships for children of employees. Flexible work hours and sports and recreational opportunities are also available.
BRANDS/DIVISIONS/AFFILIATES: Pharmacia Corp. Diflucan Zoloft Neurontin Viracept Celebrex Zithromax Lipitor
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Henry A. McKinnell, Jr., CEO David L. Shedlarz, CFO Robert W. Norton, Sr. VP-Human Resources Peter B. Corr, Sr. VP-Science and Tech. John W. Mitchell, VP-Global Mfg. Jeffrey B. Kindler, General Counsel Frederick W. Telling, VP-Corp. Strategic Planning Chuck Hardwick, Sr. VP Karen Katen, Pres.-Pfizer Global Pharmaceuticals Henry A. McKinnell, Jr., Chmn.
Phone: 212-573-2323 Fax: 212-573-7851 Toll-Free: Address: 235 E. 42nd St., New York, NY 10017-5755 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $32,373,000 (12 months) 2002 Profits: $9,126,000 (12 months) Stock Ticker: PFE 2001 Sales: $32,259,000 2001 Profits: $7,788,000 Employees: 98,000 2000 Sales: $29,574,000 2000 Profits: $3,726,000 Fiscal Year Ends: 12/31 1999 Sales: $27,376,000 1999 Profits: $4,952,000 1998 Sales: $23,231,000 1998 Profits: $4,633,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $1,516,667 Stock Purch. Plan: Second Exec. Salary: $944,600 ADVANTAGE: Products are available in more than 150 countries/Acquisition of Pharmacia.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $2,780,800 Bonus: $1,062,700
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
PHARMACEUTICAL FORMULATIONS INC Industry Group Code: 325412 Ranks within this company's industry group: Sales:61 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
www.pfiotc.com
Profits:52 Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Generic Contract Manufacturing
Pharmaceutical Formulations, Inc. is a private label manufacturer and distributor of over-the-counter solid dose pharmaceutical products. Such products are primarily sold under its customers’ store brands or other private labels or manufactured under contract for national brand pharmaceutical companies. The company’s largest retail customers include Dollar General Stores, Target, Costco Wholesale, CVS Corp. and BJ’s Wholesale Club. Additionally, the firm’s products are often sold in bulk to companies that repackage them for sale to small independent retailers or other manufacturers that are not approved by the government to produce certain medications. Pharmaceutical Formulations’ products include internal analgesics, laxatives, sleep aides, effervescent denture cleaners and allergy, sinus, cold and cough medications. The firm also markets a line of antifungal aerosols and generic over-the-counter products under its own brand names. Recently, Pharmaceutical Formulations acquired Konsyl Pharmaceuticals, Inc., a manufacturer and distributor of powdered, dietary natural fiber supplements. Though a majority of its products are sold to pharmaceutical wholesalers, drugstore chains, mass merchandisers and grocery store chains, Konsyl Pharmaceuticals also manufactures a gastrointestinal diagnostic product, Stizmarks, that is sold to hospitals, radiologists and colon and rectal surgeons.
BRANDS/DIVISIONS/AFFILIATES: Konsyl Pharmaceuticals, Inc. Stizmarks Health+Cross Health Pharm
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John L. Oram, CEO James Ingram, COO James Ingram, Pres. Walter Kreil, CFO Anthony Cantaffa, VP-Sales & Mktg. Ward Barney, VP-Oper. Brian Barbee, VP-Regulatory Affairs Lenny Luongo, Dir.-Sales Admin. Helen Kushner, Mgr.-Customer Rel. John L. Oram, Chmn.
Phone: 732-985-7100 Fax: 732-819-3330 Toll-Free: Address: 460 Plainfield Ave., Edison, NJ 08818 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $53,600 (12 months) 2002 Profits: $-6,900 (12 months) Stock Ticker: PHFR 2001 Sales: $49,200 2001 Profits: $-14,600 Employees: 376 2000 Sales: $76,600 2000 Profits: $-7,900 Fiscal Year Ends: 6/30 1999 Sales: $82,200 1999 Profits: $-6,600 1998 Sales: $80,800 1998 Profits: $1,900
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $244,231 Bonus: $7,500 Stock Purch. Plan: Second Exec. Salary: $180,000 Bonus: $ ADVANTAGE: PFI is one of the largest solid dosage generic pharmaceutical manufacturers in the country.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
PHARMACEUTICAL RESOURCES INC Industry Group Code: 325412 Ranks within this company's industry group: Sales:38 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
www.parpharm.com Profits:25
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Generic
Pharmaceutical Resources, Inc. (PRI) is a holding company that develops, manufactures and distributes a broad line of generic drugs in the United States. The firm operates primarily through subsidiary Par Pharmaceutical, Inc. PRI's product line consists of approximately 120 prescription and over-the-counter drug products, including varying dosage strengths. In addition to its own manufactured products, the company has strategic alliances with several pharmaceutical and chemical companies that provide it with products for sale through distribution, development or licensing agreements. These products are marketed primarily to wholesalers, retail drug store chains, drug distributors and repackagers principally through its own sales staff. Drug products include treatments for central nervous system disorders, cardiovascular drugs, analgesics and anti-inflammatory products, anti-bacterials, anti-diabetics, antihistamines, anti-virals, cholesterol-lowering drugs and ovulation stimulants. Among these are generic versions of Advil, Daypro, Glucophage, Zantac and Clomid. In 2001, the company introduced three new products, including generic versions of Megace and Prozac. In mid-2002, PRI also acquired the rights to five products from Bristol-Meyers Squibb, including Capoten, Capozide, Questran and Questran Light and Sumycin. In late 2001, Par entered into an agreement with Elan Corp. to develop a range of modified-release drugs over a five-year period. In recent news, Par announced that it filed an abbreviated new drug application with the FDA for a generic version of Ultracet acetaminophen tablets. The company was also granted tentative approval for generic Prilosec.
BRANDS/DIVISIONS/AFFILIATES: Par Pharmaceutical, Inc. Acyclovir Akineton BusPIRone HCI Captopril Famotidine Fluoxetine IBU
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Kenneth I. Sawyer, CEO Kenneth I. Sawyer, Pres. Dennis J. O'Connor, VP/CFO Dennis J. O'Connor, Corp. Sec. Scott L. Tarriff, CEO/Pres., Par Pharmaceutical, Inc. Kenneth I. Sawyer, Chmn.
Phone: 845-425-7100 Fax: 845-425-7907 Toll-Free: Address: One Ram Ridge Rd., Spring Valley, NY 10977-6714 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $381,600 (12 months) 2002 Profits: $79,500 (12 months) Stock Ticker: PRX 2001 Sales: $271,000 2001 Profits: $53,900 Employees: 456 2000 Sales: $85,022 2000 Profits: $- 929 Fiscal Year Ends: 9/30 1999 Sales: $80,315 1999 Profits: $-1,774 1998 Sales: $59,705 1998 Profits: $-9,628
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Continual approval of new drugs.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $397,088 Second Exec. Salary: $220,510
Bonus: $55,000 Bonus: $50,000
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
PHARMACOPEIA INC
www.pharmacopeia.com
Industry Group Code: 541710 Ranks within this company's industry group: Sales:5 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:6
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Research & Development-Drug Discovery Support Molecular Combinational Chemistry
Pharmacopeia, Inc. is engaged in the design, development and marketing of products and services that are intended to improve and accelerate drug discovery and chemical development. The company’s Drug Discovery subsidiary integrates proprietary small molecule combinatorial and medicinal chemistry, high-throughput screening, in-vitro pharmacology, computational methods and informatics to discover and optimize potential drugs. The subsidiary’s ECLiPS encoding technology enables it to generate thousands of small molecule compounds at a fraction of the cost of traditional chemical synthesis methods. Pharmacopeia Drug Discovery’s customers include AstraZeneca, Novartis, Schering AG and Antigenics. The company’s Accelrys subsidiary develops and commercializes molecular modeling and simulation software, cheminformatics and decision support systems and bioinformatics tools. Accelrys’ modeling technology simulates subatomic, interatomic and intermolecular interactions and a wide range of corresponding properties, including molecular structure and activity. The subsidiary’s GCG Wisconsin Package software features gene sequence comparison, DNA/RNA secondary structure prediction, evolutionary analysis and protein analysis. Accelrys also offers a number of chemical databases, including the Failed Reactions Database, which offers data on reactions that afford unexpected results, and BIOSTER, which features a compilation of thousands of bio-analogous molecule pairs. The subsidiary’s customers include Bristol Myers Squibb, Amgen, Monsanto and Unilever.
BRANDS/DIVISIONS/AFFILIATES: Pharmacopeia Drug Discovery ECLiPS Accelrys GCG Wisconsin Package Failed Reactions Database BIOSTER
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Joseph A. Mollica, CEO Joseph A. Mollica, Pres. John J. Hanlon, CFO William J. DeLorbe, Exec. VP-Human Resources Michael G. Lenahan, Corp. Sec. Michael G. Lenahan, General Counsel Arthur E. Roke, Chief Acc. Officer/VP-Finance Mark J. Emkjer, Pres., Accelrys Scott D. Kahn, Chief Science Officer, Accelrys Stephen A. Spearman, COO, Pharmacopeia Drug Discovery Joseph A. Mollica, Chmn.
Phone: 609-452-3600 Fax: 609-452-3672 Toll-Free: Address: 3000 Eastpark Blvd., Cranbury, NJ 08512 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $124,400 (12 months) 2002 Profits: $-11,600 (12 months) Stock Ticker: PCOP 2001 Sales: $122,300 2001 Profits: $-14,300 Employees: 687 2000 Sales: $119,400 2000 Profits: $1,200 Fiscal Year Ends: 12/31 1999 Sales: $104,000 1999 Profits: $3,800 1998 Sales: $92,200 1998 Profits: $-10,200
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $526,667 Stock Purch. Plan: Y Second Exec. Salary: $296,333 ADVANTAGE: Ability to use state-of-the-art computer technology for new compound discovery.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $242,500 Bonus: $151,200
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
PHILIPP HOLZMANN GROUP
www.philipp-holzmann.de
Industry Group Code: 541310 Ranks within this company's industry group: Sales: Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Y Y Y
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Engineering and Construction Services Design Services
Philipp Holzmann Group is engaged in the design, planning and execution of construction and infrastructure projects and industrial plants. The firm operates and maintains buildings and systems and includes Lockwood Greene Engineers, Inc.; J.A. Jones, Inc.; Imbau Industrielles Bauen GmbH; Deutsche Asphalt; and HSG Holzmann Technischer Service GmbH. In recent news, Philipp Holzmann, once owned by the Algerian Khalifa Group, has been taken over by a group of investors from the Middle East. Both parties have agreed that Khalifa Group remains the exclusive representative of Philipp Holzmann in Algeria. The company will continue to be active on the international market with its more than 10 business units worldwide. The company also recently filed for bankruptcy protection. The group is undergoing management reorganization and the selling of assets.
BRANDS/DIVISIONS/AFFILIATES: Lockwood Greene J.A. Jones, Inc. Imbau Industrielles Bauen Bauverein GA HOCHTIEF Deutsche Asphalt HSG Holzmann Technischer Service
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Wolfgang Gäbler, Managing Dir. Ulrich Kästner, Managing Dir. Konrad Hinrichs, Chmn.
Phone: 49-69-262-1 Fax: 49-69-26-2-433 Toll-Free: Address: Taunusanlage 1, Frankfurt, 60299 Germany
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Foreign 2001 Sales: $ 2001 Profits: $ Employees: 2000 Sales: $ 2000 Profits: $ Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Bonus: $ Stock Purch. Plan: Second Exec. Salary: $ Bonus: $ ADVANTAGE: Founded in 1849, the firm is responsible for major engineering and construction projects around the globe/ Reorganizing under bankruptcy.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
PITNEY BOWES INC
www.pb.com
Industry Group Code: 333313 Ranks within this company's industry group: Sales:2 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Business Machines-Postage Meters Business Equipment
Pitney Bowes, Inc. is a global provider of informed mail and messaging management. The company operates in three primary business segments: global mailing, enterprise solutions and capital services. The operations of the global mailing segment consist primarily of the rental of postage meters and the sale, rental and financing of mailing equipment, software-based shipping, transportation and logistics systems. Additional products include mailing machines, address software, manifest systems, letter and parcel scales, mail openers, mailroom furniture, folders, paper handling and shipping equipment. The enterprise solutions segment is comprised of Pitney Bowes Management Services and Document Messaging Technologies. Pitney Bowes Management Services offers advanced mailing, secure mail services, reprographic, document management and other services. Document Messaging Technologies markets, services and finances high-speed, software-enabled production mail systems; sorting equipment; incoming mail systems; electronic statement, billing and payment solutions; and mailing software. The company’s capital services division provides external large-ticket financing and fee-based programs covering a broad range of products and other financial services to commercial and industrial markets in the U.S. The company recently announced that it would stop active pursuit of, and growth in, long-term capital services financing transactions, including long-term financing of postal and related equipment. It will continue to provide lease financing for its products through internal financing operations.
BRANDS/DIVISIONS/AFFILIATES: Pitney Bowes Management Services Document Messaging Technologies DM1000 Mailing System
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Michael J. Critelli, CEO Bruce P. Nolop, Exec. VP/CFO Meredith B. Fischer, VP-Corp. Mktg. Johnna G. Torsone, Sr. VP/Chief Human Resources Officer Joseph E. Wall, Chief Tech. Officer Gregory E. Buoncontri, Sr. VP/CIO Amy C. Corn, VP/Corp. Sec. Michele Mayes, Sr. VP/General Counsel Luis A. Jimenez, Sr. VP/Chief Strategy Officer Dessa Bokides, VP/Treas. Matthew S. Kissner, Exec. VP/Group Pres.-Info.-Based Solutions Murray D. Martin, Exec. VP/Group Pres.-Global Mailing Systems Karen M. Garrison, Exec. VP/Group Pres.-Bus. Services Brian M. Baxebdale, Exec. VP/Pres.-Enterprise Relationship Dev. Michael J. Critelli, Chmn.
Phone: 203-356-5000 Fax: 203-351-7336 Toll-Free: 800-672-6937 Address: One Elmcroft Rd., Stamford, CT 06926-0700 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $4,409,800 (12 months) 2002 Profits: $475,700 (12 months) Stock Ticker: PBI 2001 Sales: $4,122,500 2001 Profits: $488,300 Employees: 33,130 2000 Sales: $3,880,900 2000 Profits: $622,500 Fiscal Year Ends: 12/31 1999 Sales: $4,432,600 1999 Profits: $636,200 1998 Sales: $4,100,464 1998 Profits: $576,400
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $925,000 Stock Purch. Plan: Second Exec. Salary: $575,000 ADVANTAGE: Vast market share in postage meters/Diversified operations.
OTHER THOUGHTS: Apparent Women Officers or Directors: 6 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $1,202,500 Bonus: $431,300
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
PLUG POWER INC
www.plugpower.com
Industry Group Code: 333298 Ranks within this company's industry group: Sales:4 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:2
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Fuel Cell Technology
Plug Power, Inc. designs, develops and manufactures onsite electrical power generation systems utilizing proton exchange membrane (PEM) fuel cells for stationary applications. Formed in 1997 as a joint venture between Edison Development Company (EDC) and Mechanical Technology, Inc. (MTI), Plug Power has established an extended enterprise through strategic relationships with marketing, technology, supply chain and government partners. The company focuses on fuel cell systems with electrical output of approximately 1-100 kilowatts (kW), fueled by natural gas, liquid petroleum gas (LPG) and hydrogen gas. Plug Power is developing a technology platform from which it expects to offer multiple products, from DC back-up power for telecom applications to AC prime power for residential and light commercial applications. The company’s initial product is a fully integrated, grid-parallel 5-kW fuel cell system that operates on natural gas. It is being marketed to a select number of customers, including utilities, government entities and its distribution partners, GE Fuel Cell Systems and DTE Energy Technologies, Inc. The product is intended to offer quality power, provide valuable field testing experience and data and demonstrate fuel cells as a preferred form of alternative distributed power generation. In June 2002, the fuel cell became the first to be certified by the California Energy Commission under the state’s grid interconnection standard. In July 2002, the firm launched the GenSys 5C, which added the capability of capturing heat for combined heat and power applications. Additionally, during 2002 Plug Power expanded its customer base from nine to 30, delivering 121 systems to 19 U.S. states and three other countries. The company has also significantly reduced the unit cost, size, weight and part count of its systems. In recent news, Plug Power and Valliant GmbH partnered to deliver 13 PEM fuel cells to homes and businesses in Germany, The Netherlands, Austria and Luxembourg. Plug Power offers employees a comprehensive benefits package, including stock options.
BRANDS/DIVISIONS/AFFILIATES: Edison Development Company Mechanical Technology, Inc. GenSys 5C
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Roger B. Saillant, CEO Gregory A. Silvestri, COO Roger B. Saillant, Pres. David A. Neumann, VP/CFO Mark A. Sperry, VP/Chief Mktg. Officer Glenn A. Eisman, Chief Tech. Officer Robert A. Sinuc, VP-Eng. Paul J. Burton, VP-Mfg. Ana-Maria Galeano, Corp. Sec. Ana-Maria Galeano, General Counsel Cynthia M. Mahoney, Mgr.-Public Rel. John Elter, VP-Research and System Architecture William D. Ernst, VP/Chief Scientist
Phone: 518-782-7700 Fax: 518-782-9060 Toll-Free: Address: 968 Albany-Shaker Rd., Latham, NY 12110 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $11,800 (12 months) 2002 Profits: $-47,200 (12 months) Stock Ticker: PLUG 2001 Sales: $5,700 2001 Profits: $-73,100 Employees: 348 2000 Sales: $8,400 2000 Profits: $-86,200 Fiscal Year Ends: 12/31 1999 Sales: $11,000 1999 Profits: $-33,500 1998 Sales: $6,500 1998 Profits: $-9,600
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $300,000 Stock Purch. Plan: Second Exec. Salary: $250,000 ADVANTAGE: Expertise in fuel cell technology/Relationships with major firms including GE.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $60,000 Bonus: $48,500
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
PMC-SIERRA INC
www.pmc-sierra.com
Industry Group Code: 334413 Ranks within this company's industry group: Sales:21 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:13
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Broadband Networking Technology Provider
PMC-Sierra, Inc. designs, develops, markets and supports high-performance semiconductor networking products and is a leading manufacturer of high-speed, high-density broadband communications solutions. The company provides broadband semiconductor technology used in restructuring the global telecommunications and data communications infrastructure. Its products adhere to major networking standards and perform common networking functions required by the most widely deployed types of Internet infrastructure equipment. PMC-Sierra designs its products for a wide variety of networking equipment including WAN access, transmission and switching equipment, as well as LAN equipment. The company also offers a broad, highly integrated range of product chip sets for ATM, Internet protocol (IP), SONET/SDH, T1/E1 and T3/E3 applications. Products include carrier switches, MIPS processors, ATM layer and switch products and packet processors. Customers include Cisco Systems, Lucent Technologies, Nortel, Alcatel, Ericsson and NEC. PMC-Sierra also supplies products to dozens of smaller specialized start-ups developing the technology for new classes of broadband and optical networking equipment.
BRANDS/DIVISIONS/AFFILIATES: SATURN Toucan Technology AANetcom Extreme Packet Devices Malleable Technologies Datum Telegraphic Quantum Effect Devices SwitchOn Networks
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Robert L. Bailey, CEO Greg Aasen, COO Robert L. Bailey, Pres. Alan Krock, VP-Finance/CFO Haresh Patel, VP-Sales Steffan M. Perna, VP/Mgr.-Service Provider Div. Thomas Riordan, VP/Mgr.-Microprocessor Products Div. Mark C. Stibitz, VP/Mgr.-Enterprise and Storage Div. Tom Sun, VP-Asia-Pacific Oper. Alexandre Balkanski, Chmn.
Phone: 408-239-8000 Fax: 408-492-9192 Toll-Free: Address: 3975 Freedom Cir., Santa Clara, CA 95054 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $218,100 (12 months) 2002 Profits: $-65,000 (12 months) Stock Ticker: PMCS 2001 Sales: $322,700 2001 Profits: $-639,100 Employees: 1,099 2000 Sales: $694,700 2000 Profits: $75,300 Fiscal Year Ends: 12/31 1999 Sales: $295,800 1999 Profits: $71,800 1998 Sales: $174,300 1998 Profits: $-21,700
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Excellent technology.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $361,044 Second Exec. Salary: $227,267
Bonus: $350,000 Bonus: $200,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
POLAROID CORP
www.polaroid.com
Industry Group Code: 333314 Ranks within this company's industry group: Sales: Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Photography Equipment-Consumer Film Recorders Software
The assets of the Polaroid Corporation, which filed for bankruptcy, were acquired by One Equity Partners Imaging Operating Corporation (OEPI) in July 2002. OEPI then changed its name to Polaroid Corporation. The new Polaroid Corporation remains a leading instant imaging company and the only manufacturer of traditional silverhalide or chemical-based instant cameras and film in the United States. The company’s products include instant film, instant cameras, digital and digital microscope cameras, film recorders, printers, scanners and software. The firm also designs, develops and manufactures hardware accessories for the instant imaging market, conventional 35mm cameras, film and videotapes. Polaroid products include the i-Zone camera, Polaroid One, DMC 2, ProPalette 8067, SprintScan 4000 Plus and Spectra film. Polaroid recently released new products: Polaroid T690, which is professional peel-apart instant film, the Polaroid OneStep camera, Polaroid Digital MiniPortrait all-in-one digital camera and thermal printing system and Polaroid instant digital prints kiosk. The company also sold its Commercial Optics Division to Precision Optical Systems, Inc. As a result of the sale, Polaroid gained a minority equity interest in Precision.
BRANDS/DIVISIONS/AFFILIATES: One Equity Partners Imaging Operating Corporation Polaroid One Precision Optical Systems, Inc. Polaroid T690 I-Zone Products Polaroid OneStep Camera Polaroid Digital MiniPortrait All-in-One Camera
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. J. Michael Pocock, CEO J. Michael Pocock, Pres. William L. Flaherty, Exec. VP/CFO Jacques A. Nasser, Chmn.
Phone: 781-386-2000 Fax: 781-386-3924 Toll-Free: Address: 1265 Main St., Bldg. W3, Waltham, MA 02451 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Private 2001 Sales: $1,350,000 2001 Profits: $ Employees: 9,274 2000 Sales: $1,855,600 2000 Profits: $37,700 Fiscal Year Ends: 12/31 1999 Sales: $1,978,600 1999 Profits: $8,700 1998 Sales: $1,845,900 1998 Profits: $-51,000
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $838,950 Bonus: $107,232 Stock Purch. Plan: Second Exec. Salary: $436,546 Bonus: $33,294 Filed for bankruptcy in October 2001; was then acquired by a Bank One investment unit. ADVANTAGE:
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
PRAXAIR INC
www.praxair.com
Industry Group Code: 325000 Ranks within this company's industry group: Sales:7 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:4
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Y Other: Y
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Industrial Gas Manufacturing Process Gases
Praxair, Inc. was the first company in the United States to produce oxygen from air using a cryogenic process. The company is one of the largest industrial gases firms in the world. The firm is also one of the world’s largest suppliers of carbon dioxide. Praxair’s primary industrial gas products are atmospheric gases (oxygen, nitrogen, argon, rare gases) and process gases (carbon dioxide, helium, hydrogen, electronic gases, specialty gases, acetylene). The company’s surface technology segment, operated through Praxair Surface Technologies, Inc., supplies wearresistant and high-temperature corrosion-resistant metallic and ceramic coatings and powders. Industrial gases account for 92% of sales. Gases produced by the company find wide use in the aerospace, chemicals, electronics, energy, food and beverage, health care, manufacturing and metals industries. It also provides aircraft engine and airframe component overhaul services. Praxair conducts its industrial gases business through subsidiary and affiliated companies in Argentina, Australia, Belgium, Bolivia, Brazil, Canada, Chile, Colombia, Costa Rica, France, Germany, India, Israel, Italy, Japan, South Korea, Malayasia, Mexico, the Netherlands, the People's Republic of China, Paraguay, Peru, Portugal, Spain, Taiwan, Thailand, Turkey, Uruguay and Venezuela. In recent news, the company announced the completion of two gas plants in California to supply industrial and medical gasses. The company has several incentive and rewards programs for its employees and offers access to seminars and other programs to keep employees on the leading edge of the industry.
BRANDS/DIVISIONS/AFFILIATES: Praxair Surface Technologies, Inc. CBI Technologies, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Dennis H. Reilley, CEO Dennis H. Reilley, Pres. James S. Sawyer, Sr. VP/CFO Randy S. Kramer, Sr. VP-Sales Sally A. Savoia, VP-Human Resources Steven L. Lerner, Sr. VP/Chief Tech. Officer John F. Hill, CIO Theodore W. Dougher, VP-Eng. David H. Chaifetz, Corp. Sec. David H. Chaifetz, VP/General Counsel Sunil Matto, VP-Strategic Planning and Mktg. Nigel D. Muir, VP-Comm. and Public Rel. Michael J. Allan, VP/Treas. Stephen F. Angel, Exec. VP Paul J. Bilek, Exec. VP Thomas W. von Krannichfeldt, Exec. VP Theodore W. Dougher, VP-Supply Systems Dennis H. Reilley, Chmn. Domingos H. G. Bulus, Pres.-Praxair Asia Peter M. Mayer, VP-Procurement and Materials Mgmt.
Phone: 203-837-2000 Fax: 800-772-9985 Toll-Free: 800-772-9247 Address: 39 Old Ridgebury Rd., Danbury, CT 06810-5113 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $5,128,000 (12 months) 2002 Profits: $409,000 (12 months) Stock Ticker: PX 2001 Sales: $5,158,000 2001 Profits: $430,000 Employees: 25,010 2000 Sales: $5,043,000 2000 Profits: $363,000 Fiscal Year Ends: 12/31 1999 Sales: $4,639,000 1999 Profits: $431,000 1998 Sales: $4,833,000 1998 Profits: $425,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $912,500 Stock Purch. Plan: Second Exec. Salary: $480,500 World's third-largest industrial gas firm. ADVANTAGE:
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $1,150,000 Bonus: $415,200
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
PROTEIN DESIGN LABS INC
www.pdl.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:68 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:60
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Kidney Transplant Rejection Humanized Monoclonal Antibodies Autoimmune Disease Drugs
Protein Design Labs, Inc. (PDL) is a leading developer of humanized monoclonal antibodies for the prevention and treatment of disease. The company focuses on and has current drug development projects in the areas of oncology, inflammatory and autoimmune diseases and asthma. The company’s Zenapax was developed for the prevention of kidney transplant rejection. The product is currently licensed to Hoffman-La Roche, Inc. for marketing in the United States, Europe and other countries. Zenapax is also being tested for the treatment of autoimmune and inflammatory conditions, transplant and cancer. The company is currently partnered with Exelixis, Inc. to discover and develop cancer-fighting antibodies. Exelixis provides its model organism genetics technology for identification purposes and PDL develops the new antibody drug candidates. In addition, PDL announced favorable results of its SMART Anti-Gamma Interferon Antibody Phase I/Phase II trials to treat Crohn's disease. The company is also conducting Phase II trials in order to review its Remitogen drug effectiveness in cancer patients. Other drugs in the beginning stages of development include Zamyl for acute myeloid leukemia, SMART Anti-L-Selectin for trauma patients, and Nuvion for graft-versus-host disease. The company recently acquired privately held Eos Biotechnology, Inc. Under the terms of the merger, PDL acquired 100% of Eos’s outstanding shares valued at approximately $37.5 million. PDL offers a summer internship program for college students in a variety of disciplines such as Biochemistry, Accounting, Molecular and Cell Biology, Environmental Health and Safety, Information Sciences, Marketing and Human Resources. The company’s comprehensive employee benefits package includes medical, dental and vision insurance, paid vacation and a stock option plan. . The firm has locations in Fremont, California; Plymouth, Minnesota; and Somerville, New Jersey.
BRANDS/DIVISIONS/AFFILIATES: Eos Biotechnology, Inc. Zenapax Zamyl Remitogen Nuvion SMART
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Mark McDade, CEO Glen Y. Sato, CFO Jaisim Shah, VP-Mktg. Frances G. Charlson, VP-Human Resources William R. Benjamin, VP-Research Patrick M. Caldwell, Controller Douglas O. Ebersole, Corp. Sec. Sergio Garcia-Rodriguez, General Counsel Brett L. Schmidli, Sr. VP-Tech. Oper. Robert L. Kirkman, VP-Bus. Dev. Robert L. Kirkman, VP-Corp. Comm. Corine Klingbeil, VP-Preclinical Dev. Douglas O. Ebersole, Sr. VP-Legal and Licensing Lyn D. Olson, VP-Quality and Compliance Barbara K. Finck, VP-Clinical Dev. Laurence J. Korn, Chmn.
Phone: 510-574-1400 Fax: 510-574-1500 Toll-Free: Address: 34801 Campus Dr., Fremont, CA 94555 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $46,400 (12 months) 2002 Profits: $-14,600 (12 months) Stock Ticker: PDLI 2001 Sales: $79,500 2001 Profits: $2,600 Employees: 397 2000 Sales: $63,056 2000 Profits: $ 647 Fiscal Year Ends: 12/31 1999 Sales: $35,754 1999 Profits: $-10,333 1998 Sales: $30,828 1998 Profits: $-9,502
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $512,075 Stock Purch. Plan: Y Second Exec. Salary: $408,553 ADVANTAGE: A leading developer of humanized monoclonal antibodies.
OTHER THOUGHTS: Apparent Women Officers or Directors: 4 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $ Bonus: $50,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
PROXIM CORPORATION
www.proxim.com
Industry Group Code: 334210 Ranks within this company's industry group: Sales:17 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:9
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Telecommunications Equipment-Radio-Frequency Components Home and Office Networking
Proxim Corporation, formerly Western Multiplex, offers a comprehensive array of integrated networking solutions. The company, which changed its name after acquiring Proxim, Inc., designs, manufactures and markets wireless network equipment, offering secure network connections within a building as well as between locations. The company focuses on inter-location networking, using point-to-point wireless Ethernet bridges and point-tomultipoint systems. Proxim markets a complete range of in-house flexible, multi-standard wireless networking solutions for the home, small businesses, service providers and enterprises. The company’s Symphony product family offers wireless networking capabilities for the home environment, allowing consumers to network laptops, computers, stereos, televisions and even clock radios. Other product families developed by the company include ORiNOCO, Harmony, Tsunami and Lynx Spread Spectrum Radio. Recently, the company acquired Agere Systems’ wireless LAN business. In other news, the company and Trillion have provided 400,000 elementary and high school students throughout Alabama, Tennessee, Florida, Georgia, South Carolina, Mississippi and Louisiana with wireless Internet connections using Proxim’s Tsunami point-to-point and point-to-multipoint radios. There are plans to provide for an additional 250 schools in the near future. Proxim offers employees department activities such as days out and white water rafting excursions.
BRANDS/DIVISIONS/AFFILIATES: Proxim, Inc. Western Multiplex ORiNOCO Harmony Tsunami Lynx Spread Spectrum Radio Symphony
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jonathan N. Zakin, CEO David C. King, COO David C. King, Pres. Keith Glover, Exec. VP/CFO James Regel, VP-Sales Amir Zoufnoun, Exec. VP/Tech. Gordana Pance, VP-Eng. Keith Glover, Corp. Sec. Keith Glover, VP-Admin. Christopher M. Jones, Sr. VP/General Mgr.-North American Sales Ihab Abu-Hakima, VP/General Mgr.-Int'l Sales Angela M. Champness, Sr. VP/General Mgr.-LAN Div. Jonathan N. Zakin, Chmn.
Phone: 408-731-2700 Fax: 408-731-3675 Toll-Free: 800-229-1630 Address: 935 Stewart Dr., Sunnyvale, CA 94085 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $144,700 (12 months) 2002 Profits: $-239,900 (12 months) Stock Ticker: PROX 2001 Sales: $105,730 2001 Profits: $-25,598 Employees: 433 2000 Sales: $105,508 2000 Profits: $6,295 Fiscal Year Ends: 12/31 1999 Sales: $44,750 1999 Profits: $1,177 1998 Sales: $32,903 1998 Profits: $1,835
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $257,830 Stock Purch. Plan: Y Second Exec. Salary: $228,725 ADVANTAGE: A leader in the wireless LAN technology market/Growth through acquisitions.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $275,521 Bonus: $189,283
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
PSA PEUGEOT CITROEN SA
www.psa-peugeot-citroen.com
Industry Group Code: 336111 Ranks within this company's industry group: Sales:7 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Profits:7
Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Automobiles, Manufacturing Automotive Equipment Financial Services Industrial Equipment
PSA Peugeot Citroen (PSAPC), based in France, is the number-two automobile manufacturer in Europe, boasting 15.5% of the market. The firm produces cars and light commercial vehicles under the Peugeot and Citroen brand names. In addition, the group includes Faurecia, which makes automotive equipment and components, such as seats and exhaust systems; Gefco, a provider of transportation and logistics services; Banque PSA Finance; Peugeot Motocycles, the third largest maker of scooters and motorcycles in Europe; Peugeot Citroen Moteurs, which sells engines and gearboxes to outside customers; and Process Conception Ingenierie, which designs and manufactures industrial equipment for the company and other carmakers around the globe. PSAPC has begun construction on a joint Citroen/Toyota production facility in the Czech Republic, to produce 300,000 vehicles by 2005. The firm also formed a joint venture, Dong Feng Peugeot Citroen Automobiles, to expand cooperative production of these models in China. In recent news, PSAPC announced plans to build a new assembly plant in Slovakia.
BRANDS/DIVISIONS/AFFILIATES: Peugeot Citroen Faurecia Gefco Peugeot Motocycles Banque PSA Finance Peugeot Citroen Moteurs Process Conception Ingenierie
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jean-Martin Folz, Exec. Mgr. Yann Delabriere, Exec. Dir.-Finance and Control Jean-Luc Vergne, Exec. Dir.-Human Resources and Employee Rel. Jean-Louis Silvant, Exec. Dir.-Tech. Affairs and Platforms Roland Vardanega, Exec. Dir.-Mfg. and Components Jean-Claude Hanus, Sr. Dir.-Legal Affairs Jean-Marc Nicolle, Exec. Dir.-Strategy and Products Liliane Lacourt, Sr. Dir.-Corp. Comm. Xavier Fels, Sr. Dir.-Public Rel. Frederic Saint-Geours, Managing Dir.-Peugeot Claude Satinet, Managing Dir.-Citroen Jean-Louis Gregoire, Sr. Dir.-Exec. Dev. Robert Peugeot, Exec. Dir.-Innovation and Quality
Phone: 33-1-40-66-55-11 Fax: 33-1-40-66-55-11 Toll-Free: Address: 75 Ave. de la Grande-Armee, Paris, 75116 France
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $57,054,000 (12 months) 2002 Profits: $1,771,000 (12 months) Stock Ticker: Foreign 2001 Sales: $45,763,000 2001 Profits: $1,498,000 Employees: 198,600 2000 Sales: $41,600,800 2000 Profits: $1,235,400 Fiscal Year Ends: 12/31 1999 Sales: $38,071,600 1999 Profits: $779,400 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Large market share in Europe.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $ Second Exec. Salary: $
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
PURE WORLD INC
www.pureworld.com
Industry Group Code: 325411 Ranks within this company's industry group: Sales:6 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:2
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Botanical Extracts Manufacturing
PureWorld, Inc. develops, manufactures and sells natural ingredients that are derived from plant materials using the firm’s proprietary extraction technology. PureWorld applies a solution consisting of water and alcohol to raw materials in order to draw out various commercial ingredients of plants. The resultant extract can be converted into fluid extract, solid extract or powdered extract, which can then be encapsulated or tableted. Extracts can be used in liquids, tablets, sprays, capsules and lozenges. The firm has the ability to extract over 15,000 pounds of material per day. The company, which operates through its PureWorld Botanicals, Inc. subsidiary, has produced more than 1,000 botanical extracts, which are used by the cosmetic, food, flavor, vitamin, mineral, anti-oxidants, herb and pharmaceutical industries. PureWorld’s line of over 50 products includes American Ginseng, KavaPure, MacaPure, OlePure Olive Leaf, St. John’s Wort, Valerian, Goldenseal, Hawthorn, Saw Palmetto and Passion Flower. The company has the largest botanical extraction facility in North America. Situated on 4.5 acres, the 138,000-square-foot facility contains custom-designed stainless steel equipment.
BRANDS/DIVISIONS/AFFILIATES: PureWorld Botanicals, Inc. American Ginseng Gaia Herbs PureWorld Veragel MacaPure KavaPure OlePure Goldenseal
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Natalie I. Koether, Pres. John W. Galuchie, Jr., Exec. VP/Corp. Sec. John W. Galuchie, Jr., Treas. Natalie I. Koether, Pres., PureWorld Botanicals Qun Y. Zheng, Exec. VP-PureWorld Botanicals Paul O. Koether, Chmn.
Phone: 908-234-9220 Fax: 908-234-9355 Toll-Free: Address: 376 Main St., Bedminster, NJ 07921 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $18,100 (12 months) 2002 Profits: $-1,800 (12 months) Stock Ticker: PURW 2001 Sales: $18,200 2001 Profits: $-2,900 Employees: 107 2000 Sales: $10,400 2000 Profits: $ 200 Fiscal Year Ends: 12/31 1999 Sales: $15,800 1999 Profits: $-2,100 1998 Sales: $23,000 1998 Profits: $5,700
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Innovative plant extract technology.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $192,921 Second Exec. Salary: $160,937
Bonus: $ Bonus: $6,923
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
QUALCOMM INC
www.qualcomm.com
Industry Group Code: 334210 Ranks within this company's industry group: Sales:8 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:4
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Telecommunications Equipment Digital Wireless Communications Products Fleet Management Systems
QUALCOMM, Inc. is a leading provider of digital wireless communications products, technologies and services. The firm designs application-specific integrated circuits based on CDMA technology, then licenses and receives royalty payments on this technology from major domestic and international telecommunications equipment suppliers. QUALCOMM's CDMA technology has been adopted as an industry standard for digital cellular, PCS and wireless local loop networks. QUALCOMM also produces the email software Eudora and sells Binary Runtime Environment for Wirelesss (BREW) software and services to network operators, handset manufacturers and application developers. BREW is an open standard platform that can be made to interface with many different wireless applications. The company has two subsidiaries, Wireless Knowledge and Snaptrack. Wireless Knowledge focuses on speeding the acceptance of new wireless and digital technologies and on assisting customers in building wireless corporate networks. Snaptrack is a location services company that markets the industry’s only technology that integrates GPS with wireless networks. Additionally, QUALCOMM offers the fleet management systems OmniTRACS and OmniEXPRESS, satellite and digital wireless mobile communication systems. The company also bundles operational software with these products, which offers dispatch, accounting and payroll functions to fleet managers. The firm’s growth strategy focuses on increasing the acceptance of and migration to the 3G CDMA technology for wireless communications. QUALCOMM recently announced a line of products that use the technology, which the company expects to further increase demand for 3G-enabled products. QUALCOMM offers its employees an assistance program and a computer loan program. The company also provides amenities such as a fitness center, tennis courts, a swimming pool and a sand volleyball court. In addition, the company pays 100% of its employees' health insurance premiums.
BRANDS/DIVISIONS/AFFILIATES: Wireless Knowledge Snaptrack CDMA Eudora OmniTRACS OmniEXPRESS Technicolor Digital Cinema BREW
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Irwin M. Jacobs, CEO Anthony S. Thornley, COO Anthony S. Thornley, Pres. William E. Keitel, Sr. VP/CFO Daniel L. Sullivan, Exec. VP-Human Resources Roberto Padovani, Exec. VP/Chief Tech. Officer Norm Fjeldheim, Sr. VP/CIO Peggy L. Johnson, Pres.-Internet Services Julie C. Cunningham, Sr. VP-Investor Rel. Paul E. Jacobs, Pres.-Wireless and Internet Donald E. Schrock, Pres.-CDMA Tech. Steven R. Altman, Exec. VP/Pres.-Tech. Licenses Jeff Jacobs, Pres.-Global Dev.
Phone: 858-587-1121 Fax: 858-658-2100 Toll-Free: Address: 5775 Morehouse Dr., San Diego, CA 92121-1714 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $3,039,600 (12 months) 2002 Profits: $359,700 (12 months) Stock Ticker: QCOM 2001 Sales: $2,679,800 2001 Profits: $-548,700 Employees: 8,100 2000 Sales: $3,196,780 2000 Profits: $670,211 Fiscal Year Ends: 9/30 1999 Sales: $3,937,299 1999 Profits: $200,879 1998 Sales: $3,347,870 1998 Profits: $108,532
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $950,019 Stock Purch. Plan: Y Second Exec. Salary: $574,630 ADVANTAGE: Owns CDMA, a leading wireless communications standard.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $800,000 Bonus: $400,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
QUANTUM CORP
www.quantum.com
Industry Group Code: 334112 Ranks within this company's industry group: Sales:6 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:4
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Storage Equipment-Hard Disk & Tape Drives Media Cartridges
Quantum Corporation is a leader in data protection. The company’s products provide backup, archiving and recovery of business-critical data. The firm consists of two segments, the digital linear tape (DLT) group and the storage solutions group. The DLT group designs, develops, manufactures, licenses, services and markets DLTtape and SuperDLTtape drives as well as the media cartridges used in them. The firm earns revenue from the sale of these drives and cartridges and from licenses sold to other companies. DLTtape is a leader in mid-range UNIX and NT system backup and archive applications. The storage solutions group designs and manufactures tape automation systems and network attached storage solutions. Quantum’s tape automation systems, libraries and autoloaders serve the entire tape library data storage market from desktop computers to enterprise class computers. These systems are used to manage, store and transfer data in enterprise networked computing environments. The firm recently sold its hard disk drive group to Maxtor Corporation. In addition, Quantum completed the acquisition of M4 Data Holdings, Ltd. and certain assets of Connex, Inc. An unusual aspect of the company is its practice of placing lower-level and mid-level employees in the outer windowed offices, while placing management in the windowless interior. Everyone from entry-level to CEO is on the same bonus plan. Quantum's benefits include maternity, telecommuting and a business-casual dress code. The company also provides auto and homeowners' insurance, an employee referral program, disk drive discounts, an on-site fitness facility and other benefits.
BRANDS/DIVISIONS/AFFILIATES: DLTtape SuperDLTtape M4 Data Holdings, Ltd. ATL ValueLoader ATL SuperLoader Snap Server Rushmore NTE Trailblazer
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Rick Belluaao, CEO Michael J. Lambert, CFO Barbara Nelson, Exec. VP-Corp. Mktg. Jerald L. Maurer, Exec. VP-Human Resources Barbara Nelson, Exec. VP-IT Barbara Nelson, Exec. VP-Strategy John B. Gannon, Pres.-DLT Group Lawrence M. Orecklin, Pres.-Storage Solutions Group Jerald L. Maurer, Exec. VP-Real Estate/Corp. Service Michael A. Brown, Chmn.
Phone: 408-944-4000 Fax: 408-944-4040 Toll-Free: Address: 501 Sycamore Dr., Milpitas, CA 95035 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,087,800 (12 months) 2002 Profits: $42,500 (12 months) Stock Ticker: DSS 2001 Sales: $1,405,800 2001 Profits: $160,600 Employees: 3,100 2000 Sales: $4,727,204 2000 Profits: $40,844 Fiscal Year Ends: 3/31 1999 Sales: $4,902,056 1999 Profits: $-29,535 1998 Sales: $5,805,235 1998 Profits: $170,801
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $959,999 Stock Purch. Plan: Y Second Exec. Salary: $461,105 ADVANTAGE: Industry volume leader since 1993/Broad range of storage products.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $250,000 Bonus: $84,443
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
QUIDEL CORP
www.quidel.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:31 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:32
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Equipment/Supplies-Manufacturer Point-of-Care Diagnostic Tests
Quidel Corporation is a leader in discovering, manufacturing and marketing point-of-care rapid diagnostic tests for the detection and management of a variety of medical conditions and illnesses, including reproductive and general women’s health, infectious diseases, allergies and autoimmune disorders. Products are sold to hospitals, clinical labs, physicians’ offices and wellness screening centers. Currently, the firm manufactures testing products for influenza, strep, mononucleosis, H. pylori, chlamydia, pregnancy, ovulation, allergies and bone health. Quidel has launched its QuickVue Advance pH and Amines and QuickVue Advance G. vaginalis tests. In addition, its QuickVue Dipstick Strep A test received regulatory approval and a reimbursement code from the Japanese Ministry of Health and Welfare, allowing for the test to be sold in Japan. These tests are sold through the company's Japanese distributor, Sumitomo Seiyaku Biomedical Co., Ltd. The company has also made available its UrinQuick Urine Chemistry Analyzer. The UrinQuick instrument is used in automating the reading of its QuickVue UrinChek test strips, thereby enabling the practioner to make timely patient management decisions as an aid in the diagnosis of diabetes, liver and kidney disease, urinary tract infections and other health parameters. In recent news, the company announced the introduction of the QuickVue Influenza test to evaluate respiratory symptoms. The QuickVue Influenza test provides accurate results in 10 minutes to assist the physician in obtaining the patient diagnosis.
BRANDS/DIVISIONS/AFFILIATES: QuickVue Influenza Test UrinQuick Urine Chemistry Analyzer QuickVue UrinChek Test Strips QuickVue Dipstick Strep A Test QuickVue Advance pH Test QuickVue Advance G Test
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. S. Wayne Kay, CEO S. Wayne Kay, Pres. Paul E. Landers, CFO/Sr. VP-Finance John D. Tamerius, VP-Research and Dev. Mark E. Paiz, Sr. VP-Tech. Paul E. Landers, Corp. Sec. Paul E. Landers, Sr. VP-Admin. Mark E. Paiz, Sr. VP-Bus. Dev. André de Bruin, Chmn.
Phone: 858-552-1100 Fax: 858-546-8955 Toll-Free: 800-874-1517 Address: 10165 McKellar Ct., San Diego, CA 92121 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $74,600 (12 months) 2002 Profits: $1,300 (12 months) Stock Ticker: QDEL 2001 Sales: $74,100 2001 Profits: $ 900 Employees: 330 2000 Sales: $68,400 2000 Profits: $-5,800 Fiscal Year Ends: 12/31 1999 Sales: $38,900 1999 Profits: $-1,500 1998 Sales: $47,200 1998 Profits: $7,700
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $395,681 Bonus: $ Stock Purch. Plan: Y Second Exec. Salary: $203,568 Bonus: $ ADVANTAGE: Focus on rapid medical diagnostics for point-of-care settings worldwide/Proprietary microarray technology.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
QUINTILES TRANSNATIONAL CORP Industry Group Code: 541710 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y Y
Engineering: Design: Construction: Eng. Services: Consulting:
www.quintiles.com Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Research & Development Sales and Marketing Services
Quintiles Transnational Corporation is a leading provider of full-service contract research, sales and marketing services to the global pharmaceutical, biotechnology and medical device industries. The company provides a broad range of contract services to speed the process from development to peak sales of a new drug or medical device. The firm also offers market research solutions and strategic analyses to support health care decisions and policy consulting to governments and other organizations worldwide. Quintiles operates in three primary business segments: the product development group, the commercialization group and the PharmaBio development group. The product development group provides a full range of drug development services from strategic planning and preclinical services to regulatory submission and approval. The commercial services group engages in sales force deployment and strategic marketing services as well as consulting services for its customers. This group operates under the company’s Innovex brand name. The PharmaBio development group works with the other service groups to enter into strategic transactions that it believes will position the company to explore new opportunities and areas for potential growth. PharmaBio also acquires the rights to market pharmaceutical products. Recently, the company signed an agreement with Columbia Laboratories to commercialize Columbia’s Straint product for the treatment of hypogonadism in men. The two companies will also collaborate to promote Columbia’s women’s health products. In other news, the firm recently announced that its chairman and founder plans to take the company private in a transaction valued at $1.7 billion. Quintiles Transnational offers its employees a comprehensive benefits package including on-the-job training, recreational activities and community support activities.
BRANDS/DIVISIONS/AFFILIATES: PharmaBio Development Innovex
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Pamela J. Kirby, CEO James L. Bierman, Exec. VP/CFO John S. Russell, Exec. VP-Human Resources John S. Russell, Exec. VP/Corp. Sec. John S. Russell, General Counsel Pat Grebe, VP-Corp. Comm. Greg Connors, Investor Rel. Dennis B. Gillings, Chmn.
Phone: 919-998-2000 Fax: 919-998-2094 Toll-Free: Address: 4709 Creekstone Dr., Ste. 200, Durham, NC 277098411 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,992,400 (12 months) 2002 Profits: $127,400 (12 months) Stock Ticker: QTRN 2001 Sales: $1,619,900 2001 Profits: $-33,900 Employees: 15,548 2000 Sales: $1,659,900 2000 Profits: $418,900 Fiscal Year Ends: 12/31 1999 Sales: $1,607,100 1999 Profits: $109,300 1998 Sales: $1,221,800 1998 Profits: $88,600
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $600,000 Bonus: $31,875 Stock Purch. Plan: Second Exec. Salary: $368,749 Bonus: $12,031 ADVANTAGE: Leading provider of full-service contract research, sales and marketing services to the global pharmaceutical, biotechnology, and medical device industries.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
RADISYS CORP
www.radisys.com
Industry Group Code: 334111 Ranks within this company's industry group: Sales:11 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:6
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Computer Hardware-Intel-Based Embedded Computers DSP Modules and Algorithms Embedded Software Systems Engineering Systems Integration Services
RadiSys Corp. designs and manufactures building blocks for next-generation Internet, communications, industrial automation, medical equipment and transaction terminal applications. The company’s products include Intel-based embedded computers, DSP modules and algorithms, network interfaces and protocols, systems platforms, embedded software, systems engineering and integration services. The firm focuses on working in a close virtual division relationship with its customers, which significantly reduces cost and increases time-to-market advantage. RayiSys and Comverse Technology, Inc., one of the firm’s four largest customers, have partnered to develop nextgeneration embedded computing solutions for the enhanced services market. RadiSys will supply embedded computer solutions to Comverse and will be responsible for meeting its embedded computing production requirements, demand and inventory management and product logistics. IBM, Nokia and Nortel, along with Comverse, represent 43% of RadiSys’s business. The company’s presence in the Far Eastern market has been greatly enhanced by an agreement with Dragon Technology Distribution Co., Ltd. to distribute RadiSys products in China. Dragon Technology is a technical design organization serving the Chinese market, one of the fastest growing telecommunications markets in the world. RadiSys provides employees with a variety of health and wellness programs, tuition reimbursement, discount purchase programs, awards programs and companysponsored social events.
BRANDS/DIVISIONS/AFFILIATES:
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Scott C. Grout, CEO Ronald A. Dilbeck, COO Scott C. Grout, Pres. Julia A. Harper, VP-Finance/CFO George Shenoda, Chief Tech. Officer Keith Lambert, VP-Mfg. Oper. Julia A. Harper, VP-Admin. Seamus Gilchrist, VP-Signaling Products Design Center Fred Yentz, VP/General Mgr.-Comm. Products Div. C. Scott Gibson, Chmn.
Phone: 503-615-1100 Fax: 503-615-1121 Toll-Free: 800-950-0044 Address: 5445 NE Dawson Creek Dr., Hillsboro, OR 97124 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $200,100 (12 months) 2002 Profits: $-3,300 (12 months) Stock Ticker: RSYS 2001 Sales: $227,800 2001 Profits: $-34,500 Employees: 563 2000 Sales: $340,700 2000 Profits: $32,600 Fiscal Year Ends: 12/31 1999 Sales: $251,090 1999 Profits: $18,997 1998 Sales: $186,548 1998 Profits: $7,818
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $366,535 Stock Purch. Plan: Y Second Exec. Salary: $243,039 ADVANTAGE: Strategic partnerships and acquisitions.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $216,100 Bonus: $98,925
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
RATIONAL SOFTWARE CORP
www.rational.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:28 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:28
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Software Development
Rational Software Corp., a business segment of IBM Software, provides open, industry-standard tools, best practices and services for developing business applications and building software products and systems, including embedded software for devices such as cell phones and medical systems. Rational provides a software development platform that can improve the speed, quality and predictability of software projects. Of the Fortune 100, 98 companies, including IBM, use Rational tools and services. Rational provides the broadest support for enterprise application development on J2EE, .NET, Linux and other platforms to support the deployment of solutions on the customer’s choice of hardware and software platforms. Rational’s tools are also used to build technical software, commercial software products and software for embedded devices and realtime systems, such as pagers, cell phones, medical devices, air traffic control systems and government defense systems. The firm's portfolio of products includes Rational Suite, Rational Integrated Solutions and Rational Unified Process, as well as visual modeling solutions, automated testing solutions, integrated development environmental solutions and requirements management solutions. IBM merged Rational’s business operations and employees into the IBM Software group as a new division and fifth brand, joining WebSphere, Lotus, Tivoli and DB2. Rational Software provides employees with benefits including flexible spending accounts; five different health care plans including dental and vision coverage; and educational assistance.
BRANDS/DIVISIONS/AFFILIATES: IBM Software Rational Integrated Solutions Rational Suite NeuVis, Inc. Rational Rose RequisitePro AnalystStudio DevelopmentStudio
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Thomas F. Bogan, COO Thomas F. Bogan, Pres. Michael T. Devlin, General Mgr.
Phone: 408-863-9900 Fax: 408-863-4120 Toll-Free: Address: 18880 Homestead Rd., Cupertino, CA 95014-0721 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $689,800 (12 months) 2002 Profits: $-75,900 (12 months) Stock Ticker: RATL 2001 Sales: $814,900 2001 Profits: $72,100 Employees: 3,561 2000 Sales: $572,200 2000 Profits: $85,300 Fiscal Year Ends: 3/31 1999 Sales: $411,800 1999 Profits: $59,200 1998 Sales: $310,700 1998 Profits: $-38,300
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $378,125 Bonus: $340,700 Stock Purch. Plan: Y Second Exec. Salary: $260,417 Bonus: $340,700 ADVANTAGE: Serves a wide range of industry segments/Operates a worldwide field organization of software engineers and technical sales professionals.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
RAYTHEON CO
www.raytheon.com
Industry Group Code: 336410 Ranks within this company's industry group: Sales:5 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Profits:9 Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Aerospace & Defense-Diversified Commercial Electronics Corporate and General Aviation Aircraft Missile Systems Space Exploration Devices Communication and Information Systems
Raytheon Company is a leader in the production of defense and commercial electronics, engineering and construction services and special mission aircraft, including Beechcraft and Hawker corporate aircraft. The company designs and manufactures advanced electronic devices, marine electronics equipment and systems for commercial and government customers. The electronic systems segment concentrates on anti-ballistic missile systems, air defense, naval and maritime systems, ship self-defense systems, torpedoes and other missiles. Additionally, it developed the Patriot ground-based air defense missile system which is capable of tracking and intercepting enemy aircraft. Raytheon’s command, control, communication and information segment produces air traffic control systems, tactical radios, satellite communication ground terminals, surveillance systems, transportation systems and other defense-related systems. Raytheon Technical Services Company provides technical services, training programs and logistics and base operations support throughout the U.S. and in 22 other countries. Raytheon Aircraft is one of the leading providers of business and special mission aircraft and delivers a broad line of jet, turboprop and pistonpowered airplanes to corporate and government customers worldwide. The company was recently awarded a contract from the Naval Air Systems Command to produce joint standoff weapons for the U.S. Navy and Air Force. Raytheon’s missle systems business will complete the production of these weapons by early 2005. Through LifeCare.com, the firm's employees have 24-hour access to information about child care, pre-natal care, parenting, adult care, adoption, college and other services. Additionally, employees can purchase home and auto insurance through the company.
BRANDS/DIVISIONS/AFFILIATES: Patriot Missile System Sea-Sparrow Raytheon Aircraft AN/QS-20 Hawker Beechcraft Raytheon Technical Services
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. William H. Swanson, CEO Edward S. Pliner, CFO/Sr. VP
Phone: 781-862-6600 Fax: 781-860-2172 Toll-Free: Address: 141 Spring St., Lexington, MA 02421 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $16,760,000 (12 months) 2002 Profits: $-587,000 (12 months) Stock Ticker: RTNB 2001 Sales: $16,867,000 2001 Profits: $-763,000 Employees: 76,400 2000 Sales: $16,895,000 2000 Profits: $141,000 Fiscal Year Ends: 12/31 1999 Sales: $19,841,000 1999 Profits: $404,000 1998 Sales: $19,419,000 1998 Profits: $844,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $1,021,023 Stock Purch. Plan: Second Exec. Salary: $608,903 ADVANTAGE: One of the largest U.S. defense contractors.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $1,500,000 Bonus: $925,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
READ-RITE CORP
www.readrite.com
Industry Group Code: 334112 Ranks within this company's industry group: Sales:10 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:10
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Storage Equipment-Magnetic Recording Heads Head Gimbal Assemblies Optical Communications Components
Read-Rite Corporation is a leading manufacturer of magnetic recording heads, head gimbal assemblies and head stack assemblies for disk drives and tape drives. The firm’s products offer customers data storage devices with the ability to store increasingly large quantities of data in ever-smaller areas of thin-film disks in computer hard drives or other media. Increases in this ability, the areal density, reduce disk drive costs and influence portability, speed and other features of computers and computing products. In response to the disk drive market’s demand for higher performance products, Read-Rite has pursued and continues to aggressively pursue a range of new and emerging technologies to increase the areal density capability of its products. Furthermore, the firm’s tape head unit has launched development programs for certain customers of multi-channel magnetoresistive tape heads in an effort to penetrate the digital linear tape drive market. Read-Rite's three main customers, Western Digital, Maxtor and Samsung, represent 91% of net sales. The company’s Scion Photonics, Inc. subsidiary designs, develops, manufactures and sells both custom and standard dense wavelength division multiplexers and other optical communications components to address the rapidly growing worldwide fiber-optic network expansion. Scion Photonics also operates Optical Systems Corporation, a maker of precision automated tooling for the fiber-optics component manufacturing industry. This gives the subsidiary the opportunity to participate in the architecture of optical component designs, which enables it to implement design-for-automation concepts very early in the product design cycle. Read-Rite offers its employees tuition reimbursement, vision and dental insurance.
BRANDS/DIVISIONS/AFFILIATES: Scion Photonics, Inc. Optical Systems Corp.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Alan S. Lowe, CEO Alan S. Lowe, Pres. Andrew C. Holcomb, CFO Sherry F. McVicar, VP-Human Resources Mark Re, VP-Research and Dev. Michael A. Klyszeiko, VP-Oper. Andrew C. Holcomb, VP-Bus. Dev. James Murphy, Exec. VP-Customer Bus. Units Cyril J. Yansouni, Chmn.
Phone: 510-683-6100 Fax: 510-683-7060 Toll-Free: Address: 44100 Osgood Rd., Freemont, CA 94539 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $262,800 (12 months) 2002 Profits: $-234,700 (12 months) Stock Ticker: RDRT 2001 Sales: $712,900 2001 Profits: $35,900 Employees: 8,494 2000 Sales: $555,860 2000 Profits: $-124,829 Fiscal Year Ends: 9/30 1999 Sales: $716,460 1999 Profits: $-155,715 1998 Sales: $808,622 1998 Profits: $-319,747
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $482,692 Stock Purch. Plan: Y Second Exec. Salary: $347,538 ADVANTAGE: One of the world's leading independent suppliers of magnetic recording heads.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $612,500 Bonus: $180,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
REGENERON PHARMACEUTICALS INC www.regeneron.com Industry Group Code: 325412 Ranks within this company's industry group: Sales:87 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:90
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Diversified Protein-Based Drug Development
Regeneron Pharmaceuticals, Inc. identifies, develops and markets therapeutic drugs for the treatment of serious unmet medical conditions. The company is currently expanding its focus on degenerative neurological diseases to include drug therapies for obesity, rheumatoid arthritis, cancer, allergies, asthma and other disorders. Regeneron’s current leading clinical and preclinical research programs include Axokine and Pegylated Axokine, for the treatment of obesity; Interleukin-1 Cytokine Trap, for the treatment of rheumatoid arthritis and other inflammatory diseases; Interleukin-4 and Interleukin-13 Cytokines Trap, which play a role in diseases such as asthma and allergic disorders; and Angiopoietins, a new family of growth factors for treatment of stroke and diabetic retinopathy. The firm’s platform technologies are targeted genomics, Velocigene and designer protein therapeutics. The company is currently conducting research with Procter & Gamble in muscle diseases and other fields. It is also collaborating with Medarex, Inc. to discover, develop and commercialize certain human antibodies as therapeutics. In partnership with Amgen, Inc., Regeneron has development rights to Neurotrophin-3, a clinical compound for the treatment of constipating conditions.
BRANDS/DIVISIONS/AFFILIATES: Axokine Pegylated Axokine Interleukin-1 Cytokine Trap Interleukin-4 Cytokine Trap Interleukin-13 Cytokine Trap Neurotrophin-3 Angiopoietins Velocigene
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Leonard S. Schleifer, CEO Leonard S. Schleifer, Pres. Murray A. Goldberg, Sr. VP-Finance/CFO George D. Yancopoulos, Exec. VP/Chief Scientific Officer Randall G. Rupp, Sr. VP-Mfg. Murray A. Goldberg, VP-Admin. Murray A. Goldberg, Treas. George D. Yancopoulos, Pres., Regeneron Research Laboratories Neil Stahl, Sr. VP-Preclinical Dev. and Biomolecular Science Randall G. Rupp, VP-Process Science P. Roy Vagelos, Chmn.
Phone: 914-347-7000 Fax: 914-347-2113 Toll-Free: Address: 777 Old Saw Mill River Rd., Tarrytown, NY 10591-6707 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $22,000 (12 months) 2002 Profits: $-124,400 (12 months) Stock Ticker: REGN 2001 Sales: $22,000 2001 Profits: $-76,200 Employees: 669 2000 Sales: $59,300 2000 Profits: $-23,200 Fiscal Year Ends: 12/31 1999 Sales: $34,500 1999 Profits: $-23,100 1998 Sales: $38,300 1998 Profits: $-8,600
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $574,327 Bonus: $335,000 Stock Purch. Plan: Y Second Exec. Salary: $449,519 Bonus: $125,000 ADVANTAGE: Molecular biology expertise/Lucrative agreements with Merck and Proctor & Gamble.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
RESPIRONICS INC
www.respironics.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:24 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:23
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Equipment/Supplies-Respiratory Devices Ventilators
Respironics, Inc. is a leading developer, manufacturer and marketer of medical devices that are used for the treatment of patients suffering from respiratory disorders. The company operates in four divisions: homecare, hospital, asthma and allergy and international. Specifically, Respironics develops products for treatment of sleep apnea, infant monitoring, asthma therapy and drug delivery systems. The firm also rents portable volume ventilators to dealers and directly to end users in the United States. The company’s products are designed to reduce costs while improving the effectiveness of patient care and are used primarily in homes, hospitals and emergency medical settings. In addition to patients with sleep-oriented conditions, the company targets patients who have suffered congestive heart failure and strokes. The firm is currently in a purchasing agreement with Apria Healthcare Group, Inc., one of the nation's largest home health care companies, whereby Respironics acts as Apria’s primary supplier of sleep therapy units and ventilators and as an alternate supplier for oxygen concentrators. Respironics' marketing strategy includes the Power Programs for Providers, which is designed for customers' use in staff training to enhance staff productivity and general knowledge so that they may better treat their patients. The Power Programs are focused on sleep apnea, pulmonary disease, asthma and other respiratory disorders. The firm’s acquisitions include Navametrix Medical Systems; Fuji, RC Co., Ltd.; and the recent purchase of Children’s Medical Ventures, a provider of developmental care products and services that improve the quality of care for premature infants. The company compensates its employees with medical and dental benefits, including full disability insurance. Some are allowed to telecommute from home. Other benefits include wellness programs and fitness centers, educational reimbursement, savings bonds, stock options and shares, awards and access to a credit union.
BRANDS/DIVISIONS/AFFILIATES: BiPAP Vision Itamar Medical, Ltd. AmeriNet Power Programs for Providers REMstar Children's Medical Ventures Fuji, RC Co., Ltd. Navametrix Medical Systems
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. James Liken, CEO Craig B. Reynolds, COO/Exec. VP James Liken, Pres. Daniel J. Bevevino, VP/CFO Bill Decker, Dir.-Human Resources Susan A. Lloyd, VP-Asthma and Allergy Div. Paul L. Woodring, Pres.-Hospital Div. Geoffrey C. Waters, Pres.-Int'l Div. William Post, Pres.-Homecare Div. Gerald E. McGinnis, Chmn.
Phone: 724-387-5200 Fax: Toll-Free: 800-345-6443 Address: 1010 Murry Ridge Ln., Murrysville, PA 15668-8525 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $494,900 (12 months) 2002 Profits: $38,400 (12 months) Stock Ticker: RESP 2001 Sales: $422,400 2001 Profits: $33,600 Employees: 2,600 2000 Sales: $368,200 2000 Profits: $5,800 Fiscal Year Ends: 6/30 1999 Sales: $357,600 1999 Profits: $23,100 1998 Sales: $351,600 1998 Profits: $-1,800
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $317,812 Stock Purch. Plan: Y Second Exec. Salary: $291,622 ADVANTAGE: A leading producer of respiratory devices.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $51,000 Bonus: $92,197
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ROCKWELL AUTOMATION
www.rockwellautomation.com
Industry Group Code: 335999 Ranks within this company's industry group: Sales:6 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:3
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y Y Y
GROWTH PLANS/SPECIAL FEATURES:
Industrial Automation Solutions Power Transmission Products Contact Center Solutions
Rockwell Automation is a leading global provider of industrial automation power, control and information products and services. The organization is includes three operating segments: control systems, power systems and FirstPoint Contact. The control systems segment is a supplier of industrial automation products, systems, software and services focused on helping customers control and improve manufacturing processes and is further divided into three units: the components and packaged applications group (CPAG), the automation control and information group (ACIG) and global manufacturing solutions (GMS). CPAG produces industrial components, power control and motor management products and packaged and engineered products. ACIG’s products include programmable logic controllers (PLCs), which are used to automate the control and monitoring of industrial plants and processes and typically consist of a computer processor and input/ output devices. The company’s Logix integrated architecture integrates multiple types of control disciplines including discrete, process, drive and motion control across various factory floor operating systems. GMS provides multivendor automation and information systems and solutions which help customers improve their manufacturing operations. The power systems segment is divided into two units: the mechanical power transmission business and the industrial motor and drive business. In addition, the power systems group provides product repair, motor and mechanical maintenance solutions, plant maintenance, training and consulting services to OEMs, end users and distributors. FirstPoint Contact provides customer contact center solutions that support multiple channels (voice, e-mail, web and wireless) through open interaction infrastructure. Products include automatic call distributors, computer telephony integration software, information collection, reporting, queuing and management systems, call center systems and consulting services. The company offers its employees a health package, and many of its locations have fitness and day care centers.
BRANDS/DIVISIONS/AFFILIATES: Allen-Bradley Reliance Electric Co. Rockwell Collins FirstPoint Contact Rockwell Software Rockwell Samsung Automation Rockwell Scientific Co. Rockwell Automation Services
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Don H. Davis, Jr., CEO Michael A. Bless, Sr. VP/CFO Mary Jane Hall, Sr. VP-Human Resources William J. Calise, Jr., Sr. VP/Corp. Sec. William J. Calise, Jr., General Counsel John D. Cohn, Sr. VP-Strategic Dev. John D. Cohn, Sr. VP-Comm. Keith Nosbusch, Pres.-Control Systems Joseph D. Swann, Pres.-Power Systems Don H. Davis, Jr., Chmn.
Phone: 414-212-5200 Fax: 414-212-5279 Toll-Free: Address: 777 E. Wisconsin Ave., Ste. 1400, Milwaukee, WI 53202 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $3,909,000 (12 months) 2002 Profits: $121,000 (12 months) Stock Ticker: ROK 2001 Sales: $4,279,000 2001 Profits: $293,000 Employees: 22,000 2000 Sales: $7,151,000 2000 Profits: $636,000 Fiscal Year Ends: 9/30 1999 Sales: $7,043,000 1999 Profits: $562,000 1998 Sales: $6,752,000 1998 Profits: $-427,000
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $920,354 Stock Purch. Plan: Second Exec. Salary: $444,876 ADVANTAGE: State-of-the-art technology and production.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $750,000 Bonus: $297,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ROYAL DUTCH PETROLEUM CO
www.shell.com
Industry Group Code: 211111 Ranks within this company's industry group: Sales:3 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:3
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Y Chemicals: Y Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Oil & Gas, Exploration and Production Petrochemical Manufacturing
The companies of the Royal Dutch/Shell Group produce, process and deliver energy- and oil-related products. The group operates in more than 130 countries and is the world’s third-largest oil conglomerate. With a network of more than 46,000 petrol stations spanning the globe, Shell companies serve approximately 20 million fuel customers every day. The group has five core businesses: exploration and production; oil products; chemicals; gas and power; and renewables. The firm’s exploration and production unit searches for oil and gas fields by means of seismic surveys and exploration wells. The chemicals division produces and sells base chemicals, petrochemicals and polyolefins globally. The gas and power generation division invests in processing and transportation infrastructure, liquefied natural gas, marketing and the trading of natural gas and electricity to industrial and domestic customers. The firm is also a developer and operator of renewable energy solutions. Other companies of the group include Shell Internet Ventures, Shell Hydrogen, Shell Global Solutions and Shell Trading. Shell Renewables’ U.S. wind energy operation, Shell WindEnergy, Inc., completed the acquisition of its first project with the purchase of the 50megawatt Rock River I wind farm in Wyoming, representing the first major step in achieving its wind energy strategy, by moving from experimental to commercial scale in the business. Shell Hydrogen, Ballard Power Systems and Westcoast Energy created Chrysalix Energy, a Vancouver-based, private-capital joint venture focused on promoting early-stage companies with high growth potential in fuel cells and related systems, hydrogen infrastructure, maintenance and support techniques. In recent news, Shell has teamed with Volkswagen to produce 25 Golf cars that will be fuelled by Shell gas-to-liquids, a synthetic fuel that is derived from natural gas, at a lower cost. The company offers jobs around the world. It offers employees tuition reimbursement and study leave; sabbatical programs; foreign language schooling; and subsidized sports facilities in some locations.
BRANDS/DIVISIONS/AFFILIATES: Shell Exploration and Production Shell Service Stations Shell Trading Chrysalix Energy Shell International Trading and Shipping Shell Global Solutions Shell Renewable Shell WindEnergy, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jeroen van der Veer, CEO Jeroen van der Veer, Pres. Robbert van der Vlist, General Attorney Gaurdie Banister, VP-Bus. Dev. and Tech., Shell Exploration David Sexton, U.S. Investor Rel. Harry Roels, Managing Dir. Paul Skinner, Managing Dir. Walter van de Vijver, Managing Dir. Aad Jacobs, Chmn.
Phone: 31-70-377-9111 Fax: 31-70-377-3115 Toll-Free: Address: 30 Carel van Bylandtlaan, The Hague, 2596 HR The Netherlands
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $107,659,000 (12 months) 2002 Profits: $5,651,000 (12 months) Stock Ticker: RD 2001 Sales: $81,127,000 2001 Profits: $6,511,000 Employees: 111,000 2000 Sales: $89,488,000 2000 Profits: $7,632,000 Fiscal Year Ends: 12/31 1999 Sales: $63,220,000 1999 Profits: $5,151,000 1998 Sales: $56,216,000 1998 Profits: $211,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Majority shareholder of Royal Dutch/Shell Group.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ROYAL PHILIPS ELECTRONICS
www.philips.com
Industry Group Code: 335999 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:10
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Electrical and Electronic Equipment, Manufacturing Consumer Electronics Semiconductors Consulting Services
Royal Philips Electronics (Philips) is one of the world’s leading electronics companies. It is a leader in television sets, lighting, electric shavers, medical diagnostic imaging and patient monitoring products. The company is organized into five divisions: consumer electronics, domestic appliances and personal care, lighting, medical systems and semiconductors. The consumer electronics division manufactures and markets products such as wide screen televisions, optical disc products, digital television systems, cellular phones, digital cameras and LCD projectors. Philips’ domestic appliances division produces electric shavers, kitchen appliances, vacuum cleaners and irons. The lighting division offers a range of lamps including incandescent, halogen, fluorescent, fixtures and automotive lamps. The company’s medical systems division portfolio includes x-ray, ultrasound, magnetic resonance, nuclear medicine and positron emission tomography. Furthermore, this division offers training and education, business consultancy, finance, leasing and ebusiness services in the health care sector. Finally, the semiconductor division manufactures semiconductors from 18 manufacturing and assembly sites, 30 design centers and more than 100 offices. Philips recently announced plans to return the semiconductor division of the company to profitability by the end of this year.
BRANDS/DIVISIONS/AFFILIATES:
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Gerard Kleisterlee, CEO Gerard Kleisterlee, Pres. Jan Hommen, Exec. VP/CFO Andrea Ragnetti, Sr. VP/Chief Mktg. Officer Tjerk Hooghiemstra, Sr. VP-Human Resources Ad Huijser, Exec. VP/Chief Tech. Officer Arie Westerlaken, Sr. VP/Chief Legal Officer Jan Oosterveld, Sr. VP-Corp. Strategy Arthur van der Poel, Exec. VP Gottfried Dutine, Exec. VP/CEO-Consumer Electronics Scott McGregor, Sr. VP/CEO-Semiconductors David Hamill, Sr. VP/CEO-Lighting Gerard Kleisterlee, Chmn.
Phone: 877-248-4237 Fax: 201-324-3284 Toll-Free: 877-248-4237 Address: Breitner Center, Amstelplein 2, Amsterdam, 1096 BC The Netherlands
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $33,421,000 (12 months) 2002 Profits: $-3,367,000 (12 months) Stock Ticker: Foreign 2001 Sales: $28,824,000 2001 Profits: $2,321,000 Employees: 170,087 2000 Sales: $35,658,000 2000 Profits: $9,043,000 Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Global distribution.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $721,775 Second Exec. Salary: $635,292
Bonus: $248,520 Bonus: $370,625
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
SAMSUNG ELECTRONICS CO LTD www.samsungelectronics.com Industry Group Code: 334210 Ranks within this company's industry group: Sales:2 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y Y Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Electronics Manufacturer Consumer Electronics Computers Printers Fuel Cell Technology Digital Cameras
Samsung Electronics Co. is a global leader in semiconductor, telecommunications and digital convergence technology. The company’s products include mobile phones, laptops, personal digital assistants (PDAs), digital cameras, monitors, hard drives, printers, TVs, VCRs, DVD players and microwaves. Recently, the firm launched SCH-X590, the world’s first CDMA2000 1X mobile phone with color display and embedded chargecoupled device camera. The embedded camera can rotate 180 degrees, comes with a 4-power zoom lens and has 20 different aperture settings. The SCH-X590 can store up to 100 photos in its memory, and the multi-display function allows the user to search through the image archive by as many as six images at a time. Furthermore, the company has introduced a two-inch thin film transistorliquid crystal display for mobile phones. The new screen, which reproduces 260,000 color tones, incorporates advanced transmissive with micro reflective technology for improved outdoor resolution. Samsung Electronics has also developed a CPU for next-generation post-PC products such as PDAs, electronic books, game machines and smart phones. The CPU features a microprocessor and customized memory and peripheral logic functions, which previously required separate chips. In partnership with Sanyo, the firm is investing heavily in the development of advanced fuel cell technology. The firm has displayed its ability to lead the industry in advancements with its recent launch of the first TDMA mobile phone with color display. Samsung has strategic alliances with some of the industry’s leading companies, including Sony, Dell, AOL-Time Warner and Intel. The company is dedicated to providing women workers with the same opportunities as their male counterparts. In testimony to this commitment, Samsung has opened the Women's Dream Plaza, a facility specifically designed for women and their needs in the areas of maternity, health and career advancement.
BRANDS/DIVISIONS/AFFILIATES: SCH-X590
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jong-Yong Yun, CEO Hak-Soo Lee, Pres. Doh-Seok Choi, CFO Seung-Jun Ahn, Human Resources Yoon-Woo Lee, Pres.-Semiconductor Bus. Lee Kun-Hee, Chmn.
Phone: 82-2-727-7114 Fax: 82-2-727-7985 Toll-Free: Address: 250, 2-ga, Taepyung-ro, Chung-gu, Seoul, 100-742 South Korea
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $50,175,000 (12 months) 2002 Profits: $5,941,000 (12 months) Stock Ticker: Foreign 2001 Sales: $24,463,400 2001 Profits: $2,226,400 Employees: 50,000 2000 Sales: $27,060,200 2000 Profits: $4,747,300 Fiscal Year Ends: 12/31 1999 Sales: $22,860,900 1999 Profits: $2,775,100 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Advanced cellular telephone products.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
SANGSTAT MEDICAL CORP
www.sangstat.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:50 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:43
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Organ Rejection and Viability Specialty Pharmacy
SangStat Medical Corporation is a global biotechnology company expanding on its transplantation foundation to discover, develop and market high value therapeutic products in immunology, hematology/oncology and autoimmune disease. The company’s subsidiaries include SangStat Europe and SangStat, Canada, Ltd. The firm recently decided to implement a new strategy that focuses significant resources on its pharmaceutical products segment, which consists of four marketed products and three principal product candidates. It also sold its transplantation services segment, The Transplant Pharmacy, to Chronimed. The company is currently marketing the following products: Thymoglobulin, which prevents graft rejection in kidney transplants; Lymphoglobuline, which prevents and treats kidney, heart, pancreas or liver rejection (outside the U.S.); Celsior, which preserves organ viability; and Gengraf, which is copromoted with Abbott Laboratories. Products currently in development include ABX-CBL, an anti-CD 147 antibody for the treatment of steroid resistant Graft-versus-Host disease in co-development with Abgenix, Inc.; and RDP58 for the treatment of ulcerative colitis and Crohn’s disease. In recent news, SangStat announced that it has received approval from the U.S. FDA for its Investigational New Drug application for clinical studies of RDP58. The company has also received a notice of compliance from Canada Health for Thymoglobulin.
BRANDS/DIVISIONS/AFFILIATES: SangStat Europe SangStat, Canada, Ltd. Thymoglobulin Lymphoglobuline Celsior Gengraf Abgenix, Inc. RDP58
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Richard D. Murdock, CEO Richard D. Murdock, Pres. Stephen Dance, Sr. VP-Finance Steve Aselage, Sr. VP-North America Sales and Mktg. Marlene Perry, Dir.-Human Resources Timothy Fong, VP-Discovery Research Adrian Arima, Sr. VP/General Counsel Ralph Levy, Sr. VP-Oper. Brian Lundstrom, VP-Bus. Dev. Raymond J. Tesi, Sr. VP-Clinical Dev. and Medical Affairs Ross Maclean, VP-Global Regulatory Affairs
Phone: 510-789-4300 Fax: 510-789-4400 Toll-Free: Address: 6300 Dumbarton Circle, Fremont, CA 94555 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $120,100 (12 months) 2002 Profits: $6,300 (12 months) Stock Ticker: SANG 2001 Sales: $94,500 2001 Profits: $-9,300 Employees: 299 2000 Sales: $63,100 2000 Profits: $-44,300 Fiscal Year Ends: 12/31 1999 Sales: $58,200 1999 Profits: $-33,000 1998 Sales: $19,700 1998 Profits: $-38,500
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $341,040 Stock Purch. Plan: Second Exec. Salary: $235,333 ADVANTAGE: Disease management approach to transplant biotechnology.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $215,935 Bonus: $76,705
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
SANYO ELECTRIC COMPANY LTD
www.sanyo.co.jp
Industry Group Code: 335999 Ranks within this company's industry group: Sales:3 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:8
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Electrical and Electronic Equipment, Manufacturing Fuel Cell Technology Home Appliances Batteries
Sanyo Electric Co., Ltd. (Sanyo) is a world leader in the manufacture of electronics products. The company offers electronics in six categories: AV/information and communications equipment, home appliances, industrial and commercial equipment, electronic devices and batteries and others. Sanyo invests heavily in research and development and is focused on becoming a world technological leader. Specifically, the company is focused on electronics devices and on environmental technology. The firm is on the forefront of digital technology innovation, offering products such as LCD projectors and cellular phones. Furthermore, the company has announced an agreement with Samsung to develop advanced solar fuel cell technology. The company recently announced a reorganization into four business groups. The reorganization is intended to improve profitability and efficiency. The new groups are the consumer business group, commercial business group, component business group and the service business group.
BRANDS/DIVISIONS/AFFILIATES:
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Satoshi Iue, CEO Yukinori Kuwano, COO Yukinori Kuwano, Pres. Yoshio Shimoda, Exec. VP/CFO Yoichiro Furuse, Exec. VP Toshimasa Iue, Exec. VP Satoshi Iue, Chmn.
Phone: 619-661-1134 Fax: 619-661-6795 Toll-Free: Address: 5-5 Keihan-Hondori 2-Chome, Moriguchi City, Osaka, 570-8677 Japan
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $15,881,000 (12 months) 2002 Profits: $12,900 (12 months) Stock Ticker: SANY 2001 Sales: $18,072,600 2001 Profits: $340,300 Employees: 80,500 2000 Sales: $19,002,400 2000 Profits: $204,600 Fiscal Year Ends: 11/30 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Excellent technology base.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $ Second Exec. Salary: $
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
SAP AKTIENGESELLSCHAFT
www.sap.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:3 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:3
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Enterprise Management Software Support and Training Services
SAP Aktiengesellschaft (SAP) is the leading provider of enterprise software solutions worldwide and the third largest independent software producer. The firm serves nearly 19,000 companies in 120 countries. SAP is gradually shifting over 12 million users from its PC-based products to mySAP, a web-based platform. The mySAP Business Suite is the firm’s flagship product, providing a flexible suite of applications that integrate front-end and back-office systems. The suite supports databases, applications, operating systems and hardware from every major vendor. Users can manage accounting, human resources, product lifecycle, sales and service information and improve supply chain efficiencies. A significant portion of the company’s business comes from training and support services. SAP has training facilities in over 50 countries. The firm has begun expanding its software products into such areas as customer relationship and supply chain management.
BRANDS/DIVISIONS/AFFILIATES: SAP Hosting SAP Learning Solutions Asia SAP Manage SAP Retail Solutions SAP SI MySAP Business Suite NetWeaver
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Henning Kagerman, CEO Werner Brandt, Exec. VP-Finance Claus E. Heinrich, Exec. VP-Human Resources Gernard Oswald, Exec. VP-IT Infrastructure Werner Brandt, Exec. VP-Admin. William R. McDermott, CEO/Pres.-SAP America Peter Zencke, Exec. VP Shai Agassi, Exec. VP Leo Apotheker, Exec. VP Hasso Plattner, Chmn.
Phone: 49-6227-74-7474 Fax: 49-6227-75-7575 Toll-Free: Address: Neurottstrasse 16, Walldorf, 69190 Germany
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $7,786,000 (12 months) 2002 Profits: $534,000 (12 months) Stock Ticker: SAP 2001 Sales: $ 2001 Profits: $ Employees: 28,878 2000 Sales: $ 2000 Profits: $ Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: World's third largest independent software producer.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
SAS INSTITUTE
www.sas.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:17 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Software-Statistical Analysis Business Intelligence Software
SAS Institute, Inc is the world's largest privately held software specialist. The company provides statistical analysis system software, which enables users to extract, manage and analyze large volumes of data in order to influence business decisions. SAS sells software that is tailored to specific global and local industries such as banking, manufacturing and government, in order to assist in processes such as financial reporting and credit analysis. The firm serves more than 38,000 business, government and university sites in 119 countries, including 98 of the top 100 companies on the Fortune 500. SAS SRM is a comprehensive solution that achieves substantial returns through three main areas of procurement. The first is strategy alignment and score carding, which determines how well the sourcing process is functioning within a department, division or organization. Through opportunity exploration, SAS provides robust investigative tools that consolidate procurement activities, reduce costs and minimize supply risk. Thirdly, the company also provides a point-and-click environment that enables simple to advanced analytics, data manipulation and reporting capabilities. SAS also provides data warehousing services, which manage and facilitate the process of distributed data handling from a source to the target. In recent news, SAS entered into a definitive agreement to acquire Oregon-based ABC Technologies, Inc., a provider of activity-based analytic management software. The acquisition will combine SAS' performance management technology with ABC Technologies' activitybased financial management and score carding expertise. ABC Technologies has more than 4,300 software installations in 73 countries, with a wide range of customers from manufacturing companies, services, consumer goods and the public sector. This company offers on-site child care, a health center with physicians and dentists, a massage therapist, a wooded campus and a profit sharing plan to its employees. The company's workforce receives 32 hours of training each year. SAS also prepares take-home dinners and brings in a hairstylist three times a week.
BRANDS/DIVISIONS/AFFILIATES: SAS SRM ABC Technologies, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jim Goodnight, CEO Jim Goodnight, Pres. Jim Davis, Chief Mktg. Officer Keith Collins, Chief Tech. Officer John Boswell, Corp. Sec. John Boswell, General Counsel Greyson Quarles, Chief Admin. Officer Allan Russell, Sr. VP-Strategy John Sall, Exec VP Art Cooke, Pres.-SAS Int'l Mary U. Musacchia, Gov. Rel. & Public Policy Kelly Ross, VP-US Commercial Sales
Phone: 919-677-8000 Fax: 919-677-4444 Toll-Free: 800-727-0025 Address: 100 SAS Campus Dr., Cary, NC 27513-2414 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,180,000 (12 months) 2002 Profits: $ (12 months) Stock Ticker: Private 2001 Sales: $1,130,000 2001 Profits: $ Employees: 9,023 2000 Sales: $ 2000 Profits: $ Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Bonus: $ Stock Purch. Plan: Second Exec. Salary: $ Bonus: $ ADVANTAGE: Ranks among the largest privately-held software companies in the world/Proprietary software for statistical analysis.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
SCHERING-PLOUGH CORP
www.sch-plough.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:12 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:12
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Allergies and Respiratory Anti-Infective/Anti-Cancer Drugs Animal Health Products Over-the-Counter Drugs
Schering-Plough Corporation is engaged in the discovery, development, manufacture and marketing of pharmaceutical products through its pharmaceuticals, health care products and animal health subsidiaries. Schering-Plough Pharmaceuticals manufactures and markets allergy, respiratory, anti-infective, anti-cancer, dermatological, central nervous system and cardiovascular prescription pharmaceuticals. ScheringPlough HealthCare Products markets a number of overthe-counter, foot care and sun care products, including Clear Away wart remover; Dr. Scholl’s foot care products; Lotrimin and Tinactin antifungals; A & D ointment; Afrin nasal decongestant; Chlor-Trimeton antihistamine; Coricidin and Drixoral cold and decongestant products; Correctol laxative; and Bain De Soleil, Coppertone and Solarcaine sun care products. Schering-Plough Animal Health develops and markets a broad range of pharmaceuticals and biologicals for companion animals and animals involved in food production. Animal health products include Cepravin and Nuflor antimicrobials; Banamine, a non-steroidal anti-inflammatory; Ralgro, a growth promotant implant; Otomax, an otic product; a broad range of vaccines for many species; and parasiticides, sutures, bandages and nutritional products. The company currently has research collaborations with Merck & Co. and Texas Biotechnology Corp. In recent news, the company announced an agreement with Novartis Pharma AG, a leader in pharmaceuticals and consumer health. With this agreement, the two companies will jointly develop and market Asmanex, for the treatment of asthma and chronic obstructive pulmonary disease. Schering-Plough offers its employees tuition reimbursement, scholarships, adoption counseling and referral services, fitness and exercise program memberships and medical and dental insurance. The company also sponsors a number of recreational and social programs for its employees, including basketball teams, walking, running and cycling clubs and tennis tournaments.
BRANDS/DIVISIONS/AFFILIATES: Afrin Drixocal Tinactin Correctol Dr. Scholl's Coppertone Asmanex Banamine
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Fred Hassan, CEO Fred Hassan, Pres. Jack L. Wyszomierski, Exec. VP/CFO Thomas H. Kelly, VP/Controller John J. LaRosa, Corp. Sec. Joseph C. Connors, Exec. VP/General Counsel Geraldine U. Foster, Sr. VP-Investor Rel. Cecil B. Pickett, VP/Pres., Schering-Plough Research Institute Richard W. Zahn, VP/Pres., Schering Laboratories Daniel A. Nichols, Sr. VP-Taxes Fred Hassan, Chmn.
Phone: 908-298-4000 Fax: 908-298-7653 Toll-Free: Address: 2000 Galloping Hill Rd., Kenilworth, NJ 07033-0530 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $10,180,000 (12 months) 2002 Profits: $1,974,000 (12 months) Stock Ticker: SGP 2001 Sales: $9,802,000 2001 Profits: $1,943,000 Employees: 30,500 2000 Sales: $9,815,000 2000 Profits: $2,423,000 Fiscal Year Ends: 12/31 1999 Sales: $9,116,000 1999 Profits: $2,110,000 1998 Sales: $8,027,000 1998 Profits: $1,756,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $1,430,000 Stock Purch. Plan: Second Exec. Salary: $626,500 ADVANTAGE: Expertise in gene therapy/Excellent brand name recognition.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $1,872,000 Bonus: $55,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
SCICLONE PHARMACEUTICALS
www.sciclone.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:92 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:55
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Chronic Disease Immune System Enhancers
SciClone Pharmaceuticals, Inc. develops and commercializes pharmaceutical and biological therapeutic compounds that are acquired or in-licensed at the stage of late preclinical or early clinical development. SciClone's strategic goal, based on the broad therapeutic potential of its lead drug, ZADAXIN, is to become the preeminent worldwide provider of immune system enhancers (ISEs) as monotherapies and as critical components of combination drug therapies for infectious diseases and cancer. ZADAXIN has been approved for sale primarily as a monotherapy for hepatitis B in 26 countries and has been administered to more than 10,000 patients worldwide. Currently, the company is targeting major market regulatory approval for ZADAXIN as a treatment for conditions including hepatitis C and cancer in global Phase III clinical trials. SciClone is focusing on hepatitis C as the first indication for commercial registration of the drug in the U.S. At present, the largest single market for ZADAXIN is China. ZADAXIN is an immune system enhancer that helps to stimulate, maintain and direct the body's antiviral and anticancer immune response. The firm is also developing a second generation of ISEs, including SCV-07 and its related compounds, which have the potential to be orally active (as opposed to ZADAXIN, which is administered as a subcutaneous injection). In addition, SciClone continues to develop CPX, a novel small-molecule protein-repair therapy for cystic fibrosis. This product is licensed from the National Institutes of Health. Recently, the firm released the results of a study showing that ZADAXIN, in combination with pegylated interferon, had additional benefits in non-responding patients with hepatitis C.
BRANDS/DIVISIONS/AFFILIATES: SciClone Pharmaceuticals International ZADAXIN CPX SCV-07
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Donald R. Sellers, CEO Alfred R. Rudolph, COO Donald R. Sellers, Pres. Richard A. Waldron, CFO Cynthia W. Tuthill, VP-Scientific Affairs Eduardo B. Martins, Medical Dir.
Phone: 650-358-3456 Fax: 650-358-3469 Toll-Free: 800-724-2566 Address: 901 Mariner's Island Blvd., Ste. 205, San Mateo, CA 94404 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $17,800 (12 months) 2002 Profits: $-10,000 (12 months) Stock Ticker: SCLN 2001 Sales: $13,800 2001 Profits: $-6,200 Employees: 97 2000 Sales: $15,400 2000 Profits: $-1,700 Fiscal Year Ends: 12/31 1999 Sales: $9,400 1999 Profits: $-5,500 1998 Sales: $3,725 1998 Profits: $-21,100
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $432,000 Stock Purch. Plan: Second Exec. Salary: $216,000 ADVANTAGE: Rapidly growing sales of its hepatitis therapy/Marketing in 20 nations.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $144,000 Bonus: $72,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
SCIENTIFIC ATLANTA INC
www.scientificatlanta.com
Industry Group Code: 334210 Ranks within this company's industry group: Sales:9 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:6
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Telecommunications Equipment-Cable Set-Top Boxes Terrestrial and Satellite Communications Network Products Cable Modems Optoelectronics Broadband Services Turnkey Installation and Integration
Scientific-Atlanta, Inc. is a leading manufacturer of set-top boxes (cable modems) used to receive cable TV programming. The company also manufactures digital video compression products, multiplexers and signal encoders and decoders. Scientific-Atlanta organizes its product and service offerings into four categories: subscriber products, broadband access products, content distribution products and broadband services. In the subscriber products segment, the company markets Explorer set-top boxes with the PowerTV operating system. PowerTV is a subsidiary that markets operating systems for set-top boxes. Scientific-Atlanta’s broadband access products include headend systems, optoelectronics and RF electronics. The firm’s content distribution products include the PowerVu Plus range of end-to-end digital television solutions, which help customers to reduce costs, expand programming, increase distribution and manage their entire cable system. PowerVu systems were used in the broadcasts of the Olympic Games in Atlanta, Nagano and Sydney, as well as the FIFA World Cup in France and Asia. The company’s broadband services range from basic installation services or telephone support to comprehensive training and complete turnkey installation, integration, system monitoring and management. To accelerate and enhance its presence in the European and Asian markets, the company has acquired BarcoNet, a Belgium-based leading provider of multimedia distribution solutions for broadband cable and applications as well as telecom, satellite and wireless applications in Europe. The company's customers include cable operators like Time Warner, Cox Communications and Comcast and notable programmers and broacasters such as ESPN, CNN and the Discovery Channel. Scientific-Atlanta provides employees with comprehensive insurance and health plans. In addition, it offers tuition reimbursement, recognition awards and health and safety services.
BRANDS/DIVISIONS/AFFILIATES: Explore PowerVu PowerTV SciCare Broadband Services BarcoNet
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. James F. McDonald, CEO James F. McDonald, Pres. Wallace G. Haislip, Sr. VP/CFO Michael C. Veysey, Corp. Sec. Michael C. Veysey, General Counsel Wallace G. Haislip, Treas. Conrad J. Wredberg, Exec. VP James F. McDonald, Chmn.
Phone: 770-236-5000 Fax: 770-236-6777 Toll-Free: 800-433-6222 Address: 5030 Sugarloaf Pkwy., Lawrenceville, GA 30044 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,671,100 (12 months) 2002 Profits: $104,400 (12 months) Stock Ticker: SFA 2001 Sales: $2,512,000 2001 Profits: $333,700 Employees: 5,870 2000 Sales: $1,715,410 2000 Profits: $155,808 Fiscal Year Ends: 6/30 1999 Sales: $1,243,473 1999 Profits: $102,343 1998 Sales: $1,181,404 1998 Profits: $80,793
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $860,000 Bonus: $559,300 Stock Purch. Plan: Y Second Exec. Salary: $505,385 Bonus: $266,900 ADVANTAGE: Expertise in the rapidly growing satellite data transmission industry/A leading set-top box designer and manufacturer.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
SCIOS INC
www.sciosinc.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:52 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:82
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Cardiovascular and Renal Disorder Small-Molecule Drugs
Scios, Inc., a subsidiary of Johnson & Johnson, is a biopharmaceutical company developing novel treatments for cardiovascular and inflammatory diseases. The firm’s disease-based technology platform integrates expertise in protein biology with computational and medicinal chemistry to identify novel targets and design smallmolecule compounds for large markets with unmet medical needs. The company’s Natrecor medication, which is designed to treat acute congestive heart failure (CHF), brought sales in excess of $107 million. Scios recently entered into a licensing agreement with GlaxoSmithKline to commercialize Natrecor in Europe. The firm’s SCIO-469 and SCIO-323 products inhibit p38 MAP kinase, a stimulatory modulator of pro-inflammatory factors such as tumor necrosis factor-alpha and cyclooxygenase-2. Such factors frequently contribute to the progression of rheumatoid arthritis. Scios is nearing completion of a Phase II clinical trial of SCIO-469 and has begun a Phase I study of SCIO-323. Additionally, the company has initiated a transformation growth factor (TGF)-beta inhibitor program. TGF-beta is a multifunctional cytokine that may lead to CHF, chronic obstructive pulmonary disease, cirrhosis and kidney disease. The company’s TGF-beta inhibitors have shown to be effective in reducing scar formation when given orally to animals. Scios offers its employees dental and vision insurance and tuition reimbursement.
BRANDS/DIVISIONS/AFFILIATES: Johnson & Johnson Natrecor SCIO-469 SCIO-323 Fiblast
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Richard B. Brewer, CEO Richard B. Brewer, Pres. David W. Gryska, CFO/Sr. VP-Finance Randy St. Laurent, VP-Sales and Mktg. Julie Blanchard, VP-Human Resources George F. Schreiner, Chief Scientific Officer Darlene P. Horton, VP-Medical Affairs Matthew R. Hooper, General Counsel Laura Simon, VP-Corp. Planning and Dev. Jane A. Moffitt, VP-Regulatory Affairs Tricia Baldwin, VP-Quality and Product Dev.
Phone: 408-616-8200 Fax: 408-616-8206 Toll-Free: Address: 820 W. Maude Ave., Sunnyvale, CA 94085 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $107,300 (12 months) 2002 Profits: $-88,100 (12 months) Stock Ticker: Subsidiary 2001 Sales: $47,300 2001 Profits: $-62,500 Employees: 509 2000 Sales: $12,600 2000 Profits: $-42,500 Fiscal Year Ends: 12/31 1999 Sales: $28,400 1999 Profits: $-20,100 1998 Sales: $44,700 1998 Profits: $-2,400
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $460,000 Stock Purch. Plan: Second Exec. Salary: $267,750 ADVANTAGE: Expertise in protein-based and small-molecule drugs.
OTHER THOUGHTS: Apparent Women Officers or Directors: 5 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $500,000 Bonus: $180,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
SCOTTS CO
www.scottscompany.com
Industry Group Code: 325000 Ranks within this company's industry group: Sales:10 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:7
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Y Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Horticulture and Turf Products Manufacturer Fertilizers
The Scotts Company is a leading producer of products for do-it-yourself lawn care, gardening, turf care and horticulture. The firm manufactures and markets a wide variety of greenery products, which include fertilizers, herbicides, spreaders, soil conditioners, mowers and tractors, plant foods, soils and micronutrients. The company owns some of the most widely recognized brand names in the industry, including Turf Builder (consumer lawn care), Miracle-Gro (consumer garden care), Osmocote (horticulture) and Ortho (herbicides and disease-control products). The Scotts Company also maintains a strong base of operations in Europe with its Weedol herbicides, Evergreen lawn fertilizer and Levington garden products, all of which are leading lawn products in the U.K. Through its North American professional and international business segments, the firm sells products to professional turf and horticulture markets, including commercial nurseries, golf courses and sports fields. Through its global professional segment, it sells professional products to commercial nurseries, greenhouses, landscape service providers and specialty crop growers in North America, as well as internationally in locations including Africa, Australia, the Caribbean, the European Union, Japan, Latin America, the Middle East, New Zealand and Southeast Asia. Scotts' branded plants business is also a part of the global professional segment. This business arranges for the sale of high-quality annual plants to retailers. In recent news, the company was granted new U.S. patents for Pull and Spray application technology, a new water soluble fertilizer, growing media technologies and household pest technology.
BRANDS/DIVISIONS/AFFILIATES: Turf Builder Miracle-Gro Osmocote Ortho Weedol Evergreen Levington
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. James Hagedorn, CEO James Hagedorn, Pres. Chris Nagel, CFO Michael P. Kelty, Exec. VP-Info. Services David Aronowitz, Exec. VP/General Counsel Michael P. Kelty, Exec. VP-Strategic Planning Michel Farkouh, Int'l Consumer Div. Robert Stohler, Exec. VP-North America James Hagedorn, Chmn.
Phone: 614-719-5500 Fax: 614-719-5750 Toll-Free: Address: 14111 Scottslawn Rd., Marysville, OH 43041 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,760,600 (12 months) 2002 Profits: $82,500 (12 months) Stock Ticker: SMG 2001 Sales: $1,747,700 2001 Profits: $15,500 Employees: 3,411 2000 Sales: $1,764,300 2000 Profits: $73,100 Fiscal Year Ends: 9/30 1999 Sales: $1,648,300 1999 Profits: $63,200 1998 Sales: $1,113,000 1998 Profits: $36,300
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Well-known brand names.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $616,160 Second Exec. Salary: $366,000
Bonus: $577,774 Bonus: $264,913
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
SEAGATE TECHNOLOGY INC
www.seagate.com
Industry Group Code: 334112 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Storage Equipment-Disk & Tape Drives Driver Components
Seagate Technology, Inc. is the world's largest manufacturer of disc drives, magnetic discs and read-write heads, an innovator in tape drives and a leading developer of business intelligence software. From desktop PCs to enterprise network servers, Seagate's products store and allow fast access to data in capacities of up to 182 gigabytes and include brand names such as Cheetah disc drives and Viper tape drives. The company's divisions include the Internet solutions group, the removable storage solutions group and the software group. The Internet solutions group targets emerging markets and applications that are storage-intensive, specifically in the areas of consumer electronics, commercial and services opportunities related to web-based applications. The removable storage solutions group offers a broad line of tape drive solutions for backup on networks, multi-user systems, workstations, desktop and portable PCs. Seagate Software designs and markets business intelligence software to enable customers to access stored data whenever and wherever necessary. Founded in 1979, the company has experienced remarkable growth through acquisitions, including Imprimis Technology, Crystal Computer Services and Connor Peripherals. In mid-1999, Seagate merged its network and storage management group with VERITAS Software in exchange for equity in the company. More recently, VERITAS bought back the stake owned by Seagate in an agreement that also stipulated the purchase of Seagate's operating businesses by a private investor group comprised of Silver Lake Partners and Texas Pacific Group. Seagate stockholders received shares of VERITAS and cash as a result of the transaction. Seagate continues to operate as a private company. Seagate offers its employees dental and vision coverage, flexible maternity leave, telecommuting and a businesscasual dress code. In addition, the company provides long-term care, disability insurance and a discounted auto, financial and home services program.
BRANDS/DIVISIONS/AFFILIATES: Cheetah Viper VERITAS Software Silver Lake Partners Texas Pacific Group Connor Peripherals Imprimis Technology Crystal Computer Services
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Stephen J. Luczo, CEO William D. Watkins, COO William D. Watkins, Pres. Charles C. Pope, Exec. VP/CFO Brian Dexheimer, Exec. VP-Sales and Mktg. Tom H. Porter, Exec. VP/Chief Tech. Officer William L. Hudson, Corp. Sec. William L. Hudson, General Counsel Donald L. Waite, Exec. VP/Chief Admin. Officer Jeremy Tennenbaum, Exec. VP-Bus. and Corp. Dev. Dave Wickersham, Exec. VP-Global Disc Storage Oper.
Phone: 831-438-6550 Fax: 831-438-7205 Toll-Free: Address: 920 Disc Dr., Scotts Valley, CA 95067 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $6,087,000 (12 months) 2002 Profits: $153,000 (12 months) Stock Ticker: Private 2001 Sales: $5,966,000 2001 Profits: $-697,000 Employees: 46,000 2000 Sales: $6,448,000 2000 Profits: $310,000 Fiscal Year Ends: 6/30 1999 Sales: $6,802,000 1999 Profits: $1,176,000 1998 Sales: $6,819,000 1998 Profits: $-530,000
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $907,814 Stock Purch. Plan: Second Exec. Salary: $676,938 ADVANTAGE: Strategic relationships with top software and hardware developers.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $1,100,000 Bonus: $850,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
SEPRACOR INC
www.sepracor.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:41 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:99
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-New and Improved Reformulation of Existing Drugs
Sepracor, Inc. is a specialty pharmaceutical company whose goal is to develop and market products for the treatment and prevention of human disease, specifically respiratory, urology and central nervous system disorders. The company also develops and markets improved versions of widely prescribed drugs. These versions, better known as improved chemical entities, feature enhancements such as reduced side effects, increased therapeutic efficacy and improved dosage forms. Sepracor markets its and other companies’ products through its sales force, co-promotion agreements and outlicensing partnerships. Sepracor’s co-promotion agreements are with MedPointe, Inc. for the nasal-spray antihistamine, ASTELIN, and Abbott Laboratories for Sepracor’s short-acting beta-agonist, XOPENEX. Due to the company’s patents relating to the chemicals desloratadine, fexofenadine and levocetirizine, Sepracor has out-licensing agreements with Schering-Plough for CLARINEX, Aventis for ALLEGRA and UCB Farchim SA for its products, XUSAL/XYZAL and ZYRTEC. Recently, Sepracor was awarded U.S. patents for ESTORRA brand eszopiclone, a drug for the treatment of insomnia. The U.S. Food and Drug Administration also filed the New Drug Application for ESTORRA that Sepracor submitted in January 2003. Sepracor offers its employees counseling, tuition reimbursement, adoption reimbursement and a comprehensive health plan.
BRANDS/DIVISIONS/AFFILIATES: MedPointe, Inc. Abbott Laboratories UCB Farchim SA ASTELIN XOPENEX CLARINEX ZYRTEC ESTORRA Brand Eszopiclone
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Timothy J. Barberich, CEO William J. O'Shea, COO William J. O'Shea, Pres. David P. Southwell, Exec. VP/CFO Mark Corrigan, Exec. VP-Research and Dev. David P. Sothwell, Sec. Douglas E. Reedich, Sr. VP-Legal Affairs & Chief Patent Counsel Robert F. Scumaci, Sr. VP-Admin. Robert F. Scumaci, Treas. Stephen A. Wald, Sr. VP-Chemical Research and Dev. Robert F. Scumaci, VP-Finance Timothy J. Barberich, Chmn.
Phone: 508-481-6700 Fax: 508-357-7499 Toll-Free: Address: 84 Waterford Dr., Marlborough, MA 01752 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $239,000 (12 months) 2002 Profits: $-276,500 (12 months) Stock Ticker: SEPR 2001 Sales: $152,100 2001 Profits: $-224,000 Employees: 818 2000 Sales: $85,200 2000 Profits: $-204,000 Fiscal Year Ends: 12/31 1999 Sales: $22,700 1999 Profits: $-183,000 1998 Sales: $10,200 1998 Profits: $-93,300
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Ability to improve existing drugs.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $436,402 Second Exec. Salary: $386,124
Bonus: $180,000 Bonus: $131,051
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
SEQUENOM INC
www.sequenom.com
Industry Group Code: 541710 Ranks within this company's industry group: Sales:15 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y Y Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:19
Transportation: Aerospace: Automotive:
Y
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Chips-DNA Arrays Genotype Analysis Software
Industrial genomics firm SEQUENOM is the developer of MassARRAY, a DNA analysis platform for the evaluation of single nucleotide polymorphisms (SNPs). An SNP is a genetic variation of a DNA sequence that affects gene functions and frequently causes chronic diseases, such as cancer, diabetes and cardiovascular disease. MassARRAY examines samples of DNA and SNPs and compares them to thousands of other samples to determine the effects of a particular SNP. Used to develop pharmaceuticals and agricultural products, MassARRAY integrates a variety of technology, including mass spectrometry, to measure small molecules, SpectroChips that vaporize biomolecules to prepare them for MassARRAY analysis, BioMass assays that provide analytic information and the SpectroTyper software bioinformatics system that records genotype information. SEQUENOM recently acquired Axiom Biotechnologies, a privately held San Diego-based biotechnology company. Axiom has core competence and proprietary technologies in the fields of functional biology and lead compound optimization. The firm also has a large, well-characterized cell bank of over 100 human cell types representing all major tissues in the human body. This cell line repository can be used for the functional validation of candidate genes and for bioassays in drug discovery. Axiom has internal discovery programs including early-stage compounds in two disease areas. In other news, SEQUENOM launched a high-performance SNP discovery application for its MassARRAY platform. The company is also in the process of developing a high-precision gene expression profiling application for the platform.
BRANDS/DIVISIONS/AFFILIATES: MassARRAY MassEXTEND SpectroCHIP SpectroTYPER SpectroJET Axiom Biotechnologies
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Toni Schuh, CEO Delbert F. Foit, Jr., COO Toni Schuh, Pres. Stephen L. Zaniboni, CFO Kimberly Ellstrom, Human Resources Charles R. Cantor, Chief Scientific Officer Andreas Braun, Chief Medical Officer
Phone: 858-202-9000 Fax: 858-202-9001 Toll-Free: Address: 3595 John Hopkins Ct., San Diego, CA 92121 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $30,900 (12 months) 2002 Profits: $-205,600 (12 months) Stock Ticker: SQNM 2001 Sales: $30,700 2001 Profits: $-62,600 Employees: 216 2000 Sales: $10,000 2000 Profits: $-32,900 Fiscal Year Ends: 12/31 1999 Sales: $ 200 1999 Profits: $-21,800 1998 Sales: $ 400 1998 Profits: $-10,300
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $310,000 Bonus: $155,000 Stock Purch. Plan: Y Second Exec. Salary: $281,000 Bonus: $135,000 ADVANTAGE: Expertise in SNP analysis/Major research partnerships/Growing base of significant customers.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
SEROLOGICALS CORP
www.serologicals.com
Industry Group Code: 621991 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Specialty Human Antibody-Based Products Plasma Collection and Sales Monoclonal Antibodies Blood Proteins Biological Products
Serologicals Corp. is a leading provider of human antibodies and other blood-related products and services. The company’s products and technologies are used in the oncology, hematology, immunology, cardiology and infectious disease industries. Through its laboratories, the firm develops specialty antibodies aimed at combating diseases, including Rh incompatibility in newborns, rabies and hepatitis. The company also provides donor recruitment and management services, operating a number of donor centers across the U.S., screening donors and collecting products from them. Furthermore, Serologicals manufactures items for diagnostic products, such as monoclonal antibodies and blood proteins from animal serums that are used in blood typing reagents. Seriologicals’ division, Chemicon International, Inc., is a leading supplier of specialty reagents, kits, antibodies, molecular biology tools, monoclonal antibodies, conjugates and antibody blends. Recently, Serologicals launched Amplifluor AssayArchitect Software for users of its Amplifluor SNPs Genotyping System. The software allows users to design single nucleotide polymorphism genotyping assays.
BRANDS/DIVISIONS/AFFILIATES: Chemicon International, Inc. Serologicals, Ltd. Serologicals Proteins, Inc. Amplifluor SNPs Genotyping System Amplifluor AssayArchitect Software
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. David A. Dodd, CEO David A. Dodd, Pres. Harold W. Ingalls, VP-Finance/CFO Joseph T. Kozma, VP-Strategic Mktg. Dev. Robert P. Collins, VP-Human Resources Roland Gerritsen van der Hoop, VP-Global Research & Dev. M. Dwain Wilcox, VP-Global Info. Services Sue Sutton-Jones, VP-Global Medical Affairs James J. Kramer, VP-Global Mfg. Oper. Thomas H. Trobaugh, VP-Global Commercial Oper. Jeffrey D. Linton, Pres., Chemicon Intl., Inc. Sue Sutton-Jones, VP-Global Regulatory Affairs, Quality Assurance Roland Gerritsen van der Hoop, Chief Science Officer David L. Bellitt, VP-Global Commercial Oper.
Phone: 678-728-2000 Fax: 678-728-2247 Toll-Free: 800-842-9099 Address: 5655 Spalding Dr., Norcross, GA 30092 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $145,500 (12 months) 2002 Profits: $13,900 (12 months) Stock Ticker: SERO 2001 Sales: $109,800 2001 Profits: $17,100 Employees: 651 2000 Sales: $147,800 2000 Profits: $12,900 Fiscal Year Ends: 12/31 1999 Sales: $129,700 1999 Profits: $-15,500 1998 Sales: $123,100 1998 Profits: $16,300
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $370,330 Stock Purch. Plan: Y Second Exec. Salary: $258,894 ADVANTAGE: Unique services for the pharmaceuticals market.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $31,238 Bonus: $31,200
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
SHARP CORPORATION
www.sharp.co.jp
Industry Group Code: 335999 Ranks within this company's industry group: Sales:4 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:4
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Electrical and Electronic Equipment, Manufacturing Electronic Components Information Equipment
Sharp Corporation designs, manufactures and distributes well-known electronic components. Its consumer information products are divided into audio-visual and communication equipment, home appliances and information equipment groups. Products within the audiovisual and communication equipment segment include televisions, VCRs, DVD players, camcorders, fax machines, mobile phones, electronic calculators and digital cameras. Electric heaters, refrigerators, microwave ovens, washers, dryers, air conditioners and air purifiers are a few of the home appliance items produced by Sharp. Its information equipment division is responsible for the development of personal computers, electronic cash registers, paper copiers, printers, software and data terminals. The company’s main electronic components include flash memory, imagers, analog ICs, microcomputers, liquid crystal display (LCD) modules, satellite broadcast units and lasers. Sharp’s corporate structure involves 22 manufacturing bases in 13 countries and nine research and development bases in five countries. The company’s subsidiaries include Sharp Telecommunications of Europe, Ltd. and Sharp Laboratories of Europe, Ltd.; Sharp Laboratories of America, Inc.; Sharp Technology (Taiwan) Corporation; and Sharp Software Development India. Recently, the company and Amkor Technology announced an agreement to standardize a package design for 3DSystem in Package. This will allow for more chips to fit in a single system, such as mobile phones and PDAs, thus allowing for greater memory without increasing the size or weight of the product.
BRANDS/DIVISIONS/AFFILIATES: Sharp Telecommunications of Europe, Ltd. Sharp Laboratories of Europe, Ltd. Sharp Laboratories of America, Inc. Sharp Technology (Taiwan) Corp. Sharp Software Development India Pvt., Ltd.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Katsuhiko Machida, Pres. Terumasa Yoneda, Corp. Sr. Exec. Dir.-Sales and Mktg. Seiji Shiotsu, Group General Mgr.-Human Resources Shigeo Misaka, Corp. Sr. Exec. VP/Chief Tech. Officer Seiji Shiotsu, Corp. Sr. Exec. VP-Chief Admin. Officer Toru Kawata, Corp. Exec. Dir.-Advanced Tech. Strategic Planning Hiroshi Saji, Corp. Sr. Exec. Dir-Corp. Acc. and Control Magohiro Aramoto, Corp. Sr. Exec. VP/Chief Tokyo Rep. Officer Akihiko Kumagai, Corp. Sr. Exec. Dir-Appliance Systems Group Toshishige Hamano, Corp. Sr. Exec. Dir.-Audio Visual Systems Group Buheita Fujiwara, Corp. Sr. Exec. Dir.-General Int'l Bus. Group
Phone: 81-6-6621-1221 Fax: 81-6-6627-1759 Toll-Free: Address: 22-22 Nagaike-cho, Abeno-ku, Osaka, 545-8522 Japan
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $13,599,000 (12 months) 2002 Profits: $85,000 (12 months) Stock Ticker: SHCAY 2001 Sales: $15,933,800 2001 Profits: $305,000 Employees: 46,518 2000 Sales: $17,579,500 2000 Profits: $266,600 Fiscal Year Ends: 3/31 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Broad product line/Cutting edge technology.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
SHELL OIL CO
www.shellus.com
Industry Group Code: 211111 Ranks within this company's industry group: Sales: Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Y Chemicals: Y Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Oil and Gas Chemicals
Shell Oil Company, an affiliate of the Royal Dutch/Shell group of companies, is a chemical, oil and natural gas producer in the United States. U.S. Shell Oil operations include Shell Oil Products US, Shell Chemical, Shell Gas & Power and Shell Exploration & Production. These companies discover, develop, manufacture, transport and market crude oil, natural gas and chemical products. Shell Chemicals is involved in manufacturing chemicals for large industrial customers for uses such as cars, computers, packaging and paints. It markets the products to over 70 countries. Shell Exploration & Production currently has exploration and/or production interests in 47 countries. Natural gas customers are located in the states of Georgia and Ohio, and the company supplies electricity to customers in Texas. Services of Shell’s gas and power business involve power generation, gas pipeline transmission, receiving terminals, liquefied natural gas, shipping and coal gasification. With affiliate Motive Enterprises, Shell Oil Products US refines and ships gasoline to more than 22,000 Shell and Texaco gas stations. Shell Oil is the leading oil and gas producer in the deepwater Gulf of Mexico and is an acknowledged originator in oil and gas exploration and production technology. In recent news, the company entered into a definitive agreement with a subsidiary of Flint Hills Resource, LLC, in which the subsidiary will purchase Shell’s ownership interest in Excel Paralubes. Shell’s interest in Excel Paralubes involves its recent PennzoilQuaker State Company purchase.
BRANDS/DIVISIONS/AFFILIATES: Shell Oil Products US Shell Chemical Shell Gas & Power Shell Exploration & Production Royal Dutch/Shell Pennzoil-Quaker State Motive Enterprises
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Rob J. Routs, Pres. J. R. Eagan, VP-Finance/CFO Philip B. Watts, Chmn.
Phone: 713-241-6161 Fax: 713-241-4044 Toll-Free: Address: One Shell Plaza, Houston, TX 77002 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $ 2001 Profits: $ Employees: 2000 Sales: $ 2000 Profits: $ Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Global operations/ Relationship with Royal Dutch/Shell.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
SHIRE-BIOCHEM INC
www.shire.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-HIV Influenza Vaccine
Shire BioChem, Inc., a subsidiary of Shire Pharmaceuticals, formerly known as BioChem Pharma, is a Canada-based company that focuses on research, development and commercialization of innovative products for the prevention and treatment of human diseases. Shire BioChem currently engages in researching cancer and infectious diseases such as HIV and influenza. Shire BioChem’s 3TC is the cornerstone of the therapies that are now standard treatments for HIV and AIDS. 3TC is available in more than 100 countries and is marketed in partnership with GlaxcoSmithKline. Combivir, another of the company’s products, is a treatment that combines 3TC with Retrovir in one tablet. Among other products Shire BioChem currently has on the market are PACIS, a treatment for bladder cancer, and Zeffix, an oral treatment for chronic hepatitis B. The firm also markets Fluviral S/F, an influenza vaccine that is required for annual vaccination programs. In recent news, Shire BioChem entered into a research collaboration with Microbiotix, Inc. to develop a lead antibody compound.
BRANDS/DIVISIONS/AFFILIATES: BioChem ImmunoSystems U.S., Inc. 3TC Combivir PACIS Zeffix Fluvial S/F Biochem Pharma
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Joseph Rus, CEO Joseph Rus, Pres.
Phone: 450-978-7800 Fax: 450-978-7755 Toll-Free: Address: 275 Arman-Frappier Blvd., Laval, Quebec H7V4A7 Canada
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $ 2001 Profits: $ Employees: 500 2000 Sales: $ 2000 Profits: $ Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: 3TC technology.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $ Second Exec. Salary: $
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
SICOR INC
www.sicor.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:34 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:23
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Oncology Bulk Ingredients
With operations in Europe, the U.S. and Mexico, Sicor is a vertically integrated company that develops, manufactures and markets injectable pharmaceutical products. The company supplies active pharmaceutical ingredients, finished dosage products and contract manufacturing services to various pharmaceutical and biotechnology companies. Sicor's products are primarily designed for the oncology field, but the firm also manufactures pharmaceuticals for anesthesiology, cardiology and critical care. Its biopharmaceutical operations provide the company with an established platform for manufacturing and marketing biopharmaceutical products for developing nations initially, followed by Western Europe and, eventually, the United States. Through Sicor Biotech, Sicor currently markets recombinant human interferon (IFN [alpha]-2b) and a human growth hormone (\"hGH\"). It sells IFN [alpha]-2b in Lithuania, Latvia, Belarus, Korea, Pakistan, Bulgaria, Russia, Kazakhstan, Ukraine and Moldova, and hGH in Lithuania. The company intends to market IFN [alpha]-2b in Algeria, Mexico and Southeast Asia in the future and has pending agreements or agreements in place to begin sales of IFN [alpha]-2b in Armenia, Azerbaijan, Georgia, and Turkey. Sicor is in the process of developing several generic equivalents to existing biopharmaceutical products, including granulocyte colony stimulating factor (G-CSF), erythropoietin, interferon [alpha]-2a, and interferon [beta]. Sicor offers is employees comprehensive life and health benefits and a stock option plan.
BRANDS/DIVISIONS/AFFILIATES: Gensia Sicor Pharmaceuticals Biotechna
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Marvin Samson, CEO Frank C. Becker, Exec. VP/COO Marvin Samson, Pres. Jack Stover, CFO/Exec. VP-Finance Armand J. LeBlanc, Corp. Scientific Affairs David C. Dreyer, VP/Corp. Controller/Chief Acc. Officer Wesley N. Fach, Sr. VP/Corp. Sec. Wesley N. Fach, Sr. Legal Counsel Jack Stover, Treas. Gianpaolo Colla, Exec. VP-Italian Oper. Armand J. LeBlanc, Pres., Gensia Sicor Pharmaceuticals Michael D. Cannon, Exec. VP/Pres.-Biotech. Donald E. Panoz, Chmn.
Phone: 949-455-4700 Fax: 949-855-8210 Toll-Free: 800-729-9991 Address: 19 Hughes, Irvine, CA 92618 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $456,000 (12 months) 2002 Profits: $128,300 (12 months) Stock Ticker: SCRI 2001 Sales: $369,800 2001 Profits: $79,300 Employees: 1,905 2000 Sales: $293,800 2000 Profits: $35,600 Fiscal Year Ends: 12/31 1999 Sales: $229,000 1999 Profits: $11,700 1998 Sales: $178,500 1998 Profits: $-18,700
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $500,000 Stock Purch. Plan: Y Second Exec. Salary: $368,125 ADVANTAGE: Expertise in oncology drugs/Expansion efforts via new drug development.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $463,417 Bonus: $158,036
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
SIEBEL SYSTEMS INC
www.siebel.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:10 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:23
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Software-Customer Relations Marketing Applications
Siebel Systems, Inc. is a leading global provider of customer relations management (CRM) software applications. The company’s multichannel e-business applications and services allow organizations to create a single source of customer information that makes it easier to sell to, market to and service customers across multiple channels, including the Internet, call centers, field, resellers, retail and dealer networks. Moreover, the firm’s web-based architecture dramatically reduces the costs of deploying its e-business applications and enables organizations to provide rich customer information to partners, resellers, customers and prospects via the Internet. Siebel e-business applications for customer and partner relationship management are available in 20 industry applications designed for specific segments within multiple industries, including financial services, communications, travel and transportation, energy, the consumer sector, life sciences, the industrial sector and the public sector. Siebel 7 is one of the industry's most comprehensive suite of web-based e-business software applications, with more than 200 applications for sales, marketing, service, interactive selling, analytics, partner relationship management and employee relationship management. Unilever Bestfoods of Germany recently implemented Siebel Consumer Goods 7, in order to manage its customers across the chain. Heinz also recently joined more than 1,100 leading companies that have chosen Siebel 7 for their enterprise CRM needs. This has been one of the world's fastest growing and most successful independent software companies. By early 2003, Siebel had 3,500 customers worldwide, paying from $300,000 to several million dollars each for software and services. The firm is in the enviable position of having a 90% customer satisfaction rate, an 80% market share in the CRM sector and about $2 billion in cash in the bank.
BRANDS/DIVISIONS/AFFILIATES: Siebel 7 Siebel 2000 Siebel eMail Response Siebel eService Siebel Interactive Selling Suite
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Thomas M. Siebel, CEO Paul Wahl, COO Paul Wahl, Pres. Kenneth A. Goldman, CFO/Sr. VP-Finance Kenneth A. Goldman, Sr. VP-Admin. R. David Schmaier, Exec. VP Karen M. Riley, VP-Global Services Thomas M. Siebel, Chmn.
Phone: 650-295-5000 Fax: 650-295-5111 Toll-Free: 800-647-4300 Address: 2207 Bridgepointe Pkwy., San Mateo, CA 94404 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,635,300 (12 months) 2002 Profits: $-35,700 (12 months) Stock Ticker: SEBL 2001 Sales: $2,048,400 2001 Profits: $254,600 Employees: 5,909 2000 Sales: $1,795,384 2000 Profits: $221,899 Fiscal Year Ends: 12/31 1999 Sales: $813,461 1999 Profits: $110,025 1998 Sales: $417,861 1998 Profits: $42,290
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $643,750 Stock Purch. Plan: Y Second Exec. Salary: $429,167 ADVANTAGE: The leading global provider of software for customer information management.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $2,588,251 Bonus: $466,667
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
SIEMENS AG
www.siemens.de
Industry Group Code: 334210 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:3
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Electronics Manufacturer Mobile Phones Railway Automation Automotive Systems Health Care Systems
Siemens AG is an electronics and electrical engineering company that operates information and communications, automation and control, power, transportation, medical and lighting subsidiaries. The company’s Siemens IC Mobile division offers a wide range of mobile devices, including mobile phones, wireless modules, mobile organizers and cordless phones. The firm holds about an 8% share of the global mobile phone market. Recently, the subsidiary introduced the M46 mobile phone, which provides personalization options and a variety of downloadable ring tones and display images. The inclusion of Java technology enables users to access a rapidly growing number of gaming and entertainment features. Moreover, the phone features a built-in data and fax modem. In the spring of 2002, Siemens IC Mobile partnered with Motorola to develop Universal Mobile Telecommunications System terminals utilizing Motorola’s i.300 Innovative Convergence 3G platform. The companies anticipate that the collaboration will strengthen their respective leadership positions in 3G mobile communications. The U.S. market generates about 22% of Siemens AG’s worldwide revenues. Siemens USA currently has more than 5,900 scientists at 40 research and development facilities throughout America. Siemens AG employs people in over 190 countries, including 80,000 workers in the United States. Siemens AG is the world's seventh-largest company. Siemens also ranks fourth in sales among the world’s leading electronics and electrical equipment companies and operates 570 engineering and production facilities worldwide. The company currently holds more than 120,000 patent rights. Siemens recently announced it is providing gas turbines, a steam turbine, three generators and other equipment for a combined heat and power plant in an agreement with BASF. Siemens AG offers its employees tuition reimbursement, flexible work schedules, medical and dental insurance and scholarship programs for employees’ children. Workers are encouraged to dress casually.
BRANDS/DIVISIONS/AFFILIATES: Siemens IC Mobile Motorola Infineon Technologies Siemens USA Acuson Siemens Medical Solutions
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Heinrich von Pierer, CEO Heinrich von Pierer, Pres. Heinz-Joachim Neuburger, Exec. VP/CFO Peter Pribilla, Exec. VP-Human Resources Claus Weyrich, Exec. VP-Tech. Eberhard Posner, Corp. Comm. Bernd Stecher, Chief Economist Volker Jung, Exec. VP Edward G. Krubasik, Exec. VP Jurgen Radomski, Exec. VP
Phone: 49-89-636-3300 Fax: 49-89-636-342-42 Toll-Free: Address: Wittelsbacherplatz 2, Munich, D-80333 Germany
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $82,865,000 (12 months) 2002 Profits: $2,561,000 (12 months) Stock Ticker: SI 2001 Sales: $86,208,000 2001 Profits: $2,069,000 Employees: 426,000 2000 Sales: $71,367,800 2000 Profits: $8,160,600 Fiscal Year Ends: 9/30 1999 Sales: $63,168,300 1999 Profits: $1,718,000 1998 Sales: $55,427,000 1998 Profits: $431,800
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: One of the world's largest and most respected electronics companies.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
SIGMA ALDRICH CORP
www.sigmaaldrich.com
Industry Group Code: 325000 Ranks within this company's industry group: Sales:12
Profits:5
Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Y Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Chemicals Manufacturer Organic and Inorganic Chemicals Chromatography Products Metal Components DNA Synthesis Technology Immunoassays
Sigma-Aldrich develops and manufactures more than 85,000 products, including biochemicals, organic chemicals and chromatography products. The company’s offerings are used primarily for scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and chemical manufacturing. Additional applications for its products include molecular biology, cell biology, cell culture, protein analysis and chromatography, DNA sequencing and gene studies. Customers of the company primarily consist of life science companies, university and government institutions, hospitals, non-profit organizations, pharmaceutical, diagnostic and biotechnology companies. The company’s scientific research unit consists of biochemicals, organic chemicals and reagents. Products marketed through the biotechnology unit relate to the areas of immunochemistry, cell culture, molecular biology, cell signaling and neuroscience. The fine chemicals unit is a top supplier of large-scale organic chemicals and biochemicals used in development and production. The company currently operates in 34 countries and distributes its products in more than 150 countries. In recent news, Sigma-Aldrich signed a distribution agreement with Vistant Corporation, a provider of point-of-use automation systems. The company will present Vistant’s automated systems products to its customers within the pharmaceutical, biotechnology and academic industries.
BRANDS/DIVISIONS/AFFILIATES: Sigma Aldrich Fluka Supelco Riedel-de Haen COMPUTROL on Line
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. David R. Harvey, CEO David R. Harvey, Pres. Michael R. Hogan, CFO Terry R. Colvin, VP-Human Resources Jai P. Nagarkatti, Pres.-Scientific Research Larry S. Blazevich, VP-Info. Systems Karen J. Miller, Controller Michael R. Hogan, Corp. Sec. Michael R. Hogan, Chief Admin. Officer Kirk A. Richter, Treas. Rodney L. Kelley, VP-Safety and Quality James W. Meteer, VP-Process Improvement David W. Julien, Pres.-Biotech. Franklin D. Wicks, Pres.-Fine Chemicals David R. Harvey, Chmn.
Phone: 314-771-5765 Fax: 314-286-7874 Toll-Free: 800-521-8956 Address: 3050 Spruce St., St. Louis, MO 63103 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,207,000 (12 months) 2002 Profits: $130,700 (12 months) Stock Ticker: SIAL 2001 Sales: $1,179,400 2001 Profits: $140,700 Employees: 5,940 2000 Sales: $1,096,300 2000 Profits: $320,200 Fiscal Year Ends: 12/31 1999 Sales: $1,061,200 1999 Profits: $172,300 1998 Sales: $986,200 1998 Profits: $166,300
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $725,000 Bonus: $115,928 Stock Purch. Plan: Second Exec. Salary: $415,000 Bonus: $66,359 ADVANTAGE: A focused, worldwide supplier of chemical products and diagnostics/Production facility expansion in Europe.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
SILICON GRAPHICS INC
www.sgi.com
Industry Group Code: 334111 Ranks within this company's industry group: Sales:8 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:8
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Hardware-Advanced Graphics Symmetric Multiprocessing RISC Microprocessors
Silicon Graphics, Inc. (SGI) is a leader in highperformance computing. The company’s broad range of workstations and graphics servers delivers advanced 3-D graphics and computing capabilities for engineering and creative professionals. SGI servers are the market leaders in technical computing applications. The company’s highly scalable servers also have a growing presence in strategic business analysis, with a particular emphasis on Internet, large corporate data and telecommunications applications. SGI’s MIPS group designs and licenses the RISC microprocessor intellectual property and core technology. The company’s Alias/Wavefront subsidiary markets applications software targeted at engineering and creative professionals in the digital content creation and manufacturing sectors. The firm's computer systems range from desktop workstations to servers and supercomputers. Most of these systems are designed around MIPS. RISC microprocessors are developed by SGI’s MIPS group and the IRIX operating system, the company’s enhanced version of the UNIX operating system. The firm has been gradually introducing new generations of its products based on Intel microprocessor architecture and the Linux and Windows NT operating systems. The company diversified its line of NT-based workstations and its supercomputer business by spinning off its streaming media software operations. SGI is working on developing products for hot markets such as media streaming, digital asset management and highvolume Internet traffic. Recently, the firm’s processing systems were sold to the University of Tokyo for use in its earthquake research and to Germany’s Waterway Engineering and Research Institute in its efforts to meet future challenges. Additionally, VARBusiness Magazine awarded five-star ratings to the company in the categories of systems, storage and peripherals. Silicon Graphics provides an employee assistance program with counseling and referral services. Notably, the firm's management has a larger proportion of minorities than its overall workforce.
BRANDS/DIVISIONS/AFFILIATES: Alias/Wavefront IRIX
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Robert R. Bishop, CEO Warren C. Pratt, Exec. VP/COO Jeffrey V. Zellmer, CFO Jan Silverman, Sr. VP-Mktg. Eng Lim Goh, Sr. VP/Chief Tech. Officer Sandra M. Escher, Sr. VP/General Counsel Anthony K. Robbins, Sr. VP-North American Oper. Steve Coggins, Sr. VP-Europe, Middle East and Africa Anthony K. Robbins, Pres.-SGI Federal Bill La Rosa, Sr. VP-Intercontinental Field Oper. Robert R. Bishop, Chmn.
Phone: 650-960-1980 Fax: 650-932-0661 Toll-Free: Address: 1600 Amphitheatre Pkwy., Mountain View, CA 940431351 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,341,400 (12 months) 2002 Profits: $-46,300 (12 months) Stock Ticker: SGI 2001 Sales: $1,854,500 2001 Profits: $-493,000 Employees: 4,443 2000 Sales: $2,331,134 2000 Profits: $-829,544 Fiscal Year Ends: 6/30 1999 Sales: $2,748,957 1999 Profits: $53,829 1998 Sales: $3,100,610 1998 Profits: $-459,627
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $800,000 Bonus: $370,000 Stock Purch. Plan: Y Second Exec. Salary: $480,031 Bonus: $355,290 ADVANTAGE: World's leading supplier of 3-D computing solutions/Continually identifies and invests in key technologies.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
SKIDMORE OWINGS & MERRILL LLP Industry Group Code: 541320 Ranks within this company's industry group: Sales: Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Y Y Y
www.som.com Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Architectural and Engineering Services Urban Design Services
Skidmore, Owings & Merrill, LLP (SOM) is one of the world’s leading architecture, urban design, engineering and interior architecture firms. The company’s structural and civil engineering services include structural systems design, transportation planning and engineering, structural seismic analysis, foundation design and geotechnical engineering. The firm’s urban design services include site selection studies, project feasibility analyses, master planning and design and environmental analysis. SOM’s signature projects include the design of the Bank of America world headquarters in San Francisco, the Sears and John Hancock Towers and the Jin Mao Tower in Shanghai. Additionally, the company designed San Francisco International Airport’s new international terminal, which is the largest base-isolated building in the world. The firm has created the Center for Seismic Design, which provides consultation to many companies on projects in areas where earthquake activity is a concern. The Center will also work closely with academic institutions in order to pioneer and implement state-of-theart structural systems. Recently, SOM and ASSAR were chosen to design the new NATO headquarters building in Brussels.
BRANDS/DIVISIONS/AFFILIATES: Center for Seismic Design
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. H. Guy Leibler, CEO H. Guy Leibler, Pres. Joseph Dailey, CFO Barbara Schiola, Human Resources Marilyn J. Taylor, Chmn.
Phone: 212-298-9300 Fax: 212-298-9500 Toll-Free: Address: 14 Wall St., New York, NY 10005 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Private 2001 Sales: $149,900 2001 Profits: $ Employees: 900 2000 Sales: $ 2000 Profits: $ Fiscal Year Ends: 9/30 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Name recognition/One of the top architecture and engineering firms in the world.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
SOLA INTERNATIONAL INC
www.sola.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:23 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:27
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Supplies-Eyeglass Lenses Lens Coatings and Treatments
SOLA International is a worldwide leader in the development of eyeglass lens designs and materials. The company boasts over 100 million customers. SOLA operates sales offices in 30 countries and distributes its products in more than 50 markets worldwide, primarily in North America, Europe and Asia. SOLA manufactures progressive lenses that correct for varying distances without utilizing the segment lines of bifocals and trifocals, thus avoiding image jumps when moving from one distance zone to another. Popular products include Spectralite and ViZio 1.66, which feature high-index plastic materials that are thinner and lighter than traditional plastic or glass lenses. The company is also popular for its UTMC Anti-Reflection Coating that eliminates reflections from the front and back of lenses and enables more light to reach the eyes. Additional product lines include Percepta, Visuality, AO Compact and SOLAMAX, featuring better material construction and new technology. Its Countour Optics is the first lens developed to follow the natural curvature of the eye, resulting in a wide field of view with better optical clarity. The company recently acquired Siouxland Ophthalmic, Inc. and Kansas City Ophthalmics, LLC and announced an agreement to acquire Copeland Optical, Inc. SOLA formed a partnership with Bolle, a subsidiary of Bushnell Performance Optics, to create the b-TRU Rx program, which will enable the companies to offer a variety of customized prescription sun eyewear. The firm also formed a partnership with the Japan-based Charmant Group, one of the chief frame manufacturers in the world. Through the partnership, the groups develop the Beta 8 Series rimless frame and lens program that combines frame styles from Charmant with lens designs from SOLA. The company offers its employees medical, dental and vision plans, as well as relocation assistance, cafeteria services and bonus plans.
BRANDS/DIVISIONS/AFFILIATES: Siouxland Ophthalmic, Inc. Kansas City Ophthalmics, LLC Copeland Optical, Inc. Percepta b-TRU Rx Beta 8 Series SOLAMAX Contour Optics
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jeremy C. Bishop, CEO Jeremy C. Bishop, Pres. Steven M. Neil, Exec. VP/CFO Simon Edwards, VP-Research and Dev. Karen Roberts, VP-Product Dev. Barry J. Packham, Exec. VP-Mfg. and Logistics Steven M. Neil, Corp. Sec. Theodore Gioia, Exec. VP-Bus. Dev. and Strategy Jeff Cartwright, Dir.-Investor Rel. Steven M. Neil, Treas. Wayne Rockall, VP/Regional Dir.-Australasia Mark Ashcroft, Pres.-Americas and Europe Gaetano Sciuto, VP-Sunlens Adrian Walker, VP/Regional Dir.-Asia Maurice J. Cunniffe, Chmn.
Phone: 858-509-9899 Fax: Toll-Free: Address: 10590 W. Ocean Air Dr., San Diego, CA 92130 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $529,500 (12 months) 2002 Profits: $19,100 (12 months) Stock Ticker: SOL 2001 Sales: $545,400 2001 Profits: $-66,500 Employees: 6,983 2000 Sales: $543,400 2000 Profits: $ 700 Fiscal Year Ends: 3/31 1999 Sales: $534,100 1999 Profits: $12,500 1998 Sales: $547,700 1998 Profits: $51,100
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $400,000 Bonus: $132,000 Stock Purch. Plan: Second Exec. Salary: $263,000 Bonus: $65,093 ADVANTAGE: Sola ranks first or second in market share in each of the five major regions of the world where it has operations.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
SONY CORPORATION
www.world.sony.com
Industry Group Code: 334310 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Consumer Electronics Manufacturer Movie and Television Studio Owner Personal Computer Peripherals Entertainment Units Video Games
Sony Corporation, the largest consumer electronics firm in the world, produces a wide range of consumer and industrial electronic products including semiconductors, DVD players, cameras, home video game systems, stereo systems, televisions and VCRs. In addition, the company also owns movie and television studio Columbia TriStar and record labels Columbia and Epic. The firm is the creator of the PlayStation video game consoles, one of its most profitable units, and operates an online game web site at www.station.sony.com. Sony has focused much of its expansion plans toward building up its Internet operations. Sony Music Entertainment and Universal Music Group formed Pressplay, a joint venture that offers subscription-based online digital music that can be streamed, downloaded and burned onto a compact disc. In another significant development, Sony Pictures Entertainment entered into a joint venture for a video-ondemand distribution service called Movielink. It is offered through cable, satellite or broadband Internet and makes high quality feature film content available in a reliable and secure manner. Other methods of distribution are being explored. Movielink offers consumers a selection of recently released theatrical films, as well as additional content from film libraries that cover all genres. In recent news, Sony released a recordable DVD receiver, the BDZS77, using Blu-Ray technology in Japan. The highcapacity DVD-like optical disk can store up to 50 gigabytes of information and offers real-time content editing features. In other news, game players around the world are anticipating the release of PlayStation 3 in 2005.
BRANDS/DIVISIONS/AFFILIATES: PlayStation BDZ-S77 Columbia TriStar Motion Picture Group Sony Music Entertainment Movielink Pressplay Columbia Music Sony Pictures Entertainment
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Nobuyuki Idei, CEO Kunitake Ando, COO Kunitake Ando, Pres. Teruhisa Tokunaka, CFO Kenichiro Yonezawa, Exec. VP-Human Resources Katsuaki Tsurushima, Chief Tech. Officer Teruo Masaki, Exec. VP-General Counsel John Calley, Chm.-Sony Pictures Kenji Kitatani, Exec. VP-Bus. Planning Masayoshi Masayoshi, Exec. VP-Investor Rel. Akira Kondoh, Corp. Treas. Sir Howard Stringer, CEO-Sony Corporation of America Ken Kutaragi, Pres.-Sony Computer Entertainment Emily Susskind, Pres.-Broadband Services Robert Wiesenthal, Exec. VP-Strategy, Sony Broadband Nobuyuki Idei, Chmn.
Phone: 81-3-5448-2111 Fax: 81-3-5448-2244 Toll-Free: Address: 7-35, Kitashinagawa, 6-chome, Shinagawa-ku, Tokyo, 141-0001 Japan
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $57,117,000 (12 months) 2002 Profits: $115,000 (12 months) Stock Ticker: SNE 2001 Sales: $58,518,000 2001 Profits: $134,000 Employees: 168,000 2000 Sales: $63,082,000 2000 Profits: $1,149,000 Fiscal Year Ends: 3/31 1999 Sales: $51,059,400 1999 Profits: $1,343,300 1998 Sales: $50,735,400 1998 Profits: $1,666,400
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Wide diversification and expertise/Deep research budget/Prime consumer brands.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ST JUDE MEDICAL INC
www.sjm.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:9 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:7
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Equipment-Mechanical Heart Valves Cardiac Rhythm Management
St. Jude Medical, Inc. designs, manufactures and markets medical devices and provides services for the cardiovascular segment of the medical device industry. St. Jude Medical engages in clinical research, physical training and education, patient follow-up and patient education. Products include catheters, pacemakers, implantable cardioverter defibrillators (ICD) and mechanical and tissue heart valves. St. Jude Medical operates in three main segments. The Cardiac Rhythm Management segment develops, manufactures and distributes products related to heart rhythm maintenance. The Cardiac Surgery unit specializes in the manufacture and distribution of products related to heart surgery, such as anastomotic connectors. The Daig division works with the cardiac rhythm management segment, specializing in catheter technologies. The U.S. Sales division focuses on marketing St. Jude Medical products in the United States, whereas the St. Jude Medical International division markets the products worldwide. The company's products are distributed in more than 120 countries through a combination of direct sales personnel, independent manufacturers' representatives and distribution organizations. In recent news, St. Jude Medical completed its acquisition of the Japan-based Getz Bros. Co. Ltd., St. Jude Medical’s largest Japanese distributor. St. Jude Medical plans to acquire Epicor Medical, Inc., a developer of devices to treat atrial fibrillation (AF). In other news, the U.S. Food and Drug Administration (FDA) approved the Adx PR Pacemaker for market release in the U.S. The FDA is expected to approve the Isoflex S Lead for market release later this year. The Isoflex P Lead was implanted in an 81-year-old man under an FDA investigational device exemption study. Also, St. Jude Medical implanted the Epic + DR ICD, the world’s only ICD with AF suppression technology, in patients in Austria and Ohio. St. Jude Medical offers its employees vision insurance, tuition reimbursement and training classes.
BRANDS/DIVISIONS/AFFILIATES: Cardiac Surgery Unit Daig Division St. Jude Medical International Getz Bros. Co. Ltd. Epicor Medical, Inc. Adx PR Pacemaker Isoflex S Lead Epic + DR ICD
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Terry L. Shepherd, CEO Daniel J. Starks, COO Daniel J. Starks, Pres. John C. Heinmiller, VP-Finance & CFO Michael T. Rousseau, VP-U.S. Sales Jeri L. Lose, VP-Info. Tech. Jeri L. Lose, CIO Kevin T. O'Malley, VP/General Counsel Thomas R. Northenscold, VP-Admin. Peter L. Gove, VP-Corp. Rel. Laura C. Merriam, Dir.-Investor Rel. David W. Adinolfi, Pres., Daig Michael J. Coyle, Pres., Cardiac Rhythm Management George J. Fazio, Pres., Europe Jane J. Song, Pres., Cardiac Surgery Terry L. Shepherd, Chmn. Joseph H. McCullough, Pres., St. Jude Intl.
Phone: 651-483-2000 Fax: 651-482-8318 Toll-Free: 800-328-9634 Address: One Lillehei Plaza, St. Paul, MN 55117-9913 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,589,900 (12 months) 2002 Profits: $276,300 (12 months) Stock Ticker: STJ 2001 Sales: $1,347,400 2001 Profits: $172,600 Employees: 6,042 2000 Sales: $1,178,800 2000 Profits: $129,100 Fiscal Year Ends: 12/31 1999 Sales: $1,114,500 1999 Profits: $24,200 1998 Sales: $1,016,000 1998 Profits: $129,100
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $656,731 Bonus: $812,704 Stock Purch. Plan: Y Second Exec. Salary: $613,462 Bonus: $759,159 ADVANTAGE: The St. Jude Medical Heart Valve Division is a global leader in heart valve disease management and Daig is a pioneer in specialty catheters/Excellent acquisition strategy.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
STANDARD MICROSYSTEMS CORPORATION www.smsc.com Industry Group Code: 334413 Ranks within this company's industry group: Sales:22 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:7
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Integrated Circuits-Input/Output Metal-Oxide Semiconductors Routers Interface Cards
Standard Microsystems Corporation is a designer and worldwide supplier of advanced digital and analog input/output (I/O) system and connectivity solutions for a broad range of communications and computing applications in the areas of advanced I/O, connectivity, local area networking and embedded control systems. The company is one of the world's leading suppliers of advanced I/O integrated circuits for desktop and mobile personal computers. Standard Microsystems’ advanced I/O circuits reside on the motherboards of personal computer products sold by Compaq, Dell, Fujitsu, Gateway, Hewlett-Packard, IBM, Intel, NEC, Sony, Toshiba and most other leading manufacturers. New products include the LPC47N350 keyboard and system controller, the USB97C201 bridge controller and the USB97C210 memory card controller. The LPC47N350 features the company's unique PortSwitch interface, a patent-pending, hot-switchable external LPC interface that enables cost-effective, full-featured port replication and docking solutions. Standard Microsystems recently announced the introduction of a new Windows CE .NET driver for its LAN91C111 product, a controller for embedded systems. The company provides corporate memberships for daycare and eldercare. Tuition refund programs are available, and the company has a promote-from-within policy in which new positions are internally advertised before going out to the public. Standard Microsystems is also big on community service projects and intramural sports teams.
BRANDS/DIVISIONS/AFFILIATES: PortSwitch Ether Power II TigerStack TigerSwitch Cardbus
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Steven J. Bilodeau, CEO Steven J. Bilodeau, Pres. Andrew M. Caggia, CFO Eric M. Nowling, VP/Controller George W. Houseweart, Sr. VP/General Counsel Steven J. Bilodeau, Chmn.
Phone: 631-435-6000 Fax: 631-273-5550 Toll-Free: Address: 80 Arkay Dr., Hauppauge, NY 11788-8847 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $159,300 (12 months) 2002 Profits: $5,900 (12 months) Stock Ticker: SMSC 2001 Sales: $163,400 2001 Profits: $2,700 Employees: 428 2000 Sales: $153,247 2000 Profits: $4,669 Fiscal Year Ends: 2/28 1999 Sales: $155,826 1999 Profits: $-12,545 1998 Sales: $148,326 1998 Profits: $-18,921
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $410,000 Stock Purch. Plan: Second Exec. Salary: $263,670 ADVANTAGE: Rapid introduction of enhanced LAN products.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $574,000 Bonus: $20,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
STERIS CORP
www.steris.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:19 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:21
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Equipment-Sterilization Systems Contamination Control Products
Steris Corp. develops, manufactures and markets infection prevention, contamination prevention, microbial reduction and therapy support systems, products, services and technologies for health care, scientific, research, food and industrial customers throughout the world. The firm’s offerings include low-temperature sterilization, hightemperature sterilization, washing and decontamination systems, surgical tables and surgical lights. Steris provides health care customers with complete infection prevention material processing systems and specialty chemical products, used for cleaning, disinfecting, drying and aerating instruments and hard surfaces. The company’s STERIS SYSTEM 1 is a complete system for just-in-time sterile processing at or near the site of patient care. The firm’s illumination and space management systems are designed for a wide variety of locations where diagnostic and therapeutic procedures are performed, including emergency rooms, general surgery suites, OB/GYN suites, ICU/CCU suites and ambulatory surgery suites. The SurgiVision surgical lighting and video system combines illumination with a technically advanced video system for both acute and non-acute care customers. Through Isomedix Services, Steris provides contract sterilization and microbial reduction services to manufacturers of pre-packaged health care and consumer products. Recently, NASA’s Jet Propulsion Laboratory awarded the firm’s Strategic Technology Enterprises subsidiary a contract to provide an altered version of the firm’s proprietary sterilization technology. In the spring of 2003, the company acquired Hamo Holding AG, a provider of washing and decontamination systems.
BRANDS/DIVISIONS/AFFILIATES: STERIS SYSTEM 1 SurgiVision Isomedix Services Strategic Technology Enterprises Hamo Holding AG buySTERIS
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Les C. Vinney, CEO Les C. Vinney, Pres. Laurie Brlas, CFO Charles L. Immel, Sr. VP-Mktg. and Sales Gerard J. Reis, Human Resources Peter A. Burke, Chief Tech. Officer Michael J. Tokich, Corp. Controller David L. Crandall, VP-Mfg. and Distribution Gerard J. Reis, Sr. VP-Corp. Admin. William L. Aamoth, Corp. Treas. William A. O'Riordan, Pres.-Health Care Group Jerry E. Robertson, Chmn.
Phone: 440-354-2600 Fax: 440-354-7043 Toll-Free: 800-548-4873 Address: 5960 Heisley Rd., Mentor, OH 44060-1834 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $866,700 (12 months) 2002 Profits: $46,200 (12 months) Stock Ticker: STE 2001 Sales: $800,100 2001 Profits: $1,300 Employees: 4,496 2000 Sales: $760,600 2000 Profits: $10,500 Fiscal Year Ends: 3/31 1999 Sales: $797,600 1999 Profits: $84,900 1998 Sales: $719,700 1998 Profits: $65,500
SALARIES/BENEFITS: Pension Plan: Y Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $602,126 Bonus: $530,260 Stock Purch. Plan: Second Exec. Salary: $261,242 Bonus: $118,443 A leading provider of infection prevention, contamination control and surgical support systems, products ADVANTAGE: and technologies.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
STORAGE TECHNOLOGY CORP
www.stortek.com
Industry Group Code: 334112 Ranks within this company's industry group: Sales:5 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:2
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Storage Equipment-Disk & Tape Drives Software and Network Communications Products Advanced Packaging Technology Systems Service and Support
Also known as Storage Technology Corp., StorageTek designs, manufactures, markets and services information storage, retrieval and recovery subsystems for highperformance and midrange computer systems, as well as for computer networks. StorageTek is divided into two main business segments: storage products and storage services. The company’s principal product lines include tape and robotic storage subsystems, random access storage subsystems and network products. Nearline products include magnetic tape storage devices and automated tape libraries. Online products include rotating magnetic disk devices that utilize fault-tolerant array technology (RAID). StorageNet 6000, the company's latest in a line of storage domain managers, provides high-efficiency management of tape storage resources. StorageTek maintains a worldwide customer service organization to install, maintain and service its own and third-party equipment. The company’s storage service operation also offers consulting services with a focus on information storage systems management and solution integration services. Large corporations, government agencies and educational, financial, medical and scientific institutions worldwide use the firm’s products. StorageTek recently won Fortune Magazine’s 2003 America’s Most Admired Companies Award, in the computer peripheral category, for the second year in a row. StorageTek provides health, fitness and day care services at its state-of-the-art wellness center, located at the company headquarters in Colorado.
BRANDS/DIVISIONS/AFFILIATES: StorageNet StorageTek
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Patrick J. Martin, CEO Patrick J. Martin, Pres. Robert S. Kocol, Corp. VP/CFO Jill F. Kenney, VP-Mktg. and Corp. Strategy Roger C. Gaston, VP-Human Resources Thomas G. Arnold, Controller/Corp. VP Jeff Hodgins, VP-Worldwide Sales Initiatives Karla Kimrey, VP-Investor Rel. Heather Matzke-Hamlin, Dir.-Internal Audit Gary Francis, VP/Mgr.-Automated Tape Solutions Angel Garcia, VP-Growth Markets and Global Services Pierre Cousin, VP/Mgr.-Storage Networking Stacy Dumas, VP-Bus. Process Optimization Patrick J. Martin, Chmn. Michael Väth, VP/Mgr.-European Oper. Roy Perry, VP-Supply Chain
Phone: 303-673-5151 Fax: 303-661-7637 Toll-Free: 800-877-9220 Address: One StorageTek Dr., Louisville, CO 80028-4309 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $2,039,600 (12 months) 2002 Profits: $110,000 (12 months) Stock Ticker: STK 2001 Sales: $2,045,300 2001 Profits: $67,200 Employees: 7,100 2000 Sales: $2,060,204 2000 Profits: $-1,782 Fiscal Year Ends: 12/31 1999 Sales: $2,368,231 1999 Profits: $-74,550 1998 Sales: $2,258,222 1998 Profits: $198,248
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Constantly exploring new markets.
OTHER THOUGHTS: Apparent Women Officers or Directors: 4 Hot Spot for Advancement for Women/Minorities: Y
Top Exec. Salary: $800,000 Second Exec. Salary: $500,000
Bonus: $1,070,000 Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
STRYKER CORP
www.strykercorp.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:5 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:6
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Equipment-Surgical Instruments Powered Surgical Instruments Outpatient Physical Therapy Services Orthopedic Implants Biotechnical Engineering
Stryker Corporation develops, manufactures and markets specialty surgical and medical products, including orthopedic implants, powered surgical instruments, endoscopic systems and patient care and handling equipment for the global market. Stryker also provides outpatient physical therapy services in the United States. Stryker’s five operating groups are Stryker Howmedica Osteonics, Stryker MedSurg (Medical/Surgery), Stryker Biotech, Spine and Trauma, Physiotherapy Associates and Stryker International. Stryker Howmedica Osteonics develops and manufactures orthopedic reconstructive products. Stryker MedSurg consists of four divisions: Stryker Instruments, Stryker Endoscopy, Stryker Medical and Stryker Leibinger; that design, manufacture and sell surgical products and medical equipment. Stryker Biotech, Spine and Trauma are three interrelated divisions that develop products to treat muscolo-skeletal injuries. The Physiotherapy Associates division conducts physical, occupational and speech therapy services. Stryker International is composed of several sales and distribution divisions: Stryker Europe, Stryker Japan, Stryker Pacific, Stryker Canada and Stryker Latin America. Some of Stryker’s products include the Duracon Total Knee System, Gamma Locking Nail System, Leibinger Resorbable Plating System, Hermes Voice Control System, Neptune Waste Management System and Zoom Motorized Stretcher. Stryker’s other services include the Ambulatory Surgery Center Program, financial services, nurse education and practice and hospital marketing services. In recent news, Stryker Howmedica Osteonics’ Simplex P with Tobramycin Bone Cement, which is preblended antibiotic bone cement, received market approval from the U.S. Food and Drug Administration. The division received pre-market approval for the Trident Ceramic Acetabular Insert, a ceramic-on-ceramic hip replacement. Most of the company’s divisions offer employees fitness centers, subsidized cafeterias and casual dress codes.
BRANDS/DIVISIONS/AFFILIATES: Stryker Howmedica Osteonics Stryker MedSurg Stryker Biotech, Spine and Trauma Physiotherapy Associates Stryker International Ambulatory Surgery Center Program Simplex P with Tobramycin Bone Cement Trident Ceramic Acetabular Insert
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John W. Brown, CEO John W. Brown, Pres. Dean H. Bergy, VP/CFO Michael W. Rude, VP-Human Resources James B. Praeger, Controller Dean H. Bergy, Sec. Curtis E. Hall, General Counsel Thomas R. Winkel, VP-Admin. J. Patrick Anderson, VP-Bus. Dev. Christopher F. Homrich, VP/Treas. Edward P. Lipes, VP/Group Pres., Howmedica Osteonics Stephen Si Johnson, VP/Group Pres., MedSurg Eric Lum, VP-Tax Jeffrey R. Winter, VP-Internal Audit John W. Brown, Chmn. James E. Kemler, VP/Group Pres., Stryker Intl.
Phone: 269-385-2600 Fax: 269-385-1062 Toll-Free: Address: 2725 Fairfield Rd., Kalamazoo, MI 49002 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $3,011,600 (12 months) 2002 Profits: $345,600 (12 months) Stock Ticker: SYK 2001 Sales: $2,602,300 2001 Profits: $267,000 Employees: 14,045 2000 Sales: $2,289,400 2000 Profits: $221,000 Fiscal Year Ends: 12/31 1999 Sales: $2,103,700 1999 Profits: $19,400 1998 Sales: $1,103,200 1998 Profits: $60,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $875,000 Bonus: $925,000 Stock Purch. Plan: Second Exec. Salary: $475,000 Bonus: $475,000 ADVANTAGE: Stryker is playing a leading role in the development of solutions to orthopedic problems.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
STV GROUP INC
www.stvinc.com
Industry Group Code: 541320 Ranks within this company's industry group: Sales: Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Y Y Y
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Architectural and Engineering Services Construction Inspection Feasibility Studies Industrial Process Engineering
STV Group, Inc. is an architectural, engineering, planning, environmental and construction management firm best known for its large transportation projects and educational facilities. The employee-owned firm is comprised of several subsidiaries, including STV/Silver & Ziskind, STV Incorporated, STV Environmental, STV Construction Management, STV Architects and STV International. In addition to general architectural and engineering services, the company has developed partnerships and strategic alliances that provide everything from building finance to furnishing to maintenance. STV Group provides transportation, environmental, infrastructure and planning, construction, buildings and facilities and industrial and technical services, as well as highly specialized services that extend beyond the company’s typical services. The firm constructs airports, highways, bridges, ports, railroad systems and schools, almost all of which are in the United States. Representative projects include the MetroLink in St. Louis, Missouri; Villanova University Center for Engineering Education and Research; Sprint PCS Environmental Site Assessments in seven states; the Metra Inner Circumferential Rail Study in Chicago, Illinois; Shea Stadium in Queens, New York; and engineering and technical services for the U.S. Naval Air Warfare Center in Patuxent River, Maryland. Recently, STV Group was awarded the Federal Planning Division’s award for Best Area Development Plan, honoring the company’s design plan for the new library, learning center and multipurpose academic building at the United States Military Academy in West Point, New York.
BRANDS/DIVISIONS/AFFILIATES: STV, Inc. STV Environmental STV Construction Management STV International STV Architects STV/Silver & Ziskind
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Dominick M. Servedio, CEO Michael S. Della Rocca, COO Michael S. Della Rocca, Pres. Peter W. Knipe, CFO Linda Rosenberg, Sr. VP-Mktg. Patrick M. Austin, Dir.-Human Resources Ronald K. Wiseman, CIO Peter W. Knipe, Corp. Sec. Patrick M. Austin, Dir.-Admin. Debra B. Trace, Mgr.-Corp. Comm. Peter W. Knipe, Treas. Ralph V. Locurcio, Sr. VP/Dir.-Federal Programs Dominick M. Servedio, Chmn.
Phone: 610-385-8200 Fax: 610-385-8500 Toll-Free: Address: 205 W. Welsh Dr., Douglassville, PA 19518 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Private 2001 Sales: $187,000 2001 Profits: $ Employees: 1,287 2000 Sales: $ 2000 Profits: $ Fiscal Year Ends: 9/30 1999 Sales: $ 1999 Profits: $ 1998 Sales: $105,300 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Diversified engineering services/Special expertise in transportation projects.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
SUN MICROSYSTEMS INC
www.sun.com
Industry Group Code: 334111 Ranks within this company's industry group: Sales:4 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:12
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Hardware-UNIX-Based Workstation Computers Consulting Services Systems Integration Office Application Software Professional Services
Sun Microsystems, Inc. (Sun) is a worldwide provider of products, services and support solutions for building and maintaining network computing environments. The company sells scalable computer systems, high-speed microprocessors and a complete line of high-performance software for operating network computing equipment and storage products. Sun also provides a full range of support, education and professional services. Sun’s products are used for many demanding commercial and technical applications in virtually all industries. Much of the company’s success comes from its adherence to open industry standards, the Solaris Operating Environment, the UNIX platform and the UltraSPARC (Ultra Scalable Processor Architecture) microprocessor architecture. Sun’s Star Office software suite runs on a server/thin client network, offering full functionality similar to that of Microsoft Office, without the need to install software on each workstation. Services, including training, installation and remote monitoring, account for about $2.3 billion in yearly revenue. Sun recently introduced new products and services for networks including storage and network elements, as well as a comprehensive set of services. Sun’s lifecycle services range from design through implementation and product management. Notably, 28.7% of Sun's workforce and 21.8% of its managers are minorities. Spot bonuses average $2,300. The company also offers on-site concierge services, massage therapy, auto and bike service and an equipment purchase discount. Employees are encouraged to dress casually.
BRANDS/DIVISIONS/AFFILIATES: Star Office SunSoft, Inc. Sun Microelectronics JavaSoft SPARC Technology Solaris LSC, Inc. HighGround Systems, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Scott G. McNealy, CEO Scott G. McNealy, Pres. Stephen McGowan, CFO Robert Youngjohns, Exec. VP/Global Sales Oper. Crawford Beveridge, Exec. VP/Chief Human Resources Officer Bill Joy, Chief Scientist H. William Howard, CIO John Croll, Sr. VP/Corp. Sec. John Croll, General Counsel Marissa Peterson, Exec. VP-Worldwide Oper. Mark Tolliver, Exec. VP/Chief Strategy Officer William T. Agnello, Sr. VP-Workplace Resources Greg Papadopoulos, Exec. VP/Chief Tech. Officer Jonathan Schwartz, Exec. VP-Software Group Patricia C. Sueltz, Exec. VP-Sun Services Scott G. McNealy, Chmn.
Phone: 650-960-1300 Fax: 650-336-0646 Toll-Free: 800-801-7869 Address: 901 San Antonio Rd., Palo Alto, CA 94303 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $12,496,000 (12 months) 2002 Profits: $-587,000 (12 months) Stock Ticker: SUNW 2001 Sales: $18,250,000 2001 Profits: $927,000 Employees: 39,400 2000 Sales: $15,721,000 2000 Profits: $1,854,000 Fiscal Year Ends: 6/30 1999 Sales: $11,806,000 1999 Profits: $1,030,000 1998 Sales: $9,862,000 1998 Profits: $755,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $800,000 Stock Purch. Plan: Y Second Exec. Salary: $600,000 World-class workstations and servers based on excellent technology. ADVANTAGE:
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $241,800 Bonus: $122,850
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
SUNGARD DATA SYSTEMS INC
www.sungard.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:6 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:5
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Software-Investment Operation Outsourced Information Processing and Services Internet Access
SunGard Data Systems, Inc. (SunGard) is a global leader in integrated information technology solutions for financial services companies. The company serves more than 20,000 clients in over 50 countries, including the vast majority of the 50 largest financial services institutions. SunGard’s products and services are generally delivered and supported through individual business units that offer product-specific development and customer support. The firm develops and implements integrated financial software for institutional investors, such as mutual or pension funds; financial intermediaries, such as brokers or dealers; and for corporations and governments. SunGard also manages one of the industry’s largest multi-platform data processing centers. The firm provides information processing and network services on an outsourced basis, as well as Internet access, co-location and web hosting services. Moreover, SunGard is an application service provider and offers turnkey access to third-party applications and its own financial software solutions. The company recently announced an agreement with Sun Microsystems to jointly offer business continuity solutions. SunGard offers its employees a benefits package including performance awards.
BRANDS/DIVISIONS/AFFILIATES: Global Plus AddVantage
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Cristobal Conde, CEO Cristobal Conde, Pres. Michael J. Ruane, Sr. VP/CFO Paul C. Jeffers, VP-Human Resources Andrew P. Bronstein, VP/Controller Lawrence A. Gross, Sr. VP/General Counsel Richard C. Tarbox, Sr. VP-Corp. Dev. Michael J. Ruane, Sr. VP/Treas. Robert Greifeld, Exec. VP David E. Robinson, Exec. VP Michael K. Muratore, Exec. VP James L. Mann, Chmn.
Phone: 610-341-8700 Fax: 610-341-8851 Toll-Free: Address: 1285 Drummers Ln., Wayne, PA 19087-1586 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $2,530,300 (12 months) 2002 Profits: $325,600 (12 months) Stock Ticker: SDS 2001 Sales: $1,928,700 2001 Profits: $246,100 Employees: 8,800 2000 Sales: $1,660,700 2000 Profits: $213,000 Fiscal Year Ends: 12/31 1999 Sales: $1,444,501 1999 Profits: $111,201 1998 Sales: $1,312,248 1998 Profits: $130,382
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $737,000 Stock Purch. Plan: Y Second Exec. Salary: $553,000 Solid customer base/Powerful strategic alliances. ADVANTAGE:
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $429,750 Bonus: $322,263
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
SUNRISE MEDICAL INC
www.sunrisemedical.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales: Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Supplies-Wheelchairs Home Respiratory Devices Patient-Room Beds and Furnishings
Sunrise Medical, Inc. designs, manufactures and markets medical products that address the recovery, rehabilitation and respiratory needs of patients in institutional and home care settings. The firm’s products include custom manual and power wheelchairs and related seating systems, ambulatory, bathing and lifting products, health care beds and furniture and therapeutic mattresses. Sunrise’s broad range of wheelchairs includes the Quickie line, which is designed for sports such as tennis and basketball, and the Zippie line, which is designed for children. Recently, the company introduced Quickie Chameleon, the newest addition to its line of manual folding wheelchairs. The Quickie Chameleon line, which features depth and angle adjustable seating, interchangeable parts and footrests that swing in and out, enables dealers to customize each consumer’s chair. Additionally, the company’s DeVilbiss subsidiary manufactures and markets a broad array of home respiratory products, including aerosol products, oxygen concentrators and sleep therapy products. DynaVox, another subsidiary, markets speech communication devices. These devices feature dynamic touch screen technology, predictive natural language software and a life-like voice synthesizer to speak for people with speech disorders.
BRANDS/DIVISIONS/AFFILIATES: Quickie Zippie Quickie Chameleon DeVilbiss DynaVox Breezy Guardian
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Michael N. Hammes, CEO Raymond Huggenberger, COO Michael N. Hammes, Pres. James L. Fetter, CFO Heather Hand, Human Resources Raymond Huggenberger, Pres.-Global Oper. Michael N. Hammes, Chmn.
Phone: 760-930-1500 Fax: 760-930-1585 Toll-Free: Address: 2382 Faraday Ave., Ste. 200, Carlsbad, CA 92008 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Private 2001 Sales: $ 2001 Profits: $ Employees: 4,470 2000 Sales: $ 2000 Profits: $ Fiscal Year Ends: 6/30 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Bonus: $ Stock Purch. Plan: Second Exec. Salary: $ Bonus: $ ADVANTAGE: Sunrise has invested heavily in a number of growth initiatives designed to increase revenues and improve customer service.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
SUPERGEN INC
www.supergen.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:96 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:76
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Research & Development-Late-Stage Drug Commercialization Oncology Drugs
SuperGen is a pharmaceutical company dedicated to the development and commercialization of products intended to treat life-threatening diseases, particularly cancer. The company possesses a large portfolio of proprietary oncological drugs that treat a variety of solid tumors and hematological malignancies. Nipent is its chemotherapy agent used in the treatment of hairy cell leukemia. Multiple clinical trials are currently ongoing for other disease states. Mitomycin is the firm’s generic brand of the chemotherapy agent Mutamycin. Surface Safe is a patented two-step application kit used to clean and inactivate anti-cancer drugs on chemotherapy work surfaces. The company’s strategy is to identify, acquire and develop pharmaceutical products that are in the later stages of development. This shortens research and development times and costs, making the process of drug commercialization more efficient. SuperGen also licenses or acquires rights to compounds that are normally at the pre-clinical or early clinical stages of development. In a significant development, the firm recently received approval from the FDA to market Mitozytrex , its proprietary version of the generic drug Mitomycin. The drug may be used in the therapy of disseminated adenocarcinoma of the stomach or pancreas, in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. Mitozytrex becomes the first approved drug based on SuperGen’s patented supergenerics Extra technology platform. The firm provides employees with benefits such as dental and vision coverage, incentive stock options and transportation assistance in the form of a complimentary shuttle between Dublin/Pleasanton Bart and its corporate offices.
BRANDS/DIVISIONS/AFFILIATES: Nipent Rubitecan Cisplatin Extra Dauno Extra Lucanthone Etoposide Extra Mito Extra Mitozytrex
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Joseph Rubinfeld, CEO Joseph Rubinfeld, Pres. Edward Jacobs, CFO Tipp Nelson, VP-Mktg. Christina Wang, Mgr.-Human Resources Craig S. Rosenfeld, Chief Scientific Officer Sam Jason, Controller Karl Mettinger, Sr. VP-Medical Affairs Edward L. Jacobs, Exec. VP-Commercial Oper. Timothy L. Enns, VP-Bus. Dev. Timothy L. Enns, VP-Investor Rel. R. David Lauper, VP-Professional Services Frederick Grab, VP-Compliance Simeon Wrenn, VP-Biotech. Audrey F. Jakubowski, VP-Regulatory Affairs
Phone: 925-560-0100 Fax: 925-560-0101 Toll-Free: Address: 4140 Dublin Blvd., Ste. 200, Dublin, CA 94568 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $15,300 (12 months) 2002 Profits: $-49,500 (12 months) Stock Ticker: SUPG 2001 Sales: $11,500 2001 Profits: $-55,600 Employees: 107 2000 Sales: $7,100 2000 Profits: $-35,300 Fiscal Year Ends: 12/31 1999 Sales: $4,700 1999 Profits: $-37,000 1998 Sales: $3,000 1998 Profits: $-15,600
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $530,000 Stock Purch. Plan: Second Exec. Salary: $260,000 ADVANTAGE: Continuing success of clinical trials of anticancer drugs.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $466,000 Bonus: $42,300
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
SUZUKI MOTOR CORPORATION
www.globalsuzuki.com
Industry Group Code: 336111 Ranks within this company's industry group: Sales:16
Profits:12
Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Automobiles, Manufacturing Motorcycles Generators Engines Wheelchairs Ultrasonic Products
With operations in over 190 countries around the world, Suzuki Motor Corp. is the largest manufacturer of minicars and the third largest manufacturer of motorcycles in Japan. U.S. products include the Vitara and Grand Vitara SUVs, the XL-7 and the Aerio and Aerio SX sedans. The Bandit, Katana and Marauder are among its motorcycle models. Other non-vehicle products include outboard motors, boats, generators, welders, general-purpose engines, electric scooters, motorized wheelchairs, ultrasonic products (such as cleaners and cutters) and prefabricated houses. The company has partnered with General Motors and Kawasaki to make automobiles, allterrain vehicles (ATVs) and motorcycles. In recent news, Suzuki developed an ultra-low-emission, direct-injection turbo engine for the minicar category in Japan. The company also recently released the Hayabusa, the fastest mass-produced street bike ever created. Other new products include the world's first four-wheel ATV and two racing machines that combine motorcycle and automotive engineering. The firm offers employees medical, dental and vision insurance, a car lease program, flexible hours and a casual dress policy.
BRANDS/DIVISIONS/AFFILIATES: American Suzuki Motor Corp. Suzuki Precision Industries Suzuki Marin Co. Suzuki Transportation and Packing Co. Suzuki Akita Auto Parts Mfg. Co. Grand Vitara Esteem Bandit
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Osamu Suzuki, CEO Masao Toda, COO Masao Toda, Pres. Akira Tsutsui, Exec. VP Sokichi Nakano, Exec. VP Chuichi Mizuguchi, Sr. Dir. Hiroshi Tsuda, Sr. Dir. Osamu Suzuki, Chmn.
Phone: 81-53-440-2061 Fax: 81-53-440-2776 Toll-Free: Address: 300 Takatsuka, Hamamatsu, Shizuoka, 432-8611 Japan
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $12,577,000 (12 months) 2002 Profits: $169,000 (12 months) Stock Ticker: SZKMF 2001 Sales: $12,667,600 2001 Profits: $160,300 Employees: 14,260 2000 Sales: $14,417,900 2000 Profits: $254,800 Fiscal Year Ends: 3/31 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Known for quality performance engineering.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
SYBASE INC
www.sybase.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:25 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:29
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Computer Software-Database Management Internet Applications Wireless Software Solutions
Sybase, Inc., one of the 10 largest independent software companies in the world, helps businesses gain competitive advantages by providing database solutions and ebusiness innovations. Sybase enables its clients to integrate and distribute information anywhere it is needed. The company delivers focused solutions in the areas of business intelligence, mobile computing and e-business, as well as vertical solutions for financial services, government, health care, telecommunications and media. Its software products and consulting services provide a comprehensive platform that distributes data throughout a client company in an integrated fashion. Offerings include enterprise portal (EP) products, wireless technology and vertical market software and services. iAnywhere Solutions, a majority-owned subsidiary of Sybase, is consistently a leader in the mobile database market. Its SQL Anywhere Studio software has been deployed in 5 million workstations. Financial Fusion, Inc., a subsidiary that caters to small and medium-sized financial organizations, provides enterprise class e-finance solutions to leading financial institutions, combining applications and middleware on a single, integrated circuit. Sybase’s customer base is comprised primarily Fortune 1000 companies in North America. The firm serves companies in the financial services, insurance, telecommunications and health care industries as well as defense and government agencies. Its products are available on hardware platforms created by Compaq, Hewlett-Packard, IBM and Sun Microsystems. Sybase features a casual dress environment. The company offers workers exceptional health plans as well as a tax-free day care reimbursement account. It also offers education assistance, a fitness center and spousal equivalent benefits. Employees of over five years are offered six weeks of sabbatical leave. Students are actively recruited and offered flexible hours and free training.
BRANDS/DIVISIONS/AFFILIATES: Sybase Professional Services iAnywhere Solutions Financial Fusion, Inc. SQL Anywhere Studio
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John S. Chen, CEO John S. Chen, Pres. Pieter A. Van der Vorst, CFO Marty J. Beard, VP-Mktg. Nita White-Ivy, VP-Human Resources Eric Miles, Sr. VP/Mgr.-Bus. Intelligence Martin J. Healy, Controller Dan R. Carl, Corp. Sec. Dan R. Carl, General Counsel Michael W. Bealmear, Pres.-Worldwide Field Oper. Marty J. Beard, VP-Corp. Dev. Billy Ho, Sr. VP/Mgr.-e-Bus. Div. Pamela J. George, VP-Corp. Affairs Raj Nathan, Sr. VP/Mgr.-Enterprise Solutions Div. Terry Stepien, Pres., iAnywhere Solutions David A. Lavanty, VP-Worldwide Professional Services Richard J. Moore, Pres., Financial Fusion John S. Chen, Chmn.
Phone: 925-236-5000 Fax: 925-236-4321 Toll-Free: 800-879-2273 Address: One Sybase Dr., Dublin, CA 94568 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $829,900 (12 months) 2002 Profits: $-94,700 (12 months) Stock Ticker: SY 2001 Sales: $926,100 2001 Profits: $-25,500 Employees: 3,917 2000 Sales: $960,500 2000 Profits: $72,100 Fiscal Year Ends: 12/31 1999 Sales: $871,633 1999 Profits: $62,495 1998 Sales: $867,469 1998 Profits: $-93,128
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $821,500 Bonus: $314,635 Stock Purch. Plan: Y Second Exec. Salary: $305,550 Bonus: $12,604 ADVANTAGE: One of the world's largest independent suppliers of enterprise client/server relational database products and service/Long list of financial industry clients.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
SYMANTEC CORP
www.symantec.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:20 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:22
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Software-Security Remote Productivity Products
California-based Symantec Corp., a world leader in Internet security technology, provides a broad range of content and network security solutions to individuals and enterprises. The company is a leading provider of virus protection, risk management, Internet content, e-mail filtering, remote management and mobile code detection technologies. Symantec provides client, gateway and server security solutions for virus protection, firewall and virtual private network, vulnerability management, intrusion detection, as well as security services to enterprises and service providers worldwide. The firm’s enterprise administration tools provide secure, economical, centralized network management for rolling out new desktop computers or transferring existing desktops to new operating systems. Its well-known brand of Norton consumer security products is a leader in worldwide retail sales and has won numerous industry awards. Additionally, the firm provides information security services through three units: consulting services, which provides comprehensive security assessments and planning to help businesses protect mission-critical assets; managed security services, which provides outsourced services for the management and monitoring of security systems; and education services, which helps develop internal security skills and resources. The company has manufacturing, technical support, development and customer service operations in 38 countries. Symantec recently launched DeepSight Threat Management System 4.0, which provides businesses with a comprehensive overview of global Internet attacks and quick analyses and countermeasures to protect against threats. The system tracks security threats as they occur, gathering data from firewalls and intrusion detection systems from over 19,000 partners in nearly 180 countries. Symantec offers its employees dental, vision and prescription drug plans. The company also provides an adoption assistance program, health club reimbursement, tuition assistance and credit union membership.
BRANDS/DIVISIONS/AFFILIATES: Norton AntiVirus I-Gear DeepSight Navarre Norton CleanSweep Norton SystemWorks Expert
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John W. Thompson, CEO John Schwarz, COO John Schwarz, Pres. Greg Myers, CFO Dieter Giesbrecht, Sr. VP-Worldwide Mktg. and Sales Rebecca Ranninger, Sr. VP-Human Resources Robert A. Clyde, Chief Tech. Officer Art Courville, VP/General Counsel Mansour Safai, VP/General Mgr.-Internet Tools Donald E. Frischmann, Sr. VP-Worldwide Comm. Steven Messick, VP-North American Sales Akihiko Narita, VP-Symantec Japan Cecil Perez, VP-Latin America Garry Sexton, VP-Asia Pacific Stephen G. Cullen, Sr. VP-Product Delivery
Phone: 408-517-8000 Fax: 408-253-3968 Toll-Free: Address: 20330 Stevens Creek Blvd., Cupertino, CA 95014 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,071,400 (12 months) 2002 Profits: $-28,200 (12 months) Stock Ticker: SYMC 2001 Sales: $853,600 2001 Profits: $63,900 Employees: 3,900 2000 Sales: $745,725 2000 Profits: $170,148 Fiscal Year Ends: 3/31 1999 Sales: $592,628 1999 Profits: $50,201 1998 Sales: $532,940 1998 Profits: $85,089
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $700,000 Stock Purch. Plan: Y Second Exec. Salary: $425,000 ADVANTAGE: Name recognition of products/Strategic acquisitions of products and tools.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $481,250 Bonus: $302,109
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
SYMBOL TECHNOLOGIES INC
www.symbol.com
Industry Group Code: 334119 Ranks within this company's industry group: Sales:2 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:2
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Accessories-Bar Code Scanners and Portable Data Terminals Wireless Networking and Information Systems
Symbol Technologies, Inc. is a leading global provider of wireless networking and information systems and bar code verification products. The firm manufactures and services scanner integrated mobile and wireless information management systems that consist of software, programming tools, wireless local area networking systems and bar code reading, network appliances, peripheral and mobile computing devices. These systems are used in a variety of applications from facilitating ecommerce transactions to collecting and transmitting information from remote locations. Recently, Symbol Technologies began deploying its switched-wireless infrastructure across the campuses of New York Institute of Technology. The new system allows students and faculty to access multimedia applications from anywhere on campus. The company's mobile computing devices are microprocessor-based, lightweight and batteryoperated. Information may be captured by a device that reads bar codes or may be manually entered via a keyboard, a touch screen or a pen computer display/entry device. The information collected by the mobile computing device can then be transmitted instantly to a host computer across a wireless local area network (WLAN) or in some instances by modems. Over 90% of the company's mobile computing devices include an integrated bar code reader, and approximately 90% offer optional integrated wide area network or WLAN communication capability. In the spring of 2003, the firm introduced the Symbol LS 220, a handheld laser bar code scanner that is capable of migrating from one host terminal to another by a simple cable change. Symbol Technologies offers its employees referral bonuses and dry-cleaning services.
BRANDS/DIVISIONS/AFFILIATES: Symbol LS 220
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Richard Bravman, CEO William R. Nuti, COO William R. Nuti, Pres. Mark T. Greenquist, CFO Carole DeMayo, Sr. VP-Human Resources Jerome Swartz, Chief Scientist Leonard H. Goldner, Corp. Sec. Leonard H. Goldner, General Counsel Jerome Swartz, Chmn.
Phone: 631-738-2400 Fax: 631-738-5990 Toll-Free: 800-722-6234 Address: One Symbol Plaza, Holtsville, NY 11742-1300 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,320,100 (12 months) 2002 Profits: $10,500 (12 months) Stock Ticker: SBL 2001 Sales: $1,452,700 2001 Profits: $-53,900 Employees: 5,250 2000 Sales: $1,449,490 2000 Profits: $-68,966 Fiscal Year Ends: 12/31 1999 Sales: $1,139,290 1999 Profits: $116,364 1998 Sales: $977,901 1998 Profits: $92,964
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $100,002 Stock Purch. Plan: Y Second Exec. Salary: $100,002 ADVANTAGE: A global leader in secure mobile information systems.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $1,092,800 Bonus: $949,400
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
SYNBIOTICS CORP
www.synbiotics.com
Industry Group Code: 325413 Ranks within this company's industry group: Sales:9 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:11
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Supplies-Animal Health Care Diagnostic Test Kits Internet Portal for Veterinarians
Synbiotics Corp. is a global company dedicated to delivering innovative animal health products and services to the veterinary market. The firm has evolved from a research and development company to a developer, manufacturer and marketer of veterinary diagnostics, vaccines and other animal health-related products worldwide since its creation in 1982. Synbiotics has discontinued its Internet and chemical analyzer businesses. The firm is the sole provider of the SCA2000, an innovative, patient-side instrument used to measure veterinary blood coagulation factors. The firm’s business strategy in animal health is to grow from its established position in the market through new products and technologies, expanded distribution, enhanced marketing, aquisitions and licensing. Synbiotics plans to combine its ability to generate products through acquisitions, licensing agreements, research and development with its ability to distribute products through established worldwide marketing channels. The company’s CEO and CFO recently resigned unexpectedly to pursue other interests. The firm has operations is San Diego, California and Lyon, France.
BRANDS/DIVISIONS/AFFILIATES: International Canine Genetics Rhone Merieux Diagnostics Prisma Systems SCA2000 Kirkegaard & Perry Laboratories W3Commerce, LLC Capsule Report (The) Witness Ehrlichia
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Paul A. Rosinack, CEO Paul R. Hays, COO Paul R. Hays, Pres. Keith A. Butler, CFO Robert A. Buchanan, VP-Mktg. and Sales Serge Leterme, VP-Research and Dev. Clifford Frank, Dir.-Oper. Gregory A. Soulds, Dir.-Bus. Dev. Francois Guillemin, VP-Animal Health/Pres., Synbiotics Europe
Phone: 858-451-3771 Fax: 858-451-5719 Toll-Free: Address: 11011 Via Frontera, San Diego, CA 92127 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $21,671 (12 months) 2002 Profits: $-14,401 (12 months) Stock Ticker: SBIO 2001 Sales: $27,500 2001 Profits: $ 400 Employees: 94 2000 Sales: $31,300 2000 Profits: $-18,500 Fiscal Year Ends: 12/31 1999 Sales: $30,800 1999 Profits: $-1,400 1998 Sales: $31,700 1998 Profits: $-1,900
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $227,148 Bonus: $18,750 Stock Purch. Plan: Second Exec. Salary: $185,124 Bonus: $ ADVANTAGE: Sole provider of the SCA2000, a veterinary instrument that measures blood coagulation factors.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
SYNCOR INTERNATIONAL CORPORATION www.syncor.com Industry Group Code: 325412 Ranks within this company's industry group: Sales: Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Radiopharmaceuticals Nuclear Pharmacy Services
Syncor International Corp., now the nuclear pharmacy services business of Cardinal Health, provides specialty services and products used in the diagnosis, treatment and management of heart disease, cancer and other disorders. The firm is the nation’s leading provider of radiopharmacy services and a leading provider of outpatient medical imaging services. Syncor’s 130 domestic radiopharmacies serve hospitals, medical clinics and medical imaging centers in 48 states, supplying over 50% of the U.S. market. The firm also operates 19 radiopharmacies in 13 foreign countries and in Puerto Rico. These facilities compound, dispense and distribute patient-specific prescriptions used in nuclear diagnostic imaging procedures. The company also distributes radiopharmaceuticals in bulk for manufacturers. Additionally, Syncor operates 65 outpatient medical imaging centers located primarily in the southeast, southwest and western U.S., as well as 19 international imaging centers. Services are primarily noninvasive procedures that generate representations of internal anatomy and convert them to film or digital media, aiding in the detection and diagnosis of diseases and disorders. These services include MRI, CT, traditional x-ray, mammography, ultrasound and fluoroscopy imaging, as well as PET scanning services. Principal radiopharmacy clients are corporate account customers, such as GPOs; local independent hospitals and medical clinics; and community-based, multiple-facility integrated health care networks. The company recently signed an agreement with Michigan State University (MSU) to introduce a PET cyclotron to the health care system of Michigan. It will be located at the MSU Radiology Center. Syncor offers employees medical, dental, vision and life insurance.
BRANDS/DIVISIONS/AFFILIATES: Cardiolite Xigris SYNtrac Cardinal Health
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Robert G. Funari, CEO Robert G. Funari, Pres. William P. Forster, Sr. VP/CFO Sheila H. Coop, Sr. VP-Human Resources Lewis W. Terry, Jr., Sr. Corp. VP/CIO John S. Baumann, Sr. VP/General Counsel Jack L. Coffey, Sr. VP-Quality and Regulatory Sheila H. Coop, Sr. VP-Comm. William P. Forster, Treas. Rodney E. Boone, Exec. VP/Pres.-Pharmacy Services David L. Ward, Exec. VP/Pres.-Comprehensive Medical Imaging Haig S. Bagerdjian, Exec. VP
Phone: 818-737-4000 Fax: 818-737-4468 Toll-Free: 800-678-6779 Address: 6464 Canoga Ave., Woodland Hills, CA 91367-2407 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 6 months. 2002 Sales: $362,000 ( 6 months) 2002 Profits: $-4,086 ( 6 months) Stock Ticker: Subsidiary 2001 Sales: $774,700 2001 Profits: $37,900 Employees: 4,200 2000 Sales: $629,400 2000 Profits: $29,500 Fiscal Year Ends: 12/31 1999 Sales: $520,300 1999 Profits: $19,200 1998 Sales: $449,000 1998 Profits: $13,900
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $500,000 Bonus: $247,000 Stock Purch. Plan: Y Second Exec. Salary: $340,992 Bonus: $176,000 ADVANTAGE: A premier provider of radiopharmaceuticals to the health care community/Expansion into imaging services.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
SYNGENTA AG
www.syngenta.com
Industry Group Code: 325000 Ranks within this company's industry group: Sales:5 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:9
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Y Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Agrochemicals Crop Protection Products Flowers
Syngenta AG is the result of the merger and spin-off of the Novartis Agribusiness and Zeneca Agrochemicals units of AstraZeneca and Novartis. Syngenta manufactures a variety of agricultural chemicals including insecticides, herbicides, fungicides, field crop seeds, vegetable seeds and flowers. The global company’s research and manufacturing facilities are located in more than 50 countries worldwide. Products currently in development include cotton and rice herbicides, cornfield crops, bananas, wheat, tomatoes, lettuce, melons and cucumbers. Its leading marketed products include Dual Gold, Bicept II Magnum, Acanto, Score, Amistar, Actara, and Proclaim. Syngenta is involved in research and development collaborations with several universities and companies, including Myraid Genetics, Inc., Maxygen, Inc., Incyte Pharmaceuticals, Inc., the University of California and Wageningen Agricultural University. The University of Basel and Syngenta AG recently successfully sequenced a genetic map of a plant fungus that had never before been analyzed. In other news, Syngenta announced a collaboration with Diversa Corporation to establish a research platform and to discover products.
BRANDS/DIVISIONS/AFFILIATES: Novartis AstraZeneca Dual Gold Bicept II Magnum Acanto Proclaim Score Amistar
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Michael Patrick Pragnell, CEO John Atkin, COO-Crop Protection Richard Steiblin, CFO John Elias, Human Resources David Lawrence, VP-Research and Tech. Christoph Mader, VP-Legal and Taxes Bruce Bissell, VP-Chemical Oper. & Global Supply David Jones, VP-Planning & Bus. Dev. Jeffrey Beard, COO-Seeds Heinz Imhof, Chmn.
Phone: 41-61-697-1111 Fax: 41-61-323-2424 Toll-Free: Address: Schwarzwaldalle 215, Basel, 4058 Switzerland
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $6,197,000 (12 months) 2002 Profits: $-27,000 (12 months) Stock Ticker: SYT 2001 Sales: $6,323,000 2001 Profits: $223,000 Employees: 22,791 2000 Sales: $4,876 2000 Profits: $180,000 Fiscal Year Ends: 12/31 1999 Sales: $4,678 1999 Profits: $64,000 1998 Sales: $5,040 1998 Profits: $169,000
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Worldwide presence/Leading firm in crop bioscience.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
SYNOPSYS INC
www.sysnopsys.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:24 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:32
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Computer Software-Electronic Design Automation Consulting and Support Services
Synopsys, Inc. is a leading supplier of electronic design automation software to the global electronics industry. Its products are used by designers of integrated circuits (ICs), including system-on-a-chip ICs, and the electronic products (such as computers, cell phones and Internet routers) that use ICs to automate significant portions of their chip design process. Synopsys's products offer customers the opportunity to design ICs that are optimized for speed, area, power consumption and production cost, while reducing overall design time. In addition, the company provides consulting services to assist customers with their IC designs, as well as training and support services. The firm markets its products on a worldwide basis and has licensed its products to most of the world's leading semiconductor, computer, communications and electronics companies. These products fall into five categories: IC implementation; verification and test; IP and systems level design; transistor level design; and professional services. These include Design Compiler, the market-leading logic synthesis tool; Chip Architect; FlexRoute; Scirocco; DFT Compiler, TetraMAX; PrimeTime; Formality; DesignWare; ModelSource 3000; CoCentric; PathMill; and PowerMill. The firm's professional services unit accounts for approximately 12% of revenues. In recent news, Synopsys opened third-party access to its industry-proven Milkyway database for electronic design automation. The company also recently introduced the Galaxy design platform for advanced IC design. The product is anchored by Design Compiler and PrimeTime tools. Employees at Synopsys are offered comprehensive health care benefits, including an employee assistance program, as well as flexible spending accounts, education assistance, adoption benefits, credit union membership, referral bonuses, telecommuting options and recreational opportunities, such as an on-site gym and a summer concert series.
BRANDS/DIVISIONS/AFFILIATES: IKOS Systems, Inc. Avant! Corp. Design Compiler Chip Architect TetraMAX CoCentric Scirocco PathMill
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Aart J. de Geus, CEO Chi-Foon Chan, COO Chi-Foon Chan, Pres. Steve Shevick, Sr. VP/CFO Vicki L. Andrews, Sr. VP-Worldwide Sales Ernst W. Hirt, Sr. VP-Human Resources and Facilities Raul Camposano, Sr. VP/Chief Tech. Officer Raul Camposano, Sr. VP-Info. Systems Deirdre Hanford, Sr. VP-Worldwide Application Services Jerry Lee, Sr. VP-IC Implementation Sanjiv Kaul, Sr. VP-Corp. Applications and Mktg. John Chilton, Sr. VP-Intellectual Property and Design Services
Phone: 650-962-5000 Fax: 650-965-8637 Toll-Free: 800-541-7737 Address: 700 E. Middlefield Rd., Mountain View, CA 94043 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $906,500 (12 months) 2002 Profits: $-200,000 (12 months) Stock Ticker: SNPS 2001 Sales: $680,400 2001 Profits: $56,800 Employees: 3,223 2000 Sales: $738,778 2000 Profits: $97,778 Fiscal Year Ends: 10/31 1999 Sales: $806,098 1999 Profits: $161,362 1998 Sales: $717,940 1998 Profits: $89,446
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $400,000 Stock Purch. Plan: Y Second Exec. Salary: $400,000 ADVANTAGE: Pioneered the commercial development of synthesis technology.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $575,000 Bonus: $575,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
SYNOVIS LIFE TECHNOLOGIES INC
www.synovislife.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:35 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:31
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Supplies-Surgery Implantable Biomaterials
Synovis Life Technologies, Inc., formerly Bio Vascular, Inc., develops, manufactures and markets branded proprietary and patented specialty medical products for use in thoracic, cardiac, neuro, vascular and ophthalmic surgery. The company operates in two business segments: the surgical device business and the interventional business. Through subsidiaries Synovis Surgical Innovations and Synovis Micro Companies Alliance, the surgical device business develops, manufactures and markets implantable biomaterial products, devices for microsurgery and surgical tools that reduce risks of critical surgeries, lead to better patient outcomes and lower costs. The interventional business provides the services of concept development, engineering, rapid prototyping and manufacturing of complex micro-wire forms and polymer components used in many interventional devices in the cardiac rhythm management, neurostimulation and vascular markets. This segment is operated through subsidiaries Synovis Interventional Solutions and Synovis Precision Engineering. The company's surgical device business product lines and associated products include Ocu-Guard, Peri-Strips, Vascu-Guard, Dura-Guard, Veritas Collagen Matrix, Flo-Thru Intraluminal Shunt Flo-Rester and Microvascular Anastomotis Coupler. Peri-Strips are used to provide reinforcement at the surgical staple line to prevent potentially fatal fluid leaks, most significantly in gastric bypass surgery, a treatment for morbid obesity. The Microvascular Anastomotic Coupler System enables microsurgeons to perform highly effective anastomotic surgical procedures faster, easier and as or more dependably than traditional suture or sleeve anastomosis. In recent news, the company announced the opening of a new facility in Puerto Rico to expand the manufacturing capacity of its intervention business.
BRANDS/DIVISIONS/AFFILIATES: Synovis Surgical Innovations Synovis Micro Companies Alliance Synovis Interventional Solutions Synovis Precision Engineering Veritas Collagen Matrix Vascu-Guard Peri-Strips Bio Vascular, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Karen Gilles Larson, CEO Karen Gilles Larson, Pres. Connie L. Magnuson, CFO/VP-Finance David Buche, VP-Mktg. and Sales B. Nicholas Oray, VP-Research and Dev. Connie L. Magnuson, Corp. Sec. Evan Johnston, VP-Oper. Mary L. Frick, VP-Regulatory Affairs and Quality Assurance Michael K. Campbell, Pres., Micro Companies Alliance Fariborz Boor Boor, Pres./COO-Interventional Bus. Timothy M. Scanlan, Chmn.
Phone: 651-603-3700 Fax: 651-642-9018 Toll-Free: 800-255-4018 Address: 2575 University Ave., St. Paul, MN 55114 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $39,962 (12 months) 2002 Profits: $3,041 (12 months) Stock Ticker: SYNO 2001 Sales: $28,500 2001 Profits: $1,800 Employees: 350 2000 Sales: $21,926 2000 Profits: $ 589 Fiscal Year Ends: 10/31 1999 Sales: $18,904 1999 Profits: $- 520 1998 Sales: $12,017 1998 Profits: $- 483
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $250,000 Bonus: $46,719 Stock Purch. Plan: Second Exec. Salary: $159,769 Bonus: $32,000 ADVANTAGE: Large number of branded products for use in a wide variety of surgical procedures.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
TARGETED GENETICS CORP
www.targetedgenetics.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:89 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:69
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Acquired and Inherited Disease Cell Therapy Products
Targeted Genetics Corp. (TGC) develops gene therapy products and technologies for treating both acquired and inherited diseases. The firm’s gene therapy product candidates are designed to treat disease by regulating cellular function at a genetic level. This involves inserting genes into target cells and activating the inserted gene in a manner that provides the desired effect. The company has established expertise and development capabilities in the areas of pre-clinical research and biology, manufacturing process scale-up, quality control and assurance, regulatory affairs and clinical trial design and implementation. The firm’s gene therapy products involve the use of delivery vehicles, called vectors. TGC’s vector technologies include viral vectors and synthetic vectors. Viral vectors use modified viruses to deliver genes into cells, focusing primarily on adeno-associated virus, or AAV. The firm’s synthetic vectors deliver genes using lipids, allowing repeated, efficient delivery of therapeutic genes into rapidly dividing cells, such as certain types of tumor cells. TGC, the International AIDS Vaccine Initiative and Columbus Children’s Research Institute are currently collaborating on the development of a recombinant AAVbased vaccine designed to prevent HIV in developing nations. Additionally, the company recently entered into an alliance with Cystic Fibrosis Foundation Therapeutics, Inc. to advance TGC’s tgAAVCF product candidate, which is designed to treat patients with cystic fibrosis. The companies plan to conduct a Phase II clinical trial to evaluate the efficacy of tgAAVCF in patients with mild to moderate cystic fibrosis.
BRANDS/DIVISIONS/AFFILIATES: tgAAVCF CellExSys
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. H. Stewart Parker, CEO H. Stewart Parker, Pres. Todd Simpson, CFO/VP-Finance Geoffrey Roach, Dir.-Human Resources Barrie J. Carter, Chief Scientific Officer Todd Simpson, Corp. Sec. Todd Simpson, VP-Admin. Todd Simpson, Treas. Jeremy L. Curnock Cook, Chmn.
Phone: 206-623-7612 Fax: 206-223-0288 Toll-Free: Address: 1100 Olive Way, Ste. 100, Seattle, WA 98101 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $19,300 (12 months) 2002 Profits: $-23,800 (12 months) Stock Ticker: TGEN 2001 Sales: $18,900 2001 Profits: $-27,200 Employees: 125 2000 Sales: $11,400 2000 Profits: $-47,700 Fiscal Year Ends: 12/31 1999 Sales: $6,800 1999 Profits: $-26,700 1998 Sales: $7,500 1998 Profits: $-8,700
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $364,000 Stock Purch. Plan: Second Exec. Salary: $243,320 ADVANTAGE: Capitalizes on basic research discoveries.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $88,200 Bonus: $34,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
TARO PHARMACEUTICAL INDUSTRIES www.taropharma.com Industry Group Code: 325412 Ranks within this company's industry group: Sales:44 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:32
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Generic and Proprietary Over-the-Counter Analgesics Dermatological Drugs
Taro Pharmaceutical Industries is a multinational sciencebased pharmaceutical company that discovers, develops, manufactures and markets a wide range of health care products, from over-the-counter analgesics to vitamins. The firm’s prescription and over-the-counter medications are mainly used in dermatology, cardiology and neurology, in addition to covering a broad array of indications, from the common cold to cancer. Taro produces more than 200 pharmaceutical products, including topical preparations (creams, ointments, gels, solutions), oral medications (tablets, capsules, powders, liquids) and sterile products (injectables, ophthalmic drops, powders). In recent news, the company received FDA approval for its Ketoconazole Cream 2%, which is bioequivalent to Nizoral Cream. Nizoral, a product of Janssen Pharmaceutica Products, is a prescription product used primarily for the treatment of fungal infections of the skin. Additionally, Taro received approval from the FDA for Econazole Nitrate Cream 1%, a bioequivalent to Ortho Dermatological’s Spectazole Cream. This prescription pharmaceutical is mainly used to treat fungal infections of the skin. Taro was granted the first U.S. approval to manufacture and market a generic equivalent to Spectazole. In other news, Taro filed a new patent application for the use of T2000 as a treatment for essential tremor. T2000 is Taro’s patented, long-acting, non-sedating barbiturate compound. The new patent application was based upon an early Phase II study in patients with essential tremor, whose dysfunction appeared to lessen after taking a short-term course of treatment with T2000. The firm’s U.S. subsidiary, Taro Pharmaceuticals U.S.A., Inc., recently purchased a onethird interest in a building to house its U.S. research and development operations. After renovations, Taro USA will be located in Hawthorne, New York. Taro also recently reported its 27th consecutive quarter of record sales and its 17th consecutive quarter of record net income.
BRANDS/DIVISIONS/AFFILIATES: Taro Pharmaceuticals U.S.A., Inc. Econazole Nitrate Cream 1% Ketoconazole Cream 2% Clobetasol E NonSpil T2000
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Samuel Rubinstein, COO Aaron Levitt, Pres. Kevin Connelly, Sr. VP/CFO Zahava Rafalowicz, VP-Mktg. & Sales Puah Dekel, Dir.-Human Resources Avraham Yacobi, Sr. VP-Research and Dev. Tzvi Tal, VP-IT Mariana Bacalu, VP-Quality Assurance Ilan Ben Cnaan, VP-Oper. Sabar Sasson, VP-Strategy Daniel Saks, VP-Corp. Affairs Yohanan Dichter, VP-Pharmacist Samuel Rubinstein, Sr. VP Roman Kaplan, VP-Tech. Oper. Zalmin Lempert, VP-Regulatory Affairs
Phone: 972-9-971-1800 Fax: 972-9-955-7443 Toll-Free: Address: 14 Hakitor St., Haifa Bay, 26110 Israel
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $211,600 (12 months) 2002 Profits: $44,600 (12 months) Stock Ticker: TARO 2001 Sales: $150,100 2001 Profits: $26,000 Employees: 750 2000 Sales: $103,800 2000 Profits: $10,000 Fiscal Year Ends: 12/31 1999 Sales: $83,800 1999 Profits: $5,500 1998 Sales: $66,700 1998 Profits: $2,300
SALARIES/BENEFITS: Pension Plan: Y Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Multinational company with a wide range of products.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
TECHNE CORP
www.techne-corp.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:30 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:26
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Supplies-Cytokines, Antibodies and Assay Kits Biotechnology Products
Techne Corp. is a holding company that operates via two subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) and R&D Systems Europe, Ltd. R&D Systems is a specialty manufacturer of biological products. Its two major operating segments are hematology controls, which are utilized in clinical and hospital laboratories to monitor the accuracy of blood analysis instruments, and biotechnology products, including purified proteins and antibodies that are sold exclusively to the research market. The firm’s biotechnology division was formed in response to a growing need for highly purified, biologically active proteins. R&D Europe also distributes biotechnology products and has a German sales subsidiary, R&D Systems GmbH. Techne produces controls and calibrators for the following impedance-type instruments: Abbott Cell-Dyn, ABX, Beckman Coulter, Danam, Hycel, Roche and TOA Sysmex instruments. Currently produced controls and calibrators for laser-type instruments include products for the following: Beckman Coulter MAXM, STKS and GENS; Abbott Cell-Dyn 3000, 3200, 3500 and 4000 instruments; ABX instruments; Bayer Technicon ADVIA and H series instruments; and the TOA Sysmex NE-8000 and NE-5500 instruments. The company’s Whole Blood Flow Cytometry Control is a control for flow cytometry instruments. These instruments are used to identify and quantify white blood cells by their surface antigens. The Whole Blood Glucose/Hemoglobin Control product is designed to monitor instruments for measuring glucose and hemoglobin. R&D Systems is currently engaged in ongoing research and development in all of its major product lines: hematology controls and calibrators, biotechnology cytokines, antibodies, assays and related products.
BRANDS/DIVISIONS/AFFILIATES: Research and Diagnostic Systems, Inc. R&D Systems Europe, Ltd. R&D Systems GmbH Techne Export, Inc. Whole Blood Flow Cytometry Control Whole Blood Glucose/Hemoglobin Control Sleeping Beauty Transposona Morphanta
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Thomas E. Oland, CEO Thomas E. Oland, Pres. Lea Simoane, Dir.-Human Resources Monica Tsang, VP-Research Kathy Backes, Controller Timothy M. Heaney, Corp. Sec. Timothy M. Heaney, General Counsel Thomas E. Oland, Treas. James A. Weatherbee, VP/Chief Scientific Officer Thomas C. Detwiler, VP-Scientific and Regulatory Affairs Marcel Veronneau, VP-Hematology Oper. Thomas E. Oland, Chmn.
Phone: 612-379-8854 Fax: 612-379-6580 Toll-Free: 800-343-7475 Address: 614 McKinley Pl. NE, Minneapolis, MN 55413-2610 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $130,900 (12 months) 2002 Profits: $27,100 (12 months) Stock Ticker: TECH 2001 Sales: $115,400 2001 Profits: $34,000 Employees: 566 2000 Sales: $103,800 2000 Profits: $26,600 Fiscal Year Ends: 6/30 1999 Sales: $90,900 1999 Profits: $16,700 1998 Sales: $67,300 1998 Profits: $15,200
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $225,000 Stock Purch. Plan: Y Second Exec. Salary: $210,000 ADVANTAGE: Rapid growth potential/ High profit margins.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $39,820 Bonus: $39,480
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
TECHNIP-COFLEXIP
www.technip.com
Industry Group Code: 541310 Ranks within this company's industry group: Sales: Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Y Y Y Y
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Engineering Services-Petrochemical, Energy and Environmental
Technip-Coflexip is one of the world’s five leading fullservice engineering and construction groups, providing engineering, technologies and construction services to the oil and gas, petrochemical and other industries worldwide. The company was formed as a merger between two leading companies, Technip and Coflexip. The company designs and constructs projects involving offshore and onshore field development, gas processing and liquefaction, refining, onshore pipelines, sub-sea products, cement, buildings and petrochemicals. The firm provides all or part of the services required for basic and detail engineering, procurement, construction and project management. Its proprietary technologies include DEA High Load and MDEA for gas sweetening, RAR (ReactAbsorb-Recycle) technology for the treatment of Claus unit tail gas, the CRYOMAX process for the cryogenic extraction of natural gas liquids, FVR (Flash Vapor Recycle) for the extraction of C2+ NGL from natural gas and the TEALARC process for the liquefaction of natural gas. The company is a member of the BP Club for modified Claus process and CBA, and the APCI Club for liquefaction of natural gas. The firm has technological alliances with Shell, Texaco, BP, DSM and UOP, among others. In addition to numerous contracts that it has been awarded, Technip-Coflexip recently reached a settlement with Aker Maritime regarding the purchase of Aker Deep Water Company. Aker Maritime has agreed to pay the total sum of $43.8 million.
BRANDS/DIVISIONS/AFFILIATES: CRYOMAX RAR Technology DEA High Load FVR TEALARC Coflexip SA Aker Deep Water Co. Technip SA
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Daniel Valot, CEO Oliver DuBois, CFO Anne Decressac, Sr. VP-Human Resources Jean Deseilligny, Sr. Exec. VP-Oper., Onshore-Downstream Branch Jean Deseillingny, Sr. Exec. VP-Bus. Anne Decressac, Sr. VP-Comm. Daniel Burlin, Pres.-Onshore-Downstream Branch Ivan Replumaz, CEO-Offshore Branch Daniel Valot, Chmn.
Phone: 33-1-47782121 Fax: 33-1-47783340 Toll-Free: Address: La Defense 6-170, Place Henri Regnault, Paris La Defense Cedex, 92973 France
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: TKP 2001 Sales: $3,156,300 2001 Profits: $96,200 Employees: 18,000 2000 Sales: $2,798,400 2000 Profits: $201,700 Fiscal Year Ends: 12/31 1999 Sales: $2,801,500 1999 Profits: $174,200 1998 Sales: $2,154,700 1998 Profits: $123,000
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Engineering company with expertise in building for the petrochemical industry.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest:
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
TECHNITROL INC
www.technitrol.com
Industry Group Code: 334413 Ranks within this company's industry group: Sales:19 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:12
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Components-Electronic Electrical Contact Products
Technitrol, Inc. is a worldwide producer of electronic components, electrical contacts, assemblies and other precision-engineered parts and materials for manufacturers in the data networking, broadband/Internet access, telecommunications, computer and electrical equipment industries. The firm’s business is separated into two distinct markets: the electronic components segment, which operates under the name Pulse, and the electrical contact products segment, which operates under the name AMI Doduco. Pulse, an international leader in magnetic components for more than 40 years, designs and manufactures a wide variety of highly customized passive magnetics-based electronic components for use in the telecommunications, enterprise networking, power conversion, automotive, consumer electronics and military industries. AMI Doduco is a global leader in electrical contact technology and fabrication, servicing the appliance, automotive, building construction circuitry, electric power, commercial and industrial machinery and telephone equipment industries. Its products tend to have longer life cycles and are less susceptible to technological change, which allows customers to enjoy longer life cycle revenue streams. Both subsidiaries focus on the design, manufacture and marketing of critical components for use by original equipment manufacturers. The firm’s expansion into international markets is evident in Pulse’s recent introduction of two new asymmetric digital subscriber line splitters designed for Japan, the world’s fastest growing DSL market, and for specific use in European telephone networks.
BRANDS/DIVISIONS/AFFILIATES: Pulse Engineering, Inc. Pulse Specialty Components AMI Doduco, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. James M. Papada, III, CEO James M. Papada, III, Pres. David W. Lacey, VP-Human Resources Drew A. Moyer, Controller Drew A. Moyer, Corp. Sec. Ann Marie Janus, General Counsel David J. Stakun, VP-Corp. Comm. Thomas J. Considine, Jr., Treas. John L. Kowalski, Sr. VP/Pres., Pulse Albert Thorp, III, Sr. VP/CEO-AMI Doduco James M. Papada, III, Chmn.
Phone: 215-355-2900 Fax: 215-355-7397 Toll-Free: Address: 1210 Northbrook Dr., Ste. 385, Trevose, PA 19053 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $406,400 (12 months) 2002 Profits: $-43,500 (12 months) Stock Ticker: TNL 2001 Sales: $474,200 2001 Profits: $2,500 Employees: 19,000 2000 Sales: $664,400 2000 Profits: $99,300 Fiscal Year Ends: 12/31 1999 Sales: $530,436 1999 Profits: $44,312 1998 Sales: $448,539 1998 Profits: $33,309
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $525,300 Bonus: $1,743,200 Stock Purch. Plan: Y Second Exec. Salary: $294,015 Bonus: $822,300 ADVANTAGE: Custom engineered products designed to serve a worldwide base of manufacturers.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
TELEFLEX INC
www.teleflex.com
Industry Group Code: 335000 Ranks within this company's industry group: Sales:3 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Profits:3 Y Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Diversified Manufacturing General and Specialized Surgical Objects Automotive Products Marine Products Industrial Products and Services Medical Products and Equipment
Teleflex, Inc., formed to manufacture precision mechanical push/pull controls for military aircraft, currently operates in three business segments: commercial, medical and aerospace. The commercial segment designs and manufactures proprietary controls for the automotive and pleasure marine markets and fluid transfer products for industrial applications. The medical segment manufactures and distributes a broad range of invasive disposable and reusable devices for the urology, gastroenterology, anesthesiology and respiratory care markets. It also designs and manufactures a variety of specialty surgical products and provides instrument management services. The firm’s two major product lines within this segment are hospital supply products and surgical devices. The hospital supply division, operating as Rusch International, offers products such as catheters, endotracheal tubes, laryngoscopes, face masks, tracheostomy tubes and stents and precision tubing and wire products. The surgical devices division manufactures and distributes instruments used primarily in cardiovascular, ear, nose and throat and orthopedic procedures, as well as closure products, including ligation chips and skin staplers. Teleflex’s aerospace segment designs and manufactures cargo handling systems and containers for aviation and provides surface treatments, repair services and manufactured components for users of both flight and ground-based turbine engines. This segment primarily serves the commercial aerospace, power generation, industrial turbo-machinery and military markets. Recently, Teleflex acquired Megatech Electro, Inc., a designer and manufacturer of electronic and electrochemical products, and Beere Precision Medical Instruments, which provides surgical instrumentation for orthopedic procedures.
BRANDS/DIVISIONS/AFFILIATES: Rusch International Megatech Electro, Inc. Beere Precision Medical Instruments Morse Controls
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jeffrey P. Black, CEO Jeffrey P. Black, Pres. Harold L. Zuber, Jr., CFO Clark Handy, Exec. VP-Human Resources Stephen J. Gambone, Controller/Chief Acc. Officer Steven K. Chance, Corp. Sec. Steven K. Chance, General Counsel Kevin K. Gordon, VP-Corp. Dev. Julie McDowell, VP-Corp. Comm. C. Jeffrey Jacobs, Treas. Thomas M. Byrne, Asst. Treas. Joan Schwartz, Asst. General Counsel Lennox K. Black, Chmn.
Phone: 610-834-6301 Fax: 610-834-8228 Toll-Free: Address: 630 W. Germantown Pike, Ste. 450, Plymouth Meeting, PA 19462 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $2,076,200 (12 months) 2002 Profits: $125,300 (12 months) Stock Ticker: TFX 2001 Sales: $1,905,000 2001 Profits: $112,300 Employees: 18,100 2000 Sales: $1,764,500 2000 Profits: $109,200 Fiscal Year Ends: 12/31 1999 Sales: $1,601,100 1999 Profits: $95,200 1998 Sales: $1,437,600 1998 Profits: $82,600
SALARIES/BENEFITS: Pension Plan: Y Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $790,708 Stock Purch. Plan: Y Second Exec. Salary: $476,682 ADVANTAGE: Multifacited company/Aggressive pursiut of acquisitions.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $ Bonus: $250,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
TELEFON AB LM ERICSSON
www.ericsson.com
Industry Group Code: 334210 Ranks within this company's industry group: Sales:5 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:13
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Telecommunications Equipment Mobile Phones
Telefon AB LM Ericsson provides innovative mobile and broadband Internet solutions to communication companies around the world. The company’s solutions include network infrastructure, access equipment and terminals and application enablers. The firm markets its cell phones through a joint venture with Sony Corporation. Ericsson recently announced its creation of a new mobile messaging company, with assistance from Brainheart Capital. The new company, which is unnamed as yet, will sell mobile access to e-mail, voicemail, fax and other services. Ericsson will contribute technology from its successful messaging over IP platform. Moreover, the firm has introduced a new feature for its popular MD110 business communications system, which enables workers to use mobile phones as an extension of the company’s PBX. The new feature will allow users to use their mobile phones exactly as if they were office phones, with access to such functions as secretarial monitoring, direct dialing for customers and automatic callback.
BRANDS/DIVISIONS/AFFILIATES: CDMA2000 AAA Sony Ericsson Mobile Communications Ericsson Mobile Platforms MD110
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Carl-Henric Svanberg, CEO Per-Arne Sandstrom, COO Carl-Henric Svanberg, Pres. Karl-Henrik Sundstrom, CFO Torbjorn Nilsson, Sr. VP-Mktg. Britt Reigo, Sr. VP-Human Resources Jan Uddenfeldt, Sr. VP-Tech. Carl Olof Blomgvist, Sr. VP-Legal Affairs Torbjorn Nilsson, Sr. VP-Strategic Bus. Dev. Henry Stenson, Sr. VP-Corp. Comm. Bjorn Bostrom, Sr. VP-Supply Ragnar Back, Exec. VP-Asia Pacific Mats Dahlin, Exec. VP-Europe, Middle East, Africa Gerhard Weise, Exec. VP-Americas Michael Treschow, Chmn.
Phone: 46-8-719-0000 Fax: 46-8-18-40-85 Toll-Free: Address: Telefon AB LM Ericsson, Telefonvagen 30, Stockholm, SE-126 25 Sweden
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $16,808,000 (12 months) 2002 Profits: $-2,192,000 (12 months) Stock Ticker: ERICY 2001 Sales: $22,117,000 2001 Profits: $-2,029,000 Employees: 85,000 2000 Sales: $27,582,500 2000 Profits: $2,358,600 Fiscal Year Ends: 12/31 1999 Sales: $21,718,000 1999 Profits: $1,536,500 1998 Sales: $18,595,900 1998 Profits: $1,566,700
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: One of the world's largest makers of cellular phones and equipment.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
TELLABS INC
www.tellabs.com
Industry Group Code: 334210 Ranks within this company's industry group: Sales:10 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:10
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Telecommunications Equipment-Data, Video & Voice Transmission Voice Access Systems Optical Networking Equipment Systems Service and Support
Tellabs, Inc. designs, manufactures, markets and services optical networking, next-generation switching and broadband access solutions. The company’s Tellabs 5000, 6400, 6500 and 7000 families of digital crossconnect and optical networking systems enable service providers to deploy and optimize transport networks and dynamically manage bandwidth, ranging from individual voice channels to multiple waves of light. Broadband access systems include the Tellabs 2000 telephony distribution system, the Tellabs 6300 transport switching products and the Tellabs 8000 series of managed access systems. In addition, the company offers the Tellabs 3000 series of echo control and cancellation products. The company’s products are sold through a worldwide network of sales and distribution centers to independent telephone companies, interexchange carriers, original equipment manufacturers, cellular and other wireless service companies, cable operators, ISPs, systems integrators and government agencies. As part of its strategy to grow through the addition of new products, Tellabs operates Ocular Networks, a leader in next-generation optical solutions for the metropolitan market. This enables the firm to help service providers manage metropolitan traffic all the way to the edge of the network. Tellabs recently announced that Sprint selected the Tellabs 7100 optical transport system to enable the deployment of wavelengthbased services to local, long-distance and wireless customers. The 7100 system allows all wavelengths of light to be transported over a single pair of fiber, rather than having to reengineer the entire network every time a wavelength is added. Tellabs offers its employees onsite fitness centers, financial planning seminars, educational assistance and adoption assistance programs. Fortune Magazine ranked Tellabs as one of America's most admired companies within the telecommunications industry.
BRANDS/DIVISIONS/AFFILIATES: Ocular Networks
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Michael J. Birck, CEO Michael J. Birck, Pres. Michael C. Smiley, CFO/VP-Int'l Finance Robert W. Pullen, Sr. VP-North American Sales John C. Kohler, VP-Eng. Stephen M. McCarthy, Sr. VP-Oper. Michael C. Smiley, Treas. Thomas Gruenwald, VP-Oper., Tellabs Int'l Edward Kennedy, Exec. VP/Pres., Tellabs Operations, Inc. Michael J. Birck, Chmn. Anders Gustafsson, Pres.-Tellabs Int'l
Phone: 630-378-8800 Fax: 630-798-2000 Toll-Free: Address: 1415 W. Diehl Rd., Naperville, IL 60563 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,317,000 (12 months) 2002 Profits: $-313,100 (12 months) Stock Ticker: TLAB 2001 Sales: $2,199,700 2001 Profits: $-182,000 Employees: 4,828 2000 Sales: $3,387,400 2000 Profits: $730,800 Fiscal Year Ends: 12/31 1999 Sales: $2,319,498 1999 Profits: $559,120 1998 Sales: $1,704,210 1998 Profits: $396,120
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $556,733 Stock Purch. Plan: Second Exec. Salary: $414,992 ADVANTAGE: International contracts/ Acquisition of Ocular Networks.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $315,000 Bonus: $190,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
TERADYNE INC
www.teradyne.com
Industry Group Code: 334515 Ranks within this company's industry group: Sales:5 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:5
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Test Equipment-Semiconductor Performance High-Performance Backplane Assemblies and Connectors
Teradyne, Inc. is one of the world’s largest suppliers of automatic test equipment and software for the telecommunications and electronics industries and a leading supplier of high-performance backplane assemblies and connectors. In semiconductor testing, Teradyne is the only broadline supplier of test equipment for system-on-a-chip, analog, mixed-signal, memory and VLSI devices. In addition, the company is the world’s largest merchant supplier of telephone line test systems and one of the top two suppliers of backplane connection systems. RSW Software, the web-testing technology leader and a business unit of Teradyne, developed the industry’s first complete solution for testing wireless applications, e-TEST for WAP. Companies that require scalable and reliable wireless applications can utilize RSW’s e-TEST for WAP to perform functional testing, load testing and monitoring of applications that provide Internet access to wireless devices. The company holds a licensing agreement with Molex, Inc. under which Teradyne grants Molex the right to manufacture, market and sell the high-speed-differential version of the marketleading VHDM interconnect. The two companies work jointly to improve and enhance their respective production capabilities and insure customers of the intermateability and interchangeability of VHDM. Teradyne continues to develop improvements on existing technologies, as evident in its continuously expanding Optima 7000 Series of optical inspection systems. Teradyne’s presence in the international market has been greatly enhanced with the recent opening of a brand new facility in Shanghai, China. This facility will house testing systems for printed circuit boards and high-density connectors as well as backplane and complex system integration and test services. The company's major locations feature fitness centers as well as sports and social activities.
BRANDS/DIVISIONS/AFFILIATES: RSW Software Optima 7000 Series e-TEST for WAP
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. George W. Chamillard, CEO George W. Chamillard, Pres. Gregory W. Beecher, CFO Michael A. Bradley, Pres.-Semiconductor Test Div. Richard Schneider, Pres.-Connection Systems Div. John Casey, Pres.-Assembly Test Div. George W. Chamillard, Chmn.
Phone: 617-482-2700 Fax: 617-422-2910 Toll-Free: Address: 321 Harrison Ave., Boston, MA 02118 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,222,200 (12 months) 2002 Profits: $-718,500 (12 months) Stock Ticker: TER 2001 Sales: $1,440,600 2001 Profits: $-202,200 Employees: 7,200 2000 Sales: $3,043,900 2000 Profits: $453,600 Fiscal Year Ends: 12/31 1999 Sales: $1,790,912 1999 Profits: $191,694 1998 Sales: $1,489,151 1998 Profits: $102,117
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Stock Purch. Plan: Y ADVANTAGE: Largest firm in its field.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $616,850 Second Exec. Salary: $351,004
Bonus: $324,480 Bonus: $161,558
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
TERAYON COMMUNICATION SYSTEMS INCwww.terayon.com Industry Group Code: 334110 Ranks within this company's industry group: Sales:7 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:4
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Networking Equipment-Two-Way Data Transmission Digital Subscriber Line Systems
Terayon Communication Systems, Inc. (Terayon) provides broadband systems and solutions for the delivery of advanced voice, data and video services over cable, telecommunications and satellite networks. The company’s solutions enable its customers to use their current network architectures to deliver broadband services, which speeds market delivery and reduces the need for costly network upgrades. The firm’s CherryPicker digital video management system gives cable, satellite and telecommunications network operators increased choice, control and flexibility in managing their digital video content. CherryPicker provides statistical remultiplexing for highest channel efficiencies, customization of local digital program lineup, data injection and encapsulation and powerful variable-bit-rate compression. The company’s BandLeader product is an end-to-end voice over Internet protocol (VoIP) platform for cable operators to transport carrier-class voice services over large-scale hybrid fiber coax networks. BandLeader’s switched VoIP architecture allows operators to leverage current broadband infrastructures to simultaneously deliver telephony, data, video programming and other broadband networks via a cost-effective VoIP solution. Terayon and Siemens Atea jointly develop backbone IP solutions that provide enhanced, value-added voice and data services with end-to-end capabilities to ensure the highest level of performance. Consequently, Siemens Atea customers worldwide deploy the company’s HighLink routers, which provide bandwidth management, traffic prioritization, security, virtual private networking and routing capabilities. Terayon recently announced a restructuring plan to reduce operating costs and re-focus on its core products for cable operators. Terayon provides its workers with an employee assistance plan, flexible spending accounts and membership to a credit union. Moreover, the company sponsors billiards, bowling and miniature golf nights, walkathons, ice cream socials and other activities for its employees and their families.
BRANDS/DIVISIONS/AFFILIATES: CherryPicker HighLink BandLeader
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Zaki Rakib, CEO Shlomo Rakib, Pres. Arthur T. Taylor, CFO Peter Hung, VP-Corp. Mktg. Edward Lopez, Sr. VP-Human Resources Shlomo Rakib, Chief Tech. Officer Edward Lopez, General Counsel Gershon Schatzberg, Dir.-Oper. John Giddings, Sr. Mgr.-Media Rel.
Phone: 408-235-5500 Fax: 408-727-6204 Toll-Free: 866-483-7266 Address: 4988 Great America Pkwy., Santa Clara, CA 95054 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $129,400 (12 months) 2002 Profits: $-44,200 (12 months) Stock Ticker: TERN 2001 Sales: $279,500 2001 Profits: $-563,900 Employees: 487 2000 Sales: $339,500 2000 Profits: $-180,800 Fiscal Year Ends: 12/31 1999 Sales: $97,000 1999 Profits: $-64,100 1998 Sales: $31,700 1998 Profits: $-23,200
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $450,000 Stock Purch. Plan: Y Second Exec. Salary: $450,000 ADVANTAGE: Contracts with major cable firms such as Time Warner.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $105,000 Bonus: $79,800
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
TERRA INDUSTRIES INC
www.terraindustries.com
Industry Group Code: 325000 Ranks within this company's industry group: Sales:13 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:11
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Y Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Fertilizers-Nitrogen Methanol
Terra Industries, Inc. produces and markets nitrogen products in North America and the United Kingdom. The firm’s nitrogen manufacturing facilities produce ammonia, urea nitrogen solutions, urea and ammonium nitrate. The company’s nitrogen product customers include agricultural retail chains, farm cooperatives, independent dealers and industrial customers. Industrial customers use these products to manufacture chemicals and plastics such as acrylonitrile, polyurethanes, fibers, explosives and adhesives. Additionally, Terra Industries is a leading producer of methanol. The firm’s methanol customers are primarily large, domestic chemical or Methyl Tertiary Butyl Ether producers. Recently, Terra Industries resumed production at its Blytheville, Arkansas and Woodward, Oklahoma facilities due to a decrease in the price of natural gas. The company has entered into contracts with a number of electricity producers to provide approximately 25,000 tons of nitrogen in the form of anhydrous and aqua ammonia, urea and urea liquor. The increase in demand for these products is the result of an amendment to the Clean Air Act that requires fossil-fuel-based companies to install catalytic reduction equipment, which uses ammonia to reduce emissions of nitric oxides.
BRANDS/DIVISIONS/AFFILIATES: Terra Nitrogen Co.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Michael L. Bennett, CEO Michael L. Bennett, Pres. Francis G. Meyer, CFO W. Mark Rosenbury, Dir.-Human Resources Steven A. Savage, Sr. VP-Mfg. Mark A. Kalafut, Corp. Sec. Mark A. Kalafut, General Counsel W. Mark Rosenbury, Chief Admin. Officer Henry R. Slack, Chmn.
Phone: 712-277-1340 Fax: 712-277-7364 Toll-Free: Address: 600 4th St., Sioux City, IA 51101 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,042,400 (12 months) 2002 Profits: $-258,400 (12 months) Stock Ticker: TRA 2001 Sales: $1,032,600 2001 Profits: $-79,800 Employees: 1,207 2000 Sales: $1,001,158 2000 Profits: $-10,182 Fiscal Year Ends: 12/31 1999 Sales: $774,309 1999 Profits: $-89,887 1998 Sales: $845,551 1998 Profits: $-26,249
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Immense dealer network.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $375,000 Second Exec. Salary: $259,108
Bonus: $75,000 Bonus: $55,000
LOCATIONS: ("Y" = Yes) West:
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
TEXAS INSTRUMENTS INC
www.ti.com
Industry Group Code: 334413 Ranks within this company's industry group: Sales:2 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:17
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Chips-Digital Signal Processors Calculators Defense Electronics Products Notebook Computers Printers
Texas Instruments, Inc. is one of the world’s foremost high-technology companies, with sales and manufacturing operations in more than 30 countries. The company develops, manufactures and sells a variety of products in the commercial electronics and electrical industry, primarily for the industrial and consumer markets, including components, digital products and metallurgical materials. The company’s business is based principally on its broad semiconductor technology and application of this technology to digital solutions for the networked society. Texas Instruments’ goal is to be the center of the technology market so that every bit that is processed, every message that is communicated and every image that is projected will be reached through its technology. Furthermore, every connection in the networked society will be made through a digital signal processor (DSP), which is an exceptionally fast and smart semiconductor device. DSPs are the engines that drive the network in networked society, and Texas Instruments is the market leader in this technology. The company and TeraLogic, Inc. have a cooperative agreement to create digital consumer electronics devices. The platform being collaborated upon by the two firms would include an expandable solution for designing televisions, personal video recorders and digital set-top boxes. In addition the firm has an alliance with Microsoft Corporation to release integrated wireless solutions that deliver broadbandenabled wireless applications to consumers. E-commerce, mobile Internet access and corporate e-mail are provided with longer battery life. The company has also collaborated with Dolby Laboratories to design and develop system hardware that will allow consumers to connect PCs to home theater systems. The company has a casual dress policy and offers recreation, fitness and wellness programs. Additionally, Texas Instruments offers full tuition reimbursement and pays 100% of health insurance premiums.
BRANDS/DIVISIONS/AFFILIATES: Silicon Systems, Inc. Texas Instruments, Ltd. Texas Instruments Software, Ltd.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Thomas J. Engibous, CEO Richard K. Templeton, COO Thomas J. Engibous, Pres. William A. Aylesworth, Sr. VP/CFO Steve Leven, VP-Human Resources Joe Hubach, Corp. Sec. Joe Hubach, General Counsel Terri West, Sr. VP/Mgr.-Comm. Terri West, Sr. VP-Investor Rel. Phil Ritter, Sr. VP Thomas J. Engibous, Chmn.
Phone: 972-995-3773 Fax: 972-995-4360 Toll-Free: 800-336-5236 Address: 12500 TI Blvd., Dallas, TX 75266 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $8,383,000 (12 months) 2002 Profits: $-344,000 (12 months) Stock Ticker: TXN 2001 Sales: $8,201,000 2001 Profits: $-201,000 Employees: 34,589 2000 Sales: $11,875,000 2000 Profits: $3,058,000 Fiscal Year Ends: 12/31 1999 Sales: $9,468,000 1999 Profits: $1,406,000 1998 Sales: $8,617,000 1998 Profits: $416,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $840,000 Bonus: $500,000 Stock Purch. Plan: Y Second Exec. Salary: $600,000 Bonus: $350,000 ADVANTAGE: Diversified products/Superior technology/Large market share in components for wireless devices.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
THERAGENICS CORP
www.theragenics.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:34 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:29
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Implantable Radiation Devices
Theragenics Corp. is the manufacturer of TheraSeed, a rice-sized, FDA-cleared device used primarily in treating localized prostate cancer with a one-time, minimally invasive procedure. The biocompatible seeds emit radiation within the immediate prostate area, killing the tumor while sparing surrounding organs of significant radiation exposure. Theragenics is the world’s leading producer of Palladium-103, the radioactive isotope that supplies the therapeutic radiation for its TheraSeed implants. TheraSeed is utilized by physicians, hospitals and other health care providers located primarily in the United States. The product was previously sold through an exclusive distributor, but it is now sold directly to physicians and non-exclusive third-party distributors. The firm is also involved in the research and development of using the isotope for the treatment of macular degeneration and other diseases. The company recently initiated a clinical study of its Intravascular Brachytherapy System, which is designed to prevent restenosis following treatment of peripheral vascular disease by balloon angioplasty. Theragenics has acquired the IsoSeed business of BEBIG Isotopen-und Medizintechnik GmbH. IsoSeed is an iodine-based medical device used to treat prostate cancer. In the summer of 2002, Theragenics entered into a marketing alliance with Trace Sciences International, Inc., a supplier of enriched stable metal isotopes. Under the terms of the agreement, Trace Sciences performs global market development and limited sales activities to cultivate the unique capabilities of Theragenics’ plasma separation process technology. Theragenics offers employees medical, dental and life insurance, as well as an on-site wellness center.
BRANDS/DIVISIONS/AFFILIATES: TheraSeed Intravascular Brachytherapy System IsoSeed
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. M. Christine Jacobs, CEO M. Christine Jacobs, Pres. James A. MacLennan, CFO Karen Pfeifer, Dir.-Human Resources Bruce W. Smith, Exec. VP-Strategy and Dev. James A. MacLennan, Treas. Bruce W. Smith, Exec. VP-Acquisitions M. Christine Jacobs, Chmn.
Phone: 770-271-0233 Fax: 770-831-5294 Toll-Free: Address: 5203 Bristol Industrial Way, Buford, GA 30518 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $41,900 (12 months) 2002 Profits: $5,600 (12 months) Stock Ticker: TGX 2001 Sales: $50,000 2001 Profits: $15,100 Employees: 167 2000 Sales: $44,000 2000 Profits: $18,700 Fiscal Year Ends: 12/31 1999 Sales: $43,700 1999 Profits: $16,000 1998 Sales: $38,000 1998 Profits: $14,000
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $424,834 Bonus: $190,000 Stock Purch. Plan: Y Second Exec. Salary: $220,461 Bonus: $7,000 ADVANTAGE: Manufactures products for a type of prostate cancer therapy that is rapidly gaining popularity.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
THERMO ELECTRON CORP
www.thermo.com
Industry Group Code: 334515 Ranks within this company's industry group: Sales:2 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Measurement and Detection Equipment-Manufacturer Mammography Units General Purpose X-Ray Systems Alternative Energy Sources
Thermo Electron Corporation is a global leader in the development, manufacture and sale of technology-based instrument systems, components and solutions used in virtually every industry to monitor, collect and analyze data and provide knowledge to the user. For example, the firm’s analysis technologies help biotechnology researchers sift through data to make the discoveries that fight disease and prolong life. The company has recently completed a major reorganization, ultimately consisting of privatizing its public subsidiaries, selling its non-core businesses and spinning off its paper-recycling and medical products businesses. Thermo operates in three principal sectors: life sciences, optical technologies and measurement and control. The life sciences division addresses the biotechnology and pharmaceutical markets, as well as the clinical laboratory and health care industries, through four divisions: bioscience technologies, analytical instruments, informatics and clinical diagnostics. The optical technologies segment produces optical and semiconductor equipment systems that control and apply light for a variety of uses, including biomedical and telecommunications applications. The measurement and control segment provides a broad range of real-time, online sensors, monitors and control systems, including spectroscopy, process instruments and environmental instruments. In recent news, Thermo has acquired CRS Robotics, a global supplier of lab automation robotics, software and equipment to the drug-discovery market. In the spring of 2003, Thermo and Quest Diagnostics, Inc. developed CF Portrait, a biochip that detects cystic fibrosis gene mutations during parental screening.
BRANDS/DIVISIONS/AFFILIATES: CRS Robotics Corp. CF Portrait Thermo VG Scientific Thermo BioStar Thermo Polysonics Thermo PRISM
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Marijn E. Dekkers, CEO Marijn E. Dekkers, Pres. Theodose Melas-Kyriazi, CFO Daniel F. Kelly, VP-Mktg. Stephen G. Sheehan, VP-Human Resources Marc N. Casper, Pres., Life and Laboratory Sciences Peter E. Hornstra, Corp. Controller/Chief Acc. Officer Seth H. Hoogasian, Corp. Sec. Seth H. Hoogasian, General Counsel Peter M. Wilver, VP-Financial Oper. J. Timothy Corcoran, VP-Corp. Comm. J. Timothy Corcoran, VP-Investor Rel. Kenneth J. Apicerno, Treas. Barry S. Howe, Pres., Measurement and Control Guy Broadbent, Pres., Optical Technologies Thomas J. Burke, VP-Global Bus. Services Richard F. Syron, Exec. Chmn.
Phone: 781-622-1000 Fax: 781-622-1207 Toll-Free: Address: 81 Wyman St., Waltham, MA 02454-9046 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $2,086,400 (12 months) 2002 Profits: $309,700 (12 months) Stock Ticker: TMO 2001 Sales: $2,188,200 2001 Profits: $- 700 Employees: 10,900 2000 Sales: $2,280,500 2000 Profits: $-36,100 Fiscal Year Ends: 12/31 1999 Sales: $2,294,600 1999 Profits: $-174,600 1998 Sales: $1,880,900 1998 Profits: $181,900
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $800,000 Bonus: $741,600 Stock Purch. Plan: Y Second Exec. Salary: $533,333 Bonus: $430,000 ADVANTAGE: Great expertise in alternative energy/Leader in analytical instruments and bio-instrumentation.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
TITAN CORP (THE)
www.titan.com
Industry Group Code: 541512 Ranks within this company's industry group: Sales:5 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:8
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y Y
GROWTH PLANS/SPECIAL FEATURES:
Consulting-Government InfoTech Satellite Earth Station Networks Electronic Food Pasteurization E-Business Solutions Satellite Communication Systems Medical Equipment Sterilization
The Titan Corporation is a diversified technology company that creates, builds and launches technology-based businesses primarily from technology developed for the government. The group's core government business, Titan Systems, also provides government-funded research and development activities that generate intellectual property to form the foundation of new businesses and commercial technology applications. The company has supplemented its internal development portfolio through strategic acquisitions of other government companies. Titan is organized into the following business segments: Titan Systems, specializing in information technology (IT) and communications solutions, services and products for defense, intelligence and other agencies; Titan Wireless, specializing in satellite-based and wireless communication services and systems; Cayenta, a total services provider of IT services and software product applications for business and governmental functions; the emerging technologies and businesses unit, which develops commercial applications and businesses using Titan's technologies; and SureBeam, the firm's electronic food irradiation systems and services unit, which was recently spun off into a separate company. Titan Systems' services include design, architecture, installation, integration, testing, logistics support, maintenance, training and complete system upgrade. Titan commercial businesses currently in development or recently formed include Etenna Corp., LinCom Wireless, AverCom and Titan Scan Technologies. In recent news, the firm was awarded a $20 million contract by the U.S. Army Europe to provide support for the world's largest military automatic identification technology infrastructure. The company offers referral bonuses for employees.
BRANDS/DIVISIONS/AFFILIATES: Titan Systems Corp. Titan Wireless Cayenta Advanced Communication Systems, Inc. SureBeam Corp. Etenna Corp. Titan Scan Technologies Titan Secure Solutions
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Gene W. Ray, CEO Eric DeMarco, COO Eric DeMarco, Pres. Mark W. Sopp, Sr. VP/CFO Dianne Dyer, VP-Human Resources Tony Frederickson, Sr. VP/Pres.-Applied Tech. Sector Mike Paige, CIO/VP-Gov't Finance and Contracts Deanna J. Hom, VP/Corp. Controller Nicholas J. Costanza, Sr. VP/Corp. Sec. Nicholas J. Costanza, General Counsel Mary Jo Potts, VP-Admin. Paul Sullivan, Sr. VP-Bus. Dev. Ralph Williams, VP-Corp. Comm. Rochelle Bold, VP-Investor Rel. Mark W. Sopp, Treas. Brian Clark, VP-Strategic Transactions Bob Osterloh, Sr. VP/Pres.-Systems Integration Lawrence J. Delaney, Sr. VP/Pres.-Advanced Systems Dev. Chuck Saffell, Sr. VP/Nat'l Security Solutions
Phone: 619-552-9500 Fax: 619-552-9645 Toll-Free: Address: 3033 Science Park Rd., San Diego, CA 92121-1199 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,392,200 (12 months) 2002 Profits: $-271,400 (12 months) Stock Ticker: TTN 2001 Sales: $1,132,100 2001 Profits: $-98,600 Employees: 9,900 2000 Sales: $1,033,213 2000 Profits: $-18,728 Fiscal Year Ends: 12/31 1999 Sales: $809,139 1999 Profits: $37,757 1998 Sales: $411,180 1998 Profits: $-15,331
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Stock Purch. Plan: Y ADVANTAGE: Lucrative government contracts
OTHER THOUGHTS: Apparent Women Officers or Directors: 4 Hot Spot for Advancement for Women/Minorities: Y
Top Exec. Salary: $688,268 Second Exec. Salary: $438,734
Bonus: $560,000 Bonus: $260,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
TOYOTA MOTOR CORPORATION
www.toyota.co.jp/en
Industry Group Code: 336111 Ranks within this company's industry group: Sales:4 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Profits:2
Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Automobiles, Manufacturing Manufactured Housing Industrial Equipment Marine Equipment Telecommunications
Toyota Motor Corporation manufactures automobiles in 25 countries and regions throughout the world. The firm’s vehicles are sold in more than 160 countries and regions under the Toyota, Lexus, Daihatsu and Hino brands. In addition to its 12 plants in Japan, Toyota has 54 manufacturing companies in 27 countries, which produce Lexus and Toyota-brand vehicles and components. In terms of vehicles sold, Toyota is the world’s fourth largest automobile manufacturer. The firm's goal is to have a 15% global market share by 2010, up from about 10% in 2002. Toyota sold 1.7 million cars and trucks during 2002 in the U.S., its biggest market. Additionally, the firm operates a variety of other business segments. Lexus is the luxury vehicle division. Toyota has sold over 100,000 of its hybrid Prius compact, and it plans to increase sales to 300,000 hybrids yearly. A hybrid version of the popular Lexus RX 330 SUV will be on the market by 2005. Toyota's house manufacturing business is based on three prefabricated design units. This segment develops housing-related equipment that incorporates high-level technology. KDDI is a telecommunications enterprise that provides phone and Internet services in Japan and overseas. Toyota Financial Services Corporation was formed to streamline decision-making financial services for subsidiaries in Japan and overseas. GAZOO specializes in providing a visual vehicle information network via the Internet, as well as advanced e-commerce activities primarily through multi-media kiosks. Toyota also develops, produces and sells marine products and leverages its car-making expertise in the areas of engine and hull designs. In recent news, Toyota formed an alliance with China FAW Group Corporation in order to gain access to the potentially lucrative Chinese market. The company is also in the process of considering expansion into Russia, as well as Eastern and Central Europe. The firm has locations worldwide, including numerous offices and plants in North America. Corporate chief Cho is noted for listening to the concerns and ideas of employees at every opportunity.
BRANDS/DIVISIONS/AFFILIATES: Lexus Daihatsu Hino GAZOO Toyota Financial Services Corp. KDDI Prius
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Fujio Cho, Pres. Noritaka Shimuzu, Exec. VP Yoshio Uesaka, Exec. VP Akihiko Saito, Exec. VP Ryuji Araki, Exec. VP Hiroshi Okuda, Chmn.
Phone: 81-565-28-2121 Fax: 81-565-23-5800 Toll-Free: Address: 1 Toyota Cho, Toyota, Aichi Prefecture 471-8571 Japan
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $107,443,000 (12 months) 2002 Profits: $4,177,000 (12 months) Stock Ticker: TM 2001 Sales: $106,030,000 2001 Profits: $5,447,000 Employees: 246,702 2000 Sales: $119,656,000 2000 Profits: $4,540,000 Fiscal Year Ends: 3/31 1999 Sales: $101,086,900 1999 Profits: $3,598,500 1998 Sales: $93,109,300 1998 Profits: $3,481,300
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Exceptional technology base/Vast dealership network.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
TRANSKARYOTIC THERAPIES
www.tktx.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:76 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:92
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Anemia Gene Therapy
Transkaryotic Therapies, Inc. is a biopharmaceutical company that develops and commercializes products based on its three proprietary development platforms: gene-activated proteins, niche protein products and gene therapy. The firm’s gene activation technology is based on the activation of genes encoding therapeutic proteins in human cells, as opposed to the traditional methods of cloning and transferring these genes. This positions Transkaryotic to develop and potentially commercialize a large number of therapeutic proteins, including improved versions of many that are currently marketed. Transkaryotic’s niche protein product platform is focused on developing enzyme replacement products to treat patients suffering from certain lysosomal storage disorders and other diseases such as Fabry disease, Gaucher disease, Hunter Syndrome, Hurler Syndrome, Pompe disease and Tay-Sachs disease. The company’s gene therapy is a non-viral, ex vivo, cell-based system that is designed to genetically modify a patient’s own cells in order to produce and deliver therapeutic proteins within the body. Products currently under clinical development include Replagal enzyme replacement therapy, Dynepo Gene-Activated erythropoietin, I2S enzyme replacement therapy, Factor VIII gene therapy and A GA-II. In recent news, the European Commission expanded the summary of product characteristics for Transkaryotic’s Replagal enzyme replacement therapy for Fabry disease to include its use in females. This milestone achievement marks the first time any country has included females in the label of a product to treat Fabry Disease. In other news, Replagal received marketing authorization in Hungary and Slovakia and is now approved for commercial use in 25 countries worldwide. As of early April 2003, the firm was laying off 22% of its workforce after failing to get its drug Replagal approved in the U.S. by the FDA. The company provides its employees with reimbursement for health club memberships, discounts on eyewear and domestic partner coverage. Additionally, it offers an educational assistance program, transportation subsidies and new parent leave.
BRANDS/DIVISIONS/AFFILIATES: TKT Europe-5S AB Transkaryotic Therapy Dynepo Replagal Aventis Pharma A GA-II
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Richard F. Selden, CEO Richard F. Selden, Pres. Diane Sullivan, Dir.-Human Resources Douglas A. Treco, Sr. VP-Research and Dev. David D. Pendergast, Sr. VP-Quality William E. Aliski, VP-Health Services Renato Fuchs, Sr. VP-Mfg. Michael J. Astrue, General Counsel Michael J. Astrue, Sr. VP-Admin. Justine Koenigsberg, Dir.-Corp. Comm. Renato Fuchs, Sr. VP-Oper. Leanne Torrie, Mgr.-Patient Services
Phone: 617-349-0200 Fax: 617-613-4004 Toll-Free: Address: 700 Main St., Cambridge, MA 02139 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $36,500 (12 months) 2002 Profits: $-139,800 (12 months) Stock Ticker: TKTX 2001 Sales: $6,200 2001 Profits: $-70,200 Employees: 370 2000 Sales: $7,200 2000 Profits: $-51,000 Fiscal Year Ends: 12/31 1999 Sales: $3,900 1999 Profits: $-44,500 1998 Sales: $5,500 1998 Profits: $-20,000
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $400,000 Stock Purch. Plan: Second Exec. Salary: $285,000 ADVANTAGE: Expertise in gene activated proteins and niche protein products.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $150,000 Bonus: $100,000
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
TRC COMPANIES INC
www.trcsolutions.com
Industry Group Code: 230000 Ranks within this company's industry group: Sales:3 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Y Y
Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Construction Services Financial Risk Management Energy Services Infrastructure Services Security Services
TRC Companies, Inc. provides environmental, energy, infrastructure and infrastructure security services to companies in various industries, including health care, pipelines, railroads, government and independent power producers. The company also offers its clients technical, financial, risk management and construction services. TRC subsidiaries include TRC Cubix Corporation, TRC Lowney Associates, TRC Essex Environmental, TRC Novak Engineering, TRC Engineered Automation Systems, Inc., TRC Hunter Associates and TRC SITEBlauvelt. The company primarily focuses on infrastructure improvements and expansions, environmental management and information technology. TRC provides expertise in air quality consulting and engineering. The company has become the nation’s leading provider of Title V permitting assistance to U.S. industry, helping many Fortune 500 companies comply with the Clean Air Act Amendments of 1990. Similarly, the company is one of the leading providers of innovative and cost-effective hazardous waste services. The firm specializes in addressing the most complex or potentially costly remediation situations, isolating the real issues, effectively presenting a site hypothesis to agencies and eliminating unnecessary investigation or cleanup expenditures. In recent news, TRC was selected for four Exit Strategy contracts, valued at $27.4 million with a potential for $3 million in additional work. TRC will be responsible for the remediation and management of environmental conditions for New York City Waterfront Development, the cleanup of a maintenance facility in the Midwest, the Texas Natural Gas Plant sale and the beneficial use of a former landfill in the San Francisco Bay area.
BRANDS/DIVISIONS/AFFILIATES: TRC Essex Environmental TRC Cubix Corp. TRC Lowney Associates TRC Novak Engineering TRC Engineered Automation Systems, Inc. TRC Hunter Associates TRC SITE-Blauvelt
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Richard D. Ellison, CEO Richard D. Ellison, Pres. John W. Hohener, Sr. VP/CFO Martin H. Dodd, VP/General Counsel Miro Knezevic, Sr. VP-Western Region John H. Claussen, Sr. VP/Pres., TRC Environmental Corp. Glenn Harkness, Sr. VP-Energy Services Richard D. Ellison, Chmn.
Phone: 860-298-9692 Fax: 860-298-6291 Toll-Free: Address: 5 Waterside Crossing, Windsor, CT 06095 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $180,100 (12 months) 2002 Profits: $15,500 (12 months) Stock Ticker: TRR 2001 Sales: $124,200 2001 Profits: $9,000 Employees: 2,000 2000 Sales: $84,800 2000 Profits: $4,600 Fiscal Year Ends: 6/30 1999 Sales: $78,200 1999 Profits: $2,400 1998 Sales: $72,600 1998 Profits: $1,100
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $363,700 Stock Purch. Plan: Second Exec. Salary: $242,700 ADVANTAGE: Specialty in infrastructure improvements and expansions.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $64,100 Bonus: $215,900
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
TREVI-FINANZIARIA INDUSTRIALE SPA Industry Group Code: 541310 Ranks within this company's industry group: Sales:13 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Y Y
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
www.trevifin.com
Profits:10 Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Engineering Services-Ground Foundation, Tunneling and Drilling Machinery
Trevi-Finanziaria Industrial employs technology and searches for new solutions in order to cope with the complex problems affecting civil engineering worldwide. The company’s presence in the market is illustrated by the award of such projects as the foundation works for the Third Mainland Bridge of Lagos in Nigeria, the Alicura in Argentina, the Port of Bandar Abbas in Iran and the Khao dam in Thailand. Trevi-Finanziaria has focused its technology-based research efforts on developing more powerful and sophisticated equipment. Since its initial years of work in the field of special foundations, this focus has become a company strong point and has bolstered market success. As a result of the company’s innovation, Trevi-Finanziaria has become one of the most vital reference points at world level for the development of techniques relevant to foundations, excavations and soil consolidations. Consequently, the company has contributed to the transformation of one of the most ancient building activities of mankind, construction engineering, into one of the sectors with the highest technological content. In recent news, the company was awarded a contract for an environmental recovery plan for the industrial area of Cengio. The company will provide new walls for the factory in the restoration process.
BRANDS/DIVISIONS/AFFILIATES: Slim-Hole SOILMES S.p.A. PRETUNNEL TREVIPARK VIBROTREVI TREVIJET TREVI Contractors B.V. PROFURO INTERNATIONAL
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Davide Trevisani, Pres. Daniele Forte, CFO Oliviero Rossi, Mgr.-Personnel Federico Pagliacci, Mgr.-Research and Dev. Daniele Forti, Dir.-Admin. Gianluigi Trevisani, VP/Co-Managing Dir. Cesare Trevisani, Co-Managing Dir. Leonardo Biserna, Dir.-Foreign Department Daniele Vanni, Dir.-Domestic Department Davide Trevisani, Chmn.
Phone: 39-0547-319311 Fax: 39-0547-317395 Toll-Free: Address: Via Larga, 201, Cesena, 47023 Italy
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $391,557 (12 months) 2002 Profits: $-17,269 (12 months) Stock Ticker: TFI 2001 Sales: $327,500 2001 Profits: $ Employees: 2,445 2000 Sales: $253,398 2000 Profits: $ Fiscal Year Ends: 12/31 1999 Sales: $260,000 1999 Profits: $ 1998 Sales: $252,000 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Applies innovative technological solutions for civil engineering problems.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
TRIANGLE PHARMACEUTICALS
www.tripharm.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Viral Disease Specialty Pharmaceuticals
Triangle Pharmaceuticals develops new drug candidates primarily in the antiviral area, with a particular focus on therapies for HIV and AIDS and the hepatitis B virus. Its existing portfolio consists of several licensed drug candidates in clinical trials and others in preclinical stages. The company was founded based in part of its belief that the prolonged use of combination therapy will generate demand for new anti-HIV drugs with favorable activity, resistance, compliance and/or tolerance profiles. The company's HIV candidates are Coviracil, a nucleoside analog, and Amdoxovir, a purine dioxolane nucleoside. These products are in Phase II and III clinical studies. Triangle is also developing emtricitabine and clevudine to treat hepatitis B, currently in Phase II trials. In addition, the company has licensed immunostimulatory sequencing technology from Dynavax Technologies to study as a treatment for hepatitis B. Triangle's business strategy includes focusing on drug development over drug discovery; focusing on small-molecule drugs; and developing drugs for use in combination therapy. In recent news, the firm announced that it signed a definitive agreement to be acquired by Gilead Sciences, Inc. for the purchase price of $464 million.
BRANDS/DIVISIONS/AFFILIATES: Amdoxovir Coviracil Gilead Sciences, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Daniel G. Welch, CEO Chris A. Rallis, COO Chris A. Rallis, Pres. Robert F. Amundsen, Jr., CFO/Exec. VP Franck S. Rousseau, Exec. VP-Medical Affairs/Chief Medical Officer R. Andrew Finkle, Exec. VP/Corp. Sec. R. Andrew Finkle, General Counsel Paul A. Dreyer, Exec. VP-Commercial Oper. Anne F. McKay, VP-Drug Regulatory Affairs
Phone: 919-493-5980 Fax: 919-493-5925 Toll-Free: Address: 4 University Pl., 4611 University Dr., Durham, NC 27707 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $16,625 ( 9 months) 2002 Profits: $-17,775 ( 9 months) Stock Ticker: Subsidiary 2001 Sales: $5,800 2001 Profits: $-75,900 Employees: 115 2000 Sales: $7,294 2000 Profits: $-109,525 Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $-104,621 1998 Sales: $ 1998 Profits: $-67,271
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Developing new drugs to fight HIV.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $320,004 Second Exec. Salary: $308,196
Bonus: $100,000 Bonus: $90,055
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
TRIPOS INC
www.tripos.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:38 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:20
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Research-Pharmaceuticals Clinical Software Integrated Data Systems
Tripos, Inc. is a leading provider of bioinformatics software and discovery research and software consulting services to the pharmaceutical, biotechnology and agrochemical industries. The company’s approach to improving drug discovery provides a seamless pathway from disease target to validated drug candidate through a unique combination of core technologies. These include sophisticated software for molecular design and analysis, high-throughput chemical synthesis of designed chemical compounds and informatics consulting services that tightly integrate the entire discovery process. Recently, the company entered into a contract to provide its structureactivity relationship software, VolSurf, to Molecular Discovery, Ltd. Additionally, the firm has agreed to provide its SYBYL software to AstraZeneca in order to accelerate the creation of novel therapeutic agents. In the winter of 2002, the company introduced SYBYL 6.9, the latest version of its computational platform for drug design and discovery. This edition allows users to streamline optimization of lead compounds within a protein active site, design diverse but representative combinatorial libraries and perform rapid molecular electrostatic calculations. Additionally, the scientific modules available in SYBYL 6.9 enable users to compute topological index descriptors based on molecular structure. The firm has entered into a strategic collaboration with Pfizer, Inc. in order to expand Pfizer’s compound file collection. Under the terms of the agreement, the companies collaborate in library design and analysis, large-scale high-throughput synthesis and purification and analysis of compounds.
BRANDS/DIVISIONS/AFFILIATES: SYBYL VolSurf ChemSpace GeneFold LeadQuest UNITY MetaLayer ChemCore
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John P. McAlister, III, CEO John P. McAlister, III, Pres. B. James Rubin, CFO Elizabeth A. Holbrook, VP-Sales, North America and Pacific Rim David Summers, VP-Human Resources Richard D. Cramer, III, Chief Scientific Officer/Sr. VP-Science B. James Rubin, Corp. Sec. Mary P. Woodward, Sr. VP-Strategic Dev. Douglas A. Danne, Chief Commercial Officer Peter Hecht, Sr. VP-Discovery Research Oper. Paul L. Weber, Sr. VP-Software Consulting Services John D. Yingling, Chief Acc. Officer Ralph S. Lobdell, Chmn.
Phone: 314-647-1099 Fax: 314-647-9241 Toll-Free: 800-323-2960 Address: 1699 S. Hanley Rd., St. Louis, MO 63144-2913 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $51,100 (12 months) 2002 Profits: $ 900 (12 months) Stock Ticker: TRPS 2001 Sales: $49,100 2001 Profits: $5,900 Employees: 337 2000 Sales: $29,000 2000 Profits: $-2,100 Fiscal Year Ends: 12/31 1999 Sales: $27,200 1999 Profits: $-2,300 1998 Sales: $25,600 1998 Profits: $ 100
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Expertise in cheminformatics.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Top Exec. Salary: $312,500 Second Exec. Salary: $196,667
Bonus: $76,050 Bonus: $44,480
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
TULARIK INC
www.tularik.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:85 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:84
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Small Molecule
Tularik, Inc. is engaged in the discovery and development of a broad range of novel drugs that act through the regulation of gene expression. By resolving how genes are selectively turned on or off, and by recognizing the critical enzymes, regulatory proteins and transcription factors that control this process, the company seeks to develop orally administered, small-molecule drugs to treat a wide range of diseases caused by inappropriate gene expression. The firm’s two subsidiaries, German-based Tularik GmbH and Tularik Texas Corporation, place emphasis on the discovery and development of antibacterial and antifungal drugs. Tularik has established important alliances with Japan Tobacco, Inc., Roche Bioscience and Knoll AG. The firm recently earned a milestone payment from its corporate partner, Eli Lilly and Company. The payment is part of a multi-year collaboration established to design and optimize inhibitors of Factor Xa using Tularik's CAMD technology, as well as to investigate other potential anti-thrombotic targets. In other news, Tularik entered into a collaboration with Sankyo Company, Ltd. The two firms plan to jointly discover and develop human therapeutics that act on orphan G-protein coupled receptors. Tularik provides its employees with a tuition reimbursement program, domestic partner benefits, a casual dress code, subsidized childcare in a local preschool and an employee referral program. Additionally, the firm provides annual flu shots, on-site dry cleaning, commuting assistance, credit union membership, Costco membership and numerous social outings and events. The company also offers employees access to a subsidized cafeteria.
BRANDS/DIVISIONS/AFFILIATES: Tularik GmbH Tularik Texas Corporation CAMD Technology
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. David V. Goeddel, CEO Corinne H. Lyle, CFO Chris Smith, Dir.-Human Resources Michael D. Levy, Chief Medical Officer William Rieflin, General Counsel William Rieflin, Exec VP-Admin. Jack M. Anthony, Sr. VP-Bus. Dev. Pieter Timmermans, VP-Pharmacology Andrew J. Perlman, Exec. VP Terry J. Rosen, Exec. VP-Oper.
Phone: 650-825-7000 Fax: 650-825-7303 Toll-Free: Address: 2 Corporate Dr., South San Francisco, CA 94080 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $25,300 (12 months) 2002 Profits: $-93,800 (12 months) Stock Ticker: TLRK 2001 Sales: $32,600 2001 Profits: $-48,600 Employees: 430 2000 Sales: $25,500 2000 Profits: $-43,300 Fiscal Year Ends: 12/31 1999 Sales: $23,800 1999 Profits: $-25,500 1998 Sales: $21,400 1998 Profits: $-10,500
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $435,385 Stock Purch. Plan: Y Second Exec. Salary: $312,577 ADVANTAGE: Expertise in gene expression technology.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $115,296 Bonus: $25,971
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
UNISYS CORP
www.unisys.com
Industry Group Code: 541512 Ranks within this company's industry group: Sales:3 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:3
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y Y
GROWTH PLANS/SPECIAL FEATURES:
Consulting-Systems Integration & Technology Support Enterprise Systems and Servers Storage Products Security Solutions Servers System Middleware
Unisys Corp. is a worldwide information services and technology company providing business solutions that help customers, including commercial business and governments, utilize information technology. The firm operates in two business segments: services and technology. In the services segment, Unisys provides a range of solutions that include consulting and systems integration; outsourcing, such as management of internal information systems and business processes; network services involving the management and support of multivendor networks, desktops and servers; and security solutions to protect systems, networks, applications and data. Outsourcing and systems integration account for nearly 70% of the company's revenues. In the technology segment, the company develops servers and related products that operate in high-volume, mission-critical environments. Major offerings include enterprise-class servers based on cellular multi processing architecture (ES7000 servers) and Intel-based servers with enterpriseclass attributes (ClearPath servers), as well as system middleware, storage products, payment systems and specialized technologies. Unisys primarily serves markets including financial services, communications, transportation, media and the public sector. The firm offers its employees medical and dental benefits, flexible spending accounts, stock options, development opportunities, telecommuting, flex time, recreational facilities, employee discounts and a casual dress code.
BRANDS/DIVISIONS/AFFILIATES: ClearPath Enterprise ES7000 Server
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Lawrence A. Weinbach, CEO Lawrence A. Weinbach, Pres. Janet B. Haugen, Sr. VP/CFO Leigh Alexander, VP/Chief Mktg. Officer David O. Aker, Sr. VP-Human Resources Leo C. Daiuto, VP-Product Dev. and Tech. John C. Carrow, CIO Carol S. Sabochick, VP/Corp. Controller Nancy S. Sundheim, Sr. VP/Corp. Sec. Nancy S. Sundheim, General Counsel Richard D. Badler, Sr. VP-Corp. Comm. Jack F. McHale, VP-Investor Rel. Scott A. Battersby, VP/Treas. Joseph W. McGrath, Exec. VP/Pres.-Global Industries George R. Gazerwitz, Exec. VP/Pres.-Systems and Tech. Janet B. Wallace, Sr. VP/Pres.-Global Infrastructure Services Robert D. Evans, Sr. VP/Pres.-Global Outsourcing
Phone: 215-986-4011 Fax: 215-986-2312 Toll-Free: 800-874-8647 Address: Unisys Way, Blue Bell, PA 19424-0001 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $5,607,000 (12 months) 2002 Profits: $223,000 (12 months) Stock Ticker: UIS 2001 Sales: $6,018,000 2001 Profits: $-67,000 Employees: 36,400 2000 Sales: $6,885,000 2000 Profits: $225,000 Fiscal Year Ends: 12/31 1999 Sales: $7,544,600 1999 Profits: $510,700 1998 Sales: $7,243,900 1998 Profits: $376,400
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $1,320,000 Stock Purch. Plan: Y Second Exec. Salary: $491,679 ADVANTAGE: Large customer base/Offices in more than 100 companies.
OTHER THOUGHTS: Apparent Women Officers or Directors: 5 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $1,320,000 Bonus: $300,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
UNITED THERAPEUTICS CORP
www.unither.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:82 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:67
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Pulmonary Hypertension
United Therapeutics Corporation develops pharmaceuticals to treat vascular disease, including pulmonary hypertension and peripheral vascular disease, as well as certain other chronic conditions. The company’s lead product, Uniprost, is currently in pivotal Phase III clinical trials for advanced pulmonary hypertension. United Therapeutics has entered into a strategic alliance with Grupo Ferrer, a leading pharmaceutical company in Europe, for the distribution of Uniprost in Spain, France, Germany, Italy, Portugal, Greece, Belgium, Mexico and all countries in Latin America. In recent news, the Drug Registration Department of the Israeli Ministry of Health approved Remodulin Injection for the treatment of primary pulmonary arterial hypertension, as well as pulmonary arterial hypertension associated with connective tissue disorders. Approximately 25 patients are currently being treated with Remodulin in Israel. The product has also been approved by the U.S. FDA, as well as by the Canadian Therapeutics Products Directorate. United Therapeutics now intends to seek pricing approval for Remodulin from the Canadian provinces. Following approval of the product by the FDA, all four of the United States Medicare Durable Medical Equipment Regional Carriers recently issued policies and procedures allowing for the nationwide reimbursement of Remodulin Injection therapy. In addition to coverage for Remodulin, Medicare will also provide reimbursement for the related infusion pumps and supplies. Generally, Medicare-eligible patients with all forms of pulmonary arterial hypertension for which Remodulin is indicated will be covered under the new policies. In addition, United Therapeutics has submitted marketing applications for Remodulin in France, Switzerland and Australia, with additional European filings to follow approval in France.
BRANDS/DIVISIONS/AFFILIATES: Uniprost Beraprost Remodulin Synergy Unisense Unipeg Medicomp, Inc. Unither Pharmaceuticals, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Martine A. Rothblatt, CEO Roger Jeffs, COO Roger Jeffs, Pres. Fred T. Hadeed, CFO Paul A. Mahon, General Counsel Gilles Cloutier, Treas. Ricardo Balda, CEO, Medicomp, Inc. Barry Kanarek, CEO, Unither Pharmaceuticals David Walsh, Exec. VP-Production
Phone: 301-608-9292 Fax: 301-608-9291 Toll-Free: Address: 1110 Spring St., Silver Spring, MD 20910 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $30,100 (12 months) 2002 Profits: $-23,700 (12 months) Stock Ticker: UTHR 2001 Sales: $5,700 2001 Profits: $-37,300 Employees: 150 2000 Sales: $2,000 2000 Profits: $-75,600 Fiscal Year Ends: 12/31 1999 Sales: $ 400 1999 Profits: $-33,500 1998 Sales: $ 100 1998 Profits: $-12,800
SALARIES/BENEFITS: Pension Plan: Y Savings Plan:
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $192,308 Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Alliance with Grupo Ferrer opens European and Latin American distribution.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $7,046 Bonus: $
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
URS CORPORATION
www.urscorp.com
Industry Group Code: 541310 Ranks within this company's industry group: Sales:6 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Y Y Y
Profits:2
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Engineering Services Program and Construction Management
URS Corporation offers a broad range of planning, design, program and construction management services for transportation, hazardous waste, industrial processing, petrochemical and general building and water/wastewater projects. URS is organized into three divisions according to geographic region: the Americas, Asia/Pacific and Europe. The company is further organized into surface and rail transportation, air transportation, facilities, specialty services, industry, manufacturing, property development, state and local governments and air, water and environment businesses. The company has won many of the industry’s most distinguished awards and received numerous citations from clients for developing innovative engineering, planning, architectural and construction solutions. Recently, the company was ranked number one on Engineering News-Record’s list of the top 500 design firms. In other news, URS acquired EG&G Technical Services, a leading provider of technical operations and maintenance services to the United States government for homeland defense. URS provides full benefits for the entire family. Employees are eligible for health care benefits and enrollment in the company's flexible spending accounts immediately upon hire. The company also provides tuition reimbursement and a dependent care flexible spending account.
BRANDS/DIVISIONS/AFFILIATES: EG&G Technical Services
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Martin M. Koffel, CEO Kent P. Ainsworth, CFO Mark H. Perry, VP-Finance/Corp. Controller Randall A. Wotring, VP-Eng. and Tech. Services Div. Kent P. Ainsworth, Exec. VP/Corp. Sec. Joseph Masters, General Counsel Martin S. Tanzer, Exec. VP-Public Sector Bus. Dev. Susan B. Kilgannon, VP-Corp. Comm. David C. Nelson, Treas. George R. Melton, Pres.-EG&G Div. Irwin L. Rossenstein, Pres.-URS Div. Carol J. Brummerstedt, Asst. Sec. Lex N. Allen, VP-Aerospace Tech. Services Div. Martin M. Koffel, Chmn. James R. Miller, VP-Int'l Patrick G. Davidson, VP-Eng., Procurement and Construction Power
Phone: 415-774-2700 Fax: 415-398-1905 Toll-Free: Address: 1600 Montgomery St., 25 F, San Francisco, CA 941112727 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $2,427,800 (12 months) 2002 Profits: $55,200 (12 months) Stock Ticker: URS 2001 Sales: $2,319,400 2001 Profits: $57,900 Employees: 25,000 2000 Sales: $2,205,600 2000 Profits: $49,900 Fiscal Year Ends: 10/31 1999 Sales: $1,418,500 1999 Profits: $36,600 1998 Sales: $805,900 1998 Profits: $22,700
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $800,407 Bonus: $637,941 Stock Purch. Plan: Y Second Exec. Salary: $500,032 Bonus: $270,801 ADVANTAGE: Expertise in environmental engineering/Large number of multi-million dollar contracts.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
US LABORATORIES
www.uslaboratories.com
Industry Group Code: 541690 Ranks within this company's industry group: Sales: Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Y Y Y
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Laboratory Services-Environmental, Geotechnical and Structural Quality Control Services
U.S. Laboratories, a subsidiary of Bureau Veritas, provides quality control services to the construction, engineering and architectural design industries. The company offers services from conception to completion of a building project to verify that the project conforms to construction specifications. In other words, the company may analyze soil to determine whether it can hold a proposed structure, or examine the structural strength of concrete, masonry and steel materials to be used during construction. U.S. Laboratories' 10 subsidiaries include Professional Engineering and Inspection Co., U.S. Engineering Laboratories, Testing Engineers-San Diego, BTC Laboratories, Earth Consultants, Inc., Terra-Mar and Unitek Technical Services, Inc. Unitek was established to expand services on a national basis to energy-related companies including inspection and maintenance of power plants, pipelines, refineries and power transmission and distribution lines. The company’s clients include government agencies, real estate developers, construction managers, school districts and financial institutions.
BRANDS/DIVISIONS/AFFILIATES: Bureau Veritas U.S. Engineering Laboratories Earth Consultants, Inc. Professional Engineering and Inspection Co. Buena Engineers, Inc. BTC Laboratories, Inc. Unitek Technical Services, Inc. Robert W. Hunt Co.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Dickerson Wright, CEO Dickerson Wright, Pres. Joseph M. Wasilewski, CFO Donald C. Alford, Exec. VP/Sec. Mary Jo O'Brien, Investor Rel. Mark Baron, Exec. VP Martin B. Lowenthal, Exec. VP Dickerson Wright, Chmn.
Phone: 858-715-5800 Fax: 858-715-5810 Toll-Free: Address: 7895 Convoy Ct., Ste.18, San Diego, CA 92111 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $52,100 2001 Profits: $2,700 Employees: 700 2000 Sales: $35,200 2000 Profits: $1,700 Fiscal Year Ends: 12/31 1999 Sales: $16,400 1999 Profits: $ 700 1998 Sales: $11,900 1998 Profits: $ 600
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $251,530 Stock Purch. Plan: Second Exec. Salary: $201,199 ADVANTAGE: Profitable acquisitions/Soil and building materials testing.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $78,000 Bonus: $75,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
UTSTARCOM INC
www.utstarcom.com
Industry Group Code: 334210 Ranks within this company's industry group: Sales:13 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:5
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Telecommunications Equipment-Voice, Data & Broadband Internet Access Networking Wireline Network Access Systems
UTStarcom, Inc. designs, manufactures, markets and installs communications equipment for communications service providers that operate wireless and wireline networks. The company’s integrated suite of network access systems, optical transmission products and subscriber terminal products allows service providers to offer efficient and scalable voice, data and Internet access services. Customers can integrate UTStarcom’s standards-based systems into their existing networks or deploy the systems in new broadband, Internet protocol and wireless network rollouts. The firm’s primary market focus, China, has one of the fastest growing communications markets in the world. The company also targets other rapidly emerging markets in Asia and Latin America, including India, Vietnam, Taiwan, Thailand, Brazil, Mexico and Colombia. The UTStarcom AN-2000 broadband network solution is an integrated access platform that enables network migration from narrowband to broadband. The AN-2000 solution integrates the functions of access, DSL aggregation, transport, digital cross-connect and protocol conversion into one platform to deliver broadband as well as voice and data services to subscribers by way of copper, fiber or wireless transport. The UTStarcom PAS wireless network solutions enable network migration from wireline to wireless, allowing service providers to offer mobile wireless voice and data services within a city or community. The company’s mSwitch platform allows operators to seamlessly bridge the gap between existing circuit-switched network architectures and next-generation packet-switched architectures. UTStarcom continues to announce new deals; for example, the company recently announced a $50-million contract with China Netcom. UTStarcom offers its employees medical, dental and vision insurance and credit union membership.
BRANDS/DIVISIONS/AFFILIATES: AN-2000 PAS mSwitch
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Hong Liang Lu, CEO Hong Liang Lu, Pres. Michael J. Sophie, VP-Finance/CFO Dave Robison, VP-Int'l Mktg. and Sales Bill Huang, Chief Tech. Officer Howard Kwock, VP-Eng. Ying Wu, Exec. VP/CEO-UTS China Jerry Soloway, VP-Eng. Masayoshi Son, Chmn. Johnny Chou, Exec. VP/COO-UTS China
Phone: 510-864-8800 Fax: 510-864-8802 Toll-Free: Address: 1275 Harbor Bay Pkwy., Alameda, CA 94502 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $981,800 (12 months) 2002 Profits: $107,900 (12 months) Stock Ticker: UTSI 2001 Sales: $626,800 2001 Profits: $57,000 Employees: 3,277 2000 Sales: $368,646 2000 Profits: $27,993 Fiscal Year Ends: 12/31 1999 Sales: $187,516 1999 Profits: $11,463 1998 Sales: $105,167 1998 Profits: $- 300
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $280,000 Stock Purch. Plan: Y Second Exec. Salary: $230,000 ADVANTAGE: Powerful strategic alliances/Excellent history of profitable growth.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $140,000 Bonus: $115,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
VALLEN CORP
www.vallen.com
Industry Group Code: 333000 Ranks within this company's industry group: Sales: Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Machinery-Industrial Safety First-Aid Products
A subsidiary of Netherlands-based Hagemeyer, Vallen Corporation is engaged in providing safety products and related services to consumers, including total safety solutions programs in customers’ working environments. The manufacturing facilities in the company’s subsidiary, Encon Safety Products, Inc., produce a variety of safety products and other products for industrial and commercial applications, including a broad line of non-prescription safety eyewear distributed throughout North and South America. EVallen.com is a comprehensive, Internetbased electronic catalog, designed to provide an alternative solution for customer access to its wide variety of safety and other MRO products and related services. In an attempt to add complementary service capability in geographic areas served by Vallen’s existing safety product and service center locations, the company acquired Augusta Automatic Fire Systems and Equipment, Inc. of Augusta, Georgia. The company is also involved in a joint venture with Lion Apparel, Inc. of Dayton, Ohio, in order to receive a Virtual Prime Vendor contract from the Department of Defense’s Defense Supply Center Philadelphia (DSCP). The contract dictates that the companies will manage a procurement, inventory logistics and distribution program for military recruit clothing items for some 2,000 ordering locations in the southeast United States.
BRANDS/DIVISIONS/AFFILIATES: Hagemeyer N.V. Corp. Vallen Technical Services Encon Safety Products, Inc. Vallen Knowledge Systems Vallen Fire Services EVallen.com Augusta Automatic Fire Systems and Equipment, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Richard Harrison, CEO Richard Harrison, Pres. Ken Bourne, VP-Finance Jeff Whetzel, VP-Mktg. Cristal Ptasinski, VP-Human Resources Larry Scott, CIO Ken Bourne, Corp. Sec. James Wilson, VP-Oper. Jeff Whetzel, VP-Bus. Dev. Ken Bourne, Treas. Robin R. Hutton, Exec. VP-Sales
Phone: 281-500-4500 Fax: 281-500-4592 Toll-Free: 800-482-5536 Address: 521 N. Sam Houston Pkwy. E., Ste. 300, Houston, TX 77060 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $270,000 2001 Profits: $ Employees: 1,000 2000 Sales: $ 2000 Profits: $ Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $ Bonus: $ Stock Purch. Plan: Second Exec. Salary: $ Bonus: $ ADVANTAGE: A leading manufacturer and distributor of health, safety and maintenance products and services.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
VARIAN MEDICAL SYSTEMS INC
www.varian.com/vms
Industry Group Code: 339113 Ranks within this company's industry group: Sales:18 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:15
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Equipment-Integrated Radiotherapy Systems X-Ray Equipment Radiation Therapy Software
Varian Medical Systems, Inc. is one of the world’s leading manufacturers of integrated radiotherapy systems for treating cancer with radiation, as well as high-quality, costeffective x-ray tubes for original equipment manufacturers, replacement X-ray tubes and imaging subsystems. In addition to medical equipment, the company develops software products and devices designed to enhance the productivity and quality of its equipment, devices manufactured by other companies and the general delivery of health care services. Products can be broadly classified into three principal categories: oncology systems; x-ray products, including x-ray tubes and imaging subsystems; and brachytherapy and other technologies developed by the firm's Ginzton Technology Center (GTC). The oncology systems business designs, manufactures, sells and services hardware and software products for radiation treatment of cancer. Products include linear accelerators and accessories, treatment simulators and treatment verification products as well as software systems for planning cancer treatments and managing information and images for radiation oncology. Its Clinac series of medical linear accelerators is used to treat cancer by producing therapeutic electrons and x-rays in shaped radiation beams that target tumors and other abnormalities in a patient. The Millennium series of multileaf collimators are devices that are used with a linear accelerator to define the size, shape and intensity of the radiation beams generated by the linear accelerator. Varian also manufactures and sells an electronic portal imaging product, PortalVision, which is used to verify a patient’s treatment position, a critical component for accurate delivery of radiotherapy treatment. In recent news, Varian acquired Argus Software and its line of software products for the management of quality control data for radiation therapy products. In adddition, GTC recently managed the manufacturing and sale of the company’s products for the growing brachytherapy market, including its high-dose-rate brachytherapy afterloader, VariSource, and its brachytherapy treatment planning products, BrachyVision and VariSeed.
BRANDS/DIVISIONS/AFFILIATES: Clinac Series Argus Software, Inc. BrachyVision Millennium Series VariSource Ginzton Technology Center PortalVision VariSeed
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Richard M. Levy, CEO Garry W. Rogerson, COO Richard M. Levy, Pres. Elisha M. Finney, Corp. VP/CFO Michael S. Klein, VP-Sales and Mktg. Jack McCarthy, VP-Human Resources George A. Zdasiuk, VP-Ginzton Technology Center Duane A. Walstrom, Corp. Controller Joseph B. Phair, Corp. Sec. Joseph B. Phair, General Counsel Joseph B. Phair, Corp. VP-Admin. John A. Thorson, II, VP-Bus. Dev. Kate M. Smith, Treas. Timothy E. Guertin, Corp. VP John C. Ford, Corp. VP Robert H. Kluge, Corp. VP Richard M. Levy, Chmn.
Phone: 650-493-4000 Fax: 650-842-5196 Toll-Free: Address: 3100 Hansen Way, Palo Alto, CA 94304-1038 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $873,100 (12 months) 2002 Profits: $93,600 (12 months) Stock Ticker: VAR 2001 Sales: $773,600 2001 Profits: $54,300 Employees: 2,574 2000 Sales: $689,700 2000 Profits: $53,000 Fiscal Year Ends: 9/30 1999 Sales: $590,400 1999 Profits: $-24,200 1998 Sales: $541,500 1998 Profits: $73,800
SALARIES/BENEFITS: Pension Plan: Y Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Stock Purch. Plan: ADVANTAGE: Strength in imaging technology.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Top Exec. Salary: $723,112 Second Exec. Salary: $354,836
Bonus: $1,443,835 Bonus: $771,684
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
VERISIGN INC
www.verisign.com
Industry Group Code: 511200 Ranks within this company's industry group: Sales:16 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:38
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Computer Software-Secure Digital IDs Internet Domain Registration Web Server Certificates Payment Services Managed Public Key Infrastructure Managed Digital Certificates
VeriSign, Inc. is a leading provider of digital trust services that enable web site owners, enterprises, communications service providers, e-commerce service providers and individuals to engage in secure digital commerce and communications. The firm’s digital trust services include three core offerings: managed security and network services; registry and telecommunications services; and web presence and trust services. The company provides the critical web identity, authentication and transaction infrastructure that online businesses need to establish web identities and to conduct secure e-commerce and communications. VeriSign provides services to support businesses and consumers from the moment they establish an Internet presence through the entire lifecycle of e-commerce activities. The mass markets division of the firm focuses on delivering products and services to small and mid-sized enterprises, as well as consumers who wish to establish a web presence. The enterprise and service provider division focuses on delivering products and services to larger enterprises and service providers worldwide. Verisign’s acquisition of Network Solutions, a domain name registrar, enabled the company to offer a database of approximately 27.3 million .com, .net and .org web addresses. Notably, Network Solutions was the sole provider of domain names at the onset of Internet popularity. Service offerings also include GreatDomains.com, a marketplace to transfer and appraise domain names. Enterprise services include traditional public key infrastructure as well as enterprise naming and business-to-business payment services. VeriSign's employees can individualize their basic benefits packages. Benefits include risk management programs, flexible spending accounts, tuition reimbursement, health club reimbursement, referral bonuses, ergonomics consultation and subsidized beverages and snacks.
BRANDS/DIVISIONS/AFFILIATES: GreatDomains.com Secure Site Plus Payflow Link Payflow Pro VeriSign OnSite Go Secure! Network Solutions
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Stratton D. Sclavos, CEO Stratton D. Sclavos, Pres. Dana L. Evan, Exec. VP/CFO Bill Fasig, Sr. VP-Corp. Mktg. Barry Anderson, Sr. VP-Human Resources Robert J. Korzeniewski, Exec. VP-Corp. and Bus. Dev. Quentin P. Gallivan, Exec. VP-Worldwide Sales Judy Lin, Exec. VP-Security Services W.G. Champion Mitchell, Pres., Network Solutions Anil H.P. Pereira, Exec. VP Stratton D. Sclavos, Chmn.
Phone: 650-961-7500 Fax: 650-961-7300 Toll-Free: 888-847-2747 Address: 487 E. Middlefield Rd., Mountain View, CA 94043 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,221,700 (12 months) 2002 Profits: $-4,961,300 (12 months) Stock Ticker: VRSN 2001 Sales: $983,600 2001 Profits: $-13,356,000 Employees: 3,200 2000 Sales: $474,766 2000 Profits: $-3,115,474 Fiscal Year Ends: 12/31 1999 Sales: $84,776 1999 Profits: $3,955 1998 Sales: $38,930 1998 Profits: $-19,743
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $329,712 Stock Purch. Plan: Y Second Exec. Salary: $294,797 ADVANTAGE: A leading name in online transaction security.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $150,000 Bonus: $61,776
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
VERTEX PHARMACEUTICALS INC
www.vpharm.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:48 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:88
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Viral Disease Small-Molecule Drugs Inflammatory Disease Treatments Neurological Disorder Treatments
Vertex Pharmaceuticals, Inc. is a global biotechnology firm that discovers, develops and markets small-molecule drugs that address major unmet medical needs. Currently, the company has 15 product candidates in clinical development to treat viral diseases, inflammation, cancer, autoimmune and inflammatory diseases, neurological disorders and genetic diseases. Vertex has discovered and advanced an HIV protease inhibitor, Agenerase, to market. Another product, VX-175, currently has a new drug application pending with the U.S. FDA. The company is focusing internal development efforts on five major programs: VX-148, a second-generation IMPDH inhibitor for the treatment of psoriasis; VX-702, a secondgeneration p38 MAP kinase inhibitor for the treatment of acute and chronic inflammatory diseases; VX-563, a small-molecule modulator of gene expression with potential application in genetic disorders; VX-765, a second-generation ICE inhibitor for chronic and acute inflammatory diseases; and VX-950, a small-molecule inhibitor of hepatitis C virus protease. The company is involved in collaborations with Aventis, GlaxoSmithKline, Kissei, Novartis, Schering AG, Serono and other companies. In recent news, the company sold the products and technology rights of its PanVera subsidiary to Invitrogen. The company provides employees with tuition reimbursement and an educational seminar series.
BRANDS/DIVISIONS/AFFILIATES: Agenerase VX-175 VX-148 VX-702 VX-563 VX-765 VX-950
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Joshua S. Boger, CEO Vicki L. Sato, Pres. Ian F. Smith, VP/CFO Kenneth S. Boger, Sr. VP/General Counsel Lynne H. Brum, VP-Corp. Dev. Lynne H. Brum, VP-Corp. Comm. John J. Alam, Sr. VP-Drug Evaluation and Approval Thierry Hercend, VP-Research, Europe N. Anthony Coles, Sr. VP-Commercial Oper. Iain P.M. Buchanan, VP-European Oper. Joshua S. Boger, Chmn.
Phone: 617-444-6100 Fax: 617-444-6680 Toll-Free: Address: 130 Waverly St., Cambridge, MA 02139-4242 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $161,100 (12 months) 2002 Profits: $-108,600 (12 months) Stock Ticker: VRTX 2001 Sales: $167,500 2001 Profits: $-66,300 Employees: 980 2000 Sales: $78,127 2000 Profits: $-39,700 Fiscal Year Ends: 12/31 1999 Sales: $50,560 1999 Profits: $-41,000 1998 Sales: $29,055 1998 Profits: $-33,100
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $509,622 Bonus: $175,000 Stock Purch. Plan: Y Second Exec. Salary: $428,081 Bonus: $147,000 ADVANTAGE: A leader in the use of structure-based drug design/Powerful approach to pharmaceutical discovery.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
VINCI
www.vinci.com
Industry Group Code: 541310 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Y Y Y Y
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Building and Civil Engineering Services Infrastructure Management
VINCI Group, one of the largest construction and related services companies worldwide, is comprised of four major divisions: VINCI Concessions, VINCI Energies, VINCI Routes and VINCI Construction. VINCI Concessions is engaged in the design, turnkey construction, financing and operation of facilities, as well as outsourced infrastructure management, managing road infrastructures, car parks, large structures, airports and airport support services. Subsidiaries include Cofiroute, VINCI Park and VINCI Airports. The division also operates the Stade de France stadium near Paris. VINCI Energies, formerly GTIE, is a leading European producer of information and energy technologies, optimizing manufacturing equipment and developing equipment for living and working areas and communication infrastructure, networks and services for businesses, local authorities and operators. VINCI Routes, through Eurovia, is the leading European company in the road industry and in recycled materials, operating in roadworks, materials production and environment-related activities. VINCI Construction is an industry leader in building, civil engineering, hydraulics and facilities management. The division is composed of six main entities: VINCI Construction, VINCI Construction Grands Projets, VINCI Construction Filiales Internationales, Sogea Construction, Freyssinet and an entity comprised of the U.K., German and U.S. subsidiaries. Recently, the group became the first major partner of France’s Ministry of Cultural Heritage when the company agreed to restore the Chateau de Versailles Hall of Mirrors. The agreement ushers in the largest cultural sponsorship project ever undertaken in France.
BRANDS/DIVISIONS/AFFILIATES: VINCI Construction VINCI Concessions VINCI Energies VINCI Routes VINCI Park VINCI Airports Cofiroute Eurovia
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Antoine Zacharias, CEO Bernard Huvelin, Co-COO Christian Laberyrie, VP/CFO Pierre Coppey, VP-Human Resources and Synergies Pierre Coppey, VP-Corp. Comm. Xavier Huillard, Co-COO/CEO, VINCI Energies Roger Martin, Co-COO/CEO, VINCI Roads Dario d'Annunzio, CEO, VINCI Concessions Philippe Ratynski, CEO, VINCI Construction Antoine Zacharias, Chmn.
Phone: 33-147-16-35-00 Fax: 33-147-51-91-02 Toll-Free: Address: 1 cours Ferdinand-de-Lesseps, Rueil-Malmaison Cedex, 92851 France
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $18,423,000 (12 months) 2002 Profits: $ (12 months) Stock Ticker: DG 2001 Sales: $16,118,110 2001 Profits: $401,700 Employees: 129,000 2000 Sales: $12,626,632 2000 Profits: $282,290 Fiscal Year Ends: 12/31 1999 Sales: $8,088,200 1999 Profits: $156,100 1998 Sales: $8,030,300 1998 Profits: $75,800
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: One of the world's largest diversified engineering services and construction firms.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
VIRBAC INC
www.virbac.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:57 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:47
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Animal Health & Pet Care
Virbac is a pharmaceutical company devoted exclusively to veterinary drugs. The company was created in 1999 when the U.S. subsidiary of French veterinary products maker Virbac SA and Agri-Nutrition Group, a former Purina Mills division, finalized a merger agreement. The veterinary pharmaceutical market is divided into two segments: companion animals (household pets) and foodproducing animals (cattle, sheep, poultry and pigs). As a leader in dermatological and oral hygiene products for pets and companion animals, Virbac offers a broad array of health care products to its clients under the C.E.T., Allerderm, St. JON, Zema and Francodex brand names. The company has subsidiaries in 23 countries and production units located in France, the U.S., Australia, Mexico, Brazil and Vietnam. Additionally, Virbac maintains research facilities in France, the U.S., Mexico and Australia. The firm recently reported double-digit growth in its companion animal business. The increase was driven by the successful penetration of new strategic products, including Iverhart (a canine parasiticide) in the U.S., Equimax (an equine parasiticide) in the U.K. and Virbagen Omega (interferon for companion animals) in Europe. The company’s food-producing animal business achieved a lower growth rate mainly because of Virbac’s decision to reduce its presence in the Brazilian market to avoid exposure to economic and monetary risks. Other strongly performing products include the cat vaccine Leucogen, the dog parasiticide Preventic and Suramox, an antibiotic for pigs and poultry. International sales currently represent approximately 75% of the firm’s total sales. In other news, American subsidiary Virbac Corp. recently received FDA approval for Equell Paste, an equine anthelmintic product.
BRANDS/DIVISIONS/AFFILIATES: Iverhart Equimax C.E.T. Dental Products Virbagen Omega Zema Equell Francodex Virbac Corp.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Eric Marée, CEO Pierre Pagès, COO Eric Marée, Pres. Michel Garaudet, CFO Carole Buys-Michela, Mgr.-Human Resources Sophie Favini, VP-Corp. Comm. Christian Karst, Exec. VP Jean-Pierre Dick, VP Thomas L. Bell, CEO, Virbac USA Joseph A. Rougraff, CFO, Virbac USA
Phone: 817-831-5030 Fax: 817-831-8327 Toll-Free: Address: 3200 Meacham Blvd., Fort Worth, TX 76137 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $63,800 (12 months) 2002 Profits: $3,400 (12 months) Stock Ticker: VBAC 2001 Sales: $60,600 2001 Profits: $1,300 Employees: 278 2000 Sales: $53,000 2000 Profits: $2,900 Fiscal Year Ends: 10/31 1999 Sales: $43,717 1999 Profits: $- 543 1998 Sales: $15,051 1998 Profits: $-1,821
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $195,000 Stock Purch. Plan: Second Exec. Salary: $170,000 ADVANTAGE: Gaining a strong position in the veterinarian drug market.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $19,500 Bonus: $9,734
LOCATIONS: ("Y" = Yes) West:
Southwest: Y
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
VIROLOGIC INC
www.virologic.com
Industry Group Code: 325413 Ranks within this company's industry group: Sales:7 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:12
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Diagnostics-Viruses
Virologic, Inc. is a biotechnology company that develops and markets innovative products to guide and enhance treatment of viral diseases. The company’s proprietary technology, PhenoSense, is used to test drug resistance in viruses that cause serious diseases, such as AIDS, hepatitis B and hepatitis C. PhenoSense HIV, the company’s initial product, is a test that directly and quantitatively measures resistance of a patient’s HIV to anti-viral drugs. Also, PhenoSense HIV bypasses the need to interpret genotypic mutation patterns, which is the typical, indirect method of evaluating drug resistance. Additional technologies that the firm has developed to assess drug resistance among a number of anti-retroviral therapies include GeneSeq and PhenoScreen. Virologic recently signed a preferred provider agreement with Pfizer for HIV resistance testing technology and services to support Pfizer's HIV drug discovery and development programs. In other news, the firm and Surveillance Data, Inc. signed an agreement to create a new line of HIV market research products based on data collected through Virologic's HIV resistance testing and therapy guidance business. The new products will allow both pharmaceutical and biotech companies to purchase data on drug resistance trends and demographics. Benefits are available to all employees who work for more than 20 hours per week, as well as their domestic partners. Virologic provides dental and vision insurance, transportation assistance, education reimbursement, an employee assistance plan, credit union membership and a business causal environment. Additionally, the company offers its employees a performance bonus plan as well as spot bonuses.
BRANDS/DIVISIONS/AFFILIATES: PhenoSense HIV PhenoSense Assays Therapy Guidance System GeneSeq PhenoScreen
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. William D. Young, CEO Martin H. Goldstein, Pres. Karen J. Wilson, CFO Tien Bui, VP-Sales Patricia A. Wray, VP-Human Resources Nicholas S. Hellmann, VP-Clinical Research Frank Barker, CIO/VP-IT Kathy L. Hibbs, General Counsel Sidney S. Ho, Dir.-Public Affairs Christos J. Petropoulos, VP-Research and Dev. Karen E. Hartwig, VP-Mktg.
Phone: 650-635-1100 Fax: 650-635-1111 Toll-Free: Address: 345 Oyster Point Blvd., South San Francisco, CA 94080 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $25,300 (12 months) 2002 Profits: $-21,800 (12 months) Stock Ticker: VLGC 2001 Sales: $18,300 2001 Profits: $-26,200 Employees: 170 2000 Sales: $7,500 2000 Profits: $-23,200 Fiscal Year Ends: 12/31 1999 Sales: $1,100 1999 Profits: $-17,100 1998 Sales: $ 100 1998 Profits: $-8,100
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: PhenoSense technology.
OTHER THOUGHTS: Apparent Women Officers or Directors: 4 Hot Spot for Advancement for Women/Minorities: Y
Top Exec. Salary: $330,000 Second Exec. Salary: $210,000
Bonus: $35,000 Bonus: $30,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
VISTEON CORPORATION
www.visteon.com
Industry Group Code: 336390 Ranks within this company's industry group: Sales:2 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Profits:3
Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Automobile Parts Manufacturer Climate Control Products Multimedia Systems Powertrain Products Fuel Storage and Delivery Products Glass Products
Visteon Corp. is a leading global supplier of automotive systems, modules and components sold primarily to global vehicle manufacturers as well as to the worldwide aftermarket for replacement and appearance enhancement parts. The firm, based in Michigan, maintains regional headquarters and other facilities in 25 countries throughout the world. Formerly a subsidiary of Ford Motor Company, Visteon completed its spin-off in mid-2000. The company is divided into two operating segments, automotive operations and glass operations. Automotive operations include climate control products, interior and exterior components, energy transformation systems, chassis and multimedia systems and modules. These products include heating and air conditioning systems, powertrain systems, fuel storage and delivery products, steering and chassis components, cockpit modules, seating, trim and lighting, bumpers, in-vehicle entertainment, navigation and communication systems and safety and security electronics. The firm's glass operations are composed of the vehicle glazing products group, which includes glass products for Ford and aftermarket customers, and the commercial glass product group, which produces float glass for commercial architecture. Visteon's largest customer is Ford, accounting for more than 80% of total sales. Other major customers include Mazda Motor Corp. and other large vehicle manufacturers. Recently, the firm partnered with Sony to bring consumer electronics into the original equipment environment, combining sound management capability with vehicle integration expertise. Visteon also recently formed a strategic partnership with SmarTire Systems, Inc. to market advanced tire pressure monitoring systems. Visteon offers its employees health, dental, prescription drug and life insurance plans, an investment plan, lump sum death benefits, tuition assistance, flexible work schedules and a vehicle purchase plan.
BRANDS/DIVISIONS/AFFILIATES: Ford Motor Company
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Peter J. Pestillo, CEO Michael Johnston, COO Michael Johnston, Pres. Daniel Coulson, Exec. VP/CFO Julie Fream, VP-Mktg. Lorie Buckingham, VP/CIO Philip Pfefferle, VP/Controller Stacy Fox, Sr. VP/General Counsel Thomas Burke, VP-North American and Asia Oper. Marge Sorge, Dir.-Corp. Comm. Robert Marcin, Sr. VP-Corp. Rel. Mary Winston, VP/Treas. David Doster, VP-Alliances and Associations Gregory Gyllstrom, VP/Mgr.-Aftermarket Wilfried Janke, VP-Volkswagen, BMW and DaimlerChrysler Accounts John Kill, VP-Product Dev. Peter J. Pestillo, Chmn. Robert Pallash, VP/Mgr.-Asia
Phone: 313-755-2800 Fax: Toll-Free: 800-847-8366 Address: 17000 Rotunda Dr., Dearborn, MI 48121 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $18,395,000 (12 months) 2002 Profits: $-352,000 (12 months) Stock Ticker: VC 2001 Sales: $17,843,000 2001 Profits: $-118,000 Employees: 77,000 2000 Sales: $19,467,000 2000 Profits: $270,000 Fiscal Year Ends: 12/31 1999 Sales: $19,366,000 1999 Profits: $735,000 1998 Sales: $17,762,000 1998 Profits: $703,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $1,000,000 Stock Purch. Plan: Second Exec. Salary: $737,500 ADVANTAGE: Massive technology base/ Relationship with Ford.
OTHER THOUGHTS: Apparent Women Officers or Directors: 5 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West:
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
VOLKSWAGEN AG
www.vw.com
Industry Group Code: 336111 Ranks within this company's industry group: Sales:5 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Profits:5
Y
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Automobiles, Manufacturing Luxury Vehicles
Volkswagen AG (VW) is the number one automobile manufacturer in Europe, with yearly production of more than 5 million cars, trucks and vans. The firm's models include the New Beetle, Jetta, Passat, Golf, Eurovan and GTI, and its luxury brands include AUDI, Rolls-Royce, Bentley and Lamborghini. The company also makes family cars for the European market, including SEAT in Spain and SKODA in the Czech Republic. In addition, VW holds a 34% interest in Scania, a Swedish truck manufacturer. Other businesses include car rental services and consumer financing. The company operates facilities in North and South America, Africa, Asia Pacific and throughout Europe. VW's long-term goal is to sell 500,000 vehicles annually in the U.S. However, it sold only 356,000 in 2001, and sales were disappointing during 2002. The firm has pinned high hopes on its new Beetle convertible launched in November 2002. Other new models include an 8-cylinder Passat. In the spring of 2003, VW will launch its first SUV, the $45,000 Touareg, the company’s first-ever sports utility vehicle. This price positions it against rival SUVs made by BMW and Mercedes. Two initial models of the vehicle are available in the U.S. and Canada, one with a V6 engine and one with a V8. In addition, the company has introduced the Phaeton, a 12-cylinder luxury sedan. Priced at more than $62,000, the Phaeton is currently available in Europe and will be launched in the U.S. in the summer of 2003. The firm offers its employees benefits including health, dental, vision and life insurance, flexible spending accounts, vehicle lease and purchase plans, tuition reimbursement and casual dress.
BRANDS/DIVISIONS/AFFILIATES: Volkswagen of America, Inc. Beetle Jetta Passat AUDI Lamborghini Rolls-Royce Bentley
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Bernd Pischetsrieder, Chmn.-Board of Mgmt. Bruno Adelt, CFO Bernd Pischetsrieder, Sales & Mktg. Peter Hartz, Human Resources Bernd Pischetsrieder, Research & Dev. Bruno Adelt, Controlling & Accounting Jens Neumann, Group Strategy Bernd Pischetsrieder, Comm. Bruno Adelt, Investor Rel. Jens Neumann, Treas. Bernd Pischetsrieder, Chmn. Francisco Javier Garcia Sanz, Supply
Phone: 49-53-61-90 Fax: 49-53-61-92-8282 Toll-Free: 800-822-8987 Address: Brieffach 1848-2, Wolfsburg, D-38436 Germany
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $91,130,000 (12 months) 2002 Profits: $2,708,000 (12 months) Stock Ticker: Foreign 2001 Sales: $78,429,000 2001 Profits: $2,582,000 Employees: 324,892 2000 Sales: $80,553,100 2000 Profits: $1,941,000 Fiscal Year Ends: 12/31 1999 Sales: $75,697,000 1999 Profits: $850,000 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: The number one automobile manufacturer in Europe.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
VYSIS INC
www.vysis.com
Industry Group Code: 325413 Ranks within this company's industry group: Sales: Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Genetic Diagnostic Products Reagents
Vysis, Inc., a subsidiary of Abbott Laboratories, began as multiple scientific research units and programs focused on detection of genetic abnormalities. Today, the company is a leading genomic disease management company that develops and markets clinical products providing information critical to the evaluation and management of cancer, prenatal disorders and other genetic diseases. Fluorescence in Situ Hybridization (FISH) and Comparative Genomic Hybridization (CGH) reagents form the technology base of current Vysis products. The firm provides genomic disease management products and related customer and technical services globally. The firm recently introduced its Breast Aneusomy Probe Set for breast cancer research. This DNA probe set, which incorporates Vysis-patented FISH technology, enables laboratory researchers to detect gains or losses of chromosomes 1, 8, 11 and 17. By utilizing the Breast Aneusomy Probe Set with specimens from cell culture, ductal lavage, fine needle aspirates and nipple aspirates, researchers can study the role of aneusomies and how they relate to breast cancer. In other news, Vysis introduced its LSI MALT1 (18q21) Dual Color, Break Apart Rearrangement Probe. Using FISH technology, this product enables laboratory researchers to detect chromosomal rearrangements (translocations) of the MALT1 gene region on chromosome 18. The firm offers its employees a tuition reimbursement program.
BRANDS/DIVISIONS/AFFILIATES: Fluorescence In Situ Hybridization Comparative Genomic Hybridization Aneu Vysion Amoco Technology Company DNA FISH Breast Aneusomy Probe Set LSI MALT1 Abbott Laboratories
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John L. Bishop, CEO John L. Bishop, Pres. John R. Sluis, CFO Robert J. Koska, VP-Mktg. & Sales Susan Zint, Human Resources Steven A. Seelig, Sr. VP-Research & Dev. Steven A. Seelig, Chief Medical Officer William E. Murray, VP/Sec. William E. Murray, General Counsel R. Scott McKenzie, VP-Oper. Russel K. Enns, VP-Regulatory Affairs
Phone: 630-271-7000 Fax: 630-271-7138 Toll-Free: 800-553-7042 Address: 3100 Woodcreek Dr., Downers Grove, IL 60515-5400 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $ 2001 Profits: $ Employees: 133 2000 Sales: $ 2000 Profits: $ Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Unique genomic technology.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $ Second Exec. Salary: $
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
WATSON PHARMACEUTICALS INC
www.watsonpharm.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:21 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:20
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Diversified
Watson Pharmaceuticals, Inc. develops, manufactures and markets over 30 branded and over 130 generic pharmaceutical products. With an emphasis on niche pharmaceuticals, the company offers generic versions of popular brand-name pharmaceuticals such as the asthma drugs Proventil and Ventolin. Watson continues to invest in product development and, consequently, is capable of competing more effectively in the current health care environment. The company markets its proprietary products through its women’s health, urology/general products and nephrology divisions in order to foster close professional relationships with physicians in differing fields of medicine. Its women's health division products include oral contraceptives, a venereal disease treatment, a hormone replacement therapy and a visual cervical screening device. The urology/general products division currently includes urology, anti-hypertensive, neurology, psychiatry, pain management and dermatology products. The nephrology division consists of products for the treatment of iron-deficiency anemia. Key products within its nephrology branded product line currently include INFeD and Ferrlecit. The firm generally sells its branded products under the Watson Pharma and the Oclassen Dermatologics labels. Recently, the company acquired the U.S. rights to the Fioricet and Fiorinal product lines from Novartis. These products are indicated for the treatment of tension headaches. Watson Pharmaceuticals also received final FDA approval of its new drug application for Oxytrol. Oxytrol is produced for the treatment of overactive bladder with symptoms of urge incontinence, urgency and frequency. Watson Pharmaceuticals offers its employees a comprehensive benefits package including pet insurance, tuition reimbursement and prepaid legal advice.
BRANDS/DIVISIONS/AFFILIATES: Watson Laboratories, Inc. Watson Pharma Oclassen Dermatologics INFeD Ferrlecit Fioricet Fiorinal Oxytrol
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Allen Y. Chao, CEO Joseph Papa, COO Joseph Papa, Pres. Charles P. Slacik, Exec. VP/CFO Susan Skara, VP-Human Resources David C. Hsia, Sr. VP-Scientific Affairs Maria Chow, Sr. VP-Mfg. Oper. David Buchen, Sr. VP/Corp. Sec. David Buchen, General Counsel Charles Ebert, Sr. VP-Research and Dev. Donald A. Britt, Sr. VP-Corp. Quality Assurance Allen Y. Chao, Chmn.
Phone: 909-493-5300 Fax: 909-493-5836 Toll-Free: Address: 311 Bonnie Cir., Corona, CA 92880-2882 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,223,200 (12 months) 2002 Profits: $175,800 (12 months) Stock Ticker: WPI 2001 Sales: $1,160,700 2001 Profits: $116,400 Employees: 3,729 2000 Sales: $811,500 2000 Profits: $157,500 Fiscal Year Ends: 12/31 1999 Sales: $704,200 1999 Profits: $182,700 1998 Sales: $607,200 1998 Profits: $121,800
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $889,750 Stock Purch. Plan: Second Exec. Salary: $496,035 ADVANTAGE: Expanded niche strategy into the expanding dermatology market.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $ Bonus: $17,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
WEBMD CORPORATION
www.webmd.com
Industry Group Code: 514191A Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Business-to-Business Health Care Applications Web-Based Health Care Information
WebMD Corporation provides web-based health care information and services to facilitate connectivity and transactions among physicians, patients, payors and other health care industry participants. The company’s Internetbased information and transaction platform allows for the secure exchange of information and supports administrative transaction services, which include patient enrollment, eligibility determination, referrals and authorizations, laboratory and diagnostic test orders and results, clinical data retrieval and claims processing. Through its Porex subsidiary, WebMD also manufactures porous plastic products. The firm provides services to over 250,000 physicians, 11,000 dentists, 1,100 hospitals, 46,000 pharmacies, 650 payors and six laboratory companies. WebMD markets its services through direct sales, trade shows and industry publications. Since its founding in 1996, the firm has invested $15 billion in acquiring or partnering with leading health industry service companies to integrate its services and expand its customer base. The company’s subsidiary OnHealth Network Company is a provider of general health care information to consumers online. The company recently partnered with PracticeWorks to develop a real-time dental transaction service. The agreement will enable PracticeWorks to offer WebMD Envoy's real-time dental services to PracticeWorks providers via integrated and desktop applications. WebMD Envoy is the company’s transaction processing unit. In addition, the company has become the first to offer a single point of connectivity for providers of health plans and has introduced Intergy, a new practice and clinical management system designed to streamline workflow and improve efficiency. WebMD offers employees a choice of medical insurance, bonus programs and educational assistance programs. It also provides spousal or child life insurance plans, adoption assistance, a sabbatical program and credit union benefits.
BRANDS/DIVISIONS/AFFILIATES: Healtheon Porex Corp. WebMD Envoy WebMD Medical Manager OnHealth Network Intergy
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Martin J. Wygod, CEO Roger C. Holstein, Pres. Anthony Vuolo, CFO Martin J. Wygod, Chmn.
Phone: 201-703-3400 Fax: 201-703-3401 Toll-Free: Address: 669 River Dr., Ctr. 2, Elmwood Park, NJ 07407 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $925,900 (12 months) 2002 Profits: $-49,700 (12 months) Stock Ticker: HLTH 2001 Sales: $706,600 2001 Profits: $-6,684,300 Employees: 5,450 2000 Sales: $517,153 2000 Profits: $-3,085,608 Fiscal Year Ends: 12/31 1999 Sales: $102,149 1999 Profits: $-287,992 1998 Sales: $48,838 1998 Profits: $-54,048
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $541,667 Stock Purch. Plan: Y Second Exec. Salary: $450,000 ADVANTAGE: Broad range of online services and health care data content.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Bonus: $136,986 Bonus: $100,000
LOCATIONS: ("Y" = Yes) West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
WESTERN DIGITAL CORP
www.westerndigital.com
Industry Group Code: 334112 Ranks within this company's industry group: Sales:4 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:3
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Computer Storage Equipment-PC Hard Disk Drives
Western Digital Corporation manufactures hard drives for desktop computers, servers, network attached storage devices, video game consoles, digital video recording devices and satellite set-top boxes. The company’s hard drives currently include 1.0-inch high, 3.5-inch form factor drives with capacities ranging from eight gigabytes (GB) to 250 GB, rotation speeds of 5400 and 7200 revolutions per minute (RPM) and the Enhanced Integrated Drive Electronics (EIDE) interface in both external and internal models. Western Digital also offers a line of FireWire hard drives. The firm currently does the bulk of its manufacturing in Malaysia and Thailand. Western Digital recently scaled back its product line in response to adverse market conditions. Additionally, the company has sold a number of subsidiary operations, including Connex, Inc. and SANavigator, Inc. Another subsidiary, Keen Personal Media, Inc., ceased operations in 2002.
BRANDS/DIVISIONS/AFFILIATES: FireWire SageTree
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Matthew H. Massengill, CEO Arif Shakeel, Pres. Scott Mercer, Sr. VP/CFO Raymond M. Bukaty, VP/Corp. Sec. Raymond M. Bukaty, General Counsel Matthew H. Massengill, Chmn.
Phone: 949-672-7000 Fax: 949-672-5408 Toll-Free: Address: 20511 Lake Forest Dr., Lake Forest, CA 92630 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $2,151,200 (12 months) 2002 Profits: $65,400 (12 months) Stock Ticker: WDC 2001 Sales: $1,953,400 2001 Profits: $-98,900 Employees: 9,550 2000 Sales: $1,957,600 2000 Profits: $-188,000 Fiscal Year Ends: 6/30 1999 Sales: $2,767,200 1999 Profits: $-492,700 1998 Sales: $3,541,500 1998 Profits: $-290,200
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Stock Purch. Plan: Y ADVANTAGE: Wide variety of hard drive products.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $671,154 Second Exec. Salary: $275,000
Bonus: $1,193,750 Bonus: $223,720
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
WS ATKINS PLC
www.wsatkins.co.uk
Industry Group Code: 541310 Ranks within this company's industry group: Sales:9 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Y Y Y Y
Profits:5
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Engineering Services-Building Design & Consulting
WS Atkins, PLC is a multi-disciplined company that offers a unique portfolio of technical services and integrated solutions for the built environment. The company provides professional, technologically based consultancy and support services for a range of public sector organizations and blue chip private sector companies in the rail, roads, telecom, nuclear, aviation, water, power, process, health, education and defense markets. The firm works with governments, agencies and local authorities throughout the world offering support from policy research to expert advice and facilities management. With offices in over 25 countries, the company undertakes projects in approximately 86 countries. WS Atkins is comprised of numerous subsidiaries, including Atkins Benham, an architecture, engineering, procurement and construction management firm; Faithful & Gould, a project and cost management consultancy operating in the transport, property and industry sectors; and Lambert Smith Hamilton, a commercial property consultancy. Lambert Smith Hamilton is also a founding member of the Global Property Alliance, a collaboration of leading property advisors whose expertise covers the Americas, Europe and Asia. In recent news, the company was selected to prepare one of the largest strategic planning studies ever undertaken in the Warsaw region. The year-long study will assess the transport infrastructure needs of the city over the next 20 years.
BRANDS/DIVISIONS/AFFILIATES: Atkins Benham Lambert Smith Hampton Faithful & Gould Atkins Rail Global Property Alliance
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Michael Jeffries, CEO Stephen Billingham, Finance Dir. Alun Griffiths, Group Dir.-Human Resources Norman Schunter, Group Managing Dir.-Design and Eng. Amanda Massie, Corp. Sec. Peter Nelson, Group Dir.-Industry David Clements, Group Exec. Dir.-Investments and Gov't Services Michael Foote, Group Managing Dir.-Atkins Bus. Services Christopher Boulton, Chief Exec., Lambert Smith Hampton Michael Jeffries, Chmn.
Phone: 0-1-372-726-140 Fax: 0-1-372-740-055 Toll-Free: Address: Woodcote Grove, Ashley Rd., Epsom, Surrey KT18 5BW UK
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,149,500 (12 months) 2002 Profits: $16,800 (12 months) Stock Ticker: Foreign 2001 Sales: $954,600 2001 Profits: $27,300 Employees: 15,000 2000 Sales: $822,700 2000 Profits: $30,100 Fiscal Year Ends: 3/31 1999 Sales: $686,700 1999 Profits: $31,700 1998 Sales: $611,800 1998 Profits: $30,100
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Growth through acquisitions.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $ Second Exec. Salary: $
Bonus: $ Bonus: $
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
WYETH
www.wyeth.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:10 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:5
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Diversified Medical Devices Vaccines Over-the-Counter Drugs Wholesale Pharmaceuticals
Wyeth discovers, develops, manufacures, distributes and sells a diversified line of health care-based products, which arise from two divisions: pharmaceuticals and consumer health care. The company's name, changed from American Home Products, reflects its shift in focus from holdings in diversified businesses to research-based pharmaceuticals. The pharmaceuticals segment sells branded and generic pharmaceuticals, biologicals and nutritionals and animal biologicals and pharmaceuticals. Principal products include women's health care products, neuroscience therapies, cardiovascular products, nutritionals, gastroenterology drugs, anti-infectives, vaccines, oncology therapies, musculoskeletal therapies, hemophilia treatments and immunological products. Its branded products include Premarin, Prempro, Premphase, Triphasil, Ativan, Effexor, Altace, Inderal, Zoton, Protonix and Enbrel. Principal animal health products include vaccines, pharmaceuticals, endectocides and growth implants. The consumer health care segment's products include analgesics, cough/cold/allergy remedies, nutritional supplements, lip balm and hemorrhoidal, antacid, asthma and other relief items sold over-thecounter. The health care segment manufactures wellknown over-the-counter products, including Advil, cold medicines Robitussin and Dimetapp and nutritional supplement Centrum. In recent news, the company announced that the FDA has approved Low Dose Prempro and Low Dose Premarin for hormone therapy and Zosyn for the treatment of hospital-acquired pneumonia. Wyeth offers its employees child care subsidies, flextime and educational assistance.
BRANDS/DIVISIONS/AFFILIATES: Prempro Premarin Premphase Advil Robitussin Triphasil Zosyn American Home Products
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Robert A. Essner, CEO Robert A. Essner, Pres. Kenneth J. Martin, Sr. VP/CFO Rene R. Lewin, VP-Human Resources Bruce Fadem, CIO/VP-Corp. Systems Paul J. Jones, VP/Comptroller Eileen M. Lach, Corp. Sec. Louis L. Hoynes, Jr., Exec. VP/General Counsel John B. Adams, VP-Corp. Dev. Marilyn H. Rhudy, VP-Public Affairs Justin R. Victoria, VP-Investor Rel. Jack M. O'Connor, VP/Treas. Bernard J. Poussot, Exec. VP Joseph M. Mahady, Sr. VP Robert R. Ruffolo, Sr. VP John C. Kelly, VP-Finance Oper. Robert A. Essner, Chmn.
Phone: 973-660-5000 Fax: 973-660-7026 Toll-Free: 800-934-5556 Address: 5 Giralda Farms, Madison, NJ 07940-0874 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $14,584,000 (12 months) 2002 Profits: $4,447,200 (12 months) Stock Ticker: WYE 2001 Sales: $14,128,000 2001 Profits: $2,285,000 Employees: 52,762 2000 Sales: $13,262,754 2000 Profits: $-2,370,687 Fiscal Year Ends: 12/31 1999 Sales: $11,881,196 1999 Profits: $-1,227,200 1998 Sales: $11,268,570 1998 Profits: $2,474,300
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $1,400,000 Stock Purch. Plan: Y Second Exec. Salary: $694,900 ADVANTAGE: One of the world's leading health products companies.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $586,000 Bonus: $265,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
XEROX CORP
www.xerox.com
Industry Group Code: 333313 Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:2
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Business Machines-Digital Copiers Printers and Scanners Network Management Document Outsourcing Consulting Services
Xerox Corporation has a history of leadership in the global document market. The company develops, manufactures, markets, services and finances a complete range of document processing products and solutions designed to make organizations around the world more productive. The firm develops products for desktop, workgroup, production and multifunctional uses, making its services available to a vast market of customers. These products and services are created by its main business units, which are focused on the production market, the office market and the services market. The business group operations unit combines marketing, engineering, product development, acquisitions and manufacturing for both the office and production markets. It also manages the supplies business of the Xerox Engineering Center. The production systems group is responsible for wide-format hardware, software and supplies for the technical document and graphic arts markets. The Xerox supplies business group develops and markets a full range of document supplies for Xerox digital printing. Xerox global services provides clients with streamlined document and information business procedures such as customer communications, product life-cycle management, business records management and IT asset management. Fuji Xerox, a joint venture between the firm and Fuji Photo Film Co., Ltd., is central to Xerox operations in Japan and other markets in the Pacific Rim. The company engages in the design, manufacture and marketing of many digital color copiers and printers for Xerox worldwide. Xerox has global partnerships and alliances with hundreds of companies including EDS, IBM, Microsoft, Motorola and Sun Microsystems. Although the firm has experienced very difficult financial times in recent years, it has reported a return to profitability. This was achieved through an expanded portfolio of products and solutions, as well as aggressive cost-cutting measures. Xerox offers its employees dental and vision insurance, adoption assistance, tuition reimbursement, student loans and credit union membership.
BRANDS/DIVISIONS/AFFILIATES: Fuji Xerox DocuTech Gyricon Media, Inc. Xerox Engineering Center M. Series
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Anne Mulcahy, CEO Lawrence A. Zimmerman, CFO Diane E. McGarry, Chief Mktg. Officer Patricia M. Nazemetz, VP-Human Resources Hervé Gallaire, Chief Tech. Officer Patricia A. Cusick, CIO Harry R. Beeth, Controller Leslie F. Varon, Corp. Sec. Christina E. Clayton, General Counsel Ursula M. Burns, Sr. VP-Bus. Oper. James A. Firestone, Sr. VP-Corp. Oper. James H. Lesko, VP-e-Commerce J. Michael Farren, VP-External Affairs Rhonda Seegal, Treas. Richard F. Cerrone, Sr. VP-Europe Lance H. Davis, Dir.-Global Risk Mgmt. Thomas J. Dolan, Sr. VP-Global Services Ronald E. Rider, VP-Digital Imaging Tech. Anne Mulcahy, Chmn. Jean-Noël Machon, VP-European Solutions
Phone: 203-968-3000 Fax: 503-682-2980 Toll-Free: 800-334-6200 Address: 800 Long Ridge Rd., Stamford, CT 06904 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $15,849,000 (12 months) 2002 Profits: $91,000 (12 months) Stock Ticker: XRX 2001 Sales: $17,008,000 2001 Profits: $-71,000 Employees: 67,800 2000 Sales: $18,701,000 2000 Profits: $-257,000 Fiscal Year Ends: 12/31 1999 Sales: $19,567,000 1999 Profits: $1,339,000 1998 Sales: $19,593,000 1998 Profits: $273,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $1,200,000 Stock Purch. Plan: Second Exec. Salary: $1,000,000 One of the premier research and development companies in the world. ADVANTAGE:
OTHER THOUGHTS: Apparent Women Officers or Directors: 8 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $1,500,000 Bonus: $1,250,000
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
XILINX INC
www.xilinx.com
Industry Group Code: 334413 Ranks within this company's industry group: Sales:12 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Y
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:14
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Integrated Circuits-Field-Programmable Gate Arrays & Programmable Logic Devices Design Services
Xilinx, Inc. designs, develops and markets programmable logic and related development system software. The company’s complex programmable logic product lines include field programmable gate arrays and erasable programmable logic devices. The firm’s leading name brands are the Virtex Series, Spartan Products and CPLD, among others. The products were designed to provide high integration and quick time-to-market for electronic equipment manufacturers, primarily in the telecommunications, networking, computing, industrial and consumer markets globally. Xilinx programmable logic solutions help minimize risks for manufacturers of electronic equipment by shortening the time required to develop products and introduce them to market. Customers can design much faster using the company’s programmable devices than they could using traditional methods such as mask-programmed, fixed logic gate arrays. Moreover, because Xilinx devices are standard parts that need only be programmed, customers are not required to wait for prototypes or pay large non-recurring engineering costs. The firm has also developed a technology that enables the hardware in Xilinx-based systems to be upgraded remotely over any kind of private or public network, including the Internet, even after the equipment has been shipped to a customer. Such upgradable systems allow equipment manufacturers to remotely add new features and capabilities to installed systems or repair problems without having to physically exchange hardware. CEO Willem Roelandts does not believe in layoffs and in hard times offers early retirement and sabbaticals instead.
BRANDS/DIVISIONS/AFFILIATES: Virtex Series Spartan Products CPLD Visual Software Solutions, Inc. FPGA OpenMORE State CAD AllianceCORE
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Willem P. Roelandts, CEO Willem P. Roelandts, Pres. Kris Chellam, Sr. VP-Finance/CFO Sandeep S. Vij, VP-Worldwide Mktg. Margaret B. Wynn, VP-Human Resources Ivo Bolsen, VP/Chief Tech. Officer Sheri Anderson, VP/CIO Thomas R. Lavelle, VP/General Counsel Randy Ong, VP-Worldwide Oper. Evert A. Wolsheimer, VP-General Mgr.-CPLD Bus. Unit Richard W. Sevcik, Sr. VP-FPGA Products Group Steven D. Haynes, Sr. VP-Worldwide Sales Bernard V. Vonderschmitt, Chmn.
Phone: 408-559-7778 Fax: 408-559-7114 Toll-Free: 800-494-5469 Address: 2100 Logic Dr., San Jose, CA 95124 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,015,600 (12 months) 2002 Profits: $-113,600 (12 months) Stock Ticker: XLNX 2001 Sales: $1,659,400 2001 Profits: $35,300 Employees: 2,611 2000 Sales: $1,020,993 2000 Profits: $652,450 Fiscal Year Ends: 3/31 1999 Sales: $661,983 1999 Profits: $102,592 1998 Sales: $613,593 1998 Profits: $126,587
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $561,966 Stock Purch. Plan: Y Second Exec. Salary: $395,831 ADVANTAGE: Growth through acquisitions and collaborations.
OTHER THOUGHTS: Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
Bonus: $250,088 Bonus: $136,373
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
XOMA LTD
www.xoma.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:83 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:72
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Immunologic and Inflammatory Disorder
XOMA develops and manufactures protein and antibodyderived biopharmaceuticals in Santa Monica and Berkeley, California. Infectious diseases, immunologic and inflammatory disorders and cancer are among XOMA’s medical targets. XOMA’s antibody development platform includes products such as bactericidal/permeability-increasing protein (BPI), as well as enabling technologies, including the cell expression system and a patented human engineering method for decreasing antibody immunogenicity. BPI is the company’s infectious disease product development platform, a human protein that includes many anti-infective properties. The company’s other product development programs include Raptiva, ONYX-015, ING-1, NUEPREX, MLN01, CAB-2 and BPI-derived compounds. Through a collaboration with Genetech, XOMA is developing Raptiva for the treatment of psoriasis and rheumatoid arthritis. The company has also entered into an alliance with Onyx Pharmaceuticals, Inc., for the production of ONYX-015 for the treatment of head, neck, lung, colorectal and pancreatic cancer. ING-1 is an antibody in development to target tumor cells. XOMA licensed NUPREX to Baxter Healthcare Corporation to further develop the drug. NUPREX is being tested for the potential use in infectious diseases and inflammatory conditions such as Crohn’s disease. CAB-2 and MLN01 are being developed in collaboration with Millennium Pharmaceuticals, Inc. for use in cardiovascular diseases such as ischemic heart disease, acute myocardial infarcation and aneurisms. Recently, the company entered into a licensing agreement with Dyax Corp. in which its antibody technologies will be used by Dyax to produce antibody products. XOMA offers employees educational assistance, flexible spending accounts for medical and dependent care expenses and a share purchase plan.
BRANDS/DIVISIONS/AFFILIATES: BPI Raptiva ONYX-015 ING-1 NUEPREX MLN01 CAB-2
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John L. Castello, CEO Clarence L. Dellio, COO John L. Castello, Pres. Peter B. Davis, CFO/VP-Finance Chris Wells, VP-Human Resources Patrick J. Scannon, Sr. VP/Chief Scientific Officer Marc D. Better, VP-Tech. Dev. Patrick J. Scannon, Chief Medical Officer Christopher J. Margolin, Corp. Sec. Christopher J. Margolin, General Counsel Clarence L. Dellio, Sr. VP-Oper. Michel Bergh, VP-Bus. Dev. Daniel P. Cafaro, VP-Regulatory Affairs Robert H. Gundel, VP-Preclinical Research Stephen F. Carroll, VP-Scientific and Product Dev. Ronald H. Carlson, VP-Quality John L. Castello, Chmn.
Phone: 510-644-1170 Fax: 510-644-0471 Toll-Free: 800-246-9662 Address: 2910 7th St., Berkeley, CA 94710 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $29,900 (12 months) 2002 Profits: $-33,200 (12 months) Stock Ticker: XOMA 2001 Sales: $17,300 2001 Profits: $-28,000 Employees: 229 2000 Sales: $6,700 2000 Profits: $-29,400 Fiscal Year Ends: 12/31 1999 Sales: $2,400 1999 Profits: $-45,800 1998 Sales: $6,300 1998 Profits: $-47,200
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $500,000 Bonus: $ Stock Purch. Plan: Y Second Exec. Salary: $340,000 Bonus: $ ADVANTAGE: Successful antibody development/Marketing alliances/Has licensed its technologies to more than 20 other firms.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
LOCATIONS: ("Y" = Yes) West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
YAHOO! INC
www.yahoo.com
Industry Group Code: 541810A Ranks within this company's industry group: Sales:1 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:1
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
Y
GROWTH PLANS/SPECIAL FEATURES:
Online Portal-Search Engine Broadcast Media
Yahoo!, Inc. is a global Internet media company that offers a branded network of comprehensive information, communication and shopping services to millions of users daily. As the first online navigational guide to the World Wide Web, Yahoo.com is a leading site in terms of traffic, advertising and household and business user reach, as well as the number one Internet brand globally, reaching the largest audience worldwide. Under the Yahoo! brand, the company provides broadcast media, personal communications and direct services. The company has entered into strategic relationships with business partners that offer content, technology and distribution capabilities, including Ziff-Davis, SOFTBANK, Reuters, Granite Broadcasting, Sporting News, ESPN, The Wall Street Journal and the Motley Fool, which permit the company to bring Yahoo!-branded, targeted media products to the market more quickly. The company also operates Yahoo! Broadcast, a media channel on which users can access interactive video, audio and other multimedia content from leading providers such as ABCNEWS.com, Bthere.tv, ClassicMovies.com, The Economist, MyPrimeTime and Travelocity. The company’s acquisition of HotJobs.com, Ltd., a leading Internet job placement and recruitment company, enabled it to enter the Internet recruiting market and compete with companies like Monster.com and CareerBuilder.com. The firm recently announced the acquisition of the search engine firm Inktomi, which is part of Yahoo’s plan to build a diversified global business and provide more revenue building services. Additionally, LAUNCH, the company's music destination, recently introduced Live@LAUNCH, a service allowing Internet users on-demand access to live performances and interviews with the music industry’s biggest stars. Yahoo announced in July 2003 that it plans to acquire Overture, a highly successful service that enables advertisers to purchase paid positioning within search engine results. Yahoo! employees have an average age of about 30. The firm's benefits package includes eight weeks maternity leave, informal telecommuting, gym membership, $5,000 tuition reimbursement per year and a casual dress code.
BRANDS/DIVISIONS/AFFILIATES: Yahoo.com North Point Communications HotJobs.com, Ltd. Inktomi GeoCities LAUNCH Live@LAUNCH Overture
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Terry Semel, CEO Daniel Rosensweig, COO Susan Decker, CFO Gregory Coleman, VP-Mktg. and Sales Libby Sartain, VP-Human Resources Farzad Nazem, Chief Tech. Officer Farzad Nazem, VP-Eng. Jon Sobel, Corp. Sec. Jon Sobel, General Counsel Farzad Nazem, VP-Site Oper. Chris Castro, Chief Comm. Officer Jerry Yang, Co-Founder David Filo, Co-Founder Jim Brock, Sr. VP-Major Initiatives Wenda Hariis Millard, Chief Sales Officer
Phone: 408-731-3300 Fax: 408-731-3301 Toll-Free: Address: 701 First Ave., Sunnyvale, CA 94089 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $953,100 (12 months) 2002 Profits: $42,800 (12 months) Stock Ticker: YHOO 2001 Sales: $717,400 2001 Profits: $-92,800 Employees: 3,600 2000 Sales: $1,110,178 2000 Profits: $70,776 Fiscal Year Ends: 12/31 1999 Sales: $591,786 1999 Profits: $47,811 1998 Sales: $245,132 1998 Profits: $-13,641
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: The giant among portals.
OTHER THOUGHTS: Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
Top Exec. Salary: $500,000 Second Exec. Salary: $450,000
Bonus: $562,500 Bonus: $895,500
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ZILA INC
www.zila.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales:77 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:57
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Oral Oral Test Kits
Zila, Inc. is a manufacturer and marketer of pharmaceutical, biomedical, dental and nutritional products. The company’s business is organized into three major product groups: pharmaceuticals, biotechnology and nutraceuticals. The pharmaceuticals group develops and markets over-the-counter and prescription products, including the Zilactin family of products, Peridex prescription mouth rinse and IST swab products and ViziLite test kits for the detection of oral abnormalities. The biotechnology group conducts a research, development and licensing business, specializing in precancer/cancer detection. The segment concentrates on the development and sale of pharmaceutical-grade tuluidine blue, marketed as Zila Tolonium Chloride. Zila is the world’s only manufacturer of the product, which is the active ingredient in Zila’s OraTest oral cancer detection products. The nutraceuticals group manufactures patented and branded nutraceutical products. Products include Palmettx saw products and Ester-C, which promotes the absorption of vitamin C. Zila plans to expand production capacity of Ester-C. Both products are marketed though Inter-Cal Nutraceuticals, a division of Zila’s subsidiary Inter-Cal Corporation. Zila’s other subsidiaries include Biodental Technologies Corp., Oxycal Laboratories, Inc. and Oxycal Export, Inc.
BRANDS/DIVISIONS/AFFILIATES: Zilactin OraTest Ester-C ViziLite Peridex Biodental Technologies Corp. Oxycal Laboratories, Inc. Inter-Cal Corp.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Douglas D. Burkett, CEO Douglas D. Burkett, Pres. Bradley C. Anderson, CFO Bradley C. Anderson, Corp. Sec. Bradley C. Anderson, Treas. Douglas D. Burkett, Chmn.
Phone: 602-266-6700 Fax: 602-234-2264 Toll-Free: Address: 5227 N. 7th St., Phoenix, AZ 85014 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $34,900 (12 months) 2002 Profits: $-12,000 (12 months) Stock Ticker: ZILA 2001 Sales: $73,700 2001 Profits: $-6,300 Employees: 122 2000 Sales: $77,600 2000 Profits: $2,900 Fiscal Year Ends: 7/31 1999 Sales: $71,300 1999 Profits: $-2,000 1998 Sales: $62,100 1998 Profits: $2,300
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Stock Purch. Plan: ADVANTAGE: Strong over-the-counter drugs group.
OTHER THOUGHTS: Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
Top Exec. Salary: $276,552 Second Exec. Salary: $195,060
Bonus: $54,455 Bonus: $20,625
LOCATIONS: ("Y" = Yes) West:
Southwest: Y
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast:
International:
Plunkett Research, Ltd.
www.plunkettresearch.com
ZIMMER HOLDINGS INC
www.zimmer.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales:10 Technology: Computers: Software: Communications: Electronics: Alternative Energy:
Medical/Drugs Manufacturer: Contract Research: Medical Services: Labs: Bio. Services:
Y
Engineering: Design: Construction: Eng. Services: Consulting:
Profits:8
Transportation: Aerospace: Automotive:
TYPES OF BUSINESS:
Chemicals/Petrochem.: Oil/Gas Products: Chemicals: Oil/Chem. Svcs.: Gases: Other:
Specialty Specialty Services: Consulting: Specialty Management:: Products: Other:
GROWTH PLANS/SPECIAL FEATURES:
Orthopedic Supplies Surgical Supplies and Systems Hip Replacement Systems Fracture Management Products
Zimmer Holdings is a global leader in the design, development, manufacture and marketing of orthopedic reconstructive implants and fracture management products. These implants restore joint function lost due to disease or trauma in joints such as knees, hips, shoulders and elbows. The NexGen knee product line is a comprehensive system for knee replacement surgery with a leading position in posterior stabilized and revision procedures. The system provides surgeons with complete and versatile knee instrument options, including milling and multiple saw blade cutting instrument systems. The breadth and versatility of the NexGen knee system allows surgeons to change from one type of implant to another during surgery, according to the needs of the patient. The VerSys hip system, a Zimmer flagship brand, is an innovative, integrated family of hip products that offers surgeons design-specific options to meet varying surgical philosophies and patient needs. The firm plans to introduce approximately 340 new products to the VerSys system. Fracture management products are devices used primarily to reattach or stabilize damaged bone or tissue to support the body’s natural healing process. The M/DN nail, an intramedullary nailing system for the internal fixation of long bone fractures, incorporates implants and instruments to align and fix fractures of the tibia, femur and humerus. The system has multiple screw options to provide increased surgical flexibility. The company also manufactures and markets orthopedic surgical products, which include surgical supplies and instruments designed to aid in orthopedic surgical procedures. Zimmer manages its operations through three major geographic areas: the Americas, Asia Pacific and Europe. Zimmer offers its employees a comprehensive medical plan, a savings and investment plan. The company also provides life insurance and disability protection plans to its employees.
BRANDS/DIVISIONS/AFFILIATES: NexGen VerSys M/DN Cable-Ready TransFx Trilogy ZMR
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. J. Raymond Elliott, CEO J. Raymond Elliott, Pres. Sam R. Leno, Sr. VP/CFO Sheryl L. Conley, VP-Global Brand Mgmt. and Commercialization Dennis J. Kline, VP-Human Resources Roy D. Crowninsheld, Sr. VP/Chief Scientific Officer James T. Crines, VP/Controller Paul D. Schoenle, Corp. Sec. David Dvorak, General Counsel Kenneth Coonce, VP-Oper. and Logistics David Dvorak, Sr. VP-Corp. Affairs Bruno A. Melzi, Pres., Europe John S. Loveman-Krelle, Pres., Asia Pacific Bruce E. Peterson, Pres., Americas James P. Simpson, VP-Quality, Regulatory and Govt. Affairs
Phone: 574-267-6131 Fax: 574-372-4988 Toll-Free: 800-613-6131 Address: 345 E. Main St., Warsaw, IN 46580 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,372,400 (12 months) 2002 Profits: $257,800 (12 months) Stock Ticker: ZMH 2001 Sales: $1,178,600 2001 Profits: $149,800 Employees: 3,600 2000 Sales: $1,041,000 2000 Profits: $176,000 Fiscal Year Ends: 12/31 1999 Sales: $939,000 1999 Profits: $150,000 1998 Sales: $861,000 1998 Profits: $145,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $547,399 Stock Purch. Plan: Second Exec. Salary: $274,383 ADVANTAGE: A leading position in the marketplace/Broad product line.
OTHER THOUGHTS: Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
Bonus: $690,678 Bonus: $151,936
LOCATIONS: ("Y" = Yes) West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Northeast: Y
International: Y
Plunkett Research, Ltd.
www.plunkettresearch.com
ADDITIONAL INDEXES
CONTENTS: Index of Firms Noted as “Hot Spots for Advancement” for Women/Minorities
p. 604
Index by Subsidiaries, Brand Names and Selected Affiliations
p. 606
Plunkett Research, Ltd.
INDEX OF FIRMS NOTED AS HOT SPOTS FOR ADVANCEMENT FOR WOMEN & MINORITIES 3COM CORP ABBOTT LABORATORIES ABGENIX INC ABLE LABORATORIES ADAPTEC INC ADC TELECOMMUNICATIONS INC ADOBE SYSTEMS INC ADVANCED FIBRE COMMUNICATIONS INC AFFYMETRIX INC AGILENT TECHNOLOGIES INC ALCATEL USA INC ALLIANCE PHARMACEUTICAL CORP ALPHARMA INC ALZA CORP AMERICAN SUPERCONDUCTOR AMGEN INC AMYLIN PHARMACEUTICALS INC APPLE COMPUTER INC APPLIED MATERIALS INC ASPECT COMMUNICATIONS CORP AUTODESK INC AVAYA INC BARR LABORATORIES INC BAUSCH & LOMB INC BAXTER INTERNATIONAL INC BEA SYSTEMS INC BECTON DICKINSON & CO BIO TECHNOLOGY GENERAL CORP BIOGEN INC BIOSITE INC BOEING CO BOSTON BIOMEDICA INC BRISTOL MYERS SQUIBB CO BROADCOM CORP CABOT CORPORATION CARRINGTON LABORATORIES INC CELERA GENOMICS GROUP CELL THERAPEUTICS INC CHESAPEAKE BIOLOGICAL LAB CISCO SYSTEMS INC CITRIX SYSTEMS INC COLLATERAL THERAPEUTICS COMPUWARE CORP CONNETICS CORPORATION CORIXA CORPORATION CORNING INC CR BARD INC CURAGEN CORPORATION
www.plunkettresearch.com
CYTYC CORP DELL COMPUTER CORPORATION DIGENE CORPORATION DIVERSA CORPORATION DOW CHEMICAL COMPANY (THE) E I DU PONT DE NEMOURS & CO (DUPONT) EASTMAN KODAK CO ELAN CORP PLC ELECTRONIC ARTS INC ELECTRONIC DATA SYSTEMS CORP ELECTRONICS FOR IMAGING INC ELI LILLY & CO ENDO PHARMACEUTICALS HOLDINGS INC ENERGY CONVERSION DEVICES INC ENTERASYS NETWORKS INC ENZO BIOCHEM INC EPIX MEDICAL INC EXELIXIS INC FILENET CORP FORD MOTOR CO FOREST LABORATORIES INC FOSTER WHEELER LTD GELTEX PHARMACEUTICALS GENENTECH INC GENERAL MOTORS CORP GENZYME CORP GERBER SCIENTIFIC INC GILEAD SCIENCES INC GOODYEAR TIRE & RUBBER COMPANY (THE) GOOGLE INC GTC BIOTHERAPEUTICS INC GUIDANT CORP GUILFORD PHARMACEUTICALS INC HAEMONETICS CORPORATION HEWLETT-PACKARD CO HUGHES ELECTRONICS CORP HUTCHINSON TECHNOLOGY INC IMCLONE SYSTEMS INC IMMUNEX CORP INCYTE GENOMICS INC INFOCUS CORP INTEL CORP INTERNATIONAL BUSINESS MACHINES (IBM) INTUIT INC INVACARE CORP INVITROGEN CORPORATION IOMED INC IOMEGA CORP ISIS PHARMACEUTICALS INC ITT INDUSTRIES INC JOHNSON & JOHNSON JOHNSON CONTROLS INC KENDLE INTERNATIONAL INC
Plunkett Research, Ltd.
L3 COMMUNICATIONS HOLDINGS INC LAM RESEARCH CORP LEXICON GENETICS INC LIFECELL CORPORATION LIFECORE BIOMEDICAL INC LUCENT TECHNOLOGIES INC LYNX THERAPEUTICS INC LYONDELL CHEMICAL COMPANY MALLINCKRODT INC MATRIX PHARMACEUTICAL MAXIM INTEGRATED PRODUCTS INC MEDICIS PHARMACEUTICAL CORP MEDIMMUNE INC MEDTOX SCIENTIFIC INC MEDTRONIC AVE INC MERCK & CO INC MERIDIAN BIOSCIENCE INC MICRON TECHNOLOGY INC MICROSOFT CORP MONSANTO CO NAPRO BIOTHERAPEUTICS INC NEUROCRINE BIOSCIENCES INC NORTEL NETWORKS CORP NOVELL INC ONSITE ENERGY CORPORATION ORACLE CORP OSI PHARMACEUTICALS INC PALM INC PAREXEL INTERNATIONAL PENWEST PHARMACEUTICALS CO PEOPLESOFT INC PEROT SYSTEMS CORP PITNEY BOWES INC PLUG POWER INC PROTEIN DESIGN LABS INC PROXIM CORPORATION QUALCOMM INC SAS INSTITUTE SCIOS INC SEQUENOM INC SKIDMORE OWINGS & MERRILL LLP SONY CORPORATION ST JUDE MEDICAL INC STORAGE TECHNOLOGY CORP STV GROUP INC SUN MICROSYSTEMS INC SUPERGEN INC SYBASE INC SYNOPSYS INC SYNOVIS LIFE TECHNOLOGIES INC TECHNE CORP TELEFLEX INC THERAGENICS CORP
www.plunkettresearch.com
TITAN CORP (THE) TRANSKARYOTIC THERAPIES TRIPOS INC UNISYS CORP URS CORPORATION VALLEN CORP VARIAN MEDICAL SYSTEMS INC VERISIGN INC VERTEX PHARMACEUTICALS INC VIRBAC INC VIROLOGIC INC VISTEON CORPORATION WATSON PHARMACEUTICALS INC WYETH XEROX CORP XILINX INC YAHOO! INC
Plunkett Research, Ltd.
INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS Brand or subsidiary, followed by the name of the related corporation .Net; MICROSOFT CORP 128XP; ACUSON CORPORATION 2300 Versys Star; LAM RESEARCH CORP 3Ci; CIRRUS LOGIC INC 3i; BIOMET INC 3M Scotch-Clad TC Deck Coatings; 3M COMPANY 3M Telecom Enterprise Department; 3M COMPANY 3TC; SHIRE-BIOCHEM INC 626; MAZDA MOTOR CORPORATION A GA-II; TRANSKARYOTIC THERAPIES A.T. Kearney; ELECTRONIC DATA SYSTEMS CORP A380; AIRBUS SAS AANetcom; PMC-SIERRA INC Abbott Laboratories; SEPRACOR INC Abbott Laboratories; NAPRO BIOTHERAPEUTICS INC Abbott Laboratories; VYSIS INC ABC Technologies, Inc.; SAS INSTITUTE Abelcet; ENZON INC Abgenix, Inc.; CELL GENESYS INC Abgenix, Inc.; SANGSTAT MEDICAL CORP Able Labs; ABLE LABORATORIES ABX-EGF; ABGENIX INC AC2993; AMYLIN PHARMACEUTICALS INC AC2993 LAR; AMYLIN PHARMACEUTICALS INC AC3056; AMYLIN PHARMACEUTICALS INC Acanto; SYNGENTA AG Accelerated Intelligent Drug Discovery; NEUROGEN CORP Accelerator; ERESEARCH TECHNOLOGY INC Accelrys; PHARMACOPEIA INC Accent; HYUNDAI MOTOR COMPANY Accenture Technology Ventures; ACCENTURE AccessMAX; ADVANCED FIBRE COMMUNICATIONS INC Accolate; ASTRAZENECA PLC Accord; HONDA MOTOR CO LTD Accurun; BOSTON BIOMEDICA INC AccuVote; DIEBOLD INC Acidmantle; BRADLEY PHARMACEUTICALS ACORN; CACI INTERNATIONAL INC Acoustic Borehole Televiewer; OYO CORPORATION ACRYFLOW Resins; LYONDELL CHEMICAL COMPANY AcrySof; ALCON LABORATORIES INC ACTIMID; CELGENE CORP Actiq; CEPHALON INC Actis Manufacturing, Ltd.; DENSO CORPORATION Activase; GENENTECH INC
www.plunkettresearch.com Acumedia; NEOGEN CORPORATION AcuNav; ACUSON CORPORATION Acura; HONDA MOTOR CO LTD Acuson; SIEMENS AG Acyclovir; PHARMACEUTICAL RESOURCES INC AD20msp815 Personal Soundcomm Chipset; ANALOG DEVICES INC AD7655; ANALOG DEVICES INC AD8001; ANALOG DEVICES INC AD835 Multiplier; ANALOG DEVICES INC AD899 Complete Read Channel; ANALOG DEVICES INC ADAGEN; ENZON INC AddVantage; SUNGARD DATA SYSTEMS INC Adgen Ltd.; NEOGEN CORPORATION ADM663/666 Voltage Regulators; ANALOG DEVICES INC Adobe Acrobat; ADOBE SYSTEMS INC Adobe Pagemaker; ADOBE SYSTEMS INC Adobe Photoshop; ADOBE SYSTEMS INC Adobe Ventures; ADOBE SYSTEMS INC ADS Technologies; CIRRUS LOGIC INC AdSense; GOOGLE INC ADSP-21171; ANALOG DEVICES INC Adtranz; BOMBARDIER INC Advanced Biotechnologies, Ltd.; APOGENT TECHNOLOGIES INC Advanced Communication Systems, Inc.; TITAN CORP (THE) Advanced Medical Optics, Inc.; ALLERGAN INC Advanced Venous Access; EDWARDS LIFESCIENCES CORP Advanta; MEMC ELECTRONIC MATERIALS INC Advantage; BAYER AG Advantage; COMPUTER ASSOCIATES INTERNATIONAL INC Advantage; MENTOR GRAPHICS CORP Advantix; EASTMAN KODAK CO Advicor; KOS PHARMACEUTICALS INC Advil; WYETH AdWords; GOOGLE INC Adx PR Pacemaker; ST JUDE MEDICAL INC Aegis; MEMC ELECTRONIC MATERIALS INC Aerobid; FOREST LABORATORIES INC Aeronautical Systems; GOODRICH CORPORATION AFNET; CACI INTERNATIONAL INC AFP-Scan; IMMUNOMEDICS INC Afrin; SCHERING-PLOUGH CORP AGC Total Knee System; BIOMET INC Agdia, Inc.; NEOGEN CORPORATION Agenerase; VERTEX PHARMACEUTICALS INC Agie, Ltd.; GEORG FISCHER LTD Agila; ADAM OPEL AG Agilent 1100 Series; AGILENT TECHNOLOGIES INC Agilis Power MicroBranch; DIEBOLD INC Agip Fuel; ENI SPA Agip USA; ENI SPA
Plunkett Research, Ltd.
www.plunkettresearch.com
INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Agrinomics LLC; EXELIXIS PLANT SCIENCES INC Agritope, Inc.; EXELIXIS PLANT SCIENCES INC AIP-001; ELAN CORP PLC AIR; ALKERMES INC Air BP; BP PLC Airbus China; AIRBUS SAS Airbus Japan; AIRBUS SAS Airbus North America; AIRBUS SAS Airbus SAS; BAE SYSTEMS Airbus Transport International; AIRBUS SAS AIRCOM International; NOKIA CORPORATION Airmax; IVAX CORPORATION Airshow, Inc.; ACTERNA CORPORATION Airspan; ALCATEL USA INC Aker Deep Water Co.; TECHNIP-COFLEXIP Akineton; PHARMACEUTICAL RESOURCES INC AKT, Inc.; APPLIED MATERIALS INC Alaris Medical Systems, Inc.; ALARIS MEDICAL INC Albany Research Center; ALBANY MOLECULAR RESEARCH Albulast; ALKERMES INC Albuterol; ALKERMES INC Alcatel; ALCATEL USA INC Alchemy; AVAYA INC Alchemy Semiconductor, Inc.; ADVANCED MICRO DEVICES INC Alcon Summit Autonomous; ALCON LABORATORIES INC Aldrich; SIGMA ALDRICH CORP Aldurazyme; BIOMARIN PHARMACEUTICAL Aldurazyme; GENZYME CORP Alfa Romeo; FIAT SPA Alias/Wavefront; SILICON GRAPHICS INC Alka-Seltzer; BAYER AG Allegra; ALBANY MOLECULAR RESEARCH Allegra; AVENTIS SA Allen-Bradley; ROCKWELL AUTOMATION AllFusion; COMPUTER ASSOCIATES INTERNATIONAL INC Alliance; JOHNSON CONTROLS INC AllianceCORE; XILINX INC AlliedSignal International Finance Corp.; HONEYWELL INTERNATIONAL INC Allison Transmission; GENERAL MOTORS CORP Alloderm; LIFECELL CORPORATION ALNM Group, Inc.; KEITH COMPANIES INC (THE) Aloprim; NABI BIOPHARMACEUTICALS Alphabet Fuhrpark Management; BAYERISCHE MOTOREN WERKE AG Alphagan; ALLERGAN INC Alpharma; ASCENT PEDIATRICS INC Alrex; BAUSCH & LOMB INC Altace; KING PHARMACEUTICALS INC Altastaph; NABI BIOPHARMACEUTICALS AM Japan, LLC; APPLIED MATERIALS INC Am486; ADVANCED MICRO DEVICES INC
AmBisome; GILEAD SCIENCES INC Ambulatory Surgery Center Program; STRYKER CORP AMD-K6; ADVANCED MICRO DEVICES INC Amdocs Champaign, Inc.; AMDOCS LTD Amdocs Development, Ltd.; AMDOCS LTD Amdocs Management, Ltd.; AMDOCS LTD Amdocs Software Systems, Ltd.; AMDOCS LTD Amdocs Stamford, Inc.; AMDOCS LTD Amdocs, Inc.; AMDOCS LTD Amdoxovir; TRIANGLE PHARMACEUTICALS America Online (AOL); AOL TIME WARNER INC American Equipment Company; FLUOR CORP American Ginseng; PURE WORLD INC American Home Products; WYETH American Overseas Marine; GENERAL DYNAMICS American Suzuki Motor Corp.; SUZUKI MOTOR CORPORATION AmeriNet; RESPIRONICS INC AMEVIVE; BIOGEN INC Amey Construction; AMEY PLC Amey Rail; AMEY PLC Amgen; IMMUNEX CORP AMI Doduco, Inc.; TECHNITROL INC AMICAR; IMMUNEX CORP Amistar; SYNGENTA AG Amoco; BP PLC Amoco Technology Company; VYSIS INC Amplifluor AssayArchitect Software; SEROLOGICALS CORP Amplifluor SNPs Genotyping System; SEROLOGICALS CORP AMS Management Systems Australia; AMERICAN MANAGEMENT SYSTEMS INC AMS Management Systems Deutschland; AMERICAN MANAGEMENT SYSTEMS INC AMS Management Systems Mexico; AMERICAN MANAGEMENT SYSTEMS INC AMS Management Systems Netherlands; AMERICAN MANAGEMENT SYSTEMS INC AmVet Pharmaceuicals; NEOGEN CORPORATION AMVISC; ANIKA THERAPEUTICS INC Amylin Europe, Ltd.; AMYLIN PHARMACEUTICALS INC AN/QS-20; RAYTHEON CO AN-1792; ELAN CORP PLC AN-2000; UTSTARCOM INC AnalystStudio; RATIONAL SOFTWARE CORP Anapenil; ICN PHARMACEUTICALS INC ANCIRC Pharmaceuticals; ANDRX CORP Ancobon/Ancotil; ICN PHARMACEUTICALS INC ANCURE System; GUIDANT CORP Anda, Inc.; ANDRX CORP Andersen Consulting; ACCENTURE Andrx Laboratories; ANDRX CORP Andrx Pharmaceuticals; ANDRX CORP Anesta; CEPHALON INC
Plunkett Research, Ltd.
www.plunkettresearch.com
INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Aneu Vysion; VYSIS INC AneuRx; MEDTRONIC AVE INC AneuRX, Inc.; MEDTRONIC INC AngioDynamics, Inc.; E-Z-EM INC Angiopoietins; REGENERON PHARMACEUTICALS INC Animate; IMC GLOBAL INC ANTEGREN; BIOGEN INC Antegren; ELAN CORP PLC Antegren; GTC BIOTHERAPEUTICS INC Anthrotek, Inc.; BIOMET INC Antisense Therpeutics Limited; ISIS PHARMACEUTICALS INC Antithrombin III; GTC BIOTHERAPEUTICS INC Antizol; ORPHAN MEDICAL INC Antizol-Vet; ORPHAN MEDICAL INC APEX; ALTERA CORP APex; ASTROPOWER INC APEX/R; HONEYWELL INTERNATIONAL INC Apokinin; CEPHALON INC Apollo Consumer Products, Inc.; HEWLETTPACKARD CO Apomate; NORTH AMERICAN SCIENTIFIC Apomine; ILEX ONCOLOGY INC AppConnect; PEOPLESOFT INC Applera Corp.; CELERA GENOMICS GROUP ApplianceWatch; NETWORK APPLIANCE INC Applied Semantics; GOOGLE INC AQUAVAN Injection; GUILFORD PHARMACEUTICALS INC Arab Potash Company, Ltd.; ALBEMARLE CORPORATION Aranesp; AMGEN INC ARASCO; MARTEK BIOSCIENCES CORP ARCADIS Geraghty & Miller, Inc.; ARCADIS NV Ardent Software; ASCENTIAL SOFTWARE CORPORATION Argus Software, Inc.; VARIAN MEDICAL SYSTEMS INC Arris Interactive; NORTEL NETWORKS CORP Arrow LionHeart; ARROW INTERNATIONAL INC ARROWguard; ARROW INTERNATIONAL INC Arrow-Howes; ARROW INTERNATIONAL INC Artemis Pharmaceuticals GmbH; EXELIXIS INC Arterial Vascular Engineering, Inc.; MEDTRONIC INC Aryplase; BIOMARIN PHARMACEUTICAL Ascent Pediatrics; MEDICIS PHARMACEUTICAL CORP Asena; ALARIS MEDICAL INC ASI Specialty Chemicals; HONEYWELL INTERNATIONAL INC ASK; INFOCUS CORP Asmanex; SCHERING-PLOUGH CORP ASMO Manufacturing, Inc.; DENSO CORPORATION Aspect Adapters; ASPECT COMMUNICATIONS CORP
Aspect Telecommunications Corp.; ASPECT COMMUNICATIONS CORP Aspen; ACUSON CORPORATION Aspen Laboratories, Inc.; CONMED CORP Aspire; MITSUBISHI MOTORS CORP ASTA Medica Oncology; BAXTER INTERNATIONAL INC Astelin; MEDPOINTE INC ASTELIN; SEPRACOR INC Aston Martin; FORD MOTOR CO Aston Molecules; OSI PHARMACEUTICALS INC Astra; ADAM OPEL AG AstraZeneca; SYNGENTA AG Atersa; ASTROPOWER INC Athlon; ADVANCED MICRO DEVICES INC Atkins Benham; WS ATKINS PLC Atkins Rail; WS ATKINS PLC ATL SuperLoader; QUANTUM CORP ATL ValueLoader; QUANTUM CORP Atlantic Richfield Co.; BP PLC ATLAS; ADVANCED FIBRE COMMUNICATIONS INC ATLAS Series; ADTRAN INC Atmel Asia, Ltd.; ATMEL CORP Atmel Finance, Inc.; ATMEL CORP Atmel FSC, Inc.; ATMEL CORP Atmel Korea, Ltd.; ATMEL CORP Atmel Semiconductor Corp.; ATMEL CORP Atmel U.K., Ltd.; ATMEL CORP ATMizer; LSI LOGIC CORP Atos; HYUNDAI MOTOR COMPANY Atridox; ATRIX LABORATORIES INC Atridox; COLLAGENEX PHARMACEUTICAL Atrigel; ATRIX LABORATORIES INC Atrisorb Gtr; ATRIX LABORATORIES INC Atrisorb-Freeflow; COLLAGENEX PHARMACEUTICAL AUDI; VOLKSWAGEN AG Audi A8; AUDI AG Audi AG; AUDI AG Audi Hungaria Motor Kft.; AUDI AG Augmentin; GLAXOSMITHKLINE PLC Augusta Automatic Fire Systems and Equipment, Inc.; VALLEN CORP Aurorean; ENTERASYS NETWORKS INC AutoActive; MENTOR GRAPHICS CORP AutoCAD; AUTODESK INC AutoCAD Designer; AUTODESK INC AutoCAT; ARROW INTERNATIONAL INC Auto-Dri; DEL LABORATORIES INC Autogerma; AUDI AG Autoplex T; NABI BIOPHARMACEUTICALS AutoSketch; AUTODESK INC Autoterminal; GRUPO DRAGADOS AVA 3Xi; EDWARDS LIFESCIENCES CORP Avadex; MONSANTO CO
Plunkett Research, Ltd.
www.plunkettresearch.com
INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Avant! Corp.; SYNOPSYS INC Avastin; GENENTECH INC AVECOR Cardiovascular, Inc.; MEDTRONIC INC Aventis; DADE BEHRING INC Aventis; FIRST HORIZON PHARMACEUTICALS Aventis Behring; AVENTIS SA Aventis CropScience; EXELIXIS PLANT SCIENCES INC Aventis Cropsciences; EXELIXIS INC Aventis Pasteur; AVENTIS SA Aventis Pharma; AVENTIS SA Aventis Pharma; TRANSKARYOTIC THERAPIES AViiON; EMC CORP AVINZA; LIGAND PHARMACEUTICALS INC AVONEX; BIOGEN INC Axaron Bioscience AG; LYNX THERAPEUTICS INC Axid; ELI LILLY & CO Axiom; ISUZU MOTORS LTD Axiom Biotechnologies; SEQUENOM INC Axokine; REGENERON PHARMACEUTICALS INC AxSym; ABBOTT LABORATORIES Azelex; ALLERGAN INC Azulfidine EN-tabs; MGI PHARMA INC BAE Systems; AIRBUS SAS Bain Capital; DADE BEHRING INC Ballard Automotive; BALLARD POWER SYSTEMS Ballard Generation Systems; BALLARD POWER SYSTEMS Ballard Material Products; BALLARD POWER SYSTEMS Banamine; SCHERING-PLOUGH CORP Band-Aid; JOHNSON & JOHNSON Bandit; SUZUKI MOTOR CORPORATION BandLeader; TERAYON COMMUNICATION SYSTEMS INC Banque PSA Finance; PSA PEUGEOT CITROEN SA BarcoNet; SCIENTIFIC ATLANTA INC Bard Access Systems; CR BARD INC Bard Devices, Inc.; CR BARD INC Bard Medical Systems; CR BARD INC Barnett International; PAREXEL INTERNATIONAL Barocycler; BOSTON BIOMEDICA INC Barr Research, Inc.; BARR LABORATORIES INC Barton; ADVANCED MICRO DEVICES INC Bauverein GA; PHILIPP HOLZMANN GROUP Bavaria Wirtschaftsagentur; BAYERISCHE MOTOREN WERKE AG Baxter Healthcare Corp.; BAXTER INTERNATIONAL INC Bay Networks, Inc.; NORTEL NETWORKS CORP Bayer AG; EXELIXIS INC Bayer CropScience; EXELIXIS PLANT SCIENCES INC Bayer Diagnostics; LUMINEX CORPORATION Bayer Group (The); BAYER AG Bayferrox; BAYER AG
Baypure; BAYER AG BBI Biotech Research Laboratories; BOSTON BIOMEDICA INC BBI Diagnostics; BOSTON BIOMEDICA INC BBI Source Scientific; BOSTON BIOMEDICA INC BCN Data Systems; BECHTEL GROUP INC BD Autoguard; BECTON DICKINSON & CO BDZ-S77; SONY CORPORATION BEC2; IMCLONE SYSTEMS INC Bechtel Bettis, Inc.; BECHTEL GROUP INC Bechtel COSAPI; BECHTEL GROUP INC Beckman Coulter Primary Care Diagnostics; BECKMAN COULTER INC Beckman Coulter/Centrifuge Division; BECKMAN COULTER INC Beechcraft; RAYTHEON CO Beere Precision Medical Instruments; TELEFLEX INC Beetle; VOLKSWAGEN AG Behring Diagnostics; DADE BEHRING INC Bekaert ECD Solar Systems, LLC; ENERGY CONVERSION DEVICES INC Belfab; PERKINELMER INC Bell Canada; AMDOCS LTD Bell Laboratories; LUCENT TECHNOLOGIES INC Belmac Corp.; BENTLEY PHARMACEUTICALS INC Belmazol; BENTLEY PHARMACEUTICALS INC Belt Concepts of America, Inc.; GOODYEAR TIRE & RUBBER COMPANY (THE) Bema; ATRIX LABORATORIES INC Bentley; VOLKSWAGEN AG Beraprost; UNITED THERAPEUTICS CORP Berman; ARROW INTERNATIONAL INC Bertek Pharmaceuticals, Inc.; MYLAN LABORATORIES INC Best GmbH; ELECTRONICS FOR IMAGING INC Beta 8 Series; SOLA INTERNATIONAL INC Betaseron; CHIRON CORP BFGoodrich; COMPAGNIE MICHELIN BFGoodrich Company; GOODRICH CORPORATION Bicept II Magnum; SYNGENTA AG Bio Vascular, Inc.; SYNOVIS LIFE TECHNOLOGIES INC BioChem ImmunoSystems U.S., Inc.; SHIREBIOCHEM INC Biochem Pharma; SHIRE-BIOCHEM INC Biodental Technologies Corp.; ZILA INC BioExpress; GENE LOGIC INC Biofiner; CHIYODA CORPORATION Biofos; IMC GLOBAL INC Biogen; FLUOR CORP Biogen; IDEC PHARMACEUTICALS CORP Biogen IDEC; BIOGEN INC Biogen, Inc.; ELAN CORP PLC Bioinformatics Centre; ASTRAZENECA PLC Biomet Merck Group; BIOMET INC Bionx Implants, Inc.; CONMED CORP
Plunkett Research, Ltd.
www.plunkettresearch.com
INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Biosite Discovery; BIOSITE INC BIOSTER; PHARMACOPEIA INC Biotechna; SICOR INC BiPAP Vision; RESPIRONICS INC Birtcher Medical Systems, Inc.; CONMED CORP B-K Medical A/S; ANALOGIC CORP Blooger; GOOGLE INC Blueprint Worldwide; INTERNATIONAL BUSINESS MACHINES (IBM) BML Pharmaceuticals, Inc.; ENDO PHARMACEUTICALS HOLDINGS INC BMS Electric; DUALSTAR TECHNOLOGIES CORPORATION BMW; BAYERISCHE MOTOREN WERKE AG BMW Car IT; BAYERISCHE MOTOREN WERKE AG BMW of North America, LLC; BAYERISCHE MOTOREN WERKE AG Board Station; MENTOR GRAPHICS CORP BOC Group; AIR PRODUCTS & CHEMICALS INC Boeing Commercial Airplane Group; BOEING CO Boeing Precision Gear, Inc.; BOEING CO Boeing Space & Communications Group; BOEING CO Boole & Babbage, Inc.; BMC SOFTWARE INC Boost; BRISTOL MYERS SQUIBB CO Boston RPG Lenses; BAUSCH & LOMB INC Bothell Research Center; ALBANY MOLECULAR RESEARCH Botox; ALLERGAN INC BP Bitumen; BP PLC BP Exploration; BP PLC BP Pipelines North America; BP PLC BP Solar; BP PLC BPI; XOMA LTD BrachySeed; CYTOGEN CORPORATION BrachyVision; VARIAN MEDICAL SYSTEMS INC Breast Aneusomy Probe Set; VYSIS INC Breezy; SUNRISE MEDICAL INC BREW; QUALCOMM INC Bridge; MEDTRONIC AVE INC BrightStor; COMPUTER ASSOCIATES INTERNATIONAL INC Bristol-Myers Squibb Company; EXELIXIS INC British Aerospace; BAE SYSTEMS Bruno Biotechnology Development Center; ALBANY MOLECULAR RESEARCH BTC Laboratories, Inc.; US LABORATORIES b-TRU Rx; SOLA INTERNATIONAL INC Bubble Jet; CANON INC Buena Engineers, Inc.; US LABORATORIES Bull Information; JABIL CIRCUIT INC Bupropion; IMPAX LABORATORIES INC Bureau Veritas; US LABORATORIES Burmah Castrol; BP PLC Burrell Colour, Inc.; EASTMAN KODAK CO Burrell Professional Labs; EASTMAN KODAK CO
Business Connectivity Company; 3COM CORP Business Networks Company; 3COM CORP BusPIRone HCI; PHARMACEUTICAL RESOURCES INC Buss, Inc.; GEORG FISCHER LTD Busulfex; ORPHAN MEDICAL INC buySTERIS; STERIS CORP C&D Technologies, Inc.; JOHNSON CONTROLS INC C&E Corp.; CHIYODA CORPORATION C.E.T. Dental Products; VIRBAC INC cA2; CENTOCOR INC CAB-2; XOMA LTD Cable News Network; AOL TIME WARNER INC Cable-Ready; ZIMMER HOLDINGS INC Cabletron Systems, Inc.; ENTERASYS NETWORKS INC CablexChange; BROADCOM CORP CacheFlow, Inc.; NETWORK ASSOCIATES INC CACI Products Group; COMPUWARE CORP CADDS 5i; PARAMETRIC TECHNOLOGY CORP Cadence Berkeley Laboratories; CADENCE DESIGN SYSTEMS INC Cadillac; GENERAL MOTORS CORP Caelyx; ALZA CORP CAiCE; AUTODESK INC Calico Commerce, Inc.; PEOPLESOFT INC Caltex Corp.; CHEVRONTEXACO CORPORATION Calydon, Inc.; CELL GENESYS INC Cambrex Bio Science Baltimore, Inc.; CAMBREX CORP Cambrex Bio Science Rockland, Inc.; CAMBREX CORP Cambrex Karlskoga AB; CAMBREX CORP Cambrex Profarmaco Milano; CAMBREX CORP Cambridge Discovery Chemistry; MILLENNIUM PHARMACEUTICALS INC Cambridge Medical Publications; PAREXEL INTERNATIONAL Cambridge Technology Partners; NOVELL INC CAMD Technology; TULARIK INC CAMPATH; ILEX ONCOLOGY INC CAMPATH; MILLENNIUM PHARMACEUTICALS INC Campral; FOREST LABORATORIES INC Camptosar; HYBRIDON INC Camtronics Medical Systems; ANALOGIC CORP Cangene; CHESAPEAKE BIOLOGICAL LAB Cannon; ITT INDUSTRIES INC Canon USA, Inc.; CANON INC Capitol Vial, Inc.; APOGENT TECHNOLOGIES INC Capsule Report (The); SYNBIOTICS CORP Captopril; PHARMACEUTICAL RESOURCES INC Cardbus; STANDARD MICROSYSTEMS CORPORATION Cardiac Rhythm Management; MEDTRONIC INC Cardiac Surgery Unit; ST JUDE MEDICAL INC
Plunkett Research, Ltd.
www.plunkettresearch.com
INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Cardinal Health; SYNCOR INTERNATIONAL CORPORATION Cardiolite; SYNCOR INTERNATIONAL CORPORATION Carecast; IDX SYSTEMS CORP Carloe, Inc.; CARRINGTON LABORATORIES INC Carlyle Group (The); MEDPOINTE INC Carmol 40; BRADLEY PHARMACEUTICALS Carpentier-Edwards; EDWARDS LIFESCIENCES CORP Cartera Grupo Logistico; GRUPO DRAGADOS Carter-Wallace; MEDPOINTE INC Cartia XT; ANDRX CORP Cayenta; TITAN CORP (THE) CBI Technologies, Inc.; PRAXAIR INC CDMA; QUALCOMM INC CDMA2000 AAA; TELEFON AB LM ERICSSON CEA-Cide; IMMUNOMEDICS INC CEA-Scan; IMMUNOMEDICS INC Ceclor; ELI LILLY & CO Celebrex; PFIZER INC Celera Diagnostics; CELERA GENOMICS GROUP Celera Discovery System; CELERA GENOMICS GROUP Celeron Corp.; GOODYEAR TIRE & RUBBER COMPANY (THE) Celexa; FOREST LABORATORIES INC Celgro, Inc.; CELGENE CORP Cell Saver; HAEMONETICS CORPORATION CellExSys; TARGETED GENETICS CORP CellXpress; NETWORK EQUIPMENT TECHNOLOGIES INC Celsior; SANGSTAT MEDICAL CORP Center for Seismic Design; SKIDMORE OWINGS & MERRILL LLP Centrifugal/Mechanical Associates, Inc.; DUALSTAR TECHNOLOGIES CORPORATION Centrino; INTEL CORP Ceprotin; BAXTER INTERNATIONAL INC Ceregene, Inc.; CELL GENESYS INC Cerezyme; GENZYME CORP Cerner Millennium Platform; CERNER CORP Certen, Inc.; AMDOCS LTD CF Portrait; THERMO ELECTRON CORP CG53135; CURAGEN CORPORATION CGE International, Ltd.; JABIL CIRCUIT INC Challenger Aircraft; BOMBARDIER INC Character Studio 4; AUTODESK INC Charmilles Technologies SA; GEORG FISCHER LTD Cheetah; SEAGATE TECHNOLOGY INC ChemCore; TRIPOS INC Chemicon International, Inc.; SEROLOGICALS CORP ChemSource Corp.; IVAX CORPORATION ChemSpace; TRIPOS INC ChemStat; BOSTON BIOMEDICA INC
CherryPicker; TERAYON COMMUNICATION SYSTEMS INC Chevrolet; GENERAL MOTORS CORP Chevron Corp.; CHEVRONTEXACO CORPORATION ChevronTexaco; ENERGY CONVERSION DEVICES INC ChevronTexaco Global Gas; CHEVRONTEXACO CORPORATION Children's Medical Ventures; RESPIRONICS INC Chip Architect; SYNOPSYS INC ChipArray BGA; AMKOR TECHNOLOGY INC Chiron Biopharmaceuticals; CHIRON CORP Chiron Blood Testing; CHIRON CORP Chiron Corporation; MATRIX PHARMACEUTICAL Chiron Vaccines; CHIRON CORP Chiyoda-Dames & Moore; CHIYODA CORPORATION Chromacol, Ltd.; APOGENT TECHNOLOGIES INC Chromagen; K V PHARMACEUTICAL CO Chronimed Holdings, Inc.; CHRONIMED INC Chrysalix Energy; ROYAL DUTCH PETROLEUM CO Chrysler; DAIMLERCHRYSLER AG Chugai Pharmaceutical Co.; GELTEX PHARMACEUTICALS Cialis; ICOS CORPORATION CIBA Vision; NOVARTIS AG Cidecin; CUBIST PHARMACEUTICALS Ciprobay; BAYER AG CIRCA Technology; GOOGLE INC Cisplatin Extra; SUPERGEN INC Citroen; PSA PEUGEOT CITROEN SA Citrucel; GLAXOSMITHKLINE PLC Civacir; NABI BIOPHARMACEUTICALS Civic; HONDA MOTOR CO LTD Clairol, Inc.; BRISTOL MYERS SQUIBB CO CLARiiON; EMC CORP CLARINEX; SEPRACOR INC ClearPath Enterprise; UNISYS CORP CleverPath; COMPUTER ASSOCIATES INTERNATIONAL INC Climara; FOREST LABORATORIES INC Clinac Series; VARIAN MEDICAL SYSTEMS INC Clinical Partners, Inc.; CHRONIMED INC Clobetasol E; TARO PHARMACEUTICAL INDUSTRIES CLOFAREX; ILEX ONCOLOGY INC Clontech Laboratories, Inc.; BECTON DICKINSON & CO CNH Global; FIAT SPA CoCentric; SYNOPSYS INC Codeisan; BENTLEY PHARMACEUTICALS INC Codexis, Inc.; MAXYGEN INC Codman and Shurtleff, Inc.; DEPUY INC CoEase; ANIKA THERAPEUTICS INC Cofiroute; VINCI Coflexip SA; TECHNIP-COFLEXIP Cogent Diagnostics, Ltd.; HYCOR BIOMEDICAL INC
Plunkett Research, Ltd.
www.plunkettresearch.com
INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Cognex; FIRST HORIZON PHARMACEUTICALS COLD; FILENET CORP ColdBlue; PERKINELMER INC Cole-Parmer Instrument Company; FISHER SCIENTIFIC INTERNATIONAL INC Colilert-18; IDEXX LABORATORIES INC Colisure; IDEXX LABORATORIES INC Collectfirst; HAEMONETICS CORPORATION ColorWise; ELECTRONICS FOR IMAGING INC Col-Sur P.A.D.; MEDTRONIC AVE INC Columbia Music; SONY CORPORATION Columbia TriStar Motion Picture Group; SONY CORPORATION Columbia/HCA; GENERAL ELECTRIC CO Comau; FIAT SPA Comax; AMEY PLC CombiPatch; NOVEN PHARMACEUTICALS Combivir; SHIRE-BIOCHEM INC Comcast; MICROSOFT CORP ComCoTec; ACTERNA CORPORATION Command and Control Communications; MOTOROLA INC CommWorks Corporation; 3COM CORP Companion Animal Health; HESKA CORP Compaq Corp.; HEWLETT-PACKARD CO Comparative Genomic Hybridization; VYSIS INC Composix; CR BARD INC Compugen; GENOME THERAPEUTICS CORP Computerized Structural Analysis and Res. Corp.; MSC.SOFTWARE CORP COMPUTROL on Line; SIGMA ALDRICH CORP CONMED Andover Medical, Inc.; CONMED CORP Connect Systems Integrator; GETRONICS NV Connectrix Enterprise Storage Network; EMC CORP Connetics Center for Skin Biology; CONNETICS CORPORATION Connex; NORTEL NETWORKS CORP Connexion by Boeing; BOEING CO Connor Peripherals; SEAGATE TECHNOLOGY INC Conoco Global Power; CONOCOPHILLIPS Conoco, Inc.; CONOCOPHILLIPS Conserve-N; IMC GLOBAL INC Consolidated Converting Co.; CUBIC CORP Constant Power Manufacturing, Inc.; ENGLOBAL CORP Contour Optics; SOLA INTERNATIONAL INC ConvaTec; BRISTOL MYERS SQUIBB CO Cook Pharmaceutical Solutions; BAXTER INTERNATIONAL INC Copeland Optical, Inc.; SOLA INTERNATIONAL INC Coppertone; SCHERING-PLOUGH CORP COR Therapeutics, Inc.; MILLENNIUM PHARMACEUTICALS INC CorCAAT; ADAC LABORATORIES CORE Dynamics, Inc.; CONMED CORP CoreDirector; CIENA CORP
CoreHTS; PANVERA LLC CoreWare; LSI LOGIC CORP CORGENIC; COLLATERAL THERAPEUTICS Corian; E I DU PONT DE NEMOURS & CO (DUPONT) Correctol; SCHERING-PLOUGH CORP Corsa; ADAM OPEL AG Cosgrove-Edwards; EDWARDS LIFESCIENCES CORP Cosmoflex, Inc.; GOODYEAR TIRE & RUBBER COMPANY (THE) Cosworth Technology Limited; AUDI AG Coulter Corporation; BECKMAN COULTER INC Coulter Pharmaceutical; CORIXA CORPORATION Covance Clinical Research Unit, Inc.; COVANCE INC Covance Pharmaceutical Packaging Services, Inc.; COVANCE INC Coviracil; TRIANGLE PHARMACEUTICALS Cozaar; MERCK & CO INC CPET; ADAC LABORATORIES CPLD; XILINX INC CPX; SCICLONE PHARMACEUTICALS Creative Beauty Innovations, Inc.; CARRINGTON LABORATORIES INC Creative Technology; GENERAL DYNAMICS Crosby Mead Benton & Associates; KEITH COMPANIES INC (THE) CRS Robotics Corp.; THERMO ELECTRON CORP CR-V; HONDA MOTOR CO LTD CRYOMAX; TECHNIP-COFLEXIP CryptoLight; MARTEK BIOSCIENCES CORP Crystal; CIRRUS LOGIC INC Crystal Computer Services; SEAGATE TECHNOLOGY INC CS7410; CIRRUS LOGIC INC CSC Credit Services; COMPUTER SCIENCES CORP CSC Financial Services Group; COMPUTER SCIENCES CORP CSC Healthcare Corp.; COMPUTER SCIENCES CORP CSC Pinnacle Alliance; COMPUTER SCIENCES CORP CT-2106; CELL THERAPEUTICS INC CT-2584; CELL THERAPEUTICS INC CTG Engineering Method; CHIYODA CORPORATION Cubic Applications, Inc.; CUBIC CORP Cubic Defense Systems, Inc.; CUBIC CORP Cubic Driver Control Unit; CUBIC CORP Cubic Transportation Systems, Inc.; CUBIC CORP Customer DataMart; ASPECT COMMUNICATIONS CORP CustomerPlace; GETRONICS NV CustomerXPRESS; LYONDELL CHEMICAL COMPANY CustomSeq; AFFYMETRIX INC CustomSuites; GENE LOGIC INC CV70; ACUSON CORPORATION
Plunkett Research, Ltd.
www.plunkettresearch.com
INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Cyber IQ Systems; AVAYA INC CyberStar, LP; LORAL SPACE & COMMUNICATIONS LTD Cyclicons; HYBRIDON INC Cymetra; LIFECELL CORPORATION Cypress; ACUSON CORPORATION Cypress Group (The); MEDPOINTE INC Cypress MicroSystems; CYPRESS SEMICONDUCTOR CORP Cystadane; ORPHAN MEDICAL INC Cystrin CR; PENWEST PHARMACEUTICALS CO CytoGam; MEDIMMUNE INC Cytyc Health Corporation; CYTYC CORP D2E7; GTC BIOTHERAPEUTICS INC da Vinci Systems; ACTERNA CORPORATION Dacron; E I DU PONT DE NEMOURS & CO (DUPONT) Dade Diagnostics; DADE BEHRING INC Dade Finance, Inc.; DADE BEHRING INC Dade MicroScan, Inc.; DADE BEHRING INC Daig Division; ST JUDE MEDICAL INC Daihatsu; TOYOTA MOTOR CORPORATION DaimlerChrysler AG; MITSUBISHI MOTORS CORP Data Beam Corp.; INTERNATIONAL BUSINESS MACHINES (IBM) Data General; EMC CORP Data ONTAP; NETWORK APPLIANCE INC Data Processing Resources Corp.; COMPUWARE CORP DataFusion; MENTOR GRAPHICS CORP DataPath Systems; LSI LOGIC CORP DataStage; ASCENTIAL SOFTWARE CORPORATION DataSuites; GENE LOGIC INC DataViews; ACTERNA CORPORATION Datex-Ohmeda; INSTRUMENTARIUM Datum Telegraphic; PMC-SIERRA INC Dauno Extra; SUPERGEN INC DaunoXome; GILEAD SCIENCES INC DEA High Load; TECHNIP-COFLEXIP DecisionSpace DMS; HALLIBURTON COMPANY Deconamine; BRADLEY PHARMACEUTICALS DeepSight; SYMANTEC CORP DEFINITY; AVAYA INC Degree; MONSANTO CO Deio; INSTRUMENTARIUM Del Pharmaceuticals, Inc.; DEL LABORATORIES INC DELATESTRYL; BIO TECHNOLOGY GENERAL CORP DELFIA; PERKINELMER INC Dell Precision Workstation 360; DELL COMPUTER CORPORATION DellHost; DELL COMPUTER CORPORATION DelSite Biotechnologies, Inc.; CARRINGTON LABORATORIES INC Delta39K; CYPRESS SEMICONDUCTOR CORP
DENSO International America, Inc.; DENSO CORPORATION DENSO Sales California, Inc.; DENSO CORPORATION DENSO Wireless Systems America, Inc.; DENSO CORPORATION Depakote; ABBOTT LABORATORIES Department of Defense; FLUOR CORP Department of Energy; FLUOR CORP DePuy ACE; DEPUY INC DePuy AcroMed; DEPUY INC DePuy AcroMed, Inc.; JOHNSON & JOHNSON DePuy Casting; DEPUY INC DePuy International; DEPUY INC DePuy Orthopaedics; DEPUY INC Design Compiler; SYNOPSYS INC Detox; CORIXA CORPORATION Deutsche Asphalt; PHILIPP HOLZMANN GROUP DevelopmentStudio; RATIONAL SOFTWARE CORP DeVilbiss; SUNRISE MEDICAL INC DHASCO; MARTEK BIOSCIENCES CORP Diabetic Tussin; HI TECH PHARMACAL CO INC DiabetiSweet; HI TECH PHARMACAL CO INC Diamond Animal Health; HESKA CORP Diamond Lane Communications; NOKIA CORPORATION DiamondMax; MAXTOR CORP Didronel I.V. Infusion; MGI PHARMA INC Diebold Election Systems, Inc.; DIEBOLD INC Diflucan; PFIZER INC Digene Europe; DIGENE CORPORATION Digital Independence; CITRIX SYSTEMS INC Digitek; MYLAN LABORATORIES INC Digitek Electronics, Ltd.; JABIL CIRCUIT INC Diltia XT; ANDRX CORP Dimension; DELL COMPUTER CORPORATION Diprivan; ASTRAZENECA PLC DirecPC; HUGHES ELECTRONICS CORP Direct FuelCell; FUELCELL ENERGY INC Directed Biosynthesis; CUBIST PHARMACEUTICALS DIRECTV; HUGHES ELECTRONICS CORP DIRECWAY; HUGHES ELECTRONICS CORP Discovery Line; INVITROGEN CORPORATION DiscoveryCom; NOKIA CORPORATION Discreet; AUTODESK INC Display Products Group, Inc.; APPLIED MATERIALS INC Ditropan XL; ALZA CORP DLTtape; QUANTUM CORP DM1000 Mailing System; PITNEY BOWES INC DMAX, Ltd.; ISUZU MOTORS LTD DNA FISH; VYSIS INC DNAShuffling; MAXYGEN INC Doak Dermatologics; BRADLEY PHARMACEUTICALS
Plunkett Research, Ltd.
www.plunkettresearch.com
INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Document Messaging Technologies; PITNEY BOWES INC Document Solutions Suite; LEXMARK INT'L GROUP INC DocuTech; XEROX CORP Dodge; DAIMLERCHRYSLER AG Dovetail Software; ASCENTIAL SOFTWARE CORPORATION Dow AgroSciences; DOW CHEMICAL COMPANY (THE) Dow Corning; DOW CHEMICAL COMPANY (THE) Dow Europe; DOW CHEMICAL COMPANY (THE) Dr. Scholl's; SCHERING-PLOUGH CORP Dragados Concessions International; GRUPO DRAGADOS Dragados Industrial International; GRUPO DRAGADOS Dragados Obras Y Poryectos; GRUPO DRAGADOS Dragados Servicios; GRUPO DRAGADOS Dragon; ENTERASYS NETWORKS INC Drixocal; SCHERING-PLOUGH CORP Droit & Pharmacie; PAREXEL INTERNATIONAL DSC/Celcore, Inc.; ALCATEL USA INC DSU Series; ADTRAN INC Du Pont; CONOCOPHILLIPS Dual Gold; SYNGENTA AG DualStar Communications, Inc.; DUALSTAR TECHNOLOGIES CORPORATION Duke/Fluor Daniel; FLUOR CORP Dunlop; GOODYEAR TIRE & RUBBER COMPANY (THE) DuPont Pharmaceuticals; BRISTOL MYERS SQUIBB CO DuraSolv; CIMA LABS INC Duron; ADVANCED MICRO DEVICES INC DUROS; ALZA CORP DYNACIN; MEDICIS PHARMACEUTICAL CORP Dynafos; IMC GLOBAL INC DynaGen, Inc.; ABLE LABORATORIES Dynamic Healthcare Technologies, Inc.; CERNER CORP Dynamicon BV; ARCADIS NV Dynatech; ACTERNA CORPORATION DynaVox; SUNRISE MEDICAL INC Dynegy, Inc.; CHEVRONTEXACO CORPORATION Dynepo; TRANSKARYOTIC THERAPIES E.R.D.-Screen Urine Test; HESKA CORP EA.com; ELECTRONIC ARTS INC Eagle; DAIMLERCHRYSLER AG Earth Consultants, Inc.; US LABORATORIES Easi-Breathe; IVAX CORPORATION Eastman Gelatine Corp.; EASTMAN KODAK CO EasyShare; EASTMAN KODAK CO EASYTRAK; GUIDANT CORP eBeam; ELECTRONICS FOR IMAGING INC EBI, L.P.; BIOMET INC eBreviate; ELECTRONIC DATA SYSTEMS CORP
eBusiness Architect; ASPECT COMMUNICATIONS CORP ec-Content, Inc.; I2 TECHNOLOGIES INC EchoStar VII; LOCKHEED MARTIN CORP ECLIPS; AVAYA INC ECLiPS; PHARMACOPEIA INC Eclipse; MITSUBISHI MOTORS CORP Econazole Nitrate Cream 1%; TARO PHARMACEUTICAL INDUSTRIES Ecostar; BALLARD POWER SYSTEMS Ecton, Inc.; ACUSON CORPORATION eData Entry; ERESEARCH TECHNOLOGY INC E-difica; GRUPO DRAGADOS Edison Development Company; PLUG POWER INC EDITEK, Inc.; MEDTOX SCIENTIFIC INC EDiX Corp.; IDX SYSTEMS CORP EEPROM; MICROCHIP TECHNOLOGY INC EfiColor; ELECTRONICS FOR IMAGING INC Efudex/Efudix; ICN PHARMACEUTICALS INC EG&G Technical Services; URS CORPORATION eHealth Education; ERESEARCH TECHNOLOGY INC eKendleCollege; KENDLE INTERNATIONAL INC Elan Corp.; ATRIX LABORATORIES INC Elan Corporation, plc; KING PHARMACEUTICALS INC Elantra; HYUNDAI MOTOR COMPANY Electric Boat Company; GENERAL DYNAMICS Electrofill; NOVELLUS SYSTEMS INC Electron Vision Corporation; APPLIED MATERIALS INC Eli Lilly & Company; ISIS PHARMACEUTICALS INC Eligard; ATRIX LABORATORIES INC eLink; BEA SYSTEMS INC Eliptica; HEWLETT-PACKARD CO ELISA; HYCOR BIOMEDICAL INC Elliotts B Solution; ORPHAN MEDICAL INC EMAXplus; ADVANCED FIBRE COMMUNICATIONS INC EMI Music; AOL TIME WARNER INC EN3202; PENWEST PHARMACEUTICALS CO Enalapril Belmac; BENTLEY PHARMACEUTICALS INC Enbrel; AMGEN INC ENBREL; IMMUNEX CORP Encon Safety Products, Inc.; VALLEN CORP Endo Pharmaceuticals, Inc.; ENDO PHARMACEUTICALS HOLDINGS INC Energy Equipment Group; FOSTER WHEELER LTD Engineering and Construction Group; FOSTER WHEELER LTD Engineering-e.com; MSC.SOFTWARE CORP ENGlobal Engineering, Inc.; ENGLOBAL CORP Eni Norge AS; ENI SPA EniPower S.p.A.; ENI SPA Ensure; ABBOTT LABORATORIES
Plunkett Research, Ltd.
www.plunkettresearch.com
INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Entercept Security Technologies; NETWORK ASSOCIATES INC Enteric Products, Inc.; E-Z-EM INC Enterprise Storage Network; EMC CORP Enteryx; BOSTON SCIENTIFIC CORP Entrust Technologies, Inc.; NORTEL NETWORKS CORP EnVision; PERKINELMER INC ENVOI; ADAC LABORATORIES Enzo Clinical Labs, Inc.; ENZO BIOCHEM INC Enzo Diagnostics, Inc.; ENZO BIOCHEM INC Enzo Therapeutics, Inc.; ENZO BIOCHEM INC EnzyMed; ALBANY MOLECULAR RESEARCH Eos Biotechnology, Inc.; PROTEIN DESIGN LABS INC ePad; AMKOR TECHNOLOGY INC Epic + DR ICD; ST JUDE MEDICAL INC Epicor Medical, Inc.; ST JUDE MEDICAL INC EPITAXX, Inc.; JDS UNIPHASE CORP Epogen; AMGEN INC ePolicy Orchestrator; NETWORK ASSOCIATES INC Equell; VIRBAC INC Equimax; VIRBAC INC Equistar Chemicals, L.P.; LYONDELL CHEMICAL COMPANY Erbitux; BRISTOL MYERS SQUIBB CO Ercole Biotech, Inc.; ISIS PHARMACEUTICALS INC eResCom; ERESEARCH TECHNOLOGY INC eResearch Network; ERESEARCH TECHNOLOGY INC Ericsson Mobile Platforms; TELEFON AB LM ERICSSON eRT Operating Company; ERESEARCH TECHNOLOGY INC ES7000 Server; UNISYS CORP ESOTERICA; MEDICIS PHARMACEUTICAL CORP Estalis; NOVEN PHARMACEUTICALS Esteem; SUZUKI MOTOR CORPORATION Ester-C; ZILA INC ESTORRA Brand Eszopiclone; SEPRACOR INC Estradot; NOVEN PHARMACEUTICALS Etec Systems, Inc.; APPLIED MATERIALS INC E-TEK Dynamics, Inc.; JDS UNIPHASE CORP Etenna Corp.; TITAN CORP (THE) e-TEST for WAP; TERADYNE INC Ether Power II; STANDARD MICROSYSTEMS CORPORATION ETHEX Corporation; K V PHARMACEUTICAL CO Ethicon, Inc.; JOHNSON & JOHNSON Ethrog Biotechnologies; INVITROGEN CORPORATION Ethyol; MEDIMMUNE INC Etoposide Extra; SUPERGEN INC E-TRANS; ALZA CORP eTrust; COMPUTER ASSOCIATES INTERNATIONAL INC
Eudora; QUALCOMM INC Eureka; CHIYODA CORPORATION Eurofighter Typhoon; BAE SYSTEMS European Aeronautic Defence and Space Co.; AIRBUS SAS Eurovia; VINCI EVallen.com; VALLEN CORP Evercel; FUELCELL ENERGY INC Evergreen; SCOTTS CO EXACT System; ANALOGIC CORP Excedrin; BRISTOL MYERS SQUIBB CO Excel; HYUNDAI MOTOR COMPANY Excelerator; NOVELL INC Exelan Dielectric 2300; LAM RESEARCH CORP Exelixis Plant Sciences, Inc.; EXELIXIS INC Exelixis, Inc.; EXELIXIS PLANT SCIENCES INC Expedition; MENTOR GRAPHICS CORP EXPeRT; ERESEARCH TECHNOLOGY INC Expert; SYMANTEC CORP Explore; SCIENTIFIC ATLANTA INC Express Delivery XT; DIEBOLD INC exteNd; NOVELL INC EXTRANEAL; BAXTER INTERNATIONAL INC Extreme Packet Devices; PMC-SIERRA INC Extreme, Inc.; 3M COMPANY Exxon Chemical Company; EXXONMOBIL CORPORATION Exxon China, Inc.; EXXONMOBIL CORPORATION Exxon Coal and Minerals Company; EXXONMOBIL CORPORATION Exxon Company International; EXXONMOBIL CORPORATION Exxon Exploration Company; EXXONMOBIL CORPORATION Exxon Research and Engineering Company; EXXONMOBIL CORPORATION Exxon Ventures (CIS), Inc.; EXXONMOBIL CORPORATION E-Z-EM Canada, Inc.; E-Z-EM INC Ez-Quant; MEDTOX SCIENTIFIC INC Ez-Screen; MEDTOX SCIENTIFIC INC F.H. Faulding & Co., Ltd.; NAPRO BIOTHERAPEUTICS INC F-16; LOCKHEED MARTIN CORP F-22 Raptor; LOCKHEED MARTIN CORP Failed Reactions Database; PHARMACOPEIA INC Faithful & Gould; WS ATKINS PLC Falcon Pharmaceuticals; ALCON LABORATORIES INC Famotidine; PHARMACEUTICAL RESOURCES INC Faslodex; ASTRAZENECA PLC FastTrack 2.0 Kit; INVITROGEN CORPORATION Faurecia; PSA PEUGEOT CITROEN SA FedSelect; CACI INTERNATIONAL INC Fenofibrate; IMPAX LABORATORIES INC Ferrari; FIAT SPA
Plunkett Research, Ltd.
www.plunkettresearch.com
INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Ferrer Freeman & Company, LLC; MEDPOINTE INC Ferrlecit; WATSON PHARMACEUTICALS INC Feverall; ASCENT PEDIATRICS INC Fiat Auto; FIAT SPA Fiat Auto; GENERAL MOTORS CORP Fiblast; SCIOS INC Fibrimage; BIO TECHNOLOGY GENERAL CORP Fiery; ELECTRONICS FOR IMAGING INC Fifth Dimension Information Systems; HAEMONETICS CORPORATION FileNET P8; FILENET CORP Financial Fusion, Inc.; SYBASE INC FINDER; CACI INTERNATIONAL INC Fine Chemicals Division; ALBEMARLE CORPORATION Finn Knee Replacement System; BIOMET INC Fioricet; WATSON PHARMACEUTICALS INC Fiorinal; WATSON PHARMACEUTICALS INC Fireball; MAXTOR CORP FireWire; WESTERN DIGITAL CORP FirstCyte Ductal Lavage; CYTYC CORP FirstPoint Contact; ROCKWELL AUTOMATION Fisher Clinical Services, Inc.; FISHER SCIENTIFIC INTERNATIONAL INC Fisher Hamilton; FISHER SCIENTIFIC INTERNATIONAL INC Fisher HealthCare; FISHER SCIENTIFIC INTERNATIONAL INC Fisher Research; FISHER SCIENTIFIC INTERNATIONAL INC Fisher Science Education; FISHER SCIENTIFIC INTERNATIONAL INC FLASHlogic; ALTERA CORP FLEX 8000; ALTERA CORP fleXBGA; AMKOR TECHNOLOGY INC FlexTip Plus; ARROW INTERNATIONAL INC FlipFET; INTERNATIONAL RECTIFIER CORP Flomax; ABBOTT LABORATORIES Flourous Technologies, Inc.; ALBANY MOLECULAR RESEARCH Flovent; GLAXOSMITHKLINE PLC Flowcast; IDX SYSTEMS CORP Fluad; CHIRON CORP Fluka; SIGMA ALDRICH CORP Flunisolide HFA; FOREST LABORATORIES INC Fluor Federal Services; FLUOR CORP Fluor Global Sourcing; FLUOR CORP Fluor/AMEC; FLUOR CORP Fluorescence In Situ Hybridization; VYSIS INC Fluoxetine; PHARMACEUTICAL RESOURCES INC Fluoxetine Hydrochloride; BARR LABORATORIES INC Fluoxetine Oral Solution; HI TECH PHARMACAL CO INC Flutamide; BARR LABORATORIES INC Fluvial S/F; SHIRE-BIOCHEM INC
FMdC; MATRIX PHARMACEUTICAL Focalin; CELGENE CORP Fogarty; EDWARDS LIFESCIENCES CORP Ford Motor Co.; MAZDA MOTOR CORPORATION Ford Motor Company; VISTEON CORPORATION Forefront Diagnostics; APOGENT TECHNOLOGIES INC Forester; FUJI HEAVY INDUSTRIES LTD Formula 4; MAXTOR CORP Formulaid; MARTEK BIOSCIENCES CORP Formulation Tool Kit; LYONDELL CHEMICAL COMPANY Fosamax; MERCK & CO INC Foster Wheeler Energy Limited; FOSTER WHEELER LTD Foster Wheeler Europe Limited; FOSTER WHEELER LTD Foster Wheeler Power Machinery Co. Limited; FOSTER WHEELER LTD FPGA OpenMORE; XILINX INC FRAGMIN; CENTOCOR INC FrameXpress; NETWORK EQUIPMENT TECHNOLOGIES INC Francodex; VIRBAC INC Frazier Healthcare Ventures; MEDPOINTE INC Freeman Energy Corp.; GENERAL DYNAMICS FriendsTalk; NOKIA CORPORATION Frontera; ADAM OPEL AG Froogle; GOOGLE INC Fuji Heavy Industries; GENERAL MOTORS CORP Fuji Xerox; XEROX CORP Fuji, RC Co., Ltd.; RESPIRONICS INC Fujian Casix Lasers, Inc.; JDS UNIPHASE CORP FunctionFinder; PARADIGM GENETICS INC Fusion Medical Technologies, Inc.; BAXTER INTERNATIONAL INC FVR; TECHNIP-COFLEXIP FW Pharma Systems, Ltd.; PAREXEL INTERNATIONAL FX miniRAIL; GUIDANT CORP FX-4400; PERKINELMER INC G.A. Design International Holdings, Ltd.; HLM DESIGN INC G2E; GETRONICS NV Gabitril; CEPHALON INC Gaia Herbs; PURE WORLD INC Gala; ISUZU MOTORS LTD Galant; MITSUBISHI MOTORS CORP GAZOO; TOYOTA MOTOR CORPORATION GCG Wisconsin Package; PHARMACOPEIA INC GE Industrial Systems; AMERICAN SUPERCONDUCTOR Gefco; PSA PEUGEOT CITROEN SA GelSponge; IOMED INC GEM 231; HYBRIDON INC Geminex; PENWEST PHARMACEUTICALS CO
Plunkett Research, Ltd.
www.plunkettresearch.com
INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Gemini; ALARIS MEDICAL INC Gene Site Saturation Mutagenesis; DIVERSA CORPORATION GeneCalling; CURAGEN CORPORATION GeneChip; AFFYMETRIX INC GeneChip CustomExpress; AFFYMETRIX INC GeneExpress; GENE LOGIC INC GeneFold; TRIPOS INC Genefunction Factory; PARADIGM GENETICS INC General Electric; INSTRUMENTARIUM General Electric Aircraft Engines; GENERAL ELECTRIC CO General Electric Appliances; GENERAL ELECTRIC CO General Electric Capital Corporation; GENERAL ELECTRIC CO General Electric Lighting; GENERAL ELECTRIC CO General Electric Medical Systems; GENERAL ELECTRIC CO General Electronics, Ltd.; JABIL CIRCUIT INC General Motors; ADAM OPEL AG General Motors; ISUZU MOTORS LTD GENERX; COLLATERAL THERAPEUTICS GeneScape; CURAGEN CORPORATION GeneSeq; VIROLOGIC INC Genesis: The GeneExpress Enterprise System; GENE LOGIC INC Gene-Trak DNA; NEOGEN CORPORATION GeneTrove Division; ISIS PHARMACEUTICALS INC Genevac, Ltd.; APOGENT TECHNOLOGIES INC GENEVX; COLLATERAL THERAPEUTICS GenFlex Tag Array; AFFYMETRIX INC Gengraf; SANGSTAT MEDICAL CORP Genmab; MEDAREX INC GenomeVision Services; GENOME THERAPEUTICS CORP Gensia Sicor Pharmaceuticals; SICOR INC GenSys 5C; PLUG POWER INC GENVASCOR; COLLATERAL THERAPEUTICS Genyx Medical, Inc.; CR BARD INC Genzyme; BIOMARIN PHARMACEUTICAL Genzyme Biosurgery; GENZYME CORP Genzyme Corporation; GELTEX PHARMACEUTICALS Genzyme General; GENZYME CORP Genzyme Molecular Oncology; GENZYME CORP Genzyme Transgenics Corp.; GTC BIOTHERAPEUTICS INC GeoCities; YAHOO! INC GeoMedia; INTERGRAPH CORP GeoProtect; CH2M HILL COMPANIES LTD Gerber Coburn Optical, Inc.; GERBER SCIENTIFIC INC Gerber Garment Technology, Inc.; GERBER SCIENTIFIC INC Gerber Innovations; GERBER SCIENTIFIC INC
Gerber Scientific Products, Inc.; GERBER SCIENTIFIC INC Gerber Systems Corporation; GERBER SCIENTIFIC INC GET Manufacturing, Inc.; JABIL CIRCUIT INC Getz Bros. Co. Ltd.; ST JUDE MEDICAL INC GigaBlaze; LSI LOGIC CORP Gilead Sciences, Inc.; OSI PHARMACEUTICALS INC Gilead Sciences, Inc.; TRIANGLE PHARMACEUTICALS Ginzton Technology Center; VARIAN MEDICAL SYSTEMS INC GlaxoSmithKline plc; EXELIXIS INC GLIADEL Wafer; GUILFORD PHARMACEUTICALS INC Global Divers; GLOBAL INDUSTRIES LTD Global Knowledge Services, Inc.; APPLIED MATERIALS INC Global Offshore Mexico; GLOBAL INDUSTRIES LTD Global Pharmaceutical Corp.; IMPAX LABORATORIES INC Global Plus; SUNGARD DATA SYSTEMS INC Global Property Alliance; WS ATKINS PLC Global Supply Group; BECHTEL GROUP INC Globalstar; LORAL SPACE & COMMUNICATIONS LTD Glucobay; BAYER AG Glutofac-MX; BRADLEY PHARMACEUTICALS Glyko Biomedical; BIOMARIN PHARMACEUTICAL GM Defense; GENERAL DYNAMICS Go Secure!; VERISIGN INC Godfrey Engineering, Inc.; GOODRICH CORPORATION Gold Standard; NORTH AMERICAN SCIENTIFIC Goldenseal; PURE WORLD INC Goldman Sachs; DADE BEHRING INC Good Technology, Inc.; DELL COMPUTER CORPORATION Goodron Reality, Inc.; GOODRICH CORPORATION GPI 1485; GUILFORD PHARMACEUTICALS INC GPU International; ASTROPOWER INC Graft Jacket; LIFECELL CORPORATION Grand Laboratories, Inc.; NOVARTIS AG Grand Vitara; SUZUKI MOTOR CORPORATION GreatDomains.com; VERISIGN INC Group Lafon; CEPHALON INC GS7904L; OSI PHARMACEUTICALS INC Guardian; SUNRISE MEDICAL INC GuardiaNet Systems, Inc.; 3M COMPANY GuardWire Plus; MEDTRONIC AVE INC Gulf Sulphur Services, Ltd.; IMC GLOBAL INC Gulfstream Aerospace; GENERAL DYNAMICS GVAX Cancer Vaccine; CELL GENESYS INC Gynecare; JOHNSON & JOHNSON GYNECARE THERMACHOICE III; JOHNSON & JOHNSON
Plunkett Research, Ltd.
www.plunkettresearch.com
INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Gyricon Media, Inc.; XEROX CORP HA North American Sales AB; MEDICIS PHARMACEUTICAL CORP HaemoLite; HAEMONETICS CORPORATION Hagemeyer N.V. Corp.; VALLEN CORP Halliburton Deepwater; HALLIBURTON COMPANY Halliburton Energy Services; HALLIBURTON COMPANY Halliburton KBR; HALLIBURTON COMPANY Hammer; ADVANCED MICRO DEVICES INC Hamo Holding AG; STERIS CORP Handspring; PALM INC Hard as Nails; DEL LABORATORIES INC Harmony; PROXIM CORPORATION Harness; MONSANTO CO Harrier; BAE SYSTEMS Hauser Chemical Research, Inc.; HAUSER INC Hauser Laboratories; HAUSER INC Hauser Technical Services, Inc.; HAUSER INC Hawk; BAE SYSTEMS Hawker; RAYTHEON CO HB3000; HONEYWELL INTERNATIONAL INC hc2 High-Risk HPV DNA Test; DIGENE CORPORATION HCL Perot Systems; PEROT SYSTEMS CORP HDSL/HDSL2/HDSL4; ADTRAN INC Health Network Architecture; CERNER CORP Health Pharm; PHARMACEUTICAL FORMULATIONS INC Health+Cross; PHARMACEUTICAL FORMULATIONS INC HealthCentral.com; NBTY INC Healtheon; WEBMD CORPORATION Hepsera; GILEAD SCIENCES INC Herceptin; GENENTECH INC Hertz; FORD MOTOR CO HESKA Vet ABC-Diff Hematology Analyzer; HESKA CORP HESKA Vet/Ox G2 Digital Monitor; HESKA CORP Hewlett-Packard Co.; AGILENT TECHNOLOGIES INC Hexalen; MEDIMMUNE INC HFBR-1506AM; AGILENT TECHNOLOGIES INC HFBR-2506AM; AGILENT TECHNOLOGIES INC High Plains Solutions; COMPUWARE CORP HighGround Systems, Inc.; SUN MICROSYSTEMS INC HighLink; TERAYON COMMUNICATION SYSTEMS INC High-Rise Electric, Inc.; DUALSTAR TECHNOLOGIES CORPORATION Hino; TOYOTA MOTOR CORPORATION HLM Design Architecture, Engineering and Planning; HLM DESIGN INC HLM Design of North America, Inc.; HLM DESIGN INC HLM Design USA, Inc.; HLM DESIGN INC
HMT Technology; KOMAG INC HNA Millennium; CERNER CORP HOCHTIEF; PHILIPP HOLZMANN GROUP Holland and Barrett; NBTY INC Holmium-166 DOTMP; NEORX CORPORATION Home Box Office; AOL TIME WARNER INC Home Direct Medical Services, Inc.; CHRONIMED INC HomeFill II Convenience Pack; INVACARE CORP Homelink; JOHNSON CONTROLS INC HOMOLA Projectmanagement AG; ARCADIS NV Honda Marine; HONDA MOTOR CO LTD Honda of America Manufacturing; HONDA MOTOR CO LTD Honda R&D Americas, Inc.; HONDA MOTOR CO LTD Honeywell Aerospace Solutions; HONEYWELL INTERNATIONAL INC Honeywell Software Solutions; HONEYWELL INTERNATIONAL INC Hoppecke Automotive; JOHNSON CONTROLS INC HotBurn CD Writer; IOMEGA CORP HotJobs.com, Ltd.; YAHOO! INC Hotmail; MICROSOFT CORP HR Electrical Systems, Inc.; DUALSTAR TECHNOLOGIES CORPORATION HSB Group, Inc.; CURAGEN CORPORATION HSG Holzmann Technischer Service; PHILIPP HOLZMANN GROUP Hughes Corporation; BOEING CO Hughes Network Systems; HUGHES ELECTRONICS CORP Human Gene Trap; LEXICON GENETICS INC HuMax-CD4; MEDAREX INC Huntingdon Life Sciences Group; LIFE SCIENCES RESEARCH HVRFlex; HADCO CORP HYB 2055; HYBRIDON INC Hybrid Capture Gene Analysis System; DIGENE CORPORATION Hybritech Incorporated; BECKMAN COULTER INC Hycor Biomedical GmbH; HYCOR BIOMEDICAL INC Hycor Biomedical, Ltd.; HYCOR BIOMEDICAL INC HydroFlex; CR BARD INC Hynic-Annexin V; NORTH AMERICAN SCIENTIFIC Hypak; BECTON DICKINSON & CO HyperPHY; LSI LOGIC CORP HY-TEC 288; HYCOR BIOMEDICAL INC HY-TEC 480; HYCOR BIOMEDICAL INC Hyundai; DAIMLERCHRYSLER AG Hyundai America Technical Center; HYUNDAI MOTOR COMPANY Hyundai Motor America; HYUNDAI MOTOR COMPANY HYVISC; ANIKA THERAPEUTICS INC Hyzaar; MERCK & CO INC i2 Content; I2 TECHNOLOGIES INC i2 CRM; I2 TECHNOLOGIES INC
Plunkett Research, Ltd.
www.plunkettresearch.com
INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. i2 SCM; I2 TECHNOLOGIES INC i2 SRM; I2 TECHNOLOGIES INC iAnywhere Solutions; SYBASE INC Ibis Therapeutics Division; ISIS PHARMACEUTICALS INC IBM; ASCENTIAL SOFTWARE CORPORATION IBM; INTERNATIONAL BUSINESS MACHINES (IBM) IBM Software; RATIONAL SOFTWARE CORP iBook; APPLE COMPUTER INC IBU; PHARMACEUTICAL RESOURCES INC IC747; ICOS CORPORATION ICAgen; GENOME THERAPEUTICS CORP iConnect; GLENAYRE TECHNOLOGIES INC Ideal Instruments; NEOGEN CORPORATION IDEC; BIOGEN INC IDEC-131; IDEC PHARMACEUTICALS CORP IDEC-151; IDEC PHARMACEUTICALS CORP IDEC-201; IDEC PHARMACEUTICALS CORP IDM-1; MEDAREX INC IDS Engineering, Inc.; ENGLOBAL CORP IDXtendR; IDX SYSTEMS CORP I-Gear; SYMANTEC CORP IKOS Systems, Inc.; SYNOPSYS INC ILEX Oncology Services, Inc.; ILEX ONCOLOGY INC ILX23-7553; ILEX ONCOLOGY INC ILX-295501; ILEX ONCOLOGY INC iMac; APPLE COMPUTER INC Imagecast; IDX SYSTEMS CORP Imagyn Medical Technologies; CONMED CORP Imbau Industrielles Bauen; PHILIPP HOLZMANN GROUP IMC Phosphates; IMC GLOBAL INC IMC Potash; IMC GLOBAL INC IMC-1C11; IMCLONE SYSTEMS INC IMCB; EXELIXIS INC IMC-C225; IMCLONE SYSTEMS INC IMG Technologies; IMMUNOMEDICS INC ImmTech Biologics, Inc.; NOVARTIS AG Immunex Corp.; AMGEN INC Immuno International AG; BAXTER INTERNATIONAL INC ImmunoCard STAT; MERIDIAN BIOSCIENCE INC Immunol; ENDO PHARMACEUTICALS HOLDINGS INC Immunotech S.A.; BECKMAN COULTER INC IMO Technology; HYBRIDON INC I-MOR; CHIYODA CORPORATION IMPACS; COLLAGENEX PHARMACEUTICAL Impass; CACI INTERNATIONAL INC Impax Pharmaceuticals; IMPAX LABORATORIES INC Imprimis Technology; SEAGATE TECHNOLOGY INC INCERT; ANIKA THERAPEUTICS INC Independent Computing Architecture; CITRIX SYSTEMS INC INDeX; AVAYA INC
Indiplon; NEUROCRINE BIOSCIENCES INC Industrial Data Systems, Inc.; ENGLOBAL CORP Industrial IT; ABB LTD INFeD; WATSON PHARMACEUTICALS INC Infineon Technologies; SIEMENS AG Infiniti; NISSAN MOTOR CO LTD Infinity FloGel; INVACARE CORP InforMax, Inc.; INVITROGEN CORPORATION ING-1; XOMA LTD Inkjet; HEWLETT-PACKARD CO Inktomi; YAHOO! INC InnoCentive LLC.; ELI LILLY & CO Innovase; DIVERSA CORPORATION Innovex; QUINTILES TRANSNATIONAL CORP Innovex; CITRIX SYSTEMS INC INOVA xT; NOVELLUS SYSTEMS INC In-Sight 1700; COGNEX CORP InSpectra; HUTCHINSON TECHNOLOGY INC Inspiron; DELL COMPUTER CORPORATION InStent, Inc.; MEDTRONIC INC Instrumed; INSTRUMENTARIUM InSync III Marquis; MEDTRONIC INC InTalk Corp.; NOKIA CORPORATION Integrated Controls Enterprises, Inc.; DUALSTAR TECHNOLOGIES CORPORATION Integrated Electronics, LLC; AMERICAN SUPERCONDUCTOR Integrated Medical Systems, Inc.; ELI LILLY & CO Integrilin; MILLENNIUM PHARMACEUTICALS INC INTEGRITY; ASCENTIAL SOFTWARE CORPORATION Intelligent Network Foundation; ELECTRONIC DATA SYSTEMS CORP IntelliSense Corp.; CORNING INC IntelliWhere; INTERGRAPH CORP Inter-Cal Corp.; ZILA INC Intercept Platelet System; HAEMONETICS CORPORATION INTERGEL; LIFECORE BIOMEDICAL INC InterGen; BECHTEL GROUP INC Intergraph Government Solutions; INTERGRAPH CORP Intergraph Mapping and GIS Solutions; INTERGRAPH CORP Intergraph Process, Power and Offshore; INTERGRAPH CORP Intergraph Public Safety; INTERGRAPH CORP Intergy; WEBMD CORPORATION Interleukin-1 Cytokine Trap; REGENERON PHARMACEUTICALS INC Interleukin-13 Cytokine Trap; REGENERON PHARMACEUTICALS INC Interleukin-4 Cytokine Trap; REGENERON PHARMACEUTICALS INC International Canine Genetics; SYNBIOTICS CORP International Isotopes, Inc.; NEORX CORPORATION
Plunkett Research, Ltd.
www.plunkettresearch.com
INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. International Security Systems; ANALOGIC CORP International Water; BECHTEL GROUP INC IntraDose; MATRIX PHARMACEUTICAL IntraServer Technology; LSI LOGIC CORP Intravascular Brachytherapy System; THERAGENICS CORP Intuit Master Builder Solution Provider; INTUIT INC Inventra; MENTOR GRAPHICS CORP Invitrogen Corp.; PANVERA LLC IOGEL; IOMED INC IoGold; NORTH AMERICAN SCIENTIFIC Iomega CD-RW; IOMEGA CORP Iontocaine; IOMED INC IontoDex; IOMED INC IOT Limited; JDS UNIPHASE CORP IQ Series; ADTRAN INC IRIX; SILICON GRAPHICS INC Irofulven; MGI PHARMA INC Iron Chelators; GELTEX PHARMACEUTICALS IsFlo; ABBOTT LABORATORIES ISIS 23722; ISIS PHARMACEUTICALS INC Isoflex S Lead; ST JUDE MEDICAL INC ISO-GRID; NEOGEN CORPORATION Isomedix Services; STERIS CORP Isomil; ABBOTT LABORATORIES IsoSeed; THERAGENICS CORP i-STAT Portable Clinical Analyzer; HESKA CORP iStorage Online; IOMEGA CORP Isuzu Motors; GENERAL MOTORS CORP Isuzu Motors America, Inc.; ISUZU MOTORS LTD IT Masters International; BMC SOFTWARE INC Italgas S.p.A.; ENI SPA Itamar Medical, Ltd.; RESPIRONICS INC Itanium; INTEL CORP Itedi; FIAT SPA ITT Defense and Electronics, Inc.; ITT INDUSTRIES INC ITT Fluid Technology Corp.; ITT INDUSTRIES INC iTunes Music Store; APPLE COMPUTER INC IVAX Pharmaceuticals, Inc.; IVAX CORPORATION IVC Home Care Bed; INVACARE CORP IVC Manual Wheelchair; INVACARE CORP Iverhart; VIRBAC INC I-Zone Products; POLAROID CORP J.A. Jones, Inc.; PHILIPP HOLZMANN GROUP Jaguar; FORD MOTOR CO Jasmine; COMPUTER ASSOCIATES INTERNATIONAL INC JavaSoft; SUN MICROSYSTEMS INC Jbuilder; BEA SYSTEMS INC JCR Pharmaceuticals Co., Ltd.; NAPRO BIOTHERAPEUTICS INC JDS FITEL; JDS UNIPHASE CORP Jeep; DAIMLERCHRYSLER AG Jeppesen Sanderson, Inc.; BOEING CO Jet; CONOCOPHILLIPS
Jetdirect Autoswitch; HEWLETT-PACKARD CO Jetta; VOLKSWAGEN AG JFE Engineering Corp.; NKK CORPORATION JFE Steel Corp.; NKK CORPORATION JFE Urban Development Corp.; NKK CORPORATION JFE Welding Co., Ltd.; NKK CORPORATION Johnson & Johnson; ALZA CORP Johnson & Johnson; DEPUY INC Johnson & Johnson; SCIOS INC Johnson & Johnson; CENTOCOR INC Joint Strike Fighter; LOCKHEED MARTIN CORP Joint Strike Fighter; BAE SYSTEMS Jones Pharma, Inc.; KING PHARMACEUTICALS INC Journal of International Medical Research (The); PAREXEL INTERNATIONAL JPJ Architects, Inc.; HLM DESIGN INC JUNOS Internet Software; JUNIPER NETWORKS INC Kansas City Ophthalmics, LLC; SOLA INTERNATIONAL INC KavaPure; PURE WORLD INC Kawasaki Microelectronics; NKK CORPORATION Kawasaki Steel Corp.; NKK CORPORATION KCI International, Inc.; KINETIC CONCEPTS INC KCI USA, Inc.; KINETIC CONCEPTS INC KDDI; TOYOTA MOTOR CORPORATION KEELOQ; MICROCHIP TECHNOLOGY INC Kelly Springfield Tire Co.; GOODYEAR TIRE & RUBBER COMPANY (THE) Kelly Tires; GOODYEAR TIRE & RUBBER COMPANY (THE) KEMET Electronics Corp.; KEMET CORP Kenwood Laboratories; BRADLEY PHARMACEUTICALS Kesmai Corp.; ELECTRONIC ARTS INC Ketoconazole Cream 2%; TARO PHARMACEUTICAL INDUSTRIES Ketroprofen; ANDRX CORP Kevlar; E I DU PONT DE NEMOURS & CO (DUPONT) Khanty Mansiysk Oil Corp.; MARATHON OIL Kia Motors; HYUNDAI MOTOR COMPANY KinAir; KINETIC CONCEPTS INC Kineret; AMGEN INC King Pharmaceuticals International; KING PHARMACEUTICALS INC King Pharmaceuticals Reseach and Development; KING PHARMACEUTICALS INC Kirkegaard & Perry Laboratories; SYNBIOTICS CORP Kleber; COMPAGNIE MICHELIN Klein Associates, Inc.; OYO CORPORATION Kleiner Perkins; GOOGLE INC KM-Mouse; MEDAREX INC KnowItAll ADME/Tox; BIO RAD LABORATORIES INC KnowItAll Informatics System; BIO RAD LABORATORIES INC
Plunkett Research, Ltd.
www.plunkettresearch.com
INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Knowledge Revolution, Inc.; MSC.SOFTWARE CORP KnowledgePlace; GETRONICS NV KODAK GOLD; EASTMAN KODAK CO Komag Material Technology, Inc.; KOMAG INC Koninklijke (Royal) Philips Electronics N.V.; ADAC LABORATORIES Konsyl Pharmaceuticals, Inc.; PHARMACEUTICAL FORMULATIONS INC Kormoran; COMPAGNIE MICHELIN Kosher Care; HI TECH PHARMACAL CO INC KOVA; HYCOR BIOMEDICAL INC Lab-Line Instruments, Inc.; APOGENT TECHNOLOGIES INC LabLink; COVANCE INC LabMAP; LUMINEX CORPORATION LabOnWeb.com; GENOME THERAPEUTICS CORP Laboratorios Belmac; BENTLEY PHARMACEUTICALS INC Laboratorios Davur; BENTLEY PHARMACEUTICALS INC LADARVision; ALCON LABORATORIES INC Lambert Smith Hampton; WS ATKINS PLC Lamborghini; VOLKSWAGEN AG Lamborghini Automobili; AUDI AG Lancer Evolution; MITSUBISHI MOTORS CORP Land Rover; FORD MOTOR CO Landmark Graphics Corp.; HALLIBURTON COMPANY Lanoxin; GLAXOSMITHKLINE PLC Lantus; AVENTIS SA Laserjet; HEWLETT-PACKARD CO Lasso; MONSANTO CO LAUNCH; YAHOO! INC LDP-02; MILLENNIUM PHARMACEUTICALS INC LDP-977; MILLENNIUM PHARMACEUTICALS INC LeadQuest; TRIPOS INC Leadtech Corp.; MEDTOX SCIENTIFIC INC LEAF Optical Fiber; CORNING INC Learjet; BOMBARDIER INC LeonardoSpectrum; MENTOR GRAPHICS CORP LeukArrest; ICOS CORPORATION LEUKINE; IMMUNEX CORP LeukoScan; IMMUNOMEDICS INC LeukoSite, Inc.; MILLENNIUM PHARMACEUTICALS INC Level One Communications; INTEL CORP Levington; SCOTTS CO Levoxyl; KING PHARMACEUTICALS INC Lexgen.com; LEXICON GENETICS INC Lexicon Pharmaceuticals; LEXICON GENETICS INC Lexus; TOYOTA MOTOR CORPORATION LexVision; LEXICON GENETICS INC LFA-1; ICOS CORPORATION Lidocaine Jelly; AKORN INC Lidoderm; ENDO PHARMACEUTICALS HOLDINGS INC
Life Technologies, Inc.; INVITROGEN CORPORATION LifeExpress; INCYTE GENOMICS INC Lifepath AAA; EDWARDS LIFESCIENCES CORP LifeProt; INCYTE GENOMICS INC LifeSeq Gold; INCYTE GENOMICS INC LifeTools; INCYTE GENOMICS INC Lightscape; AUTODESK INC LightWorks; CIENA CORP Lilly ICOS, LLC; ICOS CORPORATION Lincoln Mercury; FORD MOTOR CO Linde Engineering; LINDE AG Linde Forklift; LINDE AG Linde Gas; LINDE AG Linde Hydraulics; LINDE AG Linde Material Handling; LINDE AG Linde Refrigeration; LINDE AG Link Spine Group, Inc.; JOHNSON & JOHNSON Link Spine Group, Inc.; DEPUY INC Link Win, Ltd.; JABIL CIRCUIT INC Linksys; CISCO SYSTEMS INC Linvatec Corporation; CONMED CORP Lipitor; PFIZER INC Liquette; K V PHARMACEUTICAL CO LiteShow; INFOCUS CORP Litespan-2000; ALCATEL USA INC Live@LAUNCH; YAHOO! INC Lockheed Martin Aeronautics Co.; LOCKHEED MARTIN CORP Lockheed Martin Air Traffic Management; LOCKHEED MARTIN CORP Lockheed Martin Corporation; ANALOGIC CORP Lockheed Martin Global Telecommunications; LOCKHEED MARTIN CORP Lockheed Martin Missiles and Fire Control; LOCKHEED MARTIN CORP Lockwood Greene; PHILIPP HOLZMANN GROUP LOGIC Software; HAEMONETICS CORPORATION Logos Engenharia; ARCADIS NV London Underground; BOMBARDIER INC Loral CyberStar; LORAL SPACE & COMMUNICATIONS LTD Loral Global Alliance; LORAL SPACE & COMMUNICATIONS LTD Loral Skynet; LORAL SPACE & COMMUNICATIONS LTD Loratadine; IMPAX LABORATORIES INC Loronix; COMVERSE TECHNOLOGY INC Lotus Development Corp.; INTERNATIONAL BUSINESS MACHINES (IBM) Lovenox; AVENTIS SA LSC, Inc.; SUN MICROSYSTEMS INC LSI MALT1; VYSIS INC Lucanthone; SUPERGEN INC LumAvidin; LUMINEX CORPORATION Lumigan; ALLERGAN INC
Plunkett Research, Ltd.
www.plunkettresearch.com
INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Luminex 100; LUMINEX CORPORATION Luminex XYP; LUMINEX CORPORATION Luqix; CONNETICS CORPORATION Luxiq; MGI PHARMA INC Lycra; E I DU PONT DE NEMOURS & CO (DUPONT) LymphoCide; IMMUNOMEDICS INC Lymphoglobuline; SANGSTAT MEDICAL CORP LymphoScan; IMMUNOMEDICS INC Lynx Spread Spectrum Radio; PROXIM CORPORATION Lynx Therapeutics GmbH; LYNX THERAPEUTICS INC LYONDELL-CITGO Refining LP; LYONDELL CHEMICAL COMPANY M. Series; XEROX CORP M/DN; ZIMMER HOLDINGS INC M10 Router; JUNIPER NETWORKS INC m100; PALM INC M160 Router; JUNIPER NETWORKS INC M2O Router; JUNIPER NETWORKS INC M4 Data Holdings, Ltd.; QUANTUM CORP M4O Router; JUNIPER NETWORKS INC M5 Router; JUNIPER NETWORKS INC Mac OS X; APPLE COMPUTER INC MacaPure; PURE WORLD INC Machete; MONSANTO CO MacIntosh; APPLE COMPUTER INC Mack Trucks, Inc.; AB VOLVO MacNeal-Schwendler Corp.; MSC.SOFTWARE CORP Magic Service Desk Suite; NETWORK ASSOCIATES INC Magic Solutions; NETWORK ASSOCIATES INC Magnaflow; ARROW INTERNATIONAL INC Magneti Marelli; FIAT SPA Malleable Technologies; PMC-SIERRA INC Mallinckordt Imaging; MALLINCKRODT INC Mallinckordt Respiratory; MALLINCKRODT INC Mallinckrodt Pharmaceuticals; MALLINCKRODT INC ManageWise; NOVELL INC Marathon Ashland Petroleum, LLC; MARATHON OIL Marathon Biopharmaceuticals; CAMBREX CORP Marathon Group; MARATHON OIL Marathon Petroleum Norge A/S; MARATHON OIL MARC Analysis Research Corp.; MSC.SOFTWARE CORP Marconi Electronic Systems; BAE SYSTEMS Marsh Bio Products; APOGENT TECHNOLOGIES INC Maserati; FIAT SPA MassARRAY; SEQUENOM INC MassEXTEND; SEQUENOM INC Massively Parallel Signature Sequencing (MPSS); LYNX THERAPEUTICS INC Material Service Corp.; GENERAL DYNAMICS Matrix Switches; ENTERASYS NETWORKS INC
Maverick; CIRRUS LOGIC INC Maverick; MONSANTO CO Mavik; KOS PHARMACEUTICALS INC MAX 7000; ALTERA CORP MAX 9000; ALTERA CORP MAX+PLUS II; ALTERA CORP MaxAttach; MAXTOR CORP MaxFax; MAXTOR CORP Maxia Pharmaceuticals; INCYTE GENOMICS INC Maxim Total Knee System; BIOMET INC MaxSense; ENZO BIOCHEM INC Maxtor Network Systems Group; MAXTOR CORP MaxyScan; MAXYGEN INC Maxzide; MYLAN LABORATORIES INC Mazda Motor Corp.; FORD MOTOR CO Mazda North American Operations; MAZDA MOTOR CORPORATION McAfee Anti-Virus; NETWORK ASSOCIATES INC McSEIS-3; OYO CORPORATION McSEIS-SX24; OYO CORPORATION MD110; TELEFON AB LM ERICSSON MDX-214; MEDAREX INC MDX-33; MEDAREX INC Mead Johnson Nutritionals; BRISTOL MYERS SQUIBB CO Mechanical Technology, Inc.; PLUG POWER INC Medal of Honor; ELECTRONIC ARTS INC Medco Health Solutions; MERCK & CO INC Medical Analysis Systems, Inc.; FISHER SCIENTIFIC INTERNATIONAL INC Medicomp, Inc.; UNITED THERAPEUTICS CORP MedImmune Oncology, Inc.; MEDIMMUNE INC Medisorb; ALKERMES INC Medko; INSTRUMENTARIUM Medley Medication Safety System; ALARIS MEDICAL INC MedNet Internal Medicine Information System; CERNER CORP MedPointe, Inc.; SEPRACOR INC Med-Safe Systems, Inc.; BECTON DICKINSON & CO MedSystem III; ALARIS MEDICAL INC MEDTOX Laboratories, Inc; MEDTOX SCIENTIFIC INC Medtronic Freestyle; MEDTRONIC INC Megaclone; LYNX THERAPEUTICS INC MEGALINK; GUIDANT CORP Megasort; LYNX THERAPEUTICS INC Megatech Electro, Inc.; TELEFLEX INC Megatype; LYNX THERAPEUTICS INC Melacine; CORIXA CORPORATION Menorest; NOVEN PHARMACEUTICALS Mentax; MYLAN LABORATORIES INC Mentor Corporation; NORTH AMERICAN SCIENTIFIC Mercedes Benz; DAIMLERCHRYSLER AG Merck & Co., Inc.; ISIS PHARMACEUTICALS INC
Plunkett Research, Ltd.
www.plunkettresearch.com
INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Merck KGaA; IMCLONE SYSTEMS INC Merck-Medco Managed Care, L.L.C.; MERCK & CO INC Merial; AVENTIS SA Meridian Medical Technologies, Inc.; KING PHARMACEUTICALS INC Merlin Magix; AVAYA INC MetaFrame; CITRIX SYSTEMS INC MetaLayer; TRIPOS INC MetaRecon; ASCENTIAL SOFTWARE CORPORATION MetaStor; LSI LOGIC CORP Metasys; JOHNSON CONTROLS INC Meter Release; K V PHARMACEUTICAL CO Metformin IR; ANDRX CORP MethylGene; MGI PHARMA INC MethyPatch; NOVEN PHARMACEUTICALS Metric Quad Flat Pack; AMKOR TECHNOLOGY INC MetroCor; CORNING INC Metronet Consortium; BOMBARDIER INC Metrospan; ALCATEL USA INC Miata; MAZDA MOTOR CORPORATION Michelin PAX System; COMPAGNIE MICHELIN Michigan Automotive Compressor, Inc.; DENSO CORPORATION MicroChem; BOSTON BIOMEDICA INC MicroLeadFrame; AMKOR TECHNOLOGY INC Micron Communications, Inc.; MICRON TECHNOLOGY INC Micron Construction, Inc.; MICRON TECHNOLOGY INC Micron Display Technology, Inc.; MICRON TECHNOLOGY INC Micron Electronics, Inc.; MICRON TECHNOLOGY INC Micron Investments, Inc.; MICRON TECHNOLOGY INC Micron Semiconductor, Inc.; MICRON TECHNOLOGY INC MiLife Intelligent Services Gateway; LUCENT TECHNOLOGIES INC Millenia; MAZDA MOTOR CORPORATION Millennium Predictive Medicine, Inc.; MILLENNIUM PHARMACEUTICALS INC Millennium Series; VARIAN MEDICAL SYSTEMS INC MINI; BAYERISCHE MOTOREN WERKE AG Minnesota Mining and Manufacturing Company; 3M COMPANY Minotaur; ORBITAL SCIENCES CORP Mio Relax; BENTLEY PHARMACEUTICALS INC Miracle-Gro; SCOTTS CO Mito Extra; SUPERGEN INC Mitozytrex; SUPERGEN INC Mitsubishi Motor Sales of America, Inc.; MITSUBISHI MOTORS CORP
Mitsubishi Motors Corp.; DAIMLERCHRYSLER AG MLN01; XOMA LTD Mobil Oil Corp.; EXXONMOBIL CORPORATION Modafinil; CEPHALON INC ModelSlim; MENTOR GRAPHICS CORP Molecular Biosystems; ALLIANCE PHARMACEUTICAL CORP MolecularBreeding; MAXYGEN INC Mom's Aloe Store; CARRINGTON LABORATORIES INC MonoSpot; MERIDIAN BIOSCIENCE INC Monterey Resources, Inc.; CHEVRONTEXACO CORPORATION Montero; MITSUBISHI MOTORS CORP Morphanta; TECHNE CORP Morphelan; LIGAND PHARMACEUTICALS INC Morse Controls; TELEFLEX INC Mosler, Inc.; DIEBOLD INC Motive Enterprises; SHELL OIL CO Motor City Online; ELECTRONIC ARTS INC Motorola; SIEMENS AG Movielink; SONY CORPORATION MPI 5020 Radiopotentiator; MATRIX PHARMACEUTICAL MPV; MAZDA MOTOR CORPORATION MRILab; HALLIBURTON COMPANY MS-325; EPIX MEDICAL INC MSC.Fatigue; MSC.SOFTWARE CORP MSC.SuperForge; MSC.SOFTWARE CORP MSNBC; MICROSOFT CORP mSwitch; UTSTARCOM INC Multi-Chip Module; ALTERA CORP MultiWave Metro One; CIENA CORP My.Oracle.Com; ORACLE CORP Myelos Corp.; BIO TECHNOLOGY GENERAL CORP Mylan Pharmaceuticals; MYLAN LABORATORIES INC Mylan Technologies; MYLAN LABORATORIES INC Mylar; E I DU PONT DE NEMOURS & CO (DUPONT) Mylex Corp.; INTERNATIONAL BUSINESS MACHINES (IBM) Myotrophin; CEPHALON INC Myozyme; GENZYME CORP Myriad Genetic Laboratories; MYRIAD GENETICS INC Myriad Pharmaceuticals, Inc.; MYRIAD GENETICS INC MySAP Business Suite; SAP AKTIENGESELLSCHAFT N.E.T. Federal, Inc.; NETWORK EQUIPMENT TECHNOLOGIES INC NAALADase Inhibitors; GUILFORD PHARMACEUTICALS INC Nabi-HB; NABI BIOPHARMACEUTICALS Nanogel; CABOT CORPORATION
Plunkett Research, Ltd.
www.plunkettresearch.com
INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. NaPro 102339; NAPRO BIOTHERAPEUTICS INC NaPro 80239; NAPRO BIOTHERAPEUTICS INC NaPro 80661; NAPRO BIOTHERAPEUTICS INC Nasal Ease; HI TECH PHARMACAL CO INC NatChem; CUBIST PHARMACEUTICALS NatGen; CUBIST PHARMACEUTICALS Natrecor; SCIOS INC Nature's Way; NBTY INC Naturistics; DEL LABORATORIES INC Navametrix Medical Systems; RESPIRONICS INC Navarre; SYMANTEC CORP NBC Television; GENERAL ELECTRIC CO NBI-3301; NEUROCRINE BIOSCIENCES INC Neacon 2000; PANVERA LLC Nellcor; MALLINCKRODT INC Neramexane; FOREST LABORATORIES INC Nestlé, S.A.; ALCON LABORATORIES INC NetAPP F Series; NETWORK APPLIANCE INC NetCache; NETWORK APPLIANCE INC NETGEAR, Inc.; NORTEL NETWORKS CORP Netreon, Inc.; COMPUTER ASSOCIATES INTERNATIONAL INC Netscape; AOL TIME WARNER INC Netsight Atlas; ENTERASYS NETWORKS INC NetVanta Series; ADTRAN INC NetWare; NOVELL INC NetWeaver; SAP AKTIENGESELLSCHAFT Network Alchemy; NOKIA CORPORATION Network Solutions; VERISIGN INC NetWorkPlace; GETRONICS NV Neulasta; AMGEN INC Neupogen; AMGEN INC Neurologic Gene Therapeutics; CELL GENESYS INC Neuromins; MARTEK BIOSCIENCES CORP Neurontin; PFIZER INC Neurotrophin-3; REGENERON PHARMACEUTICALS INC Neutralase; BIOMARIN PHARMACEUTICAL NeuTrexin; MEDIMMUNE INC NeuVis, Inc.; RATIONAL SOFTWARE CORP New Brighton Business Center, LLC; MEDTOX SCIENTIFIC INC New Dimension Software, Ltd.; BMC SOFTWARE INC New Dimensions in Medicine, Inc.; CONMED CORP News Corporation; HUGHES ELECTRONICS CORP NexGen; ZIMMER HOLDINGS INC NexGen, Inc.; ADVANCED MICRO DEVICES INC Nexolab; BAYERISCHE MOTOREN WERKE AG NexPress; EASTMAN KODAK CO NeXstar Pharmaceuticals, Inc.; GILEAD SCIENCES INC Nextfare Web Services; CUBIC CORP NGD 97-1; NEUROGEN CORP Niaspan; KOS PHARMACEUTICALS INC Nice n' Easy; BRISTOL MYERS SQUIBB CO NicoDerm CQ; ALZA CORP
Nicostation; KOS PHARMACEUTICALS INC NicVAX; NABI BIOPHARMACEUTICALS Nifedipine XL; PENWEST PHARMACEUTICALS CO Niferex; K V PHARMACEUTICAL CO NiMh Battery Technology; ENERGY CONVERSION DEVICES INC Nimrod; BAE SYSTEMS Nipent; SUPERGEN INC Nippon Novellus; NOVELLUS SYSTEMS INC NISSAN 180; NISSAN MOTOR CO LTD Nissan Canada; NISSAN MOTOR CO LTD Nissan Design America; NISSAN MOTOR CO LTD Nissan Logistics Corp.; NISSAN MOTOR CO LTD Nissan North America, Inc.; NISSAN MOTOR CO LTD Nissan Trading Corp.; NISSAN MOTOR CO LTD Nissan-Renault; NISSAN MOTOR CO LTD Nitrek; MYLAN LABORATORIES INC Nitto Denko; 3M COMPANY NKK Corp.; NKK CORPORATION NKT Elektronic A/S; ALCATEL USA INC No Quibble; MAXTOR CORP Nokia NetAct Optimizer; NOKIA CORPORATION Nomex, Inc.; COMPUWARE CORP NonSpil; TARO PHARMACEUTICAL INDUSTRIES Nordic Business Management Systems; AMERICAN MANAGEMENT SYSTEMS INC Norethindrone Acetate; BARR LABORATORIES INC Nortel; BARR LABORATORIES INC North American Tires; GOODYEAR TIRE & RUBBER COMPANY (THE) North Point Communications; YAHOO! INC Norton AntiVirus; SYMANTEC CORP Norton CleanSweep; SYMANTEC CORP Norton SystemWorks; SYMANTEC CORP NOVANTRONE; IMMUNEX CORP Novartis; SYNGENTA AG Novartis Agribusiness; ASTRAZENECA PLC Novartis Institute for Biomedical Research, Inc.; NOVARTIS AG Novavax, Inc.; KING PHARMACEUTICALS INC Novell Directory Services; NOVELL INC Novex Electrophoresis GmbH; INVITROGEN CORPORATION Novogyne Pharmaceuticals; NOVEN PHARMACEUTICALS NUEPREX; XOMA LTD Numby Stuff; IOMED INC NuMega Technologies, Inc.; COMPUWARE CORP NuPulse; KINETIC CONCEPTS INC Nutrition Warehouse; NBTY INC Nutropin AQ; GENENTECH INC Nutropin Depot; ALKERMES INC Nutropin Depot; GENENTECH INC NUVANCE; IMMUNEX CORP Nuvion; PROTEIN DESIGN LABS INC Oak Industries, Inc.; CORNING INC
Plunkett Research, Ltd.
www.plunkettresearch.com
INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. OakDSPCore; LSI LOGIC CORP Obralia; GRUPO DRAGADOS Obsidian, Inc.; APPLIED MATERIALS INC Oclassen Dermatologics; WATSON PHARMACEUTICALS INC Ocular Networks; TELLABS INC OcuPhor; IOMED INC Ocuvite Vitamins; BAUSCH & LOMB INC Ofoto, Inc.; EASTMAN KODAK CO Okena; CISCO SYSTEMS INC OlePure; PURE WORLD INC OLUX; CONNETICS CORPORATION OM Carrelli Alecatori S.p.A.; LINDE AG Omega; ADAM OPEL AG OmegaTech, Inc.; MARTEK BIOSCIENCES CORP Omeprazole; IMPAX LABORATORIES INC OmniBank; LEXICON GENETICS INC OmniEXPRESS; QUALCOMM INC OmniMAX; ADVANCED FIBRE COMMUNICATIONS INC OmniTRACS; QUALCOMM INC ONCASPAR; ENZON INC OncoScint; CYTOGEN CORPORATION One Equity Partners Imaging Operating Corporation; POLAROID CORP One Net; NOVELL INC OnHealth Network; WEBMD CORPORATION ONI Systems Corp.; CIENA CORP Onsite Energy de Panama; ONSITE ENERGY CORPORATION OnStar; GENERAL MOTORS CORP ONTAK; LIGAND PHARMACEUTICALS INC OnTrak Systems, Inc.; LAM RESEARCH CORP ONYX-015; XOMA LTD OPCO; MICHAEL BAKER CORPORATION Opcon Eye Drops; BAUSCH & LOMB INC Operations Management International; CH2M HILL COMPANIES LTD Opteva; DIEBOLD INC Optia; MEMC ELECTRONIC MATERIALS INC Optical Borehole Camera; OYO CORPORATION Optical Coating Laboratory, Inc.; JDS UNIPHASE CORP Optical Systems Corp.; READ-RITE CORP Opti-Free; ALCON LABORATORIES INC Optima 7000 Series; TERADYNE INC OptiMARK; MALLINCKRODT INC Optimizer; BMC SOFTWARE INC OptiPlex GX270; DELL COMPUTER CORPORATION OptiPlex SX270; DELL COMPUTER CORPORATION Optison; ALLIANCE PHARMACEUTICAL CORP Optivar; MEDPOINTE INC Oracle China; ORACLE CORP Oracle Jdeveloper; ORACLE CORP
Oracle Media Server; ORACLE CORP Oracle WebDB; ORACLE CORP Oracle9i Database; ORACLE CORP Oracle9i Real Application Clusters; ORACLE CORP Orajel; DEL LABORATORIES INC Orapred; ASCENT PEDIATRICS INC OraSolv; CIMA LABS INC OraTest; ZILA INC OraVescent; CIMA LABS INC Orchid Biocomputer; ORCHID BIOSCIENCES INC Orchid Cellmark; ORCHID BIOSCIENCES INC Orchid Diagnostics; ORCHID BIOSCIENCES INC Orchid GeneScreen; ORCHID BIOSCIENCES INC Orchid GeneShield; ORCHID BIOSCIENCES INC Orchid Life Sciences; ORCHID BIOSCIENCES INC Organichem Corp.; ALBANY MOLECULAR RESEARCH ORiNOCO; PROXIM CORPORATION OROS; ALZA CORP Ortho; SCOTTS CO Ortho-Clinical Diagnostics, Inc.; CHIRON CORP ORTHOVISC; ANIKA THERAPEUTICS INC OSAR; FILENET CORP OSI-211; OSI PHARMACEUTICALS INC OSI-760; OSI PHARMACEUTICALS INC OSIC-0961370; OSI PHARMACEUTICALS INC Osmocote; SCOTTS CO Outback; FUJI HEAVY INDUSTRIES LTD Outboard Marine Corp.; BOMBARDIER INC Outlander; MITSUBISHI MOTORS CORP Overture; YAHOO! INC OXANDRIN; BIO TECHNOLOGY GENERAL CORP OxiFirst Fetal Oxygen Monitoring System; MALLINCKRODT INC Oxsoralen-Ultra; ICN PHARMACEUTICALS INC Oxycal Laboratories, Inc.; ZILA INC Oxycodone; IMPAX LABORATORIES INC Oxygent; ALLIANCE PHARMACEUTICAL CORP Oxymorphone; ENDO PHARMACEUTICALS HOLDINGS INC OXYPRIM; ILEX ONCOLOGY INC Oxytrol; WATSON PHARMACEUTICALS INC OYO Corporation U.S.A.; OYO CORPORATION P&A Brands; COMPAGNIE MICHELIN P1000; ALARIS MEDICAL INC p38 MAPK ELISA; BIOSOURCE INTERNATIONAL INC Paceart System; MEDTRONIC INC Pacific Engineering Corporation; KEITH COMPANIES INC (THE) PACIS; SHIRE-BIOCHEM INC Pack Drain Method; CHIYODA CORPORATION PacketStar Multiservice Media Gateway; LUCENT TECHNOLOGIES INC Paclitaxel; NAPRO BIOTHERAPEUTICS INC Pafase; ICOS CORPORATION
Plunkett Research, Ltd.
www.plunkettresearch.com
INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. PAGE-4; IDEC PHARMACEUTICALS CORP PakSolv; CIMA LABS INC Palm OS; PALM INC Palm Pilot; PALM INC Palm V; PALM INC Palm VII; PALM INC PalmSource; PALM INC Palonosetron; MGI PHARMA INC Pamine; BRADLEY PHARMACEUTICALS Panagon; FILENET CORP PanAmSat; HUGHES ELECTRONICS CORP Pandel; COLLAGENEX PHARMACEUTICAL PanGenex, Inc.; CELL THERAPEUTICS INC Panorama; ADVANCED FIBRE COMMUNICATIONS INC Panorex; CENTOCOR INC Panretin; LIGAND PHARMACEUTICALS INC Panther; ISUZU MOTORS LTD Par Pharmaceutical, Inc.; PHARMACEUTICAL RESOURCES INC Parallax Graphics; ACTERNA CORPORATION Parallux; IDEXX LABORATORIES INC Parker Technologies, Inc.; APPLIED MATERIALS INC Parsons Brinckerhoff Power, Inc.; PARSONS BRINCKERHOFF INC Particle Dynamics, Inc.; K V PHARMACEUTICAL CO PAS; UTSTARCOM INC Passat; VOLKSWAGEN AG Passport.net; MICROSOFT CORP Patanol; ALCON LABORATORIES INC PathCalling; CURAGEN CORPORATION PathMill; SYNOPSYS INC PathNet Laboratory Information Systems; CERNER CORP PathoGenome Database; GENOME THERAPEUTICS CORP PathoSeq; INCYTE GENOMICS INC PatMax; COGNEX CORP Patriot Missile System; RAYTHEON CO PATROL; BMC SOFTWARE INC Paxene; IVAX CORPORATION Paxil; GLAXOSMITHKLINE PLC Paxoral; IVAX CORPORATION Payflow Link; VERISIGN INC Payflow Pro; VERISIGN INC PB Aviation, Inc.; PARSONS BRINCKERHOFF INC PB Buildings, Inc.; PARSONS BRINCKERHOFF INC PB Constructors, Inc.; PARSONS BRINCKERHOFF INC PB Facilities, Inc.; PARSONS BRINCKERHOFF INC PB Farradyne, Inc.; PARSONS BRINCKERHOFF INC PB Telecommunications, Inc.; PARSONS BRINCKERHOFF INC PCAM; ALARIS MEDICAL INC PCS; HAEMONETICS CORPORATION PCS Health Systems; ELI LILLY & CO
PCS2; HAEMONETICS CORPORATION PCSI; CIRRUS LOGIC INC PdGold; NORTH AMERICAN SCIENTIFIC PediDyne; KINETIC CONCEPTS INC Peerless; IOMEGA CORP Pegasus; ORBITAL SCIENCES CORP PEG-INTRON; ENZON INC Pegylated Axokine; REGENERON PHARMACEUTICALS INC Pelican Transportation; GLOBAL INDUSTRIES LTD Pennaco Energy, Inc.; MARATHON OIL Pennzoil-Quaker State; SHELL OIL CO Pentium; INTEL CORP PeopleSoft 8; PEOPLESOFT INC PeopleSoft eCenter; PEOPLESOFT INC PeopleSoft Workflow; PEOPLESOFT INC PeopleTools; PEOPLESOFT INC Percepta; SOLA INTERNATIONAL INC Perceptive Informatics, Inc.; PAREXEL INTERNATIONAL Percocet; ENDO PHARMACEUTICALS HOLDINGS INC Percodan; ENDO PHARMACEUTICALS HOLDINGS INC PerFix; CR BARD INC Peridex; ZILA INC Periostat; COLLAGENEX PHARMACEUTICAL Peri-Strips; SYNOVIS LIFE TECHNOLOGIES INC PERLANE; MEDICIS PHARMACEUTICAL CORP Perot Consulting; PEROT SYSTEMS CORP Perot Systems Government Services; PEROT SYSTEMS CORP Peugeot; PSA PEUGEOT CITROEN SA Peugeot Citroen Moteurs; PSA PEUGEOT CITROEN SA Peugeot Motocycles; PSA PEUGEOT CITROEN SA Pfizer, Inc.; ALZA CORP PharmaBio Development; QUINTILES TRANSNATIONAL CORP Pharmacia; ELAN CORP PLC Pharmacia Corp.; PFIZER INC Pharmacia Corporation; MONSANTO CO Pharmacopeia Drug Discovery; PHARMACOPEIA INC PhenoScreen; VIROLOGIC INC PhenoSense Assays; VIROLOGIC INC PhenoSense HIV; VIROLOGIC INC Philips Medical Systems; ADAC LABORATORIES Phillips Petroleum; CONOCOPHILLIPS Phoresor System; IOMED INC PhosFeed; IMC GLOBAL INC Physiotherapy Associates; STRYKER CORP PIC; MICROCHIP TECHNOLOGY INC Piccolo Point-of-Care Analyzer; ABAXIS INC PicoPower Technology, Inc.; CIRRUS LOGIC INC Pinnacle; ADAC LABORATORIES
Plunkett Research, Ltd.
www.plunkettresearch.com
INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Pitney Bowes Management Services; PITNEY BOWES INC Platinum 5 Concentrator; INVACARE CORP PlayStation; SONY CORPORATION PLEXION; MEDICIS PHARMACEUTICAL CORP PLM Solutions; ELECTRONIC DATA SYSTEMS CORP Plymouth; DAIMLERCHRYSLER AG Pogo Corp.; ELECTRONIC ARTS INC Polaroid Digital MiniPortrait All-in-One Camera; POLAROID CORP Polaroid One; POLAROID CORP Polaroid OneStep Camera; POLAROID CORP Polaroid T690; POLAROID CORP Polyamines; GELTEX PHARMACEUTICALS Polymer Chemicals Division; ALBEMARLE CORPORATION Pontiac; GENERAL MOTORS CORP Porex Corp.; WEBMD CORPORATION Portal.Oracle.com; ORACLE CORP PortalVision; VARIAN MEDICAL SYSTEMS INC PortSwitch; STANDARD MICROSYSTEMS CORPORATION Post-it Products; 3M COMPANY Power Mac G4 Cube; APPLE COMPUTER INC Power Programs for Providers; RESPIRONICS INC PowerApp; DELL COMPUTER CORPORATION PowerBand; ELECTRONICS FOR IMAGING INC PowerInsight; CERNER CORP PowerModule; AMERICAN SUPERCONDUCTOR PowerQuad; AMKOR TECHNOLOGY INC PowerSmart, Inc.; MICROCHIP TECHNOLOGY INC PowerTV; SCIENTIFIC ATLANTA INC PowerVu; SCIENTIFIC ATLANTA INC Pramlintide; AMYLIN PHARMACEUTICALS INC Praxair Surface Technologies, Inc.; PRAXAIR INC Precision Optical Systems, Inc.; POLAROID CORP Predator; IOMEGA CORP Prelude; HONDA MOTOR CO LTD Premarin; WYETH Premier HpSA Test; MERIDIAN BIOSCIENCE INC Premier Lab; GERBER SCIENTIFIC INC PremMAX; ADVANCED FIBRE COMMUNICATIONS INC Premphase; WYETH Prempro; WYETH Prenate GT; FIRST HORIZON PHARMACEUTICALS Pressplay; SONY CORPORATION Pretarget; NEORX CORPORATION PRETUNNEL; TREVI-FINANZIARIA INDUSTRIALE SPA Preventol; BAYER AG Prialt; ELAN CORP PLC Prilosec; ASTRAZENECA PLC Prime Switch; NETWORK EQUIPMENT TECHNOLOGIES INC
Primsol; ASCENT PEDIATRICS INC PrintMe; ELECTRONICS FOR IMAGING INC Prism Solutions; ASCENTIAL SOFTWARE CORPORATION Prisma Systems; SYNBIOTICS CORP Prius; TOYOTA MOTOR CORPORATION Pro Duct Health, Inc.; CYTYC CORP Pro/ENGINEER 3-D; PARAMETRIC TECHNOLOGY CORP Process Conception Ingenierie; PSA PEUGEOT CITROEN SA Proclaim; SYNGENTA AG Professional Engineering and Inspection Co.; US LABORATORIES Profile; MEDTOX SCIENTIFIC INC PROFURO INTERNATIONAL; TREVIFINANZIARIA INDUSTRIALE SPA Project Golden Gate; BMC SOFTWARE INC ProjectorNet; INFOCUS CORP ProLease; ALKERMES INC Proleukin; CHIRON CORP ProNet; MYRIAD GENETICS INC Pronto; INVACARE CORP Pronto; DEL LABORATORIES INC Propa pH; DEL LABORATORIES INC Property Control, Inc.; DUALSTAR TECHNOLOGIES CORPORATION Prosaptide; BIO TECHNOLOGY GENERAL CORP Prospera; NORTH AMERICAN SCIENTIFIC ProstaScint; CYTOGEN CORPORATION Protégé; MAZDA MOTOR CORPORATION Protein ProFiler; LYNX THERAPEUTICS INC Proteome; INCYTE GENOMICS INC PROTHECAN; ENZON INC Protis Software; DADE BEHRING INC Protuss; FIRST HORIZON PHARMACEUTICALS PROVAX; IDEC PHARMACEUTICALS CORP Provigil; CEPHALON INC ProXCISION; PERKINELMER INC Proxim, Inc.; PROXIM CORPORATION Proxima; INFOCUS CORP ProXPRESS; PERKINELMER INC Prozac; ELI LILLY & CO PR-Q; COLLAGENEX PHARMACEUTICAL PSMA Technology; CYTOGEN CORPORATION PsoriasisSupport.com; BIOGEN INC Pulmicort Respules; ASTRAZENECA PLC Pulmozyme; GENENTECH INC PULSAR; GUIDANT CORP PULSE; BOSTON BIOMEDICA INC Pulse Engineering, Inc.; TECHNITROL INC Pulse Specialty Components; TECHNITROL INC PureWorld Botanicals, Inc.; PURE WORLD INC PureWorld Veragel; PURE WORLD INC Puricase; BIO TECHNOLOGY GENERAL CORP Puritan Bennett; MALLINCKRODT INC
Plunkett Research, Ltd.
www.plunkettresearch.com
INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Puritan.com; NBTY INC Puritan’s Pride; NBTY INC PVAC; CORIXA CORPORATION PwC Consulting; INTERNATIONAL BUSINESS MACHINES (IBM) Pyrex; CORNING INC Pyrolase 160 Enzyme; DIVERSA CORPORATION Pyrolase 200 Enzyme; DIVERSA CORPORATION QA Life Sciences; NEOGEN CORPORATION QS-10 Guidewire; MEDTRONIC AVE INC Quadramet; CYTOGEN CORPORATION Quantase, Ltd.; BIO RAD LABORATORIES INC Quanterra, Inc.; CORNING INC Quantum Effect Devices; PMC-SIERRA INC Quartus II; ALTERA CORP Quickbid; CACI INTERNATIONAL INC QuickBooks; INTUIT INC QuickBooks Pro; INTUIT INC Quicken; INTUIT INC Quicken TurboTax; INTUIT INC QuickenMortgage; INTUIT INC Quickie; SUNRISE MEDICAL INC Quickie Chameleon; SUNRISE MEDICAL INC QuickTax; INTUIT INC QuickTime; APPLE COMPUTER INC QuickTime TV Network; APPLE COMPUTER INC QuickVue Advance G Test; QUIDEL CORP QuickVue Advance pH Test; QUIDEL CORP QuickVue Dipstick Strep A Test; QUIDEL CORP QuickVue Influenza Test; QUIDEL CORP QuickVue UrinChek Test Strips; QUIDEL CORP QuikSync; IOMEGA CORP Quintus Corp.; AVAYA INC R&D Systems Europe, Ltd.; TECHNE CORP R&D Systems GmbH; TECHNE CORP RadiaCare Gel; CARRINGTON LABORATORIES INC RadNet Radiology Information System; CERNER CORP Ramar Corp.; JDS UNIPHASE CORP Ramoplanin; GENOME THERAPEUTICS CORP Raptiva; XOMA LTD RAR Technology; TECHNIP-COFLEXIP Rational Integrated Solutions; RATIONAL SOFTWARE CORP Rational Rose; RATIONAL SOFTWARE CORP Rational Software Corp.; INTERNATIONAL BUSINESS MACHINES (IBM) Rational Suite; RATIONAL SOFTWARE CORP Raytheon Aircraft; RAYTHEON CO Raytheon Technical Services; RAYTHEON CO RDP58; SANGSTAT MEDICAL CORP Rebeccamycin; EXELIXIS INC Recovery Manager; BMC SOFTWARE INC Red Adair Company (The); GLOBAL INDUSTRIES LTD Reflect-It; MAXTOR CORP
Refresh Tears; ALLERGAN INC Regent; BASF AG Relafen; GLAXOSMITHKLINE PLC Reliance Electric Co.; ROCKWELL AUTOMATION Remedy Corp; BMC SOFTWARE INC Remicade; GTC BIOTHERAPEUTICS INC REMICADE; CENTOCOR INC Remitogen; PROTEIN DESIGN LABS INC Remodulin; UNITED THERAPEUTICS CORP RemoteTeller; DIEBOLD INC REMstar; RESPIRONICS INC Renagel; GENZYME CORP Renagel Tablets; GELTEX PHARMACEUTICALS Renault Trucks; AB VOLVO ReNu; BAUSCH & LOMB INC ReoPro; CENTOCOR INC Replagal; TRANSKARYOTIC THERAPIES Replicase; DIVERSA CORPORATION Repliform; LIFECELL CORPORATION RequisitePro; RATIONAL SOFTWARE CORP Research and Diagnostic Systems, Inc.; TECHNE CORP Research Medical, Inc.; BAXTER INTERNATIONAL INC RespiGam; MEDIMMUNE INC Restoraderm; COLLAGENEX PHARMACEUTICAL RESTORE; LIFECORE BIOMEDICAL INC RESTYLANE; MEDICIS PHARMACEUTICAL CORP RETAVASE; CENTOCOR INC REVIMID; CELGENE CORP Rhone Merieux Diagnostics; SYNBIOTICS CORP Ribapharm, Inc.; ICN PHARMACEUTICALS INC Ridaura; MGI PHARMA INC Riedel-de Haen; SIGMA ALDRICH CORP RightWorks Corp.; I2 TECHNOLOGIES INC Risperdal Consta; ALKERMES INC Rituxan; IDEC PHARMACEUTICALS CORP Rituxan; GENENTECH INC RoamAbout; ENTERASYS NETWORKS INC Robert W. Hunt Co.; US LABORATORIES Robin; FUJI HEAVY INDUSTRIES LTD Robinul; FIRST HORIZON PHARMACEUTICALS Robitussin; WYETH Rocephin; CUBIST PHARMACEUTICALS Rockwell Automation Services; ROCKWELL AUTOMATION Rockwell Collins; ROCKWELL AUTOMATION Rockwell Samsung Automation; ROCKWELL AUTOMATION Rockwell Scientific Co.; ROCKWELL AUTOMATION Rockwell Software; ROCKWELL AUTOMATION Rodeo; ISUZU MOTORS LTD Rolls-Royce; VOLKSWAGEN AG RoseEssential Plus; HAUSER INC Rosemont Pharmaceuticals, Ltd.; BIO TECHNOLOGY GENERAL CORP
Plunkett Research, Ltd.
www.plunkettresearch.com
INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Rosemount Aerospace, Inc.; GOODRICH CORPORATION RoseOx; HAUSER INC Ross; ABBOTT LABORATORIES Roundup; MONSANTO CO ROV Technologies; GLOBAL INDUSTRIES LTD Royal Dutch/Shell; SHELL OIL CO RSW Software; TERADYNE INC Rubitecan; SUPERGEN INC Rusch International; TELEFLEX INC Rushmore NTE; QUANTUM CORP Rutherford Chemicals, Inc.; CAMBREX CORP RX-7; MAZDA MOTOR CORPORATION S.T.E.P.S.; CELGENE CORP Sabila Industrial, S.A.; CARRINGTON LABORATORIES INC SafeCase; ENGLOBAL CORP Sagem; JOHNSON CONTROLS INC SageTree; WESTERN DIGITAL CORP Saipem S.p.A.; ENI SPA Salagen; MGI PHARMA INC SaliCept Oral Patch; CARRINGTON LABORATORIES INC Sally Hansen; DEL LABORATORIES INC Samco Scientific Corp.; CORNING INC Sanders Design International; ANALOGIC CORP SangStat Europe; SANGSTAT MEDICAL CORP SangStat, Canada, Ltd.; SANGSTAT MEDICAL CORP Sankyo Pharma, Inc.; GELTEX PHARMACEUTICALS Sanmina; ALCATEL USA INC Sanmina Corp.; HADCO CORP Santa Barbara Sistemas; GENERAL DYNAMICS Sanwa Chemical Industry Co.; AIR PRODUCTS & CHEMICALS INC SAP Hosting; SAP AKTIENGESELLSCHAFT SAP Learning Solutions Asia; SAP AKTIENGESELLSCHAFT SAP Manage; SAP AKTIENGESELLSCHAFT SAP Retail Solutions; SAP AKTIENGESELLSCHAFT SAP SI; SAP AKTIENGESELLSCHAFT SAS SRM; SAS INSTITUTE SATURN; PMC-SIERRA INC SB Clarite Artificial Disc; JOHNSON & JOHNSON SBS International, Inc.; BOEING CO SCA Ventures; ENZON INC SCA2000; SYNBIOTICS CORP ScanJet; HEWLETT-PACKARD CO Scanpoint Technology; CUBIC CORP Schering AG; COLLATERAL THERAPEUTICS SCH-X590; SAMSUNG ELECTRONICS CO LTD SciCare Broadband Services; SCIENTIFIC ATLANTA INC SciClone Pharmaceuticals International; SCICLONE PHARMACEUTICALS SCIO-323; SCIOS INC SCIO-469; SCIOS INC
Scion Photonics, Inc.; READ-RITE CORP Scirocco; SYNOPSYS INC Score; SYNGENTA AG Scotch Tape; 3M COMPANY ScreenPlay; INFOCUS CORP SCV-07; SCICLONE PHARMACEUTICALS Sea-Doo; BOMBARDIER INC Sea-Sparrow; RAYTHEON CO Seca; CONOCOPHILLIPS Secure Site Plus; VERISIGN INC Seek Target Validation (S-T-V) Program; LEXICON GENETICS INC Seismic Starter; OYO CORPORATION SelCIDs; CELGENE CORP Senioral; BENTLEY PHARMACEUTICALS INC SensiLight; MARTEK BIOSCIENCES CORP Sensitive Eyes Saline Solution; BAUSCH & LOMB INC Sentry; CIENA CORP Separation Technology, Inc.; APOGENT TECHNOLOGIES INC SeqCalling; CURAGEN CORPORATION Sequoia; ACUSON CORPORATION Sequoia Capital; GOOGLE INC SERM; CELGENE CORP Serologicals Proteins, Inc.; SEROLOGICALS CORP Serologicals, Ltd.; SEROLOGICALS CORP Sersi Italia; DIEBOLD INC ServerWorks; BROADCOM CORP SHARC 32-Bit Floating-Point DSP; ANALOG DEVICES INC Sharp Laboratories of America, Inc.; SHARP CORPORATION Sharp Laboratories of Europe, Ltd.; SHARP CORPORATION Sharp Software Development India Pvt., Ltd.; SHARP CORPORATION Sharp Technology (Taiwan) Corp.; SHARP CORPORATION Sharp Telecommunications of Europe, Ltd.; SHARP CORPORATION Shell Chemical; SHELL OIL CO Shell Exploration & Production; SHELL OIL CO Shell Exploration and Production; ROYAL DUTCH PETROLEUM CO Shell Gas & Power; SHELL OIL CO Shell Global Solutions; ROYAL DUTCH PETROLEUM CO Shell International Trading and Shipping; ROYAL DUTCH PETROLEUM CO Shell Oil Products US; SHELL OIL CO Shell Renewable; ROYAL DUTCH PETROLEUM CO Shell Service Stations; ROYAL DUTCH PETROLEUM CO Shell Trading; ROYAL DUTCH PETROLEUM CO Shell WindEnergy, Inc.; ROYAL DUTCH PETROLEUM CO
Plunkett Research, Ltd.
www.plunkettresearch.com
INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. ShellGel; ANIKA THERAPEUTICS INC Shiva Corporation; INTEL CORP SHOUTIP; NETWORK EQUIPMENT TECHNOLOGIES INC Siamtyre; COMPAGNIE MICHELIN Siebel 2000; SIEBEL SYSTEMS INC Siebel 7; SIEBEL SYSTEMS INC Siebel eMail Response; SIEBEL SYSTEMS INC Siebel eService; SIEBEL SYSTEMS INC Siebel Interactive Selling Suite; SIEBEL SYSTEMS INC Siemens; ACUSON CORPORATION Siemens IC Mobile; SIEMENS AG Siemens Medical Solutions; SIEMENS AG Siemens USA; SIEMENS AG Sigma; SIGMA ALDRICH CORP Signature Edition Family; ALARIS MEDICAL INC SignStorey; GERBER SCIENTIFIC INC Silicon Light Machines; CYPRESS SEMICONDUCTOR CORP Silicon Magnetic Systems; CYPRESS SEMICONDUCTOR CORP Silicon Systems, Inc.; TEXAS INSTRUMENTS INC Silicon-Film; ASTROPOWER INC Silver Lake Partners; SEAGATE TECHNOLOGY INC Sim City; ELECTRONIC ARTS INC Similac; ABBOTT LABORATORIES Simmonds Precision Products, Inc.; GOODRICH CORPORATION Simplex P with Tobramycin Bone Cement; STRYKER CORP SIMPROCESS; CACI INTERNATIONAL INC Singapore Economic Development Board; ELI LILLY & CO Singulair; MERCK & CO INC Siouxland Ophthalmic, Inc.; SOLA INTERNATIONAL INC Sitaxsentan; ICOS CORPORATION Site Builder; INTUIT INC Skeletal Targeted Radiotherapy; NEORX CORPORATION Ski-Doo; BOMBARDIER INC SKY Computers; ANALOGIC CORP SKYLight; ADAC LABORATORIES Skytop International, Ltd.; JABIL CIRCUIT INC SLAM; ABGENIX INC Sleeping Beauty Transposona; TECHNE CORP Slim-Hole; TREVI-FINANZIARIA INDUSTRIALE SPA SMART; PROTEIN DESIGN LABS INC Smart Serials; MICROCHIP TECHNOLOGY INC SmartPReP; LIFECELL CORPORATION SmartSim; ADAC LABORATORIES SmartStation; PERKINELMER INC SmartView Web Inspection; COGNEX CORP SMP; ATRIX LABORATORIES INC Snam Rete Gas S.p.A.; ENI SPA
Snamprogetti S.p.A.; ENI SPA SNAP; IDEXX LABORATORIES INC Snap Server; QUANTUM CORP SnapManager; NETWORK APPLIANCE INC Snaptrack; QUALCOMM INC Sniffer Technologies; NETWORK ASSOCIATES INC SNPCalling; CURAGEN CORPORATION SNPstream; ORCHID BIOSCIENCES INC SNPware; ORCHID BIOSCIENCES INC SofLens Multi-Focal Contact Lenses; BAUSCH & LOMB INC SofPort System; BAUSCH & LOMB INC Softcom Microsystems, Inc.; INTEL CORP SoftICE64; COMPUWARE CORP Softlab GmbH; BAYERISCHE MOTOREN WERKE AG SOILMES S.p.A.; TREVI-FINANZIARIA INDUSTRIALE SPA SOLAMAX; SOLA INTERNATIONAL INC Solaris; SUN MICROSYSTEMS INC SolarQuilt; ENERGY CONVERSION DEVICES INC Solstice; MEDTRONIC AVE INC Soltamox; BIO TECHNOLOGY GENERAL CORP Soltec Research; CONNETICS CORPORATION Solutions Consulting; PEROT SYSTEMS CORP Solutions Group; PALM INC Somatix Therapy Corp.; CELL GENESYS INC Sonata; HYUNDAI MOTOR COMPANY SONET Transmission Manager; NETWORK EQUIPMENT TECHNOLOGIES INC SonicViewer-SX; OYO CORPORATION Sony Ericsson Mobile Communications; TELEFON AB LM ERICSSON Sony Music Entertainment; SONY CORPORATION Sony Pictures Entertainment; SONY CORPORATION Soredex; INSTRUMENTARIUM Sorona; E I DU PONT DE NEMOURS & CO (DUPONT) Sound Technology; ANALOGIC CORP Soza and Company, Ltd.; PEROT SYSTEMS CORP Spacelabs Medical, Inc.; INSTRUMENTARIUM SPACEWAY; HUGHES ELECTRONICS CORP Spandex PLC; GERBER SCIENTIFIC INC SPARC Technology; SUN MICROSYSTEMS INC Spartan Products; XILINX INC Specialty Underwriters; GENERAL ELECTRIC CO SpectroCHIP; SEQUENOM INC SpectroJET; SEQUENOM INC SpectroTYPER; SEQUENOM INC SpeedFam-IPEC, Inc.; NOVELLUS SYSTEMS INC Speedway SuperAmerica, LLC; MARATHON OIL Splash; ELECTRONICS FOR IMAGING INC Spotted Array Systems; AFFYMETRIX INC SQL Anywhere Studio; SYBASE INC SSG-Shared Services Group; BOEING CO
Plunkett Research, Ltd.
www.plunkettresearch.com
INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. St. Jude Medical International; ST JUDE MEDICAL INC STAARVISC II; ANIKA THERAPEUTICS INC STAGE-1; LIFECORE BIOMEDICAL INC Stainmaster; E I DU PONT DE NEMOURS & CO (DUPONT) StaphVAX; NABI BIOPHARMACEUTICALS Star Office; SUN MICROSYSTEMS INC Starhome; COMVERSE TECHNOLOGY INC Starlight Electronics; CIRRUS LOGIC INC Starspan; ALCATEL USA INC Startel; COMVERSE TECHNOLOGY INC State CAD; XILINX INC StatScript Management Services; CHRONIMED INC Steril S.p.A.; FOSTER WHEELER LTD STERIS SYSTEM 1; STERIS CORP STILL GmbH; LINDE AG Stizmarks; PHARMACEUTICAL FORMULATIONS INC StorageNet; STORAGE TECHNOLOGY CORP StorageTek; STORAGE TECHNOLOGY CORP Strategic Technology Enterprises; STERIS CORP StrongStart; K V PHARMACEUTICAL CO Stryker Biotech, Spine and Trauma; STRYKER CORP Stryker Howmedica Osteonics; STRYKER CORP Stryker International; STRYKER CORP Stryker MedSurg; STRYKER CORP Student Survival Kit; NETWORK ASSOCIATES INC Studio Max; AUTODESK INC Study Tracker; COVANCE INC STV Architects; STV GROUP INC STV Construction Management; STV GROUP INC STV Environmental; STV GROUP INC STV International; STV GROUP INC STV, Inc.; STV GROUP INC STV/Silver & Ziskind; STV GROUP INC Subaru; FUJI HEAVY INDUSTRIES LTD Subaru of America; FUJI HEAVY INDUSTRIES LTD Subaru of Indiana Automotive, Inc.; FUJI HEAVY INDUSTRIES LTD Subaru Research and Development, Inc.; FUJI HEAVY INDUSTRIES LTD Subaru Vehicle Distribution; FUJI HEAVY INDUSTRIES LTD Sucraid; ORPHAN MEDICAL INC Sular; FIRST HORIZON PHARMACEUTICALS Sumitomo Rubber Industries; GOODYEAR TIRE & RUBBER COMPANY (THE) Sun Microelectronics; SUN MICROSYSTEMS INC SunAndSkin.com; MEDICIS PHARMACEUTICAL CORP SunChoice; ASTROPOWER INC SunLine; ASTROPOWER INC SunPharm Corporation; GELTEX PHARMACEUTICALS SunSoft, Inc.; SUN MICROSYSTEMS INC
SunUPS; ASTROPOWER INC Supelco; SIGMA ALDRICH CORP Super Arrow-Flex; ARROW INTERNATIONAL INC SuperBGA; AMKOR TECHNOLOGY INC SuperDLTtape; QUANTUM CORP Superior Pharmaceutical Co.; ABLE LABORATORIES Super-OLAC; NKK CORPORATION SureBeam Corp.; TITAN CORP (THE) SureLight; MARTEK BIOSCIENCES CORP SurgiVision; STERIS CORP SUSTAIN; LIFECORE BIOMEDICAL INC Suzuki Akita Auto Parts Mfg. Co.; SUZUKI MOTOR CORPORATION Suzuki Marin Co.; SUZUKI MOTOR CORPORATION Suzuki Precision Industries; SUZUKI MOTOR CORPORATION Suzuki Transportation and Packing Co.; SUZUKI MOTOR CORPORATION Swan-Ganz; EDWARDS LIFESCIENCES CORP SweetThoughts.com; HI TECH PHARMACAL CO INC SwitchOn Networks; PMC-SIERRA INC Sybase Professional Services; SYBASE INC SYBYL; TRIPOS INC Symbol LS 220; SYMBOL TECHNOLOGIES INC SYMLIN; AMYLIN PHARMACEUTICALS INC Symmetrix Enterprise Storage System; EMC CORP Symphar S.A.; ILEX ONCOLOGY INC Symphony; PROXIM CORPORATION Synagis; MEDIMMUNE INC SyncroDose; PENWEST PHARMACEUTICALS CO Synergy; UNITED THERAPEUTICS CORP Synergy Integra CMP; LAM RESEARCH CORP Synovis Interventional Solutions; SYNOVIS LIFE TECHNOLOGIES INC Synovis Micro Companies Alliance; SYNOVIS LIFE TECHNOLOGIES INC Synovis Precision Engineering; SYNOVIS LIFE TECHNOLOGIES INC Synovis Surgical Innovations; SYNOVIS LIFE TECHNOLOGIES INC SYNtrac; SYNCOR INTERNATIONAL CORPORATION Syracuse Research Center; ALBANY MOLECULAR RESEARCH Systemedia; NCR CORPORATION T2000; TARO PHARMACEUTICAL INDUSTRIES Tamiflu; GILEAD SCIENCES INC Tamoxifen; BARR LABORATORIES INC Tanafed; FIRST HORIZON PHARMACEUTICALS Tarceva; OSI PHARMACEUTICALS INC Targretin; LIGAND PHARMACEUTICALS INC Tarka; KOS PHARMACEUTICALS INC Taro Pharmaceuticals U.S.A., Inc.; TARO PHARMACEUTICAL INDUSTRIES Taurus; ORBITAL SCIENCES CORP Taxotere; AVENTIS SA
Plunkett Research, Ltd.
www.plunkettresearch.com
INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Taylor Pharmaceuticals, Inc.; AKORN INC Tazidime; ELI LILLY & CO Tazorac; ALLERGAN INC TEALARC; TECHNIP-COFLEXIP Teamscape Corp.; PEOPLESOFT INC Techma U.S.A., Inc.; DENSO CORPORATION Techne Export, Inc.; TECHNE CORP Technical Resource Connection; PEROT SYSTEMS CORP Technicolor Digital Cinema; QUALCOMM INC Technip SA; TECHNIP-COFLEXIP TechSync; ACTERNA CORPORATION Teflon; E I DU PONT DE NEMOURS & CO (DUPONT) Telecommunications Techniques Co.; ACTERNA CORPORATION Telekol Corp.; NOKIA CORPORATION Telenor Technology Services; JABIL CIRCUIT INC TeleTrial; COVALENT GROUP INC Telocity Delaware, Inc.; HUGHES ELECTRONICS CORP Telstar; LORAL SPACE & COMMUNICATIONS LTD Temic; ATMEL CORP Tempra FirsTabs; CIMA LABS INC Teradata; NCR CORPORATION Teres CMP; LAM RESEARCH CORP Terra Nitrogen Co.; TERRA INDUSTRIES INC TerraGen Discovery, Inc.; CUBIST PHARMACEUTICALS Terror; NETWORK EQUIPMENT TECHNOLOGIES INC TetraMAX; SYNOPSYS INC Tettemer & Associates; KEITH COMPANIES INC (THE) Texaco; CHEVRONTEXACO CORPORATION Texaco Ovonic Fuel Cell Co.; CHEVRONTEXACO CORPORATION Texas Instruments Software, Ltd.; TEXAS INSTRUMENTS INC Texas Instruments, Ltd.; TEXAS INSTRUMENTS INC Texas Pacific Group; SEAGATE TECHNOLOGY INC tgAAVCF; TARGETED GENETICS CORP TH!NK; FORD MOTOR CO THALOMID; CELGENE CORP TheraPulse; KINETIC CONCEPTS INC Therapy Guidance System; VIROLOGIC INC TheraSeed; THERAGENICS CORP Thermal Corp.; ENGLOBAL CORP ThermalAce; DIVERSA CORPORATION Thermo BioStar; THERMO ELECTRON CORP Thermo Polysonics; THERMO ELECTRON CORP Thermo PRISM; THERMO ELECTRON CORP Thermo VG Scientific; THERMO ELECTRON CORP Ther-RX Corporation; K V PHARMACEUTICAL CO
Theseus Imaging Corp.; NORTH AMERICAN SCIENTIFIC Think Shrink; AMKOR TECHNOLOGY INC ThinPrep 2000 Processor; CYTYC CORP ThinPrep 3000 Processor; CYTYC CORP ThinPrep Imaging System; CYTYC CORP ThinPrep Pap Test; CYTYC CORP ThinPrep System; CYTYC CORP THIOPLEX; IMMUNEX CORP Thompson-Hysell Engineers; KEITH COMPANIES INC (THE) Thoroughbred 121 FGD Process; CHIYODA CORPORATION Thrombosol; LIFECELL CORPORATION Thymoglobulin; SANGSTAT MEDICAL CORP Thyrogen; GENZYME CORP Tiazac; FOREST LABORATORIES INC TigerStack; STANDARD MICROSYSTEMS CORPORATION TigerSwitch; STANDARD MICROSYSTEMS CORPORATION Time, Inc.; AOL TIME WARNER INC TIMERx; PENWEST PHARMACEUTICALS CO Tinactin; SCHERING-PLOUGH CORP Titan Scan Technologies; TITAN CORP (THE) Titan Secure Solutions; TITAN CORP (THE) Titan Systems Corp.; TITAN CORP (THE) Titan Wireless; TITAN CORP (THE) Tivoli Systems, Inc.; INTERNATIONAL BUSINESS MACHINES (IBM) TKT Europe-5S AB; TRANSKARYOTIC THERAPIES TNKase; GENENTECH INC TOBI; CHIRON CORP TOPO TA Cloning Kit; INVITROGEN CORPORATION Torrent Systems; ASCENTIAL SOFTWARE CORPORATION Tosara Group; FOREST LABORATORIES INC Total Access System; ADTRAN INC Toucan Technology; PMC-SIERRA INC ToxExpress; GENE LOGIC INC ToxScreen Reports; GENE LOGIC INC ToxSuites; GENE LOGIC INC Toyota Financial Services Corp.; TOYOTA MOTOR CORPORATION Toyota Motor; DENSO CORPORATION TP-38; IVAX CORPORATION TRACER Series; ADTRAN INC Trade Service Corp.; I2 TECHNOLOGIES INC TradeMatrix Open Commerce Network; I2 TECHNOLOGIES INC Trailblazer; QUANTUM CORP Tramadol; ABLE LABORATORIES Tramco, Inc.; GOODRICH CORPORATION TransFx; ZIMMER HOLDINGS INC
Plunkett Research, Ltd.
www.plunkettresearch.com
INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Transkaryotic Therapy; TRANSKARYOTIC THERAPIES TransMAX; ADVANCED FIBRE COMMUNICATIONS INC Trans-Phage Technology; MEDAREX INC Transplant Pharmacy; CHRONIMED INC TransQ; IOMED INC Trans-Ver-Sal; BRADLEY PHARMACEUTICALS TRC Cubix Corp.; TRC COMPANIES INC TRC Engineered Automation Systems, Inc.; TRC COMPANIES INC TRC Essex Environmental; TRC COMPANIES INC TRC Hunter Associates; TRC COMPANIES INC TRC Lowney Associates; TRC COMPANIES INC TRC Novak Engineering; TRC COMPANIES INC TRC SITE-Blauvelt; TRC COMPANIES INC TREVI Contractors B.V.; TREVI-FINANZIARIA INDUSTRIALE SPA TREVIJET; TREVI-FINANZIARIA INDUSTRIALE SPA TREVIPARK; TREVI-FINANZIARIA INDUSTRIALE SPA Trexal; BARR LABORATORIES INC TriaDyne; KINETIC CONCEPTS INC Triage BNP Test; BIOSITE INC Triage Cardiac Panel; BIOSITE INC Triage Drugs of Abuse Panel; BIOSITE INC Triage Meter; BIOSITE INC Triage TOX Drug Screen; BIOSITE INC Trial Tracker; COVANCE INC TrialBase; KENDLE INTERNATIONAL INC TriAlert; KENDLE INTERNATIONAL INC TriaLine; KENDLE INTERNATIONAL INC TrialView; KENDLE INTERNATIONAL INC TrialWare; KENDLE INTERNATIONAL INC TrialWeb; KENDLE INTERNATIONAL INC Triaminic Softchews; CIMA LABS INC Triangle Pharmaceuticals, Inc.; GILEAD SCIENCES INC Tricord Systems, Inc.; ADAPTEC INC Trident Ceramic Acetabular Insert; STRYKER CORP TRILOGUE; COMVERSE TECHNOLOGY INC Trilogy; NETWORK EQUIPMENT TECHNOLOGIES INC Trilogy; ZIMMER HOLDINGS INC Triphasil; WYETH TRISENOX; CELL THERAPEUTICS INC Trooper; ISUZU MOTORS LTD TSU Series; ADTRAN INC Tsunami; PROXIM CORPORATION TT Roadster; AUDI AG TT550; HAUSER INC Tularik GmbH; TULARIK INC Tularik Texas Corporation; TULARIK INC Tums; GLAXOSMITHKLINE PLC Tunable GeneReassembly; DIVERSA CORPORATION
Turf Builder; SCOTTS CO Turkpetrol; CONOCOPHILLIPS Turner Broadcasting System; AOL TIME WARNER INC Tyco International; MALLINCKRODT INC Tylenol; JOHNSON & JOHNSON Tzamal Pharma; NAPRO BIOTHERAPEUTICS INC U.S. Bioscience, Inc.; MEDIMMUNE INC U.S. Engineering Laboratories; US LABORATORIES U.S. Precision Lens, Inc.; CORNING INC UCB Farchim SA; SEPRACOR INC UDL Laboratories, Inc.; MYLAN LABORATORIES INC Ulticom, Inc.; COMVERSE TECHNOLOGY INC Ultima Online; ELECTRONIC ARTS INC Ultima Renaissance; ELECTRONIC ARTS INC UltiMab Human Antibody Development System; MEDAREX INC ULTRA; COMVERSE TECHNOLOGY INC Ultraview; INSTRUMENTARIUM UMC1000; ADVANCED FIBRE COMMUNICATIONS INC UnderWare, Inc.; COMPUWARE CORP Unicenter; COMPUTER ASSOCIATES INTERNATIONAL INC Uniloy Milacron, Inc.; JOHNSON CONTROLS INC Union Carbide; DOW CHEMICAL COMPANY (THE) Unipeg; UNITED THERAPEUTICS CORP Uniphase, Inc.; JDS UNIPHASE CORP Uniprost; UNITED THERAPEUTICS CORP Uniroyal; COMPAGNIE MICHELIN Unisense; UNITED THERAPEUTICS CORP Uniservice Wellpoint; ITT INDUSTRIES INC United Solar Systems Corp.; ENERGY CONVERSION DEVICES INC Unitek Technical Services, Inc.; US LABORATORIES Unither Pharmaceuticals, Inc.; UNITED THERAPEUTICS CORP UNITY; TRIPOS INC Universal Analytics, Inc.; MSC.SOFTWARE CORP Universal Energy, Inc.; KEITH COMPANIES INC (THE) Urban Warfare Simulation; CACI INTERNATIONAL INC UrinQuick Urine Chemistry Analyzer; QUIDEL CORP URS Corp.; EG&G INC Uryxr; CR BARD INC V.A.C. System; KINETIC CONCEPTS INC Vacutainer; BECTON DICKINSON & CO Vallen Fire Services; VALLEN CORP Vallen Knowledge Systems; VALLEN CORP Vallen Technical Services; VALLEN CORP Vantage Release 8.5; COMPUWARE CORP Vantive Corporation (The); PEOPLESOFT INC VariSeed; VARIAN MEDICAL SYSTEMS INC VariSource; VARIAN MEDICAL SYSTEMS INC
Plunkett Research, Ltd.
www.plunkettresearch.com
INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Vascu-Guard; SYNOVIS LIFE TECHNOLOGIES INC VasoView; GUIDANT CORP VecTest; FISHER SCIENTIFIC INTERNATIONAL INC VECTOR; NOVELLUS SYSTEMS INC Vectra; ADAM OPEL AG Velocigene; REGENERON PHARMACEUTICALS INC Verdia; MAXYGEN INC Verdict; MEDTOX SCIENTIFIC INC Verint Systems; COMVERSE TECHNOLOGY INC VeriSign OnSite; VERISIGN INC Veritas Collagen Matrix; SYNOVIS LIFE TECHNOLOGIES INC VERITAS Software; SEAGATE TECHNOLOGY INC Versera Enhanced Services; GLENAYRE TECHNOLOGIES INC Versera Multimedia Messaging Suite; GLENAYRE TECHNOLOGIES INC Versera Unified Communications Suite; GLENAYRE TECHNOLOGIES INC Versera Voice Services Suite; GLENAYRE TECHNOLOGIES INC VerSys; ZIMMER HOLDINGS INC Versys Metal 2300; LAM RESEARCH CORP Versys Silicon 2300; LAM RESEARCH CORP Vertical Horizon Switches; ENTERASYS NETWORKS INC VET/OX 4404; HESKA CORP VetCom Newsletter; ABAXIS INC VetScan Chemistry System; ABAXIS INC VetScan HMT Hematology Analyzer; ABAXIS INC Vexol; ALCON LABORATORIES INC ViaMichelin; COMPAGNIE MICHELIN Vibrilase; BIOMARIN PHARMACEUTICAL VIBROTREVI; TREVI-FINANZIARIA INDUSTRIALE SPA VINCI Airports; VINCI VINCI Concessions; VINCI VINCI Construction; VINCI VINCI Energies; VINCI VINCI Park; VINCI VINCI Routes; VINCI Vioxx; COLLAGENEX PHARMACEUTICAL Vioxx; MERCK & CO INC Viper; SEAGATE TECHNOLOGY INC Viracept; PFIZER INC Viral Antigens, Inc.; MERIDIAN BIOSCIENCE INC Virazide; ICN PHARMACEUTICALS INC Virazole; ICN PHARMACEUTICALS INC Virbac Corp.; VIRBAC INC Virbagen Omega; VIRBAC INC Viread; GILEAD SCIENCES INC ViroTex; ATRIX LABORATORIES INC Virtex Series; XILINX INC Virtual HouseCall; COVALENT GROUP INC
Virtual Library; NEUROGEN CORP Virtual Screening; NEUROGEN CORP ViscoFoam; INVACARE CORP VISTA Network Integration Services, Inc.; JOHNSON CONTROLS INC Vistanta; GLENAYRE TECHNOLOGIES INC Vistide; GILEAD SCIENCES INC Visual Software Solutions, Inc.; XILINX INC VITA Technology; CUBIST PHARMACEUTICALS VITALITY AVT; GUIDANT CORP Vitamin World; NBTY INC Vitamins.com; NBTY INC Vitravene; ISIS PHARMACEUTICALS INC Vivelle; NOVEN PHARMACEUTICALS Vivelle-Dot; NOVEN PHARMACEUTICALS Vivitrex; ALKERMES INC ViziLite; ZILA INC Volera; NOVELL INC Volera, Inc.; NORTEL NETWORKS CORP Volkswagen; AUDI AG Volkswagen of America, Inc.; VOLKSWAGEN AG VolSurf; TRIPOS INC Volvo; FORD MOTOR CO Volvo Aero; AB VOLVO Volvo Bus Corporation; AB VOLVO Volvo Construction Equipment; AB VOLVO Volvo Financial Services; AB VOLVO Volvo Penta; AB VOLVO Volvo Trucks North America, Inc.; AB VOLVO VPNet Technologies; AVAYA INC VX-148; VERTEX PHARMACEUTICALS INC VX-175; VERTEX PHARMACEUTICALS INC VX-563; VERTEX PHARMACEUTICALS INC VX-702; VERTEX PHARMACEUTICALS INC VX-765; VERTEX PHARMACEUTICALS INC VX-950; VERTEX PHARMACEUTICALS INC VxTel, Inc.; INTEL CORP W3Commerce, LLC; SYNBIOTICS CORP Waeschle Maschinenfabrik GmbH; GEORG FISCHER LTD Wallace Pharmaceuticals; MEDPOINTE INC Walter Lorenz Surgical, Inc.; BIOMET INC Wang Global; GETRONICS NV Warner Bros.; AOL TIME WARNER INC Warp; CYPRESS SEMICONDUCTOR CORP Watson Laboratories, Inc.; WATSON PHARMACEUTICALS INC Watson Pharma; WATSON PHARMACEUTICALS INC WebLogic Enterprise Platform; BEA SYSTEMS INC WebLogic Server Java; BEA SYSTEMS INC WebMD Envoy; WEBMD CORPORATION WebMD Medical Manager; WEBMD CORPORATION WebTV; MICROSOFT CORP Weedol; SCOTTS CO Welchol; GELTEX PHARMACEUTICALS
Plunkett Research, Ltd.
www.plunkettresearch.com
INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Western Multiplex; PROXIM CORPORATION Whole Blood Flow Cytometry Control; TECHNE CORP Whole Blood Glucose/Hemoglobin Control; TECHNE CORP Wilcox Drug Company; HAUSER INC Windchill; PARAMETRIC TECHNOLOGY CORP Windows; MICROSOFT CORP WinRho SDF; NABI BIOPHARMACEUTICALS Wintershall AG; BASF AG Wireless Knowledge; QUALCOMM INC Witness Ehrlichia; SYNBIOTICS CORP Women's Health U.S.A., Inc.; CURAGEN CORPORATION WoundCare.com; CARRINGTON LABORATORIES INC Wright, Williams & Kelly; CH2M HILL COMPANIES LTD Wydeband; COMVERSE TECHNOLOGY INC Wyeth; ELAN CORP PLC X Technologies, Inc.; GUIDANT CORP X1; INFOCUS CORP Xbox; MICROSOFT CORP XCELLSIS; BALLARD POWER SYSTEMS XenoLogiX; EDWARDS LIFESCIENCES CORP XenoMax; ABGENIX INC XenoMouse; ABGENIX INC Xerox Engineering Center; XEROX CORP Xigris; SYNCOR INTERNATIONAL CORPORATION Xircom, Inc.; INTEL CORP xMAP; LUMINEX CORPORATION XOPENEX; SEPRACOR INC X-Pedition Routers; ENTERASYS NETWORKS INC XYOTAX; CELL THERAPEUTICS INC Xyrem; ORPHAN MEDICAL INC Yahoo.com; YAHOO! INC Yectamicina; ICN PHARMACEUTICALS INC Z/I Imaging; INTERGRAPH CORP ZADAXIN; SCICLONE PHARMACEUTICALS Zafira; ADAM OPEL AG Zamyl; PROTEIN DESIGN LABS INC Zantac; GLAXOSMITHKLINE PLC Zeffix; SHIRE-BIOCHEM INC Zema; VIRBAC INC Zenapax; PROTEIN DESIGN LABS INC Zeneca Group; ASTRAZENECA PLC Zero Blunt PCR Cloning Kit; INVITROGEN CORPORATION ZetaPharm, Inc.; HAUSER INC ZEVALIN; IDEC PHARMACEUTICALS CORP Zilactin; ZILA INC Zip Drive; IOMEGA CORP Zippie; SUNRISE MEDICAL INC Zithromax; PFIZER INC ZMR; ZIMMER HOLDINGS INC Zocor; MERCK & CO INC
Zoloft; PFIZER INC Zomig-ZMT; CIMA LABS INC Zonegran; ELAN CORP PLC ZooSeq; INCYTE GENOMICS INC Zosyn; WYETH Zoto-HC; FIRST HORIZON PHARMACEUTICALS Zydone; ENDO PHARMACEUTICALS HOLDINGS INC ZYMAR; ALLERGAN INC Zymetrics, Inc; DIVERSA CORPORATION ZYRTEC; SEPRACOR INC
